avg_score	original_tax_id	orig_organism	pref_name	chembl_id	journal	year	volume	issue	first_page	last_page	pubmed_id	doi	title	authors
949.8000000000000000	11676	Human immunodeficiency virus 1	ABACAVIR SULFATE	CHEMBL1200619	Antimicrob. Agents Chemother.	2008	52	8	2825	2830	18541728	10.1128/aac.00434-08	Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.	Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ABACAVIR SULFATE	CHEMBL1200619	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ABACAVIR SULFATE	CHEMBL1200619									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	ABACAVIR SULFATE	CHEMBL1200619									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.3666666666666667	9606	Homo sapiens	ABALOPARATIDE	CHEMBL3301581									Unpublished dataset	
886.3666666666666667	9606	Homo sapiens	ABALOPARATIDE	CHEMBL3301581									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1878.0666666666666667	9606	Homo sapiens	ABCIXIMAB	CHEMBL1201584									British National Formulary (72nd edition)	
1878.0666666666666667	9606	Homo sapiens	ABCIXIMAB	CHEMBL1201584									Unpublished dataset	
1878.0666666666666667	9606	Homo sapiens	ABCIXIMAB	CHEMBL1201584									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1878.0666666666666667	9606	Homo sapiens	ABCIXIMAB	CHEMBL1201584									WHO Anatomical Therapeutic Chemical Classification	
1878.0666666666666667	9606	Homo sapiens	ABITUZUMAB	CHEMBL2109621									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	ABL-001	CHEMBL3545115									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Bioorg. Med. Chem. Lett.	2003	13	16	2749	2754	12873507	10.1016/s0960-894x(03)00535-3	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.	Bruno-Blanch L, Gálvez J, García-Domenech R.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	J. Med. Chem.	2015	58	16	6507	6515	26214366	10.1021/acs.jmedchem.5b00544	Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.	Iakovleva I, Brännström K, Nilsson L, Gharibyan AL, Begum A, Anan I, Walfridsson M, Sauer-Eriksson AE, Olofsson A.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645	Eur J Med Chem	2017	125		101	116	27657808	10.1016/j.ejmech.2016.09.021	Synthesis, characterization and molecular docking studies of substituted 4-coumarinylpyrano[2,3-c]pyrazole derivatives as potent antibacterial and anti-inflammatory agents.	Chougala BM, Samundeeswari S, Holiyachi M, Shastri LA, Dodamani S, Jalalpure S, Dixit SR, Joshi SD, Sunagar VA.
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	ACECLOFENAC	CHEMBL93645									WHO Anatomical Therapeutic Chemical Classification	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Br. J. Clin. Pharmacol.	1980	10		291S	298S	7002186	10.1111/j.1365-2125.1980.tb01812.x	Kinetics and metabolism of paracetamol and phenacetin.	Prescott LF.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1980	23	11	1153	1158	7452663	10.1021/jm00185a001	Studies on the mechanism of toxicity of acetaminophen. Synthesis and reactions of N-acetyl-2,6-dimethyl- and N-acetyl-3,5-dimethyl-p-benzoquinone imines.	Fernando CR, Calder IC, Ham KN.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1980	23	3	304	308	7365746	10.1021/jm00177a019	Mechanism of decomposition of N-hydroxyacetaminophen, a postulated toxic metabolite of acetaminophen.	Gemborys MW, Mudge GH, Gribble GW.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1981	24	8	988	993	7328601	10.1021/jm00140a014	N-hydroxyacetaminophen: a postulated toxic metabolite of acetaminophen.	Calder IC, Hart SJ, Healey K, Ham KN.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1982	25	5	489	491	7086831	10.1021/jm00347a001	Prodrugs of L-cysteine as liver-protective agents. 2(RS)-Methylthiazolidine-4(R)-carboxylic acid, a latent cysteine.	Nagasawa HT, Goon DJ, Zera RT, Yuzon DL.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1982	25	8	885	886	7120276	10.1021/jm00350a001	Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen.	Dahlin DC, Nelson SD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1986	29	9	1737	1743	3746820	10.1021/jm00159a029	Comparative toxicities and analgesic activities of three monomethylated analogues of acetaminophen.	Harvison PJ, Forte AJ, Nelson SD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1987	30	10	1891	1896	3656363	10.1021/jm00393a034	Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids.	Roberts JC, Nagasawa HT, Zera RT, Fricke RF, Goon DJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1987	30	2	434	437	3100804	10.1021/jm00385a031	Prostaglandin-H synthase inhibition by malonamides. Ring-opened analogues of phenylbutazone.	Vennerstrom JL, Holmes TJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	1994	37	6	860	867	8145237	10.1021/jm00032a021	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies.	Myers TG, Thummel KE, Kalhorn TF, Nelson SD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Mol. Pharmacol.	1999	55	1	847	854	10220563		Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.	Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Nat. Prod.	1999	62	8	1145	1146	10479322	10.1021/np9804177	Antinociceptive activity of niga-ichigoside F1 from Rubus imperialis.	Niero R, Cechinel Filho V, Souza MM, Montanari JL, Yunes RA, Delle Monache F.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2000	10	11	1155	1158	10866370	10.1016/s0960-894x(00)00172-4	Prediction of drug solubility from Monte Carlo simulations.	Jorgensen WL, Duffy EM.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2000	43	15	2922	2928	10956200	10.1021/jm0000822	ElogPoct: a tool for lipophilicity determination in drug discovery.	Lombardo F, Shalaeva MY, Tupper KA, Gao F, Abraham MH.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Chem. Res. Toxicol.	2001	14	1	1596	1603	11743742	10.1021/tx010125x	Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.	Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2001	44	15	2490	2497	11448232	10.1021/jm0100990	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.	Lombardo F, Shalaeva MY, Tupper KA, Gao F.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2002	45	13	2867	2876	12061889	10.1021/jm0200409	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2002	45	25	5514	5522	12459019	10.1021/jm010481c	Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling.	Sharma V, Duffel MW.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Int. J. Pharm.	2003	263	1	113	122	12954186	10.1016/s0378-5173(03)00372-7	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.	Faassen F, Vogel G, Spanings H, Vromans H.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Med Chem Res	2005	14	1	26	39		10.1007/s00044-004-0123-6	ANTIPYRETIC, ANTINOCICEPTIVE AND ANTI-INFLAMMATORY ACTIVITIES OF CERTAIN -OXOBUTANOIC ACID DERIVATIVES	Abouzid KA, Youssef KM, Ahmed AAE, Hussain Al-Zuhair H
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2005	15	23	5170	5175	16183274	10.1016/j.bmcl.2005.08.063	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.	Gobec S, Brozic P, Rizner TL.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2005	48	23	7234	7242	16279782	10.1021/jm050567w	Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.	Selassie CD, Kapur S, Verma RP, Rosario M.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2006	16	13	3590	3594	16616488	10.1016/j.bmcl.2006.03.061	Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.	Majumdar S, Sloan KB.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2006	16	8	2219	2223	16455248	10.1016/j.bmcl.2006.01.033	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.	Stock N, Munoz B, Wrigley JD, Shearman MS, Beher D, Peachey J, Williamson TL, Bain G, Chen W, Jiang X, St-Jacques R, Prasit P.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2007	15	11	3756	3767	17418579	10.1016/j.bmc.2007.03.040	QSAR study on permeability of hydrophobic compounds with artificial membranes.	Fujikawa M, Nakao K, Shimizu R, Akamatsu M.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2007	15	22	6943	6955	17827020	10.1016/j.bmc.2007.07.050	Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.	Baert B, Deconinck E, Van Gele M, Slodicka M, Stoppie P, Bodé S, Slegers G, Vander Heyden Y, Lambert J, Beetens J, De Spiegeleer B.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2007	15	5	2206	2215	16919959	10.1016/j.bmc.2006.07.054	Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen analogs.	Vaccarino AL, Paul D, Mukherjee PK, Rodríguez de Turco EB, Marcheselli VL, Xu L, Trudell ML, Minguez JM, Matía MP, Sunkel C, Alvarez-Builla J, Bazan NG.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2007	17	20	5709	5714	17768049	10.1016/j.bmcl.2007.07.058	Synthesis and anti-inflammatory activity of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives.	Epifano F, Genovese S, Sosa S, Tubaro A, Curini M.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Biol. Pharm. Bull.	2007	30	1	157	161	17202677	10.1248/bpb.30.157	Pharmacokinetics/pharmacodynamics of acetaminophen analgesia in Japanese patients with chronic pain.	Shinoda S, Aoyama T, Aoyama Y, Tomioka S, Matsumoto Y, Ohe Y.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2008	16	11	5881	5889	18482840	10.1016/j.bmc.2008.04.066	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.	Brunskole M, Stefane B, Zorko K, Anderluh M, Stojan J, Lanisnik Rizner T, Gobec S.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2008	16	15	7424	7428	18579385	10.1016/j.bmc.2008.06.013	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.	Innocenti A, Vullo D, Scozzafava A, Supuran CT.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2008	16	18	8526	8534	18722128	10.1016/j.bmc.2008.08.019	Synthesis of new 1-phenyl-3-{4-[(2E)-3-phenylprop-2-enoyl]phenyl}-thiourea and urea derivatives with anti-nociceptive activity.	dos Santos L, Lima LA, Cechinel-Filho V, Corrêa R, de Campos Buzzi F, Nunes RJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2008	18	12	3593	3596	18501600	10.1016/j.bmcl.2008.04.077	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.	Innocenti A, Hilvo M, Scozzafava A, Parkkila S, Supuran CT.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	14	4059	4067	18459759	10.1021/jm800197b	Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.	Friesen RW, Mancini JA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	16	5140	5142	18666772	10.1021/jm8005228	Determination of log D via automated microfluidic liquid-liquid extraction.	Alimuddin M, Grant D, Bulloch D, Lee N, Peacock M, Dahl R.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	24	7800	7805	19053765	10.1021/jm800807k	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.	Sinning C, Watzer B, Coste O, Nüsing RM, Ott I, Ligresti A, Di Marzo V, Imming P.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2008	51	5	1260	1277	18260613	10.1021/jm7009292	Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.	Friebolin W, Jannack B, Wenzel N, Furrer J, Oeser T, Sanchez CP, Lanzer M, Yardley V, Becker K, Davioud-Charvet E.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2009	17	14	5059	5070	19527932	10.1016/j.bmc.2009.05.073	Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.	Eissa AA, Farag NA, Soliman GA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2009	19	17	4963	4966	19646868	10.1016/j.bmcl.2009.07.075	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH).	Kümmerle AE, Vieira MM, Schmitt M, Miranda AL, Fraga CA, Bourguignon JJ, Barreiro EJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	11	4596	4602	19628311	10.1016/j.ejmech.2009.06.029	Antinociceptive properties of caffeic acid derivatives in mice.	de Campos Buzzi F, Franzoi CL, Antonini G, Fracasso M, Cechinel Filho V, Yunes RA, Niero R.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	4	1600	1606	18768239	10.1016/j.ejmech.2008.07.027	First-principle, structure-based prediction of hepatic metabolic clearance values in human.	Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	4	1682	1688	18986738	10.1016/j.ejmech.2008.09.020	Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.	Khode S, Maddi V, Aragade P, Palkar M, Ronad PK, Mamledesai S, Thippeswamy AH, Satyanarayana D.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	5	2307	2312	18486995	10.1016/j.ejmech.2008.03.043	Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea.	Jesudason EP, Sridhar SK, Malar EJ, Shanmugapandiyan P, Inayathullah M, Arul V, Selvaraj D, Jayakumar R.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	9	3612	3620	19327871	10.1016/j.ejmech.2009.02.026	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates.	Barbosa ML, Melo GM, da Silva YK, Lopes Rde O, de Souza ET, de Queiroz AC, Smaniotto S, Alexandre-Moreira MS, Barreiro EJ, Lima LM.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2009	44	9	3712	3717	19410338	10.1016/j.ejmech.2009.03.039	Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.	Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Antimicrob. Agents Chemother.	2009	53	5	1898	1906	19223628	10.1128/aac.01293-08	Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.	McNamara PJ, Syverson RE, Milligan-Myhre K, Frolova O, Schroeder S, Kidder J, Hoang T, Proctor RA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2010	20	17	5299	5301	20667728	10.1016/j.bmcl.2010.06.133	Preliminary studies of 3,4-dichloroaniline amides as antiparasitic agents: structure-activity analysis of a compound library in vitro against Trichomonas vaginalis.	Dornbush PJ, Cho C, Chang ES, Xu L, Russu WA, Wrischnik LA, Land KM.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2010	20	22	6712	6715	20864340	10.1016/j.bmcl.2010.08.145	A practical deuterium-free NMR method for the rapid determination of 1-octanol/water partition coefficients of pharmaceutical agents.	Mo H, Balko KM, Colby DA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2010	45	11	4845	4855	20813430	10.1016/j.ejmech.2010.07.055	Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays.	Rosales-Hernández MC, Mendieta-Wejebe JE, Trujillo-Ferrara JG, Correa-Basurto J.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2010	53	5	2286	2298	20143779	10.1021/jm901891p	Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.	Onnis V, Congiu C, Björklund E, Hempel F, Söderström E, Fowler CJ.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Med Chem Res	2011	20	2	152	157		10.1007/s00044-010-9300-y	Synthesis and analgesic effects of 2-(2-carboxyphenylsulfanyl)-N-(4-substitutedphenyl)acetamide derivatives	Demir Ozkay U, Ozkay Y, Can OD
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Med Chem Res	2011	20	8	1294	1297		10.1007/s00044-010-9454-7	Goat brain enkephalin degrading enzyme: interaction with analgesic and antihypertensive drugs	Dhanda S, Singh J, Singh H
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2011	21	13	4078	4082	21616664	10.1016/j.bmcl.2011.04.118	N,N'-Dialkylaminoalkylcarbonyl (DAAC) prodrugs and aminoalkylcarbonyl (AAC) prodrugs of 4-hydroxyacetanilide and naltrexone with improved skin permeation properties.	Devarajan-Ketha H, Sloan KB.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2011	39	7	1247	1254	21467212	10.1124/dmd.111.039180	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.	Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J Agric Food Chem	2011	59	7	2909	2917	20879794	10.1021/jf102525e	Importance of physicochemical properties for the design of new pesticides.	Akamatsu M.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2012	40	12	2324	2331	22949628	10.1124/dmd.112.047308	Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.	Huang Q, Deshmukh RS, Ericksen SS, Tu Y, Szklarz GD.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2012	40	5	982	989	22331994	10.1124/dmd.111.044057	Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.	Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, Miners JO.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2012	55	2	576	586	22136404	10.1021/jm201320w	Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.	Chung CW, Dean AW, Woolven JM, Bamborough P.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Med Chem Res	2013	22	10	4641	4653		10.1007/s00044-013-0468-9	Synthesis, anti-inflammatory, and structure antioxidant activity relationship of novel 4-quinazoline	Hussein MA
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Med Chem Res	2013	22	9	4347	4359		10.1007/s00044-012-0449-4	Bioactivity guided isolation of antiinflammatory, analgesic, and antipyretic constituents from the leaves of Pedilanthus tithymaloides (L.)	Ghosh S, Chattopadhyay D, Mandal A, Kaity S, Samanta A
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	ACS Med. Chem. Lett.	2013	4	8	710	714	24482730	10.1021/ml4000904	Rational Design of Novel Pyridinol-Fused Ring Acetaminophen Analogues.	Shchepin RV, Liu W, Yin H, Zagol-Ikapitte I, Amin T, Jeong BS, Roberts LJ, Oates JA, Porter NA, Boutaud O.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2013	41	1	60	71	23033255	10.1124/dmd.112.048264	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.	Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Metab. Dispos.	2013	41	4	897	905	23378628	10.1124/dmd.112.050054	Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).	Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, Parkinson A.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem.	2014	22	10	2855	2866	24751552	10.1016/j.bmc.2014.03.043	Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.	Palkar MB, Singhai AS, Ronad PM, Vishwanathswamy AH, Boreddy TS, Veerapur VP, Shaikh MS, Rane RA, Karpoormath R.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2014	24	14	3131	3136	24894557	10.1016/j.bmcl.2014.05.005	Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols.	Lee H, Banskota S, Kim DG, Been JH, Jin YJ, Gautam J, Jang H, Nam TG, Kim JA, Jeong BS.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2014	24	17	4151	4157	25103602	10.1016/j.bmcl.2014.07.050	2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes.	Carballeira NM, Bwalya AG, Itoe MA, Andricopulo AD, Cordero-Maldonado ML, Kaiser M, Mota MM, Crawford AD, Guido RV, Tasdemir D.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	MedChemComm	2014	5	1	47	50		10.1039/C3MD00251A	2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis	Guzman JD, Mortazavi PN, Munshi T, Evangelopoulos D, McHugh TD, Gibbons S, Malkinson J, Bhakta S
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Eur. J. Med. Chem.	2014	82		439	448	24929294	10.1016/j.ejmech.2014.05.080	Syntheses, characterization and evaluation of novel 2,6-diarylpiperidin-4-ones as potential analgesic-antipyretic agents.	Tripathi P, Tripathi AC, Chawla V, Saraf SK.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2015	25	23	5636	5641	26520662	10.1016/j.bmcl.2015.10.021	Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.	I¿¿k S, Vullo D, Durdagi S, Ekinci D, ¿entürk M, Çetin A, ¿entürk E, Supuran CT.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	MedChemComm	2015	6	9	1587	1604		10.1039/C5MD00209E	Fragments in bromodomain drug discovery	Bamborough P, Chung C
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2016	59	10	4676	4687	27007292	10.1021/acs.jmedchem.6b00015	Discovery, Optimization, and Biological Evaluation of Sulfonamidoacetamides as an Inducer of Axon Regeneration.	Ku JM, Park K, Lee JH, Cho KJ, Nam YJ, Jeong DY, Kim YH, Kwon S, Park JY, Yang J, Nam TG, Yoon SH, Ahn S, Choi Y.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	J. Med. Chem.	2016	59	9	4121	4151	27046190	10.1021/acs.jmedchem.6b00078	Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.	Ehrt C, Brinkjost T, Koch O.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	MedChemComm	2016	7	1	114	117	27042286	10.1039/c5md00349k	Phase II Metabolic Pathways of Spectinamide Antitubercular Agents: A Comparative Study of the Reactivity of 4-Substituted Pyridines to Glutathione Conjugation.	Madhura DB, Liu J, Meibohm B, Lee RE.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	MedChemComm	2016	7	5	955	959		10.1039/C5MD00551E	Significantly improving the solubility of non-steroidal anti-inflammatory drugs in deep eutectic solvents for potential non-aqueous liquid administration	Lu C, Cao J, Wang N, Su E
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112		2016							Apoptosis signal-regulating kinase inhibitor	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg Med Chem	2017	25	9	2577	2582	28343756	10.1016/j.bmc.2017.03.026	Inhibition of Malassezia globosa carbonic anhydrase with phenols.	Entezari Heravi Y, Bua S, Nocentini A, Del Prete S, Saboury AA, Sereshti H, Capasso C, Gratteri P, Supuran CT.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg Med Chem Lett	2017	27	17	4122	4127	28765012	10.1016/j.bmcl.2017.07.036	Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.	Lee S, Park JY, Lee D, Seok S, Kwon YJ, Jang TS, Kang KS, Kim KH.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112	Bioorg Med Chem Lett	2017	27	2	319	322	27908763	10.1016/j.bmcl.2016.11.048	Development of a simple proton nuclear magnetic resonance-based procedure to estimate the approximate distribution coefficient at physiological pH (logD7.4): Evaluation and comparison to existing practices.	Stéen EJL, Nyberg N, Lehel S, Andersen VL, Di Pilato P, Knudsen GM, Kristensen JL, Herth MM.
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									British National Formulary (72nd edition)	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									Cerep in vitro phospholipidosis assay data	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									DailyMed|setid=39945812-f776-4b13-8199-e846e37aa101 | TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN - tramadol hydrochloride and acetaminophen tablet, film coated|Cadila Healthcare Limited	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									DrugMatrix	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									Drug metabolism data	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									Open TG-GATES	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									PubChem BioAssay data set	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									Unpublished dataset	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2283.1500000000000000	9606	Homo sapiens	ACETAMINOPHEN	CHEMBL112									WHO Anatomical Therapeutic Chemical Classification	
859.7000000000000000	11676	Human immunodeficiency virus 1	AD-159	CHEMBL2109444									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	J. Med. Chem.	1995	38	26	4993	5006	8544175	10.1021/jm00026a006	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.	Charpentier B, Bernardon JM, Eustache J, Millois C, Martin B, Michel S, Shroot B.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	Bioorg. Med. Chem. Lett.	1997	7	17	2289	2294		10.1016/S0960-894X(97)00405-8	Synthesis and biological activities of new heterocyclic aromatic retinoids	Diaz P, Michel S, Stella L, Charpentier B
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	J. Med. Chem.	2008	51	18	5650	5662	18759424	10.1021/jm800456k	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.	Dawson MI, Xia Z, Jiang T, Ye M, Fontana JA, Farhana L, Patel B, Xue LP, Bhuiyan M, Pellicciari R, Macchiarulo A, Nuti R, Zhang XK, Han YH, Tautz L, Hobbs PD, Jong L, Waleh N, Chao WR, Feng GS, Pang Y, Su Y.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265	J. Med. Chem.	2015	58	7	2958	2966	25790278	10.1021/jm501873p	Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor ¿1 for the treatment of pain.	Wells MM, Tillman TS, Mowrey DD, Sun T, Xu Y, Tang P.
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265									British National Formulary (72nd edition)	
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265									PubChem BioAssay data set	
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	ADAPALENE	CHEMBL1265									WHO Anatomical Therapeutic Chemical Classification	
884.4000000000000000	9606	Homo sapiens	AG-24322	CHEMBL3545420									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	ALMOTRIPTAN MALATE	CHEMBL1200521									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	ALMOTRIPTAN MALATE	CHEMBL1200521									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	ALSEROXYLON	CHEMBL1201454									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	ALSEROXYLON	CHEMBL1201454									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Science	1998	281	5376	533	538	9677190	10.1126/science.281.5376.533	Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.	Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2000	10	10	1037	1041	10843211	10.1016/s0960-894x(00)00156-6	Structure-activity relationship studies of flavopiridol analogues.	Murthi KK, Dubay M, McClure C, Brizuela L, Boisclair MD, Worland PJ, Mansuri MM, Pal K.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2000	43	1	1	18	10633033	10.1021/jm991182e	Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.	Sielecki TM, Boylan JF, Benfield PA, Trainor GL.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2000	43	22	4126	4134	11063609	10.1021/jm000231g	Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.	Kim KS, Sack JS, Tokarski JS, Qian L, Chao ST, Leith L, Kelly YF, Misra RN, Hunt JT, Kimball SD, Humphreys WG, Wautlet BS, Mulheron JG, Webster KR.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2002	45	18	3905	3927	12190313	10.1021/jm0201520	Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.	Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2003	13	6	1133	1136	12643928	10.1016/s0960-894x(03)00034-9	1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.	Misra RN, Rawlins DB, Xiao HY, Shan W, Bursuker I, Kellar KA, Mulheron JG, Sack JS, Tokarski JS, Kimball SD, Webster KR.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2003	46	5	876	879	12593668	10.1021/jm021090g	Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties.	Brachwitz K, Voigt B, Meijer L, Lozach O, Schächtele C, Molnár J, Hilgeroth A.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Mol. Pharmacol.	2003	64	1	1452	1462	14645676	10.1124/mol.64.6.1452	Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.	Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Clin. Cancer Res.	2003	9	1	3320	3328	12960118		Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.	Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2004	14	11	2973	2977	15125971	10.1016/j.bmcl.2004.02.105	Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.	Misra RN, Xiao HY, Williams DK, Kim KS, Lu S, Keller KA, Mulheron JG, Batorsky R, Tokarski JS, Sack JS, Kimball SD, Lee FY, Webster KR.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Trends Pharmacol. Sci.	2004	25	9	471	480	15559249	10.1016/j.tips.2004.07.006	Pharmacological inhibitors of glycogen synthase kinase 3.	Meijer L, Flajolet M, Greengard P.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2004	47	14	3537	3545	15214781	10.1021/jm031121n	Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.	Kristiansen M, Andersen B, Iversen LF, Westergaard N.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2004	47	7	1719	1728	15027863	10.1021/jm0305568	N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.	Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2005	15	7	1943	1947	15780638	10.1016/j.bmcl.2005.01.052	Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.	Hamdouchi C, Zhong B, Mendoza J, Collins E, Jaramillo C, De Diego JE, Robertson D, Spencer CD, Anderson BD, Watkins SA, Zhang F, Brooks HB.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Nat. Biotechnol.	2005	23	3	329	336	15711537	10.1038/nbt1068	A small molecule-kinase interaction map for clinical kinase inhibitors.	Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2005	48	22	6843	6854	16250643	10.1021/jm058013g	Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.	Braña MF, Cacho M, García ML, Mayoral EP, López B, de Pascual-Teresa B, Ramos A, Acero N, Llinares F, Muñoz-Mingarro D, Lozach O, Meijer L.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2005	48	3	737	743	15689157	10.1021/jm049353p	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.	Lu H, Chang DJ, Baratte B, Meijer L, Schulze-Gahmen U.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	AAPS J	2006	8	1	E204	E221	16584130	10.1208/aapsj080125	Selectivity and potency of cyclin-dependent kinase inhibitors.	Sridhar J, Akula N, Pattabiraman N.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem.	2007	15	2	702	713	17123821	10.1016/j.bmc.2006.10.063	Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.	Ahn YM, Vogeti L, Liu CJ, Santhapuram HK, White JM, Vasandani V, Mitscher LA, Lushington GH, Hanson PR, Powell DR, Himes RH, Roby KF, Ye Q, Georg GI.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2007	17	22	6216	6219	17904366	10.1016/j.bmcl.2007.09.018	Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.	Dwyer MP, Paruch K, Alvarez C, Doll RJ, Keertikar K, Duca J, Fischmann TO, Hruza A, Madison V, Lees E, Parry D, Seghezzi W, Sgambellone N, Shanahan F, Wiswell D, Guzi TJ.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem.	2008	16	15	7128	7133	18639462	10.1016/j.bmc.2008.06.055	Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: synthesis, SAR analysis, and biological activity.	Zhang S, Ma J, Bao Y, Yang P, Zou L, Li K, Sun X.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Nat. Biotechnol.	2008	26	1	127	132	18183025	10.1038/nbt1358	A quantitative analysis of kinase inhibitor selectivity.	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Nat. Chem. Biol.	2008	4	6	357	365	18469809	10.1038/nchembio.90	A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.	Montagnoli A, Valsasina B, Croci V, Menichincheri M, Rainoldi S, Marchesi V, Tibolla M, Tenca P, Brotherton D, Albanese C, Patton V, Alzani R, Ciavolella A, Sola F, Molinari A, Volpi D, Avanzi N, Fiorentini F, Cattoni M, Healy S, Ballinari D, Pesenti E, Isacchi A, Moll J, Bensimon A, Vanotti E, Santocanale C.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem.	2010	18	16	6149	6155	20638287	10.1016/j.bmc.2010.06.046	Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.	Bandgar BP, Totre JV, Gawande SS, Khobragade CN, Warangkar SC, Kadam PD.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem.	2010	18	3	1364	1370	20064725	10.1016/j.bmc.2009.11.066	Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents.	Bandgar BP, Gawande SS, Bodade RG, Totre JV, Khobragade CN.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem.	2010	18	5	2060	2065	20138527	10.1016/j.bmc.2009.12.077	Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.	Bandgar BP, Gawande SS.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Med Chem Res	2010	19	8	817	835		10.1007/s00044-009-9233-5	Molecular docking study on anticancer activity of plant-derived natural products	Phosrithong N, Ungwitayatorn J
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Eur. J. Med. Chem.	2010	45	9	4316	4330	20638755	10.1016/j.ejmech.2010.06.034	Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.	Al-Sha'er MA, Taha MO.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2010	53	24	8508	8522	21080703	10.1021/jm100732t	A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.	Heathcote DA, Patel H, Kroll SH, Hazel P, Periyasamy M, Alikian M, Kanneganti SK, Jogalekar AS, Scheiper B, Barbazanges M, Blum A, Brackow J, Siwicka A, Pace RD, Fuchter MJ, Snyder JP, Liotta DC, Freemont PS, Aboagye EO, Coombes RC, Barrett AG, Ali S.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2011	21	13	3957	3961	21641213	10.1016/j.bmcl.2011.05.019	Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.	Nair N, Kudo W, Smith MA, Abrol R, Goddard WA, Reddy VP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Eur. J. Med. Chem.	2011	46	6	2043	2057	21429632	10.1016/j.ejmech.2011.02.057	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.	Shallal HM, Russu WA.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2011	54	8	2980	2993	21417417	10.1021/jm200064p	Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.	Jorda R, Havlícek L, McNae IW, Walkinshaw MD, Voller J, Sturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Krystof V.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Med Chem Res	2012	21	10	3006	3014		10.1007/s00044-011-9834-7	Synthesis and biological evaluation of novel curcumin analogues as anti-inflammatory, anti-cancer and anti-oxidant agents	Bandgar BP, Hote BS, Jalde SS, Gacche RN
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Med Chem Res	2012	21	11	3369	3375		10.1007/s00044-011-9867-y	Combination of flavopiridol and embelin effectively inhibit cell growth in hepatocellular carcinoma depending on regulatory relationship between CDK6 and XIAP	Che Y, Zhang DY, Ye F, Wu B, Jiang B
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2012	22	12	4193	4197	22546672	10.1016/j.bmcl.2012.04.008	Simple, fast and efficient synthesis of ß-keto esters from the esters of heteroaryl compounds, its antimicrobial study and cytotoxicity towards various cancer cell lines.	Venkat Ragavan R, Vijayakumar V, Rajesh K, Palakshi Reddy B, Karthikeyan S, Suchetha Kumari N.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	MedChemComm	2012	3	5	605	610		10.1039/C2MD20035J	INPHARMA-based identification of ligand binding site in fragment-based drug design	Krimm I
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2012	55	3	1287	1295	22229710	10.1021/jm201439b	Binding evaluation of fragment-based scaffolds for probing allosteric enzymes.	Krimm I, Lancelin JM, Praly JP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2012	55	6	2811	2819	22352892	10.1021/jm201727w	Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases.	Nguyen TB, Lozach O, Surpateanu G, Wang Q, Retailleau P, Iorga BI, Meijer L, Guéritte F.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2013	56	3	640	659	23301767	10.1021/jm301475f	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2013	56	3	660	670	23252711	10.1021/jm301495v	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.	Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA, Noble ME.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2014	24	2	630	635	24360556	10.1016/j.bmcl.2013.11.081	Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.	Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2014	57	10	3939	3965	24742150	10.1021/jm401742r	Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.	Németh G, Greff Z, Sipos A, Varga Z, Székely R, Sebestyén M, Jászay Z, Béni S, Nemes Z, Pirat JL, Volle JN, Virieux D, Gyuris Á, Kelemenics K, Ay E, Minarovits J, Szathmary S, Kéri G, Orfi L.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Med. Chem.	2014	57	3	578	599	24417566	10.1021/jm401073p	Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).	Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR, Billa VK, Subbaiah DR, Bharathi EV, Vasquez-Del Carpio R, Padgaonkar A, Baker SJ, Reddy EP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	MedChemComm	2015	6	3	444	454	25914804	10.1039/c4md00412d	Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9.	Gao J, Fang C, Xiao Z, Huang L, Chen CH, Wang LT, Lee KH.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Bioorg. Med. Chem. Lett.	2016	26	15	3457	3463	27363938	10.1016/j.bmcl.2016.06.046	A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.	Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J Med Chem	2016	59	19	8667	8684	27171036	10.1021/acs.jmedchem.6b00150	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	ACS Med. Chem. Lett.	2016	7	3	223	228	26985305	10.1021/acsmedchemlett.5b00278	Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.	Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J. Nat. Prod.	2016	79	3	616	628	26900761	10.1021/acs.jnatprod.5b00947	Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).	Baell JB.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J Med Chem	2017	60	23	9470	9489	29144137	10.1021/acs.jmedchem.7b00663	Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.	Singh U, Chashoo G, Khan SU, Mahajan P, Nargotra A, Mahajan G, Singh A, Sharma A, Mintoo MJ, Guru SK, Aruri H, Thatikonda T, Sahu P, Chibber P, Kumar V, Mir SA, Bharate SS, Madishetti S, Nandi U, Singh G, Mondhe DM, Bhushan S, Malik F, Mignani S, Vishwakarma RA, Singh PP.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690	J Med Chem	2018	61	4	1664	1687	29370702	10.1021/acs.jmedchem.7b01765	Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.	Bharate SB, Kumar V, Jain SK, Mintoo MJ, Guru SK, Nuthakki VK, Sharma M, Bharate SS, Gandhi SG, Mondhe DM, Bhushan S, Vishwakarma RA.
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690									Unpublished dataset	
884.4000000000000000	9606	Homo sapiens	ALVOCIDIB	CHEMBL428690									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
867.7500000000000000	9606	Homo sapiens	AMA0076	CHEMBL3545073									Unpublished dataset	
886.6000000000000000	9606	Homo sapiens	AMG-108	CHEMBL2109458									Unpublished dataset	
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318	Bioorg. Med. Chem.	2010	18	11	3885	3897	20488716	10.1016/j.bmc.2010.04.035	Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines.	Read ML, Braendvang M, Miranda PO, Gundersen LL.
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318	J. Med. Chem.	2012	55	22	10160	10176	23050700	10.1021/jm3012728	A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.	Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318	Bioorg. Med. Chem. Lett.	2014	24	1	328	331	24300736	10.1016/j.bmcl.2013.11.009	Synthesis and biological evaluation of novel N-substituted 1H-dibenzo[a,c]carbazole derivatives of dehydroabietic acid as potential antimicrobial agents.	Gu W, Qiao C, Wang SF, Hao Y, Miao TT.
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318									Unpublished dataset	
2219.8000000000000000	2	Bacteria	AMIKACIN SULFATE	CHEMBL1164318									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1980	23	4	405	412	7381838	10.1021/jm00178a011	Orally active cephalosporins and penicillins.	Böhme EH, Bambury RE, Baumann RJ, Erickson RC, Harrison BL, Hoffman PF, McCarty FJ, Schnettler RA, Vaal MJ, Wenstrup DL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1981	24	12	1531	1534	6273562	10.1021/jm00144a034	Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.	Gottstein WJ, Crast LB, Graham RG, Haynes UJ, McGregor DN.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1985	28	4	518	522	3872369	10.1021/jm00382a025	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.	Gottstein WJ, Haynes UJ, McGregor DN.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1994	4	14	1667	1672		10.1016/S0960-894X(00)80358-3	The synthesis and serine -lactamase inhibitory activity of some phosphonamidate analogues of dipeptides	Bateson JH, Gasson BC, Khushi T, Neale JE, Payne DJ, Tolson DA, Walker G
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1994	4	2	345	348		10.1016/S0960-894X(01)80141-4	Substrate specificity of immobilized penicillin-G acylase towards penicillin and cephalosporin derivatives was studied. The phenylacetyl moiety can be altered at the -position with several small substituents. Depending on polarity and size of the substituent, enzyme activity decreases or increases. Insertion or deletion of atoms between the aromatic nucleus of the phenylacetyl group and the center of hydrolysis leads to substrates that are no longer recognized by the enzyme.	van der Mey M, de Vroom E
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1995	38	21	4244	4256	7473551	10.1021/jm00021a013	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.	Altamura M, Perrotta E, Sbraci P, Pestellini V, Arcamone F, Cascio G, Lorenzi L, Satta G, Morandotti G, Sperning R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1995	5	6	555	558		10.1016/0960-894X(95)00072-2	Synthesis and antibacterial activity of men 10700, a new penem antibiotic	Altamura M, Perrotta E, Sbraci P, Pestellini V, Arcamone F, Cascio G, Satta G, Morandotti G, Sperrung R
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Pharmacol. Exp. Ther.	1996	277	1	831	839	8627565		Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.	Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1996	39	18	3596	3600	8784459	10.1021/jm950882q	The chemistry of pseudomonic acid. 17. Dual-action C-1 oxazole derivatives of pseudomonic acid having an extended spectrum of antibacterial activity.	Broom NJ, Cassels R, Cheng HY, Elder JS, Hannan PC, Masson N, O'Hanlon PJ, Pope A, Wilson JM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1998	41	11	1777	1788	9599229	10.1021/jm970165r	Structure-activity relationship of 2-[[(2-pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy.	Kühler TC, Swanson M, Shcherbuchin V, Larsson H, Mellgârd B, Sjöström JE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1998	41	25	4939	4949	9836611	10.1021/jm9810102	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.	Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, Karlén A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	1998	61	2	202	206	9548847	10.1021/np970294a	Antibacterial steroidal alkaloids from Sarcococca saligna.	Rahman A, Anjum S, Farooq A, Khan MR, Parveen Z, Choudhary MI.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1998	8	11	1307	1312	9871756	10.1016/s0960-894x(98)00206-6	Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles.	Katsura Y, Nishino S, Tomishi T, Sakane K, Matsumoto Y, Ishikawa H, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1998	8	14	1897	1902	9873455	10.1016/s0960-894x(98)00335-7	Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity.	Yoshida Y, Barrett D, Azami H, Morinaga C, Matsumoto Y, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1998	8	16	2185	2190	9873510	10.1016/s0960-894x(98)00390-4	Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.	Sakurai N, Sano M, Hirayama F, Kuroda T, Uemori S, Moriguchi A, Yamamoto K, Ikeda Y, Kawakita T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1998	8	21	3007	3010	9873665	10.1016/s0960-894x(98)00536-8	Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.	Sol V, Branland P, Granet R, Kaldapa C, Verneuil B, Krausz P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Pharmacol. Exp. Ther.	1999	290	1	672	677	10411577		The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.	Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	1999	42	15	2920	2926	10425101	10.1021/jm9900671	Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles.	Katsura Y, Nishino S, Ohno M, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1999	9	10	1347	1350	10360733	10.1016/s0960-894x(99)00203-6	A highly stereoselective synthesis of plaunotol and its thiourea derivatives as potent antibacterial agents against Helicobacter pylori.	Kogen H, Tago K, Arai M, Minami E, Masuda K, Akiyama T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	1999	9	21	3123	3126	10560737	10.1016/s0960-894x(99)00549-1	Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.	Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2000	43	11	2083	2086	10841786	10.1021/jm991156g	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.	Danelian E, Karlén A, Karlsson R, Winiwarter S, Hansson A, Löfâs S, Lennernäs H, Hämäläinen MD.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2000	43	17	3315	3321	10966750	10.1021/jm000169n	Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.	Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2001	44	25	4468	4474	11728192	10.1021/jm010307o	3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents.	Ando R, Kawamura M, Chiba N.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2002	45	1	143	150	11754586	10.1021/jm010217j	Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.	Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2002	45	10	1959	1962	11985462	10.1021/jm025502x	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.	Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, Elder JS, Forrest AK, Fosberry AP, Gentry DR, Hibbs MJ, Jaworski DD, O'Hanlon PJ, Pope AJ, Rittenhouse S, Sheppard RJ, Slater-Radosti C, Worby A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2002	45	19	4282	4299	12213070	10.1021/jm0208673	Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 1.	Kühler TC, Swanson M, Christenson B, Klintenberg AC, Lamm B, Fägerhag J, Gatti R, Olwegård-Halvarsson M, Shcherbuchin V, Elebring T, Sjöström JE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2002	45	19	4300	4309	12213071	10.1021/jm020868v	Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2.	Carcanague D, Shue YK, Wuonola MA, Uria-Nickelsen M, Joubran C, Abedi JK, Jones J, Kühler TC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2003	13	16	2703	2707	12873498	10.1016/s0960-894x(03)00547-x	A specific anti-Helicobacter pylori agent NE2001: synthesis and its effect on the growth of H. pylori.	Cheng N, Xie JS, Zhang MY, Shu C, Zhu DX.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2003	13	16	2749	2754	12873507	10.1016/s0960-894x(03)00535-3	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.	Bruno-Blanch L, Gálvez J, García-Domenech R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2003	13	4	665	668	12639554	10.1016/s0960-894x(02)01027-2	Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity.	Jarvest RL, Berge JM, Brown MJ, Brown P, Elder JS, Forrest AK, Houge-Frydrych CS, O'Hanlon PJ, McNair DJ, Rittenhouse S, Sheppard RJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2004	14	10	2627	2631	15109666	10.1016/j.bmcl.2004.02.068	Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.	Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Tawara S, Takasugi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2004	47	8	2133	2156	15056010	10.1021/jm031089x	Distamycin analogues with enhanced lipophilicity: synthesis and antimicrobial activity.	Khalaf AI, Waigh RD, Drummond AJ, Pringle B, McGroarty I, Skellern GG, Suckling CJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2005	68	1	78	82	15679322	10.1021/np0497447	Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.	Melliou E, Magiatis P, Mitaku S, Skaltsounis AL, Chinou E, Chinou I.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2005	68	6	819	824	15974602	10.1021/np040188q	Anti-Helicobacter pylori compounds from Santalum album.	Ochi T, Shibata H, Higuti T, Kodama KH, Kusumi T, Takaishi Y.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2006	16	21	5523	5525	16945527	10.1016/j.bmcl.2006.08.043	In vitro inhibitory activity of boropinic acid against Helicobacter pylori.	Epifano F, Menghini L, Pagiotti R, Angelini P, Genovese S, Curini M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2006	49	9	2804	2811	16640341	10.1021/jm0580510	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.	Broccolo F, Cainelli G, Caltabiano G, Cocuzza CE, Fortuna CG, Galletti P, Giacomini D, Musumarra G, Musumeci R, Quintavalla A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2006	69	8	1177	1179	16933871	10.1021/np060217s	Chemical constituents from the peels of Citrus sudachi.	Nakagawa H, Takaishi Y, Tanaka N, Tsuchiya K, Shibata H, Higuti T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2007	15	15	5158	5165	17532639	10.1016/j.bmc.2007.05.028	Synthesis, antifungal and antimicrobial activity of alkylphospholipids.	Obando D, Widmer F, Wright LC, Sorrell TC, Jolliffe KA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2007	16	3	143	154		10.1007/s00044-007-9017-8	Synthesis and bioactivity of some new 1-tolyl-3-aryl-4-methylimidazole-2-thiones	Saeed A, Batool M
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2007	17	19	5321	5324	17719779	10.1016/j.bmcl.2007.08.021	Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2,5-dichlorothiophene moiety.	Tomar V, Bhattacharjee G, Kamaluddin, Kumar A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2007	17	22	6354	6363	17919903	10.1016/j.bmcl.2007.09.062	Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2H)-benzofuranone derivatives.	Hadj-esfandiari N, Navidpour L, Shadnia H, Amini M, Samadi N, Faramarzi MA, Shafiee A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2007	42	10	1293	1299	17337097	10.1016/j.ejmech.2007.01.022	Synthesis and in vitro antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles.	Tekiner-Gulbas B, Temiz-Arpaci O, Yildiz I, Altanlar N.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2007	50	17	4195	4204	17665895	10.1021/jm0703183	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.	Villain-Guillot P, Gualtieri M, Bastide L, Roquet F, Martinez J, Amblard M, Pugniere M, Leonetti JP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2007	50	24	5878	5881	17973471	10.1021/jm701044r	Multiple N-methylation by a designed approach enhances receptor selectivity.	Chatterjee J, Ovadia O, Zahn G, Marinelli L, Hoffman A, Gilon C, Kessler H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2007	50	24	6201	6211	17983214	10.1021/jm070836d	Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.	Hess S, Ovadia O, Shalev DE, Senderovich H, Qadri B, Yehezkel T, Salitra Y, Sheynis T, Jelinek R, Gilon C, Hoffman A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	1	208	214	17060515	10.1128/aac.00004-06	Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.	Abgueguen P, Azoulay-Dupuis E, Noel V, Moine P, Rieux V, Fantin B, Bedos JP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	1	354	358	17060532	10.1128/aac.00344-06	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.	Kamysz W, Silvestri C, Cirioni O, Giacometti A, Licci A, Della Vittoria A, Okroj M, Scalise G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	10	3699	3706	17664320	10.1128/aac.01530-06	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.	Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, Cafini F, Sevillano D, Alou L, Coronel P, Prieto J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	10	3720	3725	17646418	10.1128/aac.00318-07	Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.	Muller AE, DeJongh J, Bult Y, Goessens WH, Mouton JW, Danhof M, van den Anker JN.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	10	3763	3767	17664321	10.1128/aac.00389-07	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.	Papagiannitsis CC, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	11	4009	4014	17846134	10.1128/aac.00537-07	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.	Girlich D, Leclercq R, Naas T, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	11	4181	4183	17709463	10.1128/aac.00614-07	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.	Robin F, Delmas J, Brebion A, Dubois D, Constantin JM, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	12	4336	4341	17923485	10.1128/aac.00405-07	Estimating amoxicillin influx/efflux in chinchilla middle ear fluid and simultaneous measurement of antibacterial effect.	Huang Y, Yang Z, Cartier L, Cheung B, Sawchuk RJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	12	4486	4488	17938180	10.1128/aac.01462-06	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.	Neuwirth C, Siebor E, Robin F, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	12	4498	4501	17923492	10.1128/aac.00538-07	Antimicrobial susceptibilities and clinical sources of Dialister species.	Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, Devine R, Marchandin H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	2	631	637	17116662	10.1128/aac.01082-06	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.	Poirel L, Cattoir V, Soares A, Soussy CJ, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	3	1082	1084	17178800	10.1128/aac.00909-06	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.	Mazzariol A, Roelofsen E, Koncan R, Voss A, Cornaglia G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	4	1304	1309	17220412	10.1128/aac.01058-06	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.	Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	4	1365	1372	17242148	10.1128/aac.01152-06	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.	Naas T, Aubert D, Ozcan A, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	5	1661	1665	17353251	10.1128/aac.00744-06	Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.	Moreillon P, Wilson WR, Leclercq R, Entenza JM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	5	1837	1839	17325219	10.1128/aac.00924-06	Efficacy of the de novo-derived antimicrobial peptide WLBU2 against oral bacteria.	Novak KF, Diamond WJ, Kirakodu S, Peyyala R, Anderson KW, Montelaro RC, Mietzner TA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	2179	2184	17420213	10.1128/aac.01600-06	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.	Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	2185	2188	17353248	10.1128/aac.01439-06	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.	Papagiannitsis CC, Loli A, Tzouvelekis LS, Tzelepi E, Arlet G, Miriagou V.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	2205	2207	17403999	10.1128/aac.00056-07	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.	Könönen E, Bryk A, Niemi P, Kanervo-Nordström A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	6	2260	2264	17438055	10.1128/aac.00242-07	Beta-lactam resistance in Haemophilus parasuis Is mediated by plasmid pB1000 bearing blaROB-1.	San Millan A, Escudero JA, Catalan A, Nieto S, Farelo F, Gibert M, Moreno MA, Dominguez L, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	7	2625	2627	17502407	10.1128/aac.00107-07	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.	Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	8	2848	2854	17562794	10.1128/aac.01376-06	Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.	Skiadas I, Pefanis A, Papalois A, Kyroudi A, Triantafyllidi H, Tsaganos T, Giamarellou H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	8	2855	2860	17470647	10.1128/aac.01614-06	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.	Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	8	2988	2990	17470648	10.1128/aac.00083-07	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.	Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	8	3038	3039	17517838	10.1128/aac.00374-07	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.	Ikonomidis A, Labrou M, Afkou Z, Maniatis AN, Sofianou D, Tsakris A, Pournaras S.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2007	51	9	3465	3466	17606684	10.1128/aac.00267-07	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.	Quinteira S, Grosso F, Ramos H, Peixe L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2007	70	10	1570	1577	17883259	10.1021/np070260v	Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.	Zhu Y, Zhang P, Yu H, Li J, Wang MW, Zhao W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2008	17	9	578	586		10.1007/s00044-008-9099-y	Synthesis and in vitro anti-Helicobacter pylori activity of 2-[(chlorobenzyl)thio]-5-(5-nitro-2-furyl)-1,3,4-thiadiazoles	Mohammadhosseini N, Letafat B, Siavoshi F, Emami S, Safari F, Shafiee A, Foroumadi A
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2008	18	11	3315	3320	18442909	10.1016/j.bmcl.2008.04.033	Synthesis and anti-Helicobacter pylori activity of 5-(nitroaryl)-1,3,4-thiadiazoles with certain sulfur containing alkyl side chain.	Foroumadi A, Rineh A, Emami S, Siavoshi F, Massarrat S, Safari F, Rajabalian S, Falahati M, Lotfali E, Shafiee A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2008	43	8	1575	1580	18192086	10.1016/j.ejmech.2007.11.019	Synthesis and in vitro anti-Helicobacter pylori activity of N-[5-(5-nitro-2-heteroaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds.	Mirzaei J, Siavoshi F, Emami S, Safari F, Khoshayand MR, Shafiee A, Foroumadi A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2008	43	9	2029	2034	18450330	10.1016/j.ejmech.2007.12.004	Synthesis and in vitro antibacterial activity of new steroidal thiosemicarbazone derivatives.	Khan SA, Kumar P, Joshi R, Iqbal PF, Saleem K.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2008	43	9	2040	2044	18455270	10.1016/j.ejmech.2007.12.008	Synthesis, characterization and in vitro antibacterial activity of new steroidal 5-en-3-oxazolo and thiazoloquinoxaline.	Khan SA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	10	3725	3736	18625772	10.1128/aac.00163-08	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.	Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	10	3792	3794	18663019	10.1128/aac.00387-08	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.	Dubois V, Poirel L, Demarthe F, Arpin C, Coulange L, Minarini LA, Bezian MC, Nordmann P, Quentin C.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	11	4163	4165	18725442	10.1128/aac.00476-08	In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.	Karlowsky JA, Laing NM, Zhanel GG.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	11	4209	4210	18725443	10.1128/aac.00712-08	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.	Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, Tarragó D.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	2	551	556	18070972	10.1128/aac.01145-07	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.	Meziane-Cherif D, Decré D, Høiby EA, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	2	796	797	18056283	10.1128/aac.01180-07	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.	Cuzon G, Naas T, Demachy MC, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	3	1021	1027	18160523	10.1128/aac.01082-07	Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.	Izdebski R, Rutschmann J, Fiett J, Sadowy E, Gniadkowski M, Hryniewicz W, Hakenbeck R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	3	1147	1149	18180346	10.1128/aac.01387-07	Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.	Ressner RA, Moore MR, Jorgensen JH.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	3	1182	1183	18180358	10.1128/aac.01332-07	In vitro activity of AR-709 against Streptococcus pneumoniae.	Jansen WT, Verel A, Verhoef J, Milatovic D.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	3	1184	1186	18160517	10.1128/aac.01247-07	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.	Sevillano D, Aguilar L, Alou L, Giménez MJ, Torrico M, González N, Cafini F, Relaño MT, Coronel P, Prieto J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	3	915	919	18160520	10.1128/aac.01028-07	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.	Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	4	1257	1263	18227185	10.1128/aac.01451-07	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.	Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	4	1264	1268	18212108	10.1128/aac.00684-07	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.	Meziane-Cherif D, Lambert T, Dupêchez M, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	4	1297	1301	18212109	10.1128/aac.01060-07	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.	Stepanova MN, Pimkin M, Nikulin AA, Kozyreva VK, Agapova ED, Edelstein MV.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	5	1697	1702	18299415	10.1128/aac.01211-07	Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.	Grayo S, Join-Lambert O, Desroches MC, Le Monnier A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	5	1806	1811	18316518	10.1128/aac.01381-07	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.	Mendonça N, Manageiro V, Robin F, Salgado MJ, Ferreira E, Caniça M, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	5	1880	1883	18347113	10.1128/aac.00936-07	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.	Takahata S, Kato Y, Sanbongi Y, Maebashi K, Ida T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	5	1897	1898	18316524	10.1128/aac.01525-07	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.	Mendonça N, Manageiro V, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	6	1952	1956	18362192	10.1128/aac.01463-07	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.	Doi Y, Poirel L, Paterson DL, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	6	2279	2282	18362189	10.1128/aac.01620-07	Antistreptococcal activity of AR-709 compared to that of other agents.	Smith K, Ednie LM, Appelbaum PC, Hawser S, Lociuro S.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	7	2407	2414	18443129	10.1128/aac.00214-08	Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.	García-Cobos S, Campos J, Román F, Carrera C, Pérez-Vázquez M, Aracil B, Oteo J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	7	2573	2580	18443121	10.1128/aac.00393-08	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.	Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	7	2639	2643	18443117	10.1128/aac.00310-08	Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.	Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	7	2663	2666	18426902	10.1128/aac.01326-07	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.	Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	7	2686	2690	18474575	10.1128/aac.00081-08	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.	Betriu C, Culebras E, Gómez M, López F, Rodríguez-Avial I, Picazo JJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	8	2977	2979	18519714	10.1128/aac.00175-08	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.	Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	8	2984	2987	18490506	10.1128/aac.01634-07	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.	Espedido BA, Partridge SR, Iredell JR.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	9	3161	3168	18625771	10.1128/aac.00355-08	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.	Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	9	3210	3215	18573932	10.1128/aac.00177-08	Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.	Grayo S, Lott-Desroches MC, Dussurget O, Respaud R, Fontanet A, Join-Lambert O, Singlas E, Le Monnier A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	9	3244	3252	18591273	10.1128/aac.00063-08	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.	Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D'Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	9	3461	3462	18644966	10.1128/aac.00770-08	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.	Picão RC, Poirel L, Demarta A, Petrini O, Corvaglia AR, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2008	52	9	3463	3464	18644970	10.1128/aac.00543-08	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.	Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	1	239	250	18403059	10.1016/j.ejmech.2008.02.021	2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors.	Farhanullah, Kang T, Yoon EJ, Choi EC, Kim S, Lee J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	12	4985	4997	19782439	10.1016/j.ejmech.2009.09.002	Stereoselective synthesis and antimicrobial activity of benzofuran-based (1E)-1-(piperidin-1-yl)-N2-arylamidrazones.	Abdel-Aziz HA, Mekawey AA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	5	2270	2274	18715679	10.1016/j.ejmech.2008.06.008	Synthesis, spectral studies and in vitro antibacterial activity of steroidal thiosemicarbazone and their palladium (Pd (II)) complexes.	Khan SA, Yusuf M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	6	2597	2600	19211172	10.1016/j.ejmech.2008.09.004	Synthesis and biological evaluation of some thiazolidinone derivatives of steroid as antibacterial agents.	Khan SA, Asiri AM, Yusuf M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	6	2632	2635	18995932	10.1016/j.ejmech.2008.09.029	Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles.	Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2009	44	9	3637	3644	19321238	10.1016/j.ejmech.2009.02.020	Convenient synthesis and antimicrobial evaluation of some novel 2-substituted-3-methylbenzofuran derivatives.	Abdel-Aziz HA, Mekawey AA, Dawood KM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2009	52	19	5926	5936	19746934	10.1021/jm900625q	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.	Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	242	248	18981261	10.1128/aac.00642-08	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.	Pradel N, Delmas J, Wu LF, Santini CL, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	267	270	18955529	10.1128/aac.00402-08	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.	Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	277	280	19001114	10.1128/aac.00912-08	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.	Papagiannitsis CC, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	287	291	19001116	10.1128/aac.00746-08	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.	Mesko Meglic K, Koren S, Palepou MF, Karisik E, Livermore DM, Pike R, Andlovic A, Jeverica S, Krizan-Hergouth V, Müller-Premru M, Seme K, Slovenian ESBL Study Group, Woodford N.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	298	302	19015361	10.1128/aac.00657-08	Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.	Llobet E, March C, Giménez P, Bengoechea JA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	323	326	19001118	10.1128/aac.00608-08	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.	Mammeri H, Galleni M, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	1	75	80	18955527	10.1128/aac.00636-08	Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates.	Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	10	4225	4230	19651910	10.1128/aac.00192-09	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.	Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K, Kaku M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	10	4320	4326	19651915	10.1128/aac.01607-08	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.	Zeba B, De Luca F, Dubus A, Delmarcelle M, Simporé J, Nacoulma OG, Rossolini GM, Frère JM, Docquier JD.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	10	4518	4521	19620330	10.1128/aac.00461-09	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.	Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	11	4955	4956	19687235	10.1128/aac.00547-09	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.	Mulvey MR, Boyd DA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	12	5035	5038	19770279	10.1128/aac.00856-09	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.	Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	2	552	556	19015339	10.1128/aac.01324-08	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.	McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	2	845	846	19029319	10.1128/aac.01312-08	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.	Welch TJ, Evenhuis J, White DG, McDermott PF, Harbottle H, Miller RA, Griffin M, Wise D.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	3	1256	1259	19104021	10.1128/aac.01284-08	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.	Zioga A, Whichard JM, Kotsakis SD, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	3	1278	1280	19124661	10.1128/aac.01519-08	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.	Prakash V, Lewis JS, Herrera ML, Wickes BL, Jorgensen JH.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	3	1281	1284	19075048	10.1128/aac.01247-08	In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.	Morgenstern K, Baljer G, Norris DE, Kraiczy P, Hanssen-Hübner C, Hunfeld KP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	3	876	882	19075063	10.1128/aac.00946-08	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.	Poirel L, Rodriguez-Martinez JM, Plésiat P, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	3	977	986	19075050	10.1128/aac.01155-08	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.	Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	4	1592	1597	19204190	10.1128/aac.01242-08	Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice.	De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	4	1630	1635	19188377	10.1128/aac.01431-08	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.	Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, Jajic-Bencic I, Gniadkowski M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	4	1667	1669	19188384	10.1128/aac.00692-08	Contribution of the autolysin AtlA to the bactericidal activity of amoxicillin against Enterococcus faecalis JH2-2.	Bravetti AL, Mesnage S, Lefort A, Chau F, Eckert C, Garry L, Arthur M, Fantin B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	4	1720	1721	19188389	10.1128/aac.00049-09	Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.	Suzuki H, Nishizawa T, Muraoka H, Hibi T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	5	1766	1771	19258272	10.1128/aac.01410-08	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	5	1944	1951	19273683	10.1128/aac.01581-08	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.	Doublet B, Granier SA, Robin F, Bonnet R, Fabre L, Brisabois A, Cloeckaert A, Weill FX.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	5	2163	2170	19223615	10.1128/aac.01557-08	Antianaerobic activity of sulopenem compared to six other agents.	Ednie LM, Appelbaum PC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	5	2176	2180	19237649	10.1128/aac.01566-08	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.	Kosowska-Shick K, McGhee P, Appelbaum PC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	6	2492	2498	19332679	10.1128/aac.00033-09	Integron mobilization unit as a source of mobility of antibiotic resistance genes.	Poirel L, Carrër A, Pitout JD, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	6	2539	2543	19364876	10.1128/aac.00061-09	Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region.	Pitout JD, Campbell L, Church DL, Gregson DB, Laupland KB.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	6	2663	2666	19332673	10.1128/aac.00046-09	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.	Goy G, Greub G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	7	3010	3016	19380596	10.1128/aac.01164-08	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.	Potron A, Poirel L, Croizé J, Chanteperdrix V, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	8	3357	3364	19506058	10.1128/aac.01655-08	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.	Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	8	3399	3404	19528282	10.1128/aac.01522-08	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.	San Millan A, Escudero JA, Gutierrez B, Hidalgo L, Garcia N, Llagostera M, Dominguez L, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	8	3520	3523	19470510	10.1128/aac.00219-09	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	9	3777	3781	19596876	10.1128/aac.00026-09	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.	Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2009	53	9	4028	4031	19581456	10.1128/aac.00457-09	Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.	Hurdle JG, Yendapally R, Sun D, Lee RE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2010	18	19	7078	7084	20810286	10.1016/j.bmc.2010.08.003	QSAR-based solubility model for drug-like compounds.	Gozalbes R, Pineda-Lucena A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2010	18	9	3053	3058	20382539	10.1016/j.bmc.2010.03.045	Azetidinone-isothiazolidinones: stereoselective synthesis and antibacterial evaluation of new monocyclic beta-lactams.	Ceri¿ H, Sindler-Kulyk M, Kovacevi¿ M, Peri¿ M, Zivkovi¿ A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2010	19	2	193	209		10.1007/s00044-009-9184-x	Design and synthesis of 2-quinolones as antioxidants and antimicrobials: a rational approach	Jayashree BS, Thomas S, Nayak Y
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2010	19	6	576	588		10.1007/s00044-009-9214-8	Synthesis and biological activity of new cycloalkylthiophene-Schiff bases and their Cr(III) and Zn(II) complexes	Altundas A, Sar N, Colak N, Ogutcu H
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2010	20	15	4635	4638	20576430	10.1016/j.bmcl.2010.05.110	Propenylamide and propenylsulfonamide cephalosporins as a novel class of anti-MRSA beta-lactams.	Pohlmann J, Vasilevich NI, Glushkov AI, Kellenberger L, Shapiro S, Caspers P, Page MG, Danel F.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2010	20	18	5462	5465	20705463	10.1016/j.bmcl.2010.07.094	Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.	Lai CH, Rao YK, Fang SH, Sing YT, Tzeng YM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2010	45	11	4983	4989	20813436	10.1016/j.ejmech.2010.08.005	Synthesis and antimicrobial activity of 2-substituted [4-(1,3,4-oxadiazol-2-yl methyl)] phthalazin-1(2H)-one derivatives.	Sridhara AM, Reddy KR, Keshavayya J, Goud PS, Somashekar BC, Bose P, Peethambar SK, Gaddam SK.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2010	45	12	5848	5855	20934788	10.1016/j.ejmech.2010.09.049	Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.	Al-Tel TH, Al-Qawasmeh RA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2010	45	7	2994	3004	20399543	10.1016/j.ejmech.2010.03.028	Synthesis and biological evaluation of some thio containing pyrrolo [2,3-d]pyrimidine derivatives for their anti-inflammatory and anti-microbial activities.	Mohamed MS, Kamel R, Fatahala SS.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	328	332	19901091	10.1128/aac.00961-09	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	45	51	19884377	10.1128/aac.00427-09	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.	Doublet B, Robin F, Casin I, Fabre L, Le Fleche A, Bonnet R, Weill FX.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	466	470	19901092	10.1128/aac.00017-09	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.	Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	471	476	19917750	10.1128/aac.00458-09	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.	Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	533	535	19884378	10.1128/aac.00859-09	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.	Poirel L, Docquier JD, De Luca F, Verlinde A, Ide L, Rossolini GM, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	1	578	579	19884362	10.1128/aac.00861-09	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	11	4864	4871	20696873	10.1128/aac.00771-10	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES ß-lactamases.	Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	11	4914	4916	20823289	10.1128/aac.00878-10	Emergence of metallo-ß-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.	Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	3	1218	1225	20008776	10.1128/aac.00944-09	Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG.	Fàbrega A, Martin RG, Rosner JL, Tavio MM, Vila J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	3	1331	1333	20065056	10.1128/aac.01561-09	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	3	1369	1373	20086157	10.1128/aac.01312-09	Spread of OXA-48-encoding plasmid in Turkey and beyond.	Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	4	1506	1511	20086141	10.1128/aac.01489-09	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.	San Millan A, Garcia-Cobos S, Escudero JA, Hidalgo L, Gutierrez B, Carrilero L, Campos J, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	4	1547	1554	20124004	10.1128/aac.01252-09	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.	De Luca F, Giraud-Morin C, Rossolini GM, Docquier JD, Fosse T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	5	2231	2234	20308380	10.1128/aac.00791-09	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.	Guillon H, Eb F, Mammeri H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	5	2271	2272	20211886	10.1128/aac.01442-09	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.	Manageiro V, Ferreira E, Albuquerque L, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	6	2420	2424	20308383	10.1128/aac.01456-09	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.	Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	6	2525	2533	20308375	10.1128/aac.01682-09	Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate.	Bucki R, Leszczynska K, Byfield FJ, Fein DE, Won E, Cruz K, Namiot A, Kulakowska A, Namiot Z, Savage PB, Diamond SL, Janmey PA.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	6	2716	2719	20308374	10.1128/aac.01797-09	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.	Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	8	3107	3112	20516281	10.1128/aac.00128-10	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.	Chen TL, Chang WC, Kuo SC, Lee YT, Chen CP, Siu LK, Cho WL, Fung CP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	9	3545	3550	20566768	10.1128/aac.00111-10	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.	Harada S, Ishii Y, Saga T, Tateda K, Yamaguchi K.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2010	54	9	4000	4002	20547799	10.1128/aac.01754-09	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.	Bent ZW, Young GM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2011	20	5	587	594		10.1007/s00044-010-9354-x	Design, synthesis and in vitro antibacterial and antifungal activities of some novel spiro[azetidine-2,3-indole]-2,4(1H)-dione	Shah RJ, Modi NR, Patel MJ, Patel LJ, Chauhan BF, Patel MM
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2011	20	7	1033	1041		10.1007/s00044-010-9440-0	Synthesis and antimicrobial activity of new pyridine derivatives-I	Patel NB, Agravat SN, Shaikh FM
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2011	21	3	1060	1063	21185180	10.1016/j.bmcl.2010.11.102	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.	Shi W, Ma H, Duan Y, Aubart K, Fang Y, Zonis R, Yang L, Hu W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	2	704	711	21211872	10.1016/j.ejmech.2010.12.005	Synthesis of elastin based peptides conjugated to benzisoxazole as a new class of potent antimicrobials--A novel approach to enhance biocompatibility.	Suhas R, Chandrashekar S, Gowda DC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	5	1874	1881	21414694	10.1016/j.ejmech.2011.02.051	Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.	Al-Tel TH, Al-Qawasmeh RA, Zaarour R.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	6	2132	2140	21440339	10.1016/j.ejmech.2011.02.066	Amberlite-IRA-402 (OH) ion exchange resin mediated synthesis of indolizines, pyrrolo [1,2-a] quinolines and isoquinolines: antibacterial and antifungal evaluation of the products.	Hazra A, Mondal S, Maity A, Naskar S, Saha P, Paira R, Sahu KB, Paira P, Ghosh S, Sinha C, Samanta A, Banerjee S, Mondal NB.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	7	3022	3029	21549457	10.1016/j.ejmech.2011.04.034	New condensed pyrroles of potential biological interest syntheses and structure-activity relationship studies.	Mohamed MS, Kamel R, Fatahala SS.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2011	46	7	3158	3166	21530014	10.1016/j.ejmech.2011.04.013	3-(1,3,4-Thiadiazole-2-yl)quinoline derivatives: synthesis, characterization and anti-microbial activity.	Bhat AR, Tazeem, Azam A, Choi I, Athar F.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Antimicrob. Agents Chemother.	2011	55	2	910	912	21098238	10.1128/aac.01230-10	The in vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalis.	Dubée V, Chau F, Arthur M, Garry L, Benadda S, Mesnage S, Lefort A, Fantin B.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2012	21	10	3233	3239		10.1007/s00044-011-9857-0	Synthesis and biological evaluation of chalcones and acetyl pyrazoline derivatives comprising furan nucleus as an antitubercular agents	Bhoot D, Khunt RC, Parekh HH
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2012	21	11	3897	3901		10.1007/s00044-011-9933-5	11-Chloro-3-methyl-3H-imidazo[4,5-a]acridine (CMIA) as a potent and selective antimicrobial agent against clinical isolates of highly antibiotic-resistant Acinetobacter baumannii	Sadeghian A, Pordel M, Safdari H, Fahmidekar MA, Sadeghian H
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2012	21	7	1237	1244		10.1007/s00044-011-9634-0	Synthesis, characterization and antimicrobial evaluation of novel derivatives of isoniazid	Malhotra M, Sharma S, Deep A
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2012	21	9	2133	2140		10.1007/s00044-011-9733-y	Synthesis and biological evaluation of naphthalene, furan and pyrrole based chalcones as cytotoxic and antimicrobial agents	Budhiraja A, Kadian K, Kaur M, Aggarwal V, Garg A, Sapra S, Nepali K, Suri OP, Dhar KL
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2012	21	9	2340	2348		10.1007/s00044-011-9755-5	Antioxidant and antimicrobial studies of novel N-(substituted-2-chloroquinolin-3-yl)methylidene-4-hydroxy-2H-1,2-benzothiazine-3-carbohydrazides 1,1-dioxides	Ahmad M, Rizvi SUF, Siddiqui HL, Ahmad S, Parvez M, Suliman R
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2012	22	19	6166	6172	22932314	10.1016/j.bmcl.2012.08.021	Novel pleuromutilin derivatives as antibacterial agents: synthesis, biological evaluation and molecular docking studies.	Wang X, Ling Y, Wang H, Yu J, Tang J, Zheng H, Zhao X, Wang D, Chen G, Qiu W, Tao J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2012	22	20	6343	6346	22999415	10.1016/j.bmcl.2012.08.084	Synthesis of ß-ionone derived chalcones as potent antimicrobial agents.	Sharma V, Singh G, Kaur H, Saxena AK, Ishar MP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2012	22	24	7730	7734	23102890	10.1016/j.bmcl.2012.09.083	Microwave-assisted synthesis and in vitro antibacterial activity of novel steroidal thiosemicarbazone derivatives.	Zhao Z, Shi Z, Liu M, Liu X.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2012	48		179	191	22209564	10.1016/j.ejmech.2011.12.012	Synthesis of uriedo and thiouriedo derivatives of peptide conjugated heterocycles - A new class of promising antimicrobials.	Suhas R, Chandrashekar S, Gowda DC.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2012	48		244	254	22217866	10.1016/j.ejmech.2011.12.021	Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.	Chang CS, Liu JF, Lin HJ, Lin CD, Tang CH, Lu DY, Sing YT, Chen LY, Kao MC, Kuo SC, Lai CH.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	1	323	329		10.1007/s00044-012-0032-z	Bioactive metabolites from an endophytic fungus of Aspergillus species isolated from seeds of Gloriosa superba Linn.	Budhiraja A, Nepali K, Sapra S, Gupta S, Kumar S, Dhar KL
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	1	94	104		10.1007/s00044-012-0011-4	Synthesis and in vitro study of antibacterial, antifungal activities of some novel bisquinolines	Sahu KB, Ghosh S, Banerjee M, Maity A, Mondal S, Paira R, Saha P, Naskar S, Hazra A, Banerjee S, Samanta A, Mondal NB
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	2	580	587		10.1007/s00044-012-0039-5	Spectroscopic characterization of novel d-amino acid-Schiff bases and their Cr(III) and Ni(II) complexes as antimicrobial agents	Sar N, Piskin N, Ogutcu H, Kurnaz N
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	3	1090	1101		10.1007/s00044-012-0084-0	Synthesis of novel 2-alkyl-4-substituted-amino-pyrazolo[3,4-d]pyrimidines as new leads for anti-bacterial and anti-cancer activity	Devarakonda M, Doonaboina R, Vanga S, Vemu J, Boni S, Mailavaram RP
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	4	1998	2004		10.1007/s00044-012-0155-2	Synthesis of steroidal thiazolidinones as antibacterial agents based on the in vitro and quantum chemistry calculation	Khan SA, Asiri AM, Sharma K
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	4	2023	2037		10.1007/s00044-012-0202-z	I2 catalyzed FriedelCrafts alkylation reaction of substituted anilines with ninhydrin: formation of novel products and their antimicrobial evaluation	Sahu KB, Banerjee M, Ghosh S, Maity A, Mondal S, Paira R, Hazra A, Karmakar S, Samanta A, Mondal NB
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Med Chem Res	2013	22	6	2755	2767		10.1007/s00044-012-0270-0	Design, characterization, computational studies, and pharmacological evaluation of substituted-N-[(1E) substituted-phenylmethylidene]benzohydrazide analogs	Bala S, Uppal G, Kamboj S, Saini V, Prasad DN
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Metab. Dispos.	2013	41	1	60	71	23033255	10.1124/dmd.112.048264	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.	Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Med. Chem.	2013	56	5	1974	1983	23409972	10.1021/jm301650g	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.	Odagiri T, Inagaki H, Sugimoto Y, Nagamochi M, Miyauchi RN, Kuroyanagi J, Kitamura T, Komoriya S, Takahashi H.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2013	60		451	455	23321259	10.1016/j.ejmech.2012.12.034	Synthesis and evaluation of antibacterial activity of 7-alkyloxy-4,5-dihydro-imidazo[1,2-a]quinoline derivatives.	Sun XY, Wu R, Wen X, Guo L, Zhou CP, Li J, Quan ZS, Bao J.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2014	24	11	2412	2414	24775303	10.1016/j.bmcl.2014.04.041	Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.	Tseng YY, Liou JM, Hsu TL, Cheng WC, Wu MS, Wong CH.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2014	24	11	2535	2538	24751446	10.1016/j.bmcl.2014.03.097	Cell permeable vanX inhibitors as vancomycin re-sensitizing agents.	Muthyala R, Rastogi N, Shin WS, Peterson ML, Sham YY.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2014	78		72	85	24681067	10.1016/j.ejmech.2014.03.037	Synthesis and biological evaluation of N-dehydrodipeptidyl-N,N'-dicyclohexylurea analogs.	Haseena banu B, Prasad KV, Bharathi K.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2014	86		133	152	25151577	10.1016/j.ejmech.2014.07.106	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.	Yang S, Shi W, Xing D, Zhao Z, Lv F, Yang L, Yang Y, Hu W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2014	86		335	351	25173852	10.1016/j.ejmech.2014.08.066	SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.	Poce G, Cocozza M, Consalvi S, Biava M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2015	23	15	4860	4865	26048027	10.1016/j.bmc.2015.05.026	Synthesis, molecular docking and biological evaluation of 3-arylfuran-2(5H)-ones as anti-gastric ulcer agent.	Wang XD, Wei W, Wang PF, Yi LC, Shi WK, Xie YX, Wu LZ, Tang N, Zhu LS, Peng J, Liu C, Li XH, Tang S, Xiao ZP, Zhu HL.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2015	23	19	6355	6363	26344592	10.1016/j.bmc.2015.08.031	Deprotometalation-iodolysis and computed CH acidity of 1,2,3- and 1,2,4-triazoles. Application to the synthesis of resveratrol analogues.	Nagaradja E, Bentabed-Ababsa G, Scalabrini M, Chevallier F, Philippot S, Fontanay S, Duval RE, Halauko YS, Ivashkevich OA, Matulis VE, Roisnel T, Mongin F.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2015	25	16	3125	3128	26099531	10.1016/j.bmcl.2015.06.010	Antibacterial activity of diketopiperazines isolated from a marine fungus using t-butoxycarbonyl group as a simple tool for purification.	El-Gendy Bel-D, Rateb ME.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2015	25	19	4314	4319	26277407	10.1016/j.bmcl.2015.07.071	Re-engineering nalidixic acid's chemical scaffold: A step towards the development of novel anti-tubercular and anti-bacterial leads for resistant pathogens.	Peraman R, Varma RV, Reddy YP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2015	78	11	2511	2520	26577190	10.1021/acs.jnatprod.5b00008	Synergistic Antifungal Meroterpenes and Dioxolanone Derivatives from the Endophytic Fungus Guignardia sp.	Li TX, Yang MH, Wang XB, Wang Y, Kong LY.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2015	78	4	597	603	25756503	10.1021/np5003252	Antibacterial Polyketide Heterodimers from Pyrenacantha kaurabassana Tubers.	Boudesocque-Delaye L, Agostinho D, Bodet C, Thery-Kone I, Allouchi H, Gueiffier A, Nuzillard JM, Enguehard-Gueiffier C.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J. Nat. Prod.	2015	78	6	1348	1356	26034885	10.1021/acs.jnatprod.5b00206	Antibacterial Labdane Diterpenoids from Vitex vestita.	Corlay N, Lecsö-Bornet M, Leborgne E, Blanchard F, Cachet X, Bignon J, Roussi F, Butel MJ, Awang K, Litaudon M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur. J. Med. Chem.	2015	95		514	525	25847769	10.1016/j.ejmech.2015.03.021	Novel imidazo[2,1-b]-1,3,4-thiadiazoles as promising antifungal agents against clinical isolate of Cryptococcus neoformans.	Alwan WS, Karpoormath R, Palkar MB, Patel HM, Rane RA, Shaikh MS, Kajee A, Mlisana KP.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem.	2016	24	6	1298	1307	26867485	10.1016/j.bmc.2016.01.059	Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.	Samala G, Devi PB, Saxena S, Meda N, Yogeeswari P, Sriram D.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2016	26	10	2498	2502	27040660	10.1016/j.bmcl.2016.03.098	Antibacterial activity of Mannich bases derived from 2-naphthols, aromatic aldehydes and secondary aliphatic amines.	Roman G, N¿stas¿ V, Bost¿naru AC, Mare¿ M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg. Med. Chem. Lett.	2016	26	2	512	517	26681508	10.1016/j.bmcl.2015.11.084	Naphtho[1',2':4,5]imidazo[1,2-a]pyridine-5,6-diones: Synthesis, enzymatic reduction and cytotoxic activity.	¿arlauskas J, Pe¿iukaityt¿-Alksn¿ M, Misevi¿ien¿ L, Marozien¿ A, Polmickait¿ E, Staniulyt¿ Z, ¿¿nas N, Anusevi¿ius ¿.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J Med Chem	2016	59	19	8830	8847	27575438	10.1021/acs.jmedchem.6b00580	The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases.	Boibessot T, Zschiedrich CP, Lebeau A, Bénimèlis D, Dunyach-Rémy C, Lavigne JP, Szurmant H, Benfodda Z, Meffre P.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Eur J Med Chem	2017	128		98	106	28157594	10.1016/j.ejmech.2017.01.038	Synthesis, surfactant properties and antimicrobial activities of methyl glycopyranoside ethers.	Belmessieri D, Gozlan C, Duclos MC, Molinier V, Aubry JM, Dumitrescu O, Lina G, Redl A, Duguet N, Lemaire M.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	Bioorg Med Chem	2017	25	15	3971	3979	28600080	10.1016/j.bmc.2017.05.037	Novel pyridyl nitrofuranyl isoxazolines show antibacterial activity against multiple drug resistant Staphylococcus species.	Picconi P, Prabaharan P, Auer JL, Sandiford S, Cascio F, Chowdhury M, Hind C, Wand ME, Sutton JM, Rahman KM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082	J Med Chem	2017	60	14	6045	6059	28650661	10.1021/acs.jmedchem.7b00108	Triaryl Benzimidazoles as a New Class of Antibacterial Agents against Resistant Pathogenic Microorganisms.	Picconi P, Hind C, Jamshidi S, Nahar K, Clifford M, Wand ME, Sutton JM, Rahman KM.
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									DrugMatrix	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									Unpublished dataset	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	AMOXICILLIN	CHEMBL1082									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1978	21	1	82	87	619151	10.1021/jm00199a015	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.	Harnden MR, Bailey S, Boyd MR, Taylor DR, Wright ND.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1982	25	4	457	469	7069725	10.1021/jm00346a024	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.	Hannah J, Johnson CR, Wagner AF, Walton E.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1983	26	5	753	757	6341590	10.1021/jm00359a600	Synthesis and biological activities of the Z isomers of carbapenem antibiotics.	Harada S, Tsubotani S, Asai M, Okonogi K, Kondo M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	1984	47	5	815	818	6512534	10.1021/np50035a010	Antibacterial constituents of the diatom Navicula delognei.	Findlay JA, Patil AD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1986	29	6	1023	1030	3086556	10.1021/jm00156a021	The lysine pathway as a target for a new genera of synthetic antibacterial antibiotics?	Girodeau JM, Agouridas C, Masson M, Pineau R, Le Goffic F.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1987	30	12	2309	2313	3681901	10.1021/jm00395a022	Design and synthesis of peptide derivatives of a 3-deoxy-D-manno-2-octulosonic acid (KDO) analogue as novel antibacterial agents acting upon lipopolysaccharide biosynthesis.	Claesson A, Jansson AM, Pring BG, Hammond SM, Ekström B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1987	30	8	1469	1474	3039137	10.1021/jm00391a032	Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.	Micetich RG, Maiti SN, Spevak P, Hall TW, Yamabe S, Ishida N, Tanaka M, Yamazaki T, Nakai A, Ogawa K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1989	32	6	1398	1401	2724308	10.1021/jm00126a041	Synthesis and antimicrobial properties of substituted beta-aminoxypropionyl penicillins and cephalosporins.	Balsamo A, Broccali G, Lapucci A, Macchia B, Macchia F, Orlandini E, Rossello A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	1993	3	11	2211	2218		10.1016/S0960-894X(01)80927-6	Synthesis and antibacterial activity of (1R,5R,6R)-2-tert-butyl-6-(1-hydroxyethyl)oxapenem-3-carboxylic acid	Pfaendler HR, Weisner F, Metzger K
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	1993	3	11	2255	2258		10.1016/S0960-894X(01)80935-5	Synthesis and -lactamase inhibitory activity of 6-hydroxyethyl thiaclavulanic acid.	Cabri W, Bedeschi A, Perrone E, Visentin G, Jabes D, Giovanni F
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	1993	3	11	2323	2328		10.1016/S0960-894X(01)80948-3	Probing the binding site of the penicillin side-chain based on the tipper-strominger hypothesis	Hanessian S, Couture CA, Georgopapadakou N
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	1994	4	2	345	348		10.1016/S0960-894X(01)80141-4	Substrate specificity of immobilized penicillin-G acylase towards penicillin and cephalosporin derivatives was studied. The phenylacetyl moiety can be altered at the -position with several small substituents. Depending on polarity and size of the substituent, enzyme activity decreases or increases. Insertion or deletion of atoms between the aromatic nucleus of the phenylacetyl group and the center of hydrolysis leads to substrates that are no longer recognized by the enzyme.	van der Mey M, de Vroom E
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1995	38	12	2152	2157	7783146	10.1021/jm00012a015	Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.	Tsubouchi H, Tsuji K, Yasumura K, Matsumoto M, Shitsuta T, Ishikawa H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Pharm. Res.	1996	13	1	1631	1634	8956326	10.1023/a:1016476220296	Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells.	Covitz KM, Amidon GL, Sadée W.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	1997	60	10	976	981	9358638	10.1021/np970207e	New steroidal alkaloids from Buxus longifolia.	Atta-ur-Rahman, Noor-e-ain F, Choudhary MI, Parveen Z, Türköz S, Sener B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	1998	41	21	4080	4100	9767644	10.1021/jm980240d	Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.	Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	1998	61	2	202	206	9548847	10.1021/np970294a	Antibacterial steroidal alkaloids from Sarcococca saligna.	Rahman A, Anjum S, Farooq A, Khan MR, Parveen Z, Choudhary MI.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Pharmacol. Exp. Ther.	1999	289	1	448	454	10087037		Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.	Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	1999	9	21	3075	3080	10560728	10.1016/s0960-894x(99)00534-x	Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.	Denis A, Agouridas C, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N, Pejac JM, Perron S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2000	63	11	1529	1530	11087599	10.1021/np000204t	Metabolites of Colletotrichum gloeosporioides, an endophytic fungus in Artemisia mongolica.	Zou WX, Meng JC, Lu H, Chen GX, Shi GX, Zhang TY, Tan RX.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2000	63	3	416	418	10757736	10.1021/np990381y	Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete Ganoderma pfeifferi.	Mothana RA, Jansen R, Jülich WD, Lindequist U.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2001	64	8	1093	1094	11520236	10.1021/np010025r	Verbalactone, a new macrocyclic dimer lactone from the roots of Verbascum undulatum with antibacterial activity.	Magiatis P, Spanakis D, Mitaku S, Tsitsa E, Mentis A, Harvala C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2002	12	17	2435	2437	12161151	10.1016/s0960-894x(02)00437-7	The activity of p-methoxybenzylisothiocyanate against Neisseria gonorrhoeae, Haemophilus ducreyi, and other microorganisms.	Swart H, Van Dyk S, Malan SF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2002	45	14	3032	3040	12086488	10.1021/jm010546b	Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.	Heinisch L, Wittmann S, Stoiber T, Berg A, Ankel-Fuchs D, Möllmann U.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2002	45	19	4359	4370	12213077	10.1021/jm020183v	Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.	Pirrung MC, Tumey LN, Raetz CR, Jackman JE, Snehalatha K, McClerren AL, Fierke CA, Gantt SL, Rusche KM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2002	65	4	566	569	11975502	10.1021/np010298m	Antimicrobial activities of a new schizozygane indoline alkaloid from Schizozygia coffaeoides and the revised structure of isoschizogaline.	Kariba RM, Houghton PJ, Yenesew A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2002	65	7	960	964	12141853	10.1021/np020064i	Isolation of S-n-butylcysteine sulfoxide and six n-butyl-containing thiosulfinates from Allium siculum.	Kubec R, Kim S, McKeon DM, Musah RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2003	13	16	2749	2754	12873507	10.1016/s0960-894x(03)00535-3	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.	Bruno-Blanch L, Gálvez J, García-Domenech R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Pesticide Sci	2003	28	2	183	187		10.1584/jpestics.28.183	Effect of Antibiotics on Formation of Aerial Mycelium and Production of Phytotoxins in Streptomyces spp.	NATSUME M, MATSUMOTO M, OHSHIRO A, KOZONE I, HASHIMOTO M, ABE H
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2003	66	12	1606	1610	14695805	10.1021/np030283j	New triterpene glycosides from the stems of Anomospermum grandifolium.	Plaza A, Cinco M, Tubaro A, Pizza C, Piacente S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2004	14	16	4185	4190	15261267	10.1016/j.bmcl.2004.06.014	Synthesis and QSAR studies of pyrimido[4,5-d]pyrimidine-2,5-dione derivatives as potential antimicrobial agents.	Sharma P, Rane N, Gurram VK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2004	14	23	5831	5833	15501050	10.1016/j.bmcl.2004.09.038	Screening of antimicrobial activity of diarylamines in the 2,3,5-trimethylbenzo[b]thiophene series: a structure-activity evaluation study.	Ferreira IC, Calhelha RC, Estevinho LM, Queiroz MJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2004	67	5	778	782	15165137	10.1021/np0304058	5-methylcoumaranones from Mutisia friesiana and their bioactivity.	Viturro CI, de la Fuente JR, Maier MS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2005	15	19	4295	4298	16040241	10.1016/j.bmcl.2005.06.041	Aqua mediated synthesis of substituted 2-amino-4H-chromenes and in vitro study as antibacterial agents.	Kidwai M, Saxena S, Khan MK, Thukral SS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2005	15	4	937	943	15686890	10.1016/j.bmcl.2004.12.050	Studies on synthesis and evaluation of quantitative structure-activity relationship of 5-[(3'-chloro-4',4'-disubstituted-2-oxoazetidinyl)(N-nitro)amino]-6-hydroxy-3-alkyl/aryl[1,3]azaphospholo[1,5-a]pyridin-1-yl-phosphorus dichlorides.	Sharma P, Kumar A, Sharma S, Rane N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2005	48	5	1395	1400	15743183	10.1021/jm049652e	Beta-lactam screening by specific residues of the OmpF eyelet.	Vidal S, Bredin J, Pagès JM, Barbe J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2006	16	14	3824	3828	16650986	10.1016/j.bmcl.2006.04.020	Synthesis and antibacterial evaluation of ureides of Baylis-Hillman derivatives.	Nag S, Pathak R, Kumar M, Shukla PK, Batra S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2006	16	16	4205	4208	16781152	10.1016/j.bmcl.2006.05.081	Lactones from a brown alga endophytic fungus (No. ZZF36) from the South China Sea and their antimicrobial activities.	Yang RY, Li CY, Lin YC, Peng GT, She ZG, Zhou SN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2006	16	22	5883	5887	16949283	10.1016/j.bmcl.2006.08.060	Naphtho[2,3-b][1,4]-thiazine-5,10-diones and 3-substituted-1,4-dioxo-1,4-dihydronaphthalen-2-yl-thioalkanoate derivatives: synthesis and biological evaluation as potential antibacterial and antifungal agents.	Tandon VK, Maurya HK, Yadav DB, Tripathi A, Kumar M, Shukla PK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2006	16	9	2484	2491	16464586	10.1016/j.bmcl.2006.01.080	Studies on synthesis and evaluation of quantitative structure-activity relationship of 10-methyl-6-oxo-5-arylazo-6,7-dihydro-5H-[1,3]azaphospholo[1,5-d][1,4]benzodiazepin-2-phospha-3-ethoxycarbonyl-1-phosphorus dichlorides.	Kumar A, Sharma P, Gurram VK, Rane N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Nat. Chem. Biol.	2006	2	8	415	416	16816845	10.1038/nchembio806	A clinical drug library screen identifies astemizole as an antimalarial agent.	Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Proc. Natl. Acad. Sci. U.S.A.	2007	104	30	12282	12287	17630285	10.1073/pnas.0702760104	Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.	Lujan SA, Guogas LM, Ragonese H, Matson SW, Redinbo MR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	15	5105	5109	17544281	10.1016/j.bmc.2007.05.037	Synthesis, characterization and antimicrobial activity of new aliphatic sulfonamide.	Ozbek N, Katircio¿lu H, Karacan N, Baykal T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	16	5480	5486	17572093	10.1016/j.bmc.2007.05.048	Identification of antibacterial and antiviral activities of novel fused 1,2,4-triazine esters.	Sztanke K, Pasternak K, Rajtar B, Sztanke M, Majek M, Polz-Dacewicz M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	17	5738	5751	17587585	10.1016/j.bmc.2007.06.006	1-Acylthiosemicarbazides, 1,2,4-triazole-5(4H)-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: synthesis, analgesic-anti-inflammatory and antimicrobial activities.	Salgin-Gök¿en U, Gökhan-Kelekçi N, Gökta¿ O, Köysal Y, Kiliç E, I¿ik S, Aktay G, Ozalp M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	18	6012	6017	17618124	10.1016/j.bmc.2007.06.049	Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4-dione derivatives.	Bozda¿-Dündar O, Ozgen O, Mente¿e A, Altanlar N, Atli O, Kendi E, Ertan R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	18	6227	6235	17600721	10.1016/j.bmc.2007.06.023	Utility of 6-amino-2-thiouracil as a precursor for the synthesis of bioactive pyrimidine derivatives.	Mohamed NR, El-Saidi MM, Ali YM, Elnagdi MH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	6	2322	2333	17276071	10.1016/j.bmc.2007.01.029	Synthesis and structure-antibacterial activity relationship investigation of isomeric 2,3,5-substituted perhydropyrrolo[3,4-d]isoxazole-4,6-diones.	Agirbas H, Guner S, Budak F, Keceli S, Kandemirli F, Shvets N, Kovalishyn V, Dimoglo A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2007	15	8	2837	2849	17331732	10.1016/j.bmc.2007.02.024	Identification of antitumour activity of novel derivatives of 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione and 8-aryl-4-imino-2,3,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3(6H)-one.	Sztanke K, Pasternak K, Rzymowska J, Sztanke M, Kandefer-Szersze¿ M, Dyba¿a I, Kozio¿ AE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2007	16	4	170	178		10.1007/s00044-007-9021-z	Studies on the synthesis of some new substituted benzylamino and phenyl-acrylamido-methyl flavone derivatives	Ceylan-Unlusoy M, Bozdag-Dundar O, Altanlar N, Ertan R
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2007	16	5	205	212		10.1007/s00044-007-9024-9	Synthesis of 2,4-dihalogenofluorobenzenes and their antimicrobial and antifungal activity studies	Katrcoglu H, Logoglu E, Tilki T, Oktemer A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	1	239	242	17027268	10.1016/j.bmcl.2006.09.051	New antifungal flavonoid glycoside from Vitex negundo.	Sathiamoorthy B, Gupta P, Kumar M, Chaturvedi AK, Shukla PK, Maurya R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	15	4102	4106	17570664	10.1016/j.bmcl.2007.05.065	Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.	Lv J, Qian Y, Liu T, Wang Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	3	707	711	17150357	10.1016/j.bmcl.2006.10.094	Design, synthesis, and evaluation of efflux substrate-metal chelator conjugates as potential antimicrobial agents.	Zhang Y, Eric Ballard C, Zheng SL, Gao X, Ko KC, Yang H, Brandt G, Lou X, Tai PC, Lu CD, Wang B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	5	1355	1357	17258454	10.1016/j.bmcl.2006.11.079	Anti-mycobacterial activity of a bis-sulfonamide.	Wilkinson BL, Bornaghi LF, Wright AD, Houston TA, Poulsen SA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	6	1601	1607	17257839	10.1016/j.bmcl.2006.12.090	Synthesis of pseudopeptides based L-tryptophan as a potential antimicrobial agent.	Lv J, Yin L, Liu T, Wang Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2007	17	8	2233	2236	17289382	10.1016/j.bmcl.2007.01.061	Synthesis and antimicrobial activity of some novel phenyl and benzimidazole substituted benzyl ethers.	Güven OO, Erdo¿an T, Göker H, Yildiz S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Biol. Chem.	2007	282	42	30414	30422	17646161	10.1074/jbc.m704286200	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.	Mainardi JL, Hugonnet JE, Rusconi F, Fourgeaud M, Dubost L, Moumi AN, Delfosse V, Mayer C, Gutmann L, Rice LB, Arthur M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Biol. Chem.	2007	282	7	4437	4446	17170117	10.1074/jbc.m607667200	Fatty acyl benzamido antibacterials based on inhibition of DnaK-catalyzed protein folding.	Liebscher M, Jahreis G, Lücke C, Grabley S, Raina S, Schiene-Fischer C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	10	1293	1299	17337097	10.1016/j.ejmech.2007.01.022	Synthesis and in vitro antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles.	Tekiner-Gulbas B, Temiz-Arpaci O, Yildiz I, Altanlar N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	2	205	213	17189664	10.1016/j.ejmech.2006.09.023	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.	Aghatabay NM, Neshat A, Karabiyik T, Somer M, Haciu D, Dülger B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	2	235	242	17129641	10.1016/j.ejmech.2006.10.003	Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles.	Kadi AA, El-Brollosy NR, Al-Deeb OA, Habib EE, Ibrahim TM, El-Emam AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	4	517	520	17084947	10.1016/j.ejmech.2006.09.012	Synthesis, in vitro antibacterial and antifungal evaluations of 2-amino-4-(1-naphthyl)-6-arylpyrimidines.	Ingarsal N, Saravanan G, Amutha P, Nagarajan S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	7	948	954	17316908	10.1016/j.ejmech.2006.12.025	Synthesis and antimicrobial evaluation of some new thiazole, thiazolidinone and thiazoline derivatives starting from 1-chloro-3,4-dihydronaphthalene-2-carboxaldehyde.	Bondock S, Khalifa W, Fadda AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2007	42	8	1069	1075	17350734	10.1016/j.ejmech.2007.01.011	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.	Aghatabay NM, Somer M, Senel M, Dulger B, Gucin F.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Nature	2007	447	7140	87	91	17450125	10.1038/nature05756	PTC124 targets genetic disorders caused by nonsense mutations.	Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2007	50	11	2612	2621	17489580	10.1021/jm061349l	Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.	Velu SE, Mou L, Luan CH, Yang ZW, DeLucas LJ, Brouillette CG, Brouillette WJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2007	50	23	5644	5654	17956081	10.1021/jm070643q	Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.	Venturelli A, Tondi D, Cancian L, Morandi F, Cannazza G, Segatore B, Prati F, Amicosante G, Shoichet BK, Costi MP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	1	169	174	17060530	10.1128/aac.00261-06	Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.	Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	10	3720	3725	17646418	10.1128/aac.00318-07	Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.	Muller AE, DeJongh J, Bult Y, Goessens WH, Mouton JW, Danhof M, van den Anker JN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	11	4105	4110	17724159	10.1128/aac.00616-07	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.	Xu X, Wu S, Ye X, Liu Y, Shi W, Zhang Y, Wang M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	12	4374	4381	17938183	10.1128/aac.00854-07	The PhoQ-activating potential of antimicrobial peptides contributes to antimicrobial efficacy and is predictive of the induction of bacterial resistance.	Kindrachuk J, Paur N, Reiman C, Scruten E, Napper S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	12	4512	4514	17875998	10.1128/aac.00491-07	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.	Fonseca F, Sarmento AC, Henriques I, Samyn B, van Beeumen J, Domingues P, Domingues MR, Saavedra MJ, Correia A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	12	4529	4530	17876007	10.1128/aac.01115-07	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.	Hawley JS, Murray CK, Jorgensen JH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	2	453	460	17116681	10.1128/aac.00960-06	Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.	Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	2	535	542	17043131	10.1128/aac.00600-06	Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.	Chen S, Cui S, McDermott PF, Zhao S, White DG, Paulsen I, Meng J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	3	1082	1084	17178800	10.1128/aac.00909-06	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.	Mazzariol A, Roelofsen E, Koncan R, Voss A, Cornaglia G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	3	923	929	17210767	10.1128/aac.01048-06	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.	Elkins CA, Mullis LB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	4	1223	1227	17242140	10.1128/aac.01195-06	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.	Wu JJ, Ko WC, Tsai SH, Yan JJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	4	1293	1303	17220404	10.1128/aac.01128-06	Increased genome instability in Escherichia coli lon mutants: relation to emergence of multiple-antibiotic-resistant (Mar) mutants caused by insertion sequence elements and large tandem genomic amplifications.	Nicoloff H, Perreten V, Levy SB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	4	1527	1529	17220425	10.1128/aac.00780-06	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.	Castanheira M, Pereira AS, Nicoletti AG, Pignatari AC, Barth AL, Gales AC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	5	1589	1595	17325223	10.1128/aac.01545-06	Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.	Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, Hoshiko S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	2043	2047	17438057	10.1128/aac.00131-07	Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.	Arias CA, Singh KV, Panesso D, Murray BE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	2092	2099	17420206	10.1128/aac.00052-07	PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli.	Li Y, Zhang Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	2179	2184	17420213	10.1128/aac.01600-06	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.	Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	6	2185	2188	17353248	10.1128/aac.01439-06	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.	Papagiannitsis CC, Loli A, Tzouvelekis LS, Tzelepi E, Arlet G, Miriagou V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	7	2359	2365	17438050	10.1128/aac.01395-06	Biochemical characterization of PER-2 and genetic environment of blaPER-2.	Power P, Di Conza J, Rodríguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	7	2366	2372	17452479	10.1128/aac.00044-07	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.	Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M, Stefanou I, Avlami A, Katsilambros N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	7	2464	2469	17470656	10.1128/aac.00143-07	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.	Périchon B, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	7	2564	2573	17470649	10.1128/aac.00354-07	Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.	García-Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García-Rey C, Pérez-Vázquez M, Oteo J, de Abajo F.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	7	2611	2614	17470660	10.1128/aac.00838-06	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.	Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	8	2937	2942	17502412	10.1128/aac.00011-07	Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.	Suvorov M, Vakulenko SB, Mobashery S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	8	2988	2990	17470648	10.1128/aac.00083-07	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.	Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	8	3017	3019	17517851	10.1128/aac.00279-07	Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene.	Bae IK, Lee YN, Lee WG, Lee SH, Jeong SH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3155	3161	17620383	10.1128/aac.00335-07	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.	Cerquetti M, Giufrè M, Cardines R, Mastrantonio P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3354	3360	17548499	10.1128/aac.00339-07	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.	Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T, Arakawa Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3420	3424	17606689	10.1128/aac.00100-07	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.	Jansen WT, Verel A, Verhoef J, Milatovic D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3431	3433	17576842	10.1128/aac.01433-06	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.	Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2007	51	9	3463	3464	17606681	10.1128/aac.00190-07	Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?	Billal DS, Hotomi M, Yamanaka N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2007	70	1	118	120	17253862	10.1021/np060444u	Antimicrobial arylcoumarins from Asphodelus microcarpus.	El-Seedi HR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2008	16	23	9898	9903	18990580	10.1016/j.bmc.2008.10.033	Hetero-Diels-Alder reaction of 1,3-bis(trimethylsilyloxy)-1,3-butadienes with arylsulfonylcyanides. Synthesis and antimicrobial activity of 4-hydroxy-2-(arylsulfonyl)pyridines.	Hussain I, Yawer MA, Lalk M, Lindequist U, Villinger A, Fischer C, Langer P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2008	16	24	10319	10325	18977661	10.1016/j.bmc.2008.10.043	Synthesis and antimicrobial activity of 2-alkenylchroman-4-ones, 2-alkenylthiochroman-4-ones and 2-alkenylquinol-4-ones.	Hoettecke N, Rotzoll S, Albrecht U, Lalk M, Fischer C, Langer P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2008	16	7	3714	3724	18299196	10.1016/j.bmc.2008.02.001	2-Heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: synthesis and structure-activity relationship.	Vicini P, Geronikaki A, Incerti M, Zani F, Dearden J, Hewitt M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2008	16	7	4120	4126	18276144	10.1016/j.bmc.2008.01.018	Bioactive alkenylphenols from Piper obliquum.	Valdivia C, Marquez N, Eriksson J, Vilaseca A, Muñoz E, Sterner O.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2008	17	8	495	506		10.1007/s00044-008-9093-4	Simple and efficient synthetic routes to bioactive s-triazinyl dithiocarbamate derivatives	Desai RM, Dodiya DK, Trivedi AR, Shah VH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	1	104	108	18053715	10.1016/j.bmcl.2007.11.003	Antimicrobial activities of the bromophenols from the red alga Odonthalia corymbifera and some synthetic derivatives.	Oh KB, Lee JH, Chung SC, Shin J, Shin HJ, Kim HK, Lee HS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	16	4678	4681	18650090	10.1016/j.bmcl.2008.07.007	Substituted 3-((Z)-2-(4-nitrophenyl)-2-(1H-tetrazol-5-yl) vinyl)-4H-chromen-4-ones as novel anti-MRSA agents: synthesis, SAR, and in-vitro assessment.	Diwakar SD, Bhagwat SS, Shingare MS, Gill CH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	19	5222	5227	18783947	10.1016/j.bmcl.2008.08.071	Design and synthesis of 3-pyrazolyl-thiophene, thieno[2,3-d]pyrimidines as new bioactive and pharmacological activities.	Hafez HN, El-Gazzar AB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	20	5377	5380	18824352	10.1016/j.bmcl.2008.09.059	Inhibition of Candida albicans isocitrate lyase activity by sesterterpene sulfates from the tropical sponge Dysidea sp.	Lee D, Shin J, Yoon KM, Kim TI, Lee SH, Lee HS, Oh KB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	4	1308	1311	18226902	10.1016/j.bmcl.2008.01.031	Synthesis and biological evaluation of novel 1,3,5-triazine derivatives as antimicrobial agents.	Zhou C, Min J, Liu Z, Young A, Deshazer H, Gao T, Chang YT, Kallenbach NR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2008	18	6	2043	2047	18267360	10.1016/j.bmcl.2008.01.102	Synthesis and antimicrobial activity of beta-lactam-bile acid conjugates linked via triazole.	Vatmurge NS, Hazra BG, Pore VS, Shirazi F, Chavan PS, Deshpande MV.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2008	43	10	2122	2129	18255196	10.1016/j.ejmech.2007.12.009	Synthesis and antimicrobial activity of some new heterocycles incorporating antipyrine moiety.	Bondock S, Rabie R, Etman HA, Fadda AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2008	43	11	2316	2322	18313174	10.1016/j.ejmech.2008.01.010	Synthesis and biological evaluation of diversely substituted indolin-2-ones.	Bouchikhi F, Rossignol E, Sancelme M, Aboab B, Anizon F, Fabbro D, Prudhomme M, Moreau P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2008	43	2	404	419	17531354	10.1016/j.ejmech.2007.03.033	Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives.	Sztanke K, Tuzimski T, Rzymowska J, Pasternak K, Kandefer-Szersze¿ M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2008	43	3	456	463	17532544	10.1016/j.ejmech.2007.03.030	Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents.	Bekhit AA, Ashour HM, Abdel Ghany YS, Bekhit Ael-D, Baraka A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2008	43	7	1390	1402	18022733	10.1016/j.ejmech.2007.10.009	Synthesis, potent anti-staphylococcal activity and QSARs of some novel 2-anilinobenzazoles.	Ozden S, Atabey D, Yildiz S, Göker H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2008	51	7	1991	1994	18330977	10.1021/jm8000136	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.	Hirokawa Y, Kinoshita H, Tanaka T, Nakata K, Kitadai N, Fujimoto K, Kashimoto S, Kojima T, Kato S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	10	3589	3596	18644957	10.1128/aac.00465-08	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.	Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	10	3725	3736	18625772	10.1128/aac.00163-08	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.	Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	10	3792	3794	18663019	10.1128/aac.00387-08	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.	Dubois V, Poirel L, Demarthe F, Arpin C, Coulange L, Minarini LA, Bezian MC, Nordmann P, Quentin C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	11	3837	3843	18725452	10.1128/aac.00570-08	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.	Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	11	4115	4120	18725447	10.1128/aac.00366-08	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.	Zarrilli R, Vitale D, Di Popolo A, Bagattini M, Daoud Z, Khan AU, Afif C, Triassi M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	11	4194	4197	18765691	10.1128/aac.01337-07	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.	Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	11	4209	4210	18725443	10.1128/aac.00712-08	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.	Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, Tarragó D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	12	4492	4496	18838581	10.1128/aac.00696-08	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.	Snydman DR, Jacobus NV, McDermott LA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	2	427	434	18070962	10.1128/aac.00375-07	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.	Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	2	551	556	18070972	10.1128/aac.01145-07	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.	Meziane-Cherif D, Decré D, Høiby EA, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	2	753	756	18070955	10.1128/aac.00914-07	Combined real-time PCR and pyrosequencing strategy for objective, sensitive, specific, and high-throughput identification of reduced susceptibility to penicillins in Neisseria meningitidis.	Thulin S, Olcén P, Fredlund H, Unemo M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	2	794	795	18025117	10.1128/aac.01399-07	RmtC 16S rRNA methyltransferase in Australia.	Zong Z, Partridge SR, Iredell JR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	3	1198	1200	18086856	10.1128/aac.00682-07	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.	Hu RM, Huang KJ, Wu LT, Hsiao YJ, Yang TC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	3	915	919	18160520	10.1128/aac.01028-07	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.	Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	3	991	994	18180352	10.1128/aac.01094-07	Reduced Susceptibility of Proteus mirabilis to triclosan.	Stickler DJ, Jones GL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	4	1264	1268	18212108	10.1128/aac.00684-07	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.	Meziane-Cherif D, Lambert T, Dupêchez M, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	4	1297	1301	18212109	10.1128/aac.01060-07	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.	Stepanova MN, Pimkin M, Nikulin AA, Kozyreva VK, Agapova ED, Edelstein MV.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	4	1525	1528	18212097	10.1128/aac.01485-07	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.	Okazaki A, Avison MB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	5	1613	1617	18299404	10.1128/aac.00978-07	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.	Poirel L, Mansour W, Bouallegue O, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	5	1653	1662	18316525	10.1128/aac.01383-07	In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.	Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	5	1846	1849	18299417	10.1128/aac.01176-07	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.	Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	5	1880	1883	18347113	10.1128/aac.00936-07	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.	Takahata S, Kato Y, Sanbongi Y, Maebashi K, Ida T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	6	2014	2018	18332176	10.1128/aac.01539-07	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.	Cai JC, Zhou HW, Zhang R, Chen GX.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	6	2061	2068	18362191	10.1128/aac.01150-07	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.	Higashide M, Kuroda M, Omura CT, Kumano M, Ohkawa S, Ichimura S, Ohta T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	6	2250	2252	18362187	10.1128/aac.01025-07	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.	Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2340	2345	18443128	10.1128/aac.00018-08	Fitness trade-offs in blaTEM evolution.	Mroczkowska JE, Barlow M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2383	2388	18443115	10.1128/aac.01641-07	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.	Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2407	2414	18443129	10.1128/aac.00214-08	Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.	García-Cobos S, Campos J, Román F, Carrera C, Pérez-Vázquez M, Aracil B, Oteo J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2473	2479	18443127	10.1128/aac.01062-07	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.	Stoczko M, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2503	2511	18458127	10.1128/aac.00298-08	Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.	Danilchanka O, Mailaender C, Niederweis M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	7	2647	2652	18443122	10.1128/aac.01398-07	In vitro activity of telavancin against resistant gram-positive bacteria.	Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2718	2726	18519731	10.1128/aac.00144-08	Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli.	Hansen S, Lewis K, Vuli¿ M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2734	2741	18519732	10.1128/aac.00205-08	Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2.	Pränting M, Negrea A, Rhen M, Andersson DI.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2750	2754	18411316	10.1128/aac.00044-08	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.	Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2806	2812	18519725	10.1128/aac.00247-08	Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.	Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2890	2897	18490507	10.1128/aac.00185-08	First molecular characterization of group B streptococci with reduced penicillin susceptibility.	Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2905	2908	18559652	10.1128/aac.00166-08	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.	Samuelsen Ø, Castanheira M, Walsh TR, Spencer J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2915	2918	18541727	10.1128/aac.00461-08	Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics.	Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Schrag S, Nizet V, Beall BW.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2940	2942	18519722	10.1128/aac.01581-07	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.	Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	8	2955	2958	18505859	10.1128/aac.00072-08	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.	Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P, Alba V, Fernández-Cuenca F, Pascual A, Vila J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2008	52	9	3398	3407	18625769	10.1128/aac.00149-08	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.	Ge Y, Biek D, Talbot GH, Sahm DF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2008	71	11	1866	1871	18973387	10.1021/np8003694	Scalarane sesterterpenes from the sponge Smenospongia sp.	Song J, Jeong W, Wang N, Lee HS, Sim CJ, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2008	71	4	551	557	18341287	10.1021/np0780147	Sesterterpenoids from the sponge Sarcotragus sp.	Wang N, Song J, Jang KH, Lee HS, Li X, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2008	71	8	1481	1484	18681480	10.1021/np800305b	Bioactive 5alpha-pregnane-type steroidal alkaloids from Sarcococca hookeriana.	Devkota KP, Lenta BN, Wansi JD, Choudhary MI, Kisangau DP, Naz Q, Samreen, Sewald N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2009	17	13	4323	4326	19481948	10.1016/j.bmc.2009.05.023	Synthesis and antimicrobial activity of 4-hydroxy-4-(pyridyl)alk-3-en-2-ones.	Riahi A, Wurster M, Lalk M, Lindequist U, Langer P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2009	17	4	1693	1700	19150600	10.1016/j.bmc.2008.12.050	Synthesis and antimicrobial evaluation of some new substituted purine derivatives.	Tunçbilek M, Ate¿-Alagöz Z, Altanlar N, Karayel A, Ozbey S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2009	17	8	3028	3036	19324556	10.1016/j.bmc.2009.03.011	Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococcus aureus.	Jorge SD, Masunari A, Rangel-Yagui CO, Pasqualoto KF, Tavares LC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2009	18	5	383	395		10.1007/s00044-008-9135-y	Synthesis of bioactive spiro-2-[3-(2-phenyl)-3H-indolyl]-1-aryl-3-phenylaziridines and SAR studies on their antimicrobial behavior	Sharma P, Kumar A, Sahu V, Upadhyay S, Singh J
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2009	19	3	945	948	19097894	10.1016/j.bmcl.2008.11.089	Synthesis and antimicrobial activities of halogenated bis(hydroxyphenyl)methanes.	Oh KB, Lee JH, Lee JW, Yoon KM, Chung SC, Jeon HB, Shin J, Lee HS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	1	365	372	18417256	10.1016/j.ejmech.2008.02.038	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.	Aghatabay NM, Mahmiani Y, Cevik H, Dulger B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	10	4028	4033	19482384	10.1016/j.ejmech.2009.04.037	Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives.	Ansari KF, Lal C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	10	4148	4152	19540629	10.1016/j.ejmech.2009.05.005	Synthesis, characterization and in vitro antimicrobial activity of novel 2-thioxo-4-thiazolidinones and 4,4'-bis(2-thioxo-4-thiazolidinone-3-yl)diphenylsulfones.	El-Gaby MS, El-Hag Ali GA, El-Maghraby AA, Abd El-Rahman MT, Helal MH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4362	4366	19647352	10.1016/j.ejmech.2009.05.022	Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.	Bayrak H, Demirbas A, Demirbas N, Karaoglu SA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4434	4440	19581025	10.1016/j.ejmech.2009.06.002	Synthesis and antibacterial activity of some new thiazole and thiophene derivatives.	Khalil AM, Berghot MA, Gouda MA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4448	4454	19570595	10.1016/j.ejmech.2009.06.003	Synthesis and antibacterial activity of some new heterocycles incorporating phthalazine.	Khalil AM, Berghot MA, Gouda MA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4522	4527	19640616	10.1016/j.ejmech.2009.06.020	Synthesis, characterization and antibacterial activity of 2-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-5-(substituted-phenyl)-[1,3,4]oxadiazoles.	Rai NP, Narayanaswamy VK, Shashikanth S, Arunachalam PN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4681	4689	19700225	10.1016/j.ejmech.2009.07.003	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.	Aghatabay NM, Ba¿ A, Kircali A, Sen G, Yazicio¿lu MB, Gücin F, Dülger B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	11	4752	4757	19616347	10.1016/j.ejmech.2009.06.021	Synthesis, characterization and evaluation of antibacterial activity of some thiazolo[3,2-b][1,2,4]triazole incorporating diphenylsulfone moieties.	Barbuceanu SF, Almajan GL, Saramet I, Draghici C, Tarcomnicu AI, Bancescu G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	3	1024	1033	18718694	10.1016/j.ejmech.2008.06.026	Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA.	Tunçbilek M, Kiper T, Altanlar N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	3	1057	1066	18676062	10.1016/j.ejmech.2008.06.019	Synthesis of some new 1,2,4-triazoles, their Mannich and Schiff bases and evaluation of their antimicrobial activities.	Bayrak H, Demirbas A, Karaoglu SA, Demirbas N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	4	1537	1544	18760509	10.1016/j.ejmech.2008.07.017	Synthesis, characterization and antimicrobial activity of Co(II), Zn(II) and Cd(II) complexes with N-benzyloxycarbonyl-S-phenylalanine.	Miti¿ D, Milenkovi¿ M, Milosavljevi¿ S, Godevac D, Miodragovi¿ Z, Andelkovi¿ K, Miodragovi¿ D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	5	2038	2043	19027993	10.1016/j.ejmech.2008.10.006	Synthesis, antimicrobial and cytotoxic activities of some 5-arylidene-4-thioxo-thiazolidine-2-ones.	Gouveia FL, de Oliveira RM, de Oliveira TB, da Silva IM, do Nascimento SC, de Sena KX, de Albuquerque JF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	5	2294	2299	18316140	10.1016/j.ejmech.2008.01.022	Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents.	Ansari KF, Lal C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	6	2621	2625	18996622	10.1016/j.ejmech.2008.09.035	Physicochemical and biological characterization of novel macrocycles derived from o-phthalaldehyde.	Reddy PM, Ho YP, Shanker K, Rohini R, Ravinder V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	7	2828	2833	19168262	10.1016/j.ejmech.2008.12.019	Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-b][1,3,4]thiadiazole derivatives.	Lamani RS, Shetty NS, Kamble RR, Khazi IA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	7	2896	2903	19167136	10.1016/j.ejmech.2008.12.005	Synthesis of some new 1,3,4-thiadiazol-2-ylmethyl-1,2,4-triazole derivatives and investigation of their antimicrobial activities.	Demirbas A, Sahin D, Demirbas N, Karaoglu SA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	8	3330	3339	19371978	10.1016/j.ejmech.2009.03.022	Mono and bis-6-arylbenzimidazo[1,2-c]quinazolines: a new class of antimicrobial agents.	Rohini R, Shanker K, Reddy PM, Ho YP, Ravinder V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2009	44	9	3805	3809	19419801	10.1016/j.ejmech.2009.04.017	A facile one-pot green synthesis and antibacterial activity of 2-amino-4H-pyrans and 2-amino-5-oxo-5,6,7,8-tetrahydro-4H-chromenes.	Kumar D, Reddy VB, Sharad S, Dube U, Kapur S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2009	52	19	5926	5936	19746934	10.1021/jm900625q	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.	Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2009	52	21	6539	6542	19888756	10.1021/jm9012592	Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.	Deng L, Sundriyal S, Rubio V, Shi ZZ, Song Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	1	104	111	18936188	10.1128/aac.00852-08	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.	Ma L, Lin CJ, Chen JH, Fung CP, Chang FY, Lai YK, Lin JC, Siu LK, Taiwan Surveillance of Antimicrobial Resistance Project.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	1	267	270	18955529	10.1128/aac.00402-08	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.	Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	1	281	286	18955526	10.1128/aac.00441-08	Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.	Finegold SM, Molitoris D, Väisänen ML.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4225	4230	19651910	10.1128/aac.00192-09	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.	Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K, Kaku M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4240	4246	19667280	10.1128/aac.00242-09	Cotransfer of antibiotic resistance genes and a hylEfm-containing virulence plasmid in Enterococcus faecium.	Arias CA, Panesso D, Singh KV, Rice LB, Murray BE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4258	4263	19596873	10.1128/aac.00546-09	AI-2/LuxS is involved in increased biofilm formation by Streptococcus intermedius in the presence of antibiotics.	Ahmed NA, Petersen FC, Scheie AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4320	4326	19651915	10.1128/aac.01607-08	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.	Zeba B, De Luca F, Dubus A, Delmarcelle M, Simporé J, Nacoulma OG, Rossolini GM, Frère JM, Docquier JD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4529	4532	19651906	10.1128/aac.00624-09	In vitro activities of panduratin A against clinical Staphylococcus strains.	Rukayadi Y, Lee K, Han S, Yong D, Hwang JK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	11	4628	4639	19721076	10.1128/aac.00454-09	Induction of multidrug resistance mechanism in Escherichia coli biofilms by interplay between tetracycline and ampicillin resistance genes.	May T, Ito A, Okabe S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	11	4944	4948	19721064	10.1128/aac.00787-09	Combined inactivation of lon and ycgE decreases multidrug susceptibility by reducing the amount of OmpF porin in Escherichia coli.	Duval V, Nicoloff H, Levy SB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	12	5035	5038	19770279	10.1128/aac.00856-09	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.	Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	12	5046	5054	19770275	10.1128/aac.00774-09	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.	Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	12	5155	5162	19805572	10.1128/aac.00532-09	Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.	Denève C, Bouttier S, Dupuy B, Barbut F, Collignon A, Janoir C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	12	5230	5235	19752278	10.1128/aac.00631-09	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.	Maseda H, Hashida Y, Konaka R, Shirai A, Kourai H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	519	524	18936192	10.1128/aac.00886-08	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.	Ma J, Zeng Z, Chen Z, Xu X, Wang X, Deng Y, Lü D, Huang L, Zhang Y, Liu J, Wang M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	525	530	19015356	10.1128/aac.00917-08	Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo.	Mellbye BL, Puckett SE, Tilley LD, Iversen PL, Geller BL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	696	702	19064898	10.1128/aac.00652-07	Prevalence of sulfonamide resistance genes in bacterial isolates from manured agricultural soils and pig slurry in the United Kingdom.	Byrne-Bailey KG, Gaze WH, Kay P, Boxall AB, Hawkey PM, Wellington EM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	735	747	19029325	10.1128/aac.00754-08	Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac).	Zheng B, Tomita H, Inoue T, Ike Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	776	778	19015335	10.1128/aac.01128-08	Identification of a novel trimethoprim resistance gene, dfrK, in a methicillin-resistant Staphylococcus aureus ST398 strain and its physical linkage to the tetracycline resistance gene tet(L).	Kadlec K, Schwarz S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	2	845	846	19029319	10.1128/aac.01312-08	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.	Welch TJ, Evenhuis J, White DG, McDermott PF, Harbottle H, Miller RA, Griffin M, Wise D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1080	1087	19104017	10.1128/aac.01005-08	Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.	O'Regan E, Quinn T, Pagès JM, McCusker M, Piddock L, Fanning S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1177	1184	19029333	10.1128/aac.00485-08	Genetic variability among ampC genes from acinetobacter genomic species 3.	Beceiro A, Pérez A, Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Vila J, Rodríguez-Baño J, Cisneros JM, Pachón J, Bou G, Spanish Group for Nosocomial Infection (GEIH).
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1204	1209	19064900	10.1128/aac.00471-08	Effect of DNase and antibiotics on biofilm characteristics.	Tetz GV, Artemenko NK, Tetz VV.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1221	1224	19114678	10.1128/aac.01260-08	Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.	Fritsche TR, Biedenbach DJ, Jones RN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1256	1259	19104021	10.1128/aac.01284-08	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.	Zioga A, Whichard JM, Kotsakis SD, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	1260	1263	19124664	10.1128/aac.01453-08	Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.	Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	876	882	19075063	10.1128/aac.00946-08	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.	Poirel L, Rodriguez-Martinez JM, Plésiat P, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	3	977	986	19075050	10.1128/aac.01155-08	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.	Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	4	1395	1402	19223646	10.1128/aac.01087-08	Contribution of oxidative damage to antimicrobial lethality.	Wang X, Zhao X.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	4	1561	1566	19188396	10.1128/aac.00994-08	Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.	Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	4	1630	1635	19188377	10.1128/aac.01431-08	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.	Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, Jajic-Bencic I, Gniadkowski M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	5	1892	1897	19258263	10.1128/aac.01400-08	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.	Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	5	1944	1951	19273683	10.1128/aac.01581-08	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.	Doublet B, Granier SA, Robin F, Bonnet R, Fabre L, Brisabois A, Cloeckaert A, Weill FX.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	5	2163	2170	19223615	10.1128/aac.01557-08	Antianaerobic activity of sulopenem compared to six other agents.	Ednie LM, Appelbaum PC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	5	2171	2175	19289528	10.1128/aac.00129-09	Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.	Sader HS, Fritsche TR, Jones RN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	6	2450	2454	19332670	10.1128/aac.01282-08	Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.	Mandomando I, Jaintilal D, Pons MJ, Vallès X, Espasa M, Mensa L, Sigaúque B, Sanz S, Sacarlal J, Macete E, Abacassamo F, Alonso PL, Ruiz J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	6	2663	2666	19332673	10.1128/aac.00046-09	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.	Goy G, Greub G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	7	3112	3114	19451298	10.1128/aac.00239-09	First report of plasmid-mediated quinolone resistance determinant qnrS1 in an Escherichia coli strain of animal origin in Italy.	Cerquetti M, García-Fernández A, Giufrè M, Fortini D, Accogli M, Graziani C, Luzzi I, Caprioli A, Carattoli A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	7	3143	3146	19380592	10.1128/aac.01473-08	First detection of plasmid-encoded blaOXY beta-lactamase.	González-López JJ, Coelho A, Larrosa MN, Lavilla S, Bartolomé R, Prats G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	7	3159	3161	19414578	10.1128/aac.00133-09	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.	Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	8	3280	3284	19506060	10.1128/aac.00426-09	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.	Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	8	3357	3364	19506058	10.1128/aac.01655-08	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.	Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	8	3528	3533	19487447	10.1128/aac.00178-09	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.	D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	9	3700	3704	19581453	10.1128/aac.00099-09	Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer.	Mitev GM, Mellbye BL, Iversen PL, Geller BL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	9	3996	4001	19581457	10.1128/aac.00908-08	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.	Finegold SM, Bolanos M, Sumannen PH, Molitoris DR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2009	72	11	1949	1953	19874044	10.1021/np900572g	Bioactive constituents of the stem bark of Mitrephora glabra.	Li C, Lee D, Graf TN, Phifer SS, Nakanishi Y, Riswan S, Setyowati FM, Saribi AM, Soejarto DD, Farnsworth NR, Falkinham JO, Kroll DJ, Kinghorn AD, Wani MC, Oberlies NH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2009	72	2	248	252	19159274	10.1021/np800606e	Glionitrin A, an antibiotic-antitumor metabolite derived from competitive interaction between abandoned mine microbes.	Park HB, Kwon HC, Lee CH, Yang HO.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2009	72	4	690	695	19388705	10.1021/np800827w	Limazepines A-F, pyrrolo[1,4]benzodiazepine Antibiotics from an Indonesian Micrococcus sp.	Fotso S, Zabriskie TM, Proteau PJ, Flatt PM, Santosa DA, Mahmud T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	1	426	432	19914077	10.1016/j.bmc.2009.10.041	Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.	Omar K, Geronikaki A, Zoumpoulakis P, Camoutsis C, Sokovi¿ M, Ciri¿ A, Glamoclija J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	14	5137	5147	20558071	10.1016/j.bmc.2010.05.065	Novel antimicrobial peptides that exhibit activity against select agents and other drug resistant bacteria.	Venugopal D, Klapper D, Srouji AH, Bhonsle JB, Borschel R, Mueller A, Russell AL, Williams BC, Hicks RP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	14	5148	5156	20573514	10.1016/j.bmc.2010.05.060	Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays.	Henriksen ST, Liu J, Estiu G, Oltvai ZN, Wiest O.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	2	663	674	20044260	10.1016/j.bmc.2009.12.003	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.	Huigens RW, Reyes S, Reed CS, Bunders C, Rogers SA, Steinhauer AT, Melander C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	6	2123	2130	20188576	10.1016/j.bmc.2010.02.005	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.	Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2010	18	8	2902	2911	20363141	10.1016/j.bmc.2010.03.010	Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives.	Karakurt A, Ozalp M, I¿ik S, Stables JP, Dalkara S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2010	19	2	120	126		10.1007/s00044-009-9177-9	Synthesis and antimicrobial activity studies of some novel substituted phenylhydrazono-1H-tetrazol-5-yl-acetonitriles	Yavuz S, Aydn O, Cete S, Disli A, Yldrr Y
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2010	19	5	490	497		10.1007/s00044-009-9206-8	Synthesis and biological activity studies of furan derivatives	Logoglu E, Yilmaz M, Katircioglu H, Yakut M, Mercan S
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2010	19	6	576	588		10.1007/s00044-009-9214-8	Synthesis and biological activity of new cycloalkylthiophene-Schiff bases and their Cr(III) and Zn(II) complexes	Altundas A, Sar N, Colak N, Ogutcu H
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2010	19	8	757	770		10.1007/s00044-009-9228-2	Synthesis and antimicrobial study of fluoroquinolone-based 4-thiazolidinones	Patel NB, Patel SD
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2010	20	18	5572	5576	20724151	10.1016/j.bmcl.2010.07.019	Synthesis and antimicrobial activity of novel fluorine containing 4-(substituted-2-hydroxybenzoyl)-1H-pyrazoles and pyrazolyl benzo[d]oxazoles.	Gadakh AV, Pandit C, Rindhe SS, Karale BK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2010	20	21	6324	6326	20850303	10.1016/j.bmcl.2010.06.001	Bernthsen synthesis, antimicrobial activities and cytotoxicity of acridine derivatives.	Patel MM, Mali MD, Patel SK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2010	20	22	6644	6648	20888765	10.1016/j.bmcl.2010.09.015	Bromophenols as Candida albicans isocitrate lyase inhibitors.	Oh KB, Jeon HB, Han YR, Lee YJ, Park J, Lee SH, Yang D, Kwon M, Shin J, Lee HS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2010	20	23	6882	6885	21035332	10.1016/j.bmcl.2010.10.029	Synthetic analogs of indole-containing natural products as inhibitors of sortase A and isocitrate lyase.	Lee YJ, Han YR, Park W, Nam SH, Oh KB, Lee HS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2010	20	8	2456	2460	20335035	10.1016/j.bmcl.2010.03.016	Antimicrobial selaginellin derivatives from Selaginella pulvinata.	Cao Y, Chen JJ, Tan NH, Oberer L, Wagner T, Wu YP, Zeng GZ, Yan H, Wang Q.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	11	4726	4732	20727622	10.1016/j.ejmech.2010.07.018	Cyclization of some carbothioamide derivatives containing antipyrine and triazole moieties and investigation of their antimicrobial activities.	Bayrak H, Demirbas A, Demirbas N, Karaoglu SA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	11	5006	5011	20801553	10.1016/j.ejmech.2010.08.007	Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole derivatives.	Kadi AA, Al-Abdullah ES, Shehata IA, Habib EE, Ibrahim TM, El-Emam AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	11	5056	5063	20805011	10.1016/j.ejmech.2010.08.014	Design, synthesis and in vitro evaluation of antitubercular and antimicrobial activity of some novel pyranopyrimidines.	Kamdar NR, Haveliwala DD, Mistry PT, Patel SK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	11	5243	5250	20828885	10.1016/j.ejmech.2010.08.043	Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives as antibacterial and antifungal agents.	Hilmy KM, Khalifa MM, Hawata MA, Keshk RM, el-Torgman AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	12	6027	6038	20970223	10.1016/j.ejmech.2010.10.001	Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.	Bekhit AA, Fahmy HT, Rostom SA, El-Din A Bekhit A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	12	6139	6146	21036422	10.1016/j.ejmech.2010.10.007	Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives.	Almajan GL, Barbuceanu SF, Bancescu G, Saramet I, Saramet G, Draghici C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	2	510	518	19926364	10.1016/j.ejmech.2009.10.037	Synthesis of some new S-triazine based chalcones and their derivatives as potent antimicrobial agents.	Solankee A, Kapadia K, Ana Ciri¿, Sokovi¿ M, Doytchinova I, Geronikaki A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	3	1200	1205	20005020	10.1016/j.ejmech.2009.11.038	Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c]quinazolines.	Rohini R, Muralidhar Reddy P, Shanker K, Hu A, Ravinder V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	4	1338	1345	20064677	10.1016/j.ejmech.2009.12.020	Synthesis and antimicrobial activities of some new thiazole and pyrazole derivatives based on 4,5,6,7-tetrahydrobenzothiophene moiety.	Gouda MA, Berghot MA, Abd El-Ghani GE, Khalil AM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	4	1502	1507	20116901	10.1016/j.ejmech.2009.12.058	An eco-friendly synthesis and antimicrobial activities of dihydro-2H-benzo- and naphtho-1,3-oxazine derivatives.	Mathew BP, Kumar A, Sharma S, Shukla PK, Nath M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	4	1552	1559	20117862	10.1016/j.ejmech.2009.12.064	Synthesis and study of some new 1,3-isoindoledione derivatives as potential antibacterial agents.	Khalil AM, Berghot MA, Gouda MA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	5	1843	1848	20144494	10.1016/j.ejmech.2010.01.021	Synthesis and antimicrobial of new anthraquinone derivatives incorporating pyrazole moiety.	Gouda MA, Berghot MA, Shoeib AI, Khalil AM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	5	1935	1940	20163896	10.1016/j.ejmech.2010.01.035	Synthesis, spectroscopic and biological studies on the new symmetric Schiff base derived from 2,6-diformyl-4-methylphenol with N-aminopyrimidine.	Sönmez M, Celebi M, Berber I.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	6	2677	2682	20231043	10.1016/j.ejmech.2010.02.021	Design, synthesis, characterization, and antibacterial activity of {5-chloro-2-[(3-substitutedphenyl-1,2,4-oxadiazol-5-yl)-methoxy]-phenyl}-(phenyl)-methanones.	Rai NP, Narayanaswamy VK, Govender T, Manuprasad BK, Shashikanth S, Arunachalam PN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	7	3191	3195	20307919	10.1016/j.ejmech.2010.02.057	New 6-amino-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b] [1,3,4]thiadiazin-6-ones: synthesis, characterization and antibacterial activity evaluation.	Almajan GL, Barbuceanu SF, Saramet I, Draghici C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	8	3446	3452	20556891	10.1016/j.ejmech.2010.04.035	Synthesis, antibacterial activity evaluation and QSAR studies of novel dispiropyrrolidines.	Karthikeyan K, Sivakumar PM, Doble M, Perumal PT.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	8	3490	3496	20451305	10.1016/j.ejmech.2010.03.039	Synthesis, characterization, in vitro and molecular docking studies of new 2,5-dichloro thienyl substituted thiazole derivatives for antimicrobial properties.	Sarojini BK, Krishna BG, Darshanraj CG, Bharath BR, Manjunatha H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	9	4026	4034	20691339	10.1016/j.ejmech.2010.05.060	Synthesis of substituted thieno[2,3-d]pyrimidine-2,4-dithiones and their S-glycoside analogues as potential antiviral and antibacterial agents.	Hafez HN, Hussein HA, El-Gazzar AR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	9	4089	4095	20591538	10.1016/j.ejmech.2010.05.069	A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities.	Aytemir MD, Ozçelik B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	9	4293	4299	20630629	10.1016/j.ejmech.2010.06.031	Pharmacological evaluation and characterizations of newly synthesized 1,2,4-triazoles.	Patel NB, Khan IH, Rajani SD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2010	45	9	4365	4369	20579782	10.1016/j.ejmech.2010.05.061	Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d][ 1,2,3]-triazin-4(3H)-ones as potential antimicrobial agents.	Saravanan J, Mohan S, Roy JJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	1	164	169	19901088	10.1128/aac.00310-09	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.	Faure S, Perrin-Guyomard A, Delmas JM, Chatre P, Laurentie M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	1	328	332	19901091	10.1128/aac.00961-09	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	1	367	374	19917752	10.1128/aac.00801-09	Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes.	O'Regan E, Quinn T, Frye JG, Pagès JM, Porwollik S, Fedorka-Cray PJ, McClelland M, Fanning S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	1	560	562	19752282	10.1128/aac.00762-09	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.	Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	1	65	71	19884366	10.1128/aac.00966-09	Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.	Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, Kang Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	10	4219	4224	20696876	10.1128/aac.00139-10	Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment.	Zhao J, Chen Z, Chen S, Deng Y, Liu Y, Tian W, Huang X, Wu C, Sun Y, Sun Y, Zeng Z, Liu JH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	10	4343	4351	20696874	10.1128/aac.00409-10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.	Docquier JD, Benvenuti M, Calderone V, Stoczko M, Menciassi N, Rossolini GM, Mangani S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	10	4352	4359	20679504	10.1128/aac.00356-10	Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.	Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	10	4416	4423	20643901	10.1128/aac.00503-10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.	Collins B, Curtis N, Cotter PD, Hill C, Ross RP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	11	4772	4779	20713660	10.1128/aac.00009-10	ampG gene of Pseudomonas aeruginosa and its role in ß-lactamase expression.	Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	11	4864	4871	20696873	10.1128/aac.00771-10	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES ß-lactamases.	Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	11	4900	4902	20805396	10.1128/aac.00594-10	A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes.	Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	12	5021	5027	20921306	10.1128/aac.00598-10	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.	Higgins PG, Schneiders T, Hamprecht A, Seifert H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	12	5366	5368	20876376	10.1128/aac.00719-10	Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.	Dhamdhere G, Krishnamoorthy G, Zgurskaya HI.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	2	757	762	19949056	10.1128/aac.00524-09	Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.	Nakamura S, Yanagihara K, Araki N, Yamada K, Morinaga Y, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Kamihira S, Kohno S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	2	799	803	19949057	10.1128/aac.01045-09	Transferable quinolone resistance in Vibrio cholerae.	Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque AS, Salam MA, Khan WA, Qadri F, Calderwood SB, Jacoby GA, Hooper DC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	2	890	897	20008772	10.1128/aac.00693-09	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.	Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	2	915	918	20008780	10.1128/aac.01091-09	Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	2	953	955	19917749	10.1128/aac.00983-09	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.	Henry X, Amoroso A, Coyette J, Joris B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	3	1007	1015	20038628	10.1128/aac.01126-09	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.	Elkins CA, Mullis LB, Lacher DW, Jung CM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	4	1414	1424	20086146	10.1128/aac.00743-09	Penicillin sulfone inhibitors of class D beta-lactamases.	Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	4	1506	1511	20086141	10.1128/aac.01489-09	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.	San Millan A, Garcia-Cobos S, Escudero JA, Hidalgo L, Gutierrez B, Carrilero L, Campos J, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	4	1547	1554	20124004	10.1128/aac.01252-09	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.	De Luca F, Giraud-Morin C, Rossolini GM, Docquier JD, Fosse T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	4	1564	1571	20123999	10.1128/aac.01219-09	Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.	Jiang SS, Liu MC, Teng LJ, Wang WB, Hsueh PR, Liaw SJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	5	1800	1806	20160052	10.1128/aac.01714-09	Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.	Lim SP, Nikaido H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	5	2078	2084	20194701	10.1128/aac.01398-09	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.	Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, Li SY.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	6	2420	2424	20308383	10.1128/aac.01456-09	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.	Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	6	2677	2680	20350943	10.1128/aac.01536-09	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.	Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	2867	2877	20421396	10.1128/aac.00197-10	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.	Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	3015	3017	20404121	10.1128/aac.01173-09	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.	Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	3031	3034	20457818	10.1128/aac.01808-09	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).	Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	3043	3046	20421398	10.1128/aac.00265-10	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).	Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	7	3070	3071	20421403	10.1128/aac.01615-09	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.	Rodríguez MM, Power P, Sader H, Galleni M, Gutkind G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	8	3197	3204	20498317	10.1128/aac.01336-09	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.	Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	8	3475	3477	20498309	10.1128/aac.00464-10	Identification of the novel dfrK-carrying transposon Tn559 in a porcine methicillin-susceptible Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	8	3529	3530	20547812	10.1128/aac.00710-10	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.	Goswami M, Jawali N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	3790	3798	20585113	10.1128/aac.01783-09	Different classes of antibiotics differentially influence shiga toxin production.	McGannon CM, Fuller CA, Weiss AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	3991	3992	20585124	10.1128/aac.00225-10	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.	Morita M, Takai N, Terajima J, Watanabe H, Kurokawa M, Sagara H, Ohnishi K, Izumiya H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	3998	3999	20585134	10.1128/aac.00264-10	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.	Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2010	54	9	4000	4002	20547799	10.1128/aac.01754-09	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.	Bent ZW, Young GM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Chem Pharm Bull (Tokyo)	2010	58	2	160	167	20118573	10.1248/cpb.58.160	Sulfonamide-1,2,4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.	Camoutsis C, Geronikaki A, Ciric A, Sokovi¿ M, Zoumpoulakis P, Zervou M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2010	73	2	258	262	20055495	10.1021/np9005629	Discorhabdins from the Korean marine sponge Sceptrella sp.	Jeon JE, Na Z, Jung M, Lee HS, Sim CJ, Nahm K, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	10	3135	3140	21524583	10.1016/j.bmc.2011.04.007	Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation.	Liaras K, Geronikaki A, Glamo¿lija J, Ciri¿ A, Sokovi¿ M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	15	4506	4512	21723735	10.1016/j.bmc.2011.06.024	Synthesis of some new [1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles starting from 5-nitro-2-furoic acid and evaluation of their antimicrobial activity.	Badr SM, Barwa RM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	16	5031	5038	21757359	10.1016/j.bmc.2011.06.034	Novel benzofuroxan derivatives against multidrug-resistant Staphylococcus aureus strains: design using Topliss' decision tree, synthesis and biological assay.	Jorge SD, Palace-Berl F, Masunari A, Cechinel CA, Ishii M, Pasqualoto KF, Tavares LC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	21	6292	6301	21962987	10.1016/j.bmc.2011.09.009	Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents.	Ishii M, Jorge SD, de Oliveira AA, Palace-Berl F, Sonehara IY, Pasqualoto KF, Tavares LC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2011	19	24	7349	7356	22079864	10.1016/j.bmc.2011.10.059	Novel (E)-1-(4-methyl-2-(alkylamino)thiazol-5-yl)-3-arylprop-2-en-1-ones as potent antimicrobial agents.	Liaras K, Geronikaki A, Glamo¿lija J, Ciri¿ A, Sokovi¿ M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	1	1	8		10.1007/s00044-009-9273-x	Synthesis and evaluation of a series of aminocyanopyridines as antimicrobial agents	Altundas A, Ayvaz S, Logoglu E
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	1	109	115		10.1007/s00044-009-9279-4	The synthesis and screening of the antimicrobial activity of some novel 3-(furan-2-yl)-1-(aryl)-3-(phenylthio) propan-1-one derivatives	Ceylan M, Gurdere MB, Karaman I, Gezegen H
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	1	93	100		10.1007/s00044-009-9288-3	Synthesis and in vitro antimicrobial activity of benzo[b][1,4]thiazin-3(4H)-ones via smiles rearrangement	Yang H, Fang L, Li Z, Ren F, Wang L, Tian X, Shin D, Zuo H
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	3	293	299		10.1007/s00044-010-9321-6	Synthesis and antimicrobial activities of novel bisacridine-1,8-dione derivatives	Kaya M, Yldrr Y, Celik GY
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	4	408	420		10.1007/s00044-010-9328-z	Synthesis of new series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4-ones for their bacterial and cyclin-dependent kinases (CDKs) inhibitory activities	Geffken D, Soliman R, Soliman FSG, Abdel-Khalek MM, Issa DAE
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	4	443	452		10.1007/s00044-010-9338-x	Synthesis and biological activities of new Mannich bases of chlorokojic acid derivatives	Aytemir MD, Ozcelik B
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	6	670	677		10.1007/s00044-010-9360-z	Synthesis of benzo[b][1,4]oxazin-3(4H)-ones via smiles rearrangement for antimicrobial activity	Fang L, Zuo H, Li Z, He X, Wang L, Tian X, Zhao B, Miao J, Shin D
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	6	782	789		10.1007/s00044-010-9388-0	Microwave-assisted synthesis of some new tetrazolo[1,5-a]quinoline-based benzimidazoles catalyzed by p-TsOH and investigation of their antimicrobial activity	Mungra DC, Patel MP, Patel RG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	7	1033	1041		10.1007/s00044-010-9440-0	Synthesis and antimicrobial activity of new pyridine derivatives-I	Patel NB, Agravat SN, Shaikh FM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	7	854	864		10.1007/s00044-010-9399-x	Synthesis and evaluation of in vitro antitubercular activity and antimicrobial activity of some novel 4H-chromeno[2,3-d]pyrimidine via 2-amino-4-phenyl-4H-chromene-3-carbonitriles	Kamdar NR, Haveliwala DD, Mistry PT, Patel SK
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	7	865	876		10.1007/s00044-010-9394-2	Synthesis of some substituted furan-2(5H)-ones and derived quinoxalinones as potential anti-microbial and anti-cancer agents	El-Tombary AA, Abdel-Ghany YS, Belal ASF, Shams El-Dine SA, Soliman FSG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2011	20	8	1170	1180		10.1007/s00044-010-9457-4	Synthesis and structureantibacterial activity relationship studies of 4-substituted phenyl-4,5-dihydrobenzo[f][1,4]oxazepin-3(2H)-thiones	Agirbas H, Kemal B, Budak F
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	1	524	527	21134751	10.1016/j.bmcl.2010.10.082	3-[Benzimidazo- and 3-[benzothiadiazoleimidazo-(1,2-c)quinazolin-5-yl]-2H-chromene-2-ones as potent antimicrobial agents.	Kuarm BS, Reddy YT, Madhav JV, Crooks PA, Rajitha B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	14	4353	4357	21658941	10.1016/j.bmcl.2011.05.031	Exploration of antimicrobial and antioxidant potential of newly synthesized 2,3-disubstituted quinazoline-4(3H)-ones.	Kumar A, Sharma P, Kumari P, Lal Kalal B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	20	6166	6169	21890359	10.1016/j.bmcl.2011.07.123	Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus.	Makawana JA, Mungra DC, Patel MP, Patel RG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	23	7142	7145	22001028	10.1016/j.bmcl.2011.09.072	Synthesis and antimicrobial activity of brominated resorcinol dimers.	Bouthenet E, Oh KB, Park S, Nagi NK, Lee HS, Matthews SE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	24	7522	7525	22071302	10.1016/j.bmcl.2011.06.087	A new antifungal briarane diterpenoid from the gorgonian Junceella juncea Pallas.	Murthy YL, Mallika D, Rajack A, Reddy GD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	3	899	903	21232949	10.1016/j.bmcl.2010.12.084	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.	Horita Y, Takii T, Kuroishi R, Chiba T, Ogawa K, Kremer L, Sato Y, Lee Y, Hasegawa T, Onozaki K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	4	1155	1161	21273067	10.1016/j.bmcl.2010.12.111	Design and synthesis of potent Gram-negative specific LpxC inhibitors.	Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2011	21	7	1958	1961	21377877	10.1016/j.bmcl.2011.02.035	Sargachromanols as inhibitors of Na+/K+ ATPase and isocitrate lyase.	Chung SC, Jang KH, Park J, Ahn CH, Shin J, Oh KB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	1	241	248	21130541	10.1016/j.ejmech.2010.11.010	Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety.	Plech T, Wujec M, Siwek A, Kosikowska U, Malm A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	11	5573	5579	21981980	10.1016/j.ejmech.2011.09.023	1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.	Akhaja TN, Raval JP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	2	738	742	21216051	10.1016/j.ejmech.2010.12.009	Synthesis and structure-activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents.	Prachayasittikul S, Worachartcheewan A, Nantasenamat C, Chinworrungsee M, Sornsongkhram N, Ruchirawat S, Prachayasittikul V.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	2	765	772	21216502	10.1016/j.ejmech.2010.12.015	Synthesis of 4H-chromene, coumarin, 12H-chromeno[2,3-d]pyrimidine derivatives and some of their antimicrobial and cytotoxicity activities.	Sabry NM, Mohamed HM, Khattab ES, Motlaq SS, El-Agrody AM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	4	1390	1399	21339031	10.1016/j.ejmech.2011.01.068	Synthesis, biopharmaceutical characterization, antimicrobial and antioxidant activities of 1-(4'-O-ß-D-glucopyranosyloxy-2'-hydroxyphenyl)-3-aryl-propane-1,3-diones.	Sheikh J, Parvez A, Juneja H, Ingle V, Chohan Z, Youssoufi M, Ben Hadda T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	5	1813	1820	21397366	10.1016/j.ejmech.2011.02.040	Applications of 2-arylhydrazononitriles in synthesis: preparation of new indole containing 1,2,3-triazole, pyrazole and pyrazolo[1,5-a]pyrimidine derivatives and evaluation of their antimicrobial activities.	Behbehani H, Ibrahim HM, Makhseed S, Mahmoud H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	5	1849	1856	21397998	10.1016/j.ejmech.2011.02.047	Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.	Izumizono Y, Arevalo S, Koseki Y, Kuroki M, Aoki S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	6	2485	2489	21481496	10.1016/j.ejmech.2011.03.037	Synthesis of 2-aziridinyl phosphonates by modified Gabriel-Cromwell reaction and their antibacterial activities.	Do¿an Ö, Babiz H, Gözen AG, Budak S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	7	2948	2954	21531049	10.1016/j.ejmech.2011.04.019	Synthesis, antitumor and antimicrobial activities of 4-(4-chlorophenyl)-3-cyano-2-(ß-O-glycosyloxy)-6-(thien-2-yl)-nicotinonitrile.	El-Sayed HA, Moustafa AH, Haikal Ael-F, Abu-El-Halawa R, El Ashry el SH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2011	46	9	4192	4200	21741732	10.1016/j.ejmech.2011.06.022	Synthesis and identification of ß-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.	Mungra DC, Patel MP, Rajani DP, Patel RG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2011	55	1	140	145	21041509	10.1128/aac.00858-10	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.	Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2011	55	1	284	290	21078949	10.1128/aac.00098-10	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.	Shimizu-Ibuka A, Oishi M, Yamada S, Ishii Y, Mura K, Sakai H, Matsuzawa H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Antimicrob. Agents Chemother.	2011	55	1	439	442	20937780	10.1128/aac.00735-10	Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.	Kalle AM, Rizvi A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	1	32	37	21158423	10.1021/np100568w	N-hydroxypyridones, phenylhydrazones, and a quinazolinone from Isaria farinosa.	Ma C, Li Y, Niu S, Zhang H, Liu X, Che Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	10	2069	2080	21973054	10.1021/np2002918	Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.	Fan JT, Kuang B, Zeng GZ, Zhao SM, Ji CJ, Zhang YM, Tan NH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	12	2520	2525	22124378	10.1021/np200625m	In vitro antibacterial activity of sphaeropsidins and chemical derivatives toward Xanthomonas oryzae pv. oryzae, the causal agent of rice bacterial blight.	Evidente A, Venturi V, Masi M, Degrassi G, Cimmino A, Maddau L, Andolfi A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	2	256	261	21226488	10.1021/np100788h	Comazaphilones A-F, azaphilone derivatives from the marine sediment-derived fungus Penicillium commune QSD-17.	Gao SS, Li XM, Zhang Y, Li CS, Cui CM, Wang BG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	2	272	278	21265557	10.1021/np1005218	Antimicrobial isopropenyl-dihydrofuranoisoflavones from Crotalaria lachnophora.	Awouafack MD, Spiteller P, Lamshöft M, Kusari S, Ivanova B, Tane P, Spiteller M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	4	847	851	21341710	10.1021/np1006873	Scalarane sesterterpenes from the sponge Hyatella sp.	Jeon JE, Bae J, Lee KJ, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	5	1111	1116	21539317	10.1021/np200050r	Verrucamides A-D, antibacterial cyclopeptides from Myrothecium verrucaria.	Zou X, Niu S, Ren J, Li E, Liu X, Che Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2011	74	8	1805	1811	21827183	10.1021/np200492k	Sesterterpenes from the tropical sponge Coscinoderma sp.	Bae J, Jeon JE, Lee YJ, Lee HS, Sim CJ, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2012	20	13	4082	4087	22652254	10.1016/j.bmc.2012.05.002	Beta-carboline alkaloids derived from the ascidian Synoicum sp.	Won TH, Jeon JE, Lee SH, Rho BJ, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2012	20	15	4653	4660	22750009	10.1016/j.bmc.2012.06.018	Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.	Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, Kulp SK, Teng LJ, Chen CS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2012	20	17	5290	5295	22863526	10.1016/j.bmc.2012.06.030	Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola.	Kim H, Lantvit D, Hwang CH, Kroll DJ, Swanson SM, Franzblau SG, Orjala J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2012	20	24	6924	6928	23131412	10.1016/j.bmc.2012.10.014	Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases.	Shen S, Liu D, Wei C, Proksch P, Lin W.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2012	20	4	1569	1583	22264752	10.1016/j.bmc.2011.12.031	Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies.	Zoumpoulakis P, Camoutsis Ch, Pairas G, Sokovi¿ M, Glamo¿lija J, Potamitis C, Pitsas A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	2762	2771		10.1007/s00044-011-9808-9	Design, synthesis, and in vitro antimicrobial activities of novel azetidinyl-3-quinazolin-4-one hybrids	Myangar KN, Raval JP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	2896	2901		10.1007/s00044-011-9827-6	Synthesis, single crystal X-ray studies and antimicrobial activities of novel Indole barbiturates	Laxmi SV, Janardhan B, Rajitha B, Raghavaiah P, Srinivas P
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	2969	2974		10.1007/s00044-011-9830-y	Synthesis, characterization and biological activity of Schiff bases derived from metronidazole	Saadeh HA, Shaireh EAA, Mosleh IM, Al-Bakri AG, Mubarak MS
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	2981	2989		10.1007/s00044-011-9833-8	Synthesis, characterization, and antimicrobial evaluation of novel naphthalene-based 1,2,4-triazoles	Desai NC, Shihora PN, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM, Dodiya AM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	3214	3223		10.1007/s00044-011-9876-x	New thiazolidine-2,4-diones as antimicrobial and cytotoxic agent	Alegaon SG, Alagawadi KR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	10	3233	3239		10.1007/s00044-011-9857-0	Synthesis and biological evaluation of chalcones and acetyl pyrazoline derivatives comprising furan nucleus as an antitubercular agents	Bhoot D, Khunt RC, Parekh HH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	11	3406	3416		10.1007/s00044-011-9861-4	Microwave-assisted synthesis of 3-indolyl substituted 4H-chromenes catalyzed by DMAP and their antimicrobial activity	Kathrotiya HG, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4074	4082		10.1007/s00044-011-9964-y	Synthesis, DNA affinity, and antimicrobial activity of 4-substituted phenyl-2,2-bichalcophenes and aza-analogues	Youssef MM, Al-Omair MA, Ismail MA
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4108	4119		10.1007/s00044-011-9952-2	In vitro antimicrobial and antitubercular studies of novel 6-substituted (pyrrolidin-1-yl)-2(1H)-pyridinones	Patel NB, Sharma RD, Rajani SD
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4403	4411		10.1007/s00044-012-9973-5	Synthesis, pharmacological evaluation and molecular docking studies of indanone derivatives	Patel A, Giles D, Basavarajaswamy G, Sreedhar C, Patel A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4412	4421		10.1007/s00044-012-9980-6	An efficient, solvent-free microwave-assisted synthesis and antimicrobial screening of 1,6-dihydropyrimidine analogues	Desai NC, Pandya DD, Satodiya HM, Rajpara KM, Joshi VV, Vaghani HV
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4437	4446		10.1007/s00044-012-9988-y	Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives	Desai NC, Pandya MR, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4463	4472		10.1007/s00044-012-9990-4	Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus	Desai NC, Pandya DD, Joshi VV, Rajpara KM, Vaghani HV, Satodiya HM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4485	4498		10.1007/s00044-012-9992-2	Design and synthesis of some azole derivatives as potential antimicrobial agents	Sahin D, Bayrak H, Demirbas A, Demirbas N, Alpay-Karaoglu S
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	12	4499	4505		10.1007/s00044-011-9951-3	Photodynamic activities of protoporphyrin IX and its dopamine conjugate against cancer and bacterial cell viability	Sagir T, Gencer S, Kemikli N, Abasiyanik MF, Isik S, Ozturk R
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	2	157	164		10.1007/s00044-010-9505-0	Predictions and correlations of structure activity relationship of some aminoantipyrine derivatives on the basis of theoretical and experimental ground	Ali P, Meshram J, Sheikh J, Tiwari V, Dongre R, Hadda TB
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	2	174	184		10.1007/s00044-010-9517-9	Synthesis, in vitro cytotoxicity, and anti-microbial studies of 1,4-bis(4-substituted-5-mercapto-1,2,4-triazol-3-yl)butanes	Purohit M, Mayur YC
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	2	212	223		10.1007/s00044-010-9531-y	Synthesis and biological activity studies of new hybrid molecules containing tryptamine moiety	Bektas H, Demirbas A, Demirbas N, Karaoglu SA
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	5	616	623		10.1007/s00044-011-9568-6	Synthesis and in vitro antimicrobial evaluation of penta-substituted pyridine derivatives bearing the quinoline nucleus	Makawana JA, Patel MP, Patel RG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	6	816	824		10.1007/s00044-011-9598-0	New thiazolidinedione-5-acetic acid amide derivatives: synthesis, characterization and investigation of antimicrobial and cytotoxic properties	Alegaon SG, Alagawadi KR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	7	1098	1106		10.1007/s00044-011-9611-7	Microwave-assisted synthesis of some novel and potent antibacterial and antifungal compounds with biological screening	Bapna M, Parashar B, Sharma VK, Chouhan LS
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	7	1107	1119		10.1007/s00044-011-9612-6	Synthesis, anticancer, anti-HIV-1, and antimicrobial activity of some tricyclic triazino and triazolo[4,3-e]purine derivatives	Ashour FA, Rida SM, El-Hawash SAM, ElSemary MM, Badr MH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	7	1127	1135		10.1007/s00044-011-9621-5	Dimeric 2-(2-chlorophenyl)-quinazolin-4-ones as potential antimicrobial agents	Desai NC, Dodiya A, Bhatt N, Kumar M
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	7	1188	1198		10.1007/s00044-011-9628-y	Zn(OTf)2-catalyzed three component, one-pot cyclocondensation reaction of some new octahydroquinazolinone derivatives and access their bio-potential	Shah PM, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	7	1480	1490		10.1007/s00044-011-9670-9	Conventional and microwave techniques for synthesis and antimicrobial studies of novel 1-[2-(2-chloro(3-quinolyl))-5-(4-nitrophenyl)-(1,3,4-oxadiazolin-3-yl)]-3-(aryl)prop-2-en-1-ones	Desai NC, Dodiya AM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	8	1577	1586		10.1007/s00044-011-9674-5	A clubbed quinazolinone and 4-thiazolidinone as potential antimicrobial agents	Desai NC, Dodiya AM, Shihora PN
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	8	1660	1664		10.1007/s00044-011-9682-5	Design, synthesis of some 2,6,9-trisubstituted purinyl thioureido derivatives and evaluation of antimicrobial activity	Modi JA, Patel KC
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	8	1751	1761		10.1007/s00044-011-9693-2	Synthesis, characterization and biological activity of some new carbostyril bearing 1H-pyrazole moiety	Thumar NJ, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	8	1984	1990		10.1007/s00044-011-9723-0	Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases	Jarrahpour A, Fathi J, Mimouni M, Hadda TB, Sheikh J, Chohan Z, Parvez A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	8	2044	2055		10.1007/s00044-011-9728-8	Pyridoquinolones containing azetidinones: synthesis and their biological evaluation	Patel NB, Pathak KK
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	9	2320	2328		10.1007/s00044-011-9752-8	Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives	Desai NC, Dodiya AM, Makwana AH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	9	2458	2464		10.1007/s00044-011-9769-z	A novel and eco-friendly procedure for the synthesis of some pyrazolo-thiadiazolo-pyrimidinones and its in vitro anti-bacterial activity	Ranganath D, Mazumdar A, Mulukuri S, Doonaboina R, Devarakonda M, Raghu Prasad M
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	9	2548	2556		10.1007/s00044-011-9778-y	Rapid synthesis, characterization, anticancer and antimicrobial activity studies of substituted thiadiazoles and their dinucleating ligand metal complexes	Jha A, Murthy YLN, Sanyal U, Durga G
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	9	2579	2586		10.1007/s00044-011-9782-2	A search of novel antimicrobial based on benzimidazole and 2-pyridone heterocycles	Desai NC, Dodiya AM, Shihory NR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2012	21	9	2615	2623		10.1007/s00044-011-9783-1	Synthesis and biological evaluation of some new Thiazolo[3,2-a][1,3,5]triazine derivatives	Hamama WS, Ismail MA, Shaaban S, Zoorob HH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	11	3816	3821	22560587	10.1016/j.bmcl.2012.03.100	An efficient one-pot synthesis, structure, antimicrobial and antioxidant investigations of some novel quinolyldibenzo[b,e][1,4]diazepinones.	Parmar NJ, Barad HA, Pansuriya BR, Teraiya SB, Gupta VK, Kant R.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	12	4075	4079	22607678	10.1016/j.bmcl.2012.04.070	An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines.	Parmar NJ, Pansuriya BR, Barad HA, Kant R, Gupta VK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	17	5555	5558	22853996	10.1016/j.bmcl.2012.07.016	Two novel bioactive glucosinolates from Broccoli (Brassica oleracea L. var. italica) florets.	Survay NS, Kumar B, Jang M, Yoon DY, Jung YS, Yang DC, Park SW.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	17	5727	5730	22832312	10.1016/j.bmcl.2012.06.072	Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.	Shelke SN, Mhaske GR, Bonifácio VD, Gawande MB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	18	6016	6023	22901391	10.1016/j.bmcl.2012.05.003	Design, solvent free synthesis, and antimicrobial evaluation of 1,4 dihydropyridines.	Murthy YL, Rajack A, Taraka Ramji M, Jeson babu J, Praveen Ch, Aruna Lakshmi K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	2	1078	1081	22182501	10.1016/j.bmcl.2011.11.105	Bioactive lipids from the sponge Spirastrella abata.	Jang KH, Lee Y, Sim CJ, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	20	6377	6380	22989532	10.1016/j.bmcl.2012.08.074	Zizimauritic acids A-C, three novel nortriterpenes from Ziziphus mauritiana.	Ji CJ, Zeng GZ, Han J, He WJ, Zhang YM, Tan NH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	7	2388	2392	22406116	10.1016/j.bmcl.2012.02.036	Discovery of loperamide as an antagonist of angiopoietin1 and angiopoietin2 by virtual screening.	Gong XW, Mai JH, Xu YH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	8	2872	2876	22440624	10.1016/j.bmcl.2012.02.056	Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3,4-dihydropyrimidinones of curcumin.	Lal J, Gupta SK, Thavaselvam D, Agarwal DD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2012	22	9	3044	3049	22494615	10.1016/j.bmcl.2012.03.079	Preparation, antibacterial evaluation and preliminary structure-activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives.	Ouyang L, Huang Y, Zhao Y, He G, Xie Y, Liu J, He J, Liu B, Wei Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2012	3	1	86	89		10.1039/C1MD00272D	Membrane disrupting antimicrobial peptide dendrimers with multiple amino termini	Stach M, Maillard N, Kadam RU, Kalbermatter D, Meury M, Page MGP, Fotiadis D, Darbre T, Reymond J
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2012	3	12	1548	1554		10.1039/C2MD20272G	OH radical production stimulated by (RW)4D, a synthetic antimicrobial agent and indolicidin	Liu Z, Cai Y, Young AW, Totsingan F, Jiwrajka N, Shi Z, Kallenbach NR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	47		580	584	22100136	10.1016/j.ejmech.2011.10.055	Studies on the synthesis and antibacterial activity of 3,6-disubstituted 1,2,4-triazolo[3,4-b]1,3,4-thiadiazoles.	Plech T, Wujec M, Kosikowska U, Malm A, Kapro¿ B.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	49		164	171	22264895	10.1016/j.ejmech.2012.01.007	Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.	Lu X, Liu X, Wan B, Franzblau SG, Chen L, Zhou C, You Q.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	51		124	136	22405287	10.1016/j.ejmech.2012.02.030	Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 5,6-dihydro-3,6-disubstituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.	Chidananda N, Poojary B, Sumangala V, Kumari NS, Shetty P, Arulmoli T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	54		239	247	22652224	10.1016/j.ejmech.2012.05.004	New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.	Shah NM, Patel MP, Patel RG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2012	55	5	2025	2034	22320306	10.1021/jm2011595	From a marine neuropeptide to antimicrobial pseudopeptides containing aza-ß(3)-amino acids: structure and activity.	Laurencin M, Legrand B, Duval E, Henry J, Baudy-Floc'h M, Zatylny-Gaudin C, Bondon A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	56		375	386	22939606	10.1016/j.ejmech.2012.07.022	"Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones ""In-Water"" and their biological evaluation as antibacterial and antifungal agents."	Tandon VK, Kumar S, Mishra NN, Shukla PK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2012	58		478	484	23159805	10.1016/j.ejmech.2012.09.050	Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives.	Giles D, Roopa K, Sheeba FR, Gurubasavarajaswamy PM, Divakar G, Vidhya T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2012	75	12	2055	2061	23145909	10.1021/np3005562	Brominated aromatic furanones and related esters from the ascidian Synoicum sp.	Won TH, Jeon JE, Kim SH, Lee SH, Rho BJ, Oh DC, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2012	75	2	148	152	22283451	10.1021/np2006742	Asperolides A-C, tetranorlabdane diterpenoids from the marine alga-derived endophytic fungus Aspergillus wentii EN-48.	Sun HF, Li XM, Meng L, Cui CM, Gao SS, Li CS, Huang CG, Wang BG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2012	75	4	605	609	22537363	10.1021/np200788u	Phenanthrene derivatives from Cymbidium Great Flower Marie Laurencin and their biological activities.	Yoshikawa K, Ito T, Iseki K, Baba C, Imagawa H, Yagi Y, Morita H, Asakawa Y, Kawano S, Hashimoto T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2013	21	2	532	539	23219856	10.1016/j.bmc.2012.10.046	Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.	Apostolidis I, Liaras K, Geronikaki A, Hadjipavlou-Litina D, Gavalas A, Sokovi¿ M, Glamo¿lija J, ¿iri¿ A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2013	21	21	6574	6581	24045008	10.1016/j.bmc.2013.08.029	New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.	Pauk K, Zadra¿ilová I, Imramovský A, Vin¿ová J, Pokorná M, Masa¿íková M, Cí¿ek A, Jampílek J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	1	312	322		10.1007/s00044-012-0031-0	New N-arylamino biquinoline derivatives: microwave-assisted synthesis and their antimicrobial activities	Shah NM, Patel MP, Patel RG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	1	78	87		10.1007/s00044-012-0017-y	5-phenyl-1-benzofuran-2-yl derivatives: synthesis, antimicrobial, and antioxidant activity	Aswathanarayanappa C, Bheemappa E, Bodke YD, Bhovi VK, Ningegowda R, Shivakumar MC, Peethambar SK, Telkar S
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	10	4700	4707		10.1007/s00044-013-0472-0	New carbodithioate derivatives: synthesis, characterization, and in vitro antibacterial, antifungal, antitubercular, and antimalarial activity	Akhaja TN, Raval JP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	10	4745	4754		10.1007/s00044-013-0489-4	Synthesis of a new series of 2-(2-oxo-2H-chromen-3-yl)-5H-chromeno[4,3-b]pyridin-5-ones by two facile methods and evaluation of their antimicrobial activity	Patel AA, Lad HB, Pandya KR, Patel CV, Brahmbhatt DI
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	10	4930	4945		10.1007/s00044-013-0498-3	Preparation and antimicrobial activity evaluation of some new bi- and triheterocyclic azoles	Demirci S, Basoglu S, Bozdereci A, Demirbas N
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	11	5129	5140		10.1007/s00044-013-0484-9	Synthesis and SAR investigation of natural phenylpropene-derived methoxylated cinnamaldehydes and their novel Schiff bases as potent antimicrobial and antioxidant agents	Sharma UK, Sood S, Sharma N, Rahi P, Kumar R, Sinha AK, Gulati A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	11	5184	5196		10.1007/s00044-012-0320-7	Synthesis and in vitro antimicrobial activity of some newer quinazolinonesulfonamide linked hybrid heterocyclic entities derived from glycine	Vanparia SF, Patel TS, Dixit RB, Dixit BC
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	11	5466	5471		10.1007/s00044-013-0541-4	Synthesis, anticancer and antibacterial activities of piperine analogs	Umadevi P, Deepti K, Venugopal DVR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	11	5598	5609		10.1007/s00044-013-0524-5	Synthesis and characterization of new types of 2-(6-methoxy-2-naphthyl)propionamide derivatives as potential antibacterial and antifungal agents	Helal MH, Abbas SY, Salem MA, Farag AA, Ammar YA
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	12	5685	5699		10.1007/s00044-013-0550-3	Synthesis and characterization of flurbiprofen hydrazide derivatives as potential anti-HCV, anticancer and antimicrobial agents	Ckla P, Tatar E, Kucukguzel I, Sahin F, Yurdakul D, Basu A, Krishnan R, Nichols DB, Kaushik-Basu N, Kucukguzel SG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	12	5789	5797		10.1007/s00044-013-0568-6	Synthesis, characterization, and antimicrobial screening of some Mannich base sydnone derivatives	Savaliya PP, Akbari VK, Modi JA, Patel KC
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	12	5848	5860		10.1007/s00044-013-0576-6	Thermal, kinetic, spectroscopic studies and anti-microbial, anti-tuberculosis, anti-oxidant properties of clioquinol and benzo-coumarin derivatives mixed complexes with copper ion	Dholariya HR, Patel KS, Patel JC, Patel AK, Patel KD
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	2	580	587		10.1007/s00044-012-0039-5	Spectroscopic characterization of novel d-amino acid-Schiff bases and their Cr(III) and Ni(II) complexes as antimicrobial agents	Sar N, Piskin N, Ogutcu H, Kurnaz N
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	2	905	915		10.1007/s00044-012-0085-z	Microwave-assisted CAN-catalyzed solvent-free synthesis of N-allyl quinolone-based pyrano[4,3-b]chromene and benzopyrano[3,2-c]chromene derivatives and their antimicrobial activity	Jardosh HH, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	2	964	975		10.1007/s00044-012-0089-8	Antibacterial, antifungal and antioxidant activity of some new water-soluble -diketones	Sheikh J, Hadda TB
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	3	1163	1171		10.1007/s00044-012-0117-8	Synthesis, antioxidant, and antibacterial studies of phenolic esters and amides of 2-(1-benzofuran-2-yl) quinoline-4-carboxylic acid	Shankerrao S, Bodke YD, Mety SS
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	3	1172	1183		10.1007/s00044-012-0121-z	Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides	Desai NC, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	3	1320	1329		10.1007/s00044-012-0129-4	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles	Patel NB, Khan IH, Pannecouque C, De Clercq E
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	4	1689	1699		10.1007/s00044-012-0154-3	Synthesis, antimicrobial and antioxidant activities of 2-[1-{3,5-diaryl-4,5-dihydro-1H-pyrazolenyl}]-4-(4-nitrophenyl)-[1,3]-thiazoles	Lobo PL, Poojary B, Kumsi M, Chandra V, Kumari NS, Chandrashekar KR
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	4	1788	1794		10.1007/s00044-012-0178-8	Mild and highly efficient copper (II) sulfate catalyzed one pot synthesis of 2-aryl benzimidazole using atmospheric air as an oxidant and its antibacterial study	Jain R, Agarwal DD, Sahu PK, Selvam DT, Sharma Y, Gupta R, Prakash A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	4	1893	1908		10.1007/s00044-012-0190-z	Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus	Desai NC, Joshi VV, Rajpara KM, Vaghani HV, Satodiya HM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	5	2163	2173		10.1007/s00044-012-0209-5	Synthesis, in vitro cytotoxicity, and antibacterial studies of new asymmetric bis-1,2,4-triazoles	Singh R, Pujar GV, Purohit MN, Chandrashekar VM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	5	2266	2272		10.1007/s00044-012-0220-x	Synthesis, characterization, and antimicrobial activity of some new 2-diazo-benzimidazole derivatives and their Ni(II), Cu(II), and Ag(I) complexes	Murthy YLN, Durga G, Jha A
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	5	2360	2375		10.1007/s00044-012-0230-8	Synthesis, molecular modeling study, preliminary antibacterial, and antitumor evaluation of N-substituted naphthalimides and their structural analogues	El-Azab AS, Alanazi AM, Abdel-Aziz NI, Al-Suwaidan IA, El-Sayed MAA, El-Sherbeny MA, Abdel-Aziz AA
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	5	2531	2537	23543889	10.1007/s00044-012-0248-y	Microbiologically active Mannich bases derived from 1,2,4-triazoles. The effect of C-5 substituent on antibacterial activity.	Plech T, Wujec M, Majewska M, Kosikowska U, Malm A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	6	2553	2560		10.1007/s00044-012-0253-1	Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities	Tiryaki D, Sukuroglu M, Dogruer DS, Akkol E, Ozgen S, Sahin MF
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	6	2912	2920		10.1007/s00044-012-0292-7	Synthesis and in vitro antimicrobial evaluation of novel 2-amino-6-(phenylthio)-4-(2-(phenylthio)quinolin-3-yl)pyridine-3,5-dicarbonitriles	Kanani MB, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	6	2954	2963		10.1007/s00044-012-0301-x	Microwave-induced CAN promoted atom-economic synthesis of 1H-benzo[b]xanthene and 4H-benzo[g]chromene derivatives of N-allyl quinolone and their antimicrobial activity	Jardosh HH, Patel MP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	6	3035	3047		10.1007/s00044-012-0322-5	Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of -aryloxyquinoline and their antimicrobial and antituberculosis activities	Sangani CB, Jardosh HH, Patel MP, Patel RG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	7	3289	3308		10.1007/s00044-012-0324-3	Synthesis and biological evaluation of novel series of thieno[2,3-d]pyrimidine derivatives as anticancer and antimicrobial agents	Habib NS, Soliman R, El-Tombary AA, El-Hawash SA, Shaaban OG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	8	3629	3639	23807823	10.1007/s00044-012-0318-1	Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containing an azole nucleus.	Bekta¿ H, Ceylan S, Demirba¿ N, Alpay-Karao¿lu S, Sökmen BB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	8	3663	3674		10.1007/s00044-012-0377-3	Synthesis of new quinoline-2-pyrazoline-based thiazolinone derivatives as potential antimicrobial agents	Desai NC, Joshi VV, Rajpara KM
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	8	3743	3750		10.1007/s00044-012-0363-9	Synthesis of novel 4-thiazolidione derivatives as antibacterial agents against drug-resistant Staphylococcus epidermidis	Zhao D, Liu H, Zheng L, He G, Qu D, Han S
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	8	3831	3842		10.1007/s00044-012-0381-7	Microwave-assisted synthesis of novel 4H-chromene derivatives bearing 2-aryloxyquinoline and their antimicrobial activity assessment	Sangani CB, Shah NM, Patel MP, Patel RG
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	9	4202	4210		10.1007/s00044-012-0421-3	Synthesis, biopharmaceutical characterization, and antimicrobial study of novel azo dyes of 7-hydroxy-4-methylcoumarin	Jogi PS, Meshram J, Sheikh J, Ben Hadda T
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	9	4223	4227		10.1007/s00044-012-0425-z	Synthesis of tetracyclic aza-/oxa-naphthalen-8-ones and their antimicrobial activity	Soman SS, Thaker TH
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013	22	9	4338	4346		10.1007/s00044-012-0437-8	One pot synthesis of some novel coumarins containing 5-(substituted-2-hydroxybenzoyl) pyridine as a new class of antimicrobial and antituberculosis agents	Bhila VG, Patel CV, Patel NH, Brahmbhatt DI
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2013	23	6	1656	1661	23414843	10.1016/j.bmcl.2013.01.079	An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano- and thiopyrano-fused heterocycles.	Parmar NJ, Patel RA, Parmar BD, Talpada NP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2013	23	7	2250	2253	23434418	10.1016/j.bmcl.2013.01.041	Microwave assisted nano (ZnO-TiO2) catalyzed synthesis of some new 4,5,6,7-tetrahydro-6-((5-substituted-1,3,4-oxadiazol-2-yl)methyl)thieno[2,3-c]pyridine as antimicrobial agents.	Sangshetti JN, Dharmadhikari PP, Chouthe RS, Fatema B, Lad V, Karande V, Darandale SN, Shinde DB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2013	23	8	2426	2431	23473681	10.1016/j.bmcl.2013.02.005	Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA.	Barker CA, Allison SE, Zlitni S, Nguyen ND, Das R, Melacini G, Capretta AA, Brown ED.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2013	23	9	2632	2635	23522562	10.1016/j.bmcl.2013.02.099	Green synthesis of tetrahydropyrimidine analogues and evaluation of their antimicrobial activity.	Darandale SN, Pansare DN, Mulla NA, Shinde DB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	ACS Med. Chem. Lett.	2013	4	10	958	963	24900592	10.1021/ml4002248	Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.	Anand N, Ramakrishna KK, Gupt MP, Chaturvedi V, Singh S, Srivastava KK, Sharma P, Rai N, Ramachandran R, Dwivedi AK, Gupta V, Kumar B, Pandey S, Shukla PK, Pandey SK, Lal J, Tripathi RP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Drug Metab. Dispos.	2013	41	4	791	800	23344796	10.1124/dmd.112.049569	Organic anion transporter 3 interacts selectively with lipophilic ß-lactam antibiotics.	Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2013	56	18	7177	7189	23961953	10.1021/jm400499k	Screening and evaluation of small organic molecules as ClpB inhibitors and potential antimicrobials.	Martin I, Underhaug J, Celaya G, Moro F, Teigen K, Martinez A, Muga A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2013	56	3	1084	1097	23252553	10.1021/jm301490d	Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) ß-lactamase.	Winkler ML, Rodkey EA, Taracila MA, Drawz SM, Bethel CR, Papp-Wallace KM, Smith KM, Xu Y, Dwulit-Smith JR, Romagnoli C, Caselli E, Prati F, van den Akker F, Bonomo RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	59		120	131	23229055	10.1016/j.ejmech.2012.10.038	Microwave synthesis, characterization and bio-efficacy evaluation of novel chalcone based 6-carbethoxy-2-cyclohexen-1-one and 2H-indazol-3-ol derivatives.	Shakil NA, Singh MK, Sathiyendiran M, Kumar J, Padaria JC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	59		23	30	23202847	10.1016/j.ejmech.2012.09.004	Synthesis and antibacterial and antifungal evaluation of some chalcone based sulfones and bisulfones.	Konduru NK, Dey S, Sajid M, Owais M, Ahmed N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	60		421	430	23318903	10.1016/j.ejmech.2012.11.017	Synthesis and antimicrobial activity of some new benzo and naphthonitrile derivatives.	Fadda AA, Afsah el-SM, Awad RS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	62		270	279	23357308	10.1016/j.ejmech.2012.12.050	Synthesis of some new 2-(3-pyridyl)-4,5-disubstituted thiazoles as potent antimicrobial agents.	Bondock S, Naser T, Ammar YA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	62		677	687	23434641	10.1016/j.ejmech.2012.12.055	New 2-benzylsulfanyl-nicotinic acid based 1,3,4-oxadiazoles: their synthesis and biological evaluation.	Patel NB, Purohit AC, Rajani DP, Moo-Puc R, Rivera G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	63		185	195	23474904	10.1016/j.ejmech.2013.02.010	Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.	El-Gohary NS, Shaaban MI.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	63		675	684	23567957	10.1016/j.ejmech.2013.03.017	Synthesis and identification of ß-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.	Kathrotiya HG, Patel MP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	64		314	320	23644214	10.1016/j.ejmech.2013.03.039	Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.	Kanawade SB, Toche RB, Rajani DP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	65		195	204	23708013	10.1016/j.ejmech.2013.04.055	Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives.	Abbas SE, Abdel Gawad NM, George RF, Akar YA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	65		348	359	23747804	10.1016/j.ejmech.2013.05.003	Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.	Jardosh HH, Patel MP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	65		517	526	23787438	10.1016/j.ejmech.2013.04.005	Synthesis and biological evaluation of some novel thiazole compounds as potential anti-inflammatory agents.	Helal MH, Salem MA, El-Gaby MS, Aljahdali M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	66		276	295	23811090	10.1016/j.ejmech.2013.05.028	Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.	Fargualy AM, Habib NS, Ismail KA, Hassan AM, Sarg MT.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	67		208	220	23867605	10.1016/j.ejmech.2013.06.017	Discovery of the first inhibitors of bacterial enzyme D-aspartate ligase from Enterococcus faecium (Aslfm).	¿kedelj V, Perdih A, Brvar M, Krofli¿ A, Dubbée V, Savage V, O'Neill AJ, Solmajer T, Be¿ter-Roga¿ M, Blanot D, Hugonnet JE, Magnet S, Arthur M, Mainardi JL, Stojan J, Zega A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	67		230	242	23871903	10.1016/j.ejmech.2013.06.045	Microwave assisted synthesis of some hybrid molecules derived from norfloxacin and investigation of their biological activities.	Mentese MY, Bayrak H, Uygun Y, Mermer A, Ulker S, Karaoglu SA, Demirbas N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	68		96	102	23973821	10.1016/j.ejmech.2013.07.024	Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones.	El-Emam AA, Al-Tamimi AM, Al-Omar MA, Alrashood KA, Habib EE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	69		348	355	24077525	10.1016/j.ejmech.2013.08.050	Synthesis, antibacterial and antioxidant activities of new 1-alkyl-4-(1-alkyl-4-oxo-1,4-dihydroquinolin-2-yl)pyridinium bromides.	Kahriman N, Yayl¿ B, Akta¿ A, Iskefiyeli Z, Beri¿ F¿, Yayl¿ N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	69		622	631	24095755	10.1016/j.ejmech.2013.07.040	Design, synthesis and biological activities of some 7-aminocephalosporanic acid derivatives.	Basoglu S, Demirbas A, Ulker S, Alpay-Karaoglu S, Demirbas N.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	70		294	307	24161706	10.1016/j.ejmech.2013.09.046	Phosphorus-nitrogen compounds part 27. Syntheses, structural characterizations, antimicrobial and cytotoxic activities, and DNA interactions of new phosphazenes bearing secondary amino and pendant (4-fluorobenzyl)spiro groups.	Akba¿ H, Okumu¿ A, K¿l¿ç Z, Hökelek T, Süzen Y, Koç LY, Aç¿k L, Celik ZB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2013	70		419	426	24184775	10.1016/j.ejmech.2013.09.003	Synthesis and antimicrobial activity of some novel hydrazide, benzochromenone, dihydropyridine, pyrrole, thiazole and thiophene derivatives.	Refat HM, Fadda AA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2013	76	1	107	112	23294378	10.1021/np300806a	Arundinols A-C and arundinones A and B from the plant endophytic fungus Microsphaeropsis arundinis.	Luo J, Liu X, Li E, Guo L, Che Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2013	76	1	97	102	23320609	10.1021/np300773x	Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.	Talontsi FM, Lamshöft M, Bauer JO, Razakarivony AA, Andriamihaja B, Strohmann C, Spiteller M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2013	76	11	2009	2018	24224794	10.1021/np400145u	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.	Cai G, Napolitano JG, McAlpine JB, Wang Y, Jaki BU, Suh JW, Yang SH, Lee IA, Franzblau SG, Pauli GF, Cho S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2013	76	12	2263	2268	24251399	10.1021/np4006025	Cytotoxic and antibacterial marfuraquinocins from the deep South China Sea-derived Streptomyces niveus SCSIO 3406.	Song Y, Huang H, Chen Y, Ding J, Zhang Y, Sun A, Zhang W, Ju J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	10		10.1007/s00044-013-0720-3	Design, synthesis, and antimicrobial activity of some novel homodrimane sesquiterpenoids with diazine skeleton	Kuchkova K, Aricu A, Secara E, Barba A, Vlad P, Ungur N, Tuchilus C, Shova S, Zbancioc G, Mangalagiu II
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	14		10.1007/s00044-013-0803-1	Synthesis and evaluation of new chalcones, derived pyrazoline and cyclohexenone derivatives as potent antimicrobial, antitubercular and antileishmanial agents	Monga V, Goyal K, Steindel M, Malhotra M, Rajani DP, Rajani SD
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	6		10.1007/s00044-013-0844-5	Synergistic effects of berberines with antibiotics on clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA)	Zuo G, Li Y, Wang G, Li Z, Han J
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	7		10.1007/s00044-013-0799-6	Synthesis and pharmacological evaluation of novel 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one derivatives as potential antimicrobial agents	Patel V, Bhatt N, Bhatt P, Joshi HD
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	9		10.1007/s00044-013-0839-2	Synthesis and biological evaluation of novel quinazoline derivatives obtained by Suzuki CC coupling	Patel AB, Chikhalia KH, Kumari P
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Med Chem Res	2013			1	9		10.1007/s00044-013-0840-9	An efficient synthesis, characterization, and antimicrobial screening of tetrahydropyrimidine derivatives	Godhani DR, Dobariya PB, Jogel AA, Sanghani AM, Mehta JP
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2014	22	10	2844	2854	24751553	10.1016/j.bmc.2014.03.044	Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.	Zorzi RR, Jorge SD, Palace-Berl F, Pasqualoto KF, Bortolozzo Lde S, de Castro Siqueira AM, Tavares LC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2014	22	21	6047	6052	25277281	10.1016/j.bmc.2014.09.004	Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome.	Kim JH, Ryu YB, Lee WS, Kim YH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2014	24	1	367	370	24269165	10.1016/j.bmcl.2013.10.072	Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus.	Lam KH, Gambari R, Lee KK, Chen YX, Kok SH, Wong RS, Lau FY, Cheng CH, Wong WY, Bian ZX, Chan AS, Tang JC, Chui CH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2014	24	15	3569	3573	24951333	10.1016/j.bmcl.2014.05.051	One pot three components microwave assisted and conventional synthesis of new 3-(4-chloro-2-hydroxyphenyl)-2-(substituted) thiazolidin-4-one as antimicrobial agents.	Pansare DN, Mulla NA, Pawar CD, Shende VR, Shinde DB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2014	24	6	1605	1610	24513045	10.1016/j.bmcl.2014.01.035	Synthesis, antileishmanial activity and docking study of N'-substitutedbenzylidene-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetohydrazides.	Sangshetti JN, Shaikh RI, Khan FA, Patil RH, Marathe SD, Gade WN, Shinde DB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2014	5	7	915	922		10.1039/C4MD00124A	Thiazole-based aminopyrimidines and N-phenylpyrazolines as potent antimicrobial agents: synthesis and biological evaluation	Liaras K, Geronikaki A, Glamoclija J, Ciric A, Sokovic M
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2014	57	20	8398	8420	25238443	10.1021/jm500853v	Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.	Feng L, Maddox MM, Alam MZ, Tsutsumi LS, Narula G, Bruhn DF, Wu X, Sandhaus S, Lee RB, Simmons CJ, Tse-Dinh YC, Hurdle JG, Lee RE, Sun D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2014	57	6	2536	2548	24499135	10.1021/jm401808n	First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.	Fontaine F, Hequet A, Voisin-Chiret AS, Bouillon A, Lesnard A, Cresteil T, Jolivalt C, Rault S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2014	57	9	3845	3855	24694215	10.1021/jm500219c	Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria.	Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	71		24	30	24269513	10.1016/j.ejmech.2013.10.059	Access to a new class of biologically active quinoline based 1,2,4-triazoles.	Patel RV, Park SW.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	74		388	397	24486419	10.1016/j.ejmech.2013.12.055	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.	Abou-Elkhair RA, Moustafa AH, Haikal AZ, Ibraheem AM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	75		31	42	24508829	10.1016/j.ejmech.2013.09.029	Toward new classes of potent antibiotics: synthesis and antimicrobial activity of novel metallosaldach-imidazolium salts.	Elshaarawy RF, Janiak C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2014	77	6	1329	1335	24913558	10.1021/np5003302	Eremophilane-type sesquiterpenoids with diverse skeletons from Ligularia sagitta.	Chen JJ, Chen CJ, Yao XJ, Jin XJ, Gao K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2014	77	6	1396	1403	24828374	10.1021/np500156n	Suvanine sesterterpenes and deacyl irciniasulfonic acids from a tropical Coscinoderma sp. sponge.	Kim CK, Song IH, Park HY, Lee YJ, Lee HS, Sim CJ, Oh DC, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	78		207	216	24681985	10.1016/j.ejmech.2014.02.015	Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.	Kalaria PN, Satasia SP, Raval DK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	81		253	266	24852274	10.1016/j.ejmech.2014.05.024	Synthesis of symmetrically substituted 3,3-dibenzyl-4-hydroxy-3,4-dihydro-1H-quinolin-2-ones, as novel quinoline derivatives with antibacterial activity.	Ferretti MD, Neto AT, Morel AF, Kaufman TS, Larghi EL.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	81		267	276	24849271	10.1016/j.ejmech.2014.05.004	Synthesis and biological evaluation of some 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-arylethanones: antibacterial, DNA photocleavage, and anticancer activities.	Kumar V, Kaur K, Karelia DN, Beniwal V, Gupta GK, Sharma AK, Gupta AK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	82		565	573	24941130	10.1016/j.ejmech.2014.05.084	Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells.	Emirda¿-Öztürk S, Karay¿ld¿r¿m T, Çapc¿-Karagöz A, Alanku¿-Çal¿¿kan Ö, Özmen A, Poyrazo¿lu-Çoban E.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	83		474	489	24992075	10.1016/j.ejmech.2014.06.048	Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.	Sharma S, Saquib M, Verma S, Mishra NN, Shukla PK, Srivastava R, Prabhakar YS, Shaw AK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	83		655	664	25010936	10.1016/j.ejmech.2014.06.071	Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.	Kalaria PN, Satasia SP, Avalani JR, Raval DK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	84		491	504	25050881	10.1016/j.ejmech.2014.07.052	Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety.	Nasr T, Bondock S, Eid S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	84		51	58	25016227	10.1016/j.ejmech.2014.07.008	Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.	Karad SC, Purohit VB, Raval DK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	84		516	529	25055342	10.1016/j.ejmech.2014.07.051	Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1,2,4-triazoles as potential antitubercular agents.	Mohan Krishna K, Inturi B, Pujar GV, Purohit MN, Vijaykumar GS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	84		639	650	25063946	10.1016/j.ejmech.2014.01.014	New thiophene-1,2,4-triazole-5(3)-ones: highly bioactive thiosemicarbazides, structures of Schiff bases and triazole-thiols.	Ünver Y, Sancak K, Çelik F, Birinci E, Küçük M, Soylu S, Burnaz NA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	84		739	745	25064350	10.1016/j.ejmech.2014.07.065	Discovery of diethyl 2,5-diaminothiophene-3,4-dicarboxylate derivatives as potent anticancer and antimicrobial agents and screening of anti-diabetic activity: synthesis and in vitro biological evaluation. Part 1.	Bozorov K, Ma HR, Zhao JY, Zhao HQ, Chen H, Bobakulov K, Xin XL, Elmuradov B, Shakhidoyatov K, Aisa HA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	86		605	612	25218909	10.1016/j.ejmech.2014.09.025	Anti-tyrosinase, antioxidant, and antibacterial activities of novel 5-hydroxy-4-acetyl-2,3-dihydronaphtho[1,2-b]furans.	Xia L, Idhayadhulla A, Lee YR, Wee YJ, Kim SH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2014	87		662	676	25305333	10.1016/j.ejmech.2014.10.005	Phosphorus-nitrogen compounds. Part 29. Syntheses, crystal structures, spectroscopic and stereogenic properties, electrochemical investigations, antituberculosis, antimicrobial and cytotoxic activities and DNA interactions of ansa-spiro-ansa cyclotetraphosphazenes.	Elmas G, Okumu¿ A, Koç LY, Soltanzade H, K¿l¿ç Z, Hökelek T, Dal H, Aç¿k L, Üstünda¿ Z, Dündar D, Yavuz M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	101		313	325	26160112	10.1016/j.ejmech.2015.06.013	Imidazolidine-4-one derivatives in the search for novel chemosensitizers of Staphylococcus aureus MRSA: synthesis, biological evaluation and molecular modeling studies.	Matys A, Podlewska S, Witek K, Witek J, Bojarski AJ, Schabikowski J, Otr¿bska-Machaj E, Latacz G, Szyma¿ska E, Kie¿-Kononowicz K, Molnar J, Amaral L, Handzlik J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	101		442	451	26186150	10.1016/j.ejmech.2015.07.002	Design and synthesis of some new pyrazolyl-pyrazolines as potential anti-inflammatory, analgesic and antibacterial agents.	Viveka S, Dinesha, Shama P, Nagaraja GK, Ballav S, Kerkar S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2015	23	13	3687	3695	25891984	10.1016/j.bmc.2015.04.015	Synthesis and biological evaluation of caracasine acid derivatives.	Chávez K, Compagnone RS, Álvarez A, Figarella K, Galindo-Castro I, Marsiccobetre S, Triviño J, Arocha I, Taddei A, Orsini G, Tillett S, Suárez AI.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2015	23	21	7061	7068	26432604	10.1016/j.bmc.2015.09.027	Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.	Jin J, Cui J, Chaudhary AS, Hsieh YH, Damera K, Zhang H, Yang H, Wang B, Tai PC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	22	5025	5027	26497285	10.1016/j.bmcl.2015.10.045	Synthesis and evaluation of antibacterial activity of (R)-2-methylheptyl isonicotinate, a putative naturally occurring bioactive agent.	Cao J, Adler B, Perlmutter P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	24	5732	5736	26546212	10.1016/j.bmcl.2015.10.088	PPL catalyzed four-component PASE synthesis of 5-monosubstituted barbiturates: Structure and pharmacological properties.	Bihani M, Bora PP, Verma AK, Baruah R, Boruah HP, Bez G.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	24	5762	5766	26564265	10.1016/j.bmcl.2015.10.073	Click-based synthesis of bromotyrosine alkaloid analogs as potential anti-biofilm leads for SAR studies.	Andjouh S, Blache Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	24	5797	5803	26542964	10.1016/j.bmcl.2015.10.042	Synthesis, biological activity evaluation and molecular docking studies of novel coumarin substituted thiazolyl-3-aryl-pyrazole-4-carbaldehydes.	Vaarla K, Kesharwani RK, Santosh K, Vedula RR, Kotamraju S, Toopurani MK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	7	1420	1426	25765910	10.1016/j.bmcl.2015.02.043	Rapid 'one-pot' synthesis of a novel benzimidazole-5-carboxylate and its hydrazone derivatives as potential anti-inflammatory and antimicrobial agents.	Vasantha K, Basavarajaswamy G, Vaishali Rai M, Boja P, Pai VR, Shruthi N, Bhat M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2015	25	8	1778	1781	25791454	10.1016/j.bmcl.2015.02.056	Studies on antimicrobial effects of four ligands and their transition metal complexes with 8-mercaptoquinoline and pyridine terminal groups.	Zhang LJ, Zhang JA, Zou XZ, Liu YJ, Li N, Zhang ZJ, Li Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2015	6	1	202	211		10.1039/C4MD00257A	Design, synthesis and biological evaluation of novel 1,2,4-triazolo and 1,2,4-triazino[4,3-a]quinoxalines as potential anticancer and antimicrobial agents	Issa DAE, Habib NS, Abdel Wahab AE
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2015	6	2	319	326		10.1039/C4MD00399C	4-Thiazolidinone derivatives as potent antimicrobial agents: microwave-assisted synthesis, biological evaluation and docking studies	Pitta E, Tsolaki E, Geronikaki A, Petrovic J, Glamoclija J, Sokovic M, Crespan E, Maga G, Bhunia SS, Saxena AK
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	ACS Med. Chem. Lett.	2015	6	4	466	471	25941556	10.1021/acsmedchemlett.5b00024	Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria.	Hurley KA, Heinrich VA, Hershfield JR, Demons ST, Weibel DB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2015	6	5	839	845		10.1039/C4MD00525B	Synthesis and biological evaluation of novel 2-isoxazoline fused cyclopentane derivatives as potential antimicrobial and anticancer agents	Prajapti SK, Shrivastava S, Bihade U, Gupta AK, Naidu VGM, Banerjee UC, Babu BN
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	1	2	9	25524452	10.1021/np5004092	Teucrium polium phenylethanol and iridoid glycoside characterization and flavonoid inhibition of biofilm-forming Staphylococcus aureus.	Elmasri WA, Yang T, Tran P, Hegazy ME, Hamood AN, Mechref Y, Paré PW.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	1	93	102	25517209	10.1021/np500735f	Structure and antimicrobial activity of phloroglucinol derivatives from Achyrocline satureioides.	Casero C, Machín F, Méndez-Álvarez S, Demo M, Ravelo ÁG, Pérez-Hernández N, Joseph-Nathan P, Estévez-Braun A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	11	2768	2775	26510047	10.1021/acs.jnatprod.5b00752	Identification of Elaiophylin Skeletal Variants from the Indonesian Streptomyces sp. ICBB 9297.	Sheng Y, Lam PW, Shahab S, Santosa DA, Proteau PJ, Zabriskie TM, Mahmud T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	11	2814	2821	26551342	10.1021/acs.jnatprod.5b00867	Meroterpenoids from a Tropical Dysidea sp. Sponge.	Kim CK, Woo JK, Kim SH, Cho E, Lee YJ, Lee HS, Sim CJ, Oh DC, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	2	218	224	25634623	10.1021/np500753q	Additional sesterterpenes and a nortriterpene saponin from the sponge Clathria gombawuiensis.	Woo JK, Kim CK, Ahn CH, Oh DC, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	2	325	329	25668638	10.1021/np500793g	Puupehenol, a potent antioxidant antimicrobial meroterpenoid from a Hawaiian deep-water Dactylospongia sp. sponge.	Hagiwara K, Garcia Hernandez JE, Harper MK, Carroll A, Motti CA, Awaya J, Nguyen HY, Wright AD.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	3	349	354	25581396	10.1021/np500683u	Alkaloidal metabolites from a marine-derived Aspergillus sp. fungus.	Liao L, You M, Chung BK, Oh DC, Oh KB, Shin J.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	3	524	529	25495422	10.1021/np500736b	Pentacyclic antibiotics from a tidal mud flat-derived actinomycete.	Moon K, Chung B, Shin Y, Rheingold AL, Moore CE, Park SJ, Park S, Lee SK, Oh KB, Shin J, Oh DC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	4	939	943	25760525	10.1021/np501012n	Antibacterial Biphenanthrenes from the Fibrous Roots of Bletilla striata.	Qian CD, Jiang FS, Yu HS, Shen Y, Fu YH, Cheng DQ, Gan LS, Ding ZS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	7	1486	1494	26090896	10.1021/np500905g	HPLC-NMR and HPLC-MS Profiling and Bioassay-Guided Identification of Secondary Metabolites from the Australian Plant Haemodorum spicatum.	Brklja¿a R, Urban S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	7	1600	1608	26151487	10.1021/acs.jnatprod.5b00161	Phytochemical Investigation of the Constituents Derived from the Australian Plant Macropidia fuliginosa.	Brklja¿a R, White JM, Urban S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Nat. Prod.	2015	78	7	1708	1715	26147490	10.1021/acs.jnatprod.5b00357	Cytotoxic Homoisoflavones from the Bulbs of Bellevalia eigii.	Alali F, El-Elimat T, Albataineh H, Al-Balas Q, Al-Gharaibeh M, Falkinham JO, Chen WL, Swanson SM, Oberlies NH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	95		185	198	25817769	10.1016/j.ejmech.2015.02.056	Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.	Fontaine F, Héquet A, Voisin-Chiret AS, Bouillon A, Lesnard A, Cresteil T, Jolivalt C, Rault S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	95		64	75	25794790	10.1016/j.ejmech.2015.01.015	Pentacyclic triterpene derivatives possessing polyhydroxyl ring A inhibit gram-positive bacteria growth by regulating metabolism and virulence genes expression.	Huang L, Luo H, Li Q, Wang D, Zhang J, Hao X, Yang X.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	97		190	201	25969171	10.1016/j.ejmech.2015.05.002	Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation.	Shaaban S, Negm A, Sobh MA, Wessjohann LA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2015	97		83	93	25982329	10.1016/j.ejmech.2015.04.042	Benzaldehyde Schiff bases regulation to the metabolism, hemolysis, and virulence genes expression in vitro and their structure-microbicidal activity relationship.	Xia L, Xia YF, Huang LR, Xiao X, Lou HY, Liu TJ, Pan WD, Luo H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur. J. Med. Chem.	2016	112		270	279	26900659	10.1016/j.ejmech.2016.02.016	Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.	Karad SC, Purohit VB, Thakor P, Thakkar VR, Raval DK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2016	24	14	3166	3173	27259400	10.1016/j.bmc.2016.05.044	The influence of halogen substituents on the biological properties of sulfur-containing flavonoids.	Bahrin LG, Sarbu LG, Hopf H, Jones PG, Babii C, Stefan M, Birsa ML.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2016	24	16	3649	3656	27301680	10.1016/j.bmc.2016.06.004	Novel benzimidazol-2-ylidene carbene precursors and their silver(I) complexes: Potential antimicrobial agents.	Kalo¿lu M, Kalo¿lu N, Özdemir ¿, Günal S, Özdemir ¿.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2016	24	21	5592	5601	27658791	10.1016/j.bmc.2016.09.018	Synthesis, characterization, and evaluation of (E)-methyl 2-((2-oxonaphthalen-1(2H)-ylidene)methylamino)acetate as a biological agent and an anion sensor.	Zeyrek CT, Boyacio¿lu B, Y¿ld¿z M, Ünver H, Yolal D, Demir N, Elmali A, Tadesse S, Aslan K.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2016	24	24	6276	6290	27234886	10.1016/j.bmc.2016.05.021	Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.	Molloy EM, Tietz JI, Blair PM, Mitchell DA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem.	2016	24	6	1376	1383	26879853	10.1016/j.bmc.2016.02.013	Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.	Kong X, Zhang H, Cao C, Zhou S, Pang G, Shi Y.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	1	218	221	26590101	10.1016/j.bmcl.2015.10.085	Discovery of bisindolyl-substituted cycloalkane-anellated indoles as novel class of antibacterial agents against S. aureus and MRSA.	El-Sayed MT, Suzen S, Altanlar N, Ohlsen K, Hilgeroth A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	13	2980	2983	27216998	10.1016/j.bmcl.2016.05.030	Caged xanthones: Potent inhibitors of global predominant MRSA USA300.	Chaiyakunvat P, Anantachoke N, Reutrakul V, Jiarpinitnun C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	13	3127	3134	27184767	10.1016/j.bmcl.2016.04.089	GroEL/ES inhibitors as potential antibiotics.	Abdeen S, Salim N, Mammadova N, Summers CM, Frankson R, Ambrose AJ, Anderson GG, Schultz PG, Horwich AL, Chapman E, Johnson SM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	16	3950	3954	27423480	10.1016/j.bmcl.2016.07.006	Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents.	Zhao Y, Shadrick WR, Wallace MJ, Wu Y, Griffith EC, Qi J, Yun MK, White SW, Lee RE.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	3	1005	1010	26725026	10.1016/j.bmcl.2015.12.044	Efficiently functionalized oxacalix[4]arenes: Synthesis, characterization and exploration of their biological profile as novel HDAC inhibitors.	Mehta V, Athar M, Jha PC, Panchal M, Modi K, Jain VK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	5	1428	1433	26832786	10.1016/j.bmcl.2016.01.067	Synthesis and SAR of 4-methyl-5-pentylbenzene-1,3-diol (MPBD), produced by Dictyostelium discoideum.	Murata C, Ogura T, Narita S, Kondo AP, Iwasaki N, Saito T, Usuki T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	7	1704	1708	26927426	10.1016/j.bmcl.2016.02.056	Facile synthesis of 1,3-thiazolidin-4-ones as antitubercular agents.	Subhedar DD, Shaikh MH, Arkile MA, Yeware A, Sarkar D, Shingate BB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	7	1776	1783	26920799	10.1016/j.bmcl.2016.02.043	Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.	Desai NC, Somani H, Trivedi A, Bhatt K, Nawale L, Khedkar VM, Jha PC, Sarkar D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg. Med. Chem. Lett.	2016	26	9	2278	2283	27013391	10.1016/j.bmcl.2016.03.045	Novel tetrazoloquinoline-rhodanine conjugates: Highly efficient synthesis and biological evaluation.	Subhedar DD, Shaikh MH, Nawale L, Yeware A, Sarkar D, Khan FA, Sangshetti JN, Shingate BB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Med Chem	2016	59	11	5542	5554	27165692	10.1021/acs.jmedchem.6b00660	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.	Lund BA, Christopeit T, Guttormsen Y, Bayer A, Leiros HK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2016	59	11	5471	5487	27191386	10.1021/acs.jmedchem.6b00483	Targeting the Motion of Shikimate Kinase: Development of Competitive Inhibitors that Stabilize an Inactive Open Conformation of the Enzyme.	Prado V, Lence E, Maneiro M, Vázquez-Ucha JC, Beceiro A, Thompson P, Hawkins AR, González-Bello C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2016	59	5	1791	1799	26881456	10.1021/acs.jmedchem.5b01264	A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.	Jin L, Bai X, Luan N, Yao H, Zhang Z, Liu W, Chen Y, Yan X, Rong M, Lai R, Lu Q.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2016	59	5	2126	2138	26765953	10.1021/acs.jmedchem.5b01797	Robenidine Analogues as Gram-Positive Antibacterial Agents.	Abraham RJ, Stevens AJ, Young KA, Russell C, Qvist A, Khazandi M, Wong HS, Abraham S, Ogunniyi AD, Page SW, O'Handley R, McCluskey A, Trott DJ.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J. Med. Chem.	2016	59	7	3140	3151	26964758	10.1021/acs.jmedchem.5b01912	Antibacterial Diamines Targeting Bacterial Membranes.	Wang B, Pachaiyappan B, Gruber JD, Schmidt MG, Zhang YM, Woster PM.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2016	7	1	118	127		10.1039/C5MD00325C	Tabtoxinine--lactam is a stealth -lactam antibiotic that evades -lactamase-mediated antibiotic resistance	Hart KM, Reck M, Bowman GR, Wencewicz TA
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	MedChemComm	2016	7	9	1832	1848		10.1039/C6MD00278A		
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Nat Prod	2016	79	7	1886	1890	27367579	10.1021/acs.jnatprod.6b00268	Actinomadurol, an Antibacterial Norditerpenoid from a Rare Actinomycete, Actinomadura sp. KC 191.	Shin B, Kim BY, Cho E, Oh KB, Shin J, Goodfellow M, Oh DC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Nat Prod	2016	79	9	2315	2323	27536968	10.1021/acs.jnatprod.6b00452	Halogenated Sesquiterpenoids from the Red Alga Laurencia tristicha Collected in Taiwan.	Chen JY, Huang CY, Lin YS, Hwang TL, Wang WL, Chiou SF, Sheu JH.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Nat Prod	2016	79	9	2391	2396	27588436	10.1021/acs.jnatprod.6b00621	Total Synthesis of (±)-Isoperbergins and Correction of the Chemical Structure of Perbergin.	Almabruk KH, Chang JH, Mahmud T.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur J Med Chem	2017	125		385	399	27688192	10.1016/j.ejmech.2016.09.059	Quinolidene-rhodanine conjugates: Facile synthesis and biological evaluation.	Subhedar DD, Shaikh MH, Shingate BB, Nawale L, Sarkar D, Khedkar VM, Kalam Khan FA, Sangshetti JN.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur J Med Chem	2017	126		894	909	27988464	10.1016/j.ejmech.2016.12.016	Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.	Karad SC, Purohit VB, Thummar RP, Vaghasiya BK, Kamani RD, Thakor P, Thakkar VR, Thakkar SS, Ray A, Raval DK.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Eur J Med Chem	2017	132		333	340	28411559	10.1016/j.ejmech.2017.03.065	Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.	Abhale YK, Sasane AV, Chavan AP, Shekh SH, Deshmukh KK, Bhansali S, Nawale L, Sarkar D, Mhaske PC.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2017	25	1	132	137	27793449	10.1016/j.bmc.2016.10.019	Antibacterial profiling of abietane-type diterpenoids.	Helfenstein A, Vahermo M, Nawrot DA, Demirci F, ¿¿can G, Krogerus S, Yli-Kauhaluoma J, Moreira VM, Tammela P.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2017	25	1	58	66	27769670	10.1016/j.bmc.2016.10.009	Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.	Shrestha SK, Kril LM, Green KD, Kwiatkowski S, Sviripa VM, Nickell JR, Dwoskin LP, Watt DS, Garneau-Tsodikova S.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2017	25	15	4064	4075	28634040	10.1016/j.bmc.2017.05.054	1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.	Thakkar SS, Thakor P, Doshi H, Ray A.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem	2017	25	20	5396	5406	28789907	10.1016/j.bmc.2017.07.057	Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.	Thakkar SS, Thakor P, Ray A, Doshi H, Thakkar VR.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	11	2397	2400	28416134	10.1016/j.bmcl.2017.04.017	Syntheses of benzophenone-xanthone hybrid polyketides and their antibacterial activities.	Kodama T, Ito T, Dibwe DF, Woo SY, Morita H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	12	2674	2677	28476568	10.1016/j.bmcl.2017.04.039	Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.	Pang GX, Niu C, Mamat N, Aisa HA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	13	2873	2880	28487071	10.1016/j.bmcl.2017.04.083	Diversity-oriented sustainable synthesis of antimicrobial spiropyrrolidine/thiapyrrolizidine oxindole derivatives: New ligands for a metallo-ß-lactamase from Klebsiella pneumonia.	Dandia A, Khan S, Soni P, Indora A, Mahawar DK, Pandya P, Chauhan CS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	14	3043	3047	28558970	10.1016/j.bmcl.2017.05.060	New merosesquiterpenes from a Vietnamese marine sponge of Spongia sp. and their biological activities.	Nguyen HM, Ito T, Kurimoto SI, Ogawa M, Win NN, Hung VQ, Nguyen HT, Kubota T, Kobayashi J, Morita H.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	2	288	294	27914801	10.1016/j.bmcl.2016.11.056	New bithiazolyl hydrazones: Novel synthesis, characterization and antitubercular evaluation.	Bhalerao MB, Dhumal ST, Deshmukh AR, Nawale LU, Khedkar V, Sarkar D, Mane RA.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	3	567	573	28003139	10.1016/j.bmcl.2016.12.018	Antileishmanial evaluation of clubbed bis(indolyl)-pyridine derivatives: One-pot synthesis, in vitro biological evaluations and in silico ADME prediction.	Khan FA, Zaheer Z, Sangshetti JN, Patil RH, Farooqui M.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	3	695	699	28065567	10.1016/j.bmcl.2016.06.038	Synthesis, identification and in vitro biological evaluation of some novel quinoline incorporated 1,3-thiazinan-4-one derivatives.	Umamatheswari S, Sankar C.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	4	922	928	28110868	10.1016/j.bmcl.2017.01.004	Quinolidene based monocarbonyl curcumin analogues as promising antimycobacterial agents: Synthesis and molecular docking study.	Subhedar DD, Shaikh MH, Nawale L, Sarkar D, Khedkar VM, Shingate BB.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	Bioorg Med Chem Lett	2017	27	7	1538	1546	28262524	10.1016/j.bmcl.2017.02.042	Biologically active perspective synthesis of heteroannulated 8-nitroquinolines with green chemistry approach.	Arasakumar T, Mathusalini S, Gopalan S, Shyamsivappan S, Ata A, Mohan PS.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Med Chem	2017	60	14	6098	6118	28654257	10.1021/acs.jmedchem.7b00355	Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.	Seydlová G, Pohl R, Zborníková E, Ehn M, ¿imák O, Panova N, Kolá¿ M, Bogdanová K, Ve¿e¿ová R, Fi¿er R, ¿anderová H, Vítovská D, Sudzinová P, Pospí¿il J, Benada O, K¿í¿ek T, Sedlák D, Bart¿n¿k P, Krásný L, Rejman D.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174	J Nat Prod	2017	80	2	269	277	28128554	10.1021/acs.jnatprod.6b00478	Discovery of C-Glycosylpyranonaphthoquinones in Streptomyces sp. MBT76 by a Combined NMR-Based Metabolomics and Bioinformatics Workflow.	Wu C, Du C, Ichinose K, Choi YH, van Wezel GP.
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									DrugMatrix	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									Drug metabolism data	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									Unpublished dataset	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	AMPICILLIN	CHEMBL174									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	J. Nat. Prod.	2009	72	9	1712	1715	19708679	10.1021/np900302w	Spirobisnaphthalene analogues from the endophytic fungus Preussia sp.	Chen X, Shi Q, Lin G, Guo S, Yang J.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	Eur. J. Med. Chem.	2012	50		296	303	22365561	10.1016/j.ejmech.2012.02.008	Three novel cyclic hexapeptides from Streptomyces alboflavus 313 and their antibacterial activity.	Ji Z, Wei S, Fan L, Wu W.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	J. Med. Chem.	2012	55	22	10160	10176	23050700	10.1021/jm3012728	A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.	Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	Med Chem Res	2013			1	9		10.1007/s00044-013-0790-2	Synthesis and antibacterial activity evaluation of 2,6-bis(6-substituted-1,2,4-triazolo[3,4-b][1,3,4]thiadiazol-3-yl)pyridine derivatives	Xiao H, Li P, Guo D, Hu J, Chai Y, He W
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758	Bioorg. Med. Chem. Lett.	2016	26	2	580	583	26681509	10.1016/j.bmcl.2015.11.070	Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones.	Dai JK, Dan WJ, Li N, Du HT, Zhang JW, Wang JR.
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758									Unpublished dataset	
962.7500000000000000	2	Bacteria	AMPICILLIN SODIUM	CHEMBL1200758									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.6000000000000000	9606	Homo sapiens	ANAKINRA	CHEMBL1201570									British National Formulary (72nd edition)	
886.6000000000000000	9606	Homo sapiens	ANAKINRA	CHEMBL1201570									Unpublished dataset	
886.6000000000000000	9606	Homo sapiens	ANAKINRA	CHEMBL1201570									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.6000000000000000	9606	Homo sapiens	ANAKINRA	CHEMBL1201570									WHO Anatomical Therapeutic Chemical Classification	
895.6500000000000000	9606	Homo sapiens	ANILERIDINE HYDROCHLORIDE	CHEMBL1201047	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
895.6500000000000000	9606	Homo sapiens	ANILERIDINE HYDROCHLORIDE	CHEMBL1201047	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
895.6500000000000000	9606	Homo sapiens	ANILERIDINE HYDROCHLORIDE	CHEMBL1201047	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
895.6500000000000000	9606	Homo sapiens	ANILERIDINE HYDROCHLORIDE	CHEMBL1201047									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	ANILERIDINE HYDROCHLORIDE	CHEMBL1201047									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
895.6500000000000000	9606	Homo sapiens	ANILERIDINE PHOSPHATE	CHEMBL1200543									Unpublished dataset	
882.4000000000000000	9606	Homo sapiens	ANLOTINIB	CHEMBL3545021									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	ANTITHROMBIN ALFA	CHEMBL1201554									British National Formulary (72nd edition)	
958.5500000000000000	9606	Homo sapiens	ANTITHROMBIN ALFA	CHEMBL1201554									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	APRICOXIB	CHEMBL1835207	Bioorg. Med. Chem. Lett.	2011	21	20	6071	6073	21903394	10.1016/j.bmcl.2011.08.050	Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.	Mandal PK, Freiter EM, Bagsby AL, Robertson FM, McMurray JS.
886.5000000000000000	9606	Homo sapiens	APRICOXIB	CHEMBL1835207									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	APRICOXIB	CHEMBL1835207									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1994	37	23	3889	3901	7966150	10.1021/jm00049a008	Design and synthesis of potent and highly selective thrombin inhibitors.	Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadváry P, Labler L, Müller K, Schmid G, Tschopp TB.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	1994	4	18	2165	2170		10.1016/S0960-894X(00)80064-5	Argatroban analogs: Synthesis, thrombin inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates	Misra RN, Kelly YF, Brown BR, Roberts DG, Chong S, Seiler SM
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1996	39	16	3039	3043	8759623	10.1021/jm9603274	Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.	Costanzo MJ, Maryanoff BE, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Kauffman JA, Lewis JM, Krishnan R, Tulinsky A.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1997	40	11	1565	1569	9171866	10.1021/jm970140s	Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.	Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Baskin EP, Woltmann R, Lynch JJ, Lyle EA, Appleby SD, Chen IW, Dancheck KB, Vacca JP.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1997	40	19	3091	3099	9301673	10.1021/jm960668h	Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.	Stürzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikström P.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1997	40	22	3687	3693	9357536	10.1021/jm970397q	Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.	Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Sisko JT, Lynch JJ, Lyle EA, Baskin EP, Woltmann RF, Appleby SD, Chen IW, Dancheck KB, Naylor-Olsen AM, Krueger JA, Cooper CM, Vacca JP.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	1997	7	17	2205	2210		10.1016/S0960-894X(97)00403-4	Design and synthesis of conformationally constrained arginal thrombin inhibitors	Salimbeni A, Paleari F, Canevotti R, Criscuoli M, Criscuoli M, Lippi A, Angiolini M, Belvisi L, Scolastico C, Colombo L
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	1997	7	5	533	538		10.1016/S0960-894X(97)00057-7	Peptidyl -keto thiazole as potent thrombin inhibitors	Akiyama Y, Tsutsumi S, Hatsushiba E, Ohuchi S, Okonogi T
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1998	41	17	3210	3219	9703466	10.1021/jm9801713	Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.	Tucker TJ, Brady SF, Lumma WC, Lewis SD, Gardell SJ, Naylor-Olsen AM, Yan Y, Sisko JT, Stauffer KJ, Lucas BJ, Lynch JJ, Cook JJ, Stranieri MT, Holahan MA, Lyle EA, Baskin EP, Chen IW, Dancheck KB, Krueger JA, Cooper CM, Vacca JP.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	1999	42	22	4584	4603	10579821	10.1021/jm9811209	Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency.	Brundish D, Bull A, Donovan V, Fullerton JD, Garman SM, Hayler JF, Janus D, Kane PD, McDonnell M, Smith GP, Wakeford R, Walker CV, Howarth G, Hoyle W, Allen MC, Ambler J, Butler K, Talbot MD.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	1999	9	9	1227	1232	10340604	10.1016/s0960-894x(99)00179-1	Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety.	Adang AE, Peters AM, Gerritsma S, de Zwart E, Veeneman G.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2000	43	3	305	341	10669559	10.1021/jm990412m	Protease inhibitors: current status and future prospects.	Leung D, Abbenante G, Fairlie DP.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2000	43	9	1793	1806	10794696	10.1021/jm9903693	Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.	Supuran CT, Scozzafava A, Briganti F, Clare BW.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	2001	11	15	1989	1992	11454464	10.1016/s0960-894x(01)00351-1	A short synthesis of argatroban. a potent selective thrombin inhibitor.	Cossy J, Belotti D.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	2002	12	1	41	44	11738569	10.1016/s0960-894x(01)00664-3	Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.	Das J, Kimball SD, Reid JA, Wang TC, Lau WF, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	2002	12	1	45	49	11738570	10.1016/s0960-894x(01)00667-9	Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.	Das J, Kimball SD, Hall SE, Han WC, Iwanowicz E, Lin J, Moquin RV, Reid JA, Sack JS, Malley MF, Chang CY, Chong S, Wang-Iverson DB, Roberts DG, Seiler SM, Schumacher WA, Ogletree ML.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2002	45	20	4419	4432	12238922	10.1021/jm011110z	Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.	Adang AE, de Man AP, Vogel GM, Grootenhuis PD, Smit MJ, Peters CA, Visser A, Rewinkel JB, van Dinther T, Lucas H, Kelder J, van Aelst S, Meuleman DG, van Boeckel CA.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2003	46	17	3612	3622	12904065	10.1021/jm030025j	Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.	Lee K, Park CW, Jung WH, Park HD, Lee SH, Chung KH, Park SK, Kwon OH, Kang M, Park DH, Lee SK, Kim EE, Yoon SK, Kim A.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2005	48	24	7592	7603	16302799	10.1021/jm050448g	3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.	Frédérick R, Robert S, Charlier C, de Ruyck J, Wouters J, Pirotte B, Masereel B, Pochet L.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2005	48	6	1984	2008	15771442	10.1021/jm0303857	In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.	Costanzo MJ, Almond HR, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2005	48	9	3313	3318	15857136	10.1021/jm049066l	Conformation mining: an algorithm for finding biologically relevant conformations.	Putta S, Landrum GA, Penzotti JE.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Nat. Prod.	2007	70	10	1570	1577	17883259	10.1021/np070260v	Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.	Zhu Y, Zhang P, Yu H, Li J, Wang MW, Zhao W.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	2008	18	16	4533	4537	18674905	10.1016/j.bmcl.2008.07.044	Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.	Shiraishi T, Kadono S, Haramura M, Kodama H, Ono Y, Iikura H, Esaki T, Koga T, Hattori K, Watanabe Y, Sakamoto A, Yoshihashi K, Kitazawa T, Esaki K, Ohta M, Sato H, Kozono T.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2010	53	4	1843	1856	20102150	10.1021/jm901802n	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.	Lu T, Markotan T, Ballentine SK, Giardino EC, Spurlino J, Crysler CS, Brown K, Maryanoff BE, Tomczuk BE, Damiano BP, Shukla U, End D, Andrade-Gordon P, Bone RF, Player MR.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem. Lett.	2013	23	17	4779	4784	23899618	10.1016/j.bmcl.2013.07.008	Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.	Park HD, Lee SH, Kim TH, Lee SH, Cho KH, Kim A.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J. Med. Chem.	2014	57	20	8563	8575	25268757	10.1021/jm5010754	How a ß-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.	Belviso BD, Caliandro R, de Candia M, Zaetta G, Lopopolo G, Incampo F, Colucci M, Altomare CD.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg. Med. Chem.	2015	23	23	7405	7416	26537784	10.1016/j.bmc.2015.10.036	Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.	Chen D, Wang S, Diao X, Zhu Q, Shen H, Han X, Wang Y, Gong G, Xu Y.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Eur. J. Med. Chem.	2015	96		122	138	25874337	10.1016/j.ejmech.2015.04.012	Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.	Li ML, Ren YJ, Dong MH, Ren WX.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	Bioorg Med Chem	2017	25	2	458	470	27884512	10.1016/j.bmc.2016.11.012	Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.	Chen D, Shi J, Liu J, Zhang X, Deng X, Yang Y, Cui S, Zhu Q, Gong G, Xu Y.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166	J Med Chem	2018	61	6	2166	2210	28850227	10.1021/acs.jmedchem.7b00315	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.	Talele TT.
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166									PubChem BioAssay data set	
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	ARGATROBAN	CHEMBL1166									WHO Anatomical Therapeutic Chemical Classification	
1033.7000000000000000	9606	Homo sapiens	AS-703988	CHEMBL3545243									Unpublished dataset	
1273.9250000000000000	9606	Homo sapiens	ASAPIPRANT	CHEMBL3545043		2012							Sulfonamide derivative having PGD2 receptor antagonistic activity	
1273.9250000000000000	9606	Homo sapiens	ASAPIPRANT	CHEMBL3545043									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	ASM-024	CHEMBL3707249									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	AT-13148	CHEMBL3544960		2013							Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases	
867.7500000000000000	9606	Homo sapiens	AT-13148	CHEMBL3544960	Bioorg Med Chem Lett	2017	27	13	2838	2848	28506751	10.1016/j.bmcl.2017.04.090	Recent progress towards clinically relevant ATP-competitive Akt inhibitors.	Huck BR, Mochalkin I.
867.7500000000000000	9606	Homo sapiens	AT-13148	CHEMBL3544960	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
867.7500000000000000	9606	Homo sapiens	AT-13148	CHEMBL3544960									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	J. Med. Chem.	2009	52	2	379	388	19143567	10.1021/jm800984v	Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.	Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovi¿ M, Wyatt PG.
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	J. Med. Chem.	2009	52	9	2629	2651	19320489	10.1021/jm8012129	Discovery and development of aurora kinase inhibitors as anticancer agents.	Pollard JR, Mortimore M.
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	Bioorg. Med. Chem. Lett.	2013	23	12	3523	3530	23664099	10.1016/j.bmcl.2013.04.039	Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.	Zheng Y, Zheng M, Ling X, Liu Y, Xue Y, An L, Gu N, Ji M.
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	Bioorg Med Chem	2017	25	9	2609	2616	28351607	10.1016/j.bmc.2017.03.018	Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.	Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN.
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727	ACS Med Chem Lett	2017	8	6	618	621	28626521	10.1021/acsmedchemlett.7b00153	Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.	Puleo DE, Kucera K, Hammarén HM, Ungureanu D, Newton AS, Silvennoinen O, Jorgensen WL, Schlessinger J.
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727								10.6019/CHEMBL3885741	K4DD drug target binding kinetics data	Doris A.Schuetz, Wilhelmus Egbertus Arnout de Witte, Yin Cheong Wong, Bernhard Knasmueller, Lars Richter, Daria B. Kokh, S. Kashif Sadiq, Reggie Bosma, Indira Nederpelt, Laura H. Heitman, Elena Segala, Marta Amaral, Dong Guo, Dorothee Andres, Victoria Georgi, Leigh A. Stoddart, Steve Hill, Robert M. Cooke, Chris De Graaf, Rob Leurs, Matthias Frech, Rebecca C. Wade, Elizabeth Cunera Mariade Lange, Adriaan P. IJzerman, Anke Müller-Fahrnow, Gerhard F. Ecker
924.8000000000000000	9606	Homo sapiens	AT-9283	CHEMBL495727									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	ATAGABALIN	CHEMBL593430	Bioorg. Med. Chem. Lett.	2010	20	1	248	251	19910190	10.1016/j.bmcl.2009.10.121	Synthesis and in vivo evaluation of 3,4-disubstituted gababutins.	Blakemore DC, Bryans JS, Carnell P, Field MJ, Kinsella N, Kinsora JK, Meltzer LT, Osborne SA, Thompson LR, Williams SC.
1494.3800000000000000	9606	Homo sapiens	ATAGABALIN	CHEMBL593430	Bioorg. Med. Chem. Lett.	2010	20	2	461	464	20005103	10.1016/j.bmcl.2009.11.118	Synthesis and in vivo evaluation of bicyclic gababutins.	Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC.
1494.3800000000000000	9606	Homo sapiens	ATAGABALIN	CHEMBL593430									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	ATAGABALIN	CHEMBL593430									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356	J. Med. Chem.	1995	38	24	4768	4775	7490726	10.1021/jm00024a004	(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.	Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C.
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356	J. Med. Chem.	1996	39	14	2629	2654	8709092	10.1021/jm960088k	Modulators of leukotriene biosynthesis and receptor activation.	Brooks CD, Summers JB.
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356	J. Med. Chem.	1997	40	13	1955	1968	9207936	10.1021/jm9700474	Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.	Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356	J. Med. Chem.	1998	41	4	420	427	9484493	10.1021/jm970034q	Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid.	Hopper AT, Witiak DT, Ziemniak J.
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356	Bioorg. Med. Chem. Lett.	2004	14	9	2265	2268	15081022	10.1016/j.bmcl.2004.02.005	5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.	Lewis TA, Bayless L, Eckman JB, Ellis JL, Grewal G, Libertine L, Marie Nicolas J, Scannell RT, Wels BF, Wenberg K, Wypij DM.
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
943.5000000000000000	9606	Homo sapiens	ATRELEUTON	CHEMBL59356									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
998.6000000000000000	9606	Homo sapiens	AVE0847	CHEMBL3545295									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	AXOMADOL	CHEMBL3989680									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	AXOMADOL	CHEMBL3989680									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	AZD-0424	CHEMBL3545177									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	AZD-8330	CHEMBL3182621	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	AZD-8330	CHEMBL3182621									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	AZD-8330	CHEMBL3182621									Unpublished dataset	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1993	3	6	1287	1292		10.1016/S0960-894X(00)80333-9	The synthesis of novel 8a-aza-8a-homoerythromycin derivatives via the beckmann rearrangement of (9z)-erythromycin a oxime	Wilkening RR, Ratcliffe RW, Doss GA, Bartizal KF, Graham AC, Herbert CM
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1994	4	9	1111	1116		10.1016/S0960-894X(01)80238-9	Preparation and activities of 4-epi and 4-deoxy-4-amino analogs derived from 9-deoxo-8a-aza-8a-homoerythromycin A	Shankaran K, Wilkening RR, Blizzard TA, Ratcliffe RW, Heck JV, Graham AC, Herbert CM
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	1996	39	20	3853	3874	8831751	10.1021/jm960294s	New directions in antibacterial research.	Chu DT, Plattner JJ, Katz L.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	1996	39	3	680	685	8576910	10.1021/jm950956y	Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.	Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	1997	40	6	1041	1045	9083494	10.1021/jm960435q	Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.	McFarland JW, Hecker SJ, Jaynes BH, Jefson MR, Lundy KM, Vu CB, Glazer EA, Froshauer SA, Hayashi SF, Kamicker BJ, Reese CP, Olson JA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	1997	40	9	1340	1346	9135031	10.1021/jm960436i	Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.	McFarland JW, Berger CM, Froshauer SA, Hayashi SF, Hecker SJ, Jaynes BH, Jefson MR, Kamicker BJ, Lipinski CA, Lundy KM, Reese CP, Vu CB.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	1998	41	21	4080	4100	9767644	10.1021/jm980240d	Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.	Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1998	8	11	1321	1326	9871759	10.1016/s0960-894x(98)00227-3	Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin.	Waddell ST, Santorelli GM, Blizzard TA, Graham A, Occi J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1998	8	18	2427	2432	9873555	10.1016/s0960-894x(98)00402-8	Synthesis of 6-O-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime.	Denis A, Agouridas C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1998	8	5	549	554	9871616	10.1016/s0960-894x(98)00070-5	"Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: I. 4"", 11 and 12-OMe derivatives via direct methylation."	Waddell ST, Santorelli GM, Blizzard TA, Graham A, Occi J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	1999	9	21	3075	3080	10560728	10.1016/s0960-894x(99)00534-x	Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.	Denis A, Agouridas C, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N, Pejac JM, Perron S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2000	10	17	2019	2022	10987440	10.1016/s0960-894x(00)00392-9	Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides.	Denis A, Bretin F, Fromentin C, Bonnet A, Piltan G, Bonnefoy A, Agouridas C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2000	43	6	1045	1049	10737737	10.1021/jm990618n	Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens.	Or YS, Clark RF, Wang S, Chu DT, Nilius AM, Flamm RK, Mitten M, Ewing P, Alder J, Ma Z.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Chem. Res. Toxicol.	2001	14	1	1596	1603	11743742	10.1021/tx010125x	Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.	Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2001	44	24	4137	4156	11708916	10.1021/jm0102349	Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.	Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA, Chu DT, Plattner JJ, Zhang X, Zhong P, Cao Z, Nilius AM, Shortridge VD, Flamm R, Mitten M, Meulbroek J, Ewing P, Alder J, Or YS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2002	12	17	2431	2434	12161150	10.1016/s0960-894x(02)00434-1	Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent Gram-positive and Gram-negative antibacterial agents.	Cheng H, Dirlam JP, Ziegler CB, Lundy KM, Hayashi SF, Kamicker BJ, Dutra JK, Daniel KL, Santoro SL, George DM, Bertsche CD, Sakya SM, Suarez-Contreras M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2003	46	13	2706	2715	12801234	10.1021/jm020568d	Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.	Tanikawa T, Asaka T, Kashimura M, Suzuki K, Sugiyama H, Sato M, Kameo K, Morimoto S, Nishida A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Pharmacol.	2004	484	1	333	339	14744620	10.1016/j.ejphar.2003.11.035	Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.	Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2005	15	5	1307	1310	15713376	10.1016/j.bmcl.2005.01.027	Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics.	Liang CH, Yao S, Chiu YH, Leung PY, Robert N, Seddon J, Sears P, Hwang CK, Ichikawa Y, Romero A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Xenobiotica	2005	35	2	191	210	16019946	10.1080/00498250400028197	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.	Ward KW, Nagilla R, Jolivette LJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Nat. Prod.	2006	69	11	1641	1644	17125239	10.1021/np060334n	Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus.	Fang W, Ruan J, Wang Z, Zhao Z, Zou J, Zhou D, Cai Y.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Biol. Chem.	2007	282	4	2494	2504	17110371	10.1074/jbc.m608615200	In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.	Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	1	23	27	17060522	10.1128/aac.00788-06	Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis.	Soltow SM, Brenner GM.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	1	376	378	17043112	10.1128/aac.00858-06	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.	Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, Jorgensen JH.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	10	3485	3490	17698630	10.1128/aac.00527-07	Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast.	Dahl EL, Rosenthal PJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	10	3677	3687	17620382	10.1128/aac.01011-06	Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.	Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, Givskov M, Høiby N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	11	4191	4195	17875997	10.1128/aac.00550-07	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.	Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	11	4196	4201	17876003	10.1128/aac.00827-07	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.	Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	12	4243	4248	17876004	10.1128/aac.00613-07	Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa.	Köhler T, Dumas JL, Van Delden C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	12	4267	4275	17908942	10.1128/aac.00962-07	Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.	Binet R, Maurelli AT.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	12	4382	4389	17908940	10.1128/aac.00971-07	National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.	Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	12	4529	4530	17876007	10.1128/aac.01115-07	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.	Hawley JS, Murray CK, Jorgensen JH.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	2	623	630	17145801	10.1128/aac.01033-06	Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.	Chan YY, Ong YM, Chua KL.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	2	651	656	17116669	10.1128/aac.01023-06	In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.	Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	2	770	773	17116666	10.1128/aac.01150-06	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.	Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	3	975	981	17210769	10.1128/aac.01142-06	Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.	Cigana C, Assael BM, Melotti P.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	5	1666	1670	17296742	10.1128/aac.01303-06	EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.	Bermudez LE, Motamedi N, Chee C, Baimukanova G, Kolonoski P, Inderlied C, Aralar P, Wang G, Phan LT, Young LS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	5	1741	1752	17353244	10.1128/aac.01459-06	Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.	Yasuda Y, Kasahara K, Mizuno F, Nishi K, Mikasa K, Kita E.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	6	1926	1933	17371812	10.1128/aac.01607-06	Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.	Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	6	2205	2207	17403999	10.1128/aac.00056-07	Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.	Könönen E, Bryk A, Niemi P, Kanervo-Nordström A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2007	51	9	3240	3246	17606677	10.1128/aac.00157-07	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.	Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2008	16	2	739	745	17964793	10.1016/j.bmc.2007.10.021	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.	Knuckley B, Luo Y, Thompson PR.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2008	43	3	478	485	17544548	10.1016/j.ejmech.2007.04.002	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.	Abraham MH, Ibrahim A, Acree WE.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	1	137	145	17954687	10.1128/aac.00607-07	Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.	Starner TD, Shrout JD, Parsek MR, Appelbaum PC, Kim G.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	1	348	350	17954691	10.1128/aac.00779-07	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.	Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	1	77	84	17938189	10.1128/aac.01229-07	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.	Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	10	3776	3778	18663020	10.1128/aac.00849-08	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	11	4141	4144	18676884	10.1128/aac.00511-08	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.	Sugimura M, Maseda H, Hanaki H, Nakae T.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	11	4184	4186	18725441	10.1128/aac.00695-08	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.	Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	2	418	426	18070971	10.1128/aac.00678-07	Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.	Shin SJ, Collins MT.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	2	427	434	18070962	10.1128/aac.00375-07	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.	Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	2	557	562	18086852	10.1128/aac.00732-07	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.	Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	2	774	777	18056275	10.1128/aac.00892-07	Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum.	Barthel D, Schlitzer M, Pradel G.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	3	1182	1183	18180358	10.1128/aac.01332-07	In vitro activity of AR-709 against Streptococcus pneumoniae.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	3	866	874	18086834	10.1128/aac.01266-07	Induction of erm(C) expression by noninducing antibiotics.	Bailey M, Chettiath T, Mankin AS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	5	1653	1662	18316525	10.1128/aac.01383-07	In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.	Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	6	2279	2282	18362189	10.1128/aac.01620-07	Antistreptococcal activity of AR-709 compared to that of other agents.	Smith K, Ednie LM, Appelbaum PC, Hawser S, Lociuro S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	7	2639	2643	18443117	10.1128/aac.00310-08	Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.	Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	8	2750	2754	18411316	10.1128/aac.00044-08	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.	Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	8	2767	2770	18519724	10.1128/aac.00481-08	Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.	Achard A, Guérin-Faublée V, Pichereau V, Villers C, Leclercq R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	8	2955	2958	18505859	10.1128/aac.00072-08	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.	Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P, Alba V, Fernández-Cuenca F, Pascual A, Vila J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2008	52	9	3229	3236	18591267	10.1128/aac.00405-08	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.	Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Møller N, Nagai J, Takano M, Vaara T.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2009	17	16	5857	5867	19628398	10.1016/j.bmc.2009.07.013	Free and bound state structures of 6-O-methyl homoerythromycins and epitope mapping of their interactions with ribosomes.	Novak P, Barber J, Cikos A, Arsic B, Plavec J, Lazarevski G, Tepes P, Kosuti¿-Hulita N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2009	19	15	4079	4083	19560350	10.1016/j.bmcl.2009.06.023	Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.	Xu P, Liu L, Chen XZ, Li Y, Liu J, Jin ZP, Wang GQ, Lei PS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2009	19	6	1698	1701	19232491	10.1016/j.bmcl.2009.01.092	Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives.	Ma S, Jiao B, Liu Z, Wang H, Xian R, Zheng M, Lou H.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2009	44	10	4010	4020	19464769	10.1016/j.ejmech.2009.04.030	Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin.	Ma S, Ma R, Liu Z, Ma C, Shen X.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2009	44	9	3459	3470	19303171	10.1016/j.ejmech.2009.02.001	Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens.	Bukvi¿ Krajaci¿ M, Novak P, Dumi¿ M, Cindri¿ M, Paljetak HC, Kujundzi¿ N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	1	329	330	18936189	10.1128/aac.00921-08	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.	Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	11	4938	4939	19738019	10.1128/aac.00724-09	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.	Hamasuna R, Jensen JS, Osada Y.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	12	5317	5318	19738013	10.1128/aac.00746-09	In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.	Rao SS, Raghunathan R, Ekambaram R, Raghunathan M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	3	1204	1209	19064900	10.1128/aac.00471-08	Effect of DNase and antibiotics on biofilm characteristics.	Tetz GV, Artemenko NK, Tetz VV.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	4	1552	1560	19188376	10.1128/aac.01264-08	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.	Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	1786	1792	19223626	10.1128/aac.01270-08	Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.	Jiang LJ, Wang M, Or YS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	1874	1883	19223616	10.1128/aac.01605-07	Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.	Sandberg A, Hessler JH, Skov RL, Blom J, Frimodt-Møller N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	1921	1925	19258262	10.1128/aac.01065-08	Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.	Blackman Northwood J, Del Grosso M, Cossins LR, Coley MD, Creti R, Pantosti A, Farrell DJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	2020	2027	19273669	10.1128/aac.01349-08	Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.	Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	2139	2141	19258276	10.1128/aac.00090-09	Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	2158	2159	19273685	10.1128/aac.01563-08	Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China.	Xin D, Mi Z, Han X, Qin L, Li J, Wei T, Chen X, Ma S, Hou A, Li G, Shi D.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	5	2160	2162	19273684	10.1128/aac.01684-08	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.	Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	6	2663	2666	19332673	10.1128/aac.00046-09	Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.	Goy G, Greub G.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	8	3218	3225	19451282	10.1128/aac.00022-09	Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study.	Jiang LJ, Or YS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	8	3552	3560	19506065	10.1128/aac.00418-09	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.	Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	9	3734	3743	19564365	10.1128/aac.00203-09	Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.	Lemaire S, Van Bambeke F, Tulkens PM.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2009	53	9	4040	4042	19596882	10.1128/aac.00312-09	Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.	Starzengruber P, Thriemer K, Haque R, Khan WA, Fuehrer HP, Siedl A, Hofecker V, Ley B, Wernsdorfer WH, Noedl H.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2010	18	17	6547	6558	20621489	10.1016/j.bmc.2010.06.050	Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit.	Skugor MM, Stimac V, Palej I, Lugari¿ D, Paljetak HC, Fili¿ D, Modri¿ M, Dilovi¿ I, Gembarovski D, Mutak S, Erakovi¿ Haber V, Holmes DJ, Ivezi¿-Schoenfeld Z, Alihodzi¿ S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2010	18	17	6559	6568	20634078	10.1016/j.bmc.2010.06.049	4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens.	Fajdeti¿ A, Cipci¿ Paljetak H, Lazarevski G, Hutinec A, Alihodzi¿ S, Derek M, Stimac V, Andreotti D, Sunji¿ V, Berge JM, Mutak S, Dumi¿ M, Lociuro S, Holmes DJ, Marsi¿ N, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2010	18	17	6569	6577	20673633	10.1016/j.bmc.2010.06.048	6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile.	Kapi¿ S, Cipci¿ Paljetak H, Alihodzi¿ S, Antolovi¿ R, Erakovi¿ Haber V, Jarvest RL, Holmes DJ, Broskey JP, Hunt E.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2010	18	17	6578	6588	20688524	10.1016/j.bmc.2010.07.007	Synthesis and properties of macrolones characterized by two ether bonds in the linker.	Jakopovi¿ IP, Kragol G, Forrest AK, Frydrych CS, Stimac V, Kapi¿ S, Skugor MM, Ilijas M, Paljetak HC, Jeli¿ D, Holmes DJ, Hickey DM, Verbanac D, Erakovi¿ Haber V, Alihodzi¿ S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2010	18	24	8566	8582	21055953	10.1016/j.bmc.2010.10.024	Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials.	Pavlovi¿ D, Fajdeti¿ A, Mutak S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2010	20	11	3244	3249	20462754	10.1016/j.bmcl.2010.04.062	Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.	Hutinec A, Derek M, Lazarevski G, Sunji¿ V, Paljetak HC, Alihodzi¿ S, Erakovi¿ Haber V, Dumi¿ M, Marsi¿ N, Mutak S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2010	20	11	3272	3274	20462756	10.1016/j.bmcl.2010.04.051	Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives.	Ju Y, Xian R, Zhang L, Ma R, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2010	20	9	2880	2883	20356738	10.1016/j.bmcl.2010.03.038	Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.	Liang JH, Wang YY, Wang H, Li XL, An K, Xu YC, Yao GW.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2010	45	3	915	922	19945195	10.1016/j.ejmech.2009.11.032	Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.	Zhang L, Song L, Liu Z, Li H, Lu Y, Li Z, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2010	45	9	3627	3635	20627377	10.1016/j.ejmech.2010.05.008	Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues.	Liang JH, Dong LJ, Wang H, An K, Li XL, Yang L, Yao GW, Xu YC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2010	45	9	3636	3644	20554083	10.1016/j.ejmech.2010.05.009	Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides.	Wu Z, Lu Y, Luo M, He X, Xiao Y, Yang J, Pan Y, Qiu G, Guo H, Hu H, Zhou D, Hu X.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2010	53	15	5868	5880	20684614	10.1021/jm100711p	Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides.	Pavlovi¿ D, Mutak S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	1	230	238	19884376	10.1128/aac.01123-09	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.	McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	1	506	508	19884363	10.1128/aac.01168-09	Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.	Kamal N, Shafer WM.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	10	4518	4519	20660671	10.1128/aac.00235-10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.	Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	12	4971	4977	20855724	10.1128/aac.00834-10	Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.	Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	12	5379	5380	20855744	10.1128/aac.00553-10	In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.	Donati M, Di Francesco A, D'Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	2	866	870	19933801	10.1128/aac.00567-09	Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects.	Furuie H, Saisho Y, Yoshikawa T, Shimada J.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	3	1358	1359	20038627	10.1128/aac.01343-09	In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.	Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	4	1652	1653	20123998	10.1128/aac.01506-09	New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae.	Galarza PG, Abad R, Canigia LF, Buscemi L, Pagano I, Oviedo C, Vázquez JA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	5	1678	1683	20145081	10.1128/aac.00737-08	Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.	Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	5	1909	1913	20231391	10.1128/aac.01570-09	Nucleotide selectivity of antibiotic kinases.	Shakya T, Wright GD.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	6	2437	2447	20231397	10.1128/aac.01424-09	Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas.	Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D, Murphy BS.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	6	2540	2548	20385873	10.1128/aac.01723-09	Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.	Lemaire S, Tulkens PM, Van Bambeke F.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	6	2707	2711	20231401	10.1128/aac.01565-09	Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.	Wang Q, Sun FJ, Liu Y, Xiong LR, Xie LL, Xia PY.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	7	2823	2829	20404127	10.1128/aac.01845-09	Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.	Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	8	3341	3346	20479195	10.1128/aac.01439-09	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.	Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	8	3498	3501	20498312	10.1128/aac.01678-09	In vitro activity of azithromycin against nontyphoidal Salmonella enterica.	Gunell M, Kotilainen P, Jalava J, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	9	3790	3798	20585113	10.1128/aac.01783-09	Different classes of antibiotics differentially influence shiga toxin production.	McGannon CM, Fuller CA, Weiss AA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	9	3812	3816	20585125	10.1128/aac.00309-10	High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes.	Chisholm SA, Dave J, Ison CA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2010	54	9	4009	4011	20625152	10.1128/aac.01812-09	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.	Biedenbach DJ, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2011	19	23	7270	7280	22041174	10.1016/j.bmc.2011.07.011	Synthesis and activity of new macrolones: conjugates between 6(7)-(2'-aminoethyl)-amino-1-cyclopropyl-3-carboxylic acid (2'-hydroxyethyl) amides and 4¿-propenoyl-azithromycin.	Kapi¿ S, Fajdeti¿ A, Ko¿trun S, Ciko¿ A, Paljetak H¿, Antolovi¿ R, Holmes DJ, Alihod¿i¿ S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2011	19	23	7281	7298	22047805	10.1016/j.bmc.2011.07.010	Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity.	Kapi¿ S, Cip¿i¿ Paljetak H, Palej Jakopovi¿ I, Fajdeti¿ A, Ilija¿ M, Stimac V, Braj¿a K, Holmes DJ, Berge J, Alihod¿i¿ S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2011	19	5	1692	1701	21316974	10.1016/j.bmc.2011.01.030	An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics.	Hutinec A, Rup¿i¿ R, Ziher D, Smith KS, Milhous W, Ellis W, Ohrt C, Schönfeld ZI.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	ACS Med. Chem. Lett.	2011	2	5	331	336	24900314	10.1021/ml100253p	Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.	Pavlovi¿ D, Mutak S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2011	21	2	853	856	21185182	10.1016/j.bmcl.2010.11.079	Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae.	Bukvi¿ Kraja¿i¿ M, Dumi¿ M, Novak P, Cindri¿ M, Ko¿trun S, Fajdeti¿ A, Alihod¿i¿ S, Braj¿a K, Kujund¿i¿ N.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2011	21	4	1155	1161	21273067	10.1016/j.bmcl.2010.12.111	Design and synthesis of potent Gram-negative specific LpxC inhibitors.	Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2011	46	10	5196	5205	21855183	10.1016/j.ejmech.2011.08.001	Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation.	Ma X, Zhang L, Wang R, Cao J, Liu C, Fang Y, Wang J, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2011	46	2	556	566	21159410	10.1016/j.ejmech.2010.11.035	Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4¿ elongated arylalkyl groups against macrolide-resistant strains.	Ma S, Jiao B, Ju Y, Zheng M, Ma R, Liu L, Zhang L, Shen X, Ma C, Meng Y, Wang H, Qi Y, Ma X, Cui W.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2011	46	7	3105	3111	21524827	10.1016/j.ejmech.2011.04.004	Synthesis and antibacterial activity of novel 4¿-O-benzimidazolyl clarithromycin derivatives.	Cong C, Wang H, Hu Y, Liu C, Ma S, Li X, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2011	46	8	3388	3397	21600677	10.1016/j.ejmech.2011.05.002	Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones.	Fajdeti¿ A, Vinter A, Paljetak H¿, Padovan J, Jakopovi¿ IP, Kapi¿ S, Alihod¿i¿ S, Fili¿ D, Modri¿ M, Ko¿uti¿-Hulita N, Antolovi¿ R, Schoenfeld ZI, Mutak S, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2011	54	10	3595	3605	21476508	10.1021/jm2001585	Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides.	Bukvi¿ Kraja¿i¿ M, Peri¿ M, Smith KS, Schönfeld ZI, ¿iher D, Fajdeti¿ A, Kujund¿i¿ N, Schönfeld W, Landek G, Padovan J, Jeli¿ D, Ager A, Milhous WK, Ellis W, Spaventi R, Ohrt C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2011	54	3	719	733	21207938	10.1021/jm101317f	Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties.	Stepani¿ V, Ko¿trun S, Malnar I, Hlevnjak M, Butkovi¿ K, ¿aleta I, Duk¿i M, Kragol G, Makaruha-Stegi¿ O, Mikac L, Rali¿ J, Tati¿ I, Tav¿ar B, Valko K, Zulfikari S, Muni¿ V.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2011	54	8	2792	2804	21428405	10.1021/jm101593u	Chemistry and biology of macrolide antiparasitic agents.	Lee Y, Choi JY, Fu H, Harvey C, Ravindran S, Roush WR, Boothroyd JC, Khosla C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Antimicrob. Agents Chemother.	2011	55	2	703	712	21098249	10.1128/aac.00788-10	Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.	Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Nat. Prod.	2011	74	4	574	579	21384863	10.1021/np100472d	Bioactive sesqui- and diterpenoids from the Argentine liverwort Porella chilensis.	Gilabert M, Ramos AN, Schiavone MM, Arena ME, Bardón A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2012	20	10	3180	3185	22537683	10.1016/j.bmc.2012.03.074	An efficient and convenient microwave-assisted chemical synthesis of (thio)xanthones with additional in vitro and in silico characterization.	Verbanac D, Jain SC, Jain N, Chand M, Cip¿i¿ Paljetak H, Matija¿i¿ M, Peri¿ M, Stepani¿ V, Saso L.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2012	22	1	476	481	22153939	10.1016/j.bmcl.2011.10.101	Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.	Kumar R, Rathy S, Hajare AK, Surase YB, Dullu J, Jadhav JS, Venkataramanan R, Chakrabarti A, Pandya M, Bhateja P, Ramkumar G, Das B.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2012	22	10	3527	3530	22503348	10.1016/j.bmcl.2012.03.076	Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity.	Jakopovi¿ IP, Kraja¿i¿ MB, Skugor MM, Stimac V, Pe¿i¿ D, Vujasinovi¿ I, Alihod¿i¿ S, ¿ip¿i¿ Paljetak H, Kragol G.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2012	22	17	5739	5743	22858102	10.1016/j.bmcl.2012.06.092	Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides.	Sugimoto T, Shimazaki Y, Manaka A, Tanikawa T, Suzuki K, Nanaumi K, Kaneda Y, Yamasaki Y, Sugiyama H.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2012	49		289	303	22301216	10.1016/j.ejmech.2012.01.023	Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities.	Liang JH, Li XL, Wang H, An K, Wang YY, Xu YC, Yao GW.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2012	49		365	378	22321992	10.1016/j.ejmech.2012.01.039	Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents.	Star¿evi¿ K, Pe¿i¿ D, Toplak A, Landek G, Alihod¿i¿ S, Herreros E, Ferrer S, Spaventi R, Peri¿ M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2012	55	13	6111	6123	22697905	10.1021/jm300356u	N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.	Bosnar M, Kragol G, Ko¿trun S, Vujasinovi¿ I, Bo¿njak B, Benceti¿ Mihaljevi¿ V, Maru¿i¿ I¿tuk Z, Kapi¿ S, Hrva¿i¿ B, Braj¿a K, Tav¿ar B, Jeli¿ D, Glojnari¿ I, Verbanac D, Culi¿ O, Padovan J, Alihod¿i¿ S, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2012	55	2	606	622	22148555	10.1021/jm201467r	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.	Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2012	55	3	1389	1401	22148880	10.1021/jm201615t	Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin.	Peri¿ M, Fajdeti¿ A, Rup¿i¿ R, Alihod¿i¿ S, Ziher D, Bukvi¿ Kraja¿i¿ M, Smith KS, Ivezi¿-Schönfeld Z, Padovan J, Landek G, Jeli¿ D, Hutinec A, Mesi¿ M, Ager A, Ellis WY, Milhous WK, Ohrt C, Spaventi R.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2012	55	3	995	1012	22122518	10.1021/jm201095h	Targeting the liver stage of malaria parasites: a yet unmet goal.	Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2012	55	7	3216	3227	22380766	10.1021/jm201676t	Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides.	Pe¿i¿ D, Star¿evi¿ K, Toplak A, Herreros E, Vidal J, Almela MJ, Jeli¿ D, Alihod¿i¿ S, Spaventi R, Peri¿ M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2013	21	1	321	332	23199485	10.1016/j.bmc.2012.10.036	Macrolactonolides: a novel class of anti-inflammatory compounds.	Toma¿kovi¿ L, Komac M, Makaruha Stegi¿ O, Muni¿ V, Rali¿ J, Stani¿ B, Banjanac M, Markovi¿ S, Hrva¿i¿ B, ¿ip¿i¿ Paljetak H, Padovan J, Glojnari¿ I, Erakovi¿ Haber V, Mesi¿ M, Mer¿ep M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2013	23	18	5057	5060	23937982	10.1016/j.bmcl.2013.07.042	Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents.	Zhang L, Chai X, Wang B, Yu S, Hu H, Zou Y, Zhao Q, Meng Q, Wu Q.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2013	23	5	1387	1393	23375796	10.1016/j.bmcl.2012.12.070	Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.	Liang JH, Lv W, Li XL, An K, Cushman M, Wang H, Xu YC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2013	56	21	8377	8388	24088053	10.1021/jm400813y	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.	Végner L, Peragovics Á, Tombor L, Jelinek B, Czobor P, Bender A, Simon Z, Málnási-Csizmadia A.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2013	56	5	1974	1983	23409972	10.1021/jm301650g	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.	Odagiri T, Inagaki H, Sugimoto Y, Nagamochi M, Miyauchi RN, Kuroyanagi J, Kitamura T, Komoriya S, Takahashi H.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2013	56	6	2348	2358	23410043	10.1021/jm301678j	Antimalarial activities of 6-iodouridine and its prodrugs and potential for combination therapy.	Crandall IE, Wasilewski E, Bello AM, Mohmmed A, Malhotra P, Pai EF, Kain KC, Kotra LP.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2013	59		209	217	23229056	10.1016/j.ejmech.2012.11.028	Synthesis and antibacterial evaluation of novel 11,4¿-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.	Li X, Ma S, Yan M, Wang Y, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur. J. Med. Chem.	2013	59		54	63	23202851	10.1016/j.ejmech.2012.10.054	Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides.	Liang JH, An K, Lv W, Cushman M, Wang H, Xu YC.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Nat. Prod.	2013	76	11	2153	2157	24164206	10.1021/np4006794	Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening.	Wu C, Tan Y, Gan M, Wang Y, Guan Y, Hu X, Zhou H, Shang X, You X, Yang Z, Xiao C.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Med Chem Res	2013			1	6		10.1007/s00044-013-0844-5	Synergistic effects of berberines with antibiotics on clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA)	Zuo G, Li Y, Wang G, Li Z, Han J
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	ACS Med. Chem. Lett.	2014	5	10	1133	1137	25313326	10.1021/ml500279k	Synthesis and Structure-Activity Relationships of ¿-Amino-¿-lactone Ketolides: A Novel Class of Macrolide Antibiotics.	Pavlovi¿ D, Mutak S, Andreotti D, Biondi S, Cardullo F, Paio A, Piga E, Donati D, Lociuro S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2014	57	14	6060	6082	24959892	10.1021/jm500462x	Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).	Basarab GS, Hill PJ, Garner CE, Hull K, Green O, Sherer BA, Dangel PB, Manchester JI, Bist S, Hauck S, Zhou F, Uria-Nickelsen M, Illingworth R, Alm R, Rooney M, Eakin AE.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2015	23	16	5198	5209	26037612	10.1016/j.bmc.2015.04.078	Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.	Washington AZ, Tapadar S, George A, Oyelere AK.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2015	23	17	5334	5344	26264847	10.1016/j.bmc.2015.07.062	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.	Tran TP, Vo DD, Di Giorgio A, Duca M.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem.	2015	23	23	7448	7463	26578325	10.1016/j.bmc.2015.10.042	1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-Moraxella catarrhalis activity.	Mara¿i¿ S, Kraljevi¿ TG, Paljetak H¿, Peri¿ M, Matija¿i¿ M, Verbanac D, Cetina M, Rai¿-Mali¿ S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg. Med. Chem. Lett.	2015	25	16	3325	3329	26071635	10.1016/j.bmcl.2015.05.070	Gageopeptins A and B, new inhibitors of zoospore motility of the phytopathogen Phytophthora capsici from a marine-derived bacterium Bacillus sp. 109GGC020.	Tareq FS, Hasan CM, Lee HS, Lee YJ, Lee JS, Surovy MZ, Islam MT, Shin HJ.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J. Med. Chem.	2015	58	15	5691	5698	25799158	10.1021/acs.jmedchem.5b00201	Volume of Distribution in Drug Design.	Smith DA, Beaumont K, Maurer TS, Di L.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	MedChemComm	2015	6	4	581	585		10.1039/C4MD00489B	Synthesis of 17-membered azalides from a 16-membered macrolide utilizing amide-selective silane reduction	Seki A, Mori T, Sasaki K, Takahashi Y, Miyake T, Akamatsu Y
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg Med Chem	2016	24	24	6379	6389	27381365	10.1016/j.bmc.2016.06.044	A Gestalt approach to Gram-negative entry.	Silver LL.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg Med Chem	2016	24	24	6409	6419	27469981	10.1016/j.bmc.2016.07.029	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.	Tanaka SK, Steenbergen J, Villano S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur J Med Chem	2017	125		210	224	27657812	10.1016/j.ejmech.2016.09.022	Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.	Pavlovi¿ D, Kimmins S, Mutak S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Eur J Med Chem	2017	127		874	884	27836198	10.1016/j.ejmech.2016.10.065	Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives.	Yan M, Ma R, Jia L, Venter H, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg Med Chem Lett	2017	27	16	3693	3697	28711353	10.1016/j.bmcl.2017.07.017	Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.	Jia L, Yan M, Shen Y, Qin Y, Qiang S, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	Bioorg Med Chem Lett	2017	27	16	3872	3877	28655423	10.1016/j.bmcl.2017.06.044	Synthesis and antibacterial activity of novel 4¿-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs.	Wang Y, Cong C, Chai WC, Dong R, Jia L, Song D, Zhou Z, Ma S.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529	J Med Chem	2017	60	12	5002	5014	28549219	10.1021/acs.jmedchem.7b00377	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									Cerep in vitro phospholipidosis assay data	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									DrugMatrix	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									Unpublished dataset	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	AZITHROMYCIN	CHEMBL529									WHO Anatomical Therapeutic Chemical Classification	
924.8000000000000000	9606	Homo sapiens	AZM-475271	CHEMBL3545150									Unpublished dataset	
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	1987	30	3	528	536	3820225	10.1021/jm00386a015	Heteroatom-activated beta-lactam antibiotics: considerations of differences in the biological activity of [[3(S)-(acylamino)-2-oxo-1-azetidinyl]oxy]acetic acids (oxamazins) and the corresponding sulfur analogues (thiamazins).	Boyd DB, Eigenbrot C, Indelicato JM, Miller MJ, Pasini CE, Woulfe SR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	1988	31	6	1227	1230	3373491	10.1021/jm00401a026	The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.	Indelicato JM, Pasini CE.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	1989	32	8	1749	1753	2754701	10.1021/jm00128a014	N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues.	Curran WV, Lenhard RH.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem. Lett.	1993	3	11	2241	2246		10.1016/S0960-894X(01)80932-X	N-acyl-3-alkylidenyl- and 3-alkyl azeitidin-2-ones: a new class of monocyclic -lactam antibacterial agents 2. Synthesis and structure-activity relationships of heteroatom substituted 3-isopropylidene and 3-isopropyl analogs	Brickner SJ, Gaikema JJ, Greenfield LJ, Zurenko GE, Manninen PR
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem. Lett.	1994	4	13	1601	1606		10.1016/S0960-894X(01)80574-6	Synthesis and anti-pseudomonal activity of new 2-isocephems with a dihydroxypyridone moiety at C-7	Tsuji K, Ishikawa H
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem. Lett.	2005	15	8	2123	2128	15808482	10.1016/j.bmcl.2005.02.029	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.	Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem.	2007	15	22	7087	7097	17869116	10.1016/j.bmc.2007.07.039	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.	Yoshida K, Nakayama K, Ohtsuka M, Kuru N, Yokomizo Y, Sakamoto A, Takemura M, Hoshino K, Kanda H, Nitanai H, Namba K, Yoshida K, Imamura Y, Zhang JZ, Lee VJ, Watkins WJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	10	3531	3536	17682106	10.1128/aac.00503-07	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.	Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson MO, Couetdic G, Plésiat P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	10	3763	3767	17664321	10.1128/aac.00389-07	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.	Papagiannitsis CC, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	11	3844	3852	17724156	10.1128/aac.01512-06	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.	Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin JF.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	11	4009	4014	17846134	10.1128/aac.00537-07	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.	Girlich D, Leclercq R, Naas T, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	11	4181	4183	17709463	10.1128/aac.00614-07	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.	Robin F, Delmas J, Brebion A, Dubois D, Constantin JM, Bonnet R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	12	4329	4335	17938181	10.1128/aac.00810-07	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.	Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	12	4486	4488	17938180	10.1128/aac.01462-06	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.	Neuwirth C, Siebor E, Robin F, Bonnet R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	12	4512	4514	17875998	10.1128/aac.00491-07	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.	Fonseca F, Sarmento AC, Henriques I, Samyn B, van Beeumen J, Domingues P, Domingues MR, Saavedra MJ, Correia A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	2	417	422	17158943	10.1128/aac.00851-06	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.	Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	2	631	637	17116662	10.1128/aac.01082-06	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.	Poirel L, Cattoir V, Soares A, Soussy CJ, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	2	763	765	17145797	10.1128/aac.01053-06	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.	Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	3	1082	1084	17178800	10.1128/aac.00909-06	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.	Mazzariol A, Roelofsen E, Koncan R, Voss A, Cornaglia G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	3	1085	1088	17158942	10.1128/aac.00954-06	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.	Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	3	852	856	17158944	10.1128/aac.01345-06	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.	Doi Y, de Oliveira Garcia D, Adams J, Paterson DL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	4	1223	1227	17242140	10.1128/aac.01195-06	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.	Wu JJ, Ko WC, Tsai SH, Yan JJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	4	1304	1309	17220412	10.1128/aac.01058-06	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.	Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, Bonnet R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	4	1341	1350	17261619	10.1128/aac.01278-06	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.	Reinhardt A, Köhler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	4	1365	1372	17242148	10.1128/aac.01152-06	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.	Naas T, Aubert D, Ozcan A, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	1967	1971	17420207	10.1128/aac.01483-06	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.	Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	1987	1994	17387156	10.1128/aac.01509-06	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.	Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	2179	2184	17420213	10.1128/aac.01600-06	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.	Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	2185	2188	17353248	10.1128/aac.01439-06	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.	Papagiannitsis CC, Loli A, Tzouvelekis LS, Tzelepi E, Arlet G, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	6	2211	2214	17404005	10.1128/aac.01139-06	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.	Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, Pagani L, Bonomo RA, Rossolini GM, Toniolo A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2359	2365	17438050	10.1128/aac.01395-06	Biochemical characterization of PER-2 and genetic environment of blaPER-2.	Power P, Di Conza J, Rodríguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2366	2372	17452479	10.1128/aac.00044-07	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.	Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M, Stefanou I, Avlami A, Katsilambros N.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2611	2614	17470660	10.1128/aac.00838-06	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.	Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2621	2624	17470659	10.1128/aac.00029-07	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.	Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	7	2636	2638	17438051	10.1128/aac.01043-06	blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.	Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	2855	2860	17470647	10.1128/aac.01614-06	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.	Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	2988	2990	17470648	10.1128/aac.00083-07	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.	Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	3004	3007	17526756	10.1128/aac.00167-07	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.	Chen YT, Lauderdale TL, Liao TL, Shiau YR, Shu HY, Wu KM, Yan JJ, Su IJ, Tsai SF.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	3017	3019	17517851	10.1128/aac.00279-07	Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene.	Bae IK, Lee YN, Lee WG, Lee SH, Jeong SH.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	3026	3029	17562800	10.1128/aac.00299-07	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.	Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	8	3038	3039	17517838	10.1128/aac.00374-07	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.	Ikonomidis A, Labrou M, Afkou Z, Maniatis AN, Sofianou D, Tsakris A, Pournaras S.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	9	3049	3055	17576827	10.1128/aac.01522-06	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.	Vinks AA, van Rossem RN, Mathôt RA, Heijerman HG, Mouton JW.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	9	3431	3433	17576842	10.1128/aac.01433-06	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.	Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2007	51	9	3465	3466	17606684	10.1128/aac.00267-07	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.	Quinteira S, Grosso F, Ramos H, Peixe L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	10	3589	3596	18644957	10.1128/aac.00465-08	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.	Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	10	3725	3736	18625772	10.1128/aac.00163-08	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.	Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	10	3792	3794	18663019	10.1128/aac.00387-08	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.	Dubois V, Poirel L, Demarthe F, Arpin C, Coulange L, Minarini LA, Bezian MC, Nordmann P, Quentin C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	11	3922	3927	18779353	10.1128/aac.00341-08	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.	Schmidtke AJ, Hanson ND.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	11	4023	4029	18809945	10.1128/aac.00707-08	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.	Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	11	4141	4144	18676884	10.1128/aac.00511-08	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.	Sugimura M, Maseda H, Hanaki H, Nakae T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	11	4194	4197	18765691	10.1128/aac.01337-07	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.	Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	2	551	556	18070972	10.1128/aac.01145-07	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.	Meziane-Cherif D, Decré D, Høiby EA, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	2	570	573	18070960	10.1128/aac.01114-07	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.	Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	2	794	795	18025117	10.1128/aac.01399-07	RmtC 16S rRNA methyltransferase in Australia.	Zong Z, Partridge SR, Iredell JR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	2	796	797	18056283	10.1128/aac.01180-07	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.	Cuzon G, Naas T, Demachy MC, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	3	1198	1200	18086856	10.1128/aac.00682-07	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.	Hu RM, Huang KJ, Wu LT, Hsiao YJ, Yang TC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	3	915	919	18160520	10.1128/aac.01028-07	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.	Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	4	1257	1263	18227185	10.1128/aac.01451-07	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.	Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	4	1264	1268	18212108	10.1128/aac.00684-07	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.	Meziane-Cherif D, Lambert T, Dupêchez M, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	4	1510	1512	18250190	10.1128/aac.01529-07	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.	Davies TA, Shang W, Bush K, Flamm RK.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	5	1613	1617	18299404	10.1128/aac.00978-07	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.	Poirel L, Mansour W, Bouallegue O, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	5	1790	1793	18347108	10.1128/aac.01440-07	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.	de Oliveira Garcia D, Doi Y, Szabo D, Adams-Haduch JM, Vaz TM, Leite D, Padoveze MC, Freire MP, Silveira FP, Paterson DL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	5	1806	1811	18316518	10.1128/aac.01381-07	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.	Mendonça N, Manageiro V, Robin F, Salgado MJ, Ferreira E, Caniça M, Bonnet R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	5	1894	1896	18285473	10.1128/aac.01414-07	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.	Loli A, Tzouvelekis LS, Gianneli D, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	5	1897	1898	18316524	10.1128/aac.01525-07	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.	Mendonça N, Manageiro V, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	6	1952	1956	18362192	10.1128/aac.01463-07	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.	Doi Y, Poirel L, Paterson DL, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	6	2014	2018	18332176	10.1128/aac.01539-07	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.	Cai JC, Zhou HW, Zhang R, Chen GX.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	6	2250	2252	18362187	10.1128/aac.01025-07	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.	Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	7	2455	2462	18474583	10.1128/aac.01107-07	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.	Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	7	2473	2479	18443127	10.1128/aac.01062-07	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.	Stoczko M, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	7	2573	2580	18443121	10.1128/aac.00393-08	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.	Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	7	2680	2682	18426899	10.1128/aac.00158-08	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.	Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2905	2908	18559652	10.1128/aac.00166-08	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.	Samuelsen Ø, Castanheira M, Walsh TR, Spencer J.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2943	2946	18490501	10.1128/aac.00679-07	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.	Garza-Ramos U, Morfin-Otero R, Sader HS, Jones RN, Hernández E, Rodriguez-Noriega E, Sanchez A, Carrillo B, Esparza-Ahumada S, Silva-Sanchez J.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2962	2965	18519713	10.1128/aac.01341-07	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.	Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2977	2979	18519714	10.1128/aac.00175-08	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.	Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	8	2984	2987	18490506	10.1128/aac.01634-07	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.	Espedido BA, Partridge SR, Iredell JR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	9	2999	3005	18591275	10.1128/aac.01684-07	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.	Bratu S, Landman D, Martin DA, Georgescu C, Quale J.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2008	52	9	3463	3464	18644970	10.1128/aac.00543-08	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.	Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	1	277	280	19001114	10.1128/aac.00912-08	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.	Papagiannitsis CC, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	1	323	326	19001118	10.1128/aac.00608-08	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.	Mammeri H, Galleni M, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	1	333	334	19015350	10.1128/aac.00736-08	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.	Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	10	4320	4326	19651915	10.1128/aac.01607-08	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.	Zeba B, De Luca F, Dubus A, Delmarcelle M, Simporé J, Nacoulma OG, Rossolini GM, Frère JM, Docquier JD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	10	4518	4521	19620330	10.1128/aac.00461-09	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.	Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	11	4783	4788	19738025	10.1128/aac.00574-09	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	11	4930	4933	19738007	10.1128/aac.00900-09	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.	Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	12	5035	5038	19770279	10.1128/aac.00856-09	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.	Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	12	5046	5054	19770275	10.1128/aac.00774-09	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.	Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	12	5288	5290	19770278	10.1128/aac.00822-09	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.	Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	2	557	562	19015357	10.1128/aac.00734-08	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.	Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	3	1177	1184	19029333	10.1128/aac.00485-08	Genetic variability among ampC genes from acinetobacter genomic species 3.	Beceiro A, Pérez A, Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Vila J, Rodríguez-Baño J, Cisneros JM, Pachón J, Bou G, Spanish Group for Nosocomial Infection (GEIH).
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	3	1256	1259	19104021	10.1128/aac.01284-08	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.	Zioga A, Whichard JM, Kotsakis SD, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	3	876	882	19075063	10.1128/aac.00946-08	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.	Poirel L, Rodriguez-Martinez JM, Plésiat P, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	3	977	986	19075050	10.1128/aac.01155-08	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.	Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	4	1552	1560	19188376	10.1128/aac.01264-08	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.	Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	5	1766	1771	19258272	10.1128/aac.01410-08	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	5	1944	1951	19273683	10.1128/aac.01581-08	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.	Doublet B, Granier SA, Robin F, Bonnet R, Fabre L, Brisabois A, Cloeckaert A, Weill FX.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	5	1987	1997	19258280	10.1128/aac.01024-08	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Vettoretti L, Plésiat P, Muller C, El Garch F, Phan G, Attrée I, Ducruix A, Llanes C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	5	1998	2004	19258268	10.1128/aac.01355-08	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.	Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	5	2221	2222	19223629	10.1128/aac.01573-08	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.	Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	6	2274	2282	19273679	10.1128/aac.01617-08	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.	Asgarali A, Stubbs KA, Oliver A, Vocadlo DJ, Mark BL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	6	2327	2334	19349516	10.1128/aac.01360-08	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.	Kitao T, Miyoshi-Akiyama T, Kirikae T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	6	2360	2366	19349512	10.1128/aac.01452-08	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.	Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	6	2483	2491	19332676	10.1128/aac.00428-08	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.	Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	7	2902	2907	19414581	10.1128/aac.01513-08	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.	Yang TC, Huang YW, Hu RM, Huang SC, Lin YT.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	7	3010	3016	19380596	10.1128/aac.01164-08	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.	Potron A, Poirel L, Croizé J, Chanteperdrix V, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	7	3143	3146	19380592	10.1128/aac.01473-08	First detection of plasmid-encoded blaOXY beta-lactamase.	González-López JJ, Coelho A, Larrosa MN, Lavilla S, Bartolomé R, Prats G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	7	3159	3161	19414578	10.1128/aac.00133-09	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.	Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	8	3357	3364	19506058	10.1128/aac.01655-08	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.	Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	8	3520	3523	19470510	10.1128/aac.00219-09	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	8	3579	3581	19451292	10.1128/aac.00072-09	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.	Moubareck C, Brémont S, Conroy MC, Courvalin P, Lambert T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	9	3908	3913	19596871	10.1128/aac.00453-09	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.	Picão RC, Poirel L, Gales AC, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	9	3923	3928	19528273	10.1128/aac.00268-09	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.	Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2009	53	9	4048	4050	19581459	10.1128/aac.00690-09	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.	Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2010	45	12	6139	6146	21036422	10.1016/j.ejmech.2010.10.007	Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives.	Almajan GL, Barbuceanu SF, Bancescu G, Saramet I, Saramet G, Draghici C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2010	53	1	119	127	20000576	10.1021/jm900615h	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.	Baussanne I, Bussière A, Halder S, Ganem-Elbaz C, Ouberai M, Riou M, Paris JM, Ennifar E, Mingeot-Leclercq MP, Décout JL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	143	148	19805554	10.1128/aac.00248-09	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.	King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	328	332	19901091	10.1128/aac.00961-09	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	45	51	19884377	10.1128/aac.00427-09	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.	Doublet B, Robin F, Casin I, Fabre L, Le Fleche A, Bonnet R, Weill FX.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	466	470	19901092	10.1128/aac.00017-09	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.	Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	471	476	19917750	10.1128/aac.00458-09	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.	Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	533	535	19884378	10.1128/aac.00859-09	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.	Poirel L, Docquier JD, De Luca F, Verlinde A, Ide L, Rossolini GM, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	560	562	19752282	10.1128/aac.00762-09	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.	Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	1	578	579	19884362	10.1128/aac.00861-09	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	10	4178	4184	20660683	10.1128/aac.01301-09	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.	García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	11	4864	4871	20696873	10.1128/aac.00771-10	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES ß-lactamases.	Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	11	4914	4916	20823289	10.1128/aac.00878-10	Emergence of metallo-ß-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.	Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	12	5057	5061	20876374	10.1128/aac.00768-10	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.	Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	2	846	851	19933793	10.1128/aac.00834-09	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.	Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	3	1029	1041	20028819	10.1128/aac.00963-09	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.	Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	3	1213	1217	20086158	10.1128/aac.01104-09	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.	Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	3	1331	1333	20065056	10.1128/aac.01561-09	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	3	1369	1373	20086157	10.1128/aac.01312-09	Spread of OXA-48-encoding plasmid in Turkey and beyond.	Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	3	969	976	19995920	10.1128/aac.01009-09	Updated functional classification of beta-lactamases.	Bush K, Jacoby GA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	4	1492	1497	20100880	10.1128/aac.01495-09	Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa.	Yoneyama H, Akiba K, Hori H, Ando T, Nakae T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	4	1506	1511	20086141	10.1128/aac.01489-09	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.	San Millan A, Garcia-Cobos S, Escudero JA, Hidalgo L, Gutierrez B, Carrilero L, Campos J, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	4	1547	1554	20124004	10.1128/aac.01252-09	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.	De Luca F, Giraud-Morin C, Rossolini GM, Docquier JD, Fosse T.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	4	1650	1651	20124003	10.1128/aac.01821-09	In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates.	Endimiani A, Bethel C, Choudhary Y, Bonomo RA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	5	2219	2224	20194693	10.1128/aac.00816-09	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	5	2231	2234	20308380	10.1128/aac.00791-09	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.	Guillon H, Eb F, Mammeri H.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	5	2239	2243	20211889	10.1128/aac.01677-09	Effect of NlpE overproduction on multidrug resistance in Escherichia coli.	Nishino K, Yamasaki S, Hayashi-Nishino M, Yamaguchi A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	5	2271	2272	20211886	10.1128/aac.01442-09	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.	Manageiro V, Ferreira E, Albuquerque L, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	6	2291	2302	20308379	10.1128/aac.01525-09	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.	Page MG, Dantier C, Desarbre E.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	6	2420	2424	20308383	10.1128/aac.01456-09	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.	Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	6	2583	2589	20385866	10.1128/aac.01283-09	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.	Huang YW, Lin CW, Hu RM, Lin YT, Chung TC, Yang TC.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	6	2687	2691	20231393	10.1128/aac.01359-09	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	6	2699	2703	20368407	10.1128/aac.01624-09	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.	Huang LY, Lu PL, Chen TL, Chang FY, Fung CP, Siu LK.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	7	2855	2866	20385874	10.1128/aac.01790-09	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.	Shin YP, Park HJ, Shin SH, Lee YS, Park S, Jo S, Lee YH, Lee IH.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	7	3002	3006	20350950	10.1128/aac.01818-09	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.	Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	7	3070	3071	20421403	10.1128/aac.01615-09	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.	Rodríguez MM, Power P, Sader H, Galleni M, Gutkind G.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	8	3197	3204	20498317	10.1128/aac.01336-09	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.	Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	8	3493	3497	20498315	10.1128/aac.00080-10	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.	Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	8	3512	3515	20547814	10.1128/aac.01646-09	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.	Hocquet D, Plésiat P, Dehecq B, Mariotte P, Talon D, Bertrand X, ONERBA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	9	3557	3563	20566764	10.1128/aac.00385-10	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.	Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2010	54	9	3956	3959	20566763	10.1128/aac.00110-10	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.	Uemura S, Yokota S, Mizuno H, Sakawaki E, Sawamoto K, Maekawa K, Tanno K, Mori K, Asai Y, Fujii N.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	ACS Med. Chem. Lett.	2011	2	5	385	390	24900319	10.1021/ml200012f	Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.	Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2011	55	1	140	145	21041509	10.1128/aac.00858-10	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.	Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Antimicrob. Agents Chemother.	2011	55	1	284	290	21078949	10.1128/aac.00098-10	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.	Shimizu-Ibuka A, Oishi M, Yamada S, Ishii Y, Mura K, Sakai H, Matsuzawa H.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem. Lett.	2012	22	18	5989	5994	22892121	10.1016/j.bmcl.2012.07.005	Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.	Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2012	55	2	914	923	22175825	10.1021/jm2014748	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2012	55	4	1662	1670	22257165	10.1021/jm2014875	Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.	Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Drug Metab. Dispos.	2013	41	4	791	800	23344796	10.1124/dmd.112.049569	Organic anion transporter 3 interacts selectively with lipophilic ß-lactam antibiotics.	Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2013	56	13	5541	5552	23755848	10.1021/jm400560z	Pyridone-conjugated monobactam antibiotics with gram-negative activity.	Brown MF, Mitton-Fry MJ, Arcari JT, Barham R, Casavant J, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Lall MS, Lemmon MM, Li C, Lin J, McCurdy SP, McElroy E, McPherson C, Marr ES, Mueller JP, Mullins L, Nikitenko AA, Noe MC, Penzien J, Plummer MS, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Tomaras A, Young JA, Zaniewski RP.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2014	57	9	3845	3855	24694215	10.1021/jm500219c	Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria.	Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J. Med. Chem.	2015	58	5	2195	2205	25658376	10.1021/jm501506f	Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.	Murphy-Benenato KE, Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahi¿ H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	ACS Med. Chem. Lett.	2015	6	5	537	542	26005529	10.1021/acsmedchemlett.5b00026	SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.	Murphy-Benenato KE, Dangel B, Davis HE, Durand-Réville TF, Ferguson AD, Gao N, Jahi¿ H, Mueller JP, Manyak EL, Quiroga O, Rooney M, Sha L, Sylvester M, Wu F, Zambrowski M, Zhao SX.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Eur. J. Med. Chem.	2016	110		151	163	26827160	10.1016/j.ejmech.2016.01.024	Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.	Fu HG, Hu XX, Li CR, Li YH, Wang YX, Jiang JD, Bi CW, Tang S, You XF, Song DQ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg. Med. Chem.	2016	24	5	1121	1131	26833242	10.1016/j.bmc.2016.01.041	Metal-based biologically active azoles and ß-lactams derived from sulfa drugs.	Ebrahimi HP, Hadi JS, Almayah AA, Bolandnazar Z, Swadi AG, Ebrahimi A.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	Bioorg Med Chem Lett	2016	26	22	5539	5544	27765507	10.1016/j.bmcl.2016.10.004	5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics.	Faulkner KC, Hurley KA, Weibel DB.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J Med Chem	2017	60	21	8933	8944	28994597	10.1021/acs.jmedchem.7b01164	Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted ß-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii.	Carosso S, Liu R, Miller PA, Hecker SJ, Glinka T, Miller MJ.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158	J Med Chem	2017	60	7	2669	2684	28287720	10.1021/acs.jmedchem.6b01261	Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.	Tan L, Tao Y, Wang T, Zou F, Zhang S, Kou Q, Niu A, Chen Q, Chu W, Chen X, Wang H, Yang Y.
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									DrugMatrix	
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									Unpublished dataset	
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	AZTREONAM	CHEMBL158									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	BACAMPICILLIN HYDROCHLORIDE	CHEMBL1200965	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	BACAMPICILLIN HYDROCHLORIDE	CHEMBL1200965									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	BACAMPICILLIN HYDROCHLORIDE	CHEMBL1200965									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	BACAMPICILLIN HYDROCHLORIDE	CHEMBL1200965									Unpublished dataset	
962.7500000000000000	2	Bacteria	BACAMPICILLIN HYDROCHLORIDE	CHEMBL1200965									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	BAFETINIB	CHEMBL206834	Bioorg. Med. Chem. Lett.	2006	16	5	1421	1425	16332440	10.1016/j.bmcl.2005.11.042	Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.	Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T.
924.8000000000000000	9606	Homo sapiens	BAFETINIB	CHEMBL206834	Bioorg. Med. Chem. Lett.	2007	17	10	2712	2717	17376680	10.1016/j.bmcl.2007.03.002	Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.	Horio T, Hamasaki T, Inoue T, Wakayama T, Itou S, Naito H, Asaki T, Hayase H, Niwa T.
924.8000000000000000	9606	Homo sapiens	BAFETINIB	CHEMBL206834	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	BAFETINIB	CHEMBL206834									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	BAFETINIB	CHEMBL206834									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	BALAMAPIMOD	CHEMBL2104954									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	BALAMAPIMOD	CHEMBL2104954									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	BALSALAZIDE DISODIUM	CHEMBL1200760									British National Formulary (72nd edition)	
943.5000000000000000	9606	Homo sapiens	BALSALAZIDE DISODIUM	CHEMBL1200760									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	BALSALAZIDE DISODIUM	CHEMBL1200760									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg. Med. Chem. Lett.	2008	18	6	1814	1819	18308563	10.1016/j.bmcl.2008.02.025	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.	Jones P, Altamura S, De Francesco R, Gallinari P, Lahm A, Neddermann P, Rowley M, Serafini S, Steinkühler C.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2008	51	6	1505	1529	18247554	10.1021/jm7011408	Histone deacetylase inhibitors: from bench to clinic.	Paris M, Porcelloni M, Binaschi M, Fattori D.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2010	53	2	822	839	20017493	10.1021/jm901502p	Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.	Thaler F, Colombo A, Mai A, Amici R, Bigogno C, Boggio R, Cappa A, Carrara S, Cataudella T, Fusar F, Gianti E, di Ventimiglia SJ, Moroni M, Munari D, Pain G, Regalia N, Sartori L, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C, Varasi M.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Nat. Chem. Biol.	2010	6	3	238	243	20139990	10.1038/nchembio.313	Chemical phylogenetics of histone deacetylases.	Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg. Med. Chem. Lett.	2011	21	16	4909	4912	21742496	10.1016/j.bmcl.2011.06.015	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.	Shultz M, Fan J, Chen C, Cho YS, Davis N, Bickford S, Buteau K, Cao X, Holmqvist M, Hsu M, Jiang L, Liu G, Lu Q, Patel C, Suresh JR, Selvaraj M, Urban L, Wang P, Yan-Neale Y, Whitehead L, Zhang H, Zhou L, Atadja P.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2011	54	13	4694	4720	21634430	10.1021/jm2003552	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.	Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW, Deng W, Ng MC, Lu T, Khoo ML, Poulsen A, Sangthongpitag K, Wu X, Hu C, Goh KC, Wang X, Fang L, Goh KL, Khng HH, Goh SK, Yeo P, Liu X, Bonday Z, Wood JM, Dymock BW, Kantharaj E, Sun ET.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2011	54	13	4752	4772	21650221	10.1021/jm200388e	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.	Shultz MD, Cao X, Chen CH, Cho YS, Davis NR, Eckman J, Fan J, Fekete A, Firestone B, Flynn J, Green J, Growney JD, Holmqvist M, Hsu M, Jansson D, Jiang L, Kwon P, Liu G, Lombardo F, Lu Q, Majumdar D, Meta C, Perez L, Pu M, Ramsey T, Remiszewski S, Skolnik S, Traebert M, Urban L, Uttamsingh V, Wang P, Whitebread S, Whitehead L, Yan-Neale Y, Yao YM, Zhou L, Atadja P.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2011	54	8	3051	3064	21417419	10.1021/jm200146u	Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.	Varasi M, Thaler F, Abate A, Bigogno C, Boggio R, Carenzi G, Cataudella T, Dal Zuffo R, Fulco MC, Rozio MG, Mai A, Dondio G, Minucci S, Mercurio C.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg. Med. Chem. Lett.	2013	23	11	3200	3203	23639537	10.1016/j.bmcl.2013.04.004	Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.	Zhou M, Ning C, Liu R, He Y, Yu N.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Eur. J. Med. Chem.	2014	85		468	479	25113875	10.1016/j.ejmech.2014.08.020	Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity.	Mehndiratta S, Hsieh YL, Liu YM, Wang AW, Lee HY, Liang LY, Kumar S, Teng CM, Yang CR, Liou JP.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg. Med. Chem.	2015	23	16	5151	5155	25637120	10.1016/j.bmc.2014.12.066	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).	Carrillo AK, Guiguemde WA, Guy RK.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg. Med. Chem. Lett.	2015	25	11	2382	2385	25937017	10.1016/j.bmcl.2015.04.016	Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6.	Kozlov MV, Kleymenova AA, Romanova LI, Konduktorov KA, Kamarova KA, Smirnova OA, Prassolov VS, Kochetkov SN.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J. Med. Chem.	2015	58	2	785	800	25490700	10.1021/jm501330g	Hydroxamic acids block replication of hepatitis C virus.	Ai T, Xu Y, Qiu L, Geraghty RJ, Chen L.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Eur. J. Med. Chem.	2015	98		30	48	26005022	10.1016/j.ejmech.2015.05.012	Synthesis and antiproliferative activity of ¿-branched ¿,ß-unsaturated ketones in human hematological and solid cancer cell lines.	Karpavi¿ien¿ I, Valiulien¿ G, Ra¿kevi¿ius V, Lebedyt¿ I, Bruk¿tus A, Kairys V, Navakauskien¿ R, ¿ikotien¿ I.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Eur J Med Chem	2016	122		92	101	27344487	10.1016/j.ejmech.2016.06.023	2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.	Lee HY, Chang CY, Su CJ, Huang HL, Mehndiratta S, Chao YH, Hsu CM, Kumar S, Sung TY, Huang YZ, Li YH, Yang CR, Liou JP.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Eur J Med Chem	2017	134		13	23	28395150	10.1016/j.ejmech.2017.03.079	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.	Mehndiratta S, Wang RS, Huang HL, Su CJ, Hsu CM, Wu YW, Pan SL, Liou JP.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	Bioorg Med Chem Lett	2017	27	17	4051	4055	28765013	10.1016/j.bmcl.2017.07.054	Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.	Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513	J Med Chem	2017	60	5	1817	1828	28218840	10.1021/acs.jmedchem.6b01507	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.	Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang J.
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	BELINOSTAT	CHEMBL408513									WHO Anatomical Therapeutic Chemical Classification	
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	BEPRIDIL HYDROCHLORIDE	CHEMBL1200382									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	BETAZOLE HYDROCHLORIDE	CHEMBL1200949									PubChem BioAssay data set	
939.2000000000000000	9606	Homo sapiens	BETAZOLE HYDROCHLORIDE	CHEMBL1200949									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	BETAZOLE HYDROCHLORIDE	CHEMBL1200949									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
837.2000000000000000	9606	Homo sapiens	BHQ-880	CHEMBL2109381									Unpublished dataset	
932.0000000000000000	11676	Human immunodeficiency virus 1	BICTEGRAVIR	CHEMBL3989866									Unpublished dataset	
932.0000000000000000	11676	Human immunodeficiency virus 1	BICTEGRAVIR	CHEMBL3989866									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723	Bioorg. Med. Chem. Lett.	2015	25	19	4047	4056	26298497	10.1016/j.bmcl.2015.07.093	Recent progress on MAP kinase pathway inhibitors.	Uehling DE, Harris PA.
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	BINIMETINIB	CHEMBL3187723									WHO Anatomical Therapeutic Chemical Classification	
958.5500000000000000	9606	Homo sapiens	BIVALIRUDIN	CHEMBL2103749	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
958.5500000000000000	9606	Homo sapiens	BIVALIRUDIN	CHEMBL2103749	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
958.5500000000000000	9606	Homo sapiens	BIVALIRUDIN	CHEMBL2103749									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	BIVALIRUDIN	CHEMBL2103749									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	BIVALIRUDIN	CHEMBL2103749									WHO Anatomical Therapeutic Chemical Classification	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2001	44	23	3965	3977	11689083	10.1021/jm0102250	Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.	Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, Tischler M, Arndt K, Discafani C, Etienne C, Gibbons J, Grod J, Lucas J, Weber JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2002	12	15	2011	2014	12113830	10.1016/s0960-894x(02)00302-5	Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles.	Boschelli DH, Wang DY, Ye F, Yamashita A, Zhang N, Powell D, Weber J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2002	12	20	2989	2992	12270190	10.1016/s0960-894x(02)00577-2	Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors.	Berger D, Dutia M, Powell D, Wissner A, DeMorin F, Raifeld Y, Weber J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2003	13	18	2977	2980	12941315	10.1016/s0960-894x(03)00628-0	Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines.	Boschelli DH, Powell D, Golas JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2003	13	21	3797	3800	14552782	10.1016/j.bmcl.2003.07.001	Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity.	Boschelli DH, Ye F, Wu B, Wang YD, Barrios Sosa AC, Yaczko D, Powell D, Golas JM, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2004	14	9	2155	2158	15080999	10.1016/j.bmcl.2004.02.035	Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles.	Barrios Sosa AC, Boschelli DH, Ye F, Golas JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2004	47	7	1599	1601	15027848	10.1021/jm0499458	7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases.	Boschelli DH, Wang YD, Johnson S, Wu B, Ye F, Barrios Sosa AC, Golas JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2005	15	21	4681	4684	16125383	10.1016/j.bmcl.2005.07.061	Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles.	Boschelli DH, Wu B, Barrios Sosa AC, Chen JJ, Golas JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2005	15	6	1743	1747	15745832	10.1016/j.bmcl.2005.01.004	Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.	Barrios Sosa AC, Boschelli DH, Wu B, Wang Y, Golas JM.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2005	48	11	3891	3902	15916442	10.1021/jm050175p	Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.	Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Chen JJ, Wang Y, Golas JM, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2005	48	19	5909	5920	16161995	10.1021/jm050512u	4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.	Berger DM, Dutia M, Birnberg G, Powell D, Boschelli DH, Wang YD, Ravi M, Yaczko D, Golas J, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2005	48	21	6523	6543	16220969	10.1021/jm058225d	Designed multiple ligands. An emerging drug discovery paradigm.	Morphy R, Rankovic Z.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2006	49	19	5759	5768	16970400	10.1021/jm060380k	Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.	Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2006	49	26	7868	7876	17181170	10.1021/jm061031t	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.	Boschelli DH, Wu B, Ye F, Wang Y, Golas JM, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem.	2008	16	1	405	412	17905586	10.1016/j.bmc.2007.09.028	Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.	Boschelli DH, Wu B, Ye F, Durutlic H, Golas JM, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem.	2008	16	11	5890	5898	18485715	10.1016/j.bmc.2008.04.065	Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase.	Cao X, You QD, Li ZY, Guo QL, Shang J, Yan M, Chern JW, Chen ML.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2008	18	23	6206	6209	18930653	10.1016/j.bmcl.2008.10.006	The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.	Cao X, You QD, Li ZY, Liu XR, Xu D, Guo QL, Shang J, Chern JW, Chen ML.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem.	2009	17	8	3152	3161	19321350	10.1016/j.bmc.2009.02.054	Structure-based virtual screening of Src kinase inhibitors.	Lee K, Kim J, Jeong KW, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2009	19	17	5071	5074	19632113	10.1016/j.bmcl.2009.07.043	4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.	Zhang N, Wu B, Boschelli DH, Golas JM, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Leukemia	2009	23	3	477	485	19039322	10.1038/leu.2008.334	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.	Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem. Lett.	2010	20	9	2924	2927	20363128	10.1016/j.bmcl.2010.03.025	Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.	Boschelli DH, Wang D, Wang Y, Wu B, Honores EE, Barrios Sosa AC, Chaudhary I, Golas J, Lucas J, Boschelli F.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2010	53	4	1413	1437	20166671	10.1021/jm901132v	Selectively nonselective kinase inhibition: striking the right balance.	Morphy R.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg. Med. Chem.	2011	19	8	2517	2528	21459579	10.1016/j.bmc.2011.03.021	Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.	Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2015	58	6	2746	2763	25699576	10.1021/jm501929n	Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.	Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Bioorg Med Chem Lett	2016	26	21	5350	5353	27687671	10.1016/j.bmcl.2016.09.009	Identification of small molecules that bind to the mitochondrial protein mitoNEET.	Geldenhuys WJ, Yonutas HM, Morris DL, Sullivan PG, Darvesh AS, Leeper TC.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2016	59	3	1184	1196	26814890	10.1021/acs.jmedchem.5b01841	Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.	Sang F, Ding Y, Wang J, Sun B, Sun J, Geng Y, Zhang Z, Ding K, Wu LL, Liu JW, Bai C, Yang G, Zhang Q, Li LY, Chen Y.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2016	59	5	1984	2004	26789553	10.1021/acs.jmedchem.5b01618	Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.	Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J. Med. Chem.	2016	59	8	3593	3608	26555154	10.1021/acs.jmedchem.5b01273	AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.	Myers SH, Brunton VG, Unciti-Broceta A.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	MedChemComm	2016	7	3	484	494		10.1039/C5MD00462D	A multicomponent pharmacophore fragment-decoration approach to identify selective LRRK2-targeting probes	Tassini S, Castagnolo D, Scalacci N, Kissova M, Armijos-Rivera JI, Giagnorio F, Maga G, Costantino G, Crespan E, Radi M
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Eur J Med Chem	2017	126		754	761	27940419	10.1016/j.ejmech.2016.11.003	Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.	Murár M, Dobia¿ J, ¿ramel P, Addová G, Hanquet G, Bohá¿ A.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J Med Chem	2017	60	18	7863	7875	28792760	10.1021/acs.jmedchem.7b00996	Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.	Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441	J Med Chem	2018	61	8	3582	3594	29624387	10.1021/acs.jmedchem.8b00035	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.	Capuzzi SJ, Sun W, Muratov EN, Martínez-Romero C, He S, Zhu W, Li H, Tawa G, Fisher EG, Xu M, Shinn P, Qiu X, García-Sastre A, Zheng W, Tropsha A.
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441									British National Formulary (72nd edition)	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441									PubChem BioAssay data set	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	BOSUTINIB	CHEMBL288441									WHO Anatomical Therapeutic Chemical Classification	
1114.5000000000000000	9606	Homo sapiens	BREMELANOTIDE	CHEMBL2070241	J. Med. Chem.	2012	55	5	1969	1977	22335602	10.1021/jm201489a	Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective ¿-melanocyte-stimulating hormone (¿-MSH) analogues.	Conde-Frieboes K, Thøgersen H, Lau JF, Sensfuss U, Hansen TK, Christensen L, Spetzler J, Olsen HB, Nilsson C, Raun K, Dahl K, Hansen BS, Wulff BS.
1114.5000000000000000	9606	Homo sapiens	BREMELANOTIDE	CHEMBL2070241	J Med Chem	2018	61	8	3674	3684	29605997	10.1021/acs.jmedchem.8b00170	Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.	Durek T, Cromm PM, White AM, Schroeder CI, Kaas Q, Weidmann J, Ahmad Fuaad A, Cheneval O, Harvey PJ, Daly NL, Zhou Y, Dellsén A, Österlund T, Larsson N, Knerr L, Bauer U, Kessler H, Cai M, Hruby VJ, Plowright AT, Craik DJ.
1114.5000000000000000	9606	Homo sapiens	BREMELANOTIDE	CHEMBL2070241								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1114.5000000000000000	9606	Homo sapiens	BREMELANOTIDE	CHEMBL2070241									Unpublished dataset	
1114.5000000000000000	9606	Homo sapiens	BREMELANOTIDE	CHEMBL2070241									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1977	20	5	682	686	16135	10.1021/jm00215a013	Synthesis and narcotic agonist-antagonist evaluation of some 2,6-methano-3-benzazocine-11 propanols. Analogues of the ring C bridged oripavine-7-mehtanols.	Michne WF, Salsbury RL, Michalec SJ.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1978	21	12	1322	1324	722743	10.1021/jm00210a032	2,6-Methano-3-benzazocine-11-ropanols. Lack of antagonism between optical antipodes and observation of potent narcotic antagonism by two n-methyl derivatives.	Michne WF.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1979	22	10	1158	1163	41949	10.1021/jm00196a002	(2,6-Methano-3-benzazocin-11 beta-yl)alkanones. 1. Alkylalkanones: a new series of N-methyl derivatives with novel opiate activity profiles.	Michne WF, Lewis TR, Michalec SJ, Pierson AK, Rosenberg FJ.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1982	25	8	983	986	6181259	10.1021/jm00350a019	Novel opiates and antagonists. 4. 7-Alkanoylhydromorphones.	Quick J, Herlihy P, Razdan RK, Howes JF.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1983	26	1	42	50	6600791	10.1021/jm00355a010	Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.	Huegi BS, Ebnöther AM, Rissi E, Gadient F, Hauser D, Roemer D, Hill RC, Buescher HH, Petcher TJ.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1984	27	12	1648	1657	6094812	10.1021/jm00378a021	Functional group contributions to drug-receptor interactions.	Andrews PR, Craik DJ, Martin JL.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	1996	39	22	4377	4381	8893832	10.1021/jm960073m	Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.	Avdeef A, Barrett DA, Shaw PN, Knaggs RD, Davis SS.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Bioorg. Med. Chem. Lett.	1999	9	6	831	834	10206545	10.1016/s0960-894x(99)00085-2	Ring constrained analogues of the orvinols: the furanomorphides.	Husbands SM, Breeden SW, Grivas K, Lewis JW.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2000	43	2	139	141	10649968	10.1021/jm991165p	Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.	Husbands SM, Lewis JW.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Bioorg. Med. Chem. Lett.	2005	15	11	2886	2890	15911273	10.1016/j.bmcl.2005.03.080	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.	Tobita M, Nishikawa T, Nagashima R.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Bioorg. Med. Chem. Lett.	2006	16	13	3609	3613	16650985	10.1016/j.bmcl.2006.02.017	A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.	Park HS, Lee HY, Kim YH, Park JK, Zvartau EE, Lee H.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Biol. Chem.	2007	282	37	27126	27132	17616524	10.1074/jbc.m703272200	Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.	Nikolaev VO, Boettcher C, Dees C, Bünemann M, Lohse MJ, Zenk MH.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Biol. Chem.	2007	282	41	29803	29811	17702750	10.1074/jbc.m705540200	Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.	Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2007	50	21	5176	5182	17887741	10.1021/jm070255o	Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.	Rennison D, Neal AP, Cami-Kobeci G, Aceto MD, Martinez-Bermejo F, Lewis JW, Husbands SM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Bioorg. Med. Chem. Lett.	2009	19	1	203	208	19027293	10.1016/j.bmcl.2008.10.134	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.	Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Eur. J. Med. Chem.	2011	46	2	618	630	21185626	10.1016/j.ejmech.2010.11.042	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.	Sinha N, Sen S.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2011	54	19	6531	6537	21866885	10.1021/jm2003238	Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.	Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	Med Chem Res	2012	21	12	4357	4368		10.1007/s00044-012-9977-1	Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS	Noorizadeh H, Noorizadeh M, Farmany A
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2012	55	22	9868	9874	23043264	10.1021/jm301096s	Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible ¿ opioid receptor antagonist effects.	Moynihan HA, Derrick I, Broadbear JH, Greedy BM, Aceto MD, Harris LS, Purington LC, Thomas MP, Woods JH, Traynor JR, Husbands SM, Lewis JW.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2013	56	20	8019	8031	24063433	10.1021/jm4010829	Structure-activity relationships and discovery of a G protein biased ¿ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.	Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, Koblish M, Dewire SM, Crombie AL, Violin JD, Yamashita DS.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2013	56	8	3207	3216	23438330	10.1021/jm301543e	Orvinols with mixed kappa/mu opioid receptor agonist activity.	Greedy BM, Bradbury F, Thomas MP, Grivas K, Cami-Kobeci G, Archambeau A, Bosse K, Clark MJ, Aceto M, Lewis JW, Traynor JR, Husbands SM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2014	57	10	4049	4057	24761755	10.1021/jm401964y	Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.	Kumar V, Ridzwan IE, Grivas K, Lewis JW, Clark MJ, Meurice C, Jimenez-Gomez C, Pogozheva I, Mosberg H, Traynor JR, Husbands SM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2014	57	12	5464	5469	24933507	10.1021/jm500503k	Synthesis and evaluation of three structurally related ¹¿F-labeled orvinols of different intrinsic activities: 6-O-[¹¿F]fluoroethyl-diprenorphine ([¹¿F]FDPN), 6-O-[¹¿F]fluoroethyl-buprenorphine ([¹¿F]FBPN), and 6-O-[¹¿F]fluoroethyl-phenethyl-orvinol ([¹¿F]FPEO).	Schoultz BW, Hjørnevik T, Reed BJ, Marton J, Coello CS, Willoch F, Henriksen G.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2015	58	10	4242	4249	25898137	10.1021/acs.jmedchem.5b00130	C7ß-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.	Cueva JP, Roche C, Ostovar M, Kumar V, Clark MJ, Hillhouse TM, Lewis JW, Traynor JR, Husbands SM.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J. Med. Chem.	2015	58	19	7785	7795	26348111	10.1021/acs.jmedchem.5b00841	Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.	Fanelli R, Besserer-Offroy É, René A, Côté J, Tétreault P, Collerette-Tremblay J, Longpré JM, Leduc R, Martinez J, Sarret P, Cavelier F.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142	J Med Chem	2016	59	19	8712	8756	27299736	10.1021/acs.jmedchem.6b00472	"The ""Cyclopropyl Fragment"" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules."	Talele TT.
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142		2016							1,3-dioxanomorphides and 1,3-dioxanocodides	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142									British National Formulary (72nd edition)	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE	CHEMBL511142									WHO Anatomical Therapeutic Chemical Classification	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE HYDROCHLORIDE	CHEMBL2368861									British National Formulary (72nd edition)	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE HYDROCHLORIDE	CHEMBL2368861									PubChem BioAssay data set	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE HYDROCHLORIDE	CHEMBL2368861									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	BUPRENORPHINE HYDROCHLORIDE	CHEMBL2368861									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516	J. Med. Chem.	1985	28	3	381	388	2579237	10.1021/jm00381a019	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.	McNeal ET, Lewandowski GA, Daly JW, Creveling CR.
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516	Bioorg. Med. Chem.	2009	17	2	896	904	19056282	10.1016/j.bmc.2008.11.040	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.	Pérez-Garrido A, Morales Helguera A, Abellán Guillén A, Cordeiro MN, Garrido Escudero A.
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516	Bioorg. Med. Chem. Lett.	2011	21	24	7363	7366	22041064	10.1016/j.bmcl.2011.10.020	Butamben derivatives enhance BMP-2-stimulated commitment of C2C12 cells into osteoblasts with induction of voltage-gated potassium channel expression.	Kim HJ, Park M, Han YM, Kwon BM, Kim SH.
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516									DrugMatrix	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516									PubChem BioAssay data set	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516									Unpublished dataset	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN	CHEMBL127516									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN PICRATE	CHEMBL3142541									Unpublished dataset	
851.6000000000000000	9606	Homo sapiens	BUTAMBEN PICRATE	CHEMBL3142541									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
895.6500000000000000	9606	Homo sapiens	BUTORPHANOL TARTRATE	CHEMBL299400	J. Med. Chem.	1980	23	2	174	179	6767032	10.1021/jm00176a013	Analgesic narcotic antagonists. 2. 8-Alkymorphinan-6-ones.	Polazzi JO, Schut RN, Kotick MP, Howes JF, Osgood PF, Razdan RK, Villarreal JE.
895.6500000000000000	9606	Homo sapiens	BUTORPHANOL TARTRATE	CHEMBL299400									British National Formulary (72nd edition)	
895.6500000000000000	9606	Homo sapiens	BUTORPHANOL TARTRATE	CHEMBL299400									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	BUTORPHANOL TARTRATE	CHEMBL299400									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1066.9727272727272727	1773	Mycobacterium tuberculosis	CAPREOMYCIN SULFATE	CHEMBL2218913	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1066.9727272727272727	1773	Mycobacterium tuberculosis	CAPREOMYCIN SULFATE	CHEMBL2218913	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1066.9727272727272727	1773	Mycobacterium tuberculosis	CAPREOMYCIN SULFATE	CHEMBL2218913									Unpublished dataset	
1066.9727272727272727	1773	Mycobacterium tuberculosis	CAPREOMYCIN SULFATE	CHEMBL2218913									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260	J. Biol. Chem.	2007	282	33	23841	23853	17553798	10.1074/jbc.m703467200	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.	Kaler G, Truong DM, Khandelwal A, Nagle M, Eraly SA, Swaan PW, Nigam SK.
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260									Unpublished dataset	
962.7500000000000000	2	Bacteria	CARBENICILLIN DISODIUM	CHEMBL606260									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CARBENICILLIN INDANYL SODIUM	CHEMBL1200991	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CARBENICILLIN INDANYL SODIUM	CHEMBL1200991									Unpublished dataset	
962.7500000000000000	2	Bacteria	CARBENICILLIN INDANYL SODIUM	CHEMBL1200991									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Biol. Chem.	1999	274	1	1519	1524	9880528	10.1074/jbc.274.3.1519	Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.	Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2001	44	5	641	659	11262075	10.1021/jm990564h	Perspectives in animal health: old targets and new opportunities.	Meinke PT.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2005	48	13	4312	4331	15974585	10.1021/jm049082i	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.	Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2006	49	26	7588	7591	17181139	10.1021/jm0610200	Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.	Narlawar R, Pérez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Bioorg. Med. Chem. Lett.	2008	18	16	4655	4657	18667313	10.1016/j.bmcl.2008.07.018	New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines.	Bézière N, Goossens L, Pommery J, Vezin H, Touati N, Hénichart JP, Pommery N.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Bioorg. Med. Chem.	2010	18	19	7078	7084	20810286	10.1016/j.bmc.2010.08.003	QSAR-based solubility model for drug-like compounds.	Gozalbes R, Pineda-Lucena A.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2010	53	12	4691	4700	20503989	10.1021/jm1003073	Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity.	Hieke M, Ness J, Steri R, Dittrich M, Greiner C, Werz O, Baumann K, Schubert-Zsilavecz M, Weggen S, Zettl H.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Bioorg. Med. Chem.	2011	19	18	5372	5382	21873070	10.1016/j.bmc.2011.08.003	SAR studies of acidic dual ¿-secretase/PPAR¿ modulators.	Hieke M, Ness J, Steri R, Greiner C, Werz O, Schubert-Zsilavecz M, Weggen S, Zettl H.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2011	54	3	669	698	21141968	10.1021/jm101168r	¿-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.	Oehlrich D, Berthelot DJ, Gijsen HJ.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Eur. J. Med. Chem.	2012	53		76	82	22521372	10.1016/j.ejmech.2012.03.037	Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.	Honey, Thareja S, Kumar M, Sinha VR.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	J. Med. Chem.	2012	55	20	8807	8826	23043222	10.1021/jm3011146	Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.	Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, Dionisi M, Tarozzo G, Piomelli D, Cavalli A, De Vivo M.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316	MedChemComm	2014	5	6	737	741		10.1039/C3MD00397C	Scaffold hopping of potential anti-tumor agents by WEGA: a shape-based approach	Ge H, Wang Y, Zhao W, Lin W, Yan X, Xu J
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	CARPROFEN	CHEMBL1316									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
851.6000000000000000	9606	Homo sapiens	CB-189625	CHEMBL3707378									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018	J. Med. Chem.	1988	31	10	1997	2000	3050090	10.1021/jm00118a024	Oral absorption of cephalosporin antibiotics. 3. Synthesis and biological properties of 7 alpha-methoxy-7 beta-(arylacetamido)-3-chloro-3-cephem-4- carboxylic acids.	Pfeil-Doyle J, Kukolja S.
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018	J. Med. Chem.	1988	31	6	1190	1196	3373488	10.1021/jm00401a020	An examination of O-2-isocephems as orally absorbable antibiotics.	Mastalerz H, Menard M, Vinet V, Desiderio J, Fung-Tomc J, Kessler R, Tsai Y.
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018	J. Med. Chem.	1988	31	6	1227	1230	3373491	10.1021/jm00401a026	The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.	Indelicato JM, Pasini CE.
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018	J. Med. Chem.	1991	34	3	968	978	1825850	10.1021/jm00107a014	Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.	Dolence EK, Minnick AA, Lin CE, Miller MJ, Payne SM.
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018	Bioorg. Med. Chem. Lett.	1997	7	17	2217	2222		10.1016/S0960-894X(97)00401-0	Synthesis and biological activity of novel penem sulfoxides and sulfones	Pfaendler HR, Weishaupt R, Medicus C
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFACLOR	CHEMBL1201018									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Biochim. Biophys. Acta	1995	1235	1	461	466	7756356	10.1016/0005-2736(95)80036-f	Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney.	Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Biol. Chem.	1995	270	1	25672	25677	7592745	10.1074/jbc.270.43.25672	Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.	Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Biol. Chem.	1995	270	1	6456	6463	7896779	10.1074/jbc.270.12.6456	Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization.	Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Pharmacol. Exp. Ther.	1996	277	1	831	839	8627565		Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.	Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Pharm. Pharmacol.	1997	49	1	796	801	9379359	10.1111/j.2042-7158.1997.tb06115.x	The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine.	Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Biochem. Biophys. Res. Commun.	1998	250	1	246	251	9753615	10.1006/bbrc.1998.9298	Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.	Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Pharmacol. Exp. Ther.	1999	289	1	448	454	10087037		Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.	Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Pharmacol. Exp. Ther.	1999	290	1	672	677	10411577		The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.	Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Metabol. Pharmacokin.	2002	17	1	253	274	15618677	10.2133/dmpk.17.253	Transporter-mediated Drug Interactions.	Tsuji A.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Eur. J. Pharmacol.	2002	438	1	137	142	11909604	10.1016/s0014-2999(02)01306-7	Interaction of human organic anion transporters with various cephalosporin antibiotics.	Takeda M, Babu E, Narikawa S, Endou H.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Life Sci.	2002	70	1	1861	1874	12005172	10.1016/s0024-3205(02)01500-x	Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.	Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Antimicrob. Agents Chemother.	2010	54	5	1855	1863	20231390	10.1128/aac.00014-10	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.	Blango MG, Mulvey MA.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Bioorg. Med. Chem. Lett.	2012	22	17	5555	5558	22853996	10.1016/j.bmcl.2012.07.016	Two novel bioactive glucosinolates from Broccoli (Brassica oleracea L. var. italica) florets.	Survay NS, Kumar B, Jang M, Yoon DY, Jung YS, Yang DC, Park SW.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Metab. Dispos.	2012	40	3	515	521	22166395	10.1124/dmd.111.041731	Oral availability of cefadroxil depends on ABCC3 and ABCC4.	de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Metab. Dispos.	2013	41	4	791	800	23344796	10.1124/dmd.112.049569	Organic anion transporter 3 interacts selectively with lipophilic ß-lactam antibiotics.	Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFADROXIL	CHEMBL1644									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	1977	20	4	551	556	850241	10.1021/jm00214a018	Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole.	Firestone RA, Fahey JL, Maciejewicz NS, Patel GS, Christensen BG.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	1979	22	7	757	759	448673	10.1021/jm00193a001	Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its related 1-oxacephems.	Narisada M, Yoshida T, Onoue H, Ohtani M, Okada T, Tsuji T, Kikkawa I, Haga N, Satoh H, Itani H, Nagata W.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	1993	36	22	3224	3229	8230112	10.1021/jm00074a002	Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.	Ternansky RJ, Draheim SE, Pike AJ, Counter FT, Eudaly JA, Kasher JS.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Pharmacol. Exp. Ther.	1999	290	1	672	677	10411577		The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.	Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Eur. J. Pharmacol.	2002	438	1	137	142	11909604	10.1016/s0014-2999(02)01306-7	Interaction of human organic anion transporters with various cephalosporin antibiotics.	Takeda M, Babu E, Narikawa S, Endou H.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Life Sci.	2002	70	1	1861	1874	12005172	10.1016/s0024-3205(02)01500-x	Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1.	Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Eur. J. Pharmacol.	2003	465	1	1	7	12650826	10.1016/s0014-2999(03)01381-5	Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics.	Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2009	53	8	3248	3255	19470505	10.1128/aac.00079-09	Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.	Hu WS, Lin JF, Lin YH, Chang HY.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2009	53	8	3357	3364	19506058	10.1128/aac.01655-08	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.	Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJ.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2009	53	8	3437	3441	19487449	10.1128/aac.00317-09	Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.	Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, Fowler VG, Murray BE.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2009	53	8	3541	3543	19506059	10.1128/aac.00371-09	H-NS modulates multidrug resistance of Salmonella enterica serovar Typhimurium by repressing multidrug efflux genes acrEF.	Nishino K, Hayashi-Nishino M, Yamaguchi A.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2010	54	1	45	51	19884377	10.1128/aac.00427-09	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.	Doublet B, Robin F, Casin I, Fabre L, Le Fleche A, Bonnet R, Weill FX.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2010	54	10	4078	4084	20679509	10.1128/aac.00275-10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.	Hajdu S, Holinka J, Reichmann S, Hirschl AM, Graninger W, Presterl E.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Antimicrob. Agents Chemother.	2010	54	5	2239	2243	20211889	10.1128/aac.01677-09	Effect of NlpE overproduction on multidrug resistance in Escherichia coli.	Nishino K, Yamasaki S, Hayashi-Nishino M, Yamaguchi A.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Drug Metab. Dispos.	2012	40	3	515	521	22166395	10.1124/dmd.111.041731	Oral availability of cefadroxil depends on ABCC3 and ABCC4.	de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Drug Metab. Dispos.	2013	41	2	372	378	23139379	10.1124/dmd.112.049312	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.	Grime K, Paine SW.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFAMANDOLE	CHEMBL1146									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFAMANDOLE NAFATE	CHEMBL1618	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFAMANDOLE NAFATE	CHEMBL1618	Antimicrob. Agents Chemother.	2007	51	8	2733	2740	17548491	10.1128/aac.01249-06	Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes.	Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi A, Ragunath C, Kaplan JB.
962.7500000000000000	2	Bacteria	CEFAMANDOLE NAFATE	CHEMBL1618	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFAMANDOLE NAFATE	CHEMBL1618									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFAMANDOLE NAFATE	CHEMBL1618									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFAZOLIN SODIUM	CHEMBL1200523									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Bioorg. Med. Chem. Lett.	1993	3	11	2225	2230		10.1016/S0960-894X(01)80929-X	Synthesis and biological properties of 3-[()-2-(1,2,3-Thiadiazolyl)ethenyl]-substituted cephalosporins and related compounds: new oral cephalosporins	Kobori T, Fujita M, Yamamoto R, Hiyama T, Konda K, Numata K, Sugita K, Akashi T, Kaneda Y, Nagate T, Hanada K
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	J. Med. Chem.	1996	39	9	1864	1871	8627610	10.1021/jm950886v	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.	Heinze-Krauss I, Angehrn P, Guerry P, Hebeisen P, Hubschwerlen C, Kompis I, Page MG, Richter HG, Runtz V, Stalder H, Weiss U, Wei CC.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Biochim. Biophys. Acta	1997	1324	1	296	308	9092716	10.1016/s0005-2736(96)00234-9	Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.	Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Bioorg. Med. Chem. Lett.	2000	10	18	2123	2127	10999485	10.1016/s0960-894x(00)00425-x	Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.	Lee CS, Ryu EJ, Oh SH, Paek KS, Kim MY, Youn H.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Drug Metabol. Pharmacokin.	2002	17	1	253	274	15618677	10.2133/dmpk.17.253	Transporter-mediated Drug Interactions.	Tsuji A.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2007	51	12	4382	4389	17908940	10.1128/aac.00971-07	National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.	Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2007	51	2	770	773	17116666	10.1128/aac.01150-06	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.	Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2007	51	5	1589	1595	17325223	10.1128/aac.01545-06	Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.	Takahata S, Ida T, Senju N, Sanbongi Y, Miyata A, Maebashi K, Hoshiko S.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2008	52	5	1880	1883	18347113	10.1128/aac.00936-07	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.	Takahata S, Kato Y, Sanbongi Y, Maebashi K, Ida T.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2008	52	7	2639	2643	18443117	10.1128/aac.00310-08	Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.	Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	J. Med. Chem.	2009	52	19	5926	5936	19746934	10.1021/jm900625q	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.	Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2009	53	1	267	270	18955529	10.1128/aac.00402-08	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.	Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2009	53	3	1278	1280	19124661	10.1128/aac.01519-08	Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.	Prakash V, Lewis JS, Herrera ML, Wickes BL, Jorgensen JH.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFDINIR	CHEMBL927									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2007	51	10	3699	3706	17664320	10.1128/aac.01530-06	influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.	Torrico M, Aguilar L, González N, Giménez MJ, Echeverría O, Cafini F, Sevillano D, Alou L, Coronel P, Prieto J.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2008	52	3	1184	1186	18160517	10.1128/aac.01247-07	Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.	Sevillano D, Aguilar L, Alou L, Giménez MJ, Torrico M, González N, Cafini F, Relaño MT, Coronel P, Prieto J.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2008	52	5	1880	1883	18347113	10.1128/aac.00936-07	Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.	Takahata S, Kato Y, Sanbongi Y, Maebashi K, Ida T.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2008	52	6	1945	1951	17485507	10.1128/aac.00736-06	Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.	Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	J. Med. Chem.	2009	52	19	5926	5936	19746934	10.1021/jm900625q	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.	Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2009	53	1	267	270	18955529	10.1128/aac.00402-08	Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.	Sevillano D, Giménez MJ, Cercenado E, Cafini F, Gené A, Alou L, Marco F, Martínez-Martínez L, Coronel P, Aguilar L.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	ACS Med. Chem. Lett.	2013	4	8	715	719	24900737	10.1021/ml400092n	Design, synthesis, and evaluation of prodrugs of ertapenem.	Singh SB, Rindgen D, Bradley P, Cama L, Sun W, Hafey MJ, Suzuki T, Wang N, Wu H, Zhang B, Wang L, Ji C, Yu H, Soll R, Olsen DB, Meinke PT, Nicoll-Griffith DA.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFDITOREN PIVOXIL	CHEMBL454446									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFEPIME HYDROCHLORIDE	CHEMBL1200962									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFEPIME HYDROCHLORIDE	CHEMBL1200962									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFEPIME HYDROCHLORIDE	CHEMBL1200962									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Pharmacol. Exp. Ther.	1996	277	1	831	839	8627565		Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.	Wenzel U, Gebert I, Weintraut H, Weber WM, Clauss W, Daniel H.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Biochim. Biophys. Acta	1997	1324	1	296	308	9092716	10.1016/s0005-2736(96)00234-9	Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.	Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Pharmacol. Exp. Ther.	1997	281	1	1415	1421	9190878		Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Pharm. Pharmacol.	1997	49	1	796	801	9379359	10.1111/j.2042-7158.1997.tb06115.x	The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine.	Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Drug Metabol. Pharmacokin.	2002	17	1	253	274	15618677	10.2133/dmpk.17.253	Transporter-mediated Drug Interactions.	Tsuji A.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2007	51	2	453	460	17116681	10.1128/aac.00960-06	Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.	Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2007	51	6	2117	2122	17420216	10.1128/aac.01604-06	Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.	Lindberg R, Fredlund H, Nicholas R, Unemo M.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2007	51	7	2564	2573	17470649	10.1128/aac.00354-07	Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime.	García-Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García-Rey C, Pérez-Vázquez M, Oteo J, de Abajo F.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2007	51	9	3463	3464	17606681	10.1128/aac.00190-07	Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?	Billal DS, Hotomi M, Yamanaka N.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2008	52	10	3564	3567	18663018	10.1128/aac.00198-08	Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.	Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2008	52	7	2407	2414	18443129	10.1128/aac.00214-08	Low beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains are best detected by testing amoxicillin susceptibility by the broth microdilution method.	García-Cobos S, Campos J, Román F, Carrera C, Pérez-Vázquez M, Aracil B, Oteo J.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2009	53	7	2773	2776	19364847	10.1128/aac.01409-08	Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.	Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D, Murthy B, Derendorf H.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2009	53	9	4032	4034	19546370	10.1128/aac.00406-09	Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.	Pandori M, Barry PM, Wu A, Ren A, Whittington WL, Liska S, Klausner JD.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2010	45	12	5848	5855	20934788	10.1016/j.ejmech.2010.09.049	Post Groebke-Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents.	Al-Tel TH, Al-Qawasmeh RA.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2010	45	6	2307	2313	20181416	10.1016/j.ejmech.2010.02.006	Synthesis and antimicrobial activity of cholic acid hydrazone analogues.	Rasras AJ, Al-Tel TH, Al-Aboudi AF, Al-Qawasmeh RA.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2010	54	1	164	169	19901088	10.1128/aac.00310-09	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.	Faure S, Perrin-Guyomard A, Delmas JM, Chatre P, Laurentie M.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2010	54	11	4893	4895	20733036	10.1128/aac.00482-10	Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.	Huang CT, Yen MY, Wong WW, Li LH, Lin KY, Liao MH, Li SY.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2010	54	3	1060	1067	20028823	10.1128/aac.01010-09	Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages.	Ohnishi M, Watanabe Y, Ono E, Takahashi C, Oya H, Kuroki T, Shimuta K, Okazaki N, Nakayama S, Watanabe H.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2010	54	4	1506	1511	20086141	10.1128/aac.01489-09	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.	San Millan A, Garcia-Cobos S, Escudero JA, Hidalgo L, Gutierrez B, Carrilero L, Campos J, Gonzalez-Zorn B.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2010	54	7	3021	3023	20421400	10.1128/aac.00245-10	Identification of TEM-135 beta-lactamase in penicillinase-producing Neisseria gonorrhoeae strains in Japan.	Ohnishi M, Ono E, Shimuta K, Watanabe H, Okamura N.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	ACS Med. Chem. Lett.	2011	2	5	385	390	24900319	10.1021/ml200012f	Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.	Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2011	46	5	1874	1881	21414694	10.1016/j.ejmech.2011.02.051	Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs.	Al-Tel TH, Al-Qawasmeh RA, Zaarour R.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Antimicrob. Agents Chemother.	2011	55	2	703	712	21098249	10.1128/aac.00788-10	Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.	Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Med Chem Res	2012	21	11	3897	3901		10.1007/s00044-011-9933-5	11-Chloro-3-methyl-3H-imidazo[4,5-a]acridine (CMIA) as a potent and selective antimicrobial agent against clinical isolates of highly antibiotic-resistant Acinetobacter baumannii	Sadeghian A, Pordel M, Safdari H, Fahmidekar MA, Sadeghian H
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Med Chem Res	2012	21	7	1471	1479		10.1007/s00044-011-9669-2	Synthesis and antimicrobial evaluation of novel benzo[b]thiophenes comprising -lactam nucleus	Trivedi AR, Desai JM, Dholariya BH, Dodiya DK, Shah VH
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2012	47		452	461	22119127	10.1016/j.ejmech.2011.11.014	Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.	Arshad N, Yunus U, Razzque S, Khan M, Saleem S, Mirza B, Rashid N.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Med Chem Res	2013	22	6	2755	2767		10.1007/s00044-012-0270-0	Design, characterization, computational studies, and pharmacological evaluation of substituted-N-[(1E) substituted-phenylmethylidene]benzohydrazide analogs	Bala S, Uppal G, Kamboj S, Saini V, Prasad DN
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Med Chem Res	2013	22	8	3566	3573		10.1007/s00044-012-0343-0	Synthesis of some new 3,5-diamino-4-(4-fluorophenylazo)-1-aryl/heteroarylpyrazoles as antimicrobial agents	Aggarwal R, Kumar V, Gupta GK, Kumar V
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Drug Metab. Dispos.	2013	41	2	372	378	23139379	10.1124/dmd.112.049312	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.	Grime K, Paine SW.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2013	62		508	514	23416192	10.1016/j.ejmech.2012.11.046	Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.	Aggarwal R, Kumar S, Kaushik P, Kaushik D, Gupta GK.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Bioorg. Med. Chem. Lett.	2014	24	15	3321	3325	24961639	10.1016/j.bmcl.2014.05.103	Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate.	Singh B, Bhat HR, Kumawat MK, Singh UP.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Eur. J. Med. Chem.	2014	84		343	363	25036793	10.1016/j.ejmech.2014.07.028	Potentially bioactive organotin(IV) compounds: synthesis, characterization, in vitro bioactivities and interaction with SS-DNA.	Sirajuddin M, Ali S, McKee V, Sohail M, Pasha H.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFIXIME	CHEMBL1541									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFMENOXIME HYDROCHLORIDE	CHEMBL3183193									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFMENOXIME HYDROCHLORIDE	CHEMBL3183193									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFMENOXIME HYDROCHLORIDE	CHEMBL3183193									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFMETAZOLE SODIUM	CHEMBL1201118	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEFMETAZOLE SODIUM	CHEMBL1201118	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFMETAZOLE SODIUM	CHEMBL1201118									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFMETAZOLE SODIUM	CHEMBL1201118									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFMETAZOLE SODIUM	CHEMBL1201118									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	J. Pharmacol. Exp. Ther.	1993	265	1	1301	1312	8510010		Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats.	Sathirakul K, Suzuki H, Yasuda K, Hanano M, Tagaya O, Horie T, Sugiyama Y.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Drug Metabol. Pharmacokin.	2002	17	1	23	33	15618649	10.2133/dmpk.17.23	The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.	Horikawa M, Kato Y, Tyson CA, Sugiyama Y.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFODIZIME	CHEMBL2303613									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFONICID SODIUM	CHEMBL1201005									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFONICID SODIUM	CHEMBL1201005									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFONICID SODIUM	CHEMBL1201005									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFOPERAZONE SODIUM	CHEMBL1200482	Eur J Med Chem	2017	132		249	261	28364659	10.1016/j.ejmech.2017.03.063	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.	Lara-Ramirez EE, López-Cedillo JC, Nogueda-Torres B, Kashif M, Garcia-Perez C, Bocanegra-Garcia V, Agusti R, Uhrig ML, Rivera G.
962.7500000000000000	2	Bacteria	CEFOPERAZONE SODIUM	CHEMBL1200482									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFOPERAZONE SODIUM	CHEMBL1200482									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFOPERAZONE SODIUM	CHEMBL1200482									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFORANIDE	CHEMBL1201046									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010	Bioorg. Med. Chem. Lett.	1993	3	11	2219	2224		10.1016/S0960-894X(01)80928-8	Synthesis and antibacterial activity of some C-3-lactonyl substituted cephalosporins	Bateson JH, Burton G, Fell SC
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010									DailyMed|setid=f3c5895f-f54b-43d4-9b38-7bfbdf8335b7 | CEFOTAXIME - cefotaxime injection, powder, for solution|WOCKHARDT USA LLC.	
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFOTAXIME SODIUM	CHEMBL1010									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFOTETAN DISODIUM	CHEMBL1201098									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFOTETAN DISODIUM	CHEMBL1201098									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFOTIAM HYDROCHLORIDE	CHEMBL1200589									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530	J. Med. Chem.	2014	57	9	3707	3714	24588790	10.1021/jm401685f	Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.	Duan F, Li X, Cai S, Xin G, Wang Y, Du D, He S, Huang B, Guo X, Zhao H, Zhang R, Ma L, Liu Y, Du Q, Wei Z, Xing Z, Liang Y, Wu X, Fan C, Ji C, Zeng D, Chen Q, He Y, Liu X, Huang W.
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFOXITIN SODIUM	CHEMBL1200530									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFPIRAMIDE SODIUM	CHEMBL1200672									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFPIRAMIDE SODIUM	CHEMBL1200672									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	J. Med. Chem.	1990	33	8	2114	2121	2115587	10.1021/jm00170a011	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.	Brown RF, Kinnick MD, Morin JM, Vasileff RT, Counter FT, Davidson EO, Ensminger PW, Eudaly JA, Kasher JS, Katner AS.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	J. Med. Chem.	1995	38	12	2152	2157	7783146	10.1021/jm00012a015	Synthesis and biological evaluation of a series of new parenteral optically active 3-[[(N-alkylpyridinium-4'-yl)thio]methyl]-2-oxaisocephems.	Tsubouchi H, Tsuji K, Yasumura K, Matsumoto M, Shitsuta T, Ishikawa H.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Bioorg. Med. Chem. Lett.	1995	5	23	2777	2782		10.1016/0960-894X(95)00485-C	Synthesis and biological activity of a novel class of cephalosporins with a oxadiazolyl hydroxypyridone moiety at C-7	Obi K, Kojima A, Fukuda H, Hirai K
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Bioorg. Med. Chem. Lett.	1999	9	7	1035	1040	10230635	10.1016/s0960-894x(99)00127-4	New N-substituted 7-aminocephalosporanic acid derivatives as potential agents against Streptococcus pneumoniae. Synthesis and in vitro activity.	Balsamo A, Barontini S, Calvani F, Gentili D, Macchia M, Rossello A, Di Modugno E, Felici A.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Bioorg. Med. Chem. Lett.	2000	10	11	1143	1145	10866367	10.1016/s0960-894x(00)00130-x	Synthesis and in vitro antibacterial activity of 3-[N-methyl-N-(3-methyl-1,3-thiazolium-2-yl)aminolmethyl cephalosporin derivatives.	Kim SH, Son H, Nam G, Chi DY, Kim JH.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	J. Med. Chem.	2005	48	5	1395	1400	15743183	10.1021/jm049652e	Beta-lactam screening by specific residues of the OmpF eyelet.	Vidal S, Bredin J, Pagès JM, Barbe J.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2007	51	11	4009	4014	17846134	10.1128/aac.00537-07	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.	Girlich D, Leclercq R, Naas T, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2007	51	12	4486	4488	17938180	10.1128/aac.01462-06	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.	Neuwirth C, Siebor E, Robin F, Bonnet R.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2007	51	4	1365	1372	17242148	10.1128/aac.01152-06	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.	Naas T, Aubert D, Ozcan A, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2008	52	10	3725	3736	18625772	10.1128/aac.00163-08	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.	Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2008	52	6	2250	2252	18362187	10.1128/aac.01025-07	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.	Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	5	1944	1951	19273683	10.1128/aac.01581-08	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.	Doublet B, Granier SA, Robin F, Bonnet R, Fabre L, Brisabois A, Cloeckaert A, Weill FX.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	7	2773	2776	19364847	10.1128/aac.01409-08	Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.	Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D, Murthy B, Derendorf H.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2009	53	7	3010	3016	19380596	10.1128/aac.01164-08	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.	Potron A, Poirel L, Croizé J, Chanteperdrix V, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	1	471	476	19917750	10.1128/aac.00458-09	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.	Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	1	533	535	19884378	10.1128/aac.00859-09	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.	Poirel L, Docquier JD, De Luca F, Verlinde A, Ide L, Rossolini GM, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	1	578	579	19884362	10.1128/aac.00861-09	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	4	1547	1554	20124004	10.1128/aac.01252-09	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.	De Luca F, Giraud-Morin C, Rossolini GM, Docquier JD, Fosse T.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794		2014							Pharmaceutical Compositions Comprising Beta-Lactam Antibiotic, Sulbactam and Beta-Lactamase Inhibitor	
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFPIROME	CHEMBL65794									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFPODOXIME PROXETIL	CHEMBL1201016									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFPROZIL	CHEMBL3184906									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFPROZIL	CHEMBL3184906									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFPROZIL	CHEMBL3184906									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFPROZIL	CHEMBL3184906									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFPROZIL	CHEMBL3184906									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFSULODIN	CHEMBL3351077									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFSULODIN	CHEMBL3351077									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFTAROLINE FOSAMIL ACETATE	CHEMBL3544973	Antimicrob. Agents Chemother.	2007	51	9	3397	3400	17591849	10.1128/aac.01242-06	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.	Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Hamel A, Bugnon D, Ge JY, Potel G.
962.7500000000000000	2	Bacteria	CEFTAROLINE FOSAMIL ACETATE	CHEMBL3544973									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTAROLINE FOSAMIL ACETATE	CHEMBL3544973									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1988	31	6	1227	1230	3373491	10.1021/jm00401a026	The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.	Indelicato JM, Pasini CE.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1989	32	11	2442	2450	2810333	10.1021/jm00131a006	3-Quaternary ammonium 1-carba-1-dethiacephems.	Cook GK, McDonald JH, Alborn W, Boyd DB, Eudaly JA, Indelicato JM, Johnson R, Kasher JS, Pasini CE, Preston DA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1990	33	8	2114	2121	2115587	10.1021/jm00170a011	Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.	Brown RF, Kinnick MD, Morin JM, Vasileff RT, Counter FT, Davidson EO, Ensminger PW, Eudaly JA, Kasher JS, Katner AS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1991	34	2	669	675	1847430	10.1021/jm00106a031	Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.	Albrecht HA, Beskid G, Christenson JG, Durkin JW, Fallat V, Georgopapadakou NH, Keith DD, Konzelmann FM, Lipschitz ER, McGarry DH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1991	34	9	2857	2864	1910090	10.1021/jm00113a026	Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.	Albrecht HA, Beskid G, Christenson JG, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Rossman PL, Wei CC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1992	35	14	2631	2642	1635062	10.1021/jm00092a014	Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues.	Arnould JC, Bertrandie A, Bird TG, Boucherot D, Jung F, Lohmann JJ, Olivier A, Bailey JP, Bell W, Davies GM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1992	35	14	2643	2651	1635063	10.1021/jm00092a015	Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model.	Bird TG, Arnould JC, Bertrandie A, Jung FH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1993	36	22	3224	3229	8230112	10.1021/jm00074a002	Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.	Ternansky RJ, Draheim SE, Pike AJ, Counter FT, Eudaly JA, Kasher JS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1994	37	22	3828	3833	7966140	10.1021/jm00048a018	Synthesis and antimicrobial activity of novel 3-[(aminopyrimidiniumyl)thio]methyl cephalosporins.	Kim YZ, Lim JC, Yeo JH, Bang CS, Kim WS, Kim SS, Woo YM, Yang DH, Oh H, Nahm K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1994	37	3	400	407	8308866	10.1021/jm00029a012	Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.	Albrecht HA, Beskid G, Christenson JG, Deitcher KH, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Wei CC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1994	4	13	1601	1606		10.1016/S0960-894X(01)80574-6	Synthesis and anti-pseudomonal activity of new 2-isocephems with a dihydroxypyridone moiety at C-7	Tsuji K, Ishikawa H
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1995	5	23	2777	2782		10.1016/0960-894X(95)00485-C	Synthesis and biological activity of a novel class of cephalosporins with a oxadiazolyl hydroxypyridone moiety at C-7	Obi K, Kojima A, Fukuda H, Hirai K
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1995	5	9	963	966		10.1016/0960-894X(95)00143-H	Synthesis and antibacterial activity of cephalosporins having C-3 catechol-containing (pyridinium-4-thio)-methyl groups	Tsuji K, Yasumura K, Ishikawa H
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	1996	39	9	1864	1871	8627610	10.1021/jm950886v	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.	Heinze-Krauss I, Angehrn P, Guerry P, Hebeisen P, Hubschwerlen C, Kompis I, Page MG, Richter HG, Runtz V, Stalder H, Weiss U, Wei CC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1996	6	17	2077	2080		10.1016/0960-894X(96)00381-2	Synthesis and antibacterial activity of cephalosporins having hydroxamic acid at C-7 position	Kim MG, Jung JC, Sung MJ, Choi YK, An SG, Lee S, Yoon G, Park MH
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1997	7	1	11	14		10.1016/S0960-894X(96)00575-6	Studies on penam sulfones III. Synthesis and -lactamase inhibitory activity of sodium (6R)-6-(-hydroxybenzyl)-2-methoxyiminomethyl-2-methylpenam-3-carboxylate 1,1-dioxide and sodium 2-acyl-2-methylpenam-3-carboxylate 1,1-dioxide	Czajkowski DP, Reddy AV, Setti EL, Phillips OA, Micetich RG, Kunugita C, Maiti SN
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1997	7	5	623	628		10.1016/S0960-894X(97)00070-X	Synthesis and antibacterial activity of (1R, 5R, 6R)-2-tert-butyl-6-(1-hydroxyethyl)penem-3-carboxylic acid	Pfaendler HR, Medicus C
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Pharmacol. Exp. Ther.	1999	290	1	672	677	10411577		The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.	Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	1999	9	14	1997	2002	10450969	10.1016/s0960-894x(99)00325-x	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.	Buynak JD, Rao AS, Doppalapudi VR, Adam G, Petersen PJ, Nidamarthy SD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2000	10	11	1211	1214	10866383	10.1016/s0960-894x(00)00203-1	Synthesis and structure-activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives.	Chang KY, Kim SH, Nam G, Seo JH, Kim JH, Ha DC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2002	45	15	3222	3234	12109906	10.1021/jm020002p	Structure-based approach for binding site identification on AmpC beta-lactamase.	Powers RA, Shoichet BK.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2004	14	15	3979	3983	15225711	10.1016/j.bmcl.2004.05.054	Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.	Buzzoni V, Blazquez J, Ferrari S, Calò S, Venturelli A, Costi MP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2005	15	8	2123	2128	15808482	10.1016/j.bmcl.2005.02.029	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.	Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2005	48	5	1395	1400	15743183	10.1021/jm049652e	Beta-lactam screening by specific residues of the OmpF eyelet.	Vidal S, Bredin J, Pagès JM, Barbe J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem.	2007	15	21	6716	6732	17723304	10.1016/j.bmc.2007.08.001	A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.	Yamawaki K, Nomura T, Yasukata T, Uotani K, Miwa H, Takeda K, Nishitani Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Biol. Chem.	2007	282	29	21382	21391	17439950	10.1074/jbc.m700084200	Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.	Stubbs KA, Balcewich M, Mark BL, Vocadlo DJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	1	366	368	17074790	10.1128/aac.00841-06	Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.	Pai H, Seo MR, Choi TY.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	1	376	378	17043112	10.1128/aac.00858-06	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.	Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, Jorgensen JH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	10	3471	3484	17646423	10.1128/aac.01464-06	Global challenge of multidrug-resistant Acinetobacter baumannii.	Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	10	3531	3536	17682106	10.1128/aac.00503-07	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.	Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson MO, Couetdic G, Plésiat P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	10	3642	3649	17682103	10.1128/aac.00160-07	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.	Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	10	3763	3767	17664321	10.1128/aac.00389-07	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.	Papagiannitsis CC, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	3844	3852	17724156	10.1128/aac.01512-06	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.	Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin JF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	4009	4014	17846134	10.1128/aac.00537-07	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.	Girlich D, Leclercq R, Naas T, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	4015	4021	17724160	10.1128/aac.00576-07	First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.	Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	4022	4028	17846127	10.1128/aac.01259-06	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.	Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, Xu Y, Zhu Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	4105	4110	17724159	10.1128/aac.00616-07	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.	Xu X, Wu S, Ye X, Liu Y, Shi W, Zhang Y, Wang M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	11	4181	4183	17709463	10.1128/aac.00614-07	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.	Robin F, Delmas J, Brebion A, Dubois D, Constantin JM, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	12	4329	4335	17938181	10.1128/aac.00810-07	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.	Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	12	4486	4488	17938180	10.1128/aac.01462-06	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.	Neuwirth C, Siebor E, Robin F, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	12	4512	4514	17875998	10.1128/aac.00491-07	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.	Fonseca F, Sarmento AC, Henriques I, Samyn B, van Beeumen J, Domingues P, Domingues MR, Saavedra MJ, Correia A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	12	4529	4530	17876007	10.1128/aac.01115-07	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.	Hawley JS, Murray CK, Jorgensen JH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	2	631	637	17116662	10.1128/aac.01082-06	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.	Poirel L, Cattoir V, Soares A, Soussy CJ, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	2	763	765	17145797	10.1128/aac.01053-06	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.	Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	3	1082	1084	17178800	10.1128/aac.00909-06	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.	Mazzariol A, Roelofsen E, Koncan R, Voss A, Cornaglia G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	3	1085	1088	17158942	10.1128/aac.00954-06	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.	Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	3	826	830	17145788	10.1128/aac.00860-06	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.	Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	3	852	856	17158944	10.1128/aac.01345-06	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.	Doi Y, de Oliveira Garcia D, Adams J, Paterson DL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1223	1227	17242140	10.1128/aac.01195-06	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.	Wu JJ, Ko WC, Tsai SH, Yan JJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1304	1309	17220412	10.1128/aac.01058-06	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.	Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1341	1350	17261619	10.1128/aac.01278-06	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.	Reinhardt A, Köhler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1365	1372	17242148	10.1128/aac.01152-06	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.	Naas T, Aubert D, Ozcan A, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1527	1529	17220425	10.1128/aac.00780-06	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.	Castanheira M, Pereira AS, Nicoletti AG, Pignatari AC, Barth AL, Gales AC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	1967	1971	17420207	10.1128/aac.01483-06	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.	Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	1987	1994	17387156	10.1128/aac.01509-06	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.	Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	2065	2069	17420217	10.1128/aac.01198-06	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.	Peleg AY, Adams J, Paterson DL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	2179	2184	17420213	10.1128/aac.01600-06	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.	Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	2185	2188	17353248	10.1128/aac.01439-06	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.	Papagiannitsis CC, Loli A, Tzouvelekis LS, Tzelepi E, Arlet G, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	6	2211	2214	17404005	10.1128/aac.01139-06	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.	Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, Pagani L, Bonomo RA, Rossolini GM, Toniolo A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2324	2328	17438042	10.1128/aac.01502-06	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.	Bertini A, Poirel L, Bernabeu S, Fortini D, Villa L, Nordmann P, Carattoli A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2359	2365	17438050	10.1128/aac.01395-06	Biochemical characterization of PER-2 and genetic environment of blaPER-2.	Power P, Di Conza J, Rodríguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2366	2372	17452479	10.1128/aac.00044-07	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.	Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M, Stefanou I, Avlami A, Katsilambros N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2611	2614	17470660	10.1128/aac.00838-06	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.	Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2621	2624	17470659	10.1128/aac.00029-07	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.	Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	7	2636	2638	17438051	10.1128/aac.01043-06	blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.	Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	2855	2860	17470647	10.1128/aac.01614-06	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.	Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	2937	2942	17502412	10.1128/aac.00011-07	Cytoplasmic-membrane anchoring of a class A beta-lactamase and its capacity in manifesting antibiotic resistance.	Suvorov M, Vakulenko SB, Mobashery S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	2988	2990	17470648	10.1128/aac.00083-07	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.	Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	2997	3000	17517839	10.1128/aac.00111-07	Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.	Wolter DJ, Schmidtke AJ, Hanson ND, Lister PD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	3004	3007	17526756	10.1128/aac.00167-07	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.	Chen YT, Lauderdale TL, Liao TL, Shiau YR, Shu HY, Wu KM, Yan JJ, Su IJ, Tsai SF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	3017	3019	17517851	10.1128/aac.00279-07	Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene.	Bae IK, Lee YN, Lee WG, Lee SH, Jeong SH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	3026	3029	17562800	10.1128/aac.00299-07	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.	Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	8	3038	3039	17517838	10.1128/aac.00374-07	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.	Ikonomidis A, Labrou M, Afkou Z, Maniatis AN, Sofianou D, Tsakris A, Pournaras S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3089	3095	17591851	10.1128/aac.00218-07	Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.	Queenan AM, Shang W, Kania M, Page MG, Bush K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3431	3433	17576842	10.1128/aac.01433-06	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.	Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3440	3444	17591853	10.1128/aac.01431-06	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.	Arpin C, Coulange L, Dubois V, André C, Fischer I, Fourmaux S, Grobost F, Jullin J, Dutilh B, Couture JF, Noury P, Lagrange I, Ducastaing A, Doermann HP, Quentin C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3449	3451	17576831	10.1128/aac.01586-06	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.	Mouton JW, Punt N, Vinks AA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2007	51	9	3465	3466	17606684	10.1128/aac.00267-07	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.	Quinteira S, Grosso F, Ramos H, Peixe L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem.	2008	16	4	1632	1647	18065229	10.1016/j.bmc.2007.11.028	A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.	Yamawaki K, Nomura T, Yasukata T, Tanimoto N, Uotani K, Miwa H, Yamano Y, Takeda K, Nishitani Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem.	2008	16	5	2261	2275	18082409	10.1016/j.bmc.2007.11.074	Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.	Murano K, Yamanaka T, Toda A, Ohki H, Okuda S, Kawabata K, Hatano K, Takeda S, Akamatsu H, Itoh K, Misumi K, Inoue S, Takagi T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2008	18	11	3369	3375	18440814	10.1016/j.bmcl.2008.04.023	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.	Zhou Y, Chow C, Murphy DE, Sun Z, Bertolini T, Froelich JM, Webber SE, Hermann T, Wall D.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2008	18	17	4849	4852	18701284	10.1016/j.bmcl.2008.07.085	Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.	Toda A, Ohki H, Yamanaka T, Murano K, Okuda S, Kawabata K, Hatano K, Matsuda K, Misumi K, Itoh K, Satoh K, Inoue S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3589	3596	18644957	10.1128/aac.00465-08	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.	Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3725	3736	18625772	10.1128/aac.00163-08	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.	Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3792	3794	18663019	10.1128/aac.00387-08	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.	Dubois V, Poirel L, Demarthe F, Arpin C, Coulange L, Minarini LA, Bezian MC, Nordmann P, Quentin C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3795	3800	18694945	10.1128/aac.00464-08	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.	Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3814	3816	18663030	10.1128/aac.00877-08	Surveillance of community-based reservoirs reveals the presence of CTX-M, imported AmpC, and OXA-30 beta-lactamases in urine isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. community.	Hanson ND, Moland ES, Hong SG, Propst K, Novak DJ, Cavalieri SJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	10	3826	3827	18694947	10.1128/aac.00419-08	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.	Wu X, Wang H, Zhao X.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	3837	3843	18725452	10.1128/aac.00570-08	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.	Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	3922	3927	18779353	10.1128/aac.00341-08	Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.	Schmidtke AJ, Hanson ND.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	4023	4029	18809945	10.1128/aac.00707-08	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.	Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	4115	4120	18725447	10.1128/aac.00366-08	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.	Zarrilli R, Vitale D, Di Popolo A, Bagattini M, Daoud Z, Khan AU, Afif C, Triassi M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	4141	4144	18676884	10.1128/aac.00511-08	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.	Sugimura M, Maseda H, Hanaki H, Nakae T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	4166	4171	18725450	10.1128/aac.00245-08	Characterization of TolC efflux pump proteins from Pasteurella multocida.	Hatfaludi T, Al-Hasani K, Dunstone M, Boyce J, Adler B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	11	4194	4197	18765691	10.1128/aac.01337-07	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.	Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	12	4268	4273	18809939	10.1128/aac.00830-08	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.	Yang H, Chen H, Yang Q, Chen M, Wang H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	12	4388	4399	18779357	10.1128/aac.00381-08	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.	Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	12	4526	4527	18838598	10.1128/aac.00882-08	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.	Berçot B, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	2	441	445	17999968	10.1128/aac.00359-07	Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.	Hammond DS, Harris T, Bell J, Turnidge J, Giffard PM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	2	551	556	18070972	10.1128/aac.01145-07	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.	Meziane-Cherif D, Decré D, Høiby EA, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	2	794	795	18025117	10.1128/aac.01399-07	RmtC 16S rRNA methyltransferase in Australia.	Zong Z, Partridge SR, Iredell JR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	2	796	797	18056283	10.1128/aac.01180-07	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.	Cuzon G, Naas T, Demachy MC, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	3	915	919	18160520	10.1128/aac.01028-07	E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.	Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1257	1263	18227185	10.1128/aac.01451-07	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.	Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1264	1268	18212108	10.1128/aac.00684-07	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.	Meziane-Cherif D, Lambert T, Dupêchez M, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1297	1301	18212109	10.1128/aac.01060-07	Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains.	Stepanova MN, Pimkin M, Nikulin AA, Kozyreva VK, Agapova ED, Edelstein MV.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1510	1512	18250190	10.1128/aac.01529-07	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.	Davies TA, Shang W, Bush K, Flamm RK.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1525	1528	18212097	10.1128/aac.01485-07	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.	Okazaki A, Avison MB.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	4	1564	1566	18285488	10.1128/aac.01137-07	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.	Yamane K, Wachino J, Suzuki S, Arakawa Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1613	1617	18299404	10.1128/aac.00978-07	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.	Poirel L, Mansour W, Bouallegue O, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1790	1793	18347108	10.1128/aac.01440-07	Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.	de Oliveira Garcia D, Doi Y, Szabo D, Adams-Haduch JM, Vaz TM, Leite D, Padoveze MC, Freire MP, Silveira FP, Paterson DL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1806	1811	18316518	10.1128/aac.01381-07	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.	Mendonça N, Manageiro V, Robin F, Salgado MJ, Ferreira E, Caniça M, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1894	1896	18285473	10.1128/aac.01414-07	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.	Loli A, Tzouvelekis LS, Gianneli D, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	5	1897	1898	18316524	10.1128/aac.01525-07	Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae.	Mendonça N, Manageiro V, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	6	1952	1956	18362192	10.1128/aac.01463-07	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.	Doi Y, Poirel L, Paterson DL, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	6	2014	2018	18332176	10.1128/aac.01539-07	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.	Cai JC, Zhou HW, Zhang R, Chen GX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	6	2250	2252	18362187	10.1128/aac.01025-07	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.	Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	6	2289	2290	18362195	10.1128/aac.00299-08	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.	Martin CA, Morita K, Ribes JA, Deshpande LM, Sader HS, Castanheira M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2340	2345	18443128	10.1128/aac.00018-08	Fitness trade-offs in blaTEM evolution.	Mroczkowska JE, Barlow M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2377	2382	18443114	10.1128/aac.01658-07	Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance.	Novais A, Cantón R, Coque TM, Moya A, Baquero F, Galán JC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2473	2479	18443127	10.1128/aac.01062-07	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.	Stoczko M, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2573	2580	18443121	10.1128/aac.00393-08	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.	Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2663	2666	18426902	10.1128/aac.01326-07	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.	Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	7	2680	2682	18426899	10.1128/aac.00158-08	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.	Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2818	2824	18505851	10.1128/aac.00171-08	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.	Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2849	2854	18519723	10.1128/aac.00413-08	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.	Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2905	2908	18559652	10.1128/aac.00166-08	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.	Samuelsen Ø, Castanheira M, Walsh TR, Spencer J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2940	2942	18519722	10.1128/aac.01581-07	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.	Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2943	2946	18490501	10.1128/aac.00679-07	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.	Garza-Ramos U, Morfin-Otero R, Sader HS, Jones RN, Hernández E, Rodriguez-Noriega E, Sanchez A, Carrillo B, Esparza-Ahumada S, Silva-Sanchez J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2955	2958	18505859	10.1128/aac.00072-08	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.	Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P, Alba V, Fernández-Cuenca F, Pascual A, Vila J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2962	2965	18519713	10.1128/aac.01341-07	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.	Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	8	2977	2979	18519714	10.1128/aac.00175-08	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.	Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	2999	3005	18591275	10.1128/aac.01684-07	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.	Bratu S, Landman D, Martin DA, Georgescu C, Quale J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	3029	3034	18573929	10.1128/aac.00010-08	Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae.	Sahly H, Navon-Venezia S, Roesler L, Hay A, Carmeli Y, Podschun R, Hennequin C, Forestier C, Ofek I.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	3398	3407	18625769	10.1128/aac.00149-08	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.	Ge Y, Biek D, Talbot GH, Sahm DF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	3418	3423	18591277	10.1128/aac.00336-08	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.	Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	3461	3462	18644966	10.1128/aac.00770-08	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.	Picão RC, Poirel L, Demarta A, Petrini O, Corvaglia AR, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2008	52	9	3463	3464	18644970	10.1128/aac.00543-08	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.	Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	104	111	18936188	10.1128/aac.00852-08	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.	Ma L, Lin CJ, Chen JH, Fung CP, Chang FY, Lai YK, Lin JC, Siu LK, Taiwan Surveillance of Antimicrobial Resistance Project.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	242	248	18981261	10.1128/aac.00642-08	Sec- and Tat-dependent translocation of beta-lactamases across the Escherichia coli inner membrane.	Pradel N, Delmas J, Wu LF, Santini CL, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	277	280	19001114	10.1128/aac.00912-08	Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.	Papagiannitsis CC, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	287	291	19001116	10.1128/aac.00746-08	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.	Mesko Meglic K, Koren S, Palepou MF, Karisik E, Livermore DM, Pike R, Andlovic A, Jeverica S, Krizan-Hergouth V, Müller-Premru M, Seme K, Slovenian ESBL Study Group, Woodford N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	292	294	18852270	10.1128/aac.00931-08	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.	Bennett JW, Herrera ML, Lewis JS, Wickes BW, Jorgensen JH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	323	326	19001118	10.1128/aac.00608-08	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.	Mammeri H, Galleni M, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	333	334	19015350	10.1128/aac.00736-08	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.	Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	46	56	18852268	10.1128/aac.00489-08	Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.	Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4051	4063	19470504	10.1128/aac.00084-09	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.	Llarrull LI, Fisher JF, Mobashery S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4320	4326	19651915	10.1128/aac.01607-08	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.	Zeba B, De Luca F, Dubus A, Delmarcelle M, Simporé J, Nacoulma OG, Rossolini GM, Frère JM, Docquier JD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4333	4338	19620332	10.1128/aac.00260-09	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.	Shen P, Wei Z, Jiang Y, Du X, Ji S, Yu Y, Li L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4345	4351	19635950	10.1128/aac.01267-08	Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.	Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4352	4356	19770286	10.1128/aac.00282-09	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.	Crandon JL, Bulik CC, Nicolau DP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4504	4507	19770287	10.1128/aac.00556-09	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.	Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4518	4521	19620330	10.1128/aac.00461-09	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.	Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	11	4733	4739	19687234	10.1128/aac.00533-09	Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.	Sidjabat HE, Paterson DL, Adams-Haduch JM, Ewan L, Pasculle AW, Muto CA, Tian GB, Doi Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	11	4783	4788	19738025	10.1128/aac.00574-09	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	11	4930	4933	19738007	10.1128/aac.00900-09	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.	Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	11	4955	4956	19687235	10.1128/aac.00547-09	TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.	Mulvey MR, Boyd DA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	12	5035	5038	19770279	10.1128/aac.00856-09	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.	Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	12	5046	5054	19770275	10.1128/aac.00774-09	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.	Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	12	5288	5290	19770278	10.1128/aac.00822-09	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.	Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	12	5312	5316	19770280	10.1128/aac.00748-09	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.	Srinivasan VB, Rajamohan G, Gebreyes WA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	2	465	475	19015360	10.1128/aac.00883-08	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.	Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	2	519	524	18936192	10.1128/aac.00886-08	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.	Ma J, Zeng Z, Chen Z, Xu X, Wang X, Deng Y, Lü D, Huang L, Zhang Y, Liu J, Wang M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	2	557	562	19015357	10.1128/aac.00734-08	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.	Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	3	1177	1184	19029333	10.1128/aac.00485-08	Genetic variability among ampC genes from acinetobacter genomic species 3.	Beceiro A, Pérez A, Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Vila J, Rodríguez-Baño J, Cisneros JM, Pachón J, Bou G, Spanish Group for Nosocomial Infection (GEIH).
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	3	1256	1259	19104021	10.1128/aac.01284-08	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.	Zioga A, Whichard JM, Kotsakis SD, Tzouvelekis LS, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	3	876	882	19075063	10.1128/aac.00946-08	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.	Poirel L, Rodriguez-Martinez JM, Plésiat P, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	3	977	986	19075050	10.1128/aac.01155-08	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.	Jones CH, Ruzin A, Tuckman M, Visalli MA, Petersen PJ, Bradford PA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	4	1552	1560	19188376	10.1128/aac.01264-08	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.	Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	4	1630	1635	19188377	10.1128/aac.01431-08	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.	Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, Jajic-Bencic I, Gniadkowski M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	4	1652	1656	19164140	10.1128/aac.00822-08	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.	Tran QT, Dupont M, Lavigne JP, Chevalier J, Pagès JM, Sotto A, Davin-Regli A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	4	1660	1664	19188398	10.1128/aac.01172-08	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.	Wolter DJ, Khalaf N, Robledo IE, Vázquez GJ, Santé MI, Aquino EE, Goering RV, Hanson ND.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1766	1771	19258272	10.1128/aac.01410-08	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1808	1816	19273688	10.1128/aac.00451-08	Chromosomal integration of the extended-spectrum beta-lactamase gene blaCTX-M-15 in Salmonella enterica serotype Concord isolates from internationally adopted children.	Fabre L, Delauné A, Espié E, Nygard K, Pardos M, Polomack L, Guesnier F, Galimand M, Lassen J, Weill FX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1892	1897	19258263	10.1128/aac.01400-08	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.	Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1944	1951	19273683	10.1128/aac.01581-08	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.	Doublet B, Granier SA, Robin F, Bonnet R, Fabre L, Brisabois A, Cloeckaert A, Weill FX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1987	1997	19258280	10.1128/aac.01024-08	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Vettoretti L, Plésiat P, Muller C, El Garch F, Phan G, Attrée I, Ducruix A, Llanes C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	1998	2004	19258268	10.1128/aac.01355-08	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.	Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	2221	2222	19223629	10.1128/aac.01573-08	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.	Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	5	2225	2226	19223647	10.1128/aac.01602-08	Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.	Picão RC, Poirel L, Gales AC, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2274	2282	19273679	10.1128/aac.01617-08	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.	Asgarali A, Stubbs KA, Oliver A, Vocadlo DJ, Mark BL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2327	2334	19349516	10.1128/aac.01360-08	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.	Kitao T, Miyoshi-Akiyama T, Kirikae T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2483	2491	19332676	10.1128/aac.00428-08	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.	Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2492	2498	19332679	10.1128/aac.00033-09	Integron mobilization unit as a source of mobility of antibiotic resistance genes.	Poirel L, Carrër A, Pitout JD, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2643	2645	19289526	10.1128/aac.01534-08	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.	Kim ES, Jeong JY, Jun JB, Choi SH, Lee SO, Kim MN, Woo JH, Kim YS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	6	2657	2659	19307373	10.1128/aac.01663-08	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.	Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	7	2785	2790	19433554	10.1128/aac.00018-09	Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.	Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, He W, Queenan AM, Bush K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	7	3010	3016	19380596	10.1128/aac.01164-08	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.	Potron A, Poirel L, Croizé J, Chanteperdrix V, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	7	3143	3146	19380592	10.1128/aac.01473-08	First detection of plasmid-encoded blaOXY beta-lactamase.	González-López JJ, Coelho A, Larrosa MN, Lavilla S, Bartolomé R, Prats G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	7	3159	3161	19414578	10.1128/aac.00133-09	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.	Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	7	3178	3178	19414570	10.1128/aac.01586-08	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.	Pope CE, Carter PE, Heffernan HM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	8	3280	3284	19506060	10.1128/aac.00426-09	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.	Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	8	3520	3523	19470510	10.1128/aac.00219-09	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Tzouvelekis LS, Miriagou V.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	8	3528	3533	19487447	10.1128/aac.00178-09	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.	D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	8	3552	3560	19506065	10.1128/aac.00418-09	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.	Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	8	3579	3581	19451292	10.1128/aac.00072-09	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.	Moubareck C, Brémont S, Conroy MC, Courvalin P, Lambert T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	9	3908	3913	19596871	10.1128/aac.00453-09	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.	Picão RC, Poirel L, Gales AC, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	9	4043	4044	19546365	10.1128/aac.00274-09	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.	Iabadene H, Dallenne C, Messai Y, Geneste D, Bakour R, Arlet G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2009	53	9	4048	4050	19581459	10.1128/aac.00690-09	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.	Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Nat. Prod.	2009	72	2	265	269	19193024	10.1021/np800667e	Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.	Zhang H, Xue J, Wu P, Xu L, Xie H, Wei X.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2010	53	1	392	401	19947605	10.1021/jm901421c	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.	Tam KY, Avdeef A, Tsinman O, Sun N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	164	169	19901088	10.1128/aac.00310-09	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.	Faure S, Perrin-Guyomard A, Delmas JM, Chatre P, Laurentie M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	328	332	19901091	10.1128/aac.00961-09	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	346	352	19884381	10.1128/aac.00824-09	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.	Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, Lia A, Ranheim TE, Rajendra Y, Hermansen NO, Walsh TR, Giske CG.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	45	51	19884377	10.1128/aac.00427-09	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.	Doublet B, Robin F, Casin I, Fabre L, Le Fleche A, Bonnet R, Weill FX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	466	470	19901092	10.1128/aac.00017-09	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.	Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	471	476	19917750	10.1128/aac.00458-09	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.	Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	533	535	19884378	10.1128/aac.00859-09	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.	Poirel L, Docquier JD, De Luca F, Verlinde A, Ide L, Rossolini GM, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	557	559	19917762	10.1128/aac.00912-09	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.	Bulik CC, Christensen H, Nicolau DP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	560	562	19752282	10.1128/aac.00762-09	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.	Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	565	569	19884379	10.1128/aac.01004-09	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.	Queenan AM, Shang W, Flamm R, Bush K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	573	577	19805565	10.1128/aac.01099-09	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.	Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	1	578	579	19884362	10.1128/aac.00861-09	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4092	4097	20606064	10.1128/aac.00060-10	Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.	Queenan AM, Shang W, Bush K, Flamm RK.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4159	4167	20679510	10.1128/aac.00257-10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.	Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martínez JL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4178	4184	20660683	10.1128/aac.01301-09	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.	García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4343	4351	20696874	10.1128/aac.00409-10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.	Docquier JD, Benvenuti M, Calderone V, Stoczko M, Menciassi N, Rossolini GM, Mangani S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4373	4378	20679507	10.1128/aac.01607-09	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.	Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4416	4423	20643901	10.1128/aac.00503-10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.	Collins B, Curtis N, Cotter PD, Hill C, Ross RP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	10	4484	4486	20643895	10.1128/aac.00460-10	IncI1 plasmid carrying extended-spectrum-beta-lactamase gene blaCTX-M-1 in Salmonella enterica isolates from poultry and humans in France, 2003 to 2008.	Cloeckaert A, Praud K, Lefevre M, Doublet B, Pardos M, Granier SA, Brisabois A, Weill FX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4556	4560	20733047	10.1128/aac.01762-09	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC ß-lactamases.	Mammeri H, Guillon H, Eb F, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4575	4581	20713680	10.1128/aac.00764-10	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.	Chen TL, Lee YT, Kuo SC, Hsueh PR, Chang FY, Siu LK, Ko WC, Fung CP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4626	4635	20696867	10.1128/aac.00762-10	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.	Su HC, Ramkissoon K, Doolittle J, Clark M, Khatun J, Secrest A, Wolfgang MC, Giddings MC.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4772	4779	20713660	10.1128/aac.00009-10	ampG gene of Pseudomonas aeruginosa and its role in ß-lactamase expression.	Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4864	4871	20696873	10.1128/aac.00771-10	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES ß-lactamases.	Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4914	4916	20823289	10.1128/aac.00878-10	Emergence of metallo-ß-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.	Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	11	4948	4949	20713658	10.1128/aac.00415-10	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.	Rodríguez-Rojas A, Couce A, Blázquez J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	12	5021	5027	20921306	10.1128/aac.00598-10	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.	Higgins PG, Schneiders T, Hamprecht A, Seifert H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	12	5057	5061	20876374	10.1128/aac.00768-10	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.	Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	2	846	851	19933793	10.1128/aac.00834-09	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.	Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	2	953	955	19917749	10.1128/aac.00983-09	Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.	Henry X, Amoroso A, Coyette J, Joris B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1029	1041	20028819	10.1128/aac.00963-09	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.	Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1213	1217	20086158	10.1128/aac.01104-09	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.	Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1275	1282	20065059	10.1128/aac.00936-09	Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.	Bulitta JB, Landersdorfer CB, Hüttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sörgel F.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1331	1333	20065056	10.1128/aac.01561-09	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1338	1342	20065058	10.1128/aac.01197-09	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.	Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1354	1357	20038618	10.1128/aac.00899-09	Detection of KPC in Acinetobacter spp. in Puerto Rico.	Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	3	1369	1373	20086157	10.1128/aac.01312-09	Spread of OXA-48-encoding plasmid in Turkey and beyond.	Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	4	1547	1554	20124004	10.1128/aac.01252-09	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.	De Luca F, Giraud-Morin C, Rossolini GM, Docquier JD, Fosse T.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	1785	1792	20176901	10.1128/aac.01513-09	Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.	Propst KL, Troyer RM, Kellihan LM, Schweizer HP, Dow SW.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2078	2084	20194701	10.1128/aac.01398-09	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.	Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, Li SY.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2119	2124	20211892	10.1128/aac.01450-09	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.	Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2216	2218	20145079	10.1128/aac.01580-09	Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.	Crémet L, Caroff N, Giraudeau C, Dauvergne S, Lepelletier D, Reynaud A, Corvec S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2219	2224	20194693	10.1128/aac.00816-09	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2231	2234	20308380	10.1128/aac.00791-09	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.	Guillon H, Eb F, Mammeri H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2269	2270	20211893	10.1128/aac.00039-10	Identification and characterization of CTX-M-producing Shigella isolates in the United States.	Folster JP, Pecic G, Krueger A, Rickert R, Burger K, Carattoli A, Whichard JM.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2271	2272	20211886	10.1128/aac.01442-09	Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.	Manageiro V, Ferreira E, Albuquerque L, Bonnet R, Caniça M.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	6	2291	2302	20308379	10.1128/aac.01525-09	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.	Page MG, Dantier C, Desarbre E.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	6	2420	2424	20308383	10.1128/aac.01456-09	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.	Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	6	2687	2691	20231393	10.1128/aac.01359-09	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	6	2699	2703	20368407	10.1128/aac.01624-09	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.	Huang LY, Lu PL, Chen TL, Chang FY, Fung CP, Siu LK.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	2855	2866	20385874	10.1128/aac.01790-09	Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases.	Shin YP, Park HJ, Shin SH, Lee YS, Park S, Jo S, Lee YH, Lee IH.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	3002	3006	20350950	10.1128/aac.01818-09	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.	Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	3015	3017	20404121	10.1128/aac.01173-09	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.	Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	3031	3034	20457818	10.1128/aac.01808-09	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).	Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	3043	3046	20421398	10.1128/aac.00265-10	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).	Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	7	3070	3071	20421403	10.1128/aac.01615-09	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.	Rodríguez MM, Power P, Sader H, Galleni M, Gutkind G.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3107	3112	20516281	10.1128/aac.00128-10	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.	Chen TL, Chang WC, Kuo SC, Lee YT, Chen CP, Siu LK, Cho WL, Fung CP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3113	3120	20498323	10.1128/aac.01803-09	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.	Mima T, Schweizer HP.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3197	3204	20498317	10.1128/aac.01336-09	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.	Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3493	3497	20498315	10.1128/aac.00080-10	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.	Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	8	3512	3515	20547814	10.1128/aac.01646-09	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.	Hocquet D, Plésiat P, Dehecq B, Mariotte P, Talon D, Bertrand X, ONERBA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3545	3550	20566768	10.1128/aac.00111-10	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.	Harada S, Ishii Y, Saga T, Tateda K, Yamaguchi K.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3557	3563	20566764	10.1128/aac.00385-10	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.	Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3933	3937	20547785	10.1128/aac.00296-10	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.	Moyá B, Zamorano L, Juan C, Ge Y, Oliver A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3956	3959	20566763	10.1128/aac.00110-10	Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient.	Uemura S, Yokota S, Mizuno H, Sakawaki E, Sawamoto K, Maekawa K, Tanno K, Mori K, Asai Y, Fujii N.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3967	3969	20547789	10.1128/aac.00137-10	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.	Jiang Y, Yu D, Wei Z, Shen P, Zhou Z, Yu Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3991	3992	20585124	10.1128/aac.00225-10	Plasmid-mediated resistance to cephalosporins in Salmonella enterica serovar Typhi.	Morita M, Takai N, Terajima J, Watanabe H, Kurokawa M, Sagara H, Ohnishi K, Izumiya H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2010	54	9	3998	3999	20585134	10.1128/aac.00264-10	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.	Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Med Chem Res	2011	20	1	93	100		10.1007/s00044-009-9288-3	Synthesis and in vitro antimicrobial activity of benzo[b][1,4]thiazin-3(4H)-ones via smiles rearrangement	Yang H, Fang L, Li Z, Ren F, Wang L, Tian X, Shin D, Zuo H
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Med Chem Res	2011	20	6	670	677		10.1007/s00044-010-9360-z	Synthesis of benzo[b][1,4]oxazin-3(4H)-ones via smiles rearrangement for antimicrobial activity	Fang L, Zuo H, Li Z, He X, Wang L, Tian X, Zhao B, Miao J, Shin D
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2011	46	8	3526	3530	21570749	10.1016/j.ejmech.2011.04.053	Synthesis and antimicrobial evaluation of new benzofuran derivatives.	Jiang X, Liu W, Zhang W, Jiang F, Gao Z, Zhuang H, Fu L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2011	46	9	3639	3650	21641699	10.1016/j.ejmech.2011.05.028	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.	Zhang W, Liu W, Jiang X, Jiang F, Zhuang H, Fu L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2011	55	1	140	145	21041509	10.1128/aac.00858-10	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.	Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2011	55	1	284	290	21078949	10.1128/aac.00098-10	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.	Shimizu-Ibuka A, Oishi M, Yamada S, Ishii Y, Mura K, Sakai H, Matsuzawa H.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Antimicrob. Agents Chemother.	2011	55	1	82	85	21041503	10.1128/aac.01198-10	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.	Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Nat. Prod.	2011	74	2	163	168	21288041	10.1021/np100502y	Triterpenoid saponins from Symplocos lancifolia.	Acebey-Castellon IL, Voutquenne-Nazabadioko L, Doan Thi Mai H, Roseau N, Bouthagane N, Muhammad D, Le Magrex Debar E, Gangloff SC, Litaudon M, Sevenet T, Hung NV, Lavaud C.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Med Chem Res	2012	21	11	3897	3901		10.1007/s00044-011-9933-5	11-Chloro-3-methyl-3H-imidazo[4,5-a]acridine (CMIA) as a potent and selective antimicrobial agent against clinical isolates of highly antibiotic-resistant Acinetobacter baumannii	Sadeghian A, Pordel M, Safdari H, Fahmidekar MA, Sadeghian H
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2012	22	16	5293	5296	22795329	10.1016/j.bmcl.2012.06.040	Design, synthesis and antibacterial activities of a series of new 2-oxaisocephems.	Wu J, Wu X, Lei F, Yuan H, Hai L, Wu Y.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2012	53		246	253	22560629	10.1016/j.ejmech.2012.04.006	Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives.	Secci D, Bizzarri B, Bolasco A, Carradori S, D'Ascenzio M, Rivanera D, Mari E, Polletta L, Zicari A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2012	54		879	886	22673144	10.1016/j.ejmech.2012.05.013	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.	Liu J, Jiang F, Jiang X, Zhang W, Liu J, Liu W, Fu L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2012	55	2	914	923	22175825	10.1021/jm2014748	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem.	2013	21	23	7499	7506	24126094	10.1016/j.bmc.2013.09.041	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.	Od¿ak R, Sko¿ibu¿i¿ M, Maravi¿ A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	ACS Med. Chem. Lett.	2013	4	8	699	703	24376907	10.1021/ml400034m	Discovery of Inhibitors of Burkholderia pseudomallei Methionine Aminopeptidase with Antibacterial Activity.	Wangtrakuldee P, Byrd MS, Campos CG, Henderson MW, Zhang Z, Clare M, Masoudi A, Myler PJ, Horn JR, Cotter PA, Hagen TJ.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Drug Metab. Dispos.	2013	41	4	791	800	23344796	10.1124/dmd.112.049569	Organic anion transporter 3 interacts selectively with lipophilic ß-lactam antibiotics.	Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2013	65		102	111	23702472	10.1016/j.ejmech.2013.04.042	Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents.	Carradori S, Secci D, Bolasco A, Rivanera D, Mari E, Zicari A, Lotti LV, Bizzarri B.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Med. Chem.	2014	57	23	10144	10161	25402200	10.1021/jm501552x	Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.	Brown DG, May-Dracka TL, Gagnon MM, Tommasi R.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J. Nat. Prod.	2014	77	8	1791	1799	25089733	10.1021/np500142g	Cytotoxic and Antibacterial Quinone Sesquiterpenes from a Myrothecium Fungus.	Fu Y, Wu P, Xue J, Wei X.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2015	25	23	5520	5523	26522947	10.1016/j.bmcl.2015.10.063	Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities.	Li J, Sui YP, Xin JJ, Du XL, Li JT, Huo HR, Ma H, Wang WH, Zhou HY, Zhan HD, Wang ZJ, Li C, Sui F, Li X.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2016	107		82	96	26562544	10.1016/j.ejmech.2015.10.048	Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.	De Monte C, Carradori S, Bizzarri B, Bolasco A, Caprara F, Mollica A, Rivanera D, Mari E, Zicari A, Akdemir A, Secci D.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur. J. Med. Chem.	2016	117		144	156	27100030	10.1016/j.ejmech.2016.04.012	Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.	Secci D, Carradori S, Bizzarri B, Chimenti P, De Monte C, Mollica A, Rivanera D, Zicari A, Mari E, Zengin G, Aktumsek A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur J Med Chem	2016	124		794	808	27639370	10.1016/j.ejmech.2016.08.062	Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.	Kraljevi¿ TG, Harej A, Sedi¿ M, Paveli¿ SK, Stepani¿ V, Drenjan¿evi¿ D, Talapko J, Rai¿-Mali¿ S.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg Med Chem	2016	24	24	6390	6400	27887963	10.1016/j.bmc.2016.11.008	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.	Zhao M, Lepak AJ, Andes DR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg. Med. Chem. Lett.	2016	26	15	3617	3620	27297569	10.1016/j.bmcl.2016.06.006	Synthesis of riccardin D derivatives as potent antimicrobial agents.	Sun B, Zhang M, Li Y, Hu QW, Zheng HB, Chang WQ, Lou HX.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Bioorg Med Chem Lett	2016	26	20	4942	4946	27641467	10.1016/j.bmcl.2016.09.019	A druggable target for rescuing microRNA defects.	Asada K, Canestrari E, Paroo Z.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Med Chem	2016	59	18	8207	8220	27232275	10.1021/acs.jmedchem.6b00448	ß-Lactamases: Why and How.	Pratt RF.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Med Chem	2016	59	18	8441	8455	27524179	10.1021/acs.jmedchem.6b00867	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.	Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	MedChemComm	2016	7	1	148	156		10.1039/C5MD00373C	Synergistic activity of a short lipidated antimicrobial peptide (lipoAMP) and colistin or tobramycin against Pseudomonas aeruginosa from cystic fibrosis patients	de Gier MG, Bauke Albada H, Josten M, Willems R, Leavis H, van Mansveld R, Paganelli FL, Dekker B, Lammers JJ, Sahl H, Metzler-Nolte N
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	MedChemComm	2016	7	1	157	163		10.1039/C5MD00377F	Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles	Dahdouh E, Orgaz B, Gomez-Gil R, Mingorance J, Daoud Z, Suarez M, San Jose C
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur J Med Chem	2017	126		7	14	27744188	10.1016/j.ejmech.2016.10.010	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.	Zhang W, Liu J, Macho JM, Jiang X, Xie D, Jiang F, Liu W, Fu L.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	Eur J Med Chem	2017	127		748	756	27823890	10.1016/j.ejmech.2016.10.054	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.	Allam A, Maigre L, Alves de Sousa R, Dumont E, Vergalli J, Pagès JM, Artaud I.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Med Chem	2017	60	12	5002	5014	28549219	10.1021/acs.jmedchem.7b00377	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Med Chem	2017	60	6	2257	2270	28230992	10.1021/acs.jmedchem.6b01457	Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.	Dou X, Zhu X, Wang J, Dong N, Shan A.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354	J Med Chem	2017	60	9	3684	3702	28409644	10.1021/acs.jmedchem.6b01742	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.	Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFTAZIDIME	CHEMBL44354									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFTAZIDIME SODIUM	CHEMBL1200768									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	J. Pharmacol. Exp. Ther.	1995	275	1	1631	1637	8531138		Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.	Saito H, Okuda M, Terada T, Sasaki S, Inui K.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Biochim. Biophys. Acta	1997	1324	1	296	308	9092716	10.1016/s0005-2736(96)00234-9	Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.	Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	J. Pharmacol. Exp. Ther.	1997	281	1	1415	1421	9190878		Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Drug Metabol. Pharmacokin.	2002	17	1	253	274	15618677	10.2133/dmpk.17.253	Transporter-mediated Drug Interactions.	Tsuji A.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Antimicrob. Agents Chemother.	2008	52	10	3564	3567	18663018	10.1128/aac.00198-08	Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.	Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Bioorg. Med. Chem.	2013	21	17	5605	5617	23845282	10.1016/j.bmc.2013.05.024	Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.	Teitelbaum AM, Meissner A, Harding RA, Wong CA, Aldrich CC, Remmel RP.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFTIBUTEN	CHEMBL1605									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019	Bioorg. Med. Chem. Lett.	2016	26	15	3714	3718	27293070	10.1016/j.bmcl.2016.05.077	New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment.	Lv F, Chen C, Tang Y, Wei J, Zhu T, Hu W.
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019	J Med Chem	2017	60	7	2669	2684	28287720	10.1021/acs.jmedchem.6b01261	Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.	Tan L, Tao Y, Wang T, Zou F, Zhang S, Kou Q, Niu A, Chen Q, Chu W, Chen X, Wang H, Yang Y.
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTIZOXIME SODIUM	CHEMBL1201019									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFTOLOZANE SULFATE	CHEMBL1213250									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTOLOZANE SULFATE	CHEMBL1213250									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFTRIAXONE SODIUM	CHEMBL3183968									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFTRIAXONE SODIUM	CHEMBL3183968									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFTRIAXONE SODIUM	CHEMBL3183968									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFTRIAXONE SODIUM	CHEMBL3183968									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Antimicrob. Agents Chemother.	2008	52	7	2639	2643	18443117	10.1128/aac.00310-08	Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.	Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Eur. J. Med. Chem.	2009	44	4	1763	1767	18504062	10.1016/j.ejmech.2008.03.028	Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.	Prakash O, Kumar R, Sehrawat R.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFUROXIME AXETIL	CHEMBL1095930									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEFUROXIME SODIUM	CHEMBL2146124	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEFUROXIME SODIUM	CHEMBL2146124									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEFUROXIME SODIUM	CHEMBL2146124									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEFUROXIME SODIUM	CHEMBL2146124									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEFUROXIME SODIUM	CHEMBL2146124									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	1997	40	9	1347	1365	9135032	10.1021/jm960803q	Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).	Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, AndersonGD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1998	8	24	3443	3448	9934449	10.1016/s0960-894x(98)00627-1	Antiinflammatory 4,5-diarylimidazoles as selective cyclooxygenase inhibitors.	Barta TE, Stealey MA, Collins PW, Weier RM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	1999	42	7	1274	1281	10197970	10.1021/jm980642l	2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.	Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1999	9	13	1773	1778	10406640	10.1016/s0960-894x(99)00288-7	The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.	Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1999	9	15	2207	2212	10465547	10.1016/s0960-894x(99)00365-0	SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.	Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Léger S, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1999	9	22	3181	3186	10576684	10.1016/s0960-894x(99)00559-4	A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.	Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1999	9	22	3187	3192	10576685	10.1016/s0960-894x(99)00560-0	Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.	Lau CK, Brideau C, Chan CC, Charleson S, Cromlish WA, Ethier D, Gauthier JY, Gordon R, Guay J, Kargman S, Li CS, Prasit P, Riendeau D, Thérien M, Visco DM, Xu L.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	1999	9	8	1171	1174	10328307	10.1016/s0960-894x(99)00157-2	Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.	Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto MJ, Seibert K, Koboldt CM, Masferrer J, Zweifel B.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2000	10	15	1745	1748	10937738	10.1016/s0960-894x(00)00329-2	Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors.	Bosch J, Roca T, Catena JL, Llorens O, Pérez JJ, Lagunas C, Fernández AG, Miquel I, Fernández-Serrat A, Farrerons C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2000	43	10	2040	2048	10821716	10.1021/jm9906015	Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.	Inagaki M, Tsuri T, Jyoyama H, Ono T, Yamada K, Kobayashi M, Hori Y, Arimura A, Yasui K, Ohno K, Kakudo S, Koizumi K, Suzuki R, Kawai S, Kato M, Matsumoto S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2000	43	2	214	223	10649977	10.1021/jm991106b	Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.	Puig C, Crespo MI, Godessart N, Feixas J, Ibarzo J, Jiménez JM, Soca L, Cardelús I, Heredia A, Miralpeix M, Puig J, Beleta J, Huerta JM, López M, Segarra V, Ryder H, Palacios JM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2000	43	24	4582	4593	11101350	10.1021/jm990965x	1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.	Portevin B, Tordjman C, Pastoureau P, Bonnet J, De Nanteuil G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2000	43	5	775	777	10715145	10.1021/jm990577v	4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.	Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2001	11	12	1541	1544	11412976	10.1016/s0960-894x(00)00522-9	Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.	Price ML, Jorgensen WL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2001	11	2	165	168	11206450	10.1016/s0960-894x(00)00634-x	2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.	Shin SS, Noh MS, Byun YJ, Choi JK, Kim JY, Lim KM, Ha JY, Kim JK, Lee CH, Chung S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2001	11	20	2687	2690	11591502	10.1016/s0960-894x(01)00534-0	Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.	Feixas J, Jiménez JM, Godessart N, Puig C, Soca L, Crespo MI.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2001	44	18	2921	2927	11520200	10.1021/jm0101287	Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity.	Habeeb AG, Praveen Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2001	44	18	3039	3042	11520213	10.1021/jm010153c	Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.	Habeeb AG, Praveen Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2001	44	20	3223	3230	11563921	10.1021/jm0101343	Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.	Chavatte P, Yous S, Marot C, Baurin N, Lesieur D.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2001	44	3	350	361	11462976	10.1021/jm0009383	Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.	Almansa C, de Arriba AF, Cavalcanti FL, Gómez LA, Miralles A, Merlos M, García-Rafanell J, Forn J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2002	12	19	2753	2756	12217369	10.1016/s0960-894x(02)00537-1	Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors.	Rahim MA, Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2002	12	3	267	270	11814774	10.1016/s0960-894x(01)00825-3	Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response.	Wesolowski SS, Jorgensen WL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2002	12	4	533	537	11844666	10.1016/s0960-894x(01)00800-9	Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.	Palomer A, Pascual J, Cabré M, Borràs L, González G, Aparici M, Carabaza A, Cabré F, García ML, Mauleón D.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2002	45	22	4816	4827	12383007	10.1021/jm020089e	Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.	Liu H, Huang X, Shen J, Luo X, Li M, Xiong B, Chen G, Shen J, Yang Y, Jiang H, Chen K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2002	45	7	1402	1411	11906281	10.1021/jm010458r	Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.	Palomer A, Cabré F, Pascual J, Campos J, Trujillo MA, Entrena A, Gallo MA, García L, Mauleón D, Espinosa A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2002	45	7	1511	1517	11906292	10.1021/jm010484p	4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).	Hashimoto H, Imamura K, Haruta J, Wakitani K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Proc. Natl. Acad. Sci. U.S.A.	2003	100	1	9244	9249	12835412	10.1073/pnas.1033060100	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.	Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2003	13	10	1639	1643	12729631	10.1016/s0960-894x(03)00282-8	Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors.	Pal M, Rao Veeramaneni V, Nagabelli M, Rao Kalleda S, Misra P, Rao Casturi S, Rao Yeleswarapu K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2003	13	13	2205	2209	12798335	10.1016/s0960-894x(03)00391-3	6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.	Rao PN, Amini M, Li H, Habeeb AG, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2003	13	3	413	417	12565941	10.1016/s0960-894x(02)00952-6	2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors.	Hyup YH, Kwan JK, Kang SH, Noh MS, Ha JY, Kyu JK, Min KM, Hoon CH, Chung S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2003	13	6	1195	1198	12643942	10.1016/s0960-894x(03)00046-5	3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.	Black WC, Brideau C, Chan CC, Charleson S, Cromlish W, Gordon R, Grimm EL, Hughes G, Leger S, Li CS, Riendeau D, Thérien M, Wang Z, Xu LJ, Prasit P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2003	46	16	3463	3475	12877584	10.1021/jm030765s	Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.	Almansa C, Alfón J, de Arriba AF, Cavalcanti FL, Escamilla I, Gómez LA, Miralles A, Soliva R, Bartrolí J, Carceller E, Merlos M, García-Rafanell J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2003	46	19	3975	3984	12954051	10.1021/jm020563g	Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.	Pal M, Madan M, Padakanti S, Pattabiraman VR, Kalleda S, Vanguri A, Mullangi R, Mamidi NV, Casturi SR, Malde A, Gopalakrishnan B, Yeleswarapu KR.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2003	46	23	4872	4882	14584938	10.1021/jm0302391	Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.	Praveen Rao PN, Amini M, Li H, Habeeb AG, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2003	46	25	5484	5504	14640557	10.1021/jm030268b	Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.	Khanapure SP, Garvey DS, Young DV, Ezawa M, Earl RA, Gaston RD, Fang X, Murty M, Martino A, Shumway M, Trocha M, Marek P, Tam SW, Janero DR, Letts LG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	1	95	98	14684306	10.1016/j.bmcl.2003.10.004	Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.	Li J, DeMello KM, Cheng H, Sakya SM, Bronk BS, Rafka RJ, Jaynes BH, Ziegler CB, Kilroy C, Mann DW, Nimz EL, Lynch MP, Haven ML, Kolosko NL, Minich ML, Li C, Dutra JK, Rast B, Crosson RM, Morton BJ, Kirk GW, Callaghan KM, Koss DA, Shavnya A, Lund LA, Seibel SB, Petras CF, Silvia A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	19	4911	4914	15341950	10.1016/j.bmcl.2004.07.027	A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors.	Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	2	337	341	14698154	10.1016/j.bmcl.2003.11.014	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.	Abbate F, Coetzee A, Casini A, Ciattini S, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	2	499	504	14698190	10.1016/j.bmcl.2003.10.027	Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors.	Singh SK, Reddy PG, Rao KS, Lohray BB, Misra P, Rajjak SA, Rao YK, Venkateswarlu A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	21	5445	5448	15454242	10.1016/j.bmcl.2004.07.089	Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.	Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	24	6001	6006	15546717	10.1016/j.bmcl.2004.09.085	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.	Zimmerman S, Innocenti A, Casini A, Ferry JG, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	24	6049	6052	15546727	10.1016/j.bmcl.2004.09.073	3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.	Ranatunge RR, Earl RA, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schwalb DJ, Young DV, Zemtseva IS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	7	1683	1688	15026050	10.1016/j.bmcl.2004.01.053	Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.	Singh SK, Vobbalareddy S, Shivaramakrishna S, Krishnamraju A, Rajjak SA, Casturi SR, Akhila V, Rao YK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	8	1953	1956	15050635	10.1016/j.bmcl.2004.01.075	Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors.	Uddin MJ, Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2004	14	9	2195	2198	15081007	10.1016/j.bmcl.2004.02.028	2,3-diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors.	Hyup Joo Y, Kwan Kim J, Kang SH, Noh MS, Ha JY, Kyu Choi J, Lim KM, Chung S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	16	3972	3990	15267236	10.1021/jm049939b	Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.	Rao PN, Uddin MJ, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	24	6108	6111	15537365	10.1021/jm049523y	A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.	Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	25	6195	6206	15566290	10.1021/jm0407761	New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.	Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F, Hénichart JP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	27	6749	6759	15615524	10.1021/jm049480l	Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.	Julémont F, de Leval X, Michaux C, Renard JF, Winum JY, Montero JL, Damas J, Dogné JM, Pirotte B.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	3	550	557	14736236	10.1021/jm030912m	Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.	Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2004	47	9	2180	2193	15084117	10.1021/jm030276s	Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.	Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schroeder JD, Shumway MJ, Tam SW, Trocha AM, Young DV.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2005	15	15	3506	3509	15990304	10.1016/j.bmcl.2005.05.107	The molecular basis for coxib inhibition of p38alpha MAP kinase.	Sperandio da Silva GM, Lima LM, Fraga CA, Sant'Anna CM, Barreiro EJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2005	15	17	3930	3933	15993594	10.1016/j.bmcl.2005.05.093	In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.	Ottanà R, Carotti S, Maccari R, Landini I, Chiricosta G, Caciagli B, Vigorita MG, Mini E.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2005	15	2	439	442	15603969	10.1016/j.bmcl.2004.10.050	Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme.	Uddin MJ, Rao PN, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2005	15	4	1149	1154	15686931	10.1016/j.bmcl.2004.12.009	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.	Innocenti A, Firnges MA, Antel J, Wurl M, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2005	15	7	1793	1797	15780608	10.1016/j.bmcl.2005.02.039	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents.	Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2005	48	11	3930	3934	15916445	10.1021/jm0582064	3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.	Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2005	48	18	5721	5727	16134940	10.1021/jm050333c	Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.	Menchise V, De Simone G, Alterio V, Di Fiore A, Pedone C, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2005	48	21	6523	6543	16220969	10.1021/jm058225d	Designed multiple ligands. An emerging drug discovery paradigm.	Morphy R, Rankovic Z.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2005	48	22	6997	7004	16250658	10.1021/jm050619h	Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.	Franke L, Byvatov E, Werz O, Steinhilber D, Schneider P, Schneider G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2005	48	9	3428	3432	15857149	10.1021/jm049121q	1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.	Biava M, Porretta GC, Cappelli A, Vomero S, Manetti F, Botta M, Sautebin L, Rossi A, Makovec F, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2005	68	10	1514	1518	16252917	10.1021/np0502342	Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum.	Zou J, Jin D, Chen W, Wang J, Liu Q, Zhu X, Zhao W.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118		2005							Combination of selected analgesics and COX-II inhibitors	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2006	16	15	3921	3926	16730986	10.1016/j.bmcl.2006.05.028	N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.	Singh SK, Vobbalareddy S, Kalleda SR, Casturi SR, Mullangi R, Ramanujam R, Yeleswarapu KR, Iqbal J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2006	16	17	4440	4443	16814546	10.1016/j.bmcl.2006.06.036	Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.	Tsai WJ, Shiao YJ, Lin SJ, Chiou WF, Lin LC, Yang TH, Teng CM, Wu TS, Yang LM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2006	16	17	4483	4487	16806914	10.1016/j.bmcl.2006.06.032	Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.	Navidpour L, Amini M, Shafaroodi H, Abdi K, Ghahremani MH, Dehpour AR, Shafiee A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2006	16	2	437	442	16290146	10.1016/j.bmcl.2005.09.040	"Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ""selective"" inhibitor celecoxib."	Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Nat. Chem. Biol.	2006	2	6	329	337	16680159	10.1038/nchembio790	Identifying off-target effects and hidden phenotypes of drugs in human cells.	MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2006	49	5	1668	1683	16509583	10.1021/jm0510474	Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.	Rao PN, Chen QH, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2006	69	11	1591	1595	17125227	10.1021/np060287z	Triterpene saponins from clematis mandshurica.	Shi S, Jiang D, Dong C, Tu P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2007	15	18	6109	6118	17604631	10.1016/j.bmc.2007.06.030	'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors.	Handler N, Brunhofer G, Studenik C, Leisser K, Jaeger W, Parth S, Erker T.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2007	15	21	6796	6801	17764958	10.1016/j.bmc.2007.07.021	Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies.	Abdellatif KR, Dong Y, Chen QH, Chowdhury MA, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2007	15	23	7229	7236	17826101	10.1016/j.bmc.2007.08.037	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.	Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2007	15	5	1976	1982	17258905	10.1016/j.bmc.2006.12.041	Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.	Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR, Shafiee A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2007	17	20	5634	5637	17822894	10.1016/j.bmcl.2007.07.084	Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.	Zarghi A, Najafnia L, Daraee B, Dadrass OG, Hedayati M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2007	17	23	6430	6433	17950600	10.1016/j.bmcl.2007.10.006	Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A.	Wu F, Yi Y, Sun P, Zhang D.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2007	17	4	1022	1024	17150356	10.1016/j.bmcl.2006.11.035	Synthesis and biological evaluation of some 5-ethoxycarbonyl-6-isopropylamino-4-(substitutedphenyl)aminopyrimidines as potent analgesic and anti-inflammatory agents.	Chhabria MT, Bhatt HG, Raval HG, Oza PM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	1	21	39	17201408	10.1021/jm0602256	Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.	Kaila N, Janz K, DeBernardo S, Bedard PW, Camphausen RT, Tam S, Tsao DH, Keith JC, Nickerson-Nutter C, Shilling A, Young-Sciame R, Wang Q.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	18	4444	4452	17696334	10.1021/jm0705096	CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.	Ahlström MM, Ridderström M, Zamora I, Luthman K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	22	5382	5391	17915853	10.1021/jm070745g	CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.	Ahlström MM, Ridderström M, Zamora I.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	22	5403	5411	17915854	10.1021/jm0707525	Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.	Biava M, Porretta GC, Poce G, Supino S, Forli S, Rovini M, Cappelli A, Manetti F, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Vivoli E, Makovec F, Anzellotti P, Patrignani P, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	25	6367	6382	17994684	10.1021/jm0611861	Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.	Wey SJ, Augustyniak ME, Cochran ED, Ellis JL, Fang X, Garvey DS, Janero DR, Letts LG, Martino AM, Melim TL, Murty MG, Richardson SK, Schroeder JD, Selig WM, Trocha AM, Wexler RS, Young DV, Zemtseva IS, Zifcak BM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2007	50	7	1449	1457	17335184	10.1021/jm0607247	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.	Chegaev K, Lazzarato L, Tosco P, Cena C, Marini E, Rolando B, Carrupt PA, Fruttero R, Gasco A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	1	276	283	17937989	10.1016/j.bmc.2007.09.038	Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors.	Gadad AK, Palkar MB, Anand K, Noolvi MN, Boreddy TS, Wagwade J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	10	5547	5556	18430576	10.1016/j.bmc.2008.04.007	Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.	Abouzid K, Bekhit SA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	11	5881	5889	18482840	10.1016/j.bmc.2008.04.066	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.	Brunskole M, Stefane B, Zorko K, Anderluh M, Stojan J, Lanisnik Rizner T, Gobec S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	13	6528	6534	18513975	10.1016/j.bmc.2008.05.028	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities.	Abdellatif KR, Chowdhury MA, Dong Y, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	17	8072	8081	18752957	10.1016/j.bmc.2008.07.058	Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.	Biava M, Porretta GC, Poce G, Supino S, Manetti F, Forli S, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Norcini M, Makovec F, Giordani A, Anzellotti P, Cirilli R, Ferretti R, Gallinella B, La Torre F, Anzini M, Patrignani P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	19	8882	8888	18789699	10.1016/j.bmc.2008.08.059	Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.	Chowdhury MA, Abdellatif KR, Dong Y, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	22	9694	9698	18930406	10.1016/j.bmc.2008.10.001	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.	Abdellatif KR, Chowdhury MA, Dong Y, Velázquez C, Das D, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	4	1948	1956	18023187	10.1016/j.bmc.2007.11.003	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers.	Chowdhury MA, Dong Y, Chen QH, Abdellatif KR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	5	2697	2706	18063374	10.1016/j.bmc.2007.11.033	Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.	Lin SJ, Tsai WJ, Chiou WF, Yang TH, Yang LM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	6	3302	3308	18096394	10.1016/j.bmc.2007.12.006	Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.	Abdellatif KR, Chowdhury MA, Dong Y, Chen QH, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2008	16	7	3907	3916	18272371	10.1016/j.bmc.2008.01.047	Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.	Reddy MV, Billa VK, Pallela VR, Mallireddigari MR, Boominathan R, Gabriel JL, Reddy EP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2008	18	23	6138	6141	18945614	10.1016/j.bmcl.2008.10.009	Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.	Chowdhury MA, Abdellatif KR, Dong Y, Das D, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2008	18	4	1336	1339	18226898	10.1016/j.bmcl.2008.01.021	Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.	Zarghi A, Kakhgi S, Hadipoor A, Daraee B, Dadrass OG, Hedayati M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	1	129	134	17467123	10.1016/j.ejmech.2007.02.008	2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.	Franklin PX, Pillai AD, Rathod PD, Yerande S, Nivsarkar M, Padh H, Vasu KK, Sudarsanam V.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	12	2792	2799	18262309	10.1016/j.ejmech.2007.12.017	2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols.	Singh P, Mittal A, Kaur S, Kumar S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	3	456	463	17532544	10.1016/j.ejmech.2007.03.030	Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents.	Bekhit AA, Ashour HM, Abdel Ghany YS, Bekhit Ael-D, Baraka A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	6	1152	1159	17976864	10.1016/j.ejmech.2007.09.007	Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.	Scholz M, Ulbrich HK, Dannhardt G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	6	1222	1229	17937972	10.1016/j.ejmech.2007.08.005	Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.	Bailly F, Queffélec C, Mbemba G, Mouscadet JF, Pommery N, Pommery J, Hénichart JP, Cotelle P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2008	43	6	1297	1303	17714833	10.1016/j.ejmech.2007.06.022	Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors.	Gupta AK, Gupta RA, Soni LK, Kaskhedikar SG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	1	142	147	18072726	10.1021/jm070821f	New celecoxib derivatives as anti-inflammatory agents.	Szabó G, Fischer J, Kis-Varga A, Gyires K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	12	3388	3413	18498150	10.1021/jm701467e	Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.	McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter CL, Abraham WM, Williams C, Hegen M, Clark JD.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	15	4359	4369	18570365	10.1021/jm800219f	The many roles for fluorine in medicinal chemistry.	Hagmann WK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	15	4476	4481	18598017	10.1021/jm800084s	Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.	Anzini M, Rovini M, Cappelli A, Vomero S, Manetti F, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Norcini M, Giordani A, Makovec F, Anzellotti P, Patrignani P, Biava M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2008	51	24	8068	8076	19053751	10.1021/jm801085s	Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.	Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	1	74	84	19059783	10.1016/j.bmc.2008.11.018	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.	Lacerda RB, de Lima CK, da Silva LL, Romeiro NC, Miranda AL, Barreiro EJ, Fraga CA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	13	4503	4509	19450983	10.1016/j.bmc.2009.05.002	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.	Innocenti A, Hall RA, Schlicker C, Scozzafava A, Steegborn C, Mühlschlegel FA, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	14	5054	5058	19520577	10.1016/j.bmc.2009.05.063	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.	Bertucci A, Innocenti A, Zoccola D, Scozzafava A, Tambutté S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	14	5059	5070	19527932	10.1016/j.bmc.2009.05.073	Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.	Eissa AA, Farag NA, Soliman GA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	14	5182	5188	19500994	10.1016/j.bmc.2009.05.046	Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.	Abdellatif KR, Chowdhury MA, Dong Y, Das D, Yu G, Velázquez C, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	14	5312	5317	19560931	10.1016/j.bmc.2009.05.084	Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.	Zarghi A, Ghodsi R, Azizi E, Daraie B, Hedayati M, Dadrass OG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	15	5369	5373	19596198	10.1016/j.bmc.2009.06.056	Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.	Zarghi A, Zebardast T, Daraie B, Hedayati M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	2	558	568	19097798	10.1016/j.bmc.2008.11.074	Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.	Scholz M, Ulbrich HK, Soehnlein O, Lindbom L, Mattern A, Dannhardt G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	23	7924	7932	19884011	10.1016/j.bmc.2009.10.025	Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.	Koeberle A, Haberl EM, Rossi A, Pergola C, Dehm F, Northoff H, Troschuetz R, Sautebin L, Werz O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	3	1146	1151	19157881	10.1016/j.bmc.2008.12.032	Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives.	Wuest F, Tang X, Kniess T, Pietzsch J, Suresh M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	3	1158	1163	19124253	10.1016/j.bmc.2008.12.035	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.	Isik S, Kockar F, Aydin M, Arslan O, Guler OO, Innocenti A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2009	17	5	1991	1996	19200742	10.1016/j.bmc.2009.01.029	Inhibition of iNOS and COX-2 in human whole blood ex vivo and monocyte-macrophage J774 cells by a new group of aminothiopyrimidone derivatives.	Cardile V, Lombardo L, Granata G, Perdicaro A, Balazy M, Santagati A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2009	18	9	782	797		10.1007/s00044-009-9203-y	Synthesis of new 2(1H)-quinoxalinone derivatives for antimicrobial and antiinflammatory evaluation	El-Sabbagh OI, El-Sadek ME, Lashine SM, Yassin SH, El-Nabtity SM
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	1	255	258	19010670	10.1016/j.bmcl.2008.10.105	Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide.	Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK, Singh S, Bagchi V.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	12	3162	3165	19447036	10.1016/j.bmcl.2009.04.125	Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.	Zebardast T, Zarghi A, Daraie B, Hedayati M, Dadrass OG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	15	4504	4508	19520573	10.1016/j.bmcl.2009.02.085	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.	Swarbrick ME, Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	23	6649	6654	19846301	10.1016/j.bmcl.2009.10.009	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.	Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	24	6922	6925	19880317	10.1016/j.bmcl.2009.10.069	COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.	Coy ED, Cuca LE, Sefkow M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	3	584	588	19136259	10.1016/j.bmcl.2008.12.066	Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.	Chowdhury MA, Abdellatif KR, Dong Y, Rahman M, Das D, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2009	19	8	2270	2272	19286379	10.1016/j.bmcl.2009.02.090	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.	Feng Z, Chu F, Guo Z, Sun P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2009	44	5	1959	1971	19144452	10.1016/j.ejmech.2008.11.012	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues.	Romeiro NC, Leite RD, Lima LM, Cardozo SV, de Miranda AL, Fraga CA, Barreiro EJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2009	44	9	3798	3804	19457595	10.1016/j.ejmech.2009.04.009	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.	Husain A, Ahmad A, Alam MM, Ajmal M, Ahuja P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	19	5864	5871	19791801	10.1021/jm900702b	Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.	Renard JF, Arslan D, Garbacki N, Pirotte B, de Leval X.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	3	646	654	19193158	10.1021/jm801267c	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.	Hilvo M, Salzano AM, Innocenti A, Kulomaa MS, Scozzafava A, Scaloni A, Parkkila S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	4	1156	1171	19178292	10.1021/jm8009876	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.	Chen L, Wang W, Lee KL, Shen MW, Murphy EA, Zhang W, Xu X, Tam S, Nickerson-Nutter C, Goodwin DG, Clark JD, McKew JC.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	6	1525	1529	19296694	10.1021/jm8015188	Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.	Chowdhury MA, Abdellatif KR, Dong Y, Das D, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	8	2226	2232	19317447	10.1021/jm9000488	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.	Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2009	52	9	3116	3120	19338333	10.1021/jm9003126	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.	Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Antimicrob. Agents Chemother.	2009	53	7	2998	3002	19398640	10.1128/aac.00048-09	Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.	Chiu HC, Yang J, Soni S, Kulp SK, Gunn JS, Schlesinger LS, Chen CS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	11	3910	3924	20451397	10.1016/j.bmc.2010.04.034	Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.	Bridoux A, Millet R, Pommery J, Pommery N, Henichart JP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	14	5007	5015	20598893	10.1016/j.bmc.2010.06.002	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.	da Silva YK, Augusto CV, de Castro Barbosa ML, de Albuquerque Melo GM, de Queiroz AC, de Lima Matos Freire Dias T, Júnior WB, Barreiro EJ, Lima LM, Alexandre-Moreira MS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	15	5498	5503	20624682	10.1016/j.bmc.2010.06.056	Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors.	Kockar F, Maresca A, Aydin M, I¿ik S, Turkoglu S, Sinan S, Arslan O, Güler OO, Turan Y, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	15	5685	5696	20609589	10.1016/j.bmc.2010.06.018	Synthesis and biological evaluation of novel pyrazole compounds.	Youssef AM, Neeland EG, Villanueva EB, White MS, El-Ashmawy IM, Patrick B, Klegeris A, Abd-El-Aziz AS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	16	5855	5860	20650641	10.1016/j.bmc.2010.06.094	Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.	Zarghi A, Ghodsi R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	2	597	604	20056549	10.1016/j.bmc.2009.12.008	Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production.	Chen CS, Tan CM, Huang CH, Chang LC, Wang JP, Cheng FC, Chern JW.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	3	1029	1033	20061161	10.1016/j.bmc.2009.12.060	Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.	Ghodsi R, Zarghi A, Daraei B, Hedayati M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2010	18	5	2019	2028	20138770	10.1016/j.bmc.2010.01.021	Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.	Youssef AM, White MS, Villanueva EB, El-Ashmawy IM, Klegeris A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2010	19	8	782	793		10.1007/s00044-009-9230-8	Design and synthesis of new 2-aryl, 3-benzyl-(1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors	Zarghi A, Arefi H, Dadrass OG, Torabi S
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	14	4035	4037	20554444	10.1016/j.bmcl.2010.05.092	1,5-Diarylimidazoles with strong inhibitory activity against COX-2 catalyzed PGE2 production from LPS-induced RAW 264.7 cells.	Che H, Tuyen TN, Kim HP, Park H.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	15	4376	4381	20605094	10.1016/j.bmcl.2010.06.082	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors.	Avvaru BS, Wagner JM, Maresca A, Scozzafava A, Robbins AH, Supuran CT, McKenna R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	15	4544	4549	20576432	10.1016/j.bmcl.2010.06.022	Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.	Abdellatif KR, Chowdhury MA, Velázquez CA, Huang Z, Dong Y, Das D, Yu G, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	17	5080	5084	20673717	10.1016/j.bmcl.2010.07.033	Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.	Abdi MH, Beswick PJ, Billinton A, Chambers LJ, Charlton A, Collins SD, Collis KL, Dean DK, Fonfria E, Gleave RJ, Lejeune CL, Livermore DG, Medhurst SJ, Michel AD, Moses AP, Page L, Patel S, Roman SA, Senger S, Slingsby B, Steadman JG, Stevens AJ, Walter DS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	17	5245	5250	20655211	10.1016/j.bmcl.2010.06.155	Triaryl (Z)-olefins suitable for radiolabeling with carbon-11 or fluorine-18 radionuclides for positron emission tomography imaging of cyclooxygenase-2 expression in pathological disease.	Abdellatif KR, Velázquez CA, Huang Z, Chowdhury MA, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	23	7155	7158	21055613	10.1016/j.bmcl.2010.07.053	The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.	Wang JL, Carter J, Kiefer JR, Kurumbail RG, Pawlitz JL, Brown D, Hartmann SJ, Graneto MJ, Seibert K, Talley JJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	3	1013	1018	20045317	10.1016/j.bmcl.2009.12.047	Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.	Aparoy P, Kumar Reddy K, Kalangi SK, Chandramohan Reddy T, Reddanna P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2010	20	4	1324	1329	20097072	10.1016/j.bmcl.2010.01.014	Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.	Chowdhury MA, Abdellatif KR, Dong Y, Yu G, Huang Z, Rahman M, Das D, Velázquez CA, Suresh MR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2010	45	12	6027	6038	20970223	10.1016/j.ejmech.2010.10.001	Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.	Bekhit AA, Fahmy HT, Rostom SA, El-Din A Bekhit A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2010	45	4	1639	1647	20106561	10.1016/j.ejmech.2009.12.043	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.	Toropov AA, Toropova AP, Raska I, Benfenati E.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2010	45	9	4013	4017	20691338	10.1016/j.ejmech.2010.05.058	Design, synthesis and biological evaluation of new (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors.	Arfaie S, Zarghi A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2010	53	10	4259	4265	20426472	10.1021/jm100254w	Colloid formation by drugs in simulated intestinal fluid.	Doak AK, Wille H, Prusiner SB, Shoichet BK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2010	53	18	6560	6571	20804197	10.1021/jm100398z	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.	Harrak Y, Casula G, Basset J, Rosell G, Plescia S, Raffa D, Cusimano MG, Pouplana R, Pujol MD.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2010	53	2	723	733	19957931	10.1021/jm901269y	Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation.	Biava M, Porretta GC, Poce G, Battilocchio C, Manetti F, Botta M, Forli S, Sautebin L, Rossi A, Pergola C, Ghelardini C, Galeotti N, Makovec F, Giordani A, Anzellotti P, Patrignani P, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2010	53	5	2277	2285	20158185	10.1021/jm901855h	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.	Joseph P, Turtaut F, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Köhler S, Winum JY, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2010	53	9	3707	3717	20387815	10.1021/jm1001327	Mono-, di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation.	Singh P, Bhardwaj A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	11	3299	3311	21570308	10.1016/j.bmc.2011.04.050	Synthesis and biological evaluation of loxoprofen derivatives.	Yamakawa N, Suemasu S, Matoyama M, Tanaka K, Katsu T, Miyata K, Okamoto Y, Otsuka M, Mizushima T.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	11	3416	3424	21570309	10.1016/j.bmc.2011.04.027	Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.	El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, Asiri YA, Eltahir KE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	15	4520	4528	21724403	10.1016/j.bmc.2011.06.019	Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents.	Manivannan E, Chaturvedi SC.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	16	5023	5030	21757360	10.1016/j.bmc.2011.06.038	Inhibition studies of the ß-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.	Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	22	6827	6832	22000948	10.1016/j.bmc.2011.09.034	Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.	Lu X, Zhang H, Li X, Chen G, Li QS, Luo Y, Ruan BF, Chen XW, Zhu HL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	3	1172	1178	21251841	10.1016/j.bmc.2010.12.048	A new ß-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.	Joseph P, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Winum JY, Köhler S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2011	19	6	2074	2083	21349729	10.1016/j.bmc.2011.01.043	Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.	Li Y, Chen SH, Ou TM, Tan JH, Li D, Gu LQ, Huang ZS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	ACS Med. Chem. Lett.	2011	2	2	160	164	21318094	10.1021/ml100232q	[I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation.	Uddin MJ, Crews BC, Ghebreselasie K, Tantawy MN, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	13	3951	3956	21641217	10.1016/j.bmcl.2011.05.017	A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies.	Abdellatif KR, Huang Z, Chowdhury MA, Kaufman S, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	14	4301	4305	21664130	10.1016/j.bmcl.2011.05.061	Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents.	Bashir R, Ovais S, Yaseen S, Hamid H, Alam MS, Samim M, Singh S, Javed K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	19	5892	5896	21852133	10.1016/j.bmcl.2011.07.090	Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.	Knaus EE, Innocenti A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	2	710	714	21208801	10.1016/j.bmcl.2010.11.124	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.	Bertucci A, Innocenti A, Scozzafava A, Tambutté S, Zoccola D, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	20	6071	6073	21903394	10.1016/j.bmcl.2011.08.050	Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.	Mandal PK, Freiter EM, Bagsby AL, Robertson FM, McMurray JS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	20	6074	6080	21890358	10.1016/j.bmcl.2011.08.053	Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors.	Abdur Rahim M, Praveen Rao PN, Bhardwaj A, Kaur J, Huang Z, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	22	6636	6640	21983446	10.1016/j.bmcl.2011.09.071	A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.	Ruiz JF, Kedziora K, Keogh B, Maguire J, Reilly M, Windle H, Kelleher DP, Gilmer JF.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	3	993	996	21215625	10.1016/j.bmcl.2010.12.023	Structure-based parallel medicinal chemistry approach to improve metabolic stability of benzopyran COX-2 inhibitors.	Xing L, Hamper BC, Fletcher TR, Wendling JM, Carter J, Gierse JK, Liao S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	6	1612	1616	21345672	10.1016/j.bmcl.2011.01.116	Synthesis, biological evaluation and molecular docking studies of stellatin derivatives as cyclooxygenase (COX-1, COX-2) inhibitors and anti-inflammatory agents.	Gautam R, Jachak SM, Kumar V, Mohan CG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2011	21	6	1823	1826	21316237	10.1016/j.bmcl.2011.01.057	Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors.	Al-Hourani BJ, Sharma SK, Mane JY, Tuszynski J, Baracos V, Kniess T, Suresh M, Pietzsch J, Wuest F.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Drug Metab. Dispos.	2011	39	7	1247	1254	21467212	10.1124/dmd.111.039180	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.	Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2011	46	12	5763	5768	22019186	10.1016/j.ejmech.2011.08.015	Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents.	Bano S, Javed K, Ahmad S, Rathish IG, Singh S, Alam MS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2011	46	3	907	913	21295381	10.1016/j.ejmech.2011.01.002	Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.	Liu W, Zhou J, Bensdorf K, Zhang H, Liu H, Wang Y, Qian H, Zhang Y, Wellner A, Rubner G, Huang W, Guo C, Gust R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2011	46	5	1648	1655	21388719	10.1016/j.ejmech.2011.02.013	Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.	Abdel-Aziz AA, ElTahir KE, Asiri YA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2011	54	13	4490	4507	21591611	10.1021/jm200092b	Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid.	Hieke M, Greiner C, Dittrich M, Reisen F, Schneider G, Schubert-Zsilavecz M, Werz O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2011	54	15	5592	5596	21678971	10.1021/jm101330h	Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).	Li H, Liu A, Zhao Z, Xu Y, Lin J, Jou D, Li C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2011	54	22	7759	7771	21992176	10.1021/jm200715n	Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.	Biava M, Porretta GC, Poce G, Battilocchio C, Alfonso S, Rovini M, Valenti S, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Papa G, Ghelardini C, Di Cesare Mannelli L, Giordani A, Anzellotti P, Bruno A, Patrignani P, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2011	54	8	2529	2591	21413808	10.1021/jm1013693	Synopsis of some recent tactical application of bioisosteres in drug design.	Meanwell NA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2011	54	8	3037	3050	21434686	10.1021/jm2001376	Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.	Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Antimicrob. Agents Chemother.	2011	55	1	439	442	20937780	10.1128/aac.00735-10	Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.	Kalle AM, Rizvi A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2011	74	2	129	136	21261296	10.1021/np100373f	Bioactive compounds from the fern Lepisorus contortus.	Yang JH, Kondratyuk TP, Jermihov KC, Marler LE, Qiu X, Choi Y, Cao H, Yu R, Sturdy M, Huang R, Liu Y, Wang LQ, Mesecar AD, van Breemen RB, Pezzuto JM, Fong HH, Chen YG, Zhang HJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	10	3306	3316	22516672	10.1016/j.bmc.2012.03.044	Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.	El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AA, El-Azab AS, ElTahir KE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	11	3378	3395	22546204	10.1016/j.bmc.2012.03.069	Recent developments and biological activities of thiazolidinone derivatives: a review.	Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	11	3410	3421	22560838	10.1016/j.bmc.2012.04.022	Radiosynthesis of a ¹¿F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo.	Kniess T, Laube M, Bergmann R, Sehn F, Graf F, Steinbach J, Wuest F, Pietzsch J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	15	4653	4660	22750009	10.1016/j.bmc.2012.06.018	Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.	Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, Kulp SK, Teng LJ, Chen CS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	22	6648	6654	23062711	10.1016/j.bmc.2012.09.021	Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.	Qiu KM, Yan R, Xing M, Wang HH, Cui HE, Gong HB, Zhu HL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	24	7119	7127	23146282	10.1016/j.bmc.2012.09.069	Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.	Manivannan E, Chaturvedi SC.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	4	1403	1410	22285172	10.1016/j.bmc.2012.01.007	Cloning, characterization and sulfonamide inhibition studies of an ¿-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.	Ohradanova A, Vullo D, Pastorekova S, Pastorek J, Jackson DJ, Wörheide G, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	7	2208	2213	22386980	10.1016/j.bmc.2012.02.029	Mutation of active site residues Asn67 to Ile, Gln92 to Val and Leu204 to Ser in human carbonic anhydrase II: influences on the catalytic activity and affinity for inhibitors.	Turkoglu S, Maresca A, Alper M, Kockar F, I¿¿k S, Sinan S, Ozensoy O, Arslan O, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	7	2221	2226	22386983	10.1016/j.bmc.2012.02.021	Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2).	Sharma SK, Al-Hourani BJ, Wuest M, Mane JY, Tuszynski J, Baracos V, Suresh M, Wuest F.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2012	20	9	2860	2868	22494844	10.1016/j.bmc.2012.03.028	Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF¿ production.	Lee B, Kwak JH, Huang SW, Jang JY, Lim S, Kwak YS, Lee K, Kim HS, Han SB, Hong JT, Lee H, Song S, Seo SY, Jung JK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	12	4369	4380		10.1007/s00044-012-9975-3	Synthesis, molecular modeling and anti-inflammatory screening of new 1,2,3-benzotriazinone derivatives	Ibrahim TS, Rashad AA, Abdel-Samii ZK, El-Feky SA, Abdel-Hamid MK, Barakat W
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	7	983	994		10.1007/s00044-011-9606-4	Design and synthesis of some pyrazole derivatives of expected anti-inflammatory and analgesic activities	Abd-El Gawad NM, Hassan GS, Georgey HH
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	8	1722	1733		10.1007/s00044-011-9691-4	Synthesis and anti-inflammatory activity of some pyrazole derivatives	El-Moghazy SM, Barsoum FF, Abdel-Rahman HM, Marzouk AA
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	8	1803	1810		10.1007/s00044-011-9710-5	Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors	Zarghi A, Arfaei S, Ghodsi R
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	8	1869	1875		10.1007/s00044-011-9709-y	Design and synthesis of new 1,2-diaryl-4,5,6,7-tetrahydro-1H-benzo[d] imidazoles as selective cyclooxygenase (COX-2) inhibitors	Zarghi A, Reihanfard H, Arfaei S, Daraei B, Hedayati M
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2012	21	9	2223	2228		10.1007/s00044-011-9747-5	Synthesis and biological evaluation of ester derivatives of indomethacin as selective COX-2 inhibitors	Arockia Babu M, Shukla R, Nath C, Kaskhedikar SG
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	10	3567	3570	22516282	10.1016/j.bmcl.2012.03.013	Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.	Smith B, Chang HH, Medda F, Gokhale V, Dietrich J, Davis A, Meuillet EJ, Hulme C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	15	5031	5034	22749420	10.1016/j.bmcl.2012.06.012	Efficient synthesis and 5-LOX/COX-inhibitory activity of some 3-hydroxybenzo[b]thiophene-2-carboxylic acid derivatives.	Hansen FK, Khankischpur M, Tolaymat I, Mesaros R, Dannhardt G, Geffken D.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	19	6205	6211	22939234	10.1016/j.bmcl.2012.08.018	Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.	Besidski Y, Brown W, Bylund J, Dabrowski M, Dautrey S, Harter M, Horoszok L, Hu Y, Johnson D, Johnstone S, Jones P, Leclerc S, Kolmodin K, Kers I, Labarre M, Labrecque D, Laird J, Lundström T, Martino J, Maudet M, Munro A, Nylöf M, Penwell A, Rotticci D, Slaitas A, Sundgren-Andersson A, Svensson M, Terp G, Villanueva H, Walpole C, Zemribo R, Griffin AM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	2	793	796	22217871	10.1016/j.bmcl.2011.12.072	Enzymatic transformation of caffeic acid with enhanced cyclooxygenase-2 inhibitory activity.	Bae JS, Kim TH.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	21	6616	6620	23036953	10.1016/j.bmcl.2012.08.119	Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents.	Yewale SB, Ganorkar SB, Baheti KG, Shelke RU.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	21	6745	6749	23010270	10.1016/j.bmcl.2012.08.082	Synthesis and pharmacological evaluation of N-substituted 2-(2-oxo-2H-chromen-4-yloxy)propanamide as cyclooxygenase inhibitors.	Rambabu D, Mulakayala N, Ismail, Kumar KR, Kumar GP, Mulakayala C, Kumar CS, Kalle AM, Rao MV, Oruganti S, Pal M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	4	1629	1632	22266037	10.1016/j.bmcl.2011.12.121	New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening.	Yang W, AbdulHameed MD, Hamza A, Zhan CG.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	6	2154	2159	22361134	10.1016/j.bmcl.2012.01.130	N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.	Kaur J, Bhardwaj A, Huang Z, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2012	22	6	2235	2238	22341941	10.1016/j.bmcl.2012.01.093	Novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors.	Al-Hourani BJ, Sharma SK, Suresh M, Wuest F.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	47		111	124	22119153	10.1016/j.ejmech.2011.10.029	Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.	Eleftheriou P, Geronikaki A, Hadjipavlou-Litina D, Vicini P, Filz O, Filimonov D, Poroikov V, Chaudhaery SS, Roy KK, Saxena AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	47		351	359	22118829	10.1016/j.ejmech.2011.11.003	Structure based drug design, synthesis and evaluation of 4-(benzyloxy)-1-phenylbut-2-yn-1-ol derivatives as 5-lipoxygenase inhibitors.	Reddy NP, Chandramohan Reddy T, Aparoy P, Achari C, Sridhar PR, Reddanna P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	47		52	58	22071254	10.1016/j.ejmech.2011.10.018	Synthesis, anti-inflammatory activity and molecular docking studies of 2,5-diarylfuran amino acid derivatives.	Stefani HA, Botteselle GV, Zukerman-Schpector J, Caracelli I, da Silva Corrêa D, Farsky SH, Machado ID, Santin JR, Hebeda CB.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	49		324	333	22305614	10.1016/j.ejmech.2012.01.032	Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities.	Shafi S, Alam MM, Mulakayala N, Mulakayala C, Vanaja G, Kalle AM, Pallu R, Alam MS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	53		141	149	22551678	10.1016/j.ejmech.2012.03.050	New quinazolinone-pyrimidine hybrids: synthesis, anti-inflammatory, and ulcerogenicity studies.	Abbas SE, Awadallah FM, Ibrahin NA, Said EG, Kamel GM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	54		823	833	22796043	10.1016/j.ejmech.2012.06.040	Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.	Estevão MS, Carvalho LC, Freitas M, Gomes A, Viegas A, Manso J, Erhardt S, Fernandes E, Cabrita EJ, Marques MM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	11	5143	5150	22404396	10.1021/jm300049g	Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity.	Yamakawa N, Suemasu S, Okamoto Y, Tanaka K, Ishihara T, Asano T, Miyata K, Otsuka M, Mizushima T.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	15	6832	6848	22780961	10.1021/jm300576q	Predicting new indications for approved drugs using a proteochemometric method.	Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	22	9619	9629	23067387	10.1021/jm300878g	Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit ¿- and ß-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms.	Marini AM, Maresca A, Aggarwal M, Orlandini E, Nencetti S, Da Settimo F, Salerno S, Simorini F, La Motta C, Taliani S, Nuti E, Scozzafava A, McKenna R, Rossello A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	23	10742	10748	23181552	10.1021/jm301611m	DNA cloning, characterization, and inhibition studies of an ¿-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Isik S, Vullo D, De Luca V, Carginale V, Scozzafava A, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	5	2287	2300	22263894	10.1021/jm201528b	Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.	Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	7	3513	3520	22424239	10.1021/jm300203r	Molecular cloning, characterization, and inhibition studies of a ß-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.	Hewitson KS, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	7	3568	3572	22432682	10.1021/jm201446h	Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.	Sabatini S, Gosetto F, Serritella S, Manfroni G, Tabarrini O, Iraci N, Brincat JP, Carosati E, Villarini M, Kaatz GW, Cecchetti V.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2012	55	8	3792	3803	22449023	10.1021/jm201687d	Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).	Rörsch F, Buscató E, Deckmann K, Schneider G, Schubert-Zsilavecz M, Geisslinger G, Proschak E, Grösch S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	55		12	22	22818041	10.1016/j.ejmech.2012.06.048	New pyrimido[5,4-e]pyrrolo[1,2-c]pyrimidines: synthesis, 2D-QSAR, anti-inflammatory, analgesic and ulcerogenicity studies.	Hanna MM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	57		149	161	23047231	10.1016/j.ejmech.2012.09.005	Sulfonilamidothiopyrimidone and thiopyrimidone derivatives as selective COX-2 inhibitors: synthesis, biological evaluation, and docking studies.	Basile L, Alvarez S, Blanco A, Santagati A, Granata G, Di Pietro P, Guccione S, Muñoz-Fernández MÁ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2012	58		287	298	23131542	10.1016/j.ejmech.2012.10.014	Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.	Biava M, Battilocchio C, Poce G, Alfonso S, Consalvi S, Porretta GC, Schenone S, Calderone V, Martelli A, Testai L, Ghelardini C, Di Cesare Mannelli L, Sautebin L, Rossi A, Giordani A, Patrignani P, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	13	3695	3701	23680444	10.1016/j.bmc.2013.04.031	A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity.	Battilocchio C, Poce G, Alfonso S, Porretta GC, Consalvi S, Sautebin L, Pace S, Rossi A, Ghelardini C, Di Cesare Mannelli L, Schenone S, Giordani A, Di Francesco L, Patrignani P, Biava M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	14	4288	4295	23706267	10.1016/j.bmc.2013.04.074	1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies.	Kaur J, Bhardwaj A, Sharma SK, Wuest F.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	15	4581	4590	23769654	10.1016/j.bmc.2013.05.029	Synthesis of novel celecoxib analogues by bioisosteric replacement of sulfonamide as potent anti-inflammatory agents and cyclooxygenase inhibitors.	Chandna N, Kumar S, Kaushik P, Kaushik D, Roy SK, Gupta GK, Jachak SM, Kapoor JK, Sharma PK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	17	5168	5174	23867389	10.1016/j.bmc.2013.06.035	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.	Sethi KK, Verma SM, Tanç M, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	19	5973	5982	23965175	10.1016/j.bmc.2013.07.044	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.	Sethi KK, Vullo D, Verma SM, Tanç M, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	24	7874	7883	24183739	10.1016/j.bmc.2013.10.006	Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.	Hanke T, Rörsch F, Thieme TM, Ferreiros N, Schneider G, Geisslinger G, Proschak E, Grösch S, Schubert-Zsilavecz M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	6	1534	1538	22883029	10.1016/j.bmc.2012.07.024	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.	Vullo D, Luca VD, Scozzafava A, Carginale V, Rossi M, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	8	2355	2362	23473947	10.1016/j.bmc.2013.01.058	Synthesis, cyclooxygenase inhibitory effects, and molecular modeling study of 4-aryl-5-(4-(methylsulfonyl)phenyl)-2-alkylthio and -2-alkylsulfonyl-1H-imidazole derivatives.	Assadieskandar A, Amirhamzeh A, Salehi M, Ozadali K, Ostad SN, Shafiee A, Amini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2013	21	9	2551	2559	23517721	10.1016/j.bmc.2013.02.033	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.	Misra S, Ghatak S, Patil N, Dandawate P, Ambike V, Adsule S, Unni D, Venkateswara Swamy K, Padhye S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2013	22	10	4886	4892		10.1007/s00044-013-0500-0	Synthesis of novel pyrazolyl tetrazoles as selective COX-2 inhibitors	Swetha KS, Parameshwar R, Reddy BM, babu VH
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2013	22	3	1378	1385		10.1007/s00044-012-0130-y	Synthesis and pharmacological evaluation of some novel 2-pyrazolines bearing benzenesulfonamide as anti-inflammatory and blood glucose lowering agents	Ovais S, Bashir R, Yaseen S, Rathore P, Samim M, Javed K
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2013	22	4	1529	1537		10.1007/s00044-012-0174-z	Receptor and ligand-based 3D-QSAR study on a series of nonsteroidal anti-inflammatory drugs	Bouaziz-Terrachet S, Terrachet R, Tairi-Kellou S
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2013	22	5	2493	2504		10.1007/s00044-012-0244-2	Computer simulation of the in vitro and in vivo anti-inflammatory activities of dihydropyrimidines acid derivatives through the inhibition of cyclooxygenase-2	Dhankar R, Rahatgaonkar AM, Shukla R, Chorghade M, Tiwari A
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Med Chem Res	2013	22	8	3881	3887		10.1007/s00044-012-0387-1	Synthesis and biologic evaluation of new 3-phenoxyazetidin-2-one derivatives as selective cyclooxygenase-2 inhibitors	Arefi H, Zarghi A
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2013	23	1	163	168	23200247	10.1016/j.bmcl.2012.10.131	Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.	Bhardwaj A, Kaur J, Sharma SK, Huang Z, Wuest F, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2013	23	9	2601	2605	23528298	10.1016/j.bmcl.2013.02.107	Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.	Al-Suwaidan IA, Alanazi AM, El-Azab AS, Al-Obaid AM, ElTahir KE, Maarouf AR, Abu El-Enin MA, Abdel-Aziz AA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2013	23	9	2647	2652	23511020	10.1016/j.bmcl.2013.02.092	Carbonic anhydrase inhibitors: inhibition of the ß-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.	Vullo D, Leewattanapasuk W, Mühlschlegel FA, Mastrolorenzo A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	MedChemComm	2013	4	4	631	652		10.1039/C2MD20317K	Metabolism-guided drug design	Stepan AF, Mascitti V, Beaumont K, Kalgutkar AS
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Drug Metab. Dispos.	2013	41	5	933	951	23454828	10.1124/dmd.112.050278	Which metabolites circulate?	Loi CM, Smith DA, Dalvie D.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2013	56	18	7372	7381	23977960	10.1021/jm400939k	Cloning, characterization, and inhibition studies of a ß-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.	Syrjänen L, Vermelho AB, Rodrigues Ide A, Corte-Real S, Salonen T, Pan P, Vullo D, Parkkila S, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2013	56	21	8377	8388	24088053	10.1021/jm400813y	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.	Végner L, Peragovics Á, Tombor L, Jelinek B, Czobor P, Bender A, Simon Z, Málnási-Csizmadia A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2013	56	22	9031	9044	24171493	10.1021/jm401557w	Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.	Hanke T, Dehm F, Liening S, Popella SD, Maczewsky J, Pillong M, Kunze J, Weinigel C, Barz D, Kaiser A, Wurglics M, Lämmerhofer M, Schneider G, Sautebin L, Schubert-Zsilavecz M, Werz O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2013	56	4	1761	1771	23391336	10.1021/jm4000616	Cloning, characterization, and sulfonamide and thiol inhibition studies of an ¿-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.	Pan P, Vermelho AB, Capaci Rodrigues G, Scozzafava A, Tolvanen ME, Parkkila S, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2013	56	8	3191	3206	23534442	10.1021/jm301370e	Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors.	Anzini M, Di Capua A, Valenti S, Brogi S, Rovini M, Giuliani G, Cappelli A, Vomero S, Chiasserini L, Sega A, Poce G, Giorgi G, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Pace S, Ghelardini C, Di Cesare Mannelli L, Benetti V, Giordani A, Anzellotti P, Dovizio M, Patrignani P, Biava M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2013	62		222	231	23353741	10.1016/j.ejmech.2012.11.021	Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents.	Yao RS, Lu XQ, Guan QX, Zheng L, Lu X, Ruan BF.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2013	65		323	336	23735281	10.1016/j.ejmech.2013.04.062	Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.	Liu GZ, Xu HW, Wang P, Lin ZT, Duan YC, Zheng JX, Liu HM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2013	70		579	588	24211633	10.1016/j.ejmech.2013.10.032	Synthesis of novel 1,2,3-triazole based benzoxazolinones: their TNF-¿ based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation.	Haider S, Alam MS, Hamid H, Shafi S, Nargotra A, Mahajan P, Nazreen S, Kalle AM, Kharbanda C, Ali Y, Alam A, Panda AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2013	76	8	1393	1398	23914900	10.1021/np300899w	Rotenoids from Boerhaavia diffusa as potential anti-inflammatory agents.	Bairwa K, Singh IN, Roy SK, Grover J, Srivastava A, Jachak SM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118		2013							1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	10	2855	2866	24751552	10.1016/j.bmc.2014.03.043	Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.	Palkar MB, Singhai AS, Ronad PM, Vishwanathswamy AH, Boreddy TS, Veerapur VP, Shaikh MS, Rane RA, Karpoormath R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	11	2939	2946	24792813	10.1016/j.bmc.2014.04.006	Sulfonamide inhibition studies of two ß-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.	Nishimori I, Vullo D, Minakuchi T, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	15	4109	4118	24934992	10.1016/j.bmc.2014.05.059	Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.	Yu M, Yang H, Wu K, Ji Y, Ju L, Lu X.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	17	4537	4543	25129169	10.1016/j.bmc.2014.07.048	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the ß-class (PgiCAb) versus the ¿-class (PgiCA) enzymes.	Prete SD, Vullo D, Osman SM, Scozzafava A, AlOthman Z, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	2	772	786	24373735	10.1016/j.bmc.2013.12.008	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.	Biava M, Battilocchio C, Poce G, Alfonso S, Consalvi S, Di Capua A, Calderone V, Martelli A, Testai L, Sautebin L, Rossi A, Ghelardini C, Di Cesare Mannelli L, Giordani A, Persiani S, Colovic M, Dovizio M, Patrignani P, Anzini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	2	865	873	24361187	10.1016/j.bmc.2013.12.002	Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.	Irannejad H, Kebriaieezadeh A, Zarghi A, Montazer-Sadegh F, Shafiee A, Assadieskandar A, Amini M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	21	5804	5812	25311566	10.1016/j.bmc.2014.09.028	Synthesis and evaluation of pyrazolines bearing benzothiazole as anti-inflammatory agents.	Kharbanda C, Alam MS, Hamid H, Javed K, Bano S, Dhulap A, Ali Y, Nazreen S, Haider S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	5	1586	1595	24513184	10.1016/j.bmc.2014.01.031	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.	Sethi KK, Verma SM, Tanç M, Purper G, Calafato G, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	7	2080	2089	24631365	10.1016/j.bmc.2014.02.042	Synthesis and biological evaluation of new pyrazolone-pyridazine conjugates as anti-inflammatory and analgesic agents.	Khalil NA, Ahmed EM, Mohamed KO, Nissan YM, Zaitone SA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2014	22	8	2529	2534	24650702	10.1016/j.bmc.2014.02.032	Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.	Yamakawa N, Suzuki K, Yamashita Y, Katsu T, Hanaya K, Shoji M, Sugai T, Mizushima T.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	1	240	244	24316122	10.1016/j.bmcl.2013.11.030	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.	Vullo D, Del Prete S, Osman SM, De Luca V, Scozzafava A, Alothman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	1	275	279	24314394	10.1016/j.bmcl.2013.11.021	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the diatom Thalassiosira weissflogii.	Vullo D, Del Prete S, Osman SM, De Luca V, Scozzafava A, Alothman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	1	317	324	24295787	10.1016/j.bmcl.2013.11.015	Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.	Ghatak S, Vyas A, Misra S, O'Brien P, Zambre A, Fresco VM, Markwald RR, Swamy KV, Afrasiabi Z, Choudhury A, Khetmalas M, Padhye S.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	1	77	82	24332492	10.1016/j.bmcl.2013.11.080	Rationally designed hybrid molecules with appreciable COX-2 inhibitory and anti-nociceptive activities.	Singh P, Shaveta, Sharma S, Bhatti R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	10	2251	2255	24745964	10.1016/j.bmcl.2014.03.087	Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs.	Yadav P, Singh P, Tewari AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	18	4580	4585	25131536	10.1016/j.bmcl.2014.07.058	Design, synthesis, in silico and in vitro studies of novel 4-methylthiazole-5-carboxylic acid derivatives as potent anti-cancer agents.	Kilaru RB, Valasani KR, Yellapu NK, Osuru HP, Kuruva CS, Matcha B, Chamarthi NR.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	19	4638	4642	25219899	10.1016/j.bmcl.2014.08.050	Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.	Grover J, Kumar V, Sobhia ME, Jachak SM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	21	5015	5021	25304893	10.1016/j.bmcl.2014.09.024	Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: a search for novel nitric oxide donor anti-inflammatory agents.	Abdellatif KR, Moawad A, Knaus EE.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	22	5324	5329	25444084	10.1016/j.bmcl.2014.08.062	Synthesis of novel pyrazole¿thiadiazole hybrid as potential potent and selective cyclooxygenase-2 (COX-2) inhibitors.	Alegaon SG, Hirpara MB, Alagawadi KR, Hullatti KK, Kashniyal K.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	8	1895	1900	24679441	10.1016/j.bmcl.2014.03.014	Anti-inflammatory components of Euphorbia humifusa Willd.	Luyen BT, Tai BH, Thao NP, Eun KJ, Cha JY, Xin MJ, Lee YM, Kim YH.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	8	1952	1957	24661847	10.1016/j.bmcl.2014.02.073	Synthesis of thio-heterocyclic analogues from Baylis-Hillman bromides as potent cyclooxygenase-2 inhibitors.	Santhoshi A, Mahendar B, Mattapally S, Sadhu PS, Banerjee SK, Jayathirtha Rao V.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2014	24	8	1958	1962	24656662	10.1016/j.bmcl.2014.02.074	Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.	Kim KJ, Choi MJ, Shin JS, Kim M, Choi HE, Kang SM, Jin JH, Lee KT, Lee JY.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	ACS Med. Chem. Lett.	2014	5	10	1162	1166	25313331	10.1021/ml500299q	Synthesis of Deuterated Benzopyran Derivatives as Selective COX-2 Inhibitors with Improved Pharmacokinetic Properties.	Zhang Y, Tortorella MD, Wang Y, Liu J, Tu Z, Liu X, Bai Y, Wen D, Lu X, Lu Y, Talley JJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	ACS Med. Chem. Lett.	2014	5	5	512	516	24900871	10.1021/ml400500e	2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation.	Seth K, Garg SK, Kumar R, Purohit P, Meena VS, Goyal R, Banerjee UC, Chakraborti AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	ACS Med. Chem. Lett.	2014	5	9	983	988	25221653	10.1021/ml500156v	Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.	Radwan MF, Dalby KN, Kaoud TS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	71		105	111	24287559	10.1016/j.ejmech.2013.10.071	Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.	De Luca L, Ferro S, Damiano FM, Supuran CT, Vullo D, Chimirri A, Gitto R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	73		233	242	24412499	10.1016/j.ejmech.2013.10.083	3D QSAR studies based in silico screening of 4,5,6-triphenyl-1,2,3,4-tetrahydropyrimidine analogs for anti-inflammatory activity.	Lokwani DK, Mokale SN, Shinde DB.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	74		12	22	24440378	10.1016/j.ejmech.2013.12.033	N-(3-Arylaminopyridin-4-yl)alkanesulfonamides as pyridine analogs of nimesulide: cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism.	Renard JF, Lecomte F, Hubert P, de Leval X, Pirotte B.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	74		606	618	24531199	10.1016/j.ejmech.2013.12.023	Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.	Vitale P, Perrone MG, Malerba P, Lavecchia A, Scilimati A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	76		482	493	24607877	10.1016/j.ejmech.2014.02.033	Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents.	Hassan GS, Abou-Seri SM, Kamel G, Ali MM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	76		494	505	24602792	10.1016/j.ejmech.2014.01.030	Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents.	Gaba M, Singh S, Mohan C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2014	77	4	917	924	24689881	10.1021/np4009877	Suppression of inflammatory responses by handelin, a guaianolide dimer from Chrysanthemum boreale, via downregulation of NF-¿B signaling and pro-inflammatory cytokine production.	Pyee Y, Chung HJ, Choi TJ, Park HJ, Hong JY, Kim JS, Kang SS, Lee SK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2014	77	6	1445	1451	24844534	10.1021/np500198g	Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.	Verhoff M, Seitz S, Paul M, Noha SM, Jauch J, Schuster D, Werz O.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	77		155	165	24631895	10.1016/j.ejmech.2014.03.001	1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.	Abdel-Aziz M, Beshr EA, Abdel-Rahman IM, Ozadali K, Tan OU, Aly OM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	77		185	192	24631898	10.1016/j.ejmech.2014.03.003	Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.	Shaveta, Singh A, Kaur M, Sharma S, Bhatti R, Singh P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	80		167	174	24780593	10.1016/j.ejmech.2014.04.045	Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.	Bansal S, Bala M, Suthar SK, Choudhary S, Bhattacharya S, Bhardwaj V, Singla S, Joseph A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	80		416	422	24794773	10.1016/j.ejmech.2014.04.065	Synthesis of N-benzenesulfonamide-1H-pyrazoles bearing arylsulfonyl moiety: novel celecoxib analogs as potent anti-inflammatory agents.	Abdel-Aziz HA, Al-Rashood KA, ElTahir KE, Suddek GM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	80		47	56	24763362	10.1016/j.ejmech.2014.04.033	Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.	Grover J, Kumar V, Singh V, Bairwa K, Sobhia ME, Jachak SM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	81		204	217	24836072	10.1016/j.ejmech.2014.05.012	Synthesis of novel 2-mercaptobenzoxazole based 1,2,3-triazoles as inhibitors of proinflammatory cytokines and suppressors of COX-2 gene expression.	Haider S, Alam MS, Hamid H, Shafi S, Dhulap A, Hussain F, Alam P, Umar S, Pasha MA, Bano S, Nazreen S, Ali Y, Kharbanda C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	81		492	498	24871899	10.1016/j.ejmech.2014.05.033	Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.	Peduto A, Bruno F, Dehm F, Krauth V, de Caprariis P, Weinigel C, Barz D, Massa A, De Rosa M, Werz O, Filosa R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	83		398	408	24983538	10.1016/j.ejmech.2014.06.049	Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies.	Abuo-Rahma Gel-D, Abdel-Aziz M, Farag NA, Kaoud TS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	84		160	172	25016374	10.1016/j.ejmech.2014.07.023	Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core.	Sarnpitak P, Mujumdar P, Morisseau C, Hwang SH, Hammock B, Iurchenko V, Zozulya S, Gavalas A, Geronikaki A, Ivanenkov Y, Krasavin M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	86		122	132	25147154	10.1016/j.ejmech.2014.08.048	Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity.	Galal SA, Khairat SH, Ragab FA, Abdelsamie AS, Ali MM, Soliman SM, Mortier J, Wolber G, El Diwani HI.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2014	87		868	880	24576797	10.1016/j.ejmech.2014.01.063	Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents.	Temirak A, Shaker YM, Ragab FA, Ali MM, Ali HI, El Diwani HI.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118		2014							Anti-infective agents against intracellular pathogens	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2015	102		143	152	26263246	10.1016/j.ejmech.2015.07.036	Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice.	Lobo MM, Oliveira SM, Brusco I, Machado P, Timmers LF, de Souza ON, Martins MA, Bonacorso HG, Dos Santos JM, Canova B, da Silva TV, Zanatta N.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	10	2303	2309	25882523	10.1016/j.bmc.2015.03.081	The ß-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.	Syrjänen L, Kuuslahti M, Tolvanen M, Vullo D, Parkkila S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	17	5273	5281	26277757	10.1016/j.bmc.2015.07.070	Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents.	Firke SD, Bari SB.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	21	6807	6814	26455657	10.1016/j.bmc.2015.10.007	Isomeric methoxy analogs of nimesulide for development of brain cyclooxygense-2 (COX-2)-targeted imaging agents: Synthesis, in vitro COX-2-inhibitory potency, and cellular transport properties.	Yamamoto Y, Hisa T, Arai J, Saito Y, Yamamoto F, Mukai T, Ohshima T, Maeda M, Ohkubo Y.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	3	526	531	25533402	10.1016/j.bmc.2014.12.009	Sulfonamide inhibition studies of the ¿-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.	Vullo D, Del Prete S, Fisher GM, Andrews KT, Poulsen SA, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	4	810	820	25596758	10.1016/j.bmc.2014.12.041	Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors.	Consalvi S, Alfonso S, Di Capua A, Poce G, Pirolli A, Sabatino M, Ragno R, Anzini M, Sartini S, La Motta C, Di Cesare Mannelli L, Ghelardini C, Biava M.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	8	1728	1734	25773015	10.1016/j.bmc.2015.02.045	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2015	23	8	1828	1840	25766630	10.1016/j.bmc.2015.02.027	A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects.	Carta F, Di Cesare Mannelli L, Pinard M, Ghelardini C, Scozzafava A, McKenna R, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	11	2291	2297	25913199	10.1016/j.bmcl.2015.04.037	Sulfonamide inhibition study of the ß-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.	Dedeoglu N, DeLuca V, Isik S, Yildirim H, Kockar F, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	12	2469	2472	25980909	10.1016/j.bmcl.2015.04.085	Compounds from the insect Blaps japanensis with COX-1 and COX-2 inhibitory activities.	Yan YM, Li LJ, Qin XC, Lu Q, Tu ZC, Cheng YX.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	16	3295	3300	26081289	10.1016/j.bmcl.2015.05.059	Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors.	Bechmann N, Kniess T, Köckerling M, Pigorsch A, Steinbach J, Pietzsch J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	17	3550	3555	26174556	10.1016/j.bmcl.2015.06.079	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	19	4082	4084	26316467	10.1016/j.bmcl.2015.08.034	Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L.	Wang JF, He WJ, Zhang XX, Zhao BQ, Liu YH, Zhou XJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	20	4664	4671	26346367	10.1016/j.bmcl.2015.08.026	Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.	Yan XQ, Wang ZC, Li Z, Wang PF, Qiu HY, Chen LW, Lu XY, Lv PC, Zhu HL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	23	5485	5489	26525863	10.1016/j.bmcl.2015.10.074	Anion and sulfonamide inhibition studies of an ¿-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.	Cincinelli A, Martellini T, Vullo D, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	24	5787	5791	26546221	10.1016/j.bmcl.2015.10.047	Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of novel triarylpyrazoline derivatives as selective COX-2 inhibitors.	Abdellatif KR, Abdelgawad MA, Labib MB, Zidan TH.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	7	1630	1634	25708616	10.1016/j.bmcl.2015.01.041	Environmentally benign synthesis, molecular properties prediction and anti-inflammatory activity of novel isoxazolo[5,4-d]isoxazol-3-yl-aryl-methanones via vinylogous Henry nitroaldol adducts as synthons.	Rajanarendar E, Rama Krishna S, Nagaraju D, Govardhan Reddy K, Kishore B, Reddy YN.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	9	1947	1951	25866240	10.1016/j.bmcl.2015.03.022	Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.	Chen Z, Wang ZC, Yan XQ, Wang PF, Lu XY, Chen LW, Zhu HL, Zhang HW.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2015	25	9	1986	1989	25819096	10.1016/j.bmcl.2015.03.017	Five new phorbol esters with cytotoxic and selective anti-inflammatory activities from Croton tiglium.	Wang JF, Yang SH, Liu YQ, Li DX, He WJ, Zhang XX, Liu YH, Zhou XJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2015	58	9	3859	3874	25850459	10.1021/acs.jmedchem.5b00132	Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).	Parsons WH, Calvo RR, Cheung W, Lee YK, Patel S, Liu J, Youngman MA, Dax SL, Stone D, Qin N, Hutchinson T, Lubin ML, Zhang SP, Finley M, Liu Y, Brandt MR, Flores CM, Player MR.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	MedChemComm	2015	6	12	2081	2123		10.1039/C5MD00278H	Targeting microsomal prostaglandin E2synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs)	Chen Y, Liu H, Xu S, Wang T, Li W
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	MedChemComm	2015	6	8	1494	1500		10.1039/C5MD00171D	Synthesis of novel 1-substituted triazole linked 1,2-benzothiazine 1,1-dioxido propenone derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage differentiation	Gannarapu MR, Vasamsetti SB, Punna N, Kotamraju S, Banda N
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Nat. Prod.	2015	78	10	2332	2338	26444098	10.1021/acs.jnatprod.5b00135	Anti-inflammatory Inositol Derivatives from the Whole Plant of Inula cappa.	Wu J, Tang C, Yao S, Zhang L, Ke C, Feng L, Lin G, Ye Y.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2015	92		115	123	25549551	10.1016/j.ejmech.2014.12.039	Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.	Alanazi AM, El-Azab AS, Al-Suwaidan IA, ElTahir KE, Asiri YA, Abdel-Aziz NI, Abdel-Aziz AA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2015	97		104	123	25956953	10.1016/j.ejmech.2015.04.044	Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.	Singh P, Prasher P, Dhillon P, Bhatti R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2016	108		89	103	26638042	10.1016/j.ejmech.2015.11.013	Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.	Cai H, Huang X, Xu S, Shen H, Zhang P, Huang Y, Jiang J, Sun Y, Jiang B, Wu X, Yao H, Xu J.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2016	115		121	131	26999325	10.1016/j.ejmech.2016.03.011	Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies.	Abdel-Aziz AA, El-Azab AS, Abou-Zeid LA, ElTahir KE, Abdel-Aziz NI, Ayyad RR, Al-Obaid AM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur. J. Med. Chem.	2016	118		250	258	27131067	10.1016/j.ejmech.2016.04.049	Synthesis of new thiazolo-celecoxib analogues as dual cyclooxygenase-2/15-lipoxygenase inhibitors: Determination of regio-specific different pyrazole cyclization by 2D NMR.	Abdelall EK, Kamel GM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2016	24	16	3818	3828	27344214	10.1016/j.bmc.2016.06.026	Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies.	Abdel-Aziz AA, Abou-Zeid LA, ElTahir KE, Mohamed MA, Abu El-Enin MA, El-Azab AS.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2016	24	5	1115	1120	26850377	10.1016/j.bmc.2016.01.037	Sulfonamide inhibition studies of the ß-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Vullo D, De Luca V, Carginale V, Ferraroni M, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem.	2016	24	9	2032	2042	27025563	10.1016/j.bmc.2016.03.032	Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives.	Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, Abdel-Aziz NI, ElTahir KE, Shehatou GS, Abdel-Aziz AA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	15	3491	3498	27349331	10.1016/j.bmcl.2016.06.037	Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis.	Lu XY, Wang ZC, Ren SZ, Shen FQ, Man RJ, Zhu HL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2016	26	19	4824	4828	27554445	10.1016/j.bmcl.2016.08.023	Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors.	Kuklish SL, Antonysamy S, Bhattachar SN, Chandrasekhar S, Fisher MJ, Fretland AJ, Gooding K, Harvey A, Hughes NE, Luz JG, Manninen PR, McGee JE, Navarro A, Norman BH, Partridge KM, Quimby SJ, Schiffler MA, Sloan AV, Warshawsky AM, York JS, Yu XP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	2	401	405	26691758	10.1016/j.bmcl.2015.11.104	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.	Vullo D, Bhatt A, Mahon BP, McKenna R, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	2	406	412	26691756	10.1016/j.bmcl.2015.11.105	Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,3,5-triarylpyrazoline and 1,5-diarylpyrazole derivatives as selective COX-2 inhibitors.	Abdellatif KR, Abdelall EK, Fadaly WA, Kamel GM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2016	26	21	5218	5221	27712938	10.1016/j.bmcl.2016.09.060	Synthesis and anti-inflammatory activity of paeonol analogues in the murine model of complete Freund's adjuvant induced arthritis.	Huang L, Zhang B, Yang Y, Gong X, Chen Z, Wang Z, Zhang P, Zhang Q.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2016	26	21	5334	5339	27680589	10.1016/j.bmcl.2016.09.034	Anti-inflammatory activity effect of 2-substituted-1,4,5,6-tetrahydrocyclopenta[b]pyrrole on TPA-induced skin inflammation in mice.	Xu XT, Mou XQ, Xi QM, Liu WT, Liu WF, Sheng ZJ, Zheng X, Zhang K, Du ZY, Zhao SQ, Wang SH.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	3	814	818	26764192	10.1016/j.bmcl.2015.12.088	Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives.	Undare SS, Valekar NJ, Patravale AA, Jamale DK, Vibhute SS, Walekar LS, Kolekar GB, Deshmukh MB, Anbhule PV.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	4	1253	1259	26832216	10.1016/j.bmcl.2016.01.023	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Osman SM, AlOthman Z, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	6	1516	1520	26898334	10.1016/j.bmcl.2016.02.029	Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.	Tietz O, Dzandzi J, Bhardwaj A, Valliant JF, Wuest F.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	7	1821	1826	26920803	10.1016/j.bmcl.2016.02.032	Sulfonamide inhibition studies of the ß-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.	Emino¿lu A, Vullo D, A¿¿k A, Çolak DN, Çanakç¿ S, Beldüz AO, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg. Med. Chem. Lett.	2016	26	8	1941	1946	26972117	10.1016/j.bmcl.2016.03.014	Comparison of the sulfonamide inhibition profiles of the ¿-, ß- and ¿-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Vullo D, De Luca V, Carginale V, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2016	59	1	194	205	26653180	10.1021/acs.jmedchem.5b01249	Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors.	Schiffler MA, Antonysamy S, Bhattachar SN, Campanale KM, Chandrasekhar S, Condon B, Desai PV, Fisher MJ, Groshong C, Harvey A, Hickey MJ, Hughes NE, Jones SA, Kim EJ, Kuklish SL, Luz JG, Norman BH, Rathmell RE, Rizzo JR, Seng TW, Thibodeaux SJ, Woods TA, York JS, Yu XP.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J. Med. Chem.	2016	59	8	3920	3934	27019010	10.1021/acs.jmedchem.6b00134	Rational Design of Small Peptides for Optimal Inhibition of Cyclooxygenase-2: Development of a Highly Effective Anti-Inflammatory Agent.	Singh P, Kaur S, Kaur J, Singh G, Bhatti R.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118		2016							Derivatives of celeboxib, use thereof and preparation thereof	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur J Med Chem	2017	126		464	475	27914361	10.1016/j.ejmech.2016.11.026	Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.	Bai R, Shi Q, Liang Z, Yoon Y, Han Y, Feng A, Liu S, Oum Y, Yun CC, Shim H.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur J Med Chem	2017	127		10	21	28038322	10.1016/j.ejmech.2016.12.030	Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC.	Elshemy HAH, Abdelall EKA, Azouz AA, Moawad A, Ali WAM, Safwat NM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Eur J Med Chem	2017	127		972	985	27837994	10.1016/j.ejmech.2016.11.006	Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity.	Abdelrahman MH, Youssif BGM, Abdelgawad MA, Abdelazeem AH, Ibrahim HM, Moustafa AEGA, Treamblu L, Bukhari SNA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	13	3555	3561	28511911	10.1016/j.bmc.2017.05.007	Sulfonamide inhibition profiles of the ß-carbonic anhydrase from the pathogenic bacterium Francisella tularensis responsible of the febrile illness tularemia.	Del Prete S, Vullo D, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	16	4424	4432	28669741	10.1016/j.bmc.2017.06.027	Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.	Shrivastava SK, Srivastava P, Bandresh R, Tripathi PN, Tripathi A.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	17	4887	4893	28757100	10.1016/j.bmc.2017.07.038	Design, synthesis and bioactivities of Celecoxib analogues or derivatives.	Zhou S, Yang S, Huang G.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	2	665	676	27916468	10.1016/j.bmc.2016.11.037	Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.	Abdelazeem AH, El-Saadi MT, Safi El-Din AG, Omar HA, El-Moghazy SM.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	20	5637	5651	28916158	10.1016/j.bmc.2017.08.039	Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.	Gouda AM, Abdelazeem AH, Omar HA, Abdalla AN, Abourehab MAS, Ali HI.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	3	1202	1218	28057407	10.1016/j.bmc.2016.12.032	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.	Raji I, Yadudu F, Janeira E, Fathi S, Szymczak L, Kornacki JR, Komatsu K, Li JD, Mrksich M, Oyelere AK.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem	2017	25	7	2210	2217	28256371	10.1016/j.bmc.2017.02.037	Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects.	Fares M, Eladwy RA, Nocentini A, El Hadi SRA, Ghabbour HA, Abdel-Megeed A, Eldehna WM, Abdel-Aziz HA, Supuran CT.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	11	2377	2383	28427813	10.1016/j.bmcl.2017.04.020	Novel pyrazoles and pyrazolo[1,2-a]pyridazines as selective COX-2 inhibitors; Ultrasound-assisted synthesis, biological evaluation, and DFT calculations.	Ghareb N, Elshihawy HA, Abdel-Daim MM, Helal MA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	15	3378	3381	28610982	10.1016/j.bmcl.2017.06.002	Synthesis, potential anti-inflammatory and analgesic activities study of (S)-N-substituted-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxamides.	Guan LP, Xia YN, Jin QH, Liu BY, Wang SH.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	16	3653	3660	28720504	10.1016/j.bmcl.2017.07.020	Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.	Shen FQ, Wang ZC, Wu SY, Ren SZ, Man RJ, Wang BZ, Zhu HL.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	18	4358	4369	28844389	10.1016/j.bmcl.2017.08.023	Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids.	Abdelall EKA, Abdelhamid AO, Azouz AA.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	3	490	495	28025002	10.1016/j.bmcl.2016.12.035	Sulfonamide inhibition profile of the ¿-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.	Del Prete S, Vullo D, Di Fonzo P, Osman SM, AlOthman Z, Donald WA, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	3	602	606	28011213	10.1016/j.bmcl.2016.12.008	Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents.	Li J, Li D, Xu Y, Guo Z, Liu X, Yang H, Wu L, Wang L.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	3	620	625	28025003	10.1016/j.bmcl.2016.12.002	Chemical synthesis and biological evaluation of ¿-hydroxy polyunsaturated fatty acids.	Hwang SH, Wagner K, Xu J, Yang J, Li X, Cao Z, Morisseau C, Lee KS, Hammock BD.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	4	1017	1025	28089698	10.1016/j.bmcl.2016.12.069	Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening.	Ali Y, Alam MS, Hamid H, Husain A, Dhulap A, Bano S, Kharbanda C.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	Bioorg Med Chem Lett	2017	27	8	1721	1726	28284805	10.1016/j.bmcl.2017.02.076	Novel 2-phenyl-4,5,6,7-tetrahydro[b]benzothiophene analogues as selective COX-2 inhibitors: Design, synthesis, anti-inflammatory evaluation, and molecular docking studies.	Khatri CK, Indalkar KS, Patil CR, Goyal SN, Chaturbhuj GU.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J Med Chem	2017	60	10	4135	4146	28475316	10.1021/acs.jmedchem.6b01484	Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation.	Zhang Y, Wang Y, He C, Liu X, Lu Y, Chen T, Pan Q, Xiong J, She M, Tu Z, Qin X, Li M, Tortorella MD, Talley JJ.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118	J Med Chem	2017	60	15	6563	6586	28671460	10.1021/acs.jmedchem.7b00285	Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.	Soubhye J, Chikh Alard I, Aldib I, Prévost M, Gelbcke M, De Carvalho A, Furtmüller PG, Obinger C, Flemmig J, Tadrent S, Meyer F, Rousseau A, Nève J, Mathieu V, Zouaoui Boudjeltia K, Dufrasne F, Van Antwerpen P.
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									Drug metabolism data	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									IC50 data for the L-type calcium channel extracted from a set of literature articles	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	CELECOXIB	CHEMBL118									WHO Anatomical Therapeutic Chemical Classification	
1384.4000000000000000	9606	Homo sapiens	CEP-1347	CHEMBL290352	Bioorg. Med. Chem. Lett.	2002	12	2	147	150	11755341	10.1016/s0960-894x(01)00690-4	Mixed lineage kinase activity of indolocarbazole analogues.	Murakata C, Kaneko M, Gessner G, Angeles TS, Ator MA, O'Kane TM, McKenna BA, Thomas BA, Mathiasen JR, Saporito MS, Bozyczko-Coyne D, Hudkins RL.
1384.4000000000000000	9606	Homo sapiens	CEP-1347	CHEMBL290352	J. Med. Chem.	2008	51	18	5680	5689	18714982	10.1021/jm8005838	Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.	Hudkins RL, Diebold JL, Tao M, Josef KA, Park CH, Angeles TS, Aimone LD, Husten J, Ator MA, Meyer SL, Holskin BP, Durkin JT, Fedorov AA, Fedorov EV, Almo SC, Mathiasen JR, Bozyczko-Coyne D, Saporito MS, Scott RW, Mallamo JP.
1384.4000000000000000	9606	Homo sapiens	CEP-1347	CHEMBL290352	J. Med. Chem.	2013	56	20	8032	8048	24044867	10.1021/jm401094t	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.	Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA.
1384.4000000000000000	9606	Homo sapiens	CEP-1347	CHEMBL290352									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHALEXIN	CHEMBL1200544	J. Med. Chem.	1977	20	7	963	965	874972	10.1021/jm00217a022	Cephalosporin degradations.	Dinner A.
962.7500000000000000	2	Bacteria	CEPHALEXIN	CHEMBL1200544	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEPHALEXIN	CHEMBL1200544									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEPHALEXIN	CHEMBL1200544									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHALEXIN	CHEMBL1200544									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHALEXIN HYDROCHLORIDE	CHEMBL1200366									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHALEXIN HYDROCHLORIDE	CHEMBL1200366									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971	J. Med. Chem.	1977	20	8	1086	1090	894680	10.1021/jm00218a019	Structure--activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group.	Brain EG, Eglington AJ, James BG, Nayler JH, Osborne NF, Pearson MJ, Smale TC, Southgate R, Tolliday P, Basker MJ, Mizen LW, Sutherland R.
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971	J. Med. Chem.	1977	20	9	1164	1169	411932	10.1021/jm00219a010	Synthesis and biological activity of some broad-spectrum N-acylphenyglycine cephalosporins.	DeMarinis RM, Boehm JC, Uri JV, Guarini JR, Phillips L, Dunn GL.
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971	J. Med. Chem.	1983	26	11	1648	1650	6631918	10.1021/jm00365a019	Synthesis and antibacterial activities of new (alpha-hydrazinobenzyl)cephalosporins.	Balsamo A, Macchia B, Macchia F, Rossello A, Giani R, Pifferi G, Pinza M, Broccali G.
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971	J. Pharmacol. Exp. Ther.	1999	291	1	778	784	10525100		Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.	Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A.
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHALOGLYCIN	CHEMBL1200971									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	J. Med. Chem.	1977	20	12	1665	1668	592331	10.1021/jm00222a025	3-(3-Substituted prop-1-enyl)cephalosporins.	Beeby PJ, Edwards JA.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	Bioorg. Med. Chem. Lett.	2009	19	6	1618	1622	19243936	10.1016/j.bmcl.2009.02.018	Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.	Ganta SR, Perumal S, Pagadala SR, Samuelsen O, Spencer J, Pratt RF, Buynak JD.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHALOTHIN SODIUM	CHEMBL1632									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHAPIRIN SODIUM	CHEMBL1201043									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Pharmacol. Exp. Ther.	1995	275	1	1631	1637	8531138		Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.	Saito H, Okuda M, Terada T, Sasaki S, Inui K.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Pharmacol. Exp. Ther.	1997	281	1	1415	1421	9190878		Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Pharm. Res.	1998	15	1	1154	1159	9706043	10.1023/a:1011919319810	5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.	Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Pharm. Sci	1999	88	1	347	350	10052994	10.1021/js980132e	CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.	Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Anal. Biochem.	2000	283	1	49	55	10929807	10.1006/abio.2000.4633	Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.	Cihlar T, Ho ES.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Antimicrob. Agents Chemother.	2009	53	2	435	441	19015345	10.1128/aac.01099-08	Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.	Antignac A, Tomasz A.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Antimicrob. Agents Chemother.	2010	54	10	4416	4423	20643901	10.1128/aac.00503-10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.	Collins B, Curtis N, Cotter PD, Hill C, Ross RP.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Eur. J. Med. Chem.	2011	46	9	3639	3650	21641699	10.1016/j.ejmech.2011.05.028	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.	Zhang W, Liu W, Jiang X, Jiang F, Zhuang H, Fu L.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Bioorg. Med. Chem.	2012	20	22	6669	6679	23062825	10.1016/j.bmc.2012.09.040	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.	Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C, Vuorela P.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Drug Metab. Dispos.	2012	40	3	515	521	22166395	10.1124/dmd.111.041731	Oral availability of cefadroxil depends on ABCC3 and ABCC4.	de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Eur. J. Med. Chem.	2012	54		879	886	22673144	10.1016/j.ejmech.2012.05.013	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.	Liu J, Jiang F, Jiang X, Zhang W, Liu J, Liu W, Fu L.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604	Eur J Med Chem	2017	126		7	14	27744188	10.1016/j.ejmech.2016.10.010	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.	Zhang W, Liu J, Macho JM, Jiang X, Xie D, Jiang F, Liu W, Fu L.
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604									Unpublished dataset	
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	CEPHRADINE	CHEMBL1604									WHO Anatomical Therapeutic Chemical Classification	
998.6000000000000000	9606	Homo sapiens	CER-002	CHEMBL3544958									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1977	20	4	557	560	557559	10.1021/jm00214a019	Nitrones. 7. alpha-Quinoxalinyl-N-substituted nitrone 1,4-dioxides.	Kim HK, Miller LF, Bambury RE, Ritter HW.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1980	23	12	1299	1305	7005448	10.1021/jm00186a004	Analogues of chloramphenicol: circular dichroism spectra, inhibition of ribosomal peptidyltransferase, and possible mechanism of action.	Bhuta P, Chung HL, Hwang JS, Zemlicka J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1981	24	11	1314	1319	7310807	10.1021/jm00143a011	Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2,5-cyclohexadienes.	Johnson RE, Soria AE, O'Connor JR, Dobson RA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1984	47	5	815	818	6512534	10.1021/np50035a010	Antibacterial constituents of the diatom Navicula delognei.	Findlay JA, Patil AD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1986	29	10	2060	2068	3093682	10.1021/jm00160a045	Chloroalanyl antibiotic peptides: antagonism of their antimicrobial effects by L-alanine and L-alanyl peptides in gram-negative bacteria.	Cheung KS, Boisvert W, Lerner SA, Johnston M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1987	30	2	333	340	3543366	10.1021/jm00385a015	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.	Allen NE, Alborn WE, Kirst HA, Toth JE.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1987	50	1	19	22	3110376	10.1021/np50049a003	A direct bioautographic tlc assay for compounds possessing antibacterial activity.	Hamburger MO, Cordell GA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1988	51	1	152	154	3373224	10.1021/np50055a025	Isolation of deoxyshikonin, an antidermatophytic principle from Lithospermum erythrorhizon cell cultures.	Honda G, Sakakibara F, Yazaki K, Tabata M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	1991	1	5	253	256		10.1016/S0960-894X(01)81037-4	Chloramphenicol: High dilution FT-IR evidence for an intramolecular hydrogen bond	Fitzhugh AL
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1991	54	3	856	859	1955885	10.1021/np50075a017	Isolation and characterization of two antimicrobial agents from mace (Myristica fragrans).	Orabi KY, Mossa JS, el-Feraly FS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1991	54	4	1068	1076	1791472	10.1021/np50076a023	New cytotoxic beta-carboline alkaloids from the marine bryozoan, Cribricellina cribraria.	Prinsep MR, Blunt JW, Munro MH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1992	55	9	1165	1169	1431939	10.1021/np50087a001	A new acylated N-glycosyl lactam from Aristolochia contorta.	Lee HS, Han DS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1993	36	23	3542	3545	8246222	10.1021/jm00075a008	Aminoacyl analogs of chloramphenicol: examination of the kinetics of inhibition of peptide bond formation.	Drainas D, Mamos P, Coutsogeorgopoulos C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1993	36	9	1239	1244	8487260	10.1021/jm00061a015	Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.	Zemlicka J, Fernandez-Moyano MC, Ariatti M, Zurenko GE, Grady JE, Ballesta JP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1993	56	9	1444	1450	8254344	10.1021/np50099a002	An antifungal bibenzyl from the New Zealand liverwort, Plagiochila stephensoniana. Bioactivity-directed isolation, synthesis, and analysis.	Lorimer SD, Perry NB, Tangney RS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1994	57	1	18	26	8158163	10.1021/np50103a003	Cytotoxic and antibacterial dihydrochalcones from Piper aduncum.	Orjala J, Wright AD, Behrends H, Folkers G, Sticher O, Rüegger H, Rali T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1994	57	9	1245	1250	7798959	10.1021/np50111a009	Antibacterial triterpenoid acids from Dillenia papuana.	Nick A, Wright AD, Sticher O, Rali T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1996	59	9	850	853	8864238	10.1021/np960397d	New macrocyclic spermine (budmunchiamine) alkaloids from Albizia gummifera: with some observations on the structure--activity relationships of the budmunchiamines.	Rukunga GM, Waterman PG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	1998	41	7	1007	1010	9544199	10.1021/jm970530e	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.	Kansy M, Senner F, Gubernator K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1998	61	7	939	941	9677279	10.1021/np970529i	Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.	Orjala J, Mian P, Rali T, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	1998	8	21	3007	3010	9873665	10.1016/s0960-894x(98)00536-8	Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.	Sol V, Branland P, Granet R, Kaldapa C, Verneuil B, Krausz P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	1998	8	8	945	950	9871517	10.1016/s0960-894x(98)00149-8	Peptide inhibitors of N-succinyl diaminopimelic acid aminotransferase (DAP-AT): a novel class of antimicrobial compounds.	Cox RJ, Schouten JA, Stentiford RA, Wareing KJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Pharmacol. Exp. Ther.	1999	290	1	672	677	10411577		The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.	Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1999	62	1	70	75	9917285	10.1021/np980179f	Acylated flavonol glycosides from leaves of Stenochlaena palustris.	Liu H, Orjala J, Sticher O, Rali T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1999	62	11	1479	1483	10579856	10.1021/np990044p	Novel highly oxygenated bisabolane sesquiterpenes from Cremanthodium discoideum.	Zhu Y, Yang L, Jia ZJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	1999	62	3	502	503	10096870	10.1021/np980444x	A novel extracellular diterpenoid with antibacterial activity from the cyanobacterium Nostoc commune.	Jaki B, Orjala J, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2000	10	11	1155	1158	10866370	10.1016/s0960-894x(00)00172-4	Prediction of drug solubility from Monte Carlo simulations.	Jorgensen WL, Duffy EM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2000	10	17	2033	2036	10987443	10.1016/s0960-894x(00)00406-6	Molecular topology: a useful tool for the search of new antibacterials.	de Gregorio Alapont C, García-Domenech R, Gálvez J, Ros MJ, Wolski S, García MD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2000	43	15	2922	2928	10956200	10.1021/jm0000822	ElogPoct: a tool for lipophilicity determination in drug discovery.	Lombardo F, Shalaeva MY, Tupper KA, Gao F, Abraham MH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2000	63	1	104	108	10650088	10.1021/np990417m	New phloroglucinol derivatives from Hypericum papuanum.	Winkelmann K, Heilmann J, Zerbe O, Rali T, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2000	63	3	339	343	10757714	10.1021/np9903090	Novel extracellular diterpenoids with biological activity from the cyanobacterium Nostoc commune.	Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2000	63	7	902	904	10924162	10.1021/np990438g	New caryophyllene derivatives from Betula litwinowii.	Demirci B, Ba¿er KH, Demirci F, Hamann MT.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2000	63	9	1283	1285	11000038	10.1021/np000033s	New antibacterial metabolites from the cyanobacterium Nostoc commune(EAWAG 122b).	Jaki B, Heilmann J, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2001	44	15	2490	2497	11448232	10.1021/jm0100990	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.	Lombardo F, Shalaeva MY, Tupper KA, Gao F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2001	64	6	701	706	11421727	10.1021/np0006364	New prenylated bi- and tricyclic phloroglucinol derivatives from Hypericum papuanum.	Winkelmann K, Heilmann J, Zerbe O, Rali T, Sticher O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2001	64	7	911	914	11473422	10.1021/np010076o	Biological and mechanistic activities of xanthorrizol and 4-(1',5'-dimethylhex-4'-enyl)-2-methylphenol isolated from Iostephane heterophylla.	Mata R, Martínez E, Bye R, Morales G, Singh MP, Janso JE, Maiese WM, Timmermann B.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2002	45	13	2867	2876	12061889	10.1021/jm0200409	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2002	65	12	1857	1862	12502328	10.1021/np010599w	Antimicrobial activities of naphthazarins from Arnebia euchroma.	Shen CC, Syu WJ, Li SY, Lin CH, Lee GH, Sun CM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2002	65	5	714	717	12027747	10.1021/np010535l	New eremophilenolides from Ligulariopsis shichuana.	Wang W, Gao K, Jia Z.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2002	65	7	960	964	12141853	10.1021/np020064i	Isolation of S-n-butylcysteine sulfoxide and six n-butyl-containing thiosulfinates from Allium siculum.	Kubec R, Kim S, McKeon DM, Musah RA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2002	65	8	1107	1110	12193012	10.1021/np0201523	New furanoid diterpenes from Caesalpinia pulcherrima.	Ragasa CY, Hofileña JG, Rideout JA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Pesticide Sci	2003	28	2	183	187		10.1584/jpestics.28.183	Effect of Antibiotics on Formation of Aerial Mycelium and Production of Phytotoxins in Streptomyces spp.	NATSUME M, MATSUMOTO M, OHSHIRO A, KOZONE I, HASHIMOTO M, ABE H
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2003	66	2	242	246	12608857	10.1021/np020380x	Antibacterial diterpenes from Calceolaria pinifolia.	Woldemichael GM, Wächter G, Singh MP, Maiese WM, Timmermann BN.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2003	66	9	1175	1180	14510592	10.1021/np030147e	Cytotoxic sesquiterpene lactones from the root of Saussurea lappa.	Sun CM, Syu WJ, Don MJ, Lu JJ, Lee GH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2004	14	10	2627	2631	15109666	10.1016/j.bmcl.2004.02.068	Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.	Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Tawara S, Takasugi H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2004	14	23	5831	5833	15501050	10.1016/j.bmcl.2004.09.038	Screening of antimicrobial activity of diarylamines in the 2,3,5-trimethylbenzo[b]thiophene series: a structure-activity evaluation study.	Ferreira IC, Calhelha RC, Estevinho LM, Queiroz MJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2004	14	3	653	656	14741262	10.1016/j.bmcl.2003.11.044	Synthesis and antifungal activities of phenylenedithioureas.	Phuong T, Khac-Minh T, Van Ha NT, Ngoc Phuong HT.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2004	67	10	1732	1735	15497951	10.1021/np040114e	A novel antimicrobial indolizinium alkaloid from Aniba panurensis.	Klausmeyer P, Chmurny GN, McCloud TG, Tucker KD, Shoemaker RH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2004	67	4	537	541	15104480	10.1021/np030438n	New chromanone acids with antibacterial activity from Calophyllum brasiliense.	Cottiglia F, Dhanapal B, Sticher O, Heilmann J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2004	67	4	693	696	15104507	10.1021/np0340394	Ether-linked biflavonoids from Quintinia acutifolia.	Ariyasena J, Baek SH, Perry NB, Weavers RT.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2005	15	4	919	921	15686887	10.1016/j.bmcl.2004.12.051	Synthesis and antibacterial activities of 5-hydroxy-4-amino-2(5H)-furanones.	Lattmann E, Dunn S, Niamsanit S, Sattayasai N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2005	15	5	1521	1524	15713420	10.1016/j.bmcl.2004.12.065	In vivo incorporation of an alkyne into proteins in Escherichia coli.	Deiters A, Schultz PG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2005	15	8	2123	2128	15808482	10.1016/j.bmcl.2005.02.029	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.	Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2005	48	3	805	811	15689164	10.1021/jm049661n	In silico prediction of membrane permeability from calculated molecular parameters.	Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2005	68	9	1394	1396	16180821	10.1021/np0580053	Monoterpene lactones from the seeds of Nephelium lappaceum.	Ragasa CY, de Luna RD, Cruz WC, Rideout JA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2005	68	9	1437	1440	16180833	10.1021/np050176k	Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.	Herath KB, Jayasuriya H, Guan Z, Schulman M, Ruby C, Sharma N, MacNaul K, Menke JG, Kodali S, Galgoci A, Wang J, Singh SB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2006	16	20	5451	5456	16890435	10.1016/j.bmcl.2006.07.052	Structure-activity relationships of novel antibacterial translation inhibitors: 3,5-diamino-piperidinyl triazines.	Zhou Y, Sun Z, Froelich JM, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2006	16	8	2177	2181	16495055	10.1016/j.bmcl.2006.01.072	Synthesis and antibacterial activities of chiral 1,3-oxazinan-2-one derivatives.	Wang G, Ella-Menye JR, Sharma V.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2006	49	25	7331	7341	17149863	10.1021/jm060492b	Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.	Leon A, Liu L, Yang Y, Hudock MP, Hall P, Yin F, Studer D, Puan KJ, Morita CT, Oldfield E.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2006	69	4	585	590	16643031	10.1021/np050438i	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.	Hu JF, Garo E, Hough GW, Goering MG, O'Neil-Johnson M, Eldridge GR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Proc. Natl. Acad. Sci. U.S.A.	2007	104	18	7612	7616	17456595	10.1073/pnas.0700746104	Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.	Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, González I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2007	15	11	3756	3767	17418579	10.1016/j.bmc.2007.03.040	QSAR study on permeability of hydrophobic compounds with artificial membranes.	Fujikawa M, Nakao K, Shimizu R, Akamatsu M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2007	15	8	2837	2849	17331732	10.1016/j.bmc.2007.02.024	Identification of antitumour activity of novel derivatives of 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione and 8-aryl-4-imino-2,3,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3(6H)-one.	Sztanke K, Pasternak K, Rzymowska J, Sztanke M, Kandefer-Szersze¿ M, Dyba¿a I, Kozio¿ AE.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2007	16	5	205	212		10.1007/s00044-007-9024-9	Synthesis of 2,4-dihalogenofluorobenzenes and their antimicrobial and antifungal activity studies	Katrcoglu H, Logoglu E, Tilki T, Oktemer A
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2007	16	7	418	426		10.1007/s00044-007-9082-z	Further derivatives of 4-benzoyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid and their antibacterial activities	Bildirici I, Sener A, Tozlu I
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2007	17	15	4102	4106	17570664	10.1016/j.bmcl.2007.05.065	Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.	Lv J, Qian Y, Liu T, Wang Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2007	17	2	341	345	17098426	10.1016/j.bmcl.2006.10.064	N/C-4 substituted azetidin-2-ones: synthesis and preliminary evaluation as new class of antimicrobial agents.	Halve AK, Bhadauria D, Dubey R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2007	17	5	1206	1210	17188860	10.1016/j.bmcl.2006.12.024	Synthesis and SAR of 3,5-diamino-piperidine derivatives: novel antibacterial translation inhibitors as aminoglycoside mimetics.	Zhou Y, Gregor VE, Ayida BK, Winters GC, Sun Z, Murphy D, Haley G, Bailey D, Froelich JM, Fish S, Webber SE, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2007	17	6	1601	1607	17257839	10.1016/j.bmcl.2006.12.090	Synthesis of pseudopeptides based L-tryptophan as a potential antimicrobial agent.	Lv J, Yin L, Liu T, Wang Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2007	42	6	823	840	17331622	10.1016/j.ejmech.2006.12.010	Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues.	Mathew V, Keshavayya J, Vaidya VP, Giles D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2007	42	6	880	884	17320245	10.1016/j.ejmech.2006.12.015	Rapid synthesis of sulfone derivatives as potential anti-infectious agents.	Curti C, Laget M, Carle AO, Gellis A, Vanelle P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2007	42	7	948	954	17316908	10.1016/j.ejmech.2006.12.025	Synthesis and antimicrobial evaluation of some new thiazole, thiazolidinone and thiazoline derivatives starting from 1-chloro-3,4-dihydronaphthalene-2-carboxaldehyde.	Bondock S, Khalifa W, Fadda AA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2007	42	9	1193	1199	17408811	10.1016/j.ejmech.2007.01.025	N- and S-alpha-l-arabinopyranosyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles. First synthesis and biological evaluation.	Khalil NS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	1	169	174	17060530	10.1128/aac.00261-06	Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.	Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	1	231	238	17074796	10.1128/aac.00576-06	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.	Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, Zhu W, Musser KA, Thompson J, Kohlerschmidt D, Dumas N, Limberger RJ, Patel JB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	1	28	34	17043118	10.1128/aac.00739-06	Effect of anaerobic growth on quinolone lethality with Escherichia coli.	Malik M, Hussain S, Drlica K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	1	307	316	17060533	10.1128/aac.00808-06	Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.	Ramya TN, Mishra S, Karmodiya K, Surolia N, Surolia A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	10	3650	3658	17664315	10.1128/aac.00601-07	Role of the rapA gene in controlling antibiotic resistance of Escherichia coli biofilms.	Lynch SV, Dixon L, Benoit MR, Brodie EL, Keyhan M, Hu P, Ackerley DF, Andersen GL, Matin A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	11	4105	4110	17724159	10.1128/aac.00616-07	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.	Xu X, Wu S, Ye X, Liu Y, Shi W, Zhang Y, Wang M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	12	4267	4275	17908942	10.1128/aac.00962-07	Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.	Binet R, Maurelli AT.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	12	4498	4501	17923492	10.1128/aac.00538-07	Antimicrobial susceptibilities and clinical sources of Dialister species.	Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, Devine R, Marchandin H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	2	423	428	17116664	10.1128/aac.01244-06	Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.	Szumowski JD, Cohen DE, Kanaya F, Mayer KH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	2	453	460	17116681	10.1128/aac.00960-06	Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.	Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	2	535	542	17043131	10.1128/aac.00600-06	Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.	Chen S, Cui S, McDermott PF, Zhao S, White DG, Paulsen I, Meng J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	3	1085	1088	17158942	10.1128/aac.00954-06	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.	Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	3	1119	1122	17210778	10.1128/aac.00779-06	Effects of glutathione and ascorbic acid on streptomycin sensitivity of Escherichia coli.	Goswami M, Mangoli SH, Jawali N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	3	831	838	17101679	10.1128/aac.01306-05	Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.	Vidaillac C, Guillon J, Arpin C, Forfar-Bares I, Ba BB, Grellet J, Moreau S, Caignard DH, Jarry C, Quentin C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	3	923	929	17210767	10.1128/aac.01048-06	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.	Elkins CA, Mullis LB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	4	1293	1303	17220404	10.1128/aac.01128-06	Increased genome instability in Escherichia coli lon mutants: relation to emergence of multiple-antibiotic-resistant (Mar) mutants caused by insertion sequence elements and large tandem genomic amplifications.	Nicoloff H, Perreten V, Levy SB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	4	1527	1529	17220425	10.1128/aac.00780-06	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.	Castanheira M, Pereira AS, Nicoletti AG, Pignatari AC, Barth AL, Gales AC.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	5	1844	1848	17353242	10.1128/aac.01428-06	In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.	Llull D, Rivas L, García E.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	6	2048	2052	17404009	10.1128/aac.01066-06	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.	Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	6	2065	2069	17420217	10.1128/aac.01198-06	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.	Peleg AY, Adams J, Paterson DL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	6	2156	2163	17404004	10.1128/aac.00163-07	Targeted drug-carrying bacteriophages as antibacterial nanomedicines.	Yacoby I, Bar H, Benhar I.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	7	2359	2365	17438050	10.1128/aac.01395-06	Biochemical characterization of PER-2 and genetic environment of blaPER-2.	Power P, Di Conza J, Rodríguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	7	2464	2469	17470656	10.1128/aac.00143-07	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.	Périchon B, Courvalin P, Galimand M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	8	2679	2689	17502406	10.1128/aac.00209-07	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Meehl M, Herbert S, Götz F, Cheung A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	8	2855	2860	17470647	10.1128/aac.01614-06	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.	Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	8	3004	3007	17526756	10.1128/aac.00167-07	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.	Chen YT, Lauderdale TL, Liao TL, Shiau YR, Shu HY, Wu KM, Yan JJ, Su IJ, Tsai SF.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	9	3155	3161	17620383	10.1128/aac.00335-07	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.	Cerquetti M, Giufrè M, Cardines R, Mastrantonio P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	9	3240	3246	17606677	10.1128/aac.00157-07	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.	Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2007	51	9	3452	3454	17638695	10.1128/aac.00420-07	In vitro susceptibilities of Mycoplasma putrefaciens field isolates.	Antunes NT, Tavío MM, Mercier P, Ayling RD, Al-Momani W, Assunção P, Rosales RS, Poveda JB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2007	70	9	1539	1541	17822300	10.1021/np070305s	Benzaldehyde derivatives from Sarcodontia crocea.	Kokubun T, Rozwadowski Z, Duddeck H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2008	16	1	446	456	17905587	10.1016/j.bmc.2007.09.025	Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids.	de Aquino TM, Liesen AP, da Silva RE, Lima VT, Carvalho CS, de Faria AR, de Araújo JM, de Lima JG, Alves AJ, de Melo EJ, Góes AJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2008	16	3	1150	1161	18053730	10.1016/j.bmc.2007.10.082	Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies.	Ezabadi IR, Camoutsis C, Zoumpoulakis P, Geronikaki A, Sokovi¿ M, Glamocilija J, Ciri¿ A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2008	16	6	3395	3407	18295489	10.1016/j.bmc.2007.11.029	QSAR modeling of the rodent carcinogenicity of nitrocompounds.	Helguera AM, Cordeiro MN, Pérez MA, Combes RD, González MP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2008	16	7	4083	4092	18249550	10.1016/j.bmc.2008.01.020	Alkyl deoxy-arabino-hexopyranosides: synthesis, surface properties, and biological activities.	Silva FV, Goulart M, Justino J, Neves A, Santos F, Caio J, Lucas S, Newton A, Sacoto D, Barbosa E, Santos MS, Rauter AP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2008	16	8	4569	4578	18313934	10.1016/j.bmc.2008.02.043	Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity.	Farag AM, Mayhoub AS, Barakat SE, Bayomi AH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2008	17	8	495	506		10.1007/s00044-008-9093-4	Simple and efficient synthetic routes to bioactive s-triazinyl dithiocarbamate derivatives	Desai RM, Dodiya DK, Trivedi AR, Shah VH
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2008	18	11	3369	3375	18440814	10.1016/j.bmcl.2008.04.023	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.	Zhou Y, Chow C, Murphy DE, Sun Z, Bertolini T, Froelich JM, Webber SE, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	1	155	159	17499887	10.1016/j.ejmech.2007.03.019	New triazole and triazolothiadiazine derivatives as possible antimicrobial agents.	Kaplancikli ZA, Turan-Zitouni G, Ozdemir A, Revial G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	1	19	24	17507115	10.1016/j.ejmech.2007.03.011	Synthesis, structure and biological activity of pseudopeptidic macrolides based on an amino alcohol.	Lv J, Liu T, Wang Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	10	2122	2129	18255196	10.1016/j.ejmech.2007.12.009	Synthesis and antimicrobial activity of some new heterocycles incorporating antipyrine moiety.	Bondock S, Rabie R, Etman HA, Fadda AA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	10	2257	2261	18440096	10.1016/j.ejmech.2007.09.022	Synthesis, structure elucidation and antibacterial evaluation of new steroidal -5-en-7-thiazoloquinoxaline derivatives.	Khan SA, Saleem K, Khan Z.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	10	2272	2277	18294737	10.1016/j.ejmech.2007.12.012	Synthesis, characterization and in vitro antibacterial activity of thiourea and urea derivatives of steroids.	Khan SA, Singh N, Saleem K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	2	404	419	17531354	10.1016/j.ejmech.2007.03.033	Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives.	Sztanke K, Tuzimski T, Rzymowska J, Pasternak K, Kandefer-Szersze¿ M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	4	707	713	17618710	10.1016/j.ejmech.2007.05.006	Synthesis, physicochemical properties and antimicrobial evaluation of new (E)-chalcones.	Nowakowska Z, Kedzia B, Schroeder G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2008	43	5	917	924	17692433	10.1016/j.ejmech.2007.06.011	Synthesis and antimicrobial activity of novel sulfone-linked bis heterocycles.	Padmavathi V, Thriveni P, Sudhakar Reddy G, Deepti D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2008	51	16	5140	5142	18666772	10.1021/jm8005228	Determination of log D via automated microfluidic liquid-liquid extraction.	Alimuddin M, Grant D, Bulloch D, Lee N, Peacock M, Dahl R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	10	3550	3557	18663023	10.1128/aac.01193-07	R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.	Skripkin E, McConnell TS, DeVito J, Lawrence L, Ippolito JA, Duffy EM, Sutcliffe J, Franceschi F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	10	3604	3611	18694955	10.1128/aac.00661-08	RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.	Bailey AM, Paulsen IT, Piddock LJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	10	3826	3827	18694947	10.1128/aac.00419-08	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.	Wu X, Wang H, Zhao X.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	11	4141	4144	18676884	10.1128/aac.00511-08	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.	Sugimura M, Maseda H, Hanaki H, Nakae T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	11	4166	4171	18725450	10.1128/aac.00245-08	Characterization of TolC efflux pump proteins from Pasteurella multocida.	Hatfaludi T, Al-Hasani K, Dunstone M, Boyce J, Adler B.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	2	427	434	18070962	10.1128/aac.00375-07	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.	Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	2	557	562	18086852	10.1128/aac.00732-07	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.	Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	3	866	874	18086834	10.1128/aac.01266-07	Induction of erm(C) expression by noninducing antibiotics.	Bailey M, Chettiath T, Mankin AS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	4	1570	1572	18212098	10.1128/aac.01098-07	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.	Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	5	1703	1712	18299405	10.1128/aac.01583-07	Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.	Smith LK, Mankin AS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	6	2244	2246	18391032	10.1128/aac.00231-08	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.	Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	6	2276	2278	18411318	10.1128/aac.01584-07	In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.	Urich SK, Petersen JM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	7	2428	2434	18443112	10.1128/aac.00084-08	ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.	Abouzeed YM, Baucheron S, Cloeckaert A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	7	2455	2462	18474583	10.1128/aac.01107-07	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.	Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	7	2503	2511	18458127	10.1128/aac.00298-08	Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.	Danilchanka O, Mailaender C, Niederweis M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	7	2663	2666	18426902	10.1128/aac.01326-07	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.	Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	7	2686	2690	18474575	10.1128/aac.00081-08	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.	Betriu C, Culebras E, Gómez M, López F, Rodríguez-Avial I, Picazo JJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	8	2734	2741	18519732	10.1128/aac.00205-08	Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2.	Pränting M, Negrea A, Rhen M, Andersson DI.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	8	2806	2812	18519725	10.1128/aac.00247-08	Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.	Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	8	2923	2925	18541730	10.1128/aac.00273-08	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.	Steidl R, Pearson S, Stephenson RE, Ledala N, Sitthisak S, Wilkinson BJ, Jayaswal RK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	9	3052	3060	18591276	10.1128/aac.00475-08	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.	Long F, Rouquette-Loughlin C, Shafer WM, Yu EW.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2008	52	9	3161	3168	18625771	10.1128/aac.00355-08	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.	Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2008	71	4	701	705	18278870	10.1021/np0704304	Chromomoric acid derivatives from Tectona philippinensis.	Ragasa CY, Tepora MM, Espinelli DH, Mandia EH, Rideout JA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2008	71	6	1032	1036	18465897	10.1021/np800127b	Absolute configuration and antimicrobial activity of acylhomoserine lactones.	Pomini AM, Marsaioli AJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2008	71	8	1464	1467	18656986	10.1021/np800142n	Bioactive brominated metabolites from the red sea sponge Suberea mollis.	Abou-Shoer MI, Shaala LA, Youssef DT, Badr JM, Habib AA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2009	17	7	2823	2829	19272782	10.1016/j.bmc.2009.02.028	New pyridazine derivatives: synthesis, chemistry and biological activity.	Butnariu RM, Mangalagiu II.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2009	17	8	3028	3036	19324556	10.1016/j.bmc.2009.03.011	Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococcus aureus.	Jorge SD, Masunari A, Rangel-Yagui CO, Pasqualoto KF, Tavares LC.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2009	18	5	327	340		10.1007/s00044-008-9130-3	Synthesis and antibacterial activity of 4-benzoyl-1-(4-carboxy-phenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid and derivatives	Bildirici I, Sener A, Atalan E, Battal A, Genc H
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2009	19	2	524	527	19064318	10.1016/j.bmcl.2008.11.021	Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.	Czaplewski LG, Collins I, Boyd EA, Brown D, East SP, Gardiner M, Fletcher R, Haydon DJ, Henstock V, Ingram P, Jones C, Noula C, Kennison L, Rockley C, Rose V, Thomaides-Brears HB, Ure R, Whittaker M, Stokes NR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	11	4434	4440	19581025	10.1016/j.ejmech.2009.06.002	Synthesis and antibacterial activity of some new thiazole and thiophene derivatives.	Khalil AM, Berghot MA, Gouda MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	11	4448	4454	19570595	10.1016/j.ejmech.2009.06.003	Synthesis and antibacterial activity of some new heterocycles incorporating phthalazine.	Khalil AM, Berghot MA, Gouda MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	11	4557	4566	19631423	10.1016/j.ejmech.2009.06.024	Synthesis, antimicrobial and antioxidant activities of substituted pyrazoles, isoxazoles, pyrimidine and thioxopyrimidine derivatives.	Padmaja A, Payani T, Reddy GD, Padmavathi V.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	12	4813	4818	19683840	10.1016/j.ejmech.2009.07.024	Enaminonitrile in heterocyclic synthesis: synthesis and antimicrobial evaluation of some new pyrazole, isoxazole and pyrimidine derivatives incorporating a benzothiazole moiety.	Bondock S, Fadaly W, Metwally MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	4	1751	1757	18472189	10.1016/j.ejmech.2008.03.026	Convenient one-pot synthesis of novel 2-substituted benzimidazoles, tetrahydrobenzimidazoles and imidazoles and evaluation of their in vitro antibacterial and antifungal activities.	Sharma S, Gangal S, Rauf A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	5	2106	2112	19036476	10.1016/j.ejmech.2008.10.012	Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles.	Padmavathi V, Sudhakar Reddy G, Padmaja A, Kondaiah P, Ali-Shazia.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	5	2260	2264	18657340	10.1016/j.ejmech.2008.06.004	Organoiodine (III)-mediated synthesis of 3-aryl/heteroaryl-5,7-dimethyl-1,2,4-triazolo[4,3-c]pyrimidines as antibacterial agents.	Kumar R, Nair RR, Dhiman SS, Sharma J, Prakash O.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	5	2265	2269	18672319	10.1016/j.ejmech.2008.06.007	Synthesis and antimicrobial activity of new 1-alkyl/cyclohexyl-3,3-diaryl-1'-methylspiro[azetidine-2,3'-indoline]-2',4-diones.	Singh GS, Luntha P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	5	2275	2279	18672317	10.1016/j.ejmech.2008.06.017	Diazinium salts with dihydroxyacetophenone skeleton: Syntheses and antimicrobial activity.	Balan AM, Florea O, Moldoveanu C, Zbancioc G, Iurea D, Mangalagiu II.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	7	3083	3089	18708273	10.1016/j.ejmech.2008.07.003	Synthesis, characterization and antibacterial activity of some triazole Mannich bases carrying diphenylsulfone moieties.	Almajan GL, Barbuceanu SF, Almajan ER, Draghici C, Saramet G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	8	3209	3216	19375826	10.1016/j.ejmech.2009.03.030	Mechanism of unusual formation of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides and their antimicrobial evaluation.	Raj T, Bhatia RK, Sharma RK, Gupta V, Sharma D, Ishar MP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2009	44	9	3712	3717	19410338	10.1016/j.ejmech.2009.03.039	Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.	Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	1	329	330	18936189	10.1128/aac.00921-08	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.	Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	10	4283	4291	19635954	10.1128/aac.01709-08	Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.	Panchal RG, Ulrich RL, Lane D, Butler MM, Houseweart C, Opperman T, Williams JD, Peet NP, Moir DT, Nguyen T, Gussio R, Bowlin T, Bavari S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	10	4357	4367	19651903	10.1128/aac.00077-09	Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation.	Opperman TJ, Kwasny SM, Williams JD, Khan AR, Peet NP, Moir DT, Bowlin TL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	11	4628	4639	19721076	10.1128/aac.00454-09	Induction of multidrug resistance mechanism in Escherichia coli biofilms by interplay between tetracycline and ampicillin resistance genes.	May T, Ito A, Okabe S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	11	4673	4677	19687245	10.1128/aac.00853-09	Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor.	Vecchione JJ, Alexander B, Sello JK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	11	4944	4948	19721064	10.1128/aac.00787-09	Combined inactivation of lon and ycgE decreases multidrug susceptibility by reducing the amount of OmpF porin in Escherichia coli.	Duval V, Nicoloff H, Levy SB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	11	4957	4958	19721071	10.1128/aac.00675-09	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.	Duval V, Maiga I, Maiga A, Guillard T, Brasme L, Forte D, Madoux J, Vernet-Garnier V, De Champs C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	12	5230	5235	19752278	10.1128/aac.00631-09	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.	Maseda H, Hashida Y, Konaka R, Shirai A, Kourai H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	12	5275	5278	19805557	10.1128/aac.01032-09	Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.	Locke JB, Hilgers M, Shaw KJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	12	5312	5316	19770280	10.1128/aac.00748-09	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.	Srinivasan VB, Rajamohan G, Gebreyes WA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	512	518	19029328	10.1128/aac.00804-08	Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals.	Liu Y, Wang H, Du N, Shen E, Chen H, Niu J, Ye H, Chen M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	519	524	18936192	10.1128/aac.00886-08	High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals.	Ma J, Zeng Z, Chen Z, Xu X, Wang X, Deng Y, Lü D, Huang L, Zhang Y, Liu J, Wang M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	563	571	19029332	10.1128/aac.00870-08	Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition.	Siibak T, Peil L, Xiong L, Mankin A, Remme J, Tenson T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	696	702	19064898	10.1128/aac.00652-07	Prevalence of sulfonamide resistance genes in bacterial isolates from manured agricultural soils and pig slurry in the United Kingdom.	Byrne-Bailey KG, Gaze WH, Kay P, Boxall AB, Hawkey PM, Wellington EM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	735	747	19029325	10.1128/aac.00754-08	Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac).	Zheng B, Tomita H, Inoue T, Ike Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	779	781	19047652	10.1128/aac.01376-08	Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr.	Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	824	827	19015337	10.1128/aac.01015-08	Truncated tni module adjacent to the complex integron of salmonella genomic island 1 in Salmonella enterica serovar Virchow.	Doublet B, Chu C, Chiu CH, Fan YC, Cloeckaert A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	2	845	846	19029319	10.1128/aac.01312-08	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.	Welch TJ, Evenhuis J, White DG, McDermott PF, Harbottle H, Miller RA, Griffin M, Wise D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	3	1080	1087	19104017	10.1128/aac.01005-08	Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.	O'Regan E, Quinn T, Pagès JM, McCusker M, Piddock L, Fanning S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	4	1395	1402	19223646	10.1128/aac.01087-08	Contribution of oxidative damage to antimicrobial lethality.	Wang X, Zhao X.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	4	1561	1566	19188396	10.1128/aac.00994-08	Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.	Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	4	1652	1656	19164140	10.1128/aac.00822-08	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.	Tran QT, Dupont M, Lavigne JP, Chevalier J, Pagès JM, Sotto A, Davin-Regli A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	5	1892	1897	19258263	10.1128/aac.01400-08	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.	Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	6	2450	2454	19332670	10.1128/aac.01282-08	Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.	Mandomando I, Jaintilal D, Pons MJ, Vallès X, Espasa M, Mensa L, Sigaúque B, Sanz S, Sacarlal J, Macete E, Abacassamo F, Alonso PL, Ruiz J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	6	2483	2491	19332676	10.1128/aac.00428-08	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.	Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	7	3147	3149	19414571	10.1128/aac.00023-09	Emergence of quinolone-resistant Bordetella pertussis in Japan.	Ohtsuka M, Kikuchi K, Shimizu K, Takahashi N, Ono Y, Sasaki T, Hiramatsu K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	9	4013	4014	19581458	10.1128/aac.00584-09	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.	Roca I, Marti S, Espinal P, Martínez P, Gibert I, Vila J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2009	53	9	4025	4027	19546371	10.1128/aac.00200-09	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.	Kurokawa K, Hamamoto H, Matsuo M, Nishida S, Yamane N, Lee BL, Murakami K, Maki H, Sekimizu K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2009	72	6	1075	1080	19419186	10.1021/np900016h	Phenylphenalenones from the Australian plant Haemodorum simplex.	Dias DA, Goble DJ, Silva CA, Urban S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2009	72	8	1516	1519	19639965	10.1021/np800788n	7,7-Dimethylaporphine alkaloids from the stem of Guatteriopsis friesiana.	Costa EV, Marques FA, Pinheiro ML, Vaz NP, Duarte MC, Delarmelina C, Braga RM, Maia BH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2010	18	22	7868	7872	20943400	10.1016/j.bmc.2010.09.045	Inhibition of Helicobacter pylori aminoacyl-tRNA amidotransferase by chloramphenicol analogs.	Balg C, De Mieri M, Huot JL, Blais SP, Lapointe J, Chênevert R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2010	18	6	2123	2130	20188576	10.1016/j.bmc.2010.02.005	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.	Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2010	19	6	541	550		10.1007/s00044-009-9211-y	Iodine (III)-mediated synthesis of some 2-aryl/hetarylbenzoxazoles as antibacterial/antifungal agents	Kumar R, Nair RR, Dhiman SS, Sharma J, Prakash O
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2010	19	6	576	588		10.1007/s00044-009-9214-8	Synthesis and biological activity of new cycloalkylthiophene-Schiff bases and their Cr(III) and Zn(II) complexes	Altundas A, Sar N, Colak N, Ogutcu H
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2010	19	8	757	770		10.1007/s00044-009-9228-2	Synthesis and antimicrobial study of fluoroquinolone-based 4-thiazolidinones	Patel NB, Patel SD
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	1	236	239	19932961	10.1016/j.bmcl.2009.10.128	Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro.	Ingenito R, Burton C, Langella A, Chen X, Zytko K, Pessi A, Wang J, Bianchi E.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	1	56	59	19959361	10.1016/j.bmcl.2009.11.042	Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.	Yao J, Zhang Q, Min J, He J, Yu Z.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	1	69	73	19963379	10.1016/j.bmcl.2009.11.039	Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.	Lee PH, Conradi R, Shanmugasundaram V.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	14	4252	4258	20621732	10.1016/j.bmcl.2010.05.025	One-pot multicomponent synthesis and anti-microbial evaluation of 2'-(indol-3-yl)-2-oxospiro(indoline-3,4'-pyran) derivatives.	Nandakumar A, Thirumurugan P, Perumal PT, Vembu P, Ponnuswamy MN, Ramesh P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	18	5572	5576	20724151	10.1016/j.bmcl.2010.07.019	Synthesis and antimicrobial activity of novel fluorine containing 4-(substituted-2-hydroxybenzoyl)-1H-pyrazoles and pyrazolyl benzo[d]oxazoles.	Gadakh AV, Pandit C, Rindhe SS, Karale BK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	21	6324	6326	20850303	10.1016/j.bmcl.2010.06.001	Bernthsen synthesis, antimicrobial activities and cytotoxicity of acridine derivatives.	Patel MM, Mali MD, Patel SK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	22	6712	6715	20864340	10.1016/j.bmcl.2010.08.145	A practical deuterium-free NMR method for the rapid determination of 1-octanol/water partition coefficients of pharmaceutical agents.	Mo H, Balko KM, Colby DA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	24	7200	7204	21074427	10.1016/j.bmcl.2010.10.111	Green synthesis and biological evaluation of some novel azoles as antimicrobial agents.	Shelke S, Mhaske G, Gadakh S, Gill C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	6	1881	1884	20176480	10.1016/j.bmcl.2010.01.159	Synthesis, antibacterial and antifungal activities of some carbazole derivatives.	Zhang FF, Gan LL, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2010	20	6	1933	1938	20172722	10.1016/j.bmcl.2010.01.126	Synthesis, characterization, and in vitro antimicrobial activities of 5-alkenyl/hydroxyalkenyl-2-phenylamine-1,3,4-oxadiazoles and thiadiazoles.	Farshori NN, Banday MR, Ahmad A, Khan AU, Rauf A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	1	203	209	19853328	10.1016/j.ejmech.2009.09.045	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.	Koteswara Rao V, Janardhan Rao A, Subba Reddy S, Naga Raju C, Visweswara Rao P, Ghosh SK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	10	4631	4639	20708826	10.1016/j.ejmech.2010.07.031	Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities.	Wang XL, Wan K, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	11	4813	4826	20739103	10.1016/j.ejmech.2010.07.050	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.	Puri N, Prakash O, Manoharlal R, Sharma M, Ghosh I, Prasad R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	11	5130	5139	20801550	10.1016/j.ejmech.2010.08.025	Synthesis, characterization, oxidative degradation, antibacterial activity and acetylcholinesterase/butyrylcholinesterase inhibitory effects of some new phosphorus(V) hydrazides.	Gholivand K, Hosseini Z, Farshadian S, Naderi-Manesh H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	11	5265	5277	20875694	10.1016/j.ejmech.2010.08.046	Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic and/or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity.	Khalil NS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	12	5702	5707	20933305	10.1016/j.ejmech.2010.09.026	Antimicrobial, antitumor and 5¿-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones.	Edrees MM, Farghaly TA, El-Hag FA, Abdalla MM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	3	1094	1097	20031281	10.1016/j.ejmech.2009.12.004	Synthesis, antibacterial and antifungal activities of 6,5 fused steroidal oxazoles in cholestane series.	Shamsuzzaman, Khan MS, Alam M, Tabassum Z, Ahmad A, Khan AU.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	4	1459	1464	20106564	10.1016/j.ejmech.2009.12.052	Synthesis and characterization of novel fatty acid analogs of cholesterol: in vitro antimicrobial activity.	Banday MR, Farshori NN, Ahmad A, Khan AU, Rauf A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	4	1552	1559	20117862	10.1016/j.ejmech.2009.12.064	Synthesis and study of some new 1,3-isoindoledione derivatives as potential antibacterial agents.	Khalil AM, Berghot MA, Gouda MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	5	1843	1848	20144494	10.1016/j.ejmech.2010.01.021	Synthesis and antimicrobial of new anthraquinone derivatives incorporating pyrazole moiety.	Gouda MA, Berghot MA, Shoeib AI, Khalil AM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	7	3178	3183	20444528	10.1016/j.ejmech.2010.04.010	Synthesis and bioassay of pyrrolyl oxazolines and thiazolines.	Padmavathi V, Mahesh K, Dinneswara Reddy G, Padmaja A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	8	3293	3298	20451306	10.1016/j.ejmech.2010.04.012	Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety.	Ozkay Y, Tunali Y, Karaca H, I¿ikda¿ I.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	9	3685	3691	20541294	10.1016/j.ejmech.2010.05.017	Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.	Liesen AP, de Aquino TM, Carvalho CS, Lima VT, de Araújo JM, de Lima JG, de Faria AR, de Melo EJ, Alves AJ, Alves EW, Alves AQ, Góes AJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	9	3692	3701	20605657	10.1016/j.ejmech.2010.05.018	Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety.	Bondock S, Fadaly W, Metwally MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	9	4246	4251	20630628	10.1016/j.ejmech.2010.06.022	Synthesis and bioassay of aminosulfonyl-1,3,4-oxadiazoles and their interconversion to 1,3,4-thiadiazoles.	Padmavathi V, Reddy SN, Reddy GD, Padmaja A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2010	45	9	4388	4398	20598399	10.1016/j.ejmech.2010.06.012	Synthesis and biological activities of novel amine-derived bis-azoles as potential antibacterial and antifungal agents.	Fang B, Zhou CH, Rao XC.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	1	177	183	19858254	10.1128/aac.00715-09	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.	Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	1	367	374	19917752	10.1128/aac.00801-09	Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes.	O'Regan E, Quinn T, Frye JG, Pagès JM, Porwollik S, Fedorka-Cray PJ, McClelland M, Fanning S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	1	45	51	19884377	10.1128/aac.00427-09	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.	Doublet B, Robin F, Casin I, Fabre L, Le Fleche A, Bonnet R, Weill FX.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	1	65	71	19884366	10.1128/aac.00966-09	Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.	Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, Kang Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	10	4219	4224	20696876	10.1128/aac.00139-10	Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment.	Zhao J, Chen Z, Chen S, Deng Y, Liu Y, Tian W, Huang X, Wu C, Sun Y, Sun Y, Zeng Z, Liu JH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	10	4373	4378	20679507	10.1128/aac.01607-09	Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model.	Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	11	4705	4713	20696869	10.1128/aac.00644-10	Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.	Long KS, Munck C, Andersen TM, Schaub MA, Hobbie SN, Böttger EC, Vester B.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	11	4772	4779	20713660	10.1128/aac.00009-10	ampG gene of Pseudomonas aeruginosa and its role in ß-lactamase expression.	Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	11	4917	4919	20805389	10.1128/aac.01652-09	Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.	Okuda J, Hayashi N, Wakahara Y, Gotoh N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	12	4978	4984	20921317	10.1128/aac.01113-10	Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.	Shore AC, Brennan OM, Ehricht R, Monecke S, Schwarz S, Slickers P, Coleman DC.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	12	5352	5355	20837755	10.1128/aac.00714-10	Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.	Locke JB, Morales G, Hilgers M, G C K, Rahawi S, José Picazo J, Shaw KJ, Stein JL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	12	5406	5412	20855745	10.1128/aac.00580-10	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.	Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	2	915	918	20008780	10.1128/aac.01091-09	Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1007	1015	20038628	10.1128/aac.01126-09	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.	Elkins CA, Mullis LB, Lacher DW, Jung CM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1218	1225	20008776	10.1128/aac.00944-09	Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG.	Fàbrega A, Martin RG, Rosner JL, Tavio MM, Vila J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1319	1322	20028818	10.1128/aac.00993-09	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.	Hentschke M, Christner M, Sobottka I, Aepfelbacher M, Rohde H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	3	1351	1353	20065060	10.1128/aac.01208-09	Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4.	Hölzel CS, Harms KS, Schwaiger K, Bauer J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	4	1492	1497	20100880	10.1128/aac.01495-09	Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa.	Yoneyama H, Akiba K, Hori H, Ando T, Nakae T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	5	1749	1752	20160051	10.1128/aac.01533-09	Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone.	Kuete V, Ngameni B, Tangmouo JG, Bolla JM, Alibert-Franco S, Ngadjui BT, Pagès JM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	5	2125	2134	20211899	10.1128/aac.01420-09	Many chromosomal genes modulate MarA-mediated multidrug resistance in Escherichia coli.	Ruiz C, Levy SB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	6	2728	2731	20385859	10.1128/aac.01557-09	Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.	Morvan A, Moubareck C, Leclercq A, Hervé-Bazin M, Bremont S, Lecuit M, Courvalin P, Le Monnier A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	8	3113	3120	20498323	10.1128/aac.01803-09	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.	Mima T, Schweizer HP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	8	3529	3530	20547812	10.1128/aac.00710-10	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.	Goswami M, Jawali N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	9	3953	3955	20585133	10.1128/aac.00169-10	First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces.	Dai L, Wu CM, Wang MG, Wang Y, Wang Y, Huang SY, Xia LN, Li BB, Shen JZ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2010	54	9	3993	3997	20585132	10.1128/aac.00481-10	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.	Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, Chong Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2010	73	6	1151	1155	20499922	10.1021/np900597w	Dihydro-beta-agarofuran sesquiterpenes and pentacyclic triterpenoids from the root bark of Osyris lanceolata.	Yeboah EM, Majinda RR, Kadziola A, Muller A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2010	73	6	1180	1183	20476748	10.1021/np100013r	Alkaloids from the bark of Guatteria hispida and their evaluation as antioxidant and antimicrobial agents.	Costa EV, Pinheiro ML, Barison A, Campos FR, Salvador MJ, Maia BH, Cabral EC, Eberlin MN.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2010	73	7	1309	1312	20545334	10.1021/np100135b	Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea.	Schneemann I, Kajahn I, Ohlendorf B, Zinecker H, Erhard A, Nagel K, Wiese J, Imhoff JF.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2011	19	17	5225	5230	21813280	10.1016/j.bmc.2011.07.006	Tylosema esculentum extractives and their bioactivity.	Mazimba O, Majinda RR, Modibedi C, Masesane IB, Cenci¿ A, Chingwaru W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2011	19	2	926	938	21215645	10.1016/j.bmc.2010.11.060	Synthesis of sugars embodying conjugated carbonyl systems and related triazole derivatives from carboxymethyl glycoside lactones. Evaluation of their antimicrobial activity and toxicity.	Xavier NM, Goulart M, Neves A, Justino J, Chambert S, Rauter AP, Queneau Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2011	20	5	535	541		10.1007/s00044-010-9347-9	7-Hydroxy-coumarin derivatives: synthesis, characterization and preliminary antimicrobial activities	Farshori NN, Banday MR, Ahmad A, Khan AU, Rauf A
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2011	20	6	782	789		10.1007/s00044-010-9388-0	Microwave-assisted synthesis of some new tetrazolo[1,5-a]quinoline-based benzimidazoles catalyzed by p-TsOH and investigation of their antimicrobial activity	Mungra DC, Patel MP, Patel RG
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2011	20	7	1068	1073		10.1007/s00044-010-9432-0	Synthesis of novel porphyrin-based lipids and their antibacterial activity	Velidandi A, Gadidasu KK, Patri VS
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2011	20	9	1438	1444		10.1007/s00044-010-9376-4	Zn(Proline)2-catalyzed Knoevenagel condensation under solvent-free/aqueous conditions and biological evaluation of products	Siddiqui ZN, Musthafa TNM, Praveen S, Farooq F
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2011	20	9	1473	1481		10.1007/s00044-010-9386-2	Microwave-assisted solvent-free synthesis of biologically active novel heterocycles from 3-formylchromones	Mohammed Musthafa TN, Siddiqui ZN, Husain FM, Ahmad I
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2011	21	14	4349	4352	21669530	10.1016/j.bmcl.2011.05.042	Synthesis and activities of naphthalimide azoles as a new type of antibacterial and antifungal agents.	Zhang YY, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2011	21	20	6166	6169	21890359	10.1016/j.bmcl.2011.07.123	Microwave assisted synthesis and antimicrobial evaluation of new fused pyran derivatives bearing 2-morpholinoquinoline nucleus.	Makawana JA, Mungra DC, Patel MP, Patel RG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2011	21	21	6559	6562	21920741	10.1016/j.bmcl.2011.08.049	Synthesis and biological evaluation of some novel triazol-3-ones as antimicrobial agents.	Pardeshi S, Bobade VD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2011	21	3	956	960	21215620	10.1016/j.bmcl.2010.12.059	Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents.	Shi Y, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2011	21	4	1155	1161	21273067	10.1016/j.bmcl.2010.12.111	Design and synthesis of potent Gram-negative specific LpxC inhibitors.	Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	11	5317	5326	21906854	10.1016/j.ejmech.2011.08.032	Synthesis and antimicrobial activity of amido linked pyrrolyl and pyrazolyl-oxazoles, thiazoles and imidazoles.	Padmavathi V, Prema Kumari C, Venkatesh BC, Padmaja A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	11	5573	5579	21981980	10.1016/j.ejmech.2011.09.023	1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.	Akhaja TN, Raval JP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	2	567	578	21185109	10.1016/j.ejmech.2010.11.036	Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a]thienotetrahydroisoquinoline derivatives.	Kamal AM, Radwan SM, Zaki RM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	4	1367	1373	21342736	10.1016/j.ejmech.2011.01.063	Synthesis and biological activity of 2-(bis((1,3,4-oxadiazolyl/1,3,4-thiadiazolyl)methylthio)methylene)malononitriles.	Padmavathi V, Dinneswara Reddy G, Nagi Reddy S, Mahesh K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2011	46	6	2555	2561	21489661	10.1016/j.ejmech.2011.03.045	Synthesis and antimicrobial activity of some new 4-hetarylpyrazole and furo[2,3-c]pyrazole derivatives.	Bondock S, Khalifa W, Fadda AA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2011	54	22	7884	7898	22007704	10.1021/jm2009343	Lipophosphonoxins: new modular molecular structures with significant antibacterial properties.	Rejman D, Rabatinová A, Pombinho AR, Kova¿ková S, Pohl R, Zborníková E, Kolá¿ M, Bogdanová K, Ny¿ O, Sanderová H, Látal T, Bart¿n¿k P, Krásný L.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2011	55	1	439	442	20937780	10.1128/aac.00735-10	Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.	Kalle AM, Rizvi A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Antimicrob. Agents Chemother.	2011	55	2	934	936	21115785	10.1128/aac.01247-10	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.	Poirel L, Revathi G, Bernabeu S, Nordmann P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Agric Food Chem	2011	59	7	2909	2917	20879794	10.1021/jf102525e	Importance of physicochemical properties for the design of new pesticides.	Akamatsu M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2011	74	6	1517	1520	21542602	10.1021/np200120d	Brominated arginine-derived alkaloids from the red sea sponge Suberea mollis.	Shaala LA, Bamane FH, Badr JM, Youssef DT.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2011	74	6	1526	1530	21568306	10.1021/np200187z	Arthrobotrisins A-C, oligosporons from the nematode-trapping fungus Arthrobotrys oligospora.	Wei LX, Zhang HX, Tan JL, Chu YS, Li N, Xue HX, Wang YL, Niu XM, Zhang Y, Zhang KQ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2012	20	13	3954	3971	22632793	10.1016/j.bmc.2012.04.061	Morita-Baylis-Hillman adducts: biological activities and potentialities to the discovery of new cheaper drugs.	Lima-Junior CG, Vasconcellos ML.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2012	20	15	4653	4660	22750009	10.1016/j.bmc.2012.06.018	Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.	Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, Kulp SK, Teng LJ, Chen CS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2012	20	8	2713	2720	22401914	10.1016/j.bmc.2012.02.023	Semisynthesis and antimicrobial activity of novel guttiferone-A derivatives.	Dias KS, Januário JP, D' Dego JL, Dias AL, dos Santos MH, Camps I, Coelho LF, Viegas C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	10	2762	2771		10.1007/s00044-011-9808-9	Design, synthesis, and in vitro antimicrobial activities of novel azetidinyl-3-quinazolin-4-one hybrids	Myangar KN, Raval JP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	12	4381	4388		10.1007/s00044-012-9978-0	Synthesis, characterization and biological evaluation of some pyridine and quinoline fused chromenone derivatives	Patel MA, Bhila VG, Patel NH, Patel AK, Brahmbhatt DI
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	6	867	873		10.1007/s00044-011-9596-2	Synthesis of novel 2-(3-aryl-sydnon-4-ylidene)-5-substituted-[1,3,4]-thiadiazolylamines and [1,3,4]-thiadiazol-2-yl-3-oxo-[1,2,4]-triazoles as antimicrobial agents	Bansode S, Kamble R
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	6	932	935		10.1007/s00044-011-9605-5	Antibacterial and antifungal activities of some trimethoprim salts	Tunal Y, Karaca H, Iscan G, Demirci F, Benkli K
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	7	1188	1198		10.1007/s00044-011-9628-y	Zn(OTf)2-catalyzed three component, one-pot cyclocondensation reaction of some new octahydroquinazolinone derivatives and access their bio-potential	Shah PM, Patel MP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	7	1471	1479		10.1007/s00044-011-9669-2	Synthesis and antimicrobial evaluation of novel benzo[b]thiophenes comprising -lactam nucleus	Trivedi AR, Desai JM, Dholariya BH, Dodiya DK, Shah VH
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	8	1751	1761		10.1007/s00044-011-9693-2	Synthesis, characterization and biological activity of some new carbostyril bearing 1H-pyrazole moiety	Thumar NJ, Patel MP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	8	2044	2055		10.1007/s00044-011-9728-8	Pyridoquinolones containing azetidinones: synthesis and their biological evaluation	Patel NB, Pathak KK
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2012	21	8	2072	2078		10.1007/s00044-011-9732-z	Synthesis and antimicrobial activity of morpholinyl/piperazinylbenzothiazines	Sharma PK, Kumar M, Vats S
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	10	3449	3454	22520260	10.1016/j.bmcl.2012.03.094	Synthesis and biological evaluation of some novel thiazole substituted benzotriazole derivatives.	Gaikwad ND, Patil SV, Bobade VD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	11	3816	3821	22560587	10.1016/j.bmcl.2012.03.100	An efficient one-pot synthesis, structure, antimicrobial and antioxidant investigations of some novel quinolyldibenzo[b,e][1,4]diazepinones.	Parmar NJ, Barad HA, Pansuriya BR, Teraiya SB, Gupta VK, Kant R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	12	4075	4079	22607678	10.1016/j.bmcl.2012.04.070	An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines.	Parmar NJ, Pansuriya BR, Barad HA, Kant R, Gupta VK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	14	4555	4560	22727643	10.1016/j.bmcl.2012.05.112	Synthesis and anti Methicillin resistant Staphylococcus aureus activity of substituted chalcones alone and in combination with non-beta-lactam antibiotics.	Tran TD, Do TH, Tran NC, Ngo TD, Huynh TN, Tran CD, Thai KM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	14	4650	4653	22727636	10.1016/j.bmcl.2012.05.088	Cristatumins A-D, new indole alkaloids from the marine-derived endophytic fungus Eurotium cristatum EN-220.	Du FY, Li XM, Li CS, Shang Z, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	17	5363	5366	22884108	10.1016/j.bmcl.2012.07.064	Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.	Wang Y, Damu GL, Lv JS, Geng RX, Yang DC, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	17	5727	5730	22832312	10.1016/j.bmcl.2012.06.072	Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.	Shelke SN, Mhaske GR, Bonifácio VD, Gawande MB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	2	1031	1035	22200598	10.1016/j.bmcl.2011.11.125	Synthesis, characterization and in vitro biological evaluation of some novel diarylsulfonylureas as potential cytotoxic and antimicrobial agents.	Avupati VR, Yejella RP, Guntuku G, Gunta P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2012	22	20	6442	6450	22981328	10.1016/j.bmcl.2012.08.052	Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.	Avupati VR, Yejella RP, Akula A, Guntuku GS, Doddi BR, Vutla VR, Anagani SR, Adimulam LS, Vyricharla AK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	47		228	238	22119150	10.1016/j.ejmech.2011.10.046	Synthesis, antimicrobial, antimycobacterial and structure-activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b]indoles.	Yamuna E, Kumar RA, Zeller M, Rajendra Prasad KJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	48		92	96	22178093	10.1016/j.ejmech.2011.11.038	Synthesis of pyrazolo[3,4-b]pyridines under microwave irradiation in multi-component reactions and their antitumor and antimicrobial activities - Part 1.	El-borai MA, Rizk HF, Abd-Aal MF, El-Deeb IY.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	54		239	247	22652224	10.1016/j.ejmech.2012.05.004	New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.	Shah NM, Patel MP, Patel RG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	54		605	614	22748281	10.1016/j.ejmech.2012.06.014	Synthesis, antimicrobial and cytotoxic activities of sulfone linked bis heterocycles.	Muralikrishna A, Venkatesh BC, Padmavathi V, Padmaja A, Kondaiah P, Krishna NS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2012	55	1	126	139	22122484	10.1021/jm201082a	In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.	Fischer H, Atzpodien EA, Csato M, Doessegger L, Lenz B, Schmitt G, Singer T.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2012	55		164	175	22863183	10.1016/j.ejmech.2012.07.015	Synthesis and biological evaluation of novel benzimidazole derivatives and their binding behavior with bovine serum albumin.	Zhang SL, Damu GL, Zhang L, Geng RX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2012	75	11	1888	1895	23148724	10.1021/np300377b	Meroterpenoid and diphenyl ether derivatives from Penicillium sp. MA-37, a fungus isolated from marine mangrove rhizospheric soil.	Zhang Y, Li XM, Shang Z, Li CS, Ji NY, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2012	75	2	225	229	22276775	10.1021/np2009219	Cytotoxic phloroglucinols from the leaves of Myrtus communis.	Cottiglia F, Casu L, Leonti M, Caboni P, Floris C, Busonera B, Farci P, Ouhtit A, Sanna G.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2012	75	7	1400	1404	22775474	10.1021/np2009626	Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species.	Ohlendorf B, Schulz D, Erhard A, Nagel K, Imhoff JF.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2013	21	1	135	145	23218781	10.1016/j.bmc.2012.10.053	Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin.	Handzlik J, Szyma¿ska E, Alibert S, Chevalier J, Otr¿bska E, P¿kala E, Pagès JM, Kie¿-Kononowicz K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2013	21	5	1174	1179	23352753	10.1016/j.bmc.2012.12.030	Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.	Brunel JM, Lieutaud A, Lome V, Pagès JM, Bolla JM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	1	211	218		10.1007/s00044-012-0021-2	Antimicrobial and anticancer effects of some 2-(substitutedsulfanyl)-N-(5-methyl-isoxazol-3-yl)acetamide derivatives	Ozkay Y, Incesu Z, Onder NI, Tunal Y, Karaca H, Iskdag I, Ucucu U
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	1	312	322		10.1007/s00044-012-0031-0	New N-arylamino biquinoline derivatives: microwave-assisted synthesis and their antimicrobial activities	Shah NM, Patel MP, Patel RG
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	2	507	519		10.1007/s00044-012-0079-x	Novel quinazolinone derivatives: synthesis and antimicrobial activity	Habib OMO, Hassan HM, El-Mekabaty A
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	2	905	915		10.1007/s00044-012-0085-z	Microwave-assisted CAN-catalyzed solvent-free synthesis of N-allyl quinolone-based pyrano[4,3-b]chromene and benzopyrano[3,2-c]chromene derivatives and their antimicrobial activity	Jardosh HH, Patel MP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	3	1131	1141		10.1007/s00044-012-0115-x	Design, synthesis and molecular modelling of novel 4-thiazolidinones of potential activity against Gram positive bacteria	Radwan AA
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	6	2954	2963		10.1007/s00044-012-0301-x	Microwave-induced CAN promoted atom-economic synthesis of 1H-benzo[b]xanthene and 4H-benzo[g]chromene derivatives of N-allyl quinolone and their antimicrobial activity	Jardosh HH, Patel MP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	6	2975	2983		10.1007/s00044-012-0314-5	Design, synthesis and in vitro antimicrobial activity of novel phenylbenzamido-aminothiazole-based azasterol mimics	Yadlapalli RK, Chourasia OP, Jogi MP, Podile AR, Perali RS
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	7	3204	3212		10.1007/s00044-012-0326-1	Synthesis and evaluation of in vitro antimicrobial activity of novel 2,3-disubstituted-4-thiazolidinones from fatty acid hydrazides	Varshney H, Ahmad A, Farshori NN, Ahmad A, Khan AU, Rauf A
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	8	3831	3842		10.1007/s00044-012-0381-7	Microwave-assisted synthesis of novel 4H-chromene derivatives bearing 2-aryloxyquinoline and their antimicrobial activity assessment	Sangani CB, Shah NM, Patel MP, Patel RG
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013	22	8	4001	4015		10.1007/s00044-012-0389-z	Synthesis and biological evaluation of new [1,3,4]thiadiazepino[7,6-b]quinolin-2-amines as potent anti-microbial agents	Raza HM, Rizvi N, Siddiqui HL, Javaid A, Iqbal M
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	10	2883	2887	23587426	10.1016/j.bmcl.2013.03.078	Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols.	de Almeida AM, Nascimento T, Ferreira BS, de Castro PP, Silva VL, Diniz CG, Le Hyaric M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	11	3267	3272	23602443	10.1016/j.bmcl.2013.03.118	Synthesis and biological evaluation of a class of quinolone triazoles as potential antimicrobial agents and their interactions with calf thymus DNA.	Cui SF, Ren Y, Zhang SL, Peng XM, Damu GL, Geng RX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	16	4532	4539	23850201	10.1016/j.bmcl.2013.06.042	Novel pyrazoline amidoxime and their 1,2,4-oxadiazole analogues: synthesis and pharmacological screening.	Ningaiah S, Bhadraiah UK, Keshavamurthy S, Javarasetty C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	23	6280	6285	24144849	10.1016/j.bmcl.2013.09.082	Pahangensin A and B, two new antibacterial diterpenes from the rhizomes of Alpinia pahangensis Ridley.	Sivasothy Y, Ibrahim H, Paliany AS, Alias SA, Awang K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	24	6764	6768	24176398	10.1016/j.bmcl.2013.10.024	Synthesis and initial biological evaluation of substituted 1-phenylamino-2-thio-4,5-dimethyl-1H-imidazole derivatives.	Yurtta¿ L, Duran M, Demirayak ¿, Gençer HK, Tunal¿ Y.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	4	1008	1012	23312473	10.1016/j.bmcl.2012.12.036	Novel berberine triazoles: synthesis, antimicrobial evaluation and competitive interactions with metal ions to human serum albumin.	Zhang SL, Chang JJ, Damu GL, Fang B, Zhou XD, Geng RX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2013	23	6	1656	1661	23414843	10.1016/j.bmcl.2013.01.079	An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano- and thiopyrano-fused heterocycles.	Parmar NJ, Patel RA, Parmar BD, Talpada NP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	MedChemComm	2013	4	5	839	846		10.1039/C3MD00032J	Berberine azoles as antimicrobial agents: synthesis, biological evaluation and their interactions with human serum albumin	Zhang S, Chang J, Damu GLV, Geng R, Zhou C
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2013	56	13	5613	5625	23786357	10.1021/jm400707f	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.	Berkov-Zrihen Y, Green KD, Labby KJ, Feldman M, Garneau-Tsodikova S, Fridman M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	60		421	430	23318903	10.1016/j.ejmech.2012.11.017	Synthesis and antimicrobial activity of some new benzo and naphthonitrile derivatives.	Fadda AA, Afsah el-SM, Awad RS.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	62		177	186	23353739	10.1016/j.ejmech.2012.12.032	Synthesis, surface tension properties and antibacterial activities of amphiphilic D-galactopyranose derivatives.	Chaveriat L, Gosselin I, Machut C, Martin P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	62		478	485	23416189	10.1016/j.ejmech.2013.01.025	First synthesis and biological evaluation of indeno[2,1-e]pyrazolo[3,4-b]pyrazin-5-one and related derivatives.	El-Emary T, El-Kashef H.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	63		675	684	23567957	10.1016/j.ejmech.2013.03.017	Synthesis and identification of ß-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.	Kathrotiya HG, Patel MP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	64		314	320	23644214	10.1016/j.ejmech.2013.03.039	Synthetic tactics of new class of 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives acting as antimicrobial agents.	Kanawade SB, Toche RB, Rajani DP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	64		329	344	23644216	10.1016/j.ejmech.2013.03.049	Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole.	Zhang HZ, Damu GL, Cai GX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	64		389	395	23648974	10.1016/j.ejmech.2013.04.023	Synthesis and evaluation of antimicrobial activity of hydrazones derived from 3-oxido-1H-imidazole-4-carbohydrazides.	Pieczonka AM, Strzelczyk A, Sadowska B, Mlosto¿ G, St¿czek P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	64		464	476	23669354	10.1016/j.ejmech.2013.04.029	Synthesis, antibacterial activity and cytotoxicity of new fused pyrazolo[1,5-a]pyrimidine and pyrazolo[5,1-c][1,2,4]triazine derivatives from new 5-aminopyrazoles.	Al-Adiwish WM, Tahir MI, Siti-Noor-Adnalizawati A, Hashim SF, Ibrahim N, Yaacob WA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	65		348	359	23747804	10.1016/j.ejmech.2013.05.003	Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.	Jardosh HH, Patel MP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	66		106	113	23792321	10.1016/j.ejmech.2013.04.047	Regioselective synthesis, characterization and antimicrobial evaluation of S-glycosides and S,N-diglycosides of 1,2-Dihydro-5-(1H-indol-2-yl)-1,2,4-triazole-3-thione.	El Ashry el SH, El Tamany el SH, El Fattah Mel D, Boraei AT, Abd El-Nabi HM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	66		415	422	23831694	10.1016/j.ejmech.2013.04.043	Microwave-assisted synthesis of some new pyrazolopyridines and their antioxidant, antitumor and antimicrobial activities.	El-Borai MA, Rizk HF, Beltagy DM, El-Deeb IY.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	67		367	372	23891981	10.1016/j.ejmech.2013.04.069	New pyridazine-fluorine derivatives: synthesis, chemistry and biological activity. Part II.	Tucaliuc RA, Cotea VV, Niculaua M, Tuchilus C, Mantu D, Mangalagiu II.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	67		54	59	23835482	10.1016/j.ejmech.2013.06.029	Synthesis, antimicrobial and cytotoxic activities of some novel thiazole clubbed 1,3,4-oxadiazoles.	Desai NC, Bhatt N, Somani H, Trivedi A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	68		444	453	23994872	10.1016/j.ejmech.2013.07.041	Synthesis and biological evaluation of novel ocotillol-type triterpenoid derivatives as antibacterial agents.	Zhou Z, Ma C, Zhang H, Bi Y, Chen X, Tian H, Xie X, Meng Q, Lewis PJ, Xu J.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2013	70		294	307	24161706	10.1016/j.ejmech.2013.09.046	Phosphorus-nitrogen compounds part 27. Syntheses, structural characterizations, antimicrobial and cytotoxic activities, and DNA interactions of new phosphazenes bearing secondary amino and pendant (4-fluorobenzyl)spiro groups.	Akba¿ H, Okumu¿ A, K¿l¿ç Z, Hökelek T, Süzen Y, Koç LY, Aç¿k L, Celik ZB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013			1	10		10.1007/s00044-013-0720-3	Design, synthesis, and antimicrobial activity of some novel homodrimane sesquiterpenoids with diazine skeleton	Kuchkova K, Aricu A, Secara E, Barba A, Vlad P, Ungur N, Tuchilus C, Shova S, Zbancioc G, Mangalagiu II
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013			1	12		10.1007/s00044-013-0847-2	Synthesis, molecular docking studies, and in vitro screening of barbiturates/thiobarbiturates as antibacterial and cholinesterase inhibitors	Mumtaz S, Hussain R, Rauf A, Fatmi MQ, Bokhari H, Oelgemoller M, Qureshi AM
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013			1	17		10.1007/s00044-013-0775-1	Synthesis, antimicrobial and cytotoxic activity of 2-azetidinone derivatives of pyridyl benzimidazoles	Desai NC, Pandya DD, Kotadiya GM, Desai P
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013			1	7		10.1007/s00044-013-0799-6	Synthesis and pharmacological evaluation of novel 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one derivatives as potential antimicrobial agents	Patel V, Bhatt N, Bhatt P, Joshi HD
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Med Chem Res	2013			1	9		10.1007/s00044-013-0840-9	An efficient synthesis, characterization, and antimicrobial screening of tetrahydropyrimidine derivatives	Godhani DR, Dobariya PB, Jogel AA, Sanghani AM, Mehta JP
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2014	22	10	2844	2854	24751553	10.1016/j.bmc.2014.03.044	Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.	Zorzi RR, Jorge SD, Palace-Berl F, Pasqualoto KF, Bortolozzo Lde S, de Castro Siqueira AM, Tavares LC.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2014	22	8	2409	2415	24680059	10.1016/j.bmc.2014.03.004	Synthesis, molecular docking and biological evaluation of metronidazole derivatives containing piperazine skeleton as potential antibacterial agents.	Wang SF, Yin Y, Qiao F, Wu X, Sha S, Zhang L, Zhu HL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2014	24	1	308	313	24295786	10.1016/j.bmcl.2013.11.013	1,2,3-Triazole-derived naphthalimides as a novel type of potential antimicrobial agents: synthesis, antimicrobial activity, interaction with calf thymus DNA and human serum albumin.	Lv JS, Peng XM, Kishore B, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2014	24	1	49	53	24360606	10.1016/j.bmcl.2013.12.002	Synthesis and biological evaluation of ¿-hydroxyalkylphosphonates as new antimicrobial agents.	Faísca Phillips AM, Barros MT, Pacheco M, Dias R.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2014	24	19	4626	4629	25219900	10.1016/j.bmcl.2014.08.047	Synthesis and biological evaluation of a new series of N-acyldiamines as potential antibacterial and antifungal agents.	Ferreira Bda S, de Almeida AM, Nascimento TC, de Castro PP, Silva VL, Diniz CG, Le Hyaric M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2014	24	23	5525	5529	25455183	10.1016/j.bmcl.2014.09.081	Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity.	Maccari G, Sanfilippo S, De Luca F, Deodato D, Casian A, Dasso Lang MC, Zamperini C, Dreassi E, Rossolini GM, Docquier JD, Botta M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2014	24	9	2198	2201	24685541	10.1016/j.bmcl.2014.03.008	Environmentally benign synthesis and antimicrobial study of novel chalcogenophosphates.	Mitra S, Mukherjee S, Sen SK, Hajra A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	ACS Med. Chem. Lett.	2014	5	9	1005	1009	25221657	10.1021/ml5001933	2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.	Naik M, Ghorpade S, Jena LK, Gorai G, Narayan A, Guptha S, Sharma S, Dinesh N, Kaur P, Nandishaiah R, Bhat J, Balakrishnan G, Humnabadkar V, Ramachandran V, Naviri LK, Khadtare P, Panda M, Iyer PS, Chatterji M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2014	57	10	4263	4272	24801877	10.1021/jm500194e	New Ianthelliformisamine derivatives as antibiotic enhancers against resistant Gram-negative bacteria.	Pieri C, Borselli D, Di Giorgio C, De Méo M, Bolla JM, Vidal N, Combes S, Brunel JM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2014	57	20	8398	8420	25238443	10.1021/jm500853v	Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.	Feng L, Maddox MM, Alam MZ, Tsutsumi LS, Narula G, Bruhn DF, Wu X, Sandhaus S, Lee RB, Simmons CJ, Tse-Dinh YC, Hurdle JG, Lee RE, Sun D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2014	57	21	8947	8959	25280369	10.1021/jm501082n	Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.	Silvers MA, Robertson GT, Taylor CM, Waldrop GL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2014	57	22	9463	9472	25347820	10.1021/jm501069h	Exploiting the therapeutic potential of 8-ß-d-glucopyranosylgenistein: synthesis, antidiabetic activity, and molecular interaction with islet amyloid polypeptide and amyloid ß-peptide (1-42).	Jesus AR, Dias C, Matos AM, de Almeida RF, Viana AS, Marcelo F, Ribeiro RT, Macedo MP, Airoldi C, Nicotra F, Martins A, Cabrita EJ, Jiménez-Barbero J, Rauter AP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2014	57	3	1063	1078	24450337	10.1021/jm401752p	4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.	Foley TL, Rai G, Yasgar A, Daniel T, Baker HL, Attene-Ramos M, Kosa NM, Leister W, Burkart MD, Jadhav A, Simeonov A, Maloney DJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	71		148	159	24291568	10.1016/j.ejmech.2012.09.047	Synthesis and biological evaluation of ¿-triazolyl chalcones as a new type of potential antimicrobial agents and their interaction with calf thymus DNA and human serum albumin.	Yin BT, Yan CY, Peng XM, Zhang SL, Rasheed S, Geng RX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	72		46	51	24342667	10.1016/j.ejmech.2013.10.064	Synthesis, characterization, cytotoxicity and antibacterial activity of an anthracenyl-linked bis(pyrazolyl)methane ligand and its zinc(II) complexes.	Ruan BF, Zhu YZ, Liu WD, Song BA, Tian YP.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	73		187	194	24398288	10.1016/j.ejmech.2013.11.041	Synthesis and antimicrobial activity of (1,4-phenylene)bis(arylsulfonylpyrazoles and isoxazoles).	Lavanya G, Mallikarjuna Reddy L, Padmavathi V, Padmaja A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2014	77	10	2280	2287	25265160	10.1021/np5005449	Bioactive sulfur-containing sulochrin dimers and other metabolites from an Alternaria sp. isolate from a Hawaiian soil sample.	Cai S, King JB, Du L, Powell DR, Cichewicz RH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2014	77	5	1164	1169	24742254	10.1021/np4011037	Cyclohexadepsipeptides of the isaridin class from the marine-derived fungus Beauveria felina EN-135.	Du FY, Zhang P, Li XM, Li CS, Cui CM, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	78		207	216	24681985	10.1016/j.ejmech.2014.02.015	Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.	Kalaria PN, Satasia SP, Raval DK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	82		347	354	24929288	10.1016/j.ejmech.2014.06.001	Synthesis and antimicrobial activity of amine linked bis- and tris-heterocycles.	Bhanu Prakash T, Dinneswara Reddy G, Padmaja A, Padmavathi V.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	82		480	489	24934572	10.1016/j.ejmech.2014.06.004	Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs.	Desai NC, Shihory NR, Kotadiya GM, Desai P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	82		565	573	24941130	10.1016/j.ejmech.2014.05.084	Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells.	Emirda¿-Öztürk S, Karay¿ld¿r¿m T, Çapc¿-Karagöz A, Alanku¿-Çal¿¿kan Ö, Özmen A, Poyrazo¿lu-Çoban E.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	84		51	58	25016227	10.1016/j.ejmech.2014.07.008	Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.	Karad SC, Purohit VB, Raval DK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2014	87		662	676	25305333	10.1016/j.ejmech.2014.10.005	Phosphorus-nitrogen compounds. Part 29. Syntheses, crystal structures, spectroscopic and stereogenic properties, electrochemical investigations, antituberculosis, antimicrobial and cytotoxic activities and DNA interactions of ansa-spiro-ansa cyclotetraphosphazenes.	Elmas G, Okumu¿ A, Koç LY, Soltanzade H, K¿l¿ç Z, Hökelek T, Dal H, Aç¿k L, Üstünda¿ Z, Dündar D, Yavuz M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2015	103		594	599	26414807	10.1016/j.ejmech.2013.12.036	Synthesis, characterization, crystal structure determination and biological screening of novel N-1 and C5 alkyl substituted scaffolds of pyrimidine.	Pathan NB, Parvez A, Bader A, Shaheen U, Hadda TB.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2015	23	13	3163	3174	26001343	10.1016/j.bmc.2015.04.069	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.	Magoulas GE, Kostopoulou ON, Garnelis T, Athanassopoulos CM, Kournoutou GG, Leotsinidis M, Dinos GP, Papaioannou D, Kalpaxis DL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2015	23	16	5198	5209	26037612	10.1016/j.bmc.2015.04.078	Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.	Washington AZ, Tapadar S, George A, Oyelere AK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2015	23	17	5334	5344	26264847	10.1016/j.bmc.2015.07.062	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.	Tran TP, Vo DD, Di Giorgio A, Duca M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem.	2015	23	18	6148	6156	26304108	10.1016/j.bmc.2015.07.075	Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents.	Guo ZH, Yin Y, Wang C, Wang PF, Zhang XT, Wang ZC, Zhu HL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	12	2963	2967	26611524	10.1021/acs.jnatprod.5b00674	Bacaryolanes A-C, Rare Bacterial Caryolanes from a Mangrove Endophyte.	Ding L, Goerls H, Dornblut K, Lin W, Maier A, Fiebig HH, Hertweck C.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	3	402	412	25646964	10.1021/np500775e	Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.	Whalen KE, Poulson-Ellestad KL, Deering RW, Rowley DC, Mincer TJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	4	844	849	25763602	10.1021/acs.jnatprod.5b00004	Antimicrobial Phenolic Bisabolanes and Related Derivatives from Penicillium aculeatum SD-321, a Deep Sea Sediment-Derived Fungus.	Li XD, Li XM, Xu GM, Zhang P, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	4	909	913	25730346	10.1021/np5007839	Rubrumazines A-C, Indolediketopiperazines of the Isoechinulin Class from Eurotium rubrum MA-150, a Fungus Obtained from Marine Mangrove-Derived Rhizospheric Soil.	Meng LH, Du FY, Li XM, Pedpradab P, Xu GM, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	5	1147	1153	25927817	10.1021/acs.jnatprod.5b00155	Antibacterial Balsacones J-M, Hydroxycinnamoylated Dihydrochalcones from Populus balsamifera Buds.	Simard F, Gauthier C, Chiasson É, Lavoie S, Mshvildadze V, Legault J, Pichette A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Nat. Prod.	2015	78	6	1348	1356	26034885	10.1021/acs.jnatprod.5b00206	Antibacterial Labdane Diterpenoids from Vitex vestita.	Corlay N, Lecsö-Bornet M, Leborgne E, Blanchard F, Cachet X, Bignon J, Roussi F, Butel MJ, Awang K, Litaudon M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2015	92		514	530	25599949	10.1016/j.ejmech.2015.01.026	Medicinal uses, phytochemistry and pharmacology of family Sterculiaceae: a review.	Al Muqarrabun LM, Ahmat N.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur. J. Med. Chem.	2016	112		270	279	26900659	10.1016/j.ejmech.2016.02.016	Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.	Karad SC, Purohit VB, Thakor P, Thakkar VR, Raval DK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2016	122		205	215	27371924	10.1016/j.ejmech.2016.06.031	Design, synthesis and biological evaluation of berberine-benzimidazole hybrids as new type of potentially DNA-targeting antimicrobial agents.	Jeyakkumar P, Zhang L, Avula SR, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2016	122		647	655	27448921	10.1016/j.ejmech.2016.06.014	Synthesis and antimicrobial activity of styryl/pyrrolyl/pyrazolyl sulfonylmethyl-1,3,4-oxadiazolyl amines and styryl/pyrrolyl/pyrazolyl sulfonylmethyl-1,3,4-thiadiazolyl amines.	Sravya G, Yamini G, Padmavathi V, Padmaja A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2016	124		935	945	27769037	10.1016/j.ejmech.2016.10.011	Multi-targeting exploration of new 2-aminothiazolyl quinolones: Synthesis, antimicrobial evaluation, interaction with DNA, combination with topoisomerase IV and penetrability into cells.	Cheng Y, Avula SR, Gao WW, Addla D, Tangadanchu VKR, Zhang L, Lin JM, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2016	24	24	6276	6290	27234886	10.1016/j.bmc.2016.05.021	Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide family of natural products.	Molloy EM, Tietz JI, Blair PM, Mitchell DA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2016	26	13	3127	3134	27184767	10.1016/j.bmcl.2016.04.089	GroEL/ES inhibitors as potential antibiotics.	Abdeen S, Salim N, Mammadova N, Summers CM, Frankson R, Ambrose AJ, Anderson GG, Schultz PG, Horwich AL, Chapman E, Johnson SM.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2016	26	13	3167	3171	27173802	10.1016/j.bmcl.2016.04.080	Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities.	Tantak MP, Gupta V, Nikhil K, Arun V, Singh RP, Jha PN, Shah K, Kumar D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg. Med. Chem. Lett.	2016	26	16	3950	3954	27423480	10.1016/j.bmcl.2016.07.006	Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents.	Zhao Y, Shadrick WR, Wallace MJ, Wu Y, Griffith EC, Qi J, Yun MK, White SW, Lee RE.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2016	26	20	5029	5031	27612543	10.1016/j.bmcl.2016.08.093	Citrinovirin with a new norditerpene skeleton from the marine algicolous fungus Trichoderma citrinoviride.	Liang XR, Miao FP, Song YP, Liu XH, Ji NY.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2016	26	21	5300	5303	27680587	10.1016/j.bmcl.2016.09.044	Allyl and prenyl ethers of mansonone G, new potential semisynthetic antibacterial agents.	Hairani R, Mongkol R, Chavasiri W.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2016	59	10	4488	4510	27115717	10.1021/acs.jmedchem.5b01678	Novel 3-Aminothiazolquinolones: Design, Synthesis, Bioactive Evaluation, SARs, and Preliminary Antibacterial Mechanism.	Cui SF, Addla D, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J. Med. Chem.	2016	59	2	624	646	26818454	10.1021/acs.jmedchem.5b01451	Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity.	Goodreid JD, Janetzko J, Santa Maria JP, Wong KS, Leung E, Eger BT, Bryson S, Pai EF, Gray-Owen SD, Walker S, Houry WA, Batey RA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	MedChemComm	2016	7	10	1988	1994		10.1039/C6MD00357E		
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Nat Prod	2016	79	5	1347	1353	27148955	10.1021/acs.jnatprod.5b01153	Aspewentins D-H, 20-Nor-isopimarane Derivatives from the Deep Sea Sediment-Derived Fungus Aspergillus wentii SD-310.	Li XD, Li XM, Li X, Xu GM, Liu Y, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Nat Prod	2016	79	8	2045	2052	27489998	10.1021/acs.jnatprod.6b00349	Oryzamides A-E, Cyclodepsipeptides from the Sponge-Derived Fungus Nigrospora oryzae PF18.	Ding LJ, Yuan W, Liao XJ, Han BN, Wang SP, Li ZY, Xu SH, Zhang W, Lin HW.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2017	126		894	909	27988464	10.1016/j.ejmech.2016.12.016	Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.	Karad SC, Purohit VB, Thummar RP, Vaghasiya BK, Kamani RD, Thakor P, Thakkar VR, Thakkar SS, Ray A, Raval DK.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Eur J Med Chem	2017	127		748	756	27823890	10.1016/j.ejmech.2016.10.054	New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E. aerogenes Gram-negative bacteria.	Allam A, Maigre L, Alves de Sousa R, Dumont E, Vergalli J, Pagès JM, Artaud I.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2017	25	1	132	137	27793449	10.1016/j.bmc.2016.10.019	Antibacterial profiling of abietane-type diterpenoids.	Helfenstein A, Vahermo M, Nawrot DA, Demirci F, ¿¿can G, Krogerus S, Yli-Kauhaluoma J, Moreira VM, Tammela P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2017	25	11	2868	2877	28366267	10.1016/j.bmc.2017.03.040	Metabolite diversification by cultivation of the endophytic fungus Dothideomycete sp. in halogen containing media: Cultivation of terrestrial fungus in seawater.	Wijesekera K, Mahidol C, Ruchirawat S, Kittakoop P.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2017	25	15	4064	4075	28634040	10.1016/j.bmc.2017.05.054	1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.	Thakkar SS, Thakor P, Doshi H, Ray A.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2017	25	16	4433	4443	28666857	10.1016/j.bmc.2017.06.029	Structure-activity relationship studies on thiaplidiaquinones A and B as novel inhibitors of Plasmodium falciparum and farnesyltransferase.	Cadelis MM, Bourguet-Kondracki ML, Dubois J, Kaiser M, Brunel JM, Barker D, Copp BR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem	2017	25	20	5396	5406	28789907	10.1016/j.bmc.2017.07.057	Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.	Thakkar SS, Thakor P, Ray A, Doshi H, Thakkar VR.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2017	27	11	2302	2307	28434766	10.1016/j.bmcl.2017.04.044	Stereoselective synthesis of enantiopure N-substituted pyrrolidin-2,5-dione derivatives by 1,3-dipolar cycloaddition and assessment of their in vitro antioxidant and antibacterial activities.	Ghannay S, Bakari S, Ghabi A, Kadri A, Msaddek M, Aouadi K.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2017	27	14	3148	3155	28539243	10.1016/j.bmcl.2017.05.032	Synthesis, SAR and molecular docking studies of benzo[d]thiazole-hydrazones as potential antibacterial and antifungal agents.	Zha GF, Leng J, Darshini N, Shubhavathi T, Vivek HK, Asiri AM, Marwani HM, Rakesh KP, Mallesha N, Qin HL.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2017	27	3	387	392	28065568	10.1016/j.bmcl.2016.12.068	Synthesis and antimicrobial studies of novel derivatives of 4-(4-formyl-3-phenyl-1H-pyrazol-1-yl)benzoic acid as potent anti-Acinetobacter baumannii agents.	Allison D, Delancey E, Ramey H, Williams C, Alsharif ZA, Al-Khattabi H, Ontko A, Gilmore D, Alam MA.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	Bioorg Med Chem Lett	2017	27	8	1737	1743	28302402	10.1016/j.bmcl.2017.02.071	Novel benzimidazolyl tetrahydroprotoberberines: Design, synthesis, antimicrobial evaluation and multi-targeting exploration.	Jeyakkumar P, Liu HB, Gopala L, Cheng Y, Peng XM, Geng RX, Zhou CH.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Med Chem	2017	60	14	6098	6118	28654257	10.1021/acs.jmedchem.7b00355	Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.	Seydlová G, Pohl R, Zborníková E, Ehn M, ¿imák O, Panova N, Kolá¿ M, Bogdanová K, Ve¿e¿ová R, Fi¿er R, ¿anderová H, Vítovská D, Sudzinová P, Pospí¿il J, Benada O, K¿í¿ek T, Sedlák D, Bart¿n¿k P, Krásný L, Rejman D.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Med Chem	2017	60	9	3684	3702	28409644	10.1021/acs.jmedchem.6b01742	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.	Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Med Chem	2017	60	9	3902	3912	28383902	10.1021/acs.jmedchem.7b00204	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.	Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130	J Nat Prod	2017	80	1	162	168	27992187	10.1021/acs.jnatprod.6b00797	Antioxidant Hydroanthraquinones from the Marine Algal-Derived Endophytic Fungus Talaromyces islandicus EN-501.	Li HL, Li XM, Li X, Wang CY, Liu H, Kassack MU, Meng LH, Wang BG.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									DrugMatrix	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									Open TG-GATES	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL	CHEMBL130									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL PALMITATE	CHEMBL1506									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL SODIUM SUCCINATE	CHEMBL1200729									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL SODIUM SUCCINATE	CHEMBL1200729									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CHLORAMPHENICOL SODIUM SUCCINATE	CHEMBL1200729									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CHLORTETRACYCLINE HYDROCHLORIDE	CHEMBL2146063									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Biochem. J.	2000	351	1	95	105	10998351	10.1042/0264-6021:3510095	Specificity and mechanism of action of some commonly used protein kinase inhibitors.	Davies SP, Reddy H, Caivano M, Cohen P.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Bioorg. Med. Chem. Lett.	2003	13	18	3031	3034	12941327	10.1016/s0960-894x(03)00640-1	Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade.	Berger D, Dutia M, Powell D, Wu B, Wissner A, Boschelli DH, Floyd MB, Zhang N, Torres N, Levin J, Du X, Wojciechowicz D, Discafani C, Kohler C, Kim SC, Feldberg LR, Collins K, Mallon R.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Biochem. J.	2007	408	3	297	315	17850214	10.1042/bj20070797	The selectivity of protein kinase inhibitors: a further update.	Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	J. Med. Chem.	2007	50	21	5090	5102	17880056	10.1021/jm0704548	4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.	Spicer JA, Rewcastle GW, Kaufman MD, Black SL, Plummer MS, Denny WA, Quin J, Shahripour AB, Barrett SD, Whitehead CE, Milbank JB, Ohren JF, Gowan RC, Omer C, Camp HS, Esmaeil N, Moore K, Sebolt-Leopold JS, Pryzbranowski S, Merriman RL, Ortwine DF, Warmus JS, Flamme CM, Pavlovsky AG, Tecle H.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Bioorg. Med. Chem. Lett.	2008	18	23	6171	6174	18951019	10.1016/j.bmcl.2008.10.015	2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).	Warmus JS, Flamme C, Zhang LY, Barrett S, Bridges A, Chen H, Gowan R, Kaufman M, Sebolt-Leopold J, Leopold W, Merriman R, Ohren J, Pavlovsky A, Przybranowski S, Tecle H, Valik H, Whitehead C, Zhang E.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Bioorg. Med. Chem. Lett.	2008	18	24	6501	6504	18952427	10.1016/j.bmcl.2008.10.054	The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.	Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Bioorg. Med. Chem. Lett.	2008	18	7	2346	2350	18346893	10.1016/j.bmcl.2008.02.068	Pharmacophore identification of Raf-1 kinase inhibitors.	Zhu T, Jiao Y, Chen YD, Wang X, Li HF, Zhang LY, Lu T.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Bioorg. Med. Chem. Lett.	2010	20	15	4526	4530	20580230	10.1016/j.bmcl.2010.06.030	Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.	Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442	Eur. J. Med. Chem.	2012	47		125	137	22074985	10.1016/j.ejmech.2011.10.031	3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.	Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S.
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442		2013							5-substituted-2-phenylamino benzamides as MEK inhibitors	
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	CI-1040	CHEMBL105442									Unpublished dataset	
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2002	45	5	1045	1051	11855984	10.1021/jm0102598	Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.	Goodman SL, Hölzemann G, Sulyok GA, Kessler H.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2005	48	24	7675	7687	16302808	10.1021/jm050698x	Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.	Casiraghi G, Rassu G, Auzzas L, Burreddu P, Gaetani E, Battistini L, Zanardi F, Curti C, Nicastro G, Belvisi L, Motto I, Castorina M, Giannini G, Pisano C.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2006	49	5	1808	1817	16509596	10.1021/jm0511334	Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.	Dal Pozzo A, Ni M, Muzi L, de Castiglione R, Mondelli R, Mazzini S, Penco S, Pisano C, Castorina M, Giannini G.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Eur. J. Med. Chem.	2007	42	3	334	343	17184884	10.1016/j.ejmech.2006.10.015	Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.	Raboisson P, Desjarlais RL, Reed R, Lattanze J, Chaikin M, Manthey CL, Tomczuk BE, Marugán JJ.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Bioorg. Med. Chem.	2008	16	8	4262	4271	18343671	10.1016/j.bmc.2008.02.080	Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.	Salvati M, Cordero FM, Pisaneschi F, Melani F, Gratteri P, Cini N, Bottoncetti A, Brandi A.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2008	51	6	1771	1782	18303826	10.1021/jm701214z	Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.	Zanardi F, Burreddu P, Rassu G, Auzzas L, Battistini L, Curti C, Sartori A, Nicastro G, Menchi G, Cini N, Bottoncetti A, Raspanti S, Casiraghi G.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Bioorg. Med. Chem.	2009	17	4	1542	1549	19195898	10.1016/j.bmc.2009.01.006	Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity.	Cini N, Trabocchi A, Menchi G, Bottoncetti A, Raspanti S, Pupi A, Guarna A.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2010	53	11	4332	4353	20218623	10.1021/jm9018756	Emerging targets in osteoporosis disease modification.	Allen JG, Fotsch C, Babij P.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Bioorg. Med. Chem. Lett.	2013	23	22	6068	6072	24095096	10.1016/j.bmcl.2013.09.031	Synthesis and in vitro evaluation of a novel radioligand for ¿vß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).	Monaco A, Zoete V, Alghisi GC, Rüegg C, Michelin O, Prior J, Scapozza L, Seimbille Y.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2013	56	4	1509	1519	23362923	10.1021/jm301221x	Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes ¿5ß1 and ¿vß6: conformational control through flanking amino acids.	Bochen A, Marelli UK, Otto E, Pallarola D, Mas-Moruno C, Di Leva FS, Boehm H, Spatz JP, Novellino E, Kessler H, Marinelli L.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2014	57	13	5829	5834	24949551	10.1021/jm5004478	Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.	Hegemann JD, De Simone M, Zimmermann M, Knappe TA, Xie X, Di Leva FS, Marinelli L, Novellino E, Zahler S, Kessler H, Marahiel MA.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2014	57	15	6301	6315	24568695	10.1021/jm5000547	Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.	Sheldrake HM, Patterson LH.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	J. Med. Chem.	2014	57	8	3410	3417	24654918	10.1021/jm500092w	Pharmacophoric modifications lead to superpotent ¿vß3 integrin ligands with suppressed ¿5ß1 activity.	Neubauer S, Rechenmacher F, Brimioulle R, Di Leva FS, Bochen A, Sobahi TR, Schottelius M, Novellino E, Mas-Moruno C, Marinelli L, Kessler H.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Bioorg. Med. Chem.	2016	24	4	703	711	26753814	10.1016/j.bmc.2015.12.039	Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual ¿Vß3 and ¿5ß1 integrin ligands.	Sernissi L, Trabocchi A, Scarpi D, Bianchini F, Occhiato EG.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876	Bioorg. Med. Chem.	2016	24	5	989	994	26818999	10.1016/j.bmc.2016.01.023	Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.	Vasile F, Menchi G, Lenci E, Guarna A, Potenza D, Trabocchi A.
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876									Unpublished dataset	
1878.0666666666666667	9606	Homo sapiens	CILENGITIDE	CHEMBL429876									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1977	20	10	1317	1323	903918	10.1021/jm00220a018	Compounds with gastric antisecretory activity. 1. Phenoxyalkylamines.	Cross PE, Dickinson RP, Kemp JE, Leeming PR, Pullman LG.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1977	20	4	537	540	850239	10.1021/jm00214a015	Experimental antiulcer drugs. 1. Indole-1-alkanamides and pyrrole-1-alkanamides.	Bell MR, Zalay AW, Oesterlin R, Clemans SD, Dumas DJ, Bradford JC, Rozitis J.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1977	20	7	901	906	17751	10.1021/jm00217a007	Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine.	Durant GJ, Emmett JC, Ganellin CR, Miles PD, Parsons ME, Prain HD, White GR.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1977	20	8	1068	1071	894677	10.1021/jm00218a016	Experimental antiulcer drugs. 2. 2-Substituted 2,4,5,6-tetrahydro-1,3,4,6,6-pentamethylcyclopenta[c]pyrrole-4-carboxamides.	Oesterlin R, Bell MR, McGarry RH, Hlavac AG, Bradford JC, Rozitis J.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1981	24	8	1010	1013	7328593	10.1021/jm00140a020	Gastric antisecretory agents. 2. Antisecretory activity of 9-[(aminoalkyl)thio]-9H-xanthenes and 5-[(aminoalkyl)thio]-5H-[1]benzopyrano[2,3-b]pyridines.	Bristol JA, Gold EH, Gross I, Lovey RG, Long JF.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1981	24	8	927	932	7328596	10.1021/jm00140a004	Gastric antisecretory agents. 1. Antisecretory and antiulcer activity of 5H-[1]benzopyrano[2,3-b]pyridin-5-ylureas and 5H-[1]benzothiopyrano[2,3-b]pyridin-5-ylureas.	Bristol JA, Gold EH, Lovey RG, Long JF.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1981	24	9	1095	1097	6116806	10.1021/jm00141a017	Potential histamine H2-receptor blockers. 3- and 2-indole derivatives as immobile analogues of tautomeric forms of cimetidine.	Tecle H, Robichaud L, Schwender CF.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1982	25	3	207	210	6121913	10.1021/jm00345a002	Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists.	Lumma WC, Anderson PS, Baldwin JJ, Bolhofer WA, Habecker CN, Hirshfield JM, Pietruszkiewicz AM, Randall WC, Torchiana ML, Britcher SF, Clineschmidt BV, Denny GH, Hirschmann R, Hoffman MJ, Phillips BT, Streeter KB.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1982	25	3	210	212	6121914	10.1021/jm00345a003	1,2,5-thiadiazole 1-oxide and 1,1-dioxide derivatives. A new class of potent histamine H2-receptor antagonists.	Algieri AA, Luke GM, Standridge RT, Brown M, Partyka RA, Crenshaw RR.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1982	25	8	975	982	6126589	10.1021/jm00350a018	Pyridazinones. 1. Synthesis and antisecretory and antiulcer activities of thio amide derivatives.	Yamada T, Nobuhara Y, Yamaguchi A, Ohki M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	1	1	6	6131126	10.1021/jm00355a001	Bioisosteric design of conformationally restricted pyridyltriazole histamine H2-receptor antagonists.	Lipinski CA.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	11	1650	1653	6631919	10.1021/jm00365a020	A deuterium isotope effect on the inhibition of gastric secretion by N,N-dimethyl-N'-[2-(diisopropylamino)ethyl]-N'-(4,6-dimethyl-2-pyridyl)urea. Synthesis of metabolites.	Hoffman JM, Habecker CN, Pietruszkiewicz AM, Bolhofer WA, Cragoe EJ, Torchiana ML, Hirschmann R.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	2	140	144	6131129	10.1021/jm00356a005	Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidine.	Hoffman JM, Pietruszkiewicz AM, Habecker CN, Phillips BT, Bolhofer WA, Cragoe EJ, Torchiana ML, Lumma WC, Baldwin JJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	3	373	381	6402597	10.1021/jm00357a012	Pyridazinones. 2. Synthesis and antisecretory and antiulcer activities of thiourea and 2-cyanoguanidine derivatives.	Yamada T, Nobuhara Y, Shimamura H, Tsukamoto Y, Yoshihara K, Yamaguchi A, Ohki M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	4	535	538	6834385	10.1021/jm00358a014	4-(Diphenylmethyl)-1-[(imino)methyl]piperidines as gastric antisecretory agents.	Scott MK, Jacoby HI, Mills JE, Bonfilio AC, Rasmussen CR.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	4	538	544	6834386	10.1021/jm00358a015	Inhibitors of gastric acid secretion: antisecretory 2-pyridylurea derivatives.	Bolhofer WA, Deana AA, Habecker CN, Hoffman JM, Gould NP, Pietruszkiewicz AM, Prugh JD, Torchiana ML, Cragoe EJ, Hirschmann R.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1983	26	8	1144	1149	6876082	10.1021/jm00362a011	Pyridazinones. 3. Synthesis, antisecretory, and antiulcer activities of 2-cyanoguanidine derivatives.	Yamada T, Shimamura H, Tsukamoto Y, Yamaguchi A, Ohki M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1984	27	3	380	386	6142117	10.1021/jm00369a025	(Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists.	Donetti A, Cereda E, Bellora E, Gallazzi A, Bazzano C, Vanoni P, Del Soldato P, Micheletti R, Pagani F, Giachetti A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1984	27	7	849	857	6145803	10.1021/jm00373a007	Histamine H2 receptor antagonists. 1. Synthesis of N-cyano and N-carbamoyl amidine derivatives and their biological activities.	Yanagisawa I, Hirata Y, Ishii Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1985	28	11	1628	1636	2866245	10.1021/jm00149a015	Pseudosymmetry and bioisosterism in biaryl pyridyl competitive histamine H2-receptor antagonists.	Lipinski CA, LaMattina JL, Hohnke LA.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1985	28	3	381	388	2579237	10.1021/jm00381a019	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.	McNeal ET, Lewandowski GA, Daly JW, Creveling CR.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1986	29	1	44	49	3941412	10.1021/jm00151a007	Dipole moment in relation to H2 receptor histamine antagonist activity for cimetidine analogues.	Young RC, Durant GJ, Emmett JC, Ganellin CR, Graham MJ, Mitchell RC, Prain HD, Roantree ML.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1986	29	11	2154	2163	2878075	10.1021/jm00161a005	Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists.	Lipinski CA, LaMattina JL, Oates PJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	1	208	211	3806596	10.1021/jm00384a036	Studies on the active molecular species of the H2 receptor antagonists cimetidine and mifentidine.	Haaksma EE, Rademaker B, Kramer K, Eriks JC, Bast A, Timmerman H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	1	24	29	3806600	10.1021/jm00384a004	Synthesis and antisecretory and antiulcer activities of derivatives and analogues of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide.	Aloup JC, Bouchaudon J, Farge D, James C, Deregnaucourt J, Hardy-Houis M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	10	1787	1793	2888895	10.1021/jm00393a018	Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives.	Yanagisawa I, Hirata Y, Ishii Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	11	2031	2046	3669011	10.1021/jm00394a018	Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues.	Kaminski JJ, Hilbert JM, Pramanik BN, Solomon DM, Conn DJ, Rizvi RK, Elliott AJ, Guzik H, Lovey RG, Domalski MS.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	12	2270	2277	3681897	10.1021/jm00395a015	2-Oxo-1,8-naphthyridine-3-carboxylic acid derivatives with potent gastric antisecretory properties.	Santilli AA, Scotese AC, Bauer RF, Bell SC.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	5	894	899	3572978	10.1021/jm00388a025	Antisecretory activity of human, dog, and rat metabolites of fenoctimine.	Scott MK, Jacoby HI, Bonfilio AC, Corcoran TW, Lopez IS.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1987	30	7	1150	1156	2885416	10.1021/jm00390a006	Zwitterionic analogues of cimetidine as H2 receptor antagonists.	Young RC, Ganellin CR, Graham MJ, Mitchell RC, Roantree ML, Tashma Z.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1988	31	3	656	671	2894467	10.1021/jm00398a028	Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.	Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1988	31	4	779	785	3351856	10.1021/jm00399a016	Synthesis and antiulcer activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.	Kumazawa T, Harakawa H, Obase H, Oiji Y, Tanaka H, Shuto K, Ishii A, Oka T, Nakamizo N.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1988	31	9	1778	1785	2842503	10.1021/jm00117a018	Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity.	Sanfilippo PJ, Urbanski M, Press JB, Hajos ZG, Shriver DA, Scott CK.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1990	33	1	4	11	1967317	10.1021/jm00163a001	Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?	Timmerman H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1990	33	2	543	552	2153817	10.1021/jm00164a012	Antiulcer agents. 4-substituted 2-guanidinothiazoles: reversible, competitive, and selective inhibitors of gastric H+,K(+)-ATPase.	LaMattina JL, McCarthy PA, Reiter LA, Holt WF, Yeh LA.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1991	34	3	869	877	2002467	10.1021/jm00107a001	Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.	Mason RP, Rhodes DG, Herbette LG.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1992	35	12	2231	2238	1613748	10.1021/jm00090a013	Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor.	Hirschfeld J, Buschauer A, Elz S, Schunack W, Ruat M, Traiffort E, Schwartz JC.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1992	35	13	2446	2451	1352351	10.1021/jm00091a012	Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.	Miyashita M, Matsumoto T, Matsukubo H, Iinuma F, Taga F, Sekiguchi H, Hamada K, Okamura K, Nishino K.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1992	35	18	3413	3422	1326634	10.1021/jm00096a018	Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines.	Ife RJ, Brown TH, Keeling DJ, Leach CA, Meeson ML, Parsons ME, Reavill DR, Theobald CJ, Wiggall KJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1994	37	1	57	66	7904648	10.1021/jm00027a007	Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.	Katsura Y, Inoue Y, Tomishi T, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1995	38	14	2763	2773	7629814	10.1021/jm00014a027	Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.	Ife RJ, Brown TH, Blurton P, Keeling DJ, Leach CA, Meeson ML, Parsons ME, Theobald CJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1995	38	25	4937	4943	8523407	10.1021/jm00025a011	Synthesis and biological evaluation of substituted flavones as gastroprotective agents.	Ares JJ, Outt PE, Randall JL, Murray PD, Weisshaar PS, O'Brien LM, Ems BL, Kakodkar SV, Kelm GR, Kershaw WC.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1996	39	1	176	182	8568804	10.1021/jm950409c	New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.	Berardi F, Colabufo NA, Giudice G, Perrone R, Tortorella V, Govoni S, Lucchi L.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1996	39	24	4750	4755	8941388	10.1021/jm960163r	Computation of brain-blood partitioning of organic solutes via free energy calculations.	Lombardo F, Blake JF, Curatolo WJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	1996	6	13	1421	1426		10.1016/S0960-894X(96)00248-X	Design, synthesis, and pharmacological evaluation of dual histamine H2 and gastrin receptor antagonists	Kawanishi Y, Ishihara S, Tsushima T, Seno K, Miyagoshi M, Hagishita S, Ishikawa M, Shima N, Shimamura M, Ishihara Y
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	1996	6	13	1427	1430		10.1016/S0960-894X(96)00249-1	Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonists	Kawanishi Y, Ishihara S, Tsushima T, Seno K, Miyagoshi M, Hagishita S, Ishikawa M, Shima N, Shimamura M, Ishihara Y
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	1996	6	15	1795	1798		10.1016/0960-894X(96)00313-7	Synthesis of a piperidinomethylthiophene derivative as H2-antagonist with inhibitory activity against Helicobacter pylori	Kojima K, Nakajima K, Kurata H, Tabata K, Utsui Y
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	1996	6	8	995	998		10.1016/0960-894X(96)00134-5	Synthesis and biological evaluation of flavonoids and related compounds as gastroprotective agents	Ares JJ, Outt PE, Randall JL, Johnston JN, Murray PD, O'Brien LM, Weisshaar PS, Ems BL
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Biol. Chem.	1997	272	1	16548	16554	9195965	10.1074/jbc.272.26.16548	Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A).	Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1997	282	1	955	960	9262363		Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.	Ito T, Yano I, Tanaka K, Inui KI.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1997	40	16	2462	2465	9258352	10.1021/jm970407n	Anti-Helicobacter pylori agents. 1. 2-(Alkylguanidino)-4-furylthiazoles and related compounds.	Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	1997	51	1	913	921	9187257	10.1124/mol.51.6.913	Cloning and functional expression of a human liver organic cation transporter.	Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Nat. Neurosci.	1998	1	1	349	351	10196521	10.1038/1557	Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.	Gründemann D, Schechinger B, Rappold GA, Schömig E.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Biochem. Biophys. Res. Commun.	1998	246	1	589	595	9618255	10.1006/bbrc.1998.8669	cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.	Wu X, Prasad PD, Leibach FH, Ganapathy V.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Biol. Chem.	1998	273	1	15971	15979	9632645	10.1074/jbc.273.26.15971	Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.	Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1998	286	1	354	361	9655880		Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).	Zhang L, Schaner ME, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1998	287	1	800	805	9808712		Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.	Urakami Y, Okuda M, Masuda S, Saito H, Inui KI.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	1998	8	11	1307	1312	9871756	10.1016/s0960-894x(98)00206-6	Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles.	Katsura Y, Nishino S, Tomishi T, Sakane K, Matsumoto Y, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Biochim. Biophys. Acta	1999	1417	1	224	231	10082798	10.1016/s0005-2736(99)00005-x	Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes.	Okuda M, Urakami Y, Saito H, Inui K.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Biol. Chem.	1999	274	1	13675	13680	10224140	10.1074/jbc.274.19.13675	Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.	Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1999	289	1	768	773	10215651		Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.	Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1999	290	1	1482	1492	10454528		Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.	Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	1999	291	1	778	784	10525100		Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.	Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	1999	42	15	2920	2926	10425101	10.1021/jm9900671	Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles.	Katsura Y, Nishino S, Ohno M, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Toxicol. Sci.	1999	47	1	181	186	10220855	10.1093/toxsci/47.2.181	A transfected cell model for the renal toxin transporter, rOCT2.	Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	1999	56	1	1	10	10385678	10.1124/mol.56.1.1	Selective substrates for non-neuronal monoamine transporters.	Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Pharm. Sci.	2000	11	1	207	214	11042226	10.1016/s0928-0987(00)00097-x	Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.	van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Br. J. Pharmacol.	2000	131	1	71	79	10960071	10.1038/sj.bjp.0703518	The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers.	Dudley AJ, Bleasby K, Brown CD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Biochim. Biophys. Acta	2000	1466	1	315	327	10825452	10.1016/s0005-2736(00)00189-9	Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.	Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Pharm. Res.	2000	17	1	1456	1460	11303953	10.1023/a:1007692622216	Influence of passive permeability on apparent P-glycoprotein kinetics.	Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Am. J. Physiol. Renal Physiol.	2000	279	1	F449	F458	10966924	10.1152/ajprenal.2000.279.3.f449	Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.	Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2000	43	11	2204	2216	10841799	10.1021/jm990968+	Predicting blood-brain barrier permeation from three-dimensional molecular structure.	Crivori P, Cruciani G, Carrupt PA, Testa B.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2000	43	17	3315	3321	10966750	10.1021/jm000169n	Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.	Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Pharm. Res.	2001	18	1	1660	1668	11785684	10.1023/a:1013358126640	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.	Adachi Y, Suzuki H, Sugiyama Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Cell Biol.	2001	21	1	5471	5477	11463829	10.1128/mcb.21.16.5471-5477.2001	Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene.	Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	2001	299	2	620	628	11602674		Rational use of in vitro P-glycoprotein assays in drug discovery.	Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2001	44	12	1927	1937	11384238	10.1021/jm001101a	Experimental and computational screening models for the prediction of intestinal drug absorption.	Stenberg P, Norinder U, Luthman K, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2001	44	15	2490	2497	11448232	10.1021/jm0100990	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.	Lombardo F, Shalaeva MY, Tupper KA, Gao F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2001	44	6	923	930	11300874	10.1021/jm001020e	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.	Wohnsland F, Faller B.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	2001	59	1	1277	1286	11306713	10.1124/mol.59.5.1277	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.	Cha SH, Sekine T, Fukushima  JI, Kanai Y, Kobayashi Y, Goya T, Endou H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Life Sci.	2001	69	1	2123	2135	11669456	10.1016/s0024-3205(01)01296-6	Characterization of ochratoxin A transport by human organic anion transporters.	Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Am. Soc. Nephrol.	2002	13	1	1703	1710	12089365	10.1097/01.asn.0000019413.78751.46	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.	Urakami Y, Akazawa M, Saito H, Okuda M, Inui K.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Toxicol. Appl. Pharmacol.	2002	183	1	83	91	12387747	10.1006/taap.2002.9461	Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.	Romiti N, Tramonti G, Chieli E.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Biochem. Biophys. Res. Commun.	2002	296	1	644	650	12176030	10.1016/s0006-291x(02)00926-9	Functional characterization of mouse cation transporter mOCT2 compared with mOCT1.	Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2002	45	1	143	150	11754586	10.1021/jm010217j	Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.	Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2002	45	13	2867	2876	12061889	10.1021/jm0200409	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	2002	61	1	982	988	11961115	10.1124/mol.61.5.982	Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.	Nagata Y, Kusuhara H, Endou H, Sugiyama Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	2002	62	1	7	14	12065749	10.1124/mol.62.1.7	Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.	Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Cell Physiol. Biochem.	2003	13	1	249	256	14586168	10.1159/000074539	Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.	Bakhiya A, Bahn A, Burckhardt G, Wolff N.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2003	13	10	1717	1720	12729649	10.1016/s0960-894x(03)00235-x	Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine.	Li L, Kracht J, Peng S, Bernhardt G, Elz S, Buschauer A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Pharm. Res.	2003	20	1	537	544	12739759	10.1023/a:1023278211849	Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.	Wang EJ, Casciano CN, Clement RP, Johnson WW.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Cereb. Blood Flow Metab.	2003	23	1	432	440	12679720	10.1097/00004647-200304000-00007	Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.	Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Am. J. Physiol. Renal Physiol.	2003	284	1	F503	F509	12429554	10.1152/ajprenal.00290.2002	Transport of cimetidine by flounder and human renal organic anion transporter 1.	Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2003	46	9	1716	1725	12699389	10.1021/jm021012t	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.	Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Med Chem Res	2004	13	1	78	87		10.1007/s00044-004-0012-z	Improgan-like Analgesics: A Family of Compounds Derived From Histamine Anatgonists	Hough L, Nalwalk J, Menge W, Leurs R, Timmerman H
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	2004	309	1	1273	1281	14762099	10.1124/jpet.103.063370	Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.	Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2004	32	1	479	483	15100168	10.1124/dmd.32.5.479	Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.	Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Pharmacol.	2004	503	1	25	30	15496291	10.1016/j.ejphar.2004.09.032	Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).	Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Sci.	2004	94	1	197	202	14978359	10.1254/jphs.94.197	Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.	Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Pharmacol. Exp. Ther.	2005	316	1	1187	1194	16291876	10.1124/jpet.105.094052	Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.	Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2005	48	2	604	613	15658873	10.1021/jm049711o	Exploring the role of different drug transport routes in permeability screening.	Matsson P, Bergström CA, Nagahara N, Tavelin S, Norinder U, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2008	18	23	6202	6205	18951789	10.1016/j.bmcl.2008.10.007	Possible involvement of radical intermediates in the inhibition of cysteine proteases by allenyl esters and amides.	Takeuchi Y, Fujiwara T, Shimone Y, Miyataka H, Satoh T, Kirk KL, Hori H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	14	4150	4169	18588282	10.1021/jm701575k	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.	Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	16	5140	5142	18666772	10.1021/jm8005228	Determination of log D via automated microfluidic liquid-liquid extraction.	Alimuddin M, Grant D, Bulloch D, Lee N, Peacock M, Dahl R.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	22	7094	7098	18983139	10.1021/jm8007618	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.	Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2008	51	7	2062	2077	18324764	10.1021/jm7009765	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2009	44	7	2913	2922	19128860	10.1016/j.ejmech.2008.12.004	Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.	Roy K, Pratim Roy P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2009	52	7	2157	2160	19296600	10.1021/jm900047j	Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.	Ettari R, Micale N, Schirmeister T, Gelhaus C, Leippe M, Nizi E, Di Francesco ME, Grasso S, Zappalà M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2010	18	21	7675	7699	20875743	10.1016/j.bmc.2010.07.034	Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.	Hayashi S, Nakata E, Morita A, Mizuno K, Yamamura K, Kato A, Ohashi K.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2010	53	24	8441	8460	20853847	10.1021/jm100888d	Aldehyde oxidase: an enzyme of emerging importance in drug discovery.	Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Antimicrob. Agents Chemother.	2010	54	9	3597	3604	20547797	10.1128/aac.00431-10	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.	Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2011	39	3	353	362	21149540	10.1124/dmd.110.035998	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.	Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2011	39	4	724	728	21212239	10.1124/dmd.110.036780	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.	Akiyoshi T, Saito T, Murase S, Miyazaki M, Murayama N, Yamazaki H, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2011	46	10	4970	4979	21871694	10.1016/j.ejmech.2011.08.002	Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced ß-amyloid aggregation inhibitors.	Tang H, Zhao LZ, Zhao HT, Huang SL, Zhong SM, Qin JK, Chen ZF, Huang ZS, Liang H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2011	54	13	4548	4558	21599003	10.1021/jm2001629	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	Kido Y, Matsson P, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2012	22	6	2257	2261	22341944	10.1016/j.bmcl.2012.01.090	Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.	Tang H, Zhao HT, Zhong SM, Wang ZY, Chen ZF, Liang H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2012	40	2	397	406	22096083	10.1124/dmd.111.041665	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.	Farrell TL, Poquet L, Dew TP, Barber S, Williamson G.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2013	21	10	2764	2771	23582449	10.1016/j.bmc.2013.03.016	Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.	Veinberg G, Vorona M, Zvejniece L, Vilskersts R, Vavers E, Liepinsh E, Kazoka H, Belyakov S, Mishnev A, Kuznecovs J, Vikainis S, Orlova N, Lebedev A, Ponomaryov Y, Dambrova M.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2013	23	3	715	719	23265898	10.1016/j.bmcl.2012.11.102	Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.	Bozdag M, Dreker T, Henry C, Tosco P, Vallaro M, Fruttero R, Scozzafava A, Carta F, Supuran CT.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Metab. Dispos.	2013	41	1	60	71	23033255	10.1124/dmd.112.048264	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.	Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2013	56	18	7232	7242	23984907	10.1021/jm400966v	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.	Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Börjesson L, Gustavsson L.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2013	56	3	781	795	23241029	10.1021/jm301302s	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.	Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2013	63		85	94	23466604	10.1016/j.ejmech.2013.01.044	Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.	Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G, Giorgi G, Mennuni L, Lanza M, Giordani A, Caselli G, Letari O, Makovec F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Med Chem Res	2013			1	8	24489456	10.1007/s00044-013-0742-x	Synthesis and pharmacological evaluation of pyrazolopyrimidopyrimidine derivatives: anti-inflammatory agents with gastroprotective effect in rats.	Karoui A, Allouche F, Deghrigue M, Agrebi A, Bouraoui A, Chabchoub F.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2014	22	19	5298	5307	25156301	10.1016/j.bmc.2014.07.053	Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with ß-amyloid and tau anti-aggregating properties.	Pérez-Areales FJ, Di Pietro O, Espargaró A, Vallverdú-Queralt A, Galdeano C, Ragusa IM, Viayna E, Guillou C, Clos MV, Pérez B, Sabaté R, Lamuela-Raventós RM, Luque FJ, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2014	24	2	576	579	24365159	10.1016/j.bmcl.2013.12.024	The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.	Rajagopalan R, Bandyopadhyaya A, Rajagopalan DR, Rajagopalan P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem. Lett.	2014	24	23	5435	5438	25454267	10.1016/j.bmcl.2014.10.025	Synthesis and antiprotozoal activity of oligomethylene- and  p-phenylene-bis(methylene)-linked bis(+)-huprines.	Sola I, Artigas A, Taylor MC, Gbedema SY, Pérez B, Clos MV, Wright CW, Kelly JM, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	MedChemComm	2014	5	1	72	81		10.1039/C3MD00245D	Synthesis, SAR and selectivity of 2-acyl- and 2-cyano-1-hetarylalkyl-guanidines at the four histamine receptor subtypes: a bioisosteric approach	Geyer R, Igel P, Kaske M, Elz S, Buschauer A
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J. Med. Chem.	2014	57	7	3005	3010	24601604	10.1021/jm401963n	A high-throughput cell-based method to predict the unbound drug fraction in the brain.	Mateus A, Matsson P, Artursson P.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2014	73		141	152	24389509	10.1016/j.ejmech.2013.12.008	1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.	Di Pietro O, Viayna E, Vicente-García E, Bartolini M, Ramón R, Juárez-Jiménez J, Clos MV, Pérez B, Andrisano V, Luque FJ, Lavilla R, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2014	84		107	117	25016233	10.1016/j.ejmech.2014.07.021	Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting ß-amyloid, tau, and cholinesterase pathologies.	Di Pietro O, Pérez-Areales FJ, Juárez-Jiménez J, Espargaró A, Clos MV, Pérez B, Lavilla R, Sabaté R, Luque FJ, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2015	105		120	137	26479031	10.1016/j.ejmech.2015.10.007	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.	Di Pietro O, Vicente-García E, Taylor MC, Berenguer D, Viayna E, Lanzoni A, Sola I, Sayago H, Riera C, Fisa R, Clos MV, Pérez B, Kelly JM, Lavilla R, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Eur. J. Med. Chem.	2015	92		49	63	25544686	10.1016/j.ejmech.2014.12.028	Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach.	Goracci L, Buratta S, Urbanelli L, Ferrara G, Di Guida R, Emiliani C, Cross S.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30		2015							Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30		2015							Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg Med Chem	2016	24	21	5162	5171	27591008	10.1016/j.bmc.2016.08.036	Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.	Sola I, Artigas A, Taylor MC, Pérez-Areales FJ, Viayna E, Clos MV, Pérez B, Wright CW, Kelly JM, Muñoz-Torrero D.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg. Med. Chem.	2016	24	8	1793	1810	26988801	10.1016/j.bmc.2016.03.006	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.	Waszkielewicz AM, Gunia-Krzy¿ak A, Powro¿nik B, S¿oczy¿ska K, P¿kala E, Walczak M, Bednarski M, ¿es¿awska E, Nitek W, Marona H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	Bioorg Med Chem	2017	25	2	471	482	27876250	10.1016/j.bmc.2016.11.014	Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3.	Gunia-Krzy¿ak A, ¿elaszczyk D, Rapacz A, ¿es¿awska E, Waszkielewicz AM, Pa¿czyk K, S¿oczy¿ska K, P¿kala E, Nitek W, Filipek B, Marona H.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J Med Chem	2017	60	1	349	361	27997171	10.1021/acs.jmedchem.6b01422	Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.	Odell LR, Abdel-Hamid MK, Hill TA, Chau N, Young KA, Deane FM, Sakoff JA, Andersson S, Daniel JA, Robinson PJ, McCluskey A.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30	J Med Chem	2017	60	7	2685	2696	28230985	10.1021/acs.jmedchem.6b01317	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).	Chen EC, Khuri N, Liang X, Stecula A, Chien HC, Yee SW, Huang Y, Sali A, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30								10.6019/CHEMBL3392926	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning	Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									British National Formulary (72nd edition)	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									DrugMatrix	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									Drug metabolism data	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									Open TG-GATES	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									PubChem BioAssay data set	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE	CHEMBL30									WHO Anatomical Therapeutic Chemical Classification	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE HYDROCHLORIDE	CHEMBL1201051									Drug metabolism data	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE HYDROCHLORIDE	CHEMBL1201051									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	CIMETIDINE HYDROCHLORIDE	CHEMBL1201051									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	1997	40	9	1340	1346	9135031	10.1021/jm960436i	Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.	McFarland JW, Berger CM, Froshauer SA, Hayashi SF, Hecker SJ, Jaynes BH, Jefson MR, Kamicker BJ, Lipinski CA, Lundy KM, Reese CP, Vu CB.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1997	7	5	641	646		10.1016/S0960-894X(97)00078-4	Novel 3-deoxy-3-descladinosyl-6-O-methyl erythromycin a analogues. Synthesis and in vitro activity	Elliott RL, Pireh D, Nilius AM, Johnson PM, Flamm RK, Chu DT, Plattner JJ, Or YS
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	1998	41	10	1651	1659	9572890	10.1021/jm970547x	Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues.	Elliott RL, Pireh D, Griesgraber G, Nilius AM, Ewing PJ, Bui MH, Raney PM, Flamm RK, Kim K, Henry RF, Chu DT, Plattner JJ, Or YS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	1998	41	10	1660	1670	9572891	10.1021/jm970548p	Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues.	Griesgraber G, Kramer MJ, Elliott RL, Nilius AM, Ewing PJ, Raney PM, Bui MH, Flamm RK, Chu DT, Plattner JJ, Or YS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	1998	41	21	4080	4100	9767644	10.1021/jm980240d	Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.	Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1998	8	14	1897	1902	9873455	10.1016/s0960-894x(98)00335-7	Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity.	Yoshida Y, Barrett D, Azami H, Morinaga C, Matsumoto Y, Takasugi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1998	8	16	2185	2190	9873510	10.1016/s0960-894x(98)00390-4	Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.	Sakurai N, Sano M, Hirayama F, Kuroda T, Uemori S, Moriguchi A, Yamamoto K, Ikeda Y, Kawakita T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	1999	42	15	2920	2926	10425101	10.1021/jm9900671	Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles.	Katsura Y, Nishino S, Ohno M, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1999	9	2	193	194	10021926	10.1016/s0960-894x(98)00726-4	In vitro susceptibility of Helicobacter pylori to trifluoromethyl ketones.	Kawase M, Harada H, Saito S, Cui J, Tani S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1999	9	21	3075	3080	10560728	10.1016/s0960-894x(99)00534-x	Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.	Denis A, Agouridas C, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N, Pejac JM, Perron S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	1999	9	21	3123	3126	10560737	10.1016/s0960-894x(99)00549-1	Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.	Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Takasugi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2000	10	17	2019	2022	10987440	10.1016/s0960-894x(00)00392-9	Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides.	Denis A, Bretin F, Fromentin C, Bonnet A, Piltan G, Bonnefoy A, Agouridas C.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2000	10	8	815	819	10782693	10.1016/s0960-894x(00)00106-2	Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives.	Clark RF, Ma Z, Wang S, Griesgraber G, Tufano M, Yong H, Li L, Zhang X, Nilius AM, Chu DT, Or YS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Clin. Exp. Pharmacol. Physiol.	2000	27	1	587	593	10901387	10.1046/j.1440-1681.2000.03308.x	Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.	Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, Yokogawa K, Miyamoto KI, Hasegawa T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2000	43	17	3315	3321	10966750	10.1021/jm000169n	Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives.	Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Biochem. Biophys. Res. Commun.	2001	289	1	580	585	11716514	10.1006/bbrc.2001.6000	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.	Wang EJ, Casciano CN, Clement RP, Johnson WW.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Pharmacol. Exp. Ther.	2001	299	2	620	628	11602674		Rational use of in vitro P-glycoprotein assays in drug discovery.	Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2001	44	24	4027	4030	11708904	10.1021/jm015566s	Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics.	Tanikawa T, Asaka T, Kashimura M, Misawa Y, Suzuki K, Sato M, Kameo K, Morimoto S, Nishida A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2001	44	24	4137	4156	11708916	10.1021/jm0102349	Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.	Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA, Chu DT, Plattner JJ, Zhang X, Zhong P, Cao Z, Nilius AM, Shortridge VD, Flamm R, Mitten M, Meulbroek J, Ewing P, Alder J, Or YS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2001	44	25	4468	4474	11728192	10.1021/jm010307o	3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents.	Ando R, Kawamura M, Chiba N.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2002	45	1	143	150	11754586	10.1021/jm010217j	Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.	Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2002	45	19	4282	4299	12213070	10.1021/jm0208673	Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 1.	Kühler TC, Swanson M, Christenson B, Klintenberg AC, Lamm B, Fägerhag J, Gatti R, Olwegård-Halvarsson M, Shcherbuchin V, Elebring T, Sjöström JE.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2002	45	19	4300	4309	12213071	10.1021/jm020868v	Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2.	Carcanague D, Shue YK, Wuonola MA, Uria-Nickelsen M, Joubran C, Abedi JK, Jones J, Kühler TC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Nat. Prod.	2002	65	4	611	613	11975515	10.1021/np010126p	Derrisin, a new rotenoid from Derris malaccensis plain and anti-Helicobacter pylori activity of its related constituents.	Takashima J, Chiba N, Yoneda K, Ohsaki A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2003	13	16	2773	2775	12873512	10.1016/s0960-894x(03)00492-x	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.	Keserü GM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2003	46	13	2706	2715	12801234	10.1021/jm020568d	Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.	Tanikawa T, Asaka T, Kashimura M, Suzuki K, Sugiyama H, Sato M, Kameo K, Morimoto S, Nishida A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2004	14	18	4771	4777	15324906	10.1016/j.bmcl.2004.06.070	The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.	Du LP, Tsai KC, Li MY, You QD, Xia L.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Pharmacol. Exp. Ther.	2004	311	1	246	255	15175422	10.1124/jpet.104.069583	Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption.	Dey S, Gunda S, Mitra AK.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2004	32	1	828	833	15258108	10.1124/dmd.32.8.828	Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein.	Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2005	15	11	2886	2890	15911273	10.1016/j.bmcl.2005.03.080	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.	Tobita M, Nishikawa T, Nagashima R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2005	15	18	4076	4084	15990295	10.1016/j.bmcl.2005.06.015	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.	Wang YH, Li Y, Li YH, Yang SL, Yang L.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2005	33	1	619	622	15708966	10.1124/dmd.104.003301	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver.	Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2005	48	22	7012	7017	16250660	10.1021/jm058167w	Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria.	Rai D, Johar M, Manning T, Agrawal B, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Nat. Prod.	2005	68	6	819	824	15974602	10.1021/np040188q	Anti-Helicobacter pylori compounds from Santalum album.	Ochi T, Shibata H, Higuti T, Kodama KH, Kusumi T, Takaishi Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2006	16	17	4692	4696	16784845	10.1016/j.bmcl.2006.05.104	Synthesis and antibacterial activity of C12 des-methyl ketolides.	Lin X, Rico AC, Chu DT, Carroll GL, Barker L, Shawar R, Desai MC, Plattner JJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2006	16	21	5523	5525	16945527	10.1016/j.bmcl.2006.08.043	In vitro inhibitory activity of boropinic acid against Helicobacter pylori.	Epifano F, Menghini L, Pagiotti R, Angelini P, Genovese S, Curini M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2006	16	3	569	572	16275089	10.1016/j.bmcl.2005.10.045	Design, synthesis, and anti-Helicobacter pylori activity of erythromycin A (E)-9-oxime ether derivatives.	Nam G, Kang TW, Shin JH, Choi KI.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2006	16	6	1506	1509	16387493	10.1016/j.bmcl.2005.12.033	Synthesis and biological investigation of new 4''-malonyl tethered derivatives of erythromycin and clarithromycin.	Sherman D, Xiong L, Mankin AS, Melman A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2006	49	5	1730	1743	16509588	10.1021/jm051157a	Synthesis and antibacterial activity of novel C12 vinyl ketolides.	Burger MT, Lin X, Chu DT, Hiebert C, Rico AC, Seid M, Carroll GL, Barker L, Huh K, Langhorne M, Shawar R, Kidney J, Young K, Anderson S, Desai MC, Plattner JJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2007	15	5	2045	2053	17218105	10.1016/j.bmc.2006.12.032	Studies on acyclic pyrimidines as inhibitors of mycobacteria.	Srivastav NC, Manning T, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2007	17	12	3330	3334	17459704	10.1016/j.bmcl.2007.03.107	Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides.	Xu P, Liu L, Jin Z, Lei P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2007	17	18	5265	5269	17681467	10.1016/j.bmcl.2007.02.019	A novel ketolide class: Synthesis and antibacterial activity of a lead compound.	Andreotti D, Bientinesi I, Biondi S, Donati D, Erbetti I, Lociuro S, Marchioro C, Pozzan A, Ratti E, Terreni S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2007	42	1	54	63	17010479	10.1016/j.ejmech.2006.08.007	Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall.	Gobec S, Plantan I, Mravljak J, Svajger U, Wilson RA, Besra GS, Soares SL, Appelberg R, Kikelj D.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2007	50	15	3696	3705	17602465	10.1021/jm0703901	Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs.	Johar M, Manning T, Tse C, Desroches N, Agrawal B, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2007	50	19	4766	4774	17696514	10.1021/jm070391t	Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.	Rai D, Johar M, Srivastav NC, Manning T, Agrawal B, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	10	3737	3739	17664316	10.1128/aac.00730-07	Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.	Ji B, Chauffour A, Robert J, Lefrançois S, Jarlier V.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	11	4071	4076	17709469	10.1128/aac.00410-07	In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.	Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, Fukushima K, Kohno S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	11	4196	4201	17876003	10.1128/aac.00827-07	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.	Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	2	453	460	17116681	10.1128/aac.00960-06	Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.	Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	2	770	773	17116666	10.1128/aac.01150-06	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.	Kosowska-Shick K, Credito KL, Pankuch GA, DeWasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	4	1380	1385	17210775	10.1128/aac.00055-06	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.	Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	4	1494	1496	17220421	10.1128/aac.00666-06	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.	Giacometti A, Cirioni O, Riva A, Kamysz W, Silvestri C, Nadolski P, Della Vittoria A, ¿ukasiak J, Scalise G.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	5	1666	1670	17296742	10.1128/aac.01303-06	EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.	Bermudez LE, Motamedi N, Chee C, Baimukanova G, Kolonoski P, Inderlied C, Aralar P, Wang G, Phan LT, Young LS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	5	1741	1752	17353244	10.1128/aac.01459-06	Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.	Yasuda Y, Kasahara K, Mizuno F, Nishi K, Mikasa K, Kita E.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	6	2278	2279	17387152	10.1128/aac.01561-06	Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.	Yamazaki T, Sasaki T, Takahata M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	7	2625	2627	17502407	10.1128/aac.00107-07	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.	Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	9	3185	3189	17606673	10.1128/aac.00532-07	Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.	Traunmüller F, Zeitlinger M, Zeleny P, Müller M, Joukhadar C.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2007	51	9	3212	3216	17606685	10.1128/aac.01592-06	Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni.	Gibreel A, Wetsch NM, Taylor DE.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2008	16	1	232	239	17936632	10.1016/j.bmc.2007.09.044	A new insight into solid-state conformation of macrolide antibiotics.	Miroshnyk I, Mirza S, Zorky PM, Heinämäki J, Yli-Kauhaluoma J, Yliruusi J.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2008	16	11	6252	6260	18448342	10.1016/j.bmc.2008.04.028	Support vector machines classification of hERG liabilities based on atom types.	Jia L, Sun H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2008	16	7	3985	4002	18258437	10.1016/j.bmc.2008.01.027	Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues.	Miura T, Kurihara K, Furuuchi T, Yoshida T, Ajito K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2008	51	7	1991	1994	18330977	10.1021/jm8000136	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.	Hirokawa Y, Kinoshita H, Tanaka T, Nakata K, Kitadai N, Fujimoto K, Kashimoto S, Kojima T, Kato S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	1	348	350	17954691	10.1128/aac.00779-07	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.	Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	11	4184	4186	18725441	10.1128/aac.00695-08	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.	Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	12	4351	4355	18779356	10.1128/aac.00086-08	Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.	Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Riva A, Kamysz E, Castelletti S, Rocchi M, Saba V, Scalise G, Giacometti A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	2	427	434	18070962	10.1128/aac.00375-07	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.	Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	2	435	440	18056269	10.1128/aac.01074-07	Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.	Wolter N, Smith AM, Farrell DJ, Northwood JB, Douthwaite S, Klugman KP.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	3	866	874	18086834	10.1128/aac.01266-07	Induction of erm(C) expression by noninducing antibiotics.	Bailey M, Chettiath T, Mankin AS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	4	1430	1437	18285482	10.1128/aac.01538-07	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.	Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	4	1538	1541	18212111	10.1128/aac.00140-07	Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.	Tsuda T, Ishikawa C, Konishi H, Hayashi Y, Nakagawa N, Matsuki M, Mizutani H, Yamanishi K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	6	2019	2026	18378709	10.1128/aac.00986-07	Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.	Greendyke R, Byrd TF.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	6	2061	2068	18362191	10.1128/aac.01150-07	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.	Higashide M, Kuroda M, Omura CT, Kumano M, Ohkawa S, Ichimura S, Ohta T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	8	2750	2754	18411316	10.1128/aac.00044-08	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.	Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	9	3229	3236	18591267	10.1128/aac.00405-08	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.	Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Møller N, Nagai J, Takano M, Vaara T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2008	52	9	3465	3466	18606842	10.1128/aac.00445-08	Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori.	Rimbara E, Noguchi N, Kawai T, Sasatsu M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Nat. Prod.	2008	71	7	1291	1293	18582112	10.1021/np800106x	Antibacterial activity of labdane diterpenoids from Stemodia foliosa.	da Silva LL, Nascimento MS, Cavalheiro AJ, Silva DH, Castro-Gamboa I, Furlan M, Bolzani Vda S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2009	19	15	4079	4083	19560350	10.1016/j.bmcl.2009.06.023	Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.	Xu P, Liu L, Chen XZ, Li Y, Liu J, Jin ZP, Wang GQ, Lei PS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2009	19	6	1698	1701	19232491	10.1016/j.bmcl.2009.01.092	Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives.	Ma S, Jiao B, Liu Z, Wang H, Xian R, Zheng M, Lou H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2009	44	10	4010	4020	19464769	10.1016/j.ejmech.2009.04.030	Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin.	Ma S, Ma R, Liu Z, Ma C, Shen X.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2009	44	4	1737	1744	18450331	10.1016/j.ejmech.2008.03.010	Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl beta-aldehyde ketone derivatives.	Liu J, Cao R, Wu Q, Ma C, Wang Z, Peng W, Song H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2009	52	23	7446	7457	19775168	10.1021/jm900729s	Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.	Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	1	329	330	18936189	10.1128/aac.00921-08	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.	Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	11	4927	4929	19738016	10.1128/aac.00689-09	ATP synthase inhibition of Mycobacterium avium is not bactericidal.	Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	11	4938	4939	19738019	10.1128/aac.00724-09	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.	Hamasuna R, Jensen JS, Osada Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	3	1281	1284	19075048	10.1128/aac.01247-08	In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.	Morgenstern K, Baljer G, Norris DE, Kraiczy P, Hanssen-Hübner C, Hunfeld KP.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	4	1367	1376	19171799	10.1128/aac.01275-08	A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.	Nash KA, Brown-Elliott BA, Wallace RJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	4	1592	1597	19204190	10.1128/aac.01242-08	Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice.	De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	4	1690	1692	19139284	10.1128/aac.01388-08	In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.	Zhanel GG, Karlowsky JA.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	5	1760	1765	19258275	10.1128/aac.01540-08	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.	Ishikawa C, Tsuda T, Konishi H, Nakagawa N, Yamanishi K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	5	1786	1792	19223626	10.1128/aac.01270-08	Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.	Jiang LJ, Wang M, Or YS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	5	1921	1925	19258262	10.1128/aac.01065-08	Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.	Blackman Northwood J, Del Grosso M, Cossins LR, Coley MD, Creti R, Pantosti A, Farrell DJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	5	2020	2027	19273669	10.1128/aac.01349-08	Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.	Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	5	2160	2162	19273684	10.1128/aac.01684-08	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.	Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	6	2690	2692	19332671	10.1128/aac.01424-08	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.	Spyridaki I, Psaroulaki A, Vranakis I, Tselentis Y, Gikas A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	9	3642	3649	19546358	10.1128/aac.00206-09	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.	Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	9	3734	3743	19564365	10.1128/aac.00203-09	Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.	Lemaire S, Van Bambeke F, Tulkens PM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	9	3777	3781	19596876	10.1128/aac.00026-09	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.	Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2009	53	9	4022	4024	19546360	10.1128/aac.00145-09	Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia.	Alvarez A, Moncayo JI, Santacruz JJ, Santacoloma M, Corredor LF, Reinosa E.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2010	18	17	6559	6568	20634078	10.1016/j.bmc.2010.06.049	4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens.	Fajdeti¿ A, Cipci¿ Paljetak H, Lazarevski G, Hutinec A, Alihodzi¿ S, Derek M, Stimac V, Andreotti D, Sunji¿ V, Berge JM, Mutak S, Dumi¿ M, Lociuro S, Holmes DJ, Marsi¿ N, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2010	18	17	6569	6577	20673633	10.1016/j.bmc.2010.06.048	6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile.	Kapi¿ S, Cipci¿ Paljetak H, Alihodzi¿ S, Antolovi¿ R, Erakovi¿ Haber V, Jarvest RL, Holmes DJ, Broskey JP, Hunt E.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2010	18	7	2735	2747	20236827	10.1016/j.bmc.2010.02.017	Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities.	Miura T, Natsume S, Kanemoto K, Shitara E, Fushimi H, Yoshida T, Ajito K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2010	20	11	3272	3274	20462756	10.1016/j.bmcl.2010.04.051	Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives.	Ju Y, Xian R, Zhang L, Ma R, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2010	20	18	5462	5465	20705463	10.1016/j.bmcl.2010.07.094	Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.	Lai CH, Rao YK, Fang SH, Sing YT, Tzeng YM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2010	20	18	5527	5531	20716487	10.1016/j.bmcl.2010.07.072	A new series of macrolide derivatives with 4''-O-saccharide substituents.	Xu P, Chen XZ, Liu L, Jin ZP, Lei PS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2010	20	9	2880	2883	20356738	10.1016/j.bmcl.2010.03.038	Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.	Liang JH, Wang YY, Wang H, Li XL, An K, Xu YC, Yao GW.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2010	45	12	5943	5949	20970894	10.1016/j.ejmech.2010.09.060	Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides.	Hu L, Lan P, Song QL, Huang ZJ, Sun PH, Zhuo C, Wang Y, Xiao S, Chen WM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2010	45	3	915	922	19945195	10.1016/j.ejmech.2009.11.032	Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.	Zhang L, Song L, Liu Z, Li H, Lu Y, Li Z, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2010	45	9	3627	3635	20627377	10.1016/j.ejmech.2010.05.008	Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues.	Liang JH, Dong LJ, Wang H, An K, Li XL, Yang L, Yao GW, Xu YC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2010	45	9	3636	3644	20554083	10.1016/j.ejmech.2010.05.009	Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides.	Wu Z, Lu Y, Luo M, He X, Xiao Y, Yang J, Pan Y, Qiu G, Guo H, Hu H, Zhou D, Hu X.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	1	230	238	19884376	10.1128/aac.01123-09	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.	McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	1	65	71	19884366	10.1128/aac.00966-09	Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.	Bae S, Lee J, Lee J, Kim E, Lee S, Yu J, Kang Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	10	4329	4334	20696880	10.1128/aac.00455-10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.	Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	10	4518	4519	20660671	10.1128/aac.00235-10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.	Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	12	5379	5380	20855744	10.1128/aac.00553-10	In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.	Donati M, Di Francesco A, D'Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	2	757	762	19949056	10.1128/aac.00524-09	Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.	Nakamura S, Yanagihara K, Araki N, Yamada K, Morinaga Y, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Kamihira S, Kohno S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	2	866	870	19933801	10.1128/aac.00567-09	Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects.	Furuie H, Saisho Y, Yoshikawa T, Shimada J.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	3	1358	1359	20038627	10.1128/aac.01343-09	In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.	Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	5	1909	1913	20231391	10.1128/aac.01570-09	Nucleotide selectivity of antibiotic kinases.	Shakya T, Wright GD.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	5	2182	2187	20176910	10.1128/aac.01662-09	CEM-101 activity against Gram-positive organisms.	Woosley LN, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	6	2707	2711	20231401	10.1128/aac.01565-09	Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.	Wang Q, Sun FJ, Liu Y, Xiong LR, Xie LL, Xia PY.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	7	2806	2813	20421401	10.1128/aac.00400-10	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.	Zhang T, Bishai WR, Grosset JH, Nuermberger EL.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	8	3113	3120	20498323	10.1128/aac.01803-09	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.	Mima T, Schweizer HP.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	8	3341	3346	20479195	10.1128/aac.01439-09	A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.	Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Antimicrob. Agents Chemother.	2010	54	9	4009	4011	20625152	10.1128/aac.01812-09	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.	Biedenbach DJ, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2011	19	23	7281	7298	22047805	10.1016/j.bmc.2011.07.010	Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity.	Kapi¿ S, Cip¿i¿ Paljetak H, Palej Jakopovi¿ I, Fajdeti¿ A, Ilija¿ M, Stimac V, Braj¿a K, Holmes DJ, Berge J, Alihod¿i¿ S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	ACS Med. Chem. Lett.	2011	2	3	234	237	24900300	10.1021/ml100252s	"Synthesis and antibacterial activity of a novel class of 15-membered macrolide antibiotics, ""11a-azalides""."	Sugimoto T, Tanikawa T.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	MedChemComm	2011	2	4	331	336		10.1039/C0MD00251H	Erythromycin B: conformational analysis and antibacterial activity	Tyson P, Hassanzadeh A, Mordi MN, Allison DG, Marquez V, Barber J
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2011	46	1	208	217	21130543	10.1016/j.ejmech.2010.11.004	Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains.	Chen XZ, Xu P, Liu L, Zheng D, Lei PS.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2011	46	2	556	566	21159410	10.1016/j.ejmech.2010.11.035	Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4¿ elongated arylalkyl groups against macrolide-resistant strains.	Ma S, Jiao B, Ju Y, Zheng M, Ma R, Liu L, Zhang L, Shen X, Ma C, Meng Y, Wang H, Qi Y, Ma X, Cui W.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2011	46	7	3105	3111	21524827	10.1016/j.ejmech.2011.04.004	Synthesis and antibacterial activity of novel 4¿-O-benzimidazolyl clarithromycin derivatives.	Cong C, Wang H, Hu Y, Liu C, Ma S, Li X, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2011	54	3	719	733	21207938	10.1021/jm101317f	Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties.	Stepani¿ V, Ko¿trun S, Malnar I, Hlevnjak M, Butkovi¿ K, ¿aleta I, Duk¿i M, Kragol G, Makaruha-Stegi¿ O, Mikac L, Rali¿ J, Tati¿ I, Tav¿ar B, Valko K, Zulfikari S, Muni¿ V.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2011	54	8	2792	2804	21428405	10.1021/jm101593u	Chemistry and biology of macrolide antiparasitic agents.	Lee Y, Choi JY, Fu H, Harvey C, Ravindran S, Roush WR, Boothroyd JC, Khosla C.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2012	20	13	4088	4097	22664188	10.1016/j.bmc.2012.05.004	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.	Shakya N, Srivastav NC, Bhavanam S, Tse C, Desroches N, Agrawal B, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2012	20	19	5787	5801	22925450	10.1016/j.bmc.2012.08.007	Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'.	Sugimoto T, Tanikawa T, Suzuki K, Yamasaki Y.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2012	22	1	476	481	22153939	10.1016/j.bmcl.2011.10.101	Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.	Kumar R, Rathy S, Hajare AK, Surase YB, Dullu J, Jadhav JS, Venkataramanan R, Chakrabarti A, Pandya M, Bhateja P, Ramkumar G, Das B.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2012	22	10	3527	3530	22503348	10.1016/j.bmcl.2012.03.076	Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity.	Jakopovi¿ IP, Kraja¿i¿ MB, Skugor MM, Stimac V, Pe¿i¿ D, Vujasinovi¿ I, Alihod¿i¿ S, ¿ip¿i¿ Paljetak H, Kragol G.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2012	22	17	5739	5743	22858102	10.1016/j.bmcl.2012.06.092	Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides.	Sugimoto T, Shimazaki Y, Manaka A, Tanikawa T, Suzuki K, Nanaumi K, Kaneda Y, Yamasaki Y, Sugiyama H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2012	22	2	1091	1094	22178557	10.1016/j.bmcl.2011.11.114	Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.	Srivastav NC, Shakya N, Bhavanam S, Agrawal A, Tse C, Desroches N, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2012	22	24	7402	7405	23122862	10.1016/j.bmcl.2012.10.064	Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides.	Chen X, Xu P, Xu Y, Liu L, Liu Y, Zhu D, Lei P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2012	40	8	1596	1602	22593038	10.1124/dmd.112.045732	Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.	Jigorel E, Houston JB.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2012	48		244	254	22217866	10.1016/j.ejmech.2011.12.021	Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.	Chang CS, Liu JF, Lin HJ, Lin CD, Tang CH, Lu DY, Sing YT, Chen LY, Kao MC, Kuo SC, Lai CH.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2012	49		289	303	22301216	10.1016/j.ejmech.2012.01.023	Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities.	Liang JH, Li XL, Wang H, An K, Wang YY, Xu YC, Yao GW.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2013	21	17	5282	5291	23850103	10.1016/j.bmc.2013.06.027	Synthesis of novel isothiazolopyridines and their in vitro evaluation against Mycobacterium and Propionibacterium acnes.	Malinka W, Swi¿tek P, Sliwi¿ska M, Szponar B, Gamian A, Karczmarzyk Z, Fruzi¿ski A.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Med Chem Res	2013	22	9	4228	4238		10.1007/s00044-012-0429-8	Synthesis and antibacterial activities of para-alkoxy phenyl--ketoaldehyde derivatives	Liu J, Wu F, Song H, Wang Z, Zhao L
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2013	23	11	3452	3457	23591116	10.1016/j.bmcl.2013.03.057	Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives.	Jiang JW, Sun Y, Nie Y, Zhi HJ, Zhang XJ, Li X, Sun HP, You QD.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2013	23	23	6274	6279	24139585	10.1016/j.bmcl.2013.09.083	Synthesis of 4¿-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities.	Zhu D, Xu Y, Liu Y, Chen X, Zhao Z, Lei P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2013	23	5	1387	1393	23375796	10.1016/j.bmcl.2012.12.070	Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.	Liang JH, Lv W, Li XL, An K, Cushman M, Wang H, Xu YC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2013	23	6	1727	1731	23414806	10.1016/j.bmcl.2013.01.067	Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates.	Magee TV, Han S, McCurdy SP, Nguyen TT, Granskog K, Marr ES, Maguire BA, Huband MD, Chen JM, Subashi TA, Shanmugasundaram V.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Metab. Dispos.	2013	41	5	933	951	23454828	10.1124/dmd.112.050278	Which metabolites circulate?	Loi CM, Smith DA, Dalvie D.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J. Med. Chem.	2013	56	5	1974	1983	23409972	10.1021/jm301650g	Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.	Odagiri T, Inagaki H, Sugimoto Y, Nagamochi M, Miyauchi RN, Kuroyanagi J, Kitamura T, Komoriya S, Takahashi H.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2013	59		209	217	23229056	10.1016/j.ejmech.2012.11.028	Synthesis and antibacterial evaluation of novel 11,4¿-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.	Li X, Ma S, Yan M, Wang Y, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2013	59		54	63	23202851	10.1016/j.ejmech.2012.10.054	Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides.	Liang JH, An K, Lv W, Cushman M, Wang H, Xu YC.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur. J. Med. Chem.	2013	69		174	181	24021890	10.1016/j.ejmech.2013.08.023	Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides.	Xu Y, Chen X, Zhu D, Liu Y, Zhao Z, Jin L, Liu C, Lei P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2014	24	11	2412	2414	24775303	10.1016/j.bmcl.2014.04.041	Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.	Tseng YY, Liou JM, Hsu TL, Cheng WC, Wu MS, Wong CH.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem.	2015	23	19	6437	6453	26349628	10.1016/j.bmc.2015.08.020	Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity.	Han X, Lv W, Guo SY, Cushman M, Liang JH.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem	2016	24	21	5521	5533	27665179	10.1016/j.bmc.2016.09.008	Investigation of C-5 alkynyl (alkynyloxy or hydroxymethyl) and/or N-3 propynyl substituted pyrimidine nucleoside analogs as a new class of antimicrobial agents.	Garg S, Shakya N, Srivastav NC, Agrawal B, Kunimoto DY, Kumar R.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur J Med Chem	2017	125		210	224	27657812	10.1016/j.ejmech.2016.09.022	Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.	Pavlovi¿ D, Kimmins S, Mutak S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Eur J Med Chem	2017	127		874	884	27836198	10.1016/j.ejmech.2016.10.065	Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives.	Yan M, Ma R, Jia L, Venter H, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem	2017	25	1	132	137	27793449	10.1016/j.bmc.2016.10.019	Antibacterial profiling of abietane-type diterpenoids.	Helfenstein A, Vahermo M, Nawrot DA, Demirci F, ¿¿can G, Krogerus S, Yli-Kauhaluoma J, Moreira VM, Tammela P.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem	2017	25	8	2313	2326	28302508	10.1016/j.bmc.2017.02.041	Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group.	Anwar HF, Andrei M, Undheim K.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem Lett	2017	27	16	3693	3697	28711353	10.1016/j.bmcl.2017.07.017	Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.	Jia L, Yan M, Shen Y, Qin Y, Qiang S, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem Lett	2017	27	16	3872	3877	28655423	10.1016/j.bmcl.2017.06.044	Synthesis and antibacterial activity of novel 4¿-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs.	Wang Y, Cong C, Chai WC, Dong R, Jia L, Song D, Zhou Z, Ma S.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	Bioorg Med Chem Lett	2017	27	7	1513	1524	28256375	10.1016/j.bmcl.2017.02.041	Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides.	Tian JC, Han X, Lv W, Li YX, Wang H, Fan BZ, Cushman M, Liang JH.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741	J Med Chem	2017	60	9	3902	3912	28383902	10.1021/acs.jmedchem.7b00204	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.	Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M.
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									DailyMed|setid=d9db2fd3-a668-4d37-9082-18f6ceb8c3cb | CLARITHROMYCIN - clarithromycin tablet, film coated, extended release|Dispensing Solutions, Inc.	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									DailyMed|setid=f21494ed-c5e8-4ddf-b140-ecd68c5c312b | CLARITHROMYCIN EXTENDED RELEASE - clarithromycin tablet, film coated, extended release|Ranbaxy Pharmaceuticals Inc.	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									DrugMatrix	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									Drug metabolism data	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CLARITHROMYCIN	CHEMBL1741									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588	Antimicrob. Agents Chemother.	2010	54	1	98	102	19805566	10.1128/aac.00804-09	Clindamycin-induced CovS-mediated regulation of the production of virulent exoproteins streptolysin O, NAD glycohydrolase, and streptokinase in Streptococcus pyogenes.	Minami M, Kamimura T, Isaka M, Tatsuno I, Ohta M, Hasegawa T.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588	J. Med. Chem.	2012	55	22	10160	10176	23050700	10.1021/jm3012728	A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.	Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN HYDROCHLORIDE	CHEMBL1200588									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PALMITATE HYDROCHLORIDE	CHEMBL1200632									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PALMITATE HYDROCHLORIDE	CHEMBL1200632									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PALMITATE HYDROCHLORIDE	CHEMBL1200632									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512	J. Med. Chem.	2014	57	9	3707	3714	24588790	10.1021/jm401685f	Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.	Duan F, Li X, Cai S, Xin G, Wang Y, Du D, He S, Huang B, Guo X, Zhao H, Zhang R, Ma L, Liu Y, Du Q, Wei Z, Xing Z, Liang Y, Wu X, Fan C, Ji C, Zeng D, Chen Q, He Y, Liu X, Huang W.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512									Unpublished dataset	
2219.8000000000000000	2	Bacteria	CLINDAMYCIN PHOSPHATE	CHEMBL3184512									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883	ACS Med. Chem. Lett.	2012	3	5	416	421	24900486	10.1021/ml300049d	Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).	Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S.
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883	Drug Metab. Dispos.	2012	40	5	919	927	22315332	10.1124/dmd.111.043778	Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.	Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K, Martini JF, Kassees R, Aoyama RG, Ramaiya A, Johnston SH.
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883									British National Formulary (72nd edition)	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB	CHEMBL2146883									WHO Anatomical Therapeutic Chemical Classification	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB FUMARATE	CHEMBL2364607									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	COBIMETINIB FUMARATE	CHEMBL2364607									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797		2008							Multi-functional small molecules as anti-proliferative agents	
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797	J. Med. Chem.	2010	53	4	1413	1437	20166671	10.1021/jm901132v	Selectively nonselective kinase inhibition: striking the right balance.	Morphy R.
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797	J. Med. Chem.	2010	53	5	2000	2009	20143778	10.1021/jm901453q	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.	Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C.
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797	Bioorg Med Chem	2017	25	1	27	37	27769671	10.1016/j.bmc.2016.10.006	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.	Ding C, Chen S, Zhang C, Hu G, Zhang W, Li L, Chen YZ, Tan C, Jiang Y.
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797	J Med Chem	2017	60	5	1817	1828	28218840	10.1021/acs.jmedchem.6b01507	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.	Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang J.
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797									PubChem BioAssay data set	
1146.4083333333333333	9606	Homo sapiens	CUDC-101	CHEMBL598797									Unpublished dataset	
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	J. Biol. Chem.	1995	270	1	25672	25677	7592745	10.1074/jbc.270.43.25672	Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2.	Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	Am. J. Physiol.	1997	273	1	F706	F711	9374833		Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.	Terada T, Saito H, Mukai M, Inui K.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	J. Biol. Chem.	2000	275	1	1699	1707	10636865	10.1074/jbc.275.3.1699	beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.	Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	Eur. J. Pharm. Biopharm.	2005	59	1	17	24	15567297	10.1016/j.ejpb.2004.07.008	Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.	Luckner P, Brandsch M.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	Bioorg. Med. Chem.	2011	19	15	4544	4551	21741846	10.1016/j.bmc.2011.06.027	Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.	Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356									Unpublished dataset	
962.7500000000000000	2	Bacteria	CYCLACILLIN	CHEMBL1200356									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	J. Med. Chem.	2002	45	9	1757	1766	11960487	10.1021/jm0109513	Structure-based design of novel potent nonpeptide thrombin inhibitors.	Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur. J. Med. Chem.	2012	50		255	263	22365562	10.1016/j.ejmech.2012.01.059	Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.	Ili¿ M, Kikelj D, Ila¿ J.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	J. Med. Chem.	2012	55	8	3934	3944	22494098	10.1021/jm3001339	Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).	Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur. J. Med. Chem.	2012	57		21	28	23043765	10.1016/j.ejmech.2012.09.016	Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity.	Yang XZ, Yang WH, Xu YG, Diao XJ, He GW, Gong GQ.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	J. Med. Chem.	2013	56	23	9441	9456	24175584	10.1021/jm4005835	5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.	Meneyrol J, Follmann M, Lassalle G, Wehner V, Barre G, Rousseaux T, Altenburger JM, Petit F, Bocskei Z, Schreuder H, Alet N, Herault JP, Millet L, Dol F, Florian P, Schaeffer P, Sadoun F, Klieber S, Briot C, Bono F, Herbert JM.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	J. Med. Chem.	2013	56	3	781	795	23241029	10.1021/jm301302s	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.	Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur. J. Med. Chem.	2013	64		302	313	23644213	10.1016/j.ejmech.2013.03.056	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.	Trstenjak U, Ila¿ J, Kikelj D.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Bioorg. Med. Chem.	2015	23	10	2328	2343	25882520	10.1016/j.bmc.2015.03.072	Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.	Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Bioorg. Med. Chem.	2015	23	23	7405	7416	26537784	10.1016/j.bmc.2015.10.036	Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.	Chen D, Wang S, Diao X, Zhu Q, Shen H, Han X, Wang Y, Gong G, Xu Y.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur. J. Med. Chem.	2015	96		122	138	25874337	10.1016/j.ejmech.2015.04.012	Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.	Li ML, Ren YJ, Dong MH, Ren WX.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur J Med Chem	2016	120		148	159	27187866	10.1016/j.ejmech.2016.05.020	Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.	Ren W, Ren Y, Wang S.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Bioorg. Med. Chem.	2016	24	12	2739	2753	27166573	10.1016/j.bmc.2016.04.038	Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues.	Wang F, Ren YJ, Dong MH.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Bioorg. Med. Chem.	2016	24	2	73	84	26690913	10.1016/j.bmc.2015.11.025	Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors.	Dong MH, Chen HF, Ren YJ, Shao FM.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Eur J Med Chem	2017	126		799	809	27951488	10.1016/j.ejmech.2016.12.015	Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.	Yang H, Liu Q, Gao X, Ren Y, Gao Y.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361	Bioorg Med Chem	2017	25	2	458	470	27884512	10.1016/j.bmc.2016.11.012	Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.	Chen D, Shi J, Liu J, Zhang X, Deng X, Yang Y, Cui S, Zhu Q, Gong G, Xu Y.
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361									PubChem BioAssay data set	
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	DABIGATRAN	CHEMBL48361									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	DABIGATRAN ETEXILATE MESYLATE	CHEMBL1615369									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	DABIGATRAN ETEXILATE MESYLATE	CHEMBL1615369									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	1976	19	5	615	619	1271403	10.1021/jm00227a008	Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.	Mirrlees MS, Moulton SJ, Murphy CT, Taylor PJ.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	1980	23	4	384	391	6991693	10.1021/jm00178a008	2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 3. C-Benzylation of aminopyridines with phenolic Mannich bases. Synthesis of 1- and 3-deaza analogues of trimethoprim.	Rauckman BS, Roth B.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	1985	28	3	381	388	2579237	10.1021/jm00381a019	[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.	McNeal ET, Lewandowski GA, Daly JW, Creveling CR.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Bioorg. Med. Chem. Lett.	1992	2	8	855	860		10.1016/S0960-894X(00)80544-2	Acetylcholine releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas	Thomas AJ, Kester JA, Butler DE, Hershenson FM, Davis RE, Marriott JG, Schwarz RD, Spencer CJ, Symons JP, Moos WH
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Bioorg. Med. Chem. Lett.	1997	7	10	1283	1288		10.1016/S0960-894X(97)00210-2	DERIVATIVES OF 4-AMINO-PYRIDINE AS SELECTIVE THROMBIN INHIBITORS	von der Saal W, Kucznierz R, Leinert H, Engh RA
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	1999	42	20	4225	4231	10514292	10.1021/jm990224w	Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions.	Carlier PR, Chow ES, Han Y, Liu J, El Yazal J, Pang YP.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Bioorg. Med. Chem. Lett.	2004	14	18	4771	4777	15324906	10.1016/j.bmcl.2004.06.070	The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.	Du LP, Tsai KC, Li MY, You QD, Xia L.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	2004	47	9	2326	2336	15084131	10.1021/jm030523s	Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.	Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hänsel W, Wulff H.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Bioorg. Med. Chem. Lett.	2008	18	1	309	312	18023348	10.1016/j.bmcl.2007.10.077	4-Aminopyridine derivatives with anticholinesterase and antiamnesic activity.	Scipione L, De Vita D, Musella A, Flammini L, Bertoni S, Barocelli E.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Bioorg. Med. Chem. Lett.	2010	20	16	4870	4877	20637607	10.1016/j.bmcl.2010.06.090	3-D-QSAR and docking studies on the neuronal choline transporter.	Geldenhuys WJ, Allen DD, Lockman PR.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	2010	53	15	5367	5382	20356304	10.1021/jm901688m	alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.	Mattes H, Carcache D, Kalkman HO, Koller M.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	Eur. J. Med. Chem.	2011	46	2	618	630	21185626	10.1016/j.ejmech.2010.11.042	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.	Sinha N, Sen S.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	2011	54	1	211	221	21126022	10.1021/jm1010572	Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.	Ferrari S, Morandi F, Motiejunas D, Nerini E, Henrich S, Luciani R, Venturelli A, Lazzari S, Calò S, Gupta S, Hannaert V, Michels PA, Wade RC, Costi MP.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J. Med. Chem.	2011	54	19	6482	6491	21834513	10.1021/jm2001103	Aryl H-phosphonates 17: (N-aryl)phosphoramidates of pyrimidine nucleoside analogues and their synthesis, selected properties, and anti-HIV activity.	Romanowska J, Sobkowski M, Szyma¿ska-Michalak A, Ko¿odziej K, D¿browska A, Lipniacki A, Piasek A, Pietrusiewicz ZM, Figlerowicz M, Guranowski A, Boryski J, Stawi¿ski J, Kraszewski A.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348		2013							Use of acacetin and related compounds as potassium channel inhibitors	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348	J Med Chem	2017	60	6	2245	2256	28225274	10.1021/acs.jmedchem.6b01262	A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.	Al-Sabi A, Daly D, Hoefer P, Kinsella GK, Metais C, Pickering M, Herron C, Kaza SK, Nolan K, Dolly JO.
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348									British National Formulary (72nd edition)	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348									PubChem BioAssay data set	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348									Unpublished dataset	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
853.5000000000000000	9606	Homo sapiens	DALFAMPRIDINE	CHEMBL284348									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	DALFOPRISTIN	CHEMBL1200937	J. Med. Chem.	1996	39	20	3853	3874	8831751	10.1021/jm960294s	New directions in antibacterial research.	Chu DT, Plattner JJ, Katz L.
2219.8000000000000000	2	Bacteria	DALFOPRISTIN	CHEMBL1200937	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	DALFOPRISTIN	CHEMBL1200937	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	DALFOPRISTIN	CHEMBL1200937									Unpublished dataset	
2219.8000000000000000	2	Bacteria	DALFOPRISTIN	CHEMBL1200937									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1769.8333333333333333	9606	Homo sapiens	DARATUMUMAB	CHEMBL1743007									Unpublished dataset	
1769.8333333333333333	9606	Homo sapiens	DARATUMUMAB	CHEMBL1743007									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1769.8333333333333333	9606	Homo sapiens	DARATUMUMAB	CHEMBL1743007									WHO Anatomical Therapeutic Chemical Classification	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2004	47	27	6658	6661	15615512	10.1021/jm049486a	Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.	Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2006	49	23	6819	6832	17154512	10.1021/jm060727j	2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.	Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Proc. Natl. Acad. Sci. U.S.A.	2007	104	33	13283	13288	17684099	10.1073/pnas.0702654104	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.	Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Proc. Natl. Acad. Sci. U.S.A.	2007	104	51	20523	20528	18077363	10.1073/pnas.0708800104	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Proc. Natl. Acad. Sci. U.S.A.	2007	104	9	3520	3525	17360676	10.1073/pnas.0611681104	c-Src protein kinase inhibitors block assembly and maturation of dengue virus.	Chu JJ, Yang PL.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2007	50	23	5853	5857	17956080	10.1021/jm070342g	Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.	Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Nat. Biotechnol.	2008	26	1	127	132	18183025	10.1038/nbt1358	A quantitative analysis of kinase inhibitor selectivity.	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Nat. Chem. Biol.	2008	4	11	691	699	18849971	10.1038/nchembio.117	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.	Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem.	2009	17	8	3152	3161	19321350	10.1016/j.bmc.2009.02.054	Structure-based virtual screening of Src kinase inhibitors.	Lee K, Kim J, Jeong KW, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2009	19	24	6872	6876	19889540	10.1016/j.bmcl.2009.10.085	Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.	Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Leukemia	2009	23	3	477	485	19039322	10.1038/leu.2008.334	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.	Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Nat. Chem. Biol.	2009	5	3	144	145	19219016	10.1038/nchembio0309-144	A pulse at the heart of targeted therapy.	Bradner JE.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Nat. Chem. Biol.	2009	5	6	394	396	19396179	10.1038/nchembio.162	A new screening assay for allosteric inhibitors of cSrc.	Simard JR, Klüter S, Grütter C, Getlik M, Rabiller M, Rode HB, Rauh D.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2009	52	13	3915	3926	19462975	10.1021/jm9002928	Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.	Getlik M, Grütter C, Simard JR, Klüter S, Rabiller M, Rode HB, Robubi A, Rauh D.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem.	2010	18	5	1789	1797	20156689	10.1016/j.bmc.2010.01.056	Colony stimulating factor-1 receptor as a target for small molecule inhibitors.	Mashkani B, Griffith R, Ashman LK.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2010	53	4	1413	1437	20166671	10.1021/jm901132v	Selectively nonselective kinase inhibition: striking the right balance.	Morphy R.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem.	2011	19	8	2517	2528	21459579	10.1016/j.bmc.2011.03.021	Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.	Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2011	21	19	5870	5875	21855335	10.1016/j.bmcl.2011.07.101	Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.	Zeng H, Belanger DB, Curran PJ, Shipps GW, Miao H, Bracken JB, Arshad Siddiqui M, Malkowski M, Wang Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2011	46	6	2043	2057	21429632	10.1016/j.ejmech.2011.02.057	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.	Shallal HM, Russu WA.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2011	46	9	4311	4323	21794960	10.1016/j.ejmech.2011.07.001	Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors.	Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Lannigan D, Smith J, Scudiero D, Kondapaka S, Shoemaker RH.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2012	22	1	339	342	22130133	10.1016/j.bmcl.2011.11.003	Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.	Wang J, Wang X, Chen Y, Chen S, Chen G, Tong L, Meng L, Xie Y, Ding J, Yang C.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2012	22	17	5579	5583	22853993	10.1016/j.bmcl.2012.07.014	A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: from in silico screening to cyclodextrin formulation.	Radi M, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, Musumeci F, Schenone S, Lorens JB, Botta M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2012	22	2	806	810	22217877	10.1016/j.bmcl.2011.12.070	Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.	Cai J, Zhang S, Zheng M, Wu X, Chen J, Ji M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2012	22	23	7232	7236	23099099	10.1016/j.bmcl.2012.09.043	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3ß inhibitors through virtual screening.	Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2012	55	10	4539	4550	22394077	10.1021/jm300035p	Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.	Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2012	55	11	4896	4933	22409598	10.1021/jm300065h	Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.	Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2012	55	22	10033	10046	23088644	10.1021/jm301188x	Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)¿isoleucine(315) mutant.	Li Y, Shen M, Zhang Z, Luo J, Pan X, Lu X, Long H, Wen D, Zhang F, Leng F, Li Y, Tu Z, Ren X, Ding K, Ding K.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2013	23	15	4398	4403	23787099	10.1016/j.bmcl.2013.05.072	Identification of potent Yes1 kinase inhibitors using a library screening approach.	Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Scientific Reports	2013	3		1	7	23812503	10.1038/srep02100	MICE models: superior to the HERG model in predicting Torsade de Pointes.	Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	ACS Med. Chem. Lett.	2013	4	8	779	783	24015327	10.1021/ml400175d	Development of a chimeric c-Src kinase and HDAC inhibitor.	Ko KS, Steffey ME, Brandvold KR, Soellner MB.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	1	84	96	23253074	10.1021/jm301187e	Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.	Lafleur K, Dong J, Huang D, Caflisch A, Nevado C.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	17	6991	7002	23937569	10.1021/jm400798j	Selectivity data: assessment, predictions, concordance, and implications.	Gao C, Cahya S, Nicolaou CA, Wang J, Watson IA, Cummins DJ, Iversen PW, Vieth M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	21	8377	8388	24088053	10.1021/jm400813y	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.	Végner L, Peragovics Á, Tombor L, Jelinek B, Czobor P, Bender A, Simon Z, Málnási-Csizmadia A.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	3	879	894	23301703	10.1021/jm301581y	Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.	Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y, Zhuang X, Zhang F, Liu J, Leng F, Lang X, Bai Y, She M, Tu Z, Pan J, Ding K, Ding K.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	8	3281	3295	23521020	10.1021/jm301824k	Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.	Gao M, Duan L, Luo J, Zhang L, Lu X, Zhang Y, Zhang Z, Tu Z, Xu Y, Ren X, Ding K, Ding K.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2013	56	9	3531	3545	23600806	10.1021/jm301891t	Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.	Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, Hong S.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2013	61		41	48	22770610	10.1016/j.ejmech.2012.06.007	Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.	Rohe A, Göllner C, Wichapong K, Erdmann F, Al-Mazaideh GM, Sippl W, Schmidt M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2013	61		95	103	23047001	10.1016/j.ejmech.2012.09.021	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3ß (GSK-3ß).	Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2013	63		702	712	23567960	10.1016/j.ejmech.2013.03.013	Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.	Cai J, Sun M, Wu X, Chen J, Wang P, Zong X, Ji M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2014	24	24	5639	5643	25467150	10.1016/j.bmcl.2014.10.078	Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3ß (GSK-3ß) with cellular activity of promoting glucose uptake.	Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2014	57	10	4252	4262	24754677	10.1021/jm500167q	Identification of type II and III DDR2 inhibitors.	Richters A, Nguyen HD, Phan T, Simard JR, Grütter C, Engel J, Rauh D.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2014	57	15	6428	6443	25004409	10.1021/jm500413g	Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.	Lee S, Lee H, Kim J, Lee S, Kim SJ, Choi BS, Hong SS, Hong S.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2014	57	15	6834	6844	25076195	10.1021/jm5009242	Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.	Unzue A, Dong J, Lafleur K, Zhao H, Frugier E, Caflisch A, Nevado C.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2014	57	19	7900	7915	25101911	10.1021/jm501177w	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.	Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J Pharmacol Toxicol Methods	2014	70		246	254	25087753	10.1016/j.vascn.2014.07.002	Prediction of Thorough QT study results using action potential simulations based on ion channel screens.	Mirams GR, Davies MR, Brough SJ, Bridgland-Taylor MH, Cui Y, Gavaghan DJ, Abi-Gerges N.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2014	87		677	702	25305334	10.1016/j.ejmech.2014.10.010	A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.	Bhakat S, Karubiu W, Jayaprakash V, Soliman ME.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2015	103		312	324	26363867	10.1016/j.ejmech.2015.08.048	¿(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.	Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, Bertoni S, Giorgio C, Hassan-Mohamed I, Zanotti I, Bugatti A, Rusnati M, Festuccia C, Rivara S, Barocelli E, Mor M, Lodola A.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2015	104		139	147	26451772	10.1016/j.ejmech.2015.09.034	Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.	Shan Y, Dong J, Pan X, Zhang L, Zhang J, Dong Y, Wang M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2015	25	17	3458	3463	26195136	10.1016/j.bmcl.2015.07.006	Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.	Lu X, Zhang Z, Ren X, Pan X, Wang D, Zhuang X, Luo J, Yu R, Ding K.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2015	25	19	4320	4324	26264503	10.1016/j.bmcl.2015.07.065	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.	Muthyala R, Shin WS, Xie J, Sham YY.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Bioorg. Med. Chem. Lett.	2015	25	3	708	716	25529740	10.1016/j.bmcl.2014.11.070	Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.	An XD, Liu H, Xu ZL, Jin Y, Peng X, Yao YM, Geng M, Long YQ.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	1	347	361	25469771	10.1021/jm5013159	Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.	Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	12	4964	4975	26039671	10.1021/acs.jmedchem.5b00108	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.	Vincetti P, Caporuscio F, Kaptein S, Gioiello A, Mancino V, Suzuki Y, Yamamoto N, Crespan E, Lossani A, Maga G, Rastelli G, Castagnolo D, Neyts J, Leyssen P, Costantino G, Radi M.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	6	2746	2763	25699576	10.1021/jm501929n	Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.	Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	8	3287	3301	25569119	10.1021/jm5012319	Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.	Li Y, Lu X, Ren X, Ding K.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	8	3393	3410	25822739	10.1021/jm501759m	Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.	Kovackova S, Chang L, Bekerman E, Neveu G, Barouch-Bentov R, Chaikuad A, Heroven C, ¿ála M, De Jonghe S, Knapp S, Einav S, Herdewijn P.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2015	58	9	3957	3974	25835317	10.1021/acs.jmedchem.5b00270	Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.	Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	ACS Med. Chem. Lett.	2015	6	3	313	317	25815152	10.1021/ml500496u	Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.	P¿unescu E, Clavel CM, Nowak-Sliwinska P, Griffioen AW, Dyson PJ.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	ACS Med. Chem. Lett.	2015	6	7	798	803	26191369	10.1021/acsmedchemlett.5b00143	Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.	Murray CW, Berdini V, Buck IM, Carr ME, Cleasby A, Coyle JE, Curry JE, Day JE, Day PJ, Hearn K, Iqbal A, Lee LY, Martins V, Mortenson PN, Munck JM, Page LW, Patel S, Roomans S, Smith K, Tamanini E, Saxty G.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur. J. Med. Chem.	2015	96		269	280	25899332	10.1016/j.ejmech.2015.04.027	Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.	Zhou W, Huang A, Zhang Y, Lin Q, Guo W, You Z, Yi Z, Liu M, Chen Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur J Med Chem	2016	119		70	82	27155464	10.1016/j.ejmech.2016.04.056	Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.	Munikrishnappa CS, Puranik SB, Kumar GV, Prasad YR.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur J Med Chem	2016	123		1	13	27474918	10.1016/j.ejmech.2016.07.034	Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.	El-Moghazy SM, George RF, Osman EEA, Elbatrawy AA, Kissova M, Colombo A, Crespan E, Maga G.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2016	59	10	4697	4710	27115835	10.1021/acs.jmedchem.6b00065	Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.	Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC, Brunton VG, Patton EE, Carragher NO, Unciti-Broceta A.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2016	59	3	1184	1196	26814890	10.1021/acs.jmedchem.5b01841	Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.	Sang F, Ding Y, Wang J, Sun B, Sun J, Geng Y, Zhang Z, Ding K, Wu LL, Liu JW, Bai C, Yang G, Zhang Q, Li LY, Chen Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2016	59	5	1984	2004	26789553	10.1021/acs.jmedchem.5b01618	Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.	Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J. Med. Chem.	2016	59	8	3886	3905	27010810	10.1021/acs.jmedchem.6b00087	Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.	Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	MedChemComm	2016	7	6	1245	1255		10.1039/C6MD00170J	Histone demethylating agents as potential S-adenosyl-l-methionine-competitors	Navakauskiene R, Mori M, Christodoulou MS, Zentelyte A, Botta B, Via LD, Ricci F, Damia G, Passarella D, Zilio C, Martinet N
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Eur J Med Chem	2017	135		370	381	28460311	10.1016/j.ejmech.2017.04.039	The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3ß inhibitors for the treatment of ovarian cancer.	Gao Y, Ye DY, Zhou WC, Chu Y.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J Med Chem	2017	60	18	7863	7875	28792760	10.1021/acs.jmedchem.7b00996	Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.	Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	J Med Chem	2017	60	4	1598	1604	28117588	10.1021/acs.jmedchem.6b01439	Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.	Astolfi A, Felicetti T, Iraci N, Manfroni G, Massari S, Pietrella D, Tabarrini O, Kaatz GW, Barreca ML, Sabatini S, Cecchetti V.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	ACS Med Chem Lett	2017	8	4	401	406	28435526	10.1021/acsmedchemlett.6b00488	RITA Mimics: Synthesis and Mechanistic Evaluation of Asymmetric Linked Trithiazoles.	Pietkiewicz AL, Zhang Y, Rahimi MN, Stramandinoli M, Teusner M, McAlpine SR.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421	ACS Med Chem Lett	2017	8	6	632	635	28626524	10.1021/acsmedchemlett.7b00084	19F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors.	Skora L, Jahnke W.
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421									British National Formulary (72nd edition)	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421									PubChem BioAssay data set	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421									Unpublished dataset	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
941.6000000000000000	9606	Homo sapiens	DASATINIB	CHEMBL1421									WHO Anatomical Therapeutic Chemical Classification	
998.6000000000000000	9606	Homo sapiens	DB959	CHEMBL3545176									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	DE-104	CHEMBL3545153									Unpublished dataset	
863.7500000000000000	9606	Homo sapiens	DECOGLURANT	CHEMBL3301593									Unpublished dataset	
863.7500000000000000	9606	Homo sapiens	DECOGLURANT	CHEMBL3301593									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem. Lett.	1995	5	16	1875	1880		10.1016/0960-894X(95)00311-G	Design and synthesis of a conformationally constrained analog of the bis(heteroaryl)piperazine (BHAP) HIV-1 reverse transcriptase inhibitor atevirdine	Genin MJ, Chidester CG, Rohrer DC, Romero DL
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	J. Med. Chem.	1996	39	19	3769	3789	8809165	10.1021/jm960158n	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.	Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Stefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG, Thomas RC.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem. Lett.	2000	10	2	193	195	10673109	10.1016/s0960-894x(99)00672-1	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Gearhart LA, Ko SS, Rodgers JD, Cordova BC, Klabe RM, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	J. Med. Chem.	2000	43	5	1034	1040	10715167	10.1021/jm990383f	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.	Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG, Yagi Y, Romero DL.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem. Lett.	2001	11	17	2225	2228	11527703	10.1016/s0960-894x(01)00410-3	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).	Ludovici DW, Kukla MJ, Grous PG, Krishnan S, Andries K, de Béthune MP, Azijn H, Pauwels R, De Clercq E, Arnold E, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem. Lett.	2001	11	4	523	528	11229762	10.1016/s0960-894x(01)00011-7	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.	Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	J. Med. Chem.	2002	45	26	5721	5726	12477355	10.1021/jm020949r	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	El-Brollosy NR, Jørgensen PT, Dahan B, Boel AM, Pedersen EB, Nielsen C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	J. Nat. Prod.	2004	67	6	994	998	15217281	10.1021/np030469i	New 3-O-acyl betulinic acids from Strychnos vanprukii Craib.	Nguyen QC, Nguyen VH, Santarsiero BD, Mesecar AD, Nguyen MC, Soejarto DD, Pezzuto JM, Fong HH, Tan GT.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	J. Med. Chem.	2010	53	10	4259	4265	20426472	10.1021/jm100254w	Colloid formation by drugs in simulated intestinal fluid.	Doak AK, Wille H, Prusiner SB, Shoichet BK.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Bioorg. Med. Chem. Lett.	2013	23	24	6593	6597	24239481	10.1016/j.bmcl.2013.10.059	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Liu X, Meng Q, Wang D, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929	Eur J Med Chem	2017	130		209	222	28254696	10.1016/j.ejmech.2017.02.047	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.	Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	DELAVIRDINE MESYLATE	CHEMBL929									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Bioorg. Med. Chem. Lett.	2012	22	4	1709	1711	22257890	10.1016/j.bmcl.2011.12.103	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.	Maiti M, Nauwelaerts K, Herdewijn P.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474									Unpublished dataset	
2219.8000000000000000	2	Bacteria	DEMECLOCYCLINE HYDROCHLORIDE	CHEMBL1200474									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	DESIRUDIN	CHEMBL1201662									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	DESIRUDIN	CHEMBL1201662									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	DESIRUDIN	CHEMBL1201662									WHO Anatomical Therapeutic Chemical Classification	
895.6500000000000000	9606	Homo sapiens	DEZOCINE	CHEMBL1685	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
895.6500000000000000	9606	Homo sapiens	DEZOCINE	CHEMBL1685	Bioorg. Med. Chem. Lett.	2009	19	4	1228	1232	19168350	10.1016/j.bmcl.2008.12.095	Discovery of mu-opioid selective ligands derived from 1-aminotetralin scaffolds made via metal-catalyzed ring-opening reactions.	Dockendorff C, Jin S, Olsen M, Lautens M, Coupal M, Hodzic L, Spear N, Payza K, Walpole C, Tomaszewski MJ.
895.6500000000000000	9606	Homo sapiens	DEZOCINE	CHEMBL1685									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	DEZOCINE	CHEMBL1685									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
895.6500000000000000	9606	Homo sapiens	DEZOCINE	CHEMBL1685									WHO Anatomical Therapeutic Chemical Classification	
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1990	33	3	978	985	2106581	10.1021/jm00165a015	Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.	Marquez VE, Tseng CK, Mitsuya H, Aoki S, Kelley JA, Ford H, Roth JS, Broder S, Johns DG, Driscoll JS.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1990	33	6	1553	1561	2342052	10.1021/jm00168a006	Synthesis and structure-activity relationships of 6-substituted 2',3'-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents.	Chu CK, Ullas GV, Jeong LS, Ahn SK, Doboszewski B, Lin ZX, Beach JW, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1991	34	11	3187	3197	1956037	10.1021/jm00115a007	Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2.	Kukla MJ, Breslin HJ, Diamond CJ, Grous PP, Ho CY, Miranda M, Rodgers JD, Sherrill RG, De Clercq E, Pauwels R.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1991	34	2	746	751	1995896	10.1021/jm00106a040	Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.	Kukla MJ, Breslin HJ, Pauwels R, Fedde CL, Miranda M, Scott MK, Sherrill RG, Raeymaekers A, Van Gelder J, Andries K.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1991	34	4	1408	1414	1901911	10.1021/jm00108a025	Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity.	Piantadosi C, Marasco CJ, Morris-Natschke SL, Meyer KL, Gumus F, Surles JR, Ishaq KS, Kucera LS, Iyer N, Wallen CA.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1991	34	5	1606	1612	2033586	10.1021/jm00109a012	Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.	Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H, Driscoll JS, Kelley JA, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1991	34	5	1647	1655	2033591	10.1021/jm00109a018	Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.	Barchi JJ, Marquez VE, Driscoll JS, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1992	35	13	2347	2354	1619614	10.1021/jm00091a001	Synthesis and anti-HIV activity of isonucleosides.	Huryn DM, Sluboski BC, Tam SY, Weigele M, Sim I, Anderson BD, Mitsuya H, Broder S.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1993	3	8	1723	1728		10.1016/S0960-894X(00)80050-5	A novel class of 1,3-oxathiolane nucleoside analogues having potent anti-HIV activity	Belleau B, Brasili L, Chan L, DiMarco MP, Zacharie B, Nguyen-Ba N, Jenkinson HJ, Coates JA, Cameron JM
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1993	36	3	378	384	8426365	10.1021/jm00055a009	Novel 6-alkoxypurine 2',3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus.	Burns CL, St Clair MH, Frick LW, Spector T, Averett DR, English ML, Holmes TJ, Krenitsky TA, Koszalka GW.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1994	37	16	2520	2526	7520081	10.1021/jm00042a005	HIV-1 reverse transcriptase inhibitor design using artificial neural networks.	Tetko IV, Tanchuk VYu, Chentsova NP, Antonenko SV, Poda GI, Kukhar VP, Luik AI.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1994	37	21	3534	3541	7523675	10.1021/jm00047a011	Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.	Franchetti P, Cappellacci L, Grifantini M, Messini L, abu Sheikha G, Loi AG, Tramontano E, de Montis A, Spiga MG, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1995	38	7	1189	1195	7707321	10.1021/jm00007a015	Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.	Ford H, Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H, Shirasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1995	5	14	1461	1466		10.1016/0960-894X(95)00257-T	Synthesis and anti HIV-1 activity of new thiadiazepindioxides	Giannotti D, Viti G, Nannicini R, Pestellini V, Bellarosa D
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1995	5	19	2273	2276		10.1016/0960-894X(95)00395-A	Enantiomerically pure synthesis and antiviral evaluation of [(2S, 3S)-bis(hydroxymethyl)azetidin-1-yl] purine nucleosides: Analogs of oxetanocin-A	Nishiyama S, Kikuchi Y, Kurata H, Yamamura S, Izawa T, Nagahata T, Ikeda R, Kato K
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1996	39	14	2856	2859	8709116	10.1021/jm9507901	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.	Gueiffier A, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade JC, Kerbal A, Essassi EM, Debouzy JC, Witvrouw M, Blache Y, Balzarini J, De Clercq E, Chapat JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1996	39	8	1619	1625	8648601	10.1021/jm9509197	Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.	Driscoll JS, Siddiqui MA, Ford H, Kelley JA, Roth JS, Mitsuya H, Tanaka M, Marquez VE.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1996	6	11	1279	1284		10.1016/0960-894X(96)00216-8	Design, synthesis and antiproliferative activity of methyl 4-Iodo-1--D-ribofuranosyl-pyrazole-3-carboxylate and related compounds	Manfredini S, Bazzanini R, Baraldi PG, Simoni D, Vertuani S, Pani A, Pinna E, Scintu F, Lichino D, Colla PL
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1996	6	14	1657	1662		10.1016/0960-894X(96)00293-4	Anti-human immunodeficiency and anti-hepatitis B virus activities of -l-2,3-dideoxy purine nucleosides	Bolon PJ, Peiyuan Wang, Chu CK, Gosselin G, Boudou V, Pierra C, Mathe C, Imbach J, Faraj A, Alaoui Ae, Sommadossi J, Pai S, Yong-Lian Zhu, Ju-Sheng Lin, Yung-Chi Cheng, Schinazi RF
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1996	6	2	179	184		10.1016/0960-894X(95)00585-H	Synthesis, enzymatic phosphorylation and antiviral activity of acyclic dienyl phosphonate derivatives of guanine	Nave J, Casara PJ, Taylor DL, Stanley Tyms A, Kenny M, HalazyS S
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	1997	40	15	2363	2373	9240351	10.1021/jm9607921	Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.	Kim DK, Gam J, Kim YW, Lim J, Kim HT, Kim KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	1999	9	11	1577	1582	10386939	10.1016/s0960-894x(99)00228-0	Lipase-catalyzed protection of the hydroxy groups of the nucleosides inosine and 2'-deoxyinosine: a new chemoenzymatic synthesis of the antiviral drug 2',3'-dideoxyinosine.	Ciuffreda P, Casati S, Santaniello E.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Pharmacol. Exp. Ther.	2000	294	1	844	849	10945832		Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Nat. Prod.	2001	64	2	265	277	11430019	10.1021/np0003995	Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.	Yang SS, Cragg GM, Newman DJ, Bader JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Nat. Prod.	2002	65	11	1649	1656	12444692	10.1021/np020234r	New saponins from the starfish Certonardoa semiregularis.	Wang W, Li F, Alam N, Liu Y, Hong J, Lee CK, Im KS, Jung JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	2004	14	12	3173	3176	15149669	10.1016/j.bmcl.2004.04.008	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.	He Y, Chen F, Sun G, Wang Y, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Nat. Prod.	2004	67	4	659	663	15104498	10.1021/np034052o	Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.	Ishikawa T, Nishigaya K, Takami K, Uchikoshi H, Chen IS, Tsai IL.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	2005	48	2	604	613	15658873	10.1021/jm049711o	Exploring the role of different drug transport routes in permeability screening.	Matsson P, Bergström CA, Nagahara N, Tavelin S, Norinder U, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2007	15	1	227	234	17046264	10.1016/j.bmc.2006.09.066	Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives.	Kim KR, Moon HR, Park AY, Chun MW, Jeong LS.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	2007	17	8	2237	2240	17276686	10.1016/j.bmcl.2007.01.062	Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV.	Lalanne M, Paci A, Andrieux K, Dereuddre-Bosquet N, Clayette P, Deroussent A, Ré M, Vassal G, Couvreur P, Desmaële D.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2007	42	2	198	204	17095124	10.1016/j.ejmech.2006.09.018	Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ji L, Chen FE, Xie B, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2007	42	7	993	1003	17321639	10.1016/j.ejmech.2007.01.003	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.	Balzarini J, Orzeszko B, Maurin JK, Orzeszko A.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2007	51	12	4489	4491	17876005	10.1128/aac.00687-07	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.	Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2007	51	7	2531	2539	17470651	10.1128/aac.00039-07	Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.	Lund KC, Peterson LL, Wallace KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2008	43	6	1230	1236	17869386	10.1016/j.ejmech.2007.08.001	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.	Xiong YZ, Chen FE, Balzarini J, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2008	52	1	329	332	17967913	10.1128/aac.01004-07	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.	Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2008	52	4	1519	1521	18285481	10.1128/aac.01241-07	Anti-BK virus activity of nucleoside analogs.	Randhawa P, Zemlicka J, Sauerbrei A, Meier C, Hostetler KY, Beadle JR, Farasati NA, Huang Y, Bradley M.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2008	52	8	2825	2830	18541728	10.1128/aac.00434-08	Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.	Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2009	44	1	303	311	18420310	10.1016/j.ejmech.2008.02.039	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.	Balzarini J, Orzeszko-Krzesi¿ska B, Maurin JK, Orzeszko A.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2009	44	10	3874	3879	19433342	10.1016/j.ejmech.2009.04.008	Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats.	Høyem S, Bruheim S, Maelandsmo G, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2009	44	3	1016	1023	18692274	10.1016/j.ejmech.2008.06.028	Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wang YP, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2009	53	7	2748	2751	19433557	10.1128/aac.00364-09	Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug.	Venhoff AC, Lebrecht D, Reuss FU, Heckl-Ostreicher B, Wehr R, Walker UA, Venhoff N.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2010	18	16	6012	6023	20638854	10.1016/j.bmc.2010.06.067	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.	Casano G, Dumètre A, Pannecouque C, Hutter S, Azas N, Robin M.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2011	19	13	3945	3955	21658957	10.1016/j.bmc.2011.05.026	Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.	Park AY, Kim WH, Kang JA, Lee HJ, Lee CK, Moon HR.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2013	62		534	544	23419738	10.1016/j.ejmech.2013.01.015	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.	Malpani Y, Achary R, Kim SY, Jeong HC, Kim P, Han SB, Kim M, Lee CK, Kim JN, Jung YS.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2014	22	1	633	642	24275349	10.1016/j.bmc.2013.10.033	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.	Zhang L, Zhan P, Chen X, Li Z, Xie Z, Zhao T, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	MedChemComm	2014	5	5	622	631		10.1039/C4MD00003J	Biological evaluation and molecular modelling of didanosine derivatives	Ravetti S, De Candia CA, Gualdesi MS, Pampuro S, Turk G, Quevedo MA, Brinon MC
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Nat. Prod.	2014	77	6	1505	1512	24926807	10.1021/np500271u	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.	Nothias-Scaglia LF, Retailleau P, Paolini J, Pannecouque C, Neyts J, Dumontet V, Roussi F, Leyssen P, Costa J, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	2015	25	2	241	244	25515560	10.1016/j.bmcl.2014.11.065	Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents.	Xu X, Wang J, Yao Q.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem. Lett.	2015	25	6	1232	1235	25682562	10.1016/j.bmcl.2015.01.058	Design, synthesis of new ß-carboline derivatives and their selective anti-HIV-2 activity.	Ashok P, Chander S, Balzarini J, Pannecouque C, Murugesan S.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	J. Nat. Prod.	2015	78	5	1119	1128	25946116	10.1021/acs.jnatprod.5b00116	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.	Olivon F, Palenzuela H, Girard-Valenciennes E, Neyts J, Pannecouque C, Roussi F, Grondin I, Leyssen P, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur. J. Med. Chem.	2016	117		230	240	27105027	10.1016/j.ejmech.2016.04.019	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.	Patel SB, Patel BD, Pannecouque C, Bhatt HG.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Eur J Med Chem	2016	121		58	70	27214512	10.1016/j.ejmech.2016.05.017	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.	Kulaba¿ N, Tatar E, Bingöl Özakp¿nar Ö, Özsavc¿ D, Pannecouque C, De Clercq E, Küçükgüzel ¿.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2016	24	11	2476	2485	27112451	10.1016/j.bmc.2016.04.010	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.	Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN, Pannecouque C, Naesens L, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460	Bioorg Med Chem	2017	25	16	4397	4406	28659246	10.1016/j.bmc.2017.06.022	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.	Huang B, Wang X, Liu X, Chen Z, Li W, Sun S, Liu H, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	DIDANOSINE	CHEMBL1460									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517									British National Formulary (72nd edition)	
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	DIHYDROERGOTAMINE MESYLATE	CHEMBL1200517									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	DIHYDROSTREPTOMYCIN SULFATE	CHEMBL3188576	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	DIHYDROSTREPTOMYCIN SULFATE	CHEMBL3188576									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	DIHYDROSTREPTOMYCIN SULFATE	CHEMBL3188576									Unpublished dataset	
2219.8000000000000000	2	Bacteria	DIHYDROSTREPTOMYCIN SULFATE	CHEMBL3188576									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	J. Med. Chem.	2013	56	10	3768	3782	23600925	10.1021/jm301234k	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.	Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	Eur. J. Med. Chem.	2016	108		701	719	26741853	10.1016/j.ejmech.2015.12.023	Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.	Baltus CB, Jorda R, Marot C, Berka K, Bazgier V, Kry¿tof V, Prié G, Viaud-Massuard MC.
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	Eur. J. Med. Chem.	2016	110		291	301	26851505	10.1016/j.ejmech.2016.01.011	5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.	Vym¿talová L, Havlí¿ek L, ¿turc A, Skrá¿ková Z, Jorda R, Pospí¿il T, Strnad M, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	J Med Chem	2016	59	19	8667	8684	27171036	10.1021/acs.jmedchem.6b00150	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A.
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	MedChemComm	2016	7	8	1580	1586		10.1039/C6MD00159A		
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	Nat Rev Drug Discov	2017	16	6	424	440	28280261	10.1038/nrd.2016.266	Non-kinase targets of protein kinase inhibitors.	Munoz L.
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840									Unpublished dataset	
884.4000000000000000	9606	Homo sapiens	DINACICLIB	CHEMBL2103840									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	DIPIVEFRIN HYDROCHLORIDE	CHEMBL1200833									British National Formulary (72nd edition)	
886.9000000000000000	9606	Homo sapiens	DIPIVEFRIN HYDROCHLORIDE	CHEMBL1200833									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	DIPIVEFRIN HYDROCHLORIDE	CHEMBL1200833									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	DIPIVEFRIN HYDROCHLORIDE	CHEMBL1200833									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471	Antimicrob. Agents Chemother.	2007	51	3	923	929	17210767	10.1128/aac.01048-06	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.	Elkins CA, Mullis LB.
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471									Unpublished dataset	
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	DIRITHROMYCIN	CHEMBL3039471									WHO Anatomical Therapeutic Chemical Classification	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	1996	39	19	3606	3616	8809151	10.1021/jm960375o	Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors.	Rice WG, Turpin JA, Schaeffer CA, Graham L, Clanton D, Buckheit RW, Zaharevitz D, Summers MF, Wallqvist A, Covell DG.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	1997	40	13	1969	1976	9207937	10.1021/jm970147+	Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS.	McDonnell NB, De Guzman RN, Rice WG, Turpin JA, Summers MF.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Antimicrob. Agents Chemother.	2007	51	12	4495	4497	17876006	10.1128/aac.00753-07	Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.	Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, Sullivan D, Liu JO, Zhang Y.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	2009	52	22	7310	7314	19883085	10.1021/jm901323s	Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors.	Kapanda CN, Muccioli GG, Labar G, Poupaert JH, Lambert DM.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Eur. J. Med. Chem.	2010	45	11	4813	4826	20739103	10.1016/j.ejmech.2010.07.050	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.	Puri N, Prakash O, Manoharlal R, Sharma M, Ghosh I, Prasad R.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	2010	53	14	5085	5107	20356305	10.1021/jm100062h	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.	Baraldi PG, Preti D, Materazzi S, Geppetti P.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	2010	53	7	2757	2765	20222671	10.1021/jm901757t	Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer.	Brahemi G, Kona FR, Fiasella A, Buac D, Soukupová J, Brancale A, Burger AM, Westwell AD.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Bioorg. Med. Chem.	2012	20	7	2376	2381	22377672	10.1016/j.bmc.2012.02.002	Tea catechins and flavonoids from the leaves of Camellia sinensis inhibit yeast alcohol dehydrogenase.	Manir MM, Kim JK, Lee BG, Moon SS.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Bioorg. Med. Chem. Lett.	2012	22	24	7641	7646	23122865	10.1016/j.bmcl.2012.10.010	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.	Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Eur. J. Med. Chem.	2014	84		284	301	25036789	10.1016/j.ejmech.2014.06.078	Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.	Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964	Bioorg. Med. Chem. Lett.	2016	26	15	3826	3829	27311892	10.1016/j.bmcl.2016.04.075	Cupriphilic compounds to aid in proteasome inhibition.	Mukherjee S, Sparks R, Metcalf R, Brooks W, Daniel K, Guida WC.
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									British National Formulary (72nd edition)	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									DrugMatrix	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									Open TG-GATES	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									PubChem BioAssay data set	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									Unpublished dataset	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
889.7333333333333333	9606	Homo sapiens	DISULFIRAM	CHEMBL964									WHO Anatomical Therapeutic Chemical Classification	
932.0000000000000000	11676	Human immunodeficiency virus 1	DOLUTEGRAVIR SODIUM	CHEMBL1213165	Antimicrob. Agents Chemother.	2010	54	1	254	258	19884365	10.1128/aac.00842-09	Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.	Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC.
932.0000000000000000	11676	Human immunodeficiency virus 1	DOLUTEGRAVIR SODIUM	CHEMBL1213165	Antimicrob. Agents Chemother.	2011	55	2	813	821	21115794	10.1128/aac.01209-10	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.	Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	DOLUTEGRAVIR SODIUM	CHEMBL1213165	J. Med. Chem.	2013	56	14	5901	5916	23845180	10.1021/jm400645w	Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).	Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R, Fuji M, Tanimoto N, Jeffrey J, Foster SA, Yoshinaga T, Seki T, Kobayashi M, Sato A, Johnson MN, Garvey EP, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	DOLUTEGRAVIR SODIUM	CHEMBL1213165									Unpublished dataset	
932.0000000000000000	11676	Human immunodeficiency virus 1	DOLUTEGRAVIR SODIUM	CHEMBL1213165									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	DONITRIPTAN	CHEMBL1742428									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	DONITRIPTAN	CHEMBL1742428									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2007	51	10	3471	3484	17646423	10.1128/aac.01464-06	Global challenge of multidrug-resistant Acinetobacter baumannii.	Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2007	51	8	2716	2719	17517836	10.1128/aac.01623-06	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.	Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	1	365	373	17938185	10.1128/aac.00910-07	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.	Credito KL, Ednie LM, Appelbaum PC.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	10	3795	3800	18694945	10.1128/aac.00464-08	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.	Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	12	4388	4399	18779357	10.1128/aac.00381-08	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.	Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	12	4492	4496	18838581	10.1128/aac.00696-08	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.	Snydman DR, Jacobus NV, McDermott LA.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	2	761	766	18070958	10.1128/aac.01128-07	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.	Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	4	1510	1512	18250190	10.1128/aac.01529-07	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.	Davies TA, Shang W, Bush K, Flamm RK.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	7	2497	2502	18458125	10.1128/aac.01252-07	In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.	Kim A, Banevicius MA, Nicolau DP.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2008	52	9	3161	3168	18625771	10.1128/aac.00355-08	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.	Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	1	319	322	18955522	10.1128/aac.00595-08	In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.	Tanaka K, Mikamo H, Nakao K, Ichiishi T, Goto T, Yamagishi Y, Watanabe K.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	10	4352	4356	19770286	10.1128/aac.00282-09	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.	Crandon JL, Bulik CC, Nicolau DP.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	10	4518	4521	19620330	10.1128/aac.00461-09	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.	Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	4	1567	1573	19188391	10.1128/aac.01133-08	Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.	Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	7	3115	3117	19364859	10.1128/aac.00893-08	In vitro activity of doripenem against Burkholderia pseudomallei.	Thamlikitkul V, Trakulsomboon S.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2009	53	9	3782	3792	19581455	10.1128/aac.00837-08	Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.	Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	1	565	569	19884379	10.1128/aac.01004-09	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.	Queenan AM, Shang W, Flamm R, Bush K.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	10	4112	4115	20660688	10.1128/aac.00026-10	In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.	Bulik CC, Nicolau DP.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	3	1160	1164	20086165	10.1128/aac.01446-09	Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.	Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	3	1354	1357	20038618	10.1128/aac.00899-09	Detection of KPC in Acinetobacter spp. in Puerto Rico.	Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	5	2119	2124	20211892	10.1128/aac.01450-09	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.	Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	6	2360	2364	20385857	10.1128/aac.01843-09	Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.	Samtani MN, Flamm R, Kaniga K, Nandy P.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	6	2638	2645	20308371	10.1128/aac.01721-09	Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.	Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	6	2687	2691	20231393	10.1128/aac.01359-09	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	6	2692	2695	20308376	10.1128/aac.00033-10	Mutant prevention concentrations of four carbapenems against gram-negative rods.	Credito K, Kosowska-Shick K, Appelbaum PC.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2010	54	7	2867	2877	20421396	10.1128/aac.00197-10	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.	Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2011	55	2	934	936	21115785	10.1128/aac.01247-10	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.	Poirel L, Revathi G, Bernabeu S, Nordmann P.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Antimicrob. Agents Chemother.	2011	55	3	1187	1193	21199922	10.1128/aac.01063-10	Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.	Cirillo I, Vaccaro N, Balis D, Redman R, Matzke GR.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	ACS Med. Chem. Lett.	2014	5	5	556	560	24900879	10.1021/ml5000096	Expansion of Antibacterial Spectrum of Muraymycins toward Pseudomonas aeruginosa.	Takeoka Y, Tanino T, Sekiguchi M, Yonezawa S, Sakagami M, Takahashi F, Togame H, Tanaka Y, Takemoto H, Ichikawa S, Matsuda A.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	J Pharmacol Toxicol Methods	2014	70		246	254	25087753	10.1016/j.vascn.2014.07.002	Prediction of Thorough QT study results using action potential simulations based on ion channel screens.	Mirams GR, Davies MR, Brough SJ, Bridgland-Taylor MH, Cui Y, Gavaghan DJ, Abi-Gerges N.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	J Med Chem	2016	59	18	8441	8455	27524179	10.1021/acs.jmedchem.6b00867	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.	Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	J. Med. Chem.	2016	59	7	3427	3438	26937999	10.1021/acs.jmedchem.6b00096	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by ß-Lactamase BlaC.	Iannazzo L, Soroka D, Triboulet S, Fonvielle M, Compain F, Dubée V, Mainardi JL, Hugonnet JE, Braud E, Arthur M, Etheve-Quelquejeu M.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571	J Med Chem	2017	60	12	5002	5014	28549219	10.1021/acs.jmedchem.7b00377	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571									Unpublished dataset	
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	DORIPENEM	CHEMBL491571									WHO Anatomical Therapeutic Chemical Classification	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE	CHEMBL1200699									Unpublished dataset	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE	CHEMBL1200699									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE CALCIUM	CHEMBL2364574									Unpublished dataset	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE CALCIUM	CHEMBL2364574									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE HYCLATE	CHEMBL3989740									British National Formulary (72nd edition)	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE HYCLATE	CHEMBL3989740									Unpublished dataset	
1019.8333333333333333	9606	Homo sapiens	DOXYCYCLINE HYCLATE	CHEMBL3989740									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	DROXIDOPA	CHEMBL2103827	J. Biol. Chem.	2001	276	1	17221	17228	11278508	10.1074/jbc.m009462200	Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.	Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H.
886.9000000000000000	9606	Homo sapiens	DROXIDOPA	CHEMBL2103827	Drug Metab. Dispos.	2011	39	1	151	159	20966043	10.1124/dmd.110.035105	Identification of clinically used drugs that activate pregnane X receptors.	Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, Xia M.
886.9000000000000000	9606	Homo sapiens	DROXIDOPA	CHEMBL2103827									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	DROXIDOPA	CHEMBL2103827									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	DROXIDOPA	CHEMBL2103827									WHO Anatomical Therapeutic Chemical Classification	
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	EBROTIDINE	CHEMBL1742471									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	1999	42	20	4150	4160	10514285	10.1021/jm990095j	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.	Högberg M, Sahlberg C, Engelhardt P, Noréen R, Kangasmetsä J, Johansson NG, Oberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lövgren S, Fridborg K, Bäckbro K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	1999	9	19	2805	2810	10522695	10.1016/s0960-894x(99)00486-2	Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors.	Patel M, Ko SS, McHugh RJ, Markwalder JA, Srivastava AS, Cordova BC, Klabe RM, Erickson-Viitanen S, Trainor GL, Seitz SP.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	1999	9	22	3221	3224	10576692	10.1016/s0960-894x(99)00565-x	Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).	Patel M, McHugh RJ, Cordova BC, Klabe RM, Erickson-Viitanen S, Trainor GL, Ko SS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2000	10	15	1729	1731	10937734	10.1016/s0960-894x(00)00321-8	Synthesis and evaluation of quinoxalinones as HIV-1 reverse transcriptase inhibitors.	Patel M, McHugh RJ, Cordova BC, Klabe RM, Erickson-Viitanen S, Trainor GL, Rodgers JD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2000	10	2	193	195	10673109	10.1016/s0960-894x(99)00672-1	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Gearhart LA, Ko SS, Rodgers JD, Cordova BC, Klabe RM, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2000	43	10	2019	2030	10821714	10.1021/jm990580e	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, Diamond S, Jeffrey S, Klabe RM, Cordova BC, Garber S, Logue K, Trainor GL, Anderson PS, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	11	1389	1392	11378361	10.1016/s0960-894x(01)00239-6	4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.	Cocuzza AJ, Chidester DR, Cordova BC, Klabe RM, Jeffrey S, Diamond S, Weigelt CA, Ko SS, Bacheler LT, Erickson-Viitanen SK, Rodgers JD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	14	1943	1945	11459666	10.1016/s0960-894x(01)00331-6	Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors.	Patel M, McHugh RJ, Cordova BC, Klabe RM, Bacheler LT, Erickson-Viitanen S, Rodgers JD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	17	2235	2239	11527705	10.1016/s0960-894x(01)00412-7	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.	Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	2	211	214	11206461	10.1016/s0960-894x(00)00624-7	3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Pan S, Markwalder JA, Cordova BC, Klabe RM, Garber S, Rodgers JD, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	21	2799	2802	11597403	10.1016/s0960-894x(01)00510-8	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.	Wang DP, Rizzo RC, Tirado-Rives J, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	3	309	312	11212098	10.1016/s0960-894x(00)00662-4	Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.	Corbett JW, Kresge KJ, Pan S, Cordova BC, Klabe RM, Rodgers JD, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	5	619	622	11266155	10.1016/s0960-894x(01)00012-9	Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.	Markwalder JA, Christ DD, Mutlib A, Cordova BC, Klabe RM, Seitz SP.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2001	11	9	1177	1179	11354371	10.1016/s0960-894x(01)00192-5	Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.	Cocuzza AJ, Chidester DR, Cordova BC, Jeffrey S, Parsons RL, Bacheler LT, Erickson-Viitanen S, Trainor GL, Ko SS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2001	44	12	1853	1865	11384232	10.1021/jm001095i	Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.	Rodríguez-Barrios F, Pérez C, Lobatón E, Velázquez S, Chamorro C, San-Félix A, Pérez-Pérez MJ, Camarasa MJ, Pelemans H, Balzarini J, Gago F.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2001	44	12	1866	1882	11384233	10.1021/jm0004906	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.	Chan JH, Hong JS, Hunter  RN, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews  CW, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2001	44	16	2544	2554	11472208	10.1021/jm010853h	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mai A, Sbardella G, Artico M, Ragno R, Massa S, Novellino E, Greco G, Lavecchia A, Musiu C, La Colla M, Murgioni C, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2001	44	3	305	315	11462972	10.1021/jm0010365	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.	Campiani G, Aiello F, Fabbrini M, Morelli E, Ramunno A, Armaroli S, Nacci V, Garofalo A, Greco G, Novellino E, Maga G, Spadari S, Bergamini A, Ventura L, Bongiovanni B, Capozzi M, Bolacchi F, Marini S, Coletta M, Guiso G, Caccia S.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2002	45	14	2970	2987	12086483	10.1021/jm010580q	Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.	Rizzo RC, Udier-Blagovi¿ M, Wang DP, Watkins EK, Kroeger Smith MB, Smith RH, Tirado-Rives J, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2002	45	26	5721	5726	12477355	10.1021/jm020949r	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	El-Brollosy NR, Jørgensen PT, Dahan B, Boel AM, Pedersen EB, Nielsen C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2003	13	24	4309	4312	14643315	10.1016/j.bmcl.2003.09.045	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Benjahad A, Guillemont J, Andries K, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2004	14	10	2677	2680	15109677	10.1016/s0960-894x(04)00205-7	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.	Yadav A, Singh SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2004	14	12	3173	3176	15149669	10.1016/j.bmcl.2004.04.008	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.	He Y, Chen F, Sun G, Wang Y, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	10	2550	2560	15115397	10.1021/jm030558s	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	15	3892	3896	15239667	10.1021/jm031147e	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.	Silvestri R, Artico M, De Martino G, La Regina G, Loddo R, La Colla M, Mura M, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	22	5501	5514	15481987	10.1021/jm0407658	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.	Benjahad A, Courté K, Guillemont J, Mabire D, Coupa S, Poncelet A, Csoka I, Andries K, Pauwels R, de Béthune MP, Monneret C, Bisagni E, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	24	5923	5936	15537347	10.1021/jm040072r	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.	Freeman GA, Andrews Iii CW, Hopkins AL, Lowell GS, Schaller LT, Cowan JR, Gonzales SS, Koszalka GW, Hazen RJ, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Reynolds DJ, Milton J, Ren J, Stuart DI, Stammers DK, Chan JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	4	928	934	14761194	10.1021/jm0309856	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.	Ragno R, Mai A, Sbardella G, Artico M, Massa S, Musiu C, Mura M, Marturana F, Cadeddu A, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2004	47	5	1175	1182	14971897	10.1021/jm030255y	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.	Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2005	15	20	4451	4455	16115762	10.1016/j.bmcl.2005.07.046	Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives.	Bal TR, Anand B, Yogeeswari P, Sriram D.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	1	213	223	15634015	10.1021/jm040854k	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.	Ragno R, Artico M, De Martino G, La Regina G, Coluccia A, Di Pasquali A, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	11	3858	3873	15916438	10.1021/jm049252r	Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.	Ranise A, Spallarossa A, Cesarini S, Bondavalli F, Schenone S, Bruno O, Menozzi G, Fossa P, Mosti L, La Colla M, Sanna G, Murreddu M, Collu G, Busonera B, Marongiu ME, Pani A, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	13	4378	4388	15974590	10.1021/jm050273a	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.	De Martino G, La Regina G, Di Pasquali A, Ragno R, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	22	6776	6778	16250634	10.1021/jm0507330	6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase.	Bartolini S, Mai A, Artico M, Paesano N, Rotili D, Spadafora C, Sbardella G.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	23	7153	7165	16279773	10.1021/jm050257d	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.	Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	25	8000	8008	16335924	10.1021/jm050744t	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.	Manetti F, Esté JA, Clotet-Codina I, Armand-Ugón M, Maga G, Crespan E, Cancio R, Mugnaini C, Bernardini C, Togninelli A, Carmi C, Alongi M, Petricci E, Massa S, Corelli F, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	6	1689	1696	15771411	10.1021/jm040127p	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.	De Corte BL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	6	1901	1909	15771434	10.1021/jm040840e	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).	Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Béthune MP, Pauwels R, Das K, Clark AD, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	6	1910	1918	15771435	10.1021/jm040829e	Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.	Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, Vinkers M, Van Aken KJ, Arnold E, Das K, Kilonda A, Hoornaert GJ, Compernolle F, Cegla M, Azzam RA, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	6	1948	1964	15771439	10.1021/jm0408621	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.	Benjahad A, Croisy M, Monneret C, Bisagni E, Mabire D, Coupa S, Poncelet A, Csoka I, Guillemont J, Meyer C, Andries K, Pauwels R, de Béthune MP, Himmel DM, Das K, Arnold E, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	6	2072	2079	15771449	10.1021/jm040838n	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.	Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, Vinkers MH, Arnold E, Das K, Pauwels R, Andries K, de Béthune MP, Bettens E, Hertogs K, Wigerinck P, Timmerman P, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2005	48	7	2432	24444	15801834	10.1021/jm049606e	Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.	Wang J, Kang X, Kuntz ID, Kollman PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Med Chem Res	2006	15	9	492	510		10.1007/s00044-007-9004-0	Design, synthesis, and biological evaluation of new 3-hydroxy-2-oxo-3-trifluoromethylindole as potential HIV-1 reverse transcriptase inhibitors	Boechat N, Kover WB, Bastos MM, Romeiro NC, Silva ASC, Santos FC, Valverde AL, Azevedo MLG, Wollinger W, Souza TML, de Souza SLO, de Frugulhetti ICPP
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	11	3034	3038	16527484	10.1016/j.bmcl.2006.02.049	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.	Krajewski K, Zhang Y, Parrish D, Deschamps J, Roller PP, Pathak VK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	13	3430	3433	16632349	10.1016/j.bmcl.2006.04.012	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.	Wu B, Kuhen K, Ngoc Nguyen T, Ellis D, Anaclerio B, He X, Yang K, Karanewsky D, Yin H, Wolff K, Bieza K, Caldwell J, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	13	3541	3544	16621553	10.1016/j.bmcl.2006.03.080	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.	Mugnaini C, Manetti F, Esté JA, Clotet-Codina I, Maga G, Cancio R, Botta M, Corelli F.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	16	4174	4177	16781149	10.1016/j.bmcl.2006.05.096	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.	Wang Z, Wu B, Kuhen KL, Bursulaya B, Nguyen TN, Nguyen DG, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	16	4246	4251	16782337	10.1016/j.bmcl.2006.05.073	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Ellis D, Kuhen KL, Anaclerio B, Wu B, Wolff K, Yin H, Bursulaya B, Caldwell J, Karanewsky D, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	17	4444	4449	16806925	10.1016/j.bmcl.2006.06.048	Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase.	De La Rosa M, Kim HW, Gunic E, Jenket C, Boyle U, Koh YH, Korboukh I, Allan M, Zhang W, Chen H, Xu W, Nilar S, Yao N, Hamatake R, Lang SA, Hong Z, Zhang Z, Girardet JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	21	5664	5667	16931015	10.1016/j.bmcl.2006.08.037	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Thakur VV, Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	8	2105	2108	16480865	10.1016/j.bmcl.2006.01.073	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.	Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Wu TY, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2006	16	8	2109	2112	16464578	10.1016/j.bmcl.2006.01.066	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.	Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Tuntland T, Zhang K, Karanewsky D, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2006	49	11	3172	3184	16722636	10.1021/jm0512490	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.	Ragno R, Coluccia A, La Regina G, De Martino G, Piscitelli F, Lavecchia A, Novellino E, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2006	49	2	727	739	16420058	10.1021/jm050670l	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.	Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2007	17	1	260	265	17035019	10.1016/j.bmcl.2006.09.047	4-Aminopyrimidines as novel HIV-1 inhibitors.	Gadhachanda VR, Wu B, Wang Z, Kuhen KL, Caldwell J, Zondler H, Walter H, Havenhand M, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2007	17	3	712	716	17157017	10.1016/j.bmcl.2006.10.082	Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.	Benjahad A, Oumouch S, Guillemont J, Pasquier E, Mabire D, Andries K, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2007	17	7	1956	1960	17276064	10.1016/j.bmcl.2007.01.025	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.	Barreca ML, Rao A, De Luca L, Iraci N, Monforte AM, Maga G, De Clercq E, Pannecouque C, Balzarini J, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Biol. Chem.	2007	282	11	8005	8010	17172472	10.1074/jbc.m608274200	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.	Grobler JA, Dornadula G, Rice MR, Simcoe AL, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Drug Metab. Dispos.	2007	35	3	340	344	17172311	10.1124/dmd.106.012765	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.	Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2007	42	5	567	579	17223230	10.1016/j.ejmech.2006.11.014	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.	Mordant C, Schmitt B, Pasquier E, Demestre C, Queguiner L, Masungi C, Peeters A, Smeulders L, Bettens E, Hertogs K, Heeres J, Lewi P, Guillemont J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2007	50	20	4854	4867	17803290	10.1021/jm070382k	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.	Cullen MD, Deng BL, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, Clercq ED, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2007	50	20	5034	5038	17803291	10.1021/jm070488f	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.	Regina GL, Coluccia A, Piscitelli F, Bergamini A, Sinistro A, Cavazza A, Maga G, Samuele A, Zanoli S, Novellino E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2007	50	22	5324	5329	17918923	10.1021/jm070683u	From docking false-positive to active anti-HIV agent.	Barreiro G, Kim JT, Guimarães CR, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2007	50	22	5412	5424	17910429	10.1021/jm070811e	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.	Mai A, Artico M, Rotili D, Tarantino D, Clotet-Codina I, Armand-Ugón M, Ragno R, Simeoni S, Sbardella G, Nawrozkij MB, Samuele A, Maga G, Esté JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2007	50	26	6580	6595	18052319	10.1021/jm0708230	Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.	Mugnaini C, Alongi M, Togninelli A, Gevariya H, Brizzi A, Manetti F, Bernardini C, Angeli L, Tafi A, Bellucci L, Corelli F, Massa S, Maga G, Samuele A, Facchini M, Clotet-Codina I, Armand-Ugón M, Esté JA, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2007	51	10	3554	3561	17646410	10.1128/aac.00643-07	Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.	Blair WS, Cao J, Jackson L, Jimenez J, Peng Q, Wu H, Isaacson J, Butler SL, Chu A, Graham J, Malfait AM, Tortorella M, Patick AK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2007	51	2	429	437	17116677	10.1128/aac.01032-06	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.	Zhang Z, Xu W, Koh YH, Shim JH, Girardet JL, Yeh LT, Hamatake RK, Hong Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2007	51	2	638	644	17116672	10.1128/aac.00749-06	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.	Aguiar RS, Costa LJ, Pereira HS, Brindeiro RM, Tanuri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	1	511	517	17904371	10.1016/j.bmc.2007.09.015	Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.	Danel K, Larsen LM, Pedersen EB, Sanna G, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	12	6353	6363	18502646	10.1016/j.bmc.2008.05.010	Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Cesarini S, Spallarossa A, Ranise A, Schenone S, Bruno O, La Colla P, Casula L, Collu G, Sanna G, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	15	7429	7435	18585918	10.1016/j.bmc.2008.06.012	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.	Monforte AM, Rao A, Logoteta P, Ferro S, De Luca L, Barreca ML, Iraci N, Maga G, De Clercq E, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	7	3887	3894	18267363	10.1016/j.bmc.2008.01.039	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wang YP, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	7	4160	4172	18226532	10.1016/j.bmc.2007.12.050	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates.	Cesarini S, Spallarossa A, Ranise A, Fossa P, La Colla P, Sanna G, Collu G, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2008	16	7	4173	4185	18226533	10.1016/j.bmc.2007.12.046	Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate.	Cesarini S, Spallarossa A, Ranise A, Bruno O, La Colla P, Secci B, Collu G, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2008	18	15	4352	4354	18632268	10.1016/j.bmcl.2008.06.072	Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Sweeney ZK, Dunn JP, Li Y, Heilek G, Dunten P, Elworthy TR, Han X, Harris SF, Hirschfeld DR, Hogg JH, Huber W, Kaiser AC, Kertesz DJ, Kim W, Mirzadegan T, Roepel MG, Saito YD, Silva TM, Swallow S, Tracy JL, Villasenor A, Vora H, Zhou AS, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2008	18	20	5368	5371	18824350	10.1016/j.bmcl.2008.09.055	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Zhan P, Liu X, Cao Y, Wang Y, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2008	18	21	5777	5777	18842407	10.1016/j.bmcl.2008.09.070	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.	Radi M, Angeli L, Franchi L, Contemori L, Maga G, Samuele A, Zanoli S, Armand-Ugon M, Gonzalez E, Llano A, Esté JA, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2008	18	3	1131	1134	18083512	10.1016/j.bmcl.2007.11.127	Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.	Kirschberg TA, Balakrishnan M, Huang W, Hluhanich R, Kutty N, Liclican AC, McColl DJ, Squires NH, Lansdon EB.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2008	51	15	4641	4652	18630898	10.1021/jm800340w	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.	Nawrozkij MB, Rotili D, Tarantino D, Botta G, Eremiychuk AS, Musmuca I, Ragno R, Samuele A, Zanoli S, Armand-Ugón M, Clotet-Codina I, Novakov IA, Orlinson BS, Maga G, Esté JA, Artico M, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2008	51	16	5000	5008	18665583	10.1021/jm8004493	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, Boone L, Chan JH, Stammers DK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2008	51	20	6503	6511	18826204	10.1021/jm800856c	Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.	Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Reid JC, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2008	51	23	7449	7458	19007201	10.1021/jm800527x	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.	Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2008	52	1	225	236	17967909	10.1128/aac.00972-07	Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.	Buckheit RW, Hartman TL, Watson KM, Chung SG, Cho EH.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2008	52	3	901	908	18160521	10.1128/aac.01218-07	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.	Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2008	52	5	1759	1767	18316521	10.1128/aac.01313-07	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.	Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, Dicker I, Gali V, Higley H, Parkin N, Tenney D, Krystal M, Colonno R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2008	52	8	2861	2869	18541726	10.1128/aac.00210-08	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.	Hombrouck A, Van Remoortel B, Michiels M, Noppe W, Christ F, Eneroth A, Sahlberg BL, Benkestock K, Vrang L, Johansson NG, Barreca ML, De Luca L, Ferro S, Chimirri A, Debyser Z, Witvrouw M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2009	17	16	5775	5781	19643613	10.1016/j.bmc.2009.07.028	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Zhu J, Fang Z, Li Z, Pannecouque C, Clercq ED.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2009	17	16	5962	5967	19616956	10.1016/j.bmc.2009.06.068	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.	Monforte AM, Logoteta P, Ferro S, De Luca L, Iraci N, Maga G, Clercq ED, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2009	17	7	2767	2774	19269831	10.1016/j.bmc.2009.02.039	Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors.	Xu B, Sun Y, Guo Y, Cao Y, Yu T.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Med Chem Res	2009	18	7	555	565		10.1007/s00044-008-9149-5	Synthesis of new derivatives of 2,2-dimethyl-2,3-dihydro-7-benzo[b]furanol with potential antimicrobial activity	Kossakowski J, Ostrowska K, Struga M, Stefanska J
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2009	19	19	5599	5602	19709880	10.1016/j.bmcl.2009.08.039	Pyrazole NNRTIs 1: design and initial optimisation of a novel template.	Mowbray CE, Burt C, Corbau R, Perros M, Tran I, Stupple PA, Webster R, Wood A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2009	19	19	5603	5606	19717303	10.1016/j.bmcl.2009.08.043	Pyrazole NNRTIs 3: optimisation of physicochemical properties.	Mowbray CE, Corbau R, Hawes M, Jones LH, Mills JE, Perros M, Selby MD, Stupple PA, Webster R, Wood A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2009	19	20	5857	5860	19748778	10.1016/j.bmcl.2009.08.080	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.	Mowbray CE, Burt C, Corbau R, Gayton S, Hawes M, Perros M, Tran I, Price DA, Quinton FJ, Selby MD, Stupple PA, Webster R, Wood A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2009	44	11	4648	4653	19628308	10.1016/j.ejmech.2009.06.037	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Fang Z, Li Z, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2009	44	12	4960	4969	19781821	10.1016/j.ejmech.2009.08.013	Synthesis, pharmacological and antiviral activity of 1,3-thiazepine derivatives.	Struga M, Kossakowski J, Koziol AE, Kedzierska E, Fidecka S, La Colla P, Ibba C, Collu G, Sanna G, Secci B, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2009	44	12	5117	5122	19775780	10.1016/j.ejmech.2009.08.012	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.	Carta A, Pricl S, Piras S, Fermeglia M, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2009	44	4	1650	1663	18954921	10.1016/j.ejmech.2008.09.024	Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Spallarossa A, Cesarini S, Ranise A, Bruno O, Schenone S, La Colla P, Collu G, Sanna G, Secci B, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2009	44	5	2190	2201	19058881	10.1016/j.ejmech.2008.10.032	Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Spallarossa A, Cesarini S, Ranise A, Schenone S, Bruno O, Borassi A, La Colla P, Pezzullo M, Sanna G, Collu G, Secci B, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	12	3636	3643	19469474	10.1021/jm801438e	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.	Le Van K, Cauvin C, de Walque S, Georges B, Boland S, Martinelli V, Demonté D, Durant F, Hevesi L, Van Lint C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	22	7163	7169	19883100	10.1021/jm901230r	Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.	Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, Lu M, Lai MT, Touch S, Moyer G, DiStefano DJ, Flynn JA, Liang Y, Sanchez R, Perlow-Poehnelt R, Miller M, Vacca JP, Williams TM, Anthony NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	23	7473	7487	19645483	10.1021/jm900802y	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.	Guillemont J, Benjahad A, Oumouch S, Decrane L, Palandjian P, Vernier D, Queguiner L, Andries K, de Béthune MP, Hertogs K, Grierson DS, Nguyen CH.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	3	840	851	19140683	10.1021/jm801330n	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.	Radi M, Maga G, Alongi M, Angeli L, Samuele A, Zanoli S, Bellucci L, Tafi A, Casaluce G, Giorgi G, Armand-Ugon M, Gonzalez E, Esté JA, Baltzinger M, Bec G, Dumas P, Ennifar E, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	4	1219	1223	19175319	10.1021/jm801322h	Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.	Jones LH, Allan G, Barba O, Burt C, Corbau R, Dupont T, Knöchel T, Irving S, Middleton DS, Mowbray CE, Perros M, Ringrose H, Swain NA, Webster R, Westby M, Phillips C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	4	1224	1228	19170521	10.1021/jm801395v	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.	Butini S, Brindisi M, Cosconati S, Marinelli L, Borrelli G, Coccone SS, Ramunno A, Campiani G, Novellino E, Zanoli S, Samuele A, Giorgi G, Bergamini A, Di Mattia M, Lalli S, Galletti B, Gemma S, Maga G.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2009	52	7	1922	1934	19281225	10.1021/jm801470b	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.	Piscitelli F, Coluccia A, Brancale A, La Regina G, Sansone A, Giordano C, Balzarini J, Maga G, Zanoli S, Samuele A, Cirilli R, La Torre F, Lavecchia A, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	10	4407	4413	19635964	10.1128/aac.01594-08	Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?	Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Tréluyer JM.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	11	4667	4672	19704127	10.1128/aac.00800-09	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.	Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	12	5080	5087	19805571	10.1128/aac.00759-09	New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.	Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, Murray E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	2	487	495	19029331	10.1128/aac.01156-08	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.	Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	3	1194	1203	19104010	10.1128/aac.00984-08	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.	Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	6	2424	2431	19289522	10.1128/aac.01559-08	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.	Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2009	53	7	2791	2798	19433561	10.1128/aac.01537-08	Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.	Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, García MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2010	1	1	79	83		10.1039/C0MD00009D	Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase	Kennedy-Smith JJ, Arora N, Billedeau JR, Fretland J, Hang JQ, Heilek GM, Harris SF, Hirschfeld D, Javanbakht H, Li Y, Liang W, Roetz R, Smith M, Su G, Suh JM, Villasenor AG, Wu J, Yasuda D, Klumpp K, Sweeney ZK
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2010	18	13	4601	4605	20570527	10.1016/j.bmc.2010.05.036	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.	Liang YH, He QQ, Zeng ZS, Liu ZQ, Feng XQ, Chen FE, Balzarini J, Pannecouque C, Clercq ED.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2010	18	14	5039	5047	20598556	10.1016/j.bmc.2010.05.081	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.	Zeng ZS, He QQ, Liang YH, Feng XQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2010	18	4	1702	1710	20097079	10.1016/j.bmc.2009.12.059	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Monforte AM, Logoteta P, De Luca L, Iraci N, Ferro S, Maga G, De Clercq E, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2010	18	7	2370	2374	20307984	10.1016/j.bmc.2010.03.007	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.	Feng XQ, Zeng ZS, Liang YH, Chen FE, Pannecouque C, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Med Chem Res	2010	19	4	311	336		10.1007/s00044-009-9192-x	(Hetero)aroyl esters of 2-(N-phthalimido)ethanol and analogues: parallel synthesis, anti-HIV-1 activity and cytotoxicity	Cesarini S, Spallarossa A, Ranise A, Schenone S, La Colla P, Collu G, Sanna G, Loddo R
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Med Chem Res	2010	19	7	652	663		10.1007/s00044-009-9220-x	Synthesis and anti-HIV activity evaluation of novel N-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides	Zhan P, Liu H, Liu X, Wang Y, Pannecouque C, Witvrouw M, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	14	4215	4218	20538456	10.1016/j.bmcl.2010.05.040	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.	Kertesz DJ, Brotherton-Pleiss C, Yang M, Wang Z, Lin X, Qiu Z, Hirschfeld DR, Gleason S, Mirzadegan T, Dunten PW, Harris SF, Villaseñor AG, Hang JQ, Heilek GM, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	15	4328	4332	20609585	10.1016/j.bmcl.2010.06.083	Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.	Su DS, Lim JJ, Tinney E, Tucker TJ, Saggar S, Sisko JT, Wan BL, Young MB, Anderson KD, Rudd D, Munshi V, Bahnck C, Felock PJ, Lu M, Lai MT, Touch S, Moyer G, Distefano DJ, Flynn JA, Liang Y, Sanchez R, Perlow-Poehnelt R, Miller M, Vacca JP, Williams TM, Anthony NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	20	6020	6023	20829038	10.1016/j.bmcl.2010.08.068	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.	Tang G, Kertesz DJ, Yang M, Lin X, Wang Z, Li W, Qiu Z, Chen J, Mei J, Chen L, Mirzadegan T, Harris SF, Villaseñor AG, Fretland J, Fitch WL, Hang JQ, Heilek G, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	22	6592	6596	20888224	10.1016/j.bmcl.2010.09.034	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.	Liu B, Lee Y, Zou J, Petrassi HM, Joseph RW, Chao W, Michelotti EL, Bukhtiyarova M, Springman EB, Dorsey BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	5	1585	1588	20137928	10.1016/j.bmcl.2010.01.086	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mitchell ML, Son JC, Lee IY, Lee CK, Kim HS, Guo H, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Eisenberg G, Geleziunas R, Xu L, Kim CU.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	5	1589	1592	20138513	10.1016/j.bmcl.2010.01.085	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mitchell ML, Son JC, Guo H, Im YA, Cho EJ, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Graupe D, Rhodes G, He GX, Geleziunas R, Xu L, Kim CU.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2010	20	8	2485	2488	20304641	10.1016/j.bmcl.2010.03.006	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.	Leung CS, Zeevaart JG, Domaoal RA, Bollini M, Thakur VV, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	10	4185	4191	20660679	10.1128/aac.00283-10	No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.	Burhenne J, Matthée AK, Pasáková I, Röder C, Heinrich T, Haefeli WE, Mikus G, Weiss J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	10	4451	4463	20660667	10.1128/aac.01455-09	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.	Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	2	718	727	19933797	10.1128/aac.00986-09	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.	Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	2	728	733	20008779	10.1128/aac.01335-09	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.	Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	2	835	845	19995924	10.1128/aac.01308-09	Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.	Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	4	1596	1602	20124001	10.1128/aac.01480-09	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.	Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	5	1973	1980	20194692	10.1128/aac.00870-09	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.	Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2010	54	6	2401	2408	20308384	10.1128/aac.01795-09	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.	Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	14	4366	4376	21683601	10.1016/j.bmc.2011.05.024	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhang J, Zhan P, Wu J, Li Z, Jiang Y, Ge W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	17	5117	5124	21824782	10.1016/j.bmc.2011.07.023	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.	Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	19	5794	5802	21903401	10.1016/j.bmc.2011.08.025	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.	Novikov MS, Ivanova ON, Ivanov AV, Ozerov AA, Valuev-Elliston VT, Temburnikar K, Gurskaya GV, Kochetkov SN, Pannecouque C, Balzarini J, Seley-Radtke KL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	20	5924	5934	21930388	10.1016/j.bmc.2011.08.060	Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).	Venkatraj M, Ariën KK, Heeres J, Dirié B, Joossens J, Van Goethem S, Van der Veken P, Michiels J, Vande Velde CM, Vanham G, Lewi PJ, Augustyns K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	23	7070	7084	22047799	10.1016/j.bmc.2011.10.009	Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors.	Carta A, Briguglio I, Piras S, Corona P, Boatto G, Nieddu M, Giunchedi P, Marongiu ME, Giliberti G, Iuliano F, Blois S, Ibba C, Busonera B, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2011	19	23	7093	7099	22037050	10.1016/j.bmc.2011.10.002	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.	Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2011	46	9	4178	4183	21745701	10.1016/j.ejmech.2011.06.020	Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.	Wang Q, Hu W, Wang S, Pan Z, Tao L, Guo X, Qian K, Chen CH, Lee KH, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2011	54	16	5927	5936	21755950	10.1021/jm200734j	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.	Sbardella G, Mai A, Bartolini S, Castellano S, Cirilli R, Rotili D, Milite C, Santoriello M, Orlando S, Sciamanna I, Serafino A, Lavia P, Spadafora C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2011	54	24	8582	8591	22081993	10.1021/jm201134m	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.	Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2011	54	6	1587	1598	21366296	10.1021/jm101614j	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Gatti V, Maga G, Samuele A, Pannecouque C, Schols D, Balzarini J, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2011	54	8	3091	3096	21438533	10.1021/jm101626c	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.	Rotili D, Tarantino D, Artico M, Nawrozkij MB, Gonzalez-Ortega E, Clotet B, Samuele A, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2011	55	1	42	49	21060108	10.1128/aac.01064-10	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.	Koh Y, Haim H, Engelman A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2011	55	2	813	821	21115794	10.1128/aac.01209-10	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.	Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Antimicrob. Agents Chemother.	2011	55	3	1282	1284	21189339	10.1128/aac.01527-10	Interaction potential of etravirine with drug transporters assessed in vitro.	Zembruski NC, Haefeli WE, Weiss J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2011	74	6	1408	1413	21650224	10.1021/np200087d	Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.	Fang PL, Cao YL, Yan H, Pan LL, Liu SC, Gong NB, Lü Y, Chen CX, Zhong HM, Guo Y, Liu HY.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2011	74	6	1444	1452	21627109	10.1021/np2001896	Bioactive neolignans and lignans from the bark of Machilus robusta.	Li Y, Cheng W, Zhu C, Yao C, Xiong L, Tian Y, Wang S, Lin S, Hu J, Yang Y, Guo Y, Yang Y, Li Y, Yuan Y, Chen N, Shi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2012	20	18	5527	5536	22883027	10.1016/j.bmc.2012.07.026	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Zhan P, Liu H, Li D, Wang L, Chen X, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2012	20	23	6795	6802	23098609	10.1016/j.bmc.2012.09.058	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.	Zhan P, Chen W, Li Z, Li X, Chen X, Tian Y, Pannecouque C, Clercq ED, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2012	22	23	7155	7162	23084898	10.1016/j.bmcl.2012.09.062	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.	Zhan P, Li X, Li Z, Chen X, Tian Y, Chen W, Liu X, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2012	22	24	7641	7646	23122865	10.1016/j.bmcl.2012.10.010	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.	Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Drug Metab. Dispos.	2012	40	4	717	725	22232427	10.1124/dmd.111.042416	Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.	Xu C, Ogburn ET, Guo Y, Desta Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	50		216	229	22361685	10.1016/j.ejmech.2012.01.056	Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.	Distinto S, Esposito F, Kirchmair J, Cardia MC, Gaspari M, Maccioni E, Alcaro S, Markt P, Wolber G, Zinzula L, Tramontano E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	53		229	234	22575532	10.1016/j.ejmech.2012.04.004	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.	Gu SX, Li ZM, Ma XD, Yang SQ, He QQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	53		83	97	22513121	10.1016/j.ejmech.2012.03.038	5-acetyl-2-arylbenzimidazoles as antiviral agents. Part 4.	Vitale G, Corona P, Loriga M, Carta A, Paglietti G, Giliberti G, Sanna G, Farci P, Marongiu ME, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	54		159	174	22652226	10.1016/j.ejmech.2012.04.038	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.	Puig-de-la-Bellacasa R, Giménez L, Pettersson S, Pascual R, Gonzalo E, Esté JA, Clotet B, Borrell JI, Teixidó J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2012	55	14	6634	6638	22712652	10.1021/jm300477h	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Famiglini V, Cosconati S, Maga G, Samuele A, Gonzalez E, Clotet B, Schols D, Esté JA, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2012	55	23	10601	10609	23137340	10.1021/jm301294g	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Chong P, Sebahar P, Youngman M, Garrido D, Zhang H, Stewart EL, Nolte RT, Wang L, Ferris RG, Edelstein M, Weaver K, Mathis A, Peat A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2012	55	7	3558	3562	22428851	10.1021/jm201308v	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.	Rotili D, Samuele A, Tarantino D, Ragno R, Musmuca I, Ballante F, Botta G, Morera L, Pierini M, Cirilli R, Nawrozkij MB, Gonzalez E, Clotet B, Artico M, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2012	55		205	213	22884523	10.1016/j.ejmech.2012.07.020	Disubstituted thiourea derivatives and their activity on CNS: synthesis and biological evaluation.	Stefanska J, Szulczyk D, Koziol AE, Miroslaw B, Kedzierska E, Fidecka S, Busonera B, Sanna G, Giliberti G, La Colla P, Struga M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2012	75	3	414	419	22148316	10.1021/np200855d	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.	Vidal V, Potterat O, Louvel S, Hamy F, Mojarrab M, Sanglier JJ, Klimkait T, Hamburger M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2013	21	23	7398	7405	24134904	10.1016/j.bmc.2013.09.051	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.	Rai D, Chen W, Tian Y, Chen X, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2013	21	5	1150	1158	23357038	10.1016/j.bmc.2012.12.027	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.	Novikov MS, Valuev-Elliston VT, Babkov DA, Paramonova MP, Ivanov AV, Gavryushov SA, Khandazhinskaya AL, Kochetkov SN, Pannecouque C, Andrei G, Snoeck R, Balzarini J, Seley-Radtke KL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2013	21	7	2128	2134	23415090	10.1016/j.bmc.2012.12.049	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.	Li D, Zhan P, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2013	23	18	5209	5212	23899617	10.1016/j.bmcl.2013.06.093	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.	Bollini M, Frey KM, Cisneros JA, Spasov KA, Das K, Bauman JD, Arnold E, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2013	23	18	5213	5216	23937980	10.1016/j.bmcl.2013.06.091	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.	Bollini M, Cisneros JA, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2013	23	24	6593	6597	24239481	10.1016/j.bmcl.2013.10.059	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Liu X, Meng Q, Wang D, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2013	23	4	1110	1113	23298809	10.1016/j.bmcl.2012.11.115	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.	Bollini M, Gallardo-Macias R, Spasov KA, Tirado-Rives J, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2013	23	5	1493	1497	23375792	10.1016/j.bmcl.2012.12.049	Synthesis and biological evaluation of phosphonate analogues of nevirapine.	Parrish J, Tong L, Wang M, Chen X, Lansdon EB, Cannizzaro C, Zheng X, Desai MC, Xu L.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2013	4	11	1443	1451		10.1039/C3MD00225J	Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase	Matyugina ES, Valuev-Elliston VT, Geisman AN, Novikov MS, Chizhov AO, Kochetkov SN, Seley-Radtke KL, Khandazhinskaya AL
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2013	4	4	709	719		10.1039/C3MD00014A	Discovery of an HIV integrase inhibitor with an excellent resistance profile	Pryde DC, Webster R, Butler SL, Murray EJ, Whitby K, Pickford C, Westby M, Palmer MJ, Bull DJ, Vuong H, Blakemore DC, Stead D, Ashcroft C, Gardner I, Bru C, Cheung W, Roberts IO, Morton J, Bissell RA
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2013	4	4	741	748		10.1039/C3MD00036B	5-Nor carbocyclic nucleosides: unusual nonnucleoside inhibitors of HIV-1 reverse transcriptase	Matyugina ES, Valuev-Elliston VT, Babkov DA, Novikov MS, Ivanov AV, Kochetkov SN, Balzarini J, Seley-Radtke KL, Khandazhinskaya AL
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2013	4	5	810	816		10.1039/C3MD00028A	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach	Song Y, Zhan P, Kang D, Li X, Tian Y, Li Z, Chen X, Chen W, Pannecouque C, De Clercq E, Liu X
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Drug Metab. Dispos.	2013	41	2	422	429	23166317	10.1124/dmd.112.049601	Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.	Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Drug Metab. Dispos.	2013	41	5	933	951	23454828	10.1124/dmd.112.050278	Which metabolites circulate?	Loi CM, Smith DA, Dalvie D.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2013	56	4	1656	1669	23360431	10.1021/jm3016377	Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248).	Regueiro-Ren A, Xue QM, Swidorski JJ, Gong YF, Mathew M, Parker DD, Yang Z, Eggers B, D'Arienzo C, Sun Y, Malinowski J, Gao Q, Wu D, Langley DR, Colonno RJ, Chien C, Grasela DM, Zheng M, Lin PF, Meanwell NA, Kadow JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2013	65		134	143	23707918	10.1016/j.ejmech.2013.04.052	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2013	76	12	2298	2306	24308675	10.1021/np400683h	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.	Ma X, Li L, Zhu T, Ba M, Li G, Gu Q, Guo Y, Li D.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2013	76	6	1039	1046	23691978	10.1021/np400029d	Diterpenoids with diverse skeletons from the roots of Euphorbia micractina.	Tian Y, Xu W, Zhu C, Lin S, Guo Y, Shi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Med Chem Res	2013			1	18	24489455	10.1007/s00044-013-0740-z	Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.	Szulczyk D, Bielenica A, Dobrowolski MA, Dobrzycki L, Krawiecka M, Kuran B, Struga M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	1	633	642	24275349	10.1016/j.bmc.2013.10.033	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.	Zhang L, Zhan P, Chen X, Li Z, Xie Z, Zhao T, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	12	3220	3226	24794751	10.1016/j.bmc.2014.03.020	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	17	4893	4909	25082514	10.1016/j.bmc.2014.06.043	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.	Tonelli M, Novelli F, Tasso B, Vazzana I, Sparatore A, Boido V, Sparatore F, La Colla P, Sanna G, Giliberti G, Busonera B, Farci P, Ibba C, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	19	5241	5248	25199582	10.1016/j.bmc.2014.08.005	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.	Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	19	5290	5297	25150090	10.1016/j.bmc.2014.08.001	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Lu X, Chen W, Liu H, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	4	1459	1467	24457088	10.1016/j.bmc.2013.12.045	Design and synthesis of N¿-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.	Monforte AM, Ferro S, De Luca L, Lo Surdo G, Morreale F, Pannecouque C, Balzarini J, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2014	22	8	2535	2541	24680058	10.1016/j.bmc.2014.02.030	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Huang XY, Wu HQ, Chen WX, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2014	24	3	917	922	24412110	10.1016/j.bmcl.2013.12.070	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.	Côté B, Burch JD, Asante-Appiah E, Bayly C, Bédard L, Blouin M, Campeau LC, Cauchon E, Chan M, Chefson A, Coulombe N, Cromlish W, Debnath S, Deschênes D, Dupont-Gaudet K, Falgueyret JP, Forget R, Gagné S, Gauvreau D, Girardin M, Guiral S, Langlois E, Li CS, Nguyen N, Papp R, Plamondon S, Roy A, Roy S, Seliniotakis R, St-Onge M, Ouellet S, Tawa P, Truchon JF, Vacca J, Wrona M, Yan Y, Ducharme Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	ACS Med. Chem. Lett.	2014	5	10	1156	1161	25309681	10.1021/ml500297n	Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz.	Cox PM, Bumpus NN.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	ACS Med. Chem. Lett.	2014	5	11	1259	1262	25408842	10.1021/ml5003713	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.	Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Bollini M, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2014	5	11	1685	1692		10.1039/C4MD00282B	Novel anti-HIV-1 NNRTIs based on a pyrazolo[4,3-d]isoxazole backbone scaffold: design, synthesis and insights into the molecular basis of action	Gomha SM, Badrey MG, Abdalla MM, Arafa RK
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2014	5	4	468	473		10.1039/C3MD00247K	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase	Wu H, Pannecouque C, Yan Z, Chen W, He Q, Chen F, Balzarini J, Daelemans D, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2014	57	12	5169	5178	24805780	10.1021/jm500139a	Synthesis of novel fluoro analogues of MKC442 as microbicides.	Loksha YM, Pedersen EB, Loddo R, Sanna G, Collu G, Giliberti G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2014	57	12	5212	5225	24933420	10.1021/jm500284x	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.	Rotili D, Tarantino D, Nawrozkij MB, Babushkin AS, Botta G, Marrocco B, Cirilli R, Menta S, Badia R, Crespan E, Ballante F, Ragno R, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2014	57	23	9945	9957	25418038	10.1021/jm5011622	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Riveira-Muñoz E, Esté JA, Ferretti R, Cirilli R, Zamperini C, Botta M, Schols D, Limongelli V, Agostino B, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	76		531	538	24602795	10.1016/j.ejmech.2014.02.047	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.	Wang J, Zhan P, Li Z, Liu H, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Nat. Prod.	2014	77	7	1632	1643	24957203	10.1021/np500253m	Uralsaponins M-Y, antiviral triterpenoid saponins from the roots of Glycyrrhiza uralensis.	Song W, Si L, Ji S, Wang H, Fang XM, Yu LY, Li RY, Liang LN, Zhou D, Ye M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	80		101	111	24769348	10.1016/j.ejmech.2014.04.027	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Clotet B, Esté JA, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	82		600	611	24952305	10.1016/j.ejmech.2014.05.059	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.	Meng G, Liu Y, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	84		8	16	25014745	10.1016/j.ejmech.2014.07.011	Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.	Loddo R, Briguglio I, Corona P, Piras S, Loriga M, Paglietti G, Carta A, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	85		27	42	25072874	10.1016/j.ejmech.2014.07.072	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.	Xu Z, Ba M, Zhou H, Cao Y, Tang C, Yang Y, He R, Liang Y, Zhang X, Li Z, Zhu L, Guo Y, Guo C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	101		111	125	26119992	10.1016/j.ejmech.2015.06.027	Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety.	Bielenica A, Stefa¿ska J, St¿pie¿ K, Napiórkowska A, Augustynowicz-Kope¿ E, Sanna G, Madeddu S, Boi S, Giliberti G, Wrzosek M, Struga M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	102		215	222	26276435	10.1016/j.ejmech.2015.08.007	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.	Wan ZY, Yao J, Mao TQ, Wang XL, Wang HF, Chen WX, Yin H, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	105		63	79	26479028	10.1016/j.ejmech.2015.10.002	Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.	Briguglio I, Loddo R, Laurini E, Fermeglia M, Piras S, Corona P, Giunchedi P, Gavini E, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P, Pricl S, Carta A.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	13	3860	3868	25907370	10.1016/j.bmc.2015.03.037	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.	Mao TQ, He QQ, Wan ZY, Chen WX, Chen FE, Tang GF, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	15	4248	4255	26162497	10.1016/j.bmc.2015.06.048	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Wan ZY, Tao Y, Wang YF, Mao TQ, Yin H, Chen FE, Piao HR, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	19	6327	6334	26358281	10.1016/j.bmc.2015.08.028	Isolation and anticancer, anthelminthic, and antiviral (HIV) activity of acylphloroglucinols, and regioselective synthesis of empetrifranzinans from Hypericum roeperianum.	Fobofou SA, Franke K, Sanna G, Porzel A, Bullita E, La Colla P, Wessjohann LA.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	20	6587	6593	26385446	10.1016/j.bmc.2015.09.020	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.	Gu SX, Qiao H, Zhu YY, Shu QC, Liu H, Ju XL, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	21	7024	7034	26443549	10.1016/j.bmc.2015.09.035	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.	Loddo R, Novelli F, Sparatore A, Tasso B, Tonelli M, Boido V, Sparatore F, Collu G, Delogu I, Giliberti G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2015	23	5	1069	1081	25638501	10.1016/j.bmc.2015.01.002	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.	Babkov DA, Valuev-Elliston VT, Paramonova MP, Ozerov AA, Ivanov AV, Chizhov AO, Khandazhinskaya AL, Kochetkov SN, Balzarini J, Daelemans D, Pannecouque C, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem. Lett.	2015	25	11	2401	2404	25913116	10.1016/j.bmcl.2015.04.006	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.	Fioravanti R, Desideri N, Biava M, Droghini P, Atzori EM, Ibba C, Collu G, Sanna G, Delogu I, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	ACS Med. Chem. Lett.	2015	6	10	1075	1079	26487915	10.1021/acsmedchemlett.5b00254	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.	Gray WT, Frey KM, Laskey SB, Mislak AC, Spasov KA, Lee WG, Bollini M, Siliciano RF, Jorgensen WL, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	MedChemComm	2015	6	2	319	326		10.1039/C4MD00399C	4-Thiazolidinone derivatives as potent antimicrobial agents: microwave-assisted synthesis, biological evaluation and docking studies	Pitta E, Tsolaki E, Geronikaki A, Petrovic J, Glamoclija J, Sokovic M, Crespan E, Maga G, Bhunia SS, Saxena AK
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	ACS Med. Chem. Lett.	2015	6	7	753	757	26191361	10.1021/acsmedchemlett.5b00036	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.	Cox BD, Prosser AR, Sun Y, Li Z, Lee S, Huang MB, Bond VC, Snyder JP, Krystal M, Wilson LJ, Liotta DC.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	93		452	460	25728026	10.1016/j.ejmech.2015.02.032	(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.	Meleddu R, Distinto S, Corona A, Bianco G, Cannas V, Esposito F, Artese A, Alcaro S, Matyus P, Bogdan D, Cottiglia F, Tramontano E, Maccioni E.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2015	97		1	9	25935383	10.1016/j.ejmech.2015.04.050	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wan ZY, Yao J, Tao Y, Mao TQ, Wang XL, Lu YP, Wang HF, Yin H, Wu Y, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2016	108		455	465	26708112	10.1016/j.ejmech.2015.11.025	Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.	Bastos MM, Costa CC, Bezerra TC, da Silva Fde C, Boechat N.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2016	109		294	304	26802545	10.1016/j.ejmech.2015.11.039	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.	Yang J, Chen W, Kang D, Lu X, Li X, Liu Z, Huang B, Daelemans D, Pannecouque C, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2016	121		352	363	27267005	10.1016/j.ejmech.2016.05.054	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.	Chen W, Zhan P, Daelemans D, Yang J, Huang B, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2016	122		185	195	27371922	10.1016/j.ejmech.2016.06.026	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.	¿imon P, Baszczy¿ski O, ¿aman D, Stepan G, Hu E, Lansdon EB, Jansa P, Janeba Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2016	123		309	316	27484516	10.1016/j.ejmech.2016.07.047	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.	Xu Z, Guo J, Yang Y, Zhang M, Ba M, Li Z, Cao Y, He R, Yu M, Zhou H, Li X, Huang X, Guo Y, Guo C.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2016	24	11	2476	2485	27112451	10.1016/j.bmc.2016.04.010	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.	Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN, Pannecouque C, Naesens L, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg. Med. Chem.	2016	24	9	2125	2136	27039251	10.1016/j.bmc.2016.03.043	Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.	Yang L, Wang P, Wu JF, Yang LM, Wang RR, Pang W, Li YG, Shen YM, Zheng YT, Li X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J Med Chem	2016	59	17	7991	8007	27541578	10.1021/acs.jmedchem.6b00738	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.	Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J. Med. Chem.	2016	59	5	1891	1898	26804933	10.1021/acs.jmedchem.5b01430	Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.	Dousson C, Alexandre FR, Amador A, Bonaric S, Bot S, Caillet C, Convard T, da Costa D, Lioure MP, Roland A, Rosinovsky E, Maldonado S, Parsy C, Trochet C, Storer R, Stewart A, Wang J, Mayes BA, Musiu C, Poddesu B, Vargiu L, Liuzzi M, Moussa A, Jakubik J, Hubbard L, Seifer M, Standring D.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J Nat Prod	2016	79	9	2229	2235	27434426	10.1021/acs.jnatprod.6b00299	Eremophilane Sesquiterpenes from an Endophytic Fungus Periconia Species.	Liu J, Zhang D, Zhang M, Zhao J, Chen R, Wang N, Zhang D, Dai J.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2017	126		190	201	27750153	10.1016/j.ejmech.2016.10.009	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.	Li X, Gao P, Huang B, Zhou Z, Yu Z, Yuan Z, Liu H, Pannecouque C, Daelemans D, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2017	130		209	222	28254696	10.1016/j.ejmech.2017.02.047	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.	Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Eur J Med Chem	2017	130		248	260	28254698	10.1016/j.ejmech.2017.02.054	Natural product-inspired esters and amides of ferulic and caffeic acid as dual inhibitors of HIV-1 reverse transcriptase.	Sonar VP, Corona A, Distinto S, Maccioni E, Meleddu R, Fois B, Floris C, Malpure NV, Alcaro S, Tramontano E, Cottiglia F.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg Med Chem	2017	25	14	3861	3870	28559060	10.1016/j.bmc.2017.05.040	Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors.	Ferro S, Buemi MR, De Luca L, Agharbaoui FE, Pannecouque C, Monforte AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg Med Chem	2017	25	8	2491	2497	28314514	10.1016/j.bmc.2017.03.009	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.	Lu HH, Xue P, Zhu YY, Ju XL, Zheng XJ, Zhang X, Xiao T, Pannecouque C, Li TT, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg Med Chem Lett	2017	27	1	61	65	27894873	10.1016/j.bmcl.2016.11.030	Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.	Chander S, Wang P, Ashok P, Yang LM, Zheng YT, Sankaranarayanan M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg Med Chem Lett	2017	27	16	3851	3855	28668194	10.1016/j.bmcl.2017.06.049	Discovery of novel dengue virus entry inhibitors via a structure-based approach.	Leal ES, Aucar MG, Gebhard LG, Iglesias NG, Pascual MJ, Casal JJ, Gamarnik AV, Cavasotto CN, Bollini M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	Bioorg Med Chem Lett	2017	27	8	1640	1643	28314598	10.1016/j.bmcl.2017.03.009	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.	Xue P, Lu HH, Zhu YY, Ju XL, Pannecouque C, Zheng XJ, Liu GY, Zhang XL, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J Med Chem	2017	60	10	4424	4443	28481112	10.1021/acs.jmedchem.7b00332	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.	Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J Med Chem	2017	60	15	6528	6547	28628334	10.1021/acs.jmedchem.6b01906	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.	Famiglini V, La Regina G, Coluccia A, Masci D, Brancale A, Badia R, Riveira-Muñoz E, Esté JA, Crespan E, Brambilla A, Maga G, Catalano M, Limatola C, Formica FR, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228	J Nat Prod	2017	80	2	371	376	28117586	10.1021/acs.jnatprod.6b00829	Griseofulvin Derivative and Indole Alkaloids from Penicillium griseofulvum CPCC 400528.	Zhang D, Zhao L, Wang L, Fang X, Zhao J, Wang X, Li L, Liu H, Wei Y, You X, Cen S, Yu L.
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	EFAVIRENZ	CHEMBL223228									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	ELETRIPTAN HYDROBROMIDE	CHEMBL1201003									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	ELETRIPTAN HYDROBROMIDE	CHEMBL1201003									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
914.1000000000000000	9606	Homo sapiens	ELPETRIGINE	CHEMBL29919	J. Med. Chem.	2001	44	2	115	137	11170622	10.1021/jm000155h	Medicinal chemistry of neuronal voltage-gated sodium channel blockers.	Anger T, Madge DJ, Mulla M, Riddall D.
914.1000000000000000	9606	Homo sapiens	ELPETRIGINE	CHEMBL29919									Unpublished dataset	
914.1000000000000000	9606	Homo sapiens	ELPETRIGINE	CHEMBL29919									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2006	49	5	1506	1508	16509568	10.1021/jm0600139	Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.	Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S, Kodama E, Matsuoka M, Shinkai H.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Eur. J. Med. Chem.	2007	42	9	1159	1168	17367896	10.1016/j.ejmech.2007.01.024	Development of integrase inhibitors for treatment of AIDS: an overview.	Dubey S, Satyanarayana YD, Lavania H.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem. Lett.	2008	18	9	2891	2895	18417342	10.1016/j.bmcl.2008.03.089	A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.	De Luca L, Barreca ML, Ferro S, Iraci N, Michiels M, Christ F, Debyser Z, Witvrouw M, Chimirri A.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2008	51	16	5125	5129	18665580	10.1021/jm8003784	Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structure-activity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors.	Pasquini S, Mugnaini C, Tintori C, Botta M, Trejos A, Arvela RK, Larhed M, Witvrouw M, Michiels M, Christ F, Debyser Z, Corelli F.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2008	51	24	7717	7730	19053754	10.1021/jm8007085	Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.	Billamboz M, Bailly F, Barreca ML, De Luca L, Mouscadet JF, Calmels C, Andréola ML, Witvrouw M, Christ F, Debyser Z, Cotelle P.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2008	52	3	901	908	18160521	10.1128/aac.01218-07	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.	Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2008	52	6	2069	2078	18378713	10.1128/aac.00911-07	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.	Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2008	52	8	2861	2869	18541726	10.1128/aac.00210-08	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.	Hombrouck A, Van Remoortel B, Michiels M, Noppe W, Christ F, Eneroth A, Sahlberg BL, Benkestock K, Vrang L, Johansson NG, Barreca ML, De Luca L, Ferro S, Chimirri A, Debyser Z, Witvrouw M.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2009	52	15	4869	4882	19719237	10.1021/jm900460z	Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors.	Sato M, Kawakami H, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Matsuzaki Y, Yamataka K, Ikeda S, Shinkai H.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2009	53	10	4275	4282	19651917	10.1128/aac.00397-09	Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.	Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem.	2010	18	15	5510	5518	20630765	10.1016/j.bmc.2010.06.063	New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.	Ferro S, De Luca L, Barreca ML, De Grazia S, Christ F, Debyser Z, Chimirri A.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Eur. J. Med. Chem.	2010	45	8	3413	3419	20488589	10.1016/j.ejmech.2010.04.030	CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.	Lu P, Wei X, Zhang R.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2010	53	2	521	538	19785437	10.1021/jm900492g	Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?	Mehellou Y, De Clercq E.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2010	54	9	3938	3948	20479206	10.1128/aac.01720-09	Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.	Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem.	2011	19	16	5039	5045	21763149	10.1016/j.bmc.2011.06.020	Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity.	He QQ, Gu SX, Liu J, Wu HQ, Zhang X, Yang LM, Zheng YT, Chen FE.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem.	2011	19	18	5553	5558	21862337	10.1016/j.bmc.2011.07.037	Synthesis and biological evaluation of HQCAs with aryl or benzyl substituents on N-1 position as potential HIV-1 integrase inhibitors.	He QQ, Zhang X, Wu HQ, Gu SX, Ma XD, Yang LM, Zheng YT, Chen FE.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem. Lett.	2011	21	2	760	763	21185178	10.1016/j.bmcl.2010.11.108	6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors.	Nagasawa JY, Song J, Chen H, Kim HW, Blazel J, Ouk S, Groschel B, Borges V, Ong V, Yeh LT, Girardet JL, Vernier JM, Raney AK, Pinkerton AB.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Eur. J. Med. Chem.	2011	46	2	756	764	21227550	10.1016/j.ejmech.2010.12.012	HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.	De Luca L, De Grazia S, Ferro S, Gitto R, Christ F, Debyser Z, Chimirri A.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2011	55	1	42	49	21060108	10.1128/aac.01064-10	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.	Koh Y, Haim H, Engelman A.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Antimicrob. Agents Chemother.	2011	55	2	813	821	21115794	10.1128/aac.01209-10	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.	Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2012	55	20	8735	8744	22963135	10.1021/jm3010459	Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.	Kawasuji T, Johns BA, Yoshida H, Taishi T, Taoda Y, Murai H, Kiyama R, Fuji M, Yoshinaga T, Seki T, Kobayashi M, Sato A, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2013	56	3	1124	1135	23316884	10.1021/jm301550c	Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.	Kawasuji T, Johns BA, Yoshida H, Weatherhead JG, Akiyama T, Taishi T, Taoda Y, Mikamiyama-Iwata M, Murai H, Kiyama R, Fuji M, Tanimoto N, Yoshinaga T, Seki T, Kobayashi M, Sato A, Garvey EP, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2014	57	3	539	566	24025027	10.1021/jm400674a	Inhibiting the HIV integration process: past, present, and the future.	Di Santo R.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2014	57	8	3223	3234	24684270	10.1021/jm5001503	Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.	Costi R, Métifiot M, Chung S, Cuzzucoli Crucitti G, Maddali K, Pescatori L, Messore A, Madia VN, Pupo G, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SF, Corona A, Pommier Y, Marchand C, Di Santo R.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	Bioorg. Med. Chem.	2015	23	13	3860	3868	25907370	10.1016/j.bmc.2015.03.037	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.	Mao TQ, He QQ, Wan ZY, Chen WX, Chen FE, Tang GF, De Clercq E, Daelemans D, Pannecouque C.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656	J. Med. Chem.	2015	58	11	4610	4623	25961960	10.1021/acs.jmedchem.5b00159	N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.	Pescatori L, Métifiot M, Chung S, Masoaka T, Cuzzucoli Crucitti G, Messore A, Pupo G, Madia VN, Saccoliti F, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SF, Pommier Y, Marchand C, Costi R, Di Santo R.
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656									British National Formulary (72nd edition)	
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656									Unpublished dataset	
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
932.0000000000000000	11676	Human immunodeficiency virus 1	ELVITEGRAVIR	CHEMBL204656									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	ELZASONAN HYDROCHLORIDE	CHEMBL3989805									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	ELZASONAN HYDROCHLORIDE	CHEMBL3989805									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	J. Med. Chem.	1993	36	2	181	195	8423591	10.1021/jm00054a001	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.	Jeong LS, Schinazi RF, Beach JW, Kim HO, Nampalli S, Shanmuganathan K, Alves AJ, McMillan A, Chu CK, Mathis R.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	J. Med. Chem.	1996	39	9	1757	1759	8627596	10.1021/jm950836q	Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro.	Lin TS, Luo MZ, Liu MC, Zhu YL, Gullen E, Dutschman GE, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg. Med. Chem. Lett.	2000	10	23	2687	2690	11128652	10.1016/s0960-894x(00)00544-8	Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.	Perni RB, Conway SC, Ladner SK, Zaifert K, Otto MJ, King RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg. Med. Chem. Lett.	2007	17	22	6350	6353	17888662	10.1016/j.bmcl.2007.08.065	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.	Tang YB, Peng ZG, Liu ZY, Li YP, Jiang JD, Li ZR.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Drug Metab. Dispos.	2007	35	3	340	344	17172311	10.1124/dmd.106.012765	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.	Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2007	51	12	4489	4491	17876005	10.1128/aac.00687-07	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.	Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2007	51	7	2523	2530	17404006	10.1128/aac.00001-07	Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.	Matthes E, Funk A, Krahn I, Gaertner K, von Janta-Lipinski M, Lin L, Will H, Sirma H.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2007	51	9	3177	3184	17606676	10.1128/aac.00325-07	Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi RF, Chu CK, Cote PJ, Gerin JL, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2008	52	1	329	332	17967913	10.1128/aac.01004-07	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.	Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2008	52	10	3617	3632	18676881	10.1128/aac.00654-08	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2009	53	3	1194	1203	19104010	10.1128/aac.00984-08	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.	Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	J. Med. Chem.	2012	55	6	2672	2687	22352809	10.1021/jm201551m	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Quiterio M, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg. Med. Chem.	2016	24	11	2410	2422	27117260	10.1016/j.bmc.2016.03.052	Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.	Rawson JM, Roth ME, Xie J, Daly MB, Clouser CL, Landman SR, Reilly CS, Bonnac L, Kim B, Patterson SE, Mansky LM.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	J. Med. Chem.	2016	59	5	1869	1879	26878150	10.1021/acs.jmedchem.5b01357	A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing.	Cheung PK, Horhant D, Bandy LE, Zamiri M, Rabea SM, Karagiosov SK, Matloobi M, McArthur S, Harrigan PR, Chabot B, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885	Bioorg Med Chem Lett	2017	27	9	1934	1937	28351588	10.1016/j.bmcl.2017.03.031	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	EMTRICITABINE	CHEMBL885									WHO Anatomical Therapeutic Chemical Classification	
958.4000000000000000	9606	Homo sapiens	ENMD-981693	CHEMBL52885	J. Med. Chem.	1992	35	1	177	184	1732526	10.1021/jm00079a024	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.	Davis PD, Hill CH, Lawton G, Nixon JS, Wilkinson SE, Hurst SA, Keech E, Turner SE.
958.4000000000000000	9606	Homo sapiens	ENMD-981693	CHEMBL52885									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	1999	42	15	3001	3003	10425110	10.1021/jm980565u	Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.	Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2002	12	10	1347	1349	11992774	10.1016/s0960-894x(02)00175-0	Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.	Uesato S, Kitagawa M, Nagaoka Y, Maeda T, Kuwajima H, Yamori T.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2002	12	23	3443	3447	12419380	10.1016/s0960-894x(02)00754-0	Trifluoromethyl ketones as inhibitors of histone deacetylase.	Frey RR, Wada CK, Garland RB, Curtin ML, Michaelides MR, Li J, Pease LJ, Glaser KB, Marcotte PA, Bouska JJ, Murphy SS, Davidsen SK.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2003	13	22	3909	3913	14592473	10.1016/j.bmcl.2003.09.007	Heterocyclic ketones as inhibitors of histone deacetylase.	Vasudevan A, Ji Z, Frey RR, Wada CK, Steinman D, Heyman HR, Guo Y, Curtin ML, Guo J, Li J, Pease L, Glaser KB, Marcotte PA, Bouska JJ, Davidsen SK, Michaelides MR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2003	46	24	5097	5116	14613312	10.1021/jm0303094	Histone deacetylase inhibitors.	Miller TA, Witter DJ, Belvedere S.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2003	46	26	5745	5751	14667227	10.1021/jm030377q	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.	Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW, Im GJ, Kim TK, Seo JW, Park HJ, Yoo J, Park JH, Kim TY, Bang YJ.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2003	46	5	820	830	12593661	10.1021/jm020377a	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.	Bouchain G, Leit S, Frechette S, Khalil EA, Lavoie R, Moradei O, Woo SH, Fournel M, Yan PT, Kalita A, Trachy-Bourget MC, Beaulieu C, Li Z, Robert MF, MacLeod AR, Besterman JM, Delorme D.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2004	14	1	283	287	14684344	10.1016/j.bmcl.2003.08.083	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.	Vaisburg A, Bernstein N, Frechette S, Allan M, Abou-Khalil E, Leit S, Moradei O, Bouchain G, Wang J, Woo SH, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Beaulieu C, Li Z, MacLeod AR, Besterman JM, Delorme D.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2006	16	15	4048	4052	16713259	10.1016/j.bmcl.2006.05.005	Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.	Moradei O, Leit S, Zhou N, Fréchette S, Paquin I, Raeppel S, Gaudette F, Bouchain G, Woo SH, Vaisburg A, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Li Z, Rahil J, MacLeod AR, Besterman JM, Delorme D.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2006	16	23	5948	5952	16987657	10.1016/j.bmcl.2006.09.002	A series of novel, potent, and selective histone deacetylase inhibitors.	Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, Ingenito R, Meinke PT, Petrocchi A, Rowley M, Scarpelli R, Serafini S, Steinkühler C.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Proc. Natl. Acad. Sci. U.S.A.	2007	104	44	17335	17340	17956988	10.1073/pnas.0706487104	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.	Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, Bottomley MJ, Lo Surdo P, Carfí A, Koch U, De Francesco R, Steinkühler C, Gallinari P.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2007	17	17	4746	4752	17606370	10.1016/j.bmcl.2007.06.063	Trithiocarbonates: exploration of a new head group for HDAC inhibitors.	Dehmel F, Ciossek T, Maier T, Weinbrenner S, Schmidt B, Zoche M, Beckers T.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2007	17	8	2216	2219	17307359	10.1016/j.bmcl.2007.01.117	Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.	Bieliauskas AV, Weerasinghe SV, Pflum MK.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Biol. Chem.	2007	282	39	28408	28418	17675290	10.1074/jbc.m703586200	Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.	Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2007	50	10	2497	2505	17447750	10.1021/jm070028m	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.	Pérez-Balado C, Nebbioso A, Rodríguez-Graña P, Minichiello A, Miceli M, Altucci L, de Lera AR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2007	50	23	5543	5546	17941625	10.1021/jm701079h	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.	Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, Fournel M, Bonfils C, Trachy-Bourget MC, Liu J, Yan TP, Lu AH, Rahil J, Wang J, Lefebvre S, Li Z, Vaisburg AF, Besterman JM.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2008	16	17	7992	8002	18701301	10.1016/j.bmc.2008.07.066	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.	Su H, Nebbioso A, Carafa V, Chen Y, Yang B, Altucci L, You Q.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2008	16	6	3352	3360	18166465	10.1016/j.bmc.2007.12.007	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.	Gediya LK, Belosay A, Khandelwal A, Purushottamachar P, Njar VC.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2008	18	2	726	731	18060775	10.1016/j.bmcl.2007.11.047	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).	Witter DJ, Harrington P, Wilson KJ, Chenard M, Fleming JC, Haines B, Kral AM, Secrist JP, Miller TA.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2008	18	6	1814	1819	18308563	10.1016/j.bmcl.2008.02.025	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.	Jones P, Altamura S, De Francesco R, Gallinari P, Lahm A, Neddermann P, Rowley M, Serafini S, Steinkühler C.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2008	18	8	2530	2535	18381238	10.1016/j.bmcl.2008.03.055	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.	Mai A, Perrone A, Nebbioso A, Rotili D, Valente S, Tardugno M, Massa S, De Bellis F, Altucci L.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2008	51	6	1505	1529	18247554	10.1021/jm7011408	Histone deacetylase inhibitors: from bench to clinic.	Paris M, Porcelloni M, Binaschi M, Fattori D.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2008	51	8	2350	2353	18370373	10.1021/jm800079s	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.	Jones P, Altamura S, De Francesco R, Paz OG, Kinzel O, Mesiti G, Monteagudo E, Pescatore G, Rowley M, Verdirame M, Steinkühler C.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Antimicrob. Agents Chemother.	2008	52	4	1454	1461	18212103	10.1128/aac.00757-07	Potent antimalarial activity of histone deacetylase inhibitor analogues.	Andrews KT, Tran TN, Lucke AJ, Kahnberg P, Le GT, Boyle GM, Gardiner DL, Skinner-Adams TS, Fairlie DP.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2009	17	6	2189	2198	19022675	10.1016/j.bmc.2008.10.077	Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.	McCulloch MW, Coombs GS, Banerjee N, Bugni TS, Cannon KM, Harper MK, Veltri CA, Virshup DM, Ireland CM.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2009	19	13	3651	3656	19457659	10.1016/j.bmcl.2009.04.102	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.	Riester D, Hildmann C, Haus P, Galetovic A, Schober A, Schwienhorst A, Meyer-Almes FJ.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2009	19	4	1218	1223	19131248	10.1016/j.bmcl.2008.12.075	N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).	Allan M, Manku S, Therrien E, Nguyen N, Styhler S, Robert MF, Goulet AC, Petschner AJ, Rahil G, Robert Macleod A, Déziel R, Besterman JM, Nguyen H, Wahhab A.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2009	52	11	3453	3456	19441846	10.1021/jm9004303	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.	Kinzel O, Llauger-Bufi L, Pescatore G, Rowley M, Schultz-Fademrecht C, Monteagudo E, Fonsi M, Gonzalez Paz O, Fiore F, Steinkühler C, Jones P.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2009	52	15	4551	4573	19534534	10.1021/jm900187v	Recent advances in the development of polyamine analogues as antitumor agents.	Casero RA, Woster PM.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2009	52	8	2185	2187	19317450	10.1021/jm801654y	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.	Patel V, Mazitschek R, Coleman B, Nguyen C, Urgaonkar S, Cortese J, Barker RH, Greenberg E, Tang W, Bradner JE, Schreiber SL, Duraisingh MT, Wirth DF, Clardy J.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759		2009							Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2010	18	11	3925	3933	20452226	10.1016/j.bmc.2010.04.033	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.	Kiyokawa S, Hirata Y, Nagaoka Y, Shibano M, Taniguchi M, Yasuda M, Baba K, Uesato S.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2010	18	11	4103	4110	20472442	10.1016/j.bmc.2010.03.080	On the inhibition of histone deacetylase 8.	Estiu G, West N, Mazitschek R, Greenberg E, Bradner JE, Wiest O.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2010	20	23	7067	7070	20947351	10.1016/j.bmcl.2010.09.100	Inhibitors selective for HDAC6 in enzymes and cells.	Gupta PK, Reid RC, Liu L, Lucke AJ, Broomfield SA, Andrews MR, Sweet MJ, Fairlie DP.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2010	53	12	4654	4667	20491440	10.1021/jm100244y	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.	Souto JA, Vaz E, Lepore I, Pöppler AC, Franci G, Alvarez R, Altucci L, de Lera AR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Nat. Chem. Biol.	2010	6	1	25	33	19966789	10.1038/nchembio.275	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.	Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Nat. Chem. Biol.	2010	6	3	238	243	20139990	10.1038/nchembio.313	Chemical phylogenetics of histone deacetylases.	Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2011	19	12	3637	3649	21215647	10.1016/j.bmc.2010.12.026	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.	García J, Franci G, Pereira R, Benedetti R, Nebbioso A, Rodríguez-Barrios F, Gronemeyer H, Altucci L, de Lera AR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	1	110	116	21145737	10.1016/j.bmcl.2010.11.063	Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.	Wong JC, Guo L, Peng Z, Zhang W, Zhang N, Lai W, Zhang Z, Zhang C, Zhang X, Song S, Pan D, Xie C, Li J, Ning Z, Lu X, He Y, Chen L.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	14	4164	4169	21696956	10.1016/j.bmcl.2011.05.098	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.	Kemp MM, Wang Q, Fuller JH, West N, Martinez NM, Morse EM, Weïwer M, Schreiber SL, Bradner JE, Koehler AN.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	16	4909	4912	21742496	10.1016/j.bmcl.2011.06.015	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.	Shultz M, Fan J, Chen C, Cho YS, Davis N, Bickford S, Buteau K, Cao X, Holmqvist M, Hsu M, Jiang L, Liu G, Lu Q, Patel C, Suresh JR, Selvaraj M, Urban L, Wang P, Yan-Neale Y, Whitehead L, Zhang H, Zhou L, Atadja P.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	16	4924	4927	21741834	10.1016/j.bmcl.2011.06.001	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.	Lu A, Luo H, Shi M, Wu G, Yuan Y, Liu J, Tang F.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	18	5202	5205	21840716	10.1016/j.bmcl.2011.07.053	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.	Yu D, Sakurai F, Corey DR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2011	21	20	6139	6142	21889343	10.1016/j.bmcl.2011.08.027	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.	Choi SE, Weerasinghe SV, Pflum MK.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2011	54	13	4752	4772	21650221	10.1021/jm200388e	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.	Shultz MD, Cao X, Chen CH, Cho YS, Davis NR, Eckman J, Fan J, Fekete A, Firestone B, Flynn J, Green J, Growney JD, Holmqvist M, Hsu M, Jansson D, Jiang L, Kwon P, Liu G, Lombardo F, Lu Q, Majumdar D, Meta C, Perez L, Pu M, Ramsey T, Remiszewski S, Skolnik S, Traebert M, Urban L, Uttamsingh V, Wang P, Whitebread S, Whitehead L, Yan-Neale Y, Yao YM, Zhou L, Atadja P.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2012	20	14	4430	4436	22705022	10.1016/j.bmc.2012.05.031	Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.	Li X, Liu JL, Yang XH, Lu X, Zhao TT, Gong HB, Zhu HL.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Med Chem Res	2012	21	5	568	577		10.1007/s00044-011-9571-y	An efficient anticancer histone deacetylase inhibitor and its analogues for human HDAC8	Noureen N, Rashid H, Kalsoom S
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2012	22	23	7084	7086	23089527	10.1016/j.bmcl.2012.09.093	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.	Choi SE, Pflum MK.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2012	22	5	1926	1930	22321215	10.1016/j.bmcl.2012.01.053	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.	Hirata Y, Hirata M, Kawaratani Y, Shibano M, Taniguchi M, Yasuda M, Ohmomo Y, Nagaoka Y, Baba K, Uesato S.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur. J. Med. Chem.	2012	53		390	397	22541394	10.1016/j.ejmech.2012.03.058	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.	Rajak H, Kumar P, Parmar P, Thakur BS, Veerasamy R, Sharma PC, Sharma AK, Gupta AK, Dangi JS.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2012	55	20	8903	8925	23061376	10.1021/jm3011838	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.	Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2013	21	17	5339	5354	23820574	10.1016/j.bmc.2013.06.009	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).	Feng T, Wang H, Su H, Lu H, Yu L, Zhang X, Sun H, You Q.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	ACS Med. Chem. Lett.	2013	4	10	994	999	24900596	10.1021/ml400289e	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.	Borretto E, Lazzarato L, Spallotta F, Cencioni C, D'Alessandra Y, Gaetano C, Fruttero R, Gasco A.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2013	56	11	4816	4820	23672185	10.1021/jm400390r	Discovery of the first histone deacetylase 6/8 dual inhibitors.	Olson DE, Wagner FF, Kaya T, Gale JP, Aidoud N, Davoine EL, Lazzaro F, Weïwer M, Zhang YL, Holson EB.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2014	57	14	6259	6265	24972008	10.1021/jm500303u	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.	Valente S, Trisciuoglio D, De Luca T, Nebbioso A, Labella D, Lenoci A, Bigogno C, Dondio G, Miceli M, Brosch G, Del Bufalo D, Altucci L, Mai A.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur. J. Med. Chem.	2015	100		270	276	26140961	10.1016/j.ejmech.2015.05.045	Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.	Li Y, Wang Y, Xie N, Xu M, Qian P, Zhao Y, Li S.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2015	23	13	3457	3471	25953722	10.1016/j.bmc.2015.04.028	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.	Cai J, Wei H, Hong KH, Wu X, Zong X, Cao M, Wang P, Li L, Sun C, Chen B, Zhou G, Chen J, Ji M.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem.	2015	23	24	7597	7606	26613635	10.1016/j.bmc.2015.11.005	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.	Mendoza-Sanchez R, Cotnoir-White D, Kulpa J, Jutras I, Pottel J, Moitessier N, Mader S, Gleason JL.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2015	58	2	785	800	25490700	10.1021/jm501330g	Hydroxamic acids block replication of hepatitis C virus.	Ai T, Xu Y, Qiu L, Geraghty RJ, Chen L.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur. J. Med. Chem.	2015	96		1	13	25874326	10.1016/j.ejmech.2015.04.002	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.	Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur. J. Med. Chem.	2016	116		126	135	27060764	10.1016/j.ejmech.2016.03.046	Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.	Yoo J, Kim SJ, Son D, Seo H, Baek SY, Maeng CY, Lee C, Kim IS, Jung YH, Lee SM, Park HJ.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2016	26	12	2931	2935	27142751	10.1016/j.bmcl.2016.04.034	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.	Zhang Z, Hou S, Chen H, Ran T, Jiang F, Bian Y, Zhang D, Zhi Y, Wang L, Zhang L, Li H, Zhang Y, Tang W, Lu T, Chen Y.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg Med Chem Lett	2016	26	21	5222	5228	27717544	10.1016/j.bmcl.2016.09.058	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.	Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, Ray S, Zende D, Nayak AK, Miglani SK, Sathe BD, Raja M, Farias O, Alfaro I, Belmar S, Guerrero J, Bernales S, Chakravarty S, Hung DT, Lindquist JN, Rai R.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg. Med. Chem. Lett.	2016	26	9	2365	2369	26996372	10.1016/j.bmcl.2016.03.010	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.	Son D, Kim CS, Lee KR, Park HJ.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J. Med. Chem.	2016	59	4	1613	1633	26681404	10.1021/acs.jmedchem.5b01632	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.	Reddy DN, Ballante F, Chuang T, Pirolli A, Marrocco B, Marshall GR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759		2016							Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur J Med Chem	2017	127		531	553	28109947	10.1016/j.ejmech.2016.12.032	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.	Reddy DR, Ballante F, Zhou NJ, Marshall GR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur J Med Chem	2017	132		42	62	28340413	10.1016/j.ejmech.2017.03.024	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.	Abdizadeh T, Kalani MR, Abnous K, Tayarani-Najaran Z, Khashyarmanesh BZ, Abdizadeh R, Ghodsi R, Hadizadeh F.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur J Med Chem	2017	134		13	23	28395150	10.1016/j.ejmech.2017.03.079	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.	Mehndiratta S, Wang RS, Huang HL, Su CJ, Hsu CM, Wu YW, Pan SL, Liou JP.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Eur J Med Chem	2017	134		185	206	28415009	10.1016/j.ejmech.2017.03.069	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.	Li X, Zhang Y, Jiang Y, Wu J, Inks ES, Chou CJ, Gao S, Hou J, Ding Q, Li J, Wang X, Huang Y, Xu W.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg Med Chem	2017	25	12	2981	2994	28511906	10.1016/j.bmc.2017.03.036	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.	Gao S, Zang J, Gao Q, Liang X, Ding Q, Li X, Xu W, Chou CJ, Zhang Y.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg Med Chem	2017	25	15	4123	4132	28629630	10.1016/j.bmc.2017.05.062	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.	Tan S, He F, Kong T, Wu J, Liu Z.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg Med Chem	2017	25	7	2105	2132	28259528	10.1016/j.bmc.2017.02.020	Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.	Ballante F, Reddy DR, Zhou NJ, Marshall GR.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	Bioorg Med Chem Lett	2017	27	13	2943	2945	28501514	10.1016/j.bmcl.2017.05.004	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.	Tian Y, Lv W, Li X, Wang C, Wang D, Wang PG, Jin J, Shen J.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J Med Chem	2017	60	13	5334	5348	28581289	10.1021/acs.jmedchem.6b01538	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.	Stenzel K, Hamacher A, Hansen FK, Gertzen CGW, Senger J, Marquardt V, Marek L, Marek M, Romier C, Remke M, Jung M, Gohlke H, Kassack MU, Kurz T.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J Med Chem	2017	60	5	1817	1828	28218840	10.1021/acs.jmedchem.6b01507	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.	Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang J.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J Med Chem	2018	61	5	1745	1766	28771357	10.1021/acs.jmedchem.7b00115	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).	Bourguet E, Ozdarska K, Moroy G, Jeanblanc J, Naassila M.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759	J Med Chem	2018	61	8	3454	3477	29589441	10.1021/acs.jmedchem.7b01593	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.	Sellmer A, Stangl H, Beyer M, Grünstein E, Leonhardt M, Pongratz H, Eichhorn E, Elz S, Striegl B, Jenei-Lanzl Z, Dove S, Straub RH, Krämer OH, Mahboobi S.
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759									PubChem BioAssay data set	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	ENTINOSTAT	CHEMBL27759									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1976	19	1	127	131	1246034	10.1021/jm00223a022	Synthesis and biological activity of 2- and 4-substituted 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines.	Smissman EE, Reid JR, Walsh DA, Borchardt RT.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1978	21	6	548	554	671451	10.1021/jm00204a009	Oxidative and cardiovascular studies on natural and synthetic catecholamines.	Chavdarian CG, Karashima D, Castagnoli N, Hundley HK.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1978	21	9	922	930	31486	10.1021/jm00207a015	Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.	Dunn WJ, Wold S.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1979	22	10	1186	1193	229222	10.1021/jm00196a008	Troponoids. 3. Synthesis and antiallergy activity of N-troponyloxamic acid esters.	Bagli JF, Bogri T, Palameta B, Martel R, Robinson W, Pugsley T, Lippmann W.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1981	24	10	1258	1260	7328588	10.1021/jm00142a026	Synthesis and adrenoceptor affinity of some highly polar beta-substituted catecholamines.	Henkel JG, Sikand N, Makriyannis A, Gianutsos G.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1981	24	10	1261	1263	7328589	10.1021/jm00142a027	(alpha S)-erythro-alpha-methylepinephrine: preparation and stereoselective binding to adrenergic receptors in rat forebrain.	Taylor CA, Smith HE, Goldberg MR, Robertson D.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1982	25	12	1413	1417	7154001	10.1021/jm00354a004	Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.	Solmajer T, Lukovits I, Hadzi D.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1984	27	2	186	189	6319700	10.1021/jm00368a014	Resorcinol congeners of dopamine derived from benzocycloheptene and indan.	Cannon JG, Pease JP, Hamer RL, Ilhan M, Bhatnagar RK, Long JP.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1986	29	2	278	286	3005570	10.1021/jm00152a017	Mapping the turkey erythrocyte beta receptor: a distance geometry approach.	Linschoten MR, Bultsma T, IJzerman AP, Timmerman H.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1987	30	7	1241	1244	3037080	10.1021/jm00390a021	Radioiodinated p-iodoclonidine: a high-affinity probe for the alpha 2-adrenergic receptor.	Van Dort M, Neubig R, Counsell RE.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1988	31	10	1972	1977	2845082	10.1021/jm00118a019	Syntheses and adrenergic activities of ring-fluorinated epinephrines.	Adejare A, Gusovsky F, Padgett W, Creveling CR, Daly JW, Kirk KL.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1988	31	6	1069	1079	2836587	10.1021/jm00401a004	Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.	Donné-Op den Kelder GM, Bultsma T, Timmerman H, Rademaker B.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1993	36	24	3947	3955	8254623	10.1021/jm00076a024	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.	Chen GT, King M, Gusovsky F, Creveling CR, Daly JW, Chen BH, Nie JY, Kirk KL.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1994	37	17	2678	2685	8064796	10.1021/jm00043a007	Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library.	Zuckermann RN, Martin EJ, Spellmeyer DC, Stauber GB, Shoemaker KR, Kerr JM, Figliozzi GM, Goff DA, Siani MA, Simon RJ.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1995	38	19	3681	3716	7562902	10.1021/jm00019a001	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.	Ruffolo RR, Bondinell W, Hieble JP.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1996	39	4	850	859	8632409	10.1021/jm950447w	Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.	Brusniak MY, Pearlman RS, Neve KA, Wilcox RE.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Nat. Prod.	1997	60	4	419	420	9182127	10.1021/np960482l	Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.	Lewin G, Schaeffer C, Dacquet C.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Br. J. Pharmacol.	1998	125	1	218	224	9776363	10.1038/sj.bjp.0702065	Catecholamine transport by the organic cation transporter type 1 (OCT1).	Breidert T, Spitzenberger F, Gründemann D, Schömig E.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Biol. Chem.	1998	273	1	30915	30920	9812985	10.1074/jbc.273.47.30915	Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.	Gründemann D, Köster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermüller N, Schömig E.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	1999	42	16	3116	3125	10447956	10.1021/jm991004l	Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.	Carmignani M, Volpe AR, Delle Monache F, Botta B, Espinal R, De Bonnevaux SC, De Luca C, Botta M, Corelli F, Tafi A, Ripanti G, Monache GD.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem. Lett.	1999	9	16	2375	2378	10476872	10.1016/s0960-894x(99)00395-9	Dopamine-selective response in membrane potential by homooxacalix[3]arene triether host incorporated in PVC liquid membrane.	Odashima K, Yagi K, Tohda K, Umezawa Y.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	2000	43	8	1611	1619	10780918	10.1021/jm990599h	Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities.	Lu SF, Herbert B, Haufe G, Laue KW, Padgett WL, Oshunleti O, Daly JW, Kirk KL.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Pharm. Res.	2001	18	1	1528	1534	11758759	10.1023/a:1013070128668	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.	Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Mol. Pharmacol.	2001	59	1	358	366	11160873	10.1124/mol.59.2.358	Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.	Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Nat. Chem. Biol.	2006	2	8	417	422	16799554	10.1038/nchembio801	Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.	Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, Kobilka B.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Proc. Natl. Acad. Sci. U.S.A.	2007	104	31	12873	12878	17646643	10.1073/pnas.0705611104	Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor.	Urayama A, Grubb JH, Banks WA, Sly WS.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2007	15	8	2850	2855	17336075	10.1016/j.bmc.2007.02.026	Computational approach to the basicity of a series of alpha1-adrenoceptor ligands in aqueous solution.	Kinsella GK, Rodriguez F, Watson GW, Rozas I.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem. Lett.	2007	17	3	628	635	17127057	10.1016/j.bmcl.2006.11.027	Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV.	Temperini C, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2008	16	5	2473	2488	18083578	10.1016/j.bmc.2007.11.060	Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.	Perrone MG, Santandrea E, Bleve L, Vitale P, Colabufo NA, Jockers R, Milazzo FM, Sciarroni AF, Scilimati A.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2009	17	4	1630	1635	19157885	10.1016/j.bmc.2008.12.063	Interaction study of bioactive molecules with fibrinogen and human platelets determined by 1H NMR relaxation experiments.	Bonechi C, Martini S, Rossi C.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Eur. J. Med. Chem.	2009	44	7	2840	2846	19168263	10.1016/j.ejmech.2008.12.016	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.	Soriano-Ursúa MA, Valencia-Hernández I, Arellano-Mendoza MG, Correa-Basurto J, Trujillo-Ferrara JG.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Nat. Chem. Biol.	2010	6	3	231	237	20081854	10.1038/nchembio.307	Rapid behavior-based identification of neuroactive small molecules in the zebrafish.	Kokel D, Bryan J, Laggner C, White R, Cheung CY, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ, Macrae CA, Shoichet B, Peterson RT.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Drug Metab. Dispos.	2012	40	2	397	406	22096083	10.1124/dmd.111.041665	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.	Farrell TL, Poquet L, Dew TP, Barber S, Williamson G.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem. Lett.	2013	23	19	5376	5381	23954364	10.1016/j.bmcl.2013.07.052	ß2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.	Peterson YK, Cameron RB, Wills LP, Trager RE, Lindsey CC, Beeson CC, Schnellmann RG.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2016	24	12	2641	2653	27132867	10.1016/j.bmc.2016.04.028	Structure-guided development of dual ß2 adrenergic/dopamine D2 receptor agonists.	Weichert D, Stanek M, Hübner H, Gmeiner P.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem.	2016	24	14	3174	3183	27265687	10.1016/j.bmc.2016.05.043	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.	Vucicevic J, Srdic-Rajic T, Pieroni M, Laurila JM, Perovic V, Tassini S, Azzali E, Costantino G, Glisic S, Agbaba D, Scheinin M, Nikolic K, Radi M, Veljkovic N.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg. Med. Chem. Lett.	2016	26	5	1381	1385	26856923	10.1016/j.bmcl.2016.01.078	Carbonic anhydrase activators: Activation of the ß-carbonic anhydrase from Malassezia globosa with amines and amino acids.	Vullo D, Del Prete S, Capasso C, Supuran CT.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679	Bioorg Med Chem Lett	2017	27	1	77	80	27881231	10.1016/j.bmcl.2016.11.027	Burkholderia pseudomallei ¿-carbonic anhydrase is strongly activated by amino acids and amines.	Vullo D, Del Prete S, Osman SM, AlOthman Z, Capasso C, Donald WA, Supuran CT.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									British National Formulary (72nd edition)	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									DrugMatrix	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE	CHEMBL679									WHO Anatomical Therapeutic Chemical Classification	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958	J. Med. Chem.	1977	20	7	978	981	195059	10.1021/jm00217a028	Agonist effects of beta-phenethylamines on the noradrenergic cyclic adenosine 3',5'-monophosphate generating system in rat limbic forebrain. Stereoisomers of p-hydroxynorephedrine.	Smith HE, Burrows EP.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	EPINEPHRINE BITARTRATE	CHEMBL1256958									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	ERGOLOID MESYLATES	CHEMBL2311030									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	ERGOLOID MESYLATES	CHEMBL2311030									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	ERGOLOID MESYLATES	CHEMBL2311030									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	ERGOLOID MESYLATES	CHEMBL2311030									WHO Anatomical Therapeutic Chemical Classification	
1092.8888888888888889	9606	Homo sapiens	ERGOTAMINE TARTRATE	CHEMBL2448612									British National Formulary (72nd edition)	
1092.8888888888888889	9606	Homo sapiens	ERGOTAMINE TARTRATE	CHEMBL2448612									PubChem BioAssay data set	
1092.8888888888888889	9606	Homo sapiens	ERGOTAMINE TARTRATE	CHEMBL2448612									Unpublished dataset	
1092.8888888888888889	9606	Homo sapiens	ERGOTAMINE TARTRATE	CHEMBL2448612									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232	J. Pharmacol. Exp. Ther.	2001	296	1	723	735	11181899		In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.	Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH.
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232	Bioorg. Med. Chem. Lett.	2003	13	24	4399	4403	14643334	10.1016/j.bmcl.2003.09.039	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.	Lee JH, Lee KS, Kang YK, Yoo KH, Shin KJ, Kim DC, Kong JY, Lee Y, Lee SJ, Kim DJ.
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232	J. Med. Chem.	2014	57	20	8421	8444	25265501	10.1021/jm500879a	Design, synthesis, structure-function relationship, bioconversion, and pharmacokinetic evaluation of ertapenem prodrugs.	Singh SB, Rindgen D, Bradley P, Suzuki T, Wang N, Wu H, Zhang B, Wang L, Ji C, Yu H, Soll RM, Olsen DB, Meinke PT, Nicoll-Griffith DA.
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232									Unpublished dataset	
962.7500000000000000	2	Bacteria	ERTAPENEM SODIUM	CHEMBL1232									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1977	20	5	732	736	404425	10.1021/jm00215a025	Structure-activity relationships among the O-acyl derivatives of leucomycin. Correlation of minimal inhibitory concentrations with binding to Escherichia coli ribosomes.	Omura S, Nakagawa A, Sakakibara H, Okekawa O, Brandsch R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1987	30	11	1941	1943	3669001	10.1021/jm00394a001	Macrolides with gastrointestinal motor stimulating activity.	Omura S, Tsuzuki K, Sunazuka T, Marui S, Toyoda H, Inatomi N, Itoh Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1988	31	8	1631	1641	3398001	10.1021/jm00403a025	Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.	Kirst HA, Toth JE, Debono M, Willard KE, Truedell BA, Ott JL, Counter FT, Felty-Duckworth AM, Pekarek RS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1989	32	9	2200	2204	2504922	10.1021/jm00129a027	Synthesis and biological activity of photoactive derivatives of erythromycin.	Arévalo MA, Tejedor F, Polo F, Ballesta JP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1990	33	11	3086	3094	2231610	10.1021/jm00173a028	Synthesis and structure-activity relationships of new 9-N-alkyl derivatives of 9(S)-erythromycylamine.	Kirst HA, Wind JA, Leeds JP, Willard KE, Debono M, Bonjouklian R, Greene JM, Sullivan KA, Paschal JW, Deeter JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1990	33	7	1914	1919	2362268	10.1021/jm00169a014	Structure-activity relationships of antineoplastic agents in multidrug resistance.	Selassie CD, Hansch C, Khwaja TA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1991	34	3	1117	1125	2002453	10.1021/jm00107a036	A comparative NMR study between the macrolide antibiotic roxithromycin and erythromycin A with different biological properties.	Gharbi-Benarous J, Delaforge M, Jankowski CK, Girault JP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1993	3	10	1999	2004		10.1016/S0960-894X(01)81003-9	Assessment of the biological value of the 11-hydroxy group of the azalides.	Jones A, Herbert CM
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1993	3	6	1287	1292		10.1016/S0960-894X(00)80333-9	The synthesis of novel 8a-aza-8a-homoerythromycin derivatives via the beckmann rearrangement of (9z)-erythromycin a oxime	Wilkening RR, Ratcliffe RW, Doss GA, Bartizal KF, Graham AC, Herbert CM
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1994	4	9	1111	1116		10.1016/S0960-894X(01)80238-9	Preparation and activities of 4-epi and 4-deoxy-4-amino analogs derived from 9-deoxo-8a-aza-8a-homoerythromycin A	Shankaran K, Wilkening RR, Blizzard TA, Ratcliffe RW, Heck JV, Graham AC, Herbert CM
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1995	38	10	1793	1798	7752203	10.1021/jm00010a024	"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate."	Lartey PA, Nellans HN, Faghih R, Petersen A, Edwards CM, Freiberg L, Quigley S, Marsh K, Klein LL, Plattner JJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1995	5	8	835	838		10.1016/0960-894X(95)00122-A	Macrolide-type motilin receptor agonists: Acid-stable 12-O-methyl-8,9-anhydroerythromycin A 6,9-hemiacetals	Koga H, Tsuzuki K, Sato T, Yogo K, Takanashi H
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Mol. Pharmacol.	1996	49	1	311	318	8632764		Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.	Schuetz EG, Beck WT, Schuetz JD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1997	40	9	1340	1346	9135031	10.1021/jm960436i	Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.	McFarland JW, Berger CM, Froshauer SA, Hayashi SF, Hecker SJ, Jaynes BH, Jefson MR, Kamicker BJ, Lipinski CA, Lundy KM, Reese CP, Vu CB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Arch. Biochem. Biophys.	1998	350	1	340	347	9473310	10.1006/abbi.1997.0537	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Schuetz EG, Yasuda K, Arimori K, Schuetz JD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Pharmacol.	1998	358	1	289	294	9822896	10.1016/s0014-2999(98)00607-4	Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.	Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1998	41	10	1651	1659	9572890	10.1021/jm970547x	Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues.	Elliott RL, Pireh D, Griesgraber G, Nilius AM, Ewing PJ, Bui MH, Raney PM, Flamm RK, Kim K, Henry RF, Chu DT, Plattner JJ, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1998	41	10	1660	1670	9572891	10.1021/jm970548p	Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues.	Griesgraber G, Kramer MJ, Elliott RL, Nilius AM, Ewing PJ, Raney PM, Bui MH, Flamm RK, Chu DT, Plattner JJ, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	1998	41	21	4080	4100	9767644	10.1021/jm980240d	Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.	Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1998	8	21	3007	3010	9873665	10.1016/s0960-894x(98)00536-8	Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.	Sol V, Branland P, Granet R, Kaldapa C, Verneuil B, Krausz P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1998	8	7	805	810	9871545	10.1016/s0960-894x(98)00111-5	"Preparation of 9-deoxo-4""-deoxy-6,9-epoxyerythromycin lactams ""motilactides"": potent and orally active prokinetic agents."	Faghih R, Nellans HN, Lartey PA, Petersen A, Marsh K, Bennani YL, Plattner JJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Pharm. Res.	1999	16	1	408	414	10213372	10.1023/a:1018877803319	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.	Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	1999	27	1	866	871	10421612		OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.	Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	1999	9	2	193	194	10021926	10.1016/s0960-894x(98)00726-4	In vitro susceptibility of Helicobacter pylori to trifluoromethyl ketones.	Kawase M, Harada H, Saito S, Cui J, Tani S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2000	10	8	815	819	10782693	10.1016/s0960-894x(00)00106-2	Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives.	Clark RF, Ma Z, Wang S, Griesgraber G, Tufano M, Yong H, Li L, Zhang X, Nilius AM, Chu DT, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Clin. Exp. Pharmacol. Physiol.	2000	27	1	587	593	10901387	10.1046/j.1440-1681.2000.03308.x	Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.	Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, Yokogawa K, Miyamoto KI, Hasegawa T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2000	43	6	1045	1049	10737737	10.1021/jm990618n	Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens.	Or YS, Clark RF, Wang S, Chu DT, Nilius AM, Flamm RK, Mitten M, Ewing P, Alder J, Ma Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2000	44	1	1697	1700	10817732	10.1128/aac.44.6.1697-1700.2000	Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.	Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Pharmacol. Exp. Ther.	2001	299	2	620	628	11602674		Rational use of in vitro P-glycoprotein assays in drug discovery.	Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2001	44	24	4027	4030	11708904	10.1021/jm015566s	Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics.	Tanikawa T, Asaka T, Kashimura M, Misawa Y, Suzuki K, Sato M, Kameo K, Morimoto S, Nishida A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2001	44	24	4137	4156	11708916	10.1021/jm0102349	Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.	Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA, Chu DT, Plattner JJ, Zhang X, Zhong P, Cao Z, Nilius AM, Shortridge VD, Flamm R, Mitten M, Meulbroek J, Ewing P, Alder J, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2001	64	9	1153	1156	11575947	10.1021/np010173h	A new naphthopyrone derivative from Cassia quinquangulata and structural revision of quinquangulin and its glycosides.	Li XC, Dunbar DC, ElSohly HN, Jacob MR, Nimrod AC, Walker LA, Clark AM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Pharmacol. Exp. Ther.	2002	303	1	323	332	12235267	10.1124/jpet.102.037549	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.	Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2002	45	10	1959	1962	11985462	10.1021/jm025502x	Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.	Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, Elder JS, Forrest AK, Fosberry AP, Gentry DR, Hibbs MJ, Jaworski DD, O'Hanlon PJ, Pope AJ, Rittenhouse S, Sheppard RJ, Slater-Radosti C, Worby A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Mol. Pharmacol.	2002	61	1	964	973	11961113	10.1124/mol.61.5.964	Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.	Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Mol. Pharmacol.	2002	62	1	7	14	12065749	10.1124/mol.62.1.7	Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.	Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2003	46	10	1795	1798	12723941	10.1021/jm025580k	Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens.	Keyes RF, Carter JJ, Englund EE, Daly MM, Stone GG, Nilius AM, Ma Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2003	46	13	2706	2715	12801234	10.1021/jm020568d	Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.	Tanikawa T, Asaka T, Kashimura M, Suzuki K, Sugiyama H, Sato M, Kameo K, Morimoto S, Nishida A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2003	46	9	1716	1725	12699389	10.1021/jm021012t	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.	Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2003	66	9	1236	1238	14510605	10.1021/np030131o	Hyperatomarin, an antibacterial prenylated phloroglucinol from Hypericumatomarium ssp. degenii.	Savikin-Fodulovi¿ K, Aljanci¿ I, Vajs V, Menkovi¿ N, Macura S, Gojgi¿ G, Milosavljevi¿ S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2004	14	10	2417	2421	15109624	10.1016/j.bmcl.2004.03.020	Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.	Beebe X, Yang F, Bui MH, Mitten MJ, Ma Z, Nilius AM, Djuric SW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2004	14	14	3809	3813	15203167	10.1016/j.bmcl.2004.04.077	Synthesis and antibacterial activity of novel bifunctional macrolides.	Akritopoulou-Zanze I, Phelan KM, Marron TG, Yong H, Ma Z, Stone GG, Daly MM, Hensey DM, Nilius AM, Djuric SW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2004	14	17	4495	4499	15357979	10.1016/j.bmcl.2004.06.045	Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.	Henninger TC, Xu X, Abbanat D, Baum EZ, Foleno BD, Hilliard JJ, Bush K, Hlasta DJ, Macielag MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2004	14	18	4771	4777	15324906	10.1016/j.bmcl.2004.06.070	The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.	Du LP, Tsai KC, Li MY, You QD, Xia L.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2004	14	6	1599	1602	15006412	10.1016/j.bmcl.2003.12.059	Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.	Randolph JT, Sauer DR, Haviv F, Nilius AM, Greer J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2004	32	1	1239	1246	15286055	10.1124/dmd.104.000521	Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.	Sun H, Huang Y, Frassetto L, Benet LZ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2004	47	12	2965	2968	15163176	10.1021/jm034233n	Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.	Phan LT, Jian T, Chen Z, Qiu YL, Wang Z, Beach T, Polemeropoulos A, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2004	47	6	1487	1513	14998336	10.1021/jm0310232	New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.	Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2004	47	7	1704	1708	15027861	10.1021/jm0304865	Discovery of a potent and novel motilin agonist.	Li JJ, Chao HG, Wang H, Tino JA, Lawrence RM, Ewing WR, Ma Z, Yan M, Slusarchyk D, Seethala R, Sun H, Li D, Burford NT, Stoffel RH, Salyan ME, Li CY, Witkus M, Zhao N, Rich A, Gordon DA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2004	47	7	1783	1788	15027870	10.1021/jm0309001	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.	Suomalainen P, Johans C, Söderlund T, Kinnunen PK.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Pharmacol.	2004	484	1	333	339	14744620	10.1016/j.ejphar.2003.11.035	Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.	Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2005	15	10	2653	2658	15863336	10.1016/j.bmcl.2005.03.011	Design, synthesis and structure-activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae.	Yong H, Gu YG, Clark RF, Marron T, Ma Z, Soni N, Stone GG, Nilius AM, Marsh K, Djuric SW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2005	15	18	4076	4084	15990295	10.1016/j.bmcl.2005.06.015	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.	Wang YH, Li Y, Li YH, Yang SL, Yang L.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2005	15	4	883	887	15686880	10.1016/j.bmcl.2004.12.067	Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes.	Xu X, Henninger T, Abbanat D, Bush K, Foleno B, Hilliard J, Macielag M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2005	33	1	619	622	15708966	10.1124/dmd.104.003301	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver.	Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Xenobiotica	2005	35	2	191	210	16019946	10.1080/00498250400028197	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.	Ward KW, Nagilla R, Jolivette LJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	22	5801	5804	16982191	10.1016/j.bmcl.2006.08.076	Design, synthesis and in vivo activity of 9-(S)-dihydroerythromycin derivatives as potent anti-inflammatory agents.	Mereu A, Moriggi E, Napoletano M, Regazzoni C, Manfredini S, Mercurio TP, Pellacini F.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	23	5963	5967	16997550	10.1016/j.bmcl.2006.08.130	Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases.	Baker SJ, Akama T, Zhang YK, Sauro V, Pandit C, Singh R, Kully M, Khan J, Plattner JJ, Benkovic SJ, Lee V, Maples KR.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	24	6231	6235	16997549	10.1016/j.bmcl.2006.09.036	Synthesis and antibacterial activity of C6-carbazate ketolides.	Tennakoon MA, Henninger TC, Abbanat D, Foleno BD, Hilliard JJ, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	4	1054	1059	16289812	10.1016/j.bmcl.2005.10.074	Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives.	Zhu B, Marinelli BA, Abbanat D, Foleno BD, Henninger TC, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	4	794	797	16309904	10.1016/j.bmcl.2005.11.028	Design, synthesis, and biological evaluation of BODIPY-erythromycin probes for bacterial ribosomes.	Li J, Kim IH, Roche ED, Beeman D, Lynch AS, Ding CZ, Ma Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	5	1259	1266	16343900	10.1016/j.bmcl.2005.11.061	Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.	Fu H, Marquez S, Gu X, Katz L, Myles DC.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	6	1506	1509	16387493	10.1016/j.bmcl.2005.12.033	Synthesis and biological investigation of new 4''-malonyl tethered derivatives of erythromycin and clarithromycin.	Sherman D, Xiong L, Mankin AS, Melman A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2006	16	7	1929	1933	16446089	10.1016/j.bmcl.2005.12.097	Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides.	Grant EB, Guiadeen D, Abbanat D, Foleno BD, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Nat. Chem. Biol.	2006	2	11	591	595	16980961	10.1038/nchembio820	An oxidation-sensing mechanism is used by the global regulator MgrA in Staphylococcus aureus.	Chen PR, Bae T, Williams WA, Duguid EM, Rice PA, Schneewind O, He C.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2006	49	7	2222	2231	16570918	10.1021/jm060055x	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.	Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2006	69	11	1641	1644	17125239	10.1021/np060334n	Acetylated flavanone glycosides from the rhizomes of Cyclosorus acuminatus.	Fang W, Ruan J, Wang Z, Zhao Z, Zou J, Zhou D, Cai Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2006	69	2	251	254	16499325	10.1021/np050462w	Antibacterial galloylated alkylphloroglucinol glucosides from myrtle (Myrtus communis).	Appendino G, Maxia L, Bettoni P, Locatelli M, Valdivia C, Ballero M, Stavri M, Gibbons S, Sterner O.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2006	69	4	585	590	16643031	10.1021/np050438i	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.	Hu JF, Garo E, Hough GW, Goering MG, O'Neil-Johnson M, Eldridge GR.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2007	15	13	4498	4510	17467993	10.1016/j.bmc.2007.04.021	Novel 9a-carbamoyl- and 9a-thiocarbamoyl-3-decladinosyl-6-hydroxy and 6-methoxy derivatives of 15-membered macrolides.	Istuk ZM, Mutak S, Kujundzi¿ N, Kragol G.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2007	17	14	3900	3904	17502142	10.1016/j.bmcl.2007.04.104	Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives.	Zhu B, Marinelli BA, Abbanat D, Foleno BD, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2007	17	22	6340	6344	17869508	10.1016/j.bmcl.2007.08.068	Design and synthesis via click chemistry of 8,9-anhydroerythromycin A 6,9-hemiketal analogues with anti-MRSA and -VRE activity.	Sugawara A, Sunazuka T, Hirose T, Nagai K, Yamaguchi Y, Hanaki H, Sharpless KB, Omura S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Biol. Chem.	2007	282	4	2494	2504	17110371	10.1074/jbc.m608615200	In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.	Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2007	35	3	493	500	17194716	10.1124/dmd.106.013888	Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.	Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2007	50	17	4195	4204	17665895	10.1021/jm0703183	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.	Villain-Guillot P, Gualtieri M, Bastide L, Roquet F, Martinez J, Amblard M, Pugniere M, Leonetti JP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	128	136	17060524	10.1128/aac.00604-06	Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.	Nielsen EI, Viberg A, Löwdin E, Cars O, Karlsson MO, Sandström M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	169	174	17060530	10.1128/aac.00261-06	Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.	Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	231	238	17074796	10.1128/aac.00576-06	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.	Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, Zhu W, Musser KA, Thompson J, Kohlerschmidt D, Dumas N, Limberger RJ, Patel JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	354	358	17060532	10.1128/aac.00344-06	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.	Kamysz W, Silvestri C, Cirioni O, Giacometti A, Licci A, Della Vittoria A, Okroj M, Scalise G.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	361	365	17101672	10.1128/aac.01017-06	In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.	Foleno BD, Abbanat D, Goldschmidt RM, Flamm RK, Paget SD, Webb GC, Wira E, Macielag MJ, Bush K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	386	389	17060526	10.1128/aac.01016-06	Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.	Obert CA, Miller ML, Montgomery J, Adamkiewicz T, Tuomanen EI.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	11	3880	3886	17724154	10.1128/aac.00846-07	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.	Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A, Canadian Nosocomial Infection Surveillance Program.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	12	4267	4275	17908942	10.1128/aac.00962-07	Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.	Binet R, Maurelli AT.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	12	4361	4365	17923495	10.1128/aac.00672-07	Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes.	Dreier J, Amantea E, Kellenberger L, Page MG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	12	4498	4501	17923492	10.1128/aac.00538-07	Antimicrobial susceptibilities and clinical sources of Dialister species.	Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, Devine R, Marchandin H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	2	423	428	17116664	10.1128/aac.01244-06	Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.	Szumowski JD, Cohen DE, Kanaya F, Mayer KH.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	2	623	630	17145801	10.1128/aac.01033-06	Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.	Chan YY, Ong YM, Chua KL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	2	673	678	17101677	10.1128/aac.00802-06	Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.	Szczepanowski R, Krahn I, Bohn N, Pühler A, Schlüter A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	3	923	929	17210767	10.1128/aac.01048-06	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.	Elkins CA, Mullis LB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	4	1209	1216	17261630	10.1128/aac.01484-06	Genetic elements carrying erm(B) in Streptococcus pyogenes and association with tet(M) tetracycline resistance gene.	Brenciani A, Bacciaglia A, Vecchi M, Vitali LA, Varaldo PE, Giovanetti E.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	4	1524	1526	17261628	10.1128/aac.00905-06	Comparison of disk diffusion and agar dilution methods for erythromycin and ciprofloxacin susceptibility testing of Campylobacter jejuni subsp. jejuni.	Gaudreau C, Girouard Y, Ringuette L, Tsimiklis C.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	5	1678	1686	17353243	10.1128/aac.01411-06	Effect of macrolide usage on emergence of erythromycin-resistant Campylobacter isolates in chickens.	Lin J, Yan M, Sahin O, Pereira S, Chang YJ, Zhang Q.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	5	1741	1752	17353244	10.1128/aac.01459-06	Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.	Yasuda Y, Kasahara K, Mizuno F, Nishi K, Mikasa K, Kita E.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	5	1844	1848	17353242	10.1128/aac.01428-06	In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.	Llull D, Rivas L, García E.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	5	1865	1868	17307980	10.1128/aac.01341-06	Tetracycline resistance in group a streptococci: emergence on a global scale and influence on multiple-drug resistance.	Ayer V, Tewodros W, Manoharan A, Skariah S, Luo F, Bessen DE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	5	1885	1887	17325224	10.1128/aac.00187-07	Molecular epidemiology of telithromycin-resistant pneumococci in Finland.	Rantala M, Nyberg S, Lindgren M, Huovinen P, Jalava J, Skyttä R, Teirilä L, Vainio A, Virolainen-Julkunen A, Kaijalainen T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	6	1956	1961	17387155	10.1128/aac.00062-07	Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.	Heller S, Kellenberger L, Shapiro S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	7	2508	2513	17371822	10.1128/aac.00603-06	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.	Chow VC, Hawkey PM, Chan EW, Chin ML, Au TK, Fung DK, Chan RC.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	7	2591	2593	17420210	10.1128/aac.01562-06	In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.	Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	7	2625	2627	17502407	10.1128/aac.00107-07	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.	Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	8	2679	2689	17502406	10.1128/aac.00209-07	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Meehl M, Herbert S, Götz F, Cheung A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3212	3216	17606685	10.1128/aac.01592-06	Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni.	Gibreel A, Wetsch NM, Taylor DE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3240	3246	17606677	10.1128/aac.00157-07	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.	Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3354	3360	17548499	10.1128/aac.00339-07	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.	Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T, Arakawa Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3420	3424	17606689	10.1128/aac.00100-07	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2007	51	9	3452	3454	17638695	10.1128/aac.00420-07	In vitro susceptibilities of Mycoplasma putrefaciens field isolates.	Antunes NT, Tavío MM, Mercier P, Ayling RD, Al-Momani W, Assunção P, Rosales RS, Poveda JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	16	4678	4681	18650090	10.1016/j.bmcl.2008.07.007	Substituted 3-((Z)-2-(4-nitrophenyl)-2-(1H-tetrazol-5-yl) vinyl)-4H-chromen-4-ones as novel anti-MRSA agents: synthesis, SAR, and in-vitro assessment.	Diwakar SD, Bhagwat SS, Shingare MS, Gill CH.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	18	5078	5082	18762418	10.1016/j.bmcl.2008.07.118	Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: length optimization and zero carbon linker oximes.	Tang D, Gai Y, Polemeropoulos A, Chen Z, Wang Z, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	20	5512	5517	18805690	10.1016/j.bmcl.2008.09.013	Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.	Bavikar SN, Salunke DB, Hazra BG, Pore VS, Dodd RH, Thierry J, Shirazi F, Deshpande MV, Kadreppa S, Chattopadhyay S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	22	6007	6011	18819795	10.1016/j.bmcl.2008.09.019	Catalytic site-selective synthesis and evaluation of a series of erythromycin analogs.	Lewis CA, Merkel J, Miller SJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	24	6315	6318	18996692	10.1016/j.bmcl.2008.10.109	Synthesis of 3,6-bicyclolides: a novel class of macrolide antibiotics.	Gai Y, Tang D, Xu G, Chen Z, Polemeropoulos A, Wang Z, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	24	6423	6428	18980843	10.1016/j.bmcl.2008.10.071	Identification of small molecule agonists of the motilin receptor.	Heightman TD, Conway E, Corbett DF, Macdonald GJ, Stemp G, Westaway SM, Celestini P, Gagliardi S, Riccaboni M, Ronzoni S, Vaidya K, Butler S, McKay F, Muir A, Powney B, Winborn K, Wise A, Jarvie EM, Sanger GJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2008	18	24	6429	6436	19006669	10.1016/j.bmcl.2008.10.072	The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.	Westaway SM, Brown SL, Conway E, Heightman TD, Johnson CN, Lapsley K, Macdonald GJ, MacPherson DT, Mitchell DJ, Myatt JW, Seal JT, Stanway SJ, Stemp G, Thompson M, Celestini P, Colombo A, Consonni A, Gagliardi S, Riccaboni M, Ronzoni S, Briggs MA, Matthews KL, Stevens AJ, Bolton VJ, Boyfield I, Jarvie EM, Stratton SC, Sanger GJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2008	43	3	478	485	17544548	10.1016/j.ejmech.2007.04.002	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.	Abraham MH, Ibrahim A, Acree WE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2008	51	7	1991	1994	18330977	10.1021/jm8000136	Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.	Hirokawa Y, Kinoshita H, Tanaka T, Nakata K, Kitadai N, Fujimoto K, Kashimoto S, Kojima T, Kato S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	1	137	145	17954687	10.1128/aac.00607-07	Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.	Starner TD, Shrout JD, Parsek MR, Appelbaum PC, Kim G.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	1	348	350	17954691	10.1128/aac.00779-07	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.	Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	10	3542	3549	18644962	10.1128/aac.00582-08	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.	Wolff BJ, Thacker WL, Schwartz SB, Winchell JM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	10	3776	3778	18663020	10.1128/aac.00849-08	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	11	3947	3954	18779354	10.1128/aac.00450-08	Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.	Caldwell DB, Wang Y, Lin J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	11	4166	4171	18725450	10.1128/aac.00245-08	Characterization of TolC efflux pump proteins from Pasteurella multocida.	Hatfaludi T, Al-Hasani K, Dunstone M, Boyce J, Adler B.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	11	4184	4186	18725441	10.1128/aac.00695-08	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.	Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	11	4209	4210	18725443	10.1128/aac.00712-08	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.	Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, Tarragó D.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	12	4475	4477	18838597	10.1128/aac.00767-08	Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin, and tetracycline susceptibility testing of Campylobacter coli and for tetracycline susceptibility testing of Campylobacter jejuni subsp. jejuni.	Gaudreau C, Girouard Y, Gilbert H, Gagnon J, Bekal S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	2	435	440	18056269	10.1128/aac.01074-07	Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.	Wolter N, Smith AM, Farrell DJ, Northwood JB, Douthwaite S, Klugman KP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	2	452	457	18056272	10.1128/aac.00908-07	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.	Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	2	557	562	18086852	10.1128/aac.00732-07	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.	Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	3	1147	1149	18180346	10.1128/aac.01387-07	Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.	Ressner RA, Moore MR, Jorgensen JH.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	3	1153	1155	18180353	10.1128/aac.01351-07	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	3	1156	1158	18195060	10.1128/aac.00923-07	Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event.	Gentry DR, Holmes DJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	3	866	874	18086834	10.1128/aac.01266-07	Induction of erm(C) expression by noninducing antibiotics.	Bailey M, Chettiath T, Mankin AS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	4	1285	1290	18285489	10.1128/aac.01457-07	erm(B)-carrying elements in tetracycline-resistant pneumococci and correspondence between Tn1545 and Tn6003.	Cochetti I, Tili E, Mingoia M, Varaldo PE, Montanari MP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	4	1538	1541	18212111	10.1128/aac.00140-07	Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes.	Tsuda T, Ishikawa C, Konishi H, Hayashi Y, Nakagawa N, Matsuki M, Mizutani H, Yamanishi K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	4	1559	1563	18268083	10.1128/aac.01052-07	Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.	Hernould M, Gagné S, Fournier M, Quentin C, Arpin C.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	4	1567	1569	18285483	10.1128/aac.01325-07	Prevalence of the erm(T) gene in clinical isolates of erythromycin-resistant group D Streptococcus and Enterococcus.	DiPersio LP, DiPersio JR, Frey KC, Beach JA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	4	1570	1572	18212098	10.1128/aac.01098-07	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.	Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	5	1653	1662	18316525	10.1128/aac.01383-07	In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.	Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	5	1703	1712	18299405	10.1128/aac.01583-07	Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.	Smith LK, Mankin AS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	1964	1969	18362188	10.1128/aac.01487-07	Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).	de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galán JC, Baquero F, Reinert RR, Cantón R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2061	2068	18362191	10.1128/aac.01150-07	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.	Higashide M, Kuroda M, Omura CT, Kumano M, Ohkawa S, Ichimura S, Ohta T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2183	2189	18378706	10.1128/aac.01395-07	The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.	Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2244	2246	18391032	10.1128/aac.00231-08	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.	Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2260	2262	18378707	10.1128/aac.01270-07	Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia.	Reinert RR, Filimonova OY, Al-Lahham A, Grudinina SA, Ilina EN, Weigel LM, Sidorenko SV.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2266	2269	18413298	10.1128/aac.00046-08	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.	Hsieh YC, Chang KY, Huang YC, Lin HC, Ho YH, Huang LM, Hsueh PR.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	6	2276	2278	18411318	10.1128/aac.01584-07	In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.	Urich SK, Petersen JM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	7	2389	2394	18411322	10.1128/aac.01422-07	Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.	Laohavaleeson S, Tessier PR, Nicolau DP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	7	2503	2511	18458127	10.1128/aac.00298-08	Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.	Danilchanka O, Mailaender C, Niederweis M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	7	2647	2652	18443122	10.1128/aac.01398-07	In vitro activity of telavancin against resistant gram-positive bacteria.	Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	8	2767	2770	18519724	10.1128/aac.00481-08	Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.	Achard A, Guérin-Faublée V, Pichereau V, Villers C, Leclercq R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	8	2806	2812	18519725	10.1128/aac.00247-08	Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.	Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	8	2923	2925	18541730	10.1128/aac.00273-08	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.	Steidl R, Pearson S, Stephenson RE, Ledala N, Sitthisak S, Wilkinson BJ, Jayaswal RK.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	8	2994	2995	18505854	10.1128/aac.00230-08	Detection of the erythromycin rRNA methylase gene erm(A) in Enterococcus faecalis.	Schwaiger K, Bauer J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	9	3229	3236	18591267	10.1128/aac.00405-08	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.	Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Møller N, Nagai J, Takano M, Vaara T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	9	3398	3407	18625769	10.1128/aac.00149-08	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.	Ge Y, Biek D, Talbot GH, Sahm DF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2008	52	9	3418	3423	18591277	10.1128/aac.00336-08	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.	Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2008	71	4	520	524	18260639	10.1021/np070195p	Chemical constituents and diversity of Ligularia lankongensis in Yunnan Province of China.	Onuki H, Yamazaki M, Nakamura A, Hanai R, Kuroda C, Gong X, Shen Y, Hirota H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2008	71	8	1427	1430	18681481	10.1021/np8002673	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.	Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2008	71	8	1464	1467	18656986	10.1021/np800142n	Bioactive brominated metabolites from the red sea sponge Suberea mollis.	Abou-Shoer MI, Shaala LA, Youssef DT, Badr JM, Habib AA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2009	44	7	2913	2922	19128860	10.1016/j.ejmech.2008.12.004	Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.	Roy K, Pratim Roy P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2009	44	7	2936	2943	19152987	10.1016/j.ejmech.2008.12.014	Synthesis and evaluation of antibacterial activities of andrographolide analogues.	Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, Tian Z, Wright SC, Larrick JW, Wang Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2009	52	21	6851	6859	19821563	10.1021/jm901107f	Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety.	Shaw SJ, Chen Y, Zheng H, Fu H, Burlingame MA, Marquez S, Li Y, Claypool M, Carreras CW, Crumb W, Hardy DJ, Myles DC, Liu Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2009	52	4	1180	1189	19191554	10.1021/jm801332q	Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.	Westaway SM, Brown SL, Fell SC, Johnson CN, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, McKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ, Jarvie EM, Sanger GJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	1	329	330	18936189	10.1128/aac.00921-08	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.	Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	1	35	40	18725436	10.1128/aac.00237-08	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.	del Pozo JL, Rouse MS, Mandrekar JN, Sampedro MF, Steckelberg JM, Patel R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	10	4240	4246	19667280	10.1128/aac.00242-09	Cotransfer of antibiotic resistance genes and a hylEfm-containing virulence plasmid in Enterococcus faecium.	Arias CA, Panesso D, Singh KV, Rice LB, Murray BE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	10	4529	4532	19651906	10.1128/aac.00624-09	In vitro activities of panduratin A against clinical Staphylococcus strains.	Rukayadi Y, Lee K, Han S, Yong D, Hwang JK.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	11	4628	4639	19721076	10.1128/aac.00454-09	Induction of multidrug resistance mechanism in Escherichia coli biofilms by interplay between tetracycline and ampicillin resistance genes.	May T, Ito A, Okabe S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	12	5060	5063	19738006	10.1128/aac.00985-09	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.	Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	12	5312	5316	19770280	10.1128/aac.00748-09	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.	Srinivasan VB, Rajamohan G, Gebreyes WA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	2	512	518	19029328	10.1128/aac.00804-08	Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals.	Liu Y, Wang H, Du N, Shen E, Chen H, Niu J, Ye H, Chen M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	2	563	571	19029332	10.1128/aac.00870-08	Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition.	Siibak T, Peil L, Xiong L, Mankin A, Remme J, Tenson T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	2	735	747	19029325	10.1128/aac.00754-08	Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac).	Zheng B, Tomita H, Inoue T, Ike Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	2	779	781	19047652	10.1128/aac.01376-08	Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr.	Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1221	1224	19114678	10.1128/aac.01260-08	Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.	Fritsche TR, Biedenbach DJ, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1245	1247	19075054	10.1128/aac.00801-08	Antimicrobial activities of jadomycin B and structurally related analogues.	Jakeman DL, Bandi S, Graham CL, Reid TR, Wentzell JR, Douglas SE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1260	1263	19124664	10.1128/aac.01453-08	Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.	Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1281	1284	19075048	10.1128/aac.01247-08	In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.	Morgenstern K, Baljer G, Norris DE, Kraiczy P, Hanssen-Hübner C, Hunfeld KP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	3	1293	1294	19104015	10.1128/aac.01066-08	New composite genetic element of the Tn916 family with dual macrolide resistance genes in a Streptococcus pneumoniae isolate belonging to clonal complex 271.	Del Grosso M, Camilli R, Libisch B, Füzi M, Pantosti A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	4	1367	1376	19171799	10.1128/aac.01275-08	A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.	Nash KA, Brown-Elliott BA, Wallace RJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	4	1411	1419	19164155	10.1128/aac.01425-08	Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity.	Kouvela EC, Kalpaxis DL, Wilson DN, Dinos GP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	4	1528	1531	19164148	10.1128/aac.00971-08	Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.	Banères-Roquet F, Gualtieri M, Villain-Guillot P, Pugnière M, Leonetti JP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	4	1561	1566	19188396	10.1128/aac.00994-08	Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.	Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	1786	1792	19223626	10.1128/aac.01270-08	Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.	Jiang LJ, Wang M, Or YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	1921	1925	19258262	10.1128/aac.01065-08	Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.	Blackman Northwood J, Del Grosso M, Cossins LR, Coley MD, Creti R, Pantosti A, Farrell DJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	2020	2027	19273669	10.1128/aac.01349-08	Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.	Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	2066	2073	19273677	10.1128/aac.01464-08	Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.	Siira L, Rantala M, Jalava J, Hakanen AJ, Huovinen P, Kaijalainen T, Lyytikäinen O, Virolainen A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	2158	2159	19273685	10.1128/aac.01563-08	Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China.	Xin D, Mi Z, Han X, Qin L, Li J, Wei T, Chen X, Ma S, Hou A, Li G, Shi D.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	2160	2162	19273684	10.1128/aac.01684-08	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.	Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	5	2171	2175	19289528	10.1128/aac.00129-09	Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	8	3248	3255	19470505	10.1128/aac.00079-09	Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.	Hu WS, Lin JF, Lin YH, Chang HY.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	8	3515	3519	19528288	10.1128/aac.00012-09	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.	Wolff KA, Nguyen HT, Cartabuke RH, Singh A, Ogwang S, Nguyen L.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	8	3589	3591	19470508	10.1128/aac.00570-09	Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	8	3602	3603	19487445	10.1128/aac.00313-09	Characterization of ermA in macrolide-susceptible strains of methicillin-resistant Staphylococcus aureus.	Wong H, Louie L, Watt C, Sy E, Lo RY, Mulvey MR, Simor AE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	9	3642	3649	19546358	10.1128/aac.00206-09	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.	Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	9	4013	4014	19581458	10.1128/aac.00584-09	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.	Roca I, Marti S, Espinal P, Martínez P, Gibert I, Vila J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2009	72	5	841	847	19334707	10.1021/np800783b	Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.	Zhang C, Herath K, Jayasuriya H, Ondeyka JG, Zink DL, Occi J, Birdsall G, Venugopal J, Ushio M, Burgess B, Masurekar P, Barrett JF, Singh SB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2009	72	6	1191	1194	19445517	10.1021/np800581s	Antibacterial diterpenes from Plectranthus ernstii.	Stavri M, Paton A, Skelton BW, Gibbons S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	MedChemComm	2010	1	3	183	198		10.1039/C0MD00119H	Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications	Trippier PC, McGuigan C
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2010	18	21	7651	7658	20869254	10.1016/j.bmc.2010.08.035	9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety.	Liu Y, Li Y, Myles DC, Claypool M, Carreras CW, Shaw SJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2010	18	6	2123	2130	20188576	10.1016/j.bmc.2010.02.005	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.	Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Med Chem Res	2010	19	2	120	126		10.1007/s00044-009-9177-9	Synthesis and antimicrobial activity studies of some novel substituted phenylhydrazono-1H-tetrazol-5-yl-acetonitriles	Yavuz S, Aydn O, Cete S, Disli A, Yldrr Y
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	1	56	59	19959361	10.1016/j.bmcl.2009.11.042	Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.	Yao J, Zhang Q, Min J, He J, Yu Z.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	11	3272	3274	20462756	10.1016/j.bmcl.2010.04.051	Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives.	Ju Y, Xian R, Zhang L, Ma R, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	19	5658	5661	20801039	10.1016/j.bmcl.2010.08.030	9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.	Liu Y, Li Y, Chen Y, Zheng H, Claypool M, Myles DC, Carreras CW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	22	6712	6715	20864340	10.1016/j.bmcl.2010.08.145	A practical deuterium-free NMR method for the rapid determination of 1-octanol/water partition coefficients of pharmaceutical agents.	Mo H, Balko KM, Colby DA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	3	1165	1168	20022753	10.1016/j.bmcl.2009.12.020	The antimicrobial activity of compounds from the leaf and stem of Vitis amurensis against two oral pathogens.	Yim N, Ha do T, Trung TN, Kim JP, Lee S, Na M, Jung H, Kim HS, Kim YH, Bae K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	5	1771	1775	20138759	10.1016/j.bmcl.2010.01.040	Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides.	Urakawa H, Yamada K, Komagoe K, Ando S, Oku H, Katsu T, Matsuo I.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2010	20	8	2671	2674	20338761	10.1016/j.bmcl.2010.01.153	Synthesis and antibacterial activity of new 9-O-arylpropenyloxime ketolides.	Nam G, Kim YS, Choi KI.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2010	45	12	5943	5949	20970894	10.1016/j.ejmech.2010.09.060	Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides.	Hu L, Lan P, Song QL, Huang ZJ, Sun PH, Zhuo C, Wang Y, Xiao S, Chen WM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2010	45	8	3365	3373	20510483	10.1016/j.ejmech.2010.04.020	Synthesis of some new 4(3H)-quinazolinone-2-carboxaldehyde thiosemicarbazones and their metal complexes and a study on their anticonvulsant, analgesic, cytotoxic and antimicrobial activities - part-1.	Aly MM, Mohamed YA, El-Bayouki KA, El-Bayouki KA, Basyouni WM, Basyouni WM, Abbas SY.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2010	45	9	3636	3644	20554083	10.1016/j.ejmech.2010.05.009	Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides.	Wu Z, Lu Y, Luo M, He X, Xiao Y, Yang J, Pan Y, Qiu G, Guo H, Hu H, Zhou D, Hu X.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2010	53	21	7664	7674	20932010	10.1021/jm1008083	Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae.	Keurulainen L, Salin O, Siiskonen A, Kern JM, Alvesalo J, Kiuru P, Maass M, Yli-Kauhaluoma J, Vuorela P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	1	177	183	19858254	10.1128/aac.00715-09	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.	Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	1	230	238	19884376	10.1128/aac.01123-09	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.	McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	1	506	508	19884363	10.1128/aac.01168-09	Biologic activities of the TolC-like protein of Neisseria meningitidis as assessed by functional complementation in Escherichia coli.	Kamal N, Shafer WM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	1	509	512	19917763	10.1128/aac.00940-09	Method for screening compounds that influence virulence gene expression in Staphylococcus aureus.	Nielsen A, Nielsen KF, Frees D, Larsen TO, Ingmer H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	11	4589	4595	20713672	10.1128/aac.00470-10	Diversity of staphylococcal cassette chromosome mec elements in predominant methicillin-resistant Staphylococcus aureus clones in a small geographic area.	Basset P, Senn L, Vogel V, Zanetti G, Blanc DS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	11	4744	4749	20713681	10.1128/aac.00798-09	Characterization of two newly identified genes, vgaD and vatH, [corrected] conferring resistance to streptogramin A in Enterococcus faecium.	Jung YH, Shin ES, Kim O, Yoo JS, Lee KM, Yoo JI, Chung GT, Lee YS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	11	4942	4944	20713669	10.1128/aac.00064-10	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.	Joo HS, Chan JL, Cheung GY, Otto M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	4978	4984	20921317	10.1128/aac.01113-10	Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.	Shore AC, Brennan OM, Ehricht R, Monecke S, Schwarz S, Slickers P, Coleman DC.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	5359	5362	20855730	10.1128/aac.00723-10	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.	Jeong JW, Jung SJ, Lee HH, Kim YZ, Park TK, Cho YL, Chae SE, Baek SY, Woo SH, Lee HS, Kwak JH.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	5366	5368	20876376	10.1128/aac.00719-10	Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.	Dhamdhere G, Krishnamoorthy G, Zgurskaya HI.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	5379	5380	20855744	10.1128/aac.00553-10	In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.	Donati M, Di Francesco A, D'Antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	5406	5412	20855745	10.1128/aac.00580-10	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.	Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	12	5413	5417	20837756	10.1128/aac.00426-10	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.	Severin JA, Lestari ES, Kuntaman K, Pastink M, Snijders SV, Lemmens-den Toom N, Horst-Kreft D, Hadi U, Duerink DO, Goessens WH, Fluit AC, van Wamel W, van Belkum A, Verbrugh HA, AMRIN Study Group.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	2	915	918	20008780	10.1128/aac.01091-09	Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	3	1007	1015	20038628	10.1128/aac.01126-09	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.	Elkins CA, Mullis LB, Lacher DW, Jung CM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	3	1218	1225	20008776	10.1128/aac.00944-09	Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG.	Fàbrega A, Martin RG, Rosner JL, Tavio MM, Vila J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	3	1351	1353	20065060	10.1128/aac.01208-09	Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4.	Hölzel CS, Harms KS, Schwaiger K, Bauer J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	5	1909	1913	20231391	10.1128/aac.01570-09	Nucleotide selectivity of antibiotic kinases.	Shakya T, Wright GD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	5	1955	1964	20176911	10.1128/aac.01374-09	In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.	Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	5	2182	2187	20176910	10.1128/aac.01662-09	CEM-101 activity against Gram-positive organisms.	Woosley LN, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	5	2273	2275	20308391	10.1128/aac.00090-10	In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.	Biedenbach DJ, Ross JE, Putnam SD, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2525	2533	20308375	10.1128/aac.01682-09	Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate.	Bucki R, Leszczynska K, Byfield FJ, Fein DE, Won E, Cruz K, Namiot A, Kulakowska A, Namiot Z, Savage PB, Diamond SL, Janmey PA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2677	2680	20350943	10.1128/aac.01536-09	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.	Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2704	2706	20385851	10.1128/aac.00301-10	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.	Mendes RE, Moet GJ, Janechek MJ, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2707	2711	20231401	10.1128/aac.01565-09	Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.	Wang Q, Sun FJ, Liu Y, Xiong LR, Xie LL, Xia PY.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2716	2719	20308374	10.1128/aac.01797-09	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.	Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	6	2728	2731	20385859	10.1128/aac.01557-09	Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.	Morvan A, Moubareck C, Leclercq A, Hervé-Bazin M, Bremont S, Lecuit M, Courvalin P, Le Monnier A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	7	2806	2813	20421401	10.1128/aac.00400-10	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.	Zhang T, Bishai WR, Grosset JH, Nuermberger EL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	7	2823	2829	20404127	10.1128/aac.01845-09	Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.	Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	7	2953	2959	20439616	10.1128/aac.01548-09	Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).	Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Respiratory Pathogens.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	8	3113	3120	20498323	10.1128/aac.01803-09	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.	Mima T, Schweizer HP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	8	3475	3477	20498309	10.1128/aac.00464-10	Identification of the novel dfrK-carrying transposon Tn559 in a porcine methicillin-susceptible Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	8	3498	3501	20498312	10.1128/aac.01678-09	In vitro activity of azithromycin against nontyphoidal Salmonella enterica.	Gunell M, Kotilainen P, Jalava J, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	8	3516	3519	20498319	10.1128/aac.01756-09	Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae.	Zähner D, Zhou X, Chancey ST, Pohl J, Shafer WM, Stephens DS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	8	3529	3530	20547812	10.1128/aac.00710-10	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.	Goswami M, Jawali N.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	3804	3811	20585117	10.1128/aac.00351-10	Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States.	McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, Summers AO, Patel JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	3812	3816	20585125	10.1128/aac.00309-10	High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes.	Chisholm SA, Dave J, Ison CA.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	3825	3833	20606069	10.1128/aac.00361-10	Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.	Bourne CR, Barrow EW, Bunce RA, Bourne PC, Berlin KD, Barrow WW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	3953	3955	20585133	10.1128/aac.00169-10	First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces.	Dai L, Wu CM, Wang MG, Wang Y, Wang Y, Huang SY, Xia LN, Li BB, Shen JZ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2010	54	9	4009	4011	20625152	10.1128/aac.01812-09	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.	Biedenbach DJ, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	MedChemComm	2011	2	4	331	336		10.1039/C0MD00251H	Erythromycin B: conformational analysis and antibacterial activity	Tyson P, Hassanzadeh A, Mordi MN, Allison DG, Marquez V, Barber J
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2011	21	11	3373	3376	21524580	10.1016/j.bmcl.2011.04.004	Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents.	Sugawara A, Sueki A, Hirose T, Nagai K, Gouda H, Hirono S, Shima H, Akagawa KS, Omura S, Sunazuka T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2011	21	12	3712	3714	21570844	10.1016/j.bmcl.2011.04.078	The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.	Liu Y, Carreras CW, Claypool M, Myles DC, Shaw SJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2011	39	6	1054	1057	21393461	10.1124/dmd.111.038208	A refined cytochrome P540 IC¿¿ shift assay for reliably identifying CYP3A time-dependent inhibitors.	Li P, Lu C, Balani SK, Gan LS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2011	39	7	1247	1254	21467212	10.1124/dmd.111.039180	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.	Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2011	46	10	5196	5205	21855183	10.1016/j.ejmech.2011.08.001	Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation.	Ma X, Zhang L, Wang R, Cao J, Liu C, Fang Y, Wang J, Ma S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2011	46	2	556	566	21159410	10.1016/j.ejmech.2010.11.035	Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4¿ elongated arylalkyl groups against macrolide-resistant strains.	Ma S, Jiao B, Ju Y, Zheng M, Ma R, Liu L, Zhang L, Shen X, Ma C, Meng Y, Wang H, Qi Y, Ma X, Cui W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2011	46	7	3105	3111	21524827	10.1016/j.ejmech.2011.04.004	Synthesis and antibacterial activity of novel 4¿-O-benzimidazolyl clarithromycin derivatives.	Cong C, Wang H, Hu Y, Liu C, Ma S, Li X, Cao J, Ma S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2011	46	9	3681	3689	21664730	10.1016/j.ejmech.2011.05.032	Stereoselective synthesis and antimicrobial activity of steroidal C-20 tertiary alcohols with thiazole/pyridine side chain.	Shingate BB, Hazra BG, Salunke DB, Pore VS, Shirazi F, Deshpande MV.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2011	54	8	2792	2804	21428405	10.1021/jm101593u	Chemistry and biology of macrolide antiparasitic agents.	Lee Y, Choi JY, Fu H, Harvey C, Ravindran S, Roush WR, Boothroyd JC, Khosla C.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2011	55	1	373	375	20876371	10.1128/aac.01124-10	Novel apramycin resistance gene apmA in bovine and porcine methicillin-resistant Staphylococcus aureus ST398 isolates.	Fessler AT, Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2011	55	2	631	636	21115784	10.1128/aac.00965-10	Different genetic elements carrying the tet(W) gene in two human clinical isolates of Streptococcus suis.	Palmieri C, Princivalli MS, Brenciani A, Varaldo PE, Facinelli B.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2011	55	2	703	712	21098249	10.1128/aac.00788-10	Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.	Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2011	74	6	1517	1520	21542602	10.1021/np200120d	Brominated arginine-derived alkaloids from the red sea sponge Suberea mollis.	Shaala LA, Bamane FH, Badr JM, Youssef DT.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2012	20	24	7012	7029	23127490	10.1016/j.bmc.2012.10.009	3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents.	Kelley C, Zhang Y, Parhi A, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Med Chem Res	2012	21	12	4499	4505		10.1007/s00044-011-9951-3	Photodynamic activities of protoporphyrin IX and its dopamine conjugate against cancer and bacterial cell viability	Sagir T, Gencer S, Kemikli N, Abasiyanik MF, Isik S, Ozturk R
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	1	476	481	22153939	10.1016/j.bmcl.2011.10.101	Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.	Kumar R, Rathy S, Hajare AK, Surase YB, Dullu J, Jadhav JS, Venkataramanan R, Chakrabarti A, Pandya M, Bhateja P, Ramkumar G, Das B.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	14	4555	4560	22727643	10.1016/j.bmcl.2012.05.112	Synthesis and anti Methicillin resistant Staphylococcus aureus activity of substituted chalcones alone and in combination with non-beta-lactam antibiotics.	Tran TD, Do TH, Tran NC, Ngo TD, Huynh TN, Tran CD, Thai KM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	14	4575	4578	22738632	10.1016/j.bmcl.2012.05.110	Synthesis and antibacterial activity of desosamine-modified macrolide derivatives.	LeTourneau N, Vimal P, Klepacki D, Mankin A, Melman A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	18	5956	5960	22892120	10.1016/j.bmcl.2012.07.059	An expeditious regioselective synthesis of novel bioactive indole-substituted chromene derivatives via one-pot three-component reaction.	Hossein nia R, Mamaghani M, Tabatabaeian K, Shirini F, Rassa M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	22	6962	6966	23058886	10.1016/j.bmcl.2012.08.123	Antibacterial activity of substituted dibenzo[a,g]quinolizin-7-ium derivatives.	Parhi A, Lu S, Kelley C, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	23	7080	7083	23084900	10.1016/j.bmcl.2012.09.097	Antibacterial activity of substituted 5-methylbenzo[c]phenanthridinium derivatives.	Parhi A, Kelley C, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2012	22	24	7402	7405	23122862	10.1016/j.bmcl.2012.10.064	Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides.	Chen X, Xu P, Xu Y, Liu L, Liu Y, Zhu D, Lei P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2012	40	8	1596	1602	22593038	10.1124/dmd.112.045732	Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.	Jigorel E, Houston JB.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2012	50		441	448	22365410	10.1016/j.ejmech.2012.02.002	Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.	Palumbo Piccionello A, Musumeci R, Cocuzza C, Fortuna CG, Guarcello A, Pierro P, Pace A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2012	51		35	41	22424614	10.1016/j.ejmech.2011.12.039	Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.	Jada S, Doma MR, Singh PP, Kumar S, Malik F, Sharma A, Khan IA, Qazi GN, Kumar HM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2012	55	1	126	139	22122484	10.1021/jm201082a	In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.	Fischer H, Atzpodien EA, Csato M, Doessegger L, Lenz B, Schmitt G, Singer T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2012	55	22	10160	10176	23050700	10.1021/jm3012728	A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.	Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Antimicrob. Agents Chemother.	2012	56	2	1059	1064	22083477	10.1128/aac.05490-11	Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.	Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2012	75	12	2251	2255	23215246	10.1021/np300554f	Marthiapeptide A, an anti-infective and cytotoxic polythiazole cyclopeptide from a 60 L scale fermentation of the deep sea-derived Marinactinospora thermotolerans SCSIO 00652.	Zhou X, Huang H, Chen Y, Tan J, Song Y, Zou J, Tian X, Hua Y, Ju J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2012	75	2	280	284	22264203	10.1021/np2008279	JBIR-78 and JBIR-95: phenylacetylated peptides isolated from Kibdelosporangium sp. AK-AA56.	Izumikawa M, Takagi M, Shin-Ya K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2012	75	3	336	343	21899267	10.1021/np2003319	Antibacterial acylphloroglucinols from Hypericum olympicum.	Shiu WK, Rahman MM, Curry J, Stapleton P, Zloh M, Malkinson JP, Gibbons S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2013	21	17	5282	5291	23850103	10.1016/j.bmc.2013.06.027	Synthesis of novel isothiazolopyridines and their in vitro evaluation against Mycobacterium and Propionibacterium acnes.	Malinka W, Swi¿tek P, Sliwi¿ska M, Szponar B, Gamian A, Karczmarzyk Z, Fruzi¿ski A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2013	21	5	1174	1179	23352753	10.1016/j.bmc.2012.12.030	Polyamino geranic derivatives as new chemosensitizers to combat antibiotic resistant gram-negative bacteria.	Brunel JM, Lieutaud A, Lome V, Pagès JM, Bolla JM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2013	23	17	4968	4974	23891185	10.1016/j.bmcl.2013.06.048	Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines.	Parhi AK, Zhang Y, Saionz KW, Pradhan P, Kaul M, Trivedi K, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2013	23	18	5057	5060	23937982	10.1016/j.bmcl.2013.07.042	Design, synthesis and biological evaluation of azithromycin glycosyl derivatives as potential antibacterial agents.	Zhang L, Chai X, Wang B, Yu S, Hu H, Zou Y, Zhao Q, Meng Q, Wu Q.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2013	23	24	6842	6846	24206766	10.1016/j.bmcl.2013.10.010	Anti-tubercular agents. Part 8: synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1,2,3-triazoles.	Kamal A, Hussaini SM, Faazil S, Poornachandra Y, Narender Reddy G, Kumar CG, Rajput VS, Rani C, Sharma R, Khan IA, Jagadeesh Babu N.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2013	23	7	2001	2006	23481648	10.1016/j.bmcl.2013.02.016	Substituted 1,6-diphenylnaphthalenes as FtsZ-targeting antibacterial agents.	Zhang Y, Giurleo D, Parhi A, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2013	41	1	60	71	23033255	10.1124/dmd.112.048264	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.	Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Metab. Dispos.	2013	41	2	372	378	23139379	10.1124/dmd.112.049312	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.	Grime K, Paine SW.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2013	56	3	781	795	23241029	10.1021/jm301302s	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.	Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2013	56	4	1418	1430	23409840	10.1021/jm301499r	Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.	Desroy N, Denis A, Oliveira C, Atamanyuk D, Briet S, Faivre F, LeFralliec G, Bonvin Y, Oxoby M, Escaich S, Floquet S, Drocourt E, Vongsouthi V, Durant L, Moreau F, Verhey TB, Lee TW, Junop MS, Gerusz V.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2013	56	5	1908	1921	23445125	10.1021/jm400097h	Vectorization efforts to increase Gram-negative intracellular drug concentration: a case study on HldE-K inhibitors.	Atamanyuk D, Faivre F, Oxoby M, Ledoussal B, Drocourt E, Moreau F, Gerusz V.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2013	59		209	217	23229056	10.1016/j.ejmech.2012.11.028	Synthesis and antibacterial evaluation of novel 11,4¿-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.	Li X, Ma S, Yan M, Wang Y, Ma S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2013	60		395	409	23314053	10.1016/j.ejmech.2012.12.027	Antimicrobial activity of various 4- and 5-substituted 1-phenylnaphthalenes.	Kelley C, Lu S, Parhi A, Kaul M, Pilch DS, Lavoie EJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2013	76	11	2009	2018	24224794	10.1021/np400145u	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.	Cai G, Napolitano JG, McAlpine JB, Wang Y, Jaki BU, Suh JW, Yang SH, Lee IA, Franzblau SG, Pauli GF, Cho S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2013	76	11	2153	2157	24164206	10.1021/np4006794	Identification of elaiophylin derivatives from the marine-derived actinomycete Streptomyces sp. 7-145 using PCR-based screening.	Wu C, Tan Y, Gan M, Wang Y, Guan Y, Hu X, Zhou H, Shang X, You X, Yang Z, Xiao C.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Med Chem Res	2013			1	11		10.1007/s00044-013-0755-5	Synthesis, antibacterial screening, and POM analyses of novel bis-isoxazolyl/pyrazolyl-1,3-diols	Juneja H, Panchbhai D, Sheikh J, Ingle V, Hadda TB
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2014	22	1	194	203	24332858	10.1016/j.bmc.2013.11.037	The synthesis of novel taxoids for oral administration.	Jing YR, Zhou W, Li WL, Zhao LX, Wang YF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2014	24	13	2905	2908	24835633	10.1016/j.bmcl.2014.04.084	Synthesis, cytotoxicity, antimicrobial and anti-biofilm activities of novel pyrazolo[3,4-b]pyridine and pyrimidine functionalized 1,2,3-triazole derivatives.	Nagender P, Malla Reddy G, Naresh Kumar R, Poornachandra Y, Ganesh Kumar C, Narsaiah B.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2014	57	6	2536	2548	24499135	10.1021/jm401808n	First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.	Fontaine F, Hequet A, Voisin-Chiret AS, Bouillon A, Lesnard A, Cresteil T, Jolivalt C, Rault S.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2014	77	8	1759	1763	25046128	10.1021/np400742p	Structure and Stereochemical Determination of Hypogeamicins from a Cave-Derived Actinomycete.	Derewacz DK, McNees CR, Scalmani G, Covington CL, Shanmugam G, Marnett LJ, Polavarapu PL, Bachmann BO.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur. J. Med. Chem.	2014	82		565	573	24941130	10.1016/j.ejmech.2014.05.084	Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells.	Emirda¿-Öztürk S, Karay¿ld¿r¿m T, Çapc¿-Karagöz A, Alanku¿-Çal¿¿kan Ö, Özmen A, Poyrazo¿lu-Çoban E.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2015	23	13	3163	3174	26001343	10.1016/j.bmc.2015.04.069	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.	Magoulas GE, Kostopoulou ON, Garnelis T, Athanassopoulos CM, Kournoutou GG, Leotsinidis M, Dinos GP, Papaioannou D, Kalpaxis DL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem.	2015	23	17	5334	5344	26264847	10.1016/j.bmc.2015.07.062	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.	Tran TP, Vo DD, Di Giorgio A, Duca M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2015	25	15	2943	2947	26048810	10.1016/j.bmcl.2015.05.041	Synthesis of novel amide functionalized 2H-chromene derivatives by Ritter amidation of primary alcohol using HBF4·OEt2 as a mild and versatile reagent and evaluation of their antimicrobial and anti-biofilm activities.	Ratnakar Reddy K, Poornachandra Y, Jitender Dev G, Mallareddy G, Nanubolu JB, Kumar CG, Narsaiah B.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2015	25	17	3468	3475	26189081	10.1016/j.bmcl.2015.07.010	Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space.	Ross AG, Benton BM, Chin D, De Pascale G, Fuller J, Leeds JA, Reck F, Richie DL, Vo J, LaMarche MJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2015	25	3	597	601	25537269	10.1016/j.bmcl.2014.12.010	Synthesis and anti-biofilm activities of dihydro-pyrrol-2-one derivatives on Pseudomonas aeruginosa.	Ye Y, Fang F, Li Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg. Med. Chem. Lett.	2015	25	9	1915	1919	25838145	10.1016/j.bmcl.2015.03.034	One-pot catalyst free synthesis of novel kojic acid tagged 2-aryl/alkyl substituted-4H-chromenes and evaluation of their antimicrobial and anti-biofilm activities.	Bingi C, Emmadi NR, Chennapuram M, Poornachandra Y, Kumar CG, Nanubolu JB, Atmakur K.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2015	58	12	4984	4997	26030312	10.1021/acs.jmedchem.5b00175	Creation of Customized Bioactivity within a 14-Membered Macrolide Scaffold: Design, Synthesis, and Biological Evaluation Using a Family-18 Chitinase.	Sugawara A, Maita N, Gouda H, Yamamoto T, Hirose T, Kimura S, Saito Y, Nakano H, Kasai T, Nakano H, Shiomi K, Hirono S, Watanabe T, Taniguchi H, Omura S, Sunazuka T.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Med. Chem.	2015	58	15	5691	5698	25799158	10.1021/acs.jmedchem.5b00201	Volume of Distribution in Drug Design.	Smith DA, Beaumont K, Maurer TS, Di L.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J. Nat. Prod.	2015	78	3	402	412	25646964	10.1021/np500775e	Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.	Whalen KE, Poulson-Ellestad KL, Deering RW, Rowley DC, Mincer TJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur J Med Chem	2016	122		419	428	27393950	10.1016/j.ejmech.2016.06.051	New imidazolidineiminothione derivatives: Synthesis, spectral characterization and evaluation of antitumor, antiviral, antibacterial and antifungal activities.	Moussa Z, El-Sharief MAMS, Abbas SY.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg Med Chem	2016	24	24	6379	6389	27381365	10.1016/j.bmc.2016.06.044	A Gestalt approach to Gram-negative entry.	Silver LL.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Eur J Med Chem	2017	135		296	306	28458135	10.1016/j.ejmech.2017.04.042	Inhibitors of cytochrome P450 (CYP) 1B1.	Dutour R, Poirier D.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	Bioorg Med Chem	2017	25	1	261	268	27865644	10.1016/j.bmc.2016.10.033	Bioactivity of topologically confined gramicidin A dimers.	Jadhav KB, Stein C, Makarewicz O, Pradel G, Lichtenecker RJ, Sack H, Heinemann SH, Arndt HD.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Med Chem	2017	60	6	2425	2438	28248504	10.1021/acs.jmedchem.6b01780	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.	Mohammad H, Younis W, Chen L, Peters CE, Pogliano J, Pogliano K, Cooper B, Zhang J, Mayhoub A, Oldfield E, Cushman M, Seleem MN.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Med Chem	2017	60	9	3684	3702	28409644	10.1021/acs.jmedchem.6b01742	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.	Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Med Chem	2017	60	9	3902	3912	28383902	10.1021/acs.jmedchem.7b00204	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.	Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532	J Med Chem	2018	61	1	224	250	29243920	10.1021/acs.jmedchem.7b01300	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.	Li B, Ni S, Mao F, Chen F, Liu Y, Wei H, Chen W, Zhu J, Lan L, Li J.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									Cerep in vitro phospholipidosis assay data	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									DrugMatrix	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									Drug metabolism data	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN	CHEMBL532									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877	Hepatology	2014	60	3	1015	1022	24799086	10.1002/hep.27206	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.	Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ESTOLATE	CHEMBL2218877									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688									Open TG-GATES	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN GLUCEPTATE	CHEMBL3545060									Drug metabolism data	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN GLUCEPTATE	CHEMBL3545060									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN GLUCEPTATE	CHEMBL3545060									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN LACTOBIONATE	CHEMBL1200506	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN LACTOBIONATE	CHEMBL1200506									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN LACTOBIONATE	CHEMBL1200506									Drug metabolism data	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN LACTOBIONATE	CHEMBL1200506									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN LACTOBIONATE	CHEMBL1200506									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510									Drug metabolism data	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510									Unpublished dataset	
2219.8000000000000000	2	Bacteria	ERYTHROMYCIN STEARATE	CHEMBL1200510									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1878.0666666666666667	9606	Homo sapiens	ETARACIZUMAB	CHEMBL1743014									Unpublished dataset	
1878.0666666666666667	9606	Homo sapiens	ETARACIZUMAB	CHEMBL1743014									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	J. Nat. Prod.	1997	60	12	1275	1280	9428161	10.1021/np9700681	Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity.	Ulubelen A, Topcu G, Johansson CB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Bioorg. Med. Chem. Lett.	2004	14	15	3923	3924	15225698	10.1016/j.bmcl.2004.05.060	Antituberculous activity of some aryl semicarbazone derivatives.	Sriram D, Yogeeswari P, Thirumurugan R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2007	51	11	3824	3829	17785510	10.1128/aac.00433-07	Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.	Korduláková J, Janin YL, Liav A, Barilone N, Dos Vultos T, Rauzier J, Brennan PJ, Gicquel B, Jackson M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2007	51	3	1055	1063	17220416	10.1128/aac.01063-06	EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.	Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, Besra GS, Kremer L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2009	53	12	5279	5283	19786608	10.1128/aac.00803-09	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.	Miller CH, Nisa S, Dempsey S, Jack C, O'Toole R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2010	54	11	4789	4793	20713679	10.1128/aac.00661-10	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.	Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Antimicrob. Agents Chemother.	2010	54	9	3776	3782	20566771	10.1128/aac.00453-10	Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.	Wang F, Jain P, Gulten G, Liu Z, Feng Y, Ganesula K, Motiwala AS, Ioerger TR, Alland D, Vilchèze C, Jacobs WR, Sacchettini JC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Bioorg. Med. Chem. Lett.	2011	21	3	899	903	21232949	10.1016/j.bmcl.2010.12.084	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.	Horita Y, Takii T, Kuroishi R, Chiba T, Ogawa K, Kremer L, Sato Y, Lee Y, Hasegawa T, Onozaki K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Bioorg. Med. Chem.	2012	20	6	2035	2041	22361273	10.1016/j.bmc.2012.01.041	Anti-mycobacterial activities of some cationic and anionic calix[4]arene derivatives.	Mourer M, Massimba Dibama H, Constant P, Daffé M, Regnouf-de-Vains JB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Eur. J. Med. Chem.	2012	49		1	23	22280816	10.1016/j.ejmech.2011.12.029	Recent advances in antitubercular natural products.	García A, Bocanegra-García V, Palma-Nicolás JP, Rivera G.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	J. Med. Chem.	2014	57	15	6572	6582	24967731	10.1021/jm500833f	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.	Bellale E, Naik M, V B V, Ambady A, Narayan A, Ravishankar S, Ramachandran V, Kaur P, McLaughlin R, Whiteaker J, Morayya S, Guptha S, Sharma S, Raichurkar A, Awasthy D, Achar V, Vachaspati P, Bandodkar B, Panda M, Chatterji M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Eur. J. Med. Chem.	2015	106		157	166	26544630	10.1016/j.ejmech.2015.10.033	Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.	Choi J, Park SJ, Jee JG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441	Eur J Med Chem	2017	126		491	501	27914363	10.1016/j.ejmech.2016.11.048	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.	Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									British National Formulary (72nd edition)	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									Open TG-GATES	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									PubChem BioAssay data set	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									Unpublished dataset	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ETHIONAMIDE	CHEMBL1441									WHO Anatomical Therapeutic Chemical Classification	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1976	19	3	391	395	1255663	10.1021/jm00225a010	Etodolic acid and related compounds. Chemistry and antiinflammatory actions of some potent di- and trisubstituted 1, 3, 4, 9-tetrahydropyrano[3, 4-b]indole-1-acetic acids.	Martel RR, Demerson CA, Humber LG, Philipp AH.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1976	19	6	787	792	950647	10.1021/jm00228a010	Cycloalkanoindoles. 1. Syntheses and antiinflammatory actions of some acidic tetrahydrocarbazoles, cyclopentindoles, and cycloheptindoles.	Asselin AA, Humber LG, Dobson TA, Komlossy J.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1983	26	12	1778	1780	6227748	10.1021/jm00366a025	Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers.	Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1988	31	11	2211	2217	3263504	10.1021/jm00119a024	Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent.	Mobilio D, Humber LG, Katz AH, Demerson CA, Hughes P, Brigance R, Conway K, Shah U, Williams G, Labbadia F.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1988	31	6	1244	1250	3373493	10.1021/jm00401a029	Synthesis and analgesic activity of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]ind ole-1- acetic acid).	Katz AH, Demerson CA, Shaw CC, Asselin AA, Humber LG, Conway KM, Gavin G, Guinosso C, Jensen NP, Mobilio D.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1988	31	9	1712	1719	2970548	10.1021/jm00117a009	Etodolac, a novel antiinflammatory agent. The syntheses and biological evaluation of its metabolites.	Humber LG, Ferdinandi E, Demerson CA, Ahmed S, Shah U, Mobilio D, Sabatucci J, De Lange B, Labbadia F, Hughes P.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	1989	32	9	2134	2137	2527995	10.1021/jm00129a018	Synthesis and biological evaluation of 4,6-diethyl-1,3,4,5-tetrahydropyrano[4,3-b]indole-4-acetic acid, an isomer of etodolac.	Hughes P, DeVirgilio J, Humber LG, Chau T, Weichman B, Neuman G.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Pharmacol. Exp. Ther.	2000	295	1	10	15	10991954		Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.	Mulato AS, Ho ES, Cihlar T.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	2003	46	21	4477	4486	14521410	10.1021/jm030191r	Identification and prediction of promiscuous aggregating inhibitors among known drugs.	Seidler J, McGovern SL, Doman TN, Shoichet BK.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	2004	47	20	4875	4880	15369391	10.1021/jm049950b	Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.	Hsu N, Cai D, Damodaran K, Gomez RF, Keck JG, Laborde E, Lum RT, Macke TJ, Martin G, Schow SR, Simon RJ, Villar HO, Wick MM, Beroza P.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem. Lett.	2005	15	23	5170	5175	16183274	10.1016/j.bmcl.2005.08.063	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.	Gobec S, Brozic P, Rizner TL.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem.	2008	16	11	5881	5889	18482840	10.1016/j.bmc.2008.04.066	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.	Brunskole M, Stefane B, Zorko K, Anderluh M, Stojan J, Lanisnik Rizner T, Gobec S.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem.	2008	16	17	8072	8081	18752957	10.1016/j.bmc.2008.07.058	Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.	Biava M, Porretta GC, Poce G, Supino S, Manetti F, Forli S, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Norcini M, Makovec F, Giordani A, Anzellotti P, Cirilli R, Ferretti R, Gallinella B, La Torre F, Anzini M, Patrignani P.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Eur. J. Med. Chem.	2009	44	4	1600	1606	18768239	10.1016/j.ejmech.2008.07.027	First-principle, structure-based prediction of hepatic metabolic clearance values in human.	Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem. Lett.	2010	20	8	2546	2548	20299217	10.1016/j.bmcl.2010.02.093	Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.	Kapadia GJ, Azuine MA, Shigeta Y, Suzuki N, Tokuda H.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem.	2011	19	11	3320	3340	21571536	10.1016/j.bmc.2011.04.045	Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).	Kouznetsova VL, Tsigelny IF, Nagle MA, Nigam SK.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Bioorg. Med. Chem. Lett.	2011	21	12	3550	3556	21601448	10.1016/j.bmcl.2011.04.133	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.	Wenlock MC, Barton P, Luker T.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Drug Metab. Dispos.	2012	40	9	1771	1777	22685216	10.1124/dmd.112.045476	Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.	Nakamori F, Naritomi Y, Hosoya K, Moriguchi H, Tetsuka K, Furukawa T, Kadono K, Yamano K, Terashita S, Teramura T.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Eur. J. Med. Chem.	2012	53		76	82	22521372	10.1016/j.ejmech.2012.03.037	Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.	Honey, Thareja S, Kumar M, Sinha VR.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	J. Med. Chem.	2013	56	21	8377	8388	24088053	10.1021/jm400813y	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.	Végner L, Peragovics Á, Tombor L, Jelinek B, Czobor P, Bender A, Simon Z, Málnási-Csizmadia A.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									Drug metabolism data	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	ETODOLAC	CHEMBL622									WHO Anatomical Therapeutic Chemical Classification	
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	1998	8	19	2777	2782	9873621	10.1016/s0960-894x(98)00499-5	2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.	Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong E, Visco D, Xu LJ, Young RN.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2001	11	8	1059	1062	11327589	10.1016/s0960-894x(01)00135-4	In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).	Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2004	14	21	5445	5448	15454242	10.1016/j.bmcl.2004.07.089	Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.	Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	J. Med. Chem.	2004	47	15	3874	3886	15239665	10.1021/jm049882t	Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.	Caturla F, Jiménez JM, Godessart N, Amat M, Cárdenas A, Soca L, Beleta J, Ryder H, Crespo MI.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2005	15	15	3506	3509	15990304	10.1016/j.bmcl.2005.05.107	The molecular basis for coxib inhibition of p38alpha MAP kinase.	Sperandio da Silva GM, Lima LM, Fraga CA, Sant'Anna CM, Barreiro EJ.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	J. Med. Chem.	2005	48	11	3930	3934	15916445	10.1021/jm0582064	3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.	Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2006	16	12	3209	3212	16616494	10.1016/j.bmcl.2006.03.052	Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.	Caturla F, Amat M, Reinoso RF, Córdoba M, Warrellow G.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2006	16	13	3605	3608	16647258	10.1016/j.bmcl.2006.03.101	Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.	Caturla F, Amat M, Reinoso RF, Calaf E, Warrellow G.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2007	17	24	6816	6820	18029174	10.1016/j.bmcl.2007.10.033	Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.	Côté B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2009	19	15	4504	4508	19520573	10.1016/j.bmcl.2009.02.085	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.	Swarbrick ME, Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Bioorg. Med. Chem. Lett.	2010	20	23	6978	6982	20965723	10.1016/j.bmcl.2010.09.129	Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.	Wu TY, Juteau H, Ducharme Y, Friesen RW, Guiral S, Dufresne L, Poirier H, Salem M, Riendeau D, Mancini J, Brideau C.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146	Eur. J. Med. Chem.	2013	67		352	358	23887055	10.1016/j.ejmech.2013.06.050	Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)-4,5-dihydropyridazi-3(2H)-ones.	Ovais S, Javed K, Yaseen S, Bashir R, Rathore P, Yaseen R, Hameed AD, Samim M.
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	ETORICOXIB	CHEMBL416146									WHO Anatomical Therapeutic Chemical Classification	
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2001	11	17	2235	2239	11527705	10.1016/s0960-894x(01)00412-7	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.	Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2004	47	10	2550	2560	15115397	10.1021/jm030558s	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2005	48	6	1689	1696	15771411	10.1021/jm040127p	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.	De Corte BL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2005	48	6	1974	1983	15771441	10.1021/jm049439i	Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.	Frenkel YV, Clark AD, Das K, Wang YH, Lewi PJ, Janssen PA, Arnold E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2006	16	21	5664	5667	16931015	10.1016/j.bmcl.2006.08.037	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Thakur VV, Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2006	16	3	663	667	16263277	10.1016/j.bmcl.2005.10.038	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2006	16	3	668	671	16298131	10.1016/j.bmcl.2005.10.037	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Ruiz-Caro J, Basavapathruni A, Kim JT, Bailey CM, Wang L, Anderson KS, Hamilton AD, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2007	50	22	5324	5329	17918923	10.1021/jm070683u	From docking false-positive to active anti-HIV agent.	Barreiro G, Kim JT, Guimarães CR, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2008	43	3	471	477	17583387	10.1016/j.ejmech.2007.04.005	SAR and QSAR studies: modelling of new DAPY derivatives.	Thakur A, Thakur M, Bharadwaj A, Thakur S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2008	51	23	7449	7458	19007201	10.1021/jm800527x	Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.	Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2008	52	12	4228	4232	18838586	10.1128/aac.00487-08	Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.	Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, Wenning LA, Stone JA, Hoetelmans RM, Wagner JA, Iwamoto M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2009	19	18	5452	5457	19666223	10.1016/j.bmcl.2009.07.095	Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.	Grimberg BT, Jaworska MM, Hough LB, Zimmerman PA, Phillips JG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2009	19	18	5482	5485	19666220	10.1016/j.bmcl.2009.07.080	Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Tian X, Qin B, Lu H, Lai W, Jiang S, Lee KH, Chen CH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2009	44	2	625	631	18457904	10.1016/j.ejmech.2008.03.021	QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains.	Liang YH, Chen FE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2009	52	3	840	851	19140683	10.1021/jm801330n	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.	Radi M, Maga G, Alongi M, Angeli L, Samuele A, Zanoli S, Bellucci L, Tafi A, Casaluce G, Giorgi G, Armand-Ugon M, Gonzalez E, Esté JA, Baltzinger M, Bec G, Dumas P, Ennifar E, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2009	53	11	4667	4672	19704127	10.1128/aac.00800-09	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.	Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2009	53	6	2424	2431	19289522	10.1128/aac.01559-08	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.	Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2010	20	14	4215	4218	20538456	10.1016/j.bmcl.2010.05.040	Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.	Kertesz DJ, Brotherton-Pleiss C, Yang M, Wang Z, Lin X, Qiu Z, Hirschfeld DR, Gleason S, Mirzadegan T, Dunten PW, Harris SF, Villaseñor AG, Hang JQ, Heilek GM, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2010	20	20	6020	6023	20829038	10.1016/j.bmcl.2010.08.068	Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.	Tang G, Kertesz DJ, Yang M, Lin X, Wang Z, Li W, Qiu Z, Chen J, Mei J, Chen L, Mirzadegan T, Harris SF, Villaseñor AG, Fretland J, Fitch WL, Hang JQ, Heilek G, Klumpp K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2010	20	5	1585	1588	20137928	10.1016/j.bmcl.2010.01.086	N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mitchell ML, Son JC, Lee IY, Lee CK, Kim HS, Guo H, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Eisenberg G, Geleziunas R, Xu L, Kim CU.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2010	20	5	1589	1592	20138513	10.1016/j.bmcl.2010.01.085	N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mitchell ML, Son JC, Guo H, Im YA, Cho EJ, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Graupe D, Rhodes G, He GX, Geleziunas R, Xu L, Kim CU.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2010	20	8	2485	2488	20304641	10.1016/j.bmcl.2010.03.006	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.	Leung CS, Zeevaart JG, Domaoal RA, Bollini M, Thakur VV, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2010	53	10	4259	4265	20426472	10.1021/jm100254w	Colloid formation by drugs in simulated intestinal fluid.	Doak AK, Wille H, Prusiner SB, Shoichet BK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2010	53	13	4906	4916	20527972	10.1021/jm1002952	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.	Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L, Qian K, Chen CH, Huang R, Jiang S, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2010	53	23	8287	8297	21049929	10.1021/jm100738d	Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Tian X, Qin B, Wu Z, Wang X, Lu H, Morris-Natschke SL, Chen CH, Jiang S, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2010	54	10	4451	4463	20660667	10.1128/aac.01455-09	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.	Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2010	54	2	718	727	19933797	10.1128/aac.00986-09	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.	Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2010	54	2	728	733	20008779	10.1128/aac.01335-09	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.	Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2010	54	4	1596	1602	20124001	10.1128/aac.01480-09	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.	Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2010	54	6	2401	2408	20308384	10.1128/aac.01795-09	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.	Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2011	19	17	5117	5124	21824782	10.1016/j.bmc.2011.07.023	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.	Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2011	19	23	7093	7099	22037050	10.1016/j.bmc.2011.10.002	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.	Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2011	54	24	8582	8591	22081993	10.1021/jm201134m	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.	Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Antimicrob. Agents Chemother.	2011	55	3	1282	1284	21189339	10.1128/aac.01527-10	Interaction potential of etravirine with drug transporters assessed in vitro.	Zembruski NC, Haefeli WE, Weiss J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2012	53		229	234	22575532	10.1016/j.ejmech.2012.04.004	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.	Gu SX, Li ZM, Ma XD, Yang SQ, He QQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2012	55	14	6634	6638	22712652	10.1021/jm300477h	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Famiglini V, Cosconati S, Maga G, Samuele A, Gonzalez E, Clotet B, Schols D, Esté JA, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2012	55	16	7219	7229	22856541	10.1021/jm3007678	Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.	Sun LQ, Zhu L, Qian K, Qin B, Huang L, Chen CH, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2012	55	23	10601	10609	23137340	10.1021/jm301294g	Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Chong P, Sebahar P, Youngman M, Garrido D, Zhang H, Stewart EL, Nolte RT, Wang L, Ferris RG, Edelstein M, Weaver K, Mathis A, Peat A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2012	55	8	3595	3613	22268494	10.1021/jm200990c	Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.	Li D, Zhan P, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2012	58		485	492	23159806	10.1016/j.ejmech.2012.10.036	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.	Ribone SR, Leen V, Madrid M, Dehaen W, Daelemans D, Pannecouque C, Briñón MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2013	21	7	2128	2134	23415090	10.1016/j.bmc.2012.12.049	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.	Li D, Zhan P, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2013	23	18	5213	5216	23937980	10.1016/j.bmcl.2013.06.091	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.	Bollini M, Cisneros JA, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2013	23	4	1110	1113	23298809	10.1016/j.bmcl.2012.11.115	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.	Bollini M, Gallardo-Macias R, Spasov KA, Tirado-Rives J, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2013	65		134	143	23707918	10.1016/j.ejmech.2013.04.052	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	1	633	642	24275349	10.1016/j.bmc.2013.10.033	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.	Zhang L, Zhan P, Chen X, Li Z, Xie Z, Zhao T, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	12	3220	3226	24794751	10.1016/j.bmc.2014.03.020	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	19	5241	5248	25199582	10.1016/j.bmc.2014.08.005	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.	Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	6	1863	1872	24581546	10.1016/j.bmc.2014.01.054	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.	Chen W, Zhan P, Rai D, De Clercq E, Pannecouque C, Balzarini J, Zhou Z, Liu H, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	7	2052	2059	24631361	10.1016/j.bmc.2014.02.029	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.	Tian Y, Du D, Rai D, Wang L, Liu H, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2014	22	8	2535	2541	24680058	10.1016/j.bmc.2014.02.030	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Huang XY, Wu HQ, Chen WX, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem. Lett.	2014	24	3	917	922	24412110	10.1016/j.bmcl.2013.12.070	Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.	Côté B, Burch JD, Asante-Appiah E, Bayly C, Bédard L, Blouin M, Campeau LC, Cauchon E, Chan M, Chefson A, Coulombe N, Cromlish W, Debnath S, Deschênes D, Dupont-Gaudet K, Falgueyret JP, Forget R, Gagné S, Gauvreau D, Girardin M, Guiral S, Langlois E, Li CS, Nguyen N, Papp R, Plamondon S, Roy A, Roy S, Seliniotakis R, St-Onge M, Ouellet S, Tawa P, Truchon JF, Vacca J, Wrona M, Yan Y, Ducharme Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	ACS Med. Chem. Lett.	2014	5	11	1259	1262	25408842	10.1021/ml5003713	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.	Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Bollini M, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	MedChemComm	2014	5	4	468	473		10.1039/C3MD00247K	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase	Wu H, Pannecouque C, Yan Z, Chen W, He Q, Chen F, Balzarini J, Daelemans D, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2014	57	12	5169	5178	24805780	10.1021/jm500139a	Synthesis of novel fluoro analogues of MKC442 as microbicides.	Loksha YM, Pedersen EB, Loddo R, Sanna G, Collu G, Giliberti G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J. Med. Chem.	2014	57	23	9945	9957	25418038	10.1021/jm5011622	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Riveira-Muñoz E, Esté JA, Ferretti R, Cirilli R, Zamperini C, Botta M, Schols D, Limongelli V, Agostino B, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J Pharmacol Toxicol Methods	2014	70		246	254	25087753	10.1016/j.vascn.2014.07.002	Prediction of Thorough QT study results using action potential simulations based on ion channel screens.	Mirams GR, Davies MR, Brough SJ, Bridgland-Taylor MH, Cui Y, Gavaghan DJ, Abi-Gerges N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2014	76		531	538	24602795	10.1016/j.ejmech.2014.02.047	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.	Wang J, Zhan P, Li Z, Liu H, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2014	80		101	111	24769348	10.1016/j.ejmech.2014.04.027	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Clotet B, Esté JA, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2015	102		215	222	26276435	10.1016/j.ejmech.2015.08.007	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.	Wan ZY, Yao J, Mao TQ, Wang XL, Wang HF, Chen WX, Yin H, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2015	23	13	3860	3868	25907370	10.1016/j.bmc.2015.03.037	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.	Mao TQ, He QQ, Wan ZY, Chen WX, Chen FE, Tang GF, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2015	23	15	4248	4255	26162497	10.1016/j.bmc.2015.06.048	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Wan ZY, Tao Y, Wang YF, Mao TQ, Yin H, Chen FE, Piao HR, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2015	23	20	6587	6593	26385446	10.1016/j.bmc.2015.09.020	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.	Gu SX, Qiao H, Zhu YY, Shu QC, Liu H, Ju XL, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2015	97		1	9	25935383	10.1016/j.ejmech.2015.04.050	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wan ZY, Yao J, Tao Y, Mao TQ, Wang XL, Lu YP, Wang HF, Yin H, Wu Y, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2016	109		294	304	26802545	10.1016/j.ejmech.2015.11.039	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.	Yang J, Chen W, Kang D, Lu X, Li X, Liu Z, Huang B, Daelemans D, Pannecouque C, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur J Med Chem	2016	121		352	363	27267005	10.1016/j.ejmech.2016.05.054	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.	Chen W, Zhan P, Daelemans D, Yang J, Huang B, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur J Med Chem	2016	122		185	195	27371922	10.1016/j.ejmech.2016.06.026	Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.	¿imon P, Baszczy¿ski O, ¿aman D, Stepan G, Hu E, Lansdon EB, Jansa P, Janeba Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2016	24	11	2476	2485	27112451	10.1016/j.bmc.2016.04.010	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.	Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN, Pannecouque C, Naesens L, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J Med Chem	2016	59	17	7991	8007	27541578	10.1021/acs.jmedchem.6b00738	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.	Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur J Med Chem	2017	126		190	201	27750153	10.1016/j.ejmech.2016.10.009	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.	Li X, Gao P, Huang B, Zhou Z, Yu Z, Yuan Z, Liu H, Pannecouque C, Daelemans D, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Eur J Med Chem	2017	130		209	222	28254696	10.1016/j.ejmech.2017.02.047	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.	Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg Med Chem	2017	25	16	4397	4406	28659246	10.1016/j.bmc.2017.06.022	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.	Huang B, Wang X, Liu X, Chen Z, Li W, Sun S, Liu H, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg Med Chem	2017	25	8	2491	2497	28314514	10.1016/j.bmc.2017.03.009	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.	Lu HH, Xue P, Zhu YY, Ju XL, Zheng XJ, Zhang X, Xiao T, Pannecouque C, Li TT, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg Med Chem Lett	2017	27	12	2788	2792	28465101	10.1016/j.bmcl.2017.04.068	Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.	Wei L, Wang HL, Huang L, Chen CH, Morris-Natschke SL, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	Bioorg Med Chem Lett	2017	27	8	1640	1643	28314598	10.1016/j.bmcl.2017.03.009	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.	Xue P, Lu HH, Zhu YY, Ju XL, Pannecouque C, Zheng XJ, Liu GY, Zhang XL, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J Med Chem	2017	60	10	4424	4443	28481112	10.1021/acs.jmedchem.7b00332	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.	Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954	J Med Chem	2017	60	15	6528	6547	28628334	10.1021/acs.jmedchem.6b01906	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.	Famiglini V, La Regina G, Coluccia A, Masci D, Brancale A, Badia R, Riveira-Muñoz E, Esté JA, Crespan E, Brambilla A, Maga G, Catalano M, Limatola C, Formica FR, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	ETRAVIRINE	CHEMBL308954									WHO Anatomical Therapeutic Chemical Classification	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Med. Chem.	1998	41	6	973	980	9526571	10.1021/jm970701f	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.	Rosenblum SB, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, Burnett DA.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	1998	8	3	313	318	9871676	10.1016/s0960-894x(98)00008-0	Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar.	Vaccaro WD, Davis HR.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2002	12	3	311	314	11814785	10.1016/s0960-894x(01)00750-8	Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.	Burnett DA, Caplen MA, Domalski MS, Browne ME, Davis HR, Clader JW.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2002	12	3	315	318	11814786	10.1016/s0960-894x(01)00752-1	Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.	Burnett DA, Caplen MA, Browne ME, Zhau H, Altmann SW, Davis HR, Clader JW.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Med. Chem.	2004	47	1	1	9	14695813	10.1021/jm030283g	The discovery of ezetimibe: a view from outside the receptor.	Clader JW.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Med. Chem.	2005	48	19	6035	6053	16162006	10.1021/jm050422p	Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption.	Kvaernø L, Werder M, Hauser H, Carreira EM.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2007	17	1	101	104	17049851	10.1016/j.bmcl.2006.09.078	Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions.	Xu X, Fu R, Chen J, Chen S, Bai X.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2008	18	2	546	553	18063367	10.1016/j.bmcl.2007.11.083	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption.	Pfefferkorn JA, Larsen SD, Van Huis C, Sorenson R, Barton T, Winters T, Auerbach B, Wu C, Wolfram TJ, Cai H, Welch K, Esmaiel N, Davis J, Bousley R, Olsen K, Mueller SB, Mertz T.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Eur. J. Med. Chem.	2009	44	4	1638	1643	18990470	10.1016/j.ejmech.2008.09.033	2-Azetidinone derivatives: design, synthesis and evaluation of cholesterol absorption inhibitors.	Wang Y, Zhang H, Huang W, Kong J, Zhou J, Zhang B.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Nat. Prod.	2009	72	1	24	28	19102680	10.1021/np8004453	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.	Yu BZ, Kaimal R, Bai S, El Sayed KA, Tatulian SA, Apitz RJ, Jain MK, Deng R, Berg OG.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2010	20	23	6929	6932	21030254	10.1016/j.bmcl.2010.09.138	Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.	Howell KL, DeVita RJ, Garcia-Calvo M, Meurer RD, Lisnock J, Bull HG, McMasters DR, McCann ME, Mills SG.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Eur. J. Med. Chem.	2010	45	12	5541	5560	20970895	10.1016/j.ejmech.2010.09.035	2-Azetidinone--a new profile of various pharmacological activities.	Mehta PD, Sengar NP, Pathak AK.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Med. Chem.	2011	54	8	2529	2591	21413808	10.1021/jm1013693	Synopsis of some recent tactical application of bioisosteres in drug design.	Meanwell NA.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Drug Metab. Dispos.	2012	40	3	450	460	22112382	10.1124/dmd.111.041095	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.	Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Drug Metab. Dispos.	2012	40	4	825	835	22275465	10.1124/dmd.111.043984	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.	Gill KL, Houston JB, Galetin A.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem.	2013	21	17	5297	5309	23830695	10.1016/j.bmc.2013.06.022	Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.	Karaki F, Ohgane K, Dodo K, Hashimoto Y.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Med Chem Res	2013	22	9	4286	4292		10.1007/s00044-012-0263-z	Synthesis and antihyperlipidemic activity of novel condensed 2-fluoromethylpyrimidines	Kathiravan MK, More KD, Raskar VK, Jain KS, Maheshwar M, Gadhwe S, Jain DP, Nagras MA, Phoujdar MS
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Eur. J. Med. Chem.	2014	87		722	734	25305716	10.1016/j.ejmech.2014.10.014	Novel amino-ß-lactam derivatives as potent cholesterol absorption inhibitors.	Dra¿i¿ T, Mol¿anov K, Sachdev V, Malnar M, He¿imovi¿ S, Patankar JV, Obrowsky S, Levak-Frank S, Habu¿ I, Kratky D.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem.	2015	23	10	2353	2359	25882530	10.1016/j.bmc.2015.03.067	Synthesis and evaluation of novel amide amino-ß-lactam derivatives as cholesterol absorption inhibitors.	Dra¿i¿ T, Sachdev V, Leopold C, Patankar JV, Malnar M, He¿imovi¿ S, Levak-Frank S, Habu¿ I, Kratky D.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg. Med. Chem. Lett.	2016	26	3	849	853	26783178	10.1016/j.bmcl.2015.12.077	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.	Yuan X, Lu P, Xue X, Qin H, Fan C, Wang Y, Zhang Q.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138	Bioorg Med Chem Lett	2017	27	4	1055	1061	28089347	10.1016/j.bmcl.2016.12.058	Virtual screening and experimental validation identify novel modulators of nuclear receptor RXR¿ from Drugbank database.	Xu D, Cai L, Guo S, Xie L, Yin M, Chen Z, Zhou H, Su Y, Zeng Z, Zhang X.
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138									British National Formulary (72nd edition)	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138									PubChem BioAssay data set	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138									Unpublished dataset	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1398.8000000000000000	9606	Homo sapiens	EZETIMIBE	CHEMBL1138									WHO Anatomical Therapeutic Chemical Classification	
882.4000000000000000	9606	Homo sapiens	FAMITINIB	CHEMBL3545026									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	1987	30	10	1787	1793	2888895	10.1021/jm00393a018	Studies on histamine H2 receptor antagonists. 2. Synthesis and pharmacological activities of N-sulfamoyl and N-sulfonyl amidine derivatives.	Yanagisawa I, Hirata Y, Ishii Y.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	1992	35	13	2446	2451	1352351	10.1021/jm00091a012	Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity.	Miyashita M, Matsumoto T, Matsukubo H, Iinuma F, Taga F, Sekiguchi H, Hamada K, Okamura K, Nishino K.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	1994	37	1	57	66	7904648	10.1021/jm00027a007	Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury.	Katsura Y, Inoue Y, Tomishi T, Ishikawa H, Takasugi H.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2000	43	11	2100	2114	10841789	10.1021/jm990322h	Developing a dynamic pharmacophore model for HIV-1 integrase.	Carlson HA, Masukawa KM, Rubins K, Bushman FD, Jorgensen WL, Lins RD, Briggs JM, McCammon JA.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2001	44	6	923	930	11300874	10.1021/jm001020e	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.	Wohnsland F, Faller B.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Bioorg. Med. Chem. Lett.	2003	13	10	1717	1720	12729649	10.1016/s0960-894x(03)00235-x	Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine.	Li L, Kracht J, Peng S, Bernhardt G, Elz S, Buschauer A.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Metab. Dispos.	2004	32	1	479	483	15100168	10.1124/dmd.32.5.479	Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.	Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Eur. J. Pharmacol.	2004	503	1	25	30	15496291	10.1016/j.ejphar.2004.09.032	Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).	Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Pharmacol. Exp. Ther.	2005	316	1	1187	1194	16291876	10.1124/jpet.105.094052	Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.	Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Bioorg. Med. Chem. Lett.	2008	18	23	6202	6205	18951789	10.1016/j.bmcl.2008.10.007	Possible involvement of radical intermediates in the inhibition of cysteine proteases by allenyl esters and amides.	Takeuchi Y, Fujiwara T, Shimone Y, Miyataka H, Satoh T, Kirk KL, Hori H.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Bioorg. Med. Chem.	2010	18	19	7078	7084	20810286	10.1016/j.bmc.2010.08.003	QSAR-based solubility model for drug-like compounds.	Gozalbes R, Pineda-Lucena A.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2010	53	1	392	401	19947605	10.1021/jm901421c	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.	Tam KY, Avdeef A, Tsinman O, Sun N.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Antimicrob. Agents Chemother.	2010	54	9	3597	3604	20547797	10.1128/aac.00431-10	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.	Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	J. Med. Chem.	2013	56	3	781	795	23241029	10.1021/jm301302s	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.	Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									British National Formulary (72nd edition)	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									DrugMatrix	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									Drug metabolism data	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									Open TG-GATES	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									PubChem BioAssay data set	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	FAMOTIDINE	CHEMBL902									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	FENFLURAMINE HYDROCHLORIDE	CHEMBL2106217	J. Med. Chem.	1978	21	5	460	464	660590	10.1021/jm00203a010	3-Aryl- and 3-hydroxy-3-aryloctahydropyrido[2,1-c][1,4]oxazines. Synthesis, stereochemistry, and central nervous system pharmacological actions.	Rankin GO, Riley TN, Murphy JC.
1098.4250000000000000	9606	Homo sapiens	FENFLURAMINE HYDROCHLORIDE	CHEMBL2106217									British National Formulary (72nd edition)	
1098.4250000000000000	9606	Homo sapiens	FENFLURAMINE HYDROCHLORIDE	CHEMBL2106217									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	FENFLURAMINE HYDROCHLORIDE	CHEMBL2106217									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2007	51	8	2716	2719	17517836	10.1128/aac.01623-06	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.	Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2008	52	11	4163	4165	18725442	10.1128/aac.00476-08	In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.	Karlowsky JA, Laing NM, Zhanel GG.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2009	53	1	223	228	18955525	10.1128/aac.01442-07	Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.	Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2009	53	1	261	263	18955523	10.1128/aac.01443-07	OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.	Louie TJ, Emery J, Krulicki W, Byrne B, Mah M.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2010	54	5	2273	2275	20308391	10.1128/aac.00090-10	In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.	Biedenbach DJ, Ross JE, Putnam SD, Jones RN.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Antimicrob. Agents Chemother.	2010	54	6	2674	2676	20308366	10.1128/aac.01842-09	Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.	Babakhani F, Seddon J, Robert N, Shue YK, Sears P.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800	Bioorg. Med. Chem. Lett.	2014	24	2	595	600	24360560	10.1016/j.bmcl.2013.12.015	Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.	Chen C, Dolla NK, Casadei G, Bremner JB, Lewis K, Kelso MJ.
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800									British National Formulary (72nd edition)	
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800									Unpublished dataset	
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1084.5000000000000000	1496	Clostridium difficile	FIDAXOMICIN	CHEMBL1255800									WHO Anatomical Therapeutic Chemical Classification	
1146.4083333333333333	9606	Homo sapiens	FIMEPINOSTAT	CHEMBL3622533	ACS Med. Chem. Lett.	2015	6	8	948	952	26288699	10.1021/acsmedchemlett.5b00128	High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma.	Quartararo CE, Reznik E, deCarvalho AC, Mikkelsen T, Stockwell BR.
1146.4083333333333333	9606	Homo sapiens	FIMEPINOSTAT	CHEMBL3622533	J. Med. Chem.	2016	59	11	5488	5504	27186676	10.1021/acs.jmedchem.6b00579	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.	Chen Y, Wang X, Xiang W, He L, Tang M, Wang F, Wang T, Yang Z, Yi Y, Wang H, Niu T, Zheng L, Lei L, Li X, Song H, Chen L.
1146.4083333333333333	9606	Homo sapiens	FIMEPINOSTAT	CHEMBL3622533									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	FIMEPINOSTAT	CHEMBL3622533									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	FLUMATINIB	CHEMBL3545413									Unpublished dataset	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308	J. Med. Chem.	1979	22	4	356	359	219196	10.1021/jm00190a005	3-Substituted pyrazole derivatives as inhibitors and inactivators of liver alcohol dehydrogenase.	Fries RW, Bohlken DP, Plapp BV.
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308	J. Med. Chem.	1986	29	5	615	620	2939242	10.1021/jm00155a005	A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.	Hansch C, Klein T, McClarin J, Langridge R, Cornell NW.
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									DrugMatrix	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									Drug metabolism data	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									PubChem BioAssay data set	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									Unpublished dataset	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1130.8000000000000000	9606	Homo sapiens	FOMEPIZOLE	CHEMBL1308									WHO Anatomical Therapeutic Chemical Classification	
879.7000000000000000	83333	Escherichia coli K-12	FOSFOMYCIN TROMETHAMINE	CHEMBL1200331									Unpublished dataset	
879.7000000000000000	83333	Escherichia coli K-12	FOSFOMYCIN TROMETHAMINE	CHEMBL1200331									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	FROVATRIPTAN SUCCINATE	CHEMBL2138684									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	FROVATRIPTAN SUCCINATE	CHEMBL2138684									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	FROVATRIPTAN SUCCINATE	CHEMBL2138684									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	1991	34	7	2295	2298	2067001	10.1021/jm00111a053	3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.	Silverman RB, Andruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	1993	3	5	813	818		10.1016/S0960-894X(00)80672-1	Evaluation of the intestinal permeability and hepatic handling of peptidomimetic analogs	Hamilton H, Steinbaugh B, Blankley J, Taylor M, Chan O, Stewart B, Schroeder R, Ryan M, Rapundalo S, Cook J, Bernabei A, Stewart C
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	1994	4	6	823	826		10.1016/S0960-894X(01)80855-6	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant.	Yuen P, Kanter GD, Taylor CP, Vartanian MG
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	1997	7	19	2481	2484		10.1016/S0960-894X(97)10002-6	Investigation into the preferred conformation of gabapentin for interaction with its binding site on the 2 subunit of a calcium channel	Bryans JS, Davies N, Gee NS, Horwell DC, Kneen CO, Morrell AI, O'Neill JA, Ratcliffe GS
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	1999	9	16	2329	2334	10476863	10.1016/s0960-894x(99)00383-2	Synthesis and biological evaluation of conformationally restricted Gabapentin analogues.	Receveur JM, Bryans JS, Field MJ, Singh L, Horwell DC.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2003	13	16	2749	2754	12873507	10.1016/s0960-894x(03)00535-3	Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.	Bruno-Blanch L, Gálvez J, García-Domenech R.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2004	14	10	2537	2541	15109646	10.1016/j.bmcl.2004.02.094	Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.	Hong-Ju Y, He L, Wei-Guo S, Nan Z, Wei-Xiu Y, Zhong-Wei J, Jun-Wei W, Zheng-Hua G, Bo-Hua Z, Zhi-Pu L, Zhe-Hui G.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2004	14	8	1913	1916	15050626	10.1016/j.bmcl.2004.01.087	N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels.	Lim J, Stock N, Pracitto R, Boueres JK, Munoz B, Chaudhary A, Santini AM, Orr K, Schaffhauser H, Bezverkov RE, Aiyar J, Venkatraman S.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Xenobiotica	2005	35	2	191	210	16019946	10.1080/00498250400028197	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.	Ward KW, Nagilla R, Jolivette LJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2005	48	7	2294	2307	15801823	10.1021/jm049762l	Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.	Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2006	16	5	1138	1141	16380257	10.1016/j.bmcl.2005.11.108	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels.	Mortell KH, Anderson DJ, Lynch JJ, Nelson SL, Sarris K, McDonald H, Sabet R, Baker S, Honore P, Lee CH, Jarvis MF, Gopalakrishnan M.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2006	16	9	2333	2336	15946842	10.1016/j.bmcl.2005.05.016	Carboxylate bioisosteres of gabapentin.	Burgos-Lepley CE, Thompson LR, Kneen CO, Osborne SA, Bryans JS, Capiris T, Suman-Chauhan N, Dooley DJ, Donovan CM, Field MJ, Vartanian MG, Kinsora JJ, Lotarski SM, El-Kattan A, Walters K, Cherukury M, Taylor CP, Wustrow DJ, Schwarz JB.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Proc. Natl. Acad. Sci. U.S.A.	2007	104	20	8520	8525	17483457	10.1073/pnas.0611364104	A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.	Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2007	50	10	2459	2467	17451232	10.1021/jm061431g	Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.	Yogeeswari P, Ragavendran JV, Sriram D, Nageswari Y, Kavya R, Sreevatsan N, Vanitha K, Stables J.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2007	50	11	2569	2575	17489571	10.1021/jm060650z	Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.	Field MJ, Li Z, Schwarz JB.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2008	16	6	3224	3232	18171618	10.1016/j.bmc.2007.12.015	Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.	Farina C, Gagliardi S, Ghelardini C, Martinelli M, Norcini M, Parini C, Petrillo P, Ronzoni S.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2008	18	9	2830	2835	18430570	10.1016/j.bmcl.2008.04.006	Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.	Worm K, Zhou QJ, Saeui CT, Green RC, Cassel JA, Stabley GJ, DeHaven RN, Conway-James N, LaBuda CJ, Koblish M, Little PJ, Dolle RE.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2008	51	20	6547	6557	18817367	10.1021/jm800670r	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.	Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, Fix-Stenzel SR, McPherson MJ, Adair RM, Wetter JM, Bettencourt BM, Marsh KC, Sullivan JP, Honore P, Esbenshade TA, Brioni JD.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940		2008							Pharmaceutical compositions and their methods of use	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2009	19	1	247	250	19010672	10.1016/j.bmcl.2008.10.101	Oxadiazolone bioisosteres of pregabalin and gabapentin.	Wustrow DJ, Belliotti TR, Capiris T, Kneen CO, Bryans JS, Field MJ, Williams D, El-Kattan A, Buchholz L, Kinsora JJ, Lotarski SM, Vartanian MG, Taylor CP, Donevan SD, Thorpe AJ, Schwarz JB.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2009	44	3	1349	1354	18406016	10.1016/j.ejmech.2008.02.025	Solution-phase parallel synthesis and evaluation of anticonvulsant activity of N-substituted-3,4-dihydroisoquinoline-2(1H)-carboxamides.	Gitto R, Pagano B, Citraro R, Scicchitano F, De Sarro G, Chimirri A.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2009	52	20	6233	6243	19764786	10.1021/jm901036q	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.	Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2009	52	23	7528	7536	19388676	10.1021/jm801432r	Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies.	Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, Malatynska E, White HS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Iannucci R, Leclercq L, Cuyckens F, Reitz AB, Maryanoff BE.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2009	52	9	3010	3017	19378992	10.1021/jm900143u	Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.	Rephaeli A, Gil-Ad I, Aharoni A, Tarasenko I, Tarasenko N, Geffen Y, Halbfinger E, Nisemblat Y, Weizman A, Nudelman A.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2010	18	16	5938	5944	20659804	10.1016/j.bmc.2010.06.082	Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.	Kam YL, Rhee HK, Rhim H, Back SK, Na HS, Choo HY.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2010	20	1	248	251	19910190	10.1016/j.bmcl.2009.10.121	Synthesis and in vivo evaluation of 3,4-disubstituted gababutins.	Blakemore DC, Bryans JS, Carnell P, Field MJ, Kinsella N, Kinsora JK, Meltzer LT, Osborne SA, Thompson LR, Williams SC.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2010	20	1	362	365	19897364	10.1016/j.bmcl.2009.10.089	Synthesis and in vivo evaluation of 3-substituted gababutins.	Blakemore DC, Bryans JS, Carnell P, Chessum NE, Field MJ, Kinsella N, Kinsora JK, Osborne SA, Williams SC.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2010	20	24	7312	7316	21055935	10.1016/j.bmcl.2010.10.068	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.	Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, Shen C.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2010	45	4	1447	1452	20079559	10.1016/j.ejmech.2009.12.049	Synthesis, characterization and in vitro pharmacology of novel pregabalin derivatives.	Horvat S, Hamersak Z, Stipeti¿ I, Jolas T.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2010	53	2	887	896	20020710	10.1021/jm901497b	Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.	Fritch PC, McNaughton-Smith G, Amato GS, Burns JF, Eargle CW, Roeloffs R, Harrison W, Jones L, Wickenden AD.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2010	53	21	7739	7755	20931971	10.1021/jm100828n	Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.	Payne JE, Bonnefous C, Symons KT, Nguyen PM, Sablad M, Rozenkrants N, Zhang Y, Wang L, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2011	21	12	3764	3766	21601457	10.1016/j.bmcl.2011.04.045	Part 1: N-alkylated glycines as potent ¿2¿ ligands.	Thompson LR, Blakemore DC, Brugier D, Bryans JS, Chu WL, Maw GN, Poinsard C, Rawson DJ, Warren AN.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2011	21	12	3767	3770	21550803	10.1016/j.bmcl.2011.04.056	Part 2: Design, synthesis and evaluation of hydroxyproline-derived ¿2¿ ligands.	Rawson DJ, Brugier D, Harrison A, Hough J, Newman J, Otterburn J, Maw GN, Price J, Thompson LR, Turnpenny P, Warren AN.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2011	21	12	3771	3773	21550802	10.1016/j.bmcl.2011.04.058	Part 3: Design and synthesis of proline-derived ¿2¿ ligands.	Rawson DJ, Brugier D, Harrison A, Hough J, Newman J, Otterburn J, Maw GN, Price J, Thompson LR, Turnpenny P, Warren AN.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2011	21	19	5910	5915	21843937	10.1016/j.bmcl.2011.07.087	Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.	Woo HM, Lee YS, Roh EJ, Seo SH, Song CM, Chung HJ, Pae AN, Shin KJ.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Drug Metab. Dispos.	2011	39	3	353	362	21149540	10.1124/dmd.110.035998	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.	Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2011	46	7	2964	2970	21536354	10.1016/j.ejmech.2011.04.021	Discovery of molecules for the treatment of neuropathic pain: synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones.	Yogeeswari P, Menon N, Semwal A, Arjun M, Sriram D.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2012	20	17	5269	5276	22863530	10.1016/j.bmc.2012.06.042	Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent.	Walls TH, Grindrod SC, Beraud D, Zhang L, Baheti AR, Dakshanamurthy S, Patel MK, Brown ML, MacArthur LH.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Med Chem Res	2012	21	12	4357	4368		10.1007/s00044-012-9977-1	Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS	Noorizadeh H, Noorizadeh M, Farmany A
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2012	22	11	3639	3642	22560585	10.1016/j.bmcl.2012.04.051	Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives.	Yamamoto T, Niwa S, Tokumasu M, Onishi T, Ohno S, Hagihara M, Koganei H, Fujita S, Takeda T, Saitou Y, Iwayama S, Takahara A, Iwata S, Shoji M.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2012	22	4	1716	1718	22277280	10.1016/j.bmcl.2011.12.100	Discovery of diphenyl lactam derivatives as N-type calcium channel blockers.	Doherty GA, Bhatia P, Vortherms TA, Marsh KC, Wetter JM, Mack H, Scott VE, Jarvis MF, Stewart AO.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2012	55	22	9847	9855	23098566	10.1021/jm301056k	Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.	Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2013	23	12	3640	3645	23652221	10.1016/j.bmcl.2013.03.121	A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.	Hoyt SB, London C, Abbadie C, Felix JP, Garcia ML, Jochnowitz N, Karanam BV, Li X, Lyons KA, McGowan E, Priest BT, Smith MM, Warren VA, Thomas-Fowlkes BS, Kaczorowski GJ, Duffy JL.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2013	23	22	6188	6191	24070783	10.1016/j.bmcl.2013.08.092	Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain.	Wu YJ, Conway CM, Sun LQ, Machet F, Chen J, Chen P, He H, Bourin C, Calandra V, Polino JL, Davis CD, Heman K, Gribkoff VK, Boissard CG, Knox RJ, Thompson MW, Fitzpatrick W, Weaver D, Harden DG, Natale J, Dworetzky SI, Starrett JE.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2013	23	5	1472	1476	23333207	10.1016/j.bmcl.2012.12.056	Synthesis and biological evaluation of 2-(arylethynyl)quinoline derivatives as mGluR5 antagonists for the treatment of neuropathic pain.	Son MH, Kim JY, Lim EJ, Baek DJ, Choi K, Lee JK, Pae AN, Min SJ, Cho YS.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2013	56	20	7851	7861	24050112	10.1021/jm400766k	New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.	Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2013	56	22	9019	9030	24205976	10.1021/jm400894u	Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).	McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, Maryanoff BE.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2013	64		477	487	23676307	10.1016/j.ejmech.2013.04.019	Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted)benzylidene]hydrazinecarbothioamides-a potential anticonvulsant approach.	Tripathi L, Kumar P.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2013	66		211	220	23807113	10.1016/j.ejmech.2013.05.022	Discovery of novel tetrahydro-pyrazolo [4,3-c] pyridines for the treatment of neuropathic pain: synthesis and neuropharmacology.	Yogeeswari P, Sharma M, Samala G, Gangadhar M, Karthick S, Mallipeddi S, Semwal A, Sriram D.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem.	2014	22	4	1479	1486	24468631	10.1016/j.bmc.2013.12.017	Gabapentin hybrid peptides and bioconjugates.	Lebedyeva IO, Ostrov DA, Neubert J, Steel PJ, Patel K, Sileno SM, Goncalves K, Ibrahim MA, Alamry KA, Katritzky AR.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg. Med. Chem. Lett.	2015	25	6	1324	1328	25677662	10.1016/j.bmcl.2015.01.035	Synthesis and biological evaluation of aryl isoxazole derivatives as metabotropic glutamate receptor 1 antagonists: a potential treatment for neuropathic pain.	Cho GH, Kim T, Son WS, Seo SH, Min SJ, Cho YS, Keum G, Jeong KS, Koh HY, Lee J, Pae AN.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	ACS Med. Chem. Lett.	2015	6	6	641	644	26101566	10.1021/acsmedchemlett.5b00023	Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.	Zhang Q, Xia Z, Joshi S, Scott VE, Jarvis MF.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	ACS Med. Chem. Lett.	2015	6	7	804	808	26191370	10.1021/acsmedchemlett.5b00150	Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.	Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Nat. Prod.	2015	78	12	2887	2895	26599832	10.1021/acs.jnatprod.5b00456	Antinociceptive Grayanoids from the Roots of Rhododendron molle.	Li Y, Liu YB, Zhang JJ, Liu Y, Ma SG, Qu J, Lv HN, Yu SS.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur. J. Med. Chem.	2015	97		245	258	25984841	10.1016/j.ejmech.2015.04.060	Discovery and biological evaluation of tetrahydrothieno[2,3-c]pyridine derivatives as selective metabotropic glutamate receptor 1 antagonists for the potential treatment of neuropathic pain.	Nam M, Kim T, Kwak J, Seo SH, Ko MK, Lim EJ, Min SJ, Cho YS, Keum G, Baek DJ, Lee J, Pae AN.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Eur J Med Chem	2016	123		665	672	27517811	10.1016/j.ejmech.2016.07.032	Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment.	Kim JH, Keum G, Chung H, Nam G.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J. Med. Chem.	2016	59	8	3953	3963	27022999	10.1021/acs.jmedchem.6b00132	Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain.	Huang B, Zhang F, Yu G, Song Y, Wang X, Wang M, Gong Z, Su R, Jia Y.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg Med Chem	2017	25	17	4677	4685	28720324	10.1016/j.bmc.2017.07.008	Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives.	Hong JR, Choi YJ, Keum G, Nam G.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg Med Chem	2017	25	20	5490	5505	28818462	10.1016/j.bmc.2017.08.012	Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.	Wu YJ, Guernon J, McClure A, Luo G, Rajamani R, Ng A, Easton A, Newton A, Bourin C, Parker D, Mosure K, Barnaby O, Soars MG, Knox RJ, Matchett M, Pieschl R, Herrington J, Chen P, Sivarao DV, Bristow LJ, Meanwell NA, Bronson J, Olson R, Thompson LA, Dzierba C.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	Bioorg Med Chem Lett	2017	27	17	4146	4149	28729057	10.1016/j.bmcl.2017.07.031	Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT6 receptor antagonists.	Hong JR, Choo H, Nam G.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940	J Med Chem	2017	60	18	7799	7809	28759215	10.1021/acs.jmedchem.7b00825	Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain.	Rais R, Vávra J, Tichý T, Dash RP, Gadiano AJ, Tenora L, Monincová L, Ba¿inka C, Alt J, Zimmermann SC, Slusher CE, Wu Y, Wozniak K, Majer P, Tsukamoto T, Slusher BS.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									British National Formulary (72nd edition)	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									DrugMatrix	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									PubChem BioAssay data set	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN	CHEMBL940									WHO Anatomical Therapeutic Chemical Classification	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN ENACARBIL	CHEMBL1628502	Bioorg. Med. Chem.	2014	22	4	1479	1486	24468631	10.1016/j.bmc.2013.12.017	Gabapentin hybrid peptides and bioconjugates.	Lebedyeva IO, Ostrov DA, Neubert J, Steel PJ, Patel K, Sileno SM, Goncalves K, Ibrahim MA, Alamry KA, Katritzky AR.
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN ENACARBIL	CHEMBL1628502									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	GABAPENTIN ENACARBIL	CHEMBL1628502									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	J. Nat. Prod.	1999	62	2	386	388	10075797	10.1021/np980411h	Antifungal and antibacterial metabolites from a sclerotium-colonizing isolate of Mortierella vinacea.	Soman AG, Gloer JB, Wicklow DT.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	J. Nat. Prod.	1999	62	5	730	733	10346956	10.1021/np980530x	New verticillin and glisoprenin analogues from gliocladium catenulatum, a mycoparasite of aspergillus flavus sclerotia	Joshi BK, Gloer JB, Wicklow DT.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Phytochemistry	2005	66	2	241	247	15652581	10.1016/j.phytochem.2004.11.016	Bioactive ellagitannins from Cunonia macrophylla, an endemic Cunoniaceae from New Caledonia.	Fogliani B, Raharivelomanana P, Bianchini JP, Bouraïma-Madjèbi S, Hnawia E.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem. Lett.	2006	16	14	3824	3828	16650986	10.1016/j.bmcl.2006.04.020	Synthesis and antibacterial evaluation of ureides of Baylis-Hillman derivatives.	Nag S, Pathak R, Kumar M, Shukla PK, Batra S.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem. Lett.	2006	16	24	6310	6315	16997553	10.1016/j.bmcl.2006.09.013	Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.	Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, Ben-Yosef T, Baasov T.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem.	2007	15	5	2032	2044	17223562	10.1016/j.bmc.2006.12.035	Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents.	Ertan T, Yildiz I, Ozkan S, Temiz-Arpaci O, Kaynak F, Yalcin I, Aki-Sener E, Abbasoglu U.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Eur. J. Med. Chem.	2008	43	7	1423	1431	18023934	10.1016/j.ejmech.2007.09.023	Synthesis and biological activity of some new benzoxazoles.	Temiz-Arpaci O, Yildiz I, Ozkan S, Kaynak F, Aki-Sener E, Yalçin I.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Eur. J. Med. Chem.	2009	44	2	501	510	18524419	10.1016/j.ejmech.2008.04.001	Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.	Ertan T, Yildiz I, Tekiner-Gulbas B, Bolelli K, Temiz-Arpaci O, Ozkan S, Kaynak F, Yalcin I, Aki E.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem. Lett.	2010	20	14	4252	4258	20621732	10.1016/j.bmcl.2010.05.025	One-pot multicomponent synthesis and anti-microbial evaluation of 2'-(indol-3-yl)-2-oxospiro(indoline-3,4'-pyran) derivatives.	Nandakumar A, Thirumurugan P, Perumal PT, Vembu P, Ponnuswamy MN, Ramesh P.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Eur. J. Med. Chem.	2010	45	3	1078	1086	20034711	10.1016/j.ejmech.2009.12.002	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.	Singh RK, Rai D, Yadav D, Bhargava A, Balzarini J, De Clercq E.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	J. Nat. Prod.	2010	73	3	404	408	19928955	10.1021/np900613d	Hymenopsins A and B and a macrophorin analogue from a fungicolous Hymenopsis sp.	Schmidt LE, Deyrup ST, Baltrusaitis J, Swenson DC, Wicklow DT, Gloer JB.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	MedChemComm	2011	2	3	165	171		10.1039/C0MD00195C	Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations	Kandasamy J, Atia-Glikin D, Belakhov V, Baasov T
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Eur. J. Med. Chem.	2011	46	9	4642	4647	21849221	10.1016/j.ejmech.2011.08.003	Synthesis of novel 6-phenyl-2,4-disubstituted pyrimidine-5-carbonitriles as potential antimicrobial agents.	Al-Abdullah ES, Al-Obaid AR, Al-Deeb OA, Habib EE, El-Emam AA.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	J. Nat. Prod.	2011	74	3	395	401	21247198	10.1021/np100791b	Phomalevones A-C: dimeric and pseudodimeric polyketides from a fungicolous Hawaiian isolate of Phoma sp. (Cucurbitariaceae).	Shim SH, Baltrusaitis J, Gloer JB, Wicklow DT.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Med Chem Res	2012	21	11	3818	3825		10.1007/s00044-011-9918-4	Synthesis of novel 2-[4-(4-substitutedbenzamido/phenylacetamido)phenyl]benzothiazoles as antimicrobial agents	Bolelli K, Yalcin I, Ertan-Bolelli T, Ozgen S, Kaynak-Onurdag F, Yildiz I, Aki E
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	J. Med. Chem.	2012	55	23	10630	10643	23148581	10.1021/jm3012992	Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.	Kandasamy J, Atia-Glikin D, Shulman E, Shapira K, Shavit M, Belakhov V, Baasov T.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Med Chem Res	2013	22	9	4096	4109		10.1007/s00044-012-0408-0	Synthesis, biological evaluation and QSAR study of a series of substituted quinazolines as antimicrobial agents	Buha VM, Rana DN, Chhabria MT, Chikhalia KH, Mahajan BM, Brahmkshatriya PS, Shah NK
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem. Lett.	2014	24	7	1719	1723	24630564	10.1016/j.bmcl.2014.02.044	Synthesis and evaluation of new diaryl ether and quinoline hybrids as potential antiplasmodial and antimicrobial agents.	Mishra A, Batchu H, Srivastava K, Singh P, Shukla PK, Batra S.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594	Bioorg. Med. Chem. Lett.	2015	25	4	898	903	25592711	10.1016/j.bmcl.2014.12.066	Synthesis, antimicrobial activity and molecular docking of novel tetracyclic scaffolds incorporating a flavonoid framework with medium sized oxygen heterocycles.	Dongamanti A, Aamate VK, Devulapally MG, Gundu S, Kotni MK, Manga V, Balasubramanian S, Ernala P.
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594									Unpublished dataset	
2219.8000000000000000	2	Bacteria	GENTAMICIN SULFATE	CHEMBL3039594									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1296.7000000000000000	9606	Homo sapiens	GRC-15300	CHEMBL3707319									Unpublished dataset	
851.6000000000000000	9606	Homo sapiens	GRC-17536	CHEMBL3707318									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	GSK163090	CHEMBL1631540	J. Med. Chem.	2010	53	23	8228	8240	21053897	10.1021/jm100714c	Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.	Leslie CP, Biagetti M, Bison S, Bromidge SM, Di Fabio R, Donati D, Falchi A, Garnier MJ, Jaxa-Chamiec A, Manchee G, Merlo G, Pizzi DA, Stasi LP, Tibasco J, Vong A, Ward SE, Zonzini L.
1098.4250000000000000	9606	Homo sapiens	GSK163090	CHEMBL1631540									Unpublished dataset	
853.5000000000000000	9606	Homo sapiens	GUANIDINE HYDROCHLORIDE	CHEMBL1200728	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
853.5000000000000000	9606	Homo sapiens	GUANIDINE HYDROCHLORIDE	CHEMBL1200728	Bioorg. Med. Chem. Lett.	2014	24	24	5576	5580	25466178	10.1016/j.bmcl.2014.11.004	Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR.	Zeiger M, Stark S, Kalden E, Ackermann B, Ferner J, Scheffer U, Shoja-Bazargani F, Erdel V, Schwalbe H, Göbel MW.
853.5000000000000000	9606	Homo sapiens	GUANIDINE HYDROCHLORIDE	CHEMBL1200728									British National Formulary (72nd edition)	
853.5000000000000000	9606	Homo sapiens	GUANIDINE HYDROCHLORIDE	CHEMBL1200728									Unpublished dataset	
1769.8333333333333333	9606	Homo sapiens	HUMAX-CD38	CHEMBL2109269									Unpublished dataset	
1769.8333333333333333	9606	Homo sapiens	HUMAX-IL15	CHEMBL2109468									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.9000000000000000	9606	Homo sapiens	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705									British National Formulary (72nd edition)	
886.9000000000000000	9606	Homo sapiens	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	HYDROXYAMPHETAMINE HYDROBROMIDE	CHEMBL1200705									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297	Bioorg. Med. Chem. Lett.	2012	22	14	4750	4755	22695126	10.1016/j.bmcl.2012.05.067	Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.	Curtin ML, Heyman HR, Frey RR, Marcotte PA, Glaser KB, Jankowski JR, Magoc TJ, Albert DH, Olson AM, Reuter DR, Bouska JJ, Montgomery DA, Palma JP, Donawho CK, Stewart KD, Tse C, Michaelides MR.
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297	Bioorg. Med. Chem. Lett.	2012	22	9	3208	3212	22465635	10.1016/j.bmcl.2012.03.035	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.	Curtin ML, Frey RR, Heyman HR, Soni NB, Marcotte PA, Pease LJ, Glaser KB, Magoc TJ, Tapang P, Albert DH, Osterling DJ, Olson AM, Bouska JJ, Guan Z, Preusser LC, Polakowski JS, Stewart KD, Tse C, Davidsen SK, Michaelides MR.
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297	ACS Med. Chem. Lett.	2012	3	5	383	386	24900482	10.1021/ml300012r	Targeted kinase selectivity from kinase profiling data.	Milletti F, Hermann JC.
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297		2014							Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile	
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297									PubChem BioAssay data set	
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297									Unpublished dataset	
958.4000000000000000	9606	Homo sapiens	ILORASERTIB	CHEMBL1980297									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	IMAGABALIN	CHEMBL2103836									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	IMAGABALIN	CHEMBL2103836									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	J. Pharmacol. Exp. Ther.	2003	307	1	824	828	12975485	10.1124/jpet.103.055574	Interaction of imatinib mesilate with human P-glycoprotein.	Hamada A, Miyano H, Watanabe H, Saito H.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Blood	2004	104	1	2940	2942	15251980	10.1182/blood-2004-04-1398	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.	Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Cancer Res.	2004	64	1	2333	2337	15059881	10.1158/0008-5472.can-03-3344	Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.	Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Bioorg. Med. Chem. Lett.	2006	16	14	3789	3792	16678414	10.1016/j.bmcl.2006.04.043	3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.	McBride CM, Renhowe PA, Gesner TG, Jansen JM, Lin J, Ma S, Zhou Y, Shafer CM.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Proc. Natl. Acad. Sci. U.S.A.	2007	104	51	20523	20528	18077363	10.1073/pnas.0708800104	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	J. Biol. Chem.	2007	282	6	3428	3432	17178722	10.1074/jbc.c600277200	Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.	Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Eur. J. Med. Chem.	2008	43	11	2386	2394	18339455	10.1016/j.ejmech.2008.01.007	Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.	Maggio B, Raffa D, Raimondi MV, Cascioferro S, Plescia F, Tolomeo M, Barbusca E, Cannizzo G, Mancuso S, Daidone G.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642		2008							Substituted tricyclic compounds as protein kinase inhibitors	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	ACS Med. Chem. Lett.	2010	1	7	306	310	24900212	10.1021/ml100062z	Targeting the c-Kit Promoter G-quadruplexes with 6-Substituted Indenoisoquinolines.	Bejugam M, Gunaratnam M, Müller S, Sanders DA, Sewitz S, Fletcher JA, Neidle S, Balasubramanian S.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Eur. J. Med. Chem.	2011	46	12	5817	5824	22000207	10.1016/j.ejmech.2011.09.039	Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents.	Kamal A, Dastagiri D, Ramaiah MJ, Reddy JS, Bharathi EV, Reddy MK, Sagar MV, Reddy TL, Pushpavalli SN, Pal-Bhadra M.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642		2012							Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Bioorg. Med. Chem.	2013	21	17	5145	5153	23867390	10.1016/j.bmc.2013.06.040	Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.	Salerno L, Pittalà V, Romeo G, Modica MN, Siracusa MA, Di Giacomo C, Acquaviva R, Barbagallo I, Tibullo D, Sorrenti V.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	Drug Metab. Dispos.	2013	41	1	50	59	23028140	10.1124/dmd.112.048017	Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.	Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642	J Med Chem	2017	60	3	1189	1209	28075592	10.1021/acs.jmedchem.6b01745	Total Syntheses and Biological Activities of Vinylamycin Analogues.	Wang J, Kuang B, Guo X, Liu J, Ding Y, Li J, Jiang S, Liu Y, Bai F, Li L, Zhang Q, Zhu XY, Xia B, Li CQ, Wang L, Yang G, Chen Y.
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									British National Formulary (72nd edition)	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									Drug metabolism data	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									Open TG-GATES	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									PubChem BioAssay data set	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	IMATINIB MESYLATE	CHEMBL1642									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
882.4000000000000000	9606	Homo sapiens	IMC-3C5	CHEMBL2109602									Unpublished dataset	
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	J. Med. Chem.	1992	35	10	1828	1839	1588561	10.1021/jm00088a019	Dual-action penems and carbapenems.	Corraz AJ, Dax SL, Dunlap NK, Georgopapadakou NH, Keith DD, Pruess DL, Rossman PL, Then R, Unowsky J, Wei CC.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1993	3	11	2165	2170		10.1016/S0960-894X(01)80919-7	Activity of new penems against defined MRSA strains	Jabes D, Rossi R, Bruna CD, Perrone E, Alpegiani M, Andreini BP, Visentin G, Zarini F, Franceschi G
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1993	3	11	2187	2192		10.1016/S0960-894X(01)80923-9	The synthesis and antibacterial activity of 2-para-quarternary ammoniomethylphenyl-carbapenems.	DiNinno F, Muthard DA, Salzmann TN
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1995	5	21	2535	2540		10.1016/0960-894X(95)00445-Y	Tricyclic -lactams: total synthesis and antibacterial activity of 5- and 5-methoxy-tribactams	Hanessian S, Rozema MJ, Reddy G, Braganza JF
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1996	6	22	2705	2708		10.1016/S0960-894X(96)00495-7	Synthesis and biological evaluation of novel 2-vinyl carbapenems. Remarkable DHP-1 stability of 1-substituted analogs	Yamada A, Hattori K, Kuroda S, Chiba T, Kamimura T, Sakane K
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1996	6	4	491	496		10.1016/0960-894X(96)00056-X	Synthesis and antibacterial activity of 4- and 8-methoxy trinems	Andreotti D, Rossi T, Gaviraghi G, Donati D, Marchioro C, Modugno ED, Perboni A
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1996	6	5	525	528		10.1016/0960-894X(96)00061-3	Synthesis and biological activity of novel tricyclic -lactams	Biondi S, Gaviraghi G, Rossi T
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	1997	7	13	1665	1670		10.1016/S0960-894X(97)00281-3	Peptidic prodrugs of novel aminomethyl-THF 1-methylcarbapenems	Lin Y, Bitha P, Sakya SM, Li Z, Lang SA, Yang Y, Bhachech N, Weiss WJ, Petersen PJ, Jacobus NV, Bush K, Testa RT
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	2000	10	2	109	113	10673091	10.1016/s0960-894x(99)00657-5	Structure-activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems. Part 1: J-111,347 and related compounds.	Imamura H, Ohtake N, Shimizu A, Jona H, Sato H, Nagano R, Ushijima R, Yamada K, Hashizume T, Morishima H.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	2000	10	2	115	118	10673092	10.1016/s0960-894x(99)00656-3	Structure-activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenems. Part 2: J-111,225, J-114,870, J-114,871 and related compounds.	Imamura H, Ohtake N, Shimizu A, Sato H, Sugimoto Y, Sakuraba S, Kiyonaga H, Suzuki-Sato C, Nakano M, Nagano R, Yamada K, Hashizume T, Morishima H.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	J. Med. Chem.	2000	43	20	3632	3640	11020277	10.1021/jm000213z	Design, synthesis, and SAR of novel carbapenem antibiotics with high stability to Xanthomonas maltophilia oxyiminocephalosporinase type II.	Hakimelahi GH, Moosavi-Movahedi AA, Tsay SC, Tsai FY, Wright JD, Dudev T, Hakimelahi S, Lim C.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	2001	11	17	2397	2399	11527740	10.1016/s0960-894x(01)00451-6	Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.	Shin KJ, Koo KD, Yoo KH, Kang YK, Park SW, Kim DJ.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Bioorg. Med. Chem. Lett.	2003	13	3	463	466	12565951	10.1016/s0960-894x(02)00948-4	Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.	Kang YK, Lee KS, Yoo KH, Shin KJ, Kim DC, Lee CS, Kong JY, Kim DJ.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708									Unpublished dataset	
962.7500000000000000	2	Bacteria	IMIPENEM	CHEMBL43708									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1878.0666666666666667	9606	Homo sapiens	INTETUMUMAB	CHEMBL1743032									Unpublished dataset	
1878.0666666666666667	9606	Homo sapiens	INTETUMUMAB	CHEMBL1743032									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	IRX4310	CHEMBL3545173									Unpublished dataset	
1769.8333333333333333	9606	Homo sapiens	ISATUXIMAB	CHEMBL3545131									Unpublished dataset	
1769.8333333333333333	9606	Homo sapiens	ISATUXIMAB	CHEMBL3545131									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Pharm. Sci	1974	63	8	1191	1197	4851320	10.1002/jps.2600630804	Determination of isoniazid and metabolites in biological fluids.	Boxenbaum HG, Riegelman S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1976	19	4	483	492	817022	10.1021/jm00226a007	Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.	Seydel JK, Schaper KJ, Wempe E, Cordes HP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1976	19	4	524	530	1263204	10.1021/jm00226a016	Syntheses of heterocylic fused thiazole acetic acids. 2.	Bell SC, Wei PH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1978	21	4	403	405	650670	10.1021/jm00202a020	Antitubercular 2,8-bis(alkylaminomethyl)phenazines.	Murdock KC, Lin Y, Thomas JP, Lang SA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1981	24	11	1314	1319	7310807	10.1021/jm00143a011	Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2,5-cyclohexadienes.	Johnson RE, Soria AE, O'Connor JR, Dobson RA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1985	28	12	1772	1779	3934384	10.1021/jm00150a006	Synthesis and antibacterial activity of 2,2'-dithiobis(benzamide) derivatives against Mycobacterium species.	Okachi R, Niino H, Kitaura K, Mineura K, Nakamizo Y, Murayama Y, Ono T, Nakamizo A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1985	28	5	653	660	2985785	10.1021/jm50001a020	Orally active and potent inhibitors of gamma-aminobutyric acid uptake.	Ali FE, Bondinell WE, Dandridge PA, Frazee JS, Garvey E, Girard GR, Kaiser C, Ku TW, Lafferty JJ, Moonsammy GI.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1988	31	4	802	806	3127589	10.1021/jm00399a021	Inhibition of copper-dependent amine oxidases by some hydrazides of pyrrol-1-ylbenzoic and pyrrol-1-ylphenylacetic acids.	Artico M, Corelli F, Massa S, Stefancich G, Avigliano L, Befani O, Marcozzi G, Sabatini S, Mondovi B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1989	32	11	2421	2426	2509708	10.1021/jm00131a002	Synthesis and antitubercular activity of N-(2-naphthyl)glycine hydrazide analogues.	Ramamurthy B, Bhatt MV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1996	39	3	680	685	8576910	10.1021/jm950956y	Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.	Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	1997	60	11	1210	1213	9392889	10.1021/np970182j	Antimycobacterial polyynes of Devil's Club (Oplopanax horridus), a North American native medicinal plant.	Kobaisy M, Abramowski Z, Lermer L, Saxena G, Hancock RE, Towers GH, Doxsee D, Stokes RW.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	1997	60	12	1275	1280	9428161	10.1021/np9700681	Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity.	Ulubelen A, Topcu G, Johansson CB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	1998	41	13	2436	2438	9632376	10.1021/jm9708745	Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids.	Wächter GA, Davis MC, Martin AR, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	1998	8	12	1493	1498	9873376	10.1016/s0960-894x(98)00248-0	N-[4-(1,1'-biphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480.	Artico M, Mai A, Sbardella G, Massa S, Lampis G, Deidda D, Pompei R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	1998	8	20	2931	2936	9873650	10.1016/s0960-894x(98)00526-5	Pyrrolnitrin and related pyrroles endowed with antibacterial activities against Mycobacterium tuberculosis.	Di Santo R, Costi R, Artico M, Massa S, Lampis G, Deidda D, Pompei R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	1998	8	7	843	846	9871552	10.1016/s0960-894x(98)00126-7	Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro.	Davis MC, Franzblau SG, Martin AR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	1999	9	20	2983	2988	10571160	10.1016/s0960-894x(99)00510-7	New pyrrole derivatives as antimycobacterial agents analogs of BM212.	Biava M, Fioravanti R, Porretta GC, Deidda D, Maullu C, Pompei R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2000	10	10	1043	1045	10843212	10.1016/s0960-894x(00)00159-1	Antimycobacterial activity of ionic fullerene derivatives.	Bosi S, Da Ros T, Castellano S, Banfi E, Prato M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2000	10	7	657	660	10762047	10.1016/s0960-894x(00)00058-5	Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9.	Bottari B, Maccari R, Monforte F, Ottanà R, Rotondo E, Vigorita MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Nature	2000	405	6789	962	966	10879539	10.1038/35016103	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.	Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2000	43	17	3304	3314	10966749	10.1021/jm000149l	A new class of antituberculosis agents.	Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, Townsend CA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2001	11	3	301	303	11212096	10.1016/s0960-894x(00)00648-x	Antimycobacterial in vitro activity of cobalt(II) isonicotinoylhydrazone complexes. Part 10.	Bottari B, Maccari R, Monforte F, Ottanà R, Rotondo E, Vigorita MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2001	44	10	1560	1563	11334565	10.1021/jm000350w	Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2.	Gezginci MH, Martin AR, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2001	64	10	1348	1349	11678665	10.1021/np0102509	Polyacetylene carboxylic acids from Mitrephora celebica.	Zgoda JR, Freyer AJ, Killmer LB, Porter JR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2001	64	3	385	388	11277765	10.1021/np0004404	Potent antiviral potamogetonyde and potamogetonol, new furanoid labdane diterpenes from Potamogeton malaianus.	Kittakoop P, Wanasith S, Watts P, Kramyu J, Tanticharoen M, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2001	64	8	1015	1018	11520217	10.1021/np010006h	Phomoxanthones A and B, novel xanthone dimers from the endophytic fungus Phomopsis species.	Isaka M, Jaturapat A, Rukseree K, Danwisetkanjana K, Tanticharoen M, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2002	12	22	3275	3278	12392731	10.1016/s0960-894x(02)00697-2	Heterocyclic benzazole derivatives with antimycobacterial in vitro activity.	Kocí J, Klimesová V, Waisser K, Kaustová J, Dahse HM, Möllmann U.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metab. Dispos.	2002	30	1	838	844	12065443	10.1124/dmd.30.7.838	Tissue distribution and chemical induction of multiple drug resistance genes in rats.	Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2002	45	16	3331	3336	12139444	10.1021/jm020891g	Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity.	Solaja BA, Terzi¿ N, Pocsfalvi G, Gerena L, Tinant B, Opsenica D, Milhous WK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2002	65	11	1554	1559	12444676	10.1021/np020198w	Antimicrobial resveratrol tetramers from the stem bark of Vatica oblongifoliassp. oblongifolia.	Zgoda-Pols JR, Freyer AJ, Killmer LB, Porter JR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2002	65	9	1346	1348	12350163	10.1021/np020055+	Hirsutellide A, a new antimycobacterial cyclohexadepsipeptide from the entomopathogenic fungus Hirsutella kobayasii.	Vongvanich N, Kittakoop P, Isaka M, Trakulnaleamsai S, Vimuttipong S, Tanticharoen M, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64		2002							Inha inhibitors and methods of use thereof	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2003	13	10	1755	1757	12729658	10.1016/s0960-894x(03)00241-5	Anilinopyrimidines as novel antituberculosis agents.	Morgan J, Haritakul R, Keller PA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2003	13	17	2829	2832	14611838	10.1016/s0960-894x(03)00596-1	Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin.	Hotoda H, Furukawa M, Daigo M, Murayama K, Kaneko M, Muramatsu Y, Ishii MM, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Harasaki T, Fukuoka T, Utsui Y, Ohya S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2003	13	17	2833	2836	14611839	10.1016/s0960-894x(03)00597-3	Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.	Hotoda H, Daigo M, Furukawa M, Murayama K, Hasegawa CA, Kaneko M, Muramatsu Y, Ishii MM, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Fukuoka T, Utsui Y, Ohya S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2003	13	7	1253	1255	12657257	10.1016/s0960-894x(03)00111-2	Antimycobacterial pimarane diterpenes from the Fungus Diaporthe sp.	Dettrakul S, Kittakoop P, Isaka M, Nopichai S, Suyarnsestakorn C, Tanticharoen M, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2003	46	12	2397	2403	12773043	10.1021/jm020452h	Synthesis of ethyl 5-phenyl-6-oxa-1-azabicyclo[3.1.0]hexane-2-carboxylate derivatives and evaluation of their antimalarial activities.	Ningsanont N, Black DS, Chanphen R, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2003	66	4	540	543	12713411	10.1021/np0204489	Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum.	Chumkaew P, Karalai C, Ponglimanont C, Chantrapromma K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2003	66	5	709	711	12762815	10.1021/np0205598	Antimalarial dihydroisocoumarins produced by Geotrichum sp., an endophytic fungus of Crassocephalum crepidioides.	Kongsaeree P, Prabpai S, Sriubolmas N, Vongvein C, Wiyakrutta S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2003	66	6	868	870	12828479	10.1021/np030067a	New antimycobacterial and antimalarial 8,9-secokaurane diterpenes from Croton kongensis.	Thongtan J, Kittakoop P, Ruangrungsi N, Saenboonrueng J, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2004	14	15	3923	3924	15225698	10.1016/j.bmcl.2004.05.060	Antituberculous activity of some aryl semicarbazone derivatives.	Sriram D, Yogeeswari P, Thirumurugan R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2004	14	23	5731	5733	15501030	10.1016/j.bmcl.2004.09.052	In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.	Maccari R, Ottanà R, Bottari B, Rotondo E, Vigorita MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2004	14	6	1537	1541	15006398	10.1016/j.bmcl.2004.01.010	Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.	Sbardella G, Mai A, Artico M, Loddo R, Setzu MG, La Colla P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2004	47	13	3455	3461	15189042	10.1021/jm030479g	Novel pyridazino[4,3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase.	Velezheva VS, Brennan PJ, Marshakov VY, Gusev DV, Lisichkina IN, Peregudov AS, Tchernousova LN, Smirnova TG, Andreevskaya SN, Medvedev AE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2004	47	15	3755	3764	15239654	10.1021/jm049913k	Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.	Pasqualoto KF, Ferreira EI, Santos-Filho OA, Hopfinger AJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2004	47	21	5276	5283	15456272	10.1021/jm049972y	Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents.	Tangallapally RP, Yendapally R, Lee RE, Hevener K, Jones VC, Lenaerts AJ, McNeil MR, Wang Y, Franzblau S, Lee RE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2004	67	10	1767	1770	15497961	10.1021/np0498354	Antitubercular sesterterpenes from the Thai sponge Brachiaster sp.	Wonganuchitmeta SN, Yuenyongsawad S, Keawpradub N, Plubrukarn A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2004	67	12	2108	2110	15620264	10.1021/np049706n	Antimycobacterial coumarins from the sardinian giant fennel (Ferula communis).	Appendino G, Mercalli E, Fuzzati N, Arnoldi L, Stavri M, Gibbons S, Ballero M, Maxia A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2004	67	3	485	486	15043440	10.1021/np030429e	Lakoochins A and B, new antimycobacterial stilbene derivatives from Artocarpus lakoocha.	Puntumchai A, Kittakoop P, Rajviroongit S, Vimuttipong S, Likhitwitayawuid K, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2004	67	6	968	972	15217275	10.1021/np030519j	New bioactive prenylflavonoids and dibenzocycloheptene derivative from roots of Dendrolobium lanceolatum.	Kanokmedhakul S, Kanokmedhakul K, Nambuddee K, Kongsaeree P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	10	2509	2513	15863306	10.1016/j.bmcl.2005.03.065	In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.	Maccari R, Ottanà R, Vigorita MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	17	3857	3859	16002282	10.1016/j.bmcl.2005.05.119	New alpha-methylene-gamma-butyrolactones with antimycobacterial properties.	Hughes MA, McFadden JM, Townsend CA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	18	4097	4099	16005211	10.1016/j.bmcl.2005.06.010	Identification of heteroarylenamines as a new class of antituberculosis lead molecules.	Copp BR, Christiansen HC, Lindsay BS, G Franzblau S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	20	4502	4505	16115763	10.1016/j.bmcl.2005.07.011	Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.	Sriram D, Yogeeswari P, Madhu K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	23	5222	5225	16171992	10.1016/j.bmcl.2005.08.045	Synthesis and antitubercular activity of 2-hydroxy-aminoalkyl derivatives of diaryloxy methano phenanthrenes.	Panda G, Shagufta, Srivastava AK, Sinha S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	6	1573	1576	15745799	10.1016/j.bmcl.2005.01.073	Synthesis of isonicotinic acid N'-arylidene-N-[2-oxo-2-(4-aryl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents.	Sinha N, Jain S, Tilekar A, Upadhayaya RS, Kishore N, Jana GH, Arora SK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	7	1923	1926	15780634	10.1016/j.bmcl.2005.01.085	Antitubercular agents. Part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents.	Kamal A, Hari Babu A, Venkata Ramana A, Sinha R, Yadav JS, Arora SK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2005	15	7	1927	1929	15780635	10.1016/j.bmcl.2005.01.084	Antitubercular agents. Part 2: new thiolactomycin analogues active against Mycobacterium tuberculosis.	Kamal A, Shaik AA, Sinha R, Yadav JS, Arora SK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Science	2005	307	5707	223	227	15591164	10.1126/science.1106753	A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.	Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2005	48	26	8261	8269	16366608	10.1021/jm050765n	Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents.	Tangallapally RP, Yendapally R, Lee RE, Lenaerts AJ, Lee RE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2005	68	2	183	188	15730240	10.1021/np049757k	New bioactive clerodane diterpenoids from the bark of Casearia grewiifolia.	Kanokmedhakul S, Kanokmedhakul K, Kanarsa T, Buayairaksa M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2005	68	7	1103	1105	16038559	10.1021/np050036a	3-Nitropropionic acid (3-NPA), a potent antimycobacterial agent from endophytic fungi: is 3-NPA in some plants produced by endophytes?	Chomcheon P, Wiyakrutta S, Sriubolmas N, Ngamrojanavanich N, Isarangkul D, Kittakoop P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2006	15	9	463	470		10.1007/s00044-007-9000-4	Synthesis and antimycobacterial activity of novel 4-[5-(substituted phenyl)-1-phenyl-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol derivatives	Ali MA, Yar MS
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2006	16	15	3947	3949	16725324	10.1016/j.bmcl.2006.05.024	Synthesis and in vitro antimycobacterial activity of N1-nicotinoyl-3-(4'-hydroxy-3'-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines.	Shaharyar M, Siddiqui AA, Ali MA, Sriram D, Yogeeswari P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2006	16	17	4571	4574	16784842	10.1016/j.bmcl.2006.06.021	Synthesis and evaluation of phenoxy acetic acid derivatives as [corrected] anti-mycobacterial agents.	Shaharyar M, Siddiqui AA, Ali MA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2006	16	19	5144	5147	16870429	10.1016/j.bmcl.2006.07.025	Search of antitubercular activities in tetrahydroacridines: synthesis and biological evaluation.	Tripathi RP, Verma SS, Pandey J, Agarwal KC, Chaturvedi V, Manju YK, Srivastva AK, Gaikwad A, Sinha S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2006	16	4	876	878	16303302	10.1016/j.bmcl.2005.11.004	Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl)hydrazono]ethyl}phenyl)thiourea.	Sriram D, Yogeeswari P, Madhu K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2006	16	4	879	883	16298528	10.1016/j.bmcl.2005.11.005	Discovery of a potent phenolic N1-benzylidene-pyridinecarboxamidrazone selective against Gram-positive bacteria.	Rathbone DL, Parker KJ, Coleman MD, Lambert PA, Billington DC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	PLoS Med.	2006	3	11	e466	e466	17132069	10.1371/journal.pmed.0030466	OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.	Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2006	49	1	31	34	16392788	10.1021/jm051060o	Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis.	Somu RV, Boshoff H, Qiao C, Bennett EM, Barry CE, Aldrich CC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2006	49	11	3045	3048	16722620	10.1021/jm050948+	Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.	Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Barbosa F, Einck L, Nacy CA, Protopopova M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2006	49	12	3448	3450	16759086	10.1021/jm060339h	Discovery of new antitubercular oxazolyl thiosemicarbazones.	Sriram D, Yogeeswari P, Thirumurugan R, Pavana RK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2006	49	16	4946	4952	16884306	10.1021/jm0602662	Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity.	Biava M, Porretta GC, Poce G, Supino S, Deidda D, Pompei R, Molicotti P, Manetti F, Botta M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2006	49	26	7623	7635	17181146	10.1021/jm061068d	Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain.	Somu RV, Wilson DJ, Bennett EM, Boshoff HI, Celia L, Beck BJ, Barry CE, Aldrich CC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2006	69	1	68	72	16441071	10.1021/np0503202	2-substituted furans from the roots of Polyalthia evecta.	Kanokmedhakul S, Kanokmedhakul K, Kantikeaw I, Phonkerd N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2006	69	10	1404	1410	17067151	10.1021/np0601197	Bioactive compounds from the seed fungus Menisporopsis theobromae BCC 3975.	Chinworrungsee M, Kittakoop P, Saenboonrueng J, Kongsaeree P, Thebtaranonth Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2006	69	10	1435	1441	17067157	10.1021/np0602012	Integerrimides A and B, cyclic heptapeptides from the latex of Jatropha integerrima.	Mongkolvisut W, Sutthivaiyakit S, Leutbecher H, Mika S, Klaiber I, Möller W, Rösner H, Beifuss U, Conrad J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2006	69	5	845	846	16724857	10.1021/np050554l	Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera.	Rojas R, Caviedes L, Aponte JC, Vaisberg AJ, Lewis WH, Lamas G, Sarasara C, Gilman RH, Hammond GB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2006	69	6	980	982	16792425	10.1021/np060164e	Chromone derivatives from the filamentous fungus Lachnum sp. BCC 2424.	Rukachaisirikul V, Chantaruk S, Pongcharoen W, Isaka M, Lapanun S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	10	3579	3586	17368035	10.1016/j.bmc.2007.02.011	Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris.	Madikane VE, Bhakta S, Russell AJ, Campbell WE, Claridge TD, Elisha BG, Davies SG, Smith P, Sim E.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	16	5502	5508	17562368	10.1016/j.bmc.2007.05.053	Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines.	Navarrete-Vázquez G, Molina-Salinas GM, Duarte-Fajardo ZV, Vargas-Villarreal J, Estrada-Soto S, Estrada-Soto S, González-Salazar F, Hernández-Núñez E, Said-Fernández S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	24	7638	7646	17888665	10.1016/j.bmc.2007.08.064	Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase.	Mahapatra A, Mativandlela SP, Binneman B, Fourie PB, Hamilton CJ, Meyer JJ, van der Kooy F, Houghton P, Lall N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	24	7789	7794	17851083	10.1016/j.bmc.2007.08.045	Preparation and antitubercular activities of alkylated amino alcohols and their glycosylated derivatives.	Taveira AF, Hyaric ML, Reis EF, Araújo DP, Ferreira AP, de Souza MA, Alves LL, Lourenço MC, Vicente FR, de Almeida MV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	5	2177	2186	17208445	10.1016/j.bmc.2006.12.009	Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.	Prado S, Janin YL, Saint-Joanis B, Brodin P, Michel S, Koch M, Cole ST, Tillequin F, Bost PE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	7	2551	2559	17306980	10.1016/j.bmc.2007.01.051	A new modification of anti-tubercular active molecules.	Imramovský A, Polanc S, Vinsová J, Kocevar M, Jampílek J, Recková Z, Kaustová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2007	15	8	2898	2906	17321746	10.1016/j.bmc.2007.02.021	Hybrid molecules of estrone: new compounds with potential antibacterial, antifungal, and antiproliferative activities.	Adamec J, Beckert R, Weiss D, Klimesová V, Waisser K, Möllmann U, Kaustová J, Buchta V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	12	3314	3316	17467984	10.1016/j.bmcl.2007.04.004	Oxadiazole mannich bases: synthesis and antimycobacterial activity.	Ali MA, Shaharyar M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	19	5419	5422	17692520	10.1016/j.bmcl.2007.07.027	Anti-tubercular agents. Part IV: Synthesis and antimycobacterial evaluation of nitroheterocyclic-based 1,2,4-benzothiadiazines.	Kamal A, Ahmed SK, Reddy KS, Khan MN, Shetty RV, Siddhardha B, Murthy US, Khan IA, Kumar M, Sharma S, Ram AB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	20	5586	5589	17764933	10.1016/j.bmcl.2007.07.089	Design, synthesis and antitubercular activity of diarylmethylnaphthol derivatives.	Das SK, Panda G, Chaturvedi V, Manju YS, Gaikwad AK, Sinha S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	23	6459	6462	17933535	10.1016/j.bmcl.2007.09.095	An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles.	Kumar RR, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	23	6638	6642	17937983	10.1016/j.bmcl.2007.09.048	Discovery of novel isoxazolines as anti-tuberculosis agents.	Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ, Meibohm B, Lee RE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	24	6895	6898	17967538	10.1016/j.bmcl.2007.09.096	Synthesis and biological evaluation of N-(aryl)-2-thiophen-2-ylacetamides series as a new class of antitubercular agents.	Silva Lourenço MC, Rodrigues Vicente F, de Oliveira Henriques Md, Peixoto Candéa AL, Borges Gonçalves RS, Nogueira TC, de Lima Ferreira M, Nora de Souza MV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	6	1736	1740	17239593	10.1016/j.bmcl.2006.12.066	New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents.	Ballell L, Field RA, Chung GA, Young RJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	7	1888	1891	17276683	10.1016/j.bmcl.2007.01.037	N-Hydroxythiosemicarbazones: synthesis and in vitro antitubercular activity.	Sriram D, Yogeeswari P, Dhakla P, Senthilkumar P, Banerjee D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2007	17	9	2487	2491	17331717	10.1016/j.bmcl.2007.02.024	Synthesis of new sugar derivatives from Stachys sieboldi Miq and antibacterial evaluation against Mycobacterium tuberculosis, Mycobacterium avium, and Staphylococcus aureus.	Chiba T, Takii T, Nishimura K, Yamamoto Y, Morikawa H, Abe C, Onozaki K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Biol. Chem.	2007	282	35	25436	25444	17567585	10.1074/jbc.m701813200	X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy.	Freundlich JS, Wang F, Tsai HC, Kuo M, Shieh HM, Anderson JW, Nkrumah LJ, Valderramos JC, Yu M, Kumar TR, Valderramos SG, Jacobs WR, Schiehser GA, Jacobus DP, Fidock DA, Sacchettini JC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2007	42	2	268	275	17007966	10.1016/j.ejmech.2006.08.004	Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives.	Ali MA, Shaharyar M, Siddiqui AA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2007	42	3	420	424	17112641	10.1016/j.ejmech.2006.09.009	Synthesis of isonicotinoylhydrazones from anacardic acid and their in vitro activity against Mycobacterium smegmatis.	Swamy BN, Suma TK, Rao GV, Reddy GC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2007	50	15	3696	3705	17602465	10.1021/jm0703901	Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs.	Johar M, Manning T, Tse C, Desroches N, Agrawal B, Kunimoto DY, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2007	50	17	3973	3975	17658779	10.1021/jm070638m	Discovery of 1,4-dihydroxy-2-naphthoate [corrected] prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens.	Kurosu M, Narayanasamy P, Biswas K, Dhiman R, Crick DC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2007	50	24	6232	6239	17960928	10.1021/jm700999n	Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid.	Sriram D, Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	12	4495	4497	17876006	10.1128/aac.00753-07	Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.	Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, Sullivan D, Liu JO, Zhang Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	2	794	795	17145791	10.1128/aac.01145-06	Aspirin antagonism in isoniazid treatment of tuberculosis in mice.	Byrne ST, Denkin SM, Zhang Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	3	1011	1015	17178794	10.1128/aac.00898-06	Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.	Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	4	1380	1385	17210775	10.1128/aac.00055-06	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.	Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	6	2100	2104	17438054	10.1128/aac.00086-07	Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis.	Siddiqi S, Takhar P, Baldeviano C, Glover W, Zhang Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	7	2329	2336	17438043	10.1128/aac.00185-07	Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.	Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2007	51	7	2430	2435	17485499	10.1128/aac.01458-06	Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.	Ngo SC, Zimhony O, Chung WJ, Sayahi H, Jacobs WR, Welch JT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2007	70	5	795	801	17480099	10.1021/np070010e	Bioactive compounds from Bauhinia purpurea possessing antimalarial, antimycobacterial, antifungal, anti-inflammatory, and cytotoxic activities.	Boonphong S, Puangsombat P, Baramee A, Mahidol C, Ruchirawat S, Kittakoop P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2007	70	9	1434	1438	17844996	10.1021/np070174v	Antimalarial and antituberculous poly-O-acylated jatrophane diterpenoids from Pedilanthus tithymaloides.	Mongkolvisut W, Sutthivaiyakit S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2007	70	9	1536	1538	17845001	10.1021/np070293a	Bioactive constituents of the roots of Polyalthia cerasoides.	Kanokmedhakul S, Kanokmedhakul K, Lekphrom R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	10	5672	5682	18450455	10.1016/j.bmc.2008.03.062	Synthesis of methyl 5-S-alkyl-5-thio-D-arabinofuranosides and evaluation of their antimycobacterial activity.	Sanki AK, Boucau J, Srivastava P, Adams SS, Ronning DR, Sucheck SJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	14	6732	6736	18556206	10.1016/j.bmc.2008.05.061	Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.	Arai M, Sobou M, Vilchéze C, Baughn A, Hashizume H, Pruksakorn P, Ishida S, Matsumoto M, Jacobs WR, Kobayashi M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	17	8264	8272	18752967	10.1016/j.bmc.2008.06.057	A new synthetic access to furo[3,2-f]chromene analogues of an antimycobacterial.	Alvey L, Prado S, Huteau V, Saint-Joanis B, Michel S, Koch M, Cole ST, Tillequin F, Janin YL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	24	10326	10331	18977145	10.1016/j.bmc.2008.10.042	Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives.	Weis R, Schweiger K, Faist J, Rajkovic E, Kungl AJ, Fabian WM, Schunack W, Seebacher W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	5	2558	2569	18078756	10.1016/j.bmc.2007.11.050	Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.	Senthilkumar P, Dinakaran M, Banerjee D, Devakaram RV, Yogeeswari P, China A, Nagaraja V, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	6	3408	3418	18304818	10.1016/j.bmc.2007.11.016	Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.	Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2008	16	8	4516	4522	18321714	10.1016/j.bmc.2008.02.055	Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives.	Zampieri D, Mamolo MG, Laurini E, Scialino G, Banfi E, Vio L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2008	17	2	374	385		10.1007/s00044-007-9073-0	Transition metals in organic synthesis - Part 83#: Synthesis and pharmacological potential of carbazoles	Choi TA, Czerwonka R, Forke R, Jager A, Knoll J, Krahl MP, Krause T, Reddy KR, Franzblau SG, Knolker H
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2008	17	2	53	61		10.1007/s00044-007-9036-5	Synthesis and antitubercular activity of nucleoside analogs based on L-ascorbic acid and bases	Tripathi RP, Dwivedi N, Singh N, Misra M
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	1	289	292	17997304	10.1016/j.bmcl.2007.10.083	Thiophene containing triarylmethanes as antitubercular agents.	Parai MK, Panda G, Chaturvedi V, Manju YK, Sinha S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	17	4868	4871	18678487	10.1016/j.bmcl.2008.07.087	Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity.	Demaray JA, Thuener JE, Dawson MN, Sucheck SJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	2	538	541	18068364	10.1016/j.bmcl.2007.11.091	Synthesis and antimycobacterial evaluation of new trans-cinnamic acid hydrazide derivatives.	Carvalho SA, da Silva EF, de Souza MV, Lourenço MC, Vicente FR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	23	6265	6267	18926698	10.1016/j.bmcl.2008.09.082	Synthesis of Arabino glycosyl triazoles as potential inhibitors of mycobacterial cell wall biosynthesis.	Wilkinson BL, Long H, Sim E, Fairbanks AJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	24	6542	6548	18952418	10.1016/j.bmcl.2008.10.045	A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.	Aridoss G, Amirthaganesan S, Kumar NA, Kim JT, Lim KT, Kabilan S, Jeong YT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2008	18	3	1229	1236	18068979	10.1016/j.bmcl.2007.11.110	Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.	Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2008	43	4	872	879	17714832	10.1016/j.ejmech.2007.06.012	Antimycobacterial activity of diphenylpyraline derivatives.	Weis R, Faist J, di Vora U, Schweiger K, Brandner B, Kungl AJ, Seebacher W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2008	43	6	1344	1347	17923172	10.1016/j.ejmech.2007.08.003	Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives.	Lourenço MC, Ferreira Mde L, de Souza MV, Peralta MA, Vasconcelos TR, Henriques Md.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2008	43	9	1989	1996	18207286	10.1016/j.ejmech.2007.11.016	Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: a novel class of potential antibacterial and antitubercular agents.	Joshi SD, Vagdevi HM, Vaidya VP, Gadaginamath GS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2008	51	12	3644	3648	18494459	10.1021/jm701560p	1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings.	Biava M, Porretta GC, Poce G, De Logu A, Saddi M, Meleddu R, Manetti F, De Rossi E, Botta M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2008	51	18	5731	5735	18714980	10.1021/jm800545k	Discovery of antimycobacterial spiro-piperidin-4-ones: an atom economic, stereoselective synthesis, and biological intervention.	Kumar RR, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2008	51	7	1981	1990	18338841	10.1021/jm800038g	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.	Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	11	4137	4140	18694944	10.1128/aac.00196-08	Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.	Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, Peloquin CA, Orme IM, Basaraba RJ, Lenaerts AJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	2	725	729	18070968	10.1128/aac.01124-07	Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations.	Gegia M, Mdivani N, Mendes RE, Li H, Akhalaia M, Han J, Khechinashvili G, Tang YW.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	4	1513	1515	18268091	10.1128/aac.00897-07	Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.	Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS, Johnson CM, Orme IM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	6	2027	2034	18378710	10.1128/aac.01486-07	Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.	Safi H, Sayers B, Hazbón MH, Alland D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	8	2831	2835	18505852	10.1128/aac.01204-07	Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.	Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	9	3195	3201	18591268	10.1128/aac.00153-08	Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.	Verma RK, Kaur J, Kumar K, Yadav AB, Misra A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2008	52	9	3321	3326	18625764	10.1128/aac.00379-08	Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.	Vicente E, Villar R, Burguete A, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2008	71	2	292	294	18179177	10.1021/np070629g	Seco-terpenoids and other constituents from Elateriospermum tapos.	Pattamadilok D, Suttisri R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	10	3572	3579	19403314	10.1016/j.bmc.2009.04.008	New antituberculotics originated from salicylanilides with promising in vitro activity against atypical mycobacterial strains.	Imramovský A, Vinsová J, Férriz JM, Dolezal R, Jampílek J, Kaustová J, Kunc F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	11	3795	3799	19427791	10.1016/j.bmc.2009.04.042	Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.	Santos JL, Yamasaki PR, Chin CM, Takashi CH, Pavan FR, Leite CQ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	13	4681	4692	19457676	10.1016/j.bmc.2009.04.069	Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis.	Upadhayaya RS, Kulkarni GM, Vasireddy NR, Vandavasi JK, Dixit SS, Sharma V, Chattopadhyaya J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	13	4693	4707	19467603	10.1016/j.bmc.2009.04.055	Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations.	Zampieri D, Mamolo MG, Laurini E, Fermeglia M, Posocco P, Pricl S, Banfi E, Scialino G, Vio L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	16	6063	6072	19620006	10.1016/j.bmc.2009.06.051	Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies.	Gemma S, Savini L, Altarelli M, Tripaldi P, Chiasserini L, Coccone SS, Kumar V, Camodeca C, Campiani G, Novellino E, Clarizio S, Delogu G, Butini S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	20	7126	7130	19783449	10.1016/j.bmc.2009.08.061	Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents.	Guo S, Tipparaju SK, Pegan SD, Wan B, Mo S, Orjala J, Mesecar AD, Franzblau SG, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	4	1579	1586	19162489	10.1016/j.bmc.2008.12.070	Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents.	Khoshneviszadeh M, Edraki N, Javidnia K, Alborzi A, Pourabbas B, Mardaneh J, Miri R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2009	17	7	2830	2841	19285414	10.1016/j.bmc.2009.02.026	Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis.	Upadhayaya RS, Vandavasi JK, Vasireddy NR, Sharma V, Dixit SS, Chattopadhyaya J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	11	3006	3009	19403307	10.1016/j.bmcl.2009.04.029	A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles.	Karthikeyan SV, Perumal S, Shetty KA, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	2	348	351	19081718	10.1016/j.bmcl.2008.11.080	Salicylanilide esters of N-protected amino acids as novel antimicrobial agents.	Imramovský A, Vinsová J, Férriz JM, Buchta V, Jampílek J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	22	6313	6316	19828313	10.1016/j.bmcl.2009.09.095	Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosis.	Horita Y, Takii T, Chiba T, Kuroishi R, Maeda Y, Kurono Y, Inagaki E, Nishimura K, Yamamoto Y, Abe C, Mori M, Onozaki K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	24	7000	7002	19879757	10.1016/j.bmcl.2009.10.034	Synthesis and antimycobacterial evaluation of novel 5,6-dimethoxy-1-oxo-2,5-dihydro-1H-2-indenyl-5,4-substituted phenyl methanone analogues.	Ali MA, Samy JG, Manogaran E, Sellappan V, Hasan MZ, Ahsan MJ, Pandian S, ShaharYar M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	4	1152	1154	19131245	10.1016/j.bmcl.2008.12.088	5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species.	Sriram D, Yogeeswari P, Dhakla P, Senthilkumar P, Banerjee D, Manjashetty TH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2009	19	8	2203	2205	19299129	10.1016/j.bmcl.2009.02.101	Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.	Castagnolo D, Radi M, Dessì F, Manetti F, Saddi M, Meleddu R, De Logu A, Botta M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	1	345	358	18502542	10.1016/j.ejmech.2008.02.031	Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids.	Senthilkumar P, Dinakaran M, Yogeeswari P, Sriram D, China A, Nagaraja V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	10	3954	3960	19464085	10.1016/j.ejmech.2009.04.023	Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations.	Raparti V, Chitre T, Bothara K, Kumar V, Dangre S, Khachane C, Gore S, Deshmane B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	10	4169	4178	19524330	10.1016/j.ejmech.2009.05.009	Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.	Hearn MJ, Cynamon MH, Chen MF, Coppins R, Davis J, Joo-On Kang H, Noble A, Tu-Sekine B, Terrot MS, Trombino D, Thai M, Webster ER, Wilson R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	10	4199	4210	19535178	10.1016/j.ejmech.2009.05.015	Synthesis, spectral and biological evaluation of some new thiazolidinones and thiazoles based on t-3-alkyl-r-2,c-6-diarylpiperidin-4-ones.	Aridoss G, Amirthaganesan S, Kim MS, Kim JT, Jeong YT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	11	4297	4305	19679378	10.1016/j.ejmech.2009.07.015	Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents.	Onajole OK, Govender K, Govender P, van Helden PD, Kruger HG, Maguire GE, Muthusamy K, Pillay M, Wiid I, Govender T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	11	4739	4746	19589626	10.1016/j.ejmech.2009.06.008	Synthesis of new 4-isopropylthiazole hydrazide analogs and some derived clubbed triazole, oxadiazole ring systems--a novel class of potential antibacterial, antifungal and antitubercular agents.	Mallikarjuna BP, Sastry BS, Suresh Kumar GV, Rajendraprasad Y, Chandrashekar SM, Sathisha K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	12	4978	4984	19781824	10.1016/j.ejmech.2009.09.001	L-proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines.	Indumathi S, Perumal S, Banerjee D, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	2	492	500	18538450	10.1016/j.ejmech.2008.04.013	Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives.	Kini SG, Bhat AR, Bryant B, Williamson JS, Dayan FE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	4	1705	1709	18952325	10.1016/j.ejmech.2008.09.026	A facile synthesis of alpha,alpha'-(EE)-bis(benzylidene)-cycloalkanones and their antitubercular evaluations.	Singh N, Pandey J, Yadav A, Chaturvedi V, Bhatnagar S, Gaikwad AN, Sinha SK, Kumar A, Shukla PK, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	5	2017	2029	19022537	10.1016/j.ejmech.2008.10.004	Synthesis, anti-tuberculosis activity and 3D-QSAR study of amino acid conjugates of 4-(adamantan-1-yl) group containing quinolines.	Nayyar A, Patel SR, Shaikh M, Coutinho E, Jain R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	5	2286	2293	18694614	10.1016/j.ejmech.2008.06.027	Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.	Klimesová V, Kocí J, Waisser K, Kaustová J, Möllmann U.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	6	2497	2505	19232450	10.1016/j.ejmech.2009.01.017	Diversity-oriented synthesis of furo[3,2-f]chromanes with antimycobacterial activity.	Alvey L, Prado S, Saint-Joanis B, Michel S, Koch M, Cole ST, Tillequin F, Janin YL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	8	3253	3258	19371979	10.1016/j.ejmech.2009.03.027	Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides.	Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR, Sabet R, Alborzi A, Miri R, Pourabbas B, Mardaneh J, Mousavi P, Moeinifard B, Sadeghi-Aliabadi H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	8	3350	3355	19272678	10.1016/j.ejmech.2009.02.013	Synthesis and antitubercular screening of imidazole derivatives.	Pandey J, Tiwari VK, Verma SS, Chaturvedi V, Bhatnagar S, Sinha S, Gaikwad AN, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2009	44	9	3821	3829	19524332	10.1016/j.ejmech.2009.05.010	A facile synthesis and antimycobacterial evaluation of novel spiro-pyrido-pyrrolizines and pyrrolidines.	Ranjith Kumar R, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2009	52	20	6287	6296	19757815	10.1021/jm900513a	Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.	Pieroni M, Lilienkampf A, Wan B, Wang Y, Franzblau SG, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2009	52	20	6324	6334	19827833	10.1021/jm900358q	Structure-based design of DevR inhibitor active against nonreplicating Mycobacterium tuberculosis.	Gupta RK, Thakur TS, Desiraju GR, Tyagi JS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2009	52	21	6757	6767	19817445	10.1021/jm901112f	Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.	Huang Q, Mao J, Wan B, Wang Y, Brun R, Franzblau SG, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2009	52	7	2109	2118	19271749	10.1021/jm900003c	Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.	Lilienkampf A, Mao J, Wan B, Wang Y, Franzblau SG, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2009	53	11	4598	4603	19704125	10.1128/aac.00643-09	New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.	Rieder RJ, Zhao Z, Zavizion B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2009	53	8	3181	3189	19451293	10.1128/aac.01577-08	A balancing act: efflux/influx in mycobacterial drug resistance.	Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	11	2024	2027	19943622	10.1021/np900342b	Diterpenes, sesquiterpenes, and a sesquiterpene-coumarin conjugate from Jatropha integerrima.	Sutthivaiyakit S, Mongkolvisut W, Prabpai S, Kongsaeree P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	12	2169	2171	20035557	10.1021/np800778b	Antimycobacterial flavonoids from the leaf extract of Galenia africana.	Mativandlela SP, Muthivhi T, Kikuchi H, Oshima Y, Hamilton C, Hussein AA, van der Walt ML, Houghton PJ, Lall N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	3	360	365	19093848	10.1021/np800572r	Bioactive pyridine-N-oxide disulfides from Allium stipitatum.	O'Donnell G, Poeschl R, Zimhony O, Gunaratnam M, Moreira JB, Neidle S, Evangelopoulos D, Bhakta S, Malkinson JP, Boshoff HI, Lenaerts A, Gibbons S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	4	756	759	19265430	10.1021/np800702c	Isariotins E and F, spirocyclic and bicyclic hemiacetals from the entomopathogenic fungus Isaria tenuipes BCC 12625.	Bunyapaiboonsri T, Yoiprommarat S, Intereya K, Rachtawee P, Hywel-Jones NL, Isaka M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	5	861	865	19368377	10.1021/np9000703	Biomimetic transformation and biological activities of Globiferin, a terpenoid benzoquinone from Cordia globifera.	Dettrakul S, Surerum S, Rajviroongit S, Kittakoop P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	6	1092	1096	19555123	10.1021/np900021h	Cytotoxic and antimycobacterial prenylated flavonoids from the roots of Eriosema chinense.	Sutthivaiyakit S, Thongnak O, Lhinhatrakool T, Yodchun O, Srimark R, Dowtaisong P, Chuankamnerdkarn M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	7	1245	1248	19548690	10.1021/np9000569	Macrophyllin-type bicyclo[3.2.1]octanoid neolignans from the leaves of Pleurothyrium cinereum.	Coy ED, Cuca LE, Sefkow M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	7	1341	1343	19456117	10.1021/np900082h	Isocoumarin glucosides from the scale insect fungus Torrubiella tenuis BCC 12732.	Kornsakulkarn J, Thongpanchang C, Lapanun S, Srichomthong K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	8	1442	1446	19627125	10.1021/np800805f	Prenylxanthones and a bicyclo[3.3.1]nona-2,6-diene derivative from the fungus Emericella rugulosa.	Moosophon P, Kanokmedhakul S, Kanokmedhakul K, Soytong K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2009	72	8	1487	1491	19663417	10.1021/np9003189	Antimalarial and cytotoxic depsidones from the fungus Chaetomium brasiliense.	Khumkomkhet P, Kanokmedhakul S, Kanokmedhakul K, Hahnvajanawong C, Soytong K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2010	18	12	4178	4186	20537903	10.1016/j.bmc.2010.05.016	A new class of potential anti-tuberculosis agents: Synthesis and preliminary evaluation of novel acrylic acid ethyl ester derivatives.	Kabir MS, Namjoshi OA, Verma R, Polanowski R, Krueger SM, Sherman D, Rott MA, Schwan WR, Monte A, Cook JM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2010	18	20	7274	7282	20833056	10.1016/j.bmc.2010.08.016	Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.	Khoje AD, Kulendrn A, Charnock C, Wan B, Franzblau S, Gundersen LL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2010	18	23	8178	8187	21044844	10.1016/j.bmc.2010.10.017	Highly active antimycobacterial derivatives of benzoxazine.	Petrlíková E, Waisser K, Divi¿ová H, Husáková P, Vrabcová P, Kune¿ J, Kolá¿ K, Stola¿íková J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2010	18	23	8289	8301	21041091	10.1016/j.bmc.2010.09.071	Synthesis and bio-evaluation of alkylaminoaryl phenyl cyclopropyl methanones as antitubercular and antimalarial agents.	Ajay A, Singh V, Singh S, Pandey S, Gunjan S, Dubey D, Sinha SK, Singh BN, Chaturvedi V, Tripathi R, Ramchandran R, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2010	18	3	1054	1061	20060303	10.1016/j.bmc.2009.12.055	Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.	Férriz JM, Vávrová K, Kunc F, Imramovský A, Stolaríková J, Vavríková E, Vinsová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	1	350	353	19900810	10.1016/j.bmcl.2009.10.107	A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents.	Karthikeyan SV, Bala BD, Raja VP, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	11	3352	3355	20434911	10.1016/j.bmcl.2010.04.025	Selective one-pot multicomponent synthesis and anti-tubercular evaluation of 5-(aryl/cyclohexylsulfanyl)-2-alkoxy-4,6-diarylnicotinonitriles.	Manikannan R, Muthusubramanian S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	12	3658	3663	20483615	10.1016/j.bmcl.2010.04.100	Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria.	Pruksakorn P, Arai M, Kotoku N, Vilchèze C, Baughn AD, Moodley P, Jacobs WR, Kobayashi M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	14	4173	4176	20542692	10.1016/j.bmcl.2010.05.061	In vitro antituberculosis activities of the constituents isolated from Haloxylon salicornicum.	Bibi N, Tanoli SA, Farheen S, Afza N, Siddiqi S, Zhang Y, Kazmi SU, Malik A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	15	4313	4316	20615698	10.1016/j.bmcl.2010.06.096	5-Nitro-2-furoic acid hydrazones: design, synthesis and in vitro antimycobacterial evaluation against log and starved phase cultures.	Sriram D, Yogeeswari P, Vyas DR, Senthilkumar P, Bhat P, Srividya M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	16	4762	4765	20643545	10.1016/j.bmcl.2010.06.125	Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid.	Gilani SJ, Khan SA, Siddiqui N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	20	6100	6102	20813528	10.1016/j.bmcl.2010.08.046	Novel dihydropyrimidines as a potential new class of antitubercular agents.	Trivedi AR, Bhuva VR, Dholariya BH, Dodiya DK, Kataria VB, Shah VH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	21	6175	6178	20850299	10.1016/j.bmcl.2010.08.127	Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl)prop-2-en-1-one derivatives as potent antitubercular agents.	Tawari NR, Bairwa R, Ray MK, Rajan MG, Degani MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	23	6920	6924	20970331	10.1016/j.bmcl.2010.09.137	Pyrazole derivatives from azines of substituted phenacyl aryl/cyclohexyl sulfides and their antimycobacterial activity.	Manikannan R, Venkatesan R, Muthusubramanian S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	24	7278	7282	21071220	10.1016/j.bmcl.2010.10.080	A facile 1,3-dipolar cycloaddition of azomethine ylides to 2-arylidene-1,3-indanediones: synthesis of dispiro-oxindolylpyrrolothiazoles and their antimycobacterial evaluation.	Maheswari SU, Balamurugan K, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	3	1040	1044	20056418	10.1016/j.bmcl.2009.12.045	Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents.	Eswaran S, Adhikari AV, Pal NK, Chowdhury IH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	3	1263	1268	20022500	10.1016/j.bmcl.2009.11.105	Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.	Mao J, Yuan H, Wang Y, Wan B, Pak D, He R, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	3	942	944	20045640	10.1016/j.bmcl.2009.12.062	Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.	Hans RH, Guantai EM, Lategan C, Smith PJ, Wan B, Franzblau SG, Gut J, Rosenthal PJ, Chibale K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	5	1623	1625	20138519	10.1016/j.bmcl.2010.01.031	Novel molecular hybrids of cinnamic acids and guanylhydrazones as potential antitubercular agents.	Bairwa R, Kakwani M, Tawari NR, Lalchandani J, Ray MK, Rajan MG, Degani MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2010	20	8	2597	2600	20304645	10.1016/j.bmcl.2010.02.081	Substituted hydrazinecarbothioamide as potent antitubercular agents: synthesis and quantitative structure-activity relationship (QSAR).	Singh S, Mandal PK, Singh N, Misra AK, Singh S, Chaturvedi V, Sinha S, Saxena AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	1	120	123	19942326	10.1016/j.ejmech.2009.09.033	Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives.	Sriram D, Yogeeswari P, Dinakaran M, Banerjee D, Bhat P, Gadhwal S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	1	124	133	19853329	10.1016/j.ejmech.2009.09.034	1,3-Dipolar cycloaddition of C-aryl-N-phenylnitrones to (R)-1-(1-phenylethyl)-3-[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: synthesis and antimycobacterial evaluation of enantiomerically pure spiroisoxazolidines.	Kumar RS, Perumal S, Shetty KA, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	1	142	148	19846238	10.1016/j.ejmech.2009.09.036	Application of Huisgen (3+2) cycloaddition reaction: synthesis of 1-(2,3-dihydrobenzofuran-2-yl-methyl [1,2,3]-triazoles and their antitubercular evaluations.	Tripathi RP, Yadav AK, Ajay A, Bisht SS, Chaturvedi V, Sinha SK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	1	411	422	19850377	10.1016/j.ejmech.2009.09.044	Novel three-component domino reactions of ketones, isatin and amino acids: synthesis and discovery of antimycobacterial activity of highly functionalised novel dispiropyrrolidines.	Kumar RS, Rajesh SM, Perumal S, Banerjee D, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	10	4446	4457	20691508	10.1016/j.ejmech.2010.07.003	Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.	Changtam C, Hongmanee P, Suksamrarn A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	10	4554	4561	20696503	10.1016/j.ejmech.2010.07.016	Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.	Delaine T, Bernardes-Génisson V, Quémard A, Constant P, Meunier B, Bernadou J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	10	4578	4586	20696500	10.1016/j.ejmech.2010.07.020	Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building.	Aboul-Fadl T, Bin-Jubair FA, Aboul-Wafa O.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	11	5120	5129	20797808	10.1016/j.ejmech.2010.08.023	Synthesis and pharmacological evaluation of clubbed isopropylthiazole derived triazolothiadiazoles, triazolothiadiazines and mannich bases as potential antimicrobial and antitubercular agents.	Suresh Kumar GV, Rajendra Prasad Y, Mallikarjuna BP, Chandrashekar SM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	11	5480	5485	20822833	10.1016/j.ejmech.2010.08.024	Synthesis and anti-tubercular and antimicrobial activities of some 2r,4c-diaryl-3-azabicyclo[3.3.1]nonan-9-one N-isonicotinoylhydrazone derivatives.	Sankar C, Pandiarajan K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	12	5653	5661	20932607	10.1016/j.ejmech.2010.09.019	A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of novel spiro-pyrrolothiazolyloxindoles and their antitubercular evaluation.	Prasanna P, Balamurugan K, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	12	5833	5847	20961671	10.1016/j.ejmech.2010.09.048	Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring.	Termentzi A, Khouri I, Gaslonde T, Prado S, Saint-Joanis B, Bardou F, Amanatiadou EP, Vizirianakis IS, Kordulakova J, Jackson M, Brosch R, Janin YL, Daffé M, Tillequin F, Michel S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	12	5965	5978	20970222	10.1016/j.ejmech.2010.09.063	Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols.	Bisht SS, Dwivedi N, Chaturvedi V, Anand N, Misra M, Sharma R, Kumar B, Dwivedi R, Singh S, Sinha SK, Gupta V, Mishra PR, Dwivedi AK, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	12	6085	6089	20828886	10.1016/j.ejmech.2010.08.030	Synthesis and antitubercular activities of substituted benzoic acid N'-(substituted benzylidene/furan-2-ylmethylene)-N-(pyridine-3-carbonyl)-hydrazides.	Kumar P, Narasimhan B, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	12	6106	6113	20937542	10.1016/j.ejmech.2010.09.040	New amino acid esters of salicylanilides active against MDR-TB and other microbes.	Krátký M, Vin¿ová J, Buchta V, Horvati K, Bösze S, Stola¿íková J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	3	957	966	20034708	10.1016/j.ejmech.2009.11.036	New 1,3-oxazolo[4,5-c]quinoline derivatives: synthesis and evaluation of antibacterial and antituberculosis properties.	Eswaran S, Adhikari AV, Ajay Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	5	1854	1867	20137835	10.1016/j.ejmech.2010.01.024	Novel quinoline and naphthalene derivatives as potent antimycobacterial agents.	Upadhayaya RS, Vandavasi JK, Kardile RA, Lahore SV, Dixit SS, Deokar HS, Shinde PD, Sarmah MP, Chattopadhyaya J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	5	2063	2074	20149496	10.1016/j.ejmech.2010.01.045	Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents.	Suresh Kumar GV, Rajendraprasad Y, Mallikarjuna BP, Chandrashekar SM, Kistayya C.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	7	2719	2725	20226572	10.1016/j.ejmech.2010.02.037	A note to the biological activity of benzoxazine derivatives containing the thioxo group.	Waisser K, Petrlíková E, Perina M, Klimesová V, Kunes J, Palát K, Kaustová J, Dahse HM, Möllmann U.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	7	3019	3026	20403645	10.1016/j.ejmech.2010.03.031	Synthesis and antioxidant activity evaluation of a syringic hydrazones family.	Belkheiri N, Bouguerne B, Bedos-Belval F, Duran H, Bernis C, Salvayre R, Nègre-Salvayre A, Baltas M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	8	3335	3345	20452706	10.1016/j.ejmech.2010.04.017	Discovery of new 1,3,5-triazine scaffolds with potent activity against Mycobacterium tuberculosis H37Rv.	Sunduru N, Gupta L, Chaturvedi V, Dwivedi R, Sinha S, Chauhan PM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	8	3374	3383	20537437	10.1016/j.ejmech.2010.04.022	New quinoline derivatives: synthesis and investigation of antibacterial and antituberculosis properties.	Eswaran S, Adhikari AV, Chowdhury IH, Pal NK, Thomas KD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2010	45	9	3831	3839	20576327	10.1016/j.ejmech.2010.05.035	Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.	Manna K, Agrawal YK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2010	53	10	4130	4140	20420370	10.1021/jm100165w	3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.	Shakya N, Srivastav NC, Desroches N, Agrawal B, Kunimoto DY, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2010	53	16	6180	6187	20718497	10.1021/jm100568q	Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.	Srivastav NC, Rai D, Tse C, Agrawal B, Kunimoto DY, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2010	53	2	678	688	20000577	10.1021/jm901273n	Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.	Lilienkampf A, Pieroni M, Wan B, Wang Y, Franzblau SG, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2010	53	7	2882	2891	20205479	10.1021/jm901858n	Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.	Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	1	103	108	19822701	10.1128/aac.01288-09	Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis.	Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, Alland D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	11	4789	4793	20713679	10.1128/aac.00661-10	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.	Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	3	1075	1081	20008778	10.1128/aac.00964-09	Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China.	Luo T, Zhao M, Li X, Xu P, Gui X, Pickerill S, DeRiemer K, Mei J, Gao Q.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	5	2262	2264	20160054	10.1128/aac.01423-09	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.	Rullas J, García JI, Beltrán M, Cardona PJ, Cáceres N, García-Bustos JF, Angulo-Barturen I.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	7	2806	2813	20421401	10.1128/aac.00400-10	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.	Zhang T, Bishai WR, Grosset JH, Nuermberger EL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	8	3478	3480	20516287	10.1128/aac.00287-10	In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.	Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Antimicrob. Agents Chemother.	2010	54	9	3776	3782	20566771	10.1128/aac.00453-10	Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.	Wang F, Jain P, Gulten G, Liu Z, Feng Y, Ganesula K, Motiwala AS, Ioerger TR, Alland D, Vilchèze C, Jacobs WR, Sacchettini JC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2010	73	1	55	59	20038128	10.1021/np900650c	Oblongolides from the endophytic fungus Phomopsis sp. BCC 9789.	Bunyapaiboonsri T, Yoiprommarat S, Srikitikulchai P, Srichomthong K, Lumyong S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2010	73	3	383	387	20337497	10.1021/np900281r	Anti-infective discorhabdins from a deep-water alaskan sponge of the genus Latrunculia.	Na M, Ding Y, Wang B, Tekwani BL, Schinazi RF, Franzblau S, Kelly M, Stone R, Li XC, Ferreira D, Hamann MT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2010	73	9	1507	1511	20815366	10.1021/np100282k	Anthraquinone, cyclopentanone, and naphthoquinone derivatives from the sea fan-derived fungi Fusarium spp. PSU-F14 and PSU-F135.	Trisuwan K, Khamthong N, Rukachaisirikul V, Phongpaichit S, Preedanon S, Sakayaroj J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	1	567	579	21106378	10.1016/j.bmc.2010.10.060	Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones.	Wube AA, Hüfner A, Thomaschitz C, Blunder M, Kollroser M, Bauer R, Bucar F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	11	3444	3450	21592801	10.1016/j.bmc.2011.04.033	Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides.	Ranjith Kumar R, Perumal S, Menéndez JC, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	11	3483	3491	21546254	10.1016/j.bmc.2011.04.023	Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles.	Khoje AD, Charnock C, Wan B, Franzblau S, Gundersen LL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	18	5585	5595	21840723	10.1016/j.bmc.2011.07.034	The structure-activity relationship of urea derivatives as anti-tuberculosis agents.	Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	21	6225	6232	21975068	10.1016/j.bmc.2011.09.017	Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.	Deraeve C, Dorobantu IM, Rebbah F, Le Quéméner F, Constant P, Quémard A, Bernardes-Génisson V, Bernadou J, Pratviel G.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	6	2023	2029	21334900	10.1016/j.bmc.2011.01.050	Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents.	Camacho J, Barazarte A, Gamboa N, Rodrigues J, Rojas R, Vaisberg A, Gilman R, Charris J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2011	19	7	2182	2189	21419633	10.1016/j.bmc.2011.02.034	Dihydro-ß-agarofuran sesquiterpenes isolated from Celastrus vulcanicola as potential anti-Mycobacterium tuberculosis multidrug-resistant agents.	Torres-Romero D, Jiménez IA, Rojas R, Gilman RH, López M, Bazzocchi IL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2011	2	5	378	384		10.1039/C0MD00246A	Synthesis, in silico screening and bioevaluation of dispiro-cycloalkanones as antitubercular and mycobacterial NAD+-dependent DNA ligase inhibitors	Tripathi RP, Pandey J, Kukshal V, Ajay A, Mishra M, Dube D, Chopra D, Dwivedi R, Chaturvedi V, Ramachandran R
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2011	2	6	466	470	21691438	10.1021/ml200036r	Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.	Moraski GC, Markley LD, Hipskind PA, Boshoff H, Cho S, Franzblau SG, Miller MJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2011	2	7	626	630		10.1039/C0MD00239A	Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition	Rajesh SM, Perumal S, Menendez JC, Yogeeswari P, Sriram D
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2011	20	9	1515	1522		10.1007/s00044-010-9402-6	Search of antimycobacterial activities in hybrid molecules with benzopyran skeleton	Tripathi RP, Bisht SS, Pandey VP, Pandey SK, Singh S, Sinha SK, Chaturvedi V
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2011	20	9	1611	1615		10.1007/s00044-010-9405-3	Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line	Singh M, Sasi P, Rai G, Gupta VH, Amarapurkar D, Wangikar PP
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	10	2855	2859	21507635	10.1016/j.bmcl.2011.03.079	Synthesis, structure-activity relationship of novel substituted 4H-chromen-1,2,3,4-tetrahydropyrimidine-5-carboxylates as potential anti-mycobacterial and anticancer agents.	Raju BC, Rao RN, Suman P, Yogeeswari P, Sriram D, Shaik TB, Kalivendi SV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	10	3012	3016	21498077	10.1016/j.bmcl.2011.03.045	A green expedient synthesis of pyridopyrimidine-2-thiones and their antitubercular activity.	Rajesh SM, Kumar RS, Libertsen LA, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	12	3699	3703	21570839	10.1016/j.bmcl.2011.04.072	New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents.	Torres E, Moreno E, Ancizu S, Barea C, Galiano S, Aldana I, Monge A, Pérez-Silanes S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	13	3881	3884	21641799	10.1016/j.bmcl.2011.05.032	Synthesis and antimycobacterial activity of highly functionalized tetrahydro-4(1H)-pyridinones.	Raja VP, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	13	3947	3950	21641797	10.1016/j.bmcl.2011.05.037	Synthesis and screening of (E)-1-(ß-D-galactopyranosyl)-4-(aryl)but-3-ene-2-one against Mycobacterium tuberculosis.	Mugunthan G, Ramakrishna K, Sriram D, Yogeeswari P, Ravindranathan Kartha KP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	14	4316	4319	21665469	10.1016/j.bmcl.2011.05.054	Synthesis and antitubercular evaluation of amidoalkyl dibenzofuranols and 1H-benzo[2,3]benzofuro[4,5-e][1,3]oxazin-3(2H)-ones.	Kantevari S, Yempala T, Yogeeswari P, Sriram D, Sridhar B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	15	4404	4408	21737274	10.1016/j.bmcl.2011.06.040	Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents.	Singh N, Pandey SK, Anand N, Dwivedi R, Singh S, Sinha SK, Chaturvedi V, Jaiswal N, Srivastava AK, Shah P, Siddiqui MI, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	15	4451	4453	21733688	10.1016/j.bmcl.2011.06.018	Design, synthesis and antimycobacterial evaluation of novel 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues.	Ahsan MJ, Samy JG, Dutt KR, Agrawal UK, Yadav BS, Vyas S, Kaur R, Yadav G.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	18	5149	5154	21840711	10.1016/j.bmcl.2011.07.062	Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor.	Sriram D, Yogeeswari P, Methuku S, Vyas DR, Senthilkumar P, Alvala M, Jeankumar VU.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	18	5181	5183	21824772	10.1016/j.bmcl.2011.07.068	Synthesis and biological evaluation of some novel N-aryl-1,4-dihydropyridines as potential antitubercular agents.	Trivedi AR, Dodiya DK, Dholariya BH, Kataria VB, Bhuva VR, Shah VH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	18	5259	5261	21807509	10.1016/j.bmcl.2011.07.035	Discovery of novel antitubercular 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues.	Ahsan MJ, Samy JG, Soni S, Jain N, Kumar L, Sharma LK, Yadav H, Saini L, Kalyansing RG, Devenda NS, Prasad R, Jain CB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	18	5353	5357	21807506	10.1016/j.bmcl.2011.07.015	Identification of SQ609 as a lead compound from a library of dipiperidines.	Bogatcheva E, Hanrahan C, Nikonenko B, de los Santos G, Reddy V, Chen P, Barbosa F, Einck L, Nacy C, Protopopova M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	18	5589	5593	21783364	10.1016/j.bmcl.2011.06.076	Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H¿¿Rv.	Roy KK, Singh S, Sharma SK, Srivastava R, Chaturvedi V, Saxena AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	20	6094	6099	21903392	10.1016/j.bmcl.2011.08.054	Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.	Jin Y, Gill SK, Kirchhoff PD, Wan B, Franzblau SG, Garcia GA, Showalter HD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	21	6523	6526	21917452	10.1016/j.bmcl.2011.08.076	Synthesis and preliminary biological evaluation of novel N-(3-aryl-1,2,4-triazol-5-yl) cinnamamide derivatives as potential antimycobacterial agents: an operational Topliss Tree approach.	Kakwani MD, Palsule Desai NH, Lele AC, Ray M, Rajan MG, Degani MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	21	6533	6537	21940166	10.1016/j.bmcl.2011.08.052	Chemical scaffolds with structural similarities to siderophores of nonribosomal peptide-polyketide origin as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis.	Ferreras JA, Gupta A, Amin ND, Basu A, Sinha BN, Worgall S, Jayaprakash V, Quadri LE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	22	6804	6807	21982497	10.1016/j.bmcl.2011.09.031	Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives.	Li YB, Xie YY, Du NN, Lu Y, Xu HZ, Wang B, Yu Y, Liu YX, Song DQ, Chen RX.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	24	7246	7250	22071303	10.1016/j.bmcl.2011.10.057	Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents.	Ahsan MJ, Samy JG, Khalilullah H, Nomani MS, Saraswat P, Gaur R, Singh A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	24	7273	7276	22061642	10.1016/j.bmcl.2011.10.048	Efficient synthesis and in vitro antitubercular activity of 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis.	Shanmugavelan P, Nagarajan S, Sathishkumar M, Ponnuswamy A, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	3	899	903	21232949	10.1016/j.bmcl.2010.12.084	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.	Horita Y, Takii T, Kuroishi R, Chiba T, Ogawa K, Kremer L, Sato Y, Lee Y, Hasegawa T, Onozaki K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	4	1214	1217	21237641	10.1016/j.bmcl.2010.12.082	Synthesis and antitubercular evaluation of novel substituted aryl and thiophenyl tethered dihydro-6H-quinolin-5-ones.	Kantevari S, Patpi SR, Sridhar B, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	7	2055	2058	21376591	10.1016/j.bmcl.2011.02.008	Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.	Hans RH, Wiid IJ, van Helden PD, Wan B, Franzblau SG, Gut J, Rosenthal PJ, Chibale K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	7	2125	2128	21320779	10.1016/j.bmcl.2011.01.122	Microwave assisted one-pot synthesis of highly potent novel isoniazid analogues.	Manjashetty TH, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2011	21	8	2287	2296	21429744	10.1016/j.bmcl.2011.02.103	Facile synthesis and stereochemical investigation of Mannich base derivatives: evaluation of antioxidant property and antituberculostic potency.	Parthiban P, Subalakshmi V, Balasubramanian K, Islam MN, Choi JS, Jeong YT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metabol Drug Interact	2011	26	3	113	118	21980963	10.1515/dmdi.2011.016	Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.	Bing C, Xiaomeia C, Jinhenga L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	1	106	121	21093117	10.1016/j.ejmech.2010.10.020	Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.	Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya M, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	1	341	348	21146257	10.1016/j.ejmech.2010.11.023	Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives.	Feng LS, Liu ML, Zhang S, Chai Y, Wang B, Zhang YB, Lv K, Guan Y, Guo HY, Xiao CL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	10	4827	4833	21723649	10.1016/j.ejmech.2011.06.014	Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction.	Kantevari S, Yempala T, Surineni G, Sridhar B, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	10	4834	4845	21880400	10.1016/j.ejmech.2011.07.049	Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.	Thomas KD, Adhikari AV, Chowdhury IH, Sandeep T, Mahmood R, Bhattacharya B, Sumesh E.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	10	4897	4903	21855182	10.1016/j.ejmech.2011.07.046	Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies.	Chitra S, Paul N, Muthusubramanian S, Manisankar P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	10	4937	4945	21855181	10.1016/j.ejmech.2011.07.052	New fluorine-containing hydrazones active against MDR-tuberculosis.	Vav¿íková E, Polanc S, Ko¿evar M, Horváti K, Bosze S, Stola¿íková J, Vávrová K, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	11	5283	5292	21907466	10.1016/j.ejmech.2011.07.033	Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents.	Thomas KD, Adhikari AV, Telkar S, Chowdhury IH, Mahmood R, Pal NK, Row G, Sumesh E.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	11	5293	5309	21920636	10.1016/j.ejmech.2011.08.014	Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity.	Balbi A, Anzaldi M, Macciò C, Aiello C, Mazzei M, Gangemi R, Castagnola P, Miele M, Rosano C, Viale M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	11	5465	5472	21937152	10.1016/j.ejmech.2011.09.007	A facile synthesis of carbocycle-fused mono and bis-1,2,3-selenadiazoles and their antimicrobial and antimycobacterial studies.	Chitra S, Paul N, Muthusubramanian S, Manisankar P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	11	5573	5579	21981980	10.1016/j.ejmech.2011.09.023	1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.	Akhaja TN, Raval JP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	11	5694	5697	21978838	10.1016/j.ejmech.2011.09.035	Synthesis and antimycobacterial evaluation of 3a,4-dihydro-3H-indeno [1,2-c] pyrazole-2-carboxamide analogues.	Ahsan MJ, Samy JG, Khalilullah H, Bakht MA, Hassan MZ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	12	5902	5909	22018878	10.1016/j.ejmech.2011.09.054	New series of isoniazid hydrazones linked with electron-withdrawing substituents.	Vav¿íková E, Polanc S, Ko¿evar M, Ko¿mrlj J, Horváti K, Bosze S, Stola¿íková J, Imramovský A, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	5	1849	1856	21397998	10.1016/j.ejmech.2011.02.047	Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.	Izumizono Y, Arevalo S, Koseki Y, Kuroki M, Aoki S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	6	2091	2101	21429630	10.1016/j.ejmech.2011.02.062	Synthesis of N-substituted 2-[(1E)-alkenyl]-4-(1H)-quinolone derivatives as antimycobacterial agents against non-tubercular mycobacteria.	Wube AA, Bucar F, Hochfellner C, Blunder M, Bauer R, Hüfner A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	6	2290	2294	21450375	10.1016/j.ejmech.2011.03.010	Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity.	Singh K, Singh K, Wan B, Franzblau S, Chibale K, Balzarini J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	6	2503	2512	21489660	10.1016/j.ejmech.2011.03.039	New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents.	Thomas KD, Adhikari AV, Chowdhury IH, Sumesh E, Pal NK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	7	3118	3123	21546135	10.1016/j.ejmech.2011.04.025	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.	Macabeo AP, Vidar WS, Chen X, Decker M, Heilmann J, Wan B, Franzblau SG, Galvez EV, Aguinaldo MA, Cordell GA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	9	3788	3794	21712145	10.1016/j.ejmech.2011.05.044	Synthesis and antimicrobial properties of some new thiazolyl coumarin derivatives.	Arshad A, Osman H, Bagley MC, Lam CK, Mohamad S, Zahariluddin AS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	9	4192	4200	21741732	10.1016/j.ejmech.2011.06.022	Synthesis and identification of ß-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.	Mungra DC, Patel MP, Rajani DP, Patel RG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	9	4302	4310	21764184	10.1016/j.ejmech.2011.06.037	Novel aryloxy azolyl chalcones with potent activity against Mycobacterium tuberculosis H37Rv.	Marrapu VK, Chaturvedi V, Singh S, Singh S, Sinha S, Bhandari K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	9	4521	4529	21820768	10.1016/j.ejmech.2011.07.026	Quinonoid and phenazine compounds: synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis.	Carneiro PF, Pinto Mdo C, Coelho TS, Cavalcanti BC, Pessoa C, de Simone CA, Nunes IK, de Oliveira NM, de Almeida RG, Pinto AV, de Moura KC, da Silva PA, da Silva Júnior EN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2011	46	9	4530	4536	21839549	10.1016/j.ejmech.2011.07.029	A facile four-component sequential protocol in the expedient synthesis of novel 2-aryl-5-methyl-2,3-dihydro-1H-3-pyrazolones in water and their antitubercular evaluation.	Gunasekaran P, Perumal S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2011	54	17	5988	5999	21776985	10.1021/jm2003624	Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.	Boechat N, Ferreira VF, Ferreira SB, de Lourdes G Ferreira M, de C da Silva F, Bastos MM, Dos S Costa M, Lourenço MC, Pinto AC, Krettli AU, Aguiar AC, Teixeira BM, da Silva NV, Martins PR, Bezerra FA, Camilo AL, da Silva GP, Costa CC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2011	54	5	1449	1461	21309577	10.1021/jm101510d	Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents.	De P, Koumba Yoya G, Constant P, Bedos-Belval F, Duran H, Saffon N, Daffé M, Baltas M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2011	74	10	2143	2150	21995505	10.1021/np200429b	Lanostane and hopane triterpenes from the entomopathogenic fungus Hypocrella sp. BCC 14524.	Isaka M, Chinthanom P, Sappan M, Chanthaket R, Luangsa-ard JJ, Prabpai S, Kongsaeree P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2011	74	10	2216	2218	21919533	10.1021/np200593d	Diarylpropanes and an arylpropyl quinone from Combretum griffithii.	Moosophon P, Kanokmedhakul S, Kanokmedhakul K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2011	74	10	2250	2256	21978379	10.1021/np2006555	One-pot syntheses of pseudopteroxazoles from pseudopterosins: a rapid route to non-natural congeners with improved antimicrobial activity.	McCulloch MW, Berrue F, Haltli B, Kerr RG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2011	74	4	609	613	21341709	10.1021/np100632g	Cytotoxic pentacyclic and tetracyclic aromatic sesquiterpenes from Phomopsis archeri.	Hemtasin C, Kanokmedhakul S, Kanokmedhakul K, Hahnvajanawong C, Soytong K, Prabpai S, Kongsaeree P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2011	74	9	1842	1850	21859082	10.1021/np2000667	Stereochemical analysis of leubethanol, an anti-TB-active serrulatane, from Leucophyllum frutescens.	Molina-Salinas GM, Rivas-Galindo VM, Said-Fernández S, Lankin DC, Muñoz MA, Joseph-Nathan P, Pauli GF, Waksman N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	1	137	144	22153872	10.1016/j.bmc.2011.11.020	Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity.	Gobis K, Foks H, Bojanowski K, Augustynowicz-Kope¿ E, Napiórkowska A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	10	3255	3262	22522007	10.1016/j.bmc.2012.03.058	Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.	Scherman MS, North EJ, Jones V, Hess TN, Grzegorzewicz AE, Kasagami T, Kim IH, Merzlikin O, Lenaerts AJ, Lee RE, Jackson M, Morisseau C, McNeil MR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	13	4088	4097	22664188	10.1016/j.bmc.2012.05.004	Discovery of novel 5-(ethyl or hydroxymethyl) analogs of 2'-'up' fluoro (or hydroxyl) pyrimidine nucleosides as a new class of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium inhibitors.	Shakya N, Srivastav NC, Bhavanam S, Tse C, Desroches N, Agrawal B, Kunimoto DY, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	13	4149	4154	22633120	10.1016/j.bmc.2012.04.060	Synthesis and antimycobacterial activity of some phthalimide derivatives.	Akgün H, Karameleko¿lu I, Berk B, Kurnaz I, Sar¿b¿y¿k G, Oktem S, Kocagöz T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	21	6482	6488	23000294	10.1016/j.bmc.2012.08.041	1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.	Moura KC, Carneiro PF, Pinto Mdo C, da Silva JA, Malta VR, de Simone CA, Dias GG, Jardim GA, Cantos J, Coelho TS, da Silva PE, da Silva EN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	22	6680	6686	23062712	10.1016/j.bmc.2012.09.019	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.	Matyugina E, Khandazhinskaya A, Chernousova L, Andreevskaya S, Smirnova T, Chizhov A, Karpenko I, Kochetkov S, Alexandrova L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	24	7059	7068	23140987	10.1016/j.bmc.2012.10.007	Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.	Fajkusova D, Pesko M, Keltosova S, Guo J, Oktabec Z, Vejsova M, Kollar P, Coffey A, Csollei J, Kralova K, Jampilek J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	4	1482	1493	22285027	10.1016/j.bmc.2011.12.053	Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.	McCracken ST, Kaiser M, Boshoff HI, Boyd PD, Copp BR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	6	2035	2041	22361273	10.1016/j.bmc.2012.01.041	Anti-mycobacterial activities of some cationic and anionic calix[4]arene derivatives.	Mourer M, Massimba Dibama H, Constant P, Daffé M, Regnouf-de-Vains JB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	7	2214	2220	22391032	10.1016/j.bmc.2012.02.025	Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.	Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, Hwang CH, Boshoff H, Miller MJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2012	20	8	2701	2706	22459211	10.1016/j.bmc.2012.02.039	Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.	Gröblacher B, Kunert O, Bucar F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	10	2762	2771		10.1007/s00044-011-9808-9	Design, synthesis, and in vitro antimicrobial activities of novel azetidinyl-3-quinazolin-4-one hybrids	Myangar KN, Raval JP
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	10	2831	2836		10.1007/s00044-011-9813-z	7-chloro-3-(substituted benzylidene/phenyl ethylidene amino)-2-phenylquinazolin-4(3H)-ones: synthesis, antimicrobial and antitubercular evaluation	Anand RV, Narasimhan B, Chandran RVP, Jayaveera KN
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	12	3940	3957		10.1007/s00044-011-9948-y	Isoniazid: the magic molecule	Judge V, Narasimhan B, Ahuja M
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	12	4168	4176		10.1007/s00044-011-9942-4	Antituberculosis and antibacterial evaluations of some novel phenyl pyrazolone-substituted 1h-benzo[g]pyrazolo[3,4-b]quinoline-3-ylamine derivatives	Parekh NM, Maheria KC
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	12	4177	4192		10.1007/s00044-011-9950-4	Discovery of 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(4-quinazolinyloxy)-6-piperazinyl(piperidinyl)-s-triazines as potential antibacterial agents	Patel RV, Kumari P, Rajani DP, Chikhalia KH
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	12	4335	4340		10.1007/s00044-012-9971-7	Synthesis, antibacterial, and antitubercular studies of some novel isatin derivatives	Murali K, Avinash R, Kirthiga R, Franzblau SG
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	5	653	662		10.1007/s00044-011-9573-9	Design and synthesis of novel piperazine unit condensed 2,6-diarylpiperidin-4-one derivatives as antituberculosis and antimicrobial agents	Rani M, Parthiban P, Ramachandran R, Kabilan S
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	6	810	815		10.1007/s00044-011-9638-9	Novel antitubercular diallyl/dibenzylthiosemicarbazones endowed with high activity toward multi-drug-resistant tuberculosis	Sriram D, Banerjee D, Varuna TSTV, Sankar M, Yogeeswari P
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	7	1313	1321		10.1007/s00044-011-9646-9	Synthesis, spectral studies and biological evaluation of a novel series of 2-substituted-5,6-diarylsubstituted imidazo(2,1-b)-1,3,4-thiadiazole derivatives as possible anti-tubercular agents	Palkar MB, Noolvi MN, Maddi VS, Ghatole M, Nargund LG
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	7	1451	1470		10.1007/s00044-011-9662-9	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	8	1557	1576		10.1007/s00044-011-9664-7	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives	Narang R, Narasimhan B, Sharma S, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	8	1935	1952		10.1007/s00044-011-9705-2	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	8	1977	1983		10.1007/s00044-011-9718-x	Synthesis of 1-(4-((E)-3-arylacryloyl) phenyl)-3,4-dibromo-1H-pyrrole-2,5-diones and screening for anti-Candida and antituberculosis activity	Patel JR, Dholakiya BZ
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	8	2044	2055		10.1007/s00044-011-9728-8	Pyridoquinolones containing azetidinones: synthesis and their biological evaluation	Patel NB, Pathak KK
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	8	2117	2122		10.1007/s00044-011-9788-9	Cobalt mediated ring contraction reaction of lapachol and initial antibacterial evaluation of naphthoquinones derived from lapachol	Eyong KO, Kumar SP, Kuete V, Folefoc GN, Langmi H, Meyer MJJ, Lall N, Baskaran S
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2012	21	9	2388	2394		10.1007/s00044-011-9770-6	Synthesis and antimycobacterial activities of some new N-acylhydrazone and thiosemicarbazide derivatives of 6-methyl-4,5-dihydropyridazin-3(2H)-one	Unsal Tan O, Ozadali K, Yogeeswari P, Sriram D, Balkan A
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	1	649	652	22079026	10.1016/j.bmcl.2011.10.064	Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as anti-tubercular agents.	Telvekar VN, Bairwa VK, Satardekar K, Bellubi A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	11	3603	3606	22572576	10.1016/j.bmcl.2012.04.048	Synthesis and antimycobacterial activity of prodrugs of sulfur dioxide (SO2).	Malwal SR, Sriram D, Yogeeswari P, Chakrapani H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	12	4075	4079	22607678	10.1016/j.bmcl.2012.04.070	An improved microwave assisted one-pot synthesis, and biological investigations of some novel aryldiazenyl chromeno fused pyrrolidines.	Parmar NJ, Pansuriya BR, Barad HA, Kant R, Gupta VK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	14	4629	4635	22726932	10.1016/j.bmcl.2012.05.096	Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.	Dulla B, Wan B, Franzblau SG, Kapavarapu R, Reiser O, Iqbal J, Pal M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	15	4930	4933	22749825	10.1016/j.bmcl.2012.06.047	Antimycobacterial activity: a facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines.	Wei AC, Ali MA, Yoon YK, Ismail R, Choon TS, Kumar RS, Arumugam N, Almansour AI, Osman H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	17	5727	5730	22832312	10.1016/j.bmcl.2012.06.072	Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.	Shelke SN, Mhaske GR, Bonifácio VD, Gawande MB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	19	6151	6154	22939698	10.1016/j.bmcl.2012.08.003	Three new 12-carbamoylated streptothricins from Streptomyces sp. I08A 1776.	Gan M, Zheng X, Liu Y, Guan Y, Xiao C.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	2	954	957	22197389	10.1016/j.bmcl.2011.12.022	Design, synthesis and evaluation of novel molecules with a diphenyl ether nucleus as potential antitubercular agents.	Yang Y, Wang Z, Yang J, Yang T, Pi W, Ang W, Lin Y, Liu Y, Li Z, Luo Y, Wei Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	2	969	972	22197387	10.1016/j.bmcl.2011.12.014	Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues.	Ahsan MJ, Samy JG, Jain CB, Dutt KR, Khalilullah H, Nomani MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	20	6429	6432	22967765	10.1016/j.bmcl.2012.08.061	Synthesis and evaluation of novel 1,3,4-oxadiazole derivatives of marine bromopyrrole alkaloids as antimicrobial agent.	Rane RA, Gutte SD, Sahu NU.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	22	6909	6913	23046964	10.1016/j.bmcl.2012.09.023	Synthesis and antituberculosis activity of novel unfolded and macrocyclic derivatives of ent-kaurane steviol.	Khaybullin RN, Strobykina IY, Dobrynin AB, Gubaydullin AT, Chestnova RV, Babaev VM, Kataev VE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	24	7414	7417	23137434	10.1016/j.bmcl.2012.10.060	Development of 5-nitrothiazole derivatives: identification of leads against both replicative and latent Mycobacterium tuberculosis.	Jeankumar VU, Chandran M, Samala G, Alvala M, Koushik PV, Yogeeswari P, Salina EG, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	24	7418	7421	23122863	10.1016/j.bmcl.2012.10.059	A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of new-fangled dispiropyrrolothiazoles as antimycobacterial agents.	Almansour AI, Ali S, Ali MA, Ismail R, Choon TS, Sellappan V, Elumalai KK, Pandian S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	24	7426	7430	23151429	10.1016/j.bmcl.2012.10.056	Molecular hybridization of bioactives: synthesis and antitubercular evaluation of novel dibenzofuran embodied homoisoflavonoids via Baylis-Hillman reaction.	Yempala T, Sriram D, Yogeeswari P, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	24	7539	7542	23122523	10.1016/j.bmcl.2012.10.032	Microwave-assisted synthesis, molecular docking and antitubercular activity of 1,2,3,4-tetrahydropyrimidine-5-carbonitrile derivatives.	Mohan SB, Ravi Kumar BV, Dinda SC, Naik D, Prabu Seenivasan S, Kumar V, Rana DN, Brahmkshatriya PS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	4	1643	1648	22277278	10.1016/j.bmcl.2011.12.119	Camphorsulfonic acid catalysed facile tandem double Friedlander annulation protocol for the synthesis of phenoxy linked bisquinoline derivatives and discovery of antitubercular agents.	Paul N, Murugavel M, Muthusubramanian S, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	5	1917	1921	22325950	10.1016/j.bmcl.2012.01.052	Novel imidazo[2,1-b][1,3,4]thiadiazole carrying rhodanine-3-acetic acid as potential antitubercular agents.	Alegaon SG, Alagawadi KR, Sonkusare PV, Chaudhary SM, Dadwe DH, Shah AS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	6	2343	2346	22365752	10.1016/j.bmcl.2012.01.067	Novel N'-benzylidene benzofuran-3-carbohydrazide derivatives as antitubercular and antifungal agents.	Telvekar VN, Belubbi A, Bairwa VK, Satardekar K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	8	2764	2767	22440626	10.1016/j.bmcl.2012.02.091	Synthesis of highly potent novel anti-tubercular isoniazid analogues with preliminary pharmacokinetic evaluation.	Ramani AV, Monika A, Indira VL, Karyavardhi G, Venkatesh J, Jeankumar VU, Manjashetty TH, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2012	22	8	2902	2905	22418278	10.1016/j.bmcl.2012.02.053	Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis.	Sureram S, Senadeera SP, Hongmanee P, Mahidol C, Ruchirawat S, Kittakoop P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	47		278	282	22088956	10.1016/j.ejmech.2011.10.054	Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.	Bakal RL, Gattani SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	47		452	461	22119127	10.1016/j.ejmech.2011.11.014	Electrochemical and spectroscopic investigations of isoniazide and its analogs with ds.DNA at physiological pH: evaluation of biological activities.	Arshad N, Yunus U, Razzque S, Khan M, Saleem S, Mirza B, Rashid N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	48		57	68	22182928	10.1016/j.ejmech.2011.11.033	Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents.	Cappoen D, Jacobs J, Nguyen Van T, Claessens S, Diels G, Anthonissen R, Einarsdottir T, Fauville M, Verschaeve L, Huygen K, De Kimpe N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	49		164	171	22264895	10.1016/j.ejmech.2012.01.007	Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.	Lu X, Liu X, Wan B, Franzblau SG, Chen L, Zhou C, You Q.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	49		172	182	22280817	10.1016/j.ejmech.2012.01.008	Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents.	Karuvalam RP, Haridas KR, Nayak SK, Row TN, Rajeesh P, Rishikesan R, Kumari NS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	49		95	101	22301215	10.1016/j.ejmech.2011.12.035	1,4-diarylpiperazines and analogs as anti-tubercular agents: synthesis and biological evaluation.	Forge D, Cappoen D, Laurent J, Stanicki D, Mayence A, Huang TL, Verschaeve L, Huygen K, Vanden Eynde JJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	50		433	440	22365879	10.1016/j.ejmech.2012.01.060	Antimicrobial activity of sulfonamides containing 5-chloro-2-hydroxybenzaldehyde and 5-chloro-2-hydroxybenzoic acid scaffold.	Krátký M, Vin¿ová J, Volková M, Buchta V, Trejtnar F, Stola¿íková J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	51		1	16	22421275	10.1016/j.ejmech.2012.02.033	Tuberculosis: the drug development pipeline at a glance.	Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	51		277	285	22405649	10.1016/j.ejmech.2012.02.031	Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents.	Ponaire S, Zinglé C, Tritsch D, Grosdemange-Billiard C, Rohmer M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	52		151	158	22503208	10.1016/j.ejmech.2012.03.012	Synthesis, structure-activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives.	Liu YX, Xiao CL, Wang YX, Li YH, Yang YH, Li YB, Bi CW, Gao LM, Jiang JD, Song DQ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	53		300	307	22578509	10.1016/j.ejmech.2012.04.014	Synthesis and antimycobacterial activity of novel 1,3-dimethylisocyanurate derivatives.	Shulaeva MM, Fattakhov SG, Saifina LF, Chestnova RV, Valijev RSh, Mingaleev DN, Voloshina AD, Reznik VS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	53		41	51	22516426	10.1016/j.ejmech.2012.03.033	Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents.	Patel RV, Patel PK, Kumari P, Rajani DP, Chikhalia KH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	53		416	423	22575534	10.1016/j.ejmech.2012.04.021	A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(H)-pyrans with nitrile oxides: synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles.	Almansour AI, Suresh Kumar R, Arumugam N, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	54		239	247	22652224	10.1016/j.ejmech.2012.05.004	New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.	Shah NM, Patel MP, Patel RG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	1	553	557	22128803	10.1021/jm201023g	Design, synthesis, and evaluation of thiol-activated sources of sulfur dioxide (SO¿) as antimycobacterial agents.	Malwal SR, Sriram D, Yogeeswari P, Konkimalla VB, Chakrapani H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	13	6047	6060	22691154	10.1021/jm300123s	Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.	Chopra S, Koolpe GA, Tambo-Ong AA, Matsuyama KN, Ryan KJ, Tran TB, Doppalapudi RS, Riccio ES, Iyer LV, Green CE, Wan B, Franzblau SG, Madrid PB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	8	3739	3755	22449052	10.1021/jm201608g	Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.	Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	8	3814	3826	22452568	10.1021/jm201716n	Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.	Gill SK, Xu H, Kirchhoff PD, Cierpicki T, Turbiak AJ, Wan B, Zhang N, Peng KW, Franzblau SG, Garcia GA, Showalter HD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2012	55	8	3911	3922	22449006	10.1021/jm300125e	Design, synthesis, and structure-activity correlations of novel dibenzo[b,d]furan, dibenzo[b,d]thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of Mycobacterium tuberculosis.	Patpi SR, Pulipati L, Yogeeswari P, Sriram D, Jain N, Sridhar B, Murthy R, Anjana Devi T, Kalivendi SV, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	56		108	119	22960697	10.1016/j.ejmech.2012.08.016	Synthesis and in vitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2'-hydroxybenzanilides, their thioxo analogues and benzoxazoles.	Kozic J, Novotná E, Volková M, Stola¿íková J, Trejtnar F, Wsól V, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	56		387	395	22907036	10.1016/j.ejmech.2012.07.044	Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues.	Kozic J, Novotná E, Volková M, Stola¿íková J, Trejtnar F, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2012	57		259	267	23064162	10.1016/j.ejmech.2012.08.047	The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.	Tukulula M, Little S, Gut J, Rosenthal PJ, Wan B, Franzblau SG, Chibale K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2012	75	12	2178	2182	23205944	10.1021/np3006277	Ramariolides A-D, antimycobacterial butenolides isolated from the mushroom Ramaria cystidiophora.	Centko RM, Ramón-García S, Taylor T, Patrick BO, Thompson CJ, Miao VP, Andersen RJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2012	75	3	336	343	21899267	10.1021/np2003319	Antibacterial acylphloroglucinols from Hypericum olympicum.	Shiu WK, Rahman MM, Curry J, Stapleton P, Zloh M, Malkinson JP, Gibbons S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	17	4874	4884	23891229	10.1016/j.bmc.2013.07.003	Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.	Shmalenyuk ER, Chernousova LN, Karpenko IL, Kochetkov SN, Smirnova TG, Andreevskaya SN, Chizhov AO, Efremenkova OV, Alexandrova LA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	17	5282	5291	23850103	10.1016/j.bmc.2013.06.027	Synthesis of novel isothiazolopyridines and their in vitro evaluation against Mycobacterium and Propionibacterium acnes.	Malinka W, Swi¿tek P, Sliwi¿ska M, Szponar B, Gamian A, Karczmarzyk Z, Fruzi¿ski A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	17	5355	5361	23823011	10.1016/j.bmc.2013.06.013	Synthesis and bioevaluation of some new isoniazid derivatives.	Matei L, Bleotu C, Baciu I, Draghici C, Ionita P, Paun A, Chifiriuc MC, Sbarcea A, Zarafu I.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	21	6531	6541	24075143	10.1016/j.bmc.2013.08.030	Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides.	Gonec T, Kos J, Zadrazilova I, Pesko M, Keltosova S, Tengler J, Bobal P, Kollar P, Cizek A, Kralova K, Jampilek J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	21	6574	6581	24045008	10.1016/j.bmc.2013.08.029	New derivatives of salicylamides: Preparation and antimicrobial activity against various bacterial species.	Pauk K, Zadra¿ilová I, Imramovský A, Vin¿ová J, Pokorná M, Masa¿íková M, Cí¿ek A, Jampílek J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	22	6910	6914	24103427	10.1016/j.bmc.2013.09.034	Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.	Rodrigues MO, Cantos JB, D'Oca CR, Soares KL, Coelho TS, Piovesan LA, Russowsky D, da Silva PA, D'Oca MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	24	7830	7840	24200931	10.1016/j.bmc.2013.10.011	Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis.	Tiruveedhula VV, Witzigmann CM, Verma R, Kabir MS, Rott M, Schwan WR, Medina-Bielski S, Lane M, Close W, Polanowski RL, Sherman D, Monte A, Deschamps JR, Cook JM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2013	21	4	957	963	23306052	10.1016/j.bmc.2012.12.012	Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions.	Sanchez TW, Debnath B, Christ F, Otake H, Debyser Z, Neamati N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	1	195	210		10.1007/s00044-012-0026-x	Synthesis of coumarin-based 1,3,4-oxadiazol-2ylthio-N-phenyl/benzothiazolyl acetamides as antimicrobial and antituberculosis agents	Patel RV, Kumari P, Rajani DP, Chikhalia KH
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	1	367	381		10.1007/s00044-012-0041-y	Synthesis of potential antitubercular and antimicrobial s-triazine-based scaffolds via Suzuki cross-coupling reaction	Patel AB, Patel RV, Kumari P, Rajani DP, Chikhalia KH
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	1	401	408		10.1007/s00044-012-0043-9	Novel 4H-1,2,4-triazol-3-yl cycloalkanols as potent antitubercular agents	Desai NHP, Bairwa R, Kakwani M, Tawari N, Ray MK, Rajan MG, Degani M
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	10	4700	4707		10.1007/s00044-013-0472-0	New carbodithioate derivatives: synthesis, characterization, and in vitro antibacterial, antifungal, antitubercular, and antimalarial activity	Akhaja TN, Raval JP
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	10	4755	4765		10.1007/s00044-013-0488-5	Molecular docking and in silico studies on analogues of 2-methylheptyl isonicotinate with DHDPS enzyme of Mycobacterium tuberculosis	Singh SP, Konwar BK, Bezbaruah RL, Bora TC
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	11	5141	5152		10.1007/s00044-013-0485-8	The antimycobacterial MICs, SARs, and QSARs of some ethnobotanically selected phytocompounds	Muriuki B, Midiwo JO, Mbugua PM, Keriko JM
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	12	5848	5860		10.1007/s00044-013-0576-6	Thermal, kinetic, spectroscopic studies and anti-microbial, anti-tuberculosis, anti-oxidant properties of clioquinol and benzo-coumarin derivatives mixed complexes with copper ion	Dholariya HR, Patel KS, Patel JC, Patel AK, Patel KD
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	2	635	646		10.1007/s00044-012-0060-8	Synthesis and in vitro antimicrobial and anti-tubercular evaluation of some quinoline-based azitidinone and thiazolidinone analogues	Mistry BM, Jauhari S
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	2	726	744		10.1007/s00044-012-0073-3	In vitro antimicrobial and antimycobacterial activity of some chalcones and their derivatives	Patel D, Kumari P, Patel NB
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	2	818	831		10.1007/s00044-012-0074-2	Synthesis and antibacterial, antimycobacterial and docking studies of novel N-piperazinyl fluoroquinolones	Agrawal KM, Talele GS
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	2	938	948		10.1007/s00044-012-0092-0	Synthesis and pharmacological evaluation of novel 4-isopropylthiazole-4-phenyl-1,2,4-triazole derivatives as potential antimicrobial and antitubercular agents	Suresh Kumar GV, Rajendra Prasad Y, Chandrashekar SM
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	3	1029	1042		10.1007/s00044-012-0101-3	Quinolone derivatives as antitubercular drugs	Asif M, Siddiqui AA, Husain A
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	3	1073	1089		10.1007/s00044-012-0112-0	Synthesis of new 4-(2,5-dimethylpyrrol-1-yl)/4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems: a novel class of potential antibacterial, antifungal and antitubercular agents	Joshi SD, More Y, Vagdevi HM, Vaidya VP, Gadaginamath GS, Kulkarni VH
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	3	1320	1329		10.1007/s00044-012-0129-4	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles	Patel NB, Khan IH, Pannecouque C, De Clercq E
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	5	2279	2283		10.1007/s00044-012-0222-8	Coumarinyl pyrazole derivatives of INH: promising antimycobacterial agents	Aragade P, Palkar M, Ronad P, Satyanarayana D
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	6	2737	2745		10.1007/s00044-012-0273-x	Antimicrobial activity of thiazolyl benzenesulfonamide-condensed 2,4-thiazolidinediones derivatives	Parekh NM, Juddhawala KV, Rawal BM
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	6	3035	3047		10.1007/s00044-012-0322-5	Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of -aryloxyquinoline and their antimicrobial and antituberculosis activities	Sangani CB, Jardosh HH, Patel MP, Patel RG
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	7	3364	3371		10.1007/s00044-012-0351-0	Synthesis and antitubercular activity of novel pyrazolequinazolinone hybrid analogs	Pandit U, Dodiya A
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	7	3428	3433		10.1007/s00044-012-0340-3	Oxadiazolo pyrrolidine carboxamides as enoyl-ACP reductase inhibitors: design, synthesis and antitubercular activity screening	Sonia G, Ravi TK
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	8	3863	3880		10.1007/s00044-012-0385-3	Synthesis, antitubercular activity, and QSAR analysis of substituted nitroaryl analogs: chalcone, pyrazole, isoxazole, and pyrimidines	Gupta RA, Kaskhedikar SG
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	9	4239	4252		10.1007/s00044-012-0431-1	Synthesis and pharmacological evaluation of some novel 4-isopropyl thiazole-based sulfonyl derivatives as potent antimicrobial and antitubercular agents	Suresh Kumar GV, Rajendra Prasad Y, Chandrashekar SM
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	9	4437	4454		10.1007/s00044-012-0451-x	Synthesis, characterization, and SAR studies of new (1H-indol-3-yl)alkyl-3-(1H-indol-3-yl)propanamide derivatives as possible antimicrobial and antitubercular agents	Karuvalam RP, Pakkath R, Haridas KR, Rishikesan R, Kumari NS
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013	22	9	4522	4528		10.1007/s00044-012-0458-3	Synthesis, characterization, and in vitro anti-Mycobacterium tuberculosis activity of terpene Schiff bases	Bhat MA, Al-Omar MA
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	12	3547	3550	23668986	10.1016/j.bmcl.2013.04.034	3-Anhydro-6-hydroxy-ophiobolin A, a new sesterterpene inhibiting the growth of methicillin-resistant Staphylococcus aureus and inducing the cell death by apoptosis on K562, from the phytopathogenic fungus Bipolaris oryzae.	Wang QX, Yang JL, Qi QY, Bao L, Yang XL, Liu MM, Huang P, Zhang LX, Chen JL, Cai L, Liu HW.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	12	3589	3591	23659859	10.1016/j.bmcl.2013.04.021	Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.	Servusová B, Vobicková J, Paterová P, Kubí¿ek V, Kune¿ J, Dole¿al M, Dole¿al M, Zitko J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	17	4741	4750	23910985	10.1016/j.bmcl.2013.07.006	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.	Dartois V, Barry CE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	17	4919	4922	23886691	10.1016/j.bmcl.2013.06.069	Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents.	Gao C, Ye TH, Wang NY, Zeng XX, Zhang LD, Xiong Y, You XY, Xia Y, Xu Y, Peng CT, Zuo WQ, Wei Y, Yu LT.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	18	5228	5234	23942420	10.1016/j.bmcl.2013.06.072	Design and synthesis of positional isomers of 5 and 6-bromo-1-[(phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as possible antimicrobial and antitubercular agents.	Ranjith PK, Rajeesh P, Haridas KR, Susanta NK, Row TN, Rishikesan R, Kumari NS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	19	5393	5396	23953191	10.1016/j.bmcl.2013.07.048	Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladium-copper catalysed Sonagashira coupling reaction.	Yempala T, Sridevi JP, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	2	476	479	23237840	10.1016/j.bmcl.2012.11.052	Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.	Zitko J, Paterová P, Kubí¿ek V, Mandíková J, Trejtnar F, Kune¿ J, Dole¿al M, Dole¿al M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	21	5844	5849	24074842	10.1016/j.bmcl.2013.08.101	Studies on substituted benzo[h]quinazolines, benzo[g]indazoles, pyrazoles, 2,6-diarylpyridines as anti-tubercular agents.	Maurya HK, Verma R, Alam S, Pandey S, Pathak V, Sharma S, Srivastava KK, Negi AS, Gupta A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	22	6097	6105	24095091	10.1016/j.bmcl.2013.09.027	Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents.	Jain PP, Degani MS, Raju A, Ray M, Rajan MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	22	6111	6113	24084159	10.1016/j.bmcl.2013.09.013	Inhibitory effect of oxygenated cholestan-3ß-ol derivatives on the growth of Mycobacterium tuberculosis.	Schmidt AW, Choi TA, Theumer G, Franzblau SG, Knölker HJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	24	6805	6810	24169232	10.1016/j.bmcl.2013.10.016	Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents.	Nagesh HN, Naidu KM, Rao DH, Sridevi JP, Sriram D, Yogeeswari P, Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	3	711	714	23265877	10.1016/j.bmcl.2012.11.097	One pot solvent free synthesis and in vitro antitubercular screening of 3-Aracylphthalides against Mycobacterium tuberculosis.	Limaye RA, Kumbhar VB, Natu AD, Paradkar MV, Honmore VS, Chauhan RR, Gample SP, Sarkar D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	5	1182	1186	23391589	10.1016/j.bmcl.2013.01.031	Discovery of novel inhibitors targeting the Mycobacterium tuberculosis O-acetylserine sulfhydrylase (CysK1) using virtual high-throughput screening.	Jean Kumar VU, Poyraz Ö, Saxena S, Schnell R, Yogeeswari P, Schneider G, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	5	1383	1386	23352268	10.1016/j.bmcl.2012.12.069	A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.	Wei AC, Ali MA, Yoon YK, Ismail R, Choon TS, Kumar RS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	6	1656	1661	23414843	10.1016/j.bmcl.2013.01.079	An efficient domino reaction in ionic liquid: synthesis and biological evaluation of some pyrano- and thiopyrano-fused heterocycles.	Parmar NJ, Patel RA, Parmar BD, Talpada NP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2013	23	8	2404	2407	23474387	10.1016/j.bmcl.2013.02.030	Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains.	Kumar S, Dwivedi AP, Kashyap VK, Saxena AK, Dwivedi AK, Srivastava R, Sahu DP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2013	4	10	958	963	24900592	10.1021/ml4002248	Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.	Anand N, Ramakrishna KK, Gupt MP, Chaturvedi V, Singh S, Srivastava KK, Sharma P, Rai N, Ramachandran R, Dwivedi AK, Gupta V, Kumar B, Pandey S, Shukla PK, Pandey SK, Lal J, Tripathi RP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2013	4	4	720	723		10.1039/C3MD00016H	Potent growth inhibitory activity of ()-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis	Moustafa GAI, Nojima S, Yamano Y, Aono A, Arai M, Mitarai S, Tanaka T, Yoshimitsu T
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2013	4	7	675	679	23930153	10.1021/ml400088y	Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.	Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2013	56	10	4093	4103	23611124	10.1021/jm4003878	Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.	Onajole OK, Pieroni M, Tipparaju SK, Lun S, Stec J, Chen G, Gunosewoyo H, Guo H, Ammerman NC, Bishai WR, Kozikowski AP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2013	56	21	8533	8542	24107081	10.1021/jm4012033	Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.	Shirude PS, Madhavapeddi P, Naik M, Murugan K, Shinde V, Nandishaiah R, Bhat J, Kumar A, Hameed S, Holdgate G, Davies G, McMiken H, Hegde N, Ambady A, Venkatraman J, Panda M, Bandodkar B, Sambandamurthy VK, Read JA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2013	56	21	8834	8848	24088190	10.1021/jm401268f	Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.	Kale MG, Raichurkar A, P SH, Waterson D, McKinney D, Manjunatha MR, Kranthi U, Koushik K, Jena Lk, Shinde V, Rudrapatna S, Barde S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Ghosh A, Ramya VK, Guptha S, Sharma S, Vachaspati P, Kumar KN, Giridhar J, Reddy J, Panduga V, Ganguly S, Ahuja V, Gaonkar S, Kumar CN, Ogg D, Tucker JA, Boriack-Sjodin PA, de Sousa SM, Sambandamurthy VK, Ghorpade SR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2013	56	21	8849	8859	24090347	10.1021/jm4012774	Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.	Kondreddi RR, Jiricek J, Rao SP, Lakshminarayana SB, Camacho LR, Rao R, Herve M, Bifani P, Ma NL, Kuhen K, Goh A, Chatterjee AK, Dick T, Diagana TT, Manjunatha UH, Smith PW.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2013	56	23	9756	9770	24266862	10.1021/jm401468w	SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.	Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	59		64	74	23202852	10.1016/j.ejmech.2012.10.047	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.	Hernández P, Rojas R, Gilman RH, Sauvain M, Lima LM, Barreiro EJ, González M, Cerecetto H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	60		333	339	23314046	10.1016/j.ejmech.2012.12.012	Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.	Koseki Y, Kinjo T, Kobayashi M, Aoki S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	62		693	704	23454512	10.1016/j.ejmech.2013.01.017	Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents.	Chauhan K, Sharma M, Saxena J, Singh SV, Trivedi P, Srivastava K, Puri SK, Saxena JK, Chaturvedi V, Chauhan PM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	63		675	684	23567957	10.1016/j.ejmech.2013.03.017	Synthesis and identification of ß-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.	Kathrotiya HG, Patel MP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	63		731	738	23567963	10.1016/j.ejmech.2013.03.023	Biological evaluation of bisbenzaldehydes against four Mycobacterium species.	Cappoen D, Forge D, Vercammen F, Mathys V, Kiass M, Roupie V, Anthonissen R, Verschaeve L, Vanden Eynde JJ, Huygen K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	65		348	359	23747804	10.1016/j.ejmech.2013.05.003	Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.	Jardosh HH, Patel MP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	67		98	110	23850570	10.1016/j.ejmech.2013.06.010	Synthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine.	Claes P, Cappoen D, Mbala BM, Jacobs J, Mertens B, Mathys V, Verschaeve L, Huygen K, De Kimpe N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	69		167	173	24016834	10.1016/j.ejmech.2013.06.042	Synthesis and evaluation of ¿-ketotriazoles and ¿,ß-diketotriazoles as inhibitors of Mycobacterium tuberculosis.	Menendez C, Rodriguez F, Ribeiro AL, Zara F, Frongia C, Lobjois V, Saffon N, Pasca MR, Lherbet C, Baltas M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	69		356	364	24077526	10.1016/j.ejmech.2013.08.036	Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.	Samala G, Devi PB, Nallangi R, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	69		564	576	24095750	10.1016/j.ejmech.2013.08.054	2-(2-Hydrazinyl)thiazole derivatives: design, synthesis and in vitro antimycobacterial studies.	Makam P, Kankanala R, Prakash A, Kannan T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	70		49	58	24140916	10.1016/j.ejmech.2013.09.039	Synthesis and evaluation of novel 4-nitropyrrole-based 1,3,4-oxadiazole derivatives as antimicrobial and anti-tubercular agents.	Rane RA, Bangalore P, Borhade SD, Khandare PK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	70		536	547	24189497	10.1016/j.ejmech.2013.10.034	Design, diversity-oriented synthesis and structure activity relationship studies of quinolinyl heterocycles as antimycobacterial agents.	Rachakonda V, Alla M, Kotipalli SS, Ummani R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2013	70		831	845	24246731	10.1016/j.ejmech.2013.10.029	Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.	Ventura C, Latino DA, Martins F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2013	76	10	1836	1841	24117130	10.1021/np400002p	Antimycobacterial labdane diterpenes from Leucas stelligera.	Kulkarni RR, Shurpali K, Puranik VG, Sarkar D, Joshi SP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2013	76	10	1860	1865	24079882	10.1021/np400391p	Phomapyrrolidones A-C, antitubercular alkaloids from the endophytic fungus Phoma sp. NRRL 46751.	Wijeratne EM, He H, Franzblau SG, Hoffman AM, Gunatilaka AA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2013	76	10	1916	1922	24087924	10.1021/np400497f	Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis.	Hwang CH, Jaki BU, Klein LL, Lankin DC, McAlpine JB, Napolitano JG, Fryling NA, Franzblau SG, Cho SH, Stamets PE, Wang Y, Pauli GF.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2013	76	11	2009	2018	24224794	10.1021/np400145u	Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.	Cai G, Napolitano JG, McAlpine JB, Wang Y, Jaki BU, Suh JW, Yang SH, Lee IA, Franzblau SG, Pauli GF, Cho S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013			1	11		10.1007/s00044-013-0815-x	Discovery of new antitubercular agents by combining pyrazoline and benzoxazole pharmacophores: design, synthesis and insights into the binding interactions	Rana DN, Chhabria MT, Shah NK, Brahmkshatriya PS
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013			1	7		10.1007/s00044-013-0787-x	Synthesis, antitubercular and anticancer activity of new BaylisHillman adduct-derived N-cinnamyl-substituted isatin derivatives	Kumar SB, Ravinder M, Kishore G, Jayathirtha Rao V, Yogeeswari P, Sriram D
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Med Chem Res	2013			1	9		10.1007/s00044-013-0839-2	Synthesis and biological evaluation of novel quinazoline derivatives obtained by Suzuki CC coupling	Patel AB, Chikhalia KH, Kumari P
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	1	406	418	24315189	10.1016/j.bmc.2013.11.011	Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase.	Lv W, Banerjee B, Molland KL, Seleem MN, Ghafoor A, Hamed MI, Wan B, Franzblau SG, Mesecar AD, Cushman M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	15	4073	4082	24953953	10.1016/j.bmc.2014.05.064	Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates.	Krátký M, Volková M, Novotná E, Trejtnar F, Stola¿íková J, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	15	4223	4232	24953948	10.1016/j.bmc.2014.05.038	Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.	Samala G, Nallangi R, Devi PB, Saxena S, Yadav R, Sridevi JP, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	17	4924	4934	25129171	10.1016/j.bmc.2014.06.041	Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.	Renuka J, Reddy KI, Srihari K, Jeankumar VU, Shravan M, Sridevi JP, Yogeeswari P, Babu KS, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	2	728	737	24369840	10.1016/j.bmc.2013.12.016	Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity.	Vin¿ová J, Kozic J, Krátký M, Stola¿íková J, Mandíková J, Trejtnar F, Buchta V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	21	6134	6145	25282650	10.1016/j.bmc.2014.08.031	Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.	Pedgaonkar GS, Sridevi JP, Jeankumar VU, Saxena S, Devi PB, Renuka J, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	23	6552	6563	25456076	10.1016/j.bmc.2014.10.016	An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.	Reddy KI, Srihari K, Renuka J, Sree KS, Chuppala A, Jeankumar VU, Sridevi JP, Babu KS, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	24	6837	6845	25464882	10.1016/j.bmc.2014.10.035	Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.	Tonelli M, Novelli F, Tasso B, Sparatore A, Boido V, Sparatore F, Cannas S, Molicotti P, Zanetti S, Parapini S, Loddo R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2014	22	6	1938	1947	24565972	10.1016/j.bmc.2014.01.030	Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular hybridization from known antimycobacterial leads.	Samala G, Devi PB, Nallangi R, Sridevi JP, Saxena S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	1	233	236	24314670	10.1016/j.bmcl.2013.11.031	Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.	Addla D, Jallapally A, Gurram D, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	1	268	270	24314672	10.1016/j.bmcl.2013.11.024	A novel indigoid anti-tuberculosis agent.	Klein LL, Petukhova V, Wan B, Wang Y, Santasiero BD, Lankin DC, Pauli GF, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	14	3079	3083	24878195	10.1016/j.bmcl.2014.05.018	Synthesis of novel 4-nitropyrrole-based semicarbazide and thiosemicarbazide hybrids with antimicrobial and anti-tubercular activity.	Rane RA, Naphade SS, Bangalore PK, Palkar MB, Shaikh MS, Karpoormath R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	14	3118	3120	24856062	10.1016/j.bmcl.2014.05.006	Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the Pd-catalyzed Suzuki cross-coupling and S(N)(H) reactions.	Kravchenko MA, Verbitskiy EV, Medvinskiy ID, Rusinov GL, Charushin VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	14	3126	3130	24856067	10.1016/j.bmcl.2014.05.002	Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.	Desai NC, Kotadiya GM, Trivedi AR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	15	3493	3498	24909079	10.1016/j.bmcl.2014.05.062	Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.	Moraski GC, Oliver AG, Markley LD, Cho S, Franzblau SG, Miller MJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	17	4166	4170	25127167	10.1016/j.bmcl.2014.07.061	New class of methyl tetrazole based hybrid of (Z)-5-benzylidene-2-(piperazin-1-yl)thiazol-4(%H)-one as potent antitubercular agents.	Chauhan K, Sharma M, Trivedi P, Chaturvedi V, Chauhan PM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	2	450	453	24388809	10.1016/j.bmcl.2013.12.054	Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.	Servusová B, Paterová P, Mandíková J, Kubí¿ek V, Ku¿era R, Kune¿ J, Dole¿al M, Dole¿al M, Zitko J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	21	5070	5075	25264074	10.1016/j.bmcl.2014.09.032	Synthesis, characterization, molecular docking and anti-tubercular activity of Plumbagin-Isoniazid Analog and its ß-cyclodextrin conjugate.	Dandawate P, Vemuri K, Venkateswara Swamy K, Khan EM, Sritharan M, Padhye S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	22	5181	5184	25442308	10.1016/j.bmcl.2014.09.080	Design, synthesis and molecular docking of substituted 3-hydrazinyl-3-oxo-propanamides as anti-tubercular agents.	Naqvi A, Malasoni R, Srivastava A, Pandey RR, Dwivedi AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	3	870	879	24405701	10.1016/j.bmcl.2013.12.080	Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.	Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sharma S, Nandishaiah R, Mahesh Kumar KN, Ganguly S, Ahuja V, Gaonkar S, Naveen Kumar CN, Ogg D, Boriack-Sjodin PA, Sambandamurthy VK, de Sousa SM, Ghorpade SR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	4	1089	1093	24472146	10.1016/j.bmcl.2014.01.007	Antimycobacterial evaluation of novel hybrid arylidene thiazolidine-2,4-diones.	Ponnuchamy S, Kanchithalaivan S, Ranjith Kumar R, Ali MA, Choon TS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	6	1493	1495	24582983	10.1016/j.bmcl.2014.02.012	4,5-Dihydro-1H-pyrazolo[3,4-d]pyrimidine containing phenothiazines as antitubercular agents.	Siddiqui AB, Trivedi AR, Kataria VB, Shah VH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	6	1496	1501	24582981	10.1016/j.bmcl.2014.02.025	Discovery of novel bis-oxazolidinone compounds as potential potent and selective antitubercular agents.	Ang W, Ye W, Sang Z, Liu Y, Yang T, Deng Y, Luo Y, Wei Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	7	1695	1697	24631185	10.1016/j.bmcl.2014.02.052	Synthesis and antimycobacterial activities of some new thiazolylhydrazone derivatives.	Ozadali K, Tan OU, Yogeeswari P, Dharmarajan S, Balkan A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2014	24	8	1974	1979	24679703	10.1016/j.bmcl.2014.02.061	Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis.	Addla D, Jallapally A, Gurram D, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2014	5	1	47	50		10.1039/C3MD00251A	2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis	Guzman JD, Mortazavi PN, Munshi T, Evangelopoulos D, McHugh TD, Gibbons S, Malkinson J, Bhakta S
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2014	5	10	1489	1495		10.1039/C4MD00224E	N-Arylalkylbenzo[d]thiazole-2-carboxamides as anti-mycobacterial agents: design, new methods of synthesis and biological evaluation	Shah P, Dhameliya TM, Bansal R, Nautiyal M, Kommi DN, Jadhavar PS, Sridevi JP, Yogeeswari P, Sriram D, Chakraborti AK
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2014	5	11	1761	1768		10.1039/C4MD00303A	Bile acid amphiphiles with tunable head groups as highly selective antitubercular agents	Bansal S, Singh M, Kidwai S, Bhargava P, Singh A, Sreekanth V, Singh R, Bajaj A
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2014	5	4	521	527		10.1039/C3MD00366C	Synthesis and biological evaluation of substituted N-alkylphenyl-3,5-dinitrobenzamide analogs as anti-TB agents	Munagala G, Yempalla KR, Aithagani SK, Kalia NP, Ali F, Ali I, Rajput VS, Rani C, Chib R, Mehra R, Nargotra A, Khan IA, Vishwakarma RA, Singh PP
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2014	5	7	820	825	25050172	10.1021/ml5001728	Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.	Hameed P S, Raichurkar A, Madhavapeddi P, Menasinakai S, Sharma S, Kaur P, Nandishaiah R, Panduga V, Reddy J, Sambandamurthy VK, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2014	5	9	1005	1009	25221657	10.1021/ml5001933	2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.	Naik M, Ghorpade S, Jena LK, Gorai G, Narayan A, Guptha S, Sharma S, Dinesh N, Kaur P, Nandishaiah R, Bhat J, Balakrishnan G, Humnabadkar V, Ramachandran V, Naviri LK, Khadtare P, Panda M, Iyer PS, Chatterji M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	11	4761	4771	24818517	10.1021/jm5002937	Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.	Panda M, Ramachandran S, Ramachandran V, Shirude PS, Humnabadkar V, Nagalapur K, Sharma S, Kaur P, Guptha S, Narayan A, Mahadevaswamy J, Ambady A, Hegde N, Rudrapatna SS, Hosagrahara VP, Sambandamurthy VK, Raichurkar A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	11	4889	4905	24809953	10.1021/jm500432n	Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.	Hameed P S, Patil V, Solapure S, Sharma U, Madhavapeddi P, Raichurkar A, Chinnapattu M, Manjrekar P, Shanbhag G, Puttur J, Shinde V, Menasinakai S, Rudrapatana S, Achar V, Awasthy D, Nandishaiah R, Humnabadkar V, Ghosh A, Narayan C, Ramya VK, Kaur P, Sharma S, Werngren J, Hoffner S, Panduga V, Kumar CN, Reddy J, Kumar K N M, Ganguly S, Bharath S, Bheemarao U, Mukherjee K, Arora U, Gaonkar S, Coulson M, Waterson D, Sambandamurthy VK, de Sousa SM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	12	5293	5305	24870926	10.1021/jm5003606	Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.	Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	12	5419	5434	24871036	10.1021/jm5005978	4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.	Naik M, Humnabadkar V, Tantry SJ, Panda M, Narayan A, Guptha S, Panduga V, Manjrekar P, Jena LK, Koushik K, Shanbhag G, Jatheendranath S, Manjunatha MR, Gorai G, Bathula C, Rudrapatna S, Achar V, Sharma S, Ambady A, Hegde N, Mahadevaswamy J, Kaur P, Sambandamurthy VK, Awasthy D, Narayan C, Ravishankar S, Madhavapeddi P, Reddy J, Prabhakar K, Saralaya R, Chatterji M, Whiteaker J, McLaughlin B, Chiarelli LR, Riccardi G, Pasca MR, Binda C, Neres J, Dhar N, Signorino-Gelo F, McKinney JD, Ramachandran V, Shandil R, Tommasi R, Iyer PS, Narayanan S, Hosagrahara V, Kavanagh S, Dinesh N, Ghorpade SR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	13	5728	5737	24874895	10.1021/jm500571f	Lead optimization of 1,4-azaindoles as antimycobacterial agents.	Shirude PS, Shandil RK, Manjunatha MR, Sadler C, Panda M, Panduga V, Reddy J, Saralaya R, Nanduri R, Ambady A, Ravishankar S, Sambandamurthy VK, Humnabadkar V, Jena LK, Suresh RS, Srivastava A, Prabhakar KR, Whiteaker J, McLaughlin RE, Sharma S, Cooper CB, Mdluli K, Butler S, Iyer PS, Narayanan S, Chatterji M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	15	6572	6582	24967731	10.1021/jm500833f	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.	Bellale E, Naik M, V B V, Ambady A, Narayan A, Ravishankar S, Ramachandran V, Kaur P, McLaughlin R, Whiteaker J, Morayya S, Guptha S, Sharma S, Raichurkar A, Awasthy D, Achar V, Vachaspati P, Bandodkar B, Panda M, Chatterji M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	20	8268	8279	25259627	10.1021/jm500497v	Structural basis for inhibition of mycobacterial and human adenosine kinase by 7-substituted 7-(Het)aryl-7-deazaadenine ribonucleosides.	Sná¿el J, Nau¿ P, Dostál J, Hnízda A, Fanfrlík J, Brynda J, Bourderioux A, Du¿ek M, Dvo¿áková H, Stola¿íková J, Zábranská H, Pohl R, Kone¿ný P, D¿ubák P, Votruba I, Hajdúch M, Rezá¿ová P, Veverka V, Hocek M, Pichová I.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	20	8398	8420	25238443	10.1021/jm500853v	Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.	Feng L, Maddox MM, Alam MZ, Tsutsumi LS, Narula G, Bruhn DF, Wu X, Sandhaus S, Lee RB, Simmons CJ, Tse-Dinh YC, Hurdle JG, Lee RE, Sun D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2014	57	7	2895	2907	24611928	10.1021/jm401735w	1,2,3,4,8,9,10,11-octahydrobenzo[j]phenanthridine-7,12-diones as new leads against Mycobacterium tuberculosis.	Cappoen D, Claes P, Jacobs J, Anthonissen R, Mathys V, Verschaeve L, Huygen K, De  Kimpe N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	71		160	167	24292337	10.1016/j.ejmech.2013.10.082	Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis.	Yempala T, Sridevi JP, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	71		199	218	24292339	10.1016/j.ejmech.2013.11.004	Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.	More UA, Joshi SD, Aminabhavi TM, Gadad AK, Nadagouda MN, Kulkarni VH.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	71		354	365	24361479	10.1016/j.ejmech.2013.11.002	Synthesis and characterization of new N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)amide/sulfonamide derivatives as possible antimicrobial and antitubercular agents.	Ranjith PK, Pakkath R, Haridas KR, Kumari SN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	71		46	52	24269516	10.1016/j.ejmech.2013.10.069	Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.	Matviiuk T, Mori G, Lherbet C, Rodriguez F, Pasca MR, Gorichko M, Guidetti B, Voitenko Z, Baltas M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	72		26	34	24333612	10.1016/j.ejmech.2013.11.007	Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.	Pieroni M, Wan B, Cho S, Franzblau SG, Costantino G.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	73		243	249	24412719	10.1016/j.ejmech.2013.12.013	Design, synthesis and evaluation of acridine and fused-quinoline derivatives as potential anti-tuberculosis agents.	Muscia GC, Buldain GY, Asís SE.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	74		216	224	24463437	10.1016/j.ejmech.2013.12.037	Microwave induced three-component synthesis and antimycobacterial activity of benzopyrazolo[3,4-b]quinolindiones.	Quiroga J, Diaz Y, Bueno J, Insuasty B, Abonia R, Ortiz A, Nogueras M, Cobo J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	74		333	339	24486416	10.1016/j.ejmech.2014.01.005	Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues.	Nagesh HN, Suresh N, Mahalakshmi Naidu K, Arun B, Padma Sridevi J, Sriram D, Yogeeswari P, Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	74		664	670	24268596	10.1016/j.ejmech.2013.09.061	Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.	Danac R, Mangalagiu II.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	74		85	94	24448419	10.1016/j.ejmech.2013.12.057	Biological evaluation of diazene derivatives as anti-tubercular compounds.	Cappoen D, Majce V, Uythethofken C, Urankar D, Mathys V, Ko¿evar M, Verschaeve L, Polanc S, Huygen K, Ko¿mrlj J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	75		43	56	24530490	10.1016/j.ejmech.2014.01.024	Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives.	Patel KN, Telvekar VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	76		110	117	24583350	10.1016/j.ejmech.2014.02.028	Development of antimycobacterial tetrahydrothieno[2,3-c]pyridine-3-carboxamides and hexahydrocycloocta[b]thiophene-3-carboxamides: Molecular modification from known antimycobacterial lead.	Nallangi R, Samala G, Sridevi JP, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	76		193	244	24583357	10.1016/j.ejmech.2014.02.005	Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications.	Khan I, Ibrar A, Abbas N, Saeed A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	76		274	283	24589483	10.1016/j.ejmech.2014.02.017	Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents.	Mir F, Shafi S, Zaman MS, Kalia NP, Rajput VS, Mulakayala C, Mulakayala N, Khan IA, Alam MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	76		460	469	24607876	10.1016/j.ejmech.2014.02.042	Convenient one-pot synthesis, anti-mycobacterial and anticancer activities of novel benzoxepinoisoxazolones and pyrazolones.	Saidachary G, Veera Prasad K, Divya D, Singh A, Ramesh U, Sridhar B, China Raju B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2014	77	12	2711	2715	25372601	10.1021/np500538c	Tetrahydroxanthene-1,3(2H)-dione derivatives from Uvaria valderramensis.	Macabeo AP, Martinez FP, Kurtán T, Tóth L, Mándi A, Schmidt S, Heilmann J, Alejandro GJ, Knorn M, Dahse HM, Franzblau SG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2014	77	7	1744	1748	24964393	10.1021/np5001494	NRPS substrate promiscuity leads to more potent antitubercular sansanmycin analogues.	Xie Y, Cai Q, Ren H, Wang L, Xu H, Hong B, Wu L, Chen R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	77		193	203	24631899	10.1016/j.ejmech.2014.02.065	Anti-mycobacterial activity of 1,3-diaryltriazenes.	Cappoen D, Vajs J, Uythethofken C, Virag A, Mathys V, Ko¿evar M, Verschaeve L, Gazvoda M, Polanc S, Huygen K, Ko¿mrlj J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	77		409	421	24681334	10.1016/j.ejmech.2014.03.024	2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis.	Claes P, Cappoen D, Uythethofken C, Jacobs J, Mertens B, Mathys V, Verschaeve L, Huygen K, De Kimpe N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	78		207	216	24681985	10.1016/j.ejmech.2014.02.015	Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.	Kalaria PN, Satasia SP, Raval DK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	79		57	65	24721315	10.1016/j.ejmech.2014.03.085	Facile synthesis of benzonitrile/nicotinonitrile based s-triazines as new potential antimycobacterial agents.	Patel AB, Chikhalia KH, Kumari P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	81		119	138	24836065	10.1016/j.ejmech.2014.04.077	Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.	Martins F, Santos S, Ventura C, Elvas-Leitão R, Santos L, Vitorino S, Reis M, Miranda V, Correia HF, Aires-de-Sousa J, Kovalishyn V, Latino DA, Ramos J, Viveiros M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	81		301	313	24852277	10.1016/j.ejmech.2014.05.005	Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation.	Kumar D, Beena, Khare G, Kidwai S, Tyagi AK, Singh R, Rawat DS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	82		324	340	24927053	10.1016/j.ejmech.2014.05.069	1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.	Karabanovich G, Roh J, Smutný T, N¿me¿ek J, Vicherek P, Stola¿íková J, Vejsová M, Dufková I, Vávrová K, Pávek P, Klime¿ová V, Hrabálek A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	82		480	489	24934572	10.1016/j.ejmech.2014.06.004	Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs.	Desai NC, Shihory NR, Kotadiya GM, Desai P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	83		245	255	24972340	10.1016/j.ejmech.2014.06.019	Design, synthesis and docking studies of some novel (R)-2-(4'-chlorophenyl)-3-(4'-nitrophenyl)-1,2,3,5-tetrahydrobenzo[4,5] imidazo [1,2-c]pyrimidin-4-ol derivatives as antitubercular agents.	Barot KP, Jain SV, Gupta N, Kremer L, Singh S, Takale VB, Joshi K, Ghate MD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	83		655	664	25010936	10.1016/j.ejmech.2014.06.071	Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.	Kalaria PN, Satasia SP, Avalani JR, Raval DK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	84		118	126	25016370	10.1016/j.ejmech.2014.06.075	Design, synthesis and anti-mycobacterial activity of 1,2,3,5-tetrasubstituted pyrrolyl-N-acetic acid derivatives.	Pagadala LR, Mukkara LD, Singireddi S, Singh A, Thummaluru VR, Jagarlamudi PS, Guttala RS, Perumal Y, Dharmarajan S, Upadhyayula SM, Ummanni R, Basireddy VS, Ravirala N.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	84		51	58	25016227	10.1016/j.ejmech.2014.07.008	Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.	Karad SC, Purohit VB, Raval DK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	84		516	529	25055342	10.1016/j.ejmech.2014.07.051	Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1,2,4-triazoles as potential antitubercular agents.	Mohan Krishna K, Inturi B, Pujar GV, Purohit MN, Vijaykumar GS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	84		605	613	25062011	10.1016/j.ejmech.2014.07.067	Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues.	Nagesh HN, Suresh A, Sairam SD, Sriram D, Yogeeswari P, Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	85		255	267	25089809	10.1016/j.ejmech.2014.07.100	Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents.	Patel SR, Gangwal R, Sangamwar AT, Jain R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	85		737	746	25129868	10.1016/j.ejmech.2014.08.009	Sequential synthesis of amino-1,4-naphthoquinone-appended triazoles and triazole-chromene hybrids and their antimycobacterial evaluation.	Devi Bala B, Muthusaravanan S, Choon TS, Ashraf Ali M, Perumal S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	86		335	351	25173852	10.1016/j.ejmech.2014.08.066	SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.	Poce G, Cocozza M, Consalvi S, Biava M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	86		613	627	25218910	10.1016/j.ejmech.2014.09.028	Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.	Pedgaonkar GS, Sridevi JP, Jeankumar VU, Saxena S, Devi PB, Renuka J, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	86		628	638	25218911	10.1016/j.ejmech.2014.09.029	Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.	Liu H, Huang J, Wang J, Wang M, Liu M, Wang B, Guo H, Lu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2014	87		71	78	25240097	10.1016/j.ejmech.2014.09.043	Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives.	Naidu KM, Suresh A, Subbalakshmi J, Sriram D, Yogeeswari P, Raghavaiah P, Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	100		223	234	26092447	10.1016/j.ejmech.2015.06.007	Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.	Banerjee DR, Biswas R, Das AK, Basak A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	100		44	49	26071857	10.1016/j.ejmech.2015.05.048	Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.	Pieroni M, Wan B, Zuliani V, Franzblau SG, Costantino G, Rivara M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	101		111	125	26119992	10.1016/j.ejmech.2015.06.027	Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl)phenyl moiety.	Bielenica A, Stefa¿ska J, St¿pie¿ K, Napiórkowska A, Augustynowicz-Kope¿ E, Sanna G, Madeddu S, Boi S, Giliberti G, Wrzosek M, Struga M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	101		218	235	26142487	10.1016/j.ejmech.2015.06.035	Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth.	Chollet A, Mori G, Menendez C, Rodriguez F, Fabing I, Pasca MR, Madacki J, Korduláková J, Constant P, Quémard A, Bernardes-Génisson V, Lherbet C, Baltas M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	101		692	704	26210507	10.1016/j.ejmech.2015.07.001	Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.	Baranyai Z, Krátký M, Vin¿ová J, Szabó N, Senoner Z, Horváti K, Stola¿íková J, Dávid S, B¿sze S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	101		705	715	26210508	10.1016/j.ejmech.2015.06.056	Design, synthesis of benzocoumarin-pyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies.	Reddy DS, Hosamani KM, Devarajegowda HC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	102		153	166	26263247	10.1016/j.ejmech.2015.07.050	Synthesis of arabinose glycosyl sulfamides as potential inhibitors of mycobacterial cell wall biosynthesis.	Suthagar K, Watson AJ, Wilkinson BL, Fairbanks AJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	102		243	248	26280920	10.1016/j.ejmech.2015.07.039	Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.	Mahajan NS, Dhawale SC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	103		1	16	26318054	10.1016/j.ejmech.2015.06.032	4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.	Medapi B, Suryadevara P, Renuka J, Sridevi JP, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	104		73	85	26435513	10.1016/j.ejmech.2015.09.030	Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety.	Zhang T, Shen W, Liu M, Zhang R, Wang M, Li L, Wang B, Guo H, Lu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	106		144	156	26544629	10.1016/j.ejmech.2015.10.008	Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.	Ng PS, Manjunatha UH, Rao SP, Camacho LR, Ma NL, Herve M, Noble CG, Goh A, Peukert S, Diagana TT, Smith PW, Kondreddi RR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	106		157	166	26544630	10.1016/j.ejmech.2015.10.033	Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.	Choi J, Park SJ, Jee JG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	106		75	84	26520841	10.1016/j.ejmech.2015.10.035	Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents.	Ramprasad J, Nayak N, Dalimba U.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	1	174	183	25438883	10.1016/j.bmc.2014.11.014	Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides.	Zitko J, Servusová B, Janoutová A, Paterová P, Mandíková J, Garaj V, Vejsová M, Marek J, Dole¿al M, Dole¿al M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	13	3534	3541	25934225	10.1016/j.bmc.2015.04.033	Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp.	Arai M, Kamiya K, Pruksakorn P, Sumii Y, Kotoku N, Joubert JP, Moodley P, Han C, Shin D, Kobayashi M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	13	3705	3711	25921267	10.1016/j.bmc.2015.04.001	Synthesis, anti-mycobacterial activity and DNA sequence-selectivity of a library of biaryl-motifs containing polyamides.	Brucoli F, Guzman JD, Maitra A, James CH, Fox KR, Bhakta S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	17	5410	5418	26254828	10.1016/j.bmc.2015.07.053	Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations.	Massimba-Dibama H, Mourer M, Constant P, Daffé M, Regnouf-de-Vains JB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	22	7292	7301	26526729	10.1016/j.bmc.2015.10.029	Novel derivatives of nitro-substituted salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.	Paraskevopoulos G, Krátký M, Mandíková J, Trejtnar F, Stola¿íková J, Pávek P, Besra G, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	24	7711	7716	26631439	10.1016/j.bmc.2015.11.018	Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.	Bhatt JD, Chudasama CJ, Patel KD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	4	742	752	25614114	10.1016/j.bmc.2014.12.060	Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.	Singh S, Roy KK, Khan SR, Kashyap VK, Sharma A, Jaiswal S, Sharma SK, Krishnan MY, Chaturvedi V, Lal J, Sinha S, Dasgupta A, Srivastava R, Saxena AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	4	868	875	25593095	10.1016/j.bmc.2014.12.019	Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.	Krátký M, B¿sze S, Baranyai Z, Szabó I, Stola¿íková J, Paraskevopoulos G, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	7	1402	1412	25766629	10.1016/j.bmc.2015.02.032	Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.	Saxena S, Samala G, Renuka J, Sridevi JP, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	9	1935	1943	25818768	10.1016/j.bmc.2015.03.041	Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.	Salunke SB, Azad AK, Kapuriya NP, Balada-Llasat JM, Pancholi P, Schlesinger LS, Chen CS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	9	2035	2043	25819330	10.1016/j.bmc.2015.03.018	Synthesis and antimycobacterial properties of ring-substituted 6-hydroxynaphthalene-2-carboxanilides.	Kos J, Nevin E, Soral M, Kushkevych I, Gonec T, Bobal P, Kollar P, Coffey A, O'Mahony J, Liptaj T, Kralova K, Jampilek J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	9	2062	2078	25801151	10.1016/j.bmc.2015.03.004	Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.	Medapi B, Renuka J, Saxena S, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2015	23	9	2112	2120	25797161	10.1016/j.bmc.2015.03.008	Novel 2-(2-phenalkyl)-1H-benzo[d]imidazoles as antitubercular agents. Synthesis, biological evaluation and structure-activity relationship.	Gobis K, Foks H, Suchan K, Augustynowicz-Kope¿ E, Napiórkowska A, Bojanowski K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	11	2390	2394	25908515	10.1016/j.bmcl.2015.04.009	Synthesis and anti-mycobacterial activity of 2-chloronicotinaldehydes based novel 1H-1,2,3-triazolylbenzohydrazides.	Suman P, Dayakar C, Rajkumar K, Yashwanth B, Yogeeswari P, Sriram D, Rao JV, Raju BC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	15	2918	2922	26048808	10.1016/j.bmcl.2015.05.044	Synthesis and evaluation of novel fluorinated pyrazolo-1,2,3-triazole hybrids as antimycobacterial agents.	Emmadi NR, Bingi C, Kotapalli SS, Ummanni R, Nanubolu JB, Atmakur K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	18	3867	3872	26253635	10.1016/j.bmcl.2015.07.057	Synthesis and biological evaluation of phaitanthrin congeners as anti-mycobacterial agents.	Kamal A, Reddy BV, Sridevi B, Ravikumar A, Venkateswarlu A, Sravanthi G, Sridevi JP, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	18	3903	3909	26254943	10.1016/j.bmcl.2015.07.043	The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.	Przybylski P, Pyta K, Czerwonka D, Kubicka MM, Gajecka M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2015	25	19	4308	4313	26271585	10.1016/j.bmcl.2015.07.069	Design of novel dispirooxindolopyrrolidine and dispirooxindolopyrrolothiazole derivatives as potential antitubercular agents.	Mhiri C, Boudriga S, Askri M, Knorr M, Sriram D, Yogeeswari P, Nana F, Golz C, Strohmann C.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	19	4082	4084	26316467	10.1016/j.bmcl.2015.08.034	Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L.	Wang JF, He WJ, Zhang XX, Zhao BQ, Liu YH, Zhou XJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	19	4169	4173	26298500	10.1016/j.bmcl.2015.08.009	One-pot synthesis of new triazole--Imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity.	Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	19	4185	4190	26299346	10.1016/j.bmcl.2015.08.006	Design and synthesis of 11¿-substituted bile acid derivatives as potential anti-tuberculosis agents.	Pore VS, Divse JM, Charolkar CR, Nawale LU, Khedkar VM, Sarkar D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	19	4314	4319	26277407	10.1016/j.bmcl.2015.07.071	Re-engineering nalidixic acid's chemical scaffold: A step towards the development of novel anti-tubercular and anti-bacterial leads for resistant pathogens.	Peraman R, Varma RV, Reddy YP.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	22	5058	5063	26476970	10.1016/j.bmcl.2015.10.027	Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.	Huang J, Liu H, Liu M, Zhang R, Li L, Wang B, Wang M, Wang C, Lu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	22	5178	5181	26459210	10.1016/j.bmcl.2015.09.072	Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB.	Li D, Gao N, Zhu N, Lin Y, Li Y, Chen M, You X, Lu Y, Wan K, Jiang JD, Jiang W, Si S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	22	5339	5343	26421992	10.1016/j.bmcl.2015.09.033	Synthesis and preliminary biological evaluation of a small library of hybrid compounds based on Ugi isocyanide multicomponent reactions with a marine natural product scaffold.	Avilés E, Prudhomme J, Le Roch KG, Franzblau SG, Chandrasena K, Mayer AM, Rodríguez AD.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	23	5540	5545	26520663	10.1016/j.bmcl.2015.10.057	New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.	Nayak N, Ramprasad J, Dalimba U.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	7	1390	1393	25746816	10.1016/j.bmcl.2015.02.044	Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.	Seebacher W, Wolkinger V, Faist J, Kaiser M, Brun R, Saf R, Bucar F, Gröblacher B, Brantner A, Merino V, Kalia Y, Scapozza L, Perozzo R, Weis R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	7	1398	1402	25765907	10.1016/j.bmcl.2015.02.052	Synthesis, in vitro anticancer and antimycobacterial evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino derivatives.	Polkam N, Rayam P, Anireddy JS, Yennam S, Anantaraju HS, Dharmarajan S, Perumal Y, Kotapalli SS, Ummanni R, Balasubramanian S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2015	58	14	5459	5475	26110337	10.1021/acs.jmedchem.5b00391	Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis.	Nelson KM, Viswanathan K, Dawadi S, Duckworth BP, Boshoff HI, Barry CE, Aldrich CC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2015	6	1	131	137		10.1039/C4MD00288A	Novel isoniazid-amidoether derivatives: Synthesis, characterization and antimycobacterial activity evaluation	Kumar D, Khare G, Negi B, Kidwai S, Tyagi AK, Singh R, Rawat D
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2015	6	1	174	181		10.1039/C4MD00301B	Tetrazole regioisomers in the development of nitro group-containing antitubercular agents	Karabanovich G, Roh J, Soukup O, Pavkova I, Pasdiorova M, Tambor V, Stolarikova J, Vejsova M, Vavrova K, Klimesova V, Hrabalek A
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2015	6	11	1140	1144	26617968	10.1021/acsmedchemlett.5b00367	Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors.	Lele AC, Raju A, Khambete MP, Ray MK, Rajan MG, Arkile MA, Jadhav NJ, Sarkar D, Degani MS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2015	6	2	128	133	25699139	10.1021/ml5003458	Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043.	Tiwari R, Miller PA, Cho S, Franzblau SG, Miller MJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2015	6	7	741	746	26191359	10.1021/ml500531p	Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.	Hameed P S, Manjrekar P, Raichurkar A, Shinde V, Puttur J, Shanbhag G, Chinnapattu M, Patil V, Rudrapatana S, Sharma S, Kumar CN, Nandishaiah R, Madhavapeddi P, Sriram D, Solapure S, Sambandamurthy VK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2015	6	7	814	818	26191372	10.1021/acsmedchemlett.5b00176	Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.	Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Wan B, Franzblauc SG, Zhang T, Lu X, Ding K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2015	6	7	1311	1317		10.1039/C5MD00178A	Alkylamino derivatives of N-benzylpyrazine-2-carboxamide: synthesis and antimycobacterial evaluation	Servusova-Vanaskova B, Jandourek O, Paterova P, Kordulakova J, Plevakova M, Kubicek V, Kucera R, Garaj V, Naesens L, Kunes J, Dolezal M, Zitko J
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2015	6	8	1554	1563		10.1039/C5MD00131E	Synthesis and anti-tubercular activity of conformationally-constrained and bisquinoline analogs of TMC207	Kalia D, K. S. AK, Meena G, Sethi KP, Sharma R, Trivedi P, Khan SR, Verma AS, Singh S, Sharma S, Roy KK, Kant R, Krishnan MY, Singh BN, Sinha S, Chaturvedi V, Saxena AK, Dikshit DK
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2015	78	4	615	622	25734623	10.1021/np5005328	Eremophilane Sesquiterpenes and Diphenyl Thioethers from the Soil Fungus Penicillium copticola PSU-RSPG138.	Daengrot C, Rukachaisirikul V, Tansakul C, Thongpanchang T, Phongpaichit S, Bowornwiriyapan K, Sakayaroj J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2015	78	8	1910	1925	26213786	10.1021/acs.jnatprod.5b00266	Callyaerins from the Marine Sponge Callyspongia aerizusa: Cyclic Peptides with Antitubercular Activity.	Daletos G, Kalscheuer R, Koliwer-Brandl H, Hartmann R, de Voogd NJ, Wray V, Lin W, Proksch P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	89		1	12	25462220	10.1016/j.ejmech.2014.10.026	Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.	Ganihigama DU, Sureram S, Sangher S, Hongmanee P, Aree T, Mahidol C, Ruchirawat S, Kittakoop P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	89		13	20	25462221	10.1016/j.ejmech.2014.10.031	Synthesis and evaluation of in vitro antimycobacterial activity of novel 1H-benzo[d]imidazole derivatives and analogues.	Gobis K, Foks H, Serocki M, Augustynowicz-Kope¿ E, Napiórkowska A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	89		616	627	25462270	10.1016/j.ejmech.2014.10.079	Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.	Jose G, Suresha Kumara TH, Nagendrappa G, Sowmya HB, Sriram D, Yogeeswari P, Sridevi JP, Guru Row TN, Hosamani AA, Sujan Ganapathy PS, Chandrika N, Narendra LV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2015	92		415	426	25590862	10.1016/j.ejmech.2015.01.013	Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.	Naidu KM, Nagesh HN, Singh M, Sriram D, Yogeeswari P, Gowri Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	92		401	414	25585006	10.1016/j.ejmech.2014.12.046	Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.	Saxena S, Samala G, Sridevi JP, Devi PB, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	93		511	522	25747550	10.1016/j.ejmech.2015.02.034	Synthesis, biological evaluation and 3D QSAR study of 2,4-disubstituted quinolines as anti-tuberculosis agents.	Patel SR, Gangwal R, Sangamwar AT, Jain R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	94		298	305	25771108	10.1016/j.ejmech.2015.03.014	Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase.	Lu W, Baig IA, Sun HJ, Cui CJ, Guo R, Jung IP, Wang D, Dong M, Yoon MY, Wang JG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	94		317	339	25771110	10.1016/j.ejmech.2015.03.013	Discovery of target based novel pyrrolyl phenoxy derivatives as antimycobacterial agents: an in silico approach.	More UA, Joshi SD, Aminabhavi TM, Kulkarni VH, Badiger AM, Lherbet C.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	94		378	385	25778993	10.1016/j.ejmech.2015.02.062	Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.	Kanetaka H, Koseki Y, Taira J, Umei T, Komatsu H, Sakamoto H, Gulten G, Sacchettini JC, Kitamura M, Aoki S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	95		357	368	25828928	10.1016/j.ejmech.2015.03.036	Thiophene containing trisubstituted methanes [TRSMs] as identified lead against Mycobacterium tuberculosis.	Singh P, Manna SK, Jana AK, Saha T, Mishra P, Bera S, Parai MK, Kumar M SL, Mondal S, Trivedi P, Chaturvedi V, Singh S, Sinha S, Panda G.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	95		49	63	25794789	10.1016/j.ejmech.2015.03.024	Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.	Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D, Peethambar SK, Achur R, Kumar HS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	96		30	46	25874329	10.1016/j.ejmech.2015.04.011	Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.	Chikhale R, Menghani S, Babu R, Bansode R, Bhargavi G, Karodia N, Rajasekharan MV, Paradkar A, Khedekar P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	97		225	234	25982331	10.1016/j.ejmech.2015.05.007	Synthesis, and structure-activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds.	Verbitskiy EV, Cheprakova EM, Slepukhin PA, Kravchenko MA, Skornyakov SN, Rusinov GL, Chupakhin ON, Charushin VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2015	98		160	169	26005918	10.1016/j.ejmech.2015.05.020	Synthesis, antimalarial and antitubercular activities of meridianin derivatives.	Yadav RR, Khan SI, Singh S, Khan IA, Vishwakarma RA, Bharate SB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2016	107		38	47	26562541	10.1016/j.ejmech.2015.10.054	Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.	Dixit PP, Dixit PP, Thore SN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2016	112		252	257	26900657	10.1016/j.ejmech.2016.02.008	New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.	Pajk S, ¿ivec M, ¿ink R, Sosi¿ I, Neu M, Chung CW, Martínez-Hoyos M, Pérez-Herrán E, Álvarez-Gómez D, Álvarez-Ruíz E, Mendoza-Losana A, Castro-Pichel J, Barros D, Ballell-Pages L, Young RJ, Convery MA, Encinas L, Gobec S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2016	112		270	279	26900659	10.1016/j.ejmech.2016.02.016	Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.	Karad SC, Purohit VB, Thakor P, Thakkar VR, Raval DK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur. J. Med. Chem.	2016	116		187	199	27061982	10.1016/j.ejmech.2016.03.060	Benzo[d]thiazol-2-yl(piperazin-1-yl)methanones as new anti-mycobacterial chemotypes: Design, synthesis, biological evaluation and 3D-QSAR studies.	Pancholia S, Dhameliya TM, Shah P, Jadhavar PS, Sridevi JP, Yogeshwari P, Sriram D, Chakraborti AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	121		21	39	27214509	10.1016/j.ejmech.2016.05.025	Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.	Joshi SD, Kumar D, Dixit SR, Tigadi N, More UA, Lherbet C, Aminabhavi TM, Yang KS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	122		216	231	27371925	10.1016/j.ejmech.2016.06.042	Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.	Jeankumar VU, Reshma RS, Vats R, Janupally R, Saxena S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	122		723	730	27476117	10.1016/j.ejmech.2016.07.009	Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.	Ramesh R, Shingare RD, Kumar V, Anand A, B S, Veeraraghavan S, Viswanadha S, Ummanni R, Gokhale R, Srinivasa Reddy D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	123		523	531	27508879	10.1016/j.ejmech.2016.07.039	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.	Fernandes GFDS, de Souza PC, Marino LB, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Chung MC, Pavan FR, Dos Santos JL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	123		684	703	27517813	10.1016/j.ejmech.2016.07.068	Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.	Koh JJ, Zou H, Mukherjee D, Lin S, Lim F, Tan JK, Tan DZ, Stocker BL, Timmer MSM, Corkran HM, Lakshminarayanan R, Tan DTH, Cao D, Beuerman RW, Dick T, Liu S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2016	124		160	185	27569197	10.1016/j.ejmech.2016.08.034	Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.	Chaudhari K, Surana S, Jain P, Patel HM.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	16	3771	3780	27338658	10.1016/j.bmc.2016.06.020	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.	Verbitskiy EV, Baskakova SA, Kravchenko MA, Skornyakov SN, Rusinov GL, Chupakhin ON, Charushin VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	18	4499	4508	27477207	10.1016/j.bmc.2016.07.051	Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors.	Reshma RS, Saxena S, Bobesh KA, Jeankumar VU, Gunda S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2016	24	21	5521	5533	27665179	10.1016/j.bmc.2016.09.008	Investigation of C-5 alkynyl (alkynyloxy or hydroxymethyl) and/or N-3 propynyl substituted pyrimidine nucleoside analogs as a new class of antimicrobial agents.	Garg S, Shakya N, Srivastav NC, Agrawal B, Kunimoto DY, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2016	24	21	5556	5564	27667550	10.1016/j.bmc.2016.09.012	Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.	Samala G, Brindha Devi P, Saxena S, Gunda S, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	4	877	885	26787274	10.1016/j.bmc.2016.01.011	Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.	Medapi B, Meda N, Kulkarni P, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	6	1298	1307	26867485	10.1016/j.bmc.2016.01.059	Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.	Samala G, Devi PB, Saxena S, Meda N, Yogeeswari P, Sriram D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	8	1637	1647	26951892	10.1016/j.bmc.2016.02.035	Novel nicotine analogues with potential anti-mycobacterial activity.	Gandhi PT, Athmaram TN, Arunkumar GR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem.	2016	24	8	1771	1777	26988804	10.1016/j.bmc.2016.03.003	Investigation of 4-amino-5-alkynylpyrimidine-2(1H)-ones as anti-mycobacterial agents.	Garg G, Pande M, Agrawal A, Li J, Kumar R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	10	2455	2458	27072906	10.1016/j.bmcl.2016.03.107	A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity.	Shchegol'kov EV, Shchur IV, Burgart YV, Saloutin VI, Solodnikov SY, Krasnykh OP, Kravchenko MA.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	11	2645	2648	27107949	10.1016/j.bmcl.2016.04.017	Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides.	Krasnov VP, Vigorov AY, Musiyak VV, Nizova IA, Gruzdev DA, Matveeva TV, Levit GL, Kravchenko MA, Skornyakov SN, Bekker OB, Danilenko VN, Charushin VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	11	2649	2654	27101894	10.1016/j.bmcl.2016.04.015	Click-based synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages.	Pulipati L, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	11	2663	2669	27095514	10.1016/j.bmcl.2016.04.012	Synthesis, biological evaluation and structure-activity relationship of 2-styrylquinazolones as anti-tubercular agents.	Jadhavar PS, Dhameliya TM, Vaja MD, Kumar D, Sridevi JP, Yogeeswari P, Sriram D, Chakraborti AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	13	3135	3140	27184765	10.1016/j.bmcl.2016.04.088	Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.	Pulipati L, Sridevi JP, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	14	3287	3290	27241693	10.1016/j.bmcl.2016.05.053	Antimycobacterial activity of new N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives.	Zampieri D, Mamolo MG, Vio L, Romano M, Skoko N, Baralle M, Pau V, De Logu A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	15	3684	3689	27317646	10.1016/j.bmcl.2016.05.085	Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides.	Surineni G, Yogeeswari P, Sriram D, Kantevari S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	16	4146	4153	27426298	10.1016/j.bmcl.2016.01.066	Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-N-oxide derivatives as antituberculosis agents.	Pan Y, Li P, Xie S, Tao Y, Chen D, Dai M, Hao H, Huang L, Wang Y, Wang L, Liu Z, Yuan Z.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	2	561	569	26642768	10.1016/j.bmcl.2015.11.071	Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent.	Shaikh MH, Subhedar DD, Arkile M, Khedkar VM, Jadhav N, Sarkar D, Shingate BB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	2	645	649	26675440	10.1016/j.bmcl.2015.11.057	Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents.	Jain PP, Degani MS, Raju A, Anantram A, Seervi M, Sathaye S, Ray M, Rajan MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2016	26	24	5896	5898	27866817	10.1016/j.bmcl.2016.11.010	Discovery of novel N-phenyl 1,4-dihydropyridines with a dual mode of antimycobacterial activity.	Lentz F, Hemmer M, Reiling N, Hilgeroth A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2016	26	24	5916	5919	27839917	10.1016/j.bmcl.2016.11.003	Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.	Lu X, Tang J, Liu Z, Li M, Zhang T, Zhang X, Ding K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2016	26	24	5960	5966	27839684	10.1016/j.bmcl.2016.10.082	Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.	Tanwar B, Kumar A, Yogeeswari P, Sriram D, Chakraborti AK.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	3	836	840	26755393	10.1016/j.bmcl.2015.12.083	Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases.	Malothu N, Bhandaru JS, Kulandaivelu U, Jojula M, Adidala RR, K R U, A V N D, Kaki VR, Akkinepally RR.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	3	978	985	26725953	10.1016/j.bmcl.2015.12.049	Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones.	Velezheva V, Brennan P, Ivanov P, Kornienko A, Lyubimov S, Kazarian K, Nikonenko B, Majorov K, Apt A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	7	1704	1708	26927426	10.1016/j.bmcl.2016.02.056	Facile synthesis of 1,3-thiazolidin-4-ones as antitubercular agents.	Subhedar DD, Shaikh MH, Arkile MA, Yeware A, Sarkar D, Shingate BB.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	7	1776	1783	26920799	10.1016/j.bmcl.2016.02.043	Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.	Desai NC, Somani H, Trivedi A, Bhatt K, Nawale L, Khedkar VM, Jha PC, Sarkar D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	9	2188	2193	27025343	10.1016/j.bmcl.2016.03.066	Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.	Santivañez-Veliz M, Pérez-Silanes S, Torres E, Moreno-Viguri E.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	9	2224	2228	27017114	10.1016/j.bmcl.2016.03.055	Synthesis and docking studies of pyrazine-thiazolidinone hybrid scaffold targeting dormant tuberculosis.	Chitre TS, Asgaonkar KD, Miniyar PB, Dharme AB, Arkile MA, Yeware A, Sarkar D, Khedkar VM, Jha PC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	9	2245	2250	27020525	10.1016/j.bmcl.2016.03.059	Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives.	Naidu KM, Srinivasarao S, Agnieszka N, Ewa AK, Kumar MM, Chandra Sekhar KV.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg. Med. Chem. Lett.	2016	26	9	2262	2267	27020299	10.1016/j.bmcl.2016.03.050	Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.	Huang J, Wang M, Wang B, Wu Z, Liu M, Feng L, Zhang J, Li X, Yang Y, Lu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2016	59	6	2362	2380	26948407	10.1021/acs.jmedchem.5b00608	Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.	Karabanovich G, Zemanová J, Smutný T, Székely R, ¿arkan M, Centárová I, Vocat A, Pávková I, ¿onka P, N¿me¿ek J, Stola¿íková J, Vejsová M, Vávrová K, Klime¿ová V, Hrabálek A, Pávek P, Cole ST, Miku¿ová K, Roh J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Med. Chem.	2016	59	6	2780	2793	26907951	10.1021/acs.jmedchem.6b00031	Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria.	Bhakta S, Scalacci N, Maitra A, Brown AK, Dasugari S, Evangelopoulos D, McHugh TD, Mortazavi PN, Twist A, Petricci E, Manetti F, Castagnolo D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med Chem Lett	2016	7	12	1130	1133	27994751	10.1021/acsmedchemlett.6b00330	Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.	Wu Z, Lu Y, Li L, Zhao R, Wang B, Lv K, Liu M, You X.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2016	7	2	338	344		10.1039/C5MD00346F	Ionic liquid-promoted one-pot synthesis of thiazoleimidazo[2,1-b][1,3,4]thiadiazole hybrids and their antitubercular activity	Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med. Chem. Lett.	2016	7	3	235	239	26985307	10.1021/acsmedchemlett.5b00324	2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.	Pissinate K, Villela AD, Rodrigues-Junior V, Giacobbo BC, Grams ES, Abbadi BL, Trindade RV, Roesler Nery L, Bonan CD, Back DF, Campos MM, Basso LA, Santos DS, Machado P.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2016	7	5	1022	1032		10.1039/C5MD00589B	Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway	Tantry SJ, Shinde V, Balakrishnan G, Markad SD, Gupta AK, Bhat J, Narayan A, Raichurkar A, Jena LK, Sharma S, Kumar N, Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar KR, Kandaswamy K, Kaur P, Dinesh N, Guptha S, Saralaya R, Panda M, Rudrapatna S, Mallya M, Rubin H, Yano T, Mdluili K, Cooper CB, Balasubramanian V, Sambandamurthy VK, Ramachandran V, Shandil R, Kavanagh S, Narayanan S, Iyer P, Mukherjee K, Hosagrahara VP, Solapure S, Hameed P S, Ravishankar S
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2016	7	7	1405	1420		10.1039/C6MD00085A		
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	MedChemComm	2016	7	9	1797	1801		10.1039/C6MD00231E		
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2016	79	1	161	169	26716912	10.1021/acs.jnatprod.5b00826	Antitubercular Lanostane Triterpenes from Cultures of the Basidiomycete Ganoderma sp. BCC 16642.	Isaka M, Chinthanom P, Sappan M, Danwisetkanjana K, Boonpratuang T, Choeyklin R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J. Nat. Prod.	2016	79	1	59	65	26697718	10.1021/acs.jnatprod.5b00650	Antiviral Merosesquiterpenoids Produced by the Antarctic Fungus Aspergillus ochraceopetaliformis SCSIO 05702.	Wang J, Wei X, Qin X, Tian X, Liao L, Li K, Zhou X, Yang X, Wang F, Zhang T, Tu Z, Chen B, Liu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Nat Prod	2016	79	6	1500	1507	27228159	10.1021/acs.jnatprod.5b00961	Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178.	Phainuphong P, Rukachaisirikul V, Saithong S, Phongpaichit S, Bowornwiriyapan K, Muanprasat C, Srimaroeng C, Duangjai A, Sakayaroj J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	125		41	48	27654393	10.1016/j.ejmech.2016.09.030	Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.	Lu X, Tang J, Cui S, Wan B, Franzblauc SG, Zhang T, Zhang X, Ding K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	125		807	815	27750198	10.1016/j.ejmech.2016.09.082	Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.	Kang S, Kim YM, Kim RY, Seo MJ, No Z, Nam K, Kim S, Kim J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	125		825	841	27750200	10.1016/j.ejmech.2016.09.083	Attenuation of Mycobacterium species through direct and macrophage mediated pathway by unsymmetrical diaryl urea.	Velappan AB, Charan Raja MR, Datta D, Tsai YT, Halloum I, Wan B, Kremer L, Gramajo H, Franzblau SG, Kar Mahapatra S, Debnath J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	125		890	901	27769030	10.1016/j.ejmech.2016.10.014	Differential characterization using readily accessible NMR experiments of novel N- and O-alkylated quinolin-4-ol, 1,5-naphthyridin-4-ol and quinazolin-4-ol derivatives with antimycobacterial activity.	Pitta E, Balabon O, Rogacki MK, Gómez J, Cunningham F, Joosens J, Augustyns K, van der Veken P, Bates R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	126		369	383	27907875	10.1016/j.ejmech.2016.11.041	S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents.	Karabanovich G, N¿me¿ek J, Valá¿ková L, Carazo A, Kone¿ná K, Stola¿íková J, Hrabálek A, Pavli¿ O, Pávek P, Vávrová K, Roh J, Klime¿ová V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	126		491	501	27914363	10.1016/j.ejmech.2016.11.048	New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.	Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL, Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P, Santos DS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	127		147	158	28039773	10.1016/j.ejmech.2016.12.042	Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.	Scalacci N, Brown AK, Pavan FR, Ribeiro CM, Manetti F, Bhakta S, Maitra A, Smith DL, Petricci E, Castagnolo D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	130		419	432	28279848	10.1016/j.ejmech.2017.02.058	Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents.	N¿me¿ek J, Sychra P, Machá¿ek M, Benková M, Karabanovich G, Kone¿ná K, Kavková V, Stola¿íková J, Hrabálek A, Vávrová K, Soukup O, Roh J, Klime¿ová V.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	131		275	288	28340368	10.1016/j.ejmech.2017.03.015	Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2-c]pyridine Mannich bases.	Jose G, Suresha Kumara TH, Sowmya HBV, Sriram D, Guru Row TN, Hosamani AA, More SS, Janardhan B, Harish BG, Telkar S, Ravikumar YS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Eur J Med Chem	2017	133		255	267	28390957	10.1016/j.ejmech.2017.04.002	Isoniazid derivatives and their anti-tubercular activity.	Hu YQ, Zhang S, Zhao F, Gao C, Feng LS, Lv ZS, Xu Z, Wu X.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	1	213	220	27810439	10.1016/j.bmc.2016.10.027	Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains.	Li Z, Bai X, Deng Q, Zhang G, Zhou L, Liu Y, Wang J, Wang Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	17	4835	4844	28778369	10.1016/j.bmc.2017.07.034	Discovery of new leads against Mycobacterium tuberculosis using scaffold hopping and shape based similarity.	Wavhale RD, Martis EAF, Ambre PK, Wan B, Franzblau SG, Iyer KR, Raikuvar K, Macegoniuk K, Berlicki ¿, Nandan SR, Coutinho EC.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	20	5468	5476	28835350	10.1016/j.bmc.2017.08.010	Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents.	Roh J, Karabanovich G, Vl¿ková H, Carazo A, N¿me¿ek J, Sychra P, Valá¿ková L, Pavli¿ O, Stola¿íková J, Klime¿ová V, Vávrová K, Pávek P, Hrabálek A.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	22	6167	6174	28094223	10.1016/j.bmc.2016.12.038	Anti-tuberculosis activity and structure-activity relationships of oxygenated tricyclic carbazole alkaloids and synthetic derivatives.	Börger C, Brütting C, Julich-Gruner KK, Hesse R, Kumar VP, Kutz SK, Rönnefahrt M, Thomas C, Wan B, Franzblau SG, Knölker HJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	4	1524	1532	28126437	10.1016/j.bmc.2017.01.016	Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.	Paraskevopoulos G, Monteiro S, Vosátka R, Krátký M, Navrátilová L, Trejtnar F, Stola¿íková J, Vin¿ová J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem	2017	25	6	1839	1845	28196707	10.1016/j.bmc.2017.01.045	Antimicrobial activity of rhodanine-3-acetic acid derivatives.	Krátký M, Vin¿ová J, Stola¿íková J.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	1	11	15	27894872	10.1016/j.bmcl.2016.11.047	Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents.	Balaji NV, Hari Babu B, Subbaraju GV, Purna Nagasree K, Murali Krishna Kumar M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	13	2996	3002	28512022	10.1016/j.bmcl.2017.05.011	Synthesis, antimycobacterial activity and docking study of 2-aroyl-[1]benzopyrano[4,3-c]pyrazol-4(1H)-one derivatives and related hydrazide-hydrazones.	Angelova VT, Valcheva V, Pencheva T, Voynikov Y, Vassilev N, Mihaylova R, Momekov G, Shivachev B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	13	3003	3006	28512023	10.1016/j.bmcl.2017.05.013	Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.	Verbitskiy EV, Baskakova SA, Gerasimova NA, Evstigneeva NP, Zil'berberg NV, Kungurov NV, Kravchenko MA, Skornyakov SN, Pervova MG, Rusinov GL, Chupakhin ON, Charushin VN.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	14	3071	3075	28552337	10.1016/j.bmcl.2017.05.050	One-pot microwave assisted stereoselective synthesis of novel dihydro-2'H-spiro[indene-2,1'-pyrrolo-[3,4-c]pyrrole]-tetraones and evaluation of their antimycobacterial activity and inhibition of AChE.	Bharkavi C, Vivek Kumar S, Ashraf Ali M, Osman H, Muthusubramanian S, Perumal S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	16	3643	3646	28720502	10.1016/j.bmcl.2017.07.023	Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1,2,3-triazole-isatin hybrids.	Xu Z, Zhang S, Song X, Qiang M, Lv Z.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	16	3698	3703	28712709	10.1016/j.bmcl.2017.07.008	Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents.	Aziz Ali A, Gogoi D, Chaliha AK, Buragohain AK, Trivedi P, Saikia PJ, Gehlot PS, Kumar A, Chaturvedi V, Sarma D.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	17	4165	4170	28734582	10.1016/j.bmcl.2017.07.019	The hydrolytic susceptibility of prochelator BSIH in aqueous solutions.	Wang Q, Franz KJ.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	18	4426	4430	28827112	10.1016/j.bmcl.2017.08.012	Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents.	Wang X, Ahn YM, Lentscher AG, Lister JS, Brothers RC, Kneen MM, Gerratana B, Boshoff HI, Dowd CS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	2	223	227	27914798	10.1016/j.bmcl.2016.11.071	Antimycobacterial activity of novel hydrazide-hydrazone derivatives with 2H-chromene and coumarin scaffold.	Angelova VT, Valcheva V, Vassilev NG, Buyukliev R, Momekov G, Dimitrov I, Saso L, Djukic M, Shivachev B.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	3	695	699	28065567	10.1016/j.bmcl.2016.06.038	Synthesis, identification and in vitro biological evaluation of some novel quinoline incorporated 1,3-thiazinan-4-one derivatives.	Umamatheswari S, Sankar C.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	4	808	815	28117201	10.1016/j.bmcl.2017.01.026	Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.	Saharan VD, Mahajan SS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	4	821	825	28117200	10.1016/j.bmcl.2017.01.024	Synthesis, antimycobacterial and cytotoxic activity of ¿,ß-unsaturated amides and 2,4-disubstituted oxazoline derivatives.	Avalos-Alanís FG, Hernández-Fernández E, Carranza-Rosales P, Carranza-Rosales P, López-Cortina S, Hernández-Fernández J, Ordóñez M, Guzmán-Delgado NE, Morales-Vargas A, Velázquez-Moreno VM, Santiago-Mauricio MG.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	Bioorg Med Chem Lett	2017	27	7	1593	1597	28254485	10.1016/j.bmcl.2017.02.021	A robust synthesis of functionalized 2H-indazoles via solid state melt reaction (SSMR) and their anti-tubercular activity.	Vidyacharan S, Adhikari C, Krishna VS, Reshma RS, Sriram D, Sharada DS.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	13	5876	5888	28574259	10.1021/acs.jmedchem.7b00582	Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.	Kozikowski AP, Onajole OK, Stec J, Dupont C, Viljoen A, Richard M, Chaira T, Lun S, Bishai W, Raj VS, Ordway D, Kremer L.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	16	7108	7122	28749666	10.1021/acs.jmedchem.7b00793	Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.	Azzali E, Machado D, Kaushik A, Vacondio F, Flisi S, Cabassi CS, Lamichhane G, Viveiros M, Costantino G, Pieroni M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	20	8647	8660	28968083	10.1021/acs.jmedchem.7b01332	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.	Dos Santos Fernandes GF, de Souza PC, Moreno-Viguri E, Santivañez-Veliz M, Paucar R, Pérez-Silanes S, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Man Chin C, da Silva PB, Chorilli M, Solcia MC, Ribeiro CM, Silva CSP, Marino LB, Bosquesi PL, Hunt DM, de Carvalho LPS, de Souza Costa CA, Cho SH, Wang Y, Franzblau SG, Pavan FR, Dos Santos JL.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	24	10118	10134	29148755	10.1021/acs.jmedchem.7b01347	Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.	Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	4	1379	1399	28075132	10.1021/acs.jmedchem.6b01358	Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.	Tantry SJ, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupta AK, Ambady A, Raichurkar A, Kedari C, Sharma S, Mudugal NV, Narayan A, Naveen Kumar CN, Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar KR, Kandaswamy K, Saralaya R, Kaur P, Dinesh N, Guptha S, Rich K, Murray D, Plant H, Preston M, Ashton H, Plant D, Walsh J, Alcock P, Naylor K, Collier M, Whiteaker J, McLaughlin RE, Mallya M, Panda M, Rudrapatna S, Ramachandran V, Shandil R, Sambandamurthy VK, Mdluli K, Cooper CB, Rubin H, Yano T, Iyer P, Narayanan S, Kavanagh S, Mukherjee K, Balasubramanian V, Hosagrahara VP, Solapure S, Ravishankar S, Hameed P S.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Med Chem	2017	60	7	2745	2763	28290692	10.1021/acs.jmedchem.6b01530	Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties.	Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go ML, Dick T.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med Chem Lett	2017	8	2	206	210	28197313	10.1021/acsmedchemlett.6b00417	From Dynamic Combinatorial Chemistry to in Vivo Evaluation of Reversible and Irreversible Myeloperoxidase Inhibitors.	Soubhye J, Gelbcke M, Van Antwerpen P, Dufrasne F, Boufadi MY, Nève J, Furtmüller PG, Obinger C, Zouaoui Boudjeltia K, Meyer F.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med Chem Lett	2017	8	5	533	537	28523106	10.1021/acsmedchemlett.7b00068	Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis.	Zhao H, Lu Y, Sheng L, Yuan Z, Wang B, Wang W, Li Y, Ma C, Wang X, Zhang D, Huang H.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	ACS Med Chem Lett	2017	8	6	636	641	28626525	10.1021/acsmedchemlett.7b00106	Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.	Lv K, You X, Wang B, Wei Z, Chai Y, Wang B, Wang A, Huang G, Liu M, Lu Y.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64	J Nat Prod	2017	80	2	377	383	28112509	10.1021/acs.jnatprod.6b00839	Flavonoids from Erythrina schliebenii.	Nyandoro SS, Munissi JJ, Kombo M, Mgina CA, Pan F, Gruhonjic A, Fitzpatrick P, Lu Y, Wang B, Rissanen K, Erdélyi M.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64								10.6019/CHEMBL3392926	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning	Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									British National Formulary (72nd edition)	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									DrugMatrix	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									Drug metabolism data	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									Open TG-GATES	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									PubChem BioAssay data set	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									Unpublished dataset	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1239.4000000000000000	1773	Mycobacterium tuberculosis	ISONIAZID	CHEMBL64									WHO Anatomical Therapeutic Chemical Classification	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1981	24	10	1214	1223	7328582	10.1021/jm00142a018	Retinoic acid analogues with ring modifications. Synthesis and pharmacological activity.	Dawson MI, Hobbs PD, Chan RL, Chao WR.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1982	25	11	1269	1277	6754935	10.1021/jm00353a001	Retinoids at the threshold: their biological significance and therapeutic potential.	Pawson BA, Ehmann CW, Itri LM, Sherman MI.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1988	31	1	190	196	3336018	10.1021/jm00396a031	N-(Retinoyl)amino acids. Synthesis and chemopreventive activity in vitro.	Shealy YF, Frye JL, Schiff LJ.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1988	31	6	1124	1130	2836589	10.1021/jm00401a011	Terminal bifunctional retinoids. Synthesis and evaluations related to cancer chemopreventive activity.	Shealy YF, Krauth CA, Riordan JM, Sani BP.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Nat. Prod.	1988	51	5	929	936	2849641	10.1021/np50059a019	A rapid and sensitive bioassay involving cultured rat glioma cells to screen for substances capable of elevating intracellular cyclic AMP concentration.	Swanson SM, Jiang JX, Chang YS, De Souza NJ, Pezzuto JM.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1991	34	1	430	439	1992144	10.1021/jm00105a065	Novel heteroarotinoids: synthesis and biological activity.	Spruce LW, Gale JB, Berlin KD, Verma AK, Breitman TR, Ji XH, van der Helm D.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1992	35	3	567	572	1738149	10.1021/jm00081a020	Base-catalyzed isomerization of retinoic acid. Synthesis and differentiation-inducing activities of 14-alkylated all-trans-, 13-cis-, and 20,14-retro-retinoic acids.	Tanaka H, Kagechika H, Kawachi E, Fukasawa H, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1994	37	26	4499	4507	7799400	10.1021/jm00052a009	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.	Vaezi MF, Alam M, Sani BP, Rogers TS, Simpson-Herren L, Wille JJ, Hill DL, Doran TI, Brouillette WJ, Muccio DD.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1995	38	13	2302	2310	7608895	10.1021/jm00013a006	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.	Alam M, Zhestkov V, Sani BP, Venepally P, Levin AA, Kazmer S, Li E, Norris AW, Zhang XK, Lee MO.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1996	39	19	3625	3635	8809153	10.1021/jm9603126	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.	Muccio DD, Brouillette WJ, Alam M, Vaezi MF, Sani BP, Venepally P, Reddy L, Li E, Norris AW, Simpson-Herren L, Hill DL.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	1998	41	10	1679	1687	9572893	10.1021/jm970635h	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.	Muccio DD, Brouillette WJ, Breitman TR, Taimi M, Emanuel PD, Zhang X, Chen G, Sani BP, Venepally P, Reddy L, Alam M, Simpson-Herren L, Hill DL.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Nat. Prod.	2000	63	9	1235	1238	11000026	10.1021/np0001575	Bioactive constituents of Thuja occidentalis.	Chang LC, Song LL, Park EJ, Luyengi L, Lee KJ, Farnsworth NR, Pezzuto JM, Kinghorn AD.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Antimicrob. Agents Chemother.	2007	51	7	2403	2411	17485504	10.1128/aac.01184-06	Amiodarone and bepridil inhibit anthrax toxin entry into host cells.	Sanchez AM, Thomas D, Gillespie EJ, Damoiseaux R, Rogers J, Saxe JP, Huang J, Manchester M, Bradley KA.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Eur. J. Med. Chem.	2009	44	6	2572	2576	19231037	10.1016/j.ejmech.2009.01.029	Synthesis, characterization and in vitro antiproliferative activities of new 13-cis-retinoyl ferrocene derivatives.	Long B, Liang S, Xin D, Yang Y, Xiang J.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Eur. J. Med. Chem.	2009	44	6	2689	2695	19216007	10.1016/j.ejmech.2009.01.001	Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity.	Magoulas G, Papaioannou D, Papadimou E, Drainas D.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Antimicrob. Agents Chemother.	2009	53	5	1840	1849	19258267	10.1128/aac.01614-08	Identification and characterization of mefloquine efficacy against JC virus in vitro.	Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Bioorg. Med. Chem.	2012	20	22	6669	6679	23062825	10.1016/j.bmc.2012.09.040	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.	Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C, Vuorela P.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Bioorg. Med. Chem.	2012	20	23	6877	6884	23088909	10.1016/j.bmc.2012.09.035	Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy.	Gardner CR, Cheung BB, Koach J, Black DS, Marshall GM, Kumar N.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Bioorg. Med. Chem. Lett.	2014	24	4	1080	1084	24468412	10.1016/j.bmcl.2014.01.014	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.	Shea TA, Burburan PJ, Matubia VN, Ramcharan SS, Rosario I, Parkin DW, Stockman BJ.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Hepatology	2014	60	3	1015	1022	24799086	10.1002/hep.27206	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.	Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	J. Med. Chem.	2015	58	2	778	784	25513712	10.1021/jm501543u	Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.	Fako VE, Wu X, Pflug B, Liu JY, Zhang JT.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									British National Formulary (72nd edition)	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									DailyMed|setid=517810a4-76bb-4739-893f-1f2ba94a5d0c | ZENATANE -isotretinoin capsule, gelatine coated	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									DrugMatrix	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									PubChem BioAssay data set	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	ISOTRETINOIN	CHEMBL547									WHO Anatomical Therapeutic Chemical Classification	
882.4000000000000000	9606	Homo sapiens	JNJ-26483327	CHEMBL3545133									Unpublished dataset	
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Med. Chem.	1981	24	12	1487	1492	7310825	10.1021/jm00144a023	"Chemical modification of aminoglycosides. 3. Synthesis of 2""-deoxykanamycins from neamine."	Reid RJ, Mizsak SA, Reineke LM, Zurenko GE, Stern KF, Magerlein BJ.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	1998	61	9	1150	1153	9748388	10.1021/np980044+	Antimicrobial activity of 8-alkyl- and 8-phenyl-substituted berberines and their 12-bromo derivatives.	Iwasa K, Lee DU, Kang SI, Wiegrebe W.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2001	64	3	385	388	11277765	10.1021/np0004404	Potent antiviral potamogetonyde and potamogetonol, new furanoid labdane diterpenes from Potamogeton malaianus.	Kittakoop P, Wanasith S, Watts P, Kramyu J, Tanticharoen M, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2001	64	8	1015	1018	11520217	10.1021/np010006h	Phomoxanthones A and B, novel xanthone dimers from the endophytic fungus Phomopsis species.	Isaka M, Jaturapat A, Rukseree K, Danwisetkanjana K, Tanticharoen M, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2002	65	9	1346	1348	12350163	10.1021/np020055+	Hirsutellide A, a new antimycobacterial cyclohexadepsipeptide from the entomopathogenic fungus Hirsutella kobayasii.	Vongvanich N, Kittakoop P, Isaka M, Trakulnaleamsai S, Vimuttipong S, Tanticharoen M, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Bioorg. Med. Chem. Lett.	2003	13	10	1755	1757	12729658	10.1016/s0960-894x(03)00241-5	Anilinopyrimidines as novel antituberculosis agents.	Morgan J, Haritakul R, Keller PA.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Bioorg. Med. Chem. Lett.	2003	13	7	1253	1255	12657257	10.1016/s0960-894x(03)00111-2	Antimycobacterial pimarane diterpenes from the Fungus Diaporthe sp.	Dettrakul S, Kittakoop P, Isaka M, Nopichai S, Suyarnsestakorn C, Tanticharoen M, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2003	66	4	540	543	12713411	10.1021/np0204489	Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum.	Chumkaew P, Karalai C, Ponglimanont C, Chantrapromma K.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2003	66	5	709	711	12762815	10.1021/np0205598	Antimalarial dihydroisocoumarins produced by Geotrichum sp., an endophytic fungus of Crassocephalum crepidioides.	Kongsaeree P, Prabpai S, Sriubolmas N, Vongvein C, Wiyakrutta S.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2003	66	6	868	870	12828479	10.1021/np030067a	New antimycobacterial and antimalarial 8,9-secokaurane diterpenes from Croton kongensis.	Thongtan J, Kittakoop P, Ruangrungsi N, Saenboonrueng J, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2004	67	3	485	486	15043440	10.1021/np030429e	Lakoochins A and B, new antimycobacterial stilbene derivatives from Artocarpus lakoocha.	Puntumchai A, Kittakoop P, Rajviroongit S, Vimuttipong S, Likhitwitayawuid K, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2004	67	6	968	972	15217275	10.1021/np030519j	New bioactive prenylflavonoids and dibenzocycloheptene derivative from roots of Dendrolobium lanceolatum.	Kanokmedhakul S, Kanokmedhakul K, Nambuddee K, Kongsaeree P.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2005	68	2	183	188	15730240	10.1021/np049757k	New bioactive clerodane diterpenoids from the bark of Casearia grewiifolia.	Kanokmedhakul S, Kanokmedhakul K, Kanarsa T, Buayairaksa M.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2005	68	7	1103	1105	16038559	10.1021/np050036a	3-Nitropropionic acid (3-NPA), a potent antimycobacterial agent from endophytic fungi: is 3-NPA in some plants produced by endophytes?	Chomcheon P, Wiyakrutta S, Sriubolmas N, Ngamrojanavanich N, Isarangkul D, Kittakoop P.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2006	69	1	68	72	16441071	10.1021/np0503202	2-substituted furans from the roots of Polyalthia evecta.	Kanokmedhakul S, Kanokmedhakul K, Kantikeaw I, Phonkerd N.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2006	69	10	1404	1410	17067151	10.1021/np0601197	Bioactive compounds from the seed fungus Menisporopsis theobromae BCC 3975.	Chinworrungsee M, Kittakoop P, Saenboonrueng J, Kongsaeree P, Thebtaranonth Y.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2006	69	6	980	982	16792425	10.1021/np060164e	Chromone derivatives from the filamentous fungus Lachnum sp. BCC 2424.	Rukachaisirikul V, Chantaruk S, Pongcharoen W, Isaka M, Lapanun S.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2007	70	5	795	801	17480099	10.1021/np070010e	Bioactive compounds from Bauhinia purpurea possessing antimalarial, antimycobacterial, antifungal, anti-inflammatory, and cytotoxic activities.	Boonphong S, Puangsombat P, Baramee A, Mahidol C, Ruchirawat S, Kittakoop P.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2007	70	9	1536	1538	17845001	10.1021/np070293a	Bioactive constituents of the roots of Polyalthia cerasoides.	Kanokmedhakul S, Kanokmedhakul K, Lekphrom R.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2008	71	2	292	294	18179177	10.1021/np070629g	Seco-terpenoids and other constituents from Elateriospermum tapos.	Pattamadilok D, Suttisri R.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J Agric Food Chem	2009	57	16	7288	7292	19650641	10.1021/jf901405c	Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.	Liu SY, Lo CT, Shibu MA, Leu YL, Jen BY, Peng KC.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2009	72	8	1442	1446	19627125	10.1021/np800805f	Prenylxanthones and a bicyclo[3.3.1]nona-2,6-diene derivative from the fungus Emericella rugulosa.	Moosophon P, Kanokmedhakul S, Kanokmedhakul K, Soytong K.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Nat. Prod.	2009	72	8	1487	1491	19663417	10.1021/np9003189	Antimalarial and cytotoxic depsidones from the fungus Chaetomium brasiliense.	Khumkomkhet P, Kanokmedhakul S, Kanokmedhakul K, Hahnvajanawong C, Soytong K.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Eur. J. Med. Chem.	2010	45	3	1028	1033	19962795	10.1016/j.ejmech.2009.11.045	Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: improvement of stability and proposed action mechanism.	Park KD, Cho SJ.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	Bioorg. Med. Chem. Lett.	2014	24	22	5310	5314	25293447	10.1016/j.bmcl.2014.09.047	Beta-aminoketones as prodrugs for selective irreversible inhibitors of type-1 methionine aminopeptidases.	Altmeyer M, Amtmann E, Heyl C, Marschner A, Scheidig AJ, Klein CD.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446	J. Med. Chem.	2016	59	7	3140	3151	26964758	10.1021/acs.jmedchem.5b01912	Antibacterial Diamines Targeting Bacterial Membranes.	Wang B, Pachaiyappan B, Gruber JD, Schmidt MG, Zhang YM, Woster PM.
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446									Unpublished dataset	
2219.8000000000000000	2	Bacteria	KANAMYCIN SULFATE	CHEMBL1446									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
998.6000000000000000	9606	Homo sapiens	KD3010	CHEMBL3545114									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	KW-2449	CHEMBL1908397	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
924.8000000000000000	9606	Homo sapiens	KW-2449	CHEMBL1908397	MedChemComm	2012	3	1	22	27		10.1039/C1MD00175B	Inhibitors of Stat5 protein signalling	Cumaraswamy AA, Todic A, Resetca D, Minden MD, Gunning PT
924.8000000000000000	9606	Homo sapiens	KW-2449	CHEMBL1908397	J. Med. Chem.	2013	56	20	8032	8048	24044867	10.1021/jm401094t	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.	Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA.
924.8000000000000000	9606	Homo sapiens	KW-2449	CHEMBL1908397	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	KW-2449	CHEMBL1908397									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323	J. Med. Chem.	1982	25	6	670	679	6124636	10.1021/jm00348a013	Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.	Clifton JE, Collins I, Hallett P, Hartley D, Lunts LH, Wicks PD.
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323									British National Formulary (72nd edition)	
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	LABETALOL HYDROCHLORIDE	CHEMBL1200323									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1993	3	4	693	696		10.1016/S0960-894X(01)81256-7	Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides	Choi W, Yeola S, Liotta DC, Schinazi RF, Painter GR, Davis M, St. Clair M, Furman PA
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1993	3	8	1723	1728		10.1016/S0960-894X(00)80050-5	A novel class of 1,3-oxathiolane nucleoside analogues having potent anti-HIV activity	Belleau B, Brasili L, Chan L, DiMarco MP, Zacharie B, Nguyen-Ba N, Jenkinson HJ, Coates JA, Cameron JM
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1993	36	18	2627	2638	8410975	10.1021/jm00070a006	Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents.	Jeong LS, Schinazi RF, Beach JW, Kim HO, Shanmuganathan K, Nampalli S, Chun MW, Chung WK, Choi BG, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1993	36	2	181	195	8423591	10.1021/jm00054a001	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.	Jeong LS, Schinazi RF, Beach JW, Kim HO, Nampalli S, Shanmuganathan K, Alves AJ, McMillan A, Chu CK, Mathis R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1994	37	14	2216	2223	8035429	10.1021/jm00040a014	Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates.	Charvet AS, Camplo M, Faury P, Graciet JC, Mourier N, Chermann JC, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1995	38	10	1657	1665	7538590	10.1021/jm00010a010	Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.	Wyatt PG, Bethell RC, Cammack N, Charon D, Dodic N, Dumaitre B, Evans DN, Green DV, Hopewell PL, Humber DC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1995	5	17	2011	2014		10.1016/0960-894X(95)00343-R	Dioxolane cytosine nucleosides as anti-hepatitis B agents	Lee M, Chu CK, Balakrishna Pai S, Zhu Y, Cheng Y, Chun MW, Chung WK
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1996	6	15	1775	1780		10.1016/0960-894X(96)00316-2	Modelisation, synthesis and antiviral evaluation of new 2,3-disubstituted thiazolidinone nucleoside analogues	Graciet J, Niddam V, Gamberoni M, Trabaud C, Dessolin J, Medou M, Mourier N, Zoulim F, Borel C, Hantz O, Camplo M, Chermann J, Kraus J
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1997	40	19	2991	2993	9301659	10.1021/jm9703698	Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides.	Du J, Surzhykov S, Lin JS, Newton MG, Cheng YC, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1997	7	17	2325	2328		10.1016/S0960-894X(97)00422-8	Robustaflavone, a naturally occurring biflavanoid, is a potent non-nucleoside inhibitor of hepatitis B virus replication in vitro	Lin Y, Zembower DE, Flavin MT, Schure RM, Anderson HM, Korba BE, Chen F
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1997	7	2	127	132		10.1016/S0960-894X(96)00594-X	BMS-200475, a novel carbocyclic 2-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro	Bisacchi G, Chao S, Bachard C, Daris J, Innaimo S, Jacobs G, Kocy O, Lapointe P, Martel A, Merchant Z, Slusarchyk W, Sundeen J, Young M, Colonno R, Zahler R
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1997	7	9	1199	1202		10.1016/S0960-894X(97)00178-9	Synthesis and antiviral evaluation of 4-hydroxymethyl-2, 3-dideoxy-3-thianucleosides and their cyclic monophosphates	Chao Q, Nair V
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	1998	41	12	2168	2170	9622558	10.1021/jm980038a	Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives?	Seley KL, Schneller SW, Korba B.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	1998	8	13	1589	1594	9873396	10.1016/s0960-894x(98)00277-7	Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.	Chen SH, Wang Q, Mao J, King I, Dutschman GE, Gullen EA, Cheng YC, Doyle TW.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Pharmacol. Exp. Ther.	2000	294	1	844	849	10945832		Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2000	43	21	3906	3912	11052795	10.1021/jm990113x	Synthesis and antiviral activity of oxaselenolane nucleosides.	Chu CK, Ma L, Olgen S, Pierra C, Du J, Gumina G, Gullen E, Cheng YC, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2001	11	22	2917	2920	11677126	10.1016/s0960-894x(01)00589-3	Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.	Kumar R, Tyrrell DL.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2001	64	11	1477	1479	11720540	10.1021/np010216u	Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.	Gochfeld DJ, Hamann MT.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2001	64	2	265	277	11430019	10.1021/np0003995	Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.	Yang SS, Cragg GM, Newman DJ, Bader JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Aids	2002	16	1	1743	1747	12218384	10.1097/00002030-200209060-00005	The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).	Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2002	45	10	2032	2040	11985471	10.1021/jm010410d	Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus.	Kumar R, Nath M, Tyrrell DL.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2002	45	14	3138	3142	12086499	10.1021/jm020036x	2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents.	Sekiya K, Takashima H, Ueda N, Kamiya N, Yuasa S, Fujimura Y, Ubasawa M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2002	45	22	4888	4898	12383014	10.1021/jm020246+	Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides.	Chong Y, Choo H, Choi Y, Mathew J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2003	13	12	1993	1996	12781181	10.1016/s0960-894x(03)00330-5	The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).	Choo H, Chong Y, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2003	13	15	2459	2463	12852943	10.1016/s0960-894x(03)00496-7	Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?	Anastasi C, Vlieghe P, Hantz O, Schorr O, Pannecouque C, Witvrouw M, De Clercq E, Clayette P, Dereuddre-Bosquet N, Dormont D, Gondois-Rey F, Hirsch I, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2003	46	15	3245	3256	12852755	10.1021/jm0300274	l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.	Chong Y, Gumina G, Mathew JS, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Mol. Pharmacol.	2003	63	1	65	72	12488537	10.1124/mol.63.1.65	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.	Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2004	47	13	3399	3408	15189036	10.1021/jm040027j	Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents.	Zhou W, Gumina G, Chong Y, Wang J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2004	47	27	6964	6972	15615545	10.1021/jm040093l	(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity.	Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Matsumi S, Mitsuya H, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2004	47	5	1183	1192	14971898	10.1021/jm0309708	Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.	Anastasi C, Hantz O, De Clercq E, Pannecouque C, Clayette P, Dereuddre-Bosquet N, Dormont D, Gondois-Rey F, Hirsch I, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2004	47	7	1631	1640	15027854	10.1021/jm0303148	Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents.	Zhu W, Chong Y, Choo H, Mathews J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2004	67	6	994	998	15217281	10.1021/np030469i	New 3-O-acyl betulinic acids from Strychnos vanprukii Craib.	Nguyen QC, Nguyen VH, Santarsiero BD, Mesecar AD, Nguyen MC, Soejarto DD, Pezzuto JM, Fong HH, Tan GT.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2005	15	24	5397	5401	16213713	10.1016/j.bmcl.2005.09.015	Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.	Zhang P, Zhang N, Korba BE, Hosmane RS.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2005	48	1	91	99	15634003	10.1021/jm040149b	Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity.	Yan Z, Kern ER, Gullen E, Cheng YC, Drach JC, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2005	48	11	3736	3748	15916425	10.1021/jm050096d	Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides.	Wang J, Jin Y, Rapp KL, Bennett M, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2005	48	15	5043	5046	16033283	10.1021/jm058200e	5'-Homoneplanocin A inhibits hepatitis B and hepatitis C.	Yang M, Schneller SW, Korba B.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2005	48	2	534	546	15658867	10.1021/jm034265a	Synthesis and antiviral activity of helioxanthin analogues.	Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Lee Y, Chung R, Huang ES, Austin DJ, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2006	49	12	3693	3700	16759112	10.1021/jm060102l	Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.	Kumar R, Semaine W, Johar M, Tyrrell DL, Agrawal B.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2006	49	15	4790	4794	16854087	10.1021/jm060330f	Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives.	Li YF, Wang GF, He PL, Huang WG, Zhu FH, Gao HY, Tang W, Luo Y, Feng CL, Shi LP, Ren YD, Lu W, Zuo JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2006	49	20	6120	6128	17004726	10.1021/jm0607404	9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1.	Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Tamiya S, Mitsuya H, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2006	49	6	2049	2054	16539393	10.1021/jm058271d	Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.	Semaine W, Johar M, Tyrrell DL, Kumar R, Agrawal B.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Proc. Natl. Acad. Sci. U.S.A.	2007	104	20	8526	8531	17488817	10.1073/pnas.0609883104	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.	Ying C, Li Y, Leung CH, Robek MD, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2007	17	19	5316	5320	17723297	10.1016/j.bmcl.2007.08.027	Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida.	Cheng P, Ma YB, Yao SY, Zhang Q, Wang EJ, Yan MH, Zhang XM, Zhang FX, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Drug Metab. Dispos.	2007	35	3	340	344	17172311	10.1124/dmd.106.012765	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.	Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2007	42	11	1358	1364	17499889	10.1016/j.ejmech.2007.03.005	Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus.	Li YF, Wang GF, Luo Y, Huang WG, Tang W, Feng CL, Shi LP, Ren YD, Zuo JP, Lu W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2007	50	19	4766	4774	17696514	10.1021/jm070391t	Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.	Rai D, Johar M, Srivastav NC, Manning T, Agrawal B, Kunimoto DY, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	10	3516	3522	17664328	10.1128/aac.01626-06	Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.	Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli E, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J, PACTG P1012 Team.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	12	4489	4491	17876005	10.1128/aac.00687-07	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.	Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	6	2105	2111	17438052	10.1128/aac.00831-06	Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.	Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	6	2130	2135	17403996	10.1128/aac.01543-06	Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.	Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	6	2240	2243	17371827	10.1128/aac.01440-06	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.	Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	7	2285	2292	17438047	10.1128/aac.01499-06	The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.	Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	7	2523	2530	17404006	10.1128/aac.00001-07	Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.	Matthes E, Funk A, Krahn I, Gaertner K, von Janta-Lipinski M, Lin L, Will H, Sirma H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	7	2600	2604	17470654	10.1128/aac.00212-07	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.	Shi M, Wang X, De Clercq E, Takao S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	8	2943	2947	17242147	10.1128/aac.01013-06	Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers.	Holdich T, Shiveley LA, Sawyer J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	8	2948	2953	17517847	10.1128/aac.01204-06	In vitro interactions between apricitabine and other deoxycytidine analogues.	Bethell R, De Muys J, Lippens J, Richard A, Hamelin B, Ren C, Collins P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2007	51	9	3177	3184	17606676	10.1128/aac.00325-07	Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi RF, Chu CK, Cote PJ, Gerin JL, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2008	16	13	6522	6527	18524601	10.1016/j.bmc.2008.05.029	Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro.	Liu Y, Zhao Y, Zhai X, Feng X, Wang J, Gong P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2008	18	13	3787	3789	18524583	10.1016/j.bmcl.2008.05.065	Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives.	Cheng P, Zhang Q, Ma YB, Jiang ZY, Zhang XM, Zhang FX, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2008	52	1	329	332	17967913	10.1128/aac.01004-07	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.	Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2008	52	10	3617	3632	18676881	10.1128/aac.00654-08	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2008	52	4	1519	1521	18285481	10.1128/aac.01241-07	Anti-BK virus activity of nucleoside analogs.	Randhawa P, Zemlicka J, Sauerbrei A, Meier C, Hostetler KY, Beadle JR, Farasati NA, Huang Y, Bradley M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2008	52	5	1759	1767	18316521	10.1128/aac.01313-07	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.	Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, Dicker I, Gali V, Higley H, Parkin N, Tenney D, Krystal M, Colonno R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2008	52	8	2825	2830	18541728	10.1128/aac.00434-08	Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.	Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2008	71	5	760	763	18396905	10.1021/np070479+	Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus.	Yan MH, Cheng P, Jiang ZY, Ma YB, Zhang XM, Zhang FX, Yang LM, Zheng YT, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2009	17	13	4569	4574	19457674	10.1016/j.bmc.2009.05.001	Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols.	Jia W, Liu Y, Li W, Liu Y, Zhang D, Zhang P, Gong P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2009	17	17	6407	6413	19660957	10.1016/j.bmc.2009.07.032	Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs.	Ravetti S, Gualdesi MS, Trinchero-Hernández JS, Turk G, Briñón MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2009	17	8	3118	3125	19307124	10.1016/j.bmc.2009.03.003	Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives.	Xu B, Huang Z, Liu C, Cai Z, Pan W, Cao P, Hao X, Liang G.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2009	19	17	4958	4962	19640714	10.1016/j.bmcl.2009.07.078	Schisanwilsonins A-G and related anti-HBV lignans from the fruits of Schisandra wilsoniana.	Ma WH, Lu Y, Huang H, Zhou P, Chen DF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2009	19	23	6659	6665	19853440	10.1016/j.bmcl.2009.10.006	Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors.	Zhang Q, Jiang ZY, Luo J, Ma YB, Liu JF, Guo RH, Zhang XM, Zhou J, Niu W, Du FF, Li L, Li C, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2009	19	8	2148	2153	19289281	10.1016/j.bmcl.2009.02.122	Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives.	Zhang Q, Jiang ZY, Luo J, Liu JF, Ma YB, Guo RH, Zhang XM, Zhou J, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2009	52	1	206	213	19072694	10.1021/jm801418v	Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.	Kim HJ, Sharon A, Bal C, Wang J, Allu M, Huang Z, Murray MG, Bassit L, Schinazi RF, Korba B, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	11	4640	4646	19704131	10.1128/aac.00686-09	Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.	Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	3	1194	1203	19104010	10.1128/aac.00984-08	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.	Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	6	2367	2374	19307360	10.1128/aac.01523-08	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.	Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	6	2424	2431	19289522	10.1128/aac.01559-08	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.	Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	7	2865	2870	19398648	10.1128/aac.00114-09	Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.	Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2009	72	4	676	678	19228000	10.1021/np8007864	Schisanwilsonenes A-C, anti-HBV Carotane sesquiterpenoids from the fruits of Schisandra wilsoniana.	Ma WH, Huang H, Zhou P, Chen DF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2010	18	14	5048	5055	20639110	10.1016/j.bmc.2010.05.076	Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus.	Luo Y, Yao JP, Yang L, Feng CL, Tang W, Wang GF, Zuo JP, Lu W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2010	18	21	7542	7547	20869253	10.1016/j.bmc.2010.08.048	Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses.	Srivastav NC, Shakya N, Mak M, Liang C, Tyrrell DL, Agrawal B, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2010	18	3	1213	1226	20061158	10.1016/j.bmc.2009.12.038	Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents.	Janmanchi D, Tseng YP, Wang KC, Huang RL, Lin CH, Yeh SF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2010	20	1	299	301	19897363	10.1016/j.bmcl.2009.10.119	2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly.	Zhu X, Zhao G, Zhou X, Xu X, Xia G, Zheng Z, Wang L, Yang X, Li S.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2010	20	22	6790	6793	20863701	10.1016/j.bmcl.2010.08.120	Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.	Srivastav NC, Mak M, Agrawal B, Tyrrell DL, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2010	20	24	7230	7233	21074429	10.1016/j.bmcl.2010.10.099	Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors.	Zhao Y, Liu Y, Chen D, Wei Z, Liu W, Gong P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2010	20	5	1783	1786	20117930	10.1016/j.bmcl.2010.01.010	Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.	Coughlin JE, Padmanabhan S, Zhang G, Kirk CJ, Govardhan CP, Korba BE, O'Loughlin K, Green CE, Mirsalis J, Morrey JD, Iyer RP.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2010	45	5	1919	1926	20149495	10.1016/j.ejmech.2010.01.032	Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication.	Dong WL, Liu ZX, Liu XH, Li ZM, Zhao WG.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2010	53	19	7156	7166	20857959	10.1021/jm100803c	Antiviral activity of various 1-(2'-deoxy-ß-D-lyxofuranosyl), 1-(2'-fluoro-ß-D-xylofuranosyl), 1-(3'-fluoro-ß-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.	Srivastav NC, Shakya N, Mak M, Agrawal B, Tyrrell DL, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2010	54	5	2070	2077	20176893	10.1128/aac.01764-09	Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.	Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, You XF, Song DQ, Li ZR, Yu LY, Cen S, Hong B, Sun CH, Zhao LX, Kreiswirth B, Perlin D, Shao RG, Jiang JD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2010	54	6	2670	2673	20308377	10.1128/aac.01703-09	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.	Lin K, Karwowska S, Lam E, Limoli K, Evans TG, Avila C.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2010	54	8	3280	3286	20516271	10.1128/aac.00306-10	Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?	Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Tréluyer JM, Msellati P, Urien S.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2011	19	1	41	51	21183354	10.1016/j.bmc.2010.11.063	Synthesis and in vitro anti-hepatitis B virus activity of six-membered azanucleoside analogues.	Wang D, Li YH, Wang YP, Gao RM, Zhang LH, Ye XS.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2011	19	10	3120	3127	21524588	10.1016/j.bmc.2011.04.004	Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus.	Qu SJ, Wang GF, Duan WH, Yao SY, Zuo JP, Tan CH, Zhu DY.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2011	19	18	5352	5360	21872478	10.1016/j.bmc.2011.08.001	Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents.	Qiu J, Xu B, Huang Z, Pan W, Cao P, Liu C, Hao X, Song B, Liang G.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2011	19	6	2084	2089	21334901	10.1016/j.bmc.2011.01.024	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.	Balestrieri E, Pizzimenti F, Ferlazzo A, Giofrè SV, Iannazzo D, Piperno A, Romeo R, Chiacchio MA, Mastino A, Macchi B.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2011	21	11	3313	3316	21524575	10.1016/j.bmcl.2011.04.006	Synthesis of 5-thiodidehydropyranylcytosine derivatives as potential anti-HIV agents.	Yoshimura Y, Yamazaki Y, Saito Y, Natori Y, Imamichi T, Takahata H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2011	21	21	6328	6331	21930377	10.1016/j.bmcl.2011.08.113	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.	Wang J, Singh US, Rawal RK, Sugiyama M, Yoo J, Jha AK, Scroggin M, Huang Z, Murray MG, Govindarajan R, Tanaka Y, Korba B, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2011	21	6	1644	1648	21333535	10.1016/j.bmcl.2011.01.109	Antiviral agents 3. Discovery of a novel small molecule non-nucleoside inhibitor of hepatitis B virus (HBV).	Crosby IT, Bourke DG, Jones ED, Jeynes TP, Cox S, Coates JA, Robertson AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2011	46	1	307	319	21145140	10.1016/j.ejmech.2010.11.019	Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents.	Guo RH, Zhang Q, Ma YB, Luo J, Geng CA, Wang LJ, Zhang XM, Zhou J, Jiang ZY, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2011	46	9	3832	3844	21700368	10.1016/j.ejmech.2011.05.051	Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.	Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2011	54	3	869	876	21218816	10.1021/jm101325h	Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70.	Gao LM, Han YX, Wang YP, Li YH, Shan YQ, Li X, Peng ZG, Bi CW, Zhang T, Du NN, Jiang JD, Song DQ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Antimicrob. Agents Chemother.	2011	55	2	813	821	21115794	10.1128/aac.01209-10	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.	Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2011	74	4	683	689	21401115	10.1021/np100745z	Homoflavonoid glucosides from Ophioglossum pedunculosum and their anti-HBV activity.	Wan CX, Zhang PH, Luo JG, Kong LY.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2011	74	8	1822	1825	21823575	10.1021/np200256b	Swerilactones L-O, secoiridoids with C¿¿ and C¿¿ skeletons from Swertia mileensis.	Geng CA, Zhang XM, Ma YB, Luo J, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2012	20	19	5986	5991	22944333	10.1016/j.bmc.2012.07.028	Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols.	Ugliarolo EA, Gagey D, Lantaño B, Moltrasio GY, Campos RH, Cavallaro LV, Moglioni AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2012	22	17	5451	5454	22858097	10.1016/j.bmcl.2012.07.037	Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.	Agarwal HK, Buckheit KW, Buckheit RW, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2012	22	20	6475	6480	22985854	10.1016/j.bmcl.2012.08.042	A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.	Shakya N, Vedi S, Liang C, Agrawal B, Tyrrell DL, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2012	55	10	4861	4871	22533850	10.1021/jm300492q	Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine.	Agarwal HK, Chhikara BS, Hanley MJ, Ye G, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2012	55	6	2672	2687	22352809	10.1021/jm201551m	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Quiterio M, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2012	75	3	414	419	22148316	10.1021/np200855d	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.	Vidal V, Potterat O, Louvel S, Hamy F, Mojarrab M, Sanglier JJ, Klimkait T, Hamburger M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2013	21	22	7091	7100	24119448	10.1016/j.bmc.2013.09.009	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.	Chen W, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Jiang X, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2013	23	2	503	506	23237841	10.1016/j.bmcl.2012.11.027	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.	Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, Tanaka Y, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2013	23	5	1310	1314	23369536	10.1016/j.bmcl.2012.12.097	Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV).	Han A, Li L, Qing K, Qi X, Hou L, Luo X, Shi S, Ye F.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2013	23	7	2123	2127	23434420	10.1016/j.bmcl.2013.01.118	Anti-HBV active constituents from Piper longum.	Jiang ZY, Liu WF, Zhang XM, Luo J, Ma YB, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2013	23	7	2238	2244	23434030	10.1016/j.bmcl.2013.01.046	Anti-hepatitis B virus lignans from the root of Streblus asper.	Li J, Meng AP, Guan XL, Li J, Wu Q, Deng SP, Su XJ, Yang RY.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Scientific Reports	2013	3		1	7	23812503	10.1038/srep02100	MICE models: superior to the HERG model in predicting Torsade de Pointes.	Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2013	70		326	340	24177359	10.1016/j.ejmech.2013.09.047	Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.	McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, Madela K, Meneghesso S, Pertusati F, Serpi M, Slusarczyk M, Chamberlain S, Kolykhalov A, Vernachio J, Vanpouille C, Introini A, Margolis L, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2014	22	12	3220	3226	24794751	10.1016/j.bmc.2014.03.020	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2014	24	17	4247	4249	25127104	10.1016/j.bmcl.2014.07.032	A new series of HAPs as anti-HBV agents targeting at capsid assembly.	Yang XY, Xu XQ, Guan H, Wang LL, Wu Q, Zhao GM, Li S.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2014	74		388	397	24486419	10.1016/j.ejmech.2013.12.055	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.	Abou-Elkhair RA, Moustafa AH, Haikal AZ, Ibraheem AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2014	75		267	281	24549242	10.1016/j.ejmech.2014.01.046	A review of non-nucleoside anti-hepatitis B virus agents.	Zhang F, Wang G.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2014	77	3	663	667	24404757	10.1021/np400779v	Bioactive compounds from Vitex leptobotrys.	Pan W, Liu K, Guan Y, Tan GT, Hung NV, Cuong NM, Soejarto DD, Pezzuto JM, Fong HH, Zhang H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2014	77	6	1505	1512	24926807	10.1021/np500271u	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.	Nothias-Scaglia LF, Retailleau P, Paolini J, Pannecouque C, Neyts J, Dumontet V, Roussi F, Leyssen P, Costa J, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2014	82		600	611	24952305	10.1016/j.ejmech.2014.05.059	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.	Meng G, Liu Y, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2015	23	17	5496	5501	26260336	10.1016/j.bmc.2015.07.039	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.	Liu C, Chen Q, Gorden JD, Schneller SW.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2015	23	20	6543	6550	26372075	10.1016/j.bmc.2015.09.006	Synthesis and antiviral activity of maleopimaric and quinopimaric acids' derivatives.	Tretyakova EV, Smirnova IE, Salimova EV, Odinokov VN.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem.	2015	23	4	720	728	25600408	10.1016/j.bmc.2014.12.064	Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives.	Huang TJ, Yang CL, Kuo YC, Chang YC, Yang LM, Chou BH, Lin SJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2015	25	6	1232	1235	25682562	10.1016/j.bmcl.2015.01.058	Design, synthesis of new ß-carboline derivatives and their selective anti-HIV-2 activity.	Ashok P, Chander S, Balzarini J, Pannecouque C, Murugesan S.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg. Med. Chem. Lett.	2015	25	7	1506	1508	25736995	10.1016/j.bmcl.2015.02.022	A coumarin lignanoid from the stems of Kadsura heteroclita.	Su W, Zhao J, Yang M, Yan HW, Pang T, Chen SH, Huang HY, Zhang SH, Ma XC, Guo DA, Khan IA, Wang W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2015	58	8	3445	3458	25849312	10.1021/jm501874e	ß-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.	Zhou L, Zhang HW, Tao S, Bassit L, Whitaker T, McBrayer TR, Ehteshami M, Amiralaei S, Pradere U, Cho JH, Amblard F, Bobeck D, Detorio M, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Med. Chem.	2015	58	9	3693	3703	25905540	10.1021/jm5012963	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.	Yang Q, Kang J, Zheng L, Wang XJ, Wan N, Wu J, Qiao Y, Niu P, Wang SQ, Peng Y, Wang Q, Yu W, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J. Nat. Prod.	2015	78	5	1119	1128	25946116	10.1021/acs.jnatprod.5b00116	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.	Olivon F, Palenzuela H, Girard-Valenciennes E, Neyts J, Pannecouque C, Roussi F, Grondin I, Leyssen P, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2015	90		428	435	25461891	10.1016/j.ejmech.2014.11.050	Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents.	Huang TJ, Chuang H, Liang YC, Lin HH, Horng JC, Kuo YC, Chen CW, Tsai FY, Yen SC, Chou SC, Hsu MH.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2015	95		473	482	25847765	10.1016/j.ejmech.2015.03.056	Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.	Liu S, Wei W, Li Y, Liu X, Cao X, Lei K, Zhou M.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur. J. Med. Chem.	2016	117		230	240	27105027	10.1016/j.ejmech.2016.04.019	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.	Patel SB, Patel BD, Pannecouque C, Bhatt HG.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur J Med Chem	2016	121		352	363	27267005	10.1016/j.ejmech.2016.05.054	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.	Chen W, Zhan P, Daelemans D, Yang J, Huang B, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Eur J Med Chem	2016	123		202	210	27484509	10.1016/j.ejmech.2016.07.048	Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors.	Jia H, Bai F, Liu N, Liang X, Zhan P, Ma C, Jiang X, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Med Chem	2016	59	17	7991	8007	27541578	10.1021/acs.jmedchem.6b00738	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.	Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Med Chem	2016	59	20	9513	9531	27748590	10.1021/acs.jmedchem.6b01260	Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.	Liu C, Dumbre SG, Pannecouque C, Huang C, Ptak RG, Murray MG, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Nat Prod	2016	79	12	3057	3064	27936691	10.1021/acs.jnatprod.6b00671	Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus.	Lin SJ, Su TC, Chu CN, Chang YC, Yang LM, Kuo YC, Huang TJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg Med Chem	2017	25	16	4397	4406	28659246	10.1016/j.bmc.2017.06.022	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.	Huang B, Wang X, Liu X, Chen Z, Li W, Sun S, Liu H, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg Med Chem Lett	2017	27	4	904	910	28094179	10.1016/j.bmcl.2017.01.010	Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.	Boucle S, Lu X, Bassit L, Ozturk T, Russell OO, Amblard F, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	Bioorg Med Chem Lett	2017	27	9	1934	1937	28351588	10.1016/j.bmcl.2017.03.031	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Med Chem	2017	60	13	5424	5437	28595015	10.1021/acs.jmedchem.7b00067	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.	Zhou S, Mahmoud S, Liu P, Zhou L, Ehteshami M, Bassit L, Tao S, Domaoal RA, Sari O, Schutter C, Amiralaei S, Khalil A, Ollinger Russell O, McBrayer T, Whitaker T, Abou-Taleb N, Amblard F, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141	J Med Chem	2017	60	14	6220	6238	28682067	10.1021/acs.jmedchem.7b00416	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.	Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW, Schols D, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									DrugMatrix	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	LAMIVUDINE	CHEMBL141									WHO Anatomical Therapeutic Chemical Classification	
931.8000000000000000	9606	Homo sapiens	LARAZOTIDE ACETATE	CHEMBL2103815									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	LARAZOTIDE ACETATE	CHEMBL2103815									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1273.9250000000000000	9606	Homo sapiens	LAROPIPRANT	CHEMBL426559	J. Med. Chem.	2007	50	4	794	806	17300164	10.1021/jm0603668	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).	Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM.
1273.9250000000000000	9606	Homo sapiens	LAROPIPRANT	CHEMBL426559									Unpublished dataset	
1273.9250000000000000	9606	Homo sapiens	LAROPIPRANT	CHEMBL426559									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	LEPIRUDIN	CHEMBL1201666									British National Formulary (72nd edition)	
958.5500000000000000	9606	Homo sapiens	LEPIRUDIN	CHEMBL1201666									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	LEPIRUDIN	CHEMBL1201666									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	LEPIRUDIN	CHEMBL1201666									WHO Anatomical Therapeutic Chemical Classification	
895.6500000000000000	9606	Homo sapiens	LEVALLORPHAN TARTRATE	CHEMBL2062276	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
895.6500000000000000	9606	Homo sapiens	LEVALLORPHAN TARTRATE	CHEMBL2062276	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
895.6500000000000000	9606	Homo sapiens	LEVALLORPHAN TARTRATE	CHEMBL2062276									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	LEVALLORPHAN TARTRATE	CHEMBL2062276									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	1996	39	20	3853	3874	8831751	10.1021/jm960294s	New directions in antibacterial research.	Chu DT, Plattner JJ, Katz L.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	1996	39	3	673	679	8576909	10.1021/jm9509556	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.	Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	1998	41	19	3727	3735	9733498	10.1021/jm980274l	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.	Tucker JA, Allwine DA, Grega KC, Barbachyn MR, Klock JL, Adamski JL, Brickner SJ, Hutchinson DK, Ford CW, Zurenko GE, Conradi RA, Burton PS, Jensen RM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	1998	41	26	5144	5147	9857083	10.1021/jm980546k	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.	Genin MJ, Hutchinson DK, Allwine DA, Hester JB, Emmert DE, Garmon SA, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH, Friis JM, Shobe EM, Adams WJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	1998	8	10	1231	1236	9871741	10.1016/s0960-894x(98)00194-2	Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.	Gleave DM, Brickner SJ, Manninen PR, Allwine DA, Lovasz KD, Rohrer DC, Tucker JA, Zurenko GE, Ford CW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	1999	9	18	2679	2684	10509915	10.1016/s0960-894x(99)00473-4	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.	Pae AN, Kim HY, Joo HJ, Kim BH, Cho YS, Choi KI, Choi JH, Koh HY.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	1999	9	18	2685	2690	10509916	10.1016/s0960-894x(99)00474-6	3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.	Pae AN, Kim SY, Kim HY, Joo HJ, Cho YS, Choi KI, Choi JH, Koh HY.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2000	10	15	1695	1699	10937727	10.1016/s0960-894x(00)00304-8	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.	Musicki B, Periers AM, Laurin P, Ferroud D, Benedetti Y, Lachaud S, Chatreaux F, Haesslein JL, Iltis A, Pierre C, Khider J, Tessot N, Airault M, Demassey J, Dupuis-Hamelin C, Lassaigne P, Bonnefoy A, Vicat P, Klich M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2000	43	5	953	970	10715160	10.1021/jm990373e	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.	Genin MJ, Allwine DA, Anderson DJ, Barbachyn MR, Emmert DE, Garmon SA, Graber DR, Grega KC, Hester JB, Hutchinson DK, Morris J, Reischer RJ, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2001	11	14	1829	1832	11459641	10.1016/s0960-894x(01)00305-5	Novel piperidinyloxy oxazolidinone antimicrobial agents.	Weidner-Wells MA, Boggs CM, Foleno BD, Wira E, Bush K, Goldschmidt RM, Hlasta DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2002	12	16	2121	2123	12127518	10.1016/s0960-894x(02)00352-9	The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class.	Sciotti RJ, Pliushchev M, Wiedeman PE, Balli D, Flamm R, Nilius AM, Marsh K, Stolarik D, Jolly R, Ulrich R, Djuric SW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2002	12	6	857	859	11958979	10.1016/s0960-894x(02)00043-4	Synthesis and antibacterial activity of linezolid analogues.	Yu D, Huiyuan G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2002	45	18	3953	3962	12190317	10.1021/jm020092y	Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones.	Selvakumar N, Srinivas D, Khera MK, Kumar MS, Mamidi RN, Sarnaik H, Charavaryamath C, Rao BS, Raheem MA, Das J, Iqbal J, Rajagopalan R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	13	2227	2230	12798339	10.1016/s0960-894x(03)00249-x	Synthesis and in vitro activity of new methylenepiperidinyl and methylenepyrrolidinyl oxazolidinone antibacterial agents.	Kim HY, Lee JS, Cha JH, Pae AN, Cho YS, Chang MH, Koh HY.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	14	2311	2313	12824024	10.1016/s0960-894x(03)00430-x	Synthesis and antibacterial activity of oxazolidinone containing sulphonyl group.	Cui Y, Yang Y, Chen K, Ji R, Zhang S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	22	4117	4120	14592519	10.1016/j.bmcl.2003.08.021	Synthesis and in vitro activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone antibacterial agents.	Lee JS, Cho YS, Chang MH, Koh HY, Chung BY, Pae AN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4169	4172	14622995	10.1016/j.bmcl.2003.08.068	Influence of ethylene-oxy spacer group on the activity of linezolid: synthesis of potent antibacterials possessing a thiocarbonyl group.	Selvakumar N, Raheem MA, Khera MK, Rajale TV, Kumar MS, Kandepu S, Das J, Rajagopalan R, Iqbal J, Trehan S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4173	4177	14622996	10.1016/j.bmcl.2003.08.031	Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones.	Paget SD, Foleno BD, Boggs CM, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Wira E, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4179	4186	14622997	10.1016/j.bmcl.2003.07.033	New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains.	Gravestock MB, Acton DG, Betts MJ, Dennis M, Hatter G, McGregor A, Swain ML, Wilson RG, Woods L, Wookey A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4193	4196	14622999	10.1016/j.bmcl.2003.07.018	The synthesis and antibacterial activity of 1,3,4-thiadiazole phenyl oxazolidinone analogues.	Thomasco LM, Gadwood RC, Weaver EA, Ochoada JM, Ford CW, Zurenko GE, Hamel JC, Stapert D, Moerman JK, Schaadt RD, Yagi BH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4197	4200	14623000	10.1016/j.bmcl.2003.07.017	Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials.	Johnson PD, Aristoff PA, Zurenko GE, Schaadt RD, Yagi BH, Ford CW, Hamel JC, Stapert D, Moerman JK.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4209	4212	14623003	10.1016/j.bmcl.2003.07.022	New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones.	Singh U, Raju B, Lam S, Zhou J, Gadwood RC, Ford CW, Zurenko GE, Schaadt RD, Morin SE, Adams WJ, Friis JM, Courtney M, Palandra J, Hackbarth CJ, Lopez S, Wu C, Mortell KH, Trias J, Yuan Z, Patel DV, Gordeev MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4213	4216	14623004	10.1016/j.bmcl.2003.07.021	Novel oxazolidinone-quinolone hybrid antimicrobials.	Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Gomez M, Trias J, Morin SE, Zurenko GE, Parker CN, Evans JM, White RJ, Patel DV.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4217	4221	14623005	10.1016/j.bmcl.2003.07.023	Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.	Schneider P, Hawser S, Islam K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4229	4233	14623007	10.1016/j.bmcl.2003.07.028	Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.	Hubschwerlen C, Specklin JL, Baeschlin DK, Borer Y, Haefeli S, Sigwalt C, Schroeder S, Locher HH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2003	13	23	4235	4239	14623008	10.1016/j.bmcl.2003.07.029	The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones.	Ciske FL, Barbachyn MR, Genin MJ, Grega KC, Lee CS, Dolak LA, Seest EP, Watt W, Adams WJ, Friis JM, Ford CW, Zurenko GE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2003	46	2	284	302	12519066	10.1021/jm020248u	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.	Barbachyn MR, Cleek GJ, Dolak LA, Garmon SA, Morris J, Seest EP, Thomas RC, Toops DS, Watt W, Wishka DG, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH, Adams WJ, Friis JM, Slatter JG, Sams JP, Oien NL, Zaya MJ, Wienkers LC, Wynalda MA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2003	46	6	1005	1015	12620077	10.1021/jm020328y	Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.	Inagaki H, Miyauchi S, Miyauchi RN, Kawato HC, Ohki H, Matsuhashi N, Kawakami K, Takahashi H, Takemura M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	12	3069	3072	15149646	10.1016/j.bmcl.2004.04.037	The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.	Weidner-Wells MA, Werblood HM, Goldschmidt R, Bush K, Foleno BD, Hilliard JJ, Melton J, Wira E, Macielag MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	12	3139	3142	15149661	10.1016/j.bmcl.2004.04.024	Oxazolidinone: search for highly potent antibacterial.	Lohray BB, Lohray VB, Srivastava BK, Gupta S, Solanki M, Kapadnis P, Takale V, Pandya P.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	15	3881	3883	15225689	10.1016/j.bmcl.2004.05.066	Synthesis and antibacterial activity of arylpiperazinyl oxazolidinones with diversification of the N-substituents.	Jang SY, Ha YH, Ko SW, Lee W, Lee J, Kim S, Kim YW, Lee WK, Ha HJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	18	4647	4650	15324881	10.1016/j.bmcl.2004.06.096	Synthesis and antibacterial activity of some aryloxy/thioaryloxy oxazolidinone derivatives.	Arora V, Salunkhe MM, Sinha N, Sinha RK, Jain S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	18	4735	4739	15324898	10.1016/j.bmcl.2004.06.076	Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials.	Snyder LB, Meng Z, Mate R, D'Andrea SV, Marinier A, Quesnelle CA, Gill P, DenBleyker KL, Fung-Tomc JC, Frosco M, Martel A, Barrett JF, Bronson JJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	20	5193	5198	15380226	10.1016/j.bmcl.2004.07.064	Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.	Inagaki H, Takahashi H, Takemura M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	22	5569	5572	15482926	10.1016/j.bmcl.2004.08.059	Aryl urea analogs with broad-spectrum antibacterial activity.	Seth PP, Ranken R, Robinson DE, Osgood SA, Risen LM, Rodgers EL, Migawa MT, Jefferson EA, Swayze EE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2004	14	9	2067	2072	15080980	10.1016/j.bmcl.2004.02.047	DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids.	Bürli RW, Kaizerman JA, Duan JX, Jones P, Johnson KW, Iwamoto M, Truong K, Hu W, Stanton T, Chen A, Touami S, Gross M, Jiang V, Ge Y, Moser HE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2005	15	11	2728	2733	15869878	10.1016/j.bmcl.2005.04.003	Biaryl isoxazolinone antibacterial agents.	Quesnelle CA, Gill P, Roy S, Dodier M, Marinier A, Martel A, Snyder LB, D'Andrea SV, Bronson JJ, Frosco M, Beaulieu D, Warr GA, Denbleyker KL, Stickle TM, Yang H, Chaniewski SE, Ferraro CA, Taylor D, Russell JW, Santone KS, Clarke J, Drain RL, Knipe JO, Mosure K, Barrett JF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2005	15	11	2834	2839	15911264	10.1016/j.bmcl.2005.03.099	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.	D'Andrea S, Zheng ZB, Denbleyker K, Fung-Tomc JC, Yang H, Clark J, Taylor D, Bronson J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2005	15	12	3002	3005	15908210	10.1016/j.bmcl.2005.04.045	Synthesis and antibacterial activity of novel (un)substituted benzotriazolyl oxazolidinone derivatives.	Dixit PP, Nair PS, Patil VJ, Jain S, Arora SK, Sinha N.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2005	15	19	4261	4267	16054358	10.1016/j.bmcl.2005.06.063	Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid.	Das B, Rudra S, Yadav A, Ray A, Rao AV, Srinivas AS, Soni A, Saini S, Shukla S, Pandya M, Bhateja P, Malhotra S, Mathur T, Arora SK, Rattan A, Mehta A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2005	15	2	337	343	15603950	10.1016/j.bmcl.2004.10.073	Effects of positional and geometrical isomerism on the biological activity of some novel oxazolidinones.	Das J, Rao CV, Sastry TV, Roshaiah M, Sankar PG, Khadeer A, Kumar MS, Mallik A, Selvakumar N, Iqbal J, Trehan S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2005	48	15	5009	5024	16033280	10.1021/jm058204j	Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones.	Renslo AR, Jaishankar P, Venkatachalam R, Hackbarth C, Lopez S, Patel DV, Gordeev MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2005	48	16	5232	5242	16078842	10.1021/jm050035f	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.	de Souza NJ, Gupte SV, Deshpande PK, Desai VN, Bhawsar SB, Yeole RD, Shukla MC, Strahilevitz J, Hooper DC, Bozdogan B, Appelbaum PC, Jacobs MR, Shetty N, Patel MV, Jha R, Khorakiwala HF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	13	3475	3478	16644216	10.1016/j.bmcl.2006.03.104	Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings.	Renslo AR, Luehr GW, Lam S, Westlund NE, Gómez M, Hackbarth CJ, Patel DV, Gordeev MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	16	4416	4419	16781153	10.1016/j.bmcl.2006.05.071	Synthesis of novel tricyclic oxazolidinones by a tandem SN2 and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid.	Selvakumar N, Yadi Reddy B, Sunil Kumar G, Khera MK, Srinivas D, Sitaram Kumar M, Das J, Iqbal J, Trehan S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	17	4537	4542	16806921	10.1016/j.bmcl.2006.06.023	Antibacterial activity of pyrrolopyridine-substituted oxazolidinones: synthesis and in vitro SAR of various C-5 acetamide replacements.	Paget SD, Boggs CM, Foleno BD, Goldschmidt RM, Hlasta DJ, Weidner-Wells MA, Werblood HM, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	20	5392	5397	16901693	10.1016/j.bmcl.2006.07.064	Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.	Vara Prasad JV, Boyer FE, Chupak L, Dermyer M, Ding Q, Gavardinas K, Hagen SE, Huband MD, Jiao W, Kaneko T, Maiti SN, Melnick M, Romero K, Patterson M, Wu X.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	3	529	531	16275066	10.1016/j.bmcl.2005.10.053	New potential antibacterials: a synthetic route to N-aryloxazolidinone/3-aryltetrahydroisoquinoline hybrids.	Griera R, Cantos-Llopart C, Amat M, Bosch J, del Castillo JC, Huguet J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	5	1126	1129	16387498	10.1016/j.bmcl.2005.11.093	Conformational constraint in oxazolidinone antibacterials. Part 2: Synthesis and structure-activity studies of oxa-, aza-, and thiabicyclo[3.1.0]hexylphenyl oxazolidinones.	Renslo AR, Gao H, Jaishankar P, Venkatachalam R, Gómez M, Blais J, Huband M, Vara Prasad JV, Gordeev MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	6	1557	1561	16386420	10.1016/j.bmcl.2005.12.025	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.	Lohray BB, Lohray VB, Srivastava BK, Gupta S, Solanki M, Pandya P, Kapadnis P.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2006	16	9	2391	2395	16488606	10.1016/j.bmcl.2006.01.109	Synthesis and antibacterial activity of novel oxazolidinones bearing N-hydroxyacetamidine substituent.	Takhi M, Murugan C, Munikumar M, Bhaskarreddy KM, Singh G, Sreenivas K, Sitaramkumar M, Selvakumar N, Das J, Trehan S, Iqbal J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2006	49	4	1455	1465	16480282	10.1021/jm0510023	Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.	Zhi C, Long ZY, Manikowski A, Comstock J, Xu WC, Brown NC, Tarantino PM, Holm KA, Dix EJ, Wright GE, Barnes MH, Butler MM, Foster KA, LaMarr WA, Bachand B, Bethell R, Cadilhac C, Charron S, Lamothe S, Motorina I, Storer R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Nat. Prod.	2006	69	4	585	590	16643031	10.1021/np050438i	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.	Hu JF, Garo E, Hough GW, Goering MG, O'Neil-Johnson M, Eldridge GR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Proc. Natl. Acad. Sci. U.S.A.	2007	104	18	7612	7616	17456595	10.1073/pnas.0700746104	Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.	Wang J, Kodali S, Lee SH, Galgoci A, Painter R, Dorso K, Racine F, Motyl M, Hernandez L, Tinney E, Colletti SL, Herath K, Cummings R, Salazar O, González I, Basilio A, Vicente F, Genilloud O, Pelaez F, Jayasuriya H, Young K, Cully DF, Singh SB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	16	4523	4526	17566733	10.1016/j.bmcl.2007.05.093	Synthesis and antibacterial activity of novel fluoroquinolones containing substituted piperidines.	Dang Z, Yang Y, Ji R, Zhang S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	16	4694	4698	17590334	10.1016/j.bmcl.2007.05.056	Synthesis and SAR of novel conformationally-restricted oxazolidinones possessing gram-positive and fastidious gram-negative antibacterial activity. Part 1: Substituted pyrazoles.	Boyer FE, Vara Prasad JV, Choy AL, Chupak L, Dermyer MR, Ding Q, Huband MD, Jiao W, Kaneko T, Khlebnikov V, Kim JY, Lall MS, Maiti SN, Romero K, Wu X.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	16	4699	4702	17562363	10.1016/j.bmcl.2007.05.085	Synthesis and SAR of novel conformationally restricted oxazolidinones possessing gram-positive and fastidious gram-negative antibacterial activity. Part 2: Amino substitutions on heterocyclic D-ring system.	Choy AL, Vara Prasad JV, Boyer FE, Huband MD, Dermyer MR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	17	4778	4783	17618116	10.1016/j.bmcl.2007.06.056	Synthesis and antibacterial activity of novel oxazolidinones with methylene oxygen- and methylene sulfur-linked substituents at C5-position.	Rudra S, Sangita F, Gujrati A, Pandya M, Bhateja P, Mathur T, Singhal S, Rattan A, Salman M, Das B.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	18	5036	5040	17681758	10.1016/j.bmcl.2007.07.022	A distal methyl substituent attenuates mitochondrial protein synthesis inhibition in oxazolidinone antibacterials.	Renslo AR, Atuegbu A, Herradura P, Jaishankar P, Ji M, Leach KL, Huband MD, Dermyer MR, Wu L, Vara Prasad JV, Gordeev MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	18	5227	5232	17624776	10.1016/j.bmcl.2007.06.075	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.	Srivastava BK, Soni R, Patel JZ, Solanki M, Valani D, Gupta S, Mishra B, Takale V, Pandya P, Jain MR, Patel PR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	2	337	340	17095223	10.1016/j.bmcl.2006.10.063	New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics.	Hauck SI, Cederberg C, Doucette A, Grosser L, Hales NJ, Poon G, Gravestock MB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	24	6714	6719	17980588	10.1016/j.bmcl.2007.10.061	Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700.	Rudra S, Yadav A, Raja Rao AV, Srinivas AS, Pandya M, Bhateja P, Mathur T, Malhotra S, Rattan A, Salman M, Mehta A, Cliffe IA, Das B.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2007	17	6	1626	1628	17254785	10.1016/j.bmcl.2006.12.081	A new class of anti-MRSA and anti-VRE agents: preparation and antibacterial activities of indole-containing compounds.	Yamamoto Y, Kurazono M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2007	42	2	214	225	17140706	10.1016/j.ejmech.2006.10.005	Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones.	Phillips OA, Udo EE, Ali AA, Samuel SM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2007	42	4	538	543	17150281	10.1016/j.ejmech.2006.10.013	Synthesis, SAR and antibacterial studies on novel chalcone oxazolidinone hybrids.	Selvakumar N, Kumar GS, Azhagan AM, Rajulu GG, Sharma S, Kumar MS, Das J, Iqbal J, Trehan S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2007	42	6	868	872	17222483	10.1016/j.ejmech.2006.11.019	Organoiodine(III) mediated synthesis of 3,9-diaryl- and 3,9-difuryl-bis-1,2,4-triazolo[4,3-a][4,3-c]pyrimidines as antibacterial agents.	Prakash O, Kumar R, Kumar R, Tyagi P, Kuhad RC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2007	42	8	1137	1143	17363116	10.1016/j.ejmech.2007.01.012	Synthesis and antibacterial activity of oxazolidinones containing triazolyl group.	Fan H, Xu G, Chen Y, Jiang Z, Zhang S, Yang Y, Ji R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2007	50	17	3973	3975	17658779	10.1021/jm070638m	Discovery of 1,4-dihydroxy-2-naphthoate [corrected] prenyltransferase inhibitors: new drug leads for multidrug-resistant gram-positive pathogens.	Kurosu M, Narayanasamy P, Biswas K, Dhiman R, Crick DC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2007	50	2	199	210	17228862	10.1021/jm060844e	Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.	Wang Q, Lucien E, Hashimoto A, Pais GC, Nelson DM, Song Y, Thanassi JA, Marlor CW, Thoma CL, Cheng J, Podos SD, Ou Y, Deshpande M, Pucci MJ, Buechter DD, Bradbury BJ, Wiles JA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2007	50	20	4868	4881	17722903	10.1021/jm070428+	Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.	Reck F, Zhou F, Eyermann CJ, Kern G, Carcanague D, Ioannidis G, Illingworth R, Poon G, Gravestock MB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2007	50	24	5886	5889	17988109	10.1021/jm070708p	Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.	Poel TJ, Thomas RC, Adams WJ, Aristoff PA, Barbachyn MR, Boyer FE, Brieland J, Brideau R, Brodfuehrer J, Brown AP, Choy AL, Dermyer M, Dority M, Ford CW, Gadwood RC, Hanna D, Hongliang C, Huband MD, Huber C, Kelly R, Kim JY, Martin JP, Pagano PJ, Ross D, Skerlos L, Sulavik MC, Zhu T, Zurenko GE, Prasad JV.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	1	354	358	17060532	10.1128/aac.00344-06	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.	Kamysz W, Silvestri C, Cirioni O, Giacometti A, Licci A, Della Vittoria A, Okroj M, Scalise G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	1	361	365	17101672	10.1128/aac.01017-06	In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.	Foleno BD, Abbanat D, Goldschmidt RM, Flamm RK, Paget SD, Webb GC, Wira E, Macielag MJ, Bush K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	11	3880	3886	17724154	10.1128/aac.00846-07	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.	Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A, Canadian Nosocomial Infection Surveillance Program.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	11	4191	4195	17875997	10.1128/aac.00550-07	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.	Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	3	1102	1104	17194827	10.1128/aac.01102-06	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.	Cercenado E, Marín M, Sánchez-Martínez M, Cuevas O, Martínez-Alarcón J, Bouza E.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	3	1112	1114	17210773	10.1128/aac.01347-06	In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.	Livermore DM, Warner M, Mushtaq S, North S, Woodford N.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	3	888	895	17158933	10.1128/aac.01052-06	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.	Frank KL, Reichert EJ, Piper KE, Patel R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	3	962	967	17194826	10.1128/aac.01190-06	Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia.	Garrabou G, Soriano A, López S, Guallar JP, Giralt M, Villarroya F, Martínez JA, Casademont J, Cardellach F, Mensa J, Miró O.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1268	1273	17210765	10.1128/aac.01325-06	Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.	Chin JN, Rybak MJ, Cheung CM, Savage PB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1287	1292	17242144	10.1128/aac.01194-06	Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.	Boak LM, Li J, Rayner CR, Nation RL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1380	1385	17210775	10.1128/aac.00055-06	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.	Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1491	1493	17210770	10.1128/aac.01496-06	Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.	Jones RN, Stilwell MG, Hogan PA, Sheehan DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1494	1496	17220421	10.1128/aac.00666-06	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.	Giacometti A, Cirioni O, Riva A, Kamysz W, Silvestri C, Nadolski P, Della Vittoria A, ¿ukasiak J, Scalise G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1515	1519	17242137	10.1128/aac.01201-06	Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.	Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, Vandenesch F, Etienne J, Lina G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	4	1570	1572	17220420	10.1128/aac.01352-06	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.	Huang YT, Liao CH, Teng LJ, Hsueh PR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	5	1656	1660	17353249	10.1128/aac.00350-06	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.	Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	5	1661	1665	17353251	10.1128/aac.00744-06	Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.	Moreillon P, Wilson WR, Leclercq R, Entenza JM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	5	1787	1794	17307984	10.1128/aac.00738-06	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.	Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	7	2559	2563	17470658	10.1128/aac.00247-07	Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.	Soriano A, Ortega M, García S, Peñarroja G, Bové A, Marcos M, Martínez JC, Martínez JA, Mensa J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	7	2591	2593	17420210	10.1128/aac.01562-06	In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.	Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	7	2625	2627	17502407	10.1128/aac.00107-07	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.	Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	8	2679	2689	17502406	10.1128/aac.00209-07	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Meehl M, Herbert S, Götz F, Cheung A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	9	3397	3400	17591849	10.1128/aac.01242-06	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.	Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Hamel A, Bugnon D, Ge JY, Potel G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	9	3420	3424	17606689	10.1128/aac.00100-07	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2007	51	9	3434	3436	17606686	10.1128/aac.01567-06	In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.	Gill CJ, Abruzzo GK, Flattery AM, Misura AS, Bartizal K, Hickey EJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Nat. Prod.	2007	70	9	1454	1457	17845000	10.1021/np0702032	Lipoxazolidinones A, B, and C: antibacterial 4-oxazolidinones from a marine actinomycete isolated from a Guam marine sediment.	Macherla VR, Liu J, Sunga M, White DJ, Grodberg J, Teisan S, Lam KS, Potts BC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2008	16	19	8818	8823	18804380	10.1016/j.bmc.2008.08.079	Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa.	Zhang C, Zink DL, Ushio M, Burgess B, Onishi R, Masurekar P, Barrett JF, Singh SB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	18	5150	5155	18768315	10.1016/j.bmcl.2008.03.043	Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents.	Takhi M, Singh G, Murugan C, Thaplyyal N, Maitra S, Bhaskarreddy KM, Amarnath PV, Mallik A, Harisudan T, Trivedi RK, Sreenivas K, Selvakumar N, Iqbal J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	2	856	860	18155521	10.1016/j.bmcl.2007.09.024	Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality.	Selvakumar N, Rajulu GG, Reddy KC, Chary BC, Kumar PK, Madhavi T, Praveena K, Reddy KH, Takhi M, Mallick A, Amarnath PV, Kandepu S, Iqbal J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	21	5815	5815	18842403	10.1016/j.bmcl.2008.09.034	Synthesis and antibacterial activities of novel oxazolidinones having cyclic sulfonamide moieties.	Kim SJ, Jung MH, Yoo KH, Cho JH, Oh CH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	23	6175	6178	18947996	10.1016/j.bmcl.2008.10.011	Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.	Zhou J, Bhattacharjee A, Chen S, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou R, Orbin A, Oyelere A, Salvino J, Springer D, Tran J, Wang D, Wu Y, Johnson G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	23	6179	6183	18951792	10.1016/j.bmcl.2008.10.014	Design at the atomic level: generation of novel hybrid biaryloxazolidinones as promising new antibiotics.	Zhou J, Bhattacharjee A, Chen S, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou R, Orbin A, Oyelere A, Salvino J, Springer D, Tran J, Wang D, Wu Y, Johnson G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2008	18	24	6542	6548	18952418	10.1016/j.bmcl.2008.10.045	A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.	Aridoss G, Amirthaganesan S, Kumar NA, Kim JT, Lim KT, Kabilan S, Jeong YT.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2008	43	4	683	693	17611001	10.1016/j.ejmech.2007.05.003	Synthesis and in vitro antibacterial activities of novel oxazolidinones.	Srivastava BK, Jain MR, Solanki M, Soni R, Valani D, Gupta S, Mishra B, Takale V, Kapadnis P, Patel H, Pandya P, Patel JZ, Patel PR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2008	43	5	1095	1104	18242786	10.1016/j.ejmech.2007.07.006	Synthesis and structure-antibacterial activity of triazolyl oxazolidinones containing long chain acyl moiety.	Phillips OA, Udo EE, Samuel SM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2008	43	8	1706	1714	17981369	10.1016/j.ejmech.2007.09.010	Synthesis and biological evaluation of new N-linked 5-triazolylmethyl oxazolidinones.	Fan H, Chen Y, Jiang Z, Zhang S, Zhong D, Ji R, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2008	51	17	5243	5263	18690678	10.1021/jm800318d	Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.	Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2008	51	20	6558	6562	18826297	10.1021/jm800800c	Synthesis and structure-activity relationship studies of highly potent novel oxazolidinone antibacterials.	Komine T, Kojima A, Asahina Y, Saito T, Takano H, Shibue T, Fukuda Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2008	51	7	1981	1990	18338841	10.1021/jm800038g	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.	Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	10	3550	3557	18663023	10.1128/aac.01193-07	R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.	Skripkin E, McConnell TS, DeVito J, Lawrence L, Ippolito JA, Duffy EM, Sutcliffe J, Franceschi F.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	11	4207	4208	18710909	10.1128/aac.00676-08	Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus.	Watanabe Y, Neoh HM, Cui L, Hiramatsu K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	12	4289	4299	18824611	10.1128/aac.00417-08	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.	Camargo IL, Neoh HM, Cui L, Hiramatsu K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	12	4442	4447	18838596	10.1128/aac.00859-08	In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.	Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	12	4492	4496	18838581	10.1128/aac.00696-08	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.	Snydman DR, Jacobus NV, McDermott LA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	2	452	457	18056272	10.1128/aac.00908-07	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.	Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	2	774	777	18056275	10.1128/aac.00892-07	Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum.	Barthel D, Schlitzer M, Pradel G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	2	800	801	18070973	10.1128/aac.01189-07	In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.	Hillemann D, Rüsch-Gerdes S, Richter E.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	3	1153	1155	18180353	10.1128/aac.01351-07	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	4	1430	1437	18285482	10.1128/aac.01538-07	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.	Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	4	1549	1550	18285484	10.1128/aac.00148-08	In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.	Daw-Garza A, Welsh O, Said-Fernández S, Lozano-Garza HG, Waksman de Torres N, Rocha NC, Ocampo-Candiani J, Vera-Cabrera L.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	4	1570	1572	18212098	10.1128/aac.01098-07	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.	Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	5	1618	1622	18332175	10.1128/aac.00638-07	Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.	Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	5	1653	1662	18316525	10.1128/aac.01383-07	In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.	Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	5	1703	1712	18299405	10.1128/aac.01583-07	Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.	Smith LK, Mankin AS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	5	1737	1742	18180348	10.1128/aac.01015-07	Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center.	Miller K, Dunsmore CJ, Fishwick CW, Chopra I.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	6	1940	1944	18378719	10.1128/aac.01302-07	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.	Miller K, O'Neill AJ, Wilcox MH, Ingham E, Chopra I.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	6	2226	2227	18391030	10.1128/aac.00414-07	In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.	Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	6	2244	2246	18391032	10.1128/aac.00231-08	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.	Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	7	2383	2388	18443115	10.1128/aac.01641-07	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.	Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	7	2389	2394	18411322	10.1128/aac.01422-07	Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.	Laohavaleeson S, Tessier PR, Nicolau DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	7	2486	2496	18458134	10.1128/aac.01439-07	Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.	Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	7	2647	2652	18443122	10.1128/aac.01398-07	In vitro activity of telavancin against resistant gram-positive bacteria.	Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	7	2663	2666	18426902	10.1128/aac.01326-07	In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.	Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Brickner SJ, Wade SK, Le PT, Huband MD.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	8	2806	2812	18519725	10.1128/aac.00247-08	Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.	Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	8	2974	2976	18519721	10.1128/aac.00257-08	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.	Leonard SN, Cheung CM, Rybak MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	9	3398	3407	18625769	10.1128/aac.00149-08	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.	Ge Y, Biek D, Talbot GH, Sahm DF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2008	52	9	3418	3423	18591277	10.1128/aac.00336-08	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.	Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Nat. Prod.	2008	71	12	2032	2035	19053507	10.1021/np800503z	Citreamicins with potent gram-positive activity.	Hopp DC, Milanowski DJ, Rhea J, Jacobsen D, Rabenstein J, Smith C, Romari K, Clarke M, Francis L, Irigoyen M, Luche M, Carr GJ, Mocek U.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2009	17	19	6879	6889	19736016	10.1016/j.bmc.2009.08.026	Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.	Miyauchi R, Kawakami K, Ito M, Matsuhashi N, Ohki H, Inagaki H, Takahashi H, Takemura M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	13	3531	3535	19447613	10.1016/j.bmcl.2009.04.144	Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.	Xu L, Farthing AK, Dropinski JF, Meinke PT, McCallum C, Leavitt PS, Hickey EJ, Colwell L, Barrett J, Liu K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	13	3573	3576	19447611	10.1016/j.bmcl.2009.04.133	Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial.	Varshney V, Mishra NN, Shukla PK, Sahu DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	18	5407	5410	19682897	10.1016/j.bmcl.2009.07.115	Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against Gram-positive pathogens.	Fu L, Jiang Z, Cai Z, Liu X, He H, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	2	524	527	19064318	10.1016/j.bmcl.2008.11.021	Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ.	Czaplewski LG, Collins I, Boyd EA, Brown D, East SP, Gardiner M, Fletcher R, Haydon DJ, Henstock V, Ingram P, Jones C, Noula C, Kennison L, Rockley C, Rose V, Thomaides-Brears HB, Ure R, Whittaker M, Stokes NR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	2	550	553	19064317	10.1016/j.bmcl.2008.02.052	Synthesis and structure-activity studies of novel homomorpholine oxazolidinone antibacterial agents.	Kim JY, Boyer FE, Choy AL, Huband MD, Pagano PJ, Vara Prasad JV.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	22	6424	6428	19811911	10.1016/j.bmcl.2009.09.054	Synthesis and biological activity of novel oxazolidinones.	Das B, Rajarao AV, Rudra S, Yadav A, Ray A, Pandya M, Rattan A, Mehta A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	23	6793	6796	19850474	10.1016/j.bmcl.2009.09.086	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.	Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	23	6810	6812	19837588	10.1016/j.bmcl.2009.07.106	Novel 4-N-substituted aryl but-3-ene-1,2-dione derivatives of piperazinyloxazolidinones as antibacterial agents.	Varshney V, Mishra NN, Shukla PK, Sahu DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2009	19	9	2558	2561	19345578	10.1016/j.bmcl.2009.03.025	Synthesis and antibacterial activities of novel oxazolidinones having spiro[2,4]heptane moieties.	Kim SY, Park HB, Cho JH, Yoo KH, Oh CH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2009	44	3	967	975	18715680	10.1016/j.ejmech.2008.07.005	Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones.	Edafiogho IO, Phillips OA, Udo EE, Samuel S, Rethish B.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2009	44	4	1763	1767	18504062	10.1016/j.ejmech.2008.03.028	Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy-2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones.	Prakash O, Kumar R, Sehrawat R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2009	44	8	3217	3227	19376613	10.1016/j.ejmech.2009.03.024	Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones.	Phillips OA, Udo EE, Abdel-Hamid ME, Varghese R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2009	44	9	3584	3590	19321235	10.1016/j.ejmech.2009.02.031	Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.	Boppana K, Dubey PK, Jagarlapudi SA, Vadivelan S, Rambabu G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2009	52	16	5020	5031	19653650	10.1021/jm900519b	Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.	Vooturi SK, Cheung CM, Rybak MJ, Firestine SM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	1	329	330	18936189	10.1128/aac.00921-08	Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.	Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	1	35	40	18725436	10.1128/aac.00237-08	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.	del Pozo JL, Rouse MS, Mandrekar JN, Sampedro MF, Steckelberg JM, Patel R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	10	4051	4063	19470504	10.1128/aac.00084-09	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.	Llarrull LI, Fisher JF, Mobashery S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	10	4252	4257	19635963	10.1128/aac.00208-09	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.	Murillo O, Garrigós C, Pachón ME, Euba G, Verdaguer R, Cabellos C, Cabo J, Gudiol F, Ariza J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	10	4529	4532	19651906	10.1128/aac.00624-09	In vitro activities of panduratin A against clinical Staphylococcus strains.	Rukayadi Y, Lee K, Han S, Yong D, Hwang JK.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	10	4542	4544	19651909	10.1128/aac.00766-09	In vitro bactericidal activity of iclaprim in human plasma.	Laue H, Valensise T, Seguin A, Lociuro S, Islam K, Hawser S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	11	4949	4952	19738027	10.1128/aac.00845-09	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.	Bowker KE, Caspers P, Gaucher B, MacGowan AP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	12	5039	5045	19786607	10.1128/aac.00633-09	Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.	Schmidt S, Sabarinath SN, Barbour A, Abbanat D, Manitpisitkul P, Sha S, Derendorf H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	12	5060	5063	19738006	10.1128/aac.00985-09	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.	Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	12	5141	5144	19805558	10.1128/aac.00307-09	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.	Patel N, Lubanski P, Ferro S, Bonafede M, Harrington S, Evans A, Stellrecht K, Lodise TP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	12	5275	5278	19805557	10.1128/aac.01032-09	Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.	Locke JB, Hilgers M, Shaw KJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	12	5300	5302	19752276	10.1128/aac.00984-09	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin.	Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Ge Y, Biek D, Batard E, Potel G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	2	370	384	19001109	10.1128/aac.01047-08	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.	Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	2	779	781	19047652	10.1128/aac.01376-08	Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr.	Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	3	1142	1148	19075065	10.1128/aac.00775-08	Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.	Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	3	1260	1263	19124664	10.1128/aac.01453-08	Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.	Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	3	918	925	19104027	10.1128/aac.00766-08	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.	Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, Parr TR, Moeck G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	4	1353	1361	19188385	10.1128/aac.01619-08	Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.	Clark C, Ednie LM, Lin G, Smith K, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Caspers P, Gaucher B, Mert G, Shapiro S, Appelbaum PC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	4	1427	1433	19075051	10.1128/aac.00887-08	Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.	Kalia V, Miglani R, Purnapatre KP, Mathur T, Singhal S, Khan S, Voleti SR, Upadhyay DJ, Saini KS, Rattan A, Raj VS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	4	1434	1442	19188393	10.1128/aac.01145-08	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.	Nguyen HA, Denis O, Vergison A, Theunis A, Tulkens PM, Struelens MJ, Van Bambeke F.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	5	2028	2033	19273686	10.1128/aac.00833-08	In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.	Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	5	2139	2141	19258276	10.1128/aac.00090-09	Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	5	2171	2175	19289528	10.1128/aac.00129-09	Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	6	2475	2482	19289527	10.1128/aac.01432-08	Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation.	Weiss EC, Spencer HJ, Daily SJ, Weiss BD, Smeltzer MS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	6	2687	2689	19349514	10.1128/aac.00197-09	Impact of human serum albumin on oritavancin in vitro activity against enterococci.	McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR, Moeck G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	6	2690	2692	19332671	10.1128/aac.01424-08	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.	Spyridaki I, Psaroulaki A, Vranakis I, Tselentis Y, Gikas A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	7	3118	3121	19433566	10.1128/aac.00183-09	Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.	Clark C, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Appelbaum PC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	8	3236	3239	19528279	10.1128/aac.00228-09	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.	Schaadt R, Sweeney D, Shinabarger D, Zurenko G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	8	3544	3548	19487444	10.1128/aac.00400-09	AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.	Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	3642	3649	19546358	10.1128/aac.00206-09	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.	Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	3777	3781	19596876	10.1128/aac.00026-09	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.	Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	3981	3984	19564361	10.1128/aac.01378-08	Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.	McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	3996	4001	19581457	10.1128/aac.00908-08	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.	Finegold SM, Bolanos M, Sumannen PH, Molitoris DR.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	4007	4009	19546366	10.1128/aac.01633-08	Influence of recombination on development of mutational resistance to linezolid in Enterococcus faecalis JH2-2.	Boumghar-Bourtchaï L, Dhalluin A, Malbruny B, Galopin S, Leclercq R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Nat. Prod.	2009	72	5	841	847	19334707	10.1021/np800783b	Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.	Zhang C, Herath K, Jayasuriya H, Ondeyka JG, Zink DL, Occi J, Birdsall G, Venugopal J, Ushio M, Burgess B, Masurekar P, Barrett JF, Singh SB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	MedChemComm	2010	1	2	145	148	27087912	10.1039/c0md00015a	Syntheses and biological evaluation of new cephalosporin-oxazolidinone conjugates.	Yan S, Miller MJ, Wencewicz TA, Möollmann U.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2010	20	12	3518	3520	20483613	10.1016/j.bmcl.2010.04.137	Potent antimicrobial activity of 3-(4,5-diaryl-1H-imidazol-2-yl)-1H-indole derivatives against methicillin-resistant Staphylococcus aureus.	Al-Qawasmeh RA, Huesca M, Nedunuri V, Peralta R, Wright J, Lee Y, Young A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2010	20	12	3592	3595	20510610	10.1016/j.bmcl.2010.04.123	Design, synthesis, and antibacterial activity of 2,5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.	Shi W, Duan Y, Qian Y, Li M, Yang L, Hu W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2010	20	20	6116	6120	20833545	10.1016/j.bmcl.2010.08.037	Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities.	Kobayashi Y, Ichioka M, Hirose T, Nagai K, Matsumoto A, Matsui H, Hanaki H, Masuma R, Takahashi Y, Omura S, Sunazuka T.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2010	20	3	1302	1305	20031407	10.1016/j.bmcl.2009.10.018	Syntheses and antibacterial activity studies of new oxazolidinones from nitroso Diels-Alder chemistry.	Yan S, Miller MJ, Wencewicz TA, Möllmann U.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2010	20	7	2242	2249	20207140	10.1016/j.bmcl.2010.02.015	Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.	Aridoss G, Amirthaganesan S, Jeong YT.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2010	45	1	19	24	19819597	10.1016/j.ejmech.2009.09.019	Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones.	Adibpour N, Khalaj A, Rajabalian S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2010	45	2	661	666	19942324	10.1016/j.ejmech.2009.11.009	Synthesis of nitroimidazole derived oxazolidinones as antibacterial agents.	Varshney V, Mishra NN, Shukla PK, Sahu DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	1	116	125	19884364	10.1128/aac.00642-09	In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.	Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	11	4605	4610	20733043	10.1128/aac.00177-10	Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.	Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	11	4643	4647	20733041	10.1128/aac.01710-09	vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium.	Xu X, Lin D, Yan G, Ye X, Wu S, Guo Y, Zhu D, Hu F, Zhang Y, Wang F, Jacoby GA, Wang M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	11	4705	4713	20696869	10.1128/aac.00644-10	Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.	Long KS, Munck C, Andersen TM, Schaub MA, Hobbie SN, Böttger EC, Vester B.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	11	4942	4944	20713669	10.1128/aac.00064-10	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.	Joo HS, Chan JL, Cheung GY, Otto M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	12	4978	4984	20921317	10.1128/aac.01113-10	Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate.	Shore AC, Brennan OM, Ehricht R, Monecke S, Schwarz S, Slickers P, Coleman DC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	12	5115	5119	20837760	10.1128/aac.00062-10	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.	Crandon JL, Kuti JL, Nicolau DP.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	12	5352	5355	20837755	10.1128/aac.00714-10	Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.	Locke JB, Morales G, Hilgers M, G C K, Rahawi S, José Picazo J, Shaw KJ, Stein JL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	12	5359	5362	20855730	10.1128/aac.00723-10	In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.	Jeong JW, Jung SJ, Lee HH, Kim YZ, Park TK, Cho YL, Chae SE, Baek SY, Woo SH, Lee HS, Kwak JH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	12	5406	5412	20855745	10.1128/aac.00580-10	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.	Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	2	610	613	19917746	10.1128/aac.00886-09	Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.	Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	2	915	918	20008780	10.1128/aac.01091-09	Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	3	1338	1342	20065058	10.1128/aac.01197-09	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.	Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	3	1351	1353	20065060	10.1128/aac.01208-09	Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4.	Hölzel CS, Harms KS, Schwaiger K, Bauer J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	4	1443	1452	20100878	10.1128/aac.01022-09	Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.	Ba BB, Arpin C, Bikie Bi Nso B, Dubois V, Saux MC, Quentin C.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	5	2063	2069	20231392	10.1128/aac.01569-09	Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.	Brown SD, Traczewski MM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	5	2212	2215	20176900	10.1128/aac.01653-09	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.	Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, Picazo JJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	5	2258	2261	20145088	10.1128/aac.01350-09	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.	Lin G, Ednie LM, Appelbaum PC.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	5	2262	2264	20160054	10.1128/aac.01423-09	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.	Rullas J, García JI, Beltrán M, Cardona PJ, Cáceres N, García-Bustos JF, Angulo-Barturen I.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	6	2540	2548	20385873	10.1128/aac.01723-09	Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.	Lemaire S, Tulkens PM, Van Bambeke F.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	6	2549	2559	20385852	10.1128/aac.01724-09	Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.	Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	6	2704	2706	20385851	10.1128/aac.00301-10	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.	Mendes RE, Moet GJ, Janechek MJ, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	6	2716	2719	20308374	10.1128/aac.01797-09	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.	Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	7	2806	2813	20421401	10.1128/aac.00400-10	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.	Zhang T, Bishai WR, Grosset JH, Nuermberger EL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	7	3027	3030	20404122	10.1128/aac.01516-09	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.	Saravolatz L, Pawlak J, Johnson L.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	3799	3803	20585126	10.1128/aac.00452-10	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.	Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	3825	3833	20606069	10.1128/aac.00361-10	Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.	Bourne CR, Barrow EW, Bunce RA, Bourne PC, Berlin KD, Barrow WW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	3953	3955	20585133	10.1128/aac.00169-10	First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces.	Dai L, Wu CM, Wang MG, Wang Y, Wang Y, Huang SY, Xia LN, Li BB, Shen JZ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	3974	3977	20625154	10.1128/aac.00484-10	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.	Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	4036	4037	20585131	10.1128/aac.00044-10	Clinical outcomes by methicillin-resistant Staphylococcus aureus staphylococcal cassette chromosome mec type: isolates recovered from a phase IV clinical trial of linezolid and vancomycin for complicated skin and skin structure infections.	Huang DB, Reisman A, Hogan P.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Antimicrob. Agents Chemother.	2010	54	9	4038	4040	20585116	10.1128/aac.00533-10	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.	Lee CH, Wang MC, Huang IW, Chen FJ, Lauderdale TL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	1	172	175	21126873	10.1016/j.bmcl.2010.11.043	MDCK cell permeability characteristics of a sulfenamide prodrug: strategic implications in considering sulfenamide prodrugs for oral delivery of NH-acids.	Guarino VR, Nti-Addae K, Stella VJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	1	276	279	21115249	10.1016/j.bmcl.2010.11.022	The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.	Le PT, Brickner SJ, Wade SK, Brighty K, Monahan R, Stone GG, Girard D, Finegan S, Duignan J, Schafer J, Maloney M, Zaniewski RP, Connolly AG, Liras J, Bordner J, Samardjiev I.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	10	2887	2889	21507643	10.1016/j.bmcl.2011.03.075	Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents.	Khera MK, Cliffe IA, Mathur T, Prakash O.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	14	4197	4202	21684746	10.1016/j.bmcl.2011.05.093	7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.	Xu WC, Wright GE, Brown NC, Long ZY, Zhi CX, Dvoskin S, Gambino JJ, Barnes MH, Butler MM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	18	5266	5269	21835618	10.1016/j.bmcl.2011.07.034	Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II.	Khera MK, Cliffe IA, Prakash O.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2011	21	3	1060	1063	21185180	10.1016/j.bmcl.2010.11.102	Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors.	Shi W, Ma H, Duan Y, Aubart K, Fang Y, Zonis R, Yang L, Hu W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2011	46	1	65	70	21071113	10.1016/j.ejmech.2010.10.015	Discovery of a novel nitroimidazolyl-oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation.	Khalaj A, Nakhjiri M, Negahbani AS, Samadizadeh M, Firoozpour L, Rajabalian S, Samadi N, Faramarzi MA, Adibpour N, Shafiee A, Foroumadi A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2011	46	3	893	900	21272965	10.1016/j.ejmech.2010.12.028	Anti-tubercular agents. Part 6: synthesis and antimycobacterial activity of novel arylsulfonamido conjugated oxazolidinones.	Kamal A, Shetti RV, Azeeza S, Swapna P, Khan MN, Khan IA, Sharma S, Abdullah ST.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2011	46	4	1027	1039	21292356	10.1016/j.ejmech.2011.01.014	Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.	Im WB, Choi SH, Park JY, Choi SH, Finn J, Yoon SH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2011	46	7	3038	3046	21558044	10.1016/j.ejmech.2011.04.041	A regioselective synthesis of some new pyrazol-1'-ylpyrazolo[1,5-a]pyrimidines in aqueous medium and their evaluation as antimicrobial agents.	Aggarwal R, Sumran G, Garg N, Aggarwal A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2011	54	21	7493	7502	21955296	10.1021/jm200614t	Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents.	Xin Q, Fan H, Guo B, He H, Gao S, Wang H, Huang Y, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2011	54	23	8099	8109	21999529	10.1021/jm200938f	Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids.	LaMarche MJ, Leeds JA, Amaral K, Brewer JT, Bushell SM, Dewhurst JM, Dzink-Fox J, Gangl E, Goldovitz J, Jain A, Mullin S, Neckermann G, Osborne C, Palestrant D, Patane MA, Rann EM, Sachdeva M, Shao J, Tiamfook S, Whitehead L, Yu D.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2011	54	7	2207	2224	21388139	10.1021/jm1014023	A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.	Angehrn P, Goetschi E, Gmuender H, Hebeisen P, Hennig M, Kuhn B, Luebbers T, Reindl P, Ricklin F, Schmitt-Hoffmann A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2011	54	9	3268	3282	21425851	10.1021/jm101604v	Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).	Kim HY, Wiles JA, Wang Q, Pais GC, Lucien E, Hashimoto A, Nelson DM, Thanassi JA, Podos SD, Deshpande M, Pucci MJ, Bradbury BJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2011	54	9	3418	3425	21443219	10.1021/jm2002124	Selenophene-containing inhibitors of type IIA bacterial topoisomerases.	Wiles JA, Phadke AS, Bradbury BJ, Pucci MJ, Thanassi JA, Deshpande M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2012	20	1	480	486	22100257	10.1016/j.bmc.2011.10.041	Efficient microwave-assisted synthesis, antibacterial activity and high fluorescence of 5 benzimidazolyl-2'-deoxyuridines.	Krim J, Grünewald C, Taourirte M, Engels JW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2012	20	11	3422	3428	22560837	10.1016/j.bmc.2012.04.026	Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.	Ji C, Lin W, Moraski GC, Thanassi JA, Pucci MJ, Franzblau SG, Möllmann U, Miller MJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2012	20	20	6063	6072	22995771	10.1016/j.bmc.2012.08.023	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.	Rakesh, Bruhn D, Madhura DB, Maddox M, Lee RB, Trivedi A, Yang L, Scherman MS, Gilliland JC, Gruppo V, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2012	22	2	814	819	22209487	10.1016/j.bmcl.2011.12.063	Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates.	Fu L, Liu X, Ling C, Cheng J, Guo X, He H, Ding S, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2012	22	24	7444	7447	23122868	10.1016/j.bmcl.2012.10.052	Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.	Sawada H, Okazaki M, Morita D, Kuroda T, Matsuno K, Hashimoto Y, Miyachi H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	MedChemComm	2012	3	2	244	249		10.1039/C2MD00252C	Simplified platensimycin analogues as antibacterial agents	Krsta D, Ku CK, Crosby IT, Capuano B, Manallack DT
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2012	50		441	448	22365410	10.1016/j.ejmech.2012.02.002	Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.	Palumbo Piccionello A, Musumeci R, Cocuzza C, Fortuna CG, Guarcello A, Pierro P, Pace A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2012	51		1	16	22421275	10.1016/j.ejmech.2012.02.033	Tuberculosis: the drug development pipeline at a glance.	Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2012	55	15	6916	6933	22779424	10.1021/jm300690s	Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.	Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2012	55	2	606	622	22148555	10.1021/jm201467r	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.	Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2012	55	22	9914	9928	23092194	10.1021/jm301113w	From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.	Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Nat. Prod.	2012	75	12	2049	2054	23145884	10.1021/np300544a	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.	Wang W, Kim H, Nam SJ, Rho BJ, Kang H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2013	21	3	577	591	23273607	10.1016/j.bmc.2012.11.036	Recent development of potent analogues of oxazolidinone antibacterial agents.	Michalska K, Karpiuk I, Król M, Tyski S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Med Chem Res	2013	22	8	3843	3856		10.1007/s00044-012-0394-2	Design and synthesis of new N-substituted amino methyl-[1,2,3] triazolyl moieties of fluoroquinolones as antibacterial agents	Govinda Rajulu G, Bhojya Naik HS, Viswanathan A, Agarwal DS, Sambasivam G, Koppolu KP
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2013	23	13	3697	3699	23721807	10.1016/j.bmcl.2013.05.023	Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents.	Guo B, Fan H, Xin Q, Chu W, Wang H, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2013	23	24	6563	6568	24239015	10.1016/j.bmcl.2013.10.069	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.	Sawada H, Onoda K, Morita D, Ishitsubo E, Matsuno K, Tokiwa H, Kuroda T, Miyachi H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2013	23	24	6842	6846	24206766	10.1016/j.bmcl.2013.10.010	Anti-tubercular agents. Part 8: synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1,2,3-triazoles.	Kamal A, Hussaini SM, Faazil S, Poornachandra Y, Narender Reddy G, Kumar CG, Rajput VS, Rani C, Sharma R, Khan IA, Jagadeesh Babu N.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2013	23	5	1193	1196	23385213	10.1016/j.bmcl.2013.01.033	Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.	Shin HN, Seo SH, Choo H, Kuem G, Choi KI, Nam G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2013	23	6	1727	1731	23414806	10.1016/j.bmcl.2013.01.067	Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates.	Magee TV, Han S, McCurdy SP, Nguyen TT, Granskog K, Marr ES, Maguire BA, Huband MD, Chen JM, Subashi TA, Shanmugasundaram V.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Scientific Reports	2013	3		1	7	23812503	10.1038/srep02100	MICE models: superior to the HERG model in predicting Torsade de Pointes.	Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	ACS Med. Chem. Lett.	2013	4	11	1074	1078	24900607	10.1021/ml400280z	Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.	Suzuki H, Utsunomiya I, Shudo K, Fujimura T, Tsuji M, Kato I, Aoki T, Ino A, Iwaki T.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2013	56	6	2642	2650	23428155	10.1021/jm4000598	Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.	Guo B, Fan H, Xin Q, Chu W, Wang H, Huang Y, Chen X, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	62		661	669	23434639	10.1016/j.ejmech.2013.01.034	Synthesis, biological evaluation of new oxazolidino-sulfonamides as potential antimicrobial agents.	Kamal A, Swapna P, Shetti RV, Shaik AB, Narasimha Rao MP, Gupta S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	63		811	825	23584544	10.1016/j.ejmech.2013.03.003	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.	Suzuki H, Utsunomiya I, Shudo K, Fukuhara N, Iwaki T, Yasukata T.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	64		239	251	23644207	10.1016/j.ejmech.2013.03.027	Anti-tubercular agents. Part 7: a new class of diarylpyrrole-oxazolidinone conjugates as antimycobacterial agents.	Kamal A, Swapna P, Shetti RV, Shaik AB, Narasimha Rao MP, Sultana F, Khan IA, Sharma S, Kalia NP, Kumar S, Chandrakant B.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	65		533	545	23811204	10.1016/j.ejmech.2013.03.069	New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens.	Fortuna CG, Bonaccorso C, Bulbarelli A, Caltabiano G, Rizzi L, Goracci L, Musumarra G, Pace A, Palumbo Piccionello A, Guarcello A, Pierro P, Cocuzza CE, Musumeci R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	66		246	257	23811087	10.1016/j.ejmech.2013.05.041	Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones.	Phillips OA, Udo EE, Abdel-Hamid ME, Varghese R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	69		262	277	24044938	10.1016/j.ejmech.2013.08.002	Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring.	Suzuki H, Utsunomiya I, Shudo K, Fukuhara N, Iwaki T, Yasukata T.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2013	69		779	785	24099997	10.1016/j.ejmech.2013.09.035	Novel promising linezolid analogues: rational design, synthesis and biological evaluation.	De Rosa M, Zanfardino A, Notomista E, Wichelhaus TA, Saturnino C, Varcamonti M, Soriente A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2014	22	24	6814	6825	25464880	10.1016/j.bmc.2014.10.037	New potent antibacterials against Gram-positive multiresistant pathogens: effects of side chain modification and chirality in linezolid-like 1,2,4-oxadiazoles.	Fortuna CG, Berardozzi R, Bonaccorso C, Caltabiano G, Di Bari L, Goracci L, Guarcello A, Pace A, Palumbo Piccionello A, Pescitelli G, Pierro P, Lonati E, Bulbarelli A, Cocuzza CE, Musumarra G, Musumeci R.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2014	24	1	353	359	24287381	10.1016/j.bmcl.2013.11.002	Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ.	Stokes NR, Baker N, Bennett JM, Chauhan PK, Collins I, Davies DT, Gavade M, Kumar D, Lancett P, Macdonald R, Macleod L, Mahajan A, Mitchell JP, Nayal N, Nayal YN, Pitt GR, Singh M, Yadav A, Srivastava A, Czaplewski LG, Haydon DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2014	24	17	4215	4222	25086682	10.1016/j.bmcl.2014.07.037	Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors.	Palmer JT, Axford LC, Barker S, Bennett JM, Blair M, Collins I, Davies DT, Ford L, Gannon CT, Lancett P, Logan A, Lunniss CJ, Morton CJ, Offermann DA, Pitt GR, Rao BN, Singh AK, Shukla T, Srivastava A, Stokes NR, Thomaides-Brears HB, Yadav A, Haydon DJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2014	24	6	1496	1501	24582981	10.1016/j.bmcl.2014.02.025	Discovery of novel bis-oxazolidinone compounds as potential potent and selective antitubercular agents.	Ang W, Ye W, Sang Z, Liu Y, Yang T, Deng Y, Luo Y, Wei Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2014	24	8	1901	1906	24679702	10.1016/j.bmcl.2014.03.013	Synthesis, antibiotic activity and structure-activity relationship study of some 3-enaminetetramic acids.	Jeong YC, Anwar M, Moloney MG.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2014	24	9	2177	2181	24685546	10.1016/j.bmcl.2014.03.022	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.	Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	11	4487	4497	24694071	10.1021/jm401931e	New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.	Gordeev MF, Yuan ZY.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	11	4772	4795	24874438	10.1021/jm500312x	Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents.	Ling C, Fu L, Gao S, Chu W, Wang H, Huang Y, Chen X, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	14	6060	6082	24959892	10.1021/jm500462x	Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).	Basarab GS, Hill PJ, Garner CE, Hull K, Green O, Sherer BA, Dangel PB, Manchester JI, Bist S, Hauck S, Zhou F, Uria-Nickelsen M, Illingworth R, Alm R, Rooney M, Eakin AE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	15	6572	6582	24967731	10.1021/jm500833f	Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.	Bellale E, Naik M, V B V, Ambady A, Narayan A, Ravishankar S, Ramachandran V, Kaur P, McLaughlin R, Whiteaker J, Morayya S, Guptha S, Sharma S, Raichurkar A, Awasthy D, Achar V, Vachaspati P, Bandodkar B, Panda M, Chatterji M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	21	8880	8885	25291061	10.1021/jm500960s	Synthesis and biological evaluation of novel peptide BF2 as an antibacterial agent against clinical isolates of vancomycin-resistant enterococci.	Singh K, Kumar S, Shekhar S, Dhawan B, Dey S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2014	57	21	9078	9095	25286019	10.1021/jm501174m	Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.	Basarab GS, Brassil P, Doig P, Galullo V, Haimes HB, Kern G, Kutschke A, McNulty J, Schuck VJ, Stone G, Gowravaram M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2014	84		382	394	25036796	10.1016/j.ejmech.2014.07.036	Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors.	Takhi M, Sreenivas K, Reddy CK, Munikumar M, Praveena K, Sudheer P, Rao BN, Ramakanth G, Sivaranjani J, Mulik S, Reddy YR, Narasimha Rao K, Pallavi R, Lakshminarasimhan A, Panigrahi SK, Antony T, Abdullah I, Lee YK, Ramachandra M, Yusof R, Rahman NA, Subramanya H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2014	86		133	152	25151577	10.1016/j.ejmech.2014.07.106	Synthesis, antibacterial activity, and biological evaluation of formyl hydroxyamino derivatives as novel potent peptide deformylase inhibitors against drug-resistant bacteria.	Yang S, Shi W, Xing D, Zhao Z, Lv F, Yang L, Yang Y, Hu W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2014	86		335	351	25173852	10.1016/j.ejmech.2014.08.066	SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.	Poce G, Cocozza M, Consalvi S, Biava M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2015	101		384	390	26164843	10.1016/j.ejmech.2015.06.031	Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.	Davis DC, Mohammad H, Kyei-Baffour K, Younis W, Creemer CN, Seleem MN, Dai M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur. J. Med. Chem.	2015	106		120	131	26536532	10.1016/j.ejmech.2015.10.025	Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives.	Phillips OA, D'Silva R, Bahta TO, Sharaf LH, Udo EE, Benov L, Eric Walters D.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2015	23	17	5334	5344	26264847	10.1016/j.bmc.2015.07.062	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.	Tran TP, Vo DD, Di Giorgio A, Duca M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem.	2015	23	7	1492	1499	25737087	10.1016/j.bmc.2015.02.016	Identification of Bacillus anthracis PurE inhibitors with antimicrobial activity.	Kim A, Wolf NM, Zhu T, Johnson ME, Deng J, Cook JL, Fung LW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2015	25	10	2203	2210	25838143	10.1016/j.bmcl.2015.03.053	Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents.	Xue T, Ding S, Guo B, Chu W, Wang H, Yang Y.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2015	25	13	2694	2697	25981687	10.1016/j.bmcl.2015.04.046	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.	Pardeshi KA, Malwal SR, Banerjee A, Lahiri S, Rangarajan R, Chakrapani H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2015	25	20	4481	4486	26343826	10.1016/j.bmcl.2015.08.077	Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.	Kim YG, Seo JH, Kwak JH, Shin KJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2015	25	21	4887	4889	26099542	10.1016/j.bmcl.2015.06.003	Rapid synthesis and antimicrobial activity of novel 4-oxazolidinone heterocycles.	Shymanska NV, An IH, Guevara-Zuluaga S, Pierce JG.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2015	25	4	874	880	25592714	10.1016/j.bmcl.2014.12.063	Biofilm inhibition of linezolid-like Schiff bases: synthesis, biological activity, molecular docking and in silico ADME prediction.	Sangshetti JN, Khan FA, Patil RH, Marathe SD, Gade WN, Shinde DB.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2015	58	3	1380	1389	25590813	10.1021/jm501661f	Structure-activity relationship for the oxadiazole class of antibiotics.	Spink E, Ding D, Peng Z, Boudreau MA, Leemans E, Lastochkin E, Song W, Lichtenwalter K, O'Daniel PI, Testero SA, Pi H, Schroeder VA, Wolter WR, Antunes NT, Suckow MA, Vakulenko S, Chang M, Mobashery S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2015	58	7	3156	3171	25798859	10.1021/acs.jmedchem.5b00050	X-ray crystal structures of Escherichia coli RNA polymerase with switch region binding inhibitors enable rational design of squaramides with an improved fraction unbound to human plasma protein.	Molodtsov V, Fleming PR, Eyermann CJ, Ferguson AD, Foulk MA, McKinney DC, Masse CE, Buurman ET, Murakami KS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	ACS Med. Chem. Lett.	2015	6	11	1105	1110	26617962	10.1021/acsmedchemlett.5b00213	Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.	Seetharamsingh B, Ramesh R, Dange SS, Khairnar PV, Singhal S, Upadhyay D, Veeraraghavan S, Viswanadha S, Vakkalanka S, Reddy DS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	MedChemComm	2015	6	6	1156	1172		10.1039/C5MD00101C	Synthesis and antibacterial activity evaluation of C-5 side chain modified analogues of FYL-66, a potential agent against methicillin-resistant Staphylococcus aureus	Yang X, Li Z, Wang Z, Sang Z, Long H, Tang J, Yang T, Liu Y, Luo Y
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur J Med Chem	2016	122		475	487	27423637	10.1016/j.ejmech.2016.07.001	Design, synthesis and biological evaluation of novel azaspiro analogs of linezolid as antibacterial and antitubercular agents.	Gadekar PK, Roychowdhury A, Kharkar PS, Khedkar VM, Arkile M, Manek H, Sarkar D, Sharma R, Vijayakumar V, Sarveswari S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur J Med Chem	2016	124		906	919	27676470	10.1016/j.ejmech.2016.09.007	New isoxazolidinone and 3,4-dehydro-ß-proline derivatives as antibacterial agents and MAO-inhibitors: A complex balance between two activities.	Ferrazzano L, Viola A, Lonati E, Bulbarelli A, Musumeci R, Cocuzza C, Lombardo M, Tolomelli A.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem	2016	24	24	6401	6408	27612961	10.1016/j.bmc.2016.08.034	From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.	Drusano GL.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem	2016	24	24	6409	6419	27469981	10.1016/j.bmc.2016.07.029	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.	Tanaka SK, Steenbergen J, Villano S.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2016	26	13	3148	3152	27173797	10.1016/j.bmcl.2016.04.086	Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.	Lee HY, An KM, Jung J, Koo JM, Kim JG, Yoon JM, Lee MJ, Jang H, Lee HS, Park S, Kang JH.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2016	26	15	3572	3576	27329794	10.1016/j.bmcl.2016.06.019	An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.	Kaushik A, Heuer AM, Bell DT, Culhane JC, Ebner DC, Parrish N, Ippoliti JT, Lamichhane G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2016	26	2	388	391	26711150	10.1016/j.bmcl.2015.12.002	Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.	Rakesh, Bruhn DF, Scherman MS, Singh AP, Yang L, Liu J, Lenaerts AJ, Lee RE.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg. Med. Chem. Lett.	2016	26	3	1025	1028	26725950	10.1016/j.bmcl.2015.12.027	A stepwise dechlorination/cross-coupling strategy to diversify the vancomycin 'in-chloride'.	Wadzinski TJ, Gea KD, Miller SJ.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2016	59	10	4900	4912	27187739	10.1021/acs.jmedchem.6b00233	Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.	Seleem MA, Disouky AM, Mohammad H, Abdelghany TM, Mancy AS, Bayoumi SA, Elshafeey A, El-Morsy A, Seleem MN, Mayhoub AS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2016	59	10	5011	5021	27088777	10.1021/acs.jmedchem.6b00372	Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.	Bouley R, Ding D, Peng Z, Bastian M, Lastochkin E, Song W, Suckow MA, Schroeder VA, Wolter WR, Mobashery S, Chang M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J. Med. Chem.	2016	59	8	3808	3825	27018907	10.1021/acs.jmedchem.5b02004	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.	Garrison AT, Abouelhassan Y, Norwood VM, Kallifidas D, Bai F, Nguyen MT, Rolfe M, Burch GM, Jin S, Luesch H, Huigens RW.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur J Med Chem	2017	126		604	613	27918995	10.1016/j.ejmech.2016.11.042	Phenylthiazole antibiotics: A metabolism-guided approach to overcome short duration of action.	Yahia E, Mohammad H, Abdelghany TM, Fayed E, Seleem MN, Mayhoub AS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Eur J Med Chem	2017	130		73	85	28249208	10.1016/j.ejmech.2017.02.044	Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.	Eissa IH, Mohammad H, Qassem OA, Younis W, Abdelghany TM, Elshafeey A, Abd Rabo Moustafa MM, Seleem MN, Mayhoub AS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem	2017	25	6	1867	1874	28214232	10.1016/j.bmc.2017.02.003	New nitrofurans amenable by isocyanide multicomponent chemistry are active against multidrug-resistant and poly-resistant Mycobacterium tuberculosis.	Krasavin M, Parchinsky V, Kantin G, Manicheva O, Dogonadze M, Vinogradova T, Karge B, Brönstrup M.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem Lett	2017	27	3	574	577	28043797	10.1016/j.bmcl.2016.12.016	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.	Wang W, Kim H, Patil RS, Giri AG, Won DH, Hahn D, Sung Y, Lee J, Choi H, Nam SJ, Kang H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem Lett	2017	27	4	808	815	28117201	10.1016/j.bmcl.2017.01.026	Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.	Saharan VD, Mahajan SS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	Bioorg Med Chem Lett	2017	27	5	1319	1324	28188067	10.1016/j.bmcl.2016.08.032	Methylsulfonyl benzothiazoles (MSBT) derivatives: Search for new potential antimicrobial and anticancer agents.	Lad NP, Manohar Y, Mascarenhas M, Pandit YB, Kulkarni MR, Sharma R, Salkar K, Suthar A, Pandit SS.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2017	60	19	8011	8026	28953378	10.1021/acs.jmedchem.7b00631	Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656).	Li X, Hernandez V, Rock FL, Choi W, Mak YSL, Mohan M, Mao W, Zhou Y, Easom EE, Plattner JJ, Zou W, Pérez-Herrán E, Giordano I, Mendoza-Losana A, Alemparte C, Rullas J, Angulo-Barturen I, Crouch S, Ortega F, Barros D, Alley MRK.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2017	60	19	8145	8159	28880552	10.1021/acs.jmedchem.7b00949	Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.	Ni S, Wei H, Li B, Chen F, Liu Y, Chen W, Xu Y, Qiu X, Li X, Lu Y, Liu W, Hu L, Lin D, Wang M, Zheng X, Mao F, Zhu J, Lan L, Li J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2017	60	6	2425	2438	28248504	10.1021/acs.jmedchem.6b01780	Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.	Mohammad H, Younis W, Chen L, Peters CE, Pogliano J, Pogliano K, Cooper B, Zhang J, Mayhoub A, Oldfield E, Cushman M, Seleem MN.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2017	60	9	3755	3775	28406299	10.1021/acs.jmedchem.6b01834	Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.	Panchaud P, Bruyère T, Blumstein AC, Bur D, Chambovey A, Ertel EA, Gude M, Hubschwerlen C, Jacob L, Kimmerlin T, Pfeifer T, Prade L, Seiler P, Ritz D, Rueedi G.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2017	60	9	3851	3865	28322556	10.1021/acs.jmedchem.7b00113	Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.	Mandal M, Tan Z, Madsen-Duggan C, Buevich AV, Caldwell JP, Dejesus R, Flattery A, Garlisi CG, Gill C, Ha SN, Ho G, Koseoglu S, Labroli M, Basu K, Lee SH, Liang L, Liu J, Mayhood T, McGuinness D, McLaren DG, Wen X, Parmee E, Rindgen D, Roemer T, Sheth P, Tawa P, Tata J, Yang C, Yang SW, Xiao L, Wang H, Tan C, Tang H, Walsh P, Walsh E, Wu J, Su J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	ACS Med Chem Lett	2017	8	5	533	537	28523106	10.1021/acsmedchemlett.7b00068	Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis.	Zhao H, Lu Y, Sheng L, Yuan Z, Wang B, Wang W, Li Y, Ma C, Wang X, Zhang D, Huang H.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126	J Med Chem	2018	61	1	224	250	29243920	10.1021/acs.jmedchem.7b01300	Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.	Li B, Ni S, Mao F, Chen F, Liu Y, Wei H, Chen W, Zhu J, Lan L, Li J.
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126									Unpublished dataset	
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	LINEZOLID	CHEMBL126									WHO Anatomical Therapeutic Chemical Classification	
914.8500000000000000	9606	Homo sapiens	LITHIUM CARBONATE	CHEMBL1200826	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
914.8500000000000000	9606	Homo sapiens	LITHIUM CARBONATE	CHEMBL1200826									British National Formulary (72nd edition)	
914.8500000000000000	9606	Homo sapiens	LITHIUM CARBONATE	CHEMBL1200826									PubChem BioAssay data set	
914.8500000000000000	9606	Homo sapiens	LITHIUM CARBONATE	CHEMBL1200826									Unpublished dataset	
914.8500000000000000	9606	Homo sapiens	LITHIUM CARBONATE	CHEMBL1200826									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
914.8500000000000000	9606	Homo sapiens	LITHIUM CITRATE	CHEMBL2103738									British National Formulary (72nd edition)	
914.8500000000000000	9606	Homo sapiens	LITHIUM CITRATE	CHEMBL2103738									Unpublished dataset	
914.8500000000000000	9606	Homo sapiens	LITHIUM CITRATE	CHEMBL2103738									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	LORACARBEF	CHEMBL1200610									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	LORACARBEF	CHEMBL1200610									Unpublished dataset	
962.7500000000000000	2	Bacteria	LORACARBEF	CHEMBL1200610									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	LORACARBEF	CHEMBL1200610									WHO Anatomical Therapeutic Chemical Classification	
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752	J. Med. Chem.	2009	52	20	6257	6269	19772287	10.1021/jm9004779	p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.	Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G, Walker AL.
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752	J. Med. Chem.	2010	53	6	2345	2353	19950901	10.1021/jm9012906	Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.	Goldstein DM, Kuglstatter A, Lou Y, Soth MJ.
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752									Unpublished dataset	
1019.4000000000000000	9606	Homo sapiens	LOSMAPIMOD	CHEMBL1088752									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	J. Biol. Chem.	2007	282	22	16379	16390	17434872	10.1074/jbc.m609883200	Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.	Blobaum AL, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	J. Med. Chem.	2007	50	7	1425	1441	17341061	10.1021/jm0613166	Structural and functional basis of cyclooxygenase inhibition.	Blobaum AL, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	J. Med. Chem.	2012	55	7	2932	2942	22236250	10.1021/jm201706b	Exploring activity cliffs in medicinal chemistry.	Stumpfe D, Bajorath J.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Bioorg. Med. Chem. Lett.	2013	23	21	5860	5864	24060487	10.1016/j.bmcl.2013.08.097	Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.	Windsor MA, Valk PL, Xu S, Banerjee S, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	MedChemComm	2015	6	12	2081	2123		10.1039/C5MD00278H	Targeting microsomal prostaglandin E2synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs)	Chen Y, Liu H, Xu S, Wang T, Li W
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108	Bioorg. Med. Chem. Lett.	2016	26	6	1516	1520	26898334	10.1016/j.bmcl.2016.02.029	Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.	Tietz O, Dzandzi J, Bhardwaj A, Valliant JF, Wuest F.
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	LUMIRACOXIB	CHEMBL404108									WHO Anatomical Therapeutic Chemical Classification	
863.7500000000000000	9606	Homo sapiens	LY2969822	CHEMBL3545270									Unpublished dataset	
863.7500000000000000	9606	Homo sapiens	LY404039	CHEMBL375611	J. Med. Chem.	2007	50	2	233	240	17228865	10.1021/jm060917u	Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.	Monn JA, Massey SM, Valli MJ, Henry SS, Stephenson GA, Bures M, Hérin M, Catlow J, Giera D, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD.
863.7500000000000000	9606	Homo sapiens	LY404039	CHEMBL375611									PubChem BioAssay data set	
863.7500000000000000	9606	Homo sapiens	LY404039	CHEMBL375611									Unpublished dataset	
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	1997	7	2	193	198		10.1016/S0960-894X(96)00602-6	Inhibition of Matrix Metalloproteinases: An examination of the S1 pocket	Miller A, Askew M, Beckett R, Bellamy CL, Bone EA, Coates RE, Davidson AH, Drummond AH, Huxley P, Martin FM, Saroglou L, Thompson AJ, van Dijk SE, Whittaker M
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	1998	41	8	1209	1217	9548812	10.1021/jm970404a	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	1998	8	11	1359	1364	9871766	10.1016/s0960-894x(98)00218-2	The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.	Pratt LM, Beckett RP, Bellamy CL, Corkill DJ, Cossins J, Courtney PF, Davies SJ, Davidson AH, Drummond AH, Helfrich K, Lewis CN, Mangan M, Martin FM, Miller K, Nayee P, Ricketts ML, Thomas W, Todd RS, Whittaker M.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	1998	8	22	3251	3256	9873712	10.1016/s0960-894x(98)00597-6	Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.	Sheppard GS, Florjancic AS, Giesler JR, Xu L, Guo Y, Davidsen SK, Marcotte PA, Elmore I, Albert DH, Magoc TJ, Bouska JJ, Goodfellow CL, Morgan DW, Summers JB.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	1999	42	23	4890	4908	10579851	10.1021/jm990377j	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.	Barlaam B, Bird TG, Lambert-Van Der Brempt C, Campbell D, Foster SJ, Maciewicz R.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	1999	9	12	1691	1696	10397503	10.1016/s0960-894x(99)00259-0	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	1999	9	19	2887	2892	10522712	10.1016/s0960-894x(99)00494-1	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	Martin FM, Beckett RP, Bellamy CL, Courtney PF, Davies SJ, Drummond AH, Dodd R, Pratt LM, Patel SR, Ricketts ML, Todd RS, Tuffnell AR, Ward JW, Whittaker M.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2000	10	24	2815	2817	11133099	10.1016/s0960-894x(00)00584-9	Synthesis and activity of selective MMP inhibitors with an aryl backbone.	Barta TE, Becker DP, Bedell LJ, De Crescenzo GA, McDonald JJ, Munie GE, Rao S, Shieh HS, Stegeman R, Stevens AM, Villamil CI.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2001	11	11	1465	1468	11378378	10.1016/s0960-894x(01)00259-1	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Baxter AD, Bhogal R, Bird J, Keily JF, Manallack DT, Montana JG, Owen DA, Pitt WR, Watson RJ, Wills RE.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2001	11	18	2481	2483	11549451	10.1016/s0960-894x(01)00487-5	Selective, orally active MMP inhibitors with an aryl backbone.	Barta TE, Becker DP, Bedell LJ, De Crescenzo GA, McDonald JJ, Mehta P, Munie GE, Villamil CI.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2001	11	20	2723	2725	11591510	10.1016/s0960-894x(01)00557-1	alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.	Becker DP, DeCrescenzo G, Freskos J, Getman DP, Hockerman SL, Li M, Mehta P, Munie GE, Swearingen C.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2001	11	3	295	299	11212095	10.1016/s0960-894x(00)00646-6	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Chollet AM, Le Diguarher T, Murray L, Bertrand M, Tucker GC, Sabatini M, Pierré A, Atassi G, Bonnet J, Casara P.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2001	44	16	2636	2660	11472217	10.1021/jm010127e	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2002	45	1	219	232	11754593	10.1021/jm0103920	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Wada CK, Holms JH, Curtin ML, Dai Y, Florjancic AS, Garland RB, Guo Y, Heyman HR, Stacey JR, Steinman DH, Albert DH, Bouska JJ, Elmore IN, Goodfellow CL, Marcotte PA, Tapang P, Morgan DW, Michaelides MR, Davidsen SK.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2002	45	11	2289	2293	12014967	10.1021/jm0110993	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.	Kottirsch G, Koch G, Feifel R, Neumann U.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2003	13	16	2737	2740	12873504	10.1016/s0960-894x(03)00530-4	Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.	Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2003	13	16	2741	2744	12873505	10.1016/s0960-894x(03)00531-6	Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.	Moriyama H, Tsukida T, Inoue Y, Kondo H, Yoshino K, Nishimura S.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2003	46	18	3840	3852	12930146	10.1021/jm0307638	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Le Diguarher T, Chollet AM, Bertrand M, Hennig P, Raimbaud E, Sabatini M, Guilbaud N, Pierré A, Tucker GC, Casara P.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem.	2009	17	2	444	459	19095454	10.1016/j.bmc.2008.11.067	Current perspective of TACE inhibitors: a review.	DasGupta S, Murumkar PR, Giridhar R, Yadav MR.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2009	52	21	6790	6802	19821586	10.1021/jm900648x	Hydroxamates: relationships between structure and plasma stability.	Flipo M, Charton J, Hocine A, Dassonneville S, Deprez B, Deprez-Poulain R.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	Bioorg. Med. Chem. Lett.	2015	25	24	5752	5755	26546217	10.1016/j.bmcl.2015.10.077	Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31.	France DJ, Stepek G, Houston DR, Williams L, McCormack G, Walkinshaw MD, Page AP.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2015	58	15	5808	5824	26192023	10.1021/acs.jmedchem.5b00354	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Knapinska AM, Dreymuller D, Ludwig A, Smith L, Golubkov V, Sohail A, Fridman R, Giulianotti M, LaVoi TM, Houghten RA, Fields GB, Minond D.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785	J. Med. Chem.	2016	59	1	313	327	26653735	10.1021/acs.jmedchem.5b01434	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS, Caspers N, Collins B, Grapperhaus M, Palmquist KE, Collins J, Baldus JE, Hitchcock J, Kleine HP, Rogers MD, McDonald J, Munie GE, Messing DM, Portolan S, Whiteley LO, Sunyer T, Schnute ME.
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785									PubChem BioAssay data set	
1101.7500000000000000	9606	Homo sapiens	MARIMASTAT	CHEMBL279785									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
896.6000000000000000	9606	Homo sapiens	ME-344	CHEMBL3545320									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082									PubChem BioAssay data set	
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	MECAMYLAMINE HYDROCHLORIDE	CHEMBL1237082									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772	J. Biol. Chem.	2007	282	14	10311	10324	17284452	10.1074/jbc.m608207200	Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.	Necula M, Kayed R, Milton S, Glabe CG.
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772	Bioorg. Med. Chem. Lett.	2009	19	17	4952	4957	19640715	10.1016/j.bmcl.2009.07.082	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.	Reinke AA, Seh HY, Gestwicki JE.
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772									Unpublished dataset	
2219.8000000000000000	2	Bacteria	MECLOCYCLINE SULFOSALICYLATE	CHEMBL261772									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	MECLOFENAMATE SODIUM	CHEMBL1562610									PubChem BioAssay data set	
943.5000000000000000	9606	Homo sapiens	MECLOFENAMATE SODIUM	CHEMBL1562610									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	MECLOFENAMATE SODIUM	CHEMBL1562610									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.6000000000000000	9606	Homo sapiens	MEDI-8968	CHEMBL2109607									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	1997	40	6	980	989	9083488	10.1021/jm9607010	Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.	Lazer ES, Miao CK, Cywin CL, Sorcek R, Wong HC, Meng Z, Potocki I, Hoermann M, Snow RJ, Tschantz MA, Kelly TA, McNeil DW, Coutts SJ, Churchill L, Graham AG, David E, Grob PM, Engel W, Meier H, Trummlitz G.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem. Lett.	1998	8	10	1181	1186	9871731	10.1016/s0960-894x(98)00184-x	Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.	Lazer ES, Sorcek R, Cywin CL, Thome D, Possanza GJ, Graham AG, Churchill L.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem. Lett.	1999	9	13	1773	1778	10406640	10.1016/s0960-894x(99)00288-7	The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.	Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	2000	43	11	2204	2216	10841799	10.1021/jm990968+	Predicting blood-brain barrier permeation from three-dimensional molecular structure.	Crivori P, Cruciani G, Carrupt PA, Testa B.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Xenobiotica	2005	35	2	191	210	16019946	10.1080/00498250400028197	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.	Ward KW, Nagilla R, Jolivette LJ.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Antimicrob. Agents Chemother.	2009	53	2	587	592	19015346	10.1128/aac.00530-08	Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.	Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, Laine K.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	2010	53	1	392	401	19947605	10.1021/jm901421c	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.	Tam KY, Avdeef A, Tsinman O, Sun N.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Eur. J. Med. Chem.	2011	46	2	526	534	21163557	10.1016/j.ejmech.2010.11.032	Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole.	Moldovan CM, Oniga O, Pârvu A, Tiperciuc B, Verite P, Pîrn¿u A, Cri¿an O, Boji¿¿ M, Pop R.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem. Lett.	2013	23	20	5519	5522	24012185	10.1016/j.bmcl.2013.08.061	Synthesis and anti-inflammatory activity of three nitro chalcones.	Gómez-Rivera A, Aguilar-Mariscal H, Romero-Ceronio N, Roa-de la Fuente LF, Lobato-García CE.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	MedChemComm	2015	6	2	283	299		10.1039/C4MD00392F	Synthesis, 3D pharmacophore, QSAR and docking studies of novel quinazoline derivatives with nitric oxide release moiety as preferential COX-2 inhibitors	Farag DB, Farag NA, Esmat A, Abuelezz SA, Abdel-Salam Ibrahim E, Abou El Ella DA
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	J Med Chem	2016	59	16	7544	7560	27502541	10.1021/acs.jmedchem.6b00598	Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.	Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599	Bioorg Med Chem	2017	25	1	316	326	27842798	10.1016/j.bmc.2016.10.036	Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.	¿wi¿tek P, Strzelecka M, Urniaz R, G¿bczak K, G¿barowski T, G¿siorowski K, Malinka W.
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									Open TG-GATES	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	MELOXICAM	CHEMBL599									WHO Anatomical Therapeutic Chemical Classification	
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	J. Nat. Prod.	1994	57	1	9	17	8158169	10.1021/np50103a002	Naturally occurring antiacne agents.	Kubo I, Muroi H, Kubo A.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	J. Nat. Prod.	1995	58	8	1261	1264	7595592	10.1021/np50122a018	Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.	Perrucci S, Macchioni G, Cioni PL, Flamini G, Morelli I.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Nat. Chem. Biol.	2005	1	2	85	92	16408004	10.1038/nchembio0705-85	Sensing with TRP channels.	Voets T, Talavera K, Owsianik G, Nilius B.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Ind Crops Prod	2007	26	3	278	297		10.1016/j.indcrop.2007.03.009	Toxicity of monoterpenes against larvae and adults of Colorado potato beetle, Leptinotarsa decemlineata Say (Coleoptera: Chrysomelidae)	Kordali S, Kesdek M, Cakir A.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Nat. Chem. Biol.	2007	3	3	174	182	17293875	10.1038/nchembio862	TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.	Voets T, Owsianik G, Janssens A, Talavera K, Nilius B.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Bioorg. Med. Chem. Lett.	2008	18	9	2854	2859	18424131	10.1016/j.bmcl.2008.03.091	QSAR study of mosquito repellents from terpenoid with a six-member-ring.	Wang Z, Song J, Chen J, Song Z, Shang S, Jiang Z, Han Z.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	J Agric Food Chem	2008	56	23	11361	11366	18991452	10.1021/jf802324v	Quantitative structure-activity relationship of terpenoid aphid antifeedants.	Wang Z, Song J, Han Z, Jiang Z, Zheng W, Chen J, Song Z, Shang S.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Antimicrob. Agents Chemother.	2009	53	5	1898	1906	19223628	10.1128/aac.01293-08	Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.	McNamara PJ, Syverson RE, Milligan-Myhre K, Frolova O, Schroeder S, Kidder J, Hoang T, Proctor RA.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	J. Med. Chem.	2010	53	14	5085	5107	20356305	10.1021/jm100062h	Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.	Baraldi PG, Preti D, Materazzi S, Geppetti P.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Pest Manag Sci	2011	67	12	1583	1588	21674753	10.1002/ps.2216	Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.	Han J, Kim SI, Choi BR, Lee SG, Ahn YJ.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Med Chem Res	2012	21	4	531	537		10.1007/s00044-011-9560-1	Effect of nitrogen insertion on the antitussive properties of menthol and camphor	Kumar N, Nepali K, Sapra S, Bijjem KRV, Kumar R, Suri OP, Dhar KL
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Pest Manag Sci	2012	68	8	1122	1129	22461383	10.1002/ps.3280	Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.	Tong F, Coats JR.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087	Bioorg. Med. Chem. Lett.	2013	23	22	6118	6122	24080460	10.1016/j.bmcl.2013.09.016	Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists.	Brown A, Ellis D, Favor DA, Kirkup T, Klute W, MacKenny M, McMurray G, Stennett A.
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087									British National Formulary (72nd edition)	
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087									PubChem BioAssay data set	
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087									Unpublished dataset	
851.6000000000000000	9606	Homo sapiens	MENTHOL	CHEMBL256087									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.9000000000000000	9606	Homo sapiens	MEPHENTERMINE SULFATE	CHEMBL3184799									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	MEPHENTERMINE SULFATE	CHEMBL3184799									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	MEPHENTERMINE SULFATE	CHEMBL3184799									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1993	3	11	2165	2170		10.1016/S0960-894X(01)80919-7	Activity of new penems against defined MRSA strains	Jabes D, Rossi R, Bruna CD, Perrone E, Alpegiani M, Andreini BP, Visentin G, Zarini F, Franceschi G
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1995	5	12	1235	1240		10.1016/0960-894X(95)00202-5	Synthesis and biological evaluation of 4-heterotribactams	Di Fabio R, Feriani A, Gaviraghi G, Rossi T
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1995	5	19	2199	2202		10.1016/0960-894X(95)00380-C	Synthesis and antibacterial activity of FR21818, a new, potent 1-methylcarbapenem	Azami H, Barrett D, Tanaka A, Sasaki H, Matsuda K, Chiba T, Matsumoto Y, Matsumoto S, Morinaga C, Ishiguro K, Tawara S, Sakane K, Takasugi H
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1997	7	11	1409	1414		10.1016/S0960-894X(97)00230-8	Studies on -lactam antibiotics. Synthesis and antibacterial activity of novel 1-methylcarbapenems related to FR21818: 5-membered ring analogs	Azami H, Barrett D, Tanaka A, Sasaki H, Matsuda K, Sakurai M, Matsumoto Y, Tawara S, Chiba T, Sakane K
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1997	7	13	1671	1676		10.1016/S0960-894X(97)00282-5	Synthesis and structure-activity relationships of novel THF 1-methylcarbapenems	Lin Y, Bitha P, Sakya SM, Strohmeyer TW, Li Z, Lee VJ, Lang SA, Yang Y, Bhachech N, Weiss WJ, Petersen PJ, Jacobus NV, Bush K, Testa RT, Tally FP
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1998	8	13	1607	1612	9873399	10.1016/s0960-894x(98)00270-4	Synthesis and biological properties of new 1 beta-methylcarbapenems.	Shin KJ, Yoo KH, Kim DJ, Park SW, Ko BS, Lee SJ, Huh JD, Park SY.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	1999	9	16	2385	2390	10476874	10.1016/s0960-894x(99)00407-2	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.	Kang YK, Shin KJ, Yoo KH, Seo KJ, Park SY, Kim DJ, Park SW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2000	10	13	1421	1425	10888323	10.1016/s0960-894x(00)00253-5	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.	Shin KJ, Koo KD, Yoo KH, Kim DC, Kim DJ, Park SW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2000	10	2	95	99	10673088	10.1016/s0960-894x(99)00646-0	Synthesis and antibacterial activity of new carbapenems containing isoxazole moiety.	Kang YK, Shin KJ, Yoo KH, Seo KJ, Hong CY, Lee CS, Park SY, Kim DJ, Park SW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2000	10	24	2799	2802	11133095	10.1016/s0960-894x(00)00575-8	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.	Kim DJ, Seo KJ, Lee KS, Shin KJ, Yoo KH, Kim DC, Park SW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2000	10	4	333	336	10714493	10.1016/s0960-894x(99)00692-7	Synthesis and antibacterial activity of 2alpha-functionalized 1beta-methylcarbapenems related to KR-21012.	Kwak HJ, Pyun DK, Kim JH, Kim EJ, Jeong HJ, Kim BJ, Lee CH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2001	11	17	2397	2399	11527740	10.1016/s0960-894x(01)00451-6	Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.	Shin KJ, Koo KD, Yoo KH, Kang YK, Park SW, Kim DJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2002	45	14	3032	3040	12086488	10.1021/jm010546b	Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds.	Heinisch L, Wittmann S, Stoiber T, Berg A, Ankel-Fuchs D, Möllmann U.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2003	13	24	4399	4403	14643334	10.1016/j.bmcl.2003.09.039	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.	Lee JH, Lee KS, Kang YK, Yoo KH, Shin KJ, Kim DC, Kong JY, Lee Y, Lee SJ, Kim DJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2003	13	3	463	466	12565951	10.1016/s0960-894x(02)00948-4	Synthesis and biological evaluation of novel 1 beta-methylcarbapenems with isothiazoloethenyl side chains.	Kang YK, Lee KS, Yoo KH, Shin KJ, Kim DC, Lee CS, Kong JY, Kim DJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2003	66	11	1495	1498	14640526	10.1021/np030162j	New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis.	Park Y, Liu Y, Hong J, Lee CO, Cho H, Kim DK, Im KS, Jung JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2003	66	3	384	391	12662097	10.1021/np020507i	Bioactive sterols from the starfish Certonardoa semiregularis.	Wang W, Li F, Park Y, Hong J, Lee CO, Kong JY, Shin S, Im KS, Jung JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2005	15	1	231	234	15582445	10.1016/j.bmcl.2004.09.092	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.	Lee KS, Kang YK, Yoo KH, Kim DC, Shin KJ, Paik YS, Kim DJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2005	68	5	711	715	15921415	10.1021/np049577a	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.	Bao B, Sun Q, Yao X, Hong J, Lee CO, Sim CJ, Im KS, Jung JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Biol. Chem.	2007	282	42	30414	30422	17646161	10.1074/jbc.m704286200	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.	Mainardi JL, Hugonnet JE, Rusconi F, Fourgeaud M, Dubost L, Moumi AN, Delfosse V, Mayer C, Gutmann L, Rice LB, Arthur M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Eur. J. Med. Chem.	2007	42	3	358	364	17156896	10.1016/j.ejmech.2006.10.006	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.	Jeon H, Jo NH, Yoo KH, Choi JH, Cho H, Cho JH, Oh CH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Eur. J. Med. Chem.	2007	42	9	1176	1183	17418453	10.1016/j.ejmech.2007.02.001	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.	Kim SJ, Park HB, Lee JS, Jo NH, Yoo KH, Baek D, Kang BW, Cho JH, Oh CH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	10	3471	3484	17646423	10.1128/aac.01464-06	Global challenge of multidrug-resistant Acinetobacter baumannii.	Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	10	3642	3649	17682103	10.1128/aac.00160-07	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.	Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	10	3776	3777	17682099	10.1128/aac.00837-07	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.	Evans JC, Segal H.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	11	3844	3852	17724156	10.1128/aac.01512-06	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.	Hu WS, Yao SM, Fung CP, Hsieh YP, Liu CP, Lin JF.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	11	4022	4028	17846127	10.1128/aac.01259-06	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.	Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, Xu Y, Zhu Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	12	4329	4335	17938181	10.1128/aac.00810-07	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.	Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	12	4382	4389	17908940	10.1128/aac.00971-07	National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.	Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	12	4486	4488	17938180	10.1128/aac.01462-06	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.	Neuwirth C, Siebor E, Robin F, Bonnet R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	12	4512	4514	17875998	10.1128/aac.00491-07	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.	Fonseca F, Sarmento AC, Henriques I, Samyn B, van Beeumen J, Domingues P, Domingues MR, Saavedra MJ, Correia A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	2	417	422	17158943	10.1128/aac.00851-06	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.	Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	2	453	460	17116681	10.1128/aac.00960-06	Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea.	Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	2	763	765	17145797	10.1128/aac.01053-06	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.	Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	3	1085	1088	17158942	10.1128/aac.00954-06	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.	Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	3	1102	1104	17194827	10.1128/aac.01102-06	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.	Cercenado E, Marín M, Sánchez-Martínez M, Cuevas O, Martínez-Alarcón J, Bouza E.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	3	852	856	17158944	10.1128/aac.01345-06	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.	Doi Y, de Oliveira Garcia D, Adams J, Paterson DL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1341	1350	17261619	10.1128/aac.01278-06	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.	Reinhardt A, Köhler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1481	1486	17283197	10.1128/aac.00752-06	Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.	DeRyke CA, Banevicius MA, Fan HW, Nicolau DP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1527	1529	17220425	10.1128/aac.00780-06	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.	Castanheira M, Pereira AS, Nicoletti AG, Pignatari AC, Barth AL, Gales AC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	5	1621	1626	17307973	10.1128/aac.01099-06	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.	Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	5	1627	1632	17307986	10.1128/aac.01192-06	Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin.	Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	5	1649	1655	17283189	10.1128/aac.01435-06	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.	Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	5	1725	1730	17307978	10.1128/aac.00294-06	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.	Li C, Du X, Kuti JL, Nicolau DP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	1967	1971	17420207	10.1128/aac.01483-06	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.	Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	1987	1994	17387156	10.1128/aac.01509-06	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.	Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	2065	2069	17420217	10.1128/aac.01198-06	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.	Peleg AY, Adams J, Paterson DL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	2179	2184	17420213	10.1128/aac.01600-06	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.	Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	2211	2214	17404005	10.1128/aac.01139-06	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.	Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, Pagani L, Bonomo RA, Rossolini GM, Toniolo A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	6	2282	2283	17420208	10.1128/aac.00309-07	SME-2-producing Serratia marcescens isolate from Switzerland.	Poirel L, Wenger A, Bille J, Bernabeu S, Naas T, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	7	2324	2328	17438042	10.1128/aac.01502-06	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.	Bertini A, Poirel L, Bernabeu S, Fortini D, Villa L, Nordmann P, Carattoli A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	7	2366	2372	17452479	10.1128/aac.00044-07	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.	Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M, Stefanou I, Avlami A, Katsilambros N.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	7	2611	2614	17470660	10.1128/aac.00838-06	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.	Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	7	2636	2638	17438051	10.1128/aac.01043-06	blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.	Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	8	2716	2719	17517836	10.1128/aac.01623-06	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.	Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	8	2988	2990	17470648	10.1128/aac.00083-07	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.	Perilli M, Caporale B, Celenza G, Pellegrini C, Docquier JD, Mezzatesta M, Rossolini GM, Stefani S, Amicosante G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	8	3026	3029	17562800	10.1128/aac.00299-07	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.	Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	8	3038	3039	17517838	10.1128/aac.00374-07	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.	Ikonomidis A, Labrou M, Afkou Z, Maniatis AN, Sofianou D, Tsakris A, Pournaras S.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	9	3431	3433	17576842	10.1128/aac.01433-06	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.	Kroeger LA, Hovde LB, Mitropoulos IF, Schafer J, Rotschafer JC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	9	3463	3464	17606681	10.1128/aac.00190-07	Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?	Billal DS, Hotomi M, Yamanaka N.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2007	51	9	3465	3466	17606684	10.1128/aac.00267-07	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.	Quinteira S, Grosso F, Ramos H, Peixe L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2007	70	1	2	8	17253840	10.1021/np060206z	Bisindole alkaloids of the topsentin and hamacanthin classes from a marine sponge Spongosorites sp.	Bao B, Sun Q, Yao X, Hong J, Lee CO, Cho HY, Jung JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Eur. J. Med. Chem.	2008	43	2	300	308	17513022	10.1016/j.ejmech.2007.03.023	Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 2. The synthesis and antimicrobial activity of some novel 1-(1-benzofuran-2-yl)-2-mesitylethanone derivatives.	Kirilmis C, Ahmedzade M, Servi S, Koca M, Kizirgil A, Kazaz C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	1	333	336	17967915	10.1128/aac.00689-07	Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.	Pankuch GA, Lin G, Seifert H, Appelbaum PC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	1	365	373	17938185	10.1128/aac.00910-07	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.	Credito KL, Ednie LM, Appelbaum PC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	10	3589	3596	18644957	10.1128/aac.00465-08	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.	Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	10	3795	3800	18694945	10.1128/aac.00464-08	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.	Tanimoto K, Tomita H, Fujimoto S, Okuzumi K, Ike Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	10	3826	3827	18694947	10.1128/aac.00419-08	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.	Wu X, Wang H, Zhao X.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	3837	3843	18725452	10.1128/aac.00570-08	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.	Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	4023	4029	18809945	10.1128/aac.00707-08	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.	Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, De Luca F, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	4115	4120	18725447	10.1128/aac.00366-08	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.	Zarrilli R, Vitale D, Di Popolo A, Bagattini M, Daoud Z, Khan AU, Afif C, Triassi M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	4163	4165	18725442	10.1128/aac.00476-08	In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.	Karlowsky JA, Laing NM, Zhanel GG.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	4194	4197	18765691	10.1128/aac.01337-07	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.	Sekiguchi J, Morita K, Kitao T, Watanabe N, Okazaki M, Miyoshi-Akiyama T, Kanamori M, Kirikae T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	11	4205	4206	18765689	10.1128/aac.01121-08	Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.	Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lissoir B, Nordmann P, Glupczynski Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	12	4268	4273	18809939	10.1128/aac.00830-08	High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.	Yang H, Chen H, Yang Q, Chen M, Wang H.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	12	4388	4399	18779357	10.1128/aac.00381-08	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.	Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	12	4492	4496	18838581	10.1128/aac.00696-08	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.	Snydman DR, Jacobus NV, McDermott LA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	2	570	573	18070960	10.1128/aac.01114-07	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.	Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	2	761	766	18070958	10.1128/aac.01128-07	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.	Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	2	796	797	18056283	10.1128/aac.01180-07	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.	Cuzon G, Naas T, Demachy MC, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	3	1021	1027	18160523	10.1128/aac.01082-07	Highly variable penicillin resistance determinants PBP 2x, PBP 2b, and PBP 1a in isolates of two Streptococcus pneumoniae clonal groups, Poland 23F-16 and Poland 6B-20.	Izdebski R, Rutschmann J, Fiett J, Sadowy E, Gniadkowski M, Hryniewicz W, Hakenbeck R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	3	1147	1149	18180346	10.1128/aac.01387-07	Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.	Ressner RA, Moore MR, Jorgensen JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	3	1153	1155	18180353	10.1128/aac.01351-07	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.	Sader HS, Fritsche TR, Jones RN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	3	1198	1200	18086856	10.1128/aac.00682-07	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.	Hu RM, Huang KJ, Wu LT, Hsiao YJ, Yang TC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1252	1256	18195058	10.1128/aac.01304-07	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.	Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1257	1263	18227185	10.1128/aac.01451-07	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.	Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1264	1268	18212108	10.1128/aac.00684-07	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.	Meziane-Cherif D, Lambert T, Dupêchez M, Courvalin P, Galimand M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1430	1437	18285482	10.1128/aac.01538-07	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.	Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1510	1512	18250190	10.1128/aac.01529-07	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.	Davies TA, Shang W, Bush K, Flamm RK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	4	1525	1528	18212097	10.1128/aac.01485-07	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.	Okazaki A, Avison MB.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	5	1613	1617	18299404	10.1128/aac.00978-07	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.	Poirel L, Mansour W, Bouallegue O, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	5	1846	1849	18299417	10.1128/aac.01176-07	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.	Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	5	1894	1896	18285473	10.1128/aac.01414-07	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.	Loli A, Tzouvelekis LS, Gianneli D, Tzelepi E, Miriagou V.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	6	2014	2018	18332176	10.1128/aac.01539-07	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.	Cai JC, Zhou HW, Zhang R, Chen GX.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	6	2250	2252	18362187	10.1128/aac.01025-07	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.	Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	6	2289	2290	18362195	10.1128/aac.00299-08	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.	Martin CA, Morita K, Ribes JA, Deshpande LM, Sader HS, Castanheira M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	7	2473	2479	18443127	10.1128/aac.01062-07	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.	Stoczko M, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	7	2573	2580	18443121	10.1128/aac.00393-08	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.	Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	7	2680	2682	18426899	10.1128/aac.00158-08	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.	Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2797	2805	18519727	10.1128/aac.00123-08	Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.	Lemaire S, Olivier A, Van Bambeke F, Tulkens PM, Appelbaum PC, Glupczynski Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2818	2824	18505851	10.1128/aac.00171-08	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.	Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2849	2854	18519723	10.1128/aac.00413-08	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.	Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2890	2897	18490507	10.1128/aac.00185-08	First molecular characterization of group B streptococci with reduced penicillin susceptibility.	Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2905	2908	18559652	10.1128/aac.00166-08	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.	Samuelsen Ø, Castanheira M, Walsh TR, Spencer J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2943	2946	18490501	10.1128/aac.00679-07	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.	Garza-Ramos U, Morfin-Otero R, Sader HS, Jones RN, Hernández E, Rodriguez-Noriega E, Sanchez A, Carrillo B, Esparza-Ahumada S, Silva-Sanchez J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2955	2958	18505859	10.1128/aac.00072-08	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.	Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P, Alba V, Fernández-Cuenca F, Pascual A, Vila J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2962	2965	18519713	10.1128/aac.01341-07	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.	Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	8	2977	2979	18519714	10.1128/aac.00175-08	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.	Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	2999	3005	18591275	10.1128/aac.01684-07	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.	Bratu S, Landman D, Martin DA, Georgescu C, Quale J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	3161	3168	18625771	10.1128/aac.00355-08	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.	Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	3229	3236	18591267	10.1128/aac.00405-08	Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.	Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Møller N, Nagai J, Takano M, Vaara T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	3244	3252	18591273	10.1128/aac.00063-08	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.	Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D'Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	3418	3423	18591277	10.1128/aac.00336-08	In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.	Amsler KM, Davies TA, Shang W, Jacobs MR, Bush K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2008	52	9	3463	3464	18644970	10.1128/aac.00543-08	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.	Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2008	71	12	2032	2035	19053507	10.1021/np800503z	Citreamicins with potent gram-positive activity.	Hopp DC, Milanowski DJ, Rhea J, Jacobsen D, Rabenstein J, Smith C, Romari K, Clarke M, Francis L, Irigoyen M, Luche M, Carr GJ, Mocek U.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2009	52	19	5926	5936	19746934	10.1021/jm900625q	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.	Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, Distèche-Nguyen M, Thomas A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	1	292	294	18852270	10.1128/aac.00931-08	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.	Bennett JW, Herrera ML, Lewis JS, Wickes BW, Jorgensen JH.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	1	319	322	18955522	10.1128/aac.00595-08	In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.	Tanaka K, Mikamo H, Nakao K, Ichiishi T, Goto T, Yamagishi Y, Watanabe K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	1	333	334	19015350	10.1128/aac.00736-08	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.	Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	1	69	74	18955524	10.1128/aac.00227-08	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.	Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4225	4230	19651910	10.1128/aac.00192-09	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.	Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K, Kaku M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4320	4326	19651915	10.1128/aac.01607-08	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.	Zeba B, De Luca F, Dubus A, Delmarcelle M, Simporé J, Nacoulma OG, Rossolini GM, Frère JM, Docquier JD.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4333	4338	19620332	10.1128/aac.00260-09	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.	Shen P, Wei Z, Jiang Y, Du X, Ji S, Yu Y, Li L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4345	4351	19635950	10.1128/aac.01267-08	Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.	Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4352	4356	19770286	10.1128/aac.00282-09	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.	Crandon JL, Bulik CC, Nicolau DP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4518	4521	19620330	10.1128/aac.00461-09	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.	Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	11	4783	4788	19738025	10.1128/aac.00574-09	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	11	4930	4933	19738007	10.1128/aac.00900-09	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.	Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	12	5035	5038	19770279	10.1128/aac.00856-09	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.	Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	12	5046	5054	19770275	10.1128/aac.00774-09	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.	Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	12	5288	5290	19770278	10.1128/aac.00822-09	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.	Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	12	5308	5311	19786606	10.1128/aac.00630-09	Susceptibilities of 23 Desulfovibrio isolates from humans.	Nakao K, Tanaka K, Ichiishi S, Mikamo H, Shibata T, Watanabe K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	12	5312	5316	19770280	10.1128/aac.00748-09	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.	Srinivasan VB, Rajamohan G, Gebreyes WA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	2	552	556	19015339	10.1128/aac.01324-08	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.	McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	2	557	562	19015357	10.1128/aac.00734-08	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.	Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	3	1177	1184	19029333	10.1128/aac.00485-08	Genetic variability among ampC genes from acinetobacter genomic species 3.	Beceiro A, Pérez A, Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Vila J, Rodríguez-Baño J, Cisneros JM, Pachón J, Bou G, Spanish Group for Nosocomial Infection (GEIH).
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	3	1238	1241	19104025	10.1128/aac.01433-08	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.	Koga T, Sugihara C, Kakuta M, Masuda N, Namba E, Fukuoka T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	3	876	882	19075063	10.1128/aac.00946-08	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.	Poirel L, Rodriguez-Martinez JM, Plésiat P, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	4	1325	1330	19164147	10.1128/aac.01230-08	Molecular epidemiology of outbreak-related pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene.	Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	4	1630	1635	19188377	10.1128/aac.01431-08	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.	Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, Jajic-Bencic I, Gniadkowski M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	4	1642	1644	19164142	10.1128/aac.01325-08	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.	Liu Y, Zhang B, Cao Q, Huang W, Shen L, Qin X.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	4	1660	1664	19188398	10.1128/aac.01172-08	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.	Wolter DJ, Khalaf N, Robledo IE, Vázquez GJ, Santé MI, Aquino EE, Goering RV, Hanson ND.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	5	1766	1771	19258272	10.1128/aac.01410-08	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.	Rodríguez-Martínez JM, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	5	1998	2004	19258268	10.1128/aac.01355-08	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.	Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	5	2221	2222	19223629	10.1128/aac.01573-08	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.	Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2327	2334	19349516	10.1128/aac.01360-08	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.	Kitao T, Miyoshi-Akiyama T, Kirikae T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2360	2366	19349512	10.1128/aac.01452-08	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.	Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2492	2498	19332679	10.1128/aac.00033-09	Integron mobilization unit as a source of mobility of antibiotic resistance genes.	Poirel L, Carrër A, Pitout JD, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2605	2609	19332683	10.1128/aac.01533-08	Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.	Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2650	2653	19332682	10.1128/aac.01716-08	Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.	Murayama SY, Seki C, Sakata H, Sunaoshi K, Nakayama E, Iwata S, Sunakawa K, Ubukata K, Invasive Streptococcal Disease Working Group.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2657	2659	19307373	10.1128/aac.01663-08	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.	Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	6	2667	2671	19364869	10.1128/aac.01407-08	AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii.	Post V, Hall RM.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	7	2902	2907	19414581	10.1128/aac.01513-08	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.	Yang TC, Huang YW, Hu RM, Huang SC, Lin YT.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	7	3115	3117	19364859	10.1128/aac.00893-08	In vitro activity of doripenem against Burkholderia pseudomallei.	Thamlikitkul V, Trakulsomboon S.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	7	3178	3178	19414570	10.1128/aac.01586-08	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.	Pope CE, Carter PE, Heffernan HM.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	8	3357	3364	19506058	10.1128/aac.01655-08	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.	Griggs DJ, Peake L, Johnson MM, Ghori S, Mott A, Piddock LJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	8	3528	3533	19487447	10.1128/aac.00178-09	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.	D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	8	3544	3548	19487444	10.1128/aac.00400-09	AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.	Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	8	3579	3581	19451292	10.1128/aac.00072-09	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.	Moubareck C, Brémont S, Conroy MC, Courvalin P, Lambert T.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	9	3908	3913	19596871	10.1128/aac.00453-09	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.	Picão RC, Poirel L, Gales AC, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	9	4045	4047	19564367	10.1128/aac.00292-09	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.	Figueiredo S, Poirel L, Papa A, Koulourida V, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2009	53	9	4048	4050	19581459	10.1128/aac.00690-09	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.	Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	116	125	19884364	10.1128/aac.00642-09	In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.	Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	177	183	19858254	10.1128/aac.00715-09	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.	Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	328	332	19901091	10.1128/aac.00961-09	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	466	470	19901092	10.1128/aac.00017-09	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.	Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	471	476	19917750	10.1128/aac.00458-09	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.	Rodriguez-Martinez JM, Nordmann P, Fortineau N, Poirel L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	557	559	19917762	10.1128/aac.00912-09	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.	Bulik CC, Christensen H, Nicolau DP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	565	569	19884379	10.1128/aac.01004-09	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.	Queenan AM, Shang W, Flamm R, Bush K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	573	577	19805565	10.1128/aac.01099-09	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.	Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	1	578	579	19884362	10.1128/aac.00861-09	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4112	4115	20660688	10.1128/aac.00026-10	In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.	Bulik CC, Nicolau DP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4159	4167	20679510	10.1128/aac.00257-10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.	Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martínez JL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4178	4184	20660683	10.1128/aac.01301-09	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.	García-Fernández A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, Carattoli A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4201	4207	20660684	10.1128/aac.00008-10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.	Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, Patel JB.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4343	4351	20696874	10.1128/aac.00409-10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.	Docquier JD, Benvenuti M, Calderone V, Stoczko M, Menciassi N, Rossolini GM, Mangani S.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	10	4516	4517	20679508	10.1128/aac.00570-10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.	Soledad Ramírez M, Merkier AK, Almuzara M, Vay C, Centrón D.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4556	4560	20733047	10.1128/aac.01762-09	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC ß-lactamases.	Mammeri H, Guillon H, Eb F, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4575	4581	20713680	10.1128/aac.00764-10	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.	Chen TL, Lee YT, Kuo SC, Hsueh PR, Chang FY, Siu LK, Ko WC, Fung CP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4864	4871	20696873	10.1128/aac.00771-10	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES ß-lactamases.	Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4914	4916	20823289	10.1128/aac.00878-10	Emergence of metallo-ß-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.	Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	11	4948	4949	20713658	10.1128/aac.00415-10	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.	Rodríguez-Rojas A, Couce A, Blázquez J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	12	5021	5027	20921306	10.1128/aac.00598-10	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.	Higgins PG, Schneiders T, Hamprecht A, Seifert H.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	12	5057	5061	20876374	10.1128/aac.00768-10	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.	Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	12	5395	5398	20855742	10.1128/aac.00083-10	Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.	Lee CH, Su LH, Li CC, Chien CC, Tang YF, Liu JW.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	2	804	810	19995927	10.1128/aac.01190-09	Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.	Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	2	846	851	19933793	10.1128/aac.00834-09	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.	Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1029	1041	20028819	10.1128/aac.00963-09	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.	Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1213	1217	20086158	10.1128/aac.01104-09	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.	Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1331	1333	20065056	10.1128/aac.01561-09	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.	Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1354	1357	20038618	10.1128/aac.00899-09	Detection of KPC in Acinetobacter spp. in Puerto Rico.	Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1369	1373	20086157	10.1128/aac.01312-09	Spread of OXA-48-encoding plasmid in Turkey and beyond.	Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, Matar G, Honderlick P, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	1381	1382	20047915	10.1128/aac.00399-09	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.	Santella G, Cuirolo A, Almuzara M, Palombarani S, Sly G, Radice M, Gutkind G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	3	969	976	19995920	10.1128/aac.01009-09	Updated functional classification of beta-lactamases.	Bush K, Jacoby GA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	4	1619	1622	20145085	10.1128/aac.01585-09	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.	Girlich D, Poirel L, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	1678	1683	20145081	10.1128/aac.00737-08	Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.	Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	2078	2084	20194701	10.1128/aac.01398-09	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.	Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, Li SY.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	2119	2124	20211892	10.1128/aac.01450-09	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.	Kaniga K, Flamm R, Tong SY, Lee M, Friedland I, Redman R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	2191	2193	20308390	10.1128/aac.01520-09	In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.	Vera-Cabrera L, Campos-Rivera MP, Escalante-Fuentes WG, Pucci MJ, Ocampo-Candiani J, Welsh O.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	2219	2224	20194693	10.1128/aac.00816-09	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2291	2302	20308379	10.1128/aac.01525-09	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.	Page MG, Dantier C, Desarbre E.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2420	2424	20308383	10.1128/aac.01456-09	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.	Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2583	2589	20385866	10.1128/aac.01283-09	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.	Huang YW, Lin CW, Hu RM, Lin YT, Chung TC, Yang TC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2687	2691	20231393	10.1128/aac.01359-09	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2692	2695	20308376	10.1128/aac.00033-10	Mutant prevention concentrations of four carbapenems against gram-negative rods.	Credito K, Kosowska-Shick K, Appelbaum PC.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2699	2703	20368407	10.1128/aac.01624-09	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.	Huang LY, Lu PL, Chen TL, Chang FY, Fung CP, Siu LK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	6	2724	2727	20385865	10.1128/aac.01674-09	OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.	Merino M, Acosta J, Poza M, Sanz F, Beceiro A, Chaves F, Bou G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	7	2867	2877	20421396	10.1128/aac.00197-10	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.	Papp-Wallace KM, Taracila M, Hornick JM, Hujer AM, Hujer KM, Distler AM, Endimiani A, Bonomo RA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	7	2974	2978	20479205	10.1128/aac.01582-09	Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.	Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	7	3002	3006	20350950	10.1128/aac.01818-09	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.	Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	7	3015	3017	20404121	10.1128/aac.01173-09	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.	Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	8	3107	3112	20516281	10.1128/aac.00128-10	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.	Chen TL, Chang WC, Kuo SC, Lee YT, Chen CP, Siu LK, Cho WL, Fung CP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	8	3197	3204	20498317	10.1128/aac.01336-09	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.	Borgianni L, Vandenameele J, Matagne A, Bini L, Bonomo RA, Frère JM, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	8	3484	3488	20547808	10.1128/aac.00050-10	Extended-spectrum cephalosporinase in Acinetobacter baumannii.	Rodríguez-Martínez JM, Nordmann P, Ronco E, Poirel L.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	8	3493	3497	20498315	10.1128/aac.00080-10	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.	Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3557	3563	20566764	10.1128/aac.00385-10	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.	Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3564	3568	20547788	10.1128/aac.00220-10	Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.	Tängdén T, Cars O, Melhus A, Löwdin E.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3625	3629	20606062	10.1128/aac.01397-09	In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.	Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3967	3969	20547789	10.1128/aac.00137-10	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.	Jiang Y, Yu D, Wei Z, Shen P, Zhou Z, Yu Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3970	3973	20585130	10.1128/aac.00054-10	In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.	Kishii K, Chiba N, Morozumi M, Ono A, Ida T, Ubukata K.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3985	3987	20585114	10.1128/aac.01799-09	Serum and cerebrospinal fluid levels of colistin in pediatric patients.	Antachopoulos C, Karvanen M, Iosifidis E, Jansson B, Plachouras D, Cars O, Roilides E.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3993	3997	20585132	10.1128/aac.00481-10	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.	Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, Chong Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2010	54	9	3998	3999	20585134	10.1128/aac.00264-10	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.	Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	ACS Med. Chem. Lett.	2011	2	5	385	390	24900319	10.1021/ml200012f	Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.	Flanagan ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	MedChemComm	2011	2	8	735	742		10.1039/C1MD00095K	New analyses of MIC90 data to aid antibacterial drug discovery	Brown MF, Gupta RR, Kuhn M, Flanagan ME, Mitton-Fry M
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2011	55	1	140	145	21041509	10.1128/aac.00858-10	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.	Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2011	55	1	447	448	20974865	10.1128/aac.01305-10	Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India.	Poirel L, Ros A, Carricajo A, Berthelot P, Pozzetto B, Bernabeu S, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2011	55	1	82	85	21041503	10.1128/aac.01198-10	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.	Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2011	55	2	917	920	21098239	10.1128/aac.00491-10	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.	Ravasi P, Limansky AS, Rodriguez RE, Viale AM, Mussi MA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Antimicrob. Agents Chemother.	2011	55	2	934	936	21115785	10.1128/aac.01247-10	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.	Poirel L, Revathi G, Bernabeu S, Nordmann P.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2012	22	18	5989	5994	22892121	10.1016/j.bmcl.2012.07.005	Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections.	Mitton-Fry MJ, Arcari JT, Brown MF, Casavant JM, Finegan SM, Flanagan ME, Gao H, George DM, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Irvine R, Lall MS, Megan Lemmon M, Li C, Lin J, McCurdy SP, Mueller JP, Mullins L, Niosi M, Noe MC, Pattavina D, Penzien J, Plummer MS, Risley H, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Winton J, Young JA.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem.	2013	21	17	5605	5617	23845282	10.1016/j.bmc.2013.05.024	Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.	Teitelbaum AM, Meissner A, Harding RA, Wong CA, Aldrich CC, Remmel RP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem.	2013	21	23	7499	7506	24126094	10.1016/j.bmc.2013.09.041	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.	Od¿ak R, Sko¿ibu¿i¿ M, Maravi¿ A.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2013	56	13	5541	5552	23755848	10.1021/jm400560z	Pyridone-conjugated monobactam antibiotics with gram-negative activity.	Brown MF, Mitton-Fry MJ, Arcari JT, Barham R, Casavant J, Gerstenberger BS, Han S, Hardink JR, Harris TM, Hoang T, Huband MD, Lall MS, Lemmon MM, Li C, Lin J, McCurdy SP, McElroy E, McPherson C, Marr ES, Mueller JP, Mullins L, Nikitenko AA, Noe MC, Penzien J, Plummer MS, Schuff BP, Shanmugasundaram V, Starr JT, Sun J, Tomaras A, Young JA, Zaniewski RP.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Nat. Prod.	2013	76	9	1535	1540	23972215	10.1021/np4000944	Polyketides with New Delhi metallo-ß-lactamase 1 inhibitory activity from Penicillium sp.	Gan M, Liu Y, Bai Y, Guan Y, Li L, Gao R, He W, You X, Li Y, Yu L, Xiao C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2014	57	17	7450	7458	25137478	10.1021/jm501050e	Small-molecule suppression of ß-lactam resistance in multidrug-resistant gram-negative pathogens.	Brackett CM, Melander RJ, An IH, Krishnamurthy A, Thompson RJ, Cavanagh J, Melander C.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2015	25	13	2694	2697	25981687	10.1016/j.bmcl.2015.04.046	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.	Pardeshi KA, Malwal SR, Banerjee A, Lahiri S, Rangarajan R, Chakrapani H.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2015	58	11	4703	4712	25927406	10.1021/acs.jmedchem.5b00262	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.	Sun C, Hunt DK, Chen CL, Deng Y, He M, Clark RB, Fyfe C, Grossman TH, Sutcliffe JA, Xiao XY.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2015	58	21	8671	8682	26477515	10.1021/acs.jmedchem.5b01289	Discovery of Novel Inhibitor Scaffolds against the Metallo-ß-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.	Christopeit T, Carlsen TJ, Helland R, Leiros HK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2015	58	9	3682	3692	25782055	10.1021/acs.jmedchem.5b00127	Discovery of a Cyclic Boronic Acid ß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.	Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	ACS Med. Chem. Lett.	2015	6	5	537	542	26005529	10.1021/acsmedchemlett.5b00026	SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3.	Murphy-Benenato KE, Dangel B, Davis HE, Durand-Réville TF, Ferguson AD, Gao N, Jahi¿ H, Mueller JP, Manyak EL, Quiroga O, Rooney M, Sha L, Sylvester M, Wu F, Zambrowski M, Zhao SX.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem.	2016	24	6	1376	1383	26879853	10.1016/j.bmc.2016.02.013	Synthesis of fluorinated carbazoles via C-H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities.	Kong X, Zhang H, Cao C, Zhou S, Pang G, Shi Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2016	26	15	3572	3576	27329794	10.1016/j.bmcl.2016.06.019	An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.	Kaushik A, Heuer AM, Bell DT, Culhane JC, Ebner DC, Parrish N, Ippoliti JT, Lamichhane G.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg Med Chem Lett	2016	26	22	5539	5544	27765507	10.1016/j.bmcl.2016.10.004	5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics.	Faulkner KC, Hurley KA, Weibel DB.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	Bioorg. Med. Chem. Lett.	2016	26	8	1973	1977	26976213	10.1016/j.bmcl.2016.03.004	Fragment-based discovery of inhibitor scaffolds targeting the metallo-ß-lactamases NDM-1 and VIM-2.	Christopeit T, Leiros HK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2016	59	11	5542	5554	27165692	10.1021/acs.jmedchem.6b00660	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.	Lund BA, Christopeit T, Guttormsen Y, Bayer A, Leiros HK.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2016	59	18	8441	8455	27524179	10.1021/acs.jmedchem.6b00867	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.	Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J. Med. Chem.	2016	59	7	3427	3438	26937999	10.1021/acs.jmedchem.6b00096	Routes of Synthesis of Carbapenems for Optimizing Both the Inactivation of L,D-Transpeptidase LdtMt1 of Mycobacterium tuberculosis and the Stability toward Hydrolysis by ß-Lactamase BlaC.	Iannazzo L, Soroka D, Triboulet S, Fonvielle M, Compain F, Dubée V, Mainardi JL, Hugonnet JE, Braud E, Arthur M, Etheve-Quelquejeu M.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	MedChemComm	2016	7	1	148	156		10.1039/C5MD00373C	Synergistic activity of a short lipidated antimicrobial peptide (lipoAMP) and colistin or tobramycin against Pseudomonas aeruginosa from cystic fibrosis patients	de Gier MG, Bauke Albada H, Josten M, Willems R, Leavis H, van Mansveld R, Paganelli FL, Dekker B, Lammers JJ, Sahl H, Metzler-Nolte N
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	MedChemComm	2016	7	1	157	163		10.1039/C5MD00377F	Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles	Dahdouh E, Orgaz B, Gomez-Gil R, Mingorance J, Daoud Z, Suarez M, San Jose C
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	MedChemComm	2016	7	1	190	193		10.1039/C5MD00380F	In vitro and in vivo activity of ML302F: a thioenolate inhibitor of VIM-subfamily metallo -lactamases	Betts JW, Phee LM, Abdul Momin MHF, Umland K, Brem J, Schofield CJ, Wareham DW
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2017	60	12	5002	5014	28549219	10.1021/acs.jmedchem.7b00377	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2017	60	6	2498	2512	28248499	10.1021/acs.jmedchem.6b01903	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.	Deng Y, Sun C, Hunt DK, Fyfe C, Chen CL, Grossman TH, Sutcliffe JA, Xiao XY.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2017	60	7	2669	2684	28287720	10.1021/acs.jmedchem.6b01261	Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.	Tan L, Tao Y, Wang T, Zou F, Zhang S, Kou Q, Niu A, Chen Q, Chu W, Chen X, Wang H, Yang Y.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127	J Med Chem	2017	60	9	3684	3702	28409644	10.1021/acs.jmedchem.6b01742	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.	Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									DrugMatrix	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									Unpublished dataset	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	MEROPENEM	CHEMBL127									WHO Anatomical Therapeutic Chemical Classification	
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	1983	26	9	1300	1307	6136612	10.1021/jm00363a015	A polymeric drug for treatment of inflammatory bowel disease.	Brown JP, McGarraugh GV, Parkinson TM, Wingard RE, Onderdonk AB.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Nat. Prod.	1989	52	6	1252	1257	2614420	10.1021/np50066a009	Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus.	Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki K, Naganawa H, Takeuchi T, Tatsuta K, Umezawa K.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	1993	36	26	4201	4207	8277502	10.1021/jm00078a009	Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.	Pellicciari R, Garzon-Aburbeh A, Natalini B, Marinozzi M, Clerici C, Gentili G, Morelli A.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Gut	1996	39	1	63	68	8881811	10.1136/gut.39.1.63	Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.	Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, Zinsmeister AR, Lipsky JJ.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	2003	46	21	4477	4486	14521410	10.1021/jm030191r	Identification and prediction of promiscuous aggregating inhibitors among known drugs.	Seidler J, McGovern SL, Doman TN, Shoichet BK.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem.	2007	15	14	4903	4909	17499512	10.1016/j.bmc.2007.04.045	Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.	Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem. Lett.	2007	17	7	1897	1902	17280832	10.1016/j.bmcl.2007.01.031	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Gairola N, Kandpal M, Bhatt L, Vadnerkar G, Kadam SS.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2007	42	6	885	890	17258353	10.1016/j.ejmech.2006.11.017	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Kandpal M, Vadnerkar G, Rathi B, Kadam SS.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem.	2008	16	2	739	745	17964793	10.1016/j.bmc.2007.10.021	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.	Knuckley B, Luo Y, Thompson PR.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Antimicrob. Agents Chemother.	2008	52	2	418	426	18070971	10.1128/aac.00678-07	Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.	Shin SJ, Collins MT.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Med Chem Res	2009	18	9	712	724		10.1007/s00044-009-9162-3	Study on the quantitative structuretoxicity relationships of benzoic acid derivatives in rats via oral LD50	Sun Y, Li Z, Yan X, Wang L, Meng F
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2009	44	1	131	142	18472188	10.1016/j.ejmech.2008.03.035	Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.	Dhaneshwar SS, Chail M, Patil M, Naqvi S, Vadnerkar G.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2009	44	10	3922	3929	19442419	10.1016/j.ejmech.2009.04.018	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L, Rathi B, Kadam SS.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	2010	53	1	392	401	19947605	10.1021/jm901421c	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.	Tam KY, Avdeef A, Tsinman O, Sun N.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem.	2011	19	12	3777	3786	21612933	10.1016/j.bmc.2011.04.057	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis.	Andrzejak V, Muccioli GG, Body-Malapel M, El Bakali J, Djouina M, Renault N, Chavatte P, Desreumaux P, Lambert DM, Millet R.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem. Lett.	2011	21	20	6184	6187	21889337	10.1016/j.bmcl.2011.07.081	Inhibition of xc¿ transporter-mediated cystine uptake by sulfasalazine analogs.	Shukla K, Thomas AG, Ferraris DV, Hin N, Sattler R, Alt J, Rojas C, Slusher BS, Tsukamoto T.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Drug Metab. Dispos.	2011	39	6	1097	1102	21430235	10.1124/dmd.110.034991	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.	König J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2011	46	11	5498	5511	21955679	10.1016/j.ejmech.2011.09.008	Novel natural product-based cinnamates and their thio and thiono analogs as potent inhibitors of cell adhesion molecules on human endothelial cells.	Kumar S, Singh BK, Arya P, Malhotra S, Thimmulappa R, Prasad AK, Van der Eycken E, Olsen CE, DePass AL, Biswal S, Parmar VS, Ghosh B.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2012	48		36	44	22154834	10.1016/j.ejmech.2011.11.030	Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-¿ dependent NF¿B activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.	Kim J, Kang S, Hong S, Yum S, Kim YM, Jung Y.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	2012	55	19	8493	8501	22963087	10.1021/jm3009844	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.	Liu KC, Fang JM, Jan JT, Cheng TJ, Wang SY, Yang ST, Cheng YS, Wong CH.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	J. Med. Chem.	2012	55	20	8948	8952	23017078	10.1021/jm3008568	4-Oxo-1,4-dihydropyridines as selective CB¿ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.	El Bakali J, Gilleron P, Body-Malapel M, Mansouri R, Muccioli GG, Djouina M, Barczyk A, Klupsch F, Andrzejak V, Lipka E, Furman C, Lambert DM, Chavatte P, Desreumaux P, Millet R.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2013	62		486	497	23416190	10.1016/j.ejmech.2013.01.024	Peroxisome proliferator-activated receptor-¿ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.	Brun P, Dean A, Di Marco V, Surajit P, Castagliuolo I, Carta D, Ferlin MG.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem. Lett.	2015	25	11	2314	2320	25937011	10.1016/j.bmcl.2015.04.023	Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.	Naumov RN, Panda SS, Girgis AS, George RF, Farhat M, Katritzky AR.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem. Lett.	2015	25	21	4808	4811	26183083	10.1016/j.bmcl.2015.07.001	The antioxidant properties of salicylate derivatives: A possible new mechanism of anti-inflammatory activity.	Borges RS, Castle SL.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2015	89		671	682	25462274	10.1016/j.ejmech.2014.10.081	Benzimidazole--ibuprofen/mesalamine conjugates: potential candidates for multifactorial diseases.	Bansal Y, Kaur M, Silakari O.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Eur. J. Med. Chem.	2016	108		486	494	26717200	10.1016/j.ejmech.2015.12.021	Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-ß-O-glucoside.	Li F, Wu G, Zheng H, Wang L, Zhao Z.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg. Med. Chem.	2016	24	14	3218	3230	27255176	10.1016/j.bmc.2016.05.047	Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.	Xi M, Ge J, Wang X, Sun C, Liu T, Fang L, Xiao Q, Yin D.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg Med Chem Lett	2016	26	19	4587	4591	27597248	10.1016/j.bmcl.2016.08.075	In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.	Banskota S, Kang HE, Kim DG, Park SW, Jang H, Karmacharya U, Jeong BS, Kim JA, Nam TG.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704	Bioorg Med Chem	2017	25	9	2601	2608	28341401	10.1016/j.bmc.2017.03.024	Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.	Nabeyama W, Ishihara K, Ban HS, Wada H, Nakamura H.
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704									British National Formulary (72nd edition)	
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704									PubChem BioAssay data set	
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	MESALAMINE	CHEMBL704									WHO Anatomical Therapeutic Chemical Classification	
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703	J. Med. Chem.	1998	41	23	4556	4566	9804695	10.1021/jm9803121	Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.	Aicher TD, Balkan B, Bell PA, Brand LJ, Cheon SH, Deems RO, Fell JB, Fillers WS, Fraser JD, Gao J, Knorr DC, Kahle GG, Leone CL, Nadelson J, Simpson R, Smith HC.
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703	J. Med. Chem.	2009	52	14	4142	4148	19522462	10.1021/jm900274q	The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.	Huttunen KM, Mannila A, Laine K, Kemppainen E, Leppänen J, Vepsäläinen J, Järvinen T, Rautio J.
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703	Drug Metab. Dispos.	2012	40	6	1170	1177	22407892	10.1124/dmd.112.044875	Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.	Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ.
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703	Bioorg. Med. Chem.	2013	21	8	2305	2313	23490148	10.1016/j.bmc.2013.02.015	A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.	Koh M, Lee JC, Min C, Moon A.
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703									British National Formulary (72nd edition)	
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703									Drug metabolism data	
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703									PubChem BioAssay data set	
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703									Unpublished dataset	
896.6000000000000000	9606	Homo sapiens	METFORMIN HYDROCHLORIDE	CHEMBL1703									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	Drug Metab. Dispos.	2011	39	1	151	159	20966043	10.1124/dmd.110.035105	Identification of clinically used drugs that activate pregnane X receptors.	Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, Xia M.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	Bioorg. Med. Chem. Lett.	2012	22	4	1709	1711	22257890	10.1016/j.bmcl.2011.12.103	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.	Maiti M, Nauwelaerts K, Herdewijn P.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123									Unpublished dataset	
2219.8000000000000000	2	Bacteria	METHACYCLINE HYDROCHLORIDE	CHEMBL2146123									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	METHANTHELINE BROMIDE	CHEMBL1200988									PubChem BioAssay data set	
939.2000000000000000	9606	Homo sapiens	METHANTHELINE BROMIDE	CHEMBL1200988									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	METHANTHELINE BROMIDE	CHEMBL1200988									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1045.5000000000000000	9606	Homo sapiens	METRELEPTIN	CHEMBL2107857									Unpublished dataset	
1045.5000000000000000	9606	Homo sapiens	METRELEPTIN	CHEMBL2107857									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1045.5000000000000000	9606	Homo sapiens	METRELEPTIN	CHEMBL2107857									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	MEZLOCILLIN SODIUM	CHEMBL1697708	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	MEZLOCILLIN SODIUM	CHEMBL1697708	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	MEZLOCILLIN SODIUM	CHEMBL1697708	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	MEZLOCILLIN SODIUM	CHEMBL1697708									Unpublished dataset	
962.7500000000000000	2	Bacteria	MEZLOCILLIN SODIUM	CHEMBL1697708									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829	J. Med. Chem.	2009	52	16	5152	5163	19603809	10.1021/jm9006559	Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.	Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829	J Med Chem	2017	60	18	7863	7875	28792760	10.1021/acs.jmedchem.7b00996	Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.	Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E.
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829								10.6019/CHEMBL3637841	MMV Pathogen Box	
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829								10.6019/CHEMBL3832761	MMV Pathogen Box Bioactivity Data	Nathan group, Weill Cornell Medical College; Barry Lab, NIAID NIH; Winzeler lab, UCSD; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Univ. of Antwerp; London School of Hygiene and Tropical Medicine; Parasite Chemotherapy Unit at Swiss Tropical and Public Health Institute; Huston group at the University of Vermont; Castellanos group at UTMB, Galveston, Texas; Sakanari Lab, Univ. of Calif. San Francisco; Townson (Simon) Lab, Imperial College London; Fidelis Cho-Ngwa Lab, University of Buea, Buea, Cameroon; Laboratory of Molecular Parasitology at the New York Blood Center; Bickle Lab, London School of Hygiene and Tropical Medicine; Keiser Lab, Swiss Tropical and Public Health Institute; Caffrey group at the Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego; University of Cape Town; Shanmugam group at CSIR-National Chemical Laboratory, Pune (India); Novartis Institute for Tropical Disease-Singapore; Abbvie
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829								10.6019/CHEMBL3987221	The Australian National University Dept Of Immunology Pathogen Box Compounds Screened	Anna Ehmann
884.4000000000000000	9606	Homo sapiens	MILCICLIB	CHEMBL564829									Unpublished dataset	
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Bioorg. Med. Chem. Lett.	2012	22	4	1709	1711	22257890	10.1016/j.bmcl.2011.12.103	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.	Maiti M, Nauwelaerts K, Herdewijn P.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881									Unpublished dataset	
2219.8000000000000000	2	Bacteria	MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1128.9500000000000000	9606	Homo sapiens	MK-8353	CHEMBL3545001									Unpublished dataset	
1114.5000000000000000	9606	Homo sapiens	MODIMELANOTIDE	CHEMBL3545104									Unpublished dataset	
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	J. Med. Chem.	1979	22	7	757	759	448673	10.1021/jm00193a001	Synthetic studies on beta-lactam antibiotics. Part 101. Synthesis of 7beta-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7alpha-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]-methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid disodium salt (6059-S) and its related 1-oxacephems.	Narisada M, Yoshida T, Onoue H, Ohtani M, Okada T, Tsuji T, Kikkawa I, Haga N, Satoh H, Itani H, Nagata W.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357									Unpublished dataset	
962.7500000000000000	2	Bacteria	MOXALACTAM DISODIUM	CHEMBL1200357									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	J. Med. Chem.	1982	25	6	670	679	6124636	10.1021/jm00348a013	Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.	Clifton JE, Collins I, Hallett P, Hartley D, Lunts LH, Wicks PD.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	J. Med. Chem.	2009	52	10	3416	3419	19397318	10.1021/jm9003945	Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.	Bard B, Carrupt PA, Martel S.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									Open TG-GATES	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	MOXISYLYTE	CHEMBL159226									WHO Anatomical Therapeutic Chemical Classification	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	J. Med. Chem.	1978	21	12	1260	1264	722734	10.1021/jm00210a016	4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds.	Goudie AC, Gaster LM, Lake AW, Rose CJ, Freeman PC, Hughes BO, Miller D.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Bioorg. Med. Chem. Lett.	1998	8	19	2725	2730	9873611	10.1016/s0960-894x(98)00485-5	Synthesis and biological activity of novel thiazolidinediones.	Prabhakar C, Madhusudhan G, Sahadev K, Reddy CM, Sarma MR, Reddy GO, Chakrabarti R, Rao CS, Kumar TD, Rajagopalan R.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	J. Med. Chem.	2006	49	3	1207	1211	16451086	10.1021/jm0510124	Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.	Kumpulainen H, Mähönen N, Laitinen ML, Jaurakkajärvi M, Raunio H, Juvonen RO, Vepsäläinen J, Järvinen T, Rautio J.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Bioorg. Med. Chem.	2008	16	11	5881	5889	18482840	10.1016/j.bmc.2008.04.066	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.	Brunskole M, Stefane B, Zorko K, Anderluh M, Stojan J, Lanisnik Rizner T, Gobec S.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									Drug metabolism data	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	NABUMETONE	CHEMBL1070									WHO Anatomical Therapeutic Chemical Classification	
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem.	2008	16	20	9188	9201	18829333	10.1016/j.bmc.2008.09.011	Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.	Kawai K, Hayakawa J, Miyamoto T, Imamura Y, Yamane S, Wakita H, Fujii H, Kawamura K, Matsuura H, Izumimoto N, Kobayashi R, Endo T, Nagase H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem. Lett.	2011	21	13	4104	4107	21641798	10.1016/j.bmcl.2011.04.147	Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.	Yamamoto N, Fujii H, Nemoto T, Nakajima R, Momen S, Izumimoto N, Hasebe K, Mochizuki H, Nagase H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem. Lett.	2012	22	15	5071	5074	22742909	10.1016/j.bmcl.2012.05.122	Essential structure of opioid ¿ receptor agonist nalfurafine for binding to the ¿ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.	Nagase H, Imaide S, Hirayama S, Nemoto T, Fujii H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem. Lett.	2012	22	24	7711	7714	23103094	10.1016/j.bmcl.2012.09.101	Essential structure of opioid ¿ receptor agonist nalfurafine for binding to the ¿ receptor 3: synthesis of decahydro(iminoethano)phenanthrene derivatives with an oxygen functionality at the 3-position and their pharmacologies.	Fujii H, Imaide S, Hirayama S, Nemoto T, Gouda H, Hirono S, Nagase H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem. Lett.	2012	22	8	2775	2779	22460026	10.1016/j.bmcl.2012.02.082	Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology. Part 2: Propellane derivatives with an amide side chain.	Nagase H, Akiyama J, Nakajima R, Hirayama S, Nemoto T, Gouda H, Hirono S, Fujii H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem. Lett.	2013	23	1	268	272	23200250	10.1016/j.bmcl.2012.10.100	The effect of 17-N substituents on the activity of the opioid ¿ receptor in nalfurafine derivatives.	Nemoto T, Yamamoto N, Wada N, Harada Y, Tomatsu M, Ishihara M, Hirayama S, Iwai T, Fujii H, Nagase H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg. Med. Chem.	2015	23	19	6271	6279	26346669	10.1016/j.bmc.2015.08.036	Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.	Nakajima R, Yamamoto N, Hirayama S, Iwai T, Saitoh A, Nagumo Y, Fujii H, Nagase H.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	Bioorg Med Chem Lett	2017	27	16	3920	3924	28688957	10.1016/j.bmcl.2017.06.017	Discovery of highly selective ¿-opioid receptor agonists: 10¿-Hydroxy TRK-820 derivatives.	Suzuki S, Sugawara Y, Tsuji R, Tanimura R, Kaneko C, Yuzawa N, Yagi M, Kawai K.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665	J Med Chem	2017	60	3	1018	1040	28051300	10.1021/acs.jmedchem.6b01418	Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.	Nagase H, Yamamoto N, Yata M, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ishikawa Y, Ogawa Y, Hirayama S, Kuroda D, Watanabe Y, Gouda H, Yanagisawa M.
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665									Unpublished dataset	
895.6500000000000000	9606	Homo sapiens	NALFURAFINE HYDROCHLORIDE	CHEMBL490665									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706	J. Med. Chem.	1992	35	4	750	755	1347319	10.1021/jm00082a017	Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues.	Amemiya Y, Hong SS, Venkataraman BV, Patil PN, Shams G, Romstedt K, Feller DR, Hsu FL, Miller DD.
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706	Pest Manag Sci	2013	69	1	126	134	23129510	10.1002/ps.3378	Molecular cloning and pharmacological characterisation of a tyramine receptor from the rice stem borer, Chilo suppressalis (Walker).	Wu SF, Huang J, Ye GY.
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	NAPHAZOLINE HYDROCHLORIDE	CHEMBL1706									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	NARATRIPTAN HYDROCHLORIDE	CHEMBL1200601									British National Formulary (72nd edition)	
1098.4250000000000000	9606	Homo sapiens	NARATRIPTAN HYDROCHLORIDE	CHEMBL1200601									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	NARATRIPTAN HYDROCHLORIDE	CHEMBL1200601									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	NARATRIPTAN HYDROCHLORIDE	CHEMBL1200601									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	NEOMYCIN SULFATE	CHEMBL3989769									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	NEOMYCIN SULFATE	CHEMBL3989769									Unpublished dataset	
2219.8000000000000000	2	Bacteria	NEOMYCIN SULFATE	CHEMBL3989769									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
853.5000000000000000	9606	Homo sapiens	NERISPIRDINE	CHEMBL2107762	Bioorg. Med. Chem.	2015	23	13	3831	3842	25900628	10.1016/j.bmc.2015.03.065	Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638.	Schofield J, Derdau V, Atzrodt J, Zane P, Guo Z, van Horn R, Czepczor V, Stoltz A, Pardon M.
853.5000000000000000	9606	Homo sapiens	NERISPIRDINE	CHEMBL2107762									Unpublished dataset	
853.5000000000000000	9606	Homo sapiens	NERISPIRDINE	CHEMBL2107762									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1273.6750000000000000	9606	Homo sapiens	NESIRITIDE	CHEMBL1201668									Unpublished dataset	
1273.6750000000000000	9606	Homo sapiens	NESIRITIDE	CHEMBL1201668									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1273.6750000000000000	9606	Homo sapiens	NESIRITIDE	CHEMBL1201668									WHO Anatomical Therapeutic Chemical Classification	
867.7500000000000000	9606	Homo sapiens	NETARSUDIL DIMESYLATE	CHEMBL3545126									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	NETARSUDIL DIMESYLATE	CHEMBL3545126									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	NETILMICIN SULFATE	CHEMBL3989829									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	NETILMICIN SULFATE	CHEMBL3989829									Unpublished dataset	
2219.8000000000000000	2	Bacteria	NETILMICIN SULFATE	CHEMBL3989829									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1991	34	7	2231	2241	1712395	10.1021/jm00111a045	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.	Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, Behnke ML.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1991	34	9	2922	2925	1716683	10.1021/jm00113a036	2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.	Saari WS, Hoffman JM, Wai JS, Fisher TE, Rooney CS, Smith AM, Thomas CM, Goldman ME, O'Brien JA, Nunberg JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1992	2	12	1639	1644		10.1016/S0960-894X(00)80447-3	Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones	De Lucca GV, Otto MJ
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1992	2	12	1745	1750		10.1016/S0960-894X(00)80468-0	Imidazo[2-3-:6,5]dipyrido[3,2-b:2,3-e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine	Terrett NT, Bojanic D, Merson JR, Stephenson PT
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1992	35	15	2721	2727	1495006	10.1021/jm00093a002	"3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5""-[4""-amino-1"",2""-oxathiole 2"",2""-dioxide] (TSAO) pyrimidine nucleosides."	Camarasa MJ, Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1992	35	16	2988	2995	1501224	10.1021/jm00094a009	TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.	Pérez-Pérez MJ, San-Félix A, Balzarini J, De Clercq E, Camarasa MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1992	35	21	3792	3802	1279173	10.1021/jm00099a007	Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.	Saari WS, Wai JS, Fisher TE, Thomas CM, Hoffman JM, Rooney CS, Smith AM, Jones JH, Bamberger DL, Goldman ME.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	10	1505	1508	7684450	10.1021/jm00062a027	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.	Romero DL, Morge RA, Genin MJ, Biles C, Busso M, Resnick L, Althaus IW, Reusser F, Thomas RC, Tarpley WG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	17	2526	2535	7689109	10.1021/jm00069a011	Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.	Mertens A, Zilch H, König B, Schäfer W, Poll T, Kampe W, Seidel H, Leser U, Leinert H.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	2	249	255	7678654	10.1021/jm00054a009	Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase inhibitors. 3. Pyridyl and phenyl analogs of 3-aminopyridin-2(1H)-one.	Wai JS, Williams TM, Bamberger DL, Fisher TE, Hoffman JM, Hudcosky RJ, MacTough SC, Rooney CS, Saari WS, Thomas CM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	24	3784	3794	7504733	10.1021/jm00076a005	Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines.	Livermore DG, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DV, Lamont RB, Noble SA, Orr DC, Payne JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	6	726	732	7681480	10.1021/jm00058a009	Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations.	Schäfer W, Friebe WG, Leinert H, Mertens A, Poll T, von der Saal W, Zilch H, Nuber B, Ziegler ML.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1993	36	9	1291	1294	7683725	10.1021/jm00061a022	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.	Williams TM, Ciccarone TM, MacTough SC, Rooney CS, Balani SK, Condra JH, Emini EA, Goldman ME, Greenlee WJ, Kauffman LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1994	37	15	2437	2444	7520079	10.1021/jm00041a023	Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Tucker TJ, Lyle TA, Wiscount CM, Britcher SF, Young SD, Sanders WM, Lumma WC, Goldman ME, O'Brien JA, Ball RG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1994	37	24	4185	4194	7527463	10.1021/jm00050a015	"1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5""-(4""-amino-1"",2""-oxathiole 2"",2""-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity."	Alvarez R, Velázquez S, San-Félix A, Aquaro S, De Clercq E, Perno CF, Karlsson A, Balzarini J, Camarasa MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	10	1657	1665	7538590	10.1021/jm00010a010	Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.	Wyatt PG, Bethell RC, Cammack N, Charon D, Dodic N, Dumaitre B, Evans DN, Green DV, Hopewell PL, Humber DC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	12	2038	2040	7540208	10.1021/jm00012a002	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.	Hanasaki Y, Watanabe H, Katsuura K, Takayama H, Shirakawa S, Yamaguchi K, Sakai S, Ijichi K, Fujiwara M, Konno K.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	17	3258	3263	7650679	10.1021/jm00017a010	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.	Mai A, Artico M, Sbardella G, Massa S, Loi AG, Tramontano E, Scano P, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	24	4830	4838	7490732	10.1021/jm00024a010	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.	Proudfoot JR, Hargrave KD, Kapadia SR, Patel UR, Grozinger KG, McNeil DW, Cullen E, Cardozo M, Tong L, Kelly TA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	24	4839	4847	7490733	10.1021/jm00024a011	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.	Kelly TA, Proudfoot JR, McNeil DW, Patel UR, David E, Hargrave KD, Grob PM, Cardozo M, Agarwal A, Adams J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	25	4929	4936	8523406	10.1021/jm00025a010	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.	Bell FW, Cantrell AS, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM, Noréen R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1995	38	8	1406	1410	7537334	10.1021/jm00008a019	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 3. Dipyrido[2,3-b:2',3'-e]diazepinones.	Proudfoot JR, Patel UR, Kapadia SR, Hargrave KD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1995	5	14	1461	1466		10.1016/0960-894X(95)00257-T	Synthesis and anti HIV-1 activity of new thiadiazepindioxides	Giannotti D, Viti G, Nannicini R, Pestellini V, Bellarosa D
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1995	5	2	163	166		10.1016/0960-894X(94)00478-X	The synthesis of a dipyrido[3,2-b:3,4-e][1,4]diazepinone: Convenient access to a C-ring isomer of the HIV-1 reverse transcriptase inhibitor nevirapine	Proudfoot JR
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	14	2672	2680	8709096	10.1021/jm950702c	Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.	Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Greco G, Novellino E, Altamura S, Di Renzo L.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	19	3769	3789	8809165	10.1021/jm960158n	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.	Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Stefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG, Thomas RC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	2	522	530	8558522	10.1021/jm950568w	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.	Artico M, Silvestri R, Massa S, Loi AG, Corrias S, Piras G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	21	4261	4274	8863804	10.1021/jm950639r	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.	Cantrell AS, Engelhardt P, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kangasmetsä J, Kinnick MD, Lind P, Morin JM, Muesing MA, Noreén R, Oberg B, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ, Zhang H.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	5	1069	1083	8676342	10.1021/jm950669u	Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.	Soler F, Poujade C, Evers M, Carry JC, Hénin Y, Bousseau A, Huet T, Pauwels R, De Clercq E, Mayaux JF, Le Pecq JB, Dereu N.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1996	39	8	1645	1650	8648604	10.1021/jm9508088	All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.	Gussio R, Pattabiraman N, Zaharevitz DW, Kellogg GE, Topol IA, Rice WG, Schaeffer CA, Erickson JW, Burt SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1997	40	10	1447	1454	9154967	10.1021/jm960802y	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.	Mai A, Artico M, Sbardella G, Quartarone S, Massa S, Loi AG, De Montis A, Scintu F, Putzolu M, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1997	7	14	1931	1936		10.1016/S0960-894X(97)00340-5	1-Arylsulfonyl-3-(-hydroxybenzyl)-1H-pyrroles, a novel class of anti-HIV-1 reverse transcriptase inhibitors	Artico M, Santo RD, Costi R, Massa S, Scintu F, Loi AG, De Montis A, La Colla P
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1998	41	16	2960	2971	9685235	10.1021/jm9707028	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.	Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih CK, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J, Grob PM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1998	41	16	2972	2984	9685236	10.1021/jm9707030	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.	Cywin CL, Klunder JM, Hoermann M, Brickwood JR, David E, Grob PM, Schwartz R, Pauletti D, Barringer KJ, Shih CK, Sorge CL, Erickson DA, Joseph DP, Hattox SE.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1998	41	21	4109	4117	9767646	10.1021/jm9802012	Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.	Arranz E, Díaz JA, Ingate ST, Witvrouw M, Pannecouque C, Balzarini J, De Clercq E, Vega S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1998	8	12	1511	1516	9873380	10.1016/s0960-894x(98)00249-2	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Sahlberg C, Noréen R, Engelhardt P, Högberg M, Kangasmetsä J, Vrang L, Zhang H.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1998	8	16	2169	2172	9873507	10.1016/s0960-894x(98)00369-2	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.	Dyatkin AB, Brickwood JR, Proudfoot JR.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1999	42	20	4150	4160	10514285	10.1021/jm990095j	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.	Högberg M, Sahlberg C, Engelhardt P, Noréen R, Kangasmetsä J, Johansson NG, Oberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lövgren S, Fridborg K, Bäckbro K.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1999	42	21	4462	4470	10543890	10.1021/jm990150o	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.	Campiani G, Morelli E, Fabbrini M, Nacci V, Greco G, Novellino E, Ramunno A, Maga G, Spadari S, Caliendo G, Bergamini A, Faggioli E, Uccella I, Bolacchi F, Marini S, Coletta M, Nacca A, Caccia S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	1999	42	4	619	627	10052969	10.1021/jm980260f	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.	Mai A, Artico M, Sbardella G, Massa S, Novellino E, Greco G, Loi AG, Tramontano E, Marongiu ME, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1999	9	11	1593	1598	10386942	10.1016/s0960-894x(99)00235-8	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.	Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1999	9	18	2721	2726	10509923	10.1016/s0960-894x(99)00460-6	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.	Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	1999	9	24	3411	3416	10617082	10.1016/s0960-894x(99)00624-1	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.	Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2000	10	11	1155	1158	10866370	10.1016/s0960-894x(00)00172-4	Prediction of drug solubility from Monte Carlo simulations.	Jorgensen WL, Duffy EM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2000	10	18	2071	2074	10999473	10.1016/s0960-894x(00)00398-x	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.	Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2000	10	2	193	195	10673109	10.1016/s0960-894x(99)00672-1	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Gearhart LA, Ko SS, Rodgers JD, Cordova BC, Klabe RM, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2000	10	3	253	256	10698447	10.1016/s0960-894x(99)00664-2	1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.	Silvestri R, Artico M, Massa S, Marceddu T, De Montis F, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2000	43	10	2019	2030	10821714	10.1021/jm990580e	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.	Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, Diamond S, Jeffrey S, Klabe RM, Cordova BC, Garber S, Logue K, Trainor GL, Anderson PS, Erickson-Viitanen SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2000	43	21	3949	3962	11052800	10.1021/jm0009437	Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.	Dollé V, Nguyen CH, Legraverend M, Aubertin AM, Kirn A, Andreola ML, Ventura M, Tarrago-Litvak L, Bisagni E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2000	43	5	1034	1040	10715167	10.1021/jm990383f	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.	Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG, Yagi Y, Romero DL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2000	43	9	1886	1891	10794705	10.1021/jm9901125	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.	Artico M, Silvestri R, Pagnozzi E, Bruno B, Novellino E, Greco G, Massa S, Ettorre A, Loi AG, Scintu F, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2001	11	17	2225	2228	11527703	10.1016/s0960-894x(01)00410-3	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).	Ludovici DW, Kukla MJ, Grous PG, Krishnan S, Andries K, de Béthune MP, Azijn H, Pauwels R, De Clercq E, Arnold E, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2001	11	17	2235	2239	11527705	10.1016/s0960-894x(01)00412-7	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.	Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi PJ, Heeres J, Koymans LM, de Jonge MR, Van Aken KJ, Daeyaert FF, Das K, Arnold E, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2001	11	21	2799	2802	11597403	10.1016/s0960-894x(01)00510-8	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.	Wang DP, Rizzo RC, Tirado-Rives J, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2001	11	4	523	528	11229762	10.1016/s0960-894x(01)00011-7	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.	Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2001	44	12	1866	1882	11384233	10.1021/jm0004906	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.	Chan JH, Hong JS, Hunter  RN, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews  CW, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2001	44	16	2544	2554	11472208	10.1021/jm010853h	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mai A, Sbardella G, Artico M, Ragno R, Massa S, Novellino E, Greco G, Lavecchia A, Musiu C, La Colla M, Murgioni C, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2001	44	2	145	154	11170624	10.1021/jm000255n	Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.	Rizzo RC, Tirado-Rives J, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2001	44	24	4092	4113	11708913	10.1021/jm010212m	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.	Xu G, Micklatcher M, Silvestri MA, Hartman TL, Burrier J, Osterling MC, Wargo H, Turpin JA, Buckheit RW, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2001	44	3	305	315	11462972	10.1021/jm0010365	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.	Campiani G, Aiello F, Fabbrini M, Morelli E, Ramunno A, Armaroli S, Nacci V, Garofalo A, Greco G, Novellino E, Maga G, Spadari S, Bergamini A, Ventura L, Bongiovanni B, Capozzi M, Bolacchi F, Marini S, Coletta M, Guiso G, Caccia S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2002	45	14	2970	2987	12086483	10.1021/jm010580q	Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.	Rizzo RC, Udier-Blagovi¿ M, Wang DP, Watkins EK, Kroeger Smith MB, Smith RH, Tirado-Rives J, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2002	45	26	5721	5726	12477355	10.1021/jm020949r	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.	El-Brollosy NR, Jørgensen PT, Dahan B, Boel AM, Pedersen EB, Nielsen C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2003	13	24	4309	4312	14643315	10.1016/j.bmcl.2003.09.045	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Benjahad A, Guillemont J, Andries K, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2003	46	5	768	781	12593657	10.1021/jm0209984	Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.	Ranise A, Spallarossa A, Schenone S, Bruno O, Bondavalli F, Vargiu L, Marceddu T, Mura M, La Colla P, Pani A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2004	14	10	2677	2680	15109677	10.1016/s0960-894x(04)00205-7	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.	Yadav A, Singh SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2004	14	12	3173	3176	15149669	10.1016/j.bmcl.2004.04.008	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.	He Y, Chen F, Sun G, Wang Y, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	10	2550	2560	15115397	10.1021/jm030558s	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.	Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	15	3892	3896	15239667	10.1021/jm031147e	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.	Silvestri R, Artico M, De Martino G, La Regina G, Loddo R, La Colla M, Mura M, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	22	5501	5514	15481987	10.1021/jm0407658	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.	Benjahad A, Courté K, Guillemont J, Mabire D, Coupa S, Poncelet A, Csoka I, Andries K, Pauwels R, de Béthune MP, Monneret C, Bisagni E, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	24	5912	5922	15537346	10.1021/jm040071z	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.	Hopkins AL, Ren J, Milton J, Hazen RJ, Chan JH, Stuart DI, Stammers DK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	24	5923	5936	15537347	10.1021/jm040072r	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.	Freeman GA, Andrews Iii CW, Hopkins AL, Lowell GS, Schaller LT, Cowan JR, Gonzales SS, Koszalka GW, Hazen RJ, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Reynolds DJ, Milton J, Ren J, Stuart DI, Stammers DK, Chan JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	4	928	934	14761194	10.1021/jm0309856	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.	Ragno R, Mai A, Sbardella G, Artico M, Massa S, Musiu C, Mura M, Marturana F, Cadeddu A, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2004	47	5	1175	1182	14971897	10.1021/jm030255y	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.	Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2005	15	4	1107	1109	15686922	10.1016/j.bmcl.2004.12.030	Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives.	Mashino T, Shimotohno K, Ikegami N, Nishikawa D, Okuda K, Takahashi K, Nakamura S, Mochizuki M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	1	213	223	15634015	10.1021/jm040854k	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.	Ragno R, Artico M, De Martino G, La Regina G, Coluccia A, Di Pasquali A, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	13	4378	4388	15974590	10.1021/jm050273a	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.	De Martino G, La Regina G, Di Pasquali A, Ragno R, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	22	6776	6778	16250634	10.1021/jm0507330	6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase.	Bartolini S, Mai A, Artico M, Paesano N, Rotili D, Spadafora C, Sbardella G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	23	7153	7165	16279773	10.1021/jm050257d	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.	Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	25	8000	8008	16335924	10.1021/jm050744t	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.	Manetti F, Esté JA, Clotet-Codina I, Armand-Ugón M, Maga G, Crespan E, Cancio R, Mugnaini C, Bernardini C, Togninelli A, Carmi C, Alongi M, Petricci E, Massa S, Corelli F, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	6	1689	1696	15771411	10.1021/jm040127p	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.	De Corte BL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	6	1901	1909	15771434	10.1021/jm040840e	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).	Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Béthune MP, Pauwels R, Das K, Clark AD, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	6	1948	1964	15771439	10.1021/jm0408621	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.	Benjahad A, Croisy M, Monneret C, Bisagni E, Mabire D, Coupa S, Poncelet A, Csoka I, Guillemont J, Meyer C, Andries K, Pauwels R, de Béthune MP, Himmel DM, Das K, Arnold E, Nguyen CH, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	6	2072	2079	15771449	10.1021/jm040838n	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.	Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, Vinkers MH, Arnold E, Das K, Pauwels R, Andries K, de Béthune MP, Bettens E, Hertogs K, Wigerinck P, Timmerman P, Janssen PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2005	48	7	2432	24444	15801834	10.1021/jm049606e	Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.	Wang J, Kang X, Kuntz ID, Kollman PA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2006	15	9	492	510		10.1007/s00044-007-9004-0	Design, synthesis, and biological evaluation of new 3-hydroxy-2-oxo-3-trifluoromethylindole as potential HIV-1 reverse transcriptase inhibitors	Boechat N, Kover WB, Bastos MM, Romeiro NC, Silva ASC, Santos FC, Valverde AL, Azevedo MLG, Wollinger W, Souza TML, de Souza SLO, de Frugulhetti ICPP
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	11	3034	3038	16527484	10.1016/j.bmcl.2006.02.049	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.	Krajewski K, Zhang Y, Parrish D, Deschamps J, Roller PP, Pathak VK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	13	3430	3433	16632349	10.1016/j.bmcl.2006.04.012	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.	Wu B, Kuhen K, Ngoc Nguyen T, Ellis D, Anaclerio B, He X, Yang K, Karanewsky D, Yin H, Wolff K, Bieza K, Caldwell J, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	13	3541	3544	16621553	10.1016/j.bmcl.2006.03.080	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.	Mugnaini C, Manetti F, Esté JA, Clotet-Codina I, Maga G, Cancio R, Botta M, Corelli F.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	16	4174	4177	16781149	10.1016/j.bmcl.2006.05.096	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.	Wang Z, Wu B, Kuhen KL, Bursulaya B, Nguyen TN, Nguyen DG, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	16	4246	4251	16782337	10.1016/j.bmcl.2006.05.073	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Ellis D, Kuhen KL, Anaclerio B, Wu B, Wolff K, Yin H, Bursulaya B, Caldwell J, Karanewsky D, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	21	5664	5667	16931015	10.1016/j.bmcl.2006.08.037	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Thakur VV, Kim JT, Hamilton AD, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	3	663	667	16263277	10.1016/j.bmcl.2005.10.038	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	3	668	671	16298131	10.1016/j.bmcl.2005.10.037	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Ruiz-Caro J, Basavapathruni A, Kim JT, Bailey CM, Wang L, Anderson KS, Hamilton AD, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	8	2105	2108	16480865	10.1016/j.bmcl.2006.01.073	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.	Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Wu TY, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2006	16	8	2109	2112	16464578	10.1016/j.bmcl.2006.01.066	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.	Jiang T, Kuhen KL, Wolff K, Yin H, Bieza K, Caldwell J, Bursulaya B, Tuntland T, Zhang K, Karanewsky D, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2006	49	11	3172	3184	16722636	10.1021/jm0512490	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.	Ragno R, Coluccia A, La Regina G, De Martino G, Piscitelli F, Lavecchia A, Novellino E, Bergamini A, Ciaprini C, Sinistro A, Maga G, Crespan E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2006	49	2	727	739	16420058	10.1021/jm050670l	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.	Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Proc. Natl. Acad. Sci. U.S.A.	2007	104	33	13432	13437	17652517	10.1073/pnas.0704212104	HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.	Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2007	15	23	7399	7407	17870545	10.1016/j.bmc.2007.07.058	The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors.	Lu X, Chen Y, Guo Y, Liu Z, Shi Y, Xu Y, Wang X, Zhang Z, Liu J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2007	17	1	260	265	17035019	10.1016/j.bmcl.2006.09.047	4-Aminopyrimidines as novel HIV-1 inhibitors.	Gadhachanda VR, Wu B, Wang Z, Kuhen KL, Caldwell J, Zondler H, Walter H, Havenhand M, He Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2007	17	7	1956	1960	17276064	10.1016/j.bmcl.2007.01.025	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.	Barreca ML, Rao A, De Luca L, Iraci N, Monforte AM, Maga G, De Clercq E, Pannecouque C, Balzarini J, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Biol. Chem.	2007	282	11	8005	8010	17172472	10.1074/jbc.m608274200	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.	Grobler JA, Dornadula G, Rice MR, Simcoe AL, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Metab. Dispos.	2007	35	3	340	344	17172311	10.1124/dmd.106.012765	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.	Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2007	42	5	567	579	17223230	10.1016/j.ejmech.2006.11.014	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.	Mordant C, Schmitt B, Pasquier E, Demestre C, Queguiner L, Masungi C, Peeters A, Smeulders L, Bettens E, Hertogs K, Heeres J, Lewi P, Guillemont J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2007	42	7	993	1003	17321639	10.1016/j.ejmech.2007.01.003	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.	Balzarini J, Orzeszko B, Maurin JK, Orzeszko A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	10	2370	2384	17458947	10.1021/jm0613121	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.	Herschhorn A, Lerman L, Weitman M, Gleenberg IO, Nudelman A, Hizi A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	17	4003	4015	17663538	10.1021/jm060103d	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.	Morningstar ML, Roth T, Farnsworth DW, Smith MK, Watson K, Buckheit RW, Das K, Zhang W, Arnold E, Julias JG, Hughes SH, Michejda CJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	20	4854	4867	17803290	10.1021/jm070382k	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.	Cullen MD, Deng BL, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, Clercq ED, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	20	5034	5038	17803291	10.1021/jm070488f	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.	Regina GL, Coluccia A, Piscitelli F, Bergamini A, Sinistro A, Cavazza A, Maga G, Samuele A, Zanoli S, Novellino E, Artico M, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	22	5324	5329	17918923	10.1021/jm070683u	From docking false-positive to active anti-HIV agent.	Barreiro G, Kim JT, Guimarães CR, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	22	5412	5424	17910429	10.1021/jm070811e	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.	Mai A, Artico M, Rotili D, Tarantino D, Clotet-Codina I, Armand-Ugón M, Ragno R, Simeoni S, Sbardella G, Nawrozkij MB, Samuele A, Maga G, Esté JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	26	6580	6595	18052319	10.1021/jm0708230	Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.	Mugnaini C, Alongi M, Togninelli A, Gevariya H, Brizzi A, Manetti F, Bernardini C, Angeli L, Tafi A, Bellucci L, Corelli F, Massa S, Maga G, Samuele A, Facchini M, Clotet-Codina I, Armand-Ugón M, Esté JA, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2007	50	8	1778	1786	17381078	10.1021/jm061167r	Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ji L, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2007	51	11	3870	3879	17724147	10.1128/aac.00692-07	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.	Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2007	51	2	429	437	17116677	10.1128/aac.01032-06	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.	Zhang Z, Xu W, Koh YH, Shim JH, Girardet JL, Yeh LT, Hamatake RK, Hong Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2007	51	2	638	644	17116672	10.1128/aac.00749-06	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.	Aguiar RS, Costa LJ, Pereira HS, Brindeiro RM, Tanuri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2007	51	7	2600	2604	17470654	10.1128/aac.00212-07	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.	Shi M, Wang X, De Clercq E, Takao S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2008	16	1	157	163	17964796	10.1016/j.bmc.2007.10.013	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).	Lin Y, Liu X, Yan R, Li J, Pannecouque C, Witvrouw M, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2008	16	15	7429	7435	18585918	10.1016/j.bmc.2008.06.012	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.	Monforte AM, Rao A, Logoteta P, Ferro S, De Luca L, Barreca ML, Iraci N, Maga G, De Clercq E, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2008	16	21	9487	9497	18835718	10.1016/j.bmc.2008.09.051	Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.	Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2008	18	2	469	473	18083556	10.1016/j.bmcl.2007.11.114	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.	Cullen MD, Sarkar T, Hamel E, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2008	18	20	5368	5371	18824350	10.1016/j.bmcl.2008.09.055	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Zhan P, Liu X, Cao Y, Wang Y, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2008	18	21	5777	5777	18842407	10.1016/j.bmcl.2008.09.070	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.	Radi M, Angeli L, Franchi L, Contemori L, Maga G, Samuele A, Zanoli S, Armand-Ugon M, Gonzalez E, Llano A, Esté JA, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2008	18	4	1530	1533	18222088	10.1016/j.bmcl.2007.12.015	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.	Cullen MD, Cheung YF, Houslay MD, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2008	43	12	2800	2806	18242784	10.1016/j.ejmech.2007.12.015	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.	Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2008	43	6	1230	1236	17869386	10.1016/j.ejmech.2007.08.001	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.	Xiong YZ, Chen FE, Balzarini J, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	10	3035	3039	18396854	10.1021/jm701587d	Molecular characteristics for solid-state limited solubility.	Wassvik CM, Holmén AG, Draheim R, Artursson P, Bergström CA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	15	4641	4652	18630898	10.1021/jm800340w	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.	Nawrozkij MB, Rotili D, Tarantino D, Botta G, Eremiychuk AS, Musmuca I, Ragno R, Samuele A, Zanoli S, Armand-Ugón M, Clotet-Codina I, Novakov IA, Orlinson BS, Maga G, Esté JA, Artico M, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	16	5000	5008	18665583	10.1021/jm8004493	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, Boone L, Chan JH, Stammers DK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	18	5702	5713	18800765	10.1021/jm800473d	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.	Herschhorn A, Hizi A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2008	51	24	7689	7696	19053755	10.1021/jm8003009	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).	Xie L, Guo HF, Lu H, Zhuang XM, Zhang AM, Wu G, Ruan JX, Zhou T, Yu D, Qian K, Lee KH, Jiang S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2008	52	6	2069	2078	18378713	10.1128/aac.00911-07	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.	Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2009	17	16	5775	5781	19643613	10.1016/j.bmc.2009.07.028	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Zhu J, Fang Z, Li Z, Pannecouque C, Clercq ED.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2009	17	16	5962	5967	19616956	10.1016/j.bmc.2009.06.068	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.	Monforte AM, Logoteta P, Ferro S, De Luca L, Iraci N, Maga G, Clercq ED, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2009	17	2	667	674	19091580	10.1016/j.bmc.2008.11.056	Studies on anti-HIV quinolones: new insights on the C-6 position.	Massari S, Daelemans D, Manfroni G, Sabatini S, Tabarrini O, Pannecouque C, Cecchetti V.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2009	44	1	303	311	18420310	10.1016/j.ejmech.2008.02.039	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.	Balzarini J, Orzeszko-Krzesi¿ska B, Maurin JK, Orzeszko A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2009	44	11	4648	4653	19628308	10.1016/j.ejmech.2009.06.037	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Fang Z, Li Z, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2009	44	12	5117	5122	19775780	10.1016/j.ejmech.2009.08.012	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.	Carta A, Pricl S, Piras S, Fermeglia M, La Colla P, Loddo R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2009	44	3	1210	1214	18952324	10.1016/j.ejmech.2008.09.013	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Deng BL, Zhao Y, Hartman TL, Watson K, Buckheit RW, Pannecouque C, De Clercq E, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	12	3636	3643	19469474	10.1021/jm801438e	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.	Le Van K, Cauvin C, de Walque S, Georges B, Boland S, Martinelli V, Demonté D, Durant F, Hevesi L, Van Lint C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	20	6467	6473	19775161	10.1021/jm901167t	Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.	Cullen MD, Ho WC, Bauman JD, Das K, Arnold E, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	23	7473	7487	19645483	10.1021/jm900802y	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.	Guillemont J, Benjahad A, Oumouch S, Decrane L, Palandjian P, Vernier D, Queguiner L, Andries K, de Béthune MP, Hertogs K, Grierson DS, Nguyen CH.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	3	840	851	19140683	10.1021/jm801330n	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.	Radi M, Maga G, Alongi M, Angeli L, Samuele A, Zanoli S, Bellucci L, Tafi A, Casaluce G, Giorgi G, Armand-Ugon M, Gonzalez E, Esté JA, Baltzinger M, Bec G, Dumas P, Ennifar E, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	4	1224	1228	19170521	10.1021/jm801395v	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.	Butini S, Brindisi M, Cosconati S, Marinelli L, Borrelli G, Coccone SS, Ramunno A, Campiani G, Novellino E, Zanoli S, Samuele A, Giorgi G, Bergamini A, Di Mattia M, Lalli S, Galletti B, Gemma S, Maga G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2009	52	7	1922	1934	19281225	10.1021/jm801470b	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.	Piscitelli F, Coluccia A, Brancale A, La Regina G, Sansone A, Giordano C, Balzarini J, Maga G, Zanoli S, Samuele A, Cirilli R, La Torre F, Lavecchia A, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	11	4667	4672	19704127	10.1128/aac.00800-09	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.	Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	2	487	495	19029331	10.1128/aac.01156-08	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.	Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	6	2367	2374	19307360	10.1128/aac.01523-08	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.	Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	6	2424	2431	19289522	10.1128/aac.01559-08	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.	Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2009	53	8	3606	3607	19487448	10.1128/aac.01583-08	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.	Jackson JB, Dick J, Tekle T, Simmons A, Carroll KC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	13	4601	4605	20570527	10.1016/j.bmc.2010.05.036	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.	Liang YH, He QQ, Zeng ZS, Liu ZQ, Feng XQ, Chen FE, Balzarini J, Pannecouque C, Clercq ED.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	14	5039	5047	20598556	10.1016/j.bmc.2010.05.081	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.	Zeng ZS, He QQ, Liang YH, Feng XQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	16	6012	6023	20638854	10.1016/j.bmc.2010.06.067	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.	Casano G, Dumètre A, Pannecouque C, Hutter S, Azas N, Robin M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	4	1702	1710	20097079	10.1016/j.bmc.2009.12.059	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Monforte AM, Logoteta P, De Luca L, Iraci N, Ferro S, Maga G, De Clercq E, Pannecouque C, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	5	2029	2036	20137956	10.1016/j.bmc.2010.01.023	Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.	Chauthe SK, Bharate SB, Sabde S, Mitra D, Bhutani KK, Singh IP.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	7	2370	2374	20307984	10.1016/j.bmc.2010.03.007	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.	Feng XQ, Zeng ZS, Liang YH, Chen FE, Pannecouque C, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	9	3198	3211	20381364	10.1016/j.bmc.2010.03.030	Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies.	Pawar V, Lokwani D, Bhandari S, Mitra D, Sabde S, Bothara K, Madgulkar A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2010	18	9	3231	3237	20371182	10.1016/j.bmc.2010.03.025	Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Qin H, Liu C, Guo Y, Wang R, Zhang J, Ma L, Zhang Z, Wang X, Cui Y, Liu J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2010	19	7	652	663		10.1007/s00044-009-9220-x	Synthesis and anti-HIV activity evaluation of novel N-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides	Zhan P, Liu H, Liu X, Wang Y, Pannecouque C, Witvrouw M, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2010	20	22	6592	6596	20888224	10.1016/j.bmcl.2010.09.034	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.	Liu B, Lee Y, Zou J, Petrassi HM, Joseph RW, Chao W, Michelotti EL, Bukhtiyarova M, Springman EB, Dorsey BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2010	20	8	2485	2488	20304641	10.1016/j.bmcl.2010.03.006	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.	Leung CS, Zeevaart JG, Domaoal RA, Bollini M, Thakur VV, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2010	20	9	3003	3005	20347295	10.1016/j.bmcl.2009.04.051	Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Qin H, Liu C, Zhang J, Guo Y, Zhang S, Zhang Z, Wang X, Zhang L, Liu J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2010	45	9	4096	4103	20598780	10.1016/j.ejmech.2010.05.070	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.	Dong MX, Zhang J, Peng XQ, Lu H, Yun LH, Jiang S, Dai QY.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2010	53	13	4906	4916	20527972	10.1021/jm1002952	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.	Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L, Qian K, Chen CH, Huang R, Jiang S, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2010	53	3	1397	1401	20050672	10.1021/jm901653e	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.	Xue H, Lu X, Zheng P, Liu L, Han C, Hu J, Liu Z, Ma T, Li Y, Wang L, Chen Z, Liu G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2010	53	9	3480	3488	20377249	10.1021/jm100093p	"""Viologen"" dendrimers as antiviral agents: the effect of charge number and distance."	Asaftei S, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	10	4451	4463	20660667	10.1128/aac.01455-09	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.	Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	2	718	727	19933797	10.1128/aac.00986-09	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.	Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	2	728	733	20008779	10.1128/aac.01335-09	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.	Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	4	1596	1602	20124001	10.1128/aac.01480-09	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.	Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	5	1973	1980	20194692	10.1128/aac.00870-09	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.	Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2010	54	6	2401	2408	20308384	10.1128/aac.01795-09	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.	Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	14	4227	4237	21700466	10.1016/j.bmc.2011.05.062	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.	Bode ML, Gravestock D, Moleele SS, van der Westhuyzen CW, Pelly SC, Steenkamp PA, Hoppe HC, Khan T, Nkabinde LA.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	14	4366	4376	21683601	10.1016/j.bmc.2011.05.024	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhang J, Zhan P, Wu J, Li Z, Jiang Y, Ge W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	17	5117	5124	21824782	10.1016/j.bmc.2011.07.023	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.	Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	19	5794	5802	21903401	10.1016/j.bmc.2011.08.025	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.	Novikov MS, Ivanova ON, Ivanov AV, Ozerov AA, Valuev-Elliston VT, Temburnikar K, Gurskaya GV, Kochetkov SN, Pannecouque C, Balzarini J, Seley-Radtke KL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	22	6919	6926	21982685	10.1016/j.bmc.2011.09.018	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Murugesan V, Tiwari VS, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Makwana N, Suryawanshi R, Katti SB.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	23	7093	7099	22037050	10.1016/j.bmc.2011.10.002	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.	Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	6	2084	2089	21334901	10.1016/j.bmc.2011.01.024	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.	Balestrieri E, Pizzimenti F, Ferlazzo A, Giofrè SV, Iannazzo D, Piperno A, Romeo R, Chiacchio MA, Mastino A, Macchi B.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2011	21	13	3935	3938	21636271	10.1016/j.bmcl.2011.05.020	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.	Butini S, Gemma S, Brindisi M, Borrelli G, Fiorini I, Samuele A, Karytinos A, Facchini M, Lossani A, Zanoli S, Campiani G, Novellino E, Focher F, Maga G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2011	21	2	694	697	21194939	10.1016/j.bmcl.2010.12.003	Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.	He YP, Long J, Zhang SS, Li C, Lai CC, Zhang CS, Li DX, Zhang DH, Wang H, Cai QQ, Zheng YT.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2011	21	8	2406	2409	21414776	10.1016/j.bmcl.2011.02.074	Asymmetric total synthesis of (+)- and (-)-clusianone and (+)- and (-)-clusianone methyl enol ether via ACC alkylation and evaluation of their anti-HIV activity.	Garnsey MR, Matous JA, Kwiek JJ, Coltart DM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Metab. Dispos.	2011	39	7	1247	1254	21467212	10.1124/dmd.111.039180	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.	Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2011	46	1	106	121	21093117	10.1016/j.ejmech.2010.10.020	Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.	Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya M, Sriram D.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2011	46	4	1045	1049	21295891	10.1016/j.ejmech.2011.01.016	Synthesis of 9-substituted derivatives of berberine as anti-HIV agents.	Bodiwala HS, Sabde S, Mitra D, Bhutani KK, Singh IP.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2011	54	16	5927	5936	21755950	10.1021/jm200734j	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.	Sbardella G, Mai A, Bartolini S, Castellano S, Cirilli R, Rotili D, Milite C, Santoriello M, Orlando S, Sciamanna I, Serafino A, Lavia P, Spadafora C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2011	54	24	8582	8591	22081993	10.1021/jm201134m	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.	Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2011	54	6	1587	1598	21366296	10.1021/jm101614j	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Gatti V, Maga G, Samuele A, Pannecouque C, Schols D, Balzarini J, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2011	54	8	3091	3096	21438533	10.1021/jm101626c	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.	Rotili D, Tarantino D, Artico M, Nawrozkij MB, Gonzalez-Ortega E, Clotet B, Samuele A, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2011	55	1	42	49	21060108	10.1128/aac.01064-10	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.	Koh Y, Haim H, Engelman A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Antimicrob. Agents Chemother.	2011	55	3	1282	1284	21189339	10.1128/aac.01527-10	Interaction potential of etravirine with drug transporters assessed in vitro.	Zembruski NC, Haefeli WE, Weiss J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2012	20	18	5527	5536	22883027	10.1016/j.bmc.2012.07.026	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Zhan P, Liu H, Li D, Wang L, Chen X, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2012	20	23	6795	6802	23098609	10.1016/j.bmc.2012.09.058	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.	Zhan P, Chen W, Li Z, Li X, Chen X, Tian Y, Pannecouque C, Clercq ED, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2012	20	9	3119	3127	22480850	10.1016/j.bmc.2012.02.037	Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Mokale SN, Lokwani D, Shinde DB.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2012	21	7	1451	1470		10.1007/s00044-011-9662-9	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2012	21	8	1557	1576		10.1007/s00044-011-9664-7	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives	Narang R, Narasimhan B, Sharma S, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2012	21	8	1935	1952		10.1007/s00044-011-9705-2	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2012	21	9	2526	2547		10.1007/s00044-011-9776-0	(Naphthalen-1-yloxy)-acetic acid benzylidene/(1-phenyl-ethylidene)-hydrazide derivatives: synthesis, antimicrobial evaluation, and QSAR studies	Narang R, Narasimhan B, Sharma S
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2012	22	23	7155	7162	23084898	10.1016/j.bmcl.2012.09.062	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.	Zhan P, Li X, Li Z, Chen X, Tian Y, Chen W, Liu X, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2012	22	4	1565	1568	22269110	10.1016/j.bmcl.2011.12.132	Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.	Ekkati AR, Bollini M, Domaoal RA, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2012	22	5	2119	2124	22305583	10.1016/j.bmcl.2011.12.090	Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.	Kim J, Park C, Ok T, So W, Jo M, Seo M, Kim Y, Sohn JH, Park Y, Ju MK, Kim J, Han SJ, Kim TH, Cechetto J, Nam J, Sommer P, No Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2012	22	7	2522	2526	22374216	10.1016/j.bmcl.2012.01.133	A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability.	Kim J, Ok T, Park C, So W, Jo M, Kim Y, Seo M, Lee D, Jo S, Ko Y, Choi I, Park Y, Yoon J, Ju MK, Ahn J, Kim J, Han SJ, Kim TH, Cechetto J, Nam J, Liuzzi M, Sommer P, No Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	ACS Med. Chem. Lett.	2012	3	6	470	475	24900496	10.1021/ml3000462	Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.	Hassam M, Basson AE, Liotta DC, Morris L, van Otterlo WA, Pelly SC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	ACS Med. Chem. Lett.	2012	3	8	678	682	24900529	10.1021/ml300146q	Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.	Kim J, Lee D, Park C, So W, Jo M, Ok T, Kwon J, Kong S, Jo S, Kim Y, Choi J, Kim HC, Ko Y, Choi I, Park Y, Yoon J, Ju MK, Kim J, Han SJ, Kim TH, Cechetto J, Nam J, Sommer P, Liuzzi M, Lee J, No Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Metab. Dispos.	2012	40	2	397	406	22096083	10.1124/dmd.111.041665	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.	Farrell TL, Poquet L, Dew TP, Barber S, Williamson G.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2012	53		229	234	22575532	10.1016/j.ejmech.2012.04.004	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.	Gu SX, Li ZM, Ma XD, Yang SQ, He QQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2012	54		159	174	22652226	10.1016/j.ejmech.2012.04.038	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.	Puig-de-la-Bellacasa R, Giménez L, Pettersson S, Pascual R, Gonzalo E, Esté JA, Clotet B, Borrell JI, Teixidó J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2012	55	14	6634	6638	22712652	10.1021/jm300477h	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Famiglini V, Cosconati S, Maga G, Samuele A, Gonzalez E, Clotet B, Schols D, Esté JA, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2012	55	5	2242	2250	22283377	10.1021/jm201506e	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.	Wang X, Zhang J, Huang Y, Wang R, Zhang L, Qiao K, Li L, Liu C, Ouyang Y, Xu W, Zhang Z, Zhang L, Shao Y, Jiang S, Ma L, Liu J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2012	55	7	3558	3562	22428851	10.1021/jm201308v	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.	Rotili D, Samuele A, Tarantino D, Ragno R, Musmuca I, Ballante F, Botta G, Morera L, Pierini M, Cirilli R, Nawrozkij MB, Gonzalez E, Clotet B, Artico M, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2012	55		195	204	22871486	10.1016/j.ejmech.2012.07.018	One pot efficient diversity oriented synthesis of polyfunctional styryl thiazolopyrimidines and their bio-evaluation as antimalarial and anti-HIV agents.	Fatima S, Sharma A, Saxena R, Tripathi R, Shukla SK, Pandey SK, Tripathi R, Tripathi RP.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2012	58		485	492	23159806	10.1016/j.ejmech.2012.10.036	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.	Ribone SR, Leen V, Madrid M, Dehaen W, Daelemans D, Pannecouque C, Briñón MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	18	5900	5906	23916148	10.1016/j.bmc.2013.06.061	Synthesis and evaluation of novel 3-(3,5-dimethylbenzyl)uracil analogs as potential anti-HIV-1 agents.	Sakakibara N, Hamasaki T, Baba M, Demizu Y, Kurihara M, Irie K, Iwai M, Asada E, Kato Y, Maruyama T.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	22	7091	7100	24119448	10.1016/j.bmc.2013.09.009	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.	Chen W, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Jiang X, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	23	7398	7405	24134904	10.1016/j.bmc.2013.09.051	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.	Rai D, Chen W, Tian Y, Chen X, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	5	1150	1158	23357038	10.1016/j.bmc.2012.12.027	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.	Novikov MS, Valuev-Elliston VT, Babkov DA, Paramonova MP, Ivanov AV, Gavryushov SA, Khandazhinskaya AL, Kochetkov SN, Pannecouque C, Andrei G, Snoeck R, Balzarini J, Seley-Radtke KL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2013	21	7	2128	2134	23415090	10.1016/j.bmc.2012.12.049	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.	Li D, Zhan P, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2013	22	10	4633	4640		10.1007/s00044-012-0463-6	Synthesis, biological screening and ADME prediction of benzylindole derivatives as novel anti-HIV-1, anti-fungal and anti-bacterial agents	Kashid AM, Dube PN, Alkutkar PG, Bothara KG, Mokale SN, Dhawale SC
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2013	22	3	1320	1329		10.1007/s00044-012-0129-4	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles	Patel NB, Khan IH, Pannecouque C, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Med Chem Res	2013	22	3	1438	1449		10.1007/s00044-012-0143-6	Tautomeric origin of dual effects of N1-nicotinoyl-3-(4-hydroxy-3-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines on bacterial and viral strains: POM analyses as new efficient bioinformatics platform to predict and optimize bioactivity of drugs	Hadda TB, Ali MA, Masand V, Gharby S, Fergoug T, Warad I
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	1	153	157	23206860	10.1016/j.bmcl.2012.10.134	Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors.	Kim J, Kwon J, Lee D, Jo S, Park DS, Choi J, Park E, Hwang JY, Ko Y, Choi I, Ju MK, Ahn J, Kim J, Han SJ, Kim TH, Cechetto J, Nam J, Ahn S, Sommer P, Liuzzi M, No Z, Lee J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	18	5209	5212	23899617	10.1016/j.bmcl.2013.06.093	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.	Bollini M, Frey KM, Cisneros JA, Spasov KA, Das K, Bauman JD, Arnold E, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	18	5213	5216	23937980	10.1016/j.bmcl.2013.06.091	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.	Bollini M, Cisneros JA, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	24	6593	6597	24239481	10.1016/j.bmcl.2013.10.059	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Liu X, Meng Q, Wang D, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	4	1110	1113	23298809	10.1016/j.bmcl.2012.11.115	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.	Bollini M, Gallardo-Macias R, Spasov KA, Tirado-Rives J, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2013	23	5	1493	1497	23375792	10.1016/j.bmcl.2012.12.049	Synthesis and biological evaluation of phosphonate analogues of nevirapine.	Parrish J, Tong L, Wang M, Chen X, Lansdon EB, Cannizzaro C, Zheng X, Desai MC, Xu L.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	MedChemComm	2013	4	11	1443	1451		10.1039/C3MD00225J	Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase	Matyugina ES, Valuev-Elliston VT, Geisman AN, Novikov MS, Chizhov AO, Kochetkov SN, Seley-Radtke KL, Khandazhinskaya AL
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	MedChemComm	2013	4	4	741	748		10.1039/C3MD00036B	5-Nor carbocyclic nucleosides: unusual nonnucleoside inhibitors of HIV-1 reverse transcriptase	Matyugina ES, Valuev-Elliston VT, Babkov DA, Novikov MS, Ivanov AV, Kochetkov SN, Balzarini J, Seley-Radtke KL, Khandazhinskaya AL
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	MedChemComm	2013	4	5	810	816		10.1039/C3MD00028A	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach	Song Y, Zhan P, Kang D, Li X, Tian Y, Li Z, Chen X, Chen W, Pannecouque C, De Clercq E, Liu X
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2013	56	9	3593	3608	23540737	10.1021/jm400102x	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.	Li A, Ouyang Y, Wang Z, Cao Y, Liu X, Ran L, Li C, Li L, Zhang L, Qiao K, Xu W, Huang Y, Zhang Z, Tian C, Liu Z, Jiang S, Shao Y, Du Y, Ma L, Wang X, Liu J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2013	65		134	143	23707918	10.1016/j.ejmech.2013.04.052	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2013	76	12	2298	2306	24308675	10.1021/np400683h	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.	Ma X, Li L, Zhu T, Ba M, Li G, Gu Q, Guo Y, Li D.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2013	76	4	530	537	23550966	10.1021/np3006887	Cytotoxic, antitopoisomerase II¿, and anti-HIV-1 activities of triterpenoids isolated from leaves and twigs of Gardenia carinata.	Kongkum N, Tuchinda P, Pohmakotr M, Reutrakul V, Piyachaturawat P, Jariyawat S, Suksen K, Akkarawongsapat R, Kasisit J, Napaswad C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	1	633	642	24275349	10.1016/j.bmc.2013.10.033	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.	Zhang L, Zhan P, Chen X, Li Z, Xie Z, Zhao T, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	12	3159	3170	24794742	10.1016/j.bmc.2014.04.018	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Murugesan V, Makwana N, Suryawanshi R, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Katti SB.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	12	3220	3226	24794751	10.1016/j.bmc.2014.03.020	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	17	4658	4666	25127466	10.1016/j.bmc.2014.07.018	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.	Sancineto L, Iraci N, Barreca ML, Massari S, Manfroni G, Corazza G, Cecchetti V, Marcello A, Daelemans D, Pannecouque C, Tabarrini O.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	19	5241	5248	25199582	10.1016/j.bmc.2014.08.005	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.	Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	19	5290	5297	25150090	10.1016/j.bmc.2014.08.001	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Lu X, Chen W, Liu H, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	4	1459	1467	24457088	10.1016/j.bmc.2013.12.045	Design and synthesis of N¿-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.	Monforte AM, Ferro S, De Luca L, Lo Surdo G, Morreale F, Pannecouque C, Balzarini J, Chimirri A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	6	1863	1872	24581546	10.1016/j.bmc.2014.01.054	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.	Chen W, Zhan P, Rai D, De Clercq E, Pannecouque C, Balzarini J, Zhou Z, Liu H, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	7	2052	2059	24631361	10.1016/j.bmc.2014.02.029	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.	Tian Y, Du D, Rai D, Wang L, Liu H, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2014	22	8	2535	2541	24680058	10.1016/j.bmc.2014.02.030	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Huang XY, Wu HQ, Chen WX, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2014	24	18	4376	4380	25176191	10.1016/j.bmcl.2014.08.020	Novel indole based NNRTIs with improved potency against wild type and resistant HIV.	Müller R, Mulani I, Basson AE, Pribut N, Hassam M, Morris L, van Otterlo WA, Pelly SC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2014	24	18	4381	4383	25176328	10.1016/j.bmcl.2014.08.019	Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.	Pardo-Vargas A, Ramos FA, Cirne-Santos CC, Stephens PR, Paixão IC, Teixeira VL, Castellanos L.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2014	24	23	5473	5477	25455487	10.1016/j.bmcl.2014.10.007	Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.	Kim J, Kwon J, Lee D, Jo S, Park DS, Choi J, Park E, Hwang JY, Ko Y, Choi I, Ju MK, Ahn J, Kim J, Han SJ, Kim TH, Cechetto J, Nam J, Ahn S, Sommer P, Liuzzi M, Lee J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	ACS Med. Chem. Lett.	2014	5	11	1259	1262	25408842	10.1021/ml5003713	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.	Lee WG, Frey KM, Gallardo-Macias R, Spasov KA, Bollini M, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	MedChemComm	2014	5	4	441	444		10.1039/C3MD00337J	Synthesis and biological evaluation of novel quinoxalinone-based HIV-1 reverse transcriptase inhibitors	Zhou J, Ba M, Wang B, Zhou H, Bie J, Fu D, Cao Y, Xu B, Guo Y
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	MedChemComm	2014	5	4	468	473		10.1039/C3MD00247K	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase	Wu H, Pannecouque C, Yan Z, Chen W, He Q, Chen F, Balzarini J, Daelemans D, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2014	57	12	5169	5178	24805780	10.1021/jm500139a	Synthesis of novel fluoro analogues of MKC442 as microbicides.	Loksha YM, Pedersen EB, Loddo R, Sanna G, Collu G, Giliberti G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2014	57	12	5212	5225	24933420	10.1021/jm500284x	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.	Rotili D, Tarantino D, Nawrozkij MB, Babushkin AS, Botta G, Marrocco B, Cirilli R, Menta S, Badia R, Crespan E, Ballante F, Ragno R, Esté JA, Maga G, Mai A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2014	57	23	9945	9957	25418038	10.1021/jm5011622	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Riveira-Muñoz E, Esté JA, Ferretti R, Cirilli R, Zamperini C, Botta M, Schols D, Limongelli V, Agostino B, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	76		531	538	24602795	10.1016/j.ejmech.2014.02.047	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.	Wang J, Zhan P, Li Z, Liu H, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2014	77	12	2685	2693	25495797	10.1021/np5006955	Diterpenes from a Chinese collection of the brown alga Dictyota plectens.	Cheng S, Zhao M, Sun Z, Yuan W, Zhang S, Xiang Z, Cai Y, Dong J, Huang K, Yan P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2014	77	6	1505	1512	24926807	10.1021/np500271u	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.	Nothias-Scaglia LF, Retailleau P, Paolini J, Pannecouque C, Neyts J, Dumontet V, Roussi F, Leyssen P, Costa J, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	80		101	111	24769348	10.1016/j.ejmech.2014.04.027	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Clotet B, Esté JA, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	82		600	611	24952305	10.1016/j.ejmech.2014.05.059	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.	Meng G, Liu Y, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	85		27	42	25072874	10.1016/j.ejmech.2014.07.072	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.	Xu Z, Ba M, Zhou H, Cao Y, Tang C, Yang Y, He R, Liang Y, Zhang X, Li Z, Zhu L, Guo Y, Guo C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	85		293	303	25089812	10.1016/j.ejmech.2014.07.104	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.	Wang L, Tian Y, Chen W, Liu H, Zhan P, Li D, Liu H, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	101		640	650	26209833	10.1016/j.ejmech.2015.07.021	N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.	Bala V, Mandalapu D, Gupta S, Jangir S, Kushwaha B, Chhonker YS, Chandasana H, Krishna S, Rawat K, Krishna A, Singh M, Sankhwar SN, Shukla PK, Maikhuri JP, Bhatta RS, Siddiqi MI, Tripathi R, Gupta G, Sharma VL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	102		167	179	26276432	10.1016/j.ejmech.2015.07.043	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.	Li W, Li X, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	102		215	222	26276435	10.1016/j.ejmech.2015.08.007	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.	Wan ZY, Yao J, Mao TQ, Wang XL, Wang HF, Chen WX, Yin H, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	1	149	159	25468035	10.1016/j.bmc.2014.11.012	Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs.	Cao Y, Zhang Y, Wu S, Yang Q, Sun X, Zhao J, Pei F, Guo Y, Tian C, Zhang Z, Wang H, Ma L, Liu J, Wang X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	13	3860	3868	25907370	10.1016/j.bmc.2015.03.037	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.	Mao TQ, He QQ, Wan ZY, Chen WX, Chen FE, Tang GF, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	15	4248	4255	26162497	10.1016/j.bmc.2015.06.048	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Wan ZY, Tao Y, Wang YF, Mao TQ, Yin H, Chen FE, Piao HR, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	17	5247	5263	26116177	10.1016/j.bmc.2015.06.016	Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.	Patel RV, Park SW.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	20	6587	6593	26385446	10.1016/j.bmc.2015.09.020	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.	Gu SX, Qiao H, Zhu YY, Shu QC, Liu H, Ju XL, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2015	23	5	1069	1081	25638501	10.1016/j.bmc.2015.01.002	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.	Babkov DA, Valuev-Elliston VT, Paramonova MP, Ozerov AA, Ivanov AV, Chizhov AO, Khandazhinskaya AL, Kochetkov SN, Balzarini J, Daelemans D, Pannecouque C, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2015	25	4	881	886	25592712	10.1016/j.bmcl.2014.12.062	Dithiocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies.	Bala V, Jangir S, Mandalapu D, Gupta S, Chhonker YS, Lal N, Kushwaha B, Chandasana H, Krishna S, Rawat K, Maikhuri JP, Bhatta RS, Siddiqi MI, Tripathi R, Gupta G, Sharma VL.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2015	25	6	1232	1235	25682562	10.1016/j.bmcl.2015.01.058	Design, synthesis of new ß-carboline derivatives and their selective anti-HIV-2 activity.	Ashok P, Chander S, Balzarini J, Pannecouque C, Murugesan S.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2015	58	24	9601	9614	26613134	10.1021/acs.jmedchem.5b01183	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.	Sancineto L, Mariotti A, Bagnoli L, Marini F, Desantis J, Iraci N, Santi C, Pannecouque C, Tabarrini O.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2015	78	5	1119	1128	25946116	10.1021/acs.jnatprod.5b00116	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.	Olivon F, Palenzuela H, Girard-Valenciennes E, Neyts J, Pannecouque C, Roussi F, Grondin I, Leyssen P, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Nat. Prod.	2015	78	6	1243	1252	25970729	10.1021/acs.jnatprod.5b00025	Limonoids with Anti-HIV Activity from Cipadessa cinerascens.	Yu JH, Wang GC, Han YS, Wu Y, Wainberg MA, Yue JM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2015	97		1	9	25935383	10.1016/j.ejmech.2015.04.050	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wan ZY, Yao J, Tao Y, Mao TQ, Wang XL, Lu YP, Wang HF, Yin H, Wu Y, Chen FE, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2016	109		294	304	26802545	10.1016/j.ejmech.2015.11.039	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.	Yang J, Chen W, Kang D, Lu X, Li X, Liu Z, Huang B, Daelemans D, Pannecouque C, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur. J. Med. Chem.	2016	117		230	240	27105027	10.1016/j.ejmech.2016.04.019	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.	Patel SB, Patel BD, Pannecouque C, Bhatt HG.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur J Med Chem	2016	121		352	363	27267005	10.1016/j.ejmech.2016.05.054	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.	Chen W, Zhan P, Daelemans D, Yang J, Huang B, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur J Med Chem	2016	121		58	70	27214512	10.1016/j.ejmech.2016.05.017	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.	Kulaba¿ N, Tatar E, Bingöl Özakp¿nar Ö, Özsavc¿ D, Pannecouque C, De Clercq E, Küçükgüzel ¿.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur J Med Chem	2016	123		309	316	27484516	10.1016/j.ejmech.2016.07.047	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.	Xu Z, Guo J, Yang Y, Zhang M, Ba M, Li Z, Cao Y, He R, Yu M, Zhou H, Li X, Huang X, Guo Y, Guo C.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2016	24	11	2476	2485	27112451	10.1016/j.bmc.2016.04.010	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.	Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN, Pannecouque C, Naesens L, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2016	24	11	2519	2529	27108399	10.1016/j.bmc.2016.04.018	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Viira B, Selyutina A, García-Sosa AT, Karonen M, Sinkkonen J, Merits A, Maran U.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem	2016	24	21	5115	5126	27647368	10.1016/j.bmc.2016.08.029	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.	Hamdy AM, Khaddour Z, Al-Masoudi NA, Rahman Q, Hering-Junghans C, Villinger A, Langer P.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem.	2016	24	8	1653	1657	26964674	10.1016/j.bmc.2016.02.038	Antiretroviral (HIV-1) activity of azulene derivatives.	Peet J, Selyutina A, Bredihhin A.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg. Med. Chem. Lett.	2016	26	15	3700	3704	27287366	10.1016/j.bmcl.2016.05.082	Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.	Pribut N, Veale CG, Basson AE, van Otterlo WA, Pelly SC.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J Med Chem	2016	59	17	7991	8007	27541578	10.1021/acs.jmedchem.6b00738	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.	Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J. Med. Chem.	2016	59	6	2747	2759	26898379	10.1021/acs.jmedchem.5b01979	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.	Tintori C, Brai A, Dasso Lang MC, Deodato D, Greco AM, Bizzarri BM, Cascone L, Casian A, Zamperini C, Dreassi E, Crespan E, Maga G, Vanham G, Ceresola E, Canducci F, Ariën KK, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur J Med Chem	2017	126		190	201	27750153	10.1016/j.ejmech.2016.10.009	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.	Li X, Gao P, Huang B, Zhou Z, Yu Z, Yuan Z, Liu H, Pannecouque C, Daelemans D, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Eur J Med Chem	2017	130		209	222	28254696	10.1016/j.ejmech.2017.02.047	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.	Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem	2017	25	14	3861	3870	28559060	10.1016/j.bmc.2017.05.040	Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors.	Ferro S, Buemi MR, De Luca L, Agharbaoui FE, Pannecouque C, Monforte AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem	2017	25	16	4397	4406	28659246	10.1016/j.bmc.2017.06.022	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.	Huang B, Wang X, Liu X, Chen Z, Li W, Sun S, Liu H, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem	2017	25	23	6248	6265	28442262	10.1016/j.bmc.2017.03.061	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.	Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem	2017	25	8	2491	2497	28314514	10.1016/j.bmc.2017.03.009	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.	Lu HH, Xue P, Zhu YY, Ju XL, Zheng XJ, Zhang X, Xiao T, Pannecouque C, Li TT, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	Bioorg Med Chem Lett	2017	27	8	1640	1643	28314598	10.1016/j.bmcl.2017.03.009	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.	Xue P, Lu HH, Zhu YY, Ju XL, Pannecouque C, Zheng XJ, Liu GY, Zhang XL, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J Med Chem	2017	60	10	4424	4443	28481112	10.1021/acs.jmedchem.7b00332	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.	Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J Med Chem	2017	60	15	6528	6547	28628334	10.1021/acs.jmedchem.6b01906	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.	Famiglini V, La Regina G, Coluccia A, Masci D, Brancale A, Badia R, Riveira-Muñoz E, Esté JA, Crespan E, Brambilla A, Maga G, Catalano M, Limatola C, Formica FR, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57	J Med Chem	2017	60	7	3124	3153	28266845	10.1021/acs.jmedchem.7b00179	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.	Curreli F, Kwon YD, Belov DS, Ramesh RR, Kurkin AV, Altieri A, Kwong PD, Debnath AK.
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									DrugMatrix	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	NEVIRAPINE	CHEMBL57									WHO Anatomical Therapeutic Chemical Classification	
924.8000000000000000	9606	Homo sapiens	NILOTINIB HYDROCHLORIDE MONOHYDRATE	CHEMBL1201740									Unpublished dataset	
1923.9000000000000000	9606	Homo sapiens	NIVOCASAN	CHEMBL2105721									Unpublished dataset	
1923.9000000000000000	9606	Homo sapiens	NIVOCASAN	CHEMBL2105721									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2001	44	15	2490	2497	11448232	10.1021/jm0100990	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.	Lombardo F, Shalaeva MY, Tupper KA, Gao F.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2002	45	13	2867	2876	12061889	10.1021/jm0200409	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Antimicrob. Agents Chemother.	2010	54	9	3597	3604	20547797	10.1128/aac.00431-10	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.	Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	J. Med. Chem.	2015	58	21	8683	8693	26469301	10.1021/acs.jmedchem.5b01324	Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.	Zmuda F, Malviya G, Blair A, Boyd M, Chalmers AJ, Sutherland A, Pimlott SL.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									British National Formulary (72nd edition)	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									DrugMatrix	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									PubChem BioAssay data set	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	NIZATIDINE	CHEMBL3183075									WHO Anatomical Therapeutic Chemical Classification	
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607	J. Med. Chem.	1977	20	7	907	911	195057	10.1021/jm00217a008	Synthesis, structure, and reactivity of adenosine cyclic 3',5'-phosphate benzyl triesters.	Engels J, Schlaeger EJ.
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607	Bioorg. Med. Chem. Lett.	2014	24	11	2429	2432	24792462	10.1016/j.bmcl.2014.04.040	Vascular effects of diphenylmethoxypiperidine-derived dopamine uptake inhibitors.	Pulgar VM, Keith Harp J.
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607	Bioorg. Med. Chem. Lett.	2015	25	16	3368	3372	26087939	10.1016/j.bmcl.2015.05.049	Discovery of potent ¿1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives.	Suzuki S, Okano T, Horiuchi R, Hareyama N, Amikura K, Yamamoto N, Yoshizawa Y, Yagi M, Serizawa K, Hayashi R.
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607									PubChem BioAssay data set	
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607									Unpublished dataset	
886.9000000000000000	9606	Homo sapiens	NOREPINEPHRINE BITARTRATE	CHEMBL1356607									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
846.1250000000000000	9606	Homo sapiens	NRX195183	CHEMBL107430	Bioorg. Med. Chem. Lett.	2002	12	21	3145	3148	12372520	10.1016/s0960-894x(02)00647-9	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.	Beard RL, Duong TT, Teng M, Klein ES, Standevan AM, Chandraratna RA.
846.1250000000000000	9606	Homo sapiens	NRX195183	CHEMBL107430									Unpublished dataset	
896.6000000000000000	9606	Homo sapiens	NV-128	CHEMBL3545135									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	OLSALAZINE SODIUM	CHEMBL1201013									British National Formulary (72nd edition)	
943.5000000000000000	9606	Homo sapiens	OLSALAZINE SODIUM	CHEMBL1201013									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	OLSALAZINE SODIUM	CHEMBL1201013									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Bioorg. Med. Chem. Lett.	1997	7	5	567	572		10.1016/S0960-894X(97)00046-2	Molecular connectivity to find -blockers with low toxicity	Garcia-Domenech R, de Gregorio Alapont C, de Julian-Ortiz J, Galvez J, Popa L
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Jpn. J. Pharmacol.	2002	88	1	69	76	11855680	10.1254/jjp.88.69	Human organic anion transporters mediate the transport of tetracycline.	Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	J Pesticide Sci	2003	28	2	183	187		10.1584/jpestics.28.183	Effect of Antibiotics on Formation of Aerial Mycelium and Production of Phytotoxins in Streptomyces spp.	NATSUME M, MATSUMOTO M, OHSHIRO A, KOZONE I, HASHIMOTO M, ABE H
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Antimicrob. Agents Chemother.	2007	51	9	3452	3454	17638695	10.1128/aac.00420-07	In vitro susceptibilities of Mycoplasma putrefaciens field isolates.	Antunes NT, Tavío MM, Mercier P, Ayling RD, Al-Momani W, Assunção P, Rosales RS, Poveda JB.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Med Chem Res	2008	17	8	475	486		10.1007/s00044-007-9020-0	Study of the inactivation of copper, zinc superoxide dismutase by tetracycline analogues	Wei W, Wang H, Jiang C
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Antimicrob. Agents Chemother.	2010	54	12	5406	5412	20855745	10.1128/aac.00580-10	LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.	Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Pest Manag Sci	2010	66	6	634	639	20151406	10.1002/ps.1920	Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.	Kwon HR, Choi GJ, Choi YH, Jang KS, Sung ND, Kang MS, Moon Y, Lee SK, Kim JC.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Med Chem Res	2012	21	10	3140	3145		10.1007/s00044-011-9845-4	Production and optimization of oxytetracycline by a new isolate Streptomyces rimosus using response surface methodology	Singh N, Rai V, Tripathi CKM
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Bioorg. Med. Chem.	2015	23	17	5334	5344	26264847	10.1016/j.bmc.2015.07.062	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.	Tran TP, Vo DD, Di Giorgio A, Duca M.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517	J Nat Prod	2016	79	6	1684	1688	27231731	10.1021/acs.jnatprod.6b00194	Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.	Richter C, Helaly SE, Thongbai B, Hyde KD, Stadler M.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									DrugMatrix	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									Unpublished dataset	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE	CHEMBL1517									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE CALCIUM	CHEMBL3989568									Unpublished dataset	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE CALCIUM	CHEMBL3989568									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2012	75	4	768	770	22497473	10.1021/np200776v	Hyaladione, an S-methyl cyclohexadiene-dione from Hyalangium minutum.	Okanya PW, Mohr KI, Gerth K, Steinmetz H, Huch V, Jansen R, Müller R.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2013	76	11	2141	2144	24175638	10.1021/np400609f	Gymnopalynes A and B, chloropropynyl-isocoumarin antibiotics from cultures of the basidiomycete Gymnopus sp.	Thongbai B, Surup F, Mohr K, Kuhnert E, Hyde KD, Stadler M.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	Bioorg. Med. Chem. Lett.	2014	24	4	1080	1084	24468412	10.1016/j.bmcl.2014.01.014	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.	Shea TA, Burburan PJ, Matubia VN, Ramcharan SS, Rosario I, Parkin DW, Stockman BJ.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2014	77	11	2545	2552	25397992	10.1021/np500632c	Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.	Jansen R, Sood S, Mohr KI, Kunze B, Irschik H, Stadler M, Müller R.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2014	77	2	320	326	24460410	10.1021/np400877r	Pyrronazols, metabolites from the myxobacteria Nannocystis pusilla and N. exedens, are unusual chlorinated pyrone-oxazole-pyrroles.	Jansen R, Sood S, Huch V, Kunze B, Stadler M, Müller R.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2014	77	4	1054	1060	24697522	10.1021/np500144t	Indothiazinone, an indolyl thiazolyl ketone from a novel myxobacterium belonging to the Sorangiineae.	Jansen R, Mohr KI, Bernecker S, Stadler M, Müller R.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480	J. Nat. Prod.	2015	78	4	934	938	25871540	10.1021/np5010104	Deconins A-E: Cuparenic and Mevalonic or Propionic Acid Conjugates from the Basidiomycete Deconica sp. 471.	Surup F, Thongbai B, Kuhnert E, Sudarman E, Hyde KD, Stadler M.
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480									Unpublished dataset	
2219.8000000000000000	2	Bacteria	OXYTETRACYCLINE HYDROCHLORIDE	CHEMBL1607480									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	PANOBINOSTAT LACTATE	CHEMBL3545368									Unpublished dataset	
886.3666666666666667	9606	Homo sapiens	PARATHYROID HORMONE	CHEMBL2108078									British National Formulary (72nd edition)	
886.3666666666666667	9606	Homo sapiens	PARATHYROID HORMONE	CHEMBL2108078									Unpublished dataset	
886.3666666666666667	9606	Homo sapiens	PARATHYROID HORMONE	CHEMBL2108078									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.3666666666666667	9606	Homo sapiens	PARATHYROID HORMONE	CHEMBL2108078									WHO Anatomical Therapeutic Chemical Classification	
886.5000000000000000	9606	Homo sapiens	PARECOXIB	CHEMBL1206690	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	PARECOXIB	CHEMBL1206690	Bioorg. Med. Chem. Lett.	2011	21	22	6636	6640	21983446	10.1016/j.bmcl.2011.09.071	A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.	Ruiz JF, Kedziora K, Keogh B, Maguire J, Reilly M, Windle H, Kelleher DP, Gilmer JF.
886.5000000000000000	9606	Homo sapiens	PARECOXIB	CHEMBL1206690	J Med Chem	2017	60	13	5235	5266	28252961	10.1021/acs.jmedchem.6b01287	Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.	Proschak E, Heitel P, Kalinowsky L, Merk D.
886.5000000000000000	9606	Homo sapiens	PARECOXIB	CHEMBL1206690									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	PARECOXIB	CHEMBL1206690									WHO Anatomical Therapeutic Chemical Classification	
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913	J. Med. Chem.	2000	43	9	1661	1663	10794682	10.1021/jm000069h	N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.	Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K.
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913	J. Med. Chem.	2003	46	19	3975	3984	12954051	10.1021/jm020563g	Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.	Pal M, Madan M, Padakanti S, Pattabiraman VR, Kalleda S, Vanguri A, Mullangi R, Mamidi NV, Casturi SR, Malde A, Gopalakrishnan B, Yeleswarapu KR.
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913	J. Med. Chem.	2004	47	22	5579	5582	15481993	10.1021/jm040844j	New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs.	Almansa C, Bartrolí J, Belloc J, Cavalcanti FL, Ferrando R, Gómez LA, Ramis I, Carceller E, Merlos M, García-Rafanell J.
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913	Bioorg. Med. Chem. Lett.	2006	16	15	3921	3926	16730986	10.1016/j.bmcl.2006.05.028	N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.	Singh SK, Vobbalareddy S, Kalleda SR, Casturi SR, Mullangi R, Ramanujam R, Yeleswarapu KR, Iqbal J.
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913	Bioorg. Med. Chem. Lett.	2006	16	17	4483	4487	16806914	10.1016/j.bmcl.2006.06.032	Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.	Navidpour L, Amini M, Shafaroodi H, Abdi K, Ghahremani MH, Dehpour AR, Shafiee A.
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	PARECOXIB SODIUM	CHEMBL296913									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	Bioorg. Med. Chem. Lett.	2006	16	24	6310	6315	16997553	10.1016/j.bmcl.2006.09.013	Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.	Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, Ben-Yosef T, Baasov T.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	MedChemComm	2011	2	3	165	171		10.1039/C0MD00195C	Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations	Kandasamy J, Atia-Glikin D, Belakhov V, Baasov T
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	J. Med. Chem.	2012	55	23	10630	10643	23148581	10.1021/jm3012992	Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.	Kandasamy J, Atia-Glikin D, Shulman E, Shapira K, Shavit M, Belakhov V, Baasov T.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196									Unpublished dataset	
2219.8000000000000000	2	Bacteria	PAROMOMYCIN SULFATE	CHEMBL2206196									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Biochem. J.	2007	408	3	297	315	17850214	10.1042/bj20070797	The selectivity of protein kinase inhibitors: a further update.	Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem. Lett.	2008	18	24	6501	6504	18952427	10.1016/j.bmcl.2008.10.054	The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.	Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Nat. Chem. Biol.	2010	6	2	102	104	20081824	10.1038/nchembio.282	Chemical reprogramming of Caenorhabditis elegans germ cell fate.	Morgan CT, Lee MH, Kimble J.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem. Lett.	2011	21	6	1795	1801	21316218	10.1016/j.bmcl.2011.01.062	Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.	Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schück V, Shimma N.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem. Lett.	2013	23	8	2384	2390	23474388	10.1016/j.bmcl.2013.02.028	Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.	Hartung IV, Hitchcock M, Pühler F, Neuhaus R, Scholz A, Hammer S, Petersen K, Siemeister G, Brittain D, Hillig RC.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	J. Med. Chem.	2013	56	5	1996	2015	23398453	10.1021/jm301658d	Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.	Vasbinder MM, Aquila B, Augustin M, Chen H, Cheung T, Cook D, Drew L, Fauber BP, Glossop S, Grondine M, Hennessy E, Johannes J, Lee S, Lyne P, Mörtl M, Omer C, Palakurthi S, Pontz T, Read J, Sha L, Shen M, Steinbacher S, Wang H, Wu A, Ye M.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361		2013							5-substituted-2-phenylamino benzamides as MEK inhibitors	
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	J. Med. Chem.	2014	57	21	8817	8826	25313996	10.1021/jm500847m	Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.	Deng Y, Shipps GW, Cooper A, English JM, Annis DA, Carr D, Nan Y, Wang T, Zhu HY, Chuang CC, Dayananth P, Hruza AW, Xiao L, Jin W, Kirschmeier P, Windsor WT, Samatar AA.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem.	2015	23	7	1386	1394	25766633	10.1016/j.bmc.2015.02.053	Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.	Van Dort ME, Galbán S, Wang H, Sebolt-Leopold J, Whitehead C, Hong H, Rehemtulla A, Ross BD.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem.	2016	24	16	3472	3482	27288186	10.1016/j.bmc.2016.05.055	Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents.	Sun J, Niu Y, Wang C, Zhang H, Xie B, Xu F, Jin H, Peng Y, Liang L, Xu P.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Bioorg. Med. Chem. Lett.	2016	26	1	186	193	26611920	10.1016/j.bmcl.2015.11.004	Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.	Hartung IV, Hammer S, Hitchcock M, Neuhaus R, Scholz A, Siemeister G, Bohlmann R, Hillig RC, Pühler F.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	J Med Chem	2016	59	16	7544	7560	27502541	10.1021/acs.jmedchem.6b00598	Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.	Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	J. Med. Chem.	2016	59	6	2512	2522	26943489	10.1021/acs.jmedchem.5b01655	Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).	Van Dort ME, Hong H, Wang H, Nino CA, Lombardi RL, Blanks AE, Galbán S, Ross BD.
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	PD-0325901	CHEMBL507361									Unpublished dataset	
1132.5000000000000000	9606	Homo sapiens	PEFICITINIB	CHEMBL3137308	J. Med. Chem.	2015	58	18	7596	7602	26351728	10.1021/acs.jmedchem.5b01263	Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.	Kim MK, Shin H, Park KS, Kim H, Park J, Kim K, Nam J, Choo H, Chong Y.
1132.5000000000000000	9606	Homo sapiens	PEFICITINIB	CHEMBL3137308									Unpublished dataset	
1132.5000000000000000	9606	Homo sapiens	PEFICITINIB	CHEMBL3137308									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PENICILLIN G BENZATHINE	CHEMBL3989515									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	PENICILLIN G BENZATHINE	CHEMBL3989515									Unpublished dataset	
962.7500000000000000	2	Bacteria	PENICILLIN G BENZATHINE	CHEMBL3989515									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PENICILLIN G BENZATHINE	CHEMBL3989515									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223	J. Nat. Prod.	1997	60	10	967	970	9358636	10.1021/np970181r	Laurencia rigida: chemical investigations of its antifouling dichloromethane extract.	König GM, Wright AD.
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223	J. Med. Chem.	2000	43	22	4328	4331	11063627	10.1021/jm000921k	Hydrolytic stability versus ring size in lactams: implications for the development of lactam antibiotics and other serine protease inhibitors.	Imming P, Klar B, Dix D.
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223	Bioorg. Med. Chem. Lett.	2012	22	11	3623	3631	22560472	10.1016/j.bmcl.2012.04.056	Synthesis and antimicrobial activities of structurally novel S,S'-bis(heterosubstituted) disulfides.	Ramaraju P, Gergeres D, Turos E, Dickey S, Lim DV, Thomas J, Anderson B.
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223	Bioorg. Med. Chem. Lett.	2012	22	6	2175	2181	22364815	10.1016/j.bmcl.2012.01.112	Isolation and identification of antibacterial neo-compounds from the red ants of ChangBai Mountain, Tetramorium sp.	Song ZW, Liu P, Yin WP, Jiang YL, Ren YL.
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223									Drug metabolism data	
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223									Unpublished dataset	
962.7500000000000000	2	Bacteria	PENICILLIN G POTASSIUM	CHEMBL1223									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	J. Nat. Prod.	1990	53	3	699	702		10.1021/np50069a027	Biological Activities of Avarol Derivatives, 1. Amino Derivatives	Cozzolino R, De Giulio A, De Rosa S, Strazzullo G, Gasic MJ, Sladic D, Zlatovic M
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Bioorg. Med. Chem. Lett.	1998	8	21	3007	3010	9873665	10.1016/s0960-894x(98)00536-8	Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.	Sol V, Branland P, Granet R, Kaldapa C, Verneuil B, Krausz P.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Bioorg. Med. Chem. Lett.	2004	14	1	59	62	14684298	10.1016/j.bmcl.2003.10.013	Peptide deformylase inhibitors with activity against respiratory tract pathogens.	East SP, Beckett RP, Brookings DC, Clements JM, Doel S, Keavey K, Pain G, Smith HK, Thomas W, Thompson AJ, Todd RS, Whittaker M.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	J. Biol. Chem.	2007	282	33	23841	23853	17553798	10.1074/jbc.m703467200	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.	Kaler G, Truong DM, Khandelwal A, Nagle M, Eraly SA, Swaan PW, Nigam SK.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Bioorg. Med. Chem.	2009	17	3	1006	1017	18234501	10.1016/j.bmc.2008.01.001	Synthesis and preliminary antibacterial evaluation of simplified thiomarinol analogs.	Marion O, Gao X, Marcus S, Hall DG.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Eur. J. Med. Chem.	2011	46	8	3526	3530	21570749	10.1016/j.ejmech.2011.04.053	Synthesis and antimicrobial evaluation of new benzofuran derivatives.	Jiang X, Liu W, Zhang W, Jiang F, Gao Z, Zhuang H, Fu L.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Eur. J. Med. Chem.	2011	46	9	3639	3650	21641699	10.1016/j.ejmech.2011.05.028	Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.	Zhang W, Liu W, Jiang X, Jiang F, Zhuang H, Fu L.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Eur. J. Med. Chem.	2012	54		879	886	22673144	10.1016/j.ejmech.2012.05.013	Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.	Liu J, Jiang F, Jiang X, Zhang W, Liu J, Liu W, Fu L.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	J. Med. Chem.	2014	57	9	3707	3714	24588790	10.1021/jm401685f	Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.	Duan F, Li X, Cai S, Xin G, Wang Y, Du D, He S, Huang B, Guo X, Zhao H, Zhang R, Ma L, Liu Y, Du Q, Wei Z, Xing Z, Liang Y, Wu X, Fan C, Ji C, Zeng D, Chen Q, He Y, Liu X, Huang W.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Bioorg. Med. Chem.	2015	23	20	6602	6611	26404408	10.1016/j.bmc.2015.09.018	Adenosine analogs as inhibitors of tyrosyl-tRNA synthetase: Design, synthesis and antibacterial evaluation.	Wei W, Shi WK, Wang PF, Zeng XT, Li P, Zhang JR, Li Q, Tang ZP, Peng J, Wu LZ, Xie MQ, Liu C, Li XH, Wang YC, Xiao ZP, Zhu HL.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Eur J Med Chem	2017	126		7	14	27744188	10.1016/j.ejmech.2016.10.010	Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.	Zhang W, Liu J, Macho JM, Jiang X, Xie D, Jiang F, Liu W, Fu L.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126	Eur J Med Chem	2017	133		62	68	28380394	10.1016/j.ejmech.2017.03.074	Synthesis and evaluation of adenosine containing 3-arylfuran-2(5H)-ones as tyrosyl-tRNA synthetase inhibitors.	Wei W, Liu Q, Li ZZ, Shi WK, Fu X, Liu J, Zhu X, Wang XC, Xu N, Li TF, Jiang FR, Xiao ZP, Zhu HL.
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126									Drug metabolism data	
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126									Unpublished dataset	
962.7500000000000000	2	Bacteria	PENICILLIN G SODIUM	CHEMBL1126									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Nat. Prod.	1987	50	1	19	22	3110376	10.1021/np50049a003	A direct bioautographic tlc assay for compounds possessing antibacterial activity.	Hamburger MO, Cordell GA.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1988	31	10	1987	1993	3172134	10.1021/jm00118a022	Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties, and oral bioavailability of 7-(arylacetamido)-3-chloro cephalosporins in animals.	Kukolja S, Wright WE, Quay JF, Pfeil-Doyle J, Draheim SE, Eudaly JA, Johnson RJ, Ott JL, Counter FT, Cooper RD.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1988	31	10	1993	1997	3172135	10.1021/jm00118a023	Oral absorption of cephalosporin antibiotics. 2. Expanded structure-activity relationships of 7-(arylacetamido)-3-substituted cephalosporins.	Pfeil-Doyle J, Draheim SE, Kukolja S, Ott JL, Counter FT.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1988	31	5	976	983	3129562	10.1021/jm00400a015	Coupling products of amino acids to penicillin V and cephalothin: synthesis and susceptibility to carboxypeptidases and lysosomal enzymes.	Bounkhala Z, Renard C, Baurain R, Marchand-Brynaert J, Ghosez L, Tulkens PM.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1988	31	6	1227	1230	3373491	10.1021/jm00401a026	The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones.	Indelicato JM, Pasini CE.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1990	33	1	291	297	2404120	10.1021/jm00163a048	Cephalosporins to carbapenems: 1-oxygenated carbapenems and carbapenams.	Rosati RL, Kapili LV, Morrissey P, Retsema JA.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	1991	34	5	1732	1739	2033596	10.1021/jm00109a030	Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones.	Jungheim LN, Boyd DB, Indelicato JM, Pasini CE, Preston DA, Alborn WE.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Bioorg. Med. Chem. Lett.	1993	3	11	2237	2240		10.1016/S0960-894X(01)80931-8	3-phosphono-1-carba-1-dethiacephalosporins as antibacterial agents	Ternansky RJ, Pike AJ
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Bioorg. Med. Chem. Lett.	2005	15	17	3953	3956	16046127	10.1016/j.bmcl.2005.05.045	Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin A as antibacterial agents.	Suresh Babu K, Hari Babu T, Srinivas PV, Sastry BS, Hara Kishore K, Murty US, Madhusudana Rao J.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	2005	48	13	4410	4419	15974593	10.1021/jm048982w	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.	Biegel A, Gebauer S, Hartrodt B, Brandsch M, Neubert K, Thondorf I.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Eur. J. Med. Chem.	2008	43	3	478	485	17544548	10.1016/j.ejmech.2007.04.002	Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.	Abraham MH, Ibrahim A, Acree WE.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2008	52	8	2890	2897	18490507	10.1128/aac.00185-08	First molecular characterization of group B streptococci with reduced penicillin susceptibility.	Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2009	53	4	1561	1566	19188396	10.1128/aac.00994-08	Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.	Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2009	53	7	3010	3016	19380596	10.1128/aac.01164-08	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.	Potron A, Poirel L, Croizé J, Chanteperdrix V, Nordmann P.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2009	53	9	3777	3781	19596876	10.1128/aac.00026-09	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.	Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2010	54	5	1800	1806	20160052	10.1128/aac.01714-09	Kinetic parameters of efflux of penicillins by the multidrug efflux transporter AcrAB-TolC of Escherichia coli.	Lim SP, Nikaido H.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Antimicrob. Agents Chemother.	2010	54	6	2716	2719	20308374	10.1128/aac.01797-09	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.	Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Bioorg. Med. Chem.	2012	20	24	6960	6968	23159041	10.1016/j.bmc.2012.10.027	Contribution to investigation of antimicrobial activity of styrylquinolines.	Cieslik W, Musiol R, Nycz JE, Jampilek J, Vejsova M, Wolff M, Machura B, Polanski J.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Bioorg. Med. Chem.	2012	20	24	7059	7068	23140987	10.1016/j.bmc.2012.10.007	Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.	Fajkusova D, Pesko M, Keltosova S, Guo J, Oktabec Z, Vejsova M, Kollar P, Coffey A, Csollei J, Kralova K, Jampilek J.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Drug Metab. Dispos.	2013	41	4	791	800	23344796	10.1124/dmd.112.049569	Organic anion transporter 3 interacts selectively with lipophilic ß-lactam antibiotics.	Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	ACS Med. Chem. Lett.	2014	5	2	154	157	24900789	10.1021/ml400408c	Neutral ß-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.	Dave K, Palzkill T, Pratt RF.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615									Unpublished dataset	
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PENICILLIN V	CHEMBL615									WHO Anatomical Therapeutic Chemical Classification	
962.7500000000000000	2	Bacteria	PENICILLIN V POTASSIUM	CHEMBL1200852	Bioorg. Med. Chem.	2011	19	24	7534	7540	22075235	10.1016/j.bmc.2011.10.031	Molecular drug-organiser: synthesis, characterization and biological evaluation of penicillin V and/or nalidixic acid calixarene-based podands.	Ben Salem A, Sautrey G, Fontanay S, Duval RE, Regnouf-de-Vains JB.
962.7500000000000000	2	Bacteria	PENICILLIN V POTASSIUM	CHEMBL1200852	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	PENICILLIN V POTASSIUM	CHEMBL1200852									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	PENICILLIN V POTASSIUM	CHEMBL1200852									Unpublished dataset	
962.7500000000000000	2	Bacteria	PENICILLIN V POTASSIUM	CHEMBL1200852									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
931.8000000000000000	9606	Homo sapiens	PENTOLINIUM TARTRATE	CHEMBL1318287	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
931.8000000000000000	9606	Homo sapiens	PENTOLINIUM TARTRATE	CHEMBL1318287									PubChem BioAssay data set	
931.8000000000000000	9606	Homo sapiens	PENTOLINIUM TARTRATE	CHEMBL1318287									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	PENTOLINIUM TARTRATE	CHEMBL1318287									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	J. Med. Chem.	1976	19	1	6	10	1536	10.1021/jm00223a002	Synthesis and adrenoreceptor blocking action of aziridinium ions derived from phenoxybenzamine and dibenamine.	Henkel JG, Portoghese PS, Miller JW, Lewis P.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	PHENOXYBENZAMINE HYDROCHLORIDE	CHEMBL1200787									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873									British National Formulary (72nd edition)	
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	PHENTOLAMINE MESYLATE	CHEMBL1200873									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	PIMASERTIB	CHEMBL2107832	Bioorg. Med. Chem. Lett.	2014	24	11	2555	2559	24755426	10.1016/j.bmcl.2014.03.086	Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.	Lu H, Tu W, Fei H, Xu G, Hu Q, Zhang L, Lin B, Yuan J, Yin J, Gong A, Wan M, Wang D, Zhu X, Feng J, Wang Q, Sun P.
1033.7000000000000000	9606	Homo sapiens	PIMASERTIB	CHEMBL2107832	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	PIMASERTIB	CHEMBL2107832									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	PIMASERTIB	CHEMBL2107832									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	PIMASERTIB	CHEMBL2107832									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820	J. Med. Chem.	2014	57	9	3707	3714	24588790	10.1021/jm401685f	Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.	Duan F, Li X, Cai S, Xin G, Wang Y, Du D, He S, Huang B, Guo X, Zhao H, Zhang R, Ma L, Liu Y, Du Q, Wei Z, Xing Z, Liang Y, Wu X, Fan C, Ji C, Zeng D, Chen Q, He Y, Liu X, Huang W.
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820									Unpublished dataset	
962.7500000000000000	2	Bacteria	PIPERACILLIN SODIUM	CHEMBL1200820									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	POLMACOXIB	CHEMBL166863		2002							4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors	
886.5000000000000000	9606	Homo sapiens	POLMACOXIB	CHEMBL166863	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	POLMACOXIB	CHEMBL166863									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	POLMACOXIB	CHEMBL166863									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	POLMACOXIB	CHEMBL166863									WHO Anatomical Therapeutic Chemical Classification	
863.7500000000000000	9606	Homo sapiens	POMAGLUMETAD METHIONIL	CHEMBL2110730									Unpublished dataset	
1045.6750000000000000	9606	Homo sapiens	PONATINIB HYDROCHLORIDE	CHEMBL2105708									Unpublished dataset	
1045.6750000000000000	9606	Homo sapiens	PONATINIB HYDROCHLORIDE	CHEMBL2105708									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	1994	4	6	823	826		10.1016/S0960-894X(01)80855-6	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant.	Yuen P, Kanter GD, Taylor CP, Vartanian MG
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2004	14	10	2537	2541	15109646	10.1016/j.bmcl.2004.02.094	Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.	Hong-Ju Y, He L, Wei-Guo S, Nan Z, Wei-Xiu Y, Zhong-Wei J, Jun-Wei W, Zheng-Hua G, Bo-Hua Z, Zhi-Pu L, Zhe-Hui G.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2005	48	7	2294	2307	15801823	10.1021/jm049762l	Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.	Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2005	48	8	3026	3035	15828841	10.1021/jm0491086	Novel cyclopropyl beta-amino acid analogues of pregabalin and gabapentin that target the alpha2-delta protein.	Schwarz JB, Gibbons SE, Graham SR, Colbry NL, Guzzo PR, Le VD, Vartanian MG, Kinsora JJ, Lotarski SM, Li Z, Dickerson MR, Su TZ, Weber ML, El-Kattan A, Thorpe AJ, Donevan SD, Taylor CP, Wustrow DJ.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2006	16	13	3559	3563	16621528	10.1016/j.bmcl.2006.03.083	Carboxylate bioisosteres of pregabalin.	Schwarz JB, Colbry NL, Zhu Z, Nichelson B, Barta NS, Lin K, Hudack RA, Gibbons SE, Galatsis P, DeOrazio RJ, Manning DD, Vartanian MG, Kinsora JJ, Lotarski SM, Li Z, Dickerson MR, El-Kattan A, Thorpe AJ, Donevan SD, Taylor CP, Wustrow DJ.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2006	16	9	2329	2332	16099652	10.1016/j.bmcl.2005.06.090	Heteroaromatic side-chain analogs of pregabalin.	Schelkun RM, Yuen PW, Wustrow DJ, Kinsora J, Su TZ, Vartanian MG.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2009	19	1	247	250	19010672	10.1016/j.bmcl.2008.10.101	Oxadiazolone bioisosteres of pregabalin and gabapentin.	Wustrow DJ, Belliotti TR, Capiris T, Kneen CO, Bryans JS, Field MJ, Williams D, El-Kattan A, Buchholz L, Kinsora JJ, Lotarski SM, Vartanian MG, Taylor CP, Donevan SD, Thorpe AJ, Schwarz JB.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2010	20	1	248	251	19910190	10.1016/j.bmcl.2009.10.121	Synthesis and in vivo evaluation of 3,4-disubstituted gababutins.	Blakemore DC, Bryans JS, Carnell P, Field MJ, Kinsella N, Kinsora JK, Meltzer LT, Osborne SA, Thompson LR, Williams SC.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2010	20	1	362	365	19897364	10.1016/j.bmcl.2009.10.089	Synthesis and in vivo evaluation of 3-substituted gababutins.	Blakemore DC, Bryans JS, Carnell P, Chessum NE, Field MJ, Kinsella N, Kinsora JK, Osborne SA, Williams SC.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2010	20	15	4683	4688	20566291	10.1016/j.bmcl.2010.05.026	Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain.	Myatt JW, Healy MP, Bravi GS, Billinton A, Johnson CN, Matthews KL, Jandu KS, Meng W, Hersey A, Livermore DG, Douault CB, Witherington J, Bit RA, Rowedder JE, Brown JD, Clayton NM.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Eur. J. Med. Chem.	2010	45	4	1447	1452	20079559	10.1016/j.ejmech.2009.12.049	Synthesis, characterization and in vitro pharmacology of novel pregabalin derivatives.	Horvat S, Hamersak Z, Stipeti¿ I, Jolas T.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2011	21	12	3764	3766	21601457	10.1016/j.bmcl.2011.04.045	Part 1: N-alkylated glycines as potent ¿2¿ ligands.	Thompson LR, Blakemore DC, Brugier D, Bryans JS, Chu WL, Maw GN, Poinsard C, Rawson DJ, Warren AN.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2011	21	12	3767	3770	21550803	10.1016/j.bmcl.2011.04.056	Part 2: Design, synthesis and evaluation of hydroxyproline-derived ¿2¿ ligands.	Rawson DJ, Brugier D, Harrison A, Hough J, Newman J, Otterburn J, Maw GN, Price J, Thompson LR, Turnpenny P, Warren AN.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2011	21	12	3771	3773	21550802	10.1016/j.bmcl.2011.04.058	Part 3: Design and synthesis of proline-derived ¿2¿ ligands.	Rawson DJ, Brugier D, Harrison A, Hough J, Newman J, Otterburn J, Maw GN, Price J, Thompson LR, Turnpenny P, Warren AN.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2011	54	7	2512	2516	21381762	10.1021/jm101376k	Synthesis and biological evaluation of 3,7-diazabicyclo[4.3.0]nonan-8-ones as potential nootropic and analgesic drugs.	Martini E, Di Cesare Mannelli L, Bartolucci G, Bertucci C, Dei S, Ghelardini C, Guandalini L, Manetti D, Scapecchi S, Teodori E, Romanelli MN.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2012	22	24	7602	7604	23103098	10.1016/j.bmcl.2012.10.001	(R)- and (S)-4-Amino-3-(trimethylsilyl)methylbutanoic acids ameliorate neuropathic pain without central nervous system-related side effects.	Muratake H, Ito A, Toda T, Suzuki H, Fukasawa H, Tsuda M, Inoue K, Sugiyama K, Shudo K.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2012	55	19	8211	8224	22784008	10.1021/jm3007323	Synthesis and biological evaluation of the 1-arylpyrazole class of ¿(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).	Díaz JL, Cuberes R, Berrocal J, Contijoch M, Christmann U, Fernández A, Port A, Holenz J, Buschmann H, Laggner C, Serafini MT, Burgueño J, Zamanillo D, Merlos M, Vela JM, Almansa C.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2012	55	22	9847	9855	23098566	10.1021/jm301056k	Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.	Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G, Bugianesi RM, Haedo RJ, Swensen AM, Warren VA, Smith MM, Garcia ML, McManus OB, Lyons KA, Li X, Green M, Jochnowitz N, McGowan E, Mistry S, Sun SY, Abbadie C, Kaczorowski GJ, Duffy JL.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem.	2013	21	21	6542	6553	24055075	10.1016/j.bmc.2013.08.031	Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.	Chaudhari SS, Kadam AB, Khairatkar-Joshi N, Mukhopadhyay I, Karnik PV, Raghuram A, Rao SS, Vaiyapuri TS, Wale DP, Bhosale VM, Gudi GS, Sangana RR, Thomas A.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Eur. J. Med. Chem.	2013	70		811	830	24246730	10.1016/j.ejmech.2013.10.026	Design and synthesis of potent and selective P2X¿ receptor antagonists derived from PPADS as potential pain modulators.	Cho JH, Jung KY, Jung Y, Kim MH, Ko H, Park CS, Kim YC.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Nat. Prod.	2013	76	4	737	740	23540838	10.1021/np300783a	Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea.	Nieto FR, Cobos EJ, Entrena JM, Parra A, García-Granados A, Baeyens JM.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2014	24	14	3088	3091	24863744	10.1016/j.bmcl.2014.05.016	DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.	Rajagopalan P, Tracey H, Chen Z, Bandyopadhyaya A, Veeraraghavan S, Rajagopalan DR, Salvemini D, McPhee I, Viswanadha S, Rajagopalan R.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem. Lett.	2014	24	16	4039	4043	24948568	10.1016/j.bmcl.2014.05.074	2-Alkyl/alkenyl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as highly potent TRPV1 antagonists.	Ryu H, Seo S, Cho SH, Kim HS, Jung A, Kang DW, Son K, Cui M, Hong SH, Sharma PK, Choi S, Blumberg PM, Frank-Foltyn R, Bahrenberg G, Stockhausen H, Schiene K, Christoph T, Frormann S, Lee J.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2014	57	13	5800	5816	24914455	10.1021/jm5006429	Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain.	Stachel SJ, Sanders JM, Henze DA, Rudd MT, Su HP, Li Y, Nanda KK, Egbertson MS, Manley PJ, Jones KL, Brnardic EJ, Green A, Grobler JA, Hanney B, Leitl M, Lai MT, Munshi V, Murphy D, Rickert K, Riley D, Krasowska-Zoladek A, Daley C, Zuck P, Kane SA, Bilodeau MT.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Bioorg. Med. Chem.	2015	23	15	4316	4323	26138193	10.1016/j.bmc.2015.06.038	Synthesis of new fluorinated analogs of GABA, Pregabalin bioisosteres, and their effects on [(3)H]GABA uptake by rat brain nerve terminals.	Borisova T, Pozdnyakova N, Shaitanova E, Gerus I, Dudarenko M, Mironets R, Haufe G, Kukhar V.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J. Med. Chem.	2015	58	5	2114	2134	25597334	10.1021/jm500324g	Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62.	Park JH, Lee GE, Lee SD, Hien TT, Kim S, Yang JW, Cho JH, Ko H, Lim SC, Kim YG, Kang KW, Kim YC.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	ACS Med. Chem. Lett.	2015	6	6	650	654	26101568	10.1021/acsmedchemlett.5b00059	Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.	Bagal SK, Bungay PJ, Denton SM, Gibson KR, Glossop MS, Hay TL, Kemp MI, Lane CA, Lewis ML, Maw GN, Million WA, Payne CE, Poinsard C, Rawson DJ, Stammen BL, Stevens EB, Thompson LR.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059	J Med Chem	2017	60	3	1105	1125	28001399	10.1021/acs.jmedchem.6b01496	The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors.	Bregman H, Simard JR, Andrews KL, Ayube S, Chen H, Gunaydin H, Guzman-Perez A, Hu J, Huang L, Huang X, Krolikowski PH, Lehto SG, Lewis RT, Michelsen K, Pegman P, Plant MH, Shaffer PL, Teffera Y, Yi S, Zhang M, Gingras J, DiMauro EF.
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059									British National Formulary (72nd edition)	
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059									PubChem BioAssay data set	
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	PREGABALIN	CHEMBL1059									WHO Anatomical Therapeutic Chemical Classification	
859.7000000000000000	11676	Human immunodeficiency virus 1	PRO-542	CHEMBL2109442									Unpublished dataset	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	1992	35	7	1212	1215	1560435	10.1021/jm00085a007	Antimycobacterial activity of a series of pyrazinoic acid esters.	Cynamon MH, Klemens SP, Chou TS, Gimi RH, Welch JT.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	1995	38	20	3902	3907	7562923	10.1021/jm00020a003	Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.	Cynamon MH, Gimi R, Gyenes F, Sharpe CA, Bergmann KE, Han HJ, Gregor LB, Rapolu R, Luciano G, Welch JT.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	1998	41	13	2436	2438	9632376	10.1021/jm9708745	Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids.	Wächter GA, Davis MC, Martin AR, Franzblau SG.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	1998	8	7	843	846	9871552	10.1016/s0960-894x(98)00126-7	Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro.	Davis MC, Franzblau SG, Martin AR.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2000	43	17	3304	3314	10966749	10.1021/jm000149l	A new class of antituberculosis agents.	Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, Townsend CA.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2001	44	10	1560	1563	11334565	10.1021/jm000350w	Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2.	Gezginci MH, Martin AR, Franzblau SG.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Farmaco	2002	57	2	135	144	11902656	10.1016/s0014-827x(01)01187-9	Ring substituted 3-phenyl-1-(2-pyrazinyl)-2-propen-1-ones as potential photosynthesis-inhibiting, antifungal and antimycobacterial agents.	Opletalová V, Hartl J, Patel A, Palát K, Buchta V.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2003	13	10	1755	1757	12729658	10.1016/s0960-894x(03)00241-5	Anilinopyrimidines as novel antituberculosis agents.	Morgan J, Haritakul R, Keller PA.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2006	16	8	2113	2116	16464574	10.1016/j.bmcl.2006.01.064	Synthesis of pyrazinamide Mannich bases and its antitubercular properties.	Sriram D, Yogeeswari P, Reddy SP.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	PLoS Med.	2006	3	11	e466	e466	17132069	10.1371/journal.pmed.0030466	OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.	Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2007	15	7	2551	2559	17306980	10.1016/j.bmc.2007.01.051	A new modification of anti-tubercular active molecules.	Imramovský A, Polanc S, Vinsová J, Kocevar M, Jampílek J, Recková Z, Kaustová J.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2007	17	1	86	93	17046250	10.1016/j.bmcl.2006.09.082	Microwave prompted multigram synthesis, structural determination, and photo-antiproliferative activity of fluorinated 4-hydroxyquinolinones.	Arya K, Agarwal M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	12	4495	4497	17876006	10.1128/aac.00753-07	Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis.	Byrne ST, Gu P, Zhou J, Denkin SM, Chong C, Sullivan D, Liu JO, Zhang Y.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	2	752	754	17101678	10.1128/aac.01369-06	Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.	Zimhony O, Vilchèze C, Arai M, Welch JT, Jacobs WR.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	3	1011	1015	17178794	10.1128/aac.00898-06	Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.	Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	4	1380	1385	17210775	10.1128/aac.00055-06	Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.	Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	6	2092	2099	17420206	10.1128/aac.00052-07	PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli.	Li Y, Zhang Y.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	7	2430	2435	17485499	10.1128/aac.01458-06	Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.	Ngo SC, Zimhony O, Chung WJ, Sayahi H, Jacobs WR, Welch JT.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2007	51	7	2546	2551	17452486	10.1128/aac.01550-06	Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.	Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2008	43	5	1105	1113	17870211	10.1016/j.ejmech.2007.07.013	Synthesis and antimycobacterial evaluation of substituted pyrazinecarboxamides.	Dolezal M, Dolezal M, Cmedlova P, Palek L, Vinsova J, Kunes J, Buchta V, Jampilek J, Kralova K.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2008	52	11	4137	4140	18694944	10.1128/aac.00196-08	Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.	Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, Peloquin CA, Orme IM, Basaraba RJ, Lenaerts AJ.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2008	52	5	1852	1854	18316515	10.1128/aac.00110-08	Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.	Juréen P, Werngren J, Toro JC, Hoffner S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2009	19	11	3006	3009	19403307	10.1016/j.bmcl.2009.04.029	A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles.	Karthikeyan SV, Perumal S, Shetty KA, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2009	44	11	4455	4460	19586686	10.1016/j.ejmech.2009.06.004	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.	Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2009	44	12	4954	4959	19765866	10.1016/j.ejmech.2009.08.009	Synthesis and antimycobacterial activity of N'-[(E)-(monosubstituted-benzylidene)]-2-pyrazinecarbohydrazide derivatives.	Vergara FM, Lima CH, Henriques Md, Candéa AL, Lourenço MC, Ferreira Mde L, Kaiser CR, de Souza MV.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2009	44	12	4978	4984	19781824	10.1016/j.ejmech.2009.09.001	L-proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines.	Indumathi S, Perumal S, Banerjee D, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2009	44	5	2081	2091	19028410	10.1016/j.ejmech.2008.10.011	Substituted quinolinyl chalcones and quinolinyl pyrimidines as a new class of anti-infective agents.	Sharma M, Chaturvedi V, Manju YK, Bhatnagar S, Srivastava K, Puri SK, Chauhan PM.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2009	44	9	3821	3829	19524332	10.1016/j.ejmech.2009.05.010	A facile synthesis and antimycobacterial evaluation of novel spiro-pyrido-pyrrolizines and pyrrolidines.	Ranjith Kumar R, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2009	53	1	316	318	18955515	10.1128/aac.01302-08	Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.	Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2009	53	11	4598	4603	19704125	10.1128/aac.00643-09	New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.	Rieder RJ, Zhao Z, Zavizion B.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2009	53	8	3197	3204	19451303	10.1128/aac.01681-08	Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.	Gumbo T, Dona CS, Meek C, Leff R.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2010	20	1	350	353	19900810	10.1016/j.bmcl.2009.10.107	A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents.	Karthikeyan SV, Bala BD, Raja VP, Perumal S, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2010	20	11	3352	3355	20434911	10.1016/j.bmcl.2010.04.025	Selective one-pot multicomponent synthesis and anti-tubercular evaluation of 5-(aryl/cyclohexylsulfanyl)-2-alkoxy-4,6-diarylnicotinonitriles.	Manikannan R, Muthusubramanian S, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2010	20	23	6920	6924	20970331	10.1016/j.bmcl.2010.09.137	Pyrazole derivatives from azines of substituted phenacyl aryl/cyclohexyl sulfides and their antimycobacterial activity.	Manikannan R, Venkatesan R, Muthusubramanian S, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2010	20	3	1263	1268	20022500	10.1016/j.bmcl.2009.11.105	Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.	Mao J, Yuan H, Wang Y, Wan B, Pak D, He R, Franzblau SG.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2010	45	1	411	422	19850377	10.1016/j.ejmech.2009.09.044	Novel three-component domino reactions of ketones, isatin and amino acids: synthesis and discovery of antimycobacterial activity of highly functionalised novel dispiropyrrolidines.	Kumar RS, Rajesh SM, Perumal S, Banerjee D, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2010	53	7	2882	2891	20205479	10.1021/jm901858n	Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.	Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2010	54	11	4789	4793	20713679	10.1128/aac.00661-10	Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.	Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2010	54	12	5323	5328	20876380	10.1128/aac.00529-10	Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.	Baughn AD, Deng J, Vilchèze C, Riestra A, Welch JT, Jacobs WR, Zimhony O.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2010	54	3	1068	1074	20038625	10.1128/aac.00447-09	Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.	Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2010	54	5	2262	2264	20160054	10.1128/aac.01423-09	Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.	Rullas J, García JI, Beltrán M, Cardona PJ, Cáceres N, García-Bustos JF, Angulo-Barturen I.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Antimicrob. Agents Chemother.	2010	54	7	2847	2854	20439617	10.1128/aac.01567-09	Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.	Pasipanodya JG, Gumbo T.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2011	19	4	1471	1476	21273083	10.1016/j.bmc.2010.12.054	Synthesis and antimycobacterial properties of N-substituted 6-amino-5-cyanopyrazine-2-carboxamides.	Zitko J, Dolezal M, Dolezal M, Svobodova M, Vejsova M, Kunes J, Kucera R, Jilek P.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	MedChemComm	2011	2	7	626	630		10.1039/C0MD00239A	Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition	Rajesh SM, Perumal S, Menendez JC, Yogeeswari P, Sriram D
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2011	20	9	1611	1615		10.1007/s00044-010-9405-3	Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line	Singh M, Sasi P, Rai G, Gupta VH, Amarapurkar D, Wangikar PP
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2011	21	13	3881	3884	21641799	10.1016/j.bmcl.2011.05.032	Synthesis and antimycobacterial activity of highly functionalized tetrahydro-4(1H)-pyridinones.	Raja VP, Perumal S, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2011	21	14	4316	4319	21665469	10.1016/j.bmcl.2011.05.054	Synthesis and antitubercular evaluation of amidoalkyl dibenzofuranols and 1H-benzo[2,3]benzofuro[4,5-e][1,3]oxazin-3(2H)-ones.	Kantevari S, Yempala T, Yogeeswari P, Sriram D, Sridhar B.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2011	21	14	4329	4331	21684158	10.1016/j.bmcl.2011.05.055	Synthesis and evaluation of chromenyl barbiturates and thiobarbiturates as potential antitubercular agents.	Vijaya Laxmi S, Thirupathi Reddy Y, Suresh Kuarm B, Narsimha Reddy P, Crooks PA, Rajitha B.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2011	21	16	4804	4807	21775138	10.1016/j.bmcl.2011.06.055	Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.	Sayahi H, Zimhony O, Jacobs WR, Shekhtman A, Welch JT.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2011	21	4	1214	1217	21237641	10.1016/j.bmcl.2010.12.082	Synthesis and antitubercular evaluation of novel substituted aryl and thiophenyl tethered dihydro-6H-quinolin-5-ones.	Kantevari S, Patpi SR, Sridhar B, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2011	46	10	4937	4945	21855181	10.1016/j.ejmech.2011.07.052	New fluorine-containing hydrazones active against MDR-tuberculosis.	Vav¿íková E, Polanc S, Ko¿evar M, Horváti K, Bosze S, Stola¿íková J, Vávrová K, Vin¿ová J.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2011	46	5	1564	1571	21382653	10.1016/j.ejmech.2011.02.003	Synthesis, antibacterial and antimycobacterial activities of some new 4-aryl/heteroaryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines.	Sirisha K, Bikshapathi D, Achaiah G, Reddy VM.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2011	46	9	4366	4373	21802797	10.1016/j.ejmech.2011.07.007	One-pot synthesis of pyrazoline derivatised carbazoles as antitubercular, anticancer agents, their DNA cleavage and antioxidant activities.	Taj T, Kamble RR, Gireesh TM, Hunnur RK, Margankop SB.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2012	20	1	137	144	22153872	10.1016/j.bmc.2011.11.020	Synthesis of novel 3-cyclohexylpropanoic acid-derived nitrogen heterocyclic compounds and their evaluation for tuberculostatic activity.	Gobis K, Foks H, Bojanowski K, Augustynowicz-Kope¿ E, Napiórkowska A.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2012	20	22	6680	6686	23062712	10.1016/j.bmc.2012.09.019	The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives.	Matyugina E, Khandazhinskaya A, Chernousova L, Andreevskaya S, Smirnova T, Chizhov A, Karpenko I, Kochetkov S, Alexandrova L.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2012	20	24	7059	7068	23140987	10.1016/j.bmc.2012.10.007	Anti-infective and herbicidal activity of N-substituted 2-aminobenzothiazoles.	Fajkusova D, Pesko M, Keltosova S, Guo J, Oktabec Z, Vejsova M, Kollar P, Coffey A, Csollei J, Kralova K, Jampilek J.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2012	21	10	2744	2748		10.1007/s00044-011-9802-2	Synthesis, antitubercular and antifungal activities of heteroaryl-substituted oxiranes derived from BaylisHillman adducts	Jain S, Babu N, Jetti SR, Shah H, Dhaneria SP
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2012	21	12	4177	4192		10.1007/s00044-011-9950-4	Discovery of 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(4-quinazolinyloxy)-6-piperazinyl(piperidinyl)-s-triazines as potential antibacterial agents	Patel RV, Kumari P, Rajani DP, Chikhalia KH
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2012	22	11	3603	3606	22572576	10.1016/j.bmcl.2012.04.048	Synthesis and antimycobacterial activity of prodrugs of sulfur dioxide (SO2).	Malwal SR, Sriram D, Yogeeswari P, Chakrapani H.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2012	22	14	4807	4809	22726933	10.1016/j.bmcl.2012.05.054	Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of Mycobacterium tuberculosis.	Jeyachandran M, Ramesh P, Sriram D, Senthilkumar P, Yogeeswari P.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2012	22	24	7426	7430	23151429	10.1016/j.bmcl.2012.10.056	Molecular hybridization of bioactives: synthesis and antitubercular evaluation of novel dibenzofuran embodied homoisoflavonoids via Baylis-Hillman reaction.	Yempala T, Sriram D, Yogeeswari P, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2012	22	4	1598	1601	22281187	10.1016/j.bmcl.2011.12.129	Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.	Zitko J, Jampílek J, Dobrovolný L, Svobodová M, Kune¿ J, Dole¿al M, Dole¿al M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2012	22	4	1643	1648	22277278	10.1016/j.bmcl.2011.12.119	Camphorsulfonic acid catalysed facile tandem double Friedlander annulation protocol for the synthesis of phenoxy linked bisquinoline derivatives and discovery of antitubercular agents.	Paul N, Murugavel M, Muthusubramanian S, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2012	49		1	23	22280816	10.1016/j.ejmech.2011.12.029	Recent advances in antitubercular natural products.	García A, Bocanegra-García V, Palma-Nicolás JP, Rivera G.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2012	53		41	51	22516426	10.1016/j.ejmech.2012.03.033	Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents.	Patel RV, Patel PK, Kumari P, Rajani DP, Chikhalia KH.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2012	55	8	3911	3922	22449006	10.1021/jm300125e	Design, synthesis, and structure-activity correlations of novel dibenzo[b,d]furan, dibenzo[b,d]thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of Mycobacterium tuberculosis.	Patpi SR, Pulipati L, Yogeeswari P, Sriram D, Jain N, Sridhar B, Murthy R, Anjana Devi T, Kalivendi SV, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2013	21	17	4874	4884	23891229	10.1016/j.bmc.2013.07.003	Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides.	Shmalenyuk ER, Chernousova LN, Karpenko IL, Kochetkov SN, Smirnova TG, Andreevskaya SN, Chizhov AO, Efremenkova OV, Alexandrova LA.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	1	195	210		10.1007/s00044-012-0026-x	Synthesis of coumarin-based 1,3,4-oxadiazol-2ylthio-N-phenyl/benzothiazolyl acetamides as antimicrobial and antituberculosis agents	Patel RV, Kumari P, Rajani DP, Chikhalia KH
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	1	367	381		10.1007/s00044-012-0041-y	Synthesis of potential antitubercular and antimicrobial s-triazine-based scaffolds via Suzuki cross-coupling reaction	Patel AB, Patel RV, Kumari P, Rajani DP, Chikhalia KH
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	10	4700	4707		10.1007/s00044-013-0472-0	New carbodithioate derivatives: synthesis, characterization, and in vitro antibacterial, antifungal, antitubercular, and antimalarial activity	Akhaja TN, Raval JP
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	2	647	658		10.1007/s00044-012-0061-7	Quinoline-based azetidinone and thiazolidinone analogues as antimicrobial and antituberculosis agents	Mistry BM, Jauhari S
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	2	726	744		10.1007/s00044-012-0073-3	In vitro antimicrobial and antimycobacterial activity of some chalcones and their derivatives	Patel D, Kumari P, Patel NB
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013	22	2	869	878		10.1007/s00044-012-0080-4	Synthesis and evaluation of antibacterial and antitubercular activities of some novel imidazo[2,1-b][1,3,4]thiadiazole derivatives	Joshi SD, Manish K, Badiger A
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2013	23	12	3589	3591	23659859	10.1016/j.bmcl.2013.04.021	Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.	Servusová B, Vobicková J, Paterová P, Kubí¿ek V, Kune¿ J, Dole¿al M, Dole¿al M, Zitko J.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2013	23	17	4741	4750	23910985	10.1016/j.bmcl.2013.07.006	A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.	Dartois V, Barry CE.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2013	23	19	5393	5396	23953191	10.1016/j.bmcl.2013.07.048	Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladium-copper catalysed Sonagashira coupling reaction.	Yempala T, Sridevi JP, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2013	23	2	476	479	23237840	10.1016/j.bmcl.2012.11.052	Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.	Zitko J, Paterová P, Kubí¿ek V, Mandíková J, Trejtnar F, Kune¿ J, Dole¿al M, Dole¿al M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2013	23	21	5968	5970	24044875	10.1016/j.bmcl.2013.08.063	Synthesis, characterization and in vitro biological evaluation of some novel 1,3,5-triazine-Schiff base conjugates as potential antimycobacterial agents.	Avupati VR, Yejella RP, Parala VR, Killari KN, Papasani VM, Cheepurupalli P, Gavalapu VR, Boddeda B.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013			1	7		10.1007/s00044-013-0787-x	Synthesis, antitubercular and anticancer activity of new BaylisHillman adduct-derived N-cinnamyl-substituted isatin derivatives	Kumar SB, Ravinder M, Kishore G, Jayathirtha Rao V, Yogeeswari P, Sriram D
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013			1	7		10.1007/s00044-013-0857-0	DABCO-promoted one-pot synthesis of heteroaryl-substituted benzenes and their biological evaluation	Babu GN, Ayalew HM, Jain S
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Med Chem Res	2013			1	9		10.1007/s00044-013-0839-2	Synthesis and biological evaluation of novel quinazoline derivatives obtained by Suzuki CC coupling	Patel AB, Chikhalia KH, Kumari P
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2014	24	1	233	236	24314670	10.1016/j.bmcl.2013.11.031	Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.	Addla D, Jallapally A, Gurram D, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2014	24	14	3118	3120	24856062	10.1016/j.bmcl.2014.05.006	Synthesis and antituberculosis activity of novel 5-styryl-4-(hetero)aryl-pyrimidines via combination of the Pd-catalyzed Suzuki cross-coupling and S(N)(H) reactions.	Kravchenko MA, Verbitskiy EV, Medvinskiy ID, Rusinov GL, Charushin VN.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2014	24	17	4166	4170	25127167	10.1016/j.bmcl.2014.07.061	New class of methyl tetrazole based hybrid of (Z)-5-benzylidene-2-(piperazin-1-yl)thiazol-4(%H)-one as potent antitubercular agents.	Chauhan K, Sharma M, Trivedi P, Chaturvedi V, Chauhan PM.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2014	24	2	450	453	24388809	10.1016/j.bmcl.2013.12.054	Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.	Servusová B, Paterová P, Mandíková J, Kubí¿ek V, Ku¿era R, Kune¿ J, Dole¿al M, Dole¿al M, Zitko J.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2014	24	8	1974	1979	24679703	10.1016/j.bmcl.2014.02.061	Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis.	Addla D, Jallapally A, Gurram D, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	MedChemComm	2014	5	10	1489	1495		10.1039/C4MD00224E	N-Arylalkylbenzo[d]thiazole-2-carboxamides as anti-mycobacterial agents: design, new methods of synthesis and biological evaluation	Shah P, Dhameliya TM, Bansal R, Nautiyal M, Kommi DN, Jadhavar PS, Sridevi JP, Yogeeswari P, Sriram D, Chakraborti AK
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2014	74		225	233	24463645	10.1016/j.ejmech.2013.12.061	Synthesis, structure-activity relationship of iodinated-4-aryloxymethyl-coumarins as potential anti-cancer and anti-mycobacterial agents.	Basanagouda M, Jambagi VB, Barigidad NN, Laxmeshwar SS, Devaru V, Narayanachar.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2014	79		57	65	24721315	10.1016/j.ejmech.2014.03.085	Facile synthesis of benzonitrile/nicotinonitrile based s-triazines as new potential antimycobacterial agents.	Patel AB, Chikhalia KH, Kumari P.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2015	105		194	207	26491982	10.1016/j.ejmech.2015.10.019	A click chemistry approach for the synthesis of mono and bis aryloxy linked coumarinyl triazoles as anti-tubercular agents.	Anand A, Naik RJ, Revankar HM, Kulkarni MV, Dixit SR, Joshi SD.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2015	23	1	174	183	25438883	10.1016/j.bmc.2014.11.014	Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides.	Zitko J, Servusová B, Janoutová A, Paterová P, Mandíková J, Garaj V, Vejsová M, Marek J, Dole¿al M, Dole¿al M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2015	23	9	2112	2120	25797161	10.1016/j.bmc.2015.03.008	Novel 2-(2-phenalkyl)-1H-benzo[d]imidazoles as antitubercular agents. Synthesis, biological evaluation and structure-activity relationship.	Gobis K, Foks H, Suchan K, Augustynowicz-Kope¿ E, Napiórkowska A, Bojanowski K.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2015	25	19	4308	4313	26271585	10.1016/j.bmcl.2015.07.069	Design of novel dispirooxindolopyrrolidine and dispirooxindolopyrrolothiazole derivatives as potential antitubercular agents.	Mhiri C, Boudriga S, Askri M, Knorr M, Sriram D, Yogeeswari P, Nana F, Golz C, Strohmann C.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2015	25	19	4169	4173	26298500	10.1016/j.bmcl.2015.08.009	One-pot synthesis of new triazole--Imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity.	Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2015	25	23	5540	5545	26520663	10.1016/j.bmcl.2015.10.057	New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.	Nayak N, Ramprasad J, Dalimba U.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2015	25	7	1561	1567	25740159	10.1016/j.bmcl.2015.02.013	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.	Bharate SS, Vishwakarma RA.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	MedChemComm	2015	6	7	1311	1317		10.1039/C5MD00178A	Alkylamino derivatives of N-benzylpyrazine-2-carboxamide: synthesis and antimycobacterial evaluation	Servusova-Vanaskova B, Jandourek O, Paterova P, Kordulakova J, Plevakova M, Kubicek V, Kucera R, Garaj V, Naesens L, Kunes J, Dolezal M, Zitko J
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2015	89		13	20	25462221	10.1016/j.ejmech.2014.10.031	Synthesis and evaluation of in vitro antimycobacterial activity of novel 1H-benzo[d]imidazole derivatives and analogues.	Gobis K, Foks H, Serocki M, Augustynowicz-Kope¿ E, Napiórkowska A.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur J Med Chem	2015	92		415	426	25590862	10.1016/j.ejmech.2015.01.013	Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.	Naidu KM, Nagesh HN, Singh M, Sriram D, Yogeeswari P, Gowri Chandra Sekhar KV.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2015	95		357	368	25828928	10.1016/j.ejmech.2015.03.036	Thiophene containing trisubstituted methanes [TRSMs] as identified lead against Mycobacterium tuberculosis.	Singh P, Manna SK, Jana AK, Saha T, Mishra P, Bera S, Parai MK, Kumar M SL, Mondal S, Trivedi P, Chaturvedi V, Singh S, Sinha S, Panda G.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2015	95		49	63	25794789	10.1016/j.ejmech.2015.03.024	Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.	Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D, Peethambar SK, Achur R, Kumar HS.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2015	97		225	234	25982331	10.1016/j.ejmech.2015.05.007	Synthesis, and structure-activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds.	Verbitskiy EV, Cheprakova EM, Slepukhin PA, Kravchenko MA, Skornyakov SN, Rusinov GL, Chupakhin ON, Charushin VN.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur. J. Med. Chem.	2016	116		187	199	27061982	10.1016/j.ejmech.2016.03.060	Benzo[d]thiazol-2-yl(piperazin-1-yl)methanones as new anti-mycobacterial chemotypes: Design, synthesis, biological evaluation and 3D-QSAR studies.	Pancholia S, Dhameliya TM, Shah P, Jadhavar PS, Sridevi JP, Yogeshwari P, Sriram D, Chakraborti AK.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur J Med Chem	2016	123		523	531	27508879	10.1016/j.ejmech.2016.07.039	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.	Fernandes GFDS, de Souza PC, Marino LB, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Chung MC, Pavan FR, Dos Santos JL.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur J Med Chem	2016	123		684	703	27517813	10.1016/j.ejmech.2016.07.068	Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.	Koh JJ, Zou H, Mukherjee D, Lin S, Lim F, Tan JK, Tan DZ, Stocker BL, Timmer MSM, Corkran HM, Lakshminarayanan R, Tan DTH, Cao D, Beuerman RW, Dick T, Liu S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem.	2016	24	16	3771	3780	27338658	10.1016/j.bmc.2016.06.020	Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines.	Verbitskiy EV, Baskakova SA, Kravchenko MA, Skornyakov SN, Rusinov GL, Chupakhin ON, Charushin VN.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2016	26	11	2649	2654	27101894	10.1016/j.bmcl.2016.04.015	Click-based synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages.	Pulipati L, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2016	26	11	2663	2669	27095514	10.1016/j.bmcl.2016.04.012	Synthesis, biological evaluation and structure-activity relationship of 2-styrylquinazolones as anti-tubercular agents.	Jadhavar PS, Dhameliya TM, Vaja MD, Kumar D, Sridevi JP, Yogeeswari P, Sriram D, Chakraborti AK.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2016	26	13	3135	3140	27184765	10.1016/j.bmcl.2016.04.088	Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.	Pulipati L, Sridevi JP, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2016	26	15	3684	3689	27317646	10.1016/j.bmcl.2016.05.085	Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides.	Surineni G, Yogeeswari P, Sriram D, Kantevari S.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2016	26	24	5960	5966	27839684	10.1016/j.bmcl.2016.10.082	Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.	Tanwar B, Kumar A, Yogeeswari P, Sriram D, Chakraborti AK.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg. Med. Chem. Lett.	2016	26	9	2224	2228	27017114	10.1016/j.bmcl.2016.03.055	Synthesis and docking studies of pyrazine-thiazolidinone hybrid scaffold targeting dormant tuberculosis.	Chitre TS, Asgaonkar KD, Miniyar PB, Dharme AB, Arkile MA, Yeware A, Sarkar D, Khedkar VM, Jha PC.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	J. Med. Chem.	2016	59	8	3808	3825	27018907	10.1021/acs.jmedchem.5b02004	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.	Garrison AT, Abouelhassan Y, Norwood VM, Kallifidas D, Bai F, Nguyen MT, Rolfe M, Burch GM, Jin S, Luesch H, Huigens RW.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Eur J Med Chem	2017	133		255	267	28390957	10.1016/j.ejmech.2017.04.002	Isoniazid derivatives and their anti-tubercular activity.	Hu YQ, Zhang S, Zhao F, Gao C, Feng LS, Lv ZS, Xu Z, Wu X.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2017	27	1	11	15	27894872	10.1016/j.bmcl.2016.11.047	Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents.	Balaji NV, Hari Babu B, Subbaraju GV, Purna Nagasree K, Murali Krishna Kumar M.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2017	27	10	2174	2180	28372908	10.1016/j.bmcl.2017.03.059	Novel quinoxalinyl chalcone hybrid scaffolds as enoyl ACP reductase inhibitors: Synthesis, molecular docking and biological evaluation.	Desai V, Desai S, Gaonkar SN, Palyekar U, Joshi SD, Dixit SK.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2017	27	13	3003	3006	28512023	10.1016/j.bmcl.2017.05.013	Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.	Verbitskiy EV, Baskakova SA, Gerasimova NA, Evstigneeva NP, Zil'berberg NV, Kungurov NV, Kravchenko MA, Skornyakov SN, Pervova MG, Rusinov GL, Chupakhin ON, Charushin VN.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614	Bioorg Med Chem Lett	2017	27	8	1859	1866	28274627	10.1016/j.bmcl.2017.02.031	Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.	Salve PS, Alegaon SG, Sriram D.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614								10.6019/CHEMBL3392926	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning	Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									British National Formulary (72nd edition)	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									DrugMatrix	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									PubChem BioAssay data set	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									Unpublished dataset	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1066.9727272727272727	1773	Mycobacterium tuberculosis	PYRAZINAMIDE	CHEMBL614									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	QUINUPRISTIN	CHEMBL1200649	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	QUINUPRISTIN	CHEMBL1200649	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	QUINUPRISTIN	CHEMBL1200649	Antimicrob. Agents Chemother.	2009	53	4	1367	1376	19171799	10.1128/aac.01275-08	A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.	Nash KA, Brown-Elliott BA, Wallace RJ.
2219.8000000000000000	2	Bacteria	QUINUPRISTIN	CHEMBL1200649									Unpublished dataset	
2219.8000000000000000	2	Bacteria	QUINUPRISTIN	CHEMBL1200649									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	J. Med. Chem.	2008	51	18	5843	5855	18763751	10.1021/jm800245z	Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.	Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	Bioorg. Med. Chem. Lett.	2009	19	15	4245	4249	19523819	10.1016/j.bmcl.2009.05.098	N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.	Petrocchi A, Jones P, Rowley M, Fiore F, Summa V.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	Bioorg. Med. Chem. Lett.	2010	20	19	5913	5917	20727748	10.1016/j.bmcl.2010.07.079	Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold.	Jones ED, Vandegraaff N, Le G, Choi N, Issa W, Macfarlane K, Thienthong N, Winfield LJ, Coates JA, Lu L, Li X, Feng X, Yu C, Rhodes DI, Deadman JJ.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	Antimicrob. Agents Chemother.	2011	55	2	813	821	21115794	10.1128/aac.01209-10	In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.	Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	Eur. J. Med. Chem.	2012	50		361	369	22369862	10.1016/j.ejmech.2012.02.015	Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors.	Wang Z, Wang M, Yao X, Li Y, Qiao W, Geng Y, Liu Y, Wang Q.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	Eur. J. Med. Chem.	2012	54		33	41	22608761	10.1016/j.ejmech.2012.04.020	Design, synthesis and antiviral activity of novel pyridazines.	Wang Z, Wang M, Yao X, Li Y, Tan J, Wang L, Qiao W, Geng Y, Liu Y, Wang Q.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520	J. Med. Chem.	2013	56	14	5901	5916	23845180	10.1021/jm400645w	Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).	Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R, Fuji M, Tanimoto N, Jeffrey J, Foster SA, Yoshinaga T, Seki T, Kobayashi M, Sato A, Johnson MN, Garvey EP, Fujiwara T.
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520									Unpublished dataset	
932.0000000000000000	11676	Human immunodeficiency virus 1	RALTEGRAVIR POTASSIUM	CHEMBL518520									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	RANITIDINE BISMUTH CITRATE	CHEMBL2111286									British National Formulary (72nd edition)	
939.2000000000000000	9606	Homo sapiens	RANITIDINE BISMUTH CITRATE	CHEMBL2111286									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	RANITIDINE BISMUTH CITRATE	CHEMBL2111286									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
939.2000000000000000	9606	Homo sapiens	RANITIDINE BISMUTH CITRATE	CHEMBL2111286									WHO Anatomical Therapeutic Chemical Classification	
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	Bioorg. Med. Chem.	2010	18	7	2756	2766	20206533	10.1016/j.bmc.2010.02.013	Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.	Zhang Y, Guiguemde WA, Sigal M, Zhu F, Connelly MC, Nwaka S, Guy RK.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	Antimicrob. Agents Chemother.	2010	54	9	3597	3604	20547797	10.1128/aac.00431-10	Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.	Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	J. Med. Chem.	2014	57	12	5141	5156	24874647	10.1021/jm5000408	Antileishmanial activity of a series of N²,N¿-disubstituted quinazoline-2,4-diamines.	Van Horn KS, Zhu X, Pandharkar T, Yang S, Vesely B, Vanaerschot M, Dujardin JC, Rijal S, Kyle DE, Wang MZ, Werbovetz KA, Manetsch R.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	J. Med. Chem.	2014	57	21	8860	8879	25148516	10.1021/jm500942v	Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.	Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, Sáenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372	J. Med. Chem.	2014	57	7	3075	3093	24625106	10.1021/jm500039e	Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.	Van Horn KS, Burda WN, Fleeman R, Shaw LN, Manetsch R.
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372									British National Formulary (72nd edition)	
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372									Unpublished dataset	
939.2000000000000000	9606	Homo sapiens	RANITIDINE HYDROCHLORIDE	CHEMBL2110372									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	RAUWOLFIA SERPENTINA	CHEMBL3559672									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	RAUWOLFIA SERPENTINA	CHEMBL3559672									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	RAUWOLFIA SERPENTINA	CHEMBL3559672									WHO Anatomical Therapeutic Chemical Classification	
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964		2014							Serine/threonine kinase inhibitors	
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964	Bioorg. Med. Chem. Lett.	2015	25	19	4047	4056	26298497	10.1016/j.bmcl.2015.07.093	Recent progress on MAP kinase pathway inhibitors.	Uehling DE, Harris PA.
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964		2016							Serine/threonine kinase inhibitors	
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964	J Med Chem	2017	60	8	3438	3450	28376306	10.1021/acs.jmedchem.7b00267	Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.	Ward RA, Bethel P, Cook C, Davies E, Debreczeni JE, Fairley G, Feron L, Flemington V, Graham MA, Greenwood R, Griffin N, Hanson L, Hopcroft P, Howard TD, Hudson J, James M, Jones CD, Jones CR, Lamont S, Lewis R, Lindsay N, Roberts K, Simpson I, St-Gallay S, Swallow S, Tang J, Tonge M, Wang Z, Zhai B.
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964									Unpublished dataset	
1128.9500000000000000	9606	Homo sapiens	RAVOXERTINIB	CHEMBL3544964									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
924.8000000000000000	9606	Homo sapiens	REBASTINIB	CHEMBL1738757	Bioorg. Med. Chem. Lett.	2013	23	15	4398	4403	23787099	10.1016/j.bmcl.2013.05.072	Identification of potent Yes1 kinase inhibitors using a library screening approach.	Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
924.8000000000000000	9606	Homo sapiens	REBASTINIB	CHEMBL1738757	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	REBASTINIB	CHEMBL1738757									PubChem BioAssay data set	
924.8000000000000000	9606	Homo sapiens	REBASTINIB	CHEMBL1738757									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	REBASTINIB	CHEMBL1738757									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	REFAMETINIB	CHEMBL1236682	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	REFAMETINIB	CHEMBL1236682									Unpublished dataset	
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	Bioorg. Med. Chem. Lett.	2012	22	2	789	792	22222036	10.1016/j.bmcl.2011.11.060	Small molecule inhibitors of BRAF in clinical trials.	Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ.
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	Bioorg. Med. Chem. Lett.	2013	23	13	3732	3737	23726028	10.1016/j.bmcl.2013.05.011	Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.	Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD.
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	J. Med. Chem.	2015	58	7	2958	2966	25790278	10.1021/jm501873p	Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor ¿1 for the treatment of pain.	Wells MM, Tillman TS, Mowrey DD, Sun T, Xu Y, Tang P.
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	J. Med. Chem.	2016	59	8	3886	3905	27010810	10.1021/acs.jmedchem.6b00087	Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.	Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170	J Med Chem	2017	60	21	8801	8815	28991465	10.1021/acs.jmedchem.7b00841	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.	Kaitsiotou H, Keul M, Hardick J, Mühlenberg T, Ketzer J, Ehrt C, Krüll J, Medda F, Koch O, Giordanetto F, Bauer S, Rauh D.
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170									British National Formulary (72nd edition)	
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170									PubChem BioAssay data set	
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170									Unpublished dataset	
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
987.8666666666666667	9606	Homo sapiens	REGORAFENIB	CHEMBL1946170									WHO Anatomical Therapeutic Chemical Classification	
951.4000000000000000	1314	Streptococcus pyogenes	RETAPAMULIN	CHEMBL1658									British National Formulary (72nd edition)	
951.4000000000000000	1314	Streptococcus pyogenes	RETAPAMULIN	CHEMBL1658									Unpublished dataset	
951.4000000000000000	1314	Streptococcus pyogenes	RETAPAMULIN	CHEMBL1658									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
951.4000000000000000	1314	Streptococcus pyogenes	RETAPAMULIN	CHEMBL1658									WHO Anatomical Therapeutic Chemical Classification	
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304	J. Med. Chem.	2006	49	22	6549	6560	17064073	10.1021/jm0606138	Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.	Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer P, Yin X, Smith MA, Higgins BX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304									PubChem BioAssay data set	
884.4000000000000000	9606	Homo sapiens	RG-547	CHEMBL384304									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	RG-7304	CHEMBL3545081									Unpublished dataset	
884.4000000000000000	9606	Homo sapiens	RGB-286638	CHEMBL3545083	J Med Chem	2016	59	19	8667	8684	27171036	10.1021/acs.jmedchem.6b00150	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A.
884.4000000000000000	9606	Homo sapiens	RGB-286638	CHEMBL3545083	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	RGB-286638	CHEMBL3545083									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	RILPIVIRINE HYDROCHLORIDE	CHEMBL1628504									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	RILPIVIRINE HYDROCHLORIDE	CHEMBL1628504									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	RIVICICLIB	CHEMBL3545283									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	RIZATRIPTAN BENZOATE	CHEMBL1201032	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1098.4250000000000000	9606	Homo sapiens	RIZATRIPTAN BENZOATE	CHEMBL1201032									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	RIZATRIPTAN BENZOATE	CHEMBL1201032									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	RO-4987655	CHEMBL1614766	Bioorg. Med. Chem. Lett.	2011	21	6	1795	1801	21316218	10.1016/j.bmcl.2011.01.062	Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.	Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K, Miura T, Yoshimura Y, Aida S, Miwa M, Saitoh R, Murao N, Okabe H, Belunis C, Janson C, Lukacs C, Schück V, Shimma N.
1033.7000000000000000	9606	Homo sapiens	RO-4987655	CHEMBL1614766		2013							5-substituted-2-phenylamino benzamides as MEK inhibitors	
1033.7000000000000000	9606	Homo sapiens	RO-4987655	CHEMBL1614766	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	RO-4987655	CHEMBL1614766									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	1999	42	7	1274	1281	10197970	10.1021/jm980642l	2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.	Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	1999	9	13	1773	1778	10406640	10.1016/s0960-894x(99)00288-7	The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.	Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	1999	9	15	2207	2212	10465547	10.1016/s0960-894x(99)00365-0	SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.	Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Léger S, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	1999	9	22	3181	3186	10576684	10.1016/s0960-894x(99)00559-4	A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.	Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	1999	9	22	3187	3192	10576685	10.1016/s0960-894x(99)00560-0	Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.	Lau CK, Brideau C, Chan CC, Charleson S, Cromlish WA, Ethier D, Gauthier JY, Gordon R, Guay J, Kargman S, Li CS, Prasit P, Riendeau D, Thérien M, Visco DM, Xu L.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2000	10	23	2683	2686	11128651	10.1016/s0960-894x(00)00538-2	Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).	Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2001	11	2	165	168	11206450	10.1016/s0960-894x(00)00634-x	2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.	Shin SS, Noh MS, Byun YJ, Choi JK, Kim JY, Lim KM, Ha JY, Kim JK, Lee CH, Chung S.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2001	11	20	2687	2690	11591502	10.1016/s0960-894x(01)00534-0	Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors.	Feixas J, Jiménez JM, Godessart N, Puig C, Soca L, Crespo MI.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2001	44	18	3039	3042	11520213	10.1021/jm010153c	Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.	Habeeb AG, Praveen Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2002	12	19	2753	2756	12217369	10.1016/s0960-894x(02)00537-1	Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors.	Rahim MA, Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2002	12	22	3317	3320	12392741	10.1016/s0960-894x(02)00739-4	Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.	Leblanc Y, Roy P, Wang Z, Li CS, Chauret N, Nicoll-Griffith DA, Silva JM, Aubin Y, Yergey JA, Chan CC, Riendeau D, Brideau C, Gordon R, Xu L, Webb J, Visco DM, Prasit P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2002	12	4	533	537	11844666	10.1016/s0960-894x(01)00800-9	Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.	Palomer A, Pascual J, Cabré M, Borràs L, González G, Aparici M, Carabaza A, Cabré F, García ML, Mauleón D.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2002	12	5	779	782	11859001	10.1016/s0960-894x(02)00013-6	Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.	Barbey S, Goossens L, Taverne T, Cornet J, Choesmel V, Rouaud C, Gimeno G, Yannic-Arnoult S, Michaux C, Charlier C, Houssin R, Hénichart JP.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2002	45	7	1402	1411	11906281	10.1021/jm010458r	Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.	Palomer A, Cabré F, Pascual J, Campos J, Trujillo MA, Entrena A, Gallo MA, García L, Mauleón D, Espinosa A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2002	45	7	1511	1517	11906292	10.1021/jm010484p	4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).	Hashimoto H, Imamura K, Haruta J, Wakitani K.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Nat. Prod.	2002	65	11	1517	1521	12444669	10.1021/np020023m	Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.	Huss U, Ringbom T, Perera P, Bohlin L, Vasänge M.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Proc. Natl. Acad. Sci. U.S.A.	2003	100	1	9244	9249	12835412	10.1073/pnas.1033060100	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.	Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2003	13	10	1639	1643	12729631	10.1016/s0960-894x(03)00282-8	Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors.	Pal M, Rao Veeramaneni V, Nagabelli M, Rao Kalleda S, Misra P, Rao Casturi S, Rao Yeleswarapu K.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2003	13	13	2205	2209	12798335	10.1016/s0960-894x(03)00391-3	6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.	Rao PN, Amini M, Li H, Habeeb AG, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2003	13	4	657	660	12639552	10.1016/s0960-894x(02)01006-5	Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors.	Paramashivappa R, Phani Kumar P, Subba Rao PV, Srinivasa Rao A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2003	13	6	1195	1198	12643942	10.1016/s0960-894x(03)00046-5	3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.	Black WC, Brideau C, Chan CC, Charleson S, Cromlish W, Gordon R, Grimm EL, Hughes G, Leger S, Li CS, Riendeau D, Thérien M, Wang Z, Xu LJ, Prasit P.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2003	46	16	3463	3475	12877584	10.1021/jm030765s	Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.	Almansa C, Alfón J, de Arriba AF, Cavalcanti FL, Escamilla I, Gómez LA, Miralles A, Soliva R, Bartrolí J, Carceller E, Merlos M, García-Rafanell J.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2003	46	19	3975	3984	12954051	10.1021/jm020563g	Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.	Pal M, Madan M, Padakanti S, Pattabiraman VR, Kalleda S, Vanguri A, Mullangi R, Mamidi NV, Casturi SR, Malde A, Gopalakrishnan B, Yeleswarapu KR.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2003	46	23	4872	4882	14584938	10.1021/jm0302391	Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.	Praveen Rao PN, Amini M, Li H, Habeeb AG, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2003	46	25	5484	5504	14640557	10.1021/jm030268b	Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.	Khanapure SP, Garvey DS, Young DV, Ezawa M, Earl RA, Gaston RD, Fang X, Murty M, Martino A, Shumway M, Trocha M, Marek P, Tam SW, Janero DR, Letts LG.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	19	4911	4914	15341950	10.1016/j.bmcl.2004.07.027	A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors.	Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	21	5445	5448	15454242	10.1016/j.bmcl.2004.07.089	Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.	Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	24	6049	6052	15546727	10.1016/j.bmcl.2004.09.073	3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.	Ranatunge RR, Earl RA, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schwalb DJ, Young DV, Zemtseva IS.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	5	1201	1203	14980665	10.1016/j.bmcl.2003.12.047	Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2.	Riendeau D, Salem M, Styhler A, Ouellet M, Mancini JA, Li CS.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	8	1953	1956	15050635	10.1016/j.bmcl.2004.01.075	Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors.	Uddin MJ, Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2004	14	8	1957	1960	15050636	10.1016/j.bmcl.2004.01.076	Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor.	Zarghi A, Praveen Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	15	3874	3886	15239665	10.1021/jm049882t	Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.	Caturla F, Jiménez JM, Godessart N, Amat M, Cárdenas A, Soca L, Beleta J, Ryder H, Crespo MI.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	16	3972	3990	15267236	10.1021/jm049939b	Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.	Rao PN, Uddin MJ, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	24	6108	6111	15537365	10.1021/jm049523y	A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.	Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	25	6195	6206	15566290	10.1021/jm0407761	New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.	Pommery N, Taverne T, Telliez A, Goossens L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F, Hénichart JP.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2004	47	9	2180	2193	15084117	10.1021/jm030276s	Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.	Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schroeder JD, Shumway MJ, Tam SW, Trocha AM, Young DV.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2005	15	2	439	442	15603969	10.1016/j.bmcl.2004.10.050	Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme.	Uddin MJ, Rao PN, McDonald R, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2005	15	21	4842	4845	16143531	10.1016/j.bmcl.2005.07.036	Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases.	Rao PN, Chen QH, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2005	48	11	3930	3934	15916445	10.1021/jm0582064	3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.	Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2005	48	22	6997	7004	16250658	10.1021/jm050619h	Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.	Franke L, Byvatov E, Werz O, Steinhilber D, Schneider P, Schneider G.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2005	48	9	3428	3432	15857149	10.1021/jm049121q	1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.	Biava M, Porretta GC, Cappelli A, Vomero S, Manetti F, Botta M, Sautebin L, Rossi A, Makovec F, Anzini M.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Nat. Prod.	2005	68	7	985	991	16038536	10.1021/np049655u	Expanding the ChemGPS chemical space with natural products.	Larsson J, Gottfries J, Bohlin L, Backlund A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122		2005							Combination of selected analgesics and COX-II inhibitors	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2006	16	12	3209	3212	16616494	10.1016/j.bmcl.2006.03.052	Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.	Caturla F, Amat M, Reinoso RF, Córdoba M, Warrellow G.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2006	16	13	3605	3608	16647258	10.1016/j.bmcl.2006.03.101	Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.	Caturla F, Amat M, Reinoso RF, Calaf E, Warrellow G.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Nat. Chem. Biol.	2006	2	6	329	337	16680159	10.1038/nchembio790	Identifying off-target effects and hidden phenotypes of drugs in human cells.	MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2006	49	5	1668	1683	16509583	10.1021/jm0510474	Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.	Rao PN, Chen QH, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2007	15	2	1056	1061	17067801	10.1016/j.bmc.2006.10.023	Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity.	Zarghi A, Praveen Rao PN, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2007	15	21	6796	6801	17764958	10.1016/j.bmc.2007.07.021	Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies.	Abdellatif KR, Dong Y, Chen QH, Chowdhury MA, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2007	50	7	1449	1457	17335184	10.1021/jm0607247	NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.	Chegaev K, Lazzarato L, Tosco P, Cena C, Marini E, Rolando B, Carrupt PA, Fruttero R, Gasco A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Nat. Prod.	2007	70	5	859	862	17378609	10.1021/np0605539	Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti.	Deng S, Palu 'K, West BJ, Su CX, Zhou BN, Jensen JC.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2008	16	4	1948	1956	18023187	10.1016/j.bmc.2007.11.003	Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers.	Chowdhury MA, Dong Y, Chen QH, Abdellatif KR, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2008	16	5	2183	2199	18158247	10.1016/j.bmc.2007.11.079	Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors.	Orjales A, Mosquera R, López B, Olivera R, Labeaga L, Núñez MT.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2008	16	6	3302	3308	18096394	10.1016/j.bmc.2007.12.006	Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.	Abdellatif KR, Chowdhury MA, Dong Y, Chen QH, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2008	16	7	3907	3916	18272371	10.1016/j.bmc.2008.01.047	Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.	Reddy MV, Billa VK, Pallela VR, Mallireddigari MR, Boominathan R, Gabriel JL, Reddy EP.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2008	18	1	85	89	18061444	10.1016/j.bmcl.2007.11.010	1-Toluene-sulfonyl-3-[(3'-hydroxy-5'-substituted)-gamma-butyrolactone]-indoles: synthesis, COX-2 inhibition and anti-cancer activities.	Singh P, Mittal A, Bhardwaj A, Kaur S, Kumar S.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2008	18	6	2048	2054	18291643	10.1016/j.bmcl.2008.01.103	Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.	Burch JD, Belley M, Fortin R, Deschênes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, Vigneault E, Lévesque JF, Gagné S, Wrona M, Xu D, Clark P, Rowland S, Han Y.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2008	43	1	129	134	17467123	10.1016/j.ejmech.2007.02.008	2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.	Franklin PX, Pillai AD, Rathod PD, Yerande S, Nivsarkar M, Padh H, Vasu KK, Sudarsanam V.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2008	43	12	2792	2799	18262309	10.1016/j.ejmech.2007.12.017	2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols.	Singh P, Mittal A, Kaur S, Kumar S.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2008	51	15	4476	4481	18598017	10.1021/jm800084s	Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.	Anzini M, Rovini M, Cappelli A, Vomero S, Manetti F, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Norcini M, Giordani A, Makovec F, Anzellotti P, Patrignani P, Biava M.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2009	19	15	4504	4508	19520573	10.1016/j.bmcl.2009.02.085	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.	Swarbrick ME, Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2009	19	2	459	461	19056264	10.1016/j.bmcl.2008.11.045	Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors.	Zanatta SD, Manallack DT, Jarrott B, Williams SJ.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2009	44	5	1830	1837	19084295	10.1016/j.ejmech.2008.10.039	Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors.	Dündar Y, Unlü S, Bano¿lu E, Entrena A, Costantino G, Nuñez MT, Labeaga L, Sahin MF, Noyanalpan N.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2009	52	19	5785	5788	19743867	10.1021/jm9009857	Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.	Giblin GM, Billinton A, Briggs M, Brown AJ, Chessell IP, Clayton NM, Eatherton AJ, Goldsmith P, Haslam C, Johnson MR, Mitchell WL, Naylor A, Perboni A, Slingsby BP, Wilson AW.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Antimicrob. Agents Chemother.	2009	53	7	2998	3002	19398640	10.1128/aac.00048-09	Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.	Chiu HC, Yang J, Soni S, Kulp SK, Gunn JS, Schlesinger LS, Chen CS.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2010	18	17	6367	6376	20692174	10.1016/j.bmc.2010.07.009	Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors.	Eren G, Unlü S, Nuñez MT, Labeaga L, Ledo F, Entrena A, Bano¿lu E, Costantino G, Sahin MF.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2010	20	12	3760	3763	20471829	10.1016/j.bmcl.2010.04.065	Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.	Colucci J, Boyd M, Berthelette C, Chiasson JF, Wang Z, Ducharme Y, Friesen R, Wrona M, Levesque JF, Denis D, Mathieu MC, Stocco R, Therien AG, Clarke P, Rowland S, Xu D, Han Y.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2010	20	23	6978	6982	20965723	10.1016/j.bmcl.2010.09.129	Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.	Wu TY, Juteau H, Ducharme Y, Friesen RW, Guiral S, Dufresne L, Poirier H, Salem M, Riendeau D, Mancini J, Brideau C.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2010	53	18	6560	6571	20804197	10.1021/jm100398z	Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.	Harrak Y, Casula G, Basset J, Rosell G, Plescia S, Raffa D, Cusimano MG, Pouplana R, Pujol MD.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2010	53	5	2227	2238	20163116	10.1021/jm901771h	The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.	Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M, Wrona M, Lévesque JF, Denis D, Mathieu MC, Stocco R, Vigneault E, Therien A, Clark P, Rowland S, Xu D, O'Neill G, Ducharme Y, Friesen R.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2010	53	9	3707	3717	20387815	10.1021/jm1001327	Mono-, di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation.	Singh P, Bhardwaj A.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2011	19	11	3299	3311	21570308	10.1016/j.bmc.2011.04.050	Synthesis and biological evaluation of loxoprofen derivatives.	Yamakawa N, Suemasu S, Matoyama M, Tanaka K, Katsu T, Miyata K, Okamoto Y, Otsuka M, Mizushima T.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2011	19	21	6316	6328	21958737	10.1016/j.bmc.2011.09.003	Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors.	Tan CM, Chen GS, Chen CS, Chang PT, Chern JW.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Med Chem Res	2011	20	8	1294	1297		10.1007/s00044-010-9454-7	Goat brain enkephalin degrading enzyme: interaction with analgesic and antihypertensive drugs	Dhanda S, Singh J, Singh H
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2011	21	13	3951	3956	21641217	10.1016/j.bmcl.2011.05.017	A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies.	Abdellatif KR, Huang Z, Chowdhury MA, Kaufman S, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2011	21	16	4888	4890	21752640	10.1016/j.bmcl.2011.06.029	Bioactive sulfoximines: syntheses and properties of Vioxx analogs.	Park SJ, Buschmann H, Bolm C.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2011	54	8	3037	3050	21434686	10.1021/jm2001376	Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.	Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Med Chem Res	2012	21	10	3053	3062		10.1007/s00044-011-9819-6	Alkoxyphenyl methanesulfonamides: synthesis, anti-inflammatory effect, and docking studies	Bali A, Dhillon SK, Balakumar C
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2012	22	13	4307	4309	22652053	10.1016/j.bmcl.2012.05.018	Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins.	Chen XY, Park SJ, Buschmann H, De Rosa M, Bolm C.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2012	22	2	820	823	22222039	10.1016/j.bmcl.2011.12.062	Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors.	Raghavendra NM, Jyothsna A, Venkateswara Rao A, Subrahmanyam CV.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2012	49		397	405	22318166	10.1016/j.ejmech.2012.01.018	Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents.	Bali A, Ohri R, Deb PK.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	J. Med. Chem.	2012	55	5	2287	2300	22263894	10.1021/jm201528b	Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.	Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2013	23	1	163	168	23200247	10.1016/j.bmcl.2012.10.131	Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.	Bhardwaj A, Kaur J, Sharma SK, Huang Z, Wuest F, Knaus EE.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem. Lett.	2013	23	11	3443	3447	23597790	10.1016/j.bmcl.2013.03.082	Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.	Plummer MS, Cornicelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, Lu XK, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2013	65		323	336	23735281	10.1016/j.ejmech.2013.04.062	Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.	Liu GZ, Xu HW, Wang P, Lin ZT, Duan YC, Zheng JX, Liu HM.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg. Med. Chem.	2014	22	8	2529	2534	24650702	10.1016/j.bmc.2014.02.032	Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.	Yamakawa N, Suzuki K, Yamashita Y, Katsu T, Hanaya K, Shoji M, Sugai T, Mizushima T.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	ACS Med. Chem. Lett.	2014	5	11	1254	1258	25408841	10.1021/ml500344j	Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors.	Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Eur. J. Med. Chem.	2014	84		302	311	25036790	10.1016/j.ejmech.2014.07.025	Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.	Rödl CB, Vogt D, Kretschmer SB, Ihlefeld K, Barzen S, Brüggerhoff A, Achenbach J, Proschak E, Steinhilber D, Stark H, Hofmann B.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122	Bioorg Med Chem Lett	2017	27	13	3007	3013	28512025	10.1016/j.bmcl.2017.05.017	Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect.	Sharma R, Bali A, Chaudhari BB.
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	ROFECOXIB	CHEMBL122									WHO Anatomical Therapeutic Chemical Classification	
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448	Bioorg. Med. Chem.	2011	19	12	3650	3658	21420302	10.1016/j.bmc.2011.02.024	Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.	Benelkebir H, Marie S, Hayden AL, Lyle J, Loadman PM, Crabb SJ, Packham G, Ganesan A.
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448	Bioorg. Med. Chem. Lett.	2012	22	21	6770	6772	23021104	10.1016/j.bmcl.2012.03.004	Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.	Hoque MA, Arai T, Nishino N, Kim HJ, Ito A, Yoshida M.
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448	ACS Med. Chem. Lett.	2012	3	6	505	508	24900500	10.1021/ml300081u	Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.	Vickers CJ, Olsen CA, Leman LJ, Ghadiri MR.
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448	Eur. J. Med. Chem.	2012	49		24	40	22305612	10.1016/j.ejmech.2012.01.033	Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.	Xia Y, Choi HK, Lee K.
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448									PubChem BioAssay data set	
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	ROMIDEPSIN	CHEMBL343448									WHO Anatomical Therapeutic Chemical Classification	
1019.4000000000000000	9606	Homo sapiens	RWJ-67657	CHEMBL190333	J. Med. Chem.	2005	48	7	2270	2273	15801819	10.1021/jm048978k	Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.	de Dios A, Shih C, López de Uralde B, Sánchez C, del Prado M, Martín Cabrejas LM, Pleite S, Blanco-Urgoiti J, Lorite MJ, Nevill CR, Bonjouklian R, York J, Vieth M, Wang Y, Magnus N, Campbell RM, Anderson BD, McCann DJ, Giera DD, Lee PA, Schultz RM, Li LC, Johnson LM, Wolos JA.
1019.4000000000000000	9606	Homo sapiens	RWJ-67657	CHEMBL190333	Antimicrob. Agents Chemother.	2007	51	12	4324	4328	17923491	10.1128/aac.00680-07	Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.	Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ.
1019.4000000000000000	9606	Homo sapiens	RWJ-67657	CHEMBL190333	J. Med. Chem.	2010	53	21	7767	7777	20936874	10.1021/jm100729b	Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.	Kularatne SA, Venkatesh C, Santhapuram HK, Wang K, Vaitilingam B, Henne WA, Low PS.
1019.4000000000000000	9606	Homo sapiens	RWJ-67657	CHEMBL190333									PubChem BioAssay data set	
1019.4000000000000000	9606	Homo sapiens	RWJ-67657	CHEMBL190333									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	SAR-407899	CHEMBL3545341									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	J. Med. Chem.	2006	49	22	6465	6488	17064066	10.1021/jm060434q	N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.	Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Plé PA, Warin N, Costello G.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Proc. Natl. Acad. Sci. U.S.A.	2007	104	50	19936	19941	18077425	10.1073/pnas.0707498104	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Proc. Natl. Acad. Sci. U.S.A.	2007	104	9	3520	3525	17360676	10.1073/pnas.0611681104	c-Src protein kinase inhibitors block assembly and maturation of dengue virus.	Chu JJ, Yang PL.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Bioorg. Med. Chem.	2009	17	8	3152	3161	19321350	10.1016/j.bmc.2009.02.054	Structure-based virtual screening of Src kinase inhibitors.	Lee K, Kim J, Jeong KW, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	J. Med. Chem.	2010	53	11	4332	4353	20218623	10.1021/jm9018756	Emerging targets in osteoporosis disease modification.	Allen JG, Fotsch C, Babij P.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Bioorg. Med. Chem.	2011	19	8	2517	2528	21459579	10.1016/j.bmc.2011.03.021	Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.	Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Bioorg. Med. Chem. Lett.	2013	23	15	4398	4403	23787099	10.1016/j.bmcl.2013.05.072	Identification of potent Yes1 kinase inhibitors using a library screening approach.	Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Eur. J. Med. Chem.	2014	87		677	702	25305334	10.1016/j.ejmech.2014.10.010	A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.	Bhakat S, Karubiu W, Jayaprakash V, Soliman ME.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	J. Med. Chem.	2015	58	12	4964	4975	26039671	10.1021/acs.jmedchem.5b00108	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.	Vincetti P, Caporuscio F, Kaptein S, Gioiello A, Mancino V, Suzuki Y, Yamamoto N, Crespan E, Lossani A, Maga G, Rastelli G, Castagnolo D, Neyts J, Leyssen P, Costantino G, Radi M.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	ACS Med. Chem. Lett.	2015	6	7	798	803	26191369	10.1021/acsmedchemlett.5b00143	Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.	Murray CW, Berdini V, Buck IM, Carr ME, Cleasby A, Coyle JE, Curry JE, Day JE, Day PJ, Hearn K, Iqbal A, Lee LY, Martins V, Mortenson PN, Munck JM, Page LW, Patel S, Roomans S, Smith K, Tamanini E, Saxty G.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092	J Med Chem	2017	60	18	7863	7875	28792760	10.1021/acs.jmedchem.7b00996	Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.	Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E.
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092									PubChem BioAssay data set	
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092									Unpublished dataset	
924.8000000000000000	9606	Homo sapiens	SARACATINIB	CHEMBL217092									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
998.6000000000000000	9606	Homo sapiens	SELADELPAR	CHEMBL230158	Bioorg. Med. Chem. Lett.	2007	17	14	3855	3859	17524639	10.1016/j.bmcl.2007.05.007	Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.	Zhang R, Wang A, DeAngelis A, Pelton P, Xu J, Zhu P, Zhou L, Demarest K, Murray WV, Kuo GH.
998.6000000000000000	9606	Homo sapiens	SELADELPAR	CHEMBL230158									Unpublished dataset	
998.6000000000000000	9606	Homo sapiens	SELADELPAR	CHEMBL230158									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	1997	40	4	408	412	9046330	10.1021/jm960666x	Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.	Havlícek L, Hanus J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	1998	8	7	793	798	9871543	10.1016/s0960-894x(98)00097-3	Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.	Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2000	10	5	461	464	10743948	10.1016/s0960-894x(00)00014-7	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.	Ryu CK, Kang HY, Lee SK, Nam KA, Hong CY, Ko WG, Lee BH.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2000	43	1	1	18	10633033	10.1021/jm991182e	Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.	Sielecki TM, Boylan JF, Benfield PA, Trainor GL.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2000	43	22	4098	4108	11063606	10.1021/jm000965t	3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.	Ducrot P, Legraverend M, Grierson DS.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2000	43	7	1282	1292	10753466	10.1021/jm9911130	Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.	Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2001	44	4	524	530	11170642	10.1021/jm001043t	Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.	Dreyer MK, Borcherding DR, Dumont JA, Peet NP, Tsay JT, Wright PS, Bitonti AJ, Shen J, Kim SH.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Nat. Prod.	2001	64	4	525	526	11325241	10.1021/np000546z	Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species.	Killday KB, Yarwood D, Sills MA, Murphy PT, Hooper JN, Wright AE.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2002	12	22	3283	3286	12392733	10.1016/s0960-894x(02)00693-5	Synthesis and biological activity of olomoucine II.	Krystof V, Lenobel R, Havlícek L, Kuzma M, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2002	12	7	1129	1132	11909733	10.1016/s0960-894x(02)00094-x	Beta-carbolines as specific inhibitors of cyclin-dependent kinases.	Song Y, Wang J, Teng SF, Kesuma D, Deng Y, Duan J, Wang JH, Qi RZ, Sim MM.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2002	45	12	2366	2378	12036347	10.1021/jm011002c	Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.	Naumann T, Matter H.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2003	13	18	2993	2996	12941319	10.1016/s0960-894x(03)00632-2	2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.	Moravec J, Krystof V, Hanus J, Havlícek L, Moravcová D, Fuksová K, Kuzma M, Lenobel R, Otyepka M, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2003	46	18	3877	3882	12930149	10.1021/jm0300983	Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.	Woodard CL, Li Z, Kathcart AK, Terrell J, Gerena L, Lopez-Sanchez M, Kyle DE, Bhattacharjee AK, Nichols DA, Ellis W, Prigge ST, Geyer JA, Waters NC.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2004	14	7	1703	1704	15026054	10.1016/j.bmcl.2004.01.050	Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.	Gompel M, Leost M, De Kier Joffe EB, Puricelli L, Franco LH, Palermo J, Meijer L.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Nat. Biotechnol.	2005	23	3	329	336	15711537	10.1038/nbt1068	A small molecule-kinase interaction map for clinical kinase inhibitors.	Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2005	48	3	671	679	15689152	10.1021/jm049323m	Mechanism of CDK5/p25 binding by CDK inhibitors.	Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Cancer Res.	2005	65	12	5399	5407	15958589	10.1158/0008-5472.can-05-0233	Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.	MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2006	16	14	3772	3776	16698266	10.1016/j.bmcl.2006.04.042	Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.	Kim ND, Yoon J, Kim JH, Lee JT, Chon YS, Hwang MK, Ha I, Song WJ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Nat. Chem. Biol.	2006	2	6	329	337	16680159	10.1038/nchembio790	Identifying off-target effects and hidden phenotypes of drugs in human cells.	MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2006	49	22	6500	6509	17064068	10.1021/jm0605740	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.	Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	AAPS J	2006	8	1	E204	E221	16584130	10.1208/aapsj080125	Selectivity and potency of cyclin-dependent kinase inhibitors.	Sridhar J, Akula N, Pattabiraman N.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Proc. Natl. Acad. Sci. U.S.A.	2007	104	51	20523	20528	18077363	10.1073/pnas.0708800104	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Biochem. J.	2007	408	3	297	315	17850214	10.1042/bj20070797	The selectivity of protein kinase inhibitors: a further update.	Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Nat. Biotechnol.	2008	26	1	127	132	18183025	10.1038/nbt1358	A quantitative analysis of kinase inhibitor selectivity.	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2008	43	11	2316	2322	18313174	10.1016/j.ejmech.2008.01.010	Synthesis and biological evaluation of diversely substituted indolin-2-ones.	Bouchikhi F, Rossignol E, Sancelme M, Aboab B, Anizon F, Fabbro D, Prudhomme M, Moreau P.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2008	43	7	1469	1477	17981370	10.1016/j.ejmech.2007.09.020	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies.	Logé C, Testard A, Thiéry V, Lozach O, Blairvacq M, Robert JM, Meijer L, Besson T.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2008	51	16	4986	4999	18656911	10.1021/jm800382h	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.	Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, Saxty G, Seavers LC, Smith DM, Squires MS, Trewartha G, Walker MT, Woolford AJ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2008	51	16	5035	5042	18680271	10.1021/jm8002813	NMR screening for lead compounds using tryptophan-mutated proteins.	Rothweiler U, Czarna A, Weber L, Popowicz GM, Brongel K, Kowalska K, Orth M, Stemmann O, Holak TA.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2008	51	17	5229	5242	18698753	10.1021/jm800109e	Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.	Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard ML, Myrianthopoulos V, Mikros E, Flajolet M, Greengard P, Meijer L, Galons H.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2008	51	9	2589	2599	18393402	10.1021/jm0704090	Natural products as leads to potential drugs: an old process or the new hope for drug discovery?	Newman DJ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Nat. Prod.	2008	71	4	689	692	18271552	10.1021/np070341r	Butyrolactone I derivatives from Aspergillus terreus carrying an unusual sulfate moiety.	Niu X, Dahse HM, Menzel KD, Lozach O, Walther G, Meijer L, Grabley S, Sattler I.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2009	17	17	6257	6263	19665384	10.1016/j.bmc.2009.07.051	Synthesis and kinase inhibitory activity of novel substituted indigoids.	Beauchard A, Laborie H, Rouillard H, Lozach O, Ferandin Y, Le Guével R, Guguen-Guillouzo C, Meijer L, Besson T, Thiéry V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2009	19	23	6608	6612	19846305	10.1016/j.bmcl.2009.10.025	Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.	Trova MP, Barnes KD, Barford C, Benanti T, Bielaska M, Burry L, Lehman JM, Murphy C, O'Grady H, Peace D, Salamone S, Smith J, Snider P, Toporowski J, Tregay S, Wilson A, Wyle M, Zheng X, Friedrich TD.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2009	19	23	6613	6617	19854650	10.1016/j.bmcl.2009.10.011	Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.	Trova MP, Barnes KD, Alicea L, Benanti T, Bielaska M, Bilotta J, Bliss B, Duong TN, Haydar S, Herr RJ, Hui Y, Johnson M, Lehman JM, Peace D, Rainka M, Snider P, Salamone S, Tregay S, Zheng X, Friedrich TD.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2009	19	8	2324	2328	19282176	10.1016/j.bmcl.2009.02.062	QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.	Koo KA, Kim ND, Chon YS, Jung MS, Lee BJ, Kim JH, Song WJ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2009	52	3	655	663	19128055	10.1021/jm801340z	Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.	Popowycz F, Fournet G, Schneider C, Bettayeb K, Ferandin Y, Lamigeon C, Tirado OM, Mateo-Lozano S, Notario V, Colas P, Bernard P, Meijer L, Joseph B.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Med Chem Res	2010	19	8	817	835		10.1007/s00044-009-9233-5	Molecular docking study on anticancer activity of plant-derived natural products	Phosrithong N, Ungwitayatorn J
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2010	53	24	8508	8522	21080703	10.1021/jm100732t	A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.	Heathcote DA, Patel H, Kroll SH, Hazel P, Periyasamy M, Alikian M, Kanneganti SK, Jogalekar AS, Scheiper B, Barbazanges M, Blum A, Brackow J, Siwicka A, Pace RD, Fuchter MJ, Snyder JP, Liotta DC, Freemont PS, Aboagye EO, Coombes RC, Barrett AG, Ali S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2010	53	9	3696	3706	20361800	10.1021/jm100080z	5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.	Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2011	19	1	359	373	21144757	10.1016/j.bmc.2010.11.022	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25.	Jain P, Flaherty PT, Yi S, Chopra I, Bleasdell G, Lipay J, Ferandin Y, Meijer L, Madura JD.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2011	19	22	6949	6965	21982796	10.1016/j.bmc.2011.08.051	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.	Wilson SC, Atrash B, Barlow C, Eccles S, Fischer PM, Hayes A, Kelland L, Jackson W, Jarman M, Mirza A, Moreno J, Nutley BP, Raynaud FI, Sheldrake P, Walton M, Westwood R, Whittaker S, Workman P, McDonald E.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2011	19	8	2714	2725	21440449	10.1016/j.bmc.2011.02.052	Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.	Yenugonda VM, Deb TB, Grindrod SC, Dakshanamurthy S, Yang Y, Paige M, Brown ML.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2011	21	13	3957	3961	21641213	10.1016/j.bmcl.2011.05.019	Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.	Nair N, Kudo W, Smith MA, Abrol R, Goddard WA, Reddy VP.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2011	21	7	2098	2101	21353545	10.1016/j.bmcl.2011.01.140	Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.	Laha JK, Zhang X, Qiao L, Liu M, Chatterjee S, Robinson S, Kosik KS, Cuny GD.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2011	46	11	5416	5434	21944287	10.1016/j.ejmech.2011.08.048	Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.	Kassis P, Brzeszcz J, Bénéteau V, Lozach O, Meijer L, Le Guével R, Guillouzo C, Lewi¿ski K, Bourg S, Colliandre L, Routier S, Mérour JY.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2011	46	12	5825	5832	22000924	10.1016/j.ejmech.2011.09.041	Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.	Ibrahim DA, Ismail NS.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2011	46	6	2043	2057	21429632	10.1016/j.ejmech.2011.02.057	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.	Shallal HM, Russu WA.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2011	46	6	2066	2074	21420204	10.1016/j.ejmech.2011.02.059	Studying synergism of methyl linked cyclohexyl thiophenes with triazole: synthesis and their cdk5/p25 inhibition activity.	Shiradkar M, Thomas J, Kanase V, Dighe R.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2011	54	12	4172	4186	21615147	10.1021/jm200274d	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.	Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2011	54	8	2980	2993	21417417	10.1021/jm200064p	Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.	Jorda R, Havlícek L, McNae IW, Walkinshaw MD, Voller J, Sturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Krystof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2012	22	22	6947	6951	23036956	10.1016/j.bmcl.2012.08.117	Design, synthesis and anticancer activity of 1-acyl-3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives.	Bai XG, Yu DK, Wang JX, Zhang H, He HW, Shao RG, Li XM, Wang YC.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	ACS Med. Chem. Lett.	2012	3	12	985	990	24936234	10.1021/ml3002083	Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.	Liang M, Tarr TB, Bravo-Altamirano K, Valdomir G, Rensch G, Swanson L, DeStefino NR, Mazzarisi CM, Olszewski RA, Wilson GM, Meriney SD, Wipf P.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Journal of Applied Toxicology	2012	32		858	866	22761000	10.1002/jat.2784	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.	Wi¿niowska B, Mendyk A, Fijorek K, Glinka A, Polak S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2012	56		210	216	22982525	10.1016/j.ejmech.2012.08.033	Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.	N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2012	57		225	233	23063566	10.1016/j.ejmech.2012.09.001	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K¿ inhibitors.	Bruel A, Logé C, Tauzia ML, Ravache M, Le Guevel R, Guillouzo C, Lohier JF, Oliveira Santos JS, Lozach O, Meijer L, Ruchaud S, Bénédetti H, Robert JM.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2013	21	5	1078	1081	23352483	10.1016/j.bmc.2013.01.004	New PAH derivatives functionalized by cyclic nitrone framework: synthetic design, anti-proliferative activity and interaction with DNA.	Buchlovi¿ M, K¿í¿ Z, Hofr C, Potá¿ek M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2013	21	7	2107	2116	23394865	10.1016/j.bmc.2013.01.009	Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents.	Montanaro G, Bertinaria M, Rolando B, Fruttero R, Lucas CD, Dorward DA, Rossi AG, Megson IL, Gasco A.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2013	23	1	125	131	23218601	10.1016/j.bmcl.2012.10.141	Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.	Demange L, Abdellah FN, Lozach O, Ferandin Y, Gresh N, Meijer L, Galons H.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2013	23	11	3208	3215	23623491	10.1016/j.bmcl.2013.03.129	Synthesis of pyrazolo[1,5-a]pyrimidine linked aminobenzothiazole conjugates as potential anticancer agents.	Kamal A, Tamboli JR, Nayak VL, Adil SF, Vishnuvardhan MV, Ramakrishna S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2013	23	18	5150	5154	23927974	10.1016/j.bmcl.2013.07.020	Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.	Shrestha S, Natarajan S, Park JH, Lee DY, Cho JG, Kim GS, Jeon YJ, Yeon SW, Yang DC, Baek NI.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2013	56	15	6234	6247	23829517	10.1021/jm4006884	A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.	Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, ¿ezní¿ková E, Béres T, Strnad M, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2013	56	23	9569	9585	24188002	10.1021/jm401049v	Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.	Gourdain S, Dairou J, Denhez C, Bui LC, Rodrigues-Lima F, Janel N, Delabar JM, Cariou K, Dodd RH.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2013	56	3	640	659	23301767	10.1021/jm301475f	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2013	56	3	660	670	23252711	10.1021/jm301495v	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.	Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA, Noble ME.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2013	61		61	72	22770608	10.1016/j.ejmech.2012.06.036	Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.	Zatloukal M, Jorda R, Gucký T, ¿ezní¿ková E, Voller J, Pospí¿il T, Malínková V, Adamcová H, Kry¿tof V, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2013	62		443	452	23399722	10.1016/j.ejmech.2013.01.021	Synthesis and biological evaluation of guanidino analogues of roscovitine.	Dole¿ková I, Cesnek M, Dra¿inský M, Brynda J, Voller J, Janeba Z, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2013	68		1	9	23933045	10.1016/j.ejmech.2013.07.003	Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.	Sun J, Lv XH, Qiu HY, Wang YT, Du QR, Li DD, Yang YH, Zhu HL.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2013	68		253	259	23981532	10.1016/j.ejmech.2013.08.009	Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines.	Imramovský A, Jorda R, Pauk K, Rezní¿ková E, Du¿ek J, Hanusek J, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2014	57	3	578	599	24417566	10.1021/jm401073p	Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).	Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR, Billa VK, Subbaiah DR, Bharathi EV, Vasquez-Del Carpio R, Padgaonkar A, Baker SJ, Reddy EP.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2014	78		217	224	24681986	10.1016/j.ejmech.2014.03.054	Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.	Mojzych M, ¿ubertová V, Bielawska A, Bielawski K, Bazgier V, Berka K, Gucký T, Fornal E, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2014	83		617	629	24998602	10.1016/j.ejmech.2014.06.063	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.	Putey A, Fournet G, Lozach O, Perrin L, Meijer L, Joseph B.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2015	101		274	287	26142492	10.1016/j.ejmech.2015.06.046	Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.	Boulahjar R, Ouach A, Bourg S, Bonnet P, Lozach O, Meijer L, Guguen-Guillouzo C, Le Guevel R, Lazar S, Akssira M, Troin Y, Guillaumet G, Routier S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem.	2015	23	7	1421	1429	25757603	10.1016/j.bmc.2015.02.026	New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity.	Mojzych M, Karczmarzyk Z, Wysocki W, Ceruso M, Supuran CT, Kry¿tof V, Urba¿czyk-Lipkowska Z, Kalicki P.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2015	25	11	2298	2301	25937014	10.1016/j.bmcl.2015.04.030	2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.	¿ezní¿ková E, Popa A, Gucký T, Zatloukal M, Havlí¿ek L, Bazgier V, Berka K, Jorda R, Popa I, Nasereddin A, Jaffe CL, Kry¿tof V, Strnad M.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2015	98		1	12	25988923	10.1016/j.ejmech.2015.04.062	Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents.	Chiou CT, Lee WC, Liao JH, Cheng JJ, Lin LC, Chen CY, Song JS, Wu MH, Shia KS, Li WT.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2016	108		347	353	26698538	10.1016/j.ejmech.2015.11.043	Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes.	Bhambra AS, Edgar M, Elsegood MR, Li Y, Weaver GW, Arroo RR, Yardley V, Burrell-Saward H, Krystof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2016	108		701	719	26741853	10.1016/j.ejmech.2015.12.023	Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.	Baltus CB, Jorda R, Marot C, Berka K, Bazgier V, Kry¿tof V, Prié G, Viaud-Massuard MC.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2016	110		291	301	26851505	10.1016/j.ejmech.2016.01.011	5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.	Vym¿talová L, Havlí¿ek L, ¿turc A, Skrá¿ková Z, Jorda R, Pospí¿il T, Strnad M, Kry¿tof V.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur. J. Med. Chem.	2016	115		311	325	27019296	10.1016/j.ejmech.2016.02.072	Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.	Ouach A, Boulahjar R, Vala C, Bourg S, Bonnet P, Guguen-Guillouzo C, Ravache M, Le Guevel R, Lozach O, Lazar S, Troin Y, Meijer L, Ruchaud S, Akssira M, Guillaumet G, Routier S.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg. Med. Chem. Lett.	2016	26	13	3093	3097	27189674	10.1016/j.bmcl.2016.05.004	RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.	Lamie PF.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J. Med. Chem.	2016	59	9	4121	4151	27046190	10.1021/acs.jmedchem.6b00078	Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.	Ehrt C, Brinkjost T, Koch O.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Eur J Med Chem	2017	125		696	709	27721154	10.1016/j.ejmech.2016.09.064	Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.	Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Bioorg Med Chem	2017	25	6	1817	1829	28214231	10.1016/j.bmc.2017.01.049	Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.	Thieury C, Lebouvier N, Le Guével R, Barguil Y, Herbette G, Antheaume C, Hnawia E, Asakawa Y, Nour M, Guillaudeux T.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762	J Med Chem	2017	60	12	4949	4962	28557430	10.1021/acs.jmedchem.7b00324	Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.	Cheng X, Merz KH, Vatter S, Zeller J, Muehlbeyer S, Thommet A, Christ J, Wölfl S, Eisenbrand G.
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762									PubChem BioAssay data set	
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762									Unpublished dataset	
884.4000000000000000	9606	Homo sapiens	SELICICLIB	CHEMBL14762									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Bioorg. Med. Chem. Lett.	2013	23	8	2384	2390	23474388	10.1016/j.bmcl.2013.02.028	Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.	Hartung IV, Hitchcock M, Pühler F, Neuhaus R, Scholz A, Hammer S, Petersen K, Siemeister G, Brittain D, Hillig RC.
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Eur J Med Chem	2016	122		611	618	27448918	10.1016/j.ejmech.2016.06.043	Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells.	Grasso S, Pereira GJS, Palmeira-Dos-Santos C, Calgarotto AK, Martínez-Lacaci I, Ferragut JA, Smaili SS, Bincoletto C.
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Bioorg. Med. Chem. Lett.	2016	26	1	186	193	26611920	10.1016/j.bmcl.2015.11.004	Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.	Hartung IV, Hammer S, Hitchcock M, Neuhaus R, Scholz A, Siemeister G, Bohlmann R, Hillig RC, Pühler F.
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701									PubChem BioAssay data set	
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	SELUMETINIB	CHEMBL1614701									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
857.5000000000000000	9606	Homo sapiens	SERELAXIN	CHEMBL2108358									Unpublished dataset	
857.5000000000000000	9606	Homo sapiens	SERELAXIN	CHEMBL2108358									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
857.5000000000000000	9606	Homo sapiens	SERELAXIN	CHEMBL2108358									WHO Anatomical Therapeutic Chemical Classification	
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	J. Med. Chem.	1992	35	10	1799	1806	1316966	10.1021/jm00088a015	Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.	Slusarchyk WA, Bisacchi GS, Field AK, Hockstein DR, Jacobs GA, McGeever-Rubin B, Tino JA, Tuomari AV, Yamanaka GA, Young MG.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	J. Med. Chem.	1997	40	14	2177	2183	9216836	10.1021/jm9701536	A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.	Yoshimura Y, Watanabe M, Satoh H, Ashida N, Ijichi K, Sakata S, Machida H, Matsuda A.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	Bioorg. Med. Chem.	2007	15	8	3065	3081	17324575	10.1016/j.bmc.2007.01.049	Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.	Ciliberti N, Manfredini S, Angusti A, Durini E, Solaroli N, Vertuani S, Buzzoni L, Bonache MC, Ben-Shalom E, Karlsson A, Saada A, Balzarini J.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	J. Med. Chem.	2007	50	12	2851	2857	17518459	10.1021/jm0701472	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.	Cristofoli WA, Wiebe LI, De Clercq E, Andrei G, Snoeck R, Balzarini J, Knaus EE.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046	J. Med. Chem.	2010	53	7	2902	2912	20218622	10.1021/jm901532h	3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase.	Van Poecke S, Negri A, Gago F, Van Daele I, Solaroli N, Karlsson A, Balzarini J, Van Calenbergh S.
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046									Unpublished dataset	
851.0500000000000000	10338	Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3)	SORIVUDINE	CHEMBL70046									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	SPECTINOMYCIN HYDROCHLORIDE	CHEMBL3989571									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	SPECTINOMYCIN HYDROCHLORIDE	CHEMBL3989571									Unpublished dataset	
2219.8000000000000000	2	Bacteria	SPECTINOMYCIN HYDROCHLORIDE	CHEMBL3989571									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1982	25	6	644	649	7097717	10.1021/jm00348a007	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.	Hampton A, Chawla RR, Kappler F.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1987	30	2	440	444	3643284	10.1021/jm00385a033	Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.	Lin TS, Chen MS, McLaren C, Gao YS, Ghazzouli I, Prusoff WH.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1987	30	5	862	866	3033243	10.1021/jm00388a020	Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.	Kim CH, Marquez VE, Broder S, Mitsuya H, Driscoll JS.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1987	30	8	1270	1278	3497272	10.1021/jm00391a003	3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.	Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1989	32	2	461	466	2536441	10.1021/jm00122a029	1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.	Mansuri MM, Starrett JE, Ghazzouli I, Hitchcock MJ, Sterzycki RZ, Brankovan V, Lin TS, August EM, Prusoff WH, Sommadossi JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1989	32	3	612	617	2918508	10.1021/jm00123a018	Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.	Chu CK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1989	32	3	618	622	2918509	10.1021/jm00123a019	1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.	Greengrass CW, Hoople DW, Street SD, Hamilton F, Marriott MS, Bordner J, Dalgleish AG, Mitsuya H, Broder S.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1989	32	3	622	625	2918510	10.1021/jm00123a020	A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain.	Palomino E, Kessel D, Horwitz JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1990	33	1	258	263	2153206	10.1021/jm00163a043	Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.	Palomino E, Meltsner BR, Kessel D, Horwitz JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1990	33	6	1833	1839	2342078	10.1021/jm00168a046	Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.	Van Aerschot A, Everaert D, Balzarini J, Augustyns K, Jie L, Janssen G, Peeters O, Blaton N, De Ranter C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1992	2	12	1469	1474		10.1016/S0960-894X(00)80410-2	Preparation and anti-HIV activity of N-3 amino substituted thymidine nucleoside analogs	Maillard M, Florent J, Lemaitre M, Begassat F, Bugnicourt A, Ferrieux C, Rombi C, Pacaud E, Thierry D, Zerial A, Monneret C, Grierson DS
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1992	2	5	367	370		10.1016/S0960-894X(00)80147-X	Synthesis and HIV activity of phosphonate isosteres of D4T monophosphate	Kim CU, Bronson JJ, Ferrara LM, Martin JC
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1993	3	6	1203	1206		10.1016/S0960-894X(00)80315-7	Phosphate derivatives of d4T as inhibitors of HIV	McGuigan C, Sheeka HM, Mahmood N, Hay A
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1993	36	7	826	830	8385224	10.1021/jm00059a006	Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.	Sergheraert C, Pierlot C, Tartar A, Henin Y, Lemaitre M.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1994	37	16	2520	2526	7520081	10.1021/jm00042a005	HIV-1 reverse transcriptase inhibitor design using artificial neural networks.	Tetko IV, Tanchuk VYu, Chentsova NP, Antonenko SV, Poda GI, Kukhar VP, Luik AI.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1995	5	24	2981	2984		10.1016/0960-894X(95)00525-7	Increase of the anti-HIV activity of D4T in human T-cell culture by the use of the sate pronucleotide approach	Girardet J, Perigaud C, Aubertin A, Gosselin G, Kirn A, Imbach J
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1996	39	8	1748	1753	8648614	10.1021/jm950605j	Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.	McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1996	6	10	1183	1186		10.1016/0960-894X(96)00195-3	Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells	McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1997	7	2	99	104		10.1016/S0960-894X(96)00597-5	Cyclic saligenyl phosphotriesters of 2,3-dideoxy-2,3-didehydrothymidine (d4T)  a new pro-nucleotide approach	Meier C, Lorey M, De Clercq E, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1998	41	9	1417	1427	9554875	10.1021/jm970664s	cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.	Meier C, Lorey M, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1998	8	21	2949	2954	9873653	10.1016/s0960-894x(98)00530-7	Lactate cannot substitute for alanine in d4T-based anti-HIV nucleotide prodrugs--despite efficient esterase-mediated hydrolysis.	McGuigan C, Cahard D, Ballatore C, Siddiqui A, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	1998	8	22	3121	3126	9873688	10.1016/s0960-894x(98)00547-2	Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.	Venkatachalam TK, Tai HL, Vig R, Chen CL, Jan ST, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1999	42	20	4122	4128	10514282	10.1021/jm9807104	Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.	Siddiqui AQ, McGuigan C, Ballatore C, Zuccotto F, Gilbert IH, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1999	42	3	393	399	9986709	10.1021/jm9803931	The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship.	Siddiqui AQ, Ballatore C, McGuigan C, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1999	42	9	1604	1614	10229629	10.1021/jm981096z	cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.	Meier C, Knispel T, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	1999	42	9	1615	1624	10229630	10.1021/jm981097r	cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.	Meier C, Knispel T, Marquez VE, Siddiqui MA, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2000	10	18	2145	2148	10999490	10.1016/s0960-894x(00)00418-2	Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.	Luo MZ, Liu MC, Mozdziesz DE, Lin TS, Dutschman GE, Gullen EA, Cheng YC, Sartorelli AC.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2000	10	4	381	384	10714505	10.1016/s0960-894x(99)00701-5	Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs.	Siddiqui A, McGuigan C, Ballatore C, Srinivasan S, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Pharmacol. Exp. Ther.	2000	294	1	844	849	10945832		Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Nat. Prod.	2001	64	2	265	277	11430019	10.1021/np0003995	Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.	Yang SS, Cragg GM, Newman DJ, Bader JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2002	45	6	1284	1291	11881997	10.1021/jm011011l	Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.	Khandazhinskaya AL, Shirokova EA, Skoblov YS, Victorova LS, Goryunova LY, Beabealashvilli RS, Pronyaeva TR, Fedyuk NV, Zolin VV, Pokrovsky AG, Kukhanova MK.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2003	13	12	1993	1996	12781181	10.1016/s0960-894x(03)00330-5	The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).	Choo H, Chong Y, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2003	13	21	3775	3777	14552777	10.1016/j.bmcl.2003.07.009	Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine.	Haraguchi K, Takeda S, Tanaka H, Nitanda T, Baba M, Dutschman GE, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2003	13	24	4473	4475	14643349	10.1016/j.bmcl.2003.09.031	1,3-dihydrobenzo[c]furan nucleoside analogues: additional studies of the thymine derivative.	Egron D, Périgaud C, Gosselin G, Aubertin AM, Faraj A, Sélouane M, Postel D, Len C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2003	46	15	3292	3299	12852759	10.1021/jm030116g	A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.	Choi Y, George C, Comin MJ, Barchi JJ, Kim HS, Jacobson KA, Balzarini J, Mitsuya H, Boyer PL, Hughes SH, Marquez VE.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2004	14	5	1085	1087	14980640	10.1016/j.bmcl.2004.01.007	Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS.	Sriram D, Yogeeswari P, Srichakravarthy N, Bal TR.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2004	14	9	2159	2162	15081000	10.1016/j.bmcl.2004.02.031	2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.	Shi J, Ray AS, Mathew JS, Anderson KS, Chu CK, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2004	47	14	3606	3614	15214788	10.1021/jm0310176	Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.	Shirokova EA, Jasko MV, Khandazhinskaya AL, Ivanov AV, Yanvarev DV, Skoblov YS, Mitkevich VA, Bocharov EV, Pronyaeva TR, Fedyuk NV, Kukhanova MK, Pokrovsky AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2005	48	4	1211	1220	15715487	10.1021/jm040845b	Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.	Petersen L, Jørgensen PT, Nielsen C, Hansen TH, Nielsen J, Pedersen EB.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2006	16	3	663	667	16263277	10.1016/j.bmcl.2005.10.038	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Jorgensen WL, Ruiz-Caro J, Tirado-Rives J, Basavapathruni A, Anderson KS, Hamilton AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2006	16	3	668	671	16298131	10.1016/j.bmcl.2005.10.037	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Ruiz-Caro J, Basavapathruni A, Kim JT, Bailey CM, Wang L, Anderson KS, Hamilton AD, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2006	49	26	7799	7806	17181162	10.1021/jm060030y	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.	Barral K, Priet S, Sire J, Neyts J, Balzarini J, Canard B, Alvarez K.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2006	49	26	7861	7867	17181169	10.1021/jm060980j	Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines.	Kumamoto H, Nakai T, Haraguchi K, Nakamura KT, Tanaka H, Baba M, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Proc. Natl. Acad. Sci. U.S.A.	2007	104	33	13432	13437	17652517	10.1073/pnas.0704212104	HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.	Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem.	2007	15	16	5519	5528	17562366	10.1016/j.bmc.2007.05.047	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.	Mackman RL, Zhang L, Prasad V, Boojamra CG, Douglas J, Grant D, Hui H, Kim CU, Laflamme G, Parrish J, Stoycheva AD, Swaminathan S, Wang K, Cihlar T.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2007	17	13	3666	3669	17485204	10.1016/j.bmcl.2007.04.043	Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.	Mehellou Y, McGuigan C, Brancale A, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2007	17	9	2614	2617	17317163	10.1016/j.bmcl.2007.01.107	[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.	Hunter R, Muhanji CI, Hale I, Bailey CM, Basavapathruni A, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2007	50	22	5324	5329	17918923	10.1021/jm070683u	From docking false-positive to active anti-HIV agent.	Barreiro G, Kim JT, Guimarães CR, Bailey CM, Domaoal RA, Wang L, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2007	50	6	1335	1346	17328534	10.1021/jm0611713	Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides.	Ducho C, Görbig U, Jessel S, Gisch N, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2007	50	7	1658	1667	17335187	10.1021/jm0613267	Enzymatically activated cycloSal-d4T-monophosphates: The third generation of cycloSal-pronucleotides.	Gisch N, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2007	51	11	3870	3879	17724147	10.1128/aac.00692-07	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.	Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2007	51	12	4489	4491	17876005	10.1128/aac.00687-07	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.	Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2007	51	7	2424	2429	17485498	10.1128/aac.01498-06	Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.	Asif G, Hurwitz SJ, Obikhod A, Delinsky D, Narayanasamy J, Chu CK, McClure HM, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2007	51	7	2600	2604	17470654	10.1128/aac.00212-07	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.	Shi M, Wang X, De Clercq E, Takao S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2008	51	20	6592	6598	18826203	10.1021/jm800815b	Intracellular trapping of cycloSal-pronucleotides: modification of prodrugs with amino acid esters.	Jessen HJ, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2008	51	21	6752	6760	18834186	10.1021/jm800853p	Studies on enzyme-cleavable dialkoxymethyl-cyclosaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates.	Gisch N, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2008	51	24	8115	8123	19053827	10.1021/jm801197f	5-(1-Acetoxyvinyl)-cycloSaligenyl-2',3'-dideoxy-2',3'- didehydrothymidine monophosphates, a second type of new, enzymatically activated cycloSaligenyl pronucleotides.	Gisch N, Pertenbreiter F, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2008	52	1	329	332	17967913	10.1128/aac.01004-07	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.	Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2008	52	4	1519	1521	18285481	10.1128/aac.01241-07	Anti-BK virus activity of nucleoside analogs.	Randhawa P, Zemlicka J, Sauerbrei A, Meier C, Hostetler KY, Beadle JR, Farasati NA, Huang Y, Bradley M.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2008	52	8	2825	2830	18541728	10.1128/aac.00434-08	Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.	Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2009	52	11	3464	3473	19438207	10.1021/jm900164g	Doubly loaded cycloSaligenyl-pronucleotides - 5,5'-Bis-(cycloSaligenyl-2',3'-dideoxy-2',3'-didehydrothymidine monophosphates).	Gisch N, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2009	53	11	4640	4646	19704131	10.1128/aac.00686-09	Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.	Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2009	53	3	1252	1255	19104011	10.1128/aac.01115-08	Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.	Lynx MD, LaClair DD, McKee EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem.	2010	18	13	4661	4673	20605472	10.1016/j.bmc.2010.05.025	[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.	Younis Y, Hunter R, Muhanji CI, Hale I, Singh R, Bailey CM, Sullivan TJ, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem.	2010	18	20	7186	7192	20833550	10.1016/j.bmc.2010.08.037	Synthesis and anti-HIV-1 evaluation of phosphonates which mimic the 5'-monophosphate of 4'-branched 2',3'-didehydro-2',3'-dideoxy nucleosides.	Kubota Y, Ishizaki N, Haraguchi K, Hamasaki T, Baba M, Tanaka H.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2010	20	3	841	843	20060716	10.1016/j.bmcl.2009.12.097	Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.	Li Y, Soni PB, Liu L, Zhang X, Liotta DC, Lutz S.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2010	20	8	2485	2488	20304641	10.1016/j.bmcl.2010.03.006	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.	Leung CS, Zeevaart JG, Domaoal RA, Bollini M, Thakur VV, Spasov KA, Anderson KS, Jorgensen WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2010	53	21	7675	7681	20945915	10.1021/jm100817f	Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate.	Roman CA, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2010	54	1	280	287	19805555	10.1128/aac.00914-09	Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.	Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2011	21	7	1917	1921	21382714	10.1016/j.bmcl.2011.02.070	Synthesis and biological evaluation of fatty acyl ester derivatives of 2',3'-didehydro-2',3'-dideoxythymidine.	Agarwal HK, Loethan K, Mandal D, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2012	55	16	7245	7252	22827702	10.1021/jm3008085	Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides.	Rios Morales EH, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2013	23	5	1511	1518	23380374	10.1016/j.bmcl.2012.12.015	Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.	Piao D, Basavapathruni A, Iyidogan P, Dai G, Hinz W, Ray AS, Murakami E, Feng JY, You F, Dutschman GE, Austin DJ, Parker KA, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	ACS Med. Chem. Lett.	2013	4	12	1183	1188	24900627	10.1021/ml4002979	Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.	Iyidogan P, Sullivan TJ, Chordia MD, Frey KM, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Eur. J. Med. Chem.	2013	70		326	340	24177359	10.1016/j.ejmech.2013.09.047	Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.	McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, Madela K, Meneghesso S, Pertusati F, Serpi M, Slusarczyk M, Chamberlain S, Kolykhalov A, Vernachio J, Vanpouille C, Introini A, Margolis L, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2014	24	3	817	820	24411122	10.1016/j.bmcl.2013.12.093	Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.	Gangadhara KL, Lescrinier E, Pannecouque C, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	MedChemComm	2014	5	12	1843	1848		10.1039/C4MD00237G	Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain	Chaikuad A, Petros AM, Fedorov O, Xu J, Knapp S
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	J. Med. Chem.	2015	58	15	6114	6130	26125628	10.1021/acs.jmedchem.5b00737	Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.	Weinschenk L, Schols D, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991								10.6019/CHEMBL3392926	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning	Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									DrugMatrix	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									Drug metabolism data	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	STAVUDINE	CHEMBL991									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	STREPTOMYCIN SULFATE	CHEMBL3184791									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	STREPTOMYCIN SULFATE	CHEMBL3184791									Unpublished dataset	
2219.8000000000000000	2	Bacteria	STREPTOMYCIN SULFATE	CHEMBL3184791									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	1983	26	9	1300	1307	6136612	10.1021/jm00363a015	A polymeric drug for treatment of inflammatory bowel disease.	Brown JP, McGarraugh GV, Parkinson TM, Wingard RE, Onderdonk AB.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	1993	36	26	4201	4207	8277502	10.1021/jm00078a009	Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid.	Pellicciari R, Garzon-Aburbeh A, Natalini B, Marinozzi M, Clerici C, Gentili G, Morelli A.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	1994	37	19	3062	3070	7932529	10.1021/jm00045a011	Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.	Hibi S, Okamoto Y, Tagami K, Numata H, Kobayashi N, Shinoda M, Kawahara T, Murakami M, Oketani K, Inoue T.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	1998	41	7	1007	1010	9544199	10.1021/jm970530e	Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.	Kansy M, Senner F, Gubernator K.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	1999	42	10	1739	1748	10346926	10.1021/jm980527a	Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.	Ghuloum AM, Sage CR, Jain AN.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2000	43	11	2083	2086	10841786	10.1021/jm991156g	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.	Danelian E, Karlén A, Karlsson R, Winiwarter S, Hansson A, Löfâs S, Lennernäs H, Hämäläinen MD.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2000	43	20	3714	3717	11020286	10.1021/jm000942e	Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.	Ertl P, Rohde B, Selzer P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2001	11	4	545	548	11229767	10.1016/s0960-894x(00)00718-6	Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.	Tobe M, Isobe Y, Tomizawa H, Matsumoto M, Obara F, Nagasaki T, Hayashi H.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2001	44	12	1927	1937	11384238	10.1021/jm001101a	Experimental and computational screening models for the prediction of intestinal drug absorption.	Stenberg P, Norinder U, Luthman K, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2001	44	18	3001	3013	11520209	10.1021/jm010852p	Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.	Carceller E, Salas J, Merlos M, Giral M, Ferrando R, Escamilla I, Ramis J, García-Rafanell J, Forn J.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2001	44	6	923	930	11300874	10.1021/jm001020e	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.	Wohnsland F, Faller B.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2004	47	7	1683	1693	15027859	10.1021/jm030447t	Validation of molecular docking calculations involving FGF-1 and FGF-2.	Bytheway I, Cochran S.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2005	48	2	604	613	15658873	10.1021/jm049711o	Exploring the role of different drug transport routes in permeability screening.	Matsson P, Bergström CA, Nagahara N, Tavelin S, Norinder U, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2005	48	9	3269	3279	15857133	10.1021/jm048980b	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).	Caron G, Ermondi G.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem.	2007	15	14	4903	4909	17499512	10.1016/j.bmc.2007.04.045	Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.	Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2007	17	7	1897	1902	17280832	10.1016/j.bmcl.2007.01.031	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Gairola N, Kandpal M, Bhatt L, Vadnerkar G, Kadam SS.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2007	42	6	885	890	17258353	10.1016/j.ejmech.2006.11.017	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Kandpal M, Vadnerkar G, Rathi B, Kadam SS.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2007	42	8	1084	1094	17448575	10.1016/j.ejmech.2007.01.014	Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.	Junek R, Br¿nová B, Kverka M, Panajotová V, Jandera A, Kuchar M.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem.	2008	16	20	9101	9105	18819808	10.1016/j.bmc.2008.09.028	In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.	Bayram E, Senturk M, Kufrevioglu OI, Supuran CT.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2008	51	5	1214	1222	18288794	10.1021/jm701021b	Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.	Aronov AM, McClain B, Moody CS, Murcko MA.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Antimicrob. Agents Chemother.	2008	52	2	418	426	18070971	10.1128/aac.00678-07	Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.	Shin SJ, Collins MT.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2009	44	1	131	142	18472188	10.1016/j.ejmech.2008.03.035	Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.	Dhaneshwar SS, Chail M, Patil M, Naqvi S, Vadnerkar G.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2009	44	1	332	344	18406012	10.1016/j.ejmech.2008.02.030	Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis.	Junek R, Kverka M, Jandera A, Panajotová V, Satinský D, Machácek M, Kuchar M.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2009	44	10	3922	3929	19442419	10.1016/j.ejmech.2009.04.018	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.	Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L, Rathi B, Kadam SS.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2009	44	9	3658	3664	19272677	10.1016/j.ejmech.2009.02.014	Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.	Massarelli I, Imbriani M, Coi A, Saraceno M, Carli N, Bianucci AM.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2009	52	20	6233	6243	19764786	10.1021/jm901036q	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.	Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem.	2010	18	19	7078	7084	20810286	10.1016/j.bmc.2010.08.003	QSAR-based solubility model for drug-like compounds.	Gozalbes R, Pineda-Lucena A.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2010	20	1	69	73	19963379	10.1016/j.bmcl.2009.11.039	Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.	Lee PH, Conradi R, Shanmugasundaram V.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2010	45	2	447	454	19939518	10.1016/j.ejmech.2009.10.025	Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.	Weber JE, Oakley AJ, Christ AN, Clark AG, Hayes JD, Hall R, Hume DA, Board PG, Smythe ML, Flanagan JU.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2010	45	9	4104	4112	20573425	10.1016/j.ejmech.2010.05.071	Design, synthesis and anti-ulcerogenic effect of some of furo-salicylic acid derivatives on acetic acid-induced ulcerative colitis.	Hassan GS, Soliman GA.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2011	21	20	6143	6147	21889336	10.1016/j.bmcl.2011.08.024	Oleanane-type triterpene saponins from the bark of Aralia elata and their NF-¿B inhibition and PPAR activation signal pathway.	Nhiem NX, Lim HY, Kiem PV, Minh CV, Thu VK, Tai BH, Quang TH, Song SB, Kim YH.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2011	21	20	6184	6187	21889337	10.1016/j.bmcl.2011.07.081	Inhibition of xc¿ transporter-mediated cystine uptake by sulfasalazine analogs.	Shukla K, Thomas AG, Ferraris DV, Hin N, Sattler R, Alt J, Rojas C, Slusher BS, Tsukamoto T.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Metab. Dispos.	2011	39	3	353	362	21149540	10.1124/dmd.110.035998	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.	Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2011	46	9	3581	3589	21632156	10.1016/j.ejmech.2011.05.022	In-vitro metabolic inhibition and antifertility effect facilitated by membrane alteration: search for novel antifertility agent using nifedipine analogues.	Waghmare A, Kanyalkar M, Joshi M, Srivastava S.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Nat. Prod.	2011	74	9	1908	1915	21870831	10.1021/np200382s	Anti-inflammatory triterpenoid saponins from the stem bark of Kalopanax pictus.	Quang TH, Ngan NT, Minh CV, Kiem PV, Nhiem NX, Tai BH, Thao NP, Tung NH, Song SB, Kim YH.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2012	22	21	6681	6687	23031596	10.1016/j.bmcl.2012.08.099	Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-¿B activation and PPAR transcriptional activity.	Quang TH, Ngan NT, Minh CV, Kiem PV, Yen PH, Tai BH, Nhiem NX, Thao NP, Anh Hle T, Luyen BT, Yang SY, Choi CW, Kim YH.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2012	22	7	2527	2533	22381047	10.1016/j.bmcl.2012.01.136	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.	Quang TH, Ngan NT, Minh CV, Kiem PV, Tai BH, Thao NP, Song SB, Kim YH.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Metab. Dispos.	2012	40	9	1825	1833	22711747	10.1124/dmd.112.046508	Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.	Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Metab. Dispos.	2013	41	1	60	71	23033255	10.1124/dmd.112.048264	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.	Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg. Med. Chem. Lett.	2014	24	1	228	232	24314396	10.1016/j.bmcl.2013.11.033	New anti-inflammatory cembranoid diterpenoids from the Vietnamese soft coral Lobophytum crassum.	Thao NP, Luyen BT, Ngan NT, Song SB, Cuong NX, Nam NH, Kiem PV, Kim YH, Minh CV.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2014	57	3	878	902	24397738	10.1021/jm401635n	Discovery of 7-tetrahydropyran-2-yl chromans: ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid ß-protein (Aß) in the central nervous system.	Thomas AA, Hunt KW, Volgraf M, Watts RJ, Liu X, Vigers G, Smith D, Sammond D, Tang TP, Rhodes SP, Metcalf AT, Brown KD, Otten JN, Burkard M, Cox AA, Do MK, Dutcher D, Rana S, DeLisle RK, Regal K, Wright AD, Groneberg R, Scearce-Levie K, Siu M, Purkey HE, Lyssikatos JP, Gunawardana IW.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2014	57	7	3005	3010	24601604	10.1021/jm401963n	A high-throughput cell-based method to predict the unbound drug fraction in the brain.	Mateus A, Matsson P, Artursson P.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Med. Chem.	2015	58	18	7557	7571	26321079	10.1021/acs.jmedchem.5b00964	Synthesis and Structure-Activity Relationships of Quaternary Coptisine Derivatives as Potential Anti-ulcerative Colitis Agents.	Zhang ZH, Zhang HJ, Deng AJ, Wang B, Li ZH, Liu Y, Wu LQ, Wang WJ, Qin HL.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	MedChemComm	2015	6	10	1837	1841		10.1039/C5MD00290G	Sulfasalazine in ionic liquid form with improved solubility and exposure	Shadid M, Gurau G, Shamshina JL, Chuang B, Hailu S, Guan E, Chowdhury SK, Wu J, Rizvi SAA, Griffin RJ, Rogers RD
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	J. Nat. Prod.	2015	78	6	1309	1315	26020571	10.1021/acs.jnatprod.5b00115	Bacteria-Derived Compatible Solutes Ectoine and 5¿-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease.	Abdel-Aziz H, Wadie W, Scherner O, Efferth T, Khayyal MT.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur. J. Med. Chem.	2016	108		486	494	26717200	10.1016/j.ejmech.2015.12.021	Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-ß-O-glucoside.	Li F, Wu G, Zheng H, Wang L, Zhao Z.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Bioorg Med Chem Lett	2016	26	19	4587	4591	27597248	10.1016/j.bmcl.2016.08.075	In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.	Banskota S, Kang HE, Kim DG, Park SW, Jang H, Karmacharya U, Jeong BS, Kim JA, Nam TG.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	MedChemComm	2016	7	9	1775	1782		10.1039/C6MD00235H		
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421	Eur J Med Chem	2017	132		249	261	28364659	10.1016/j.ejmech.2017.03.063	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.	Lara-Ramirez EE, López-Cedillo JC, Nogueda-Torres B, Kashif M, Garcia-Perez C, Bocanegra-Garcia V, Agusti R, Uhrig ML, Rivera G.
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									British National Formulary (72nd edition)	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									Open TG-GATES	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									PubChem BioAssay data set	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
943.5000000000000000	9606	Homo sapiens	SULFASALAZINE	CHEMBL421									WHO Anatomical Therapeutic Chemical Classification	
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849	J. Med. Chem.	2015	58	2	778	784	25513712	10.1021/jm501543u	Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.	Fako VE, Wu X, Pflug B, Liu JY, Zhang JT.
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849									PubChem BioAssay data set	
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	SULOCTIDIL	CHEMBL404849									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	1993	3	6	993	997		10.1016/S0960-894X(00)80274-7	Synthesis, biological activity and electrostatic properties of 3-[2-(dimethylamino)ethyl]-5-[(3-amino-1,2,4-thiadiazol-5-yl)methyl]-1H-indole, a novel 5-HT1D receptor agonist.	Castro JL, Matassa VG, Broughton HB, Mosley RT, Street LJ, Baker R
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1993	36	11	1529	1538	8496922	10.1021/jm00063a003	Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors.	Street LJ, Baker R, Castro JL, Chambers MS, Guiblin AR, Hobbs SC, Matassa VG, Reeve AJ, Beer MS, Middlemiss DN.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1993	36	13	1918	1919	8515429	10.1021/jm00065a015	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.	King FD, Brown AM, Gaster LM, Kaumann AJ, Medhurst AD, Parker SG, Parsons AA, Patch TL, Raval P.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1994	37	16	2509	2512	8057297	10.1021/jm00042a003	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.	Macor JE, Blank DH, Fox CB, Lebel LA, Newman ME, Post RJ, Ryan K, Schmidt AW, Schulz DW, Koe BK.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1994	37	18	2828	2830	8071931	10.1021/jm00044a001	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.	Glennon RA, Hong SS, Dukat M, Teitler M, Davis K.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1994	37	19	3023	3032	7932524	10.1021/jm00045a006	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.	Castro JL, Baker R, Guiblin AR, Hobbs SC, Jenkins MR, Russell MG, Beer MS, Stanton JA, Scholey K, Hargreaves RJ.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1995	38	10	1799	1810	7752204	10.1021/jm00010a025	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.	Street LJ, Baker R, Davey WB, Guiblin AR, Jelley RA, Reeve AJ, Routledge H, Sternfeld F, Watt AP, Beer MS.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1995	38	18	3566	3580	7658443	10.1021/jm00018a016	Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.	Glen RC, Martin GR, Hill AP, Hyde RM, Woollard PM, Salmon JA, Buckingham J, Robertson AD.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1995	38	18	3602	3607	7658447	10.1021/jm00018a020	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.	Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, John GW, Valentin JP, Halazy S.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	1995	5	22	2649	2654		10.1016/0960-894X(95)00473-7	The discovery of a series of new non-indole 5HT1D agonists	Lommen GV, De Bruyn M, Schroven M, Verschueren W, Janssens W, Verrelst J, Leysen J
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	1995	5	7	663	666		10.1016/0960-894X(95)00091-7	5-O-Carboxymethyl piperazide derivatives of serotonin: a new class of potent and selective 5-HT1D receptor agonists	Perez M, Pauwels P, Palmier C, John GW, Valentin J, Halazy S
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1996	39	1	314	322	8568822	10.1021/jm950498t	Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.	Glennon RA, Hong SS, Bondarev M, Law H, Dukat M, Rakhi S, Power P, Fan E, Kinneau D, Kamboj R, Teitler M, Herrick-Davis K, Smith C.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1996	39	24	4717	4726	8941384	10.1021/jm9604890	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.	Barf TA, de Boer P, Wikström H, Peroutka SJ, Swensson K, Ennis MD, Ghazal NB, McGuire JC, Smith MW.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1996	39	25	4920	4927	8960551	10.1021/jm960552l	Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.	Halazy S, Perez M, Fourrier C, Pallard I, Pauwels PJ, Palmier C, John GW, Valentin JP, Bonnafous R, Martinez J.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	1996	6	15	1825	1830		10.1016/0960-894X(96)00324-1	The chemical evolution of N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine (L-741,604) and analogues: Potent and selective agonists for 5-HT1D receptors	Sternfeld F, Baker R, Broughton HB, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Beer MS, Stanton JA, Hargreaves RJ, Shepheard SL, Longmore J, Razzaque Z, Graham MI, Sohal B, Street LJ
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1997	40	22	3497	3500	9357514	10.1021/jm9704558	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.	Castro JL, Street LJ, Guiblin AR, Jelley RA, Russell MG, Sternfeld F, Beer MS, Stanton JA, Matassa VG.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1997	40	22	3501	3503	9357515	10.1021/jm9704560	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.	MacLeod AM, Street LJ, Reeve AJ, Jelley RA, Sternfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1998	41	13	2180	2183	9632349	10.1021/jm980137o	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.	Ennis MD, Ghazal NB, Hoffman RL, Smith MW, Schlachter SK, Lawson CF, Im WB, Pregenzer JF, Svensson KA, Lewis RA, Hall ED, Sutter DM, Harris LT, McCall RB.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1998	41	13	2243	2251	9632357	10.1021/jm970513p	Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.	Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersad V, Prisinzano T, Glennon RA.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	1998	8	6	675	680	9871581	10.1016/s0960-894x(98)00090-0	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.	Perez M, Pauwels PJ, Fourrier C, Chopin P, Valentin JP, John GW, Marien M, Halazy S.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1999	42	24	4981	5001	10585208	10.1021/jm9910021	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.	Russell MG, Matassa VG, Pengilley RR, van Niel MB, Sohal B, Watt AP, Hitzel L, Beer MS, Stanton JA, Broughton HB, Castro JL.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1999	42	3	526	531	9986723	10.1021/jm9805945	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.	Xu YC, Schaus JM, Walker C, Krushinski J, Adham N, Zgombick JM, Liang SX, Kohlman DT, Audia JE.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1999	42	4	677	690	10052975	10.1021/jm9805687	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.	Sternfeld F, Guiblin AR, Jelley RA, Matassa VG, Reeve AJ, Hunt PA, Beer MS, Heald A, Stanton JA, Sohal B, Watt AP, Street LJ.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	1999	42	4	691	705	10052976	10.1021/jm980569z	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.	Chambers MS, Street LJ, Goodacre S, Hobbs SC, Hunt P, Jelley RA, Matassa VG, Reeve AJ, Sternfeld F, Beer MS, Stanton JA, Rathbone D, Watt AP, MacLeod AM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2000	10	15	1707	1709	10937729	10.1016/s0960-894x(00)00322-x	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.	Slassi A, Edwards L, O'Brien A, Meng CQ, Xin T, Seto C, Lee DK, MacLean N, Hynd D, Chen C, Wang H, Kamboj R, Rakhit S.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2000	10	9	903	905	10853656	10.1016/s0960-894x(00)00133-5	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.	Meng CQ, Rakhit S, Lee DK, Kamboj R, McCallum KL, Mazzocco L, Dyne K, Slassi A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Pharmacol. Exp. Ther.	2001	299	2	620	628	11602674		Rational use of in vitro P-glycoprotein assays in drug discovery.	Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2001	44	15	2490	2497	11448232	10.1021/jm0100990	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.	Lombardo F, Shalaeva MY, Tupper KA, Gao F.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2001	44	24	4031	4034	11708905	10.1021/jm0155190	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.	Xu YC, Johnson KW, Phebus LA, Cohen M, Nelson DL, Schenck K, Walker CD, Fritz JE, Kaldor SW, LeTourneau ME, Murff RE, Zgombick JM, Calligaro DO, Audia JE, Schaus JM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2001	44	5	681	693	11262079	10.1021/jm000956k	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.	Jandu KS, Barrett V, Brockwell M, Cambridge D, Farrant DR, Foster C, Giles H, Glen RC, Hill AP, Hobbs H, Honey A, Martin GR, Salmon J, Smith D, Woollard P, Selwood DL.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Pharmacol. Exp. Ther.	2002	303	1	1029	1037	12438524	10.1124/jpet.102.039255	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.	Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2002	45	13	2867	2876	12061889	10.1021/jm0200409	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2003	13	20	3419	3421	14505640	10.1016/s0960-894x(03)00779-0	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity h5-HT1B/1D ligands.	Egle I, MacLean N, Demchyshyn L, Edwards L, Slassi A, Tehim A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2003	13	24	4409	4413	14643336	10.1016/j.bmcl.2003.09.025	Design, synthesis and biological activity of novel dimethyl-[2-[6-substituted-indol-1-yl]-ethyl]-amine as potent, selective, and orally-bioavailable 5-HT(1D) agonists.	Isaac M, Slassi M, Xin T, Arora J, O'Brien A, Edwards L, MacLean N, Wilson J, Demschyshyn L, Labrie P, Naismith A, Maddaford S, Papac D, Harrison S, Wang H, Draper S, Tehim A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2004	14	18	4697	4699	15324890	10.1016/j.bmcl.2004.06.085	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.	Prisinzano T, Dukat M, Law H, Slassi A, MacLean N, DeLannoy I, Glennon RA.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2004	14	3	727	729	14741277	10.1016/j.bmcl.2003.11.023	3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT(1B/1D) ligands.	Egle I, MacLean N, Demchyshyn L, Edwards L, Slassi A, Tehim A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem.	2008	16	15	7489	7493	18572411	10.1016/j.bmc.2008.06.005	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.	Yang B, Zhang H, Verkman AS.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2008	51	12	3609	3616	18507369	10.1021/jm7011722	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.	Choi SK, Green D, Ho A, Klein U, Marquess D, Taylor R, Turner SD.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem.	2009	17	1	411	417	18182301	10.1016/j.bmc.2007.12.040	Identification of aquaporin 4 inhibitors using in vitro and in silico methods.	Huber VJ, Tsujita M, Nakada T.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2009	52	19	6107	6125	19754201	10.1021/jm901096y	Physical binding pocket induction for affinity prediction.	Langham JJ, Cleves AE, Spitzer R, Kirshner D, Jain AN.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2009	52	6	1693	1700	19256501	10.1021/jm801441s	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.	Wan H, Ahman M, Holmén AG.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2010	20	24	7312	7316	21055935	10.1016/j.bmcl.2010.10.068	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.	Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, Shen C.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2012	22	14	4723	4727	22727645	10.1016/j.bmcl.2012.05.074	The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.	Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Macci R, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Chaturvedula PV, Macor JE, Dubowchik GM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg. Med. Chem. Lett.	2013	23	11	3157	3161	23632269	10.1016/j.bmcl.2013.04.012	Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.	Chaturvedula PV, Mercer SE, Pin SS, Thalody G, Xu C, Conway CM, Keavy D, Signor L, Cantor GH, Mathias N, Moench P, Denton R, Macci R, Schartman R, Whiterock V, Davis C, Macor JE, Dubowchik GM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	MedChemComm	2013	4	4	631	652		10.1039/C2MD20317K	Metabolism-guided drug design	Stepan AF, Mascitti V, Beaumont K, Kalgutkar AS
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2013	56	18	7232	7242	23984907	10.1021/jm400966v	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.	Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Börjesson L, Gustavsson L.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2013	56	3	781	795	23241029	10.1021/jm301302s	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.	Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128		2013							Substituted indole compounds having NOS inhibitory activity	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	J. Med. Chem.	2014	57	19	7838	7858	24960305	10.1021/jm500364u	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.	Bell IM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128	Bioorg Med Chem Lett	2017	27	2	323	328	27908761	10.1016/j.bmcl.2016.11.049	Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.	Blanco MJ, Benesh DR, Knobelsdorf JA, Khilevich A, Cortez GS, Mokube F, Aicher TD, Groendyke TM, Marmsater FP, Tang TP, Johnson KW, Clemens-Smith A, Muhlhauser MA, Swanson S, Catlow J, Emkey R, Johnson MP, Schkeryantz JM.
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									DrugMatrix	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									Drug metabolism data	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN	CHEMBL128									WHO Anatomical Therapeutic Chemical Classification	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN SUCCINATE	CHEMBL1201150									British National Formulary (72nd edition)	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN SUCCINATE	CHEMBL1201150									Drug metabolism data	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN SUCCINATE	CHEMBL1201150									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN SUCCINATE	CHEMBL1201150									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	SUMATRIPTAN SUCCINATE	CHEMBL1201150									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	J. Med. Chem.	2007	50	23	5543	5546	17941625	10.1021/jm701079h	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.	Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, Fournel M, Bonfils C, Trachy-Bourget MC, Liu J, Yan TP, Lu AH, Rahil J, Wang J, Lefebvre S, Li Z, Vaisburg AF, Besterman JM.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Bioorg. Med. Chem.	2008	16	17	8109	8116	18692397	10.1016/j.bmc.2008.07.048	Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.	Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Bioorg. Med. Chem.	2008	16	6	3352	3360	18166465	10.1016/j.bmc.2007.12.007	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.	Gediya LK, Belosay A, Khandelwal A, Purushottamachar P, Njar VC.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Bioorg. Med. Chem. Lett.	2008	18	3	973	978	18182289	10.1016/j.bmcl.2007.12.031	Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).	Methot JL, Chakravarty PK, Chenard M, Close J, Cruz JC, Dahlberg WK, Fleming J, Hamblett CL, Hamill JE, Harrington P, Harsch A, Heidebrecht R, Hughes B, Jung J, Kenific CM, Kral AM, Meinke PT, Middleton RE, Ozerova N, Sloman DL, Stanton MG, Szewczak AA, Tyagarajan S, Witter DJ, Secrist JP, Miller TA.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	J. Med. Chem.	2008	51	13	3895	3904	18543902	10.1021/jm8001839	Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.	Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, Purushottamachar P, Njar VC.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Eur. J. Med. Chem.	2010	45	6	2095	2116	20223566	10.1016/j.ejmech.2010.02.030	Inside HDAC with HDAC inhibitors.	Bertrand P.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Nat. Chem. Biol.	2010	6	3	238	243	20139990	10.1038/nchembio.313	Chemical phylogenetics of histone deacetylases.	Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Bioorg. Med. Chem. Lett.	2016	26	1	154	159	26611919	10.1016/j.bmcl.2015.11.011	Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.	Zwick V, Nurisso A, Simões-Pires C, Bouchet S, Martinet N, Lehotzky A, Ovadi J, Cuendet M, Blanquart C, Bertrand P.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	Eur J Med Chem	2017	134		1	12	28391133	10.1016/j.ejmech.2017.03.038	Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.	Xie R, Yao Y, Tang P, Chen G, Liu X, Yun F, Cheng C, Wu X, Yuan Q.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191	J Med Chem	2017	60	19	7965	7983	28885834	10.1021/acs.jmedchem.7b00467	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.	Dong G, Chen W, Wang X, Yang X, Xu T, Wang P, Zhang W, Rao Y, Miao C, Sheng C.
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191									Unpublished dataset	
1146.4083333333333333	9606	Homo sapiens	TACEDINALINE	CHEMBL235191									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	TAK-733	CHEMBL1615025	Bioorg. Med. Chem. Lett.	2011	21	5	1315	1319	21310613	10.1016/j.bmcl.2011.01.071	Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.	Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O'Connell SM, Scorah N, Shi L, Wallace MB, Zhou F.
1033.7000000000000000	9606	Homo sapiens	TAK-733	CHEMBL1615025		2013							MAPK/ERK kinase inhibitors	
1033.7000000000000000	9606	Homo sapiens	TAK-733	CHEMBL1615025	Bioorg. Med. Chem. Lett.	2014	24	11	2555	2559	24755426	10.1016/j.bmcl.2014.03.086	Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.	Lu H, Tu W, Fei H, Xu G, Hu Q, Zhang L, Lin B, Yuan J, Yin J, Gong A, Wan M, Wang D, Zhu X, Feng J, Wang Q, Sun P.
1033.7000000000000000	9606	Homo sapiens	TAK-733	CHEMBL1615025	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1033.7000000000000000	9606	Homo sapiens	TAK-733	CHEMBL1615025									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657	Bioorg. Med. Chem. Lett.	2009	19	2	489	492	19058965	10.1016/j.bmcl.2008.11.040	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.	Charton J, Deprez-Poulain R, Hennuyer N, Tailleux A, Staels B, Deprez B.
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657									British National Formulary (72nd edition)	
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657									PubChem BioAssay data set	
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	TAZAROTENE	CHEMBL1657									WHO Anatomical Therapeutic Chemical Classification	
931.8000000000000000	9606	Homo sapiens	TC-6499	CHEMBL3545353									Unpublished dataset	
853.5000000000000000	9606	Homo sapiens	TEDISAMIL	CHEMBL2111110									Unpublished dataset	
853.5000000000000000	9606	Homo sapiens	TEDISAMIL	CHEMBL2111110									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
853.5000000000000000	9606	Homo sapiens	TEDISAMIL	CHEMBL2111110									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	TEDIZOLID PHOSPHATE	CHEMBL2105669	J. Med. Chem.	2014	57	11	4487	4497	24694071	10.1021/jm401931e	New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.	Gordeev MF, Yuan ZY.
2219.8000000000000000	2	Bacteria	TEDIZOLID PHOSPHATE	CHEMBL2105669	Bioorg. Med. Chem.	2016	24	9	1937	1980	27020685	10.1016/j.bmc.2016.03.004	Synthetic approaches to the 2014 new drugs.	Flick AC, Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, O'Donnell CJ.
2219.8000000000000000	2	Bacteria	TEDIZOLID PHOSPHATE	CHEMBL2105669									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TEDIZOLID PHOSPHATE	CHEMBL2105669									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588	Eur. J. Med. Chem.	2010	45	11	5420	5427	20869793	10.1016/j.ejmech.2010.09.002	Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.	Lee K, Jeong KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y.
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588	J. Med. Chem.	2012	55	24	10797	10822	23098265	10.1021/jm301085w	Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.	Musumeci F, Radi M, Brullo C, Schenone S.
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588									PubChem BioAssay data set	
882.4000000000000000	9606	Homo sapiens	TELATINIB	CHEMBL2079588									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	1999	9	21	3075	3080	10560728	10.1016/s0960-894x(99)00534-x	Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.	Denis A, Agouridas C, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N, Pejac JM, Perron S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2000	10	17	2019	2022	10987440	10.1016/s0960-894x(00)00392-9	Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides.	Denis A, Bretin F, Fromentin C, Bonnet A, Piltan G, Bonnefoy A, Agouridas C.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2000	43	6	1045	1049	10737737	10.1021/jm990618n	Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens.	Or YS, Clark RF, Wang S, Chu DT, Nilius AM, Flamm RK, Mitten M, Ewing P, Alder J, Ma Z.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2001	44	24	4137	4156	11708916	10.1021/jm0102349	Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.	Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA, Chu DT, Plattner JJ, Zhang X, Zhong P, Cao Z, Nilius AM, Shortridge VD, Flamm R, Mitten M, Meulbroek J, Ewing P, Alder J, Or YS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2003	46	10	1795	1798	12723941	10.1021/jm025580k	Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens.	Keyes RF, Carter JJ, Englund EE, Daly MM, Stone GG, Nilius AM, Ma Z.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2004	14	10	2417	2421	15109624	10.1016/j.bmcl.2004.03.020	Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.	Beebe X, Yang F, Bui MH, Mitten MJ, Ma Z, Nilius AM, Djuric SW.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2004	14	14	3809	3813	15203167	10.1016/j.bmcl.2004.04.077	Synthesis and antibacterial activity of novel bifunctional macrolides.	Akritopoulou-Zanze I, Phelan KM, Marron TG, Yong H, Ma Z, Stone GG, Daly MM, Hensey DM, Nilius AM, Djuric SW.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2004	14	17	4495	4499	15357979	10.1016/j.bmcl.2004.06.045	Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.	Henninger TC, Xu X, Abbanat D, Baum EZ, Foleno BD, Hilliard JJ, Bush K, Hlasta DJ, Macielag MJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2005	15	4	883	887	15686880	10.1016/j.bmcl.2004.12.067	Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes.	Xu X, Henninger T, Abbanat D, Bush K, Foleno B, Hilliard J, Macielag M.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2005	15	5	1307	1310	15713376	10.1016/j.bmcl.2005.01.027	Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics.	Liang CH, Yao S, Chiu YH, Leung PY, Robert N, Seddon J, Sears P, Hwang CK, Ichikawa Y, Romero A.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2006	16	17	4692	4696	16784845	10.1016/j.bmcl.2006.05.104	Synthesis and antibacterial activity of C12 des-methyl ketolides.	Lin X, Rico AC, Chu DT, Carroll GL, Barker L, Shawar R, Desai MC, Plattner JJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2006	16	24	6231	6235	16997549	10.1016/j.bmcl.2006.09.036	Synthesis and antibacterial activity of C6-carbazate ketolides.	Tennakoon MA, Henninger TC, Abbanat D, Foleno BD, Hilliard JJ, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2006	16	4	1054	1059	16289812	10.1016/j.bmcl.2005.10.074	Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives.	Zhu B, Marinelli BA, Abbanat D, Foleno BD, Henninger TC, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2006	16	5	1259	1266	16343900	10.1016/j.bmcl.2005.11.061	Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.	Fu H, Marquez S, Gu X, Katz L, Myles DC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2006	16	7	1929	1933	16446089	10.1016/j.bmcl.2005.12.097	Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides.	Grant EB, Guiadeen D, Abbanat D, Foleno BD, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2006	49	5	1730	1743	16509588	10.1021/jm051157a	Synthesis and antibacterial activity of novel C12 vinyl ketolides.	Burger MT, Lin X, Chu DT, Hiebert C, Rico AC, Seid M, Carroll GL, Barker L, Huh K, Langhorne M, Shawar R, Kidney J, Young K, Anderson S, Desai MC, Plattner JJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2007	17	14	3900	3904	17502142	10.1016/j.bmcl.2007.04.104	Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives.	Zhu B, Marinelli BA, Abbanat D, Foleno BD, Bush K, Macielag MJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2007	17	18	5013	5018	17692517	10.1016/j.bmcl.2007.07.041	Synthesis and antibacterial activity of C11, C12-cyclic urea analogues of ketolides.	Kaneko T, McMillen W, Lynch MK.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2007	17	18	5049	5053	17659873	10.1016/j.bmcl.2007.07.018	Novel tethers in ketolide antibiotics.	Kaneko T, Romero K, Li B, Buzon R.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	11	3969	3976	17698631	10.1128/aac.00422-07	Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.	Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, Yamanaka N.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	11	4196	4201	17876003	10.1128/aac.00827-07	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.	Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	12	4382	4389	17908940	10.1128/aac.00971-07	National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.	Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	12	4498	4501	17923492	10.1128/aac.00538-07	Antimicrobial susceptibilities and clinical sources of Dialister species.	Morio F, Jean-Pierre H, Dubreuil L, Jumas-Bilak E, Calvet L, Mercier G, Devine R, Marchandin H.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	5	1666	1670	17296742	10.1128/aac.01303-06	EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.	Bermudez LE, Motamedi N, Chee C, Baimukanova G, Kolonoski P, Inderlied C, Aralar P, Wang G, Phan LT, Young LS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	5	1830	1834	17325214	10.1128/aac.01453-06	Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany.	van der Linden M, Al-Lahham A, Haupts S, Reinert RR.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	6	2011	2015	17404000	10.1128/aac.01460-06	Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhus.	Kim DM, Yu KD, Lee JH, Kim HK, Lee SH.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	9	3240	3246	17606677	10.1128/aac.00157-07	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.	Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2007	51	9	3420	3424	17606689	10.1128/aac.00100-07	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2008	18	24	6315	6318	18996692	10.1016/j.bmcl.2008.10.109	Synthesis of 3,6-bicyclolides: a novel class of macrolide antibiotics.	Gai Y, Tang D, Xu G, Chen Z, Polemeropoulos A, Wang Z, Or YS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	1	348	350	17954691	10.1128/aac.00779-07	Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.	Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	1	77	84	17938189	10.1128/aac.01229-07	In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.	Clark C, Smith K, Ednie L, Bogdanovich T, Dewasse B, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	2	435	440	18056269	10.1128/aac.01074-07	Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.	Wolter N, Smith AM, Farrell DJ, Northwood JB, Douthwaite S, Klugman KP.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	2	774	777	18056275	10.1128/aac.00892-07	Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum.	Barthel D, Schlitzer M, Pradel G.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	3	1046	1051	18160519	10.1128/aac.01210-07	Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.	Lee JH, Cho YK, Jung YS, Kim YC, Lee MG.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	3	1156	1158	18195060	10.1128/aac.00923-07	Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event.	Gentry DR, Holmes DJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	3	1182	1183	18180358	10.1128/aac.01332-07	In vitro activity of AR-709 against Streptococcus pneumoniae.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	3	866	874	18086834	10.1128/aac.01266-07	Induction of erm(C) expression by noninducing antibiotics.	Bailey M, Chettiath T, Mankin AS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	5	1653	1662	18316525	10.1128/aac.01383-07	In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.	Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	6	1964	1969	18362188	10.1128/aac.01487-07	Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).	de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galán JC, Baquero F, Reinert RR, Cantón R.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	7	2639	2643	18443117	10.1128/aac.00310-08	Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.	Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2008	52	7	2647	2652	18443122	10.1128/aac.01398-07	In vitro activity of telavancin against resistant gram-positive bacteria.	Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2009	19	15	4079	4083	19560350	10.1016/j.bmcl.2009.06.023	Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.	Xu P, Liu L, Chen XZ, Li Y, Liu J, Jin ZP, Wang GQ, Lei PS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2009	52	23	7446	7457	19775168	10.1021/jm900729s	Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.	Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	11	4762	4771	19738026	10.1128/aac.00952-09	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.	Arhin FF, Draghi DC, Pillar CM, Parr TR, Moeck G, Sahm DF.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	4	1367	1376	19171799	10.1128/aac.01275-08	A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.	Nash KA, Brown-Elliott BA, Wallace RJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	4	1411	1419	19164155	10.1128/aac.01425-08	Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity.	Kouvela EC, Kalpaxis DL, Wilson DN, Dinos GP.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	5	1786	1792	19223626	10.1128/aac.01270-08	Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.	Jiang LJ, Wang M, Or YS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	5	2139	2141	19258276	10.1128/aac.00090-09	Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	6	2239	2247	19307366	10.1128/aac.01531-08	Comparative antipneumococcal activities of sulopenem and other drugs.	Kosowska-Shick K, Ednie LM, McGhee P, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	9	3734	3743	19564365	10.1128/aac.00203-09	Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.	Lemaire S, Van Bambeke F, Tulkens PM.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2009	53	9	3777	3781	19596876	10.1128/aac.00026-09	In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.	Osborne CS, Neckermann G, Fischer E, Pecanka R, Yu D, Manni K, Goldovitz J, Amaral K, Dzink-Fox J, Ryder NS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	17	6547	6558	20621489	10.1016/j.bmc.2010.06.050	Synthesis and biological activity of 4''-O-acyl derivatives of 14- and 15-membered macrolides linked to omega-quinolone-carboxylic unit.	Skugor MM, Stimac V, Palej I, Lugari¿ D, Paljetak HC, Fili¿ D, Modri¿ M, Dilovi¿ I, Gembarovski D, Mutak S, Erakovi¿ Haber V, Holmes DJ, Ivezi¿-Schoenfeld Z, Alihodzi¿ S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	17	6559	6568	20634078	10.1016/j.bmc.2010.06.049	4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens.	Fajdeti¿ A, Cipci¿ Paljetak H, Lazarevski G, Hutinec A, Alihodzi¿ S, Derek M, Stimac V, Andreotti D, Sunji¿ V, Berge JM, Mutak S, Dumi¿ M, Lociuro S, Holmes DJ, Marsi¿ N, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	17	6569	6577	20673633	10.1016/j.bmc.2010.06.048	6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile.	Kapi¿ S, Cipci¿ Paljetak H, Alihodzi¿ S, Antolovi¿ R, Erakovi¿ Haber V, Jarvest RL, Holmes DJ, Broskey JP, Hunt E.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	17	6578	6588	20688524	10.1016/j.bmc.2010.07.007	Synthesis and properties of macrolones characterized by two ether bonds in the linker.	Jakopovi¿ IP, Kragol G, Forrest AK, Frydrych CS, Stimac V, Kapi¿ S, Skugor MM, Ilijas M, Paljetak HC, Jeli¿ D, Holmes DJ, Hickey DM, Verbanac D, Erakovi¿ Haber V, Alihodzi¿ S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	24	8566	8582	21055953	10.1016/j.bmc.2010.10.024	Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials.	Pavlovi¿ D, Fajdeti¿ A, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2010	18	7	2735	2747	20236827	10.1016/j.bmc.2010.02.017	Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4'' positions: Improved antibacterial activities.	Miura T, Natsume S, Kanemoto K, Shitara E, Fushimi H, Yoshida T, Ajito K.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2010	20	11	3244	3249	20462754	10.1016/j.bmcl.2010.04.062	Novel 8a-aza-8a-homoerythromycin--4''-(3-substituted-amino)propionates with broad spectrum antibacterial activity.	Hutinec A, Derek M, Lazarevski G, Sunji¿ V, Paljetak HC, Alihodzi¿ S, Erakovi¿ Haber V, Dumi¿ M, Marsi¿ N, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2010	20	18	5527	5531	20716487	10.1016/j.bmcl.2010.07.072	A new series of macrolide derivatives with 4''-O-saccharide substituents.	Xu P, Chen XZ, Liu L, Jin ZP, Lei PS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2010	53	15	5868	5880	20684614	10.1021/jm100711p	Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides.	Pavlovi¿ D, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	1	230	238	19884376	10.1128/aac.01123-09	In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.	McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	10	4518	4519	20660671	10.1128/aac.00235-10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.	Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	2	866	870	19933801	10.1128/aac.00567-09	Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects.	Furuie H, Saisho Y, Yoshikawa T, Shimada J.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	3	1358	1359	20038627	10.1128/aac.01343-09	In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.	Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	5	1909	1913	20231391	10.1128/aac.01570-09	Nucleotide selectivity of antibiotic kinases.	Shakya T, Wright GD.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	5	2182	2187	20176910	10.1128/aac.01662-09	CEM-101 activity against Gram-positive organisms.	Woosley LN, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	8	3498	3501	20498312	10.1128/aac.01678-09	In vitro activity of azithromycin against nontyphoidal Salmonella enterica.	Gunell M, Kotilainen P, Jalava J, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Antimicrob. Agents Chemother.	2010	54	9	4009	4011	20625152	10.1128/aac.01812-09	Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.	Biedenbach DJ, Castanheira M, Jones RN.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2011	2	1	68	72	21643527	10.1021/ml1002184	Desmethyl Macrolide Analogues to Address Antibiotic Resistance: Total Synthesis and Biological Evaluation of 4,8,10-Tridesmethyl Telithromycin.	Velvadapu V, Paul T, Wagh B, Klepacki D, Guvench O, Mackerell A, Andrade RB.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2011	2	5	331	336	24900314	10.1021/ml100253p	Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.	Pavlovi¿ D, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Eur. J. Med. Chem.	2011	46	1	208	217	21130543	10.1016/j.ejmech.2010.11.004	Synthesis and antibacterial activity of novel ketolides with 11,12-sulfur contained aryl alkyl side chains.	Chen XZ, Xu P, Liu L, Zheng D, Lei PS.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Eur. J. Med. Chem.	2011	46	8	3388	3397	21600677	10.1016/j.ejmech.2011.05.002	Synthesis, activity and pharmacokinetics of novel antibacterial 15-membered ring macrolones.	Fajdeti¿ A, Vinter A, Paljetak H¿, Padovan J, Jakopovi¿ IP, Kapi¿ S, Alihod¿i¿ S, Fili¿ D, Modri¿ M, Ko¿uti¿-Hulita N, Antolovi¿ R, Schoenfeld ZI, Mutak S, Erakovi¿ Haber V, Spaventi R.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2012	20	19	5787	5801	22925450	10.1016/j.bmc.2012.08.007	Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'.	Sugimoto T, Tanikawa T, Suzuki K, Yamasaki Y.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2012	22	1	476	481	22153939	10.1016/j.bmcl.2011.10.101	Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.	Kumar R, Rathy S, Hajare AK, Surase YB, Dullu J, Jadhav JS, Venkataramanan R, Chakrabarti A, Pandya M, Bhateja P, Ramkumar G, Das B.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2012	22	14	4575	4578	22738632	10.1016/j.bmcl.2012.05.110	Synthesis and antibacterial activity of desosamine-modified macrolide derivatives.	LeTourneau N, Vimal P, Klepacki D, Mankin A, Melman A.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2012	22	24	7402	7405	23122862	10.1016/j.bmcl.2012.10.064	Synthesis and antibacterial activity of novel modified 5-O-desosamine ketolides.	Chen X, Xu P, Xu Y, Liu L, Liu Y, Zhu D, Lei P.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2012	3	12	1013	1018	24015325	10.1021/ml300230h	Desmethyl Macrolides: Synthesis and Evaluation of 4,8-Didesmethyl Telithromycin.	Wagh B, Paul T, Glassford I, Debrosse C, Klepacki D, Small MC, Mackerell AD, Andrade RB.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2012	3	3	211	215	22708010	10.1021/ml200254h	Desmethyl Macrolides: Synthesis and Evaluation of 4,10-Didesmethyl Telithromycin.	Velvadapu V, Glassford I, Lee M, Paul T, Debrosse C, Klepacki D, Small MC, Mackerell AD, Andrade RB.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2013	23	11	3452	3457	23591116	10.1016/j.bmcl.2013.03.057	Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives.	Jiang JW, Sun Y, Nie Y, Zhi HJ, Zhang XJ, Li X, Sun HP, You QD.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2013	23	23	6274	6279	24139585	10.1016/j.bmcl.2013.09.083	Synthesis of 4¿-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities.	Zhu D, Xu Y, Liu Y, Chen X, Zhao Z, Lei P.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem. Lett.	2013	23	5	1387	1393	23375796	10.1016/j.bmcl.2012.12.070	Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.	Liang JH, Lv W, Li XL, An K, Cushman M, Wang H, Xu YC.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	J. Med. Chem.	2013	56	4	1418	1430	23409840	10.1021/jm301499r	Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.	Desroy N, Denis A, Oliveira C, Atamanyuk D, Briet S, Faivre F, LeFralliec G, Bonvin Y, Oxoby M, Escaich S, Floquet S, Drocourt E, Vongsouthi V, Durant L, Moreau F, Verhey TB, Lee TW, Junop MS, Gerusz V.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Eur. J. Med. Chem.	2013	69		174	181	24021890	10.1016/j.ejmech.2013.08.023	Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides.	Xu Y, Chen X, Zhu D, Liu Y, Zhao Z, Jin L, Liu C, Lei P.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2014	5	10	1133	1137	25313326	10.1021/ml500279k	Synthesis and Structure-Activity Relationships of ¿-Amino-¿-lactone Ketolides: A Novel Class of Macrolide Antibiotics.	Pavlovi¿ D, Mutak S, Andreotti D, Biondi S, Cardullo F, Paio A, Piga E, Donati D, Lociuro S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	ACS Med. Chem. Lett.	2014	5	9	1021	1026	25221660	10.1021/ml5002097	Desmethyl macrolides: synthesis and evaluation of 4-desmethyl telithromycin.	Glassford I, Lee M, Wagh B, Velvadapu V, Paul T, Sandelin G, DeBrosse C, Klepacki D, Small MC, MacKerell AD, Andrade RB.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Hepatology	2014	60	3	1015	1022	24799086	10.1002/hep.27206	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.	Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2015	23	19	6437	6453	26349628	10.1016/j.bmc.2015.08.020	Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity.	Han X, Lv W, Guo SY, Cushman M, Liang JH.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg. Med. Chem.	2016	24	6	1255	1267	26860929	10.1016/j.bmc.2016.01.055	Synthesis and antibacterial evaluation of novel 4¿-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens.	Pavlovi¿ D, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Eur J Med Chem	2017	125		210	224	27657812	10.1016/j.ejmech.2016.09.022	Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.	Pavlovi¿ D, Kimmins S, Mutak S.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136	Bioorg Med Chem Lett	2017	27	7	1513	1524	28256375	10.1016/j.bmcl.2017.02.041	Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides.	Tian JC, Han X, Lv W, Li YX, Wang H, Fan BZ, Cushman M, Liang JH.
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									DailyMed|setid=ba1cca98-f350-4655-88e3-6ef990779fb9 | KETEK - telithromycin tablet, film coated|Physicians Total Care, Inc.	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TELITHROMYCIN	CHEMBL1136									WHO Anatomical Therapeutic Chemical Classification	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	Antimicrob. Agents Chemother.	2007	51	2	543	550	17145787	10.1128/aac.00968-06	Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.	Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	J. Med. Chem.	2008	51	14	4331	4339	18570362	10.1021/jm8001235	Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.	Dang Q, Kasibhatla SR, Jiang T, Fan K, Liu Y, Taplin F, Schulz W, Cashion DK, Reddy KR, van Poelje PD, Fujitaki JM, Potter SC, Erion MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	J. Med. Chem.	2008	51	8	2328	2345	18237108	10.1021/jm701260b	Prodrugs of phosphates and phosphonates.	Hecker SJ, Erion MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	Bioorg. Med. Chem.	2010	18	10	3606	3617	20409721	10.1016/j.bmc.2010.03.041	Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.	Mackman RL, Ray AS, Hui HC, Zhang L, Birkus G, Boojamra CG, Desai MC, Douglas JL, Gao Y, Grant D, Laflamme G, Lin KY, Markevitch DY, Mishra R, McDermott M, Pakdaman R, Petrakovsky OV, Vela JE, Cihlar T.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	Eur. J. Med. Chem.	2014	78		259	268	24686012	10.1016/j.ejmech.2014.03.051	PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.	Pertusati F, Hinsinger K, Flynn ÁS, Powell N, Tristram A, Balzarini J, McGuigan C.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	J Med Chem	2016	59	20	9513	9531	27748590	10.1021/acs.jmedchem.6b01260	Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.	Liu C, Dumbre SG, Pannecouque C, Huang C, Ptak RG, Murray MG, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	J Med Chem	2017	60	14	6220	6238	28682067	10.1021/acs.jmedchem.7b00416	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.	Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW, Schols D, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825	J Med Chem	2018	61	6	2211	2226	28792763	10.1021/acs.jmedchem.7b00734	The ProTide Prodrug Technology: From the Concept to the Clinic.	Mehellou Y, Rattan HS, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE	CHEMBL2107825									WHO Anatomical Therapeutic Chemical Classification	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE FUMARATE	CHEMBL2364637									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR ALAFENAMIDE FUMARATE	CHEMBL2364637									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Bioorg. Med. Chem.	2007	15	16	5519	5528	17562366	10.1016/j.bmc.2007.05.047	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.	Mackman RL, Zhang L, Prasad V, Boojamra CG, Douglas J, Grant D, Hui H, Kim CU, Laflamme G, Parrish J, Stoycheva AD, Swaminathan S, Wang K, Cihlar T.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Bioorg. Med. Chem. Lett.	2007	17	22	6350	6353	17888662	10.1016/j.bmcl.2007.08.065	Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.	Tang YB, Peng ZG, Liu ZY, Li YP, Jiang JD, Li ZR.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2007	51	10	3498	3504	17664327	10.1128/aac.00671-07	Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.	Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2007	51	6	2105	2111	17438052	10.1128/aac.00831-06	Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.	Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2007	51	9	3177	3184	17606676	10.1128/aac.00325-07	Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Asif G, Narayanasamy J, Butler SD, George AL, Hurwitz SJ, Schinazi RF, Chu CK, Cote PJ, Gerin JL, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2008	52	10	3617	3632	18676881	10.1128/aac.00654-08	Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.	Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2009	53	3	1194	1203	19104010	10.1128/aac.00984-08	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.	Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Antimicrob. Agents Chemother.	2011	55	1	42	49	21060108	10.1128/aac.01064-10	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.	Koh Y, Haim H, Engelman A.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	J Med Chem	2017	60	14	6220	6238	28682067	10.1021/acs.jmedchem.7b00416	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.	Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW, Schols D, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610	J. Med. Chem.	2009	52	13	3982	3993	19492813	10.1021/jm900364m	Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.	Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Yang Z, Roethke T, Smith BR, Ward KW, Lee J, Keenan RM, Bhatnagar P.
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610	Bioorg. Med. Chem.	2010	18	1	190	201	19932972	10.1016/j.bmc.2009.11.002	Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II.	Moore WJ, Kern JC, Bhat R, Bodine PV, Fukyama S, Krishnamurthy G, Magolda RL, Pitts K, Stauffer B, Trybulski EJ.
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610	J. Med. Chem.	2010	53	11	4332	4353	20218623	10.1021/jm9018756	Emerging targets in osteoporosis disease modification.	Allen JG, Fotsch C, Babij P.
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610									British National Formulary (72nd edition)	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610									Unpublished dataset	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE	CHEMBL525610									WHO Anatomical Therapeutic Chemical Classification	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE ACETATE	CHEMBL1201549									Unpublished dataset	
886.3666666666666667	9606	Homo sapiens	TERIPARATIDE ACETATE	CHEMBL1201549									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1494.3800000000000000	9606	Homo sapiens	TERODILINE HYDROCHLORIDE	CHEMBL539770	Bioorg. Med. Chem. Lett.	1998	8	14	1807	1812	9873438	10.1016/s0960-894x(98)00312-6	Novel imidazole derivatives with subtype-selective antimuscarinic activity (1).	Miyachi H, Kiyota H, Segawa M.
1494.3800000000000000	9606	Homo sapiens	TERODILINE HYDROCHLORIDE	CHEMBL539770									British National Formulary (72nd edition)	
1494.3800000000000000	9606	Homo sapiens	TERODILINE HYDROCHLORIDE	CHEMBL539770									PubChem BioAssay data set	
1494.3800000000000000	9606	Homo sapiens	TERODILINE HYDROCHLORIDE	CHEMBL539770									Unpublished dataset	
1494.3800000000000000	9606	Homo sapiens	TERODILINE HYDROCHLORIDE	CHEMBL539770									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1977	20	6	826	829	874957	10.1021/jm00216a017	Synthesis of 5-chloro-3'-nitro-4'-substituted salicylanilides, a new series of anthelmintic and antimicrobial agents.	Singh H, Singh AK, Sharma S, Iyer RN, Srivastava OP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1979	22	11	1409	1414	533889	10.1021/jm00197a024	Antibacterial N-[omega, omega'-bis(alicyclic and aryl)-sec-alkyl]poly(methylene)triamine and -tetramine hydrochloride salts.	Grier N, Dybas RA, Strelitz RA, Witzel BE, Dulaney EL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	1984	47	5	815	818	6512534	10.1021/np50035a010	Antibacterial constituents of the diatom Navicula delognei.	Findlay JA, Patil AD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1987	30	1	205	208	3806595	10.1021/jm00384a035	Substituted 2-(2-hydroxyphenyl)benzimidazoles as potential agents for the control of periodontal diseases.	Coburn RA, Clark MT, Evans RT, Genco RJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1987	30	2	333	340	3543366	10.1021/jm00385a015	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.	Allen NE, Alborn WE, Kirst HA, Toth JE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	1987	50	4	696	699	3430167	10.1021/np50052a020	Traditional medicinal plants of Thailand, VIII. Isoflavonoids of Dalbergia candenatensis.	Hamburger MO, Cordell GA, Tantivatana P, Ruangrungsi N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	1990	53	2	237	278	2199608	10.1021/np50068a001	Annonaceous acetogenins: a review.	Rupprecht JK, Hui YH, McLaughlin JL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1993	3	12	2875	2878		10.1016/S0960-894X(01)80782-4	Inhibition of cartilage breakdown by isothiazolones	Wright SW, Petraitis JJ, Abelman MM, Bostrom LL, Corbett RL, Green AM, Kindt RM, Sherk SR, Magolda RL
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1993	36	3	370	377	8426364	10.1021/jm00055a008	Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines.	Nelson ML, Park BH, Andrews JS, Georgian VA, Thomas RC, Levy SB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1994	37	1	184	188	8289194	10.1021/jm00027a023	Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines.	Sum PE, Lee VJ, Testa RT, Hlavka JJ, Ellestad GA, Bloom JD, Gluzman Y, Tally FP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	1994	37	19	3071	3078	7932530	10.1021/jm00045a012	Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown.	Wright SW, Petraitis JJ, Abelman MM, Batt DG, Bostrom LL, Corbett RL, Decicco CP, Di Meo SV, Freimark B, Giannaras JV.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1994	4	11	1375	1380		10.1016/S0960-894X(01)80365-6	Synthesis of -estradiol-3-benzoate-17-(succinyl-12A-tetracycline): A potential bone-seeking estrogen	Orme MW, Labroo VM
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1996	6	19	2301	2306		10.1016/0960-894X(96)00418-0	New cytostatic agents obtained by molecular topology	Galvez J, Gomez-Lechon M, Garcia-Domenech R, Castell J
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	1997	60	11	1207	1209	9392888	10.1021/np970338f	New phomopsolides from a Penicillium sp.	Stierle DB, Stierle AA, Ganser B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1997	7	5	567	572		10.1016/S0960-894X(97)00046-2	Molecular connectivity to find -blockers with low toxicity	Garcia-Domenech R, de Gregorio Alapont C, de Julian-Ortiz J, Galvez J, Popa L
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1998	8	21	3007	3010	9873665	10.1016/s0960-894x(98)00536-8	Nitroglycosylated meso-arylporphyrins as photoinhibitors of gram positive bacteria.	Sol V, Branland P, Granet R, Kaldapa C, Verneuil B, Krausz P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1998	8	8	945	950	9871517	10.1016/s0960-894x(98)00149-8	Peptide inhibitors of N-succinyl diaminopimelic acid aminotransferase (DAP-AT): a novel class of antimicrobial compounds.	Cox RJ, Schouten JA, Stentiford RA, Wareing KJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	1999	9	10	1459	1462	10360756	10.1016/s0960-894x(99)00216-4	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.	Sum PE, Petersen P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2000	63	3	339	343	10757714	10.1021/np9903090	Novel extracellular diterpenoids with biological activity from the cyanobacterium Nostoc commune.	Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2001	64	10	1322	1325	11678659	10.1021/np0102861	Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum.	Muhammad I, Li XC, Dunbar DC, ElSohly MA, Khan IA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2002	45	19	4300	4309	12213071	10.1021/jm020868v	Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2.	Carcanague D, Shue YK, Wuonola MA, Uria-Nickelsen M, Joubran C, Abedi JK, Jones J, Kühler TC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2002	65	7	960	964	12141853	10.1021/np020064i	Isolation of S-n-butylcysteine sulfoxide and six n-butyl-containing thiosulfinates from Allium siculum.	Kubec R, Kim S, McKeon DM, Musah RA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Jpn. J. Pharmacol.	2002	88	1	69	76	11855680	10.1254/jjp.88.69	Human organic anion transporters mediate the transport of tetracycline.	Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2004	14	13	3467	3471	15177454	10.1016/j.bmcl.2004.04.055	Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.	Dominick PK, Keppler BR, Legassie JD, Moon IK, Jarstfer MB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2004	47	16	3949	3961	15267234	10.1021/jm040760a	Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.	Ermondi G, Lorenti M, Caron G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2004	47	6	1487	1513	14998336	10.1021/jm0310232	New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.	Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2005	15	8	2123	2128	15808482	10.1016/j.bmcl.2005.02.029	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.	Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2005	68	1	50	55	15679316	10.1021/np0497189	Cicadapeptins I and II: new Aib-containing peptides from the entomopathogenic fungus Cordyceps heteropoda.	Krasnoff SB, Reátegui RF, Wagenaar MM, Gloer JB, Gibson DM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2006	15	7	407	417		10.1007/s00044-006-0015-z	Synthesis of novel 3-[5-ethyl-2-(2-phenoxy-ethyl)-pyridin]-5-substituted isoxazoline libraries via 1,3-dipolar cycloaddition and evaluation of antimicrobial activities	Gaonkar S, Rai KL, Prabhuswamy B
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2006	16	20	5451	5456	16890435	10.1016/j.bmcl.2006.07.052	Structure-activity relationships of novel antibacterial translation inhibitors: 3,5-diamino-piperidinyl triazines.	Zhou Y, Sun Z, Froelich JM, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2006	16	21	5523	5525	16945527	10.1016/j.bmcl.2006.08.043	In vitro inhibitory activity of boropinic acid against Helicobacter pylori.	Epifano F, Menghini L, Pagiotti R, Angelini P, Genovese S, Curini M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2006	16	4	999	1004	16298529	10.1016/j.bmcl.2005.10.084	Microwave-assisted synthesis of N-alkylated benzotriazole derivatives: antimicrobial studies.	Nanjunda Swamy S, Basappa, Sarala G, Priya BS, Gaonkar SL, Shashidhara Prasad J, Rangappa KS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2006	49	25	7331	7341	17149863	10.1021/jm060492b	Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.	Leon A, Liu L, Yang Y, Hudock MP, Hall P, Yin F, Studer D, Puan KJ, Morita CT, Oldfield E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2006	69	3	406	409	16562846	10.1021/np050227d	Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus.	Pereda-Miranda R, Kaatz GW, Gibbons S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2006	69	4	585	590	16643031	10.1021/np050438i	Antibacterial, partially acetylated oligorhamnosides from Cleistopholis patens.	Hu JF, Garo E, Hough GW, Goering MG, O'Neil-Johnson M, Eldridge GR.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2006	69	7	1070	1073	16872146	10.1021/np050449b	Antibiotic bisanthraquinones produced by a streptomycete isolated from a cyanobacterium associated with Ecteinascidia turbinata.	Socha AM, Garcia D, Sheffer R, Rowley DC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2007	15	6	2368	2374	17267227	10.1016/j.bmc.2007.01.026	Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.	Vidal A, Sabatini M, Rolland-Valognes G, Renard P, Madelmont JC, Mounetou E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2007	16	5	205	212		10.1007/s00044-007-9024-9	Synthesis of 2,4-dihalogenofluorobenzenes and their antimicrobial and antifungal activity studies	Katrcoglu H, Logoglu E, Tilki T, Oktemer A
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	11	3226	3230	17433674	10.1016/j.bmcl.2007.03.007	Syntheses and antibacterial activity of phendioxy substituted cyclic enediynes.	Joshi MC, Bisht GS, Rawat DS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	15	4102	4106	17570664	10.1016/j.bmcl.2007.05.065	Synthesis and evaluation of amphiphilic cationic quinine-derived for antibacterial activity against methicillin-resistant Staphylococcus aureus.	Lv J, Qian Y, Liu T, Wang Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	15	4343	4346	17553680	10.1016/j.bmcl.2007.05.015	Antimicrobial activity of rationally designed amino terminal modified peptides.	Bisht GS, Rawat DS, Kumar A, Kumar R, Pasha S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	18	5270	5273	17689076	10.1016/j.bmcl.2006.12.071	Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.	Rajakumar P, Selvam S, Shanmugaiah V, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	5	1206	1210	17188860	10.1016/j.bmcl.2006.12.024	Synthesis and SAR of 3,5-diamino-piperidine derivatives: novel antibacterial translation inhibitors as aminoglycoside mimetics.	Zhou Y, Gregor VE, Ayida BK, Winters GC, Sun Z, Murphy D, Haley G, Bailey D, Froelich JM, Fish S, Webber SE, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2007	17	8	2372	2375	17376679	10.1016/j.bmcl.2006.11.055	Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.	Sriram D, Yogeeswari P, Senchani G, Banerjee D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Biol. Chem.	2007	282	4	2494	2504	17110371	10.1074/jbc.m608615200	In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.	Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2007	42	10	1293	1299	17337097	10.1016/j.ejmech.2007.01.022	Synthesis and in vitro antimicrobial activity of new 2-[p-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles.	Tekiner-Gulbas B, Temiz-Arpaci O, Yildiz I, Altanlar N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2007	42	2	205	213	17189664	10.1016/j.ejmech.2006.09.023	Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand.	Aghatabay NM, Neshat A, Karabiyik T, Somer M, Haciu D, Dülger B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2007	42	8	1069	1075	17350734	10.1016/j.ejmech.2007.01.011	Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex.	Aghatabay NM, Somer M, Senel M, Dulger B, Gucin F.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2007	50	17	4195	4204	17665895	10.1021/jm0703183	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.	Villain-Guillot P, Gualtieri M, Bastide L, Roquet F, Martinez J, Amblard M, Pugniere M, Leonetti JP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	1	231	238	17074796	10.1128/aac.00576-06	High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.	Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, Zhu W, Musser KA, Thompson J, Kohlerschmidt D, Dumas N, Limberger RJ, Patel JB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	1	307	316	17060533	10.1128/aac.00808-06	Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.	Ramya TN, Mishra S, Karmodiya K, Surolia N, Surolia A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	11	3880	3886	17724154	10.1128/aac.00846-07	Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.	Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A, Canadian Nosocomial Infection Surveillance Program.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	11	4125	4132	17785509	10.1128/aac.00208-07	Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens.	Beckloff N, Laube D, Castro T, Furgang D, Park S, Perlin D, Clements D, Tang H, Scott RW, Tew GN, Diamond G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	11	4184	4186	17709465	10.1128/aac.00598-07	The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271.	Del Grosso M, Northwood JG, Farrell DJ, Pantosti A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	12	4374	4381	17938183	10.1128/aac.00854-07	The PhoQ-activating potential of antimicrobial peptides contributes to antimicrobial efficacy and is predictive of the induction of bacterial resistance.	Kindrachuk J, Paur N, Reiman C, Scruten E, Napper S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	2	423	428	17116664	10.1128/aac.01244-06	Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.	Szumowski JD, Cohen DE, Kanaya F, Mayer KH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	2	535	542	17043131	10.1128/aac.00600-06	Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.	Chen S, Cui S, McDermott PF, Zhao S, White DG, Paulsen I, Meng J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	3	1004	1010	17220413	10.1128/aac.01103-06	Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.	Dean CR, Narayan S, Richards J, Daigle DM, Esterow S, Leeds JA, Kamp H, Puyang X, Wiedmann B, Mueller D, Voshol H, van Oostrum J, Wall D, Koehn J, Dzink-Fox J, Ryder NS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	3	1092	1095	17210764	10.1128/aac.01153-06	High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.	Wolter N, Smith AM, Low DE, Klugman KP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	3	1119	1122	17210778	10.1128/aac.00779-06	Effects of glutathione and ascorbic acid on streptomycin sensitivity of Escherichia coli.	Goswami M, Mangoli SH, Jawali N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	3	888	895	17158933	10.1128/aac.01052-06	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.	Frank KL, Reichert EJ, Piper KE, Patel R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	3	923	929	17210767	10.1128/aac.01048-06	Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.	Elkins CA, Mullis LB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	4	1209	1216	17261630	10.1128/aac.01484-06	Genetic elements carrying erm(B) in Streptococcus pyogenes and association with tet(M) tetracycline resistance gene.	Brenciani A, Bacciaglia A, Vecchi M, Vitali LA, Varaldo PE, Giovanetti E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	4	1259	1267	17242152	10.1128/aac.01315-06	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.	Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Bradbury BJ, Deshpande M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	4	1293	1303	17220404	10.1128/aac.01128-06	Increased genome instability in Escherichia coli lon mutants: relation to emergence of multiple-antibiotic-resistant (Mar) mutants caused by insertion sequence elements and large tandem genomic amplifications.	Nicoloff H, Perreten V, Levy SB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	5	1844	1848	17353242	10.1128/aac.01428-06	In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.	Llull D, Rivas L, García E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	5	1865	1868	17307980	10.1128/aac.01341-06	Tetracycline resistance in group a streptococci: emergence on a global scale and influence on multiple-drug resistance.	Ayer V, Tewodros W, Manoharan A, Skariah S, Luo F, Bessen DE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	5	1885	1887	17325224	10.1128/aac.00187-07	Molecular epidemiology of telithromycin-resistant pneumococci in Finland.	Rantala M, Nyberg S, Lindgren M, Huovinen P, Jalava J, Skyttä R, Teirilä L, Vainio A, Virolainen-Julkunen A, Kaijalainen T.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	6	1956	1961	17387155	10.1128/aac.00062-07	Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.	Heller S, Kellenberger L, Shapiro S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	6	2048	2052	17404009	10.1128/aac.01066-06	Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin.	Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	6	2070	2077	17438056	10.1128/aac.01472-06	Polyamine effects on antibiotic susceptibility in bacteria.	Kwon DH, Lu CD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	6	2092	2099	17420206	10.1128/aac.00052-07	PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli.	Li Y, Zhang Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2359	2365	17438050	10.1128/aac.01395-06	Biochemical characterization of PER-2 and genetic environment of blaPER-2.	Power P, Di Conza J, Rodríguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2464	2469	17470656	10.1128/aac.00143-07	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.	Périchon B, Courvalin P, Galimand M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2508	2513	17371822	10.1128/aac.00603-06	High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.	Chow VC, Hawkey PM, Chan EW, Chin ML, Au TK, Fung DK, Chan RC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2591	2593	17420210	10.1128/aac.01562-06	In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.	Yum JH, Kim CK, Yong D, Lee K, Chong Y, Kim CM, Kim JM, Ro S, Cho JM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2625	2627	17502407	10.1128/aac.00107-07	Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.	Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	7	2628	2630	17502411	10.1128/aac.00206-07	Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus.	Cenizal MJ, Skiest D, Luber S, Bedimo R, Davis P, Fox P, Delaney K, Hardy RD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	8	2679	2689	17502406	10.1128/aac.00209-07	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Meehl M, Herbert S, Götz F, Cheung A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	8	2720	2725	17548490	10.1128/aac.00026-07	Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America.	Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, Gotuzzo E, Kronvall G, Paradisi F, Rossolini GM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	8	3004	3007	17526756	10.1128/aac.00167-07	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.	Chen YT, Lauderdale TL, Liao TL, Shiau YR, Shu HY, Wu KM, Yan JJ, Su IJ, Tsai SF.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	8	3036	3037	17517833	10.1128/aac.00357-07	Interdomain loop mutation Asp190Cys of the tetracycline efflux transporter TetA(B) decreases affinity for substrate.	Sapunaric FM, Levy SB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	8	3038	3039	17517838	10.1128/aac.00374-07	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.	Ikonomidis A, Labrou M, Afkou Z, Maniatis AN, Sofianou D, Tsakris A, Pournaras S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3205	3211	17620376	10.1128/aac.00625-07	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.	Tuckman M, Petersen PJ, Howe AY, Orlowski M, Mullen S, Chan K, Bradford PA, Jones CH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3212	3216	17606685	10.1128/aac.01592-06	Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni.	Gibreel A, Wetsch NM, Taylor DE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3240	3246	17606677	10.1128/aac.00157-07	Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.	Calatayud L, Ardanuy C, Cercenado E, Fenoll A, Bouza E, Pallares R, Martín R, Liñares J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3354	3360	17548499	10.1128/aac.00339-07	New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.	Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T, Arakawa Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2007	51	9	3420	3424	17606689	10.1128/aac.00100-07	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.	Jansen WT, Verel A, Verhoef J, Milatovic D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2007	70	12	1919	1924	18044842	10.1021/np070407i	Serinocyclins A and B, cyclic heptapeptides from Metarhizium anisopliae.	Krasnoff SB, Keresztes I, Gillilan RE, Szebenyi DM, Donzelli BG, Churchill AC, Gibson DM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2008	16	2	739	745	17964793	10.1016/j.bmc.2007.10.021	Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.	Knuckley B, Luo Y, Thompson PR.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2008	16	22	9790	9794	18951808	10.1016/j.bmc.2008.09.064	Structure-activity relationship of antibacterial chalcones.	Avila HP, Smânia Ede F, Monache FD, Smânia A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2008	17	8	475	486		10.1007/s00044-007-9020-0	Study of the inactivation of copper, zinc superoxide dismutase by tetracycline analogues	Wei W, Wang H, Jiang C
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	11	3369	3375	18440814	10.1016/j.bmcl.2008.04.023	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.	Zhou Y, Chow C, Murphy DE, Sun Z, Bertolini T, Froelich JM, Webber SE, Hermann T, Wall D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	15	4416	4419	18620857	10.1016/j.bmcl.2008.06.047	Synthesis of some novel imidazole-based dicationic carbazolophanes as potential antibacterials.	Rajakumar P, Sekar K, Shanmugaiah V, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	20	5512	5517	18805690	10.1016/j.bmcl.2008.09.013	Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.	Bavikar SN, Salunke DB, Hazra BG, Pore VS, Dodd RH, Thierry J, Shirazi F, Deshpande MV, Kadreppa S, Chattopadhyay S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	21	5800	5800	18842404	10.1016/j.bmcl.2008.09.057	One-pot synthesis and antibacterial activities of pyrazolo[4',3':5,6]pyrido[2,3-d]pyrimidine-dione derivatives.	Bazgir A, Khanaposhtani MM, Soorki AA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	6	2043	2047	18267360	10.1016/j.bmcl.2008.01.102	Synthesis and antimicrobial activity of beta-lactam-bile acid conjugates linked via triazole.	Vatmurge NS, Hazra BG, Pore VS, Shirazi F, Chavan PS, Deshpande MV.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	6	2156	2161	18281215	10.1016/j.bmcl.2008.01.080	Synthesis and antimicrobial activity of 3-arylamino-1-chloropropan-2-ols.	Prasad AK, Kumar P, Dhawan A, Chhillar AK, Sharma D, Yadav V, Kumar M, Jha HN, Olsen CE, Sharma GL, Parmar VS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2008	18	7	2342	2345	18342506	10.1016/j.bmcl.2008.02.065	Synthesis of novel spiropyrrolizidines as potent antimicrobial agents for human and plant pathogens.	Periyasami G, Raghunathan R, Surendiran G, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	1	248	252	17967912	10.1128/aac.00714-07	Mosaic tetracycline resistance genes and their flanking regions in Bifidobacterium thermophilum and Lactobacillus johnsonii.	van Hoek AH, Mayrhofer S, Domig KJ, Flórez AB, Ammor MS, Mayo B, Aarts HJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	10	3542	3549	18644962	10.1128/aac.00582-08	Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.	Wolff BJ, Thacker WL, Schwartz SB, Winchell JM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	10	3604	3611	18694955	10.1128/aac.00661-08	RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.	Bailey AM, Paulsen IT, Piddock LJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	10	3776	3778	18663020	10.1128/aac.00849-08	Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.	Waites KB, Crabb DM, Duffy LB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	11	3837	3843	18725452	10.1128/aac.00570-08	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.	Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	11	4001	4009	18779355	10.1128/aac.00308-08	A new tetracycline efflux gene, tet(40), is located in tandem with tet(O/32/O) in a human gut firmicute bacterium and in metagenomic library clones.	Kazimierczak KA, Rincon MT, Patterson AJ, Martin JC, Young P, Flint HJ, Scott KP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	11	4141	4144	18676884	10.1128/aac.00511-08	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.	Sugimura M, Maseda H, Hanaki H, Nakae T.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	12	4258	4267	18809936	10.1128/aac.00596-08	Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.	Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	12	4475	4477	18838597	10.1128/aac.00767-08	Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin, and tetracycline susceptibility testing of Campylobacter coli and for tetracycline susceptibility testing of Campylobacter jejuni subsp. jejuni.	Gaudreau C, Girouard Y, Gilbert H, Gagnon J, Bekal S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	12	4507	4509	18838584	10.1128/aac.00915-08	Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.	Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	427	434	18070962	10.1128/aac.00375-07	Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.	Subramanian S, Roberts CL, Hart CA, Martin HM, Edwards SW, Rhodes JM, Campbell BJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	435	440	18056269	10.1128/aac.01074-07	Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.	Wolter N, Smith AM, Farrell DJ, Northwood JB, Douthwaite S, Klugman KP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	505	512	18056270	10.1128/aac.00504-07	Role of a sodium-dependent symporter homologue in the thermosensitivity of beta-lactam antibiotic resistance and cell wall composition in Staphylococcus aureus.	Sieradzki K, Chung M, Tomasz A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	557	562	18086852	10.1128/aac.00732-07	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.	Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	570	573	18070960	10.1128/aac.01114-07	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.	Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	742	744	18025113	10.1128/aac.00960-07	Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines.	Dégrange S, Renaudin H, Charron A, Bébéar C, Bébéar CM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	2	770	773	18070963	10.1128/aac.00957-07	Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile.	Spigaglia P, Barbanti F, Mastrantonio P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	3	1153	1155	18180353	10.1128/aac.01351-07	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	4	1285	1290	18285489	10.1128/aac.01457-07	erm(B)-carrying elements in tetracycline-resistant pneumococci and correspondence between Tn1545 and Tn6003.	Cochetti I, Tili E, Mingoia M, Varaldo PE, Montanari MP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	4	1503	1505	18227183	10.1128/aac.01129-07	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.	Salas C, Calvo J, Martínez-Martínez L.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	1940	1944	18378719	10.1128/aac.01302-07	Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents.	Miller K, O'Neill AJ, Wilcox MH, Ingham E, Chopra I.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	1964	1969	18362188	10.1128/aac.01487-07	Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B).	de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galán JC, Baquero F, Reinert RR, Cantón R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	2009	2013	18378720	10.1128/aac.01594-07	Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis.	Kedar GC, Brown-Driver V, Reyes DR, Hilgers MT, Stidham MA, Shaw KJ, Finn J, Haselbeck RJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	2175	2182	18378705	10.1128/aac.01420-07	Relation between genetic markers of drug resistance and susceptibility profile of clinical Neisseria gonorrhoeae strains.	Ilina EN, Vereshchagin VA, Borovskaya AD, Malakhova MV, Sidorenko SV, Al-Khafaji NC, Kubanova AA, Govorun VM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	2244	2246	18391032	10.1128/aac.00231-08	First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.	Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	6	2276	2278	18411318	10.1128/aac.01584-07	In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.	Urich SK, Petersen JM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	7	2428	2434	18443112	10.1128/aac.00084-08	ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.	Abouzeed YM, Baucheron S, Cloeckaert A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	7	2503	2511	18458127	10.1128/aac.00298-08	Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.	Danilchanka O, Mailaender C, Niederweis M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	7	2647	2652	18443122	10.1128/aac.01398-07	In vitro activity of telavancin against resistant gram-positive bacteria.	Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	7	2677	2679	18474585	10.1128/aac.00002-08	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.	Liu CY, Huang YT, Liao CH, Hsueh PR.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2699	2708	18505858	10.1128/aac.01607-07	Role of Cj1211 in natural transformation and transfer of antibiotic resistance determinants in Campylobacter jejuni.	Jeon B, Muraoka W, Sahin O, Zhang Q.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2734	2741	18519732	10.1128/aac.00205-08	Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2.	Pränting M, Negrea A, Rhen M, Andersson DI.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2750	2754	18411316	10.1128/aac.00044-08	Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.	Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2806	2812	18519725	10.1128/aac.00247-08	Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.	Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2818	2824	18505851	10.1128/aac.00171-08	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.	Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2923	2925	18541730	10.1128/aac.00273-08	Staphylococcus aureus cell wall stress stimulon gene-lacZ fusion strains: potential for use in screening for cell wall-active antimicrobials.	Steidl R, Pearson S, Stephenson RE, Ledala N, Sitthisak S, Wilkinson BJ, Jayaswal RK.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	8	2994	2995	18505854	10.1128/aac.00230-08	Detection of the erythromycin rRNA methylase gene erm(A) in Enterococcus faecalis.	Schwaiger K, Bauer J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	9	3052	3060	18591276	10.1128/aac.00475-08	Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.	Long F, Rouquette-Loughlin C, Shafer WM, Yu EW.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2008	52	9	3441	3443	18606839	10.1128/aac.00357-08	Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.	McCalla C, Smyth DS, Robinson DA, Steenbergen J, Luperchio SA, Moise PA, Fowler VG, Sakoulas G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2008	71	6	1037	1045	18500841	10.1021/np800148w	Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides.	Chérigo L, Pereda-Miranda R, Fragoso-Serrano M, Jacobo-Herrera N, Kaatz GW, Gibbons S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2008	71	6	1078	1081	18510362	10.1021/np800095g	Bioactive isocoumarins isolated from the endophytic fungus Microdochium bolleyi.	Zhang W, Krohn K, Draeger S, Schulz B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2008	71	8	1427	1430	18681481	10.1021/np8002673	Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.	Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2009	17	24	8168	8173	19896853	10.1016/j.bmc.2009.10.035	Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents.	Bandgar BP, Gawande SS, Bodade RG, Gawande NM, Khobragade CN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2009	19	17	4952	4957	19640715	10.1016/j.bmcl.2009.07.082	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.	Reinke AA, Seh HY, Gestwicki JE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2009	19	3	680	683	19117754	10.1016/j.bmcl.2008.12.051	Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent.	Neale JR, Richter NB, Merten KE, Taylor KG, Singh S, Waite LC, Emery NK, Smith NB, Cai J, Pierce WM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2009	19	5	1396	1398	19195884	10.1016/j.bmcl.2009.01.037	Synthesis and antibacterial activity evaluation of metronidazole-triazole conjugates.	Beena, Kumar N, Rohilla RK, Roy N, Roy N, Rawat DS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	1	365	372	18417256	10.1016/j.ejmech.2008.02.038	Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds.	Aghatabay NM, Mahmiani Y, Cevik H, Dulger B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	11	4385	4392	19586688	10.1016/j.ejmech.2009.05.031	Synthesis of some novel pyrazolo[3,4-b]pyridine and pyrazolo[3,4-d]pyrimidine derivatives bearing 5,6-diphenyl-1,2,4-triazine moiety as potential antimicrobial agents.	El-Sayed Ali T.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	11	4539	4546	19615792	10.1016/j.ejmech.2009.06.022	Synthesis and antibacterial activity of some new thiadiaza/triazaphospholes, thiadiaza/triaza/tetrazaphosphinines and thiadiaza/tetrazaphosphepines containing 1,2,4-triazinone moiety.	Ali Tel-S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	11	4681	4689	19700225	10.1016/j.ejmech.2009.07.003	Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds.	Aghatabay NM, Ba¿ A, Kircali A, Sen G, Yazicio¿lu MB, Gücin F, Dülger B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	11	4752	4757	19616347	10.1016/j.ejmech.2009.06.021	Synthesis, characterization and evaluation of antibacterial activity of some thiazolo[3,2-b][1,2,4]triazole incorporating diphenylsulfone moieties.	Barbuceanu SF, Almajan GL, Saramet I, Draghici C, Tarcomnicu AI, Bancescu G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	3	959	966	18722036	10.1016/j.ejmech.2008.07.009	Regioselective synthesis and antimicrobial screening of novel ketocarbazolodispiropyrrolidine derivatives.	Periyasami G, Raghunathan R, Surendiran G, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	4	1779	1787	18539361	10.1016/j.ejmech.2008.04.019	Synthesis, characterization and structure-activity relationship analysis of novel depsides as potential antibacterials.	Lv PC, Xiao ZP, Fang RQ, Li HQ, Zhu HL, Liu CH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	5	1989	1996	19013692	10.1016/j.ejmech.2008.09.047	Novel pyridazine derivatives: Synthesis and antimicrobial activity evaluation.	Kandile NG, Mohamed MI, Zaky H, Mohamed HM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2009	44	7	3040	3045	18778877	10.1016/j.ejmech.2008.07.031	Synthesis of novel carbazole based macrocyclic amides as potential antimicrobial agents.	Rajakumar P, Sekar K, Shanmugaiah V, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2009	52	12	3784	3793	19463000	10.1021/jm9003297	High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.	Baqi Y, Atzler K, Köse M, Glänzel M, Müller CE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	10	4258	4263	19596873	10.1128/aac.00546-09	AI-2/LuxS is involved in increased biofilm formation by Streptococcus intermedius in the presence of antibiotics.	Ahmed NA, Petersen FC, Scheie AA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	10	4529	4532	19651906	10.1128/aac.00624-09	In vitro activities of panduratin A against clinical Staphylococcus strains.	Rukayadi Y, Lee K, Han S, Yong D, Hwang JK.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	11	4604	4611	19687238	10.1128/aac.00477-09	Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.	Suchland RJ, Sandoz KM, Jeffrey BM, Stamm WE, Rockey DD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	11	4628	4639	19721076	10.1128/aac.00454-09	Induction of multidrug resistance mechanism in Escherichia coli biofilms by interplay between tetracycline and ampicillin resistance genes.	May T, Ito A, Okabe S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	11	4938	4939	19738019	10.1128/aac.00724-09	Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.	Hamasuna R, Jensen JS, Osada Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	11	4944	4948	19721064	10.1128/aac.00787-09	Combined inactivation of lon and ycgE decreases multidrug susceptibility by reducing the amount of OmpF porin in Escherichia coli.	Duval V, Nicoloff H, Levy SB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	11	4957	4958	19721071	10.1128/aac.00675-09	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.	Duval V, Maiga I, Maiga A, Guillard T, Brasme L, Forte D, Madoux J, Vernet-Garnier V, De Champs C.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	12	5230	5235	19752278	10.1128/aac.00631-09	Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens.	Maseda H, Hashida Y, Konaka R, Shirai A, Kourai H.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	12	5279	5283	19786608	10.1128/aac.00803-09	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.	Miller CH, Nisa S, Dempsey S, Jack C, O'Toole R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	12	5312	5316	19770280	10.1128/aac.00748-09	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.	Srinivasan VB, Rajamohan G, Gebreyes WA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	12	5317	5318	19738013	10.1128/aac.00746-09	In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.	Rao SS, Raghunathan R, Ekambaram R, Raghunathan M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	512	518	19029328	10.1128/aac.00804-08	Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals.	Liu Y, Wang H, Du N, Shen E, Chen H, Niu J, Ye H, Chen M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	696	702	19064898	10.1128/aac.00652-07	Prevalence of sulfonamide resistance genes in bacterial isolates from manured agricultural soils and pig slurry in the United Kingdom.	Byrne-Bailey KG, Gaze WH, Kay P, Boxall AB, Hawkey PM, Wellington EM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	735	747	19029325	10.1128/aac.00754-08	Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac).	Zheng B, Tomita H, Inoue T, Ike Y.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	776	778	19015335	10.1128/aac.01128-08	Identification of a novel trimethoprim resistance gene, dfrK, in a methicillin-resistant Staphylococcus aureus ST398 strain and its physical linkage to the tetracycline resistance gene tet(L).	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	779	781	19047652	10.1128/aac.01376-08	Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr.	Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	2	845	846	19029319	10.1128/aac.01312-08	IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri.	Welch TJ, Evenhuis J, White DG, McDermott PF, Harbottle H, Miller RA, Griffin M, Wise D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1019	1026	19104019	10.1128/aac.00388-08	A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.	Wang G, Inaoka T, Okamoto S, Ochi K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1080	1087	19104017	10.1128/aac.01005-08	Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of RamA and other global regulators.	O'Regan E, Quinn T, Pagès JM, McCusker M, Piddock L, Fanning S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1231	1234	19124662	10.1128/aac.01173-08	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.	Cui L, Neoh HM, Shoji M, Hiramatsu K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1260	1263	19124664	10.1128/aac.01453-08	Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.	Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	3	1293	1294	19104015	10.1128/aac.01066-08	New composite genetic element of the Tn916 family with dual macrolide resistance genes in a Streptococcus pneumoniae isolate belonging to clonal complex 271.	Del Grosso M, Camilli R, Libisch B, Füzi M, Pantosti A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	4	1561	1566	19188396	10.1128/aac.00994-08	Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.	Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	4	1652	1656	19164140	10.1128/aac.00822-08	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.	Tran QT, Dupont M, Lavigne JP, Chevalier J, Pagès JM, Sotto A, Davin-Regli A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	1760	1765	19258275	10.1128/aac.01540-08	Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes.	Ishikawa C, Tsuda T, Konishi H, Nakagawa N, Yamanishi K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	1892	1897	19258263	10.1128/aac.01400-08	New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis.	Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S, Hooper DC, Wang M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	1921	1925	19258262	10.1128/aac.01065-08	Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.	Blackman Northwood J, Del Grosso M, Cossins LR, Coley MD, Creti R, Pantosti A, Farrell DJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	2020	2027	19273669	10.1128/aac.01349-08	Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.	Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	2066	2073	19273677	10.1128/aac.01464-08	Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.	Siira L, Rantala M, Jalava J, Hakanen AJ, Huovinen P, Kaijalainen T, Lyytikäinen O, Virolainen A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	2160	2162	19273684	10.1128/aac.01684-08	Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.	Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	5	2171	2175	19289528	10.1128/aac.00129-09	Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.	Sader HS, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	6	2450	2454	19332670	10.1128/aac.01282-08	Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.	Mandomando I, Jaintilal D, Pons MJ, Vallès X, Espasa M, Mensa L, Sigaúque B, Sanz S, Sacarlal J, Macete E, Abacassamo F, Alonso PL, Ruiz J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	6	2483	2491	19332676	10.1128/aac.00428-08	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.	Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	6	2605	2609	19332683	10.1128/aac.01533-08	Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.	Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	8	3248	3255	19470505	10.1128/aac.00079-09	Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.	Hu WS, Lin JF, Lin YH, Chang HY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	8	3331	3336	19433553	10.1128/aac.00226-09	Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI).	de Jonge BL, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	8	3399	3404	19528282	10.1128/aac.01522-08	Multiresistance in Pasteurella multocida is mediated by coexistence of small plasmids.	San Millan A, Escudero JA, Gutierrez B, Hidalgo L, Garcia N, Llagostera M, Dominguez L, Gonzalez-Zorn B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	8	3422	3429	19487442	10.1128/aac.00010-09	Antibacterial properties and mode of action of a short acyl-lysyl oligomer.	Zaknoon F, Sarig H, Rotem S, Livne L, Ivankin A, Gidalevitz D, Mor A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	8	3589	3591	19470508	10.1128/aac.00570-09	Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	9	4013	4014	19581458	10.1128/aac.00584-09	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.	Roca I, Marti S, Espinal P, Martínez P, Gibert I, Vila J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	9	4022	4024	19546360	10.1128/aac.00145-09	Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia.	Alvarez A, Moncayo JI, Santacruz JJ, Santacoloma M, Corredor LF, Reinosa E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2009	53	9	4025	4027	19546371	10.1128/aac.00200-09	Evaluation of target specificity of antibacterial agents using Staphylococcus aureus ddlA mutants and D-cycloserine in a silkworm infection model.	Kurokawa K, Hamamoto H, Matsuo M, Nishida S, Yamane N, Lee BL, Murakami K, Maki H, Sekimizu K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2009	72	6	1191	1194	19445517	10.1021/np800581s	Antibacterial diterpenes from Plectranthus ernstii.	Stavri M, Paton A, Skelton BW, Gibbons S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Toxicol Sci	2010	118	2	485	500	20829430	10.1093/toxsci/kfq269	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.	Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2010	18	2	663	674	20044260	10.1016/j.bmc.2009.12.003	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.	Huigens RW, Reyes S, Reed CS, Bunders C, Rogers SA, Steinhauer AT, Melander C.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2010	18	5	2060	2065	20138527	10.1016/j.bmc.2009.12.077	Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.	Bandgar BP, Gawande SS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2010	18	6	2123	2130	20188576	10.1016/j.bmc.2010.02.005	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.	Opperman TJ, Williams JD, Houseweart C, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2010	18	6	2225	2231	20185316	10.1016/j.bmc.2010.01.068	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.	Prado-Prado FJ, García-Mera X, González-Díaz H.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2010	19	2	120	126		10.1007/s00044-009-9177-9	Synthesis and antimicrobial activity studies of some novel substituted phenylhydrazono-1H-tetrazol-5-yl-acetonitriles	Yavuz S, Aydn O, Cete S, Disli A, Yldrr Y
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2010	19	5	490	497		10.1007/s00044-009-9206-8	Synthesis and biological activity studies of furan derivatives	Logoglu E, Yilmaz M, Katircioglu H, Yakut M, Mercan S
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2010	20	12	3698	3702	20483609	10.1016/j.bmcl.2010.04.084	Synthesis of novel beta-lactam fused spiroisoxazolidine chromanones and tetralones as potent antimicrobial agent for human and plant pathogens.	Arumugam N, Raghunathan R, Shanmugaiah V, Mathivanan N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2010	20	17	4988	4991	20674349	10.1016/j.bmcl.2010.07.063	Antimicrobial phenolic abietane diterpene from Lycopus europaeus L. (Lamiaceae).	Radulovi¿ N, Deni¿ M, Stojanovi¿-Radi¿ Z.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2010	20	24	7288	7291	21067922	10.1016/j.bmcl.2010.10.073	Stereoselective synthesis of hexahydro-3-methyl-1-arylchromeno[3,4-b]pyrrole and its annulated heterocycles as potent antimicrobial agents for human pathogens.	Purushothaman S, Prasanna R, Niranjana P, Raghunathan R, Nagaraj S, Rengasamy R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2010	20	24	7450	7453	21055931	10.1016/j.bmcl.2010.10.023	3-O-phosphate ester conjugates of 17-ß-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido)anilido]ethyl}1,3,5(10)-estratriene as novel bone-targeting agents.	Nasim S, Vartak AP, Pierce WM, Taylor KG, Smith N, Crooks PA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2010	20	3	893	895	20047831	10.1016/j.bmcl.2009.12.074	Synthesis and antibacterial activity of benzyl-[3-(benzylamino-methyl)-cyclohexylmethyl]-amine derivatives.	Kumar D, Joshi S, Rohilla RK, Roy N, Roy N, Rawat DS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	1	317	325	19897282	10.1016/j.ejmech.2009.10.016	Design, synthesis and docking studies of new furobenzopyranones and pyranobenzopyranones as photoreagent towards DNA and as antimicrobial agents.	Farag NA, El-Tayeb W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	1	387	392	19896247	10.1016/j.ejmech.2009.10.015	Poly(ethylene glycol) (PEG-400) as an alternative reaction solvent for the synthesis of some new 1-(4-(4'-chlorophenyl)-2-thiazolyl)-3-aryl-5-(2-butyl-4-chloro-1H-imidazol-5yl)-2-pyrazolines and their in vitro antimicrobial evaluation.	Dawane BS, Konda SG, Mandawad GG, Shaikh BM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	11	5243	5250	20828885	10.1016/j.ejmech.2010.08.043	Synthesis of new pyrrolo[2,3-d]pyrimidine derivatives as antibacterial and antifungal agents.	Hilmy KM, Khalifa MM, Hawata MA, Keshk RM, el-Torgman AA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	2	698	704	19962218	10.1016/j.ejmech.2009.11.016	Anti-oxidant and anti-bacterial activities of novel N'-arylmethylidene-2-(3, 4-dimethyl-5, 5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl) acetohydrazides.	Ahmad M, Siddiqui HL, Zia-ur-Rehman M, Parvez M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	4	1635	1638	20096486	10.1016/j.ejmech.2009.12.040	Synthesis and antimicrobial activity of novel pyrazolo[3,4-d]pyrimidin derivatives.	Khobragade CN, Bodade RG, Konda SG, Dawane BS, Manwar AV.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	7	3191	3195	20307919	10.1016/j.ejmech.2010.02.057	New 6-amino-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b] [1,3,4]thiadiazin-6-ones: synthesis, characterization and antibacterial activity evaluation.	Almajan GL, Barbuceanu SF, Saramet I, Draghici C.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2010	45	8	3446	3452	20556891	10.1016/j.ejmech.2010.04.035	Synthesis, antibacterial activity evaluation and QSAR studies of novel dispiropyrrolidines.	Karthikeyan K, Sivakumar PM, Doble M, Perumal PT.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2010	53	1	392	401	19947605	10.1021/jm901421c	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.	Tam KY, Avdeef A, Tsinman O, Sun N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2010	53	16	5906	5914	20420456	10.1021/jm100293f	Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy.	Melchiorre C, Bolognesi ML, Minarini A, Rosini M, Tumiatti V.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	164	169	19901088	10.1128/aac.00310-09	Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.	Faure S, Perrin-Guyomard A, Delmas JM, Chatre P, Laurentie M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	177	183	19858254	10.1128/aac.00715-09	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.	Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	312	319	19822705	10.1128/aac.00583-09	Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.	Buchholz F, Wolf A, Lerchner J, Mertens F, Harms H, Maskow T.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	367	374	19917752	10.1128/aac.00801-09	Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity island 1 genes.	O'Regan E, Quinn T, Frye JG, Pagès JM, Porwollik S, Fedorka-Cray PJ, McClelland M, Fanning S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	1	93	97	19805559	10.1128/aac.00780-09	Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.	Montes M, Tamayo E, Orden B, Larruskain J, Perez-Trallero E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	10	4219	4224	20696876	10.1128/aac.00139-10	Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment.	Zhao J, Chen Z, Chen S, Deng Y, Liu Y, Tian W, Huang X, Wu C, Sun Y, Sun Y, Zeng Z, Liu JH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	10	4518	4519	20660671	10.1128/aac.00235-10	Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.	Jones RN, Biedenbach DJ, Roblin PM, Kohlhoff SA, Hammerschlag MR.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	11	4772	4779	20713660	10.1128/aac.00009-10	ampG gene of Pseudomonas aeruginosa and its role in ß-lactamase expression.	Zhang Y, Bao Q, Gagnon LA, Huletsky A, Oliver A, Jin S, Langaee T.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	11	4907	4909	20733038	10.1128/aac.00551-10	Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum ß-lactamase in serogroup O26.	Buvens G, Bogaerts P, Glupczynski Y, Lauwers S, Piérard D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	11	4917	4919	20805389	10.1128/aac.01652-09	Reduced expression of the vca0421 gene of Vibrio cholerae O1 results in innate resistance to ciprofloxacin.	Okuda J, Hayashi N, Wakahara Y, Gotoh N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	11	4942	4944	20713669	10.1128/aac.00064-10	Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.	Joo HS, Chan JL, Cheung GY, Otto M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	12	5413	5417	20837756	10.1128/aac.00426-10	Nasal carriage of methicillin-resistant and methicillin-sensitive strains of Staphylococcus sciuri in the Indonesian population.	Severin JA, Lestari ES, Kuntaman K, Pastink M, Snijders SV, Lemmens-den Toom N, Horst-Kreft D, Hadi U, Duerink DO, Goessens WH, Fluit AC, van Wamel W, van Belkum A, Verbrugh HA, AMRIN Study Group.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	2	799	803	19949057	10.1128/aac.01045-09	Transferable quinolone resistance in Vibrio cholerae.	Kim HB, Wang M, Ahmed S, Park CH, LaRocque RC, Faruque AS, Salam MA, Khan WA, Qadri F, Calderwood SB, Jacoby GA, Hooper DC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	2	915	918	20008780	10.1128/aac.01091-09	Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	3	1007	1015	20038628	10.1128/aac.01126-09	Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.	Elkins CA, Mullis LB, Lacher DW, Jung CM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	3	1029	1041	20028819	10.1128/aac.00963-09	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.	Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	3	1152	1159	20065057	10.1128/aac.01268-09	Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.	Xu X, Cai L, Xiao M, Kong F, Oftadeh S, Zhou F, Gilbert GL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	3	1218	1225	20008776	10.1128/aac.00944-09	Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG.	Fàbrega A, Martin RG, Rosner JL, Tavio MM, Vila J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	4	1564	1571	20123999	10.1128/aac.01219-09	Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.	Jiang SS, Liu MC, Teng LJ, Wang WB, Hsueh PR, Liaw SJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	4	1623	1626	20100875	10.1128/aac.01361-09	High diversity of extended-spectrum beta-lactamases in Escherichia coli isolates from Italian broiler flocks.	Bortolaia V, Guardabassi L, Trevisani M, Bisgaard M, Venturi L, Bojesen AM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	5	1678	1683	20145081	10.1128/aac.00737-08	Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.	Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	5	1855	1863	20231390	10.1128/aac.00014-10	Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.	Blango MG, Mulvey MA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	6	2525	2533	20308375	10.1128/aac.01682-09	Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate.	Bucki R, Leszczynska K, Byfield FJ, Fein DE, Won E, Cruz K, Namiot A, Kulakowska A, Namiot Z, Savage PB, Diamond SL, Janmey PA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	6	2677	2680	20350943	10.1128/aac.01536-09	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.	Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	6	2704	2706	20385851	10.1128/aac.00301-10	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.	Mendes RE, Moet GJ, Janechek MJ, Jones RN.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	6	2728	2731	20385859	10.1128/aac.01557-09	Antimicrobial resistance of Listeria monocytogenes strains isolated from humans in France.	Morvan A, Moubareck C, Leclercq A, Hervé-Bazin M, Bremont S, Lecuit M, Courvalin P, Le Monnier A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	7	2806	2813	20421401	10.1128/aac.00400-10	Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.	Zhang T, Bishai WR, Grosset JH, Nuermberger EL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	7	2823	2829	20404127	10.1128/aac.01845-09	Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.	Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	7	3052	3055	20479200	10.1128/aac.00304-10	Two novel antibiotic resistance genes, tet(44) and ant(6)-Ib, are located within a transferable pathogenicity island in Campylobacter fetus subsp. fetus.	Abril C, Brodard I, Perreten V.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	7	3070	3071	20421403	10.1128/aac.01615-09	Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup.	Rodríguez MM, Power P, Sader H, Galleni M, Gutkind G.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	8	3113	3120	20498323	10.1128/aac.01803-09	The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.	Mima T, Schweizer HP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	8	3475	3477	20498309	10.1128/aac.00464-10	Identification of the novel dfrK-carrying transposon Tn559 in a porcine methicillin-susceptible Staphylococcus aureus ST398 strain.	Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	8	3529	3530	20547812	10.1128/aac.00710-10	N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.	Goswami M, Jawali N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	9	3770	3775	20606071	10.1128/aac.00620-10	Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.	Bohnert JA, Karamian B, Nikaido H.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	9	3804	3811	20585117	10.1128/aac.00351-10	Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States.	McDougal LK, Fosheim GE, Nicholson A, Bulens SN, Limbago BM, Shearer JE, Summers AO, Patel JB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	9	3825	3833	20606069	10.1128/aac.00361-10	Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.	Bourne CR, Barrow EW, Bunce RA, Bourne PC, Berlin KD, Barrow WW.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	9	3953	3955	20585133	10.1128/aac.00169-10	First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces.	Dai L, Wu CM, Wang MG, Wang Y, Wang Y, Huang SY, Xia LN, Li BB, Shen JZ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2010	54	9	3988	3990	20566769	10.1128/aac.00067-10	Oligochlorophens are potent inhibitors of Bacillus anthracis.	Foss MH, Weibel DB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2010	73	7	1309	1312	20545334	10.1021/np100135b	Mayamycin, a cytotoxic polyketide from a Streptomyces strain isolated from the marine sponge Halichondria panicea.	Schneemann I, Kajahn I, Ohlendorf B, Zinecker H, Erhard A, Nagel K, Wiese J, Imhoff JF.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2011	19	12	3750	3756	21612935	10.1016/j.bmc.2011.05.004	Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation.	Ouyang L, He D, Zhang J, He G, Jiang B, Wang Q, Chen Z, Pan J, Li Y, Guo L.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2011	19	17	5155	5166	21803587	10.1016/j.bmc.2011.07.015	Synthesis and antimicrobial activity of (E) stilbene derivatives.	Albert S, Horbach R, Deising HB, Siewert B, Csuk R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2011	20	1	1	8		10.1007/s00044-009-9273-x	Synthesis and evaluation of a series of aminocyanopyridines as antimicrobial agents	Altundas A, Ayvaz S, Logoglu E
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2011	20	1	109	115		10.1007/s00044-009-9279-4	The synthesis and screening of the antimicrobial activity of some novel 3-(furan-2-yl)-1-(aryl)-3-(phenylthio) propan-1-one derivatives	Ceylan M, Gurdere MB, Karaman I, Gezegen H
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2011	20	8	1214	1219		10.1007/s00044-010-9459-2	Synthesis and antimicrobial activity of some bisoctahydroxanthene-1,8-dione derivatives	Kaya M, Basar E, Colak F
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2011	21	4	1155	1161	21273067	10.1016/j.bmcl.2010.12.111	Design and synthesis of potent Gram-negative specific LpxC inhibitors.	Mansoor UF, Vitharana D, Reddy PA, Daubaras DL, McNicholas P, Orth P, Black T, Siddiqui MA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	11	5636	5640	22000920	10.1016/j.ejmech.2011.09.036	Green synthesis and antimicrobial evaluation of some new trifluoromethyl-substituted hexahydropyrimidines by grinding.	Zohdi HF, Rateb NM, Elnagdy SM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	12	6066	6074	22051065	10.1016/j.ejmech.2011.10.022	Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides.	Berest GG, Voskoboynik OY, Kovalenko SI, Antypenko OM, Nosulenko IS, Katsev AM, Shandrovskaya OS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	2	480	487	21163555	10.1016/j.ejmech.2010.11.027	Synthesis, antimicrobial activity and structure-activity relationship study of N,N-dibenzyl-cyclohexane-1,2-diamine derivatives.	Sharma M, Joshi P, Kumar N, Joshi S, Rohilla RK, Roy N, Roy N, Rawat DS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	2	600	607	21177001	10.1016/j.ejmech.2010.11.039	Synthesis and antimicrobial activity of highly functionalised novel ß-lactam grafted spiropyrrolidines and pyrrolizidines.	Arumugam N, Periyasami G, Raghunathan R, Kamalraj S, Muthumary J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	5	1564	1571	21382653	10.1016/j.ejmech.2011.02.003	Synthesis, antibacterial and antimycobacterial activities of some new 4-aryl/heteroaryl-2,6-dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines.	Sirisha K, Bikshapathi D, Achaiah G, Reddy VM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	6	2530	2540	21481990	10.1016/j.ejmech.2011.03.041	Urea/thiourea derivatives of quinazolinone-lysine conjugates: synthesis and structure-activity relationships of a new series of antimicrobials.	Suresha GP, Suhas R, Kapfo W, Gowda DC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	8	3227	3236	21570162	10.1016/j.ejmech.2011.04.036	Cytotoxic ring A-modified steroid analogues derived from Grundmann's ketone.	Mayer CD, Bracher F.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	9	3681	3689	21664730	10.1016/j.ejmech.2011.05.032	Stereoselective synthesis and antimicrobial activity of steroidal C-20 tertiary alcohols with thiazole/pyridine side chain.	Shingate BB, Hazra BG, Salunke DB, Pore VS, Shirazi F, Deshpande MV.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2011	46	9	3788	3794	21712145	10.1016/j.ejmech.2011.05.044	Synthesis and antimicrobial properties of some new thiazolyl coumarin derivatives.	Arshad A, Osman H, Bagley MC, Lam CK, Mohamad S, Zahariluddin AS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2011	54	11	3704	3731	21500832	10.1021/jm1015395	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.	Sun C, Hunt DK, Clark RB, Lofland D, O'Brien WJ, Plamondon L, Xiao XY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2011	54	22	7884	7898	22007704	10.1021/jm2009343	Lipophosphonoxins: new modular molecular structures with significant antibacterial properties.	Rejman D, Rabatinová A, Pombinho AR, Kova¿ková S, Pohl R, Zborníková E, Kolá¿ M, Bogdanová K, Ny¿ O, Sanderová H, Látal T, Bart¿n¿k P, Krásný L.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2011	54	5	1511	1528	21302930	10.1021/jm1015389	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.	Clark RB, He M, Fyfe C, Lofland D, O'Brien WJ, Plamondon L, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2011	55	1	373	375	20876371	10.1128/aac.01124-10	Novel apramycin resistance gene apmA in bovine and porcine methicillin-resistant Staphylococcus aureus ST398 isolates.	Fessler AT, Kadlec K, Schwarz S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2011	55	2	631	636	21115784	10.1128/aac.00965-10	Different genetic elements carrying the tet(W) gene in two human clinical isolates of Streptococcus suis.	Palmieri C, Princivalli MS, Brenciani A, Varaldo PE, Facinelli B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Antimicrob. Agents Chemother.	2011	55	2	703	712	21098249	10.1128/aac.00788-10	Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.	Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2011	74	2	272	278	21265557	10.1021/np1005218	Antimicrobial isopropenyl-dihydrofuranoisoflavones from Crotalaria lachnophora.	Awouafack MD, Spiteller P, Lamshöft M, Kusari S, Ivanova B, Tane P, Spiteller M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2011	74	3	365	373	21244021	10.1021/np100730b	Diversonol and blennolide derivatives from the endophytic fungus Microdiplodia sp.: absolute configuration of diversonol.	Siddiqui IN, Zahoor A, Hussain H, Ahmed I, Ahmad VU, Padula D, Draeger S, Schulz B, Meier K, Steinert M, Kurtán T, Flörke U, Pescitelli G, Krohn K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2011	74	8	1826	1829	21744790	10.1021/np200350b	Antibacterial polyketides from the jellyfish-derived fungus Paecilomyces variotii.	Liu J, Li F, Kim EL, Li JL, Hong J, Bae KS, Chung HY, Kim HS, Jung JH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2012	20	22	6589	6597	23062823	10.1016/j.bmc.2012.09.033	Synthesis of new antimicrobial pyrrolo[2,1-a]isoquinolin-3-ones.	Moreno L, Párraga J, Galán A, Cabedo N, Primo J, Cortes D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2012	20	24	7012	7029	23127490	10.1016/j.bmc.2012.10.009	3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents.	Kelley C, Zhang Y, Parhi A, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2012	20	6	2019	2024	22364744	10.1016/j.bmc.2012.01.043	Efficient synthesis and biological evaluation of proximicins A, B and C.	Brucoli F, Natoli A, Marimuthu P, Borrello MT, Stapleton P, Gibbons S, Schätzlein A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2012	21	11	3897	3901		10.1007/s00044-011-9933-5	11-Chloro-3-methyl-3H-imidazo[4,5-a]acridine (CMIA) as a potent and selective antimicrobial agent against clinical isolates of highly antibiotic-resistant Acinetobacter baumannii	Sadeghian A, Pordel M, Safdari H, Fahmidekar MA, Sadeghian H
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2012	21	12	4499	4505		10.1007/s00044-011-9951-3	Photodynamic activities of protoporphyrin IX and its dopamine conjugate against cancer and bacterial cell viability	Sagir T, Gencer S, Kemikli N, Abasiyanik MF, Isik S, Ozturk R
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2012	22	18	5956	5960	22892120	10.1016/j.bmcl.2012.07.059	An expeditious regioselective synthesis of novel bioactive indole-substituted chromene derivatives via one-pot three-component reaction.	Hossein nia R, Mamaghani M, Tabatabaeian K, Shirini F, Rassa M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2012	22	22	6962	6966	23058886	10.1016/j.bmcl.2012.08.123	Antibacterial activity of substituted dibenzo[a,g]quinolizin-7-ium derivatives.	Parhi A, Lu S, Kelley C, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2012	22	23	7080	7083	23084900	10.1016/j.bmcl.2012.09.097	Antibacterial activity of substituted 5-methylbenzo[c]phenanthridinium derivatives.	Parhi A, Kelley C, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2012	22	3	1375	1379	22230048	10.1016/j.bmcl.2011.12.061	An efficient synthesis of highly functionalized novel chromeno[4,3-b]pyrroles and indolizino[6,7-b]indoles as potent antimicrobial and antioxidant agents.	Arumugam N, Raghunathan R, Almansour AI, Karama U.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2012	47		18	23	22000923	10.1016/j.ejmech.2011.09.040	Efficient one-pot preparation of novel fused chromeno[2,3-d]pyrimidine and pyrano[2,3-d]pyrimidine derivatives.	Aly HM, Kamal MM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2012	52		98	110	22483632	10.1016/j.ejmech.2012.03.008	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.	Sarkar A, Anderson KC, Kellogg GE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2012	54		931	935	22770606	10.1016/j.ejmech.2012.06.025	Synthesis, antidepressant and antimicrobial activities of some novel stearic acid analogues.	Jubie S, Ramesh PN, Dhanabal P, Kalirajan R, Muruganantham N, Antony AS.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2012	55	2	597	605	22148514	10.1021/jm201465w	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.	Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2012	55	2	606	622	22148555	10.1021/jm201467r	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.	Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2012	55	3	995	1012	22122518	10.1021/jm201095h	Targeting the liver stage of malaria parasites: a yet unmet goal.	Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2012	58		464	469	23151322	10.1016/j.ejmech.2012.10.029	Facile water promoted synthesis of 1,2,3-triazolyl dihydropyrimidine-2-thione hybrids - highly potent antibacterial agents.	Sangaraiah N, Murugan S, Poovan S, Raja R, Alagusundaram P, Ramakrishnan V, Vellasamy S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2012	75	3	336	343	21899267	10.1021/np2003319	Antibacterial acylphloroglucinols from Hypericum olympicum.	Shiu WK, Rahman MM, Curry J, Stapleton P, Zloh M, Malkinson JP, Gibbons S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2012	75	9	1534	1538	22934636	10.1021/np300221a	Antibacterial spirobisnaphthalenes from the North American cup fungus Urnula craterium.	Liu XT, Schwan WR, Volk TJ, Rott M, Liu M, Huang P, Liu Z, Wang Y, Zitomer NC, Sleger C, Hartsel S, Monte A, Zhang L.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Fitoterapia	2012	83	3	523	526	22233864	10.1016/j.fitote.2011.12.017	Pyrenocines J-M: four new pyrenocines from the endophytic fungus, Phomopsis sp.	Hussain H, Ahmed I, Schulz B, Draeger S, Krohn K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2013	21	11	3221	3230	23601815	10.1016/j.bmc.2013.03.042	Novel isoquinoline derivatives as antimicrobial agents.	Galán A, Moreno L, Párraga J, Serrano Á, Sanz MJ, Cortes D, Cabedo N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2013	21	23	7499	7506	24126094	10.1016/j.bmc.2013.09.041	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.	Od¿ak R, Sko¿ibu¿i¿ M, Maravi¿ A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2013	21	24	7830	7840	24200931	10.1016/j.bmc.2013.10.011	Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis.	Tiruveedhula VV, Witzigmann CM, Verma R, Kabir MS, Rott M, Schwan WR, Medina-Bielski S, Lane M, Close W, Polanowski RL, Sherman D, Monte A, Deschamps JR, Cook JM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2013	22	3	1330	1338		10.1007/s00044-012-0104-0	Aromatic sulfonyl hydrazides and sulfonyl hydrazones: antimicrobial activity and physical properties	Aslan HG, Karacan N
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Med Chem Res	2013	22	6	2610	2632		10.1007/s00044-012-0257-x	Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides: synthesis, cytotoxicity, anticancer activity, COMPARE analysis and docking	Kovalenko SI, Nosulenko IS, Voskoboynik AY, Berest GG, Antipenko LN, Antipenko AN, Katsev AM
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2013	23	17	4968	4974	23891185	10.1016/j.bmcl.2013.06.048	Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines.	Parhi AK, Zhang Y, Saionz KW, Pradhan P, Kaul M, Trivedi K, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2013	23	3	860	863	23265883	10.1016/j.bmcl.2012.11.044	Discovery of nosokophic acid, a predicted intermediate of moenomycins, from nosokomycin-producing Streptomyces sp. K04-0144.	Koyama N, Tokura Y, Takahashi Y, Tomoda H.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2013	23	7	2001	2006	23481648	10.1016/j.bmcl.2013.02.016	Substituted 1,6-diphenylnaphthalenes as FtsZ-targeting antibacterial agents.	Zhang Y, Giurleo D, Parhi A, Kaul M, Pilch DS, LaVoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2013	23	8	2426	2431	23473681	10.1016/j.bmcl.2013.02.005	Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA.	Barker CA, Allison SE, Zlitni S, Nguyen ND, Das R, Melacini G, Capretta AA, Brown ED.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	MedChemComm	2013	4	5	874	880		10.1039/C3MD20311E	Antimicrobial activity and mode of action of novel, N-terminal tagged tetra-peptidomimetics	Yadav S, Joshi S, Qadar Pasha MA, Pasha S
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2013	56	15	5987	6006	23611039	10.1021/jm400161p	A new face for old antibiotics: tetracyclines in treatment of amyloidoses.	Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2013	56	21	8712	8735	24098982	10.1021/jm401208b	Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.	Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2013	60		395	409	23314053	10.1016/j.ejmech.2012.12.027	Antimicrobial activity of various 4- and 5-substituted 1-phenylnaphthalenes.	Kelley C, Lu S, Parhi A, Kaul M, Pilch DS, Lavoie EJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2013	76	11	2094	2099	24175613	10.1021/np400589h	Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.	Ola AR, Thomy D, Lai D, Brötz-Oesterhelt H, Proksch P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Pharm. Res.	2013					24249037	10.1007/s11095-013-1232-z	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.	Settimo L, Bellman K, Knegtel RM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2014	22	7	2113	2122	24631358	10.1016/j.bmc.2014.02.033	Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.	Temburnikar KW, Zimmermann SC, Kim NT, Ross CR, Gelbmann C, Salomon CE, Wilson GM, Balzarini J, Seley-Radtke KL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2014	24	1	245	248	24316123	10.1016/j.bmcl.2013.11.029	Novel pyrazole integrated 1,3,4-oxadiazoles: synthesis, characterization and antimicrobial evaluation.	Ningaiah S, Bhadraiah UK, Doddaramappa SD, Keshavamurthy S, Javarasetty C.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2014	24	11	2412	2414	24775303	10.1016/j.bmcl.2014.04.041	Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.	Tseng YY, Liou JM, Hsu TL, Cheng WC, Wu MS, Wong CH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2014	77	3	521	526	24479468	10.1021/np400788r	Pyrano-isoflavans from Glycyrrhiza uralensis with antibacterial activity against Streptococcus mutans and Porphyromonas gingivalis.	Villinski JR, Bergeron C, Cannistra JC, Gloer JB, Coleman CM, Ferreira D, Azelmat J, Grenier D, Gafner S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2014	77	6	1519	1523	24856903	10.1021/np500171z	Identification and bioactivity of 3-epi-xestoaminol C isolated from the New Zealand brown alga Xiphophora chondrophylla.	Dasyam N, Munkacsi AB, Fadzilah NH, Senanayake DS, O'Toole RF, Keyzers RA.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2014	77	7	1734	1738	25010124	10.1021/np500113r	Trimeric anthracenes from the endophytic fungus Stemphylium globuliferum.	Liu Y, Wray V, Abdel-Aziz MS, Wang CY, Lai D, Proksch P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2014	82		565	573	24941130	10.1016/j.ejmech.2014.05.084	Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells.	Emirda¿-Öztürk S, Karay¿ld¿r¿m T, Çapc¿-Karagöz A, Alanku¿-Çal¿¿kan Ö, Özmen A, Poyrazo¿lu-Çoban E.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2015	101		442	451	26186150	10.1016/j.ejmech.2015.07.002	Design and synthesis of some new pyrazolyl-pyrazolines as potential anti-inflammatory, analgesic and antibacterial agents.	Viveka S, Dinesha, Shama P, Nagaraja GK, Ballav S, Kerkar S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2015	23	13	3163	3174	26001343	10.1016/j.bmc.2015.04.069	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.	Magoulas GE, Kostopoulou ON, Garnelis T, Athanassopoulos CM, Kournoutou GG, Leotsinidis M, Dinos GP, Papaioannou D, Kalpaxis DL.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2015	23	13	3618	3628	25913865	10.1016/j.bmc.2015.04.010	Synthesis and antibacterial activities of cadiolides A, B and C and analogues.	Boulangé A, Parraga J, Galán A, Cabedo N, Leleu S, Sanz MJ, Cortes D, Franck X.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2015	23	16	5156	5167	25678015	10.1016/j.bmc.2015.01.031	Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidal-antiplasmodial activity.	Sola I, Castellà S, Viayna E, Galdeano C, Taylor MC, Gbedema SY, Pérez B, Clos MV, Jones DC, Fairlamb AH, Wright CW, Kelly JM, Muñoz-Torrero D.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2015	23	21	7061	7068	26432604	10.1016/j.bmc.2015.09.027	Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.	Jin J, Cui J, Chaudhary AS, Hsieh YH, Damera K, Zhang H, Yang H, Wang B, Tai PC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2015	25	1	67	69	25435146	10.1016/j.bmcl.2014.11.012	A potent antimicrobial compound isolated from Clathria cervicornis.	Sun X, Sun S, Ference C, Zhu W, Zhou N, Zhang Y, Zhou K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2015	25	16	3125	3128	26099531	10.1016/j.bmcl.2015.06.010	Antibacterial activity of diketopiperazines isolated from a marine fungus using t-butoxycarbonyl group as a simple tool for purification.	El-Gendy Bel-D, Rateb ME.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2015	25	17	3671	3675	26152425	10.1016/j.bmcl.2015.06.050	Novel 5-functionalized-pyrazoles: Synthesis, characterization and pharmacological screening.	Doddaramappa SD, Lokanatha Rai KM, Srikantamurthy N, Chandra, Chethan J.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2015	25	21	4887	4889	26099542	10.1016/j.bmcl.2015.06.003	Rapid synthesis and antimicrobial activity of novel 4-oxazolidinone heterocycles.	Shymanska NV, An IH, Guevara-Zuluaga S, Pierce JG.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem. Lett.	2015	25	3	542	546	25556094	10.1016/j.bmcl.2014.12.029	In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.	Kukowska M, Kukowska-Kaszuba M, Dzierzbicka K.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2015	58	11	4703	4712	25927406	10.1021/acs.jmedchem.5b00262	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.	Sun C, Hunt DK, Chen CL, Deng Y, He M, Clark RB, Fyfe C, Grossman TH, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	MedChemComm	2015	6	5	912	918	27087913	10.1039/c4md00572d	Concise Synthesis of Spergualin-Inspired Molecules With Broad-Spectrum Antibiotic Activity.	Assimon VA, Shao H, Garneau-Tsodikova S, Gestwicki JE.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	ACS Med. Chem. Lett.	2015	6	8	930	935	26288696	10.1021/acsmedchemlett.5b00205	Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens.	McKinney DC, Basarab GS, Cocozaki AI, Foulk MA, Miller MD, Ruvinsky AM, Scott CW, Thakur K, Zhao L, Buurman ET, Narayan S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2015	78	10	2471	2480	26335269	10.1021/acs.jnatprod.5b00601	Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.	Ma M, Rateb ME, Teng Q, Yang D, Rudolf JD, Zhu X, Huang Y, Zhao LX, Jiang Y, Li X, Rader C, Duan Y, Shen B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2015	78	11	2832	2836	26562481	10.1021/acs.jnatprod.5b00594	Dimeric Octaketide Spiroketals from the Jellyfish-Derived Fungus Paecilomyces variotii J08NF-1.	Wang H, Hong J, Yin J, Moon HR, Liu Y, Wei X, Oh DC, Jung JH.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Nat. Prod.	2015	78	3	402	412	25646964	10.1021/np500775e	Enhancement of antibiotic activity against multidrug-resistant bacteria by the efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a Pseudoalteromonas sp.	Whalen KE, Poulson-Ellestad KL, Deering RW, Rowley DC, Mincer TJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2015	92		637	647	25617693	10.1016/j.ejmech.2015.01.032	Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide.	Lele DS, Talat S, Kumari S, Srivastava N, Kaur KJ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2016	110		151	163	26827160	10.1016/j.ejmech.2016.01.024	Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.	Fu HG, Hu XX, Li CR, Li YH, Wang YX, Jiang JD, Bi CW, Tang S, You XF, Song DQ.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur. J. Med. Chem.	2016	113		145	166	26922234	10.1016/j.ejmech.2016.02.030	Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline-thiazolidine-based hybrids.	Havrylyuk D, Roman O, Lesyk R.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur J Med Chem	2016	124		1019	1025	27783973	10.1016/j.ejmech.2016.10.034	New family of antimicrobial agents derived from 1,4-naphthoquinone.	Janeczko M, Demchuk OM, Strzelecka D, Kubi¿ski K, Mas¿yk M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur J Med Chem	2016	124		622	636	27614409	10.1016/j.ejmech.2016.08.021	Novel urea and bis-urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation.	Perkovi¿ I, Antunovi¿ M, Marijanovi¿ I, Pavi¿ K, Ester K, Kralj M, Vlaini¿ J, Kosalec I, Schols D, Hadjipavlou-Litina D, Pontiki E, Zorc B.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg. Med. Chem.	2016	24	18	4056	4065	27387357	10.1016/j.bmc.2016.06.048	Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted C(¿) amino acids.	Hicks RP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg Med Chem Lett	2016	26	22	5492	5496	27777007	10.1016/j.bmcl.2016.10.018	The synthesis and antistaphylococcal activity of dehydroabietic acid derivatives: Modifications at C-12.	Liu ML, Pan XY, Yang T, Zhang WM, Wang TQ, Wang HY, Lin HX, Yang CG, Cui YM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2016	59	7	3140	3151	26964758	10.1021/acs.jmedchem.5b01912	Antibacterial Diamines Targeting Bacterial Membranes.	Wang B, Pachaiyappan B, Gruber JD, Schmidt MG, Zhang YM, Woster PM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J. Med. Chem.	2016	59	8	3808	3825	27018907	10.1021/acs.jmedchem.5b02004	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.	Garrison AT, Abouelhassan Y, Norwood VM, Kallifidas D, Bai F, Nguyen MT, Rolfe M, Burch GM, Jin S, Luesch H, Huigens RW.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J Nat Prod	2016	79	12	2991	2996	27966935	10.1021/acs.jnatprod.6b00458	Antimicrobial Oligophenalenone Dimers from the Soil Fungus Talaromyces stipitatus.	Zang Y, Genta-Jouve G, Escargueil AE, Larsen AK, Guedon L, Nay B, Prado S.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Eur J Med Chem	2017	127		917	927	27837995	10.1016/j.ejmech.2016.11.002	The synthesis and antistaphylococcal activity of dehydroabietic acid derivatives: modifications at C12 and C7.	Zhang WM, Yang T, Pan XY, Liu XL, Lin HX, Gao ZB, Yang CG, Cui YM.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg Med Chem	2017	25	1	132	137	27793449	10.1016/j.bmc.2016.10.019	Antibacterial profiling of abietane-type diterpenoids.	Helfenstein A, Vahermo M, Nawrot DA, Demirci F, ¿¿can G, Krogerus S, Yli-Kauhaluoma J, Moreira VM, Tammela P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg Med Chem	2017	25	11	2868	2877	28366267	10.1016/j.bmc.2017.03.040	Metabolite diversification by cultivation of the endophytic fungus Dothideomycete sp. in halogen containing media: Cultivation of terrestrial fungus in seawater.	Wijesekera K, Mahidol C, Ruchirawat S, Kittakoop P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	Bioorg Med Chem	2017	25	4	1413	1422	28094219	10.1016/j.bmc.2017.01.001	3,4-Dihydropyrimidinone-coumarin analogues as a new class of selective agent against S. aureus: Synthesis, biological evaluation and molecular modelling study.	Naik NS, Shastri LA, Joshi SD, Dixit SR, Chougala BM, Samundeeswari S, Holiyachi M, Shaikh F, Madar J, Kulkarni R, Sunagar V.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J Med Chem	2017	60	6	2498	2512	28248499	10.1021/acs.jmedchem.6b01903	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.	Deng Y, Sun C, Hunt DK, Fyfe C, Chen CL, Grossman TH, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440	J Med Chem	2017	60	9	3902	3912	28383902	10.1021/acs.jmedchem.7b00204	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.	Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M.
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									DrugMatrix	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									Open TG-GATES	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TETRACYCLINE	CHEMBL1440									WHO Anatomical Therapeutic Chemical Classification	
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	J. Nat. Prod.	1989	52	3	629	633	2778452	10.1021/np50063a025	Isolation of flavonoids and a chalcone from Helichrysum odoratissimum and synthesis of helichrysetin.	Van Puyvelde L, De Kimpe N, Costa J, Munyjabo V, Nyirankuliza S, Hakizamungu E, Schamp N.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	Antimicrob. Agents Chemother.	2007	51	1	169	174	17060530	10.1128/aac.00261-06	Antibiotic susceptibility profile of bifidobacteria as affected by oxgall, acid, and hydrogen peroxide stress.	Kheadr E, Dabour N, Le Lay C, Lacroix C, Fliss I.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	J Agric Food Chem	2007	55	17	6977	6983	17628075	10.1021/jf071568v	Isolation and structural elucidation of eight new related analogues of the mycotoxin (-)-botryodiplodin from Penicillium coalescens.	Cabedo N, López-Gresa MP, Primo J, Ciavatta ML, González-Mas MC.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	Bioorg. Med. Chem.	2009	17	3	1006	1017	18234501	10.1016/j.bmc.2008.01.001	Synthesis and preliminary antibacterial evaluation of simplified thiomarinol analogs.	Marion O, Gao X, Marcus S, Hall DG.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	J. Nat. Prod.	2011	74	4	670	674	21388191	10.1021/np100727h	Maklamicin, an antibacterial polyketide from an endophytic Micromonospora sp.	Igarashi Y, Ogura H, Furihata K, Oku N, Indananda C, Thamchaipenet A.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	Bioorg. Med. Chem. Lett.	2012	22	4	1709	1711	22257890	10.1016/j.bmcl.2011.12.103	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.	Maiti M, Nauwelaerts K, Herdewijn P.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950	Bioorg. Med. Chem. Lett.	2014	24	22	5310	5314	25293447	10.1016/j.bmcl.2014.09.047	Beta-aminoketones as prodrugs for selective irreversible inhibitors of type-1 methionine aminopeptidases.	Altmeyer M, Amtmann E, Heyl C, Marschner A, Scheidig AJ, Klein CD.
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TETRACYCLINE HYDROCHLORIDE	CHEMBL454950									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TETRACYCLINE PHOSPHATE COMPLEX	CHEMBL1201071									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TETRACYCLINE PHOSPHATE COMPLEX	CHEMBL1201071									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413									PubChem BioAssay data set	
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413									Unpublished dataset	
1048.6000000000000000	9606	Homo sapiens	TETRAHYDROZOLINE HYDROCHLORIDE	CHEMBL1200413									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698	J. Med. Chem.	2012	55	1	169	196	22148278	10.1021/jm201112g	Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.	William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW.
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698	J. Med. Chem.	2014	57	2	278	295	24044773	10.1021/jm400887j	Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?	Giordanetto F, Kihlberg J.
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698	Eur. J. Med. Chem.	2015	95		104	115	25800646	10.1016/j.ejmech.2015.03.034	Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.	Ning CQ, Lu C, Hu L, Bi YJ, Yao L, He YJ, Liu LF, Liu XY, Yu NF.
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698	J Med Chem	2016	59	19	8667	8684	27171036	10.1021/acs.jmedchem.6b00150	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A.
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
884.4000000000000000	9606	Homo sapiens	TG-02	CHEMBL1944698									Unpublished dataset	
958.4000000000000000	9606	Homo sapiens	TG100-801	CHEMBL403989	J. Med. Chem.	2008	51	6	1546	1559	18311895	10.1021/jm7011276	Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.	Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G.
958.4000000000000000	9606	Homo sapiens	TG100-801	CHEMBL403989		2008							Benzotriazine inhibitors of kinases	
958.4000000000000000	9606	Homo sapiens	TG100-801	CHEMBL403989		2013							Benzotriazine inhibitors of kinases	
958.4000000000000000	9606	Homo sapiens	TG100-801	CHEMBL403989	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
958.4000000000000000	9606	Homo sapiens	TG100-801	CHEMBL403989									Unpublished dataset	
962.7500000000000000	2	Bacteria	TICARCILLIN DISODIUM	CHEMBL1200855									British National Formulary (72nd edition)	
962.7500000000000000	2	Bacteria	TICARCILLIN DISODIUM	CHEMBL1200855									PubChem BioAssay data set	
962.7500000000000000	2	Bacteria	TICARCILLIN DISODIUM	CHEMBL1200855									Unpublished dataset	
962.7500000000000000	2	Bacteria	TICARCILLIN DISODIUM	CHEMBL1200855									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Bioorg. Med. Chem. Lett.	1999	9	10	1459	1462	10360756	10.1016/s0960-894x(99)00216-4	Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.	Sum PE, Petersen P.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Bioorg. Med. Chem. Lett.	2006	16	2	400	403	16246559	10.1016/j.bmcl.2005.09.078	Synthesis and antibacterial activity of 9-substituted minocycline derivatives.	Sum PE, Ross AT, Petersen PJ, Testa RT.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	1	376	378	17043112	10.1128/aac.00858-06	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.	Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, Jorgensen JH.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	11	4085	4089	17846139	10.1128/aac.00065-07	Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.	Rubino CM, Ma L, Bhavnani SM, Korth-Bradley J, Speth J, Ellis-Grosse E, Rodvold KR, Ambrose PG, Drusano GL.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	11	4196	4201	17876003	10.1128/aac.00827-07	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.	Clark CL, Kosowska-Shick K, Ednie LM, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	12	4529	4530	17876007	10.1128/aac.01115-07	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.	Hawley JS, Murray CK, Jorgensen JH.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	3	1102	1104	17194827	10.1128/aac.01102-06	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.	Cercenado E, Marín M, Sánchez-Martínez M, Cuevas O, Martínez-Alarcón J, Bouza E.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	4	1155	1163	17210772	10.1128/aac.01384-06	Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.	Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	4	1556	1558	17220399	10.1128/aac.00893-06	Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters.	Aslam S, Trautner BW, Ramanathan V, Darouiche RO.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	5	1621	1626	17307973	10.1128/aac.01099-06	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.	Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	5	1649	1655	17283189	10.1128/aac.01435-06	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.	Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	5	1656	1660	17353249	10.1128/aac.00350-06	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.	Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	6	1939	1945	17353238	10.1128/aac.01084-06	Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.	Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	6	2065	2069	17420217	10.1128/aac.01198-06	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.	Peleg AY, Adams J, Paterson DL.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	8	2716	2719	17517836	10.1128/aac.01623-06	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.	Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	8	3026	3029	17562800	10.1128/aac.00299-07	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.	Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	9	3205	3211	17620376	10.1128/aac.00625-07	Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.	Tuckman M, Petersen PJ, Howe AY, Orlowski M, Mullen S, Chan K, Bradford PA, Jones CH.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	11	4184	4186	18725441	10.1128/aac.00695-08	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.	Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	11	4205	4206	18765689	10.1128/aac.01121-08	Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.	Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lissoir B, Nordmann P, Glupczynski Y.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	12	4370	4373	18519719	10.1128/aac.00922-07	Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.	Bowker KE, Noel AR, Macgowan AP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	2	557	562	18086852	10.1128/aac.00732-07	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.	Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	2	570	573	18070960	10.1128/aac.01114-07	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.	Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	2	796	797	18056283	10.1128/aac.01180-07	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.	Cuzon G, Naas T, Demachy MC, Nordmann P.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	4	1430	1437	18285482	10.1128/aac.01538-07	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.	Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J, Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	4	1503	1505	18227183	10.1128/aac.01129-07	Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes.	Salas C, Calvo J, Martínez-Martínez L.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	4	1570	1572	18212098	10.1128/aac.01098-07	Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.	Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	5	1846	1849	18299417	10.1128/aac.01176-07	Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.	Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	6	2266	2269	18413298	10.1128/aac.00046-08	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.	Hsieh YC, Chang KY, Huang YC, Lin HC, Ho YH, Huang LM, Hsueh PR.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	7	2677	2679	18474585	10.1128/aac.00002-08	In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan.	Liu CY, Huang YT, Liao CH, Hsueh PR.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	7	2680	2682	18426899	10.1128/aac.00158-08	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.	Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	7	2686	2690	18474575	10.1128/aac.00081-08	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.	Betriu C, Culebras E, Gómez M, López F, Rodríguez-Avial I, Picazo JJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	8	2940	2942	18519722	10.1128/aac.01581-07	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.	Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	9	2999	3005	18591275	10.1128/aac.01684-07	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.	Bratu S, Landman D, Martin DA, Georgescu C, Quale J.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2008	52	9	3463	3464	18644970	10.1128/aac.00543-08	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.	Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Huang TD, Nordmann P.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	1	333	334	19015350	10.1128/aac.00736-08	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.	Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	10	4333	4338	19620332	10.1128/aac.00260-09	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.	Shen P, Wei Z, Jiang Y, Du X, Ji S, Yu Y, Li L.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	10	4504	4507	19770287	10.1128/aac.00556-09	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.	Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	10	4565	4567	19620323	10.1128/aac.00436-09	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.	Baraniak A, Izdebski R, Herda M, Fiett J, Hryniewicz W, Gniadkowski M, Kern-Zdanowicz I, Filczak K, ¿opaciuk U.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	11	4953	4954	19738023	10.1128/aac.01592-08	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.	Daurel C, Fiant AL, Brémont S, Courvalin P, Leclercq R.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	12	5060	5063	19738006	10.1128/aac.00985-09	Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.	Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	12	5141	5144	19805558	10.1128/aac.00307-09	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.	Patel N, Lubanski P, Ferro S, Bonafede M, Harrington S, Evans A, Stellrecht K, Lodise TP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	2	465	475	19015360	10.1128/aac.00883-08	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.	Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	2	782	784	19064899	10.1128/aac.01122-08	Postantibiotic effect of tigecycline against 14 gram-positive organisms.	Pankuch GA, Appelbaum PC.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	3	1165	1169	19114676	10.1128/aac.00647-08	Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.	Crandon JL, Banevicius MA, Nicolau DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	3	1295	1296	19075049	10.1128/aac.01097-08	In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.	Arroyo LA, Mateos I, González V, Aznar J.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	4	1434	1442	19188393	10.1128/aac.01145-08	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.	Nguyen HA, Denis O, Vergison A, Theunis A, Tulkens PM, Struelens MJ, Van Bambeke F.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	4	1546	1551	19139287	10.1128/aac.00979-08	Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.	Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, McCracken GH, Hardy RD.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	5	1998	2004	19258268	10.1128/aac.01355-08	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.	Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, Huard RC.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	6	2360	2366	19349512	10.1128/aac.01452-08	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.	Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	6	2690	2692	19332671	10.1128/aac.01424-08	Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.	Spyridaki I, Psaroulaki A, Vranakis I, Tselentis Y, Gikas A.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	7	2756	2761	19364850	10.1128/aac.01678-08	In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.	Nicasio AM, Crandon JL, Nicolau DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	7	3150	3152	19364855	10.1128/aac.01612-08	Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.	Vaudaux P, Fleury B, Gjinovci A, Huggler E, Tangomo-Bento M, Lew DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	8	3528	3533	19487447	10.1128/aac.00178-09	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.	D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	9	3642	3649	19546358	10.1128/aac.00206-09	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.	Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2009	53	9	4040	4042	19596882	10.1128/aac.00312-09	Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.	Starzengruber P, Thriemer K, Haque R, Khan WA, Fuehrer HP, Siedl A, Hofecker V, Ley B, Wernsdorfer WH, Noedl H.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	1	380	387	19858261	10.1128/aac.00155-09	Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus.	Smith K, Gould KA, Ramage G, Gemmell CG, Hinds J, Lang S.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	1	573	577	19805565	10.1128/aac.01099-09	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.	Yang Q, Wang H, Sun H, Chen H, Xu Y, Chen M.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	10	4078	4084	20679509	10.1128/aac.00275-10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.	Hajdu S, Holinka J, Reichmann S, Hirschl AM, Graninger W, Presterl E.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	11	4636	4642	20805391	10.1128/aac.00572-10	Synthesis and spectrum of the neoglycoside ACHN-490.	Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	11	4934	4938	20696871	10.1128/aac.00414-10	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.	Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	12	5021	5027	20921306	10.1128/aac.00598-10	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.	Higgins PG, Schneiders T, Hamprecht A, Seifert H.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	12	5115	5119	20837760	10.1128/aac.00062-10	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.	Crandon JL, Kuti JL, Nicolau DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	12	5180	5186	20921315	10.1128/aac.01414-09	Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.	Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, Ambrose PG.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	12	5209	5213	20921312	10.1128/aac.01051-10	Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.	Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	2	643	651	19995919	10.1128/aac.00788-09	Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.	Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	3	1207	1212	20038623	10.1128/aac.00182-09	Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.	Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	3	1232	1236	20038624	10.1128/aac.00898-09	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.	Lehtopolku M, Nakari UM, Kotilainen P, Huovinen P, Siitonen A, Hakanen AJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	3	1319	1322	20028818	10.1128/aac.00993-09	Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.	Hentschke M, Christner M, Sobottka I, Aepfelbacher M, Rohde H.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	3	1338	1342	20065058	10.1128/aac.01197-09	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.	Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	3	1354	1357	20038618	10.1128/aac.00899-09	Detection of KPC in Acinetobacter spp. in Puerto Rico.	Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	5	2278	2279	20211897	10.1128/aac.00011-10	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.	Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song JH, Ko KS.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	6	2677	2680	20350943	10.1128/aac.01536-09	Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.	Pires R, Ardanuy C, Rolo D, Morais A, Brito-Avô A, Gonçalo-Marques J, Liñares J, Santos-Sanches I.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	6	2687	2691	20231393	10.1128/aac.01359-09	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	6	2699	2703	20368407	10.1128/aac.01624-09	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.	Huang LY, Lu PL, Chen TL, Chang FY, Fung CP, Siu LK.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	7	3002	3006	20350950	10.1128/aac.01818-09	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.	Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	9	3967	3969	20547789	10.1128/aac.00137-10	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.	Jiang Y, Yu D, Wei Z, Shen P, Zhou Z, Yu Y.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2010	54	9	3974	3977	20625154	10.1128/aac.00484-10	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.	Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2011	54	11	3704	3731	21500832	10.1021/jm1015395	Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs.	Sun C, Hunt DK, Clark RB, Lofland D, O'Brien WJ, Plamondon L, Xiao XY.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2011	54	5	1511	1528	21302930	10.1021/jm1015389	8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.	Clark RB, He M, Fyfe C, Lofland D, O'Brien WJ, Plamondon L, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Antimicrob. Agents Chemother.	2011	55	2	934	936	21115785	10.1128/aac.01247-10	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.	Poirel L, Revathi G, Bernabeu S, Nordmann P.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2012	55	2	597	605	22148514	10.1021/jm201465w	Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.	Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2012	55	2	606	622	22148555	10.1021/jm201467r	Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.	Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J. Med. Chem.	2015	58	11	4703	4712	25927406	10.1021/acs.jmedchem.5b00262	Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.	Sun C, Hunt DK, Chen CL, Deng Y, He M, Clark RB, Fyfe C, Grossman TH, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	Bioorg Med Chem	2016	24	24	6409	6419	27469981	10.1016/j.bmc.2016.07.029	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.	Tanaka SK, Steenbergen J, Villano S.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140	J Med Chem	2017	60	6	2498	2512	28248499	10.1021/acs.jmedchem.6b01903	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.	Deng Y, Sun C, Hunt DK, Fyfe C, Chen CL, Grossman TH, Sutcliffe JA, Xiao XY.
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140									British National Formulary (72nd edition)	
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140									PubChem BioAssay data set	
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140									Unpublished dataset	
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
2219.8000000000000000	2	Bacteria	TIGECYCLINE	CHEMBL376140									WHO Anatomical Therapeutic Chemical Classification	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	1986	29	5	611	614	3701779	10.1021/jm00155a004	Aminoglycoside antibiotics. 6. Chemical reactions of aminoglycosides with disodium carbenicillin.	Iyengar BS, Kumar V, Wunz TP, Remers WA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	1987	30	2	333	340	3543366	10.1021/jm00385a015	Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.	Allen NE, Alborn WE, Kirst HA, Toth JE.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	1997	7	14	1951	1956		10.1016/S0960-894X(97)00339-9	Dimeric aminoglycosides: Design, synthesis and RNA binding	Wang H, Tor Y
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	1998	41	2	175	182	9457241	10.1021/jm970372r	Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.	Leclerc F, Cedergren R.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2000	10	14	1593	1595	10915059	10.1016/s0960-894x(00)00299-7	"Enhanced binding of aminoglycoside dimers to a ""dimerized"" A-site 16S rRNA construct."	Tok JB, Huffman GR.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2001	11	13	1703	1707	11425542	10.1016/s0960-894x(01)00283-9	Some 3-thioxo/alkylthio-1,2,4-triazoles with a substituted thiourea moiety as possible antimycobacterials.	Küçükgüzel I, Küçükgüzel SG, Rollas S, Kiraz M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2001	11	2	119	122	11206440	10.1016/s0960-894x(00)00615-6	Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues.	Cashman DJ, Rife JP, Kellogg GE.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2001	11	22	2987	2991	11677142	10.1016/s0960-894x(01)00602-3	Novel synthesis and RNA-binding properties of aminoglycoside dimers conjugated via a naphthalene diimide-based intercalator.	Tok JB, Fenker J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2001	11	9	1127	1131	11354359	10.1016/s0960-894x(01)00149-4	Binding of dimeric aminoglycosides to the HIV-1 rev responsive element (RRE) RNA construct.	Tok JB, Dunn LJ, Des Jean RC.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747		2001			1924	2023			Goodman and Gilman Ed. 10 | The Pharmaceutical Basis of Therapeutics| Table A-II-I: Pharmacokinetic Data	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2002	12	16	2241	2244	12127547	10.1016/s0960-894x(02)00342-6	Decoding region bubble size and aminoglycoside antibiotic binding.	Ryu DH, Rando RR.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2002	12	3	365	370	11814798	10.1016/s0960-894x(01)00760-0	Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers.	Tok JB, Wong W, Baboolal N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2004	14	14	3733	3738	15203152	10.1016/j.bmcl.2004.05.004	Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.	Yao S, Sgarbi PW, Marby KA, Rabuka D, O'Hare SM, Cheng ML, Bairi M, Hu C, Hwang SB, Hwang CK, Ichikawa Y, Sears P, Sucheck SJ.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2004	47	17	4188	4201	15293991	10.1021/jm030650o	Validation of automated docking programs for docking and database screening against RNA drug targets.	Detering C, Varani G.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2005	15	23	5324	5328	16202590	10.1016/j.bmcl.2005.08.032	Synthesis and biological evaluation of novel (L)-alpha-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents.	Tandon VK, Yadav DB, Singh RV, Chaturvedi AK, Shukla PK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2005	15	8	2123	2128	15808482	10.1016/j.bmcl.2005.02.029	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.	Liang CH, Romero A, Rabuka D, Sgarbi PW, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang SB, Shue YK, Sucheck SJ.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2005	15	8	2169	2172	15808490	10.1016/j.bmcl.2005.02.007	Fluorescence resonance energy transfer studies of aminoglycoside binding to a T box antiterminator RNA.	Means JA, Hines JV.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Nature	2007	447	7140	87	91	17450125	10.1038/nature05756	PTC124 targets genetic disorders caused by nonsense mutations.	Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2007	50	17	4195	4204	17665895	10.1021/jm0703183	Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.	Villain-Guillot P, Gualtieri M, Bastide L, Roquet F, Martinez J, Amblard M, Pugniere M, Leonetti JP.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	1	359	360	17088477	10.1128/aac.00795-06	Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.	Okazaki A, Avison MB.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	1	54	63	17088489	10.1128/aac.00729-05	Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.	Duewelhenke N, Krut O, Eysel P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	10	3531	3536	17682106	10.1128/aac.00503-07	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.	Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson MO, Couetdic G, Plésiat P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	11	4105	4110	17724159	10.1128/aac.00616-07	Prevalence and expression of the plasmid-mediated quinolone resistance determinant qnrA1.	Xu X, Wu S, Ye X, Liu Y, Shi W, Zhang Y, Wang M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	11	4209	4210	17785513	10.1128/aac.00560-07	Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America.	Doi Y, Adams JM, Yamane K, Paterson DL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	12	4329	4335	17938181	10.1128/aac.00810-07	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.	Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, Pérez JL, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	12	4401	4409	17875999	10.1128/aac.00926-07	Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.	Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	12	4466	4470	17938184	10.1128/aac.00726-07	Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.	Quiroga MP, Andres P, Petroni A, Soler Bistué AJ, Guerriero L, Vargas LJ, Zorreguieta A, Tokumoto M, Quiroga C, Tolmasky ME, Galas M, Centrón D.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	2	417	422	17158943	10.1128/aac.00851-06	Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.	Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	2	774	776	17088479	10.1128/aac.01034-06	Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.	Hainrichson M, Yaniv O, Cherniavsky M, Nudelman I, Shallom-Shezifi D, Yaron S, Baasov T.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	3	1016	1021	17194835	10.1128/aac.00704-06	Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.	El'Garch F, Jeannot K, Hocquet D, Llanes-Barakat C, Plésiat P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	3	852	856	17158944	10.1128/aac.01345-06	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.	Doi Y, de Oliveira Garcia D, Adams J, Paterson DL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	4	1341	1350	17261619	10.1128/aac.01278-06	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.	Reinhardt A, Köhler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	4	1553	1555	17261621	10.1128/aac.01405-06	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.	Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP, Colombian Nosocomial Resistance Study Group.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	5	1813	1817	17353241	10.1128/aac.01037-06	Asiatic acid and corosolic acid enhance the susceptibility of Pseudomonas aeruginosa biofilms to tobramycin.	Garo E, Eldridge GR, Goering MG, DeLancey Pulcini E, Hamilton MA, Costerton JW, James GA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	5	1849	1851	17353252	10.1128/aac.01551-06	In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.	Shen GH, Wu BD, Wu KM, Chen JH.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	6	1946	1955	17371815	10.1128/aac.01412-06	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.	Mendonça N, Leitão J, Manageiro V, Ferreira E, Caniça M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	6	1967	1971	17420207	10.1128/aac.01483-06	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.	Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	6	2065	2069	17420217	10.1128/aac.01198-06	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.	Peleg AY, Adams J, Paterson DL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	6	2211	2214	17404005	10.1128/aac.01139-06	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.	Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, Pagani L, Bonomo RA, Rossolini GM, Toniolo A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	7	2366	2372	17452479	10.1128/aac.00044-07	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.	Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M, Stefanou I, Avlami A, Katsilambros N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	7	2464	2469	17470656	10.1128/aac.00143-07	Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.	Périchon B, Courvalin P, Galimand M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	7	2574	2581	17470655	10.1128/aac.00174-07	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.	Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	7	2611	2614	17470660	10.1128/aac.00838-06	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.	Mendes RE, Castanheira M, Toleman MA, Sader HS, Jones RN, Walsh TR.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	8	2679	2689	17502406	10.1128/aac.00209-07	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Meehl M, Herbert S, Götz F, Cheung A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2007	51	9	3247	3253	17638702	10.1128/aac.00072-07	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.	Pérez A, Canle D, Latasa C, Poza M, Beceiro A, Tomás Mdel M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	10	3589	3596	18644957	10.1128/aac.00465-08	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.	Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	10	3801	3804	18644958	10.1128/aac.00638-08	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.	Cattoir V, Poirel L, Nordmann P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	10	3826	3827	18694947	10.1128/aac.00419-08	Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.	Wu X, Wang H, Zhao X.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	11	3837	3843	18725452	10.1128/aac.00570-08	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.	Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	11	4184	4186	18725441	10.1128/aac.00695-08	In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.	Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI, García-Almeida D, Gadea I, Esteban J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	12	4526	4527	18838598	10.1128/aac.00882-08	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.	Berçot B, Poirel L, Nordmann P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	3	1173	1175	18180356	10.1128/aac.01212-07	Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.	Hocquet D, Muller A, Blanc K, Plésiat P, Talon D, Monnet DL, Bertrand X.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	3	1204	1205	18195064	10.1128/aac.01320-07	Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.	Doi Y, Adams-Haduch JM, Paterson DL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	3	920	926	18172002	10.1128/aac.00382-07	Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow.	Menashe O, Kaganskaya E, Baasov T, Yaron S.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	4	1446	1453	18195062	10.1128/aac.00054-07	Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm.	Kim J, Pitts B, Stewart PS, Camper A, Yoon J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	4	1564	1566	18285488	10.1128/aac.01137-07	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.	Yamane K, Wachino J, Suzuki S, Arakawa Y.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	5	1635	1641	18285485	10.1128/aac.01071-07	Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.	Khalil H, Chen T, Riffon R, Wang R, Wang Z.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	6	2289	2290	18362195	10.1128/aac.00299-08	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.	Martin CA, Morita K, Ribes JA, Deshpande LM, Sader HS, Castanheira M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	7	2455	2462	18474583	10.1128/aac.01107-07	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.	Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	7	2680	2682	18426899	10.1128/aac.00158-08	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.	Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	8	2950	2954	18519712	10.1128/aac.01672-07	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.	Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	8	2955	2958	18505859	10.1128/aac.00072-08	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.	Marti S, Sánchez-Céspedes J, Blasco MD, Ruiz M, Espinal P, Alba V, Fernández-Cuenca F, Pascual A, Vila J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	8	2977	2979	18519714	10.1128/aac.00175-08	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.	Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	8	2984	2987	18490506	10.1128/aac.01634-07	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.	Espedido BA, Partridge SR, Iredell JR.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2008	52	9	2999	3005	18591275	10.1128/aac.01684-07	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.	Bratu S, Landman D, Martin DA, Georgescu C, Quale J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Eur. J. Med. Chem.	2009	44	8	3130	3137	19349095	10.1016/j.ejmech.2009.03.006	Design, synthesis and biological evaluation of novel nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.	Tandon VK, Maurya HK, Mishra NN, Shukla PK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2009	52	12	3753	3761	19445516	10.1021/jm9000659	Design and implementation of an ribonucleic acid (RNA) directed fragment library.	Bodoor K, Boyapati V, Gopu V, Boisdore M, Allam K, Miller J, Treleaven WD, Weldeghiorghis T, Aboul-ela F.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	1	287	291	19001116	10.1128/aac.00746-08	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.	Mesko Meglic K, Koren S, Palepou MF, Karisik E, Livermore DM, Pike R, Andlovic A, Jeverica S, Krizan-Hergouth V, Müller-Premru M, Seme K, Slovenian ESBL Study Group, Woodford N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	1	292	294	18852270	10.1128/aac.00931-08	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.	Bennett JW, Herrera ML, Lewis JS, Wickes BW, Jorgensen JH.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	1	327	328	19001117	10.1128/aac.00896-08	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.	Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martínez-Martínez L.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	1	35	40	18725436	10.1128/aac.00237-08	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.	del Pozo JL, Rouse MS, Mandrekar JN, Sampedro MF, Steckelberg JM, Patel R.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	10	4352	4356	19770286	10.1128/aac.00282-09	In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.	Crandon JL, Bulik CC, Nicolau DP.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	10	4472	4482	19687243	10.1128/aac.00688-09	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.	Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	10	4504	4507	19770287	10.1128/aac.00556-09	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.	Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	11	4930	4933	19738007	10.1128/aac.00900-09	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.	Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	11	4957	4958	19721071	10.1128/aac.00675-09	High prevalence of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Bamako, Mali.	Duval V, Maiga I, Maiga A, Guillard T, Brasme L, Forte D, Madoux J, Vernet-Garnier V, De Champs C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	12	5150	5154	19752280	10.1128/aac.00893-09	Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.	Barrow K, Kwon DH.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	12	5288	5290	19770278	10.1128/aac.00822-09	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.	Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	2	465	475	19015360	10.1128/aac.00883-08	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.	Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	2	843	844	19015330	10.1128/aac.00999-08	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	3	1225	1227	19114677	10.1128/aac.01011-08	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).	Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	4	1552	1560	19188376	10.1128/aac.01264-08	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.	Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	5	1987	1997	19258280	10.1128/aac.01024-08	Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Vettoretti L, Plésiat P, Muller C, El Garch F, Phan G, Attrée I, Ducruix A, Llanes C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	5	2221	2222	19223629	10.1128/aac.01573-08	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.	Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	5	2225	2226	19223647	10.1128/aac.01602-08	Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.	Picão RC, Poirel L, Gales AC, Nordmann P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2253	2258	19307375	10.1128/aac.00043-09	The chromosomal toxin gene yafQ is a determinant of multidrug tolerance for Escherichia coli growing in a biofilm.	Harrison JJ, Wade WD, Akierman S, Vacchi-Suzzi C, Stremick CA, Turner RJ, Ceri H.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2327	2334	19349516	10.1128/aac.01360-08	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.	Kitao T, Miyoshi-Akiyama T, Kirikae T.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2483	2491	19332676	10.1128/aac.00428-08	Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.	Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2539	2543	19364876	10.1128/aac.00061-09	Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region.	Pitout JD, Campbell L, Church DL, Gregson DB, Laupland KB.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2643	2645	19289526	10.1128/aac.01534-08	Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.	Kim ES, Jeong JY, Jun JB, Choi SH, Lee SO, Kim MN, Woo JH, Kim YS.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	6	2667	2671	19364869	10.1128/aac.01407-08	AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii.	Post V, Hall RM.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	8	3552	3560	19506065	10.1128/aac.00418-09	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.	Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	9	3923	3928	19528273	10.1128/aac.00268-09	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.	Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2009	53	9	4015	4018	19581465	10.1128/aac.00590-09	Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.	Svetlíková Z, Skovierová H, Niederweis M, Gaillard JL, McDonnell G, Jackson M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem.	2010	18	2	663	674	20044260	10.1016/j.bmc.2009.12.003	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.	Huigens RW, Reyes S, Reed CS, Bunders C, Rogers SA, Steinhauer AT, Melander C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Eur. J. Med. Chem.	2010	45	6	2418	2426	20207052	10.1016/j.ejmech.2010.02.023	'On water' assisted synthesis and biological evaluation of nitrogen and sulfur containing hetero-1,4-naphthoquinones as potent antifungal and antibacterial agents.	Tandon VK, Maurya HK, Verma MK, Kumar R, Shukla PK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2010	53	1	119	127	20000576	10.1021/jm900615h	Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives.	Baussanne I, Bussière A, Halder S, Ganem-Elbaz C, Ouberai M, Riou M, Paris JM, Ennifar E, Mingeot-Leclercq MP, Décout JL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	1	143	148	19805554	10.1128/aac.00248-09	In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.	King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	1	177	183	19858254	10.1128/aac.00715-09	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.	Padilla E, Llobet E, Doménech-Sánchez A, Martínez-Martínez L, Bengoechea JA, Albertí S.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	1	333	340	19884373	10.1128/aac.01037-09	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.	Coyne S, Guigon G, Courvalin P, Périchon B.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	1	346	352	19884381	10.1128/aac.00824-09	Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.	Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, Lia A, Ranheim TE, Rajendra Y, Hermansen NO, Walsh TR, Giske CG.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	1	557	559	19917762	10.1128/aac.00912-09	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.	Bulik CC, Christensen H, Nicolau DP.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	11	4626	4635	20696867	10.1128/aac.00762-10	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.	Su HC, Ramkissoon K, Doolittle J, Clark M, Khatun J, Secrest A, Wolfgang MC, Giddings MC.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	11	4948	4949	20713658	10.1128/aac.00415-10	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.	Rodríguez-Rojas A, Couce A, Blázquez J.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	12	5021	5027	20921306	10.1128/aac.00598-10	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.	Higgins PG, Schneiders T, Hamprecht A, Seifert H.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	2	846	851	19933793	10.1128/aac.00834-09	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.	Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	3	1029	1041	20028819	10.1128/aac.00963-09	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.	Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	3	1327	1330	20047913	10.1128/aac.01338-09	High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.	Peirano G, Richardson D, Nigrin J, McGeer A, Loo V, Toye B, Alfa M, Pienaar C, Kibsey P, Pitout JD.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	4	1590	1595	20145089	10.1128/aac.01444-09	Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.	Toth M, Frase H, Chow JW, Smith C, Vakulenko SB.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	4	1644	1646	20086144	10.1128/aac.01172-09	Fasting increases tobramycin oral absorption in mice.	De Leo L, Di Toro N, Decorti G, Malusà N, Ventura A, Not T.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	5	2078	2084	20194701	10.1128/aac.01398-09	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.	Lin YC, Hsia KC, Chen YC, Sheng WH, Chang SC, Liao MH, Li SY.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	5	2219	2224	20194693	10.1128/aac.00816-09	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.	Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	6	2385	2390	20308368	10.1128/aac.00021-10	Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.	Kogure T, Shimada R, Ishikawa J, Yazawa K, Brown JM, Mikami Y, Gonoi T.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	6	2699	2703	20368407	10.1128/aac.01624-09	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.	Huang LY, Lu PL, Chen TL, Chang FY, Fung CP, Siu LK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	7	3015	3017	20404121	10.1128/aac.01173-09	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.	Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, Wortmann G.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	8	3493	3497	20498315	10.1128/aac.00080-10	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.	Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Antimicrob. Agents Chemother.	2010	54	9	3564	3568	20547788	10.1128/aac.00220-10	Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.	Tängdén T, Cars O, Melhus A, Löwdin E.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2011	21	21	6398	6403	21930375	10.1016/j.bmcl.2011.08.095	Micelles catalyzed chemoselective synthesis 'in water' and biological evaluation of oxygen containing hetero-1,4-naphthoquinones as potential antifungal agents.	Tandon VK, Maurya HK, Mishra NN, Shukla PK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2011	54	20	7417	7421	21905738	10.1021/jm200506x	Synthesis of new 3,20-bispolyaminosteroid squalamine analogues and evaluation of their antimicrobial activities.	Djouhri-Bouktab L, Vidal N, Rolain JM, Brunel JM.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Med Chem Res	2012	21	11	3848	3857		10.1007/s00044-011-9911-y	Synthesis, anti-microbial evaluation, and molecular modeling of new pyrazolo[3,4-d]pyrimidine derivatives	Eweas AF, Swelam SA, Fathalla OA, Fawzy NM, Abdel-Moez SI
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Med Chem Res	2012	21	11	3897	3901		10.1007/s00044-011-9933-5	11-Chloro-3-methyl-3H-imidazo[4,5-a]acridine (CMIA) as a potent and selective antimicrobial agent against clinical isolates of highly antibiotic-resistant Acinetobacter baumannii	Sadeghian A, Pordel M, Safdari H, Fahmidekar MA, Sadeghian H
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2012	22	4	1709	1711	22257890	10.1016/j.bmcl.2011.12.103	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.	Maiti M, Nauwelaerts K, Herdewijn P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem.	2013	21	22	7038	7046	24094434	10.1016/j.bmc.2013.09.019	Spectroscopic identification and anti-biofilm properties of polar metabolites from the medicinal plant Helichrysum italicum against Pseudomonas aeruginosa.	D'Abrosca B, Buommino E, D'Angelo G, Coretti L, Scognamiglio M, Severino V, Pacifico S, Donnarumma G, Fiorentino A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem.	2013	21	23	7499	7506	24126094	10.1016/j.bmc.2013.09.041	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.	Od¿ak R, Sko¿ibu¿i¿ M, Maravi¿ A.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Med Chem Res	2013	22	9	4173	4182		10.1007/s00044-012-0419-x	Anti-tyrosinase, antioxidant and antimicrobial activities of hydroxycinnamoylamides	Georgiev L, Chochkova M, Totseva I, Seizova K, Marinova E, Ivanova G, Ninova M, Najdenski H, Milkova T
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	MedChemComm	2013	4	1	120	124		10.1039/C2MD20162C	Design of membrane targeting tobramycin-based cationic amphiphiles with reduced hemolytic activity	Herzog IM, Feldman M, Eldar-Boock A, Satchi-Fainaro R, Fridman M
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2013	56	13	5613	5625	23786357	10.1021/jm400707f	Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.	Berkov-Zrihen Y, Green KD, Labby KJ, Feldman M, Garneau-Tsodikova S, Fridman M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J. Med. Chem.	2013	56	19	7691	7705	24083676	10.1021/jm401148j	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.	Zimmermann L, Bussière A, Ouberai M, Baussanne I, Jolivalt C, Mingeot-Leclercq MP, Décout JL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2014	24	9	2090	2093	24709560	10.1016/j.bmcl.2014.03.055	Discovery of two aminoglycoside antibiotics as inhibitors targeting the menin-mixed lineage leukaemia interface.	Li L, Zhou R, Geng H, Yue L, Ye F, Xie Y, Liu J, Kong X, Jiang H, Huang J, Luo C.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	ACS Med. Chem. Lett.	2014	5	7	777	781	25050164	10.1021/ml5001118	Bioreductively Activated Reactive Oxygen Species (ROS) Generators as MRSA Inhibitors.	Khodade VS, Sharath Chandra M, Banerjee A, Lahiri S, Pulipeta M, Rangarajan R, Chakrapani H.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem.	2015	23	13	3566	3573	25936261	10.1016/j.bmc.2015.04.020	Colloidal and antibacterial properties of novel triple-headed, double-tailed amphiphiles: exploring structure-activity relationships and synergistic mixtures.	Marafino JN, Gallagher TM, Barragan J, Volkers BL, LaDow JE, Bonifer K, Fitzgerald G, Floyd JL, McKenna K, Minahan NT, Walsh B, Seifert K, Caran KL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2015	25	13	2694	2697	25981687	10.1016/j.bmcl.2015.04.046	Thiol activated prodrugs of sulfur dioxide (SO2) as MRSA inhibitors.	Pardeshi KA, Malwal SR, Banerjee A, Lahiri S, Rangarajan R, Chakrapani H.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	ACS Med. Chem. Lett.	2015	6	11	1134	1139	26617967	10.1021/acsmedchemlett.5b00255	Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.	Thamban Chandrika N, Green KD, Houghton JL, Garneau-Tsodikova S.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Bioorg. Med. Chem. Lett.	2016	26	1	213	217	26590102	10.1016/j.bmcl.2015.10.087	An efficient green synthesis of 2-arylbenzothiazole analogues as potent antibacterial and anticancer agents.	Chhabra M, Sinha S, Banerjee S, Paira P.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2016	59	18	8441	8455	27524179	10.1021/acs.jmedchem.6b00867	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.	Gorityala BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2016	59	20	9350	9369	27690420	10.1021/acs.jmedchem.6b00818	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.	Zimmermann L, Das I, Désiré J, Sautrey G, Barros R S V, El Khoury M, Mingeot-Leclercq MP, Décout JL.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	MedChemComm	2016	7	1	148	156		10.1039/C5MD00373C	Synergistic activity of a short lipidated antimicrobial peptide (lipoAMP) and colistin or tobramycin against Pseudomonas aeruginosa from cystic fibrosis patients	de Gier MG, Bauke Albada H, Josten M, Willems R, Leavis H, van Mansveld R, Paganelli FL, Dekker B, Lammers JJ, Sahl H, Metzler-Nolte N
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	MedChemComm	2016	7	1	157	163		10.1039/C5MD00377F	Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles	Dahdouh E, Orgaz B, Gomez-Gil R, Mingorance J, Daoud Z, Suarez M, San Jose C
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Nat Prod	2016	79	10	2446	2454	27690254	10.1021/acs.jnatprod.6b00200	Aldgamycins J-O, 16-Membered Macrolides with a Branched Octose Unit from Streptomycetes sp. and Their Antibacterial Activities.	Wang CX, Ding R, Jiang ST, Tang JS, Hu D, Chen GD, Lin F, Hong K, Yao XS, Gao H.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	Eur J Med Chem	2017	127		223	234	28063354	10.1016/j.ejmech.2016.12.060	Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.	Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, Osmak M, Ko¿mrlj J, Dowson CG.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2017	60	12	5002	5014	28549219	10.1021/acs.jmedchem.7b00377	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Piizzi G, Parker DT, Peng Y, Dobler M, Patnaik A, Wattanasin S, Liu E, Lenoir F, Nunez J, Kerrigan J, McKenney D, Osborne C, Yu D, Lanieri L, Bojkovic J, Dzink-Fox J, Lilly MD, Sprague ER, Lu Y, Wang H, Ranjitkar S, Xie L, Wang B, Glick M, Hamann LG, Tommasi R, Yang X, Dean CR.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2017	60	6	2498	2512	28248499	10.1021/acs.jmedchem.6b01903	Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.	Deng Y, Sun C, Hunt DK, Fyfe C, Chen CL, Grossman TH, Sutcliffe JA, Xiao XY.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2017	60	9	3684	3702	28409644	10.1021/acs.jmedchem.6b01742	Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.	Lyu Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2017	60	9	3902	3912	28383902	10.1021/acs.jmedchem.7b00204	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.	Mason DJ, Stott I, Ashenden S, Weinstein ZB, Karakoc I, Meral S, Kuru N, Bender A, Cokol M.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747	J Med Chem	2017	60	9	3913	3932	28399372	10.1021/acs.jmedchem.7b00156	A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.	Yang X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F.
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									British National Formulary (72nd edition)	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									DrugMatrix	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									PubChem BioAssay data set	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									Unpublished dataset	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN	CHEMBL1747									WHO Anatomical Therapeutic Chemical Classification	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN SULFATE	CHEMBL3989564									Unpublished dataset	
1014.4857142857142857	287	Pseudomonas aeruginosa	TOBRAMYCIN SULFATE	CHEMBL3989564									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1132.5000000000000000	9606	Homo sapiens	TOFACITINIB CITRATE	CHEMBL2103743									Unpublished dataset	
1132.5000000000000000	9606	Homo sapiens	TOFACITINIB CITRATE	CHEMBL2103743									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689	Nature	2010	465	7296	305	310	20485427	10.1038/nature09107	Thousands of chemical starting points for antimalarial lead identification.	Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF.
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689									British National Formulary (72nd edition)	
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689									PubChem BioAssay data set	
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689									Unpublished dataset	
993.9000000000000000	9606	Homo sapiens	TOLAZOLINE HYDROCHLORIDE	CHEMBL1689									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	TRAMETINIB DIMETHYL SULFOXIDE	CHEMBL2105741									Unpublished dataset	
1033.7000000000000000	9606	Homo sapiens	TRAMETINIB DIMETHYL SULFOXIDE	CHEMBL2105741									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1977	20	7	918	925	299711	10.1021/jm00217a011	Dihydroretinoic acids and their derivatives. Synthesis and biological activity.	Pawson BA, Cheung HC, Han RJ, Trown PW, Buck M, Hansen R, Bollag W, Ineichen U, Pleil H, Rüegg R.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1980	23	9	1013	1022	7411544	10.1021/jm00183a010	Retinoic acid analogues. Synthesis and potential as cancer chemopreventive agents.	Dawson MI, Hobbs PD, Kuhlmann K, Fung VA, Helmes CT, Chao WR.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1981	24	10	1214	1223	7328582	10.1021/jm00142a018	Retinoic acid analogues with ring modifications. Synthesis and pharmacological activity.	Dawson MI, Hobbs PD, Chan RL, Chao WR.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1981	24	5	583	592	7241516	10.1021/jm00137a019	Aromatic retinoic acid analogues. Synthesis and pharmacological activity.	Dawson MI, Hobbs PD, Chan RL, Chao WR, Fung VA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1982	25	1	81	84	6177856	10.1021/jm00343a016	Syntheses and activities of antioxidant derivatives of retinoic acids.	Welch SC, Gruber JM, Rao AS.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1982	25	11	1269	1277	6754935	10.1021/jm00353a001	Retinoids at the threshold: their biological significance and therapeutic potential.	Pawson BA, Ehmann CW, Itri LM, Sherman MI.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1982	25	8	956	960	7120285	10.1021/jm00350a014	Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids, and retinoids.	Wätjen F, Buchardt O, Langvad E.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1984	27	11	1516	1531	6208361	10.1021/jm00377a022	Conformationally restricted retinoids.	Dawson MI, Hobbs PD, Derdzinski K, Chan RL, Gruber J, Chao WR, Smith S, Thies RW, Schiff LJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1985	28	1	116	124	2578190	10.1021/jm00379a021	Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide and ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate.	Waugh KM, Berlin KD, Ford WT, Holt EM, Carrol JP, Schomber PR, Thompson MD, Schiff LJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1988	31	1	190	196	3336018	10.1021/jm00396a031	N-(Retinoyl)amino acids. Synthesis and chemopreventive activity in vitro.	Shealy YF, Frye JL, Schiff LJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1988	31	11	2182	2192	3184125	10.1021/jm00119a021	Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.	Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1988	31	6	1124	1130	2836589	10.1021/jm00401a011	Terminal bifunctional retinoids. Synthesis and evaluations related to cancer chemopreventive activity.	Shealy YF, Krauth CA, Riordan JM, Sani BP.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	1988	51	5	929	936	2849641	10.1021/np50059a019	A rapid and sensitive bioassay involving cultured rat glioma cells to screen for substances capable of elevating intracellular cyclic AMP concentration.	Swanson SM, Jiang JX, Chang YS, De Souza NJ, Pezzuto JM.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1989	32	10	2292	2296	2795600	10.1021/jm00130a011	Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity.	Kagechika H, Himi T, Kawachi E, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1989	32	4	834	840	2704028	10.1021/jm00124a016	Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids.	Kagechika H, Kawachi E, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1989	32	5	1098	1108	2709376	10.1021/jm00125a027	Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids.	Kagechika H, Himi T, Namikawa K, Kawachi E, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1989	32	7	1504	1517	2738885	10.1021/jm00127a018	Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.	Dawson MI, Hobbs PD, Derdzinski KA, Chao WR, Frenking G, Loew GH, Jetten AM, Napoli JL, Williams JB, Sani BP.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1990	33	5	1430	1437	2329565	10.1021/jm00167a024	Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60.	Yamakawa T, Kagechika H, Kawachi E, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1991	34	1	430	439	1992144	10.1021/jm00105a065	Novel heteroarotinoids: synthesis and biological activity.	Spruce LW, Gale JB, Berlin KD, Verma AK, Breitman TR, Ji XH, van der Helm D.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	1991	54	6	1677	1680	1667413	10.1021/np50078a032	Production of anti-tumor-promoting iridoid glucosides in Genipa americana and its cell cultures.	Ueda S, Iwahashi Y, Tokuda H.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1992	2	9	1133	1136		10.1016/S0960-894X(00)80633-2	4-oxygenated retinoids: unexpected chemopreventive potential for analogues originally synthesized as affinity labels	W. Curley R, Carson DL
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1992	35	3	567	572	1738149	10.1021/jm00081a020	Base-catalyzed isomerization of retinoic acid. Synthesis and differentiation-inducing activities of 14-alkylated all-trans-, 13-cis-, and 20,14-retro-retinoic acids.	Tanaka H, Kagechika H, Kawachi E, Fukasawa H, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1993	36	18	2605	2613	8410972	10.1021/jm00070a003	Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.	Jong L, Lehmann JM, Hobbs PD, Harlev E, Huffman JC, Pfahl M, Dawson MI.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1994	37	10	1508	1517	8182710	10.1021/jm00036a017	Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring.	Eyrolles L, Kagechika H, Kawachi E, Fukasawa H, Iijima T, Matsushima Y, Hashimoto Y, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1994	37	19	3051	3056	7932527	10.1021/jm00045a009	Cancer chemopreventive 3-substituted-4-oxoretinoic acids.	Shealy YF, Hosmer CA, Riordan JM, Wille JW, Rogers TS, Hill DL.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1994	37	26	4499	4507	7799400	10.1021/jm00052a009	A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicity.	Vaezi MF, Alam M, Sani BP, Rogers TS, Simpson-Herren L, Wille JJ, Hill DL, Doran TI, Brouillette WJ, Muccio DD.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1994	37	3	408	414	8308867	10.1021/jm00029a013	Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.	Boehm MF, McClurg MR, Pathirana C, Mangelsdorf D, White SK, Hebert J, Winn D, Goldman ME, Heyman RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1994	4	12	1447	1452		10.1016/S0960-894X(01)80511-4	Structural basis for the differential RXR & RAR activity of stilbene retinoid analogs	Beard RL, Gil DW, Marler DK, Henry E, Colon DF, Gillett SJ, Arefieg T, Breen TS, Krauss H, Davies PJ, Chandraratna RA
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1994	4	17	2117	2122		10.1016/S0960-894X(01)80113-X	N-linked analogs of retinoid O-glucuronides: potential cancer chemopreventive/chemotherapeutic agents	Robarge M, Repa J, Hanson K, Seth S, Clagett-Dame M, Abou-Issa H, Curley R
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	13	2302	2310	7608895	10.1021/jm00013a006	Conformationally defined 6-s-trans-retinoic acid analogs. 2. Selective agonists for nuclear receptor binding and transcriptional activity.	Alam M, Zhestkov V, Sani BP, Venepally P, Levin AA, Kazmer S, Li E, Norris AW, Zhang XK, Lee MO.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	15	2820	2829	7636843	10.1021/jm00015a004	Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.	Beard RL, Chandraratna RA, Colon DF, Gillett SJ, Henry E, Marler DK, Song T, Denys L, Garst ME, Arefieg T.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	16	3163	3173	7636879	10.1021/jm00016a020	A novel type of retinoic acid receptor antagonist: synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives.	Yoshimura H, Nagai M, Hibi S, Kikuchi K, Abe S, Hida T, Higashi S, Hishinuma I, Yamanaka T.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	17	3368	3383	7650690	10.1021/jm00017a021	Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity.	Dawson MI, Jong L, Hobbs PD, Cameron JF, Chao WR, Pfahl M, Lee MO, Shroot B, Pfahl M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	24	4764	4767	7490725	10.1021/jm00024a003	Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.	Johnson AT, Klein ES, Gillett SJ, Wang L, Song TK, Pino ME, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1995	38	26	4993	5006	8544175	10.1021/jm00026a006	Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.	Charpentier B, Bernardon JM, Eustache J, Millois C, Martin B, Michel S, Shroot B.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1995	5	22	2729	2734		10.1016/0960-894X(95)00455-3	Differential RXR & RAR activity of stilbene retinoid analogs bearing thiazole and imidazole carboxylic acids	Beard RL, Colon DF, Klein ES, Vorse KA, Chandraratna RA
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1995	5	23	2801	2804		10.1016/0960-894X(95)00489-G	Chemoenzymatic synthesis of enantiomers of a new retinoid to investigate the role of chirality in the biological response	Charpentier B, Bernardon J, Diaz P, Vion M, Millois C, Bernard B, Shroot B
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1995	5	5	523	527		10.1016/0960-894X(95)00065-2	Synthesis and pharmacological activity of conformationally restricted, acetylenic retinoid analogs	Chandraratna RA, Gillett SJ, Song TK, Attard J, Vuligonda S, Garst ME, Arefieg T, Gil DW, Wheeler L
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	12	2411	2421	8691435	10.1021/jm9502293	Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.	Yu KL, Spinazze P, Ostrowski J, Currier SJ, Pack EJ, Hammer L, Roalsvig T, Honeyman JA, Tortolani DR, Reczek PR, Mansuri MM, Starrett JE.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	14	2659	2663	8709094	10.1021/jm960285j	Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.	Zhang L, Nadzan AM, Heyman RA, Love DL, Mais DE, Croston G, Lamph WW, Boehm MF.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	16	3035	3038	8759622	10.1021/jm9603532	Identification of a retinoic acid receptor alpha subtype specific agonist.	Teng M, Duong TT, Klein ES, Pino ME, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	18	3556	3563	8784454	10.1021/jm960386h	Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.	Beard RL, Colon DF, Song TK, Davies PJ, Kochhar DM, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	19	3625	3635	8809153	10.1021/jm9603126	Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.	Muccio DD, Brouillette WJ, Alam M, Vaezi MF, Sani BP, Venepally P, Reddy L, Li E, Norris AW, Simpson-Herren L, Hill DL.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1996	39	26	5027	5030	8978832	10.1021/jm960687r	Identification of retinoic acid receptor beta subtype specific agonists.	Johnson AT, Klein ES, Wang L, Pino ME, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1996	6	2	213	218		10.1016/0960-894X(95)00588-K	Synthesis of highly potent RXR-specific retinoids: The use of a cyclopropyl group as a double bond isostere	Vuligonda V, Lin Y, Chandraratna RA
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1997	40	16	2445	2451	9258350	10.1021/jm9703911	Identification of highly potent retinoic acid receptor alpha-selective antagonists.	Teng M, Duong TT, Johnson AT, Klein ES, Wang L, Khalifa B, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1997	40	23	3851	3857	9371251	10.1021/jm9602322	Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.	Manfredini S, Simoni D, Ferroni R, Bazzanini R, Vertuani S, Hatse S, Balzarini J, De Clercq E.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1997	40	26	4222	4234	9435893	10.1021/jm9704309	Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.	Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, Gronemeyer H, Hashimoto Y, Shudo K, Kagechika H.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1997	7	17	2313	2318		10.1016/S0960-894X(97)00420-4	Synthesis and receptor binding affinity of conformationally restricted retinoic acid analogues	Wong MF, Repa JJ, Clagett-Dame M, Curley RW
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1997	7	18	2373	2378		10.1016/S0960-894X(97)00435-6	Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid	Beard RL, Teng M, Colon DF, Duong TT, Thacher SM, Arefieg T, Chandraratna RA
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Arch. Biochem. Biophys.	1998	350	1	340	347	9473310	10.1006/abbi.1997.0537	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Schuetz EG, Yasuda K, Arimori K, Schuetz JD.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1998	41	10	1679	1687	9572893	10.1021/jm970635h	Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.	Muccio DD, Brouillette WJ, Breitman TR, Taimi M, Emanuel PD, Zhang X, Chen G, Sani BP, Venepally P, Reddy L, Alam M, Simpson-Herren L, Hill DL.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1998	41	16	3062	3077	9685246	10.1021/jm9801354	Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates with retinoidal activity.	Jones P, Villeneuve GB, Fei C, DeMarte J, Haggarty AJ, Nwe KT, Martin DA, Lebuis AM, Finkelstein JM, Gour-Salin BJ, Chan TH, Leyland-Jones BR.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1998	41	17	3245	3252	9703470	10.1021/jm980058c	Syntheses and structure-activity relationships of novel retinoid X receptor agonists.	Hibi S, Kikuchi K, Yoshimura H, Nagai M, Tai K, Hida T.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	1999	42	24	4961	4969	10585206	10.1021/jm991059n	Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.	Simoni D, Invidiata FP, Rondanin R, Grimaudo S, Cannizzo G, Barbusca E, Porretto F, D'Alessandro N, Tolomeo M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1999	9	4	573	576	10098666	10.1016/s0960-894x(99)00047-5	High affinity retinoic acid receptor antagonists: analogs of AGN 193109.	Johnson AT, Wang L, Gillett SJ, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	1999	9	4	589	594	10098670	10.1016/s0960-894x(99)00048-7	Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.	Vuligonda V, Garst ME, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2000	10	12	1307	1310	10890152	10.1016/s0960-894x(00)00243-2	sp2-bridged diaryl retinoids: effects of bridge-region substitution on retinoid X receptor (RXR) selectivity.	Dawson MI, Hobbs PD, Jong L, Xiao D, Chao WR, Pan C, Zhang XK.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2000	10	12	1311	1313	10890153	10.1016/s0960-894x(00)00244-4	4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.	Dawson MI, Jong L, Hobbs PD, Xiao D, Feng KC, Chao WR, Pan C, Fontana JA, Zhang XK.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2000	10	23	2669	2673	11128648	10.1016/s0960-894x(00)00547-3	Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells.	Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Dusonchet L, Meli M, Raimondi MV, D'Alessandro N, Tolomeo M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2000	10	7	619	622	10762038	10.1016/s0960-894x(00)00066-4	Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.	Kikuchi K, Hibi S, Yoshimura H, Tai K, Hida T, Tokuhara N, Yamauchi T, Nagai M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2000	10	7	623	625	10762039	10.1016/s0960-894x(00)00067-6	Syntheses and evaluation of naphthalenyl- and chromenyl-pyrrolyl-benzoic acids as potent and selective retinoic acid receptor alpha agonists.	Hibi S, Tagami K, Kikuchi K, Yoshimura H, Tai K, Hida T, Tokuhara N, Yamauchi T, Nagai M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2000	43	15	2929	2937	10956201	10.1021/jm000098s	Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.	Yoshimura H, Kikuchi K, Hibi S, Tagami K, Satoh T, Yamauchi T, Ishibahi A, Tai K, Hida T, Tokuhara N, Nagai M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2000	43	15	2962	2966	10956204	10.1021/jm990540a	Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.	Nudelman A, Rephaeli A.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2001	11	10	1307	1311	11392543	10.1016/s0960-894x(01)00204-9	Structure-Activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei.	Endo Y, Iijima T, Yaguchi K, Kawachi E, Inoue N, Kagechika H, Kubo A, Itai A.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2001	11	12	1583	1586	11412986	10.1016/s0960-894x(01)00230-x	An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.	Weiss KL, Alshafie G, Chapman JS, Mershon SM, Abou-Issa H, Clagett-Dame M, Curley RW.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2001	11	6	765	768	11277515	10.1016/s0960-894x(01)00058-0	Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.	Beard RL, Klein ES, Standeven AM, Escobar M, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2001	44	14	2308	2318	11428925	10.1021/jm0010320	Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells.	Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Capone F, Dusonchet L, Meli M, Raimondi MV, Landino M, D'Alessandro N, Tolomeo M, Arindam D, Lu S, Benbrook DM.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2002	12	13	1747	1750	12067552	10.1016/s0960-894x(02)00255-x	A library construction of 2,5-disubstituted pyrrole compounds by using solid/solution-phase syntheses.	Kobayashi N, Kaku Y, Higurashi K, Yamauchi T, Ishibashi A, Okamoto Y.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2002	12	17	2447	2450	12161154	10.1016/s0960-894x(02)00427-4	An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.	Walker JR, Alshafie G, Abou-Issa H, Curley RW.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2002	12	21	3145	3148	12372520	10.1016/s0960-894x(02)00647-9	Synthesis and biological activity of retinoic acid receptor-alpha specific amides.	Beard RL, Duong TT, Teng M, Klein ES, Standevan AM, Chandraratna RA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2003	13	2	261	264	12482435	10.1016/s0960-894x(02)00924-1	Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.	Farmer LJ, Zhi L, Jeong S, Lamph WW, Osburn DL, Croston G, Flatten KS, Heyman RA, Nadzan AM.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2003	46	10	1931	1939	12723955	10.1021/jm020324t	Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.	Shealy YF, Riordan JM, Frye JL, Simpson-Herren L, Sani BP, Hill DL.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2004	14	16	4131	4134	15261256	10.1016/j.bmcl.2004.06.038	Design and synthesis of cyclic urea compounds: a pharmacological study for retinoidal activity.	Kurihara M, Rouf AS, Kansui H, Kagechika H, Okuda H, Miyata N.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2004	14	16	4257	4261	15261282	10.1016/j.bmcl.2004.06.002	Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.	Ivanova D, Rossin A, Gronemeyer H, Valla A, Cartier D, Le Guillou R, Labia R.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2004	47	27	6716	6729	15615521	10.1021/jm0401457	Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.	Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2005	15	13	3212	3215	15936192	10.1016/j.bmcl.2005.05.005	Cell differentiation inducers derived from thalidomide.	Noguchi T, Miyachi H, Katayama R, Naito M, Hashimoto Y.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2005	48	20	6212	6219	16190748	10.1021/jm050285w	Ligand recognition by RAR and RXR receptors: binding and selectivity.	Sussman F, de Lera AR.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2005	48	24	7517	7519	16302793	10.1021/jm050891r	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.	Lund BW, Piu F, Gauthier NK, Eeg A, Currier E, Sherbukhin V, Brann MR, Hacksell U, Olsson R.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2006	16	10	2729	2733	16504501	10.1016/j.bmcl.2006.02.020	3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.	Mulvihill MJ, Kan JL, Cooke A, Bhagwat S, Beck P, Bittner M, Cesario C, Keane D, Lazarescu V, Nigro A, Nillson C, Panicker B, Smith V, Srebernak M, Sun FL, O'Connor M, Russo S, Fischetti G, Vrkljan M, Winski S, Castelhano AL, Emerson D, Gibson NW.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Nat. Chem. Biol.	2006	2	6	329	337	16680159	10.1038/nchembio790	Identifying off-target effects and hidden phenotypes of drugs in human cells.	MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	2006	69	1	38	42	16441065	10.1021/np058080d	Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.	Akihisa T, Tokuda H, Hasegawa D, Ukiya M, Kimura Y, Enjo F, Suzuki T, Nishino H.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2007	15	2	847	853	17092729	10.1016/j.bmc.2006.10.042	Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.	Ohba T, Yamauch T, Higashiyama K, Takahashi N.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2007	17	15	4218	4222	17560107	10.1016/j.bmcl.2007.05.037	Dual bioactivity of resveratrol fatty alcohols: differentiation of neural stem cells and modulation of neuroinflammation.	Hauss F, Liu J, Michelucci A, Coowar D, Morga E, Heuschling P, Luu B.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2007	50	11	2622	2639	17489579	10.1021/jm0613323	An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.	Dawson MI, Xia Z, Liu G, Ye M, Fontana JA, Farhana L, Patel BB, Arumugarajah S, Bhuiyan M, Zhang XK, Han YH, Stallcup WB, Fukushi J, Mustelin T, Tautz L, Su Y, Harris DL, Waleh N, Hobbs PD, Jong L, Chao WR, Schiff LJ, Sani BP.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Antimicrob. Agents Chemother.	2007	51	7	2403	2411	17485504	10.1128/aac.01184-06	Amiodarone and bepridil inhibit anthrax toxin entry into host cells.	Sanchez AM, Thomas D, Gillespie EJ, Damoiseaux R, Rogers J, Saxe JP, Huang J, Manchester M, Bradley KA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	2007	70	6	918	922	17503850	10.1021/np068044u	Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.	Kikuchi T, Akihisa T, Tokuda H, Ukiya M, Watanabe K, Nishino H.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	2007	70	8	1329	1334	17663584	10.1021/np070135j	Panaxadiol glycosides that induce neuronal differentiation in neurosphere stem cells.	Liu JW, Tian SJ, de Barry J, Luu B.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2008	16	12	6387	6393	18511283	10.1016/j.bmc.2008.05.005	Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.	Kim H, Kim B, Kim H, Um S, Lee J, Ryoo H, Jung H.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2008	16	2	732	738	18029185	10.1016/j.bmc.2007.10.036	Biflavonoids isolated from Selaginella tamariscina regulate the expression of matrix metalloproteinase in human skin fibroblasts.	Lee CW, Choi HJ, Kim HS, Kim DH, Chang IS, Moon HT, Lee SY, Oh WK, Woo ER.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2008	18	13	3805	3808	18515102	10.1016/j.bmcl.2008.05.021	Design and synthesis of 4-HPR derivatives for rhabdoid tumors.	Das BC, Smith ME, Kalpana GV.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2008	51	13	3895	3904	18543902	10.1021/jm8001839	Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.	Gediya LK, Khandelwal A, Patel J, Belosay A, Sabnis G, Mehta J, Purushottamachar P, Njar VC.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2008	51	18	5650	5662	18759424	10.1021/jm800456k	Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.	Dawson MI, Xia Z, Jiang T, Ye M, Fontana JA, Farhana L, Patel B, Xue LP, Bhuiyan M, Pellicciari R, Macchiarulo A, Nuti R, Zhang XK, Han YH, Tautz L, Hobbs PD, Jong L, Waleh N, Chao WR, Feng GS, Pang Y, Su Y.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2009	19	2	489	492	19058965	10.1016/j.bmcl.2008.11.040	Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.	Charton J, Deprez-Poulain R, Hennuyer N, Tailleux A, Staels B, Deprez B.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2009	19	2	508	512	19036585	10.1016/j.bmcl.2008.11.028	Synthesis and in vitro biological activity of retinyl polyhydroxybenzoates, novel hybrid retinoid derivatives.	Kim S, Kim Y, Kong Y, Kim H, Kang J.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2009	44	6	2689	2695	19216007	10.1016/j.ejmech.2009.01.001	Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity.	Magoulas G, Papaioannou D, Papadimou E, Drainas D.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2009	44	8	3175	3187	19375825	10.1016/j.ejmech.2009.03.029	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth.	Sadikoglou E, Magoulas G, Theodoropoulou C, Athanassopoulos CM, Giannopoulou E, Theodorakopoulou O, Drainas D, Papaioannou D, Papadimitriou E.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Nat. Chem. Biol.	2009	5	10	765	771	19734910	10.1038/nchembio.215	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.	Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J, Austin CP, Su XZ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2009	52	23	7765	7777	19821610	10.1021/jm901063e	Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases.	de Medina P, Paillasse MR, Payré B, Silvente-Poirot S, Poirot M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2009	52	6	1540	1545	19239230	10.1021/jm801532e	Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.	Lund BW, Knapp AE, Piu F, Gauthier NK, Begtrup M, Hacksell U, Olsson R.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2010	18	23	8204	8217	21041094	10.1016/j.bmc.2010.10.012	Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?	Hadjipavlou-Litina D, Magoulas GE, Bariamis SE, Drainas D, Avgoustakis K, Papaioannou D.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2010	53	12	4654	4667	20491440	10.1021/jm100244y	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.	Souto JA, Vaz E, Lepore I, Pöppler AC, Franci G, Alvarez R, Altucci L, de Lera AR.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2010	53	9	3566	3584	20373811	10.1021/jm901846t	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?	Avdeef A, Tam KY.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2010	53	9	3782	3792	20405849	10.1021/jm100190c	Liposomal formulation of retinoids designed for enzyme triggered release.	Pedersen PJ, Adolph SK, Subramanian AK, Arouri A, Andresen TL, Mouritsen OG, Madsen R, Madsen MW, Peters GH, Clausen MH.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2011	46	2	468	479	21183258	10.1016/j.ejmech.2010.11.021	Synthesis and effects of some novel tetrahydronaphthalene derivatives on proliferation and nitric oxide production in lipopolysaccharide activated Raw 264.7 macrophages.	Gurkan AS, Karabay AZ, Buyukbingol Z, Buyukbingol E.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2011	46	2	721	737	21208698	10.1016/j.ejmech.2010.12.008	Syntheses, antiproliferative activity and theoretical characterization of acitretin-type retinoids with changes in the lipophilic part.	Magoulas GE, Bariamis SE, Athanassopoulos CM, Haskopoulos A, Dedes PG, Krokidis MG, Karamanos NK, Kletsas D, Papaioannou D, Maroulis G.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2011	54	11	3793	3816	21548569	10.1021/jm200051z	Heteroatom-substituted analogues of orphan nuclear receptor small heterodimer partner ligand and apoptosis inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid.	Xia Z, Farhana L, Correa RG, Das JK, Castro DJ, Yu J, Oshima RG, Reed JC, Fontana JA, Dawson MI.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2012	20	15	4646	4652	22766217	10.1016/j.bmc.2012.06.017	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBP¿.	Klausmeyer P, McCloud TG, Scudiero DA, Currens MJ, Cardellina Ii JH, Shoemaker RH.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2012	20	22	6669	6679	23062825	10.1016/j.bmc.2012.09.040	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.	Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C, Vuorela P.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2012	20	8	2520	2526	22440084	10.1016/j.bmc.2012.02.060	Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma.	Imai M, Takahashi N.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2012	22	13	4453	4457	22658364	10.1016/j.bmcl.2012.04.134	Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist.	Itoh Y, Ishikawa M, Kitaguchi R, Okuhira K, Naito M, Hashimoto Y.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2012	22	24	7641	7646	23122865	10.1016/j.bmcl.2012.10.010	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.	Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2012	48		114	123	22197381	10.1016/j.ejmech.2011.12.002	Binding sites of retinol and retinoic acid with serum albumins.	Belatik A, Hotchandani S, Bariyanga J, Tajmir-Riahi HA.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2013	21	14	4342	4350	23685180	10.1016/j.bmc.2013.04.053	Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures.	Amano Y, Noguchi M, Nakagomi M, Muratake H, Fukasawa H, Shudo K.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2013	21	19	6015	6021	23953690	10.1016/j.bmc.2013.07.039	Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.	Takahashi N, Takeda K, Imai M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	MedChemComm	2013	4	5	764	776		10.1039/C3MD00005B	Synthetic modulators of the retinoic acid receptor-related orphan receptors	Kamenecka TM, Lyda B, Chang MR, Griffin PR
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2013	56	22	9110	9121	24147937	10.1021/jm401061w	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.	Cotrina EY, Pinto M, Bosch L, Vilà M, Blasi D, Quintana J, Centeno NB, Arsequell G, Planas A, Valencia G.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2013	70		857	863	24262378	10.1016/j.ejmech.2013.09.057	Azetidinone-retinoid hybrids: synthesis and differentiative effects.	Pori M, Galletti P, Soldati R, Calzà L, Mangano C, Giacomini D.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Nat. Prod.	2013	76	1	29	35	23268742	10.1021/np300614u	Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities.	Pesca MS, Dal Piaz F, Sanogo R, Vassallo A, Bruzual de Abreu M, Rapisarda A, Germanò MP, Certo G, De Falco S, De Tommasi N, Braca A.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2014	22	12	3204	3212	24799257	10.1016/j.bmc.2014.03.047	Retinoic acid receptor agonist activity of naturally occurring diterpenes.	Tanabe H, Yasui T, Kotani H, Nagatsu A, Makishima M, Amagaya S, Inoue M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2014	22	15	3994	4000	24972725	10.1016/j.bmc.2014.05.073	Effect of p-aminophenols on tyrosinase activity.	Komori Y, Imai M, Yamauchi T, Higashiyama K, Takahashi N.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2014	22	17	4677	4683	25126713	10.1016/j.bmc.2014.07.016	Inhibitory effects of p-alkylaminophenol on melanogenesis.	Takahashi N, Imai M, Komori Y.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2014	22	4	1285	1302	24457093	10.1016/j.bmc.2014.01.006	Inhibition of I¿B kinase-ß and I¿B kinase-¿ by heterocyclic adamantyl arotinoids.	García-Rodríguez J, Pérez-Rodríguez S, Ortiz MA, Pereira R, de Lera AR, Piedrafita FJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2014	24	22	5265	5267	25305688	10.1016/j.bmcl.2014.09.053	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.	Gege C, Schlüter T, Hoffmann T.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2014	24	4	1080	1084	24468412	10.1016/j.bmcl.2014.01.014	Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.	Shea TA, Burburan PJ, Matubia VN, Ramcharan SS, Rosario I, Parkin DW, Stockman BJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2014	57	14	5871	5892	24502334	10.1021/jm401901d	Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc).	Fauber BP, Magnuson S.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2014	57	19	7990	7998	25244355	10.1021/jm500863j	Development of a novel class of mitochondrial ubiquinol-cytochrome c reductase binding protein (UQCRB) modulators as promising antiangiogenic leads.	Jung HJ, Cho M, Kim Y, Han G, Kwon HJ.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2015	23	20	6763	6773	26365710	10.1016/j.bmc.2015.08.019	Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.	Sun B, Liu K, Han J, Zhao LY, Su X, Lin B, Zhao DM, Cheng MS.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem.	2015	23	6	1356	1365	25684424	10.1016/j.bmc.2014.11.036	Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).	Zhao D, Sun B, Ren J, Li F, Song S, Lv X, Hao C, Cheng M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2015	25	6	1301	1305	25701251	10.1016/j.bmcl.2015.01.042	Synthesis and evaluation of the diarylthiourea analogs as novel anti-cancer agents.	Liu S, Louie MC, Rajagopalan V, Zhou G, Ponce E, Nguyen T, Green L.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2015	25	9	1998	2001	25838141	10.1016/j.bmcl.2015.02.075	Xanthones from the roots of Maclura cochinchinensis var. gerontogea and their retinoic acid receptor-¿ agonistic activity.	Nakashima K, Tanaka T, Murata H, Kaburagi K, Inoue M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	J. Med. Chem.	2015	58	4	1900	1914	25634130	10.1021/jm501792c	Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.	Mbatia HW, Ramalingam S, Ramamurthy VP, Martin MS, Kwegyir-Afful AK, Njar VC.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Eur. J. Med. Chem.	2015	98		30	48	26005022	10.1016/j.ejmech.2015.05.012	Synthesis and antiproliferative activity of ¿-branched ¿,ß-unsaturated ketones in human hematological and solid cancer cell lines.	Karpavi¿ien¿ I, Valiulien¿ G, Ra¿kevi¿ius V, Lebedyt¿ I, Bruk¿tus A, Kairys V, Navakauskien¿ R, ¿ikotien¿ I.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg. Med. Chem. Lett.	2016	26	4	1145	1150	26832215	10.1016/j.bmcl.2016.01.048	Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.	Stoica S, Magoulas GE, Antoniou AI, Suleiman S, Cassar A, Gatt L, Papaioannou D, Athanassopoulos CM, Schembri-Wismayer P.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38	Bioorg Med Chem Lett	2017	27	20	4664	4672	28927789	10.1016/j.bmcl.2017.09.005	Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.	Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M.
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38								10.6019/CHEMBL1201861	Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									British National Formulary (72nd edition)	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									DailyMed|setid=d3c528d2-429d-4f37-9ebf-eee8b9fd3050 | TRENTINOIN - tretinoin gel| Oceanside Pharmaceuticals	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									DrugMatrix	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									PubChem BioAssay data set	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									Unpublished dataset	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
847.5000000000000000	9606	Homo sapiens	TRETINOIN	CHEMBL38									WHO Anatomical Therapeutic Chemical Classification	
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245	Bioorg. Med. Chem. Lett.	1992	2	5	491	496		10.1016/S0960-894X(00)80176-6	Structure/activity relationships among photosensitizers related to pheophorbides and bacteriopheophorbides	Pandey RK, Shiau F, Sumlin AB, Dougherty TJ, Smith KM
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245	J Pesticide Sci	1995	20	1	57	64		10.1584/jpestics.20.57	Pharmacological Characteristics of Insect Nicotinic Acetyicholine Receptor with Its Ion Channel and the Comparison of the Effect of Nicotinoids and Neonicotinoids	TOMIZAWA M, OTSUKA H, MIYAMOTO T, ELDEFRAWI ME, YAMAMOTO I
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245	J. Med. Chem.	2002	45	2	449	461	11784149	10.1021/jm0103662	Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. II. Effects of core heteroatoms and meso-substituents on biological activity.	Hilmey DG, Abe M, Nelen MI, Stilts CE, Baker GA, Baker SN, Bright FV, Davies SR, Gollnick SO, Oseroff AR, Gibson SL, Hilf R, Detty MR.
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245									British National Formulary (72nd edition)	
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245									Unpublished dataset	
931.8000000000000000	9606	Homo sapiens	TRIMETHAPHAN CAMSYLATE	CHEMBL1245									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1128.9500000000000000	9606	Homo sapiens	ULIXERTINIB	CHEMBL3545022	Bioorg. Med. Chem. Lett.	2015	25	19	4047	4056	26298497	10.1016/j.bmcl.2015.07.093	Recent progress on MAP kinase pathway inhibitors.	Uehling DE, Harris PA.
1128.9500000000000000	9606	Homo sapiens	ULIXERTINIB	CHEMBL3545022									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2000	43	5	775	777	10715145	10.1021/jm990577v	4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.	Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2000	43	9	1661	1663	10794682	10.1021/jm000069h	N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.	Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2001	44	20	3223	3230	11563921	10.1021/jm0101343	Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.	Chavatte P, Yous S, Marot C, Baurin N, Lesieur D.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2004	14	14	3757	3762	15203157	10.1016/j.bmcl.2004.04.106	Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.	Lehtonen JM, Parkkila S, Vullo D, Casini A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2004	14	2	337	341	14698154	10.1016/j.bmcl.2003.11.014	Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.	Abbate F, Coetzee A, Casini A, Ciattini S, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2004	14	21	5445	5448	15454242	10.1016/j.bmcl.2004.07.089	Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.	Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S, Wiseman J.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2004	14	24	6001	6006	15546717	10.1016/j.bmcl.2004.09.085	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.	Zimmerman S, Innocenti A, Casini A, Ferry JG, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2004	47	20	4881	4890	15369392	10.1021/jm040782x	Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.	Di Nunno L, Vitale P, Scilimati A, Tacconelli S, Patrignani P.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2004	47	3	550	557	14736236	10.1021/jm030912m	Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.	Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2004	47	4	792	804	14761182	10.1021/jm020545z	In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.	Shin SS, Byun Y, Lim KM, Choi JK, Lee KW, Moh JH, Kim JK, Jeong YS, Kim JY, Choi YH, Koh HJ, Park YH, Oh YI, Noh MS, Chung S.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2004	47	9	2180	2193	15084117	10.1021/jm030276s	Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.	Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schroeder JD, Shumway MJ, Tam SW, Trocha AM, Young DV.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2005	15	21	4699	4702	16153836	10.1016/j.bmcl.2005.07.065	Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography.	Toyokuni T, Kumar JS, Walsh JC, Shapiro A, Talley JJ, Phelps ME, Herschman HR, Barrio JR, Satyamurthy N.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2005	15	4	1149	1154	15686931	10.1016/j.bmcl.2004.12.009	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.	Innocenti A, Firnges MA, Antel J, Wurl M, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2006	16	2	437	442	16290146	10.1016/j.bmcl.2005.09.040	"Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ""selective"" inhibitor celecoxib."	Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Nat. Chem. Biol.	2006	2	6	329	337	16680159	10.1038/nchembio790	Identifying off-target effects and hidden phenotypes of drugs in human cells.	MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2007	15	23	7229	7236	17826101	10.1016/j.bmc.2007.08.037	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.	Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2008	16	9	5322	5330	18353655	10.1016/j.bmc.2008.02.088	Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib.	Erdélyi P, Fodor T, Varga AK, Czugler M, Gere A, Fischer J.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2008	51	1	142	147	18072726	10.1021/jm070821f	New celecoxib derivatives as anti-inflammatory agents.	Szabó G, Fischer J, Kis-Varga A, Gyires K.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2008	51	15	4476	4481	18598017	10.1021/jm800084s	Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity.	Anzini M, Rovini M, Cappelli A, Vomero S, Manetti F, Botta M, Sautebin L, Rossi A, Pergola C, Ghelardini C, Norcini M, Giordani A, Makovec F, Anzellotti P, Patrignani P, Biava M.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2009	17	13	4503	4509	19450983	10.1016/j.bmc.2009.05.002	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.	Innocenti A, Hall RA, Schlicker C, Scozzafava A, Steegborn C, Mühlschlegel FA, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2009	17	14	5054	5058	19520577	10.1016/j.bmc.2009.05.063	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.	Bertucci A, Innocenti A, Zoccola D, Scozzafava A, Tambutté S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2009	17	3	1158	1163	19124253	10.1016/j.bmc.2008.12.035	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.	Isik S, Kockar F, Aydin M, Arslan O, Guler OO, Innocenti A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2009	19	15	4504	4508	19520573	10.1016/j.bmcl.2009.02.085	Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.	Swarbrick ME, Beswick PJ, Gleave RJ, Green RH, Bingham S, Bountra C, Carter MC, Chambers LJ, Chessell IP, Clayton NM, Collins SD, Corfield JA, Hartley CD, Kleanthous S, Lambeth PF, Lucas FS, Mathews N, Naylor A, Page LW, Payne JJ, Pegg NA, Price HS, Skidmore J, Stevens AJ, Stocker R, Stratton SC, Stuart AJ, Wiseman JO.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2009	19	23	6649	6654	19846301	10.1016/j.bmcl.2009.10.009	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.	Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2009	52	3	646	654	19193158	10.1021/jm801267c	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.	Hilvo M, Salzano AM, Innocenti A, Kulomaa MS, Scozzafava A, Scaloni A, Parkkila S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2009	52	8	2226	2232	19317447	10.1021/jm9000488	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.	Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2009	52	9	3116	3120	19338333	10.1021/jm9003126	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.	Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2010	53	5	2277	2285	20158185	10.1021/jm901855h	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.	Joseph P, Turtaut F, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Köhler S, Winum JY, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2010	53	5	2286	2298	20143779	10.1021/jm901891p	Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.	Onnis V, Congiu C, Björklund E, Hempel F, Söderström E, Fowler CJ.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2011	19	11	3299	3311	21570308	10.1016/j.bmc.2011.04.050	Synthesis and biological evaluation of loxoprofen derivatives.	Yamakawa N, Suemasu S, Matoyama M, Tanaka K, Katsu T, Miyata K, Okamoto Y, Otsuka M, Mizushima T.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2011	19	16	5023	5030	21757360	10.1016/j.bmc.2011.06.038	Inhibition studies of the ß-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.	Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2011	19	3	1172	1178	21251841	10.1016/j.bmc.2010.12.048	A new ß-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.	Joseph P, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Winum JY, Köhler S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2011	21	19	5892	5896	21852133	10.1016/j.bmcl.2011.07.090	Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.	Knaus EE, Innocenti A, Scozzafava A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2011	21	2	710	714	21208801	10.1016/j.bmcl.2010.11.124	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.	Bertucci A, Innocenti A, Scozzafava A, Tambutté S, Zoccola D, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2012	20	4	1403	1410	22285172	10.1016/j.bmc.2012.01.007	Cloning, characterization and sulfonamide inhibition studies of an ¿-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.	Ohradanova A, Vullo D, Pastorekova S, Pastorek J, Jackson DJ, Wörheide G, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2012	55	22	9619	9629	23067387	10.1021/jm300878g	Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit ¿- and ß-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms.	Marini AM, Maresca A, Aggarwal M, Orlandini E, Nencetti S, Da Settimo F, Salerno S, Simorini F, La Motta C, Taliani S, Nuti E, Scozzafava A, McKenna R, Rossello A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2012	55	23	10742	10748	23181552	10.1021/jm301611m	DNA cloning, characterization, and inhibition studies of an ¿-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Isik S, Vullo D, De Luca V, Carginale V, Scozzafava A, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2012	55	7	3513	3520	22424239	10.1021/jm300203r	Molecular cloning, characterization, and inhibition studies of a ß-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.	Hewitson KS, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2013	21	17	5168	5174	23867389	10.1016/j.bmc.2013.06.035	Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.	Sethi KK, Verma SM, Tanç M, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2013	21	19	5973	5982	23965175	10.1016/j.bmc.2013.07.044	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.	Sethi KK, Vullo D, Verma SM, Tanç M, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2013	21	6	1534	1538	22883029	10.1016/j.bmc.2012.07.024	The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.	Vullo D, Luca VD, Scozzafava A, Carginale V, Rossi M, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2013	23	9	2647	2652	23511020	10.1016/j.bmcl.2013.02.092	Carbonic anhydrase inhibitors: inhibition of the ß-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.	Vullo D, Leewattanapasuk W, Mühlschlegel FA, Mastrolorenzo A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Drug Metab. Dispos.	2013	41	5	933	951	23454828	10.1124/dmd.112.050278	Which metabolites circulate?	Loi CM, Smith DA, Dalvie D.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2013	56	18	7372	7381	23977960	10.1021/jm400939k	Cloning, characterization, and inhibition studies of a ß-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.	Syrjänen L, Vermelho AB, Rodrigues Ide A, Corte-Real S, Salonen T, Pan P, Vullo D, Parkkila S, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	J. Med. Chem.	2013	56	4	1761	1771	23391336	10.1021/jm4000616	Cloning, characterization, and sulfonamide and thiol inhibition studies of an ¿-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.	Pan P, Vermelho AB, Capaci Rodrigues G, Scozzafava A, Tolvanen ME, Parkkila S, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2014	22	11	2939	2946	24792813	10.1016/j.bmc.2014.04.006	Sulfonamide inhibition studies of two ß-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.	Nishimori I, Vullo D, Minakuchi T, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2014	22	17	4537	4543	25129169	10.1016/j.bmc.2014.07.048	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the ß-class (PgiCAb) versus the ¿-class (PgiCA) enzymes.	Prete SD, Vullo D, Osman SM, Scozzafava A, AlOthman Z, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2014	22	5	1586	1595	24513184	10.1016/j.bmc.2014.01.031	Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.	Sethi KK, Verma SM, Tanç M, Purper G, Calafato G, Carta F, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2014	24	1	240	244	24316122	10.1016/j.bmcl.2013.11.030	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.	Vullo D, Del Prete S, Osman SM, De Luca V, Scozzafava A, Alothman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2014	24	1	275	279	24314394	10.1016/j.bmcl.2013.11.021	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the diatom Thalassiosira weissflogii.	Vullo D, Del Prete S, Osman SM, De Luca V, Scozzafava A, Alothman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Eur. J. Med. Chem.	2014	71		105	111	24287559	10.1016/j.ejmech.2013.10.071	Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.	De Luca L, Ferro S, Damiano FM, Supuran CT, Vullo D, Chimirri A, Gitto R.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2015	23	10	2303	2309	25882523	10.1016/j.bmc.2015.03.081	The ß-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.	Syrjänen L, Kuuslahti M, Tolvanen M, Vullo D, Parkkila S, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2015	23	3	526	531	25533402	10.1016/j.bmc.2014.12.009	Sulfonamide inhibition studies of the ¿-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.	Vullo D, Del Prete S, Fisher GM, Andrews KT, Poulsen SA, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2015	23	8	1728	1734	25773015	10.1016/j.bmc.2015.02.045	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2015	25	11	2291	2297	25913199	10.1016/j.bmcl.2015.04.037	Sulfonamide inhibition study of the ß-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.	Dedeoglu N, DeLuca V, Isik S, Yildirim H, Kockar F, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2015	25	17	3550	3555	26174556	10.1016/j.bmcl.2015.06.079	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2015	25	23	5485	5489	26525863	10.1016/j.bmcl.2015.10.074	Anion and sulfonamide inhibition studies of an ¿-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.	Cincinelli A, Martellini T, Vullo D, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem.	2016	24	5	1115	1120	26850377	10.1016/j.bmc.2016.01.037	Sulfonamide inhibition studies of the ß-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Vullo D, De Luca V, Carginale V, Ferraroni M, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2016	26	2	401	405	26691758	10.1016/j.bmcl.2015.11.104	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.	Vullo D, Bhatt A, Mahon BP, McKenna R, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2016	26	4	1253	1259	26832216	10.1016/j.bmcl.2016.01.023	Sulfonamide inhibition studies of the ¿-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.	Vullo D, De Luca V, Del Prete S, Carginale V, Scozzafava A, Osman SM, AlOthman Z, Capasso C, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2016	26	7	1821	1826	26920803	10.1016/j.bmcl.2016.02.032	Sulfonamide inhibition studies of the ß-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.	Emino¿lu A, Vullo D, A¿¿k A, Çolak DN, Çanakç¿ S, Beldüz AO, Supuran CT.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg. Med. Chem. Lett.	2016	26	8	1941	1946	26972117	10.1016/j.bmcl.2016.03.014	Comparison of the sulfonamide inhibition profiles of the ¿-, ß- and ¿-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.	Del Prete S, Vullo D, De Luca V, Carginale V, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg Med Chem	2017	25	13	3555	3561	28511911	10.1016/j.bmc.2017.05.007	Sulfonamide inhibition profiles of the ß-carbonic anhydrase from the pathogenic bacterium Francisella tularensis responsible of the febrile illness tularemia.	Del Prete S, Vullo D, Osman SM, AlOthman Z, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865	Bioorg Med Chem Lett	2017	27	3	490	495	28025002	10.1016/j.bmcl.2016.12.035	Sulfonamide inhibition profile of the ¿-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.	Del Prete S, Vullo D, Di Fonzo P, Osman SM, AlOthman Z, Donald WA, Supuran CT, Capasso C.
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									British National Formulary (72nd edition)	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									DrugMatrix	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									PubChem BioAssay data set	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									Unpublished dataset	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
886.5000000000000000	9606	Homo sapiens	VALDECOXIB	CHEMBL865									WHO Anatomical Therapeutic Chemical Classification	
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2002	45	26	5687	5693	12477352	10.1021/jm020899q	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.	Manley PW, Furet P, Bold G, Brüggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A, Krüger M, Menrad A, Ottow E, Seidelmann D, Siemeister G, Thierauch KH.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2002	45	6	1300	1312	11881999	10.1021/jm011022e	Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.	Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Nat. Biotechnol.	2005	23	3	329	336	15711537	10.1038/nbt1068	A small molecule-kinase interaction map for clinical kinase inhibitors.	Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2005	48	24	7560	7581	16302797	10.1021/jm050559f	2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.	Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2005	48	5	1610	1619	15743202	10.1021/jm049538w	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.	Harris PA, Cheung M, Hunter RN, Brown ML, Veal JM, Nolte RT, Wang L, Liu W, Crosby RM, Johnson JH, Epperly AH, Kumar R, Luttrell DK, Stafford JA.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2006	16	18	4908	4912	16806916	10.1016/j.bmcl.2006.06.054	Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.	Ballard P, Bradbury RH, Harris CS, Hennequin LF, Hickinson M, Kettle JG, Kendrew J, Klinowska T, Ogilvie DJ, Pearson SE, Williams EJ, Wilson I.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2006	16	3	602	606	16275072	10.1016/j.bmcl.2005.10.058	N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.	Kiselyov AS, Piatnitski E, Semenova M, Semenov VV.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2006	16	5	1440	1444	16321531	10.1016/j.bmcl.2005.11.033	Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.	Kiselyov AS, Semenova M, Semenov VV, Piatnitski E, Ouyang S.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2006	16	6	1726	1730	16364640	10.1016/j.bmcl.2005.11.105	2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.	Kiselyov AS, Semenova M, Semenov VV, Piatnitski E.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2006	16	7	1913	1919	16460936	10.1016/j.bmcl.2005.12.090	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.	Kiselyov AS, Semenova M, Semenov VV, Milligan D.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem.	2007	15	11	3635	3648	17416531	10.1016/j.bmc.2007.03.055	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.	Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, Nittoli T, Ravi MR, Tan X, Loganzo F.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2007	17	5	1369	1375	17188873	10.1016/j.bmcl.2006.11.087	ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.	Kiselyov AS, Piatnitski EL, Samet AV, Kisliy VP, Semenov VV.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Proc. Natl. Acad. Sci. U.S.A.	2008	105	26	9059	9064	18579783	10.1073/pnas.0802982105	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.	Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrián F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2008	18	15	4344	4347	18640036	10.1016/j.bmcl.2008.06.083	Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.	Piatnitski Chekler EL, Katoch-Rouse R, Kiselyov AS, Sherman D, Ouyang X, Kim K, Wang Y, Hadari YR, Doody JF.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Nat. Biotechnol.	2008	26	1	127	132	18183025	10.1038/nbt1358	A quantitative analysis of kinase inhibitor selectivity.	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2008	51	15	4632	4640	18620382	10.1021/jm800566m	Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.	Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem.	2009	17	2	731	740	19101155	10.1016/j.bmc.2008.11.049	Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.	Duncton MA, Piatnitski Chekler EL, Katoch-Rouse R, Sherman D, Wong WC, Smith LM, Kawakami JK, Kiselyov AS, Milligan DL, Balagtas C, Hadari YR, Wang Y, Patel SN, Rolster RL, Tonra JR, Surguladze D, Mitelman S, Kussie P, Bohlen P, Doody JF.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2010	45	11	5420	5427	20869793	10.1016/j.ejmech.2010.09.002	Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.	Lee K, Jeong KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2010	45	7	2919	2927	20409618	10.1016/j.ejmech.2010.03.017	Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.	Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	MedChemComm	2011	2	1	65	72		10.1039/C0MD00183J	[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors	Garofalo A, Goossens L, Lemoine A, Ravez S, Six P, Howsam M, Farce A, Depreux P
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2011	21	7	2106	2112	21353546	10.1016/j.bmcl.2011.01.137	Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.	Garofalo A, Goossens L, Six P, Lemoine A, Ravez S, Farce A, Depreux P.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Nat. Biotechnol.	2011	29	11	1046	1051	22037378	10.1038/nbt.1990	Comprehensive analysis of kinase inhibitor selectivity.	Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2011	46	10	4887	4896	21862183	10.1016/j.ejmech.2011.07.045	Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.	Rajitha C, Dubey PK, Sunku V, Piedrafita FJ, Veeramaneni VR, Pal M.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2011	46	6	2043	2057	21429632	10.1016/j.ejmech.2011.02.057	Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.	Shallal HM, Russu WA.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2012	22	1	110	114	22169262	10.1016/j.bmcl.2011.11.061	Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.	Yu B, Tang LD, Li YL, Song SH, Ji XL, Lin MS, Wu CF.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2013	61		2	25	22749189	10.1016/j.ejmech.2012.06.005	Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.	Suárez RM, Chevot F, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V, Legraverend M.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2014	57	11	4598	4605	24801610	10.1021/jm500034j	Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors.	Marzaro G, Coluccia A, Ferrarese A, Brun P, Castagliuolo I, Conconi MT, La Regina G, Bai R, Silvestri R, Hamel E, Chilin A.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2014	86		714	723	25232968	10.1016/j.ejmech.2014.09.023	Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.	Frett B, Moccia M, Carlomagno F, Santoro M, Li HY.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2015	25	22	5137	5141	26475519	10.1016/j.bmcl.2015.10.006	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.	Peng FW, Wu TT, Ren ZW, Xue JY, Shi L.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J. Med. Chem.	2015	58	9	3672	3681	25625428	10.1021/jm501464c	Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.	Song M.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2016	107		165	179	26590508	10.1016/j.ejmech.2015.10.053	1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.	Abou-Seri SM, Eldehna WM, Ali MM, Abou El Ella DA.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2016	109		1	12	26741358	10.1016/j.ejmech.2015.12.033	Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.	Peng FW, Xuan J, Wu TT, Xue JY, Ren ZW, Liu DK, Wang XQ, Chen XH, Zhang JW, Xu YG, Shi L.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur. J. Med. Chem.	2016	112		20	32	26874741	10.1016/j.ejmech.2016.01.039	The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.	Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJ, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AI, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Bioorg. Med. Chem. Lett.	2016	26	9	2355	2359	26995527	10.1016/j.bmcl.2016.03.012	Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety.	Wang C, Xia G, Liu X, Zhang R, Chai Y, Zhang J, Li X, Yang Y, Wang J, Liu M.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	MedChemComm	2016	7	5	1007	1015		10.1039/C5MD00556F	Predictive proteochemometric models for kinases derived from 3D protein field-based descriptors	Subramanian V, Prusis P, Xhaard H, Wohlfahrt G
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Eur J Med Chem	2017	125		245	254	27688180	10.1016/j.ejmech.2016.09.039	Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.	Zhang HQ, Gong FH, Ye JQ, Zhang C, Yue XH, Li CG, Xu YG, Sun LP.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828	J Med Chem	2018	61	1	140	157	29189002	10.1021/acs.jmedchem.7b01091	Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.	Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828									British National Formulary (72nd edition)	
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828									PubChem BioAssay data set	
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828									Unpublished dataset	
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1104.6500000000000000	9606	Homo sapiens	VANDETANIB	CHEMBL24828									WHO Anatomical Therapeutic Chemical Classification	
867.7500000000000000	9606	Homo sapiens	VEROSUDIL	CHEMBL3545065	Bioorg. Med. Chem. Lett.	2016	26	10	2475	2480	27072905	10.1016/j.bmcl.2016.03.104	Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.	Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA.
867.7500000000000000	9606	Homo sapiens	VEROSUDIL	CHEMBL3545065									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	VEROSUDIL	CHEMBL3545065									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575	ACS Med. Chem. Lett.	2011	2	5	326	330	24900313	10.1021/ml1002234	Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.	Liu J, Li AR, Wang Y, Johnson MG, Su Y, Shen W, Wang X, Lively S, Brown M, Lai S, Gonzalez Lopez De Turiso F, Xu Q, Van Lengerich B, Schmitt M, Fu Z, Sun Y, Lawlis S, Seitz L, Danao J, Wait J, Ye Q, Tang HL, Grillo M, Collins TL, Sullivan TJ, Medina JC.
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575	J. Med. Chem.	2011	54	20	7299	7317	21916510	10.1021/jm200866y	Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.	Crosignani S, Prêtre A, Jorand-Lebrun C, Fraboulet G, Seenisamy J, Augustine JK, Missotten M, Humbert Y, Cleva C, Abla N, Daff H, Schott O, Schneider M, Burgat-Charvillon F, Rivron D, Hamernig I, Arrighi JF, Gaudet M, Zimmerli SC, Juillard P, Johnson Z.
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575	Drug Metab. Dispos.	2012	40	12	2239	2249	22930276	10.1124/dmd.112.047928	Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.	Foti RS, Pearson JT, Wong SL, Zalikowski JA, Boudreaux MD, Prokop SP, Davis JA, Banfield C, Emery MG, Rock DA, Wahlstrom JL, Wienkers LC, Amore BM.
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575									Unpublished dataset	
1273.9250000000000000	9606	Homo sapiens	VIDUPIPRANT	CHEMBL1951575									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1066.9727272727272727	1773	Mycobacterium tuberculosis	VIOMYCIN SULFATE	CHEMBL3989823									Unpublished dataset	
1066.9727272727272727	1773	Mycobacterium tuberculosis	VIOMYCIN SULFATE	CHEMBL3989823									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1033.7000000000000000	9606	Homo sapiens	WX-554	CHEMBL3545145									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Bioorg. Med. Chem. Lett.	2009	19	7	1960	1965	19250826	10.1016/j.bmcl.2009.02.047	Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.	Schweinitz A, Dönnecke D, Ludwig A, Steinmetzer P, Schulze A, Kotthaus J, Wein S, Clement B, Steinmetzer T.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Bioorg. Med. Chem. Lett.	2013	23	17	4779	4784	23899618	10.1016/j.bmcl.2013.07.008	Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.	Park HD, Lee SH, Kim TH, Lee SH, Cho KH, Kim A.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038	MedChemComm	2016	7	2	272	281		10.1039/C5MD00479A	Discovery of AZD8165  a clinical candidate from a novel series of neutral thrombin inhibitors	Abrahamsson K, Andersson P, Bergman J, Bredberg U, Branalt J, Egnell A, Eriksson U, Gustafsson D, Hoffman K, Nielsen S, Nilsson I, Pehrsson S, Polla MO, Skjaeret T, Strimfors M, Wern C, Olwegard-Halvarsson M, Ortengren Y
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038									PubChem BioAssay data set	
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038									Unpublished dataset	
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
958.5500000000000000	9606	Homo sapiens	XIMELAGATRAN	CHEMBL522038									WHO Anatomical Therapeutic Chemical Classification	
941.6000000000000000	9606	Homo sapiens	XL-228	CHEMBL3545085		2008							Pyrimidine Derivatives As Kinase Modulators and Method of Use	
941.6000000000000000	9606	Homo sapiens	XL-228	CHEMBL3545085	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
941.6000000000000000	9606	Homo sapiens	XL-228	CHEMBL3545085									Unpublished dataset	
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948	J. Med. Chem.	2009	52	21	6515	6518	19831390	10.1021/jm901226j	Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.	Harrison BA, Whitlock NA, Voronkov MV, Almstead ZY, Gu KJ, Mabon R, Gardyan M, Hamman BD, Allen J, Gopinathan S, McKnight B, Crist M, Zhang Y, Liu Y, Courtney LF, Key B, Zhou J, Patel N, Yates PW, Liu Q, Wilson AG, Kimball SD, Crosson CE, Rice DS, Rawlins DB.
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948	Bioorg. Med. Chem. Lett.	2010	20	11	3361	3366	20434334	10.1016/j.bmcl.2010.04.020	Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma.	Davis RL, Kahraman M, Prins TJ, Beaver Y, Cook TG, Cramp J, Cayanan CS, Gardiner EM, McLaughlin MA, Clark AF, Hellberg MR, Shiau AK, Noble SA, Borchardt AJ.
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948	Bioorg. Med. Chem. Lett.	2014	24	8	1875	1879	24684843	10.1016/j.bmcl.2014.03.017	In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.	Chen HH, Namil A, Severns B, Ward J, Kelly C, Drace C, McLaughlin MA, Yacoub S, Li B, Patil R, Sharif N, Hellberg MR, Rusinko A, Pang IH, Combrink KD.
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948	Science	2017	358	6367			29191878	10.1126/science.aan4368	The target landscape of clinical kinase drugs.	Klaeger S, Heinzlmeir S and Wilhelm M et al
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948									PubChem BioAssay data set	
867.7500000000000000	9606	Homo sapiens	Y-39983	CHEMBL571948									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1986	29	9	1561	1569	2427720	10.1021/jm00159a001	Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).	De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1987	30	2	440	444	3643284	10.1021/jm00385a033	Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.	Lin TS, Chen MS, McLaren C, Gao YS, Ghazzouli I, Prusoff WH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1987	30	5	862	866	3033243	10.1021/jm00388a020	Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.	Kim CH, Marquez VE, Broder S, Mitsuya H, Driscoll JS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1987	30	8	1270	1278	3497272	10.1021/jm00391a003	3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.	Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1989	32	12	2507	2509	2479745	10.1021/jm00132a002	A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.	Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	1	17	21	2296018	10.1021/jm00163a004	Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.	Vince R, Hua M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	1	258	263	2153206	10.1021/jm00163a043	Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.	Palomino E, Meltsner BR, Kessel D, Horwitz JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	6	1833	1839	2342078	10.1021/jm00168a046	Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.	Van Aerschot A, Everaert D, Balzarini J, Augustyns K, Jie L, Janssen G, Peeters O, Blaton N, De Ranter C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	8	2137	2145	2165161	10.1021/jm00170a015	Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).	Martin JA, Bushnell DJ, Duncan IB, Dunsdon SJ, Hall MJ, Machin PJ, Merrett JH, Parkes KE, Roberts NA, Thomas GJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	8	2145	2150	1695683	10.1021/jm00170a016	"Synthesis and anti-HIV-1 activity of 2'-""up""-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC)."	Watanabe KA, Harada K, Zeidler J, Matulic-Adamic J, Takahashi K, Ren WY, Cheng LC, Fox JJ, Chou TC, Zhu QY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1990	33	8	2150	2157	2165162	10.1021/jm00170a017	Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.	Sterzycki RZ, Ghazzouli I, Brankovan V, Martin JC, Mansuri MM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1991	1	1	65	68		10.1016/S0960-894X(01)81093-3	Preparation of the geometric isomers of DDC, DDA, D4C and D4T as potential anti-HIV agents	Mansuri MM, Farina V, Starrett JE, Benigni DA, Brankovan V, Martin JC
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1991	34	1	349	357	1992136	10.1021/jm00105a055	A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).	Tanaka H, Baba M, Hayakawa H, Sakamaki T, Miyasaka T, Ubasawa M, Takashima H, Sekiya K, Nitta I, Shigeta S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1991	34	1	421	429	1992143	10.1021/jm00105a064	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.	Phadtare S, Kessel D, Corbett TH, Renis HE, Court BA, Zimlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1991	34	5	1647	1655	2033591	10.1021/jm00109a018	Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.	Barchi JJ, Marquez VE, Driscoll JS, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1992	2	6	603	606		10.1016/S0960-894X(01)81206-3	Nucleotidic prodrugs of anti-HIV dideoxynucleosides	Puech F, Pompon A, Lefebvre I, Gosselin G, Imbach J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	10	1882	1886	1588565	10.1021/jm00088a026	Synthesis and anti-HIV activity of 9-[c-4,t-5-bis(hydroxymethyl)cyclopent-2-en-r-1-yl]-9H-adenine.	Katagiri N, Nomura M, Sato H, Kaneko C, Yusa K, Tsuruo T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	11	1996	2001	1317921	10.1021/jm00089a008	Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.	Kerr SG, Kalman TI.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	12	2195	2201	1351945	10.1021/jm00090a008	Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.	Siddiqui MA, Driscoll JS, Marquez VE, Roth JS, Shirasaka T, Mitsuya H, Barchi JJ, Kelley JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	15	2728	2735	1495007	10.1021/jm00093a003	Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.	Mullah KB, Rao TS, Balzarini J, De Clercq E, Bentrude WG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	15	2890	2897	1322989	10.1021/jm00093a023	Anti-HIV-I activity of linked lexitropsins.	Wang W, Lown JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1992	35	3	533	538	1738145	10.1021/jm00081a015	Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.	Secrist JA, Riggs RM, Tiwari KN, Montgomery JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Nat. Prod.	1992	55	4	509	512	1324982	10.1021/np50082a020	Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.	Gunasekera SP, Cross SS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1993	36	5	529	537	8388473	10.1021/jm00057a002	Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine.	Torrence PF, Kinjo J, Khamnei S, Greig NH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1994	37	16	2520	2526	7520081	10.1021/jm00042a005	HIV-1 reverse transcriptase inhibitor design using artificial neural networks.	Tetko IV, Tanchuk VYu, Chentsova NP, Antonenko SV, Poda GI, Kukhar VP, Luik AI.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1994	37	21	3554	3560	7932583	10.1021/jm00047a013	Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.	Kumar R, Wang L, Wiebe LI, Knaus EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1994	37	6	798	803	8145230	10.1021/jm00032a013	Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).	Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1995	38	20	3957	3966	7562929	10.1021/jm00020a009	Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides.	Bhattacharya BK, Ojwang JO, Rando RF, Huffman JH, Revankar GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1995	5	22	2599	2604		10.1016/0960-894X(95)00472-6	Synthesis and antiviral evaluation of enantiomeric 2,3-dideoxy- and 2,3-didehydro-2,3-dideoxy-4-thionucleosides	Young RJ, Shaw-Ponter S, Thomson JB, Miller J, Cumming JG, Pugh AW, Rider P
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1996	39	6	1303	1313	8632437	10.1021/jm950797i	Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.	Flavin MT, Rizzo JD, Khilevich A, Kucherenko A, Sheinkman AK, Vilaychack V, Lin L, Chen W, Greenwood EM, Pengsuparp T, Pezzuto JM, Hughes SH, Flavin TM, Cibulski M, Boulanger WA, Shone RL, Xu ZQ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1996	6	6	701	706		10.1016/0960-894X(96)00096-0	Anti-HIV activity of quassinoids	Okano M, Fukamiya N, Tagahara K, Cosentino M, Lee TT, Morris-Natschke S, Lee K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1997	40	15	2363	2373	9240351	10.1021/jm9607921	Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.	Kim DK, Gam J, Kim YW, Lim J, Kim HT, Kim KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1997	7	17	2325	2328		10.1016/S0960-894X(97)00422-8	Robustaflavone, a naturally occurring biflavanoid, is a potent non-nucleoside inhibitor of hepatitis B virus replication in vitro	Lin Y, Zembower DE, Flavin MT, Schure RM, Anderson HM, Korba BE, Chen F
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1997	7	3	303	308		10.1016/S0960-894X(97)00001-2	Discovery of imidazo[1,2-c]pyrimidin-5(6H)-one heterosubstituted nucleoside analogues with potent activity against human hepatitis B virus in vitro	Mansour TS, Evans CA, Charron M, Korba BE
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1998	41	1	10	23	9438017	10.1021/jm9705723	(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.	Qiu YL, Ksebati MB, Ptak RG, Fan BY, Breitenbach JM, Lin JS, Cheng YC, Kern ER, Drach JC, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	1998	41	8	1284	1298	9548818	10.1021/jm9705869	Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.	Sekiyama T, Hatsuya S, Tanaka Y, Uchiyama M, Ono N, Iwayama S, Oikawa M, Suzuki K, Okunishi M, Tsuji T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	1998	8	16	2179	2184	9873509	10.1016/s0960-894x(98)00380-1	In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.	Xu ZQ, Buckheit RW, Stup TL, Flavin MT, Khilevich A, Rizzo JD, Lin L, Zembower DE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2000	10	18	2145	2148	10999490	10.1016/s0960-894x(00)00418-2	Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.	Luo MZ, Liu MC, Mozdziesz DE, Lin TS, Dutschman GE, Gullen EA, Cheng YC, Sartorelli AC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Pharmacol. Exp. Ther.	2000	294	1	844	849	10945832		Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2000	43	10	1927	1939	10821705	10.1021/jm991125l	"Synthesis and evaluation of ""AZT-HEPT"", ""AZT-pyridinone"", and ""ddC-HEPT"" conjugates as inhibitors of HIV reverse transcriptase."	Pontikis R, Dollé V, Guillaumel J, Dechaux E, Note R, Nguyen CH, Legraverend M, Bisagni E, Aubertin AM, Grierson DS, Monneret C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2001	11	14	1897	1902	11459656	10.1016/s0960-894x(01)00323-7	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.	Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, Kodama E, Matsuoka M, Hattori T, Yamamoto N, Nakashima H, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Jpn. Pharmacol. Ther.	2001	29	1	S101	S104			TP-search Transporter Database	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Nat. Prod.	2001	64	2	265	277	11430019	10.1021/np0003995	Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.	Yang SS, Cragg GM, Newman DJ, Bader JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2002	12	6	923	928	11958995	10.1016/s0960-894x(02)00041-0	Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.	Tamamura H, Hiramatsu K, Miyamoto K, Omagari A, Oishi S, Nakashima H, Yamamoto N, Kuroda Y, Nakagawa T, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Nat. Prod.	2002	65	11	1649	1656	12444692	10.1021/np020234r	New saponins from the starfish Certonardoa semiregularis.	Wang W, Li F, Alam N, Liu Y, Hong J, Lee CK, Im KS, Jung JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2004	14	10	2677	2680	15109677	10.1016/s0960-894x(04)00205-7	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.	Yadav A, Singh SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2004	47	5	1183	1192	14971898	10.1021/jm0309708	Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.	Anastasi C, Hantz O, De Clercq E, Pannecouque C, Clayette P, Dereuddre-Bosquet N, Dormont D, Gondois-Rey F, Hirsch I, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2005	48	2	534	546	15658867	10.1021/jm034265a	Synthesis and antiviral activity of helioxanthin analogues.	Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Lee Y, Chung R, Huang ES, Austin DJ, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2005	48	4	1199	1210	15715486	10.1021/jm0495172	Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.	Prakash TP, Prhavc M, Eldrup AB, Cook PD, Carroll SS, Olsen DB, Stahlhut MW, Tomassini JE, MacCoss M, Galloway SM, Hilliard C, Bhat B.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2005	48	7	2695	2700	15801860	10.1021/jm040101y	Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcriptase.	Boyle NA, Rajwanshi VK, Prhavc M, Wang G, Fagan P, Chen F, Ewing GJ, Brooks JL, Hurd T, Leeds JM, Bruice TW, Cook PD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2007	50	19	4766	4774	17696514	10.1021/jm070391t	Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.	Rai D, Johar M, Srivastav NC, Manning T, Agrawal B, Kunimoto DY, Kumar R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Antimicrob. Agents Chemother.	2007	51	7	2531	2539	17470651	10.1128/aac.00039-07	Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.	Lund KC, Peterson LL, Wallace KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2010	20	3	841	843	20060716	10.1016/j.bmcl.2009.12.097	Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.	Li Y, Soni PB, Liu L, Zhang X, Liotta DC, Lutz S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Antimicrob. Agents Chemother.	2010	54	1	280	287	19805555	10.1128/aac.00914-09	Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.	Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Antimicrob. Agents Chemother.	2010	54	11	4887	4892	20805401	10.1128/aac.00794-10	In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.	Zhang P, Zhang L, Jiang Z, Wang T, Chen H, Xiong Y, Li Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2011	19	13	3945	3955	21658957	10.1016/j.bmc.2011.05.026	Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.	Park AY, Kim WH, Kang JA, Lee HJ, Lee CK, Moon HR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2011	19	17	5117	5124	21824782	10.1016/j.bmc.2011.07.023	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.	Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur. J. Med. Chem.	2011	46	1	218	228	21112128	10.1016/j.ejmech.2010.11.005	Prediction of drug intestinal absorption by new linear and non-linear QSPR.	Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2012	20	18	5527	5536	22883027	10.1016/j.bmc.2012.07.026	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Zhan P, Liu H, Li D, Wang L, Chen X, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2012	20	23	6795	6802	23098609	10.1016/j.bmc.2012.09.058	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.	Zhan P, Chen W, Li Z, Li X, Chen X, Tian Y, Pannecouque C, Clercq ED, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Med Chem Res	2012	21	7	1179	1187		10.1007/s00044-011-9616-2	Antiviral effects of three novel derivatives of adefovir on the replication of hepatitis B virus	Wu D, Niu J, Ding Y, Wu X, Zhong B, Feng X
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2012	22	23	7155	7162	23084898	10.1016/j.bmcl.2012.09.062	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.	Zhan P, Li X, Li Z, Chen X, Tian Y, Chen W, Liu X, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2013	21	22	7091	7100	24119448	10.1016/j.bmc.2013.09.009	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.	Chen W, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Jiang X, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	ACS Med. Chem. Lett.	2013	4	12	1183	1188	24900627	10.1021/ml4002979	Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.	Iyidogan P, Sullivan TJ, Chordia MD, Frey KM, Anderson KS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	MedChemComm	2013	4	5	810	816		10.1039/C3MD00028A	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach	Song Y, Zhan P, Kang D, Li X, Tian Y, Li Z, Chen X, Chen W, Pannecouque C, De Clercq E, Liu X
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur. J. Med. Chem.	2013	62		534	544	23419738	10.1016/j.ejmech.2013.01.015	Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.	Malpani Y, Achary R, Kim SY, Jeong HC, Kim P, Han SB, Kim M, Lee CK, Kim JN, Jung YS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2014	22	6	1863	1872	24581546	10.1016/j.bmc.2014.01.054	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.	Chen W, Zhan P, Rai D, De Clercq E, Pannecouque C, Balzarini J, Zhou Z, Liu H, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2014	24	3	817	820	24411122	10.1016/j.bmcl.2013.12.093	Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.	Gangadhara KL, Lescrinier E, Pannecouque C, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	MedChemComm	2014	5	4	468	473		10.1039/C3MD00247K	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase	Wu H, Pannecouque C, Yan Z, Chen W, He Q, Chen F, Balzarini J, Daelemans D, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Med. Chem.	2015	58	8	3445	3458	25849312	10.1021/jm501874e	ß-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.	Zhou L, Zhang HW, Tao S, Bassit L, Whitaker T, McBrayer TR, Ehteshami M, Amiralaei S, Pradere U, Cho JH, Amblard F, Bobeck D, Detorio M, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Nat. Prod.	2015	78	11	2704	2711	26517378	10.1021/acs.jnatprod.5b00621	Identification of 5-Methoxyflavone as a Novel DNA Polymerase-Beta Inhibitor and Neuroprotective Agent against Beta-Amyloid Toxicity.	Merlo S, Basile L, Giuffrida ML, Sortino MA, Guccione S, Copani A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J. Nat. Prod.	2015	78	2	315	319	25587934	10.1021/np5006696	Sesquiterpenoid tropolone glycosides from Liriosma ovata.	Ma J, Pawar RS, Grundel E, Mazzola EP, Ridge CD, Masaoka T, Le Grice SF, Wilson J, Beutler JA, Krynitsky AJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur J Med Chem	2016	121		58	70	27214512	10.1016/j.ejmech.2016.05.017	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.	Kulaba¿ N, Tatar E, Bingöl Özakp¿nar Ö, Özsavc¿ D, Pannecouque C, De Clercq E, Küçükgüzel ¿.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Bioorg Med Chem Lett	2016	26	21	5182	5186	27742238	10.1016/j.bmcl.2016.09.071	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.	Kang D, Zhang H, Zhou Z, Huang B, Naesens L, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	Eur J Med Chem	2017	126		84	100	27750154	10.1016/j.ejmech.2016.10.002	Synthesis, anti-varicella-zoster virus and anti-cytomegalovirus activity of quinazoline-2,4-diones containing isoxazolidine and phosphonate substructures.	Piotrowska DG, Andrei G, Schols D, Snoeck R, ¿ysakowska M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853	J Med Chem	2017	60	13	5424	5437	28595015	10.1021/acs.jmedchem.7b00067	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.	Zhou S, Mahmoud S, Liu P, Zhou L, Ehteshami M, Bassit L, Tao S, Domaoal RA, Sari O, Schutter C, Amiralaei S, Khalil A, Ollinger Russell O, McBrayer T, Whitaker T, Abou-Taleb N, Amblard F, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									DrugMatrix	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									Drug metabolism data	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZALCITABINE	CHEMBL853									WHO Anatomical Therapeutic Chemical Classification	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1983	26	12	1691	1696	6644738	10.1021/jm00366a006	Synthesis and biological activity of various 3'-azido and 3'-amino analogues of 5-substituted pyrimidine deoxyribonucleosides.	Lin TS, Gao YS, Mancini WR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1986	29	9	1561	1569	2427720	10.1021/jm00159a001	Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).	De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1987	30	11	2131	2137	3499515	10.1021/jm00394a034	Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis.	Herdewijn P, Pauwels R, Baba M, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1987	30	2	440	444	3643284	10.1021/jm00385a033	Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.	Lin TS, Chen MS, McLaren C, Gao YS, Ghazzouli I, Prusoff WH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1987	30	8	1270	1278	3497272	10.1021/jm00391a003	3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.	Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1988	31	10	2040	2048	3172142	10.1021/jm00118a033	Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.	Herdewijn P, Balzarini J, Baba M, Pauwels R, Van Aerschot A, Janssen G, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1988	31	2	336	340	3339606	10.1021/jm00397a011	Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).	Lin TS, Guo JY, Schinazi RF, Chu CK, Xiang JN, Prusoff WH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	12	2507	2509	2479745	10.1021/jm00132a002	A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.	Miyasaka T, Tanaka H, Baba M, Hayakawa H, Walker RT, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	2	461	466	2536441	10.1021/jm00122a029	1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.	Mansuri MM, Starrett JE, Ghazzouli I, Hitchcock MJ, Sterzycki RZ, Brankovan V, Lin TS, August EM, Prusoff WH, Sommadossi JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	3	612	617	2918508	10.1021/jm00123a018	Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.	Chu CK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	3	618	622	2918509	10.1021/jm00123a019	1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus.	Greengrass CW, Hoople DW, Street SD, Hamilton F, Marriott MS, Bordner J, Dalgleish AG, Mitsuya H, Broder S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	8	1743	1749	2754700	10.1021/jm00128a013	3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.	Van Aerschot A, Herdewijn P, Balzarini J, Pauwels R, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1989	32	8	1891	1895	2754712	10.1021/jm00128a034	Synthesis and antiviral activity of several 2,5'-anhydro analogues of 3'-azido-3'-deoxythymidine, 3'-azido-2',3'-dideoxyuridine, 3'-azido-2',3'-dideoxy-5-halouridines, and 3'-deoxythymidine against human immunodeficiency virus and Rauscher-murine leukemia virus.	Lin TS, Shen ZY, August EM, Brankovan V, Yang H, Ghazzouli I, Prusoff WH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	1	17	21	2296018	10.1021/jm00163a004	Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.	Vince R, Hua M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	1	258	263	2153206	10.1021/jm00163a043	Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.	Palomino E, Meltsner BR, Kessel D, Horwitz JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	2	845	848	2299647	10.1021/jm00164a059	Synthesis, antiretrovirus effects, and phosphorylation kinetics of 3'-isocyano-3'-deoxythymidine and 3'-isocyano-2',3'-dideoxyuridine.	Hiebl J, Zbiral E, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	4	1207	1213	2157012	10.1021/jm00166a019	Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships.	Kim CU, Luh BY, Misco PF, Bronson JJ, Hitchcock MJ, Ghazzouli I, Martin JC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	5	1281	1285	2329551	10.1021/jm00167a002	Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS.	Norbeck DW, Kern E, Hayashi S, Rosenbrook W, Sham H, Herrin T, Plattner JJ, Erickson J, Clement J, Swanson R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	5	1353	1360	2158560	10.1021/jm00167a011	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.	Béres J, Sági G, Tömösközi I, Gruber L, Baitz-Gács E, Otvös L, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	5	1505	1510	2329572	10.1021/jm00167a034	Synthesis and biological evaluation of prodrugs of zidovudine.	Aggarwal SK, Gogu SR, Rangan SR, Agrawal KC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	6	1833	1839	2342078	10.1021/jm00168a046	Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.	Van Aerschot A, Everaert D, Balzarini J, Augustyns K, Jie L, Janssen G, Peeters O, Blaton N, De Ranter C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	8	2137	2145	2165161	10.1021/jm00170a015	Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).	Martin JA, Bushnell DJ, Duncan IB, Dunsdon SJ, Hall MJ, Machin PJ, Merrett JH, Parkes KE, Roberts NA, Thomas GJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	8	2145	2150	1695683	10.1021/jm00170a016	"Synthesis and anti-HIV-1 activity of 2'-""up""-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC)."	Watanabe KA, Harada K, Zeidler J, Matulic-Adamic J, Takahashi K, Ren WY, Cheng LC, Fox JJ, Chou TC, Zhu QY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	8	2150	2157	2165162	10.1021/jm00170a017	Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.	Sterzycki RZ, Ghazzouli I, Brankovan V, Martin JC, Mansuri MM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	8	2162	2173	2165163	10.1021/jm00170a019	Synthesis and antiviral activity of some acyclic and C-acyclic pyrrolo[2,3-d]pyrimidine nucleoside analogues.	Bennett SM, Nguyen-Ba N, Ogilvie KK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	8	2188	2192	2374145	10.1021/jm00170a023	Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine.	Chu CK, Bhadti VS, Doshi KJ, Etse JT, Gallo JM, Boudinot FD, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1990	33	9	2481	2487	1697345	10.1021/jm00171a023	5'-O-phosphonomethyl-2',3'-dideoxynucleosides: synthesis and anti-HIV activity.	Jie L, Van Aerschot A, Balzarini J, Janssen G, Busson R, Hoogmartens J, De Clercq E, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	1	349	357	1992136	10.1021/jm00105a055	A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).	Tanaka H, Baba M, Hayakawa H, Sakamaki T, Miyasaka T, Ubasawa M, Takashima H, Sekiya K, Nitta I, Shigeta S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	1	421	429	1992143	10.1021/jm00105a064	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.	Phadtare S, Kessel D, Corbett TH, Renis HE, Court BA, Zimlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	11	3187	3197	1956037	10.1021/jm00115a007	Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2.	Kukla MJ, Breslin HJ, Diamond CJ, Grous PP, Ho CY, Miranda M, Rodgers JD, Sherrill RG, De Clercq E, Pauwels R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	11	3305	3309	1720175	10.1021/jm00115a022	Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes.	Goudgaon NM, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	2	746	751	1995896	10.1021/jm00106a040	Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.	Kukla MJ, Breslin HJ, Pauwels R, Fedde CL, Miranda M, Scott MK, Sherrill RG, Raeymaekers A, Van Gelder J, Andries K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	4	1377	1383	2016713	10.1021/jm00108a021	In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents.	Meyer KL, Marasco CJ, Morris-Natschke SL, Ishaq KS, Piantadosi C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	4	1394	1399	2016715	10.1021/jm00108a023	Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).	Tanaka H, Baba M, Ubasawa M, Takashima H, Sekiya K, Nitta I, Shigeta S, Walker RT, De Clercq E, Miyasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	4	1408	1414	1901911	10.1021/jm00108a025	Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity.	Piantadosi C, Marasco CJ, Morris-Natschke SL, Meyer KL, Gumus F, Surles JR, Ishaq KS, Kucera LS, Iyer N, Wallen CA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	4	1426	1430	2016718	10.1021/jm00108a028	Synthesis and antiretrovirus properties of 5'-isocyano-5'-deoxythymidine, 5'-isocyano-2',5'-dideoxyuridine, 3'-azido-5'-isocyano-3',5'-dideoxythymidine, and 3'-azido-5'-isocyano-2',3',5'-trideoxyuridine.	Hiebl J, Zbiral E, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	4	1508	1511	2016729	10.1021/jm00108a041	"Specific anti-HIV-1 ""acyclonucleosides"" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine."	Tanaka H, Baba M, Saito S, Miyasaka T, Takashima H, Sekiya K, Ubasawa M, Nitta I, Walker RT, Nakashima H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	5	1606	1612	2033586	10.1021/jm00109a012	Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.	Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H, Driscoll JS, Kelley JA, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	5	1647	1655	2033591	10.1021/jm00109a018	Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.	Barchi JJ, Marquez VE, Driscoll JS, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	6	1830	1837	1712047	10.1021/jm00110a011	Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study, and antiviral activity.	Henin Y, Gouyette C, Schwartz O, Debouzy JC, Neumann JM, Huynh-Dinh T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1991	34	7	2231	2241	1712395	10.1021/jm00111a045	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.	Hargrave KD, Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, Behnke ML.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1992	2	12	1469	1474		10.1016/S0960-894X(00)80410-2	Preparation and anti-HIV activity of N-3 amino substituted thymidine nucleoside analogs	Maillard M, Florent J, Lemaitre M, Begassat F, Bugnicourt A, Ferrieux C, Rombi C, Pacaud E, Thierry D, Zerial A, Monneret C, Grierson DS
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1992	2	2	145	148		10.1016/S0960-894X(01)80437-6	Synthesis of acid stable 5-o-fluoromethyl phosphonates of nucleosides. Evaluation as inhibitors of reverse transcriptase.	Casara PJ, Jund KC, Clauss A, Nave J, Snyder RD
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1992	2	3	235	238		10.1016/S0960-894X(01)81071-4	New hexahydroxydiphenyl derivatives as potent inhibitors of HIV replication in H9 lymphocytes	Kashiwada Y, Huang L, Kilkuskie RE, Bodner AJ, Lee K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1992	2	7	701	704		10.1016/S0960-894X(00)80395-9	Aryl phosphate derivates of AZT inhibit HIV replication in cells where the nucleoside is poorly active	McGuigan C, Pathirana RN, Mahmood N, Hay AJ
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	10	1685	1701	1588551	10.1021/jm00088a003	Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.	Thompson WJ, Fitzgerald PM, Holloway MK, Emini EA, Darke PL, McKeever BM, Schleif WA, Quintero JC, Zugay JA, Tucker TJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	11	1987	1995	1597854	10.1021/jm00089a007	Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.	Kim HO, Ahn SK, Alves AJ, Beach JW, Jeong LS, Choi BG, Van Roey P, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	15	2744	2752	1495008	10.1021/jm00093a005	HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.	Taraporewala IB, Cessac JW, Chanh TC, Delgado AV, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	15	2890	2897	1322989	10.1021/jm00093a023	Anti-HIV-I activity of linked lexitropsins.	Wang W, Lown JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	16	3016	3023	1323681	10.1021/jm00094a014	Side-chain derivatives of biologically active nucleosides. 1. Side-chain analogs of 3'-azido-3'-deoxythymidine (AZT).	Hiebl J, Zbiral E, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	16	3039	3044	1501232	10.1021/jm00094a018	Improved brain delivery of AZT using a glycosyl phosphotriester prodrug.	Namane A, Gouyette C, Fillion MP, Fillion G, Huynh-Dinh T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	17	3192	3196	1380561	10.1021/jm00095a014	3'-Azido-3',5'-dideoxythymidine-5'-methylphosphonic acid diphosphate: synthesis and HIV-1 reverse transcriptase inhibition.	Freeman GA, Rideout JL, Miller WH, Reardon JE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	18	3369	3372	1527788	10.1021/jm00096a011	3',3'-Difluoro-3'-deoxythymidine: comparison of anti-HIV activity to 3'-fluoro-3'-deoxythymidine.	Bergstrom DE, Mott AW, De Clercq E, Balzarini J, Swartling DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	2	337	345	1732552	10.1021/jm00080a020	Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity.	Tanaka H, Takashima H, Ubasawa M, Sekiya K, Nitta I, Baba M, Shigeta S, Walker RT, De Clercq E, Miyasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	21	3792	3802	1279173	10.1021/jm00099a007	Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.	Saari WS, Wai JS, Fisher TE, Thomas CM, Hoffman JM, Rooney CS, Smith AM, Jones JH, Bamberger DL, Goldman ME.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	25	4713	4719	1469700	10.1021/jm00103a009	Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.	Tanaka H, Takashima H, Ubasawa M, Sekiya K, Nitta I, Baba M, Shigeta S, Walker RT, De Clercq E, Miyasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	3	533	538	1738145	10.1021/jm00081a015	Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.	Secrist JA, Riggs RM, Tiwari KN, Montgomery JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	5	917	924	1548681	10.1021/jm00083a017	Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides.	Manfredini S, Bazzanini R, Baraldi PG, Guarneri M, Simoni D, Marongiu ME, Pani A, Tramontano E, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1992	35	8	1440	1451	1573638	10.1021/jm00086a013	Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides.	Maag H, Rydzewski RM, McRoberts MJ, Crawford-Ruth D, Verheyden JP, Prisbe EJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1992	55	4	509	512	1324982	10.1021/np50082a020	Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.	Gunasekera SP, Cross SS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1992	55	8	1067	1073	1279126	10.1021/np50086a006	Constituents of Eriobotrya japonica. A study of their antiviral properties.	De Tommasi N, De Simone F, Pizza C, Mahmood N, Moore PS, Conti C, Orsi N, Stein ML.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1993	3	12	2837	2842		10.1016/S0960-894X(01)80775-7	Novel pseudosymmetric inhibitors of HIV-1 protease	Fassler A, Rosel J, Gruther M, Tintelnot-Blomley M, Atteri E, Bold G, Lang M
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1993	3	6	1207	1210		10.1016/S0960-894X(00)80316-9	Kinase bypass: A new strategy for anti-HIV drug design	McGuigan C, Kinchington D, Nicholls SR, Nickson C, O'Connor TJ
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1993	3	8	1723	1728		10.1016/S0960-894X(00)80050-5	A novel class of 1,3-oxathiolane nucleoside analogues having potent anti-HIV activity	Belleau B, Brasili L, Chan L, DiMarco MP, Zacharie B, Nguyen-Ba N, Jenkinson HJ, Coates JA, Cameron JM
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	1	30	37	8421287	10.1021/jm00053a004	1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes.	Kim HO, Schinazi RF, Nampalli S, Shanmuganathan K, Cannon DL, Alves AJ, Jeong LS, Beach JW, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	10	1343	1355	8496903	10.1021/jm00062a006	Novel acyclonucleotides: synthesis and antiviral activity of alkenylphosphonic acid derivatives of purines and a pyrimidine.	Harnden MR, Parkin A, Parratt MJ, Perkins RM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	10	1505	1508	7684450	10.1021/jm00062a027	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.	Romero DL, Morge RA, Genin MJ, Biles C, Busso M, Resnick L, Althaus IW, Reusser F, Thomas RC, Tarpley WG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	18	2627	2638	8410975	10.1021/jm00070a006	Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents.	Jeong LS, Schinazi RF, Beach JW, Kim HO, Shanmuganathan K, Nampalli S, Chun MW, Chung WK, Choi BG, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	2	181	195	8423591	10.1021/jm00054a001	Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.	Jeong LS, Schinazi RF, Beach JW, Kim HO, Nampalli S, Shanmuganathan K, Alves AJ, McMillan A, Chu CK, Mathis R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	21	3120	3128	8230098	10.1021/jm00073a011	A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.	Humber DC, Bamford MJ, Bethell RC, Cammack N, Cobley K, Evans DN, Gray NM, Hann MM, Orr DC, Saunders J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	24	3784	3794	7504733	10.1021/jm00076a005	Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines.	Livermore DG, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DV, Lamont RB, Noble SA, Orr DC, Payne JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	5	519	528	8496934	10.1021/jm00057a001	L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.	Kim HO, Schinazi RF, Shanmuganathan K, Jeong LS, Beach JW, Nampalli S, Cannon DL, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	7	826	830	8385224	10.1021/jm00059a006	Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs.	Sergheraert C, Pierlot C, Tartar A, Henin Y, Lemaitre M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	8	1048	1052	8478904	10.1021/jm00060a013	Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT.	McGuigan C, Pathirana RN, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1993	36	9	1291	1294	7683725	10.1021/jm00061a022	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.	Williams TM, Ciccarone TM, MacTough SC, Rooney CS, Balani SK, Condra JH, Emini EA, Goldman ME, Greenlee WJ, Kauffman LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	16	2520	2526	7520081	10.1021/jm00042a005	HIV-1 reverse transcriptase inhibitor design using artificial neural networks.	Tetko IV, Tanchuk VYu, Chentsova NP, Antonenko SV, Poda GI, Kukhar VP, Luik AI.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	16	2583	2588	8057301	10.1021/jm00042a011	Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.	Fulcrand-el Kattan G, Goudgaon NM, Ilksoy N, Huang JT, Watanabe KA, Sommadossi JP, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	19	3040	3050	7932526	10.1021/jm00045a008	Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction.	Cushman M, Golebiewski WM, McMahon JB, Buckheit RW, Clanton DJ, Weislow O, Haugwitz RD, Bader JP, Graham L, Rice WG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	2	293	304	8295217	10.1021/jm00028a013	Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.	Islam I, Ng KY, Chong KT, McQuade TJ, Hui JO, Wilkinson KF, Rush BD, Ruwart MJ, Borchardt RT, Fisher JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	21	3534	3541	7523675	10.1021/jm00047a011	Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.	Franchetti P, Cappellacci L, Grifantini M, Messini L, abu Sheikha G, Loi AG, Tramontano E, de Montis A, Spiga MG, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	21	3554	3560	7932583	10.1021/jm00047a013	Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.	Kumar R, Wang L, Wiebe LI, Knaus EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	23	3947	3955	7525962	10.1021/jm00049a014	Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs.	Huang L, Kashiwada Y, Cosentino LM, Fan S, Chen CH, McPhail AT, Fujioka T, Mihashi K, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	24	4185	4194	7527463	10.1021/jm00050a015	"1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5""-(4""-amino-1"",2""-oxathiole 2"",2""-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity."	Alvarez R, Velázquez S, San-Félix A, Aquaro S, De Clercq E, Perno CF, Karlsson A, Balzarini J, Camarasa MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	25	4297	4306	7996541	10.1021/jm00051a006	Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-azido-3'-deoxythymidine (AZT).	Kumar R, Wang L, Wiebe LI, Knaus EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1994	37	7	999	1014	7512142	10.1021/jm00033a018	Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors.	Romero DL, Morge RA, Biles C, Berrios-Pena N, May PD, Palmer JR, Johnson PD, Smith HW, Busso M, Tan CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1994	4	10	1213	1218		10.1016/S0960-894X(01)80332-2	Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (R)-valinol derivatives as novel c-termini	Van Dorsselaer V, Schirlin D, Tarnus C, Taylor D, Tyms A, Weber F, Baltzer S, Remy J, Brennan T, Janowick D
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1994	4	3	427	430		10.1016/0960-894X(94)80009-X	Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside	McGuigan C, Pathirana RN, Davies MP, Balzarini J, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1994	4	4	593	598		10.1016/S0960-894X(01)80161-X	3,4-Di-o-()-camphanoyl-(+)-ciskhellactone and related compounds: A. new class of potent anti-HIV agents	Huang L, Kashiwada Y, Cosentino L, Fan S, Lee K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1994	4	7	931	934		10.1016/S0960-894X(01)80266-3	Synthesis and in vitro anti-human immunodeficiency virus activity of artemisinin (qinghaosu)-related trioxanes	Jung M, Schinazi RF
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1994	57	1	42	51	8158164	10.1021/np50103a006	Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids.	Hu CQ, Chen K, Shi Q, Kilkuskie RE, Cheng YC, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1994	57	2	243	247	8176401	10.1021/np50104a008	Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids.	Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	1	1	4	7837220	10.1021/jm00001a001	Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro.	Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N, Salomon H, Belmonte AR, Wainberg MA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	10	1641	1649	7538589	10.1021/jm00010a008	Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase.	Velázquez S, Alvarez R, San-Félix A, Jimeno ML, De Clercq E, Balzarini J, Camarasa MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	12	2038	2040	7540208	10.1021/jm00012a002	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.	Hanasaki Y, Watanabe H, Katsuura K, Takayama H, Shirakawa S, Yamaguchi K, Sakai S, Ijichi K, Fujiwara M, Konno K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	15	2860	2865	7636846	10.1021/jm00015a008	Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.	Tanaka H, Takashima H, Ubasawa M, Sekiya K, Inouye N, Baba M, Shigeta S, Walker RT, De Clercq E, Miyasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	16	3003	3008	7543578	10.1021/jm00016a002	Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents.	Xie L, Xie JX, Kashiwada Y, Cosentino LM, Liu SH, Pai RB, Cheng YC, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	17	3253	3257	7650678	10.1021/jm00017a009	Unusual single-stranded polyribonucleotides as potent anti-HIV agents.	Broom AD, Agrawal VK, Tutonda MG, Fain HD, Buckheit RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	17	3258	3263	7650679	10.1021/jm00017a010	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.	Mai A, Artico M, Sbardella G, Massa S, Loi AG, Tramontano E, Scano P, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	20	3941	3950	7562927	10.1021/jm00020a007	Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate.	Lefebvre I, Périgaud C, Pompon A, Aubertin AM, Girardet JL, Kirn A, Gosselin G, Imbach JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	20	4007	4013	7562935	10.1021/jm00020a015	Synthesis and antiviral activity of 8-aza analogs of chiral [2-(phosphonomethoxy) propyl]guanines.	Franchetti P, Sheikha GA, Cappellacci L, Grifantini M, De Montis A, Piras G, Loi AG, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	20	4106	4114	7562946	10.1021/jm00020a026	Synthesis and antiproliferative and antiviral activity of 2'-deoxy-2'-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin.	Krawczyk SH, Nassiri MR, Kucera LS, Kern ER, Ptak RG, Wotring LL, Drach JC, Townsend LB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	23	4648	4659	7473592	10.1021/jm00023a004	Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses.	Hakimelahi GH, Moosavi-Movahedi AA, Sadeghi MM, Tsay SC, Hwu JR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	23	4679	4686	7473595	10.1021/jm00023a007	A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.	Dollé V, Fan E, Nguyen CH, Aubertin AM, Kirn A, Andreola ML, Jamieson G, Tarrago-Litvak L, Bisagni E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	25	4929	4936	8523406	10.1021/jm00025a010	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.	Bell FW, Cantrell AS, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM, Noréen R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	5	794	802	7877144	10.1021/jm00005a006	Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4.	Ho W, Kukla MJ, Breslin HJ, Ludovici DW, Grous PP, Diamond CJ, Miranda M, Rodgers JD, Ho CY, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1995	38	7	1189	1195	7707321	10.1021/jm00007a015	Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.	Ford H, Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H, Shirasaka T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	12	1251	1254		10.1016/0960-894X(95)00203-6	Synthesis and HIV-1 inhibition of novel benzimidazole derivatives	Gardiner JM, Loyns CR, Burke A, Khan A, Mahmood N
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	12	1275	1280		10.1016/0960-894X(95)00208-B	Synthesis and antiviral activity of rigid acyclonucleotide analogs	Casara PJ, Altenburger J, Taylor DL, Stanley Tyms A, Kenny M, Nave J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	14	1461	1466		10.1016/0960-894X(95)00257-T	Synthesis and anti HIV-1 activity of new thiadiazepindioxides	Giannotti D, Viti G, Nannicini R, Pestellini V, Bellarosa D
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	14	1471	1474		10.1016/0960-894X(95)00260-Z	A novel non nucleoside compound with high in vitro anti-HIV-1 activity. Absolute stereochemistry determination	De la Fuente JA, Marugan JJ, Cross SS, Mateos AF, Garcia S, Menendez A
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	16	1819	1824		10.1016/0960-894X(95)00302-A	Aromatic amino acid phosphoramidate di- and triesters of 3-azido-3-deoxythymidine (AZT) are non-toxic inhibitors of HIV-1 replication	Wagner CR, McIntee EJ, Schinazi RF, Abraham TW
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	16	1843	1848		10.1016/0960-894X(95)00306-E	Rational design of irreversible, pseudo-C2-symmetric hiv-1 protease inhibitors	Park C, Koh JS, Son YC, Choi H, Lee CS, Choy N, Moon KY, Jung WH, Kim SC, Yoon H
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	19	2273	2276		10.1016/0960-894X(95)00395-A	Enantiomerically pure synthesis and antiviral evaluation of [(2S, 3S)-bis(hydroxymethyl)azetidin-1-yl] purine nucleosides: Analogs of oxetanocin-A	Nishiyama S, Kikuchi Y, Kurata H, Yamamura S, Izawa T, Nagahata T, Ikeda R, Kato K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	7	743	748		10.1016/0960-894X(95)00107-5	Synthesis and anti-HIV activities of 2-deoxy-2,2-difluoro--L-ribofuranosyl-pyrimidine and -purine nucleosides	Yuejun Xiang, Kotra LP, Chu CK, Schinazi RF
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1995	5	8	877	880		10.1016/0960-894X(95)00133-E	Anti-human immunodeficiency virus type-1 (HIV-1) and anti-hepatitis B virus (HBV) activities of (2,3-dideoxy-2-fluoro--L-threo-pentofuranosyl)nucleosides	Xiang Y, Cavalcanti S, Chu CK, Schinazi RF, Balakrishna Pai S, Young-Lian Zhu, Yung-Chi Cheng
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1995	58	7	1024	1031	7561895	10.1021/np50121a006	Mechanistic evaluation of new plant-derived compounds that inhibit HIV-1 reverse transcriptase.	Pengsuparp T, Cai L, Constant H, Fong HH, Lin LZ, Kinghorn AD, Pezzuto JM, Cordell GA, Ingolfsdóttir K, Wagner H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	10	1975	1980	8642556	10.1021/jm960008c	Antitumor agents. 166. Synthesis and biological evaluation of 5,6,7,8-substituted-2-phenylthiochromen-4-ones.	Wang HK, Bastow KF, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	10	1981	1990	8642557	10.1021/jm9507338	Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates.	Valette G, Pompon A, Girardet JL, Cappellacci L, Franchetti P, Grifantini M, La Colla P, Loi AG, Périgaud C, Gosselin G, Imbach JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	12	2427	2431	8691437	10.1021/jm9600499	Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.	Danel K, Larsen E, Pedersen EB, Vestergaard BF, Nielsen C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	14	2672	2680	8709096	10.1021/jm950702c	Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.	Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Greco G, Novellino E, Altamura S, Di Renzo L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	14	2856	2859	8709116	10.1021/jm9507901	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.	Gueiffier A, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade JC, Kerbal A, Essassi EM, Debouzy JC, Witvrouw M, Blache Y, Balzarini J, De Clercq E, Chapat JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	17	3418	3422	8765527	10.1021/jm950777g	Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine.	Tsotinis A, Calogeropoulou T, Koufaki M, Souli C, Balzarini J, De Clercq E, Makriyannis A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	2	522	530	8558522	10.1021/jm950568w	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.	Artico M, Silvestri R, Massa S, Loi AG, Corrias S, Piras G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	20	4073	4088	8831773	10.1021/jm960314q	Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity.	Holý A, Dvoráková H, Jindrich J, Masojídková M, Bud¿sínský M, Balzarini J, Andrei G, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	26	5276	5280	8978856	10.1021/jm950822k	Synthesis and HIV inhibition activity of 2',3'-dideoxy-3'-C-hydroxymethyl nucleosides.	Lee-Ruff E, Ostrowski M, Ladha A, Stynes DV, Vernik I, Jiang JL, Wan WQ, Ding SF, Joshi S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	4	826	833	8632406	10.1021/jm9408326	In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine.	Wang L, Morin KW, Kumar R, Cheraghali M, Todd KG, Baker GB, Knaus EE, Wiebe LI.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	5	1016	1017	8676334	10.1021/jm950922q	Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.	Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	6	1303	1313	8632437	10.1021/jm950797i	Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.	Flavin MT, Rizzo JD, Khilevich A, Kucherenko A, Sheinkman AK, Vilaychack V, Lin L, Chen W, Greenwood EM, Pengsuparp T, Pezzuto JM, Hughes SH, Flavin TM, Cibulski M, Boulanger WA, Shone RL, Xu ZQ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	8	1748	1753	8648614	10.1021/jm950605j	Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.	McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1996	39	9	1771	1777	8627600	10.1021/jm950620o	Nucleoside conjugates. 15. Synthesis and biological activity of anti-HIV nucleoside conjugates of ether and thioether phospholipids.	Hong CI, Nechaev A, Kirisits AJ, Vig R, West CR, Manouilov KK, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1996	59	11	1066	1068	8946749	10.1021/np9601667	Two new lignans, interiotherins A and B, as anti-HIV principles from Kadsura interior.	Chen DF, Zhang SX, Chen K, Zhou BN, Wang P, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	10	1183	1186		10.1016/0960-894X(96)00195-3	Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells	McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	11	1253	1256		10.1016/0960-894X(96)00210-7	Anti-human immunodeficiency virus activity and cytotoxicity of derivatized buckminsterfullerenes	Schuster DI, Wilson SR, Schinazi RF
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	11	1279	1284		10.1016/0960-894X(96)00216-8	Design, synthesis and antiproliferative activity of methyl 4-Iodo-1--D-ribofuranosyl-pyrazole-3-carboxylate and related compounds	Manfredini S, Bazzanini R, Baraldi PG, Simoni D, Vertuani S, Pani A, Pinna E, Scintu F, Lichino D, Colla PL
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	16	1901	1904		10.1016/0960-894X(96)00334-4	Synthesis, characterization, and anti-HIV activity of some 2-p-X-phenyl-1,3-N,N-diphenyl-amidines	Echevarria A, Santos LH, Miller J, Mahmood N
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	16	1993	1996		10.1016/0960-894X(96)00355-1	Utilization of wieland furoxan synthesis for preparation of 4-aryl-1,2,5-oxadiazole-3-yl carbamate derivatives having potent anti-HIV activity	Takayama H, Shirakawa S, Kitajima M, Aimi N, Yamaguchi K, Hanasaki Y, Ide T, Katsuura K, Fujiwara M, Ijichi K, Konno K, Sigeta S, Yokota T, Baba M
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	19	2359	2362		10.1016/0960-894X(96)00433-7	Phosphoramidate derivatives of 2,3-didehydro-2,3-dideoxyadenosine [d4A] have markedly improved anti-HIV potency and selectivity	McGuigan C, Wedgwood OM, De Clercq E, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	2	173	178		10.1016/0960-894X(95)00584-G	Synthesis of new non-nucleoside inhibitors of HIV-1	Dolle V, Aubertin A, Ludwig O, Chi Hung Nguyen, Bisagni E, Legraverend M
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	2	179	184		10.1016/0960-894X(95)00585-H	Synthesis, enzymatic phosphorylation and antiviral activity of acyclic dienyl phosphonate derivatives of guanine	Nave J, Casara PJ, Taylor DL, Stanley Tyms A, Kenny M, HalazyS S
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	20	2405	2410		10.1016/0960-894X(96)00444-1	Isosteres of nucleoside triphosphates	Weaver R, Gilbert IH, Mahmood N, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	20	2411	2416		10.1016/0960-894X(96)00443-X	Lipophilic bioisosteres of nucleoside triphosphates	Goldring AO, Gilbert IH, Mahmood N, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	20	2445	2448		10.1016/0960-894X(96)00446-5	A rapid synthesis of some 5-amino- nucleosides and nucleotides as potential antiviral compounds	McGuigan C, Turner S, Mahmood N, Hay AJ
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1996	6	9	1051	1054		10.1016/0960-894X(96)00171-0	Synthesis and anti-HIV activity of dihydroisoxazole 6-chloropurine and adenine	Yuejun Xiang, Jie Chen, Schinazi RF, Kang Zhao
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	10	1447	1454	9154967	10.1021/jm960802y	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.	Mai A, Artico M, Sbardella G, Quartarone S, Massa S, Loi AG, De Montis A, Scintu F, Putzolu M, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	10	1550	1558	9154976	10.1021/jm9600095	Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs.	Adams DR, Perez C, Maillard M, Florent JC, Evers M, Hénin Y, Litvak S, Litvak L, Monneret C, Grierson DS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	15	2363	2373	9240351	10.1021/jm9607921	Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.	Kim DK, Gam J, Kim YW, Lim J, Kim HT, Kim KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	16	2482	2490	9258355	10.1021/jm970172f	Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.	Rosowsky A, Fu H, Pai N, Mellors J, Richman DD, Hostetler KY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	21	3323	3331	9341906	10.1021/jm960694f	Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs.	McIntee EJ, Remmel RP, Schinazi RF, Abraham TW, Wagner CR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	22	3635	3644	9357530	10.1021/jm970275y	Structure-activity relationships of 2'-deoxy-2',2'-difluoro-L-erythro-pentofuranosyl nucleosides.	Kotra LP, Xiang Y, Newton MG, Schinazi RF, Cheng YC, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1997	40	4	486	494	9046339	10.1021/jm960500w	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.	Fedorov II, Kazmina EM, Gurskaya GV, Jasko MV, Zavodnic VE, Balzarini J, De Clercq E, Faraj A, Sommadossi JP, Imbach JL, Gosselin G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1997	60	9	884	888	9322359	10.1021/np9700275	In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora.	Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1997	7	14	1931	1936		10.1016/S0960-894X(97)00340-5	1-Arylsulfonyl-3-(-hydroxybenzyl)-1H-pyrroles, a novel class of anti-HIV-1 reverse transcriptase inhibitors	Artico M, Santo RD, Costi R, Massa S, Scintu F, Loi AG, De Montis A, La Colla P
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1997	7	20	2573	2578		10.1016/S0960-894X(97)10050-6	Anti-AIDS agents-XXVIII.1 Synthesis and Anti-HIV activity of methoxy substituted 3,4-Di-O-()-camphanoyl-(+)-cis-khellactone (DCK) analogues	Takeuchi Y, Xie L, Cosentino L, Lee K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1997	7	22	2897	2902		10.1016/S0960-894X(97)10108-1	Anti-AIDS agents. 291. Anti-HIV activity of modified podophyllotoxin derivatives	Lee CT, Lin VC, Zhang S, Zhu X, VanVliet D, Hu H, Beers SA, Wang Z, Mark Cosentino L, Morris-Natschke SL, Lee K
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1997	7	4	409	412		10.1016/S0960-894X(97)00022-X	Structure-activity relationships of anti-HIV-1 N-alkoxy- and N-allyloxy-benzimidazoles	Evans TM, Gardiner JM, Mahmood N, Smis M
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1997	7	5	567	572		10.1016/S0960-894X(97)00046-2	Molecular connectivity to find -blockers with low toxicity	Garcia-Domenech R, de Gregorio Alapont C, de Julian-Ortiz J, Galvez J, Popa L
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	1	10	23	9438017	10.1021/jm9705723	(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.	Qiu YL, Ksebati MB, Ptak RG, Fan BY, Breitenbach JM, Lin JS, Cheng YC, Kern ER, Drach JC, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	2	191	198	9457243	10.1021/jm970443m	Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones.	Danel K, Pedersen EB, Nielsen C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	21	4109	4117	9767646	10.1021/jm9802012	Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.	Arranz E, Díaz JA, Ingate ST, Witvrouw M, Pannecouque C, Balzarini J, De Clercq E, Vega S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	23	4648	4657	9804704	10.1021/jm980391g	Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents.	Sun IC, Wang HK, Kashiwada Y, Shen JK, Cosentino LM, Chen CH, Yang LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	8	1252	1262	9548815	10.1021/jm970559i	Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole.	Porcari AR, Devivar RV, Kucera LS, Drach JC, Townsend LB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	8	1284	1298	9548818	10.1021/jm9705869	Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.	Sekiyama T, Hatsuya S, Tanaka Y, Uchiyama M, Ono N, Iwayama S, Oikawa M, Suzuki K, Okunishi M, Tsuji T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1998	41	9	1417	1427	9554875	10.1021/jm970664s	cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system.	Meier C, Lorey M, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1998	61	4	437	439	9584397	10.1021/np970497z	Bioactive kaurane diterpenoids from Annona glabra.	Chang FR, Yang PY, Lin JY, Lee KH, Wu YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1998	61	9	1090	1095	9748372	10.1021/np9800710	Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids.	Kashiwada Y, Wang HK, Nagao T, Kitanaka S, Yasuda I, Fujioka T, Yamagishi T, Cosentino LM, Kozuka M, Okabe H, Ikeshiro Y, Hu CQ, Yeh E, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	10	1267	1272	9871747	10.1016/s0960-894x(98)00202-9	Anti-AIDS agents. 32. Synthesis and anti-HIV activity of betulin derivatives.	Sun IC, Shen JK, Wang HK, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	12	1461	1466	9873370	10.1016/s0960-894x(98)00250-9	5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.	Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	12	1483	1486	9873374	10.1016/s0960-894x(98)00254-6	Anti-AIDS agents. 31. Synthesis and anti-HIV activity of 4-substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) thiolactone analogs.	Yang ZY, Xia Y, Xia P, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	13	1585	1588	9873395	10.1016/s0960-894x(98)00278-9	Asymmetric synthesis and anti-HIV activity of L-carbocyclic 2',3'-didehydro-2',3'-dideoxyadenosine.	Wang P, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	16	2151	2156	9873504	10.1016/s0960-894x(98)00367-9	Anti-AIDS agents. 33. Synthesis and anti-HIV activity of mono-methyl substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues.	Xie L, Takeuchi Y, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	16	2179	2184	9873509	10.1016/s0960-894x(98)00380-1	In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.	Xu ZQ, Buckheit RW, Stup TL, Flavin MT, Khilevich A, Rizzo JD, Lin L, Zembower DE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	16	2213	2218	9873515	10.1016/s0960-894x(98)00384-9	Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	21	3003	3006	9873664	10.1016/s0960-894x(98)00535-6	Rational design of a new series of mixed anti-HIV pronucleotides.	Schlienger N, Beltran T, Périgaud C, Lefebvre I, Pompon A, Aubertin AM, Gosselin G, Imbach JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	22	3121	3126	9873688	10.1016/s0960-894x(98)00547-2	Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.	Venkatachalam TK, Tai HL, Vig R, Chen CL, Jan ST, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	7	847	852	9871553	10.1016/s0960-894x(98)00122-x	Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene.	Jeong LS, Yoo SJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1998	8	9	1045	1050	9871705	10.1016/s0960-894x(98)00158-9	Anti-HIV pronucleotides: decomposition pathways and correlation with biological activities.	Egron D, Lefebvre I, Périgaud C, Beltran T, Pompon A, Gosselin G, Aubertin AM, Imbach JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Biol. Chem.	1999	274	1	13675	13680	10224140	10.1074/jbc.274.19.13675	Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.	Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Pharmacol. Exp. Ther.	1999	291	1	778	784	10525100		Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.	Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	14	2662	2672	10411486	10.1021/jm9900624	Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents.	Xie L, Takeuchi Y, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	15	2901	2908	10425099	10.1021/jm990050i	Nucleosides and nucleotides. 185. Synthesis and biological activities of 4'alpha-C-branched-chain sugar pyrimidine nucleosides.	Nomura M, Shuto S, Tanaka M, Sasaki T, Mori S, Shigeta S, Matsuda A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	2	229	241	9925728	10.1021/jm980358u	New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.	Dessolin J, Galea P, Vlieghe P, Chermann JC, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	5	859	867	10072683	10.1021/jm980510s	Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase.	Shi J, McAtee JJ, Schlueter Wirtz S, Tharnish P, Juodawlkis A, Liotta DC, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	7	1320	1328	10197975	10.1021/jm980651u	Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2', 3'-unsaturated L-nucleosides.	Lee K, Choi Y, Gullen E, Schlueter-Wirtz S, Schinazi RF, Cheng YC, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	8	1401	1414	10212126	10.1021/jm980531m	Chicoric acid analogues as HIV-1 integrase inhibitors.	Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C, Strebel K, Kohn K, Witvrouw M, Pannecouque C, Debyser Z, De Clercq E, Rice WG, Pommier Y, Burke TR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	9	1604	1614	10229629	10.1021/jm981096z	cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.	Meier C, Knispel T, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	1999	42	9	1615	1624	10229630	10.1021/jm981097r	cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade.	Meier C, Knispel T, Marquez VE, Siddiqui MA, De Clercq E, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1999	62	1	94	97	9917290	10.1021/np980291d	Novel anti-HIV lancilactone C and related triterpenes from Kadsura lancilimba.	Chen DF, Zhang SX, Wang HK, Zhang SY, Sun QZ, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	1999	62	7	954	958	10425115	10.1021/np980481o	Biological evaluation of proanthocyanidin dimers and related polyphenols.	De Bruyne T, Pieters L, Witvrouw M, De Clercq E, Vanden Berghe D, Vlietinck AJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	11	1593	1598	10386942	10.1016/s0960-894x(99)00235-8	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.	Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	14	1963	1968	10450963	10.1016/s0960-894x(99)00324-8	Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis.	Mickle T, Nair V.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	18	2721	2726	10509923	10.1016/s0960-894x(99)00460-6	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.	Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	2	119	122	10021911	10.1016/s0960-894x(98)00708-2	Substituted 7H-pyrido[4,3-c]carbazoles with potent anti-HIV activity.	Hirata K, Ito C, Furukawa H, Itoigawa M, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	24	3411	3416	10617082	10.1016/s0960-894x(99)00624-1	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.	Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	3	385	388	10091689	10.1016/s0960-894x(99)00010-4	Nucleosides and nucleotides. 183. Synthesis of 4'alpha-branched thymidines as a new type of antiviral agent.	Sugimoto I, Shuto S, Mori S, Shigeta S, Matsuda A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	1999	9	6	803	806	10206539	10.1016/s0960-894x(99)00089-x	A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor.	Kimura T, Matsumoto H, Matsuda T, Hamawaki T, Akaji K, Kiso Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2000	10	1	87	90	10636251	10.1016/s0960-894x(99)00581-8	Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity.	Dong Y, Venkatachalam TK, Narla RK, Trieu VN, Sudbeck EA, Uckun FM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2000	10	10	1003	1005	10843202	10.1016/s0960-894x(00)00126-8	Anti-AIDS agents part 41: synthesis and anti-HIV activity of 3',4'-di-o-(-)-camphanoyl-(+)-cis-khellactone (DCK) lactam analogues.	Yang ZY, Xia Y, Xia P, Brossi A, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2000	10	11	1227	1231	10866387	10.1016/s0960-894x(00)00202-x	'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.	Matsumoto H, Hamawaki T, Ota H, Kimura T, Goto T, Sano K, Hayashi Y, Kiso Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2000	10	23	2633	2637	11128640	10.1016/s0960-894x(00)00535-7	Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.	Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Pharmacol. Exp. Ther.	2000	294	1	844	849	10945832		Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.	Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Annual Review of Pharmacology and Toxicology	2000	40	1	581	616	10836148	10.1146/annurev.pharmtox.40.1.581	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Tukey RH, Strassburg CP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	10	1927	1939	10821705	10.1021/jm991125l	"Synthesis and evaluation of ""AZT-HEPT"", ""AZT-pyridinone"", and ""ddC-HEPT"" conjugates as inhibitors of HIV reverse transcriptase."	Pontikis R, Dollé V, Guillaumel J, Dechaux E, Note R, Nguyen CH, Legraverend M, Bisagni E, Aubertin AM, Grierson DS, Monneret C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	11	2266	2274	10841805	10.1021/jm000110g	Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester and alkyl amide phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT).	Iyer VV, Griesgraber GW, Radmer MR, McIntee EJ, Wagner CR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	13	2575	2585	10891117	10.1021/jm0000564	QSAR model for drug human oral bioavailability.	Yoshida F, Topliss JG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	15	2915	2921	10956199	10.1021/jm000038m	Synthesis and biological evaluation of certain alpha,beta-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents.	El-Subbagh HI, Abu-Zaid SM, Mahran MA, Badria FA, Al-Obaid AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	20	3799	3802	11020296	10.1021/jm9903390	6-Aminoquinolones as new potential anti-HIV agents.	Cecchetti V, Parolin C, Moro S, Pecere T, Filipponi E, Calistri A, Tabarrini O, Gatto B, Palumbo M, Fravolini A, Palu' G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	21	3949	3962	11052800	10.1021/jm0009437	Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.	Dollé V, Nguyen CH, Legraverend M, Aubertin AM, Kirn A, Andreola ML, Ventura M, Tarrago-Litvak L, Bisagni E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	23	4516	4525	11087576	10.1021/jm000209n	Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity.	Ohrui H, Kohgo S, Kitano K, Sakata S, Kodama E, Yoshimura K, Matsuoka M, Shigeta S, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2000	43	23	4570	4574	11087582	10.1021/jm000996o	S-Acyl-2-thioethyl aryl phosphotriester derivatives as mononucleotide prodrugs.	Schlienger N, Peyrottes S, Kassem T, Imbach JL, Gosselin G, Aubertin AM, Périgaud C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Biochem. Pharmacol.	2000	60	1	215	219	10825466	10.1016/s0006-2952(00)00334-8	Role of organic cation transporters in the renal secretion of nucleosides.	Chen R, Nelson JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2000	63	12	1619	1622	11141100	10.1021/np990633v	Anti-AIDS agents 38. Anti-HIV activity of 3-O-acyl ursolic acid derivatives.	Kashiwada Y, Nagao T, Hashimoto A, Ikeshiro Y, Okabe H, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2000	63	3	357	361	10757718	10.1021/np990281s	Sesquiterpene alkaloids from Tripterygium hypoglaucum and Tripterygium wilfordii: a new class of potent anti-HIV agents.	Duan H, Takaishi Y, Imakura Y, Jia Y, Li D, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	13	1775	1777	11425558	10.1016/s0960-894x(01)00299-2	Rational design of a new series of pronucleotide.	Beltran T, Egron D, Pompon A, Lefebvre I, Périgaud C, Gosselin G, Aubertin A, Imbach J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	14	1897	1902	11459656	10.1016/s0960-894x(01)00323-7	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.	Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, Kodama E, Matsuoka M, Hattori T, Yamamoto N, Nakashima H, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	17	2291	2293	11527717	10.1016/s0960-894x(01)00437-1	Anti-AIDS agents. Part 47: Synthesis and anti-HIV activity of 3-substituted 3',4'-Di-O-(S)-camphanoyl-(3'R,4'R)-(+)-cis-khellactone derivatives.	Xie L, Allaway G, Wild C, Kilgore N, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	2	183	185	11206454	10.1016/s0960-894x(00)00635-1	3,28-Di-O-(dimethylsuccinyl)-betulin isomers as anti-HIV agents.	Kashiwada Y, Chiyo J, Ikeshiro Y, Nagao T, Okabe H, Cosentino LM, Fowke K, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	23	3085	3088	11714616	10.1016/s0960-894x(01)00635-7	Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase.	Chamorro C, Lobatón E, Bonache MC, De Clercq E, Balzarini J, Velázquez S, San-Félix A, Camarasa MJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2001	11	24	3115	3118	11720855	10.1016/s0960-894x(01)00647-3	Synthesis and anti-HIV activity of oleanolic acid derivatives.	Zhu YM, Shen JK, Wang HK, Cosentino LM, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Jpn. Pharmacol. Ther.	2001	29	1	S101	S104			TP-search Transporter Database	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Pharmacol. Exp. Ther.	2001	299	1	261	267	11561088		Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.	Takeuchi A, Masuda S, Saito H, Abe T, Inui K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	11	1702	1709	11356105	10.1021/jm001121c	Ether phospholipid-AZT conjugates possessing anti-HIV and antitumor cell activity. Synthesis, conformational analysis, and study of their thermal effects on membrane bilayers.	Mavromoustakos T, Calogeropoulou T, Koufaki M, Kolocouris A, Daliani I, Demetzos C, Meng Z, Makriyannis A, Balzarini J, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	18	3014	3021	11520210	10.1021/jm010863i	New 3'-azido-3'-deoxythymidin-5'-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: synthesis and anti-HIV evaluation.	Vlieghe P, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	2	223	231	11170632	10.1021/jm000260r	Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism.	Chang  S, Griesgraber GW, Southern PJ, Wagner CR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	23	3985	3993	11689085	10.1021/jm010256v	Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile virus.	Song GY, Paul V, Choo H, Morrey J, Sidwell RW, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	24	4092	4113	11708913	10.1021/jm010212m	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.	Xu G, Micklatcher M, Silvestri MA, Hartman TL, Burrier J, Osterling MC, Wargo H, Turpin JA, Buckheit RW, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	25	4370	4378	11728183	10.1021/jm010960b	Cheminformatic models to predict binding affinities to human serum albumin.	Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	3	305	315	11462972	10.1021/jm0010365	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.	Campiani G, Aiello F, Fabbrini M, Morelli E, Ramunno A, Armaroli S, Nacci V, Garofalo A, Greco G, Novellino E, Maga G, Spadari S, Bergamini A, Ventura L, Bongiovanni B, Capozzi M, Bolacchi F, Marini S, Coletta M, Guiso G, Caccia S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	5	664	671	11262077	10.1021/jm000070g	Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone analogues.	Xie L, Takeuchi Y, Cosentino LM, McPhail AT, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2001	44	5	777	786	11262088	10.1021/jm001033s	New 3'-azido-3'-deoxythymidin-5'-yl O-(omega-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation.	Vlieghe P, Bihel F, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, Chermann JC, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Mol. Pharmacol.	2001	59	1	1277	1286	11306713	10.1124/mol.59.5.1277	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.	Cha SH, Sekine T, Fukushima  JI, Kanai Y, Kobayashi Y, Goya T, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2001	64	10	1278	1281	11678650	10.1021/np010211x	Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.	Ito J, Chang FR, Wang HK, Park YK, Ikegaki M, Kilgore N, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2001	64	11	1477	1479	11720540	10.1021/np010216u	Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.	Gochfeld DJ, Hamann MT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2001	64	2	265	277	11430019	10.1021/np0003995	Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.	Yang SS, Cragg GM, Newman DJ, Bader JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2001	64	5	680	682	11374977	10.1021/np000518g	Naphthopyranone glycosides from Paepalanthus microphyllus.	Piacente S, Campaner Dos Santos L, Mahmood N, Zampelli A, Pizza C, Vilegas W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2001	64	7	958	960	11473435	10.1021/np0101189	Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives.	Ishida J, Wang HK, Oyama M, Cosentino ML, Hu CQ, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2002	12	17	2403	2406	12161143	10.1016/s0960-894x(02)00394-3	Synthesis and biological evaluation of novel D-2'-azido-2',3'-dideoxyarabinofuranosyl-4'-thiopyrimidines and purines.	Kim HO, Park YH, Moon HR, Jeong LS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2002	12	5	723	727	11858989	10.1016/s0960-894x(01)00838-1	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.	Kolocouris A, Dimas K, Pannecouque C, Witvrouw M, Foscolos GB, Stamatiou G, Fytas G, Zoidis G, Kolocouris N, Andrei G, Snoeck R, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2002	12	6	923	928	11958995	10.1016/s0960-894x(02)00041-0	Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.	Tamamura H, Hiramatsu K, Miyamoto K, Omagari A, Oishi S, Nakashima H, Yamamoto N, Kuroda Y, Nakagawa T, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Am. Soc. Nephrol.	2002	13	1	1703	1710	12089365	10.1097/01.asn.0000019413.78751.46	cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.	Urakami Y, Akazawa M, Saito H, Okuda M, Inui K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Aids	2002	16	1	1743	1747	12218384	10.1097/00002030-200209060-00005	The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).	Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Pharmacol. Exp. Ther.	2002	300	1	918	924	11861798	10.1124/jpet.300.3.918	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.	Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2002	45	19	4271	4275	12213068	10.1021/jm020069c	Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.	Sun IC, Chen CH, Kashiwada Y, Wu JH, Wang HK, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2002	45	22	4888	4898	12383014	10.1021/jm020246+	Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides.	Chong Y, Choo H, Choi Y, Mathew J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2002	45	6	1275	1283	11881996	10.1021/jm010969d	Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities.	Vlieghe P, Clerc T, Pannecouque C, Witvrouw M, De Clercq E, Salles JP, Kraus JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2002	45	6	1284	1291	11881997	10.1021/jm011011l	Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.	Khandazhinskaya AL, Shirokova EA, Skoblov YS, Victorova LS, Goryunova LY, Beabealashvilli RS, Pronyaeva TR, Fedyuk NV, Zolin VV, Pokrovsky AG, Kukhanova MK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2002	45	6	1313	1320	11882000	10.1021/jm010418n	Structure-activity relationships of 2'-fluoro-2',3'-unsaturated D-nucleosides as anti-HIV-1 agents.	Lee K, Choi Y, Gumina G, Zhou W, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2002	65	11	1649	1656	12444692	10.1021/np020234r	New saponins from the starfish Certonardoa semiregularis.	Wang W, Li F, Alam N, Liu Y, Hong J, Lee CK, Im KS, Jung JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2003	13	10	1813	1815	12729671	10.1016/s0960-894x(03)00197-5	Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos.	Wu JH, Wang XH, Yi YH, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2003	13	18	3045	3048	12941330	10.1016/s0960-894x(03)00643-7	Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.	Vanheusden V, Van Rompaey P, Munier-Lehmann H, Pochet S, Herdewijn P, Van Calenbergh S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2003	13	20	3499	3501	14505657	10.1016/s0960-894x(03)00730-3	Synthesis and biological evaluation of thymine nucleosides fused with 3',4'-tetrahydrofuran ring.	Kim MJ, Kim HO, Kim HD, Kim JH, Jeong LS, Chun MW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2003	13	9	1575	1576	12699758	10.1016/s0960-894x(03)00201-4	Anti-HIV agents. Part 55: 3'R,4'R-Di-(O)-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP), a novel anti-HIV agent.	Yu D, Brossi A, Kilgore N, Wild C, Allaway G, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	13	2565	2568	12801219	10.1021/jm0256225	Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.	Roy B, Chambert S, Lepoivre M, Aubertin AM, Balzarini J, Décout JL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	15	3245	3256	12852755	10.1021/jm0300274	l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.	Chong Y, Gumina G, Mathew JS, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	15	3292	3299	12852759	10.1021/jm030116g	A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude.	Choi Y, George C, Comin MJ, Barchi JJ, Kim HS, Jacobson KA, Balzarini J, Mitsuya H, Boyer PL, Hughes SH, Marquez VE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	18	3811	3821	12930144	10.1021/jm021108n	3'-C-branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.	Vanheusden V, Munier-Lehmann H, Froeyen M, Dugué L, Heyerick A, De Keukeleire D, Pochet S, Busson R, Herdewijn P, Van Calenbergh S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	21	4564	4571	14521418	10.1021/jm0308444	S-acyl-2-thioethyl phosphoramidate diester derivatives as mononucleotide prodrugs.	Egron D, Imbach JL, Gosselin G, Aubertin AM, Périgaud C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	3	389	398	12540238	10.1021/jm020376i	Synthesis, anti-HIV activity, and molecular mechanism of drug resistance of L-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides.	Choo H, Chong Y, Choi Y, Mathew J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	5	782	793	12593658	10.1021/jm021016y	S-acyl-2-thioethyl aryl phosphotriester derivatives of AZT: synthesis, antiviral activity, and stability study.	Peyrottes S, Coussot G, Lefebvre I, Imbach JL, Gosselin G, Aubertin AM, Périgaud C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2003	46	9	1764	1768	12699395	10.1021/jm020537i	Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.	Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, Maeda K, Watai Y, Arikuni H, Otaka A, Mitsuya H, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Mol. Pharmacol.	2003	63	1	65	72	12488537	10.1124/mol.63.1.65	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.	Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	10	2677	2680	15109677	10.1016/s0960-894x(04)00205-7	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.	Yadav A, Singh SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	12	3341	3343	15149703	10.1016/j.bmcl.2004.03.051	Anti-AIDS agents. Part 58: synthesis and anti-HIV activity of 1-thia-di-O-(-)-camphanoyl-(+)-cis-khellactone (1-thia-DCK) analogues.	Xia P, Yin ZJ, Chen Y, Zhang Q, Zhang B, Xia Y, Yang ZY, Kilgore N, Wild C, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	2	495	498	14698189	10.1016/j.bmcl.2003.10.036	New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.	Daoudi JM, Greiner J, Aubertin AM, Vierling P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	23	5851	5853	15501054	10.1016/j.bmcl.2004.09.033	3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents.	Kashiwada Y, Sekiya M, Ikeshiro Y, Fujioka T, Kilgore NR, Wild CT, Allaway GP, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	23	5855	5857	15501055	10.1016/j.bmcl.2004.09.032	Anti-AIDS agents. Part 62: anti-HIV activity of 2'-substituted 4-methyl-3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (4-methyl DCK) analogs.	Zhang Q, Chen Y, Xia P, Xia Y, Yang ZY, Yu D, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2004	14	9	2159	2162	15081000	10.1016/j.bmcl.2004.02.031	2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.	Shi J, Ray AS, Mathew JS, Anderson KS, Chu CK, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Pharmacol. Exp. Ther.	2004	309	1	1273	1281	14762099	10.1124/jpet.103.063370	Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.	Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	13	3399	3408	15189036	10.1021/jm040027j	Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents.	Zhou W, Gumina G, Chong Y, Wang J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	14	3512	3517	15214779	10.1021/jm030475b	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.	Yousaf M, Hammond NL, Peng J, Wahyuono S, McIntosh KA, Charman WN, Mayer AM, Hamann MT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	14	3606	3614	15214788	10.1021/jm0310176	Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.	Shirokova EA, Jasko MV, Khandazhinskaya AL, Ivanov AV, Yanvarev DV, Skoblov YS, Mitkevich VA, Bocharov EV, Pronyaeva TR, Fedyuk NV, Kukhanova MK, Pokrovsky AG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	16	4072	4082	15267246	10.1021/jm0400505	Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents.	Yu D, Chen CH, Brossi A, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	27	6964	6972	15615545	10.1021/jm040093l	(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity.	Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Matsumi S, Mitsuya H, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	3	756	760	14736256	10.1021/jm030416y	Anti-AIDS agents. 52. Synthesis and anti-HIV activity of hydroxymethyl (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone derivatives.	Xie L, Yu D, Wild C, Allaway G, Turpin J, Smith PC, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	5	1242	1250	14971904	10.1021/jm030408h	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.	Lombardo F, Obach RS, Shalaeva MY, Gao F.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2004	47	7	1631	1640	15027854	10.1021/jm0303148	Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents.	Zhu W, Chong Y, Choo H, Mathews J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2004	67	4	659	663	15104498	10.1021/np034052o	Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.	Ishikawa T, Nishigaya K, Takami K, Uchikoshi H, Chen IS, Tsai IL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Pharmacology and Therapeutics	2005	106	1	97	132	15781124	10.1016/j.pharmthera.2004.10.013	UDP-glucuronosyltransferases and clinical drug-drug interactions.	Kiang TK, Ensom MH, Chang TK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2005	48	11	3736	3748	15916425	10.1021/jm050096d	Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides.	Wang J, Jin Y, Rapp KL, Bennett M, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2005	48	2	380	391	15658852	10.1021/jm049429h	Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.	Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, Terakubo S, Trent JO, Peiper SC, Yamamoto N, Nakashima H, Otaka A, Fujii N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2005	48	23	7153	7165	16279773	10.1021/jm050257d	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.	Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2005	48	25	8000	8008	16335924	10.1021/jm050744t	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.	Manetti F, Esté JA, Clotet-Codina I, Armand-Ugón M, Maga G, Crespan E, Cancio R, Mugnaini C, Bernardini C, Togninelli A, Carmi C, Alongi M, Petricci E, Massa S, Corelli F, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2005	48	4	1188	1198	15715485	10.1021/jm0491896	Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy.	Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, Eriksson S, Tjarks W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Pharm Sci	2005	94	7	1467	1483	15920768	10.1002/jps.20373	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Jolivette LJ, Ward KW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2006	16	13	3541	3544	16621553	10.1016/j.bmcl.2006.03.080	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.	Mugnaini C, Manetti F, Esté JA, Clotet-Codina I, Maga G, Cancio R, Botta M, Corelli F.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2006	16	15	4099	4101	16698265	10.1016/j.bmcl.2006.04.085	Azadideoxyadenosine: synthesis, enzymology, and anti-HIV activity.	Nishonov AA, Ma X, Nair V.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2006	16	19	5047	5051	16879965	10.1016/j.bmcl.2006.07.042	Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro.	Torrence PF, Fan X, Zhang X, Loiseau PM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	1	43	50	16392791	10.1021/jm0504306	Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives.	Barral K, Balzarini J, Neyts J, De Clercq E, Hider RC, Camplo M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	18	5462	5469	16942019	10.1021/jm0601912	Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.	Yu D, Sakurai Y, Chen CH, Chang FR, Huang L, Kashiwada Y, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	2	445	447	16420027	10.1021/jm0508890	HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.	Nair V, Chi G, Ptak R, Neamati N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	20	6120	6128	17004726	10.1021/jm0607404	9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1.	Zhou S, Kern ER, Gullen E, Cheng YC, Drach JC, Tamiya S, Mitsuya H, Zemlicka J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	26	7799	7806	17181162	10.1021/jm060030y	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.	Barral K, Priet S, Sire J, Neyts J, Balzarini J, Canard B, Alvarez K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2006	49	5	1635	1647	16509580	10.1021/jm050912h	Synthesis and anti-HIV activity of D- and L-thietanose nucleosides.	Choo H, Chen X, Yadav V, Wang J, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2006	69	12	1697	1701	17190445	10.1021/np060239e	Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora.	Chen M, Kilgore N, Lee KH, Chen DF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2006	69	2	277	279	16499331	10.1021/np0503303	Triterpenoids from Schisandra lancifolia with anti-HIV-1 activity.	Xiao WL, Tian RR, Pu JX, Li X, Wu L, Lu Y, Li SH, Li RT, Zheng YT, Zheng QT, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2006	69	4	650	653	16643044	10.1021/np060047j	Nortriterpenoids from Schisandra lancifolia.	Xiao WL, Huang SX, Zhang L, Tian RR, Wu L, Li XL, Pu JX, Zheng YT, Lu Y, Li RT, Zheng QT, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2006	69	7	1034	1040	16872140	10.1021/np0601399	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.	Rao KV, Donia MS, Peng J, Garcia-Palomero E, Alonso D, Martinez A, Medina M, Franzblau SG, Tekwani BL, Khan SI, Wahyuono S, Willett KL, Hamann MT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2006	69	9	1271	1274	16989518	10.1021/np060124a	Tripfordines A-C, sesquiterpene pyridine alkaloids from Tripterygium wilfordii, and structure anti-HIV activity relationships of Tripterygium alkaloids.	Horiuch M, Murakami C, Fukamiya N, Yu D, Chen TH, Bastow KF, Zhang DC, Takaishi Y, Imakura Y, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Proc. Natl. Acad. Sci. U.S.A.	2007	104	20	8316	8321	17488811	10.1073/pnas.0700781104	Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.	Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	1	265	272	17055732	10.1016/j.bmc.2006.09.062	The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors.	Yuan D, He M, Pang R, Lin SS, Li Z, Yang M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	16	5448	5456	17555969	10.1016/j.bmc.2007.05.055	Exomethylene pyranonucleosides: efficient synthesis and biological evaluation of 1-(2,3,4-trideoxy-2-methylene-beta-d-glycero-hex-3-enopyranosyl)thymine.	Agelis G, Tzioumaki N, Boti¿ T, Cencic A, Komiotis D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	16	5519	5528	17562366	10.1016/j.bmc.2007.05.047	Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.	Mackman RL, Zhang L, Prasad V, Boojamra CG, Douglas J, Grant D, Hui H, Kim CU, Laflamme G, Parrish J, Stoycheva AD, Swaminathan S, Wang K, Cihlar T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	2	839	846	17085053	10.1016/j.bmc.2006.10.043	Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides.	Rao JR, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	2	980	987	17079149	10.1016/j.bmc.2006.10.033	Fluoro-ketopyranosyl nucleosides: synthesis and biological evaluation of 3-fluoro-2-keto-beta-D-glucopyranosyl derivatives of N4-benzoyl cytosine.	Manta S, Agelis G, Boti¿ T, Cencic A, Komiotis D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	21	6852	6858	17719228	10.1016/j.bmc.2006.12.013	Anti-AIDS agents 66: syntheses and anti-HIV activity of phenolic and aza 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) derivatives.	Suzuki M, Yu D, Morris-Natschke SL, Smith PC, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	3	1212	1228	17158051	10.1016/j.bmc.2006.11.026	Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors.	Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2007	15	9	3241	3247	17337193	10.1016/j.bmc.2007.02.031	An efficient synthesis of 3-fluoro-5-thio-xylofuranosyl nucleosides of thymine, uracil, and 5-fluorouracil as potential antitumor or/and antiviral agents.	Tsoukala E, Agelis G, Dolinsek J, Boti¿ T, Cencic A, Komiotis D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2007	17	11	2983	2986	17416522	10.1016/j.bmcl.2007.03.067	Design, synthesis, and antitumor activity of bile acid-polyamine-nucleoside conjugates.	Wu D, Ji S, Wu Y, Ju Y, Zhao Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2007	17	15	4316	4319	17533128	10.1016/j.bmcl.2007.05.026	Anti-AIDS agents 72. Bioisosteres (7-carbon-DCKs) of the potent anti-HIV lead DCK.	Wang Y, Huang SX, Xia P, Xia Y, Yang ZY, Kilgore N, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2007	17	16	4476	4480	17574419	10.1016/j.bmcl.2007.06.008	Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.	Cheng P, Jiang ZY, Wang RR, Zhang XM, Wang Q, Zheng YT, Zhou J, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2007	17	23	6553	6557	17935987	10.1016/j.bmcl.2007.09.081	Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives.	Qian K, Nakagawa-Goto K, Yu D, Morris-Natschke SL, Nitz TJ, Kilgore N, Allaway GP, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Biol. Chem.	2007	282	21	15743	15753	17403681	10.1074/jbc.m609864200	Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.	Rosenbluh J, Hayouka Z, Loya S, Levin A, Armon-Omer A, Britan E, Hizi A, Kotler M, Friedler A, Loyter A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Nat. Chem. Biol.	2007	3	5	268	273	17417631	10.1038/nchembio873	Chemical genetics reveals a complex functional ground state of neural stem cells.	Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2007	42	4	487	493	17188402	10.1016/j.ejmech.2006.11.002	Synthesis and antiviral activity of C-fluoro-branched cyclopropyl nucleosides.	Kim A, Hong JH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2007	50	15	3747	3750	17580846	10.1021/jm070285r	Phosphonated carbocyclic 2'-oxa-3'-azanucleosides as new antiretroviral agents.	Chiacchio U, Rescifina A, Iannazzo D, Piperno A, Romeo R, Borrello L, Sciortino MT, Balestrieri E, Macchi B, Mastino A, Romeo G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2007	50	26	6580	6595	18052319	10.1021/jm0708230	Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.	Mugnaini C, Alongi M, Togninelli A, Gevariya H, Brizzi A, Manetti F, Bernardini C, Angeli L, Tafi A, Bellucci L, Corelli F, Massa S, Maga G, Samuele A, Facchini M, Clotet-Codina I, Armand-Ugón M, Esté JA, Botta M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	10	3516	3522	17664328	10.1128/aac.01626-06	Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.	Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli E, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J, PACTG P1012 Team.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	11	3870	3879	17724147	10.1128/aac.00692-07	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.	Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	12	4489	4491	17876005	10.1128/aac.00687-07	Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.	Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	2	583	590	17158934	10.1128/aac.01078-06	Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3'-azido-3'-deoxythymidine-treated rats.	Deveaud C, Beauvoit B, Reynaud A, Bonnet J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	4	1142	1149	17220403	10.1128/aac.01227-06	Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart.	Susan-Resiga D, Bentley AT, Lynx MD, LaClair DD, McKee EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	5	1687	1693	17353236	10.1128/aac.01432-06	Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs.	Hsu CH, Hu R, Dutschman GE, Yang G, Krishnan P, Tanaka H, Baba M, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	7	2424	2429	17485498	10.1128/aac.01498-06	Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.	Asif G, Hurwitz SJ, Obikhod A, Delinsky D, Narayanasamy J, Chu CK, McClure HM, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	7	2531	2539	17470651	10.1128/aac.00039-07	Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.	Lund KC, Peterson LL, Wallace KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	7	2600	2604	17470654	10.1128/aac.00212-07	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.	Shi M, Wang X, De Clercq E, Takao S, Baba M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	8	2701	2708	17548498	10.1128/aac.00277-07	Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.	Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2007	51	8	2726	2732	17526755	10.1128/aac.00081-07	Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.	Sandrini MP, Shannon O, Clausen AR, Björck L, Piskur J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2007	70	2	265	268	17315963	10.1021/np0603166	Tetranorclerodanes and clerodane-type diterpene glycosides from Dicranopteris dichotoma.	Li XL, Yang LM, Zhao Y, Wang RR, Xu G, Zheng YT, Tu L, Peng LY, Cheng X, Zhao QS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2007	70	4	662	664	17291043	10.1021/np0605236	Bioactive lignans from Peperomia heyneana.	Zhang GL, Li N, Wang YH, Zheng YT, Zhang Z, Wang MW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2007	70	6	1056	1059	17489633	10.1021/np0700927	Triterpenoids from Schisandra rubriflora.	Xiao WL, Li XL, Wang RR, Yang LM, Li LM, Huang SX, Pu JX, Zheng YT, Li RT, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2008	16	1	157	163	17964796	10.1016/j.bmc.2007.10.013	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).	Lin Y, Liu X, Yan R, Li J, Pannecouque C, Witvrouw M, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2008	16	15	7321	7329	18585917	10.1016/j.bmc.2008.06.024	Phenyl phosphotriester derivatives of AZT: variations upon the SATE moiety.	Villard AL, Coussot G, Lefebvre I, Augustijns P, Aubertin AM, Gosselin G, Peyrottes S, Périgaud C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2008	16	17	7921	7926	18693022	10.1016/j.bmc.2008.07.078	Anti-HIV-1 activity of phloroglucinol derivative, 6,6'-bieckol, from Ecklonia cava.	Artan M, Li Y, Karadeniz F, Lee SH, Kim MM, Kim SK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2008	16	7	3887	3894	18267363	10.1016/j.bmc.2008.01.039	Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Wang YP, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Toxicol. Mech. Methods	2008	18	2	217	227	20020916	10.1080/15376510701857262	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.	Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2008	18	20	5368	5371	18824350	10.1016/j.bmcl.2008.09.055	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.	Zhan P, Liu X, Cao Y, Wang Y, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2008	18	3	1120	1123	18164198	10.1016/j.bmcl.2007.11.125	Synthesis and anti-HIV activity of GS-9148 (2'-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor.	Boojamra CG, Mackman RL, Markevitch DY, Prasad V, Ray AS, Douglas J, Grant D, Kim CU, Cihlar T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2008	18	7	2475	2478	18316190	10.1016/j.bmcl.2008.02.040	1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro.	Cheng P, Huang N, Jiang ZY, Zhang Q, Zheng YT, Chen JJ, Zhang XM, Ma YB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2008	43	12	2778	2783	18313175	10.1016/j.ejmech.2008.01.011	Simple and efficient synthesis of novel glycosyl thiourea derivatives as potential antitumor agents.	Shusheng Z, Tianrong Z, Kun C, Youfeng X, Bo Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2008	43	2	420	428	17548129	10.1016/j.ejmech.2007.04.001	Unsaturated fluoro-ketopyranosyl nucleosides: synthesis and biological evaluation of 3-fluoro-4-keto-beta-d-glucopyranosyl derivatives of N(4)-benzoyl cytosine and N(6)-benzoyl adenine.	Manta S, Agelis G, Boti¿ T, Cencic A, Komiotis D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2008	43	7	1366	1375	18037195	10.1016/j.ejmech.2007.10.014	Synthesis and molecular modelling of unsaturated exomethylene pyranonucleoside analogues with antitumor and antiviral activities.	Agelis G, Tzioumaki N, Tselios T, Boti¿ T, Cencic A, Komiotis D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2008	51	11	3275	3287	18457386	10.1021/jm7015683	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).	Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2008	51	17	5454	5458	18710207	10.1021/jm701585h	Structure-activity relationship study on anti-HIV 6-desfluoroquinolones.	Tabarrini O, Massari S, Daelemans D, Stevens M, Manfroni G, Sabatini S, Balzarini J, Cecchetti V, Pannecouque C, Fravolini A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2008	51	19	5932	5942	18788725	10.1021/jm8003152	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.	Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2008	51	21	6740	6751	18834112	10.1021/jm800656v	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.	Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	1	225	236	17967909	10.1128/aac.00972-07	Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.	Buckheit RW, Hartman TL, Watson KM, Chung SG, Cho EH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	1	329	332	17967913	10.1128/aac.01004-07	Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.	Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	4	1302	1317	18212100	10.1128/aac.01324-07	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.	Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, de Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	4	1519	1521	18285481	10.1128/aac.01241-07	Anti-BK virus activity of nucleoside analogs.	Randhawa P, Zemlicka J, Sauerbrei A, Meier C, Hostetler KY, Beadle JR, Farasati NA, Huang Y, Bradley M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	5	1759	1767	18316521	10.1128/aac.01313-07	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.	Lin PF, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L, Dicker I, Gali V, Higley H, Parkin N, Tenney D, Krystal M, Colonno R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	6	2069	2078	18378713	10.1128/aac.00911-07	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.	Hombrouck A, Voet A, Van Remoortel B, Desadeleer C, De Maeyer M, Debyser Z, Witvrouw M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	8	2825	2830	18541728	10.1128/aac.00434-08	Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.	Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	8	2861	2869	18541726	10.1128/aac.00210-08	Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.	Hombrouck A, Van Remoortel B, Michiels M, Noppe W, Christ F, Eneroth A, Sahlberg BL, Benkestock K, Vrang L, Johansson NG, Barreca ML, De Luca L, Ferro S, Chimirri A, Debyser Z, Witvrouw M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	8	2882	2889	18474584	10.1128/aac.01505-07	Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion.	Stankov MV, Schmidt RE, Behrens GM, German Competence Network HIV/AIDS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2008	52	9	3169	3179	18625767	10.1128/aac.00274-08	Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.	Shuck-Lee D, Chen FF, Willard R, Raman S, Ptak R, Hammarskjold ML, Rekosh D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2008	71	1	153	155	18088099	10.1021/np0704396	Octanorcucurbitane and cucurbitane triterpenoids from the tubers of Hemsleya endecaphylla with HIV-1 inhibitory activity.	Chen JC, Zhang GH, Zhang ZQ, Qiu MH, Zheng YT, Yang LM, Yu KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2008	71	5	760	763	18396905	10.1021/np070479+	Periglaucines A-D, anti-HBV and -HIV-1 alkaloids from Pericampylus glaucus.	Yan MH, Cheng P, Jiang ZY, Ma YB, Zhang XM, Zhang FX, Yang LM, Zheng YT, Chen JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	14	5238	5246	19515569	10.1016/j.bmc.2009.05.049	Novel 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents.	Tanaka R, Tsujii H, Yamada T, Kajimoto T, Amano F, Hasegawa J, Hamashima Y, Node M, Katoh K, Takebe Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	15	5476	5481	19581097	10.1016/j.bmc.2009.06.037	Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives.	Santos Fda C, Abreu P, Castro HC, Paixão IC, Cirne-Santos CC, Giongo V, Barbosa JE, Simonetti BR, Garrido V, Bou-Habib DC, Silva Dde O, Batalha PN, Temerozo JR, Souza TM, Nogueira CM, Cunha AC, Rodrigues CR, Ferreira VF, de Souza MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	16	5775	5781	19643613	10.1016/j.bmc.2009.07.028	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Zhu J, Fang Z, Li Z, Pannecouque C, Clercq ED.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	19	6983	6992	19734051	10.1016/j.bmc.2009.08.022	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.	Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	2	569	575	19112024	10.1016/j.bmc.2008.11.075	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.	Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, González-Díaz H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	2	667	674	19091580	10.1016/j.bmc.2008.11.056	Studies on anti-HIV quinolones: new insights on the C-6 position.	Massari S, Daelemans D, Manfroni G, Sabatini S, Tabarrini O, Pannecouque C, Cecchetti V.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	3	1404	1409	19153047	10.1016/j.bmc.2008.10.078	5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies.	Liang Y, Sharon A, Grier JP, Rapp KL, Schinazi RF, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	4	1739	1746	19179082	10.1016/j.bmc.2008.12.028	Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.	Boojamra CG, Parrish JP, Sperandio D, Gao Y, Petrakovsky OV, Lee SK, Markevitch DY, Vela JE, Laflamme G, Chen JM, Ray AS, Barron AC, Sparacino ML, Desai MC, Kim CU, Cihlar T, Mackman RL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	6	2321	2326	19254848	10.1016/j.bmc.2009.02.011	Synthesis and antiviral evaluation of thieno[3,4-d]pyrimidine C-nucleoside analogues of 2',3'-dideoxy- and 2',3'-dideoxy-2',3'-didehydro-adenosine and -inosine.	Hamann M, Pierra C, Sommadossi JP, Musiu C, Vargiu L, Liuzzi M, Storer R, Gosselin G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	7	2767	2774	19269831	10.1016/j.bmc.2009.02.039	Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors.	Xu B, Sun Y, Guo Y, Cao Y, Yu T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2009	17	9	3489	3498	19282192	10.1016/j.bmc.2009.02.033	Aryl nucleoside H-phosphonates. Part 16: synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters.	Romanowska J, Szyma¿ska-Michalak A, Boryski J, Stawi¿ski J, Kraszewski A, Loddo R, Sanna G, Collu G, Secci B, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2009	44	1	373	383	18486994	10.1016/j.ejmech.2008.02.047	Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates.	da Silva Fde C, de Souza MC, Frugulhetti II, Castro HC, Souza SL, de Souza TM, Rodrigues DQ, Souza AM, Abreu PA, Passamani F, Rodrigues CR, Ferreira VF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2009	44	11	4648	4653	19628308	10.1016/j.ejmech.2009.06.037	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhan P, Liu X, Fang Z, Li Z, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2009	44	4	1600	1606	18768239	10.1016/j.ejmech.2008.07.027	First-principle, structure-based prediction of hepatic metabolic clearance values in human.	Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	10	3248	3258	19388685	10.1021/jm900136j	Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.	Qian K, Yu D, Chen CH, Huang L, Morris-Natschke SL, Nitz TJ, Salzwedel K, Reddick M, Allaway GP, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	17	5356	5364	19678643	10.1021/jm801176e	The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.	Boyer PL, Vu BC, Ambrose Z, Julias JG, Warnecke S, Liao C, Meier C, Marquez VE, Hughes SH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	20	6233	6243	19764786	10.1021/jm901036q	Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.	Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	23	7368	7371	19537689	10.1021/jm900275m	Discovery of the first series of small molecule H5N1 entry inhibitors.	Song G, Yang S, Zhang W, Cao Y, Wang P, Ding N, Zhang Z, Guo Y, Li Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	23	7887	7891	19526990	10.1021/jm9004253	Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.	Dang Z, Lai W, Qian K, Ho P, Lee KH, Chen CH, Huang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2009	52	4	1224	1228	19170521	10.1021/jm801395v	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.	Butini S, Brindisi M, Cosconati S, Marinelli L, Borrelli G, Coccone SS, Ramunno A, Campiani G, Novellino E, Zanoli S, Samuele A, Giorgi G, Bergamini A, Di Mattia M, Lalli S, Galletti B, Gemma S, Maga G.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	11	4640	4646	19704131	10.1128/aac.00686-09	Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.	Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	12	4987	4998	19786602	10.1128/aac.00670-09	ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.	Wang H, Qi Z, Guo A, Mao Q, Lu H, An X, Xia C, Li X, Debnath AK, Wu S, Liu S, Jiang S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	3	1252	1255	19104011	10.1128/aac.01115-08	Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.	Lynx MD, LaClair DD, McKee EE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	3	997	1006	18955518	10.1128/aac.00689-08	GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.	Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	5	2196	2198	19223644	10.1128/aac.01593-08	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.	Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	6	2367	2374	19307360	10.1128/aac.01523-08	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.	Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	7	2940	2948	19451305	10.1128/aac.01727-08	The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.	Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, Huang W, Toma J, Komano J, Yanaka M, Tanaka Y, Yamamoto N.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2009	53	9	3715	3719	19596885	10.1128/aac.00392-09	Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.	Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2009	72	6	1133	1141	19413342	10.1021/np900123z	Lignans with anti-HIV activity from Schisandra propinqua var. sinensis.	Li XN, Pu JX, Du X, Yang LM, An HM, Lei C, He F, Luo X, Zheng YT, Lu Y, Xiao WL, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2009	72	6	1184	1190	19453174	10.1021/np900213w	Chemical constituents of Heteroplexis micocephala.	Fan X, Zi J, Zhu C, Xu W, Cheng W, Yang S, Guo Y, Shi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2009	72	9	1620	1626	19702283	10.1021/np900305j	Chemical Constituents of the Roots of Euphorbia micractina.	Xu W, Zhu C, Cheng W, Fan X, Chen X, Yang S, Guo Y, Ye F, Shi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2009	72	9	1678	1681	19685905	10.1021/np900292e	Bioactive Nortriterpenoids from Schisandra grandiflora.	Xiao WL, Gong YQ, Wang RR, Weng ZY, Luo X, Li XN, Yang GY, He F, Pu JX, Yang LM, Zheng YT, Lu Y, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	1	36	45	19944610	10.1016/j.bmc.2009.11.016	Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands.	Mourer M, Psychogios N, Laumond G, Aubertin AM, Regnouf-de-Vains JB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	12	4363	4373	20537902	10.1016/j.bmc.2010.04.089	Anti-AIDS agents 82: synthesis of seco-(3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) derivatives as novel anti-HIV agents.	Tang J, Qian K, Zhang BN, Chen Y, Xia P, Yu D, Xia Y, Yang ZY, Chen CH, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	14	5208	5223	20542438	10.1016/j.bmc.2010.05.057	Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.	Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, Toda M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	16	6012	6023	20638854	10.1016/j.bmc.2010.06.067	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.	Casano G, Dumètre A, Pannecouque C, Hutter S, Azas N, Robin M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	17	6451	6469	20673723	10.1016/j.bmc.2010.06.092	Conjugates of betulin derivatives with AZT as potent anti-HIV agents.	Xiong J, Kashiwada Y, Chen CH, Qian K, Morris-Natschke SL, Lee KH, Takaishi Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	20	7203	7211	20846868	10.1016/j.bmc.2010.08.031	Anti-AIDS agents 84. Synthesis and anti-human immunodeficiency virus (HIV) activity of 2'-monomethyl-4-methyl- and 1'-thia-4-methyl-(3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs.	Xu SQ, Yan X, Chen Y, Xia P, Qian K, Yu D, Xia Y, Yang ZY, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	20	7302	7309	20833052	10.1016/j.bmc.2010.07.006	Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum.	Cui H, Ruiz-Pérez LM, González-Pacanowska D, Gilbert IH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	23	8243	8256	21044845	10.1016/j.bmc.2010.10.009	Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds.	Guantai EM, Ncokazi K, Egan TJ, Gut J, Rosenthal PJ, Smith PJ, Chibale K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	23	8310	8314	21035347	10.1016/j.bmc.2010.09.070	1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents.	Novikov MS, Buckheit RW, Temburnikar K, Khandazhinskaya AL, Ivanov AV, Seley-Radtke KL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	5	2029	2036	20137956	10.1016/j.bmc.2010.01.023	Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.	Chauthe SK, Bharate SB, Sabde S, Mitra D, Bhutani KK, Singh IP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	8	2872	2879	20350812	10.1016/j.bmc.2010.03.015	Synthesis and anti-HIV activity of alkylated quinoline 2,4-diols.	Ahmed N, Brahmbhatt KG, Sabde S, Mitra D, Singh IP, Bhutani KK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2010	18	9	3261	3269	20378362	10.1016/j.bmc.2010.03.023	3'-(1,2,3-Triazol-1-yl)-3'-deoxythymidine analogs as substrates for human and Ureaplasma parvum thymidine kinase for structure-activity investigations.	Lin J, Roy V, Wang L, You L, Agrofoglio LA, Deville-Bonne D, McBrayer TR, Coats SJ, Schinazi RF, Eriksson S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2010	19	7	652	663		10.1007/s00044-009-9220-x	Synthesis and anti-HIV activity evaluation of novel N-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides	Zhan P, Liu H, Liu X, Wang Y, Pannecouque C, Witvrouw M, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	1	60	64	19948402	10.1016/j.bmcl.2009.11.031	Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.	Zhang HW, Coats SJ, Bondada L, Amblard F, Detorio M, Asif G, Fromentin E, Solomon S, Obikhod A, Whitaker T, Sluis-Cremer N, Mellors JW, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	12	3534	3536	20488700	10.1016/j.bmcl.2010.04.132	Anti HIV-1 agents 5: synthesis and anti-HIV-1 activity of some N-arylsulfonyl-3-acetylindoles in vitro.	Ran JQ, Huang N, Xu H, Yang LM, Lv M, Zheng YT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	14	4053	4056	20542430	10.1016/j.bmcl.2010.05.090	Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.	Wang Q, Li Y, Song C, Qian K, Chen CH, Lee KH, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	15	4416	4419	20598537	10.1016/j.bmcl.2010.06.052	Synthesis and evaluation of beta-carboline derivatives as inhibitors of human immunodeficiency virus.	Brahmbhatt KG, Ahmed N, Sabde S, Mitra D, Singh IP, Bhutani KK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	15	4432	4435	20598530	10.1016/j.bmcl.2010.06.056	Synthesis of highly functionalized 2,4-diaminoquinazolines as anticancer and anti-HIV agents.	Yan SJ, Zheng H, Huang C, Yan YY, Lin J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	19	5853	5858	20728351	10.1016/j.bmcl.2010.07.106	CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.	Narumi T, Ochiai C, Yoshimura K, Harada S, Tanaka T, Nomura W, Arai H, Ozaki T, Ohashi N, Matsushita S, Tamamura H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	2	763	766	20005712	10.1016/j.bmcl.2009.11.018	Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles.	Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, Toda M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2010	20	3	841	843	20060716	10.1016/j.bmcl.2009.12.097	Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.	Li Y, Soni PB, Liu L, Zhang X, Liotta DC, Lutz S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2010	45	3	930	940	20022146	10.1016/j.ejmech.2009.11.034	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.	Guerra A, Campillo NE, Páez JA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2010	45	9	4026	4034	20691339	10.1016/j.ejmech.2010.05.060	Synthesis of substituted thieno[2,3-d]pyrimidine-2,4-dithiones and their S-glycoside analogues as potential antiviral and antibacterial agents.	Hafez HN, Hussein HA, El-Gazzar AR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2010	53	13	4906	4916	20527972	10.1021/jm1002952	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.	Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L, Qian K, Chen CH, Huang R, Jiang S, Lee KH, Xie L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2010	53	4	1534	1545	20112915	10.1021/jm901758f	5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.	El Safadi Y, Paillart JC, Laumond G, Aubertin AM, Burger A, Marquet R, Vivet-Boudou V.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2010	53	8	3133	3141	20329730	10.1021/jm901782m	Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.	Qian K, Kuo RY, Chen CH, Huang L, Morris-Natschke SL, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2010	53	9	3480	3488	20377249	10.1021/jm100093p	"""Viologen"" dendrimers as antiviral agents: the effect of charge number and distance."	Asaftei S, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	1	280	287	19805555	10.1128/aac.00914-09	Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.	Stankov MV, Lücke T, Das AM, Schmidt RE, Behrens GM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	10	4451	4463	20660667	10.1128/aac.01455-09	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.	Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	11	4887	4892	20805401	10.1128/aac.00794-10	In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.	Zhang P, Zhang L, Jiang Z, Wang T, Chen H, Xiong Y, Li Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	3	1248	1255	20038617	10.1128/aac.01209-09	Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.	Hurwitz SJ, Asif G, Fromentin E, Tharnish PM, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	3	1343	1346	20086159	10.1128/aac.01448-09	Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.	Wang G, Watson KM, Peterkofsky A, Buckheit RW.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	4	1512	1519	20086149	10.1128/aac.01443-09	Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.	Ptak RG, Gentry BG, Hartman TL, Watson KM, Osterling MC, Buckheit RW, Townsend LB, Drach JC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	5	1973	1980	20194692	10.1128/aac.00870-09	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.	Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2010	54	7	2901	2909	20439609	10.1128/aac.00068-10	Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.	Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW, Mankowski MK, Osterling MC, Almond MR, Painter GR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2010	73	2	221	225	20146529	10.1021/np900849y	Chemical constituents from the leaves and stems of Schisandra rubriflora.	Xiao WL, Yang SY, Yang LM, Yang GY, Wang RR, Zhang HB, Zhao W, Pu JX, Lu Y, Zheng YT, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2010	73	3	500	516	20187635	10.1021/np900821e	Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.	Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Nat Rev Drug Discov	2010	9	3	215	236	20190787	10.1038/nrd3028	Membrane transporters in drug development.	International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	13	4028	4042	21658961	10.1016/j.bmc.2011.05.022	Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.	Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Murota M, Takaoka Y, Nakai H, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	14	4220	4226	21689939	10.1016/j.bmc.2011.05.060	Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.	Gu SX, Zhang X, He QQ, Yang LM, Ma XD, Zheng YT, Yang SQ, Chen FE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	14	4366	4376	21683601	10.1016/j.bmc.2011.05.024	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Zhang J, Zhan P, Wu J, Li Z, Jiang Y, Ge W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	15	4601	4607	21719299	10.1016/j.bmc.2011.06.007	Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ma XD, Zhang X, Dai HF, Yang SQ, Yang LM, Gu SX, Zheng YT, He QQ, Chen FE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	16	4704	4709	21788138	10.1016/j.bmc.2011.07.003	Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.	Ma XD, Zhang X, Yang SQ, Dai HF, Yang LM, Gu SX, Zheng YT, He QQ, Chen FE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	17	5117	5124	21824782	10.1016/j.bmc.2011.07.023	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.	Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	18	5648	5669	21840722	10.1016/j.bmc.2011.07.022	Synthesis and biological evaluation of 2',4'- and 3',4'-bridged nucleoside analogues.	Nicolaou KC, Ellery SP, Rivas F, Saye K, Rogers E, Workinger TJ, Schallenberger M, Tawatao R, Montero A, Hessell A, Romesberg F, Carson D, Burton D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	21	6375	6382	21945463	10.1016/j.bmc.2011.08.069	Synthesis and anticancer activity of 5'-chloromethylphosphonates of 3'-azido-3'-deoxythymidine (AZT).	Celewicz L, Jó¿wiak A, Ruszkowski P, Laskowska H, Olejnik A, Czarnecka A, Hoffmann M, H¿ado¿ B.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	23	7093	7099	22037050	10.1016/j.bmc.2011.10.002	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.	Gu SX, Yang SQ, He QQ, Ma XD, Chen FE, Dai HF, Clercq ED, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	24	7603	7611	22061826	10.1016/j.bmc.2011.10.021	Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase.	Van Poecke S, Munier-Lehmann H, Helynck O, Froeyen M, Van Calenbergh S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	3	1256	1263	21227704	10.1016/j.bmc.2010.12.031	Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5.	Bodiwala HS, Sabde S, Gupta P, Mukherjee R, Kumar R, Garg P, Bhutani KK, Mitra D, Singh IP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	6	2030	2045	21371895	10.1016/j.bmc.2011.01.047	Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.	Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	6	2084	2089	21334901	10.1016/j.bmc.2011.01.024	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.	Balestrieri E, Pizzimenti F, Ferlazzo A, Giofrè SV, Iannazzo D, Piperno A, Romeo R, Chiacchio MA, Mastino A, Macchi B.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2011	19	8	2615	2624	21458999	10.1016/j.bmc.2011.03.011	QSAR-based permeability model for drug-like compounds.	Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2011	20	8	1411	1420		10.1007/s00044-010-9513-0	Biological evaluation of novel 1,4-dithiine derivatives as potential antimicrobial agents	Bielenica A, Kossakowski J, Struga M, Dybaa I, La Colla P, Tamburini E, Loddo R
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	1	574	576	21095125	10.1016/j.bmcl.2010.10.054	Synthesis and biological activity of novel 5'-arylamino-nucleosides by microwave-assisted one-pot tandem Staudinger/aza-Wittig/reduction.	Chen H, Zhao J, Li Y, Shen F, Li X, Yin Q, Qin Z, Yan X, Wang Y, Zhang P, Zhang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	11	3443	3446	21515046	10.1016/j.bmcl.2011.03.105	Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method.	Bhavsar D, Trivedi J, Parekh S, Savant M, Thakrar S, Bavishi A, Radadiya A, Vala H, Lunagariya J, Parmar M, Paresh L, Loddo R, Shah A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	2	694	697	21194939	10.1016/j.bmcl.2010.12.003	Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.	He YP, Long J, Zhang SS, Li C, Lai CC, Zhang CS, Li DX, Zhang DH, Wang H, Cai QQ, Zheng YT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	22	6770	6772	21974951	10.1016/j.bmcl.2011.09.040	Synthesis and anti-HIV-1 activity of 4-substituted-7-(2'-deoxy-2'-fluoro-4'-azido-ß-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine analogues.	Guo X, Li Y, Tao L, Wang Q, Wang S, Hu W, Pan Z, Yang Q, Cui Y, Ge Z, Dong L, Yu X, An H, Song C, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	23	7094	7098	22014549	10.1016/j.bmcl.2011.09.089	Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5'-triphosphates.	Shi J, Zhou L, Zhang H, McBrayer TR, Detorio MA, Johns M, Bassit L, Powdrill MH, Whitaker T, Coats SJ, Götte M, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	3	961	965	21232955	10.1016/j.bmcl.2010.12.055	Compounds from Kadsura angustifolia with anti-HIV activity.	Sun R, Song HC, Wang CR, Shen KZ, Xu YB, Gao YX, Chen YG, Dong JY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	4	1141	1145	21256008	10.1016/j.bmcl.2010.12.109	Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.	Nishizawa R, Nishiyama T, Hisaichi K, Minamoto C, Matsunaga N, Takaoka Y, Nakai H, Jenkinson S, Kazmierski WM, Tada H, Sagawa K, Shibayama S, Fukushima D, Maeda K, Mitsuya H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2011	21	8	2406	2409	21414776	10.1016/j.bmcl.2011.02.074	Asymmetric total synthesis of (+)- and (-)-clusianone and (+)- and (-)-clusianone methyl enol ether via ACC alkylation and evaluation of their anti-HIV activity.	Garnsey MR, Matous JA, Kwiek JJ, Coltart DM.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2011	39	2	265	274	21051535	10.1124/dmd.110.034629	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Lin X, Skolnik S, Chen X, Wang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2011	39	3	353	362	21149540	10.1124/dmd.110.035998	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.	Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2011	39	3	448	455	21123165	10.1124/dmd.110.036608	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.	Dostalek M, Court MH, Hazarika S, Akhlaghi F.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2011	39	5	820	829	21282406	10.1124/dmd.110.037457	Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.	Deguchi T, Watanabe N, Kurihara A, Igeta K, Ikenaga H, Fusegawa K, Suzuki N, Murata S, Hirouchi M, Furuta Y, Iwasaki M, Okazaki O, Izumi T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2011	46	10	5039	5045	21872971	10.1016/j.ejmech.2011.08.011	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.	Zhan P, Chen X, Li X, Li D, Tian Y, Chen W, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2011	46	4	1045	1049	21295891	10.1016/j.ejmech.2011.01.016	Synthesis of 9-substituted derivatives of berberine as anti-HIV agents.	Bodiwala HS, Sabde S, Mitra D, Bhutani KK, Singh IP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2011	46	5	1656	1664	21376429	10.1016/j.ejmech.2011.02.014	Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative.	Kesel AJ.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2011	46	9	3832	3844	21700368	10.1016/j.ejmech.2011.05.051	Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.	Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2011	46	9	4178	4183	21745701	10.1016/j.ejmech.2011.06.020	Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents.	Wang Q, Hu W, Wang S, Pan Z, Tao L, Guo X, Qian K, Chen CH, Lee KH, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2011	54	19	6482	6491	21834513	10.1021/jm2001103	Aryl H-phosphonates 17: (N-aryl)phosphoramidates of pyrimidine nucleoside analogues and their synthesis, selected properties, and anti-HIV activity.	Romanowska J, Sobkowski M, Szyma¿ska-Michalak A, Ko¿odziej K, D¿browska A, Lipniacki A, Piasek A, Pietrusiewicz ZM, Figlerowicz M, Guranowski A, Boryski J, Stawi¿ski J, Kraszewski A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Antimicrob. Agents Chemother.	2011	55	1	42	49	21060108	10.1128/aac.01064-10	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.	Koh Y, Haim H, Engelman A.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2011	74	5	1221	1229	21534583	10.1021/np2001489	Lathyrane diterpenoids from the roots of Euphorbia micractina and their biological activities.	Tian Y, Xu W, Zhu C, Lin S, Li Y, Xiong L, Wang S, Wang L, Yang Y, Guo Y, Sun H, Wang X, Shi J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2011	74	6	1408	1413	21650224	10.1021/np200087d	Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus.	Fang PL, Cao YL, Yan H, Pan LL, Liu SC, Gong NB, Lü Y, Chen CX, Zhong HM, Guo Y, Liu HY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2011	74	6	1508	1512	21534540	10.1021/np200058c	Tigliane-type diterpenoid glycosides from Euphorbia fischeriana.	Pan LL, Fang PL, Zhang XJ, Ni W, Li L, Yang LM, Chen CX, Zheng YT, Li CT, Hao XJ, Liu HY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2011	74	6	1521	1525	21561060	10.1021/np200146x	Sesquiterpene and norsesquiterpene derivatives from Sanicula lamelligera and their biological evaluation.	Li XS, Zhou XJ, Zhang XJ, Su J, Li XJ, Yan YM, Zheng YT, Li Y, Yang LM, Cheng YX.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	11	3652	3657	22549138	10.1016/j.bmc.2012.03.047	Truncated phosphonated C-1'-branched N,O-nucleosides: a new class of antiviral agents.	Romeo R, Carnovale C, Giofrè SV, Romeo G, Macchi B, Frezza C, Marino-Merlo F, Pistarà V, Chiacchio U.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	12	3856	3864	22591854	10.1016/j.bmc.2012.04.030	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Liu X, Cheng Z, Meng C, Shao S, Pannecouque C, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	17	5277	5289	22858300	10.1016/j.bmc.2012.06.038	Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.	Aminake MN, Mahajan A, Kumar V, Hans R, Wiesner L, Taylor D, de Kock C, Grobler A, Smith PJ, Kirschner M, Rethwilm A, Pradel G, Chibale K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	18	5527	5536	22883027	10.1016/j.bmc.2012.07.026	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.	Li X, Zhan P, Liu H, Li D, Wang L, Chen X, Liu H, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	19	5802	5809	22954898	10.1016/j.bmc.2012.08.008	Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.	Zakirova NF, Shipitsyn AV, Jasko MV, Prokofjeva MM, Andronova VL, Galegov GA, Prassolov VS, Kochetkov SN.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	23	6795	6802	23098609	10.1016/j.bmc.2012.09.058	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.	Zhan P, Chen W, Li Z, Li X, Chen X, Tian Y, Pannecouque C, Clercq ED, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	23	6885	6893	23085031	10.1016/j.bmc.2012.09.026	Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2',3'-dideoxy-2',2'-difluoro-4'-azanucleosides.	Martínez-Montero S, Fernández S, Sanghvi YS, Theodorakis EA, Detorio MA, McBrayer TR, Whitaker T, Schinazi RF, Gotor V, Ferrero M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2012	20	4	1468	1474	22277590	10.1016/j.bmc.2011.12.055	Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.	Narumi T, Komoriya M, Hashimoto C, Wu H, Nomura W, Suzuki S, Tanaka T, Chiba J, Yamamoto N, Murakami T, Tamamura H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2012	21	11	3741	3749		10.1007/s00044-011-9912-x	Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives	Rizvi SUF, Siddiqui HL, Johns M, Detorio M, Schinazi RF
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2012	21	7	1451	1470		10.1007/s00044-011-9662-9	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2012	21	8	1557	1576		10.1007/s00044-011-9664-7	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives	Narang R, Narasimhan B, Sharma S, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2012	21	8	1935	1952		10.1007/s00044-011-9705-2	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides	Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2012	21	9	2526	2547		10.1007/s00044-011-9776-0	(Naphthalen-1-yloxy)-acetic acid benzylidene/(1-phenyl-ethylidene)-hydrazide derivatives: synthesis, antimicrobial evaluation, and QSAR studies	Narang R, Narasimhan B, Sharma S
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	12	4169	4172	22579418	10.1016/j.bmcl.2012.04.032	Pharmacophore-based small molecule CXCR4 ligands.	Narumi T, Tanaka T, Hashimoto C, Nomura W, Aikawa H, Sohma A, Itotani K, Kawamata M, Murakami T, Yamamoto N, Tamamura H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	15	5055	5058	22763201	10.1016/j.bmcl.2012.06.020	Oxoquinoline acyclonucleoside phosphonate analogues as a new class of specific inhibitors of human immunodeficiency virus type 1.	Faro LV, de Almeida JM, Cirne-Santos CC, Giongo VA, Castello-Branco LR, Oliveira Ide B, Barbosa JE, Cunha AC, Ferreira VF, de Souza MC, Paixão IC, de Souza MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	17	5451	5454	22858097	10.1016/j.bmcl.2012.07.037	Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.	Agarwal HK, Buckheit KW, Buckheit RW, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	23	7029	7035	23099090	10.1016/j.bmcl.2012.09.108	POMA analyses as new efficient bioinformatics' platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues.	Ahsan MJ, Govindasamy J, Khalilullah H, Mohan G, Stables JP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	23	7041	7044	23067552	10.1016/j.bmcl.2012.09.100	Synthetic bicyclic iminosugar derivatives fused thiazolidin-4-one as new potential HIV-RT inhibitors.	Chen H, Yang T, Wei S, Zhang H, Li R, Qin Z, Li X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	23	7114	7118	23099098	10.1016/j.bmcl.2012.09.070	Structural modifications of 5,6-dihydroxypyrimidines with anti-HIV activity.	Guo DL, Zhang XJ, Wang RR, Zhou Y, Li Z, Xu JY, Chen KX, Zheng YT, Liu H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	23	7155	7162	23084898	10.1016/j.bmcl.2012.09.062	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.	Zhan P, Li X, Li Z, Chen X, Tian Y, Chen W, Liu X, Pannecouque C, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2012	22	3	1415	1420	22226654	10.1016/j.bmcl.2011.12.076	Synthesis and antiviral activities of novel gossypol derivatives.	Yang J, Zhang F, Li J, Chen G, Wu S, Ouyang W, Pan W, Yu R, Yang J, Tien P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Metab. Dispos.	2012	40	2	240	248	22028316	10.1124/dmd.111.042150	Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution.	Kato Y, Nakajima M, Oda S, Fukami T, Yokoi T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	50		361	369	22369862	10.1016/j.ejmech.2012.02.015	Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors.	Wang Z, Wang M, Yao X, Li Y, Qiao W, Geng Y, Liu Y, Wang Q.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	51		60	66	22405288	10.1016/j.ejmech.2012.02.019	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Chen X, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	53		229	234	22575532	10.1016/j.ejmech.2012.04.004	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.	Gu SX, Li ZM, Ma XD, Yang SQ, He QQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	53		275	282	22546200	10.1016/j.ejmech.2012.04.010	Design, synthesis and antiviral activity of novel quinazolinones.	Wang Z, Wang M, Yao X, Li Y, Tan J, Wang L, Qiao W, Geng Y, Liu Y, Wang Q.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	54		159	174	22652226	10.1016/j.ejmech.2012.04.038	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.	Puig-de-la-Bellacasa R, Giménez L, Pettersson S, Pascual R, Gonzalo E, Esté JA, Clotet B, Borrell JI, Teixidó J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	54		33	41	22608761	10.1016/j.ejmech.2012.04.020	Design, synthesis and antiviral activity of novel pyridazines.	Wang Z, Wang M, Yao X, Li Y, Tan J, Wang L, Qiao W, Geng Y, Liu Y, Wang Q.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	10	4740	4763	22541068	10.1021/jm300212s	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	14	6634	6638	22712652	10.1021/jm300477h	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.	La Regina G, Coluccia A, Brancale A, Piscitelli F, Famiglini V, Cosconati S, Maga G, Samuele A, Gonzalez E, Clotet B, Schols D, Esté JA, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	18	8128	8136	22978745	10.1021/jm301040s	Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.	Qian K, Bori ID, Chen CH, Huang L, Lee KH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	22	10108	10117	23046280	10.1021/jm301226a	Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays.	Hu G, Li X, Zhang X, Li Y, Ma L, Yang LM, Liu G, Li W, Huang J, Shen X, Hu L, Zheng YT, Tang Y.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	6	2672	2687	22352809	10.1021/jm201551m	Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Quiterio M, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2012	55	8	3595	3613	22268494	10.1021/jm200990c	Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.	Li D, Zhan P, De Clercq E, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	58		485	492	23159806	10.1016/j.ejmech.2012.10.036	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.	Ribone SR, Leen V, Madrid M, Dehaen W, Daelemans D, Pannecouque C, Briñón MC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2012	58		504	512	23164656	10.1016/j.ejmech.2012.03.032	Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.	Ma XD, He QQ, Zhang X, Yang SQ, Yang LM, Gu SX, Zheng YT, Chen FE, Dai HF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2012	75	11	1909	1914	23078294	10.1021/np300395m	Antiviral chromones from the stem of Cassia siamea.	Hu QF, Zhou B, Gao XM, Yang LY, Shu LD, Shen Y, Li GP, Che CT, Yang GY.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2012	75	3	414	419	22148316	10.1021/np200855d	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.	Vidal V, Potterat O, Louvel S, Hamy F, Mojarrab M, Sanglier JJ, Klimkait T, Hamburger M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2013	21	18	5900	5906	23916148	10.1016/j.bmc.2013.06.061	Synthesis and evaluation of novel 3-(3,5-dimethylbenzyl)uracil analogs as potential anti-HIV-1 agents.	Sakakibara N, Hamasaki T, Baba M, Demizu Y, Kurihara M, Irie K, Iwai M, Asada E, Kato Y, Maruyama T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2013	21	21	6477	6483	24055077	10.1016/j.bmc.2013.08.040	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.	Wu HQ, Yan ZH, Chen WX, He QQ, Chen FE, De Clercq E, Balzarini J, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2013	21	5	1199	1208	23375089	10.1016/j.bmc.2012.12.044	9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro.	Kre¿merová M, Jansa P, Dra¿ínský M, Sázelová P, Ka¿i¿ka V, Neyts J, Auwerx J, Kiss E, Goris N, Stepan G, Janeba Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2013	21	7	1964	1971	23415084	10.1016/j.bmc.2013.01.025	Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.	Olomola TO, Klein R, Mautsa N, Sayed Y, Kaye PT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2013	22	12	5752	5763		10.1007/s00044-013-0567-7	Synthesis of novel biologically active methylene derivatives of sydnones	Asundaria ST, Pannecouque C, De Clercq E, Supuran CT, Patel KC
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2013	22	5	2467	2475		10.1007/s00044-012-0241-5	Synthesis, biological evaluation, and molecular modeling studies of new 1,3,4-oxadiazole- and 1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a]pyrimidines as anti-HIV-1 agents	Hajimahdi Z, Zarghi A, Zabihollahi R, Aghasadeghi MR
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Med Chem Res	2013	22	8	3675	3686		10.1007/s00044-012-0342-1	Syntheses and in vitro biological screening of 1-aryl-10H-[1,2,4]triazolo[3,4:3,4][1,2,4]triazino[5,6-b]indoles	Upadhyay K, Manvar A, Loddo R, Colla PL, Virsodiya V, Trivedi J, Chaniyara R, Shah A
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2013	23	11	3385	3388	23623492	10.1016/j.bmcl.2013.03.077	Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors.	Zhou L, Amblard F, Zhang H, McBrayer TR, Detorio MA, Whitaker T, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2013	23	2	503	506	23237841	10.1016/j.bmcl.2012.11.027	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.	Rawal RK, Singh US, Chavre SN, Wang J, Sugiyama M, Hung W, Govindarajan R, Korba B, Tanaka Y, Chu CK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2013	23	22	6146	6151	24091080	10.1016/j.bmcl.2013.09.009	Synthesis, docking, and biological studies of phenanthrene ß-diketo acids as novel HIV-1 integrase inhibitors.	Sharma H, Sanchez TW, Neamati N, Detorio M, Schinazi RF, Cheng X, Buolamwini JK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	MedChemComm	2013	4	5	810	816		10.1039/C3MD00028A	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach	Song Y, Zhan P, Kang D, Li X, Tian Y, Li Z, Chen X, Chen W, Pannecouque C, De Clercq E, Liu X
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2013	56	21	8765	8780	24102161	10.1021/jm401232v	Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.	Sirivolu VR, Vernekar SK, Ilina T, Myshakina NS, Parniak MA, Wang Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2013	63		739	745	23570720	10.1016/j.ejmech.2013.02.042	Design, synthesis, and biological evaluation of new 2'-deoxy-2'-fluoro-4'-triazole cytidine nucleosides as potent antiviral agents.	Wu J, Yu W, Fu L, He W, Wang Y, Chai B, Song C, Chang J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2013	65		134	143	23707918	10.1016/j.ejmech.2013.04.052	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.	Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, De Clercq E.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2013	70		326	340	24177359	10.1016/j.ejmech.2013.09.047	Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.	McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, Madela K, Meneghesso S, Pertusati F, Serpi M, Slusarczyk M, Chamberlain S, Kolykhalov A, Vernachio J, Vanpouille C, Introini A, Margolis L, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	12	2298	2306	24308675	10.1021/np400683h	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.	Ma X, Li L, Zhu T, Ba M, Li G, Gu Q, Guo Y, Li D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	12	2350	2354	24299567	10.1021/np400546z	Kadcotriones A-C: tricyclic triterpenoids from Kadsura coccinea.	Liang CQ, Shi YM, Li XY, Luo RH, Li Y, Zheng YT, Zhang HB, Xiao WL, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	2	250	255	23327759	10.1021/np300745q	Dibenzocyclooctadiene lignans and norlignans from fruits of Schisandra wilsoniana.	Yang GY, Wang RR, Mu HX, Li YK, Li XN, Yang LM, Zheng YT, Xiao WL, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	2	292	296	23368966	10.1021/np300727f	Antiviral phenolic compounds from Arundina gramnifolia.	Hu QF, Zhou B, Huang JM, Gao XM, Shu LD, Yang GY, Che CT.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	4	530	537	23550966	10.1021/np3006887	Cytotoxic, antitopoisomerase II¿, and anti-HIV-1 activities of triterpenoids isolated from leaves and twigs of Gardenia carinata.	Kongkum N, Tuchinda P, Pohmakotr M, Reutrakul V, Piyachaturawat P, Jariyawat S, Suksen K, Akkarawongsapat R, Kasisit J, Napaswad C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2013	76	6	1052	1057	23738539	10.1021/np400070x	Bioactive dibenzocyclooctadiene lignans from the stems of Schisandra neglecta.	Gao XM, Wang RR, Niu DY, Meng CY, Yang LM, Zheng YT, Yang GY, Hu QF, Sun HD, Xiao WL.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	1	633	642	24275349	10.1016/j.bmc.2013.10.033	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.	Zhang L, Zhan P, Chen X, Li Z, Xie Z, Zhao T, Liu H, De Clercq E, Pannecouque C, Balzarini J, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	12	3220	3226	24794751	10.1016/j.bmc.2014.03.020	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Wu HQ, Chen WX, Wu Y, Piao HR, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	21	5747	5756	25440502	10.1016/j.bmc.2014.09.046	Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs.	Wang J, Wang YJ, Chen ZS, Kwon CH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	21	6112	6116	25260957	10.1016/j.bmc.2014.08.039	Altertoxins with potent anti-HIV activity from Alternaria tenuissima QUE1Se, a fungal endophyte of Quercus emoryi.	Bashyal BP, Wellensiek BP, Ramakrishnan R, Faeth SH, Ahmad N, Gunatilaka AA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	23	6665	6671	25458500	10.1016/j.bmc.2014.10.003	Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.	Cho JH, Bondana L, Detorio MA, Montero C, Bassit LC, Amblard F, Coats SJ, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2014	22	8	2535	2541	24680058	10.1016/j.bmc.2014.02.030	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.	Yan ZH, Huang XY, Wu HQ, Chen WX, He QQ, Chen FE, De Clercq E, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2014	24	12	2640	2644	24813732	10.1016/j.bmcl.2014.04.073	Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.	Asquith CR, Meli ML, Konstantinova LS, Laitinen T, Peräkylä M, Poso A, Rakitin OA, Allenspach K, Hofmann-Lehmann R, Hilton ST.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2014	24	15	3426	3429	24953602	10.1016/j.bmcl.2014.05.079	Synthesis of bi-/tricyclic azasugars fused thiazinan-4-one and their HIV-RT inhibitory activity.	Chen H, Hao L, Zhu M, Yang T, Wei S, Qin Z, Zhang P, Li X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2014	24	22	5190	5194	25442310	10.1016/j.bmcl.2014.09.079	Synthesis and cytotoxic evaluation of novel ester-triazole-linked triterpenoid-AZT conjugates.	Dang Thi TA, Kim Tuyet NT, Pham The C, Thanh Nguyen H, Ba Thi C, Doan Duy T, D'hooghe M, Van Nguyen T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2014	24	3	817	820	24411122	10.1016/j.bmcl.2013.12.093	Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.	Gangadhara KL, Lescrinier E, Pannecouque C, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	MedChemComm	2014	5	12	1843	1848		10.1039/C4MD00237G	Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain	Chaikuad A, Petros AM, Fedorov O, Xu J, Knapp S
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	MedChemComm	2014	5	4	468	473		10.1039/C3MD00247K	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase	Wu H, Pannecouque C, Yan Z, Chen W, He Q, Chen F, Balzarini J, Daelemans D, De Clercq E
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	MedChemComm	2014	5	5	622	631		10.1039/C4MD00003J	Biological evaluation and molecular modelling of didanosine derivatives	Ravetti S, De Candia CA, Gualdesi MS, Pampuro S, Turk G, Quevedo MA, Brinon MC
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2014	57	10	3939	3965	24742150	10.1021/jm401742r	Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.	Németh G, Greff Z, Sipos A, Varga Z, Székely R, Sebestyén M, Jászay Z, Béni S, Nemes Z, Pirat JL, Volle JN, Virieux D, Gyuris Á, Kelemenics K, Ay E, Minarovits J, Szathmary S, Kéri G, Orfi L.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2014	57	11	4640	4660	24793360	10.1021/jm500109z	Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.	Suchaud V, Bailly F, Lion C, Calmels C, Andréola ML, Christ F, Debyser Z, Cotelle P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2014	57	12	5169	5178	24805780	10.1021/jm500139a	Synthesis of novel fluoro analogues of MKC442 as microbicides.	Loksha YM, Pedersen EB, Loddo R, Sanna G, Collu G, Giliberti G, La Colla P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2014	57	17	7342	7354	25156906	10.1021/jm500763m	Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.	Wang C, Lu L, Na H, Li X, Wang Q, Jiang X, Xu X, Yu F, Zhang T, Li J, Zhang Z, Zheng B, Liang G, Cai L, Jiang S, Liu K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2014	76		531	538	24602795	10.1016/j.ejmech.2014.02.047	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.	Wang J, Zhan P, Li Z, Liu H, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2014	77	1	183	187	24392742	10.1021/np400847t	4-Quinolone alkaloids from Melochia odorata.	Jadulco RC, Pond CD, Van Wagoner RM, Koch M, Gideon OG, Matainaho TK, Piskaut P, Barrows LR.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2014	77	6	1505	1512	24926807	10.1021/np500271u	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.	Nothias-Scaglia LF, Retailleau P, Paolini J, Pannecouque C, Neyts J, Dumontet V, Roussi F, Leyssen P, Costa J, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2014	80		101	111	24769348	10.1016/j.ejmech.2014.04.027	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.	Famiglini V, La Regina G, Coluccia A, Pelliccia S, Brancale A, Maga G, Crespan E, Badia R, Clotet B, Esté JA, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2014	82		600	611	24952305	10.1016/j.ejmech.2014.05.059	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.	Meng G, Liu Y, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2014	85		27	42	25072874	10.1016/j.ejmech.2014.07.072	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.	Xu Z, Ba M, Zhou H, Cao Y, Tang C, Yang Y, He R, Liang Y, Zhang X, Li Z, Zhu L, Guo Y, Guo C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2014	87		52	62	25240095	10.1016/j.ejmech.2014.09.054	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.	Liu Z, Chen W, Zhan P, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2015	104		127	138	26451771	10.1016/j.ejmech.2015.09.015	Synthesis of dihydropyrimidine ¿,¿-diketobutanoic acid derivatives targeting HIV integrase.	Sari O, Roy V, Métifiot M, Marchand C, Pommier Y, Bourg S, Bonnet P, Schinazi RF, Agrofoglio LA.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2015	23	13	3860	3868	25907370	10.1016/j.bmc.2015.03.037	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.	Mao TQ, He QQ, Wan ZY, Chen WX, Chen FE, Tang GF, De Clercq E, Daelemans D, Pannecouque C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2015	23	15	4423	4427	26094944	10.1016/j.bmc.2015.06.020	Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.	Mizuguchi T, Ohashi N, Nomura W, Komoriya M, Hashimoto C, Yamamoto N, Murakami T, Tamamura H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2015	23	3	624	631	25537532	10.1016/j.bmc.2014.11.032	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.	Wu HQ, Yao J, He QQ, Chen WX, Chen FE, Pannecouque C, De Clercq E, Daelemans D.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2015	25	11	2360	2365	25933593	10.1016/j.bmcl.2015.04.018	PMA-SiO2 catalyzed synthesis of indolo[2,3-c]quinolines as potent anti cancer agents.	Srihari P, Padmabhavani B, Ramesh S, Bharath Kumar Y, Singh A, Ummanni R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2015	25	16	3168	3171	26112446	10.1016/j.bmcl.2015.05.099	Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.	Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2015	25	6	1232	1235	25682562	10.1016/j.bmcl.2015.01.058	Design, synthesis of new ß-carboline derivatives and their selective anti-HIV-2 activity.	Ashok P, Chander S, Balzarini J, Pannecouque C, Murugesan S.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2015	25	6	1348	1351	25701249	10.1016/j.bmcl.2015.01.007	Molecular docking and antiviral activity of N-substituted benzyl/phenyl-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl)acetamides.	Ahmad M, Aslam S, Rizvi SU, Muddassar M, Ashfaq UA, Montero C, Ollinger O, Detorio M, Gardiner JM, Schinazi RF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2015	25	6	1352	1355	25702849	10.1016/j.bmcl.2014.12.047	Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.	Asquith CR, Meli ML, Konstantinova LS, Laitinen T, Poso A, Rakitin OA, Hofmann-Lehmann R, Allenspach K, Hilton ST.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2015	58	15	6114	6130	26125628	10.1021/acs.jmedchem.5b00737	Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides.	Weinschenk L, Schols D, Balzarini J, Meier C.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2015	58	24	9601	9614	26613134	10.1021/acs.jmedchem.5b01183	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.	Sancineto L, Mariotti A, Bagnoli L, Marini F, Desantis J, Iraci N, Santi C, Pannecouque C, Tabarrini O.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2015	58	8	3329	3339	25811955	10.1021/jm5015296	New organochalcogen multitarget drug: synthesis and antioxidant and antitumoral activities of chalcogenozidovudine derivatives.	de Souza D, Mariano DO, Nedel F, Schultze E, Campos VF, Seixas F, da Silva RS, Munchen TS, Ilha V, Dornelles L, Braga AL, Rocha JB, Collares T, Rodrigues OE.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Med. Chem.	2015	58	9	4016	4028	25909386	10.1021/acs.jmedchem.5b00327	5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus.	Vernekar SK, Qiu L, Zhang J, Kankanala J, Li H, Geraghty RJ, Wang Z.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	ACS Med. Chem. Lett.	2015	6	7	753	757	26191361	10.1021/acsmedchemlett.5b00036	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.	Cox BD, Prosser AR, Sun Y, Li Z, Lee S, Huang MB, Bond VC, Snyder JP, Krystal M, Wilson LJ, Liotta DC.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2015	78	11	2712	2718	26562066	10.1021/acs.jnatprod.5b00660	Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme.	Yan M, Lu Y, Chen CH, Zhao Y, Lee KH, Chen DF.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2015	78	5	1119	1128	25946116	10.1021/acs.jnatprod.5b00116	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.	Olivon F, Palenzuela H, Girard-Valenciennes E, Neyts J, Pannecouque C, Roussi F, Grondin I, Leyssen P, Litaudon M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2015	78	6	1277	1283	25970561	10.1021/acs.jnatprod.5b00073	Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.	Nothias-Scaglia LF, Pannecouque C, Renucci F, Delang L, Neyts J, Roussi F, Costa J, Leyssen P, Litaudon M, Paolini J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2015	78	8	2067	2073	26214125	10.1021/acs.jnatprod.5b00392	Kadcoccinic Acids A-J, Triterpene Acids from Kadsura coccinea.	Liang CQ, Shi YM, Wang WG, Hu ZX, Li Y, Zheng YT, Li XN, Du X, Pu JX, Xiao WL, Zhang HB, Sun HD.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2015	92		754	765	25626145	10.1016/j.ejmech.2015.01.042	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.	Huang B, Li C, Chen W, Liu T, Yu M, Fu L, Sun Y, Liu H, De Clercq E, Pannecouque C, Balzarini J, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2015	93		330	337	25707013	10.1016/j.ejmech.2015.02.022	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.	Huang B, Liang X, Li C, Chen W, Liu T, Li X, Sun Y, Fu L, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2016	109		294	304	26802545	10.1016/j.ejmech.2015.11.039	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.	Yang J, Chen W, Kang D, Lu X, Li X, Liu Z, Huang B, Daelemans D, Pannecouque C, De Clercq E, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2016	110		65	75	26807545	10.1016/j.ejmech.2016.01.014	Novel dihydropyrazole-chromen: Design and modulates hTERT inhibition proliferation of MGC-803.	Chen YY, Wu XQ, Tang WJ, Shi JB, Li J, Liu XH.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2016	115		53	62	26994843	10.1016/j.ejmech.2016.02.068	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.	Meng Q, Chen X, Kang D, Huang B, Li W, Zhan P, Daelemans D, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2016	117		230	240	27105027	10.1016/j.ejmech.2016.04.019	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.	Patel SB, Patel BD, Pannecouque C, Bhatt HG.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur. J. Med. Chem.	2016	117		256	268	27105029	10.1016/j.ejmech.2016.03.083	2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.	Billamboz M, Suchaud V, Bailly F, Lion C, Andréola ML, Christ F, Debyser Z, Cotelle P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur J Med Chem	2016	121		352	363	27267005	10.1016/j.ejmech.2016.05.054	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.	Chen W, Zhan P, Daelemans D, Yang J, Huang B, De Clercq E, Pannecouque C, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur J Med Chem	2016	121		58	70	27214512	10.1016/j.ejmech.2016.05.017	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.	Kulaba¿ N, Tatar E, Bingöl Özakp¿nar Ö, Özsavc¿ D, Pannecouque C, De Clercq E, Küçükgüzel ¿.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2016	24	11	2476	2485	27112451	10.1016/j.bmc.2016.04.010	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.	Geisman AN, Valuev-Elliston VT, Ozerov AA, Khandazhinskaya AL, Chizhov AO, Kochetkov SN, Pannecouque C, Naesens L, Seley-Radtke KL, Novikov MS.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2016	24	13	3006	3022	27234889	10.1016/j.bmc.2016.05.010	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.	Hoshi A, Sakamoto T, Takayama J, Xuan M, Okazaki M, Hartman TL, Buckheit RW, Pannecouque C, Cushman M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem	2016	24	21	5115	5126	27647368	10.1016/j.bmc.2016.08.029	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.	Hamdy AM, Khaddour Z, Al-Masoudi NA, Rahman Q, Hering-Junghans C, Villinger A, Langer P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem.	2016	24	9	2125	2136	27039251	10.1016/j.bmc.2016.03.043	Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors.	Yang L, Wang P, Wu JF, Yang LM, Wang RR, Pang W, Li YG, Shen YM, Zheng YT, Li X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2016	26	15	3652	3657	27342752	10.1016/j.bmcl.2016.05.092	Synthesis and cytotoxic evaluation of novel indenoisoquinoline-substituted triazole hybrids.	Pham Thi T, Le Nhat TG, Ngo Hanh T, Luc Quang T, Pham The C, Dang Thi TA, Nguyen HT, Nguyen TH, Hoang Thi P, Van Nguyen T.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg. Med. Chem. Lett.	2016	26	7	1738	1741	26944616	10.1016/j.bmcl.2016.02.049	Synthesis of tetracyclic iminosugars fused benzo[e][1,3]thiazin-4-one and their HIV-RT inhibitory activity.	Yin Z, Zhu M, Wei S, Shao J, Hou Y, Chen H, Li X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Med Chem	2016	59	17	7991	8007	27541578	10.1021/acs.jmedchem.6b00738	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.	Kang D, Fang Z, Li Z, Huang B, Zhang H, Lu X, Xu H, Zhou Z, Ding X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J. Nat. Prod.	2016	79	3	578	583	26756779	10.1021/acs.jnatprod.5b01012	Carolignans from the Aerial Parts of Euphorbia sikkimensis and Their Anti-HIV Activity.	Jiang C, Luo P, Zhao Y, Hong J, Morris-Natschke SL, Xu J, Chen CH, Lee KH, Gu Q.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur J Med Chem	2017	130		209	222	28254696	10.1016/j.ejmech.2017.02.047	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.	Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Eur J Med Chem	2017	134		159	184	28412530	10.1016/j.ejmech.2017.04.003	Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.	Chadha N, Silakari O.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem	2017	25	19	5128	5132	28712845	10.1016/j.bmc.2017.07.001	Dual inhibitors of the human blood-brain barrier drug efflux transporters P-glycoprotein and ABCG2 based on the antiviral azidothymidine.	Namanja-Magliano HA, Bohn K, Agrawal N, Willoughby ME, Hrycyna CA, Chmielewski J.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem	2017	25	23	6248	6265	28442262	10.1016/j.bmc.2017.03.061	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.	Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem	2017	25	8	2491	2497	28314514	10.1016/j.bmc.2017.03.009	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.	Lu HH, Xue P, Zhu YY, Ju XL, Zheng XJ, Zhang X, Xiao T, Pannecouque C, Li TT, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem Lett	2017	27	1	61	65	27894873	10.1016/j.bmcl.2016.11.030	Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.	Chander S, Wang P, Ashok P, Yang LM, Zheng YT, Sankaranarayanan M.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem Lett	2017	27	8	1640	1643	28314598	10.1016/j.bmcl.2017.03.009	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.	Xue P, Lu HH, Zhu YY, Ju XL, Pannecouque C, Zheng XJ, Liu GY, Zhang XL, Gu SX.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	Bioorg Med Chem Lett	2017	27	9	1934	1937	28351588	10.1016/j.bmcl.2017.03.031	Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.	Agarwal HK, Chhikara BS, Doncel GF, Parang K.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Med Chem	2017	60	10	4424	4443	28481112	10.1021/acs.jmedchem.7b00332	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.	Kang D, Fang Z, Huang B, Lu X, Zhang H, Xu H, Huo Z, Zhou Z, Yu Z, Meng Q, Wu G, Ding X, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Med Chem	2017	60	14	6220	6238	28682067	10.1021/acs.jmedchem.7b00416	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.	Luo M, Groaz E, Andrei G, Snoeck R, Kalkeri R, Ptak RG, Hartman T, Buckheit RW, Schols D, De Jonghe S, Herdewijn P.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Med Chem	2017	60	15	6528	6547	28628334	10.1021/acs.jmedchem.6b01906	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.	Famiglini V, La Regina G, Coluccia A, Masci D, Brancale A, Badia R, Riveira-Muñoz E, Esté JA, Crespan E, Brambilla A, Maga G, Catalano M, Limatola C, Formica FR, Cirilli R, Novellino E, Silvestri R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129	J Med Chem	2017	60	7	3124	3153	28266845	10.1021/acs.jmedchem.7b00179	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.	Curreli F, Kwon YD, Belov DS, Ramesh RR, Kurkin AV, Altieri A, Kwong PD, Debnath AK.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129								10.6019/CHEMBL3392926	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning	Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									British National Formulary (72nd edition)	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									DrugMatrix	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									PubChem BioAssay data set	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									Unpublished dataset	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
949.8000000000000000	11676	Human immunodeficiency virus 1	ZIDOVUDINE	CHEMBL129									WHO Anatomical Therapeutic Chemical Classification	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1991	34	7	2158	2165	2066989	10.1021/jm00111a035	4-hydroxythiazole inhibitors of 5-lipoxygenase.	Kerdesky FA, Holms JH, Moore JL, Bell RL, Dyer RD, Carter GW, Brooks DW.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1991	34	7	2176	2186	1648621	10.1021/jm00111a038	(Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity.	Bird, Bruneau P, Crawley GC, Edwards MP, Foster SJ, Girodeau JM, Kingston JF, McMillan RM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1992	2	12	1699	1702		10.1016/S0960-894X(00)80459-X	Development of L-689,065 - the prototype of a new class of potent 5-lipoxygenase inhibitors	Hutchinson J, Prasit P, Choo L, Riendeau D, Charleson S, Evans J, Piechuta H, Ball R
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1992	2	9	1079	1084		10.1016/S0960-894X(00)80622-8	Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors	Wright SW, Pinto DJ, Sherk SR, Green AM, Magolda RL
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1992	35	14	2501	2524	1635053	10.1021/jm00092a001	5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.	Musser JH, Kreft AF.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1992	35	14	2600	2609	1321908	10.1021/jm00092a010	Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.	Crawley GC, Dowell RI, Edwards PN, Foster SJ, McMillan RM, Walker ER, Waterson D, Bird TG, Bruneau P, Giroaeau JM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1992	35	17	3180	3183	1324317	10.1021/jm00095a012	Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.	Greco MN, Hageman WE, Powell ET, Tighe JJ, Persico FJ.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1992	35	22	4061	4068	1433212	10.1021/jm00100a011	Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis.	Wright SW, Harris RR, Kerr JS, Green AM, Pinto DJ, Bruin EM, Collins RJ, Dorow RL, Mantegna LR, Sherk SR.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1992	35	7	1299	1318	1313879	10.1021/jm00085a019	Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.	Lau CK, Bélanger PC, Dufresne C, Scheigetz J, Therien M, Fitzsimmons B, Young RN, Ford-Hutchinson AW, Riendeau D, Denis D.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1993	3	12	2565	2570		10.1016/S0960-894X(01)80717-4	Design and synthesis of achiral 5-lipoxygenase inhibitors employing the cyclobutyl group	Hodgson ST, Wates PJ, Blackwell GJ, Craig C, Yeadon M, Boughton-Smith N
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1993	36	23	3580	3594	8246226	10.1021/jm00075a013	Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.	Satoh Y, Stanton JL, Hutchison AJ, Libby AH, Kowalski TJ, Lee WH, White DH, Kimble EF.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1994	37	21	3663	3667	7932593	10.1021/jm00047a023	Synthesis and 5-lipoxygenase inhibitory activities of some novel 2-substituted 5-benzofuran hydroxamic acids.	Ohemeng KA, Appollina MA, Nguyen VN, Schwender CF, Singer M, Steber M, Ansell J, Argentieri D, Hageman W.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1994	37	4	512	518	8120869	10.1021/jm00030a010	Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.	Ducharme Y, Brideau C, Dubé D, Chan CC, Falgueyret JP, Gillard JW, Guay J, Hutchinson JH, McFarlane CS, Riendeau D.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1994	37	8	1153	1164	8164257	10.1021/jm00034a013	Thiopyrano[2,3,4-cd]indoles as 5-lipoxygenase inhibitors: synthesis, biological profile, and resolution of 2-[2-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5 -dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]ethoxy]butanoic acid.	Hutchinson JH, Riendeau D, Brideau C, Chan C, Falgueyret JP, Guay J, Jones TR, Lépine C, Macdonald D, McFarlane CS.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1994	4	12	1437	1442		10.1016/S0960-894X(01)80509-6	A congener study of zileuton reveals interesting effects on glucuronidation rates	Galeazzi E, Guzman A, Kluge A, Morgans D, Muchowski J, Jamil-Panah S, Saavedra P, Salazar MA, Talamas FX, Teitelbaum P, Young J, Yamamoto D
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1994	4	4	549	552		10.1016/S0960-894X(01)80152-9	Benzoxepin and benzothiepin derivatives as potent, orally active inhibitors of 5-lipoxygenase	Satoh Y, Libby AH, Powers C, Kowalski TJ, White D, Kimble EF
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1995	38	1	68	75	7837242	10.1021/jm00001a012	Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.	Satoh Y, Powers C, Toledo LM, Kowalski TJ, Peters PA, Kimble EF.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1995	38	24	4768	4775	7490726	10.1021/jm00024a004	(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.	Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1995	38	4	669	685	7861415	10.1021/jm00004a013	Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma.	Paris D, Cottin M, Demonchaux P, Augert G, Dupassieux P, Lenoir P, Peck MJ, Jasserand D.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1995	38	9	1473	1481	7739006	10.1021/jm00009a008	Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds.	Calhoun W, Carlson RP, Crossley R, Datko LJ, Dietrich S, Heatherington K, Marshall LA, Meade PJ, Opalko A, Shepherd RG.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	1995	5	6	643	648		10.1016/0960-894X(95)00088-B	Cmi-206: A potent dual platelet activating factor antagonist and 5-lipoxygenase inhibitor	Sajjat Hussoin M, Cai X, Scannell RT, Yaeger D, Killian DB, Eckman J, Hwang S, Libertine-Garahan L, Qian C, Grace Yen C, Ip S
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	1	237	245	8568813	10.1021/jm950363n	Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.	Malamas MS, Carlson RP, Grimes D, Howell R, Glaser K, Gunawan I, Nelson JA, Kanzelberger M, Shah U, Hartman DA.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	14	2629	2654	8709092	10.1021/jm960088k	Modulators of leukotriene biosynthesis and receptor activation.	Brooks CD, Summers JB.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	16	3148	3157	8759636	10.1021/jm950725r	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.	Hibi S, Okamoto Y, Tagami K, Numata H, Kobayashi N, Shinoda M, Kawahara T, Harada K, Miyamoto K, Yamatsu I.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	20	3929	3937	8831759	10.1021/jm960415o	1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.	Boehm JC, Smietana JM, Sorenson ME, Garigipati RS, Gallagher TF, Sheldrake PL, Bradbeer J, Badger AM, Laydon JT, Lee JC, Hillegass LM, Griswold DE, Breton JJ, Chabot-Fletcher MC, Adams JL.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	20	3951	3970	8831761	10.1021/jm960301c	Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.	Delorme D, Ducharme Y, Brideau C, Chan CC, Chauret N, Desmarais S, Dubé D, Falgueyret JP, Fortin R, Guay J, Hamel P, Jones TR, Lépine C, Li C, McAuliffe M, McFarlane CS, Nicoll-Griffith DA, Riendeau D, Yergey JA, Girard Y.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1996	39	26	5035	5046	8978834	10.1021/jm960271d	Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.	Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1997	40	13	1955	1968	9207936	10.1021/jm9700474	Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.	Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1997	40	18	2866	2875	9288168	10.1021/jm970046b	Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.	Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1997	40	5	819	824	9057869	10.1021/jm9606150	Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.	Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL, Carter GW.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1998	41	11	1970	1979	9599246	10.1021/jm980046r	(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.	Cai X, Scannell RT, Yaeger D, Hussoin MS, Killian DB, Qian C, Eckman J, Hwang SB, Libertine-Garahan L, Yeh CG, Ip SH, Shen TY.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	1998	41	4	420	427	9484493	10.1021/jm970034q	Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid.	Hopper AT, Witiak DT, Ziemniak J.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2000	43	4	690	705	10691695	10.1021/jm9904102	Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.	Kolasa T, Gunn DE, Bhatia P, Woods KW, Gane T, Stewart AO, Bouska JB, Harris RR, Hulkower KI, Malo PE, Bell RL, Carter GW, Brooks CD.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2000	43	4	721	735	10691697	10.1021/jm990496z	Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.	Penning TD, Chandrakumar NS, Chen BB, Chen HY, Desai BN, Djuric SW, Docter SH, Gasiecki AF, Haack RA, Miyashiro JM, Russell MA, Yu SS, Corley DG, Durley RC, Kilpatrick BF, Parnas BL, Askonas LJ, Gierse JK, Harding EI, Highkin MK, Kachur JF, Kim SH, Krivi GG, Villani-Price D, Pyla EY, Smith WG.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2002	12	5	779	782	11859001	10.1016/s0960-894x(02)00013-6	Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor.	Barbey S, Goossens L, Taverne T, Cornet J, Choesmel V, Rouaud C, Gimeno G, Yannic-Arnoult S, Michaux C, Charlier C, Houssin R, Hénichart JP.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Curr Drug Discov Technol	2004	1	4	243	254	16472241	10.2174/1570163043334794	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.	Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2004	14	22	5591	5594	15482930	10.1016/j.bmcl.2004.08.060	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.	Lewis TA, Young MA, Arrington MP, Bayless L, Cai X, Collart P, Eckman JB, Ellis JL, Ene DG, Libertine L, Nicolas JM, Scannell RT, Wels BF, Wenberg K, Wypij DM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2004	14	9	2265	2268	15081022	10.1016/j.bmcl.2004.02.005	5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.	Lewis TA, Bayless L, Eckman JB, Ellis JL, Grewal G, Libertine L, Marie Nicolas J, Scannell RT, Wels BF, Wenberg K, Wypij DM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2005	15	18	4076	4084	15990295	10.1016/j.bmcl.2005.06.015	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.	Wang YH, Li Y, Li YH, Yang SL, Yang L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2005	15	4	1083	1085	15686917	10.1016/j.bmcl.2004.12.023	5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.	Lewis TA, Bayless L, DiPesa AJ, Eckman JB, Gillard M, Libertine L, Scannell RT, Wypij DM, Young MA.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Curr. Drug Metab.	2005	6	1	413	454	16248836	10.2174/138920005774330639	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.	Fontana E, Dansette PM, Poli SM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2005	68	1	83	85	15679323	10.1021/np0497043	Inhibition of leukotriene biosynthesis by stilbenoids from Stemona species.	Adams M, Pacher T, Greger H, Bauer R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2007	17	9	2414	2420	17336065	10.1016/j.bmcl.2007.02.038	Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.	Zheng M, Zheng M, Ye D, Deng Y, Qiu S, Luo X, Chen K, Liu H, Jiang H.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2007	42	8	1084	1094	17448575	10.1016/j.ejmech.2007.01.014	Antileukotrienic N-arylethyl-2-arylacetamides in the treatment of ulcerative colitis.	Junek R, Br¿nová B, Kverka M, Panajotová V, Jandera A, Kuchar M.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J Chem Inf Model	2007	47	1	1196	1205	17428028	10.1021/ci6004542	Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.	Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2008	43	6	1222	1229	17937972	10.1016/j.ejmech.2007.08.005	Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.	Bailly F, Queffélec C, Mbemba G, Mouscadet JF, Pommery N, Pommery J, Hénichart JP, Cotelle P.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2008	51	12	3388	3413	18498150	10.1021/jm701467e	Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.	McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, Hu Y, Chen L, Kirincich SJ, Michalak R, Thomason J, Ipek M, Wu K, Wooder L, Ramarao MK, Murphy EA, Goodwin DG, Albert L, Xu X, Donahue F, Ku MS, Keith J, Nickerson-Nutter CL, Abraham WM, Williams C, Hegen M, Clark JD.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2008	51	24	8068	8076	19053751	10.1021/jm801085s	Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.	Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93		2008			161	304			Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2009	17	13	4459	4465	19481465	10.1016/j.bmc.2009.05.018	Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation.	Schühly W, Hüfner A, Pferschy-Wenzig EM, Prettner E, Adams M, Bodensieck A, Kunert O, Oluwemimo A, Haslinger E, Bauer R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2009	52	11	3474	3483	19492852	10.1021/jm900212y	Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.	Karg EM, Luderer S, Pergola C, Bühring U, Rossi A, Northoff H, Sautebin L, Troschütz R, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2009	52	4	1156	1171	19178292	10.1021/jm8009876	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.	Chen L, Wang W, Lee KL, Shen MW, Murphy EA, Zhang W, Xu X, Tam S, Nickerson-Nutter C, Goodwin DG, Clark JD, McKew JC.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2009	72	10	1836	1841	19775092	10.1021/np900374s	Monoterpenoid indole alkaloids from Alstonia yunnanensis.	Feng T, Li Y, Cai XH, Gong X, Liu YP, Zhang RT, Zhang XY, Tan QG, Luo XD.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2010	18	1	151	157	19942440	10.1016/j.bmc.2009.11.007	Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cys-leukotrienes.	Tani H, Hasumi K, Tatefuji T, Hashimoto K, Koshino H, Takahashi S.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2010	18	11	3910	3924	20451397	10.1016/j.bmc.2010.04.034	Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.	Bridoux A, Millet R, Pommery J, Pommery N, Henichart JP.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2010	18	7	2809	2815	20236826	10.1016/j.bmc.2009.10.031	Derivatives of schisandrin with increased inhibitory potential on prostaglandin E(2) and leukotriene B(4) formation in vitro.	Blunder M, Pferschy-Wenzig EM, Fabian WM, Hüfner A, Kunert O, Saf R, Schühly W, Bauer R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2010	20	3	1013	1018	20045317	10.1016/j.bmcl.2009.12.047	Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.	Aparoy P, Kumar Reddy K, Kalangi SK, Chandramohan Reddy T, Reddanna P.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Chem. Res. Toxicol.	2010	23	1	171	183	20014752	10.1021/tx900326k	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.	Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Chem. Res. Toxicol.	2010	23	7	1215	1222	20553011	10.1021/tx1000865	Developing structure-activity relationships for the prediction of hepatotoxicity.	Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Drug Metab. Dispos.	2010	38	12	2302	2308	20843939	10.1124/dmd.110.035113	A predictive ligand-based Bayesian model for human drug-induced liver injury.	Ekins S, Williams AJ, Xu JJ.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Mol. Pharm.	2010	7	5	1708	1714	20799726	10.1021/mp100103e	Predicting phospholipidosis using machine learning.	Lowe R, Glen RC, Mitchell JB.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Drug Discovery Today	2011	16	15-16	697	703	21624500	10.1016/j.drudis.2011.05.007	FDA-approved drug labeling for the study of drug-induced liver injury.	Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2011	46	10	5021	5033	21868137	10.1016/j.ejmech.2011.08.009	Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils.	Cal¿¿kan B, Luderer S, Özkan Y, Werz O, Banoglu E.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2011	54	23	8013	8029	22059882	10.1021/jm2008369	5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.	Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J, Santini A, Darlington J, Prodanovich P, King CD, Baccei C, Lee C, Rong H, Chapman C, Broadhead A, Lorrain D, Correa L, Hutchinson JH, Evans JF, Prasit P.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2011	74	8	1779	1786	21800856	10.1021/np200343t	Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.	Baumgartner L, Sosa S, Atanasov AG, Bodensieck A, Fakhrudin N, Bauer J, Favero GD, Ponti C, Heiss EH, Schwaiger S, Ladurner A, Widowitz U, Loggia RD, Rollinger JM, Werz O, Bauer R, Dirsch VM, Tubaro A, Stuppner H.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2012	20	11	3575	3583	22551629	10.1016/j.bmc.2012.04.003	Synthesis and biological evaluation of a class of 5-benzylidene-2-phenyl-thiazolinones as potent 5-lipoxygenase inhibitors.	Barzen S, Rödl CB, Lill A, Steinhilber D, Stark H, Hofmann B.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2012	20	16	5027	5032	22789707	10.1016/j.bmc.2012.06.019	Anacardic acid derived salicylates are inhibitors or activators of lipoxygenases.	Wisastra R, Ghizzoni M, Boltjes A, Haisma HJ, Dekker FJ.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2012	20	9	2912	2922	22475926	10.1016/j.bmc.2012.03.021	Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents.	Özadal¿ K, Özkanl¿ F, Jain S, Rao PP, Velázquez-Martínez CA.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2012	22	24	7641	7646	23122865	10.1016/j.bmcl.2012.10.010	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.	Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2012	22	5	1969	1975	22326163	10.1016/j.bmcl.2012.01.038	SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase.	Hieke M, Rödl CB, Wisniewska JM, la Buscató E, Stark H, Schubert-Zsilavecz M, Steinhilber D, Hofmann B, Proschak E.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Chem. Res. Toxicol.	2012	25	10	2067	2082	22931300	10.1021/tx300075j	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.	Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Drug Metab. Dispos.	2012	40	1	130	138	21965623	10.1124/dmd.111.040758	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.	Dawson S, Stahl S, Paul N, Barber J, Kenna JG.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Drug Metab Dispos	2012	40	12	2332	2341	22961681	10.1124/dmd.112.047068	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.	Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2012	55	6	2597	2605	22380511	10.1021/jm201497k	Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.	Wu Y, He C, Gao Y, He S, Liu Y, Lai L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2012	55	8	3792	3803	22449023	10.1021/jm201687d	Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).	Rörsch F, Buscató E, Deckmann K, Schneider G, Schubert-Zsilavecz M, Geisslinger G, Proschak E, Grösch S.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2013	21	13	3894	3899	23669189	10.1016/j.bmc.2013.04.016	Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.	Hoobler EK, Holz C, Holman TR.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2013	21	24	7874	7883	24183739	10.1016/j.bmc.2013.10.006	Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.	Hanke T, Rörsch F, Thieme TM, Ferreiros N, Schneider G, Geisslinger G, Proschak E, Grösch S, Schubert-Zsilavecz M.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2013	23	5	1433	1437	23337599	10.1016/j.bmcl.2012.12.068	N-1, C-3 substituted indoles as 5-LOX inhibitors--in vitro enzyme immunoaasay, mass spectral and molecular docking investigations.	Singh P, Pooja.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	MedChemComm	2013	4	4	631	652		10.1039/C2MD20317K	Metabolism-guided drug design	Stepan AF, Mascitti V, Beaumont K, Kalgutkar AS
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2013	56	20	7997	8007	24074025	10.1021/jm401053m	Investigating the selectivity of metalloenzyme inhibitors.	Day JA, Cohen SM.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2013	56	22	9031	9044	24171493	10.1021/jm401557w	Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.	Hanke T, Dehm F, Liening S, Popella SD, Maczewsky J, Pillong M, Kunze J, Weinigel C, Barz D, Kaiser A, Wurglics M, Lämmerhofer M, Schneider G, Sautebin L, Schubert-Zsilavecz M, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2013	56	4	1777	1781	23356879	10.1021/jm301617j	Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase.	Meirer K, Rödl CB, Wisniewska JM, George S, Häfner AK, Buscató EL, Klingler FM, Hahn S, Berressem D, Wittmann SK, Steinhilber D, Hofmann B, Proschak E.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2013	56	8	3296	3309	23527738	10.1021/jm301900x	Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.	He S, Li C, Liu Y, Lai L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2013	67		269	279	23871907	10.1016/j.ejmech.2013.06.039	Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.	Filosa R, Peduto A, Aparoy P, Schaible AM, Luderer S, Krauth V, Petronzi C, Massa A, de Rosa M, Reddanna P, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2014	22	5	1642	1648	24508141	10.1016/j.bmc.2014.01.027	Lead modification: amino acid appended indoles as highly effective 5-LOX inhibitors.	Prasher P, Pooja, Singh P.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2014	22	8	2396	2402	24685113	10.1016/j.bmc.2014.03.008	Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors.	Shang E, Liu Y, Wu Y, Zhu W, He C, Lai L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem. Lett.	2014	24	12	2764	2767	24794107	10.1016/j.bmcl.2014.04.006	Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1.	Shang E, Wu Y, Liu P, Liu Y, Zhu W, Deng X, He C, He S, Li C, Lai L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2014	57	9	3715	3723	24697244	10.1021/jm401740w	Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.	Pergola C, Gaboriaud-Kolar N, Jestädt N, König S, Kritsanida M, Schaible AM, Li H, Garscha U, Weinigel C, Barz D, Albring KF, Huber O, Skaltsounis AL, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2014	77	3	441	445	24568174	10.1021/np401010x	One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor.	Vougogiannopoulou K, Lemus C, Halabalaki M, Pergola C, Werz O, Smith AB, Michel S, Skaltsounis L, Deguin B.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2014	81		492	498	24871899	10.1016/j.ejmech.2014.05.033	Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.	Peduto A, Bruno F, Dehm F, Krauth V, de Caprariis P, Weinigel C, Barz D, Massa A, De Rosa M, Werz O, Filosa R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2014	84		302	311	25036790	10.1016/j.ejmech.2014.07.025	Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.	Rödl CB, Vogt D, Kretschmer SB, Ihlefeld K, Barzen S, Brüggerhoff A, Achenbach J, Proschak E, Steinhilber D, Stark H, Hofmann B.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2015	101		573	583	26197161	10.1016/j.ejmech.2015.07.011	Design, synthesis and evaluation of semi-synthetic triazole-containing caffeic acid analogues as 5-lipoxygenase inhibitors.	De Lucia D, Lucio OM, Musio B, Bender A, Listing M, Dennhardt S, Koeberle A, Garscha U, Rizzo R, Manfredini S, Werz O, Ley SV.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2015	101		81	95	26117820	10.1016/j.ejmech.2015.06.020	Synthesis, characterization, evaluation and molecular dynamics studies of 5, 6-diphenyl-1,2,4-triazin-3(2H)-one derivatives bearing 5-substituted 1,3,4-oxadiazole as potential anti-inflammatory and analgesic agents.	Banerjee AG, Das N, Shengule SA, Srivastava RS, Shrivastava SK.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg. Med. Chem.	2015	23	21	7069	7078	26432605	10.1016/j.bmc.2015.09.025	5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.	Kang JH, Ting Z, Moon MR, Sim JS, Lee JM, Doh KE, Hong S, Cui M, Choi S, Chang HW, Park Choo HY, Yim M.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2015	78	2	335	338	25686392	10.1021/np500909b	Myxochelins target human 5-lipoxygenase.	Schieferdecker S, König S, Koeberle A, Dahse HM, Werz O, Nett M.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2015	89		503	523	25462262	10.1016/j.ejmech.2014.10.054	Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy.	Lill AP, Rödl CB, Steinhilber D, Stark H, Hofmann B.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2015	94		132	139	25765759	10.1016/j.ejmech.2015.02.042	Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.	Filosa R, Peduto A, Schaible AM, Krauth V, Weinigel C, Barz D, Petronzi C, Bruno F, Roviezzo F, Spaziano G, D'Agostino B, De Rosa M, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2015	97		104	123	25956953	10.1016/j.ejmech.2015.04.044	Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.	Singh P, Prasher P, Dhillon P, Bhatti R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2016	108		466	475	26708113	10.1016/j.ejmech.2015.11.048	Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition.	Peduto A, Krauth V, Collarile S, Dehm F, Ambruosi M, Belardo C, Guida F, Massa A, Esposito V, Maione S, de Rosa M, Werz O, Filosa R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2016	108		89	103	26638042	10.1016/j.ejmech.2015.11.013	Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.	Cai H, Huang X, Xu S, Shen H, Zhang P, Huang Y, Jiang J, Sun Y, Jiang B, Wu X, Yao H, Xu J.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur. J. Med. Chem.	2016	113		1	10	26922224	10.1016/j.ejmech.2016.02.027	4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).	Banoglu E, Çeliko¿lu E, Völker S, Olgaç A, Gerstmeier J, Garscha U, Çal¿¿kan B, Schubert US, Carotti A, Macchiarulo A, Werz O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur J Med Chem	2016	122		510	519	27423639	10.1016/j.ejmech.2016.07.004	Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.	Levent S, Gerstmeier J, Olgaç A, Nikels F, Garscha U, Carotti A, Macchiarulo A, Werz O, Banoglu E, Çal¿¿kan B.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur J Med Chem	2016	124		428	434	27597418	10.1016/j.ejmech.2016.08.066	Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.	Ramanan M, Sinha S, Sudarshan K, Aidhen IS, Doble M.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Med. Chem.	2016	59	9	4202	4209	26290290	10.1021/acs.jmedchem.5b01011	Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.	Meng H, McClendon CL, Dai Z, Li K, Zhang X, He S, Shang E, Liu Y, Lai L.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J. Nat. Prod.	2016	79	3	590	597	26918635	10.1021/acs.jnatprod.5b01052	"Humudifucol and Bioactive Prenylated Polyphenols from Hops (Humulus lupulus cv. ""Cascade"")."	Forino M, Pace S, Chianese G, Santagostini L, Werner M, Weinigel C, Rummler S, Fico G, Werz O, Taglialatela-Scafati O.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Eur J Med Chem	2017	127		715	726	27836196	10.1016/j.ejmech.2016.10.046	Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.	Peduto A, Scuotto M, Krauth V, Roviezzo F, Rossi A, Temml V, Esposito V, Stuppner H, Schuster D, D'Agostino B, Schiraldi C, de Rosa M, Werz O, Filosa R.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg Med Chem	2017	25	16	4424	4432	28669741	10.1016/j.bmc.2017.06.027	Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.	Shrivastava SK, Srivastava P, Bandresh R, Tripathi PN, Tripathi A.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg Med Chem	2017	25	17	4533	4552	28720329	10.1016/j.bmc.2017.07.003	Recent synthetic and medicinal perspectives of tryptanthrin.	Kaur R, Manjal SK, Rawal RK, Kumar K.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg Med Chem Lett	2017	27	16	3653	3660	28720504	10.1016/j.bmcl.2017.07.020	Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.	Shen FQ, Wang ZC, Wu SY, Ren SZ, Man RJ, Wang BZ, Zhu HL.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	Bioorg Med Chem Lett	2017	27	8	1649	1653	28318946	10.1016/j.bmcl.2017.03.017	Easy and rapid preparation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase.	Tirapegui C, Acevedo-Fuentes W, Dahech P, Torrent C, Barrias P, Rojas-Poblete M, Mascayano C.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J Nat Prod	2017	80	3	699	706	28240894	10.1021/acs.jnatprod.6b01008	Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.	Svouraki A, Garscha U, Kouloura E, Pace S, Pergola C, Krauth V, Rossi A, Sautebin L, Halabalaki M, Werz O, Gaboriaud-Kolar N, Skaltsounis AL.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93	J Nat Prod	2017	80	3	731	734	28165233	10.1021/acs.jnatprod.6b01126	The Bibenzyl Canniprene Inhibits the Production of Pro-Inflammatory Eicosanoids and Selectively Accumulates in Some Cannabis sativa Strains.	Allegrone G, Pollastro F, Magagnini G, Taglialatela-Scafati O, Seegers J, Koeberle A, Werz O, Appendino G.
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93								10.6019/CHEMBL3301361	Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds	Mark Wenlock and Nicholas Tomkinson
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									British National Formulary (72nd edition)	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									DrugMatrix	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									DrugMatrix in vitro pharmacology data	Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									PubChem BioAssay data set	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									Unpublished dataset	
943.5000000000000000	9606	Homo sapiens	ZILEUTON	CHEMBL93									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	1995	38	18	3566	3580	7658443	10.1021/jm00018a016	Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.	Glen RC, Martin GR, Hill AP, Hyde RM, Woollard PM, Salmon JA, Buckingham J, Robertson AD.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	1995	38	18	3602	3607	7658447	10.1021/jm00018a020	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.	Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, John GW, Valentin JP, Halazy S.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Bioorg. Med. Chem. Lett.	1998	8	6	675	680	9871581	10.1016/s0960-894x(98)00090-0	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.	Perez M, Pauwels PJ, Fourrier C, Chopin P, Valentin JP, John GW, Marien M, Halazy S.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	2001	44	5	681	693	11262079	10.1021/jm000956k	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.	Jandu KS, Barrett V, Brockwell M, Cambridge D, Farrant DR, Foster C, Giles H, Glen RC, Hill AP, Hobbs H, Honey A, Martin GR, Salmon J, Smith D, Woollard P, Selwood DL.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Gastroenterol Clin Biol	2004	28	8-9	720	759	15646539	10.1016/s0399-8320(04)95062-2	[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].	Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Bioorg. Med. Chem.	2007	15	24	7738	7745	17870541	10.1016/j.bmc.2007.08.060	Hologram QSAR model for the prediction of human oral bioavailability.	Moda TL, Montanari CA, Andricopulo AD.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Drug Metab. Dispos.	2008	36	7	1385	1405	18426954	10.1124/dmd.108.020479	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.	Obach RS, Lombardo F, Waters NJ.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Bioorg. Med. Chem. Lett.	2009	19	23	6793	6796	19850474	10.1016/j.bmcl.2009.09.086	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.	Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	2009	52	15	4844	4852	19445515	10.1021/jm900403j	Physicochemical determinants of human renal clearance.	Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Bioorg. Med. Chem. Lett.	2010	20	24	7312	7316	21055935	10.1016/j.bmcl.2010.10.068	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.	Alelyunas YW, Empfield JR, McCarthy D, Spreen RC, Bui K, Pelosi-Kilby L, Shen C.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	2010	53	3	1098	1108	20070106	10.1021/jm901371v	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.	Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	PLOS Computational Biology	2011	7	12	1	13	22194678	10.1371/journal.pcbi.1002310	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Med Chem Res	2012	21	12	4357	4368		10.1007/s00044-012-9977-1	Advanced QSRR models of toxicological screening of basic drugs in whole blood by UPLC-TOFMS	Noorizadeh H, Noorizadeh M, Farmany A
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Bioorg. Med. Chem. Lett.	2012	22	14	4723	4727	22727645	10.1016/j.bmcl.2012.05.074	The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.	Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Macci R, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Chaturvedula PV, Macor JE, Dubowchik GM.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Toxicol Sci	2013	136	1	216	241	23956101	10.1093/toxsci/kft176	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	ACS Med. Chem. Lett.	2013	4	1	108	112	24900570	10.1021/ml300314h	De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.	Gunaydin H, Weiss MM, Sun Y.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Mol. Pharmacol.	2013	83	6	1257	1267	23571415	10.1124/mol.112.084152	Structure-based identification of OATP1B1/3 inhibitors.	De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	J. Med. Chem.	2014	57	19	7838	7858	24960305	10.1021/jm500364u	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.	Bell IM.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185	Drug Discov Today	2016	21	4	648	653	26948801	10.1016/j.drudis.2016.02.015	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.	Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									British National Formulary (72nd edition)	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									DailyMed|setid=333caafc-2e63-49f8-a0c6-534e528d228d | ZOLMITRIPTAN- zolmitriptan tablet, film coated|Glenmark Pharmaceuticals Inc., USA	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									PubChem BioAssay data set	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									Unpublished dataset	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date	
1098.4250000000000000	9606	Homo sapiens	ZOLMITRIPTAN	CHEMBL1185									WHO Anatomical Therapeutic Chemical Classification	
